Word	Tag	Begin-End
Naloxone	O	0-8
reverses	O	9-17
the	O	18-21
antihypertensive	O	22-38
effect	O	39-45
of	O	46-48
clonidine	O	49-58
.	O	58-59

In	O	60-62
unanesthetized	O	63-77
,	O	77-78
spontaneously	O	79-92
hypertensive	B	93-105
rats	O	106-110
the	O	111-114
decrease	O	115-123
in	O	124-126
blood	O	127-132
pressure	O	133-141
and	O	142-145
heart	O	146-151
rate	O	152-156
produced	O	157-165
by	O	166-168
intravenous	O	169-180
clonidine	O	181-190
,	O	190-191
5	O	192-193
to	O	194-196
20	O	197-199
micrograms	O	200-210
/	O	210-211
kg	O	211-213
,	O	213-214
was	O	215-218
inhibited	O	219-228
or	O	229-231
reversed	O	232-240
by	O	241-243
nalozone	O	244-252
,	O	252-253
0	O	254-255
.	O	255-256
2	O	256-257
to	O	258-260
2	O	261-262
mg	O	263-265
/	O	265-266
kg	O	266-268
.	O	268-269

The	O	270-273
hypotensive	B	274-285
effect	O	286-292
of	O	293-295
100	O	296-299
mg	O	300-302
/	O	302-303
kg	O	303-305
alpha	O	306-311
-	O	311-312
methyldopa	O	312-322
was	O	323-326
also	O	327-331
partially	O	332-341
reversed	O	342-350
by	O	351-353
naloxone	O	354-362
.	O	362-363

Naloxone	O	364-372
alone	O	373-378
did	O	379-382
not	O	383-386
affect	O	387-393
either	O	394-400
blood	O	401-406
pressure	O	407-415
or	O	416-418
heart	O	419-424
rate	O	425-429
.	O	429-430

In	O	431-433
brain	O	434-439
membranes	O	440-449
from	O	450-454
spontaneously	O	455-468
hypertensive	B	469-481
rats	O	482-486
clonidine	O	487-496
,	O	496-497
10	O	498-500
(	O	500-501
-	O	501-502
8	O	502-503
)	O	503-504
to	O	505-507
10	O	508-510
(	O	510-511
-	O	511-512
5	O	512-513
)	O	513-514
M	O	515-516
,	O	516-517
did	O	518-521
not	O	522-525
influence	O	526-535
stereoselective	O	536-551
binding	O	552-559
of	O	560-562
[	O	563-564
3H	O	564-566
]	O	566-567
-	O	567-568
naloxone	O	568-576
(	O	577-578
8	O	578-579
nM	O	580-582
)	O	582-583
,	O	583-584
and	O	585-588
naloxone	O	589-597
,	O	597-598
10	O	599-601
(	O	601-602
-	O	602-603
8	O	603-604
)	O	604-605
to	O	606-608
10	O	609-611
(	O	611-612
-	O	612-613
4	O	613-614
)	O	614-615
M	O	616-617
,	O	617-618
did	O	619-622
not	O	623-626
influence	O	627-636
clonidine	O	637-646
-	O	646-647
suppressible	O	647-659
binding	O	660-667
of	O	668-670
[	O	671-672
3H	O	672-674
]	O	674-675
-	O	675-676
dihydroergocryptine	O	676-695
(	O	696-697
1	O	697-698
nM	O	699-701
)	O	701-702
.	O	702-703

These	O	704-709
findings	O	710-718
indicate	O	719-727
that	O	728-732
in	O	733-735
spontaneously	O	736-749
hypertensive	B	750-762
rats	O	763-767
the	O	768-771
effects	O	772-779
of	O	780-782
central	O	783-790
alpha	O	791-796
-	O	796-797
adrenoceptor	O	797-809
stimulation	O	810-821
involve	O	822-829
activation	O	830-840
of	O	841-843
opiate	O	844-850
receptors	O	851-860
.	O	860-861

As	O	862-864
naloxone	O	865-873
and	O	874-877
clonidine	O	878-887
do	O	888-890
not	O	891-894
appear	O	895-901
to	O	902-904
interact	O	905-913
with	O	914-918
the	O	919-922
same	O	923-927
receptor	O	928-936
site	O	937-941
,	O	941-942
the	O	943-946
observed	O	947-955
functional	O	956-966
antagonism	O	967-977
suggests	O	978-986
the	O	987-990
release	O	991-998
of	O	999-1001
an	O	1002-1004
endogenous	O	1005-1015
opiate	O	1016-1022
by	O	1023-1025
clonidine	O	1026-1035
or	O	1036-1038
alpha	O	1039-1044
-	O	1044-1045
methyldopa	O	1045-1055
and	O	1056-1059
the	O	1060-1063
possible	O	1064-1072
role	O	1073-1077
of	O	1078-1080
the	O	1081-1084
opiate	O	1085-1091
in	O	1092-1094
the	O	1095-1098
central	O	1099-1106
control	O	1107-1114
of	O	1115-1117
sympathetic	O	1118-1129
tone	O	1130-1134
.	O	1134-1135

Lidocaine	O	0-9
-	O	9-10
induced	O	10-17
cardiac	B	18-25
asystole	I	26-34
.	O	34-35

Intravenous	O	36-47
administration	O	48-62
of	O	63-65
a	O	66-67
single	O	68-74
50	O	75-77
-	O	77-78
mg	O	78-80
bolus	O	81-86
of	O	87-89
lidocaine	O	90-99
in	O	100-102
a	O	103-104
67	O	105-107
-	O	107-108
year	O	108-112
-	O	107-108
old	O	113-116
man	O	117-120
resulted	O	121-129
in	O	130-132
profound	O	133-141
depression	B	142-152
of	O	153-155
the	O	156-159
activity	O	160-168
of	O	169-171
the	O	172-175
sinoatrial	O	176-186
and	O	187-190
atrioventricular	O	191-207
nodal	O	208-213
pacemakers	O	214-224
.	O	224-225

The	O	226-229
patient	O	230-237
had	O	238-241
no	O	242-244
apparent	O	245-253
associated	O	254-264
conditions	O	265-275
which	O	276-281
might	O	282-287
have	O	288-292
predisposed	O	293-304
him	O	305-308
to	O	309-311
the	O	312-315
development	O	316-327
of	O	328-330
bradyarrhythmias	B	331-347
;	O	347-348
and	O	349-352
,	O	352-353
thus	O	354-358
,	O	358-359
this	O	360-364
probably	O	365-373
represented	O	374-385
a	O	386-387
true	O	388-392
idiosyncrasy	O	393-405
to	O	406-408
lidocaine	O	409-418
.	O	418-419

Suxamethonium	O	0-13
infusion	O	14-22
rate	O	23-27
and	O	28-31
observed	O	32-40
fasciculations	B	41-55
.	O	55-56

A	O	57-58
dose	O	59-63
-	O	63-64
response	O	64-72
study	O	73-78
.	O	78-79

Suxamethonium	O	80-93
chloride	O	94-102
(	O	103-104
Sch	O	104-107
)	O	107-108
was	O	109-112
administered	O	113-125
i	O	126-127
.	O	127-128
v	O	128-129
.	O	127-128
to	O	131-133
36	O	134-136
adult	O	137-142
males	O	143-148
at	O	149-151
six	O	152-155
rates	O	156-161
:	O	161-162
0	O	163-164
.	O	164-165
25	O	165-167
mg	O	168-170
s	O	171-172
-	O	172-173
1	O	173-174
to	O	175-177
20	O	178-180
mg	O	181-183
s	O	184-185
-	O	185-186
1	O	186-187
.	O	187-188

The	O	189-192
infusion	O	193-201
was	O	202-205
discontinued	O	206-218
either	O	219-225
when	O	226-230
there	O	231-236
was	O	237-240
no	O	241-243
muscular	O	244-252
response	O	253-261
to	O	262-264
tetanic	B	265-272
stimulation	O	273-284
of	O	285-287
the	O	288-291
ulnar	O	292-297
nerve	O	298-303
or	O	304-306
when	O	307-311
Sch	O	312-315
120	O	316-319
mg	O	320-322
was	O	323-326
exceeded	O	327-335
.	O	335-336

Six	O	337-340
additional	O	341-351
patients	O	352-360
received	O	361-369
a	O	370-371
30	O	372-374
-	O	374-375
mg	O	375-377
i	O	378-379
.	O	379-380
v	O	380-381
.	O	379-380

bolus	O	383-388
dose	O	389-393
.	O	393-394

Fasciculations	B	395-409
in	O	410-412
six	O	413-416
areas	O	417-422
of	O	423-425
the	O	426-429
body	O	430-434
were	O	435-439
scored	O	440-446
from	O	447-451
0	O	452-453
to	O	454-456
3	O	457-458
and	O	459-462
summated	O	463-471
as	O	472-474
a	O	475-476
total	O	477-482
fasciculation	B	483-496
score	O	497-502
.	O	502-503

The	O	504-507
times	O	508-513
to	O	514-516
first	O	517-522
fasciculation	B	523-536
,	O	536-537
twitch	B	538-544
suppression	O	545-556
and	O	557-560
tetanus	B	561-568
suppression	O	569-580
were	O	581-585
inversely	O	586-595
related	O	596-603
to	O	604-606
the	O	607-610
infusion	O	611-619
rates	O	620-625
.	O	625-626

Fasciculations	B	627-641
in	O	642-644
the	O	645-648
six	O	649-652
areas	O	653-658
and	O	659-662
the	O	663-666
total	O	667-672
fasciculation	B	673-686
score	O	687-692
were	O	693-697
related	O	698-705
directly	O	706-714
to	O	715-717
the	O	718-721
rate	O	722-726
of	O	727-729
infusion	O	730-738
.	O	738-739

Total	O	740-745
fasciculation	B	746-759
scores	O	760-766
in	O	767-769
the	O	770-773
30	O	774-776
-	O	776-777
mg	O	777-779
bolus	O	780-785
group	O	786-791
and	O	792-795
the	O	796-799
5	O	800-801
-	O	801-802
mg	O	802-804
s	O	805-806
-	O	806-807
1	O	807-808
and	O	809-812
20	O	813-815
-	O	815-816
mg	O	816-818
s	O	819-820
-	O	820-821
1	O	821-822
infusion	O	823-831
groups	O	832-838
were	O	839-843
not	O	844-847
significantly	O	848-861
different	O	862-871
.	O	871-872

Galanthamine	O	0-12
hydrobromide	O	13-25
,	O	25-26
a	O	27-28
longer	O	29-35
acting	O	36-42
anticholinesterase	O	43-61
drug	O	62-66
,	O	66-67
in	O	68-70
the	O	71-74
treatment	O	75-84
of	O	85-87
the	O	88-91
central	O	92-99
effects	O	100-107
of	O	108-110
scopolamine	O	111-122
(	O	123-124
Hyoscine	O	124-132
)	O	132-133
.	O	133-134

Galanthamine	O	135-147
hydrobromide	O	148-160
,	O	160-161
an	O	162-164
anticholinesterase	O	165-183
drug	O	184-188
capable	O	189-196
of	O	197-199
penetrating	O	200-211
the	O	212-215
blood	O	216-221
-	O	221-222
brain	O	222-227
barrier	O	228-235
,	O	235-236
was	O	237-240
used	O	241-245
in	O	246-248
a	O	249-250
patient	O	251-258
demonstrating	O	259-272
central	O	273-280
effects	O	281-288
of	O	289-291
scopolamine	O	292-303
(	O	304-305
hyoscine	O	305-313
)	O	313-314
overdosage	B	315-325
.	O	325-326

It	O	327-329
is	O	330-332
longer	O	333-339
acting	O	340-346
than	O	347-351
physostigmine	O	352-365
and	O	366-369
is	O	370-372
used	O	373-377
in	O	378-380
anaesthesia	O	381-392
to	O	393-395
reverse	O	396-403
the	O	404-407
non	O	408-411
-	O	411-412
depolarizing	O	412-424
neuromuscular	O	425-438
block	O	439-444
.	O	444-445

However	O	446-453
,	O	453-454
studies	O	455-462
into	O	463-467
the	O	468-471
dose	O	472-476
necessary	O	477-486
to	O	487-489
combating	O	490-499
scopolamine	O	500-511
intoxication	O	512-524
are	O	525-528
indicated	O	529-538
.	O	538-539

Effects	O	0-7
of	O	8-10
uninephrectomy	O	11-25
and	O	26-29
high	O	30-34
protein	O	35-42
feeding	O	43-50
on	O	51-53
lithium	O	54-61
-	O	61-62
induced	O	62-69
chronic	B	70-77
renal	I	78-83
failure	I	84-91
in	O	92-94
rats	O	95-99
.	O	99-100

Rats	O	101-105
with	O	106-110
lithium	O	111-118
-	O	118-119
induced	O	119-126
nephropathy	B	127-138
were	O	139-143
subjected	O	144-153
to	O	154-156
high	O	157-161
protein	O	162-169
(	O	170-171
HP	O	171-173
)	O	173-174
feeding	O	175-182
,	O	182-183
uninephrectomy	O	184-198
(	O	199-200
NX	O	200-202
)	O	202-203
or	O	204-206
a	O	207-208
combination	O	209-220
of	O	221-223
these	O	224-229
,	O	229-230
in	O	231-233
an	O	234-236
attempt	O	237-244
to	O	245-247
induce	O	248-254
glomerular	O	255-265
hyperfiltration	O	266-281
and	O	282-285
further	O	286-293
progression	O	294-305
of	O	306-308
renal	B	309-314
failure	I	315-322
.	O	322-323

Newborn	O	324-331
female	O	332-338
Wistar	O	339-345
rats	O	346-350
were	O	351-355
fed	O	356-359
a	O	360-361
lithium	O	362-369
-	O	369-370
containing	O	370-380
diet	O	381-385
(	O	386-387
50	O	387-389
mmol	O	390-394
/	O	394-395
kg	O	395-397
)	O	397-398
for	O	399-402
8	O	403-404
weeks	O	405-410
and	O	411-414
then	O	415-419
randomized	O	420-430
to	O	431-433
normal	O	434-440
diet	O	441-445
,	O	445-446
HP	O	447-449
diet	O	450-454
(	O	455-456
40	O	456-458
vs	O	459-461
.	O	461-462
19	O	463-465
%	O	465-466
)	O	466-467
,	O	467-468
NX	O	469-471
or	O	472-474
HP	O	475-477
+	O	477-478
NX	O	478-480
for	O	481-484
another	O	485-492
8	O	493-494
weeks	O	495-500
.	O	500-501

Corresponding	O	502-515
non	O	516-519
-	O	519-520
lithium	O	520-527
pretreated	O	528-538
groups	O	539-545
were	O	546-550
generated	O	551-560
.	O	560-561

When	O	562-566
comparing	O	567-576
all	O	577-580
lithium	O	581-588
treated	O	589-596
versus	O	597-603
non	O	604-607
-	O	607-608
lithium	O	608-615
-	O	607-608
treated	O	616-623
groups	O	624-630
,	O	630-631
lithium	O	632-639
caused	O	640-646
a	O	647-648
reduction	O	649-658
in	O	659-661
glomerular	O	662-672
filtration	O	673-683
rate	O	684-688
(	O	689-690
GFR	O	690-693
)	O	693-694
without	O	695-702
significant	O	703-714
changes	O	715-722
in	O	723-725
effective	O	726-735
renal	O	736-741
plasma	O	742-748
flow	O	749-753
(	O	754-755
as	O	755-757
determined	O	758-768
by	O	769-771
a	O	772-773
marker	O	774-780
secreted	O	781-789
into	O	790-794
the	O	795-798
proximal	O	799-807
tubules	O	808-815
)	O	815-816
or	O	817-819
lithium	O	820-827
clearance	O	828-837
.	O	837-838

Consequently	O	839-851
,	O	851-852
lithium	O	853-860
pretreatment	O	861-873
caused	O	874-880
a	O	881-882
fall	O	883-887
in	O	888-890
filtration	O	891-901
fraction	O	902-910
and	O	911-914
an	O	915-917
increase	O	918-926
in	O	927-929
fractional	O	930-940
Li	O	941-943
excretion	O	944-953
.	O	953-954

Lithium	O	955-962
also	O	963-967
caused	O	968-974
proteinuria	B	975-986
and	O	987-990
systolic	O	991-999
hypertension	B	1000-1012
in	O	1013-1015
absence	O	1016-1023
of	O	1024-1026
glomerulosclerosis	B	1027-1045
.	O	1045-1046

HP	O	1047-1049
failed	O	1050-1056
to	O	1057-1059
accentuante	O	1060-1071
progression	O	1072-1083
of	O	1084-1086
renal	B	1087-1092
failure	I	1093-1100
and	O	1101-1104
in	O	1105-1107
fact	O	1108-1112
tended	O	1113-1119
to	O	1120-1122
increase	O	1123-1131
GFR	O	1132-1135
and	O	1136-1139
decrease	O	1140-1148
plasma	O	1149-1155
creatinine	O	1156-1166
levels	O	1167-1173
in	O	1174-1176
lithium	O	1177-1184
pretreated	O	1185-1195
rats	O	1196-1200
.	O	1200-1201

NX	O	1202-1204
caused	O	1205-1211
an	O	1212-1214
additive	O	1215-1223
deterioration	O	1224-1237
in	O	1238-1240
GFR	O	1241-1244
which	O	1245-1250
,	O	1250-1251
however	O	1252-1259
,	O	1259-1260
was	O	1261-1264
ameliorated	O	1265-1276
by	O	1277-1279
HP	O	1280-1282
.	O	1282-1283

NX	O	1284-1286
+	O	1286-1287
HP	O	1287-1289
caused	O	1290-1296
a	O	1297-1298
further	O	1299-1306
rise	O	1307-1311
in	O	1312-1314
blood	O	1315-1320
pressure	O	1321-1329
in	O	1330-1332
Li	O	1333-1335
-	O	1335-1336
pretreated	O	1336-1346
rats	O	1347-1351
.	O	1351-1352

The	O	1353-1356
results	O	1357-1364
indicate	O	1365-1373
that	O	1374-1378
Li	O	1379-1381
-	O	1381-1382
induced	O	1382-1389
nephropathy	B	1390-1401
,	O	1401-1402
even	O	1403-1407
when	O	1408-1412
the	O	1413-1416
GFR	O	1417-1420
is	O	1421-1423
only	O	1424-1428
modestly	O	1429-1437
reduced	O	1438-1445
,	O	1445-1446
is	O	1447-1449
associated	O	1450-1460
with	O	1461-1465
proteinuria	B	1466-1477
and	O	1478-1481
arterial	O	1482-1490
systolic	O	1491-1499
hypertension	B	1500-1512
.	O	1512-1513

In	O	1514-1516
this	O	1517-1521
model	O	1522-1527
of	O	1528-1530
chronic	B	1531-1538
renal	I	1539-1544
failure	I	1545-1552
the	O	1553-1556
decline	O	1557-1564
in	O	1565-1567
GFR	O	1568-1571
is	O	1572-1574
not	O	1575-1578
accompanied	O	1579-1590
by	O	1591-1593
a	O	1594-1595
corresponding	O	1596-1609
fall	O	1610-1614
in	O	1615-1617
effective	O	1618-1627
renal	O	1628-1633
plasma	O	1634-1640
flow	O	1641-1645
,	O	1645-1646
which	O	1647-1652
may	O	1653-1656
be	O	1657-1659
the	O	1660-1663
functional	O	1664-1674
expression	O	1675-1685
of	O	1686-1688
the	O	1689-1692
formation	O	1693-1702
of	O	1703-1705
nonfiltrating	O	1706-1719
atubular	O	1720-1728
glomeruli	O	1729-1738
.	O	1738-1739

The	O	1740-1743
fractional	O	1744-1754
reabsorption	O	1755-1767
of	O	1768-1770
tubular	O	1771-1778
fluid	O	1779-1784
by	O	1785-1787
the	O	1788-1791
proximal	O	1792-1800
tubules	O	1801-1808
is	O	1809-1811
reduced	O	1812-1819
,	O	1819-1820
leaving	O	1821-1828
the	O	1829-1832
distal	O	1833-1839
delivery	O	1840-1848
unchanged	O	1849-1858
.	O	1858-1859
(	O	1859-1860
ABSTRACT	O	1860-1868

TRUNCATED	O	1869-1878
AT	O	1879-1881
250	O	1882-1885
WORDS	O	1886-1891
)	O	1891-1892

Treatment	O	0-9
of	O	10-12
Crohn	B	13-18
'	I	18-19
s	I	19-20
disease	I	21-28
with	O	29-33
fusidic	O	34-41
acid	O	42-46
:	O	46-47
an	O	48-50
antibiotic	O	51-61
with	O	62-66
immunosuppressive	O	67-84
properties	O	85-95
similar	O	96-103
to	O	104-106
cyclosporin	O	107-118
.	O	118-119

Fusidic	O	120-127
acid	O	128-132
is	O	133-135
an	O	136-138
antibiotic	O	139-149
with	O	150-154
T	O	155-156
-	O	156-157
cell	O	157-161
specific	O	162-170
immunosuppressive	O	171-188
effects	O	189-196
similar	O	197-204
to	O	205-207
those	O	208-213
of	O	214-216
cyclosporin	O	217-228
.	O	228-229

Because	O	230-237
of	O	238-240
the	O	241-244
need	O	245-249
for	O	250-253
the	O	254-257
development	O	258-269
of	O	270-272
new	O	273-276
treatments	O	277-287
for	O	288-291
Crohn	B	292-297
'	I	297-298
s	I	298-299
disease	I	300-307
,	O	307-308
a	O	309-310
pilot	O	311-316
study	O	317-322
was	O	323-326
undertaken	O	327-337
to	O	338-340
estimate	O	341-349
the	O	350-353
pharmacodynamics	O	354-370
and	O	371-374
tolerability	O	375-387
of	O	388-390
fusidic	O	391-398
acid	O	399-403
treatment	O	404-413
in	O	414-416
chronic	O	417-424
active	O	425-431
,	O	431-432
therapy	O	433-440
-	O	440-441
resistant	O	441-450
patients	O	451-459
.	O	459-460

Eight	O	461-466
Crohn	B	467-472
'	I	472-473
s	I	473-474
disease	I	475-482
patients	O	483-491
were	O	492-496
included	O	497-505
.	O	505-506

Fusidic	O	507-514
acid	O	515-519
was	O	520-523
administered	O	524-536
orally	O	537-543
in	O	544-546
a	O	547-548
dose	O	549-553
of	O	554-556
500	O	557-560
mg	O	561-563
t	O	564-565
.	O	565-566
d	O	566-567
.	O	565-566
s	O	568-569
.	O	565-566
and	O	571-574
the	O	575-578
treatment	O	579-588
was	O	589-592
planned	O	593-600
to	O	601-603
last	O	604-608
8	O	609-610
weeks	O	611-616
.	O	616-617

The	O	618-621
disease	O	622-629
activity	O	630-638
was	O	639-642
primarily	O	643-652
measured	O	653-661
by	O	662-664
a	O	665-666
modified	O	667-675
individual	O	676-686
grading	O	687-694
score	O	695-700
.	O	700-701

Five	O	702-706
of	O	707-709
8	O	710-711
patients	O	712-720
(	O	721-722
63	O	722-724
%	O	724-725
)	O	725-726
improved	O	727-735
during	O	736-742
fusidic	O	743-750
acid	O	751-755
treatment	O	756-765
:	O	765-766
3	O	767-768
at	O	769-771
two	O	772-775
weeks	O	776-781
and	O	782-785
2	O	786-787
after	O	788-793
four	O	794-798
weeks	O	799-804
.	O	804-805

There	O	806-811
were	O	812-816
no	O	817-819
serious	O	820-827
clinical	O	828-836
side	O	837-841
effects	O	842-849
,	O	849-850
but	O	851-854
dose	O	855-859
reduction	O	860-869
was	O	870-873
required	O	874-882
in	O	883-885
two	O	886-889
patients	O	890-898
because	O	899-906
of	O	907-909
nausea	B	910-916
.	O	916-917

Biochemically	O	918-931
,	O	931-932
an	O	933-935
increase	O	936-944
in	O	945-947
alkaline	O	948-956
phosphatases	O	957-969
was	O	970-973
noted	O	974-979
in	O	980-982
5	O	983-984
of	O	985-987
8	O	988-989
cases	O	990-995
(	O	996-997
63	O	997-999
%	O	999-1000
)	O	1000-1001
,	O	1001-1002
and	O	1003-1006
the	O	1007-1010
greatest	O	1011-1019
increases	O	1020-1029
were	O	1030-1034
seen	O	1035-1039
in	O	1040-1042
those	O	1043-1048
who	O	1049-1052
had	O	1053-1056
elevated	O	1057-1065
levels	O	1066-1072
prior	O	1073-1078
to	O	1079-1081
treatment	O	1082-1091
.	O	1091-1092

All	O	1093-1096
reversed	O	1097-1105
to	O	1106-1108
pre	O	1109-1112
-	O	1112-1113
treatment	O	1113-1122
levels	O	1123-1129
after	O	1130-1135
cessation	O	1136-1145
of	O	1146-1148
treatment	O	1149-1158
.	O	1158-1159

The	O	1160-1163
results	O	1164-1171
of	O	1172-1174
this	O	1175-1179
pilot	O	1180-1185
study	O	1186-1191
suggest	O	1192-1199
that	O	1200-1204
fusidic	O	1205-1212
acid	O	1213-1217
may	O	1218-1221
be	O	1222-1224
of	O	1225-1227
benefit	O	1228-1235
in	O	1236-1238
selected	O	1239-1247
chronic	O	1248-1255
active	O	1256-1262
Crohn	B	1263-1268
'	I	1268-1269
s	I	1269-1270
disease	I	1271-1278
patients	O	1279-1287
in	O	1288-1290
whom	O	1291-1295
conventional	O	1296-1308
treatment	O	1309-1318
is	O	1319-1321
ineffective	O	1322-1333
.	O	1333-1334

Because	O	1335-1342
there	O	1343-1348
seems	O	1349-1354
to	O	1355-1357
exist	O	1358-1363
a	O	1364-1365
scientific	O	1366-1376
rationale	O	1377-1386
for	O	1387-1390
the	O	1391-1394
use	O	1395-1398
of	O	1399-1401
fusidic	O	1402-1409
acid	O	1410-1414
at	O	1415-1417
the	O	1418-1421
cytokine	O	1422-1430
level	O	1431-1436
in	O	1437-1439
inflammatory	B	1440-1452
bowel	I	1453-1458
disease	I	1459-1466
,	O	1466-1467
we	O	1468-1470
suggest	O	1471-1478
that	O	1479-1483
the	O	1484-1487
role	O	1488-1492
of	O	1493-1495
this	O	1496-1500
treatment	O	1501-1510
should	O	1511-1517
be	O	1518-1520
further	O	1521-1528
investigated	O	1529-1541
.	O	1541-1542

Electrocardiographic	O	0-20
evidence	O	21-29
of	O	30-32
myocardial	B	33-43
injury	I	44-50
in	O	51-53
psychiatrically	O	54-69
hospitalized	O	70-82
cocaine	O	83-90
abusers	O	91-98
.	O	98-99

The	O	100-103
electrocardiograms	O	104-122
(	O	123-124
ECG	O	124-127
)	O	127-128
of	O	129-131
99	O	132-134
cocaine	O	135-142
-	O	142-143
abusing	O	143-150
patients	O	151-159
were	O	160-164
compared	O	165-173
with	O	174-178
the	O	179-182
ECGs	O	183-187
of	O	188-190
50	O	191-193
schizophrenic	B	194-207
controls	O	208-216
.	O	216-217

Eleven	O	218-224
of	O	225-227
the	O	228-231
cocaine	O	232-239
abusers	O	240-247
and	O	248-251
none	O	252-256
of	O	257-259
the	O	260-263
controls	O	264-272
had	O	273-276
ECG	O	277-280
evidence	O	281-289
of	O	290-292
significant	O	293-304
myocardial	B	305-315
injury	I	316-322
defined	O	323-330
as	O	331-333
myocardial	B	334-344
infarction	I	345-355
,	O	355-356
ischemia	B	357-365
,	O	365-366
and	O	367-370
bundle	B	371-377
branch	I	378-384
block	I	385-390
.	O	390-391

Sulpiride	O	0-9
-	O	9-10
induced	O	10-17
tardive	B	18-25
dystonia	I	26-34
.	O	34-35

Sulpiride	O	36-45
is	O	46-48
a	O	49-50
selective	O	51-60
D2	O	61-63
-	O	63-64
receptor	O	64-72
antagonist	O	73-83
with	O	84-88
antipsychotic	O	89-102
and	O	103-106
antidepressant	O	107-121
properties	O	122-132
.	O	132-133

Although	O	134-142
initially	O	143-152
thought	O	153-160
to	O	161-163
be	O	164-166
free	O	167-171
of	O	172-174
extrapyramidal	O	175-189
side	O	190-194
effects	O	195-202
,	O	202-203
sulpiride	O	204-213
-	O	213-214
induced	O	214-221
tardive	B	222-229
dyskinesia	I	230-240
and	O	241-244
parkinsonism	B	245-257
have	O	258-262
been	O	263-267
reported	O	268-276
occasionally	O	277-289
.	O	289-290

We	O	291-293
studied	O	294-301
a	O	302-303
37	O	304-306
-	O	306-307
year	O	307-311
-	O	306-307
old	O	312-315
man	O	316-319
who	O	320-323
developed	O	324-333
persistent	O	334-344
segmental	O	345-354
dystonia	B	355-363
within	O	364-370
2	O	371-372
months	O	373-379
after	O	380-385
starting	O	386-394
sulpiride	O	395-404
therapy	O	405-412
.	O	412-413

We	O	414-416
could	O	417-422
not	O	423-426
find	O	427-431
any	O	432-435
previous	O	436-444
reports	O	445-452
of	O	453-455
sulpiride	O	456-465
-	O	465-466
induced	O	466-473
tardive	B	474-481
dystonia	I	482-490
.	O	490-491

Ocular	B	0-6
and	I	7-10
auditory	I	11-19
toxicity	I	20-28
in	O	29-31
hemodialyzed	O	32-44
patients	O	45-53
receiving	O	54-63
desferrioxamine	O	64-79
.	O	79-80

During	O	81-87
an	O	88-90
18	O	91-93
-	O	93-94
month	O	94-99
period	O	100-106
of	O	107-109
study	O	110-115
41	O	116-118
hemodialyzed	O	119-131
patients	O	132-140
receiving	O	141-150
desferrioxamine	O	151-166
(	O	167-168
10	O	168-170
-	O	170-171
40	O	171-173
mg	O	174-176
/	O	176-177
kg	O	177-179
BW	O	180-182
/	O	182-183
3	O	183-184
times	O	185-190
weekly	O	191-197
)	O	197-198
for	O	199-202
the	O	203-206
first	O	207-212
time	O	213-217
were	O	218-222
monitored	O	223-232
for	O	233-236
detection	O	237-246
of	O	247-249
audiovisual	B	250-261
toxicity	I	262-270
.	O	270-271

6	O	272-273
patients	O	274-282
presented	O	283-292
clinical	O	293-301
symptoms	O	302-310
of	O	311-313
visual	B	314-320
or	I	321-323
auditory	I	324-332
toxicity	I	333-341
.	O	341-342

Moreover	O	343-351
,	O	351-352
detailed	O	353-361
ophthalmologic	O	362-376
and	O	377-380
audiologic	O	381-391
studies	O	392-399
disclosed	O	400-409
abnormalities	O	410-423
in	O	424-426
7	O	427-428
more	O	429-433
asymptomatic	O	434-446
patients	O	447-455
.	O	455-456

Visual	B	457-463
toxicity	I	464-472
was	O	473-476
of	O	477-479
retinal	O	480-487
origin	O	488-494
and	O	495-498
was	O	499-502
characterized	O	503-516
by	O	517-519
a	O	520-521
tritan	O	522-528
-	O	528-529
type	O	529-533
dyschromatopsy	B	534-548
,	O	548-549
sometimes	O	550-559
associated	O	560-570
with	O	571-575
a	B	576-577
loss	I	578-582
of	I	583-585
visual	I	586-592
acuity	I	593-599
and	O	600-603
pigmentary	B	604-614
retinal	I	615-622
deposits	I	623-631
.	O	631-632

Auditory	B	633-641
toxicity	I	642-650
was	O	651-654
characterized	O	655-668
by	O	669-671
a	O	672-673
mid	O	674-677
-	O	677-678
to	O	679-681
high	O	682-686
-	O	686-687
frequency	O	687-696
neurosensorial	B	697-711
hearing	I	712-719
loss	I	720-724
and	O	725-728
the	O	729-732
lesion	O	733-739
was	O	740-743
of	O	744-746
the	O	747-750
cochlear	O	751-759
type	O	760-764
.	O	764-765

Desferrioxamine	O	766-781
withdrawal	O	782-792
resulted	O	793-801
in	O	802-804
a	O	805-806
complete	O	807-815
recovery	O	816-824
of	O	825-827
visual	O	828-834
function	O	835-843
in	O	844-846
1	O	847-848
patient	O	849-856
and	O	857-860
partial	O	861-868
recovery	O	869-877
in	O	878-880
3	O	881-882
,	O	882-883
and	O	884-887
a	O	888-889
complete	O	890-898
reversal	O	899-907
of	O	908-910
hearing	B	911-918
loss	I	919-923
in	O	924-926
3	O	927-928
patients	O	929-937
and	O	938-941
partial	O	942-949
recovery	O	950-958
in	O	959-961
3	O	962-963
.	O	963-964

This	O	965-969
toxicity	B	970-978
appeared	O	979-987
in	O	988-990
patients	O	991-999
receiving	O	1000-1009
the	O	1010-1013
higher	O	1014-1020
doses	O	1021-1026
of	O	1027-1029
desferrioxamine	O	1030-1045
or	O	1046-1048
coincided	O	1049-1058
with	O	1059-1063
the	O	1064-1067
normalization	O	1068-1081
of	O	1082-1084
ferritin	O	1085-1093
or	O	1094-1096
aluminium	O	1097-1106
serum	O	1107-1112
levels	O	1113-1119
.	O	1119-1120

The	O	1121-1124
data	O	1125-1129
indicate	O	1130-1138
that	O	1139-1143
audiovisual	B	1144-1155
toxicity	I	1156-1164
is	O	1165-1167
not	O	1168-1171
an	O	1172-1174
infrequent	O	1175-1185
complication	O	1186-1198
in	O	1199-1201
hemodialyzed	O	1202-1214
patients	O	1215-1223
receiving	O	1224-1233
desferrioxamine	O	1234-1249
.	O	1249-1250

Periodical	O	1251-1261
audiovisual	O	1262-1273
monitoring	O	1274-1284
should	O	1285-1291
be	O	1292-1294
performed	O	1295-1304
on	O	1305-1307
hemodialyzed	O	1308-1320
patients	O	1321-1329
receiving	O	1330-1339
the	O	1340-1343
drug	O	1344-1348
in	O	1349-1351
order	O	1352-1357
to	O	1358-1360
detect	O	1361-1367
adverse	O	1368-1375
effects	O	1376-1383
as	O	1384-1386
early	O	1387-1392
as	O	1393-1395
possible	O	1396-1404
.	O	1404-1405

Myasthenia	B	0-10
gravis	I	11-17
presenting	O	18-28
as	O	29-31
weakness	O	32-40
after	O	41-46
magnesium	O	47-56
administration	O	57-71
.	O	71-72

We	O	73-75
studied	O	76-83
a	O	84-85
patient	O	86-93
with	O	94-98
no	O	99-101
prior	O	102-107
history	O	108-115
of	O	116-118
neuromuscular	B	119-132
disease	I	133-140
who	O	141-144
became	O	145-151
virtually	O	152-161
quadriplegic	B	162-174
after	O	175-180
parenteral	O	181-191
magnesium	O	192-201
administration	O	202-216
for	O	217-220
preeclampsia	B	221-233
.	O	233-234

The	O	235-238
serum	O	239-244
magnesium	O	245-254
concentration	O	255-268
was	O	269-272
3	O	273-274
.	O	274-275
0	O	275-276
mEq	O	277-280
/	O	280-281
L	O	281-282
,	O	282-283
which	O	284-289
is	O	290-292
usually	O	293-300
well	O	301-305
tolerated	O	306-315
.	O	315-316

The	O	317-320
magnesium	O	321-330
was	O	331-334
stopped	O	335-342
and	O	343-346
she	O	347-350
recovered	O	351-360
over	O	361-365
a	O	366-367
few	O	368-371
days	O	372-376
.	O	376-377

While	O	378-383
she	O	384-387
was	O	388-391
weak	O	392-396
,	O	396-397
2	O	398-399
-	O	399-400
Hz	O	400-402
repetitive	O	403-413
stimulation	O	414-425
revealed	O	426-434
a	O	435-436
decrement	O	437-446
without	O	447-454
significant	O	455-466
facilitation	O	467-479
at	O	480-482
rapid	O	483-488
rates	O	489-494
or	O	495-497
after	O	498-503
exercise	O	504-512
,	O	512-513
suggesting	O	514-524
postsynaptic	B	525-537
neuromuscular	I	538-551
blockade	I	552-560
.	O	560-561

After	O	562-567
her	O	568-571
strength	O	572-580
returned	O	581-589
,	O	589-590
repetitive	O	591-601
stimulation	O	602-613
was	O	614-617
normal	O	618-624
,	O	624-625
but	O	626-629
single	O	630-636
fiber	O	637-642
EMG	O	643-646
revealed	O	647-655
increased	O	656-665
jitter	O	666-672
and	O	673-676
blocking	O	677-685
.	O	685-686

Her	O	687-690
acetylcholine	O	691-704
receptor	O	705-713
antibody	O	714-722
level	O	723-728
was	O	729-732
markedly	O	733-741
elevated	O	742-750
.	O	750-751

Although	O	752-760
paralysis	B	761-770
after	O	771-776
magnesium	O	777-786
administration	O	787-801
has	O	802-805
been	O	806-810
described	O	811-820
in	O	821-823
patients	O	824-832
with	O	833-837
known	O	838-843
myasthenia	B	844-854
gravis	I	855-861
,	O	861-862
it	O	863-865
has	O	866-869
not	O	870-873
previously	O	874-884
been	O	885-889
reported	O	890-898
to	O	899-901
be	O	902-904
the	O	905-908
initial	O	909-916
or	O	917-919
only	O	920-924
manifestation	O	925-938
of	O	939-941
the	O	942-945
disease	O	946-953
.	O	953-954

Patients	O	955-963
who	O	964-967
are	O	968-971
unusually	O	972-981
sensitive	O	982-991
to	O	992-994
the	O	995-998
neuromuscular	O	999-1012
effects	O	1013-1020
of	O	1021-1023
magnesium	O	1024-1033
should	O	1034-1040
be	O	1041-1043
suspected	O	1044-1053
of	O	1054-1056
having	O	1057-1063
an	O	1064-1066
underlying	O	1067-1077
disorder	B	1078-1086
of	I	1087-1089
neuromuscular	I	1090-1103
transmission	I	1104-1116
.	O	1116-1117

Chloroacetaldehyde	O	0-18
and	O	19-22
its	O	23-26
contribution	O	27-39
to	O	40-42
urotoxicity	O	43-54
during	O	55-61
treatment	O	62-71
with	O	72-76
cyclophosphamide	O	77-93
or	O	94-96
ifosfamide	O	97-107
.	O	107-108

An	O	109-111
experimental	O	112-124
study	O	125-130
/	O	130-131
short	O	131-136
communication	O	137-150
.	O	150-151

Based	O	152-157
on	O	158-160
clinical	O	161-169
data	O	170-174
,	O	174-175
indicating	O	176-186
that	O	187-191
chloroacetaldehyde	O	192-210
(	O	211-212
CAA	O	212-215
)	O	215-216
is	O	217-219
an	O	220-222
important	O	223-232
metabolite	O	233-243
of	O	244-246
oxazaphosphorine	O	247-263
cytostatics	O	264-275
,	O	275-276
an	O	277-279
experimental	O	280-292
study	O	293-298
was	O	299-302
carried	O	303-310
out	O	311-314
in	O	315-317
order	O	318-323
to	O	324-326
elucidate	O	327-336
the	O	337-340
role	O	341-345
of	O	346-348
CAA	O	349-352
in	O	353-355
the	O	356-359
development	O	360-371
of	O	372-374
hemorrhagic	B	375-386
cystitis	I	387-395
.	O	395-396

The	O	397-400
data	O	401-405
demonstrate	O	406-417
that	O	418-422
CAA	O	423-426
after	O	427-432
i	O	433-434
.	O	434-435
v	O	435-436
.	O	434-435

administration	O	438-452
does	O	453-457
not	O	458-461
contribute	O	462-472
to	O	473-475
bladder	B	476-483
damage	I	484-490
.	O	490-491

When	O	492-496
instilled	O	497-506
directly	O	507-515
into	O	516-520
the	O	521-524
bladder	O	525-532
,	O	532-533
CAA	O	534-537
exerts	O	538-544
urotoxic	O	545-553
effects	O	554-561
,	O	561-562
it	O	563-565
is	O	566-568
,	O	568-569
however	O	570-577
,	O	577-578
susceptible	O	579-590
to	O	591-593
detoxification	O	594-608
with	O	609-613
mesna	O	614-619
.	O	619-620

Source	O	0-6
of	O	7-9
pain	B	10-14
and	O	15-18
primitive	O	19-28
dysfunction	O	29-40
in	O	41-43
migraine	B	44-52
:	O	52-53
an	O	54-56
identical	O	57-66
site	O	67-71
?	O	71-72

Twenty	O	73-79
common	O	80-86
migraine	B	87-95
patients	O	96-104
received	O	105-113
a	O	114-115
one	O	116-119
sided	O	120-125
frontotemporal	O	126-140
application	O	141-152
of	O	153-155
nitroglycerin	O	156-169
(	O	170-171
10	O	171-173
patients	O	174-182
)	O	182-183
or	O	184-186
placebo	O	187-194
ointment	O	195-203
(	O	204-205
10	O	205-207
patients	O	208-216
)	O	216-217
in	O	218-220
a	O	221-222
double	O	223-229
blind	O	230-235
study	O	236-241
.	O	241-242

Early	O	243-248
onset	O	249-254
migraine	B	255-263
attacks	O	264-271
were	O	272-276
induced	O	277-284
by	O	285-287
nitroglycerin	O	288-301
in	O	302-304
seven	O	305-310
out	O	311-314
of	O	315-317
10	O	318-320
patients	O	321-329
versus	O	330-336
no	O	337-339
patient	O	340-347
in	O	348-350
the	O	351-354
placebo	O	355-362
group	O	363-368
.	O	368-369

Subsequently	O	370-382
20	O	383-385
migraine	B	386-394
patients	O	395-403
,	O	403-404
who	O	405-408
developed	O	409-418
an	O	419-421
early	O	422-427
onset	O	428-433
attack	O	434-440
with	O	441-445
frontotemporal	O	446-460
nitroglycerin	O	461-474
,	O	474-475
received	O	476-484
the	O	485-488
drug	O	489-493
in	O	494-496
a	O	497-498
second	O	499-505
induction	O	506-515
test	O	516-520
at	O	521-523
other	O	524-529
body	O	530-534
areas	O	535-540
.	O	540-541

No	O	542-544
early	O	545-550
onset	O	551-556
migraine	B	557-565
was	O	566-569
observed	O	570-578
.	O	578-579

Thus	O	580-584
the	O	585-588
migraine	B	589-597
-	O	597-598
inducing	O	598-606
effect	O	607-613
of	O	614-616
nitroglycerin	O	617-630
seems	O	631-636
to	O	637-639
depend	O	640-646
on	O	647-649
direct	O	650-656
stimulation	O	657-668
of	O	669-671
the	O	672-675
habitual	O	676-684
site	O	685-689
of	O	690-692
pain	B	693-697
,	O	697-698
suggesting	O	699-709
that	O	710-714
the	O	715-718
frontotemporal	O	719-733
region	O	734-740
is	O	741-743
of	O	744-746
crucial	O	747-754
importance	O	755-765
in	O	766-768
the	O	769-772
development	O	773-784
of	O	785-787
a	O	788-789
migraine	B	790-798
crisis	O	799-805
.	O	805-806

This	O	807-811
is	O	812-814
not	O	815-818
consistent	O	819-829
with	O	830-834
a	O	835-836
CNS	O	837-840
origin	O	841-847
of	O	848-850
migraine	B	851-859
attack	O	860-866
.	O	866-867

Clotiazepam	O	0-11
-	O	11-12
induced	O	12-19
acute	O	20-25
hepatitis	B	26-35
.	O	35-36

We	O	37-39
report	O	40-46
the	O	47-50
case	O	51-55
of	O	56-58
a	O	59-60
patient	O	61-68
who	O	69-72
developed	O	73-82
acute	O	83-88
hepatitis	B	89-98
with	O	99-103
extensive	B	104-113
hepatocellular	I	114-128
necrosis	I	129-137
,	O	137-138
7	O	139-140
months	O	141-147
after	O	148-153
the	O	154-157
onset	O	158-163
of	O	164-166
administration	O	167-181
of	O	182-184
clotiazepam	O	185-196
,	O	196-197
a	O	198-199
thienodiazepine	O	200-215
derivative	O	216-226
.	O	226-227

Clotiazepam	O	228-239
withdrawal	O	240-250
was	O	251-254
followed	O	255-263
by	O	264-266
prompt	O	267-273
recovery	O	274-282
.	O	282-283

The	O	284-287
administration	O	288-302
of	O	303-305
several	O	306-313
benzodiazepines	O	314-329
,	O	329-330
chemically	O	331-341
related	O	342-349
to	O	350-352
clotiazepam	O	353-364
,	O	364-365
did	O	366-369
not	O	370-373
interfere	O	374-383
with	O	384-388
recovery	O	389-397
and	O	398-401
did	O	402-405
not	O	406-409
induce	O	410-416
any	O	417-420
relapse	O	421-428
of	O	429-431
hepatitis	B	432-441
.	O	441-442

This	O	443-447
observation	O	448-459
shows	O	460-465
that	O	466-470
clotiazepam	O	471-482
can	O	483-486
induce	O	487-493
acute	O	494-499
hepatitis	B	500-509
and	O	510-513
suggests	O	514-522
that	O	523-527
there	O	528-533
is	O	534-536
no	O	537-539
cross	O	540-545
hepatotoxicity	B	546-560
between	O	561-568
clotiazepam	O	569-580
and	O	581-584
several	O	585-592
benzodiazepines	O	593-608
.	O	608-609

Arterial	O	0-8
hypertension	B	9-21
as	O	22-24
a	O	25-26
complication	O	27-39
of	O	40-42
prolonged	O	43-52
ketoconazole	O	53-65
treatment	O	66-75
.	O	75-76

Two	O	77-80
of	O	81-83
14	O	84-86
patients	O	87-95
with	O	96-100
Cushing	B	101-108
'	I	108-109
s	I	103-104
syndrome	I	111-119
treated	O	120-127
on	O	128-130
a	O	131-132
long	O	133-137
-	O	137-138
term	O	138-142
basis	O	143-148
with	O	149-153
ketoconazole	O	154-166
developed	O	167-176
sustained	O	177-186
hypertension	B	187-199
.	O	199-200

In	O	201-203
both	O	204-208
cases	O	209-214
normal	O	215-221
plasma	O	222-228
and	O	229-232
urinary	O	233-240
free	O	241-245
cortisol	O	246-254
levels	O	255-261
had	O	262-265
been	O	266-270
achieved	O	271-279
following	O	280-289
ketoconazole	O	290-302
therapy	O	303-310
,	O	310-311
yet	O	312-315
continuous	O	316-326
blood	O	327-332
pressure	O	333-341
monitoring	O	342-352
demonstrated	O	353-365
hypertension	B	366-378
31	O	379-381
(	O	382-383
patient	O	383-390
1	O	391-392
)	O	392-393
and	O	394-397
52	O	398-400
weeks	O	401-406
(	O	407-408
patient	O	408-415
2	O	416-417
)	O	417-418
after	O	419-424
treatment	O	425-434
.	O	434-435

In	O	436-438
patient	O	439-446
1	O	447-448
,	O	448-449
plasma	O	450-456
levels	O	457-463
of	O	464-466
deoxycorticosterone	O	467-486
and	O	487-490
11	O	491-493
-	O	493-494
deoxycortisol	O	494-507
were	O	508-512
elevated	O	513-521
.	O	521-522

In	O	523-525
patient	O	526-533
2	O	534-535
,	O	535-536
in	O	537-539
addition	O	540-548
to	O	549-551
an	O	552-554
increase	O	555-563
in	O	564-566
both	O	567-571
deoxycorticosterone	O	572-591
and	O	592-595
11	O	596-598
-	O	598-599
deoxycortisol	O	599-612
levels	O	613-619
,	O	619-620
plasma	O	621-627
aldosterone	O	628-639
values	O	640-646
were	O	647-651
raised	O	652-658
,	O	658-659
with	O	660-664
a	O	665-666
concomitant	O	667-678
suppression	O	679-690
of	O	691-693
renin	O	694-699
levels	O	700-706
.	O	706-707

Our	O	708-711
findings	O	712-720
show	O	721-725
that	O	726-730
long	O	731-735
-	O	735-736
term	O	736-740
treatment	O	741-750
with	O	751-755
high	O	756-760
doses	O	761-766
of	O	767-769
ketoconazole	O	770-782
may	O	783-786
induce	O	787-793
enzyme	O	794-800
blockade	O	801-809
leading	O	810-817
to	O	818-820
mineralocorticoid	O	821-838
-	O	838-839
related	O	839-846
hypertension	B	847-859
.	O	859-860

Effects	O	0-7
of	O	8-10
an	O	11-13
inhibitor	O	14-23
of	O	24-26
angiotensin	O	27-38
converting	O	39-49
enzyme	O	50-56
(	O	57-58
Captopril	O	58-67
)	O	67-68
on	O	69-71
pulmonary	B	72-81
and	I	82-85
renal	I	86-91
insufficiency	I	92-105
due	O	106-109
to	O	110-112
intravascular	B	113-126
coagulation	I	127-138
in	O	139-141
the	O	142-145
rat	O	146-149
.	O	149-150

Induction	O	151-160
of	O	161-163
intravascular	B	164-177
coagulation	I	178-189
and	O	190-193
inhibition	O	194-204
of	O	205-207
fibrinolysis	O	208-220
by	O	221-223
injection	O	224-233
of	O	234-236
thrombin	O	237-245
and	O	246-249
tranexamic	O	250-260
acid	O	261-265
(	O	266-267
AMCA	O	267-271
)	O	271-272
in	O	273-275
the	O	276-279
rat	O	280-283
gives	O	284-289
rise	O	290-294
to	O	295-297
pulmonary	B	298-307
and	I	308-311
renal	I	312-317
insufficiency	I	318-331
resembling	O	332-342
that	O	343-347
occurring	O	348-357
after	O	358-363
trauma	B	364-370
or	O	371-373
sepsis	B	374-380
in	O	381-383
man	O	384-387
.	O	387-388

Injection	O	389-398
of	O	399-401
Captopril	O	402-411
(	O	412-413
1	O	413-414
mg	O	415-417
/	O	417-418
kg	O	418-420
)	O	420-421
,	O	421-422
an	O	423-425
inhibitor	O	426-435
of	O	436-438
angiotensin	O	439-450
converting	O	451-461
enzyme	O	462-468
(	O	469-470
ACE	O	470-473
)	O	473-474
,	O	474-475
reduced	O	476-483
both	O	484-488
pulmonary	B	489-498
and	I	499-502
renal	I	503-508
insufficiency	I	509-522
in	O	523-525
this	O	526-530
rat	O	531-534
model	O	535-540
.	O	540-541

The	O	542-545
lung	O	546-550
weights	O	551-558
were	O	559-563
lower	O	564-569
and	O	570-573
PaO2	O	574-578
was	O	579-582
improved	O	583-591
in	O	592-594
rats	O	595-599
given	O	600-605
this	O	606-610
enzyme	O	611-617
-	O	617-618
blocking	O	618-626
agent	O	627-632
.	O	632-633

The	O	634-637
contents	O	638-646
of	O	647-649
albumin	O	650-657
in	O	658-660
the	O	661-664
lungs	O	665-670
were	O	671-675
not	O	676-679
changed	O	680-687
,	O	687-688
indicating	O	689-699
that	O	700-704
Captopril	O	705-714
did	O	715-718
not	O	719-722
influence	O	723-732
the	O	733-736
extravasation	O	737-750
of	O	751-753
protein	O	754-761
.	O	761-762

Renal	B	763-768
damage	I	769-775
as	O	776-778
reflected	O	779-788
by	O	789-791
an	O	792-794
increase	O	795-803
in	O	804-806
serum	O	807-812
urea	O	813-817
and	O	818-821
in	O	822-824
kidney	O	825-831
weight	O	832-838
was	O	839-842
prevented	O	843-852
by	O	853-855
Captopril	O	856-865
.	O	865-866

The	O	867-870
amount	O	871-877
of	O	878-880
fibrin	O	881-887
in	O	888-890
the	O	891-894
kidneys	O	895-902
was	O	903-906
also	O	907-911
considerably	O	912-924
lower	O	925-930
than	O	931-935
in	O	936-938
animals	O	939-946
which	O	947-952
received	O	953-961
thrombin	O	962-970
and	O	971-974
AMCA	O	975-979
alone	O	980-985
.	O	985-986

It	O	987-989
is	O	990-992
suggested	O	993-1002
that	O	1003-1007
the	O	1008-1011
effects	O	1012-1019
of	O	1020-1022
Captopril	O	1023-1032
on	O	1033-1035
the	O	1036-1039
lungs	O	1040-1045
may	O	1046-1049
be	O	1050-1052
attributable	O	1053-1065
to	O	1066-1068
a	O	1069-1070
vasodilatory	O	1071-1083
effect	O	1084-1090
due	O	1091-1094
to	O	1095-1097
a	O	1098-1099
reduction	O	1100-1109
in	O	1110-1112
the	O	1113-1116
circulating	O	1117-1128
level	O	1129-1134
of	O	1135-1137
Angiotension	O	1138-1150
II	O	1151-1153
and	O	1154-1157
an	O	1158-1160
increase	O	1161-1169
in	O	1170-1172
prostacyclin	O	1173-1185
(	O	1186-1187
secondary	O	1187-1196
to	O	1197-1199
an	O	1200-1202
increase	O	1203-1211
in	O	1212-1214
bradykinin	O	1215-1225
)	O	1225-1226
.	O	1226-1227

Captopril	O	1228-1237
may	O	1238-1241
,	O	1241-1242
by	O	1243-1245
the	O	1246-1249
same	O	1250-1254
mechanism	O	1255-1264
,	O	1264-1265
reduce	O	1266-1272
the	O	1273-1276
increase	O	1277-1285
in	O	1286-1288
glomerular	O	1289-1299
filtration	O	1300-1310
that	O	1311-1315
is	O	1316-1318
known	O	1319-1324
to	O	1325-1327
occur	O	1328-1333
after	O	1334-1339
an	O	1340-1342
injection	O	1343-1352
of	O	1353-1355
thrombin	O	1356-1364
,	O	1364-1365
thereby	O	1366-1373
diminishing	O	1374-1385
the	O	1386-1389
aggregation	O	1390-1401
of	O	1402-1404
fibrin	O	1405-1411
monomers	O	1412-1420
in	O	1421-1423
the	O	1424-1427
glomeruli	O	1428-1437
,	O	1437-1438
with	O	1439-1443
the	O	1444-1447
result	O	1448-1454
that	O	1455-1459
less	O	1460-1464
fibrin	O	1465-1471
will	O	1472-1476
be	O	1477-1479
deposited	O	1480-1489
and	O	1490-1493
thus	O	1494-1498
less	O	1499-1503
kidney	B	1504-1510
damage	I	1511-1517
will	O	1518-1522
be	O	1523-1525
produced	O	1526-1534
.	O	1534-1535

A	O	0-1
randomized	O	2-12
comparison	O	13-23
of	O	24-26
labetalol	O	27-36
and	O	37-40
nitroprusside	O	41-54
for	O	55-58
induced	O	59-66
hypotension	B	67-78
.	O	78-79

In	O	80-82
a	O	83-84
randomized	O	85-95
study	O	96-101
,	O	101-102
labetalol	O	103-112
-	O	112-113
induced	O	113-120
hypotension	B	121-132
and	O	133-136
nitroprusside	O	137-150
-	O	150-151
induced	O	151-158
hypotension	B	159-170
were	O	171-175
compared	O	176-184
in	O	185-187
20	O	188-190
patients	O	191-199
(	O	200-201
10	O	201-203
in	O	204-206
each	O	207-211
group	O	212-217
)	O	217-218
scheduled	O	219-228
for	O	229-232
major	O	233-238
orthopedic	O	239-249
procedures	O	250-260
.	O	260-261

Each	O	262-266
patient	O	267-274
was	O	275-278
subjected	O	279-288
to	O	289-291
an	O	292-294
identical	O	295-304
anesthetic	O	305-315
protocol	O	316-324
and	O	325-328
similar	O	329-336
drug	O	337-341
-	O	341-342
induced	O	342-349
reductions	B	350-360
in	I	361-363
mean	I	364-368
arterial	I	369-377
blood	I	378-383
pressure	I	384-392
(	O	393-394
BP	O	394-396
)	O	396-397
(	O	398-399
50	O	399-401
to	O	402-404
55	O	405-407
mmHg	O	408-412
)	O	412-413
.	O	413-414

Nitroprusside	O	415-428
infusion	O	429-437
was	O	438-441
associated	O	442-452
with	O	453-457
a	O	458-459
significant	O	460-471
(	O	472-473
p	O	473-474
less	O	475-479
than	O	480-484
0	O	485-486
.	O	486-487
05	O	487-489
)	O	489-490
increase	B	491-499
in	I	500-502
heart	I	503-508
rate	I	509-513
and	I	514-517
cardiac	I	518-525
output	I	526-532
;	O	532-533
rebound	O	534-541
hypertension	B	542-554
was	O	555-558
observed	O	559-567
in	O	568-570
three	O	571-576
patients	O	577-585
after	O	586-591
discontinuation	O	592-607
of	O	608-610
nitroprusside	O	611-624
.	O	624-625

Labetalol	O	626-635
administration	O	636-650
was	O	651-654
not	O	655-658
associated	O	659-669
with	O	670-674
any	O	675-678
of	O	679-681
these	O	682-687
findings	O	688-696
.	O	696-697

Arterial	O	698-706
PO2	O	707-710
decreased	O	711-720
in	O	721-723
both	O	724-728
groups	O	729-735
.	O	735-736

It	O	737-739
was	O	740-743
concluded	O	744-753
that	O	754-758
labetalol	O	759-768
offers	O	769-775
advantages	O	776-786
over	O	787-791
nitroprusside	O	792-805
.	O	805-806

Chronic	O	0-7
carbamazepine	O	8-21
treatment	O	22-31
in	O	32-34
the	O	35-38
rat	O	39-42
:	O	42-43
efficacy	O	44-52
,	O	52-53
toxicity	B	54-62
,	O	62-63
and	O	64-67
effect	O	68-74
on	O	75-77
plasma	O	78-84
and	O	85-88
tissue	O	89-95
folate	O	96-102
concentrations	O	103-117
.	O	117-118

Folate	O	119-125
depletion	O	126-135
has	O	136-139
often	O	140-145
been	O	146-150
a	O	151-152
problem	O	153-160
in	O	161-163
chronic	O	164-171
antiepileptic	O	172-185
drug	O	186-190
(	O	191-192
AED	O	192-195
)	O	195-196
therapy	O	197-204
.	O	204-205

Carbamazepine	O	206-219
(	O	220-221
CBZ	O	221-224
)	O	224-225
,	O	225-226
a	O	227-228
commonly	O	229-237
used	O	238-242
AED	O	243-246
,	O	246-247
has	O	248-251
been	O	252-256
implicated	O	257-267
in	O	268-270
some	O	271-275
clinical	O	276-284
studies	O	285-292
.	O	292-293

A	O	294-295
rat	O	296-299
model	O	300-305
was	O	306-309
developed	O	310-319
to	O	320-322
examine	O	323-330
the	O	331-334
effects	O	335-342
of	O	343-345
chronic	O	346-353
CBZ	O	354-357
treatment	O	358-367
on	O	368-370
folate	O	371-377
concentrations	O	378-392
in	O	393-395
the	O	396-399
rat	O	400-403
.	O	403-404

In	O	405-407
the	O	408-411
course	O	412-418
of	O	419-421
developing	O	422-432
this	O	433-437
model	O	438-443
,	O	443-444
a	O	445-446
common	O	447-453
vehicle	O	454-461
,	O	461-462
propylene	O	463-472
glycol	O	473-479
,	O	479-480
by	O	481-483
itself	O	484-490
in	O	491-493
high	O	494-498
doses	O	499-504
,	O	504-505
was	O	506-509
found	O	510-515
to	O	516-518
exhibit	O	519-526
protective	O	527-537
properties	O	538-548
against	O	549-556
induced	O	557-564
seizures	B	565-573
and	O	574-577
inhibited	O	578-587
weight	B	588-594
gain	I	595-599
.	O	599-600

Seizures	B	601-609
induced	O	610-617
by	O	618-620
hexafluorodiethyl	O	621-638
ether	O	639-644
(	O	645-646
HFDE	O	646-650
)	O	650-651
were	O	652-656
also	O	657-661
found	O	662-667
to	O	668-670
be	O	671-673
a	O	674-675
more	O	676-680
sensitive	O	681-690
measure	O	691-698
of	O	699-701
protection	O	702-712
by	O	713-715
CBZ	O	716-719
than	O	720-724
seizures	B	725-733
induced	O	734-741
by	O	742-744
maximal	O	745-752
electroshock	O	753-765
(	O	766-767
MES	O	767-770
)	O	770-771
.	O	771-772

Oral	O	773-777
administration	O	778-792
of	O	793-795
CBZ	O	796-799
as	O	800-802
an	O	803-805
aqueous	O	806-813
suspension	O	814-824
every	O	825-830
8	O	831-832
h	O	833-834
at	O	835-837
a	O	838-839
dose	O	840-844
of	O	845-847
250	O	848-851
mg	O	852-854
/	O	854-855
kg	O	855-857
was	O	858-861
continuously	O	862-874
protective	O	875-885
against	O	886-893
HFDE	O	894-898
-	O	898-899
induced	O	899-906
seizures	B	907-915
and	O	916-919
was	O	920-923
minimally	O	924-933
toxic	O	934-939
as	O	940-942
measured	O	943-951
by	O	952-954
weight	B	955-961
gain	I	962-966
over	O	967-971
8	O	972-973
weeks	O	974-979
of	O	980-982
treatment	O	983-992
.	O	992-993

The	O	994-997
CBZ	O	998-1001
levels	O	1002-1008
measured	O	1009-1017
in	O	1018-1020
plasma	O	1021-1027
and	O	1028-1031
brain	O	1032-1037
of	O	1038-1040
these	O	1041-1046
animals	O	1047-1054
,	O	1054-1055
however	O	1056-1063
,	O	1063-1064
were	O	1065-1069
below	O	1070-1075
those	O	1076-1081
normally	O	1082-1090
considered	O	1091-1101
protective	O	1102-1112
.	O	1112-1113

This	O	1114-1118
treatment	O	1119-1128
with	O	1129-1133
CBZ	O	1134-1137
had	O	1138-1141
no	O	1142-1144
apparent	O	1145-1153
adverse	O	1154-1161
effect	O	1162-1168
on	O	1169-1171
folate	O	1172-1178
concentrations	O	1179-1193
in	O	1194-1196
the	O	1197-1200
rat	O	1201-1204
,	O	1204-1205
and	O	1206-1209
,	O	1209-1210
indeed	O	1211-1217
,	O	1217-1218
the	O	1219-1222
folate	O	1223-1229
concentration	O	1230-1243
increased	O	1244-1253
in	O	1254-1256
liver	O	1257-1262
after	O	1263-1268
6	O	1269-1270
weeks	O	1271-1276
of	O	1277-1279
treatment	O	1280-1289
and	O	1290-1293
in	O	1294-1296
plasma	O	1297-1303
at	O	1304-1306
8	O	1307-1308
weeks	O	1309-1314
of	O	1315-1317
treatment	O	1318-1327
.	O	1327-1328

Inhibition	O	0-10
of	O	11-13
sympathoadrenal	O	14-29
activity	O	30-38
by	O	39-41
atrial	O	42-48
natriuretic	O	49-60
factor	O	61-67
in	O	68-70
dogs	O	71-75
.	O	75-76

In	O	77-79
six	O	80-83
conscious	O	84-93
,	O	93-94
trained	O	95-102
dogs	O	103-107
,	O	107-108
maintained	O	109-119
on	O	120-122
a	O	123-124
normal	O	125-131
sodium	O	132-138
intake	O	139-145
of	O	146-148
2	O	149-150
to	O	151-153
4	O	154-155
mEq	O	156-159
/	O	159-160
kg	O	160-162
/	O	159-160
day	O	163-166
,	O	166-167
sympathetic	O	168-179
activity	O	180-188
was	O	189-192
assessed	O	193-201
as	O	202-204
the	O	205-208
release	O	209-216
rate	O	217-221
of	O	222-224
norepinephrine	O	225-239
and	O	240-243
epinephrine	O	244-255
during	O	256-262
15	O	263-265
-	O	265-266
minute	O	266-272
i	O	273-274
.	O	274-275
v	O	275-276
.	O	274-275

infusions	O	278-287
of	O	288-290
human	O	291-296
alpha	O	297-302
-	O	302-303
atrial	O	303-309
natriuretic	O	310-321
factor	O	322-328
.	O	328-329

Mean	O	330-334
arterial	O	335-343
pressure	O	344-352
(	O	353-354
as	O	354-356
a	O	357-358
percentage	O	359-369
of	O	370-372
control	O	373-380
+	O	381-382
/	O	382-383
-	O	383-384
SEM	O	385-388
)	O	388-389
during	O	390-396
randomized	O	397-407
infusions	O	408-417
of	O	418-420
0	O	421-422
.	O	422-423
03	O	423-425
,	O	425-426
0	O	427-428
.	O	428-429
1	O	429-430
,	O	430-431
0	O	432-433
.	O	433-434
3	O	434-435
,	O	435-436
or	O	437-439
1	O	440-441
.	O	441-442
0	O	442-443
microgram	O	444-453
/	O	453-454
kg	O	454-456
/	O	453-454
min	O	457-460
was	O	461-464
99	O	465-467
+	O	468-469
/	O	469-470
-	O	470-471
1	O	472-473
,	O	473-474
95	O	475-477
+	O	478-479
/	O	479-480
-	O	480-481
1	O	482-483
(	O	484-485
p	O	485-486
less	O	487-491
than	O	492-496
0	O	497-498
.	O	498-499
05	O	499-501
)	O	501-502
,	O	502-503
93	O	504-506
+	O	507-508
/	O	508-509
-	O	509-510
1	O	511-512
(	O	513-514
p	O	514-515
less	O	516-520
than	O	521-525
0	O	526-527
.	O	527-528
01	O	528-530
)	O	530-531
,	O	531-532
or	O	533-535
79	O	536-538
+	O	539-540
/	O	540-541
-	O	541-542
6	O	543-544
%	O	544-545
(	O	546-547
p	O	547-548
less	O	549-553
than	O	554-558
0	O	559-560
.	O	560-561
001	O	561-564
)	O	564-565
,	O	565-566
respectively	O	567-579
,	O	579-580
but	O	581-584
no	O	585-587
tachycardia	B	588-599
and	O	600-603
no	O	604-606
augmentation	O	607-619
of	O	620-622
the	O	623-626
norepinephrine	O	627-641
release	O	642-649
rate	O	650-654
(	O	655-656
up	O	656-658
to	O	659-661
0	O	662-663
.	O	663-664
3	O	664-665
microgram	O	666-675
/	O	675-676
kg	O	676-678
/	O	675-676
min	O	679-682
)	O	682-683
were	O	684-688
observed	O	689-697
,	O	697-698
which	O	699-704
is	O	705-707
in	O	708-710
contrast	O	711-719
to	O	720-722
comparable	O	723-733
hypotension	B	734-745
induced	O	746-753
by	O	754-756
hydralazine	O	757-768
or	O	769-771
nitroglycerin	O	772-785
.	O	785-786

The	O	787-790
release	O	791-798
rate	O	799-803
of	O	804-806
epinephrine	O	807-818
(	O	819-820
control	O	820-827
,	O	827-828
6	O	829-830
.	O	830-831
7	O	831-832
+	O	833-834
/	O	834-835
-	O	835-836
0	O	837-838
.	O	838-839
6	O	839-840
ng	O	841-843
/	O	843-844
kg	O	844-846
/	O	843-844
min	O	847-850
)	O	850-851
declined	O	852-860
immediately	O	861-872
during	O	873-879
infusions	O	880-889
of	O	890-892
atrial	O	893-899
natriuretic	O	900-911
factor	O	912-918
to	O	919-921
a	O	922-923
minimum	O	924-931
of	O	932-934
49	O	935-937
+	O	938-939
/	O	939-940
-	O	940-941
5	O	942-943
%	O	943-944
of	O	945-947
control	O	948-955
(	O	956-957
p	O	957-958
less	O	959-963
than	O	964-968
0	O	969-970
.	O	970-971
001	O	971-974
)	O	974-975
during	O	976-982
0	O	983-984
.	O	984-985
1	O	985-986
microgram	O	987-996
/	O	996-997
kg	O	997-999
/	O	996-997
min	O	1000-1003
and	O	1004-1007
to	O	1008-1010
63	O	1011-1013
+	O	1014-1015
/	O	1015-1016
-	O	1016-1017
5	O	1018-1019
%	O	1019-1020
(	O	1021-1022
0	O	1022-1023
.	O	1023-1024
1	O	1024-1025
greater	O	1026-1033
than	O	1034-1038
p	O	1039-1040
greater	O	1041-1048
than	O	1049-1053
0	O	1054-1055
.	O	1055-1056
05	O	1056-1058
)	O	1058-1059
or	O	1060-1062
95	O	1063-1065
+	O	1066-1067
/	O	1067-1068
-	O	1068-1069
13	O	1070-1072
%	O	1072-1073
(	O	1074-1075
not	O	1075-1078
significant	O	1079-1090
)	O	1090-1091
during	O	1092-1098
0	O	1099-1100
.	O	1100-1101
3	O	1101-1102
or	O	1103-1105
1	O	1106-1107
.	O	1107-1108
0	O	1108-1109
microgram	O	1110-1119
/	O	1119-1120
kg	O	1120-1122
/	O	1119-1120
min	O	1123-1126
.	O	1126-1127

Steady	O	1128-1134
state	O	1135-1140
arterial	O	1141-1149
plasma	O	1150-1156
concentrations	O	1157-1171
of	O	1172-1174
atrial	O	1175-1181
natriuretic	O	1182-1193
factor	O	1194-1200
were	O	1201-1205
39	O	1206-1208
+	O	1209-1210
/	O	1210-1211
-	O	1211-1212
10	O	1213-1215
pg	O	1216-1218
/	O	1218-1219
ml	O	1219-1221
(	O	1222-1223
n	O	1223-1224
=	O	1225-1226
6	O	1227-1228
)	O	1228-1229
during	O	1230-1236
infusions	O	1237-1246
of	O	1247-1249
saline	O	1250-1256
and	O	1257-1260
284	O	1261-1264
+	O	1265-1266
/	O	1266-1267
-	O	1267-1268
24	O	1269-1271
pg	O	1272-1274
/	O	1274-1275
ml	O	1275-1277
(	O	1278-1279
n	O	1279-1280
=	O	1281-1282
6	O	1283-1284
)	O	1284-1285
and	O	1286-1289
1520	O	1290-1294
+	O	1295-1296
/	O	1296-1297
-	O	1297-1298
300	O	1299-1302
pg	O	1303-1305
/	O	1305-1306
ml	O	1306-1308
(	O	1309-1310
n	O	1310-1311
=	O	1312-1313
9	O	1314-1315
)	O	1315-1316
during	O	1317-1323
0	O	1324-1325
.	O	1325-1326
03	O	1326-1328
and	O	1329-1332
0	O	1333-1334
.	O	1334-1335
1	O	1335-1336
microgram	O	1337-1346
/	O	1346-1347
kg	O	1347-1349
/	O	1346-1347
min	O	1350-1353
infusions	O	1354-1363
of	O	1364-1366
the	O	1367-1370
factor	O	1371-1377
.	O	1377-1378
(	O	1378-1379
ABSTRACT	O	1379-1387

TRUNCATED	O	1388-1397
AT	O	1398-1400
250	O	1401-1404
WORDS	O	1405-1410
)	O	1410-1411

Death	B	0-5
from	O	6-10
chemotherapy	O	11-23
in	O	24-26
gestational	B	27-38
trophoblastic	I	39-52
disease	I	53-60
.	O	60-61

Multiple	O	62-70
cytotoxic	O	71-80
drug	O	81-85
administration	O	86-100
is	O	101-103
the	O	104-107
generally	O	108-117
accepted	O	118-126
treatment	O	127-136
of	O	137-139
patients	O	140-148
with	O	149-153
a	O	154-155
high	O	156-160
-	O	160-161
risk	O	161-165
stage	O	166-171
of	O	172-174
choriocarcinoma	B	175-190
.	O	190-191

Based	O	192-197
on	O	198-200
this	O	201-205
principle	O	206-215
a	O	216-217
27	O	218-220
-	O	220-221
year	O	221-225
old	O	226-229
woman	O	230-235
,	O	235-236
classified	O	237-247
as	O	248-250
being	O	251-256
in	O	257-259
the	O	260-263
high	O	264-268
-	O	268-269
risk	O	269-273
group	O	274-279
(	O	280-281
Goldstein	O	281-290
and	O	291-294
Berkowitz	O	295-304
score	O	305-310
:	O	310-311
11	O	312-314
)	O	314-315
,	O	315-316
was	O	317-320
treated	O	321-328
with	O	329-333
multiple	O	334-342
cytotoxic	O	343-352
drugs	O	353-358
.	O	358-359

The	O	360-363
multiple	O	364-372
drug	O	373-377
schema	O	378-384
consisted	O	385-394
of	O	395-397
:	O	397-398
Etoposide	O	399-408
16	O	409-411
.	O	411-412
213	O	412-415
,	O	415-416
Methotrexate	O	417-429
,	O	429-430
Cyclophosphamide	O	431-447
,	O	447-448
Actomycin	O	449-458
-	O	458-459
D	O	459-460
,	O	460-461
and	O	462-465
Cisplatin	O	466-475
.	O	475-476

On	O	477-479
the	O	480-483
first	O	484-489
day	O	490-493
of	O	494-496
the	O	497-500
schedule	O	501-509
,	O	509-510
moderate	O	511-519
high	O	520-524
doses	O	525-530
of	O	531-533
Methotrexate	O	534-546
,	O	546-547
Etoposide	O	548-557
and	O	558-561
Cyclophosphamide	O	562-578
were	O	579-583
administered	O	584-596
.	O	596-597

Within	O	598-604
8	O	605-606
hours	O	607-612
after	O	613-618
initiation	O	619-629
of	O	630-632
therapy	O	633-640
the	O	641-644
patient	O	645-652
died	O	653-657
with	O	658-662
a	O	663-664
clinical	O	665-673
picture	O	674-681
resembling	O	682-692
massive	O	693-700
pulmonary	B	701-710
obstruction	I	711-722
due	O	723-726
to	O	727-729
choriocarcinomic	O	730-746
tissue	O	747-753
plugs	O	754-759
,	O	759-760
probably	O	761-769
originating	O	770-781
from	O	782-786
the	O	787-790
uterus	O	791-797
.	O	797-798

Formation	O	799-808
of	O	809-811
these	O	812-817
plugs	O	818-823
was	O	824-827
probably	O	828-836
due	O	837-840
to	O	841-843
extensive	O	844-853
tumor	B	854-859
necrosis	B	860-868
at	O	869-871
the	O	872-875
level	O	876-881
of	O	882-884
the	O	885-888
walls	O	889-894
of	O	895-897
the	O	898-901
major	O	902-907
uterine	O	908-915
veins	O	916-921
,	O	921-922
which	O	923-928
resulted	O	929-937
in	O	938-940
an	O	941-943
open	O	944-948
exchange	O	949-957
of	O	958-960
tumor	B	961-966
plugs	O	967-972
to	O	973-975
the	O	976-979
vascular	O	980-988
spaces	O	989-995
;	O	995-996
decrease	O	997-1005
in	O	1006-1008
tumor	B	1009-1014
tissue	O	1015-1021
coherence	O	1022-1031
secondary	O	1032-1041
to	O	1042-1044
chemotherapy	O	1045-1057
may	O	1058-1061
have	O	1062-1066
further	O	1067-1074
contributed	O	1075-1086
to	O	1087-1089
the	O	1090-1093
formation	O	1094-1103
of	O	1104-1106
tumor	B	1107-1112
emboli	O	1113-1119
.	O	1119-1120

In	O	1121-1123
view	O	1124-1128
of	O	1129-1131
the	O	1132-1135
close	O	1136-1141
time	O	1142-1146
association	O	1147-1158
between	O	1159-1166
the	O	1167-1170
start	O	1171-1176
of	O	1177-1179
chemotherapy	O	1180-1192
and	O	1193-1196
the	O	1197-1200
acute	O	1201-1206
onset	O	1207-1212
of	O	1213-1215
massive	O	1216-1223
embolism	B	1224-1232
other	O	1233-1238
explanations	O	1239-1251
,	O	1251-1252
such	O	1253-1257
as	O	1258-1260
spontaneous	O	1261-1272
necrosis	B	1273-1281
,	O	1281-1282
must	O	1283-1287
be	O	1288-1290
considered	O	1291-1301
less	O	1302-1306
likely	O	1307-1313
.	O	1313-1314

Patients	O	1315-1323
with	O	1324-1328
large	O	1329-1334
pelvic	B	1335-1341
tumor	I	1342-1347
loads	O	1348-1353
are	O	1354-1357
,	O	1357-1358
according	O	1359-1368
to	O	1369-1371
existing	O	1372-1380
classifications	O	1381-1396
,	O	1396-1397
at	O	1398-1400
high	O	1401-1405
risk	O	1406-1410
to	O	1411-1413
die	O	1414-1417
and	O	1418-1421
to	O	1422-1424
develop	O	1425-1432
drug	O	1433-1437
resistance	O	1438-1448
.	O	1448-1449

Notwithstanding	O	1450-1465
these	O	1466-1471
facts	O	1472-1477
our	O	1478-1481
findings	O	1482-1490
suggest	O	1491-1498
that	O	1499-1503
these	O	1504-1509
patients	O	1510-1518
might	O	1519-1524
benefit	O	1525-1532
from	O	1533-1537
relatively	O	1538-1548
mild	O	1549-1553
initial	O	1554-1561
treatment	O	1562-1571
,	O	1571-1572
especially	O	1573-1583
true	O	1584-1588
for	O	1589-1592
patients	O	1593-1601
not	O	1602-1605
previously	O	1606-1616
exposed	O	1617-1624
to	O	1625-1627
this	O	1628-1632
drug	O	1633-1637
.	O	1637-1638

Close	O	1639-1644
observation	O	1645-1656
of	O	1657-1659
the	O	1660-1663
response	O	1664-1672
status	O	1673-1679
both	O	1680-1684
clinically	O	1685-1695
and	O	1696-1699
with	O	1700-1704
beta	O	1705-1709
-	O	1709-1710
hCG	O	1710-1713
values	O	1714-1720
may	O	1721-1724
indicate	O	1725-1733
whether	O	1734-1741
and	O	1742-1745
when	O	1746-1750
more	O	1751-1755
agressive	O	1756-1765
combination	O	1766-1777
chemotherapy	O	1778-1790
should	O	1791-1797
be	O	1798-1800
started	O	1801-1808
.	O	1808-1809
(	O	1809-1810
ABSTRACT	O	1810-1818

TRUNCATED	O	1819-1828
AT	O	1829-1831
250	O	1832-1835
WORDS	O	1836-1841
)	O	1841-1842

Sexual	B	0-6
dysfunction	I	7-18
among	O	19-24
patients	O	25-33
with	O	34-38
arthritis	B	39-48
.	O	48-49

The	O	50-53
relationship	O	54-66
of	O	67-69
arthritis	B	70-79
and	O	80-83
sexual	B	84-90
dysfunction	I	91-102
was	O	103-106
investigated	O	107-119
among	O	120-125
169	O	126-129
patients	O	130-138
with	O	139-143
rheumatoid	B	144-154
arthritis	I	155-164
,	O	164-165
osteoarthritis	B	166-180
and	O	181-184
spondyloarthropathy	B	185-204
,	O	204-205
130	O	206-209
of	O	210-212
whom	O	213-217
were	O	218-222
pair	O	223-227
-	O	227-228
matched	O	228-235
to	O	236-238
controls	O	239-247
.	O	247-248

Assessments	O	249-260
of	O	261-263
marital	O	264-271
happiness	O	272-281
and	O	282-285
depressed	B	286-295
mood	I	296-300
were	O	301-305
also	O	306-310
made	O	311-315
using	O	316-321
the	O	322-325
CES	O	326-329
-	O	329-330
D	O	330-331
and	O	332-335
the	O	336-339
Azrin	O	340-345
Marital	O	346-353
Happiness	O	354-363
Scale	O	364-369
(	O	370-371
AMHS	O	371-375
)	O	375-376
.	O	376-377

Sexual	B	378-384
dysfunctions	I	385-397
were	O	398-402
found	O	403-408
to	O	409-411
be	O	412-414
common	O	415-421
among	O	422-427
patients	O	428-436
and	O	437-440
controls	O	441-449
,	O	449-450
the	O	451-454
majority	O	455-463
in	O	464-466
both	O	467-471
groups	O	472-478
reporting	O	479-488
one	O	489-492
or	O	493-495
more	O	496-500
dysfunctions	O	501-513
.	O	513-514

Impotence	B	515-524
was	O	525-528
more	O	529-533
common	O	534-540
among	O	541-546
male	O	547-551
patients	O	552-560
than	O	561-565
controls	O	566-574
and	O	575-578
was	O	579-582
found	O	583-588
to	O	589-591
be	O	592-594
associated	O	595-605
with	O	606-610
co	O	611-613
-	O	613-614
morbidity	O	614-623
and	O	624-627
the	O	628-631
taking	O	632-638
of	O	639-641
methotrexate	O	642-654
.	O	654-655

Depressed	B	656-665
mood	I	666-670
was	O	671-674
more	O	675-679
common	O	680-686
among	O	687-692
patients	O	693-701
and	O	702-705
was	O	706-709
associated	O	710-720
with	O	721-725
certain	O	726-733
sexual	O	734-740
difficulties	O	741-753
,	O	753-754
but	O	755-758
not	O	759-762
with	O	763-767
impotence	B	768-777
.	O	777-778

Marital	O	779-786
unhappiness	O	787-798
,	O	798-799
as	O	800-802
indicated	O	803-812
by	O	813-815
AMHS	O	816-820
scores	O	821-827
,	O	827-828
was	O	829-832
not	O	833-836
associated	O	837-847
with	O	848-852
arthritis	B	853-862
but	O	863-866
was	O	867-870
associated	O	871-881
with	O	882-886
sexual	B	887-893
dysfunction	I	894-905
,	O	905-906
sexual	O	907-913
dissatisfaction	O	914-929
and	O	930-933
being	O	934-939
female	O	940-946
.	O	946-947

Does	O	0-4
paracetamol	O	5-16
cause	O	17-22
urothelial	B	23-33
cancer	I	34-40
or	O	41-43
renal	B	44-49
papillary	I	50-59
necrosis	I	60-68
?	O	68-69

The	O	70-73
risk	O	74-78
of	O	79-81
developing	O	82-92
renal	B	93-98
papillary	I	99-108
necrosis	I	109-117
or	O	118-120
cancer	B	121-127
of	I	128-130
the	I	131-134
renal	I	135-140
pelvis	I	141-147
,	I	147-148
ureter	I	149-155
or	I	156-158
bladder	I	159-166
associated	O	167-177
with	O	178-182
consumption	O	183-194
of	O	195-197
either	O	198-204
phenacetin	O	205-215
or	O	216-218
paracetamol	O	219-230
was	O	231-234
calculated	O	235-245
from	O	246-250
data	O	251-255
acquired	O	256-264
by	O	265-267
questionnaire	O	268-281
from	O	282-286
381	O	287-290
cases	O	291-296
and	O	297-300
808	O	301-304
controls	O	305-313
.	O	313-314

The	O	315-318
risk	O	319-323
of	O	324-326
renal	B	327-332
papillary	I	333-342
necrosis	I	343-351
was	O	352-355
increased	O	356-365
nearly	O	366-372
20	O	373-375
-	O	375-376
fold	O	376-380
by	O	381-383
consumption	O	384-395
of	O	396-398
phenacetin	O	399-409
,	O	409-410
which	O	411-416
also	O	417-421
increased	O	422-431
the	O	432-435
risk	O	436-440
for	O	441-444
cancer	B	445-451
of	I	452-454
the	I	455-458
renal	I	459-464
pelvis	I	465-471
and	I	472-475
bladder	I	476-483
but	O	484-487
not	O	488-491
for	O	492-495
ureteric	B	496-504
cancer	I	505-511
.	O	511-512

By	O	513-515
contrast	O	516-524
,	O	524-525
we	O	526-528
were	O	529-533
unable	O	534-540
to	O	541-543
substantiate	O	544-556
an	O	557-559
increased	O	560-569
risk	O	570-574
from	O	575-579
paracetamol	O	580-591
consumption	O	592-603
for	O	604-607
renal	B	608-613
papillary	I	614-623
necrosis	I	624-632
or	O	633-635
any	O	636-639
of	O	640-642
these	O	643-648
cancers	B	649-656
although	O	657-665
there	O	666-671
was	O	672-675
a	O	676-677
suggestion	O	678-688
of	O	689-691
an	O	692-694
association	O	695-706
with	O	707-711
cancer	B	712-718
of	I	719-721
the	I	722-725
ureter	I	726-732
.	O	732-733

Dapsone	O	0-7
-	O	7-8
associated	O	8-18
Heinz	O	19-24
body	O	25-29
hemolytic	B	30-39
anemia	I	40-46
in	O	47-49
a	O	50-51
Cambodian	O	52-61
woman	O	62-67
with	O	68-72
hemoglobin	O	73-83
E	O	84-85
trait	O	86-91
.	O	91-92

A	O	93-94
Cambodian	O	95-104
woman	O	105-110
with	O	111-115
hemoglobin	O	116-126
E	O	127-128
trait	O	129-134
(	O	135-136
AE	O	136-138
)	O	138-139
and	O	140-143
leprosy	B	144-151
developed	O	152-161
a	O	162-163
Heinz	O	164-169
body	O	170-174
hemolytic	B	175-184
anemia	I	185-191
while	O	192-197
taking	O	198-204
a	O	205-206
dose	O	207-211
of	O	212-214
dapsone	O	215-222
(	O	223-224
50	O	224-226
mg	O	227-229
/	O	229-230
day	O	230-233
)	O	233-234
not	O	235-238
usually	O	239-246
associated	O	247-257
with	O	258-262
clinical	O	263-271
hemolysis	B	272-281
.	O	281-282

Her	O	283-286
red	O	287-290
blood	O	291-296
cells	O	297-302
(	O	303-304
RBCs	O	304-308
)	O	308-309
had	O	310-313
increased	O	314-323
incubated	O	324-333
Heinz	O	334-339
body	O	340-344
formation	O	345-354
,	O	354-355
decreased	O	356-365
reduced	O	366-373
glutathione	O	374-385
(	O	386-387
GSH	O	387-390
)	O	390-391
,	O	391-392
and	O	393-396
decreased	O	397-406
GSH	O	407-410
stability	O	411-420
.	O	420-421

The	O	422-425
pentose	O	426-433
phosphate	O	434-443
shunt	O	444-449
activity	O	450-458
of	O	459-461
the	O	462-465
dapsone	O	466-473
-	O	473-474
exposed	O	474-481
AE	O	482-484
RBCs	O	485-489
was	O	490-493
increased	O	494-503
compared	O	504-512
to	O	513-515
normal	O	516-522
RBCs	O	523-527
.	O	527-528

Although	O	529-537
the	O	538-541
AE	O	542-544
RBCs	O	545-549
from	O	550-554
an	O	555-557
individual	O	558-568
not	O	569-572
taking	O	573-579
dapsone	O	580-587
had	O	588-591
increased	O	592-601
incubated	O	602-611
Heinz	O	612-617
body	O	618-622
formation	O	623-632
,	O	632-633
the	O	634-637
GSH	O	638-641
content	O	642-649
and	O	650-653
GSH	O	654-657
stability	O	658-667
were	O	668-672
normal	O	673-679
.	O	679-680

The	O	681-684
pentose	O	685-692
phosphate	O	693-702
shunt	O	703-708
activity	O	709-717
of	O	718-720
the	O	721-724
non	O	725-728
-	O	728-729
dapsone	O	729-736
-	O	728-729
exposed	O	737-744
AE	O	745-747
RBCs	O	748-752
was	O	753-756
decreased	O	757-766
compared	O	767-775
to	O	776-778
normal	O	779-785
RBCs	O	786-790
.	O	790-791

Thus	O	792-796
,	O	796-797
AE	O	798-800
RBCs	O	801-805
appear	O	806-812
to	O	813-815
have	O	816-820
an	O	821-823
increased	O	824-833
sensitivity	O	834-845
to	O	846-848
oxidant	O	849-856
stress	O	857-863
both	O	864-868
in	O	869-871
vitro	O	872-877
and	O	878-881
in	O	882-884
vivo	O	885-889
,	O	889-890
since	O	891-896
dapsone	O	897-904
does	O	905-909
not	O	910-913
cause	O	914-919
hemolytic	B	920-929
anemia	I	930-936
at	O	937-939
this	O	940-944
dose	O	945-949
in	O	950-952
hematologically	O	953-968
normal	O	969-975
individuals	O	976-987
.	O	987-988

Given	O	989-994
the	O	995-998
influx	O	999-1005
of	O	1006-1008
Southeast	O	1009-1018
Asians	O	1019-1025
into	O	1026-1030
the	O	1031-1034
United	O	1035-1041
States	O	1042-1048
,	O	1048-1049
oxidant	O	1050-1057
medications	O	1058-1069
should	O	1070-1076
be	O	1077-1079
used	O	1080-1084
with	O	1085-1089
caution	O	1090-1097
,	O	1097-1098
especially	O	1099-1109
if	O	1110-1112
an	O	1113-1115
infection	B	1116-1125
is	O	1126-1128
present	O	1129-1136
,	O	1136-1137
in	O	1138-1140
individuals	O	1141-1152
of	O	1153-1155
ethnic	O	1156-1162
backgrounds	O	1163-1174
that	O	1175-1179
have	O	1180-1184
an	O	1185-1187
increased	O	1188-1197
prevalence	O	1198-1208
of	O	1209-1211
hemoglobin	O	1212-1222
E	O	1223-1224
.	O	1224-1225

Severe	O	0-6
complications	O	7-20
of	O	21-23
antianginal	O	24-35
drug	O	36-40
therapy	O	41-48
in	O	49-51
a	O	52-53
patient	O	54-61
identified	O	62-72
as	O	73-75
a	O	76-77
poor	O	78-82
metabolizer	O	83-94
of	O	95-97
metoprolol	O	98-108
,	O	108-109
propafenone	O	110-121
,	O	121-122
diltiazem	O	123-132
,	O	132-133
and	O	134-137
sparteine	O	138-147
.	O	147-148

A	O	149-150
47	O	151-153
-	O	153-154
year	O	154-158
-	O	153-154
old	O	159-162
patient	O	163-170
suffering	O	171-180
from	O	181-185
coronary	B	186-194
artery	I	195-201
disease	I	202-209
was	O	210-213
admitted	O	214-222
to	O	223-225
the	O	226-229
CCU	O	230-233
in	O	234-236
shock	B	237-242
with	O	243-247
III	O	248-251
.	O	251-252

AV	B	253-255
block	I	256-261
,	O	261-262
severe	O	263-269
hypotension	B	270-281
,	O	281-282
and	O	283-286
impairment	B	287-297
of	I	298-300
ventricular	I	301-312
function	I	313-321
.	O	321-322

One	O	323-326
week	O	327-331
prior	O	332-337
to	O	338-340
admission	O	341-350
a	O	351-352
therapy	O	353-360
with	O	361-365
standard	O	366-374
doses	O	375-380
of	O	381-383
metoprolol	O	384-394
(	O	395-396
100	O	396-399
mg	O	400-402
t	O	403-404
.	O	404-405
i	O	405-406
.	O	404-405
d	O	407-408
.	O	404-405
and	O	410-413
then	O	414-418
100	O	419-422
mg	O	423-425
b	O	426-427
.	O	427-428
i	O	428-429
.	O	427-428
d	O	430-431
.	O	427-428
)	O	432-433
had	O	434-437
been	O	438-442
initiated	O	443-452
.	O	452-453

Two	O	454-457
days	O	458-462
before	O	463-469
admission	O	470-479
diltiazem	O	480-489
(	O	490-491
60	O	491-493
mg	O	494-496
b	O	497-498
.	O	498-499
i	O	499-500
.	O	498-499
d	O	501-502
.	O	498-499
)	O	503-504
was	O	505-508
prescribed	O	509-519
in	O	520-522
addition	O	523-531
.	O	531-532

Analyses	O	533-541
of	O	542-544
a	O	545-546
blood	O	547-552
sample	O	553-559
revealed	O	560-568
unusually	O	569-578
high	O	579-583
plasma	O	584-590
concentrations	O	591-605
of	O	606-608
metoprolol	O	609-619
(	O	620-621
greater	O	621-628
than	O	629-633
3000	O	634-638
ng	O	639-641
/	O	641-642
ml	O	642-644
)	O	644-645
and	O	646-649
diltiazem	O	650-659
(	O	660-661
526	O	661-664
ng	O	665-667
/	O	667-668
ml	O	668-670
)	O	670-671
.	O	671-672

The	O	673-676
patient	O	677-684
recovered	O	685-694
within	O	695-701
1	O	702-703
week	O	704-708
following	O	709-718
discontinuation	O	719-734
of	O	735-737
antianginal	O	738-749
therapy	O	750-757
.	O	757-758

Three	O	759-764
months	O	765-771
later	O	772-777
the	O	778-781
patient	O	782-789
was	O	790-793
exposed	O	794-801
to	O	802-804
a	O	805-806
single	O	807-813
dose	O	814-818
of	O	819-821
metoprolol	O	822-832
,	O	832-833
diltiazem	O	834-843
,	O	843-844
propafenone	O	845-856
(	O	857-858
since	O	858-863
he	O	864-866
had	O	867-870
received	O	871-879
this	O	880-884
drug	O	885-889
in	O	890-892
the	O	893-896
past	O	897-901
)	O	901-902
,	O	902-903
and	O	904-907
sparteine	O	908-917
(	O	918-919
as	O	919-921
a	O	922-923
probe	O	924-929
for	O	930-933
the	O	934-937
debrisoquine	O	938-950
/	O	950-951
sparteine	O	951-960
type	O	961-965
polymorphism	O	966-978
of	O	979-981
oxidative	O	982-991
drug	O	992-996
metabolism	O	997-1007
)	O	1007-1008
.	O	1008-1009

It	O	1010-1012
was	O	1013-1016
found	O	1017-1022
that	O	1023-1027
he	O	1028-1030
was	O	1031-1034
a	O	1035-1036
poor	O	1037-1041
metabolizer	O	1042-1053
of	O	1054-1056
all	O	1057-1060
four	O	1061-1065
drugs	O	1066-1071
,	O	1071-1072
indicating	O	1073-1083
that	O	1084-1088
their	O	1089-1094
metabolism	O	1095-1105
is	O	1106-1108
under	O	1109-1114
the	O	1115-1118
same	O	1119-1123
genetic	O	1124-1131
control	O	1132-1139
.	O	1139-1140

Therefore	O	1141-1150
,	O	1150-1151
patients	O	1152-1160
belonging	O	1161-1170
to	O	1171-1173
the	O	1174-1177
poor	O	1178-1182
-	O	1182-1183
metabolizer	O	1183-1194
phenotype	O	1195-1204
of	O	1205-1207
sparteine	O	1208-1217
/	O	1217-1218
debrisoquine	O	1218-1230
polymorphism	O	1231-1243
in	O	1244-1246
drug	O	1247-1251
metabolism	O	1252-1262
,	O	1262-1263
which	O	1264-1269
constitutes	O	1270-1281
6	O	1282-1283
.	O	1283-1284
4	O	1284-1285
%	O	1285-1286
of	O	1287-1289
the	O	1290-1293
German	O	1294-1300
population	O	1301-1311
,	O	1311-1312
may	O	1313-1316
experience	O	1317-1327
adverse	B	1328-1335
drug	I	1336-1340
reactions	I	1341-1350
when	O	1351-1355
treated	O	1356-1363
with	O	1364-1368
standard	O	1369-1377
doses	O	1378-1383
of	O	1384-1386
one	O	1387-1390
of	O	1391-1393
these	O	1394-1399
drugs	O	1400-1405
alone	O	1406-1411
.	O	1411-1412

Moreover	O	1413-1421
,	O	1421-1422
the	O	1423-1426
coadministration	O	1427-1443
of	O	1444-1446
these	O	1447-1452
frequently	O	1453-1463
used	O	1464-1468
drugs	O	1469-1474
is	O	1475-1477
expected	O	1478-1486
to	O	1487-1489
be	O	1490-1492
especially	O	1493-1503
harmful	O	1504-1511
in	O	1512-1514
this	O	1515-1519
subgroup	O	1520-1528
of	O	1529-1531
patients	O	1532-1540
.	O	1540-1541

Triazolam	O	0-9
-	O	9-10
induced	O	10-17
brief	O	18-23
episodes	O	24-32
of	O	33-35
secondary	O	36-45
mania	B	46-51
in	O	52-54
a	O	55-56
depressed	B	57-66
patient	O	67-74
.	O	74-75

Large	O	76-81
doses	O	82-87
of	O	88-90
triazolam	O	91-100
repeatedly	O	101-111
induced	O	112-119
brief	O	120-125
episodes	O	126-134
of	O	135-137
mania	B	138-143
in	O	144-146
a	O	147-148
depressed	B	149-158
elderly	O	159-166
woman	O	167-172
.	O	172-173

Features	O	174-182
of	O	183-185
organic	B	186-193
mental	I	194-200
disorder	I	201-209
(	O	210-211
delirium	B	211-219
)	O	219-220
were	O	221-225
not	O	226-229
present	O	230-237
.	O	237-238

Manic	B	239-244
excitement	O	245-255
was	O	256-259
coincident	O	260-270
with	O	271-275
the	O	276-279
duration	O	280-288
of	O	289-291
action	O	292-298
of	O	299-301
triazolam	O	302-311
.	O	311-312

The	O	313-316
possible	O	317-325
contribution	O	326-338
of	O	339-341
the	O	342-345
triazolo	O	346-354
group	O	355-360
to	O	361-363
changes	O	364-371
in	O	372-374
affective	O	375-384
status	O	385-391
is	O	392-394
discussed	O	395-404
.	O	404-405

On	O	0-2
the	O	3-6
mechanisms	O	7-17
of	O	18-20
the	O	21-24
development	O	25-36
of	O	37-39
tolerance	O	40-49
to	O	50-52
the	O	53-56
muscular	B	57-65
rigidity	I	66-74
produced	O	75-83
by	O	84-86
morphine	O	87-95
in	O	96-98
rats	O	99-103
.	O	103-104

The	O	105-108
development	O	109-120
of	O	121-123
tolerance	O	124-133
to	O	134-136
the	O	137-140
muscular	B	141-149
rigidity	I	150-158
produced	O	159-167
by	O	168-170
morphine	O	171-179
was	O	180-183
studied	O	184-191
in	O	192-194
rats	O	195-199
.	O	199-200

Saline	O	201-207
-	O	207-208
pretreated	O	208-218
controls	O	219-227
given	O	228-233
a	O	234-235
test	O	236-240
dose	O	241-245
of	O	246-248
morphine	O	249-257
(	O	258-259
20	O	259-261
mg	O	262-264
/	O	264-265
kg	O	265-267
i	O	268-269
.	O	269-270
p	O	270-271
.	O	269-270
)	O	272-273
showed	O	274-280
a	O	281-282
pronounced	O	283-293
rigidity	B	294-302
recorded	O	303-311
as	O	312-314
tonic	O	315-320
activity	O	321-329
in	O	330-332
the	O	333-336
electromyogram	O	337-351
.	O	351-352

Rats	O	353-357
treated	O	358-365
for	O	366-369
11	O	370-372
days	O	373-377
with	O	378-382
morphine	O	383-391
and	O	392-395
withdrawn	O	396-405
for	O	406-409
36	O	410-412
-	O	412-413
40	O	413-415
h	O	416-417
showed	O	418-424
differences	O	425-436
in	O	437-439
the	O	440-443
development	O	444-455
of	O	456-458
tolerance	O	459-468
:	O	468-469
about	O	470-475
half	O	476-480
of	O	481-483
the	O	484-487
animals	O	488-495
showed	O	496-502
a	O	503-504
rigidity	B	505-513
after	O	514-519
the	O	520-523
test	O	524-528
dose	O	529-533
of	O	534-536
morphine	O	537-545
that	O	546-550
was	O	551-554
not	O	555-558
significantly	O	559-572
less	O	573-577
than	O	578-582
in	O	583-585
the	O	586-589
controls	O	590-598
and	O	599-602
were	O	603-607
akinetic	B	608-616
(	O	617-618
A	O	618-619
group	O	620-625
)	O	625-626
.	O	626-627

The	O	628-631
other	O	632-637
rats	O	638-642
showed	O	643-649
a	O	650-651
strong	O	652-658
decrease	O	659-667
in	O	668-670
the	O	671-674
rigidity	B	675-683
and	O	684-687
the	O	688-691
occurrence	O	692-702
of	O	703-705
stereotyped	O	706-717
(	O	718-719
S	O	719-720
)	O	720-721
licking	O	722-729
and	O	730-733
/	O	733-734
or	O	734-736
gnawing	O	737-744
in	O	745-747
presence	O	748-756
of	O	757-759
akinetic	B	760-768
or	O	769-771
hyperkinetic	B	772-784
(	O	785-786
K	O	786-787
)	O	787-788
behaviour	O	789-798
(	O	799-800
AS	O	800-802
/	O	802-803
KS	O	803-805
group	O	806-811
)	O	811-812
,	O	812-813
suggesting	O	814-824
signs	O	825-830
of	O	831-833
dopaminergic	O	834-846
activation	O	847-857
.	O	857-858

The	O	859-862
rigidity	B	863-871
was	O	872-875
considerably	O	876-888
decreased	O	889-898
in	O	899-901
both	O	902-906
groups	O	907-913
after	O	914-919
20	O	920-922
days	O	923-927
'	O	927-928
treatment	O	929-938
.	O	938-939

In	O	940-942
a	O	943-944
further	O	945-952
series	O	953-959
of	O	960-962
experiments	O	963-974
,	O	974-975
haloperidol	O	976-987
(	O	988-989
0	O	989-990
.	O	990-991
2	O	991-992
mg	O	993-995
/	O	995-996
kg	O	996-998
i	O	999-1000
.	O	1000-1001
p	O	1001-1002
.	O	1000-1001
)	O	1003-1004
was	O	1005-1008
used	O	1009-1013
in	O	1014-1016
order	O	1017-1022
to	O	1023-1025
block	O	1026-1031
the	O	1032-1035
dopaminergic	O	1036-1048
activation	O	1049-1059
and	O	1060-1063
to	O	1064-1066
estimate	O	1067-1075
the	O	1076-1079
real	O	1080-1084
degree	O	1085-1091
of	O	1092-1094
the	O	1095-1098
tolerance	O	1099-1108
to	O	1109-1111
the	O	1112-1115
rigidity	B	1116-1124
without	O	1125-1132
any	O	1133-1136
dopaminergic	O	1137-1149
interference	O	1150-1162
.	O	1162-1163

Haloperidol	O	1164-1175
enhanced	O	1176-1184
the	O	1185-1188
rigidity	B	1189-1197
in	O	1198-1200
the	O	1201-1204
A	O	1205-1206
group	O	1207-1212
.	O	1212-1213

However	O	1214-1221
,	O	1221-1222
the	O	1223-1226
level	O	1227-1232
in	O	1233-1235
the	O	1236-1239
AS	O	1240-1242
/	O	1242-1243
KS	O	1243-1245
group	O	1246-1251
remained	O	1252-1260
considerably	O	1261-1273
lower	O	1274-1279
than	O	1280-1284
in	O	1285-1287
the	O	1288-1291
A	O	1292-1293
group	O	1294-1299
.	O	1299-1300

The	O	1301-1304
results	O	1305-1312
suggest	O	1313-1320
that	O	1321-1325
rigidity	B	1326-1334
,	O	1334-1335
which	O	1336-1341
is	O	1342-1344
assumed	O	1345-1352
to	O	1353-1355
be	O	1356-1358
due	O	1359-1362
to	O	1363-1365
an	O	1366-1368
action	O	1369-1375
of	O	1376-1378
morphine	O	1379-1387
in	O	1388-1390
the	O	1391-1394
striatum	O	1395-1403
,	O	1403-1404
can	O	1405-1408
be	O	1409-1411
antagonized	O	1412-1423
by	O	1424-1426
another	O	1427-1434
process	O	1435-1442
leading	O	1443-1450
to	O	1451-1453
dopaminergic	O	1454-1466
activation	O	1467-1477
in	O	1478-1480
the	O	1481-1484
striatum	O	1485-1493
.	O	1493-1494

Nevertheless	O	1495-1507
,	O	1507-1508
there	O	1509-1514
occurs	O	1515-1521
some	O	1522-1526
real	O	1527-1531
tolerance	O	1532-1541
to	O	1542-1544
this	O	1545-1549
effect	O	1550-1556
.	O	1556-1557

The	O	1558-1561
rapid	O	1562-1567
alternations	O	1568-1580
of	O	1581-1583
rigidity	B	1584-1592
and	O	1593-1596
the	O	1597-1600
signs	O	1601-1606
of	O	1607-1609
dopaminergic	O	1610-1622
activation	O	1623-1633
observed	O	1634-1642
in	O	1643-1645
the	O	1646-1649
animals	O	1650-1657
of	O	1658-1660
the	O	1661-1664
AS	O	1665-1667
/	O	1667-1668
KS	O	1668-1670
group	O	1671-1676
might	O	1677-1682
be	O	1683-1685
due	O	1686-1689
to	O	1690-1692
rapid	O	1693-1698
shifts	O	1699-1705
in	O	1706-1708
the	O	1709-1712
predominance	O	1713-1725
of	O	1726-1728
various	O	1729-1736
DA	O	1737-1739
-	O	1739-1740
innervated	O	1740-1750
structures	O	1751-1761
.	O	1761-1762

Compression	B	0-11
neuropathy	I	12-22
of	I	23-25
the	I	26-29
radial	I	30-36
nerve	I	37-42
due	O	43-46
to	O	47-49
pentazocine	O	50-61
-	O	61-62
induced	O	62-69
fibrous	B	70-77
myopathy	I	78-86
.	O	86-87

Fibrous	B	88-95
myopathy	I	96-104
is	O	105-107
a	O	108-109
common	O	110-116
,	O	116-117
well	O	118-122
-	O	122-123
known	O	123-128
side	O	129-133
effect	O	134-140
of	O	141-143
repeated	O	144-152
pentazocine	O	153-164
injection	O	165-174
.	O	174-175

However	O	176-183
,	O	183-184
compression	B	185-196
neuropathy	I	197-207
due	O	208-211
to	O	212-214
fibrotic	O	215-223
muscle	O	224-230
affected	O	231-239
by	O	240-242
pentazocine	O	243-254
-	O	254-255
induced	O	255-262
myopathy	B	263-271
has	O	272-275
not	O	276-279
previously	O	280-290
been	O	291-295
reported	O	296-304
.	O	304-305

In	O	306-308
a	O	309-310
37	O	311-313
-	O	313-314
year	O	314-318
-	O	313-314
old	O	319-322
woman	O	323-328
with	O	329-333
documented	O	334-344
pentazocine	O	345-356
-	O	356-357
induced	O	357-364
fibrous	B	365-372
myopathy	I	373-381
of	O	382-384
triceps	O	385-392
and	O	393-396
deltoid	O	397-404
muscles	O	405-412
bilaterally	O	413-424
and	O	425-428
a	O	429-430
three	O	431-436
-	O	436-437
week	O	437-441
history	O	442-449
of	O	450-452
right	O	453-458
wrist	O	459-464
drop	O	465-469
,	O	469-470
electrodiagnostic	O	471-488
examination	O	489-500
showed	O	501-507
a	O	508-509
severe	O	510-516
but	O	517-520
partial	O	521-528
lesion	O	529-535
of	O	536-538
the	O	539-542
right	O	543-548
radial	O	549-555
nerve	O	556-561
distal	O	562-568
to	O	569-571
the	O	572-575
branches	O	576-584
to	O	585-587
the	O	588-591
triceps	O	592-599
,	O	599-600
in	O	601-603
addition	O	604-612
to	O	613-615
the	O	616-619
fibrous	B	620-627
myopathy	I	628-636
.	O	636-637

Surgery	O	638-645
revealed	O	646-654
the	O	655-658
right	O	659-664
radial	O	665-671
nerve	O	672-677
to	O	678-680
be	O	681-683
severely	O	684-692
compressed	O	693-703
by	O	704-706
the	O	707-710
densely	O	711-718
fibrotic	O	719-727
lateral	O	728-735
head	O	736-740
of	O	741-743
the	O	744-747
triceps	O	748-755
.	O	755-756

Decompression	O	757-770
and	O	771-774
neurolysis	O	775-785
were	O	786-790
performed	O	791-800
with	O	801-805
good	O	806-810
subsequent	O	811-821
recovery	O	822-830
of	O	831-833
function	O	834-842
.	O	842-843

Recurrent	O	0-9
reversible	O	10-20
acute	B	21-26
renal	I	27-32
failure	I	33-40
from	O	41-45
amphotericin	O	46-58
.	O	58-59

A	O	60-61
patient	O	62-69
with	O	70-74
cryptogenic	O	75-86
cirrhosis	B	87-96
and	O	97-100
disseminated	O	101-113
sporotrichosis	B	114-128
developed	O	129-138
acute	B	139-144
renal	I	145-150
failure	I	151-158
immediately	O	159-170
following	O	171-180
the	O	181-184
administration	O	185-199
of	O	200-202
amphotericin	O	203-215
B	O	216-217
on	O	218-220
four	O	221-225
separate	O	226-234
occasions	O	235-244
.	O	244-245

The	O	246-249
abruptness	O	250-260
of	O	261-263
the	O	264-267
renal	B	268-273
failure	I	274-281
and	O	282-285
its	O	286-289
reversibility	O	290-303
within	O	304-310
days	O	311-315
suggests	O	316-324
that	O	325-329
there	O	330-335
was	O	336-339
a	O	340-341
functional	O	342-352
component	O	353-362
to	O	363-365
the	O	366-369
renal	B	370-375
dysfunction	I	376-387
.	O	387-388

We	O	389-391
propose	O	392-399
that	O	400-404
amphotericin	O	405-417
,	O	417-418
in	O	419-421
the	O	422-425
setting	O	426-433
of	O	434-436
reduced	O	437-444
effective	O	445-454
arterial	O	455-463
volume	O	464-470
,	O	470-471
may	O	472-475
activate	O	476-484
tubuloglomerular	O	485-501
feedback	O	502-510
,	O	510-511
thereby	O	512-519
contributing	O	520-532
to	O	533-535
acute	B	536-541
renal	I	542-547
failure	I	548-555
.	O	555-556

Pneumonitis	O	0-11
with	O	12-16
pleural	B	17-24
and	I	25-28
pericardial	I	29-40
effusion	I	41-49
and	O	50-53
neuropathy	B	54-64
during	O	65-71
amiodarone	O	72-82
therapy	O	83-90
.	O	90-91

A	O	92-93
patient	O	94-101
with	O	102-106
sinuatrial	B	107-117
disease	I	118-125
and	O	126-129
implanted	O	130-139
pacemaker	O	140-149
was	O	150-153
treated	O	154-161
with	O	162-166
amiodarone	O	167-177
(	O	178-179
maximum	O	179-186
dose	O	187-191
1000	O	192-196
mg	O	197-199
,	O	199-200
maintenance	O	201-212
dose	O	213-217
800	O	218-221
mg	O	222-224
daily	O	225-230
)	O	230-231
for	O	232-235
10	O	236-238
months	O	239-245
,	O	245-246
for	O	247-250
control	O	251-258
of	O	259-261
supraventricular	B	262-278
tachyarrhythmias	I	279-295
.	O	295-296

He	O	297-299
developed	O	300-309
pneumonitis	B	310-321
,	O	321-322
pleural	B	323-330
and	I	331-334
pericardial	I	335-346
effusions	I	347-356
,	O	356-357
and	O	358-361
a	O	362-363
predominantly	O	364-377
proximal	B	378-386
motor	I	387-392
neuropathy	I	393-403
.	O	403-404

Immediate	O	405-414
but	O	415-418
gradual	O	419-426
improvement	O	427-438
followed	O	439-447
withdrawal	O	448-458
of	O	459-461
amiodarone	O	462-472
and	O	473-476
treatment	O	477-486
with	O	487-491
prednisolone	O	492-504
.	O	504-505

Review	O	506-512
of	O	513-515
this	O	516-520
and	O	521-524
previously	O	525-535
reported	O	536-544
cases	O	545-550
indicates	O	551-560
the	O	561-564
need	O	565-569
for	O	570-573
early	O	574-579
diagnosis	O	580-589
of	O	590-592
amiodarone	O	593-603
pneumonitis	B	604-615
,	O	615-616
immediate	O	617-626
withdrawal	O	627-637
of	O	638-640
amiodarone	O	641-651
,	O	651-652
and	O	653-656
prompt	O	657-663
but	O	664-667
continued	O	668-677
steroid	O	678-685
therapy	O	686-693
to	O	694-696
ensure	O	697-703
full	O	704-708
recovery	O	709-717
.	O	717-718

Indomethacin	O	0-12
-	O	12-13
induced	O	13-20
renal	B	21-26
insufficiency	I	27-40
:	O	40-41
recurrence	O	42-52
on	O	53-55
rechallenge	O	56-67
.	O	67-68

We	O	69-71
have	O	72-76
reported	O	77-85
a	O	86-87
case	O	88-92
of	O	93-95
acute	O	96-101
oliguric	O	102-110
renal	B	111-116
failure	I	117-124
with	O	125-129
hyperkalemia	B	130-142
in	O	143-145
a	O	146-147
patient	O	148-155
with	O	156-160
cirrhosis	B	161-170
,	O	170-171
ascites	B	172-179
,	O	179-180
and	O	181-184
cor	B	185-188
pulmonale	I	189-198
after	O	199-204
indomethacin	O	205-217
therapy	O	218-225
.	O	225-226

Prompt	O	227-233
restoration	O	234-245
of	O	246-248
renal	O	249-254
function	O	255-263
followed	O	264-272
drug	O	273-277
withdrawal	O	278-288
,	O	288-289
while	O	290-295
re	O	296-298
-	O	298-299
exposure	O	299-307
to	O	308-310
a	O	311-312
single	O	313-319
dose	O	320-324
of	O	325-327
indomethacin	O	328-340
caused	O	341-347
recurrence	O	348-358
of	O	359-361
acute	O	362-367
reversible	O	368-378
oliguria	B	379-387
.	O	387-388

Our	O	389-392
case	O	393-397
supports	O	398-406
the	O	407-410
hypothesis	O	411-421
that	O	422-426
endogenous	O	427-437
renal	O	438-443
prostaglandins	O	444-458
play	O	459-463
a	O	464-465
role	O	466-470
in	O	471-473
the	O	474-477
maintenance	O	478-489
of	O	490-492
renal	O	493-498
blood	O	499-504
flow	O	505-509
when	O	510-514
circulating	O	515-526
plasma	O	527-533
volume	O	534-540
is	O	541-543
diminished	O	544-554
.	O	554-555

Since	O	556-561
nonsteroidal	O	562-574
anti	O	575-579
-	O	579-580
inflammatory	O	580-592
agents	O	593-599
interfere	O	600-609
with	O	610-614
this	O	615-619
compensatory	O	620-632
mechanism	O	633-642
and	O	643-646
may	O	647-650
cause	O	651-656
acute	B	657-662
renal	I	663-668
failure	I	669-676
,	O	676-677
they	O	678-682
should	O	683-689
be	O	690-692
used	O	693-697
with	O	698-702
caution	O	703-710
in	O	711-713
such	O	714-718
patients	O	719-727
.	O	727-728

Comparison	O	0-10
of	O	11-13
the	O	14-17
subjective	O	18-28
effects	O	29-36
and	O	37-40
plasma	O	41-47
concentrations	O	48-62
following	O	63-72
oral	O	73-77
and	O	78-81
i	O	82-83
.	O	83-84
m	O	84-85
.	O	83-84
administration	O	87-101
of	O	102-104
flunitrazepam	O	105-118
in	O	119-121
volunteers	O	122-132
.	O	132-133

Flunitrazepam	O	134-147
0	O	148-149
.	O	149-150
5	O	150-151
,	O	151-152
1	O	153-154
.	O	154-155
0	O	155-156
or	O	157-159
2	O	160-161
.	O	161-162
0	O	162-163
mg	O	164-166
was	O	167-170
given	O	171-176
by	O	177-179
the	O	180-183
oral	O	184-188
or	O	189-191
i	O	192-193
.	O	193-194
m	O	194-195
.	O	193-194
routes	O	197-203
to	O	204-206
groups	O	207-213
of	O	214-216
volunteers	O	217-227
and	O	228-231
its	O	232-235
effects	O	236-243
compared	O	244-252
.	O	252-253

Plasma	O	254-260
concentrations	O	261-275
of	O	276-278
the	O	279-282
drug	O	283-287
were	O	288-292
estimated	O	293-302
by	O	303-305
gas	O	306-309
-	O	309-310
liquid	O	310-316
chromatography	O	317-331
,	O	331-332
in	O	333-335
a	O	336-337
smaller	O	338-345
number	O	346-352
of	O	353-355
the	O	356-359
subjects	O	360-368
.	O	368-369

The	O	370-373
most	O	374-378
striking	O	379-387
effect	O	388-394
was	O	395-398
sedation	O	399-407
which	O	408-413
increased	O	414-423
with	O	424-428
the	O	429-432
dose	O	433-437
,	O	437-438
2	O	439-440
mg	O	441-443
producing	O	444-453
deep	O	454-458
sleep	O	459-464
although	O	465-473
the	O	474-477
subjects	O	478-486
could	O	487-492
still	O	493-498
be	O	499-501
aroused	O	502-509
.	O	509-510

The	O	511-514
effects	O	515-522
of	O	523-525
i	O	526-527
.	O	527-528
m	O	528-529
.	O	527-528
administration	O	531-545
were	O	546-550
apparent	O	551-559
earlier	O	560-567
and	O	568-571
sometimes	O	572-581
lasted	O	582-588
longer	O	589-595
than	O	596-600
those	O	601-606
following	O	607-616
oral	O	617-621
administration	O	622-636
.	O	636-637

Dizziness	B	638-647
was	O	648-651
less	O	652-656
marked	O	657-663
than	O	664-668
sedation	O	669-677
,	O	677-678
but	O	679-682
increased	O	683-692
with	O	693-697
the	O	698-701
dose	O	702-706
.	O	706-707

There	O	708-713
was	O	714-717
pain	B	718-722
on	O	723-725
i	O	726-727
.	O	727-728
m	O	728-729
.	O	727-728
injection	O	731-740
of	O	741-743
flunitrazepam	O	744-757
significantly	O	758-771
more	O	772-776
often	O	777-782
than	O	783-787
with	O	788-792
isotonic	O	793-801
saline	O	802-808
.	O	808-809

Plasma	O	810-816
concentrations	O	817-831
varied	O	832-838
with	O	839-843
dose	O	844-848
and	O	849-852
route	O	853-858
and	O	859-862
corresponded	O	863-875
qualitatively	O	876-889
with	O	890-894
the	O	895-898
subjective	O	899-909
effects	O	910-917
.	O	917-918

The	O	919-922
drug	O	923-927
was	O	928-931
still	O	932-937
present	O	938-945
in	O	946-948
measurable	O	949-959
quantities	O	960-970
after	O	971-976
24	O	977-979
h	O	980-981
even	O	982-986
with	O	987-991
the	O	992-995
smallest	O	996-1004
dose	O	1005-1009
.	O	1009-1010

Changes	O	0-7
in	O	8-10
heart	O	11-16
size	O	17-21
during	O	22-28
long	O	29-33
-	O	33-34
term	O	34-38
timolol	O	39-46
treatment	O	47-56
after	O	57-62
myocardial	B	63-73
infarction	I	74-84
.	O	84-85

The	O	86-89
effect	O	90-96
of	O	97-99
long	O	100-104
-	O	104-105
term	O	105-109
timolol	O	110-117
treatment	O	118-127
on	O	128-130
heart	O	131-136
size	O	137-141
after	O	142-147
myocardial	B	148-158
infarction	I	159-169
was	O	170-173
evaluated	O	174-183
by	O	184-186
X	O	187-188
-	O	188-189
ray	O	189-192
in	O	193-195
a	O	196-197
double	O	198-204
-	O	204-205
blind	O	205-210
study	O	211-216
including	O	217-226
241	O	227-230
patients	O	231-239
(	O	240-241
placebo	O	241-248
126	O	249-252
,	O	252-253
timolol	O	254-261
115	O	262-265
)	O	265-266
.	O	266-267

The	O	268-271
follow	O	272-278
-	O	278-279
up	O	279-281
period	O	282-288
was	O	289-292
12	O	293-295
months	O	296-302
.	O	302-303

The	O	304-307
timolol	O	308-315
-	O	315-316
treated	O	316-323
patients	O	324-332
showed	O	333-339
a	O	340-341
small	O	342-347
but	O	348-351
significant	O	352-363
increase	O	364-372
in	O	373-375
heart	O	376-381
size	O	382-386
from	O	387-391
baseline	O	392-400
in	O	401-403
contrast	O	404-412
to	O	413-415
a	O	416-417
decrease	O	418-426
in	O	427-429
the	O	430-433
placebo	O	434-441
group	O	442-447
.	O	447-448

These	O	449-454
differences	O	455-466
may	O	467-470
be	O	471-473
caused	O	474-480
by	O	481-483
timolol	O	484-491
-	O	491-492
induced	O	492-499
bradycardia	B	500-511
and	O	512-515
a	O	516-517
compensatory	O	518-530
increase	O	531-539
in	O	540-542
end	O	543-546
-	O	546-547
diastolic	O	547-556
volume	O	557-563
.	O	563-564

The	O	565-568
timolol	O	569-576
-	O	576-577
related	O	577-584
increase	O	585-593
in	O	594-596
heart	O	597-602
size	O	603-607
was	O	608-611
observed	O	612-620
only	O	621-625
in	O	626-628
patients	O	629-637
with	O	638-642
normal	O	643-649
and	O	650-653
borderline	O	654-664
heart	O	665-670
size	O	671-675
.	O	675-676

In	O	677-679
patients	O	680-688
with	O	689-693
cardiomegaly	B	694-706
,	O	706-707
the	O	708-711
increase	O	712-720
in	O	721-723
heart	O	724-729
size	O	730-734
was	O	735-738
similar	O	739-746
in	O	747-749
both	O	750-754
groups	O	755-761
.	O	761-762

After	O	763-768
re	O	769-771
-	O	771-772
infarction	B	772-782
,	O	782-783
heart	O	784-789
size	O	790-794
increased	O	795-804
in	O	805-807
the	O	808-811
placebo	O	812-819
group	O	820-825
and	O	826-829
remained	O	830-838
unchanged	O	839-848
in	O	849-851
the	O	852-855
timolol	O	856-863
group	O	864-869
.	O	869-870

Vitamin	O	0-7
D3	O	8-10
toxicity	B	11-19
in	O	20-22
dairy	O	23-28
cows	O	29-33
.	O	33-34

Large	O	35-40
parenteral	O	41-51
doses	O	52-57
of	O	58-60
vitamin	O	61-68
D3	O	69-71
(	O	72-73
15	O	73-75
to	O	76-78
17	O	79-81
.	O	81-82
5	O	82-83
x	O	84-85
10	O	86-88
(	O	88-89
6	O	89-90
)	O	90-91
IU	O	92-94
vitamin	O	95-102
D3	O	103-105
)	O	105-106
were	O	107-111
associated	O	112-122
with	O	123-127
prolonged	O	128-137
hypercalcemia	B	138-151
,	O	151-152
hyperphosphatemia	B	153-170
,	O	170-171
and	O	172-175
large	O	176-181
increases	O	182-191
of	O	192-194
vitamin	O	195-202
D3	O	203-205
and	O	206-209
its	O	210-213
metabolites	O	214-225
in	O	226-228
the	O	229-232
blood	O	233-238
plasma	O	239-245
of	O	246-248
nonlactating	O	249-261
nonpregnant	O	262-273
and	O	274-277
pregnant	O	278-286
Jersey	O	287-293
cows	O	294-298
.	O	298-299

Calcium	O	300-307
concentrations	O	308-322
1	O	323-324
day	O	325-328
postpartum	O	329-339
were	O	340-344
higher	O	345-351
in	O	352-354
cows	O	355-359
treated	O	360-367
with	O	368-372
vitamin	O	373-380
D3	O	381-383
about	O	384-389
32	O	390-392
days	O	393-397
prepartum	O	398-407
(	O	408-409
8	O	409-410
.	O	410-411
8	O	409-410
mg	O	413-415
/	O	415-416
100	O	416-419
ml	O	420-422
)	O	422-423
than	O	424-428
in	O	429-431
control	O	432-439
cows	O	440-444
(	O	445-446
5	O	446-447
.	O	447-448
5	O	446-447
mg	O	450-452
/	O	452-453
100	O	453-456
ml	O	457-459
)	O	459-460
.	O	460-461

None	O	462-466
of	O	467-469
the	O	470-473
cows	O	474-478
treated	O	479-486
with	O	487-491
vitamin	O	492-499
D3	O	500-502
showed	O	503-509
signs	O	510-515
of	O	516-518
milk	B	519-523
fever	I	524-529
during	O	530-536
the	O	537-540
peripartal	O	541-551
period	O	552-558
;	O	558-559
however	O	560-567
,	O	567-568
22	O	569-571
%	O	571-572
of	O	573-575
the	O	576-579
control	O	580-587
cows	O	588-592
developed	O	593-602
clinical	O	603-611
signs	O	612-617
of	O	618-620
milk	B	621-625
fever	I	626-631
during	O	632-638
this	O	639-643
period	O	644-650
.	O	650-651

Signs	O	652-657
of	O	658-660
vitamin	O	661-668
D3	O	669-671
toxicity	B	672-680
were	O	681-685
not	O	686-689
observed	O	690-698
in	O	699-701
nonlactating	O	702-714
nonpregnant	O	715-726
cows	O	727-731
;	O	731-732
however	O	733-740
,	O	740-741
pregnant	O	742-750
cows	O	751-755
commonly	O	756-764
developed	O	765-774
severe	O	775-781
signs	O	782-787
of	O	788-790
vitamin	O	791-798
D3	O	799-801
toxicity	B	802-810
and	O	811-814
10	O	815-817
of	O	818-820
17	O	821-823
cows	O	824-828
died	O	829-833
.	O	833-834

There	O	835-840
was	O	841-844
widespread	O	845-855
metastatic	O	856-866
calcification	O	867-880
in	O	881-883
the	O	884-887
cows	O	888-892
that	O	893-897
died	O	898-902
.	O	902-903

Because	O	904-911
of	O	912-914
the	O	915-918
extreme	O	919-926
toxicity	B	927-935
of	O	936-938
vitamin	O	939-946
D3	O	947-949
in	O	950-952
pregnant	O	953-961
Jersey	O	962-968
cows	O	969-973
and	O	974-977
the	O	978-981
low	O	982-985
margin	O	986-992
of	O	993-995
safety	O	996-1002
between	O	1003-1010
doses	O	1011-1016
of	O	1017-1019
vitamin	O	1020-1027
D3	O	1028-1030
that	O	1031-1035
prevent	O	1036-1043
milk	B	1044-1048
fever	I	1049-1054
and	O	1055-1058
doses	O	1059-1064
that	O	1065-1069
induce	O	1070-1076
milk	B	1077-1081
fever	I	1082-1087
,	O	1087-1088
we	O	1089-1091
concluded	O	1092-1101
that	O	1102-1106
vitamin	O	1107-1114
D3	O	1115-1117
cannot	O	1118-1124
be	O	1125-1127
used	O	1128-1132
practically	O	1133-1144
to	O	1145-1147
prevent	O	1148-1155
milk	B	1156-1160
fever	I	1161-1166
when	O	1167-1171
injected	O	1172-1180
several	O	1181-1188
weeks	O	1189-1194
prepartum	O	1195-1204
.	O	1204-1205

Diseases	B	0-8
of	I	9-11
peripheral	I	12-22
nerves	I	23-29
as	O	30-32
seen	O	33-37
in	O	38-40
the	O	41-44
Nigerian	O	45-53
African	O	54-61
.	O	61-62

The	O	63-66
anatomical	O	67-77
and	O	78-81
aetiological	O	82-94
diagnoses	O	95-104
of	O	105-107
peripheral	B	108-118
nerve	I	119-124
disease	I	125-132
excluding	O	133-142
its	O	143-146
primary	O	147-154
benign	O	155-161
and	O	162-165
malignant	O	166-175
disorders	O	176-185
,	O	185-186
as	O	187-189
seen	O	190-194
in	O	195-197
358	O	198-201
Nigerians	O	202-211
are	O	212-215
presented	O	216-225
.	O	225-226

There	O	227-232
is	O	233-235
a	O	236-237
male	O	238-242
preponderance	O	243-256
and	O	257-260
the	O	261-264
peak	O	265-269
incidence	O	270-279
is	O	280-282
in	O	283-285
the	O	286-289
fourth	O	290-296
decade	O	297-303
.	O	303-304

Sensori	B	305-312
-	I	312-313
motor	I	313-318
neuropathy	I	319-329
was	O	330-333
the	O	334-337
commonest	O	338-347
presentation	O	348-360
(	O	361-362
50	O	362-364
%	O	364-365
)	O	365-366
.	O	366-367

Guillain	B	368-376
-	I	376-377
Barr	I	377-381
syndrome	I	384-392
was	O	393-396
the	O	397-400
commonest	O	401-410
identifiable	O	411-423
cause	O	424-429
(	O	430-431
15	O	431-433
.	O	433-434
6	O	434-435
%	O	435-436
)	O	436-437
,	O	437-438
accounting	O	439-449
for	O	450-453
half	O	454-458
of	O	459-461
the	O	462-465
cases	O	466-471
with	O	472-476
motor	B	477-482
neuropathy	I	483-493
.	O	493-494

Peripheral	B	495-505
neuropathy	I	506-516
due	O	517-520
to	O	521-523
nutritional	B	524-535
deficiency	I	536-546
of	O	547-549
thiamine	O	550-558
and	O	559-562
riboflavin	O	563-573
was	O	574-577
common	O	578-584
(	O	585-586
10	O	586-588
.	O	588-589
1	O	586-587
%	O	590-591
)	O	591-592
and	O	593-596
presented	O	597-606
mainly	O	607-613
as	O	614-616
sensory	O	617-624
and	O	625-628
sensori	B	629-636
-	I	636-637
motor	I	637-642
neuropathy	I	643-653
.	O	653-654

Diabetes	B	655-663
mellitus	I	664-672
was	O	673-676
the	O	677-680
major	O	681-686
cause	O	687-692
of	O	693-695
autonomic	B	696-705
neuropathy	I	706-716
.	O	716-717

Isoniazid	O	718-727
was	O	728-731
the	O	732-735
most	O	736-740
frequent	O	741-749
agent	O	750-755
in	O	756-758
drug	O	759-763
-	O	763-764
induced	O	764-771
neuropathy	B	772-782
.	O	782-783

Migraine	B	784-792
(	O	793-794
20	O	794-796
%	O	796-797
)	O	797-798
was	O	799-802
not	O	803-806
an	O	807-809
uncommon	O	810-818
cause	O	819-824
of	O	825-827
cranial	B	828-835
neuropathy	I	836-846
although	O	847-855
malignancies	B	856-868
arising	O	869-876
from	O	877-881
the	O	882-885
reticuloendothelial	O	886-905
system	O	906-912
or	O	913-915
related	O	916-923
structures	O	924-934
of	O	935-937
the	O	938-941
head	O	942-946
and	O	947-950
neck	O	951-955
were	O	956-960
more	O	961-965
frequent	O	966-974
(	O	975-976
26	O	976-978
%	O	978-979
)	O	979-980
.	O	980-981

In	O	982-984
26	O	985-987
.	O	987-988
5	O	988-989
%	O	989-990
of	O	991-993
all	O	994-997
the	O	998-1001
cases	O	1002-1007
,	O	1007-1008
the	O	1009-1012
aetiology	O	1013-1022
of	O	1023-1025
the	O	1026-1029
neuropathy	B	1030-1040
was	O	1041-1044
undetermined	O	1045-1057
.	O	1057-1058

Heredofamilial	O	1059-1073
and	O	1074-1077
connective	B	1078-1088
tissue	I	1089-1095
disorders	I	1096-1105
were	O	1106-1110
rare	O	1111-1115
.	O	1115-1116

Some	O	1117-1121
of	O	1122-1124
the	O	1125-1128
factors	O	1129-1136
related	O	1137-1144
to	O	1145-1147
the	O	1148-1151
clinical	O	1152-1160
presentation	O	1161-1173
and	O	1174-1177
pathogenesis	O	1178-1190
of	O	1191-1193
the	O	1194-1197
neuropathies	B	1198-1210
are	O	1211-1214
briefly	O	1215-1222
discussed	O	1223-1232
.	O	1232-1233

A	O	0-1
double	O	2-8
-	O	8-9
blind	O	9-14
study	O	15-20
of	O	21-23
the	O	24-27
efficacy	O	28-36
and	O	37-40
safety	O	41-47
of	O	48-50
dothiepin	O	51-60
hydrochloride	O	61-74
in	O	75-77
the	O	78-81
treatment	O	82-91
of	O	92-94
major	O	95-100
depressive	B	101-111
disorder	I	112-120
.	O	120-121

In	O	122-124
a	O	125-126
6	O	127-128
-	O	128-129
week	O	129-133
double	O	134-140
-	O	140-141
blind	O	141-146
parallel	O	147-155
treatment	O	156-165
study	O	166-171
,	O	171-172
dothiepin	O	173-182
and	O	183-186
amitriptyline	O	187-200
were	O	201-205
compared	O	206-214
to	O	215-217
placebo	O	218-225
in	O	226-228
the	O	229-232
treatment	O	233-242
of	O	243-245
33	O	246-248
depressed	B	249-258
outpatients	O	259-270
.	O	270-271

Dothiepin	O	272-281
and	O	282-285
amitriptyline	O	286-299
were	O	300-304
equally	O	305-312
effective	O	313-322
in	O	323-325
alleviating	O	326-337
the	O	338-341
symptoms	O	342-350
of	O	351-353
depressive	B	354-364
illness	I	365-372
,	O	372-373
and	O	374-377
both	O	378-382
were	O	383-387
significantly	O	388-401
superior	O	402-410
to	O	411-413
placebo	O	414-421
.	O	421-422

The	O	423-426
overall	O	427-434
incidence	O	435-444
of	O	445-447
side	O	448-452
effects	O	453-460
and	O	461-464
the	O	465-468
frequency	O	469-478
and	O	479-482
severity	O	483-491
of	O	492-494
blurred	B	495-502
vision	I	503-509
,	O	509-510
dry	B	511-514
mouth	I	515-520
,	O	520-521
and	O	522-525
drowsiness	O	526-536
were	O	537-541
significantly	O	542-555
less	O	556-560
with	O	561-565
dothiepin	O	566-575
than	O	576-580
with	O	581-585
amitriptyline	O	586-599
.	O	599-600

Dothiepin	O	601-610
also	O	611-615
produced	O	616-624
fewer	O	625-630
CNS	O	631-634
and	O	635-638
cardiovascular	O	639-653
effects	O	654-661
.	O	661-662

There	O	663-668
were	O	669-673
no	O	674-676
clinically	O	677-687
important	O	688-697
changes	O	698-705
in	O	706-708
laboratory	O	709-719
parameters	O	720-730
.	O	730-731

Dothiepin	O	732-741
thus	O	742-746
was	O	747-750
found	O	751-756
to	O	757-759
be	O	760-762
an	O	763-765
effective	O	766-775
antidepressant	O	776-790
drug	O	791-795
associated	O	796-806
with	O	807-811
fewer	O	812-817
side	O	818-822
effects	O	823-830
than	O	831-835
amitriptyline	O	836-849
in	O	850-852
the	O	853-856
treatment	O	857-866
of	O	867-869
depressed	B	870-879
outpatients	O	880-891
.	O	891-892

Behavioral	O	0-10
effects	O	11-18
of	O	19-21
diazepam	O	22-30
and	O	31-34
propranolol	O	35-46
in	O	47-49
patients	O	50-58
with	O	59-63
panic	B	64-69
disorder	I	70-78
and	O	79-82
agoraphobia	B	83-94
.	O	94-95

The	O	96-99
effects	O	100-107
of	O	108-110
oral	O	111-115
doses	O	116-121
of	O	122-124
diazepam	O	125-133
(	O	134-135
single	O	135-141
dose	O	142-146
of	O	147-149
10	O	150-152
mg	O	153-155
and	O	156-159
a	O	160-161
median	O	162-168
dose	O	169-173
of	O	174-176
30	O	177-179
mg	O	180-182
/	O	182-183
day	O	183-186
for	O	187-190
2	O	191-192
weeks	O	193-198
)	O	198-199
and	O	200-203
propranolol	O	204-215
(	O	216-217
single	O	217-223
dose	O	224-228
of	O	229-231
80	O	232-234
mg	O	235-237
and	O	238-241
a	O	242-243
median	O	244-250
dose	O	251-255
of	O	256-258
240	O	259-262
mg	O	263-265
/	O	265-266
day	O	266-269
for	O	270-273
2	O	274-275
weeks	O	276-281
)	O	281-282
on	O	283-285
psychological	O	286-299
performance	O	300-311
of	O	312-314
patients	O	315-323
with	O	324-328
panic	B	329-334
disorders	I	335-344
and	O	345-348
agoraphobia	B	349-360
were	O	361-365
investigated	O	366-378
in	O	379-381
a	O	382-383
double	O	384-390
-	O	390-391
blind	O	391-396
,	O	396-397
randomized	O	398-408
and	O	409-412
crossover	O	413-422
design	O	423-429
.	O	429-430

Both	O	431-435
drugs	O	436-441
impaired	B	442-450
immediate	I	451-460
free	I	461-465
recall	I	466-472
but	O	473-476
the	O	477-480
decrease	O	481-489
was	O	490-493
greater	O	494-501
for	O	502-505
diazepam	O	506-514
than	O	515-519
propranolol	O	520-531
.	O	531-532

Delayed	B	533-540
free	I	541-545
recall	I	546-552
was	I	553-556
also	I	557-561
impaired	I	562-570
but	O	571-574
the	O	575-578
two	O	579-582
drugs	O	583-588
did	O	589-592
not	O	593-596
differ	O	597-603
.	O	603-604

Patients	O	605-613
tapped	O	614-620
faster	O	621-627
after	O	628-633
propranolol	O	634-645
than	O	646-650
diazepam	O	651-659
and	O	660-663
they	O	664-668
were	O	669-673
more	O	674-678
sedated	O	679-686
after	O	687-692
diazepam	O	693-701
than	O	702-706
propranolol	O	707-718
.	O	718-719

After	O	720-725
2	O	726-727
weeks	O	728-733
of	O	734-736
treatment	O	737-746
,	O	746-747
patients	O	748-756
tested	O	757-763
5	O	764-765
-	O	765-766
8	O	766-767
h	O	768-769
after	O	770-775
the	O	776-779
last	O	780-784
dose	O	785-789
of	O	790-792
medication	O	793-803
did	O	804-807
not	O	808-811
show	O	812-816
any	O	817-820
decrement	O	821-830
of	O	831-833
performance	O	834-845
.	O	845-846

These	O	847-852
results	O	853-860
are	O	861-864
similar	O	865-872
to	O	873-875
those	O	876-881
previously	O	882-892
found	O	893-898
in	O	899-901
healthy	O	902-909
subjects	O	910-918
.	O	918-919

Accumulation	O	920-932
of	O	933-935
drugs	O	936-941
was	O	942-945
not	O	946-949
reflected	O	950-959
in	O	960-962
prolonged	O	963-972
behavioral	B	973-983
impairment	I	984-994
.	O	994-995

Effect	O	0-6
of	O	7-9
aspirin	O	10-17
on	O	18-20
N	O	21-22
-	O	22-23
[	O	23-24
4	O	24-25
-	O	22-23
(	O	26-27
5	O	27-28
-	O	22-23
nitro	O	29-34
-	O	22-23
2	O	35-36
-	O	22-23
furyl	O	37-42
)	O	42-43
-	O	22-23
2	O	35-36
-	O	22-23
thiazolyl	O	46-55
]	O	55-56
-	O	22-23
formamide	O	57-66
-	O	22-23
induced	O	67-74
epithelial	O	75-85
proliferation	O	86-99
in	O	100-102
the	O	103-106
urinary	O	107-114
bladder	O	115-122
and	O	123-126
forestomach	O	127-138
of	O	139-141
the	O	142-145
rat	O	146-149
.	O	149-150

The	O	151-154
co	O	155-157
-	O	157-158
administration	O	158-172
of	O	173-175
aspirin	O	176-183
with	O	184-188
N	O	189-190
-	O	190-191
[	O	191-192
4	O	192-193
-	O	190-191
(	O	194-195
5	O	195-196
-	O	190-191
nitro	O	197-202
-	O	190-191
2	O	203-204
-	O	190-191
furyl	O	205-210
)	O	210-211
-	O	190-191
2	O	203-204
-	O	190-191
thiazolyl	O	214-223
]	O	223-224
-	O	190-191
formamide	O	225-234
(	O	235-236
FANFT	O	236-241
)	O	241-242
to	O	243-245
rats	O	246-250
resulted	O	251-259
in	O	260-262
a	O	263-264
reduced	O	265-272
incidence	O	273-282
of	O	283-285
FANFT	O	286-291
-	O	291-292
induced	O	292-299
bladder	B	300-307
carcinomas	I	308-318
but	O	319-322
a	O	323-324
concomitant	O	325-336
induction	O	337-346
of	O	347-349
forestomach	B	350-361
tumors	I	362-368
.	O	368-369

An	O	370-372
autoradiographic	O	373-389
study	O	390-395
was	O	396-399
performed	O	400-409
on	O	410-412
male	O	413-417
F	O	418-419
-	O	419-420
344	O	420-423
rats	O	424-428
fed	O	429-432
diet	O	433-437
containing	O	438-448
FANFT	O	449-454
at	O	455-457
a	O	458-459
level	O	460-465
of	O	466-468
0	O	469-470
.	O	470-471
2	O	471-472
%	O	472-473
and	O	474-477
/	O	477-478
or	O	478-480
aspirin	O	481-488
at	O	489-491
a	O	492-493
level	O	494-499
of	O	500-502
0	O	503-504
.	O	504-505
5	O	505-506
%	O	506-507
to	O	508-510
evaluate	O	511-519
the	O	520-523
effect	O	524-530
of	O	531-533
aspirin	O	534-541
on	O	542-544
the	O	545-548
increased	O	549-558
cell	O	559-563
proliferation	O	564-577
induced	O	578-585
by	O	586-588
FANFT	O	589-594
in	O	595-597
the	O	598-601
forestomach	O	602-613
and	O	614-617
bladder	O	618-625
.	O	625-626

FANFT	O	627-632
-	O	632-633
induced	O	633-640
cell	O	641-645
proliferation	O	646-659
in	O	660-662
the	O	663-666
bladder	O	667-674
was	O	675-678
significantly	O	679-692
suppressed	O	693-703
by	O	704-706
aspirin	O	707-714
co	O	715-717
-	O	717-718
administration	O	718-732
after	O	733-738
4	O	739-740
weeks	O	741-746
but	O	747-750
not	O	751-754
after	O	755-760
12	O	761-763
weeks	O	764-769
.	O	769-770

In	O	771-773
the	O	774-777
forestomach	O	778-789
,	O	789-790
and	O	791-794
also	O	795-799
in	O	800-802
the	O	803-806
liver	O	807-812
,	O	812-813
aspirin	O	814-821
did	O	822-825
not	O	826-829
affect	O	830-836
the	O	837-840
FANFT	O	841-846
-	O	846-847
induced	O	847-854
increase	O	855-863
in	O	864-866
labeling	O	867-875
index	O	876-881
.	O	881-882

The	O	883-886
present	O	887-894
results	O	895-902
are	O	903-906
consistent	O	907-917
with	O	918-922
the	O	923-926
carcinogenicity	O	927-942
experiment	O	943-953
suggesting	O	954-964
that	O	965-969
different	O	970-979
mechanisms	O	980-990
are	O	991-994
involved	O	995-1003
in	O	1004-1006
FANFT	O	1007-1012
carcinogenesis	B	1013-1027
in	O	1028-1030
the	O	1031-1034
bladder	O	1035-1042
and	O	1043-1046
forestomach	O	1047-1058
,	O	1058-1059
and	O	1060-1063
that	O	1064-1068
aspirin	O	1069-1076
'	O	1076-1077
s	O	1070-1071
effect	O	1079-1085
on	O	1086-1088
FANFT	O	1089-1094
in	O	1095-1097
the	O	1098-1101
forestomach	O	1102-1113
is	O	1114-1116
not	O	1117-1120
due	O	1121-1124
to	O	1125-1127
an	O	1128-1130
irritant	O	1131-1139
effect	O	1140-1146
associated	O	1147-1157
with	O	1158-1162
increased	O	1163-1172
cell	O	1173-1177
proliferation	O	1178-1191
.	O	1191-1192

Also	O	1193-1197
,	O	1197-1198
there	O	1199-1204
appears	O	1205-1212
to	O	1213-1215
be	O	1216-1218
an	O	1219-1221
adaptation	O	1222-1232
by	O	1233-1235
the	O	1236-1239
rats	O	1240-1244
to	O	1245-1247
the	O	1248-1251
chronic	O	1252-1259
ingestion	O	1260-1269
of	O	1270-1272
aspirin	O	1273-1280
.	O	1280-1281

Provocation	O	0-11
of	O	12-14
postural	O	15-23
hypotension	B	24-35
by	O	36-38
nitroglycerin	O	39-52
in	O	53-55
diabetic	B	56-64
autonomic	I	65-74
neuropathy	I	75-85
?	O	85-86

The	O	87-90
effect	O	91-97
of	O	98-100
nitroglycerin	O	101-114
on	O	115-117
heart	O	118-123
rate	O	124-128
and	O	129-132
systolic	O	133-141
blood	O	142-147
pressure	O	148-156
was	O	157-160
compared	O	161-169
in	O	170-172
5	O	173-174
normal	O	175-181
subjects	O	182-190
,	O	190-191
12	O	192-194
diabetic	B	195-203
subjects	O	204-212
without	O	213-220
autonomic	B	221-230
neuropathy	I	231-241
,	O	241-242
and	O	243-246
5	O	247-248
diabetic	B	249-257
subjects	O	258-266
with	O	267-271
autonomic	B	272-281
neuropathy	I	282-292
.	O	292-293

The	O	294-297
magnitude	O	298-307
and	O	308-311
time	O	312-316
course	O	317-323
of	O	324-326
the	O	327-330
increase	O	331-339
in	O	340-342
heart	O	343-348
rate	O	349-353
and	O	354-357
the	O	358-361
decrease	O	362-370
in	O	371-373
systolic	O	374-382
blood	O	383-388
pressure	O	389-397
after	O	398-403
nitroglycerin	O	404-417
were	O	418-422
similar	O	423-430
in	O	431-433
the	O	434-437
normal	O	438-444
and	O	445-448
diabetic	B	449-457
subjects	O	458-466
without	O	467-474
autonomic	B	475-484
neuropathy	I	485-495
,	O	495-496
whereas	O	497-504
a	O	505-506
lesser	O	507-513
increase	O	514-522
in	O	523-525
heart	O	526-531
rate	O	532-536
and	O	537-540
a	O	541-542
greater	O	543-550
decrease	O	551-559
in	O	560-562
systolic	O	563-571
blood	O	572-577
pressure	O	578-586
occurred	O	587-595
in	O	596-598
the	O	599-602
diabetic	B	603-611
subjects	O	612-620
with	O	621-625
autonomic	B	626-635
neuropathy	I	636-646
.	O	646-647

It	O	648-650
is	O	651-653
therefore	O	654-663
suggested	O	664-673
that	O	674-678
caution	O	679-686
should	O	687-693
be	O	694-696
exercised	O	697-706
when	O	707-711
prescribing	O	712-723
vasodilator	O	724-735
drugs	O	736-741
in	O	742-744
diabetic	B	745-753
patients	O	754-762
,	O	762-763
particularly	O	764-776
those	O	777-782
with	O	783-787
autonomic	B	788-797
neuropathy	I	798-808
.	O	808-809

Characterization	O	0-16
of	O	17-19
estrogen	O	20-28
-	O	28-29
induced	O	29-36
adenohypophyseal	B	37-53
tumors	I	54-60
in	O	61-63
the	O	64-67
Fischer	O	68-75
344	O	76-79
rat	O	80-83
.	O	83-84

Pituitary	B	85-94
tumors	I	95-101
were	O	102-106
induced	O	107-114
in	O	115-117
F344	O	118-122
female	O	123-129
rats	O	130-134
by	O	135-137
chronic	O	138-145
treatment	O	146-155
with	O	156-160
diethylstilbestrol	O	161-179
(	O	180-181
DES	O	181-184
,	O	184-185
8	O	186-187
-	O	187-188
10	O	188-190
mg	O	191-193
)	O	193-194
implanted	O	195-204
subcutaneously	O	205-219
in	O	220-222
silastic	O	223-231
capsules	O	232-240
.	O	240-241

Over	O	242-246
a	O	247-248
range	O	249-254
of	O	255-257
1	O	258-259
-	O	259-260
150	O	260-263
days	O	264-268
of	O	269-271
DES	O	272-275
treatment	O	276-285
,	O	285-286
pairs	O	287-292
of	O	293-295
control	O	296-303
and	O	304-307
DES	O	308-311
-	O	311-312
treated	O	312-319
rats	O	320-324
were	O	325-329
sacrificed	O	330-340
,	O	340-341
and	O	342-345
their	O	346-351
pituitaries	O	352-363
dissociated	O	364-375
enzymatically	O	376-389
into	O	390-394
single	O	395-401
-	O	401-402
cell	O	402-406
preparations	O	407-419
.	O	419-420

The	O	421-424
cell	O	425-429
populations	O	430-441
were	O	442-446
examined	O	447-455
regarding	O	456-465
total	O	466-471
cell	O	472-476
recovery	O	477-485
correlated	O	486-496
with	O	497-501
gland	O	502-507
weight	O	508-514
,	O	514-515
intracellular	O	516-529
prolactin	O	530-539
(	O	540-541
PRL	O	541-544
)	O	544-545
content	O	546-553
and	O	554-557
subsequent	O	558-568
release	O	569-576
in	O	577-579
primary	O	580-587
culture	O	588-595
,	O	595-596
immunocytochemical	O	597-615
PRL	O	616-619
staining	O	620-628
,	O	628-629
density	O	630-637
and	O	638-641
/	O	641-642
or	O	642-644
size	O	645-649
alterations	O	650-661
via	O	662-665
separation	O	666-676
on	O	677-679
Ficoll	O	680-686
-	O	686-687
Hypaque	O	687-694
and	O	695-698
by	O	699-701
unit	O	702-706
gravity	O	707-714
sedimentation	O	715-728
,	O	728-729
and	O	730-733
cell	O	734-738
cycle	O	739-744
analysis	O	745-753
,	O	753-754
after	O	755-760
acriflavine	O	761-772
DNA	O	773-776
staining	O	777-785
,	O	785-786
by	O	787-789
laser	O	790-795
flow	O	796-800
cytometry	O	801-810
.	O	810-811

Total	O	812-817
cell	O	818-822
yields	O	823-829
from	O	830-834
DES	O	835-838
-	O	838-839
treated	O	839-846
pituitaries	O	847-858
increased	O	859-868
from	O	869-873
1	O	874-875
.	O	875-876
3	O	876-877
times	O	878-883
control	O	884-891
yields	O	892-898
at	O	899-901
8	O	902-903
days	O	904-908
of	O	909-911
treatment	O	912-921
to	O	922-924
58	O	925-927
.	O	927-928
9	O	928-929
times	O	930-935
control	O	936-943
values	O	944-950
by	O	951-953
day	O	954-957
150	O	958-961
.	O	961-962

Intracellular	O	963-976
PRL	O	977-980
content	O	981-988
ranged	O	989-995
from	O	996-1000
1	O	1001-1002
.	O	1002-1003
9	O	1003-1004
to	O	1005-1007
9	O	1008-1009
.	O	1009-1010
4	O	1010-1011
times	O	1012-1017
control	O	1018-1025
levels	O	1026-1032
,	O	1032-1033
and	O	1034-1037
PRL	O	1038-1041
release	O	1042-1049
in	O	1050-1052
vitro	O	1053-1058
was	O	1059-1062
significantly	O	1063-1076
and	O	1077-1080
consistently	O	1081-1093
higher	O	1094-1100
than	O	1101-1105
controls	O	1106-1114
,	O	1114-1115
after	O	1116-1121
at	O	1122-1124
least	O	1125-1130
8	O	1131-1132
days	O	1133-1137
of	O	1138-1140
DES	O	1141-1144
exposure	O	1145-1153
.	O	1153-1154

Beyond	O	1155-1161
8	O	1162-1163
days	O	1164-1168
of	O	1169-1171
DES	O	1172-1175
exposure	O	1176-1184
,	O	1184-1185
the	O	1186-1189
immunochemically	O	1190-1206
PRL	O	1207-1210
-	O	1210-1211
positive	O	1211-1219
proportion	O	1220-1230
of	O	1231-1233
cells	O	1234-1239
increased	O	1240-1249
to	O	1250-1252
over	O	1253-1257
50	O	1258-1260
%	O	1260-1261
of	O	1262-1264
the	O	1265-1268
total	O	1269-1274
population	O	1275-1285
.	O	1285-1286

Increased	O	1287-1296
density	O	1297-1304
and	O	1305-1308
/	O	1308-1309
or	O	1309-1311
size	O	1312-1316
and	O	1317-1320
PRL	O	1321-1324
content	O	1325-1332
were	O	1333-1337
indicated	O	1338-1347
for	O	1348-1351
the	O	1352-1355
majority	O	1356-1364
of	O	1365-1367
the	O	1368-1371
PRL	O	1372-1375
cell	O	1376-1380
population	O	1381-1391
in	O	1392-1394
both	O	1395-1399
types	O	1400-1405
of	O	1406-1408
separation	O	1409-1419
protocols	O	1420-1429
.	O	1429-1430

All	O	1431-1434
these	O	1435-1440
effects	O	1441-1448
of	O	1449-1451
DES	O	1452-1455
were	O	1456-1460
more	O	1461-1465
pronounced	O	1466-1476
among	O	1477-1482
previously	O	1483-1493
ovariectomized	O	1494-1508
animals	O	1509-1516
.	O	1516-1517

The	O	1518-1521
data	O	1522-1526
extend	O	1527-1533
the	O	1534-1537
findings	O	1538-1546
of	O	1547-1549
other	O	1550-1555
investigators	O	1556-1569
,	O	1569-1570
further	O	1571-1578
establishing	O	1579-1591
the	O	1592-1595
DES	O	1596-1599
-	O	1599-1600
induced	O	1600-1607
tumor	B	1608-1613
as	O	1614-1616
a	O	1617-1618
model	O	1619-1624
for	O	1625-1628
study	O	1629-1634
of	O	1635-1637
PRL	O	1638-1641
cellular	O	1642-1650
control	O	1651-1658
mechanisms	O	1659-1669
.	O	1669-1670

Triamterene	O	0-11
nephrolithiasis	B	12-27
complicating	O	28-40
dyazide	O	41-48
therapy	O	49-56
.	O	56-57

A	O	58-59
case	O	60-64
of	O	65-67
triamterene	O	68-79
nephrolithiasis	B	80-95
is	O	96-98
reported	O	99-107
in	O	108-110
a	O	111-112
man	O	113-116
after	O	117-122
4	O	123-124
years	O	125-130
of	O	131-133
hydrochlorothiazide	O	134-153
-	O	153-154
triamterene	O	154-165
therapy	O	166-173
for	O	174-177
hypertension	B	178-190
.	O	190-191

The	O	192-195
stone	O	196-201
passed	O	202-208
spontaneously	O	209-222
and	O	223-226
was	O	227-230
found	O	231-236
to	O	237-239
contain	O	240-247
a	O	248-249
triamterene	O	250-261
metabolite	O	262-272
admixed	O	273-280
with	O	281-285
uric	O	286-290
acid	O	291-295
salts	O	296-301
.	O	301-302

Factors	O	303-310
affecting	O	311-320
triamterene	O	321-332
nephrolithiasis	B	333-348
are	O	349-352
discussed	O	353-362
and	O	363-366
2	O	367-368
previously	O	369-379
reported	O	380-388
cases	O	389-394
are	O	395-398
reviewed	O	399-407
.	O	407-408

Metabolic	O	0-9
involvement	O	10-21
in	O	22-24
adriamycin	O	25-35
cardiotoxicity	B	36-50
.	O	50-51

The	O	52-55
cardiotoxic	B	56-67
effects	O	68-75
of	O	76-78
adriamycin	O	79-89
were	O	90-94
studied	O	95-102
in	O	103-105
mammalian	O	106-115
myocardial	O	116-126
cells	O	127-132
in	O	133-135
culture	O	136-143
as	O	144-146
a	O	147-148
model	O	149-154
system	O	155-161
.	O	161-162

Adriamycin	O	163-173
inhibited	O	174-183
cell	O	184-188
growth	O	189-195
and	O	196-199
the	O	200-203
rhythmic	O	204-212
contractions	O	213-225
characteristic	O	226-240
of	O	241-243
myocardial	O	244-254
cells	O	255-260
in	O	261-263
culture	O	264-271
.	O	271-272

A	O	273-274
possible	O	275-283
involvement	O	284-295
of	O	296-298
energy	O	299-305
metabolism	O	306-316
was	O	317-320
suggested	O	321-330
previously	O	331-341
,	O	341-342
and	O	343-346
in	O	347-349
this	O	350-354
study	O	355-360
the	O	361-364
adenylate	O	365-374
energy	O	375-381
charge	O	382-388
and	O	389-392
phosphorylcreatine	O	393-411
mole	O	412-416
fraction	O	417-425
were	O	426-430
determined	O	431-441
in	O	442-444
the	O	445-448
adriamycin	O	449-459
-	O	459-460
treated	O	460-467
cells	O	468-473
.	O	473-474

The	O	475-478
adenylate	O	479-488
energy	O	489-495
charge	O	496-502
was	O	503-506
found	O	507-512
to	O	513-515
be	O	516-518
significantly	O	519-532
decreased	O	533-542
,	O	542-543
while	O	544-549
the	O	550-553
phophorylcreatine	O	554-571
mole	O	572-576
fraction	O	577-585
was	O	586-589
unchanged	O	590-599
.	O	599-600

Such	O	601-605
disparity	O	606-615
suggests	O	616-624
an	O	625-627
inhibition	O	628-638
of	O	639-641
creatine	O	642-650
phosphokinase	O	651-664
.	O	664-665

The	O	666-669
addition	O	670-678
of	O	679-681
1	O	682-683
mM	O	684-686
adenosine	O	687-696
to	O	697-699
the	O	700-703
myocardial	O	704-714
cell	O	715-719
cultures	O	720-728
markedly	O	729-737
increases	O	738-747
the	O	748-751
ATP	O	752-755
concentration	O	756-769
through	O	770-777
a	O	778-779
pathway	O	780-787
reportedly	O	788-798
leading	O	799-806
to	O	807-809
a	O	810-811
compartmentalized	O	812-829
ATP	O	830-833
pool	O	834-838
.	O	838-839

In	O	840-842
the	O	843-846
adriamycin	O	847-857
-	O	857-858
treated	O	858-865
cells	O	866-871
,	O	871-872
the	O	873-876
addition	O	877-885
of	O	886-888
adenosine	O	889-898
increased	O	899-908
the	O	909-912
adenylate	O	913-922
charge	O	923-929
and	O	930-933
,	O	933-934
concomitant	O	935-946
with	O	947-951
this	O	952-956
inrcease	O	957-965
,	O	965-966
the	O	967-970
cells	O	971-976
'	O	976-977
functional	O	978-988
integrity	O	989-998
,	O	998-999
in	O	1000-1002
terms	O	1003-1008
of	O	1009-1011
percentage	O	1012-1022
of	O	1023-1025
beating	O	1026-1033
cells	O	1034-1039
and	O	1040-1043
rate	O	1044-1048
of	O	1049-1051
contractions	O	1052-1064
,	O	1064-1065
was	O	1066-1069
maintained	O	1070-1080
.	O	1080-1081

Age	O	0-3
-	O	3-4
dependent	O	4-13
sensitivity	O	14-25
of	O	26-28
the	O	29-32
rat	O	33-36
to	O	37-39
neurotoxic	B	40-50
effects	O	51-58
of	O	59-61
streptomycin	O	62-74
.	O	74-75

Streptomycin	O	76-88
sulfate	O	89-96
(	O	97-98
300	O	98-101
mg	O	102-104
/	O	104-105
kg	O	105-107
s	O	108-109
.	O	109-110
c	O	110-111
.	O	109-110
)	O	112-113
was	O	114-117
injected	O	118-126
for	O	127-130
various	O	131-138
periods	O	139-146
into	O	147-151
preweanling	O	152-163
rats	O	164-168
and	O	169-172
for	O	173-176
3	O	177-178
weeks	O	179-184
into	O	185-189
weanling	O	190-198
rats	O	199-203
.	O	203-204

Beginning	O	205-214
at	O	215-217
8	O	218-219
days	O	220-224
of	O	225-227
age	O	228-231
,	O	231-232
body	O	233-237
movement	O	238-246
and	O	247-250
hearing	O	251-258
were	O	259-263
examined	O	264-272
for	O	273-276
6	O	277-278
and	O	279-282
up	O	283-285
to	O	286-288
17	O	289-291
weeks	O	292-297
,	O	297-298
respectively	O	299-311
.	O	311-312

Abnormal	B	313-321
movements	I	322-331
and	O	332-335
deafness	B	336-344
occurred	O	345-353
only	O	354-358
in	O	359-361
rats	O	362-366
treated	O	367-374
during	O	375-381
the	O	382-385
preweaning	O	386-396
period	O	397-403
;	O	403-404
within	O	405-411
this	O	412-416
period	O	417-423
the	O	424-427
greatest	O	428-436
sensitivities	O	437-450
for	O	451-454
these	O	455-460
abnormalities	O	461-474
occurred	O	475-483
from	O	484-488
2	O	489-490
to	O	491-493
11	O	494-496
-	O	496-497
17	O	497-499
and	O	500-503
5	O	504-505
to	O	506-508
11	O	509-511
days	O	512-516
of	O	517-519
age	O	520-523
,	O	523-524
respectively	O	525-537
,	O	537-538
indicating	O	539-549
that	O	550-554
the	O	555-558
cochlea	O	559-566
is	O	567-569
more	O	570-574
sensitive	O	575-584
to	O	585-587
streptomycin	O	588-600
than	O	601-605
the	O	606-609
site	O	610-614
(	O	615-616
vestibular	O	616-626
or	O	627-629
central	O	630-637
)	O	637-638
responsible	O	639-650
for	O	651-654
the	O	655-658
dyskinesias	B	659-670
.	O	670-671

Crescentic	O	0-10
fibrillary	O	11-21
glomerulonephritis	B	22-40
associated	O	41-51
with	O	52-56
intermittent	O	57-69
rifampin	O	70-78
therapy	O	79-86
for	O	87-90
pulmonary	B	91-100
tuberculosis	I	101-113
.	O	113-114

This	O	115-119
case	O	120-124
study	O	125-130
reveals	O	131-138
an	O	139-141
unusual	O	142-149
finding	O	150-157
of	O	158-160
rapidly	O	161-168
proliferative	O	169-182
crescentic	O	183-193
glomerulonephritis	B	194-212
in	O	213-215
a	O	216-217
patient	O	218-225
treated	O	226-233
with	O	234-238
rifampin	O	239-247
who	O	248-251
had	O	252-255
no	O	256-258
other	O	259-264
identifiable	O	265-277
causes	O	278-284
for	O	285-288
developing	O	289-299
this	O	300-304
disease	O	305-312
.	O	312-313

This	O	314-318
patient	O	319-326
underwent	O	327-336
a	O	337-338
10	O	339-341
-	O	341-342
month	O	342-347
regimen	O	348-355
of	O	356-358
rifampin	O	359-367
and	O	368-371
isoniazid	O	372-381
for	O	382-385
pulmonary	B	386-395
tuberculosis	I	396-408
and	O	409-412
was	O	413-416
discovered	O	417-427
to	O	428-430
have	O	431-435
developed	O	436-445
signs	O	446-451
of	O	452-454
severe	O	455-461
renal	B	462-467
failure	I	468-475
five	O	476-480
weeks	O	481-486
after	O	487-492
completion	O	493-503
of	O	504-506
therapy	O	507-514
.	O	514-515

Renal	O	516-521
biopsy	O	522-528
revealed	O	529-537
severe	O	538-544
glomerulonephritis	B	545-563
with	O	564-568
crescents	O	569-578
,	O	578-579
electron	O	580-588
dense	O	589-594
fibrillar	O	595-604
deposits	O	605-613
and	O	614-617
moderate	O	618-626
lymphocytic	O	627-638
interstitial	O	639-651
infiltrate	O	652-662
.	O	662-663

Other	O	664-669
possible	O	670-678
causes	O	679-685
of	O	686-688
rapidly	O	689-696
progressive	O	697-708
glomerulonephritis	B	709-727
were	O	728-732
investigated	O	733-745
and	O	746-749
ruled	O	750-755
out	O	756-759
.	O	759-760

This	O	761-765
report	O	766-772
documents	O	773-782
the	O	783-786
unusual	O	787-794
occurrence	O	795-805
of	O	806-808
rapidly	O	809-816
progressive	O	817-828
glomerulonephritis	B	829-847
with	O	848-852
crescents	O	853-862
and	O	863-866
fibrillar	O	867-876
glomerulonephritis	B	877-895
in	O	896-898
a	O	899-900
patient	O	901-908
treated	O	909-916
with	O	917-921
rifampin	O	922-930
.	O	930-931

Time	O	0-4
course	O	5-11
of	O	12-14
lipid	O	15-20
peroxidation	O	21-33
in	O	34-36
puromycin	O	37-46
aminonucleoside	O	47-62
-	O	62-63
induced	O	63-70
nephropathy	B	71-82
.	O	82-83

Reactive	O	84-92
oxygen	O	93-99
species	O	100-107
have	O	108-112
been	O	113-117
implicated	O	118-128
in	O	129-131
the	O	132-135
pathogenesis	O	136-148
of	O	149-151
acute	O	152-157
puromycin	O	158-167
aminonucleoside	O	168-183
(	O	184-185
PAN	O	185-188
)	O	188-189
-	O	189-190
induced	O	190-197
nephropathy	B	198-209
,	O	209-210
with	O	211-215
antioxidants	O	216-228
significantly	O	229-242
reducing	O	243-251
the	O	252-255
proteinuria	B	256-267
.	O	267-268

The	O	269-272
temporal	O	273-281
relationship	O	282-294
between	O	295-302
lipid	O	303-308
peroxidation	O	309-321
in	O	322-324
the	O	325-328
kidney	O	329-335
and	O	336-339
proteinuria	B	340-351
was	O	352-355
examined	O	356-364
in	O	365-367
this	O	368-372
study	O	373-378
.	O	378-379

Rats	O	380-384
were	O	385-389
treated	O	390-397
with	O	398-402
a	O	403-404
single	O	405-411
IV	O	412-414
injection	O	415-424
of	O	425-427
puromycin	O	428-437
aminonucleoside	O	438-453
,	O	453-454
(	O	455-456
PAN	O	456-459
,	O	459-460
7	O	461-462
.	O	462-463
5	O	463-464
mg	O	465-467
/	O	467-468
kg	O	468-470
)	O	470-471
and	O	472-475
24	O	476-478
hour	O	479-483
urine	O	484-489
samples	O	490-497
were	O	498-502
obtained	O	503-511
prior	O	512-517
to	O	518-520
sacrifice	O	521-530
on	O	531-533
days	O	534-538
3	O	539-540
,	O	540-541
5	O	541-542
,	O	540-541
7	O	543-544
,	O	540-541
10	O	545-547
,	O	540-541
17	O	548-550
,	O	540-541
27	O	551-553
,	O	540-541
41	O	554-556
(	O	557-558
N	O	558-559
=	O	560-561
5	O	562-563
-	O	563-564
10	O	564-566
per	O	567-570
group	O	571-576
)	O	576-577
.	O	577-578

The	O	579-582
kidneys	O	583-590
were	O	591-595
removed	O	596-603
,	O	603-604
flushed	O	605-612
with	O	613-617
ice	O	618-621
cold	O	622-626
TRIS	O	627-631
buffer	O	632-638
.	O	638-639

Kidney	O	640-646
cortices	O	647-655
from	O	656-660
each	O	661-665
animal	O	666-672
were	O	673-677
used	O	678-682
to	O	683-685
prepare	O	686-693
homogenates	O	694-705
.	O	705-706

Tissue	O	707-713
lipid	O	714-719
peroxidation	O	720-732
was	O	733-736
measured	O	737-745
in	O	746-748
whole	O	749-754
homogenates	O	755-766
as	O	767-769
well	O	770-774
as	O	775-777
in	O	778-780
lipid	O	781-786
extracts	O	787-795
from	O	796-800
homogenates	O	801-812
as	O	813-815
thiobarbituric	O	816-830
acid	O	831-835
reactive	O	836-844
substances	O	845-855
.	O	855-856

Proteinuria	B	857-868
was	O	869-872
evident	O	873-880
at	O	881-883
day	O	884-887
5	O	888-889
,	O	889-890
peaked	O	891-897
at	O	898-900
day	O	901-904
7	O	905-906
and	O	907-910
persisted	O	911-920
to	O	921-923
day	O	924-927
27	O	928-930
.	O	930-931

Lipid	O	932-937
peroxidation	O	938-950
in	O	951-953
homogenates	O	954-965
was	O	966-969
maximal	O	970-977
at	O	978-980
day	O	981-984
3	O	985-986
and	O	987-990
declined	O	991-999
rapidly	O	1000-1007
to	O	1008-1010
control	O	1011-1018
levels	O	1019-1025
by	O	1026-1028
day	O	1029-1032
17	O	1033-1035
.	O	1035-1036

This	O	1037-1041
study	O	1042-1047
supports	O	1048-1056
the	O	1057-1060
role	O	1061-1065
of	O	1066-1068
lipid	O	1069-1074
peroxidation	O	1075-1087
in	O	1088-1090
mediating	O	1091-1100
the	O	1101-1104
proteinuric	B	1105-1116
injury	I	1117-1123
in	O	1124-1126
PAN	O	1127-1130
nephropathy	B	1131-1142
.	O	1142-1143

Clomipramine	O	0-12
-	O	12-13
induced	O	13-20
sleep	B	21-26
disturbance	I	27-38
does	O	39-43
not	O	44-47
impair	O	48-54
its	O	55-58
prolactin	O	59-68
-	O	68-69
releasing	O	69-78
action	O	79-85
.	O	85-86

The	O	87-90
present	O	91-98
study	O	99-104
was	O	105-108
undertaken	O	109-119
to	O	120-122
examine	O	123-130
the	O	131-134
role	O	135-139
of	O	140-142
sleep	B	143-148
disturbance	I	149-160
,	O	160-161
induced	O	162-169
by	O	170-172
clomipramine	O	173-185
administration	O	186-200
,	O	200-201
on	O	202-204
the	O	205-208
secretory	O	209-218
rate	O	219-223
of	O	224-226
prolactin	O	227-236
(	O	237-238
PRL	O	238-241
)	O	241-242
in	O	243-245
addition	O	246-254
to	O	255-257
the	O	258-261
direct	O	262-268
drug	O	269-273
effect	O	274-280
.	O	280-281

Two	O	282-285
groups	O	286-292
of	O	293-295
supine	O	296-302
subjects	O	303-311
were	O	312-316
studied	O	317-324
under	O	325-330
placebo	O	331-338
-	O	338-339
controlled	O	339-349
conditions	O	350-360
,	O	360-361
one	O	362-365
during	O	366-372
the	O	373-376
night	O	377-382
,	O	382-383
when	O	384-388
sleeping	O	389-397
(	O	398-399
n	O	399-400
=	O	401-402
7	O	403-404
)	O	404-405
and	O	406-409
the	O	410-413
other	O	414-419
at	O	420-422
daytime	O	423-430
,	O	430-431
when	O	432-436
awake	O	437-442
(	O	443-444
n	O	444-445
=	O	446-447
6	O	448-449
)	O	449-450
.	O	450-451

Each	O	452-456
subject	O	457-464
received	O	465-473
a	O	474-475
single	O	476-482
50	O	483-485
mg	O	486-488
dose	O	489-493
of	O	494-496
clomipramine	O	497-509
given	O	510-515
orally	O	516-522
2	O	523-524
hours	O	525-530
before	O	531-537
blood	O	538-543
collection	O	544-554
.	O	554-555

Plasma	O	556-562
PRL	O	563-566
concentrations	O	567-581
were	O	582-586
analysed	O	587-595
at	O	596-598
10	O	599-601
min	O	602-605
intervals	O	606-615
and	O	616-619
underlying	O	620-630
secretory	O	631-640
rates	O	641-646
calculated	O	647-657
by	O	658-660
a	O	661-662
deconvolution	O	663-676
procedure	O	677-686
.	O	686-687

For	O	688-691
both	O	692-696
experiments	O	697-708
the	O	709-712
drug	O	713-717
intake	O	718-724
led	O	725-728
to	O	729-731
significant	O	732-743
increases	O	744-753
in	O	754-756
PRL	O	757-760
secretion	O	761-770
,	O	770-771
acting	O	772-778
preferentially	O	779-793
on	O	794-796
tonic	O	797-802
secretion	O	803-812
as	O	813-815
pulse	O	816-821
amplitude	O	822-831
and	O	832-835
frequency	O	836-845
did	O	846-849
not	O	850-853
differ	O	854-860
significantly	O	861-874
from	O	875-879
corresponding	O	880-893
control	O	894-901
values	O	902-908
.	O	908-909

During	O	910-916
the	O	917-920
night	O	921-926
clomipramine	O	927-939
ingestion	O	940-949
altered	O	950-957
the	O	958-961
complete	O	962-970
sleep	O	971-976
architecture	O	977-989
in	O	990-992
that	O	993-997
it	O	998-1000
suppressed	O	1001-1011
REM	O	1012-1015
sleep	O	1016-1021
and	O	1022-1025
the	O	1026-1029
sleep	O	1030-1035
cycles	O	1036-1042
and	O	1043-1046
induced	O	1047-1054
increased	O	1055-1064
wakefulness	O	1065-1076
.	O	1076-1077

As	O	1078-1080
the	O	1081-1084
relative	O	1085-1093
increase	O	1094-1102
in	O	1103-1105
PRL	O	1106-1109
secretion	O	1110-1119
expressed	O	1120-1129
as	O	1130-1132
a	O	1133-1134
percentage	O	1135-1145
of	O	1146-1148
the	O	1149-1152
mean	O	1153-1157
did	O	1158-1161
not	O	1162-1165
significantly	O	1166-1179
differ	O	1180-1186
between	O	1187-1194
the	O	1195-1198
night	O	1199-1204
and	O	1205-1208
day	O	1209-1212
time	O	1213-1217
studies	O	1218-1225
(	O	1226-1227
46	O	1227-1229
+	O	1230-1231
/	O	1231-1232
-	O	1232-1233
19	O	1234-1236
%	O	1236-1237
vs	O	1238-1240
34	O	1241-1243
+	O	1244-1245
/	O	1245-1246
-	O	1246-1247
10	O	1248-1250
%	O	1250-1251
)	O	1251-1252
,	O	1252-1253
it	O	1254-1256
can	O	1257-1260
be	O	1261-1263
concluded	O	1264-1273
that	O	1274-1278
the	O	1279-1282
observed	O	1283-1291
sleep	B	1292-1297
disturbance	I	1298-1309
did	O	1310-1313
not	O	1314-1317
interfere	O	1318-1327
with	O	1328-1332
the	O	1333-1336
drug	O	1337-1341
action	O	1342-1348
per	O	1349-1352
se	O	1353-1355
.	O	1355-1356

The	O	1357-1360
presence	O	1361-1369
of	O	1370-1372
REM	O	1373-1376
sleep	O	1377-1382
was	O	1383-1386
shown	O	1387-1392
not	O	1393-1396
to	O	1397-1399
be	O	1400-1402
a	O	1403-1404
determining	O	1405-1416
factor	O	1417-1423
either	O	1424-1430
for	O	1431-1434
secretory	O	1435-1444
pulse	O	1445-1450
amplitude	O	1451-1460
and	O	1461-1464
frequency	O	1465-1474
,	O	1474-1475
as	O	1476-1478
,	O	1478-1479
for	O	1480-1483
both	O	1484-1488
,	O	1488-1489
mean	O	1490-1494
nocturnal	O	1495-1504
values	O	1505-1511
were	O	1512-1516
similar	O	1517-1524
with	O	1525-1529
and	O	1530-1533
without	O	1534-1541
prior	O	1542-1547
clomipramine	O	1548-1560
ingestion	O	1561-1570
.	O	1570-1571

Angioedema	B	0-10
following	O	11-20
the	O	21-24
intravenous	O	25-36
administration	O	37-51
of	O	52-54
metoprolol	O	55-65
.	O	65-66

A	O	67-68
72	O	69-71
-	O	71-72
year	O	72-76
-	O	71-72
old	O	77-80
woman	O	81-86
was	O	87-90
admitted	O	91-99
to	O	100-102
the	O	103-106
hospital	O	107-115
with	O	116-120
"	O	121-122
flash	O	122-127
"	O	121-122
pulmonary	B	129-138
edema	I	139-144
,	O	144-145
preceded	O	146-154
by	O	155-157
chest	B	158-163
pain	I	164-168
,	O	168-169
requiring	O	170-179
intubation	O	180-190
.	O	190-191

Her	O	192-195
medical	O	196-203
history	O	204-211
included	O	212-220
coronary	B	221-229
artery	I	230-236
disease	I	237-244
with	O	245-249
previous	O	250-258
myocardial	B	259-269
infarctions	I	270-281
,	O	281-282
hypertension	B	283-295
,	O	295-296
and	O	297-300
diabetes	B	301-309
mellitus	I	310-318
.	O	318-319

A	O	320-321
history	O	322-329
of	O	330-332
angioedema	B	333-343
secondary	O	344-353
to	O	354-356
lisinopril	O	357-367
therapy	O	368-375
was	O	376-379
elicited	O	380-388
.	O	388-389

Current	O	390-397
medications	O	398-409
did	O	410-413
not	O	414-417
include	O	418-425
angiotensin	O	426-437
-	O	437-438
converting	O	438-448
enzyme	O	449-455
inhibitors	O	456-466
or	O	467-469
beta	O	470-474
-	O	474-475
blockers	O	475-483
.	O	483-484

She	O	485-488
had	O	489-492
no	O	493-495
previous	O	496-504
beta	O	505-509
-	O	509-510
blocking	O	510-518
drug	O	519-523
exposure	O	524-532
.	O	532-533

During	O	534-540
the	O	541-544
first	O	545-550
day	O	551-554
of	O	555-557
hospitalization	O	558-573
(	O	574-575
while	O	575-580
intubated	O	581-590
)	O	590-591
,	O	591-592
intravenous	O	593-604
metoprolol	O	605-615
was	O	616-619
given	O	620-625
,	O	625-626
resulting	O	627-636
in	O	637-639
severe	O	640-646
angioedema	B	647-657
.	O	657-658

The	O	659-662
angioedema	B	663-673
resolved	O	674-682
after	O	683-688
therapy	O	689-696
with	O	697-701
intravenous	O	702-713
steroids	O	714-722
and	O	723-726
diphenhydramine	O	727-742
hydrochloride	O	743-756
.	O	756-757

Effect	O	0-6
of	O	7-9
coniine	O	10-17
on	O	18-20
the	O	21-24
developing	O	25-35
chick	O	36-41
embryo	O	42-48
.	O	48-49

Coniine	O	50-57
,	O	57-58
an	O	59-61
alkaloid	O	62-70
from	O	71-75
Conium	O	76-82
maculatum	O	83-92
(	O	93-94
poison	O	94-100
hemlock	O	101-108
)	O	108-109
,	O	109-110
has	O	111-114
been	O	115-119
shown	O	120-125
to	O	126-128
be	O	129-131
teratogenic	O	132-143
in	O	144-146
livestock	O	147-156
.	O	156-157

The	O	158-161
major	O	162-167
teratogenic	O	168-179
outcome	O	180-187
is	O	188-190
arthrogryposis	B	191-205
,	O	205-206
presumably	O	207-217
due	O	218-221
to	O	222-224
nicotinic	O	225-234
receptor	O	235-243
blockade	O	244-252
.	O	252-253

However	O	254-261
,	O	261-262
coniine	O	263-270
has	O	271-274
failed	O	275-281
to	O	282-284
produce	O	285-292
arthrogryposis	B	293-307
in	O	308-310
rats	O	311-315
or	O	316-318
mice	O	319-323
and	O	324-327
is	O	328-330
only	O	331-335
weakly	O	336-342
teratogenic	O	343-354
in	O	355-357
rabbits	O	358-365
.	O	365-366

The	O	367-370
purpose	O	371-378
of	O	379-381
this	O	382-386
study	O	387-392
was	O	393-396
to	O	397-399
evaluate	O	400-408
and	O	409-412
compare	O	413-420
the	O	421-424
effects	O	425-432
of	O	433-435
coniine	O	436-443
and	O	444-447
nicotine	O	448-456
in	O	457-459
the	O	460-463
developing	O	464-474
chick	O	475-480
.	O	480-481

Concentrations	O	482-496
of	O	497-499
coniine	O	500-507
and	O	508-511
nicotine	O	512-520
sulfate	O	521-528
were	O	529-533
0	O	534-535
.	O	535-536
015	O	536-539
%	O	539-540
,	O	540-541
0	O	542-543
.	O	543-544
03	O	544-546
%	O	546-547
,	O	547-548
0	O	549-550
.	O	550-551
075	O	551-554
%	O	554-555
,	O	555-556
0	O	557-558
.	O	558-559
15	O	559-561
%	O	561-562
,	O	562-563
0	O	564-565
.	O	565-566
75	O	566-568
%	O	568-569
,	O	569-570
1	O	571-572
.	O	572-573
5	O	573-574
%	O	574-575
,	O	575-576
3	O	577-578
%	O	578-579
,	O	579-580
and	O	581-584
6	O	585-586
%	O	586-587
and	O	588-591
1	O	592-593
%	O	593-594
,	O	594-595
5	O	596-597
%	O	597-598
,	O	598-599
and	O	600-603
10	O	604-606
%	O	606-607
,	O	607-608
respectively	O	609-621
.	O	621-622

Both	O	623-627
compounds	O	628-637
caused	O	638-644
deformations	B	645-657
and	O	658-661
lethality	O	662-671
in	O	672-674
a	O	675-676
dose	O	677-681
-	O	681-682
dependent	O	682-691
manner	O	692-698
.	O	698-699

All	O	700-703
concentrations	O	704-718
of	O	719-721
nicotine	O	722-730
sulfate	O	731-738
caused	O	739-745
some	O	746-750
lethality	O	751-760
but	O	761-764
a	O	765-766
no	O	767-769
effect	O	770-776
level	O	777-782
for	O	783-786
coniine	O	787-794
lethality	O	795-804
was	O	805-808
0	O	809-810
.	O	810-811
75	O	811-813
%	O	813-814
.	O	810-811

The	O	816-819
deformations	B	820-832
caused	O	833-839
by	O	840-842
both	O	843-847
coniine	O	848-855
and	O	856-859
nicotine	O	860-868
sulfate	O	869-876
were	O	877-881
excessive	B	882-891
flexion	I	892-899
or	I	900-902
extension	I	903-912
of	I	913-915
one	I	916-919
or	I	920-922
more	I	923-927
toes	I	928-932
.	O	932-933

No	O	934-936
histopathological	O	937-954
alterations	O	955-966
or	O	967-969
differences	O	970-981
in	O	982-984
bone	O	985-989
formation	O	990-999
were	O	1000-1004
seen	O	1005-1009
in	O	1010-1012
the	O	1013-1016
limbs	O	1017-1022
or	O	1023-1025
toes	O	1026-1030
of	O	1031-1033
any	O	1034-1037
chicks	O	1038-1044
from	O	1045-1049
any	O	1050-1053
group	O	1054-1059
;	O	1059-1060
however	O	1061-1068
,	O	1068-1069
extensive	O	1070-1079
cranial	B	1080-1087
hemorrhage	I	1088-1098
occurred	O	1099-1107
in	O	1108-1110
all	O	1111-1114
nicotine	O	1115-1123
sulfate	O	1124-1131
-	O	1131-1132
treated	O	1132-1139
chicks	O	1140-1146
.	O	1146-1147

There	O	1148-1153
was	O	1154-1157
a	O	1158-1159
statistically	O	1160-1173
significant	O	1174-1185
(	O	1186-1187
P	O	1187-1188
<	O	1189-1190
or	O	1191-1193
=	O	1194-1195
0	O	1196-1197
.	O	1197-1198
01	O	1198-1200
)	O	1200-1201
decrease	O	1202-1210
in	O	1211-1213
movement	O	1214-1222
in	O	1223-1225
coniine	O	1226-1233
and	O	1234-1237
nicotine	O	1238-1246
sulfate	O	1247-1254
treated	O	1255-1262
chicks	O	1263-1269
as	O	1270-1272
determined	O	1273-1283
by	O	1284-1286
ultrasound	O	1287-1297
.	O	1297-1298

Control	O	1299-1306
chicks	O	1307-1313
were	O	1314-1318
in	O	1319-1321
motion	O	1322-1328
an	O	1329-1331
average	O	1332-1339
of	O	1340-1342
33	O	1343-1345
.	O	1345-1346
67	O	1346-1348
%	O	1348-1349
of	O	1350-1352
the	O	1353-1356
time	O	1357-1361
,	O	1361-1362
while	O	1363-1368
coniine	O	1369-1376
-	O	1376-1377
treated	O	1377-1384
chicks	O	1385-1391
were	O	1392-1396
only	O	1397-1401
moving	O	1402-1408
8	O	1409-1410
.	O	1410-1411
95	O	1411-1413
%	O	1413-1414
of	O	1415-1417
a	O	1418-1419
5	O	1420-1421
-	O	1421-1422
min	O	1422-1425
interval	O	1426-1434
,	O	1434-1435
and	O	1436-1439
no	O	1440-1442
movement	O	1443-1451
was	O	1452-1455
observed	O	1456-1464
for	O	1465-1468
nicotine	O	1469-1477
sulfate	O	1478-1485
treated	O	1486-1493
chicks	O	1494-1500
.	O	1500-1501

In	O	1502-1504
summary	O	1505-1512
,	O	1512-1513
the	O	1514-1517
chick	O	1518-1523
embryo	O	1524-1530
provides	O	1531-1539
a	O	1540-1541
reliable	O	1542-1550
and	O	1551-1554
simple	O	1555-1561
experimental	O	1562-1574
animal	O	1575-1581
model	O	1582-1587
of	O	1588-1590
coniine	O	1591-1598
-	O	1598-1599
induced	O	1599-1606
arthrogryposis	B	1607-1621
.	O	1621-1622

Data	O	1623-1627
from	O	1628-1632
this	O	1633-1637
model	O	1638-1643
support	O	1644-1651
a	O	1652-1653
mechanism	O	1654-1663
involving	O	1664-1673
nicotinic	O	1674-1683
receptor	O	1684-1692
blockade	O	1693-1701
with	O	1702-1706
subsequent	O	1707-1717
decreased	O	1718-1727
fetal	O	1728-1733
movement	O	1734-1742
.	O	1742-1743

Epidural	O	0-8
blood	O	9-14
flow	O	15-19
during	O	20-26
prostaglandin	O	27-40
E1	O	41-43
or	O	44-46
trimethaphan	O	47-59
induced	O	60-67
hypotension	B	68-79
.	O	79-80

To	O	81-83
evaluate	O	84-92
the	O	93-96
effect	O	97-103
of	O	104-106
prostaglandin	O	107-120
E1	O	121-123
(	O	124-125
PGE1	O	125-129
)	O	129-130
or	O	131-133
trimethaphan	O	134-146
(	O	147-148
TMP	O	148-151
)	O	151-152
induced	O	153-160
hypotension	B	161-172
on	O	173-175
epidural	O	176-184
blood	O	185-190
flow	O	191-195
(	O	196-197
EBF	O	197-200
)	O	200-201
during	O	202-208
spinal	O	209-215
surgery	O	216-223
,	O	223-224
EBF	O	225-228
was	O	229-232
measured	O	233-241
using	O	242-247
the	O	248-251
heat	O	252-256
clearance	O	257-266
method	O	267-273
in	O	274-276
30	O	277-279
patients	O	280-288
who	O	289-292
underwent	O	293-302
postero	O	303-310
-	O	310-311
lateral	O	311-318
interbody	O	319-328
fusion	O	329-335
under	O	336-341
isoflurane	O	342-352
anaesthesia	O	353-364
.	O	364-365

An	O	366-368
initial	O	369-376
dose	O	377-381
of	O	382-384
0	O	385-386
.	O	386-387
1	O	387-388
microgram	O	389-398
.	O	398-399
kg	O	399-401
-	O	401-402
1	O	402-403
.	O	398-399
min	O	404-407
-	O	401-402
1	O	402-403
of	O	410-412
PGE1	O	413-417
(	O	418-419
15	O	419-421
patients	O	422-430
)	O	430-431
,	O	431-432
or	O	433-435
10	O	436-438
micrograms	O	439-449
.	O	449-450
kg	O	450-452
-	O	452-453
1	O	453-454
.	O	449-450
min	O	455-458
-	O	452-453
1	O	453-454
of	O	461-463
TMP	O	464-467
(	O	468-469
15	O	469-471
patients	O	472-480
)	O	480-481
was	O	482-485
administered	O	486-498
intravenously	O	499-512
after	O	513-518
the	O	519-522
dural	O	523-528
opening	O	529-536
and	O	537-540
the	O	541-544
dose	O	545-549
was	O	550-553
adjusted	O	554-562
to	O	563-565
maintain	O	566-574
the	O	575-578
mean	O	579-583
arterial	O	584-592
blood	O	593-598
pressure	O	599-607
(	O	608-609
MAP	O	609-612
)	O	612-613
at	O	614-616
about	O	617-622
60	O	623-625
mmHg	O	626-630
.	O	630-631

The	O	632-635
hypotensive	B	636-647
drug	O	648-652
was	O	653-656
discontinued	O	657-669
at	O	670-672
the	O	673-676
completion	O	677-687
of	O	688-690
the	O	691-694
operative	O	695-704
procedure	O	705-714
.	O	714-715

After	O	716-721
starting	O	722-730
PGE1	O	731-735
or	O	736-738
TMP	O	739-742
,	O	742-743
MAP	O	744-747
and	O	748-751
rate	O	752-756
pressure	O	757-765
product	O	766-773
(	O	774-775
RPP	O	775-778
)	O	778-779
decreased	O	780-789
significantly	O	790-803
compared	O	804-812
with	O	813-817
preinfusion	O	818-829
values	O	830-836
(	O	837-838
P	O	838-839
<	O	840-841
0	O	842-843
.	O	843-844
01	O	844-846
)	O	846-847
,	O	847-848
and	O	849-852
the	O	853-856
degree	O	857-863
of	O	864-866
hypotension	B	867-878
due	O	879-882
to	O	883-885
PGE1	O	886-890
remained	O	891-899
constant	O	900-908
until	O	909-914
60	O	915-917
min	O	918-921
after	O	922-927
its	O	928-931
discontinuation	O	932-947
.	O	947-948

Heart	O	949-954
rate	O	955-959
(	O	960-961
HR	O	961-963
)	O	963-964
did	O	965-968
not	O	969-972
change	O	973-979
in	O	980-982
either	O	983-989
group	O	990-995
.	O	995-996

EBFF	O	997-1001
did	O	1002-1005
not	O	1006-1009
change	O	1010-1016
during	O	1017-1023
PGE1	O	1024-1028
infusion	O	1029-1037
whereas	O	1038-1045
in	O	1046-1048
the	O	1049-1052
TMP	O	1053-1056
group	O	1057-1062
,	O	1062-1063
EBF	O	1064-1067
decreased	O	1068-1077
significantly	O	1078-1091
at	O	1092-1094
30	O	1095-1097
and	O	1098-1101
60	O	1102-1104
min	O	1105-1108
after	O	1109-1114
the	O	1115-1118
start	O	1119-1124
of	O	1125-1127
TMP	O	1128-1131
(	O	1132-1133
preinfusion	O	1133-1144
:	O	1144-1145
45	O	1146-1148
.	O	1148-1149
9	O	1149-1150
+	O	1151-1152
/	O	1152-1153
-	O	1153-1154
13	O	1155-1157
.	O	1157-1158
9	O	1158-1159
ml	O	1160-1162
/	O	1162-1163
100g	O	1163-1167
/	O	1162-1163
min	O	1168-1171
.	O	1171-1172

30	O	1173-1175
min	O	1176-1179
:	O	1179-1180
32	O	1181-1183
.	O	1183-1184
3	O	1181-1182
+	O	1186-1187
/	O	1187-1188
-	O	1188-1189
9	O	1190-1191
.	O	1191-1192
9	O	1190-1191
ml	O	1194-1196
/	O	1196-1197
100	O	1197-1200
g	O	1201-1202
/	O	1202-1203
min	O	1203-1206
(	O	1207-1208
P	O	1208-1209
<	O	1210-1211
0	O	1212-1213
.	O	1213-1214
05	O	1214-1216
)	O	1216-1217
.	O	1213-1214

60	O	1219-1221
min	O	1222-1225
:	O	1225-1226
30	O	1227-1229
+	O	1230-1231
/	O	1231-1232
-	O	1232-1233
7	O	1234-1235
.	O	1235-1236
5	O	1236-1237
ml	O	1238-1240
/	O	1240-1241
100	O	1241-1244
g	O	1245-1246
/	O	1246-1247
min	O	1247-1250
(	O	1251-1252
P	O	1252-1253
<	O	1254-1255
0	O	1256-1257
.	O	1257-1258
05	O	1258-1260
)	O	1260-1261
)	O	1260-1261
.	O	1257-1258

These	O	1264-1269
results	O	1270-1277
suggest	O	1278-1285
that	O	1286-1290
PGE1	O	1291-1295
may	O	1296-1299
be	O	1300-1302
preferable	O	1303-1313
to	O	1314-1316
TMP	O	1317-1320
for	O	1321-1324
hypotensive	B	1325-1336
anaesthesia	O	1337-1348
in	O	1349-1351
spinal	O	1352-1358
surgery	O	1359-1366
because	O	1367-1374
TMP	O	1375-1378
decreased	O	1379-1388
EBF	O	1389-1392
.	O	1392-1393

Immunohistochemical	O	0-19
studies	O	20-27
with	O	28-32
antibodies	O	33-43
to	O	44-46
neurofilament	O	47-60
proteins	O	61-69
on	O	70-72
axonal	B	73-79
damage	I	80-86
in	O	87-89
experimental	O	90-102
focal	O	103-108
lesions	O	109-116
in	O	117-119
rat	O	120-123
.	O	123-124

Immunohistochemistry	O	125-145
with	O	146-150
monoclonal	O	151-161
antibodies	O	162-172
against	O	173-180
neurofilament	O	181-194
(	O	195-196
NF	O	196-198
)	O	198-199
proteins	O	200-208
of	O	209-211
middle	O	212-218
and	O	219-222
high	O	223-227
molecular	O	228-237
weight	O	238-244
class	O	245-250
,	O	250-251
NF	O	252-254
-	O	254-255
M	O	255-256
and	O	257-260
NF	O	261-263
-	O	263-264
H	O	264-265
,	O	265-266
was	O	267-270
used	O	271-275
to	O	276-278
study	O	279-284
axonal	B	285-291
injury	I	292-298
in	O	299-301
the	O	302-305
borderzone	O	306-316
of	O	317-319
focal	O	320-325
lesions	O	326-333
in	O	334-336
rats	O	337-341
.	O	341-342

Focal	O	343-348
injury	B	349-355
in	I	356-358
the	I	359-362
cortex	I	363-369
was	O	370-373
produced	O	374-382
by	O	383-385
infusion	O	386-394
of	O	395-397
lactate	O	398-405
at	O	406-408
acid	O	409-413
pH	O	414-416
or	O	417-419
by	O	420-422
stab	O	423-427
caused	O	428-434
by	O	435-437
needle	O	438-444
insertion	O	445-454
.	O	454-455

Infarcts	B	456-464
in	I	465-467
substantia	I	468-478
nigra	I	479-484
pars	I	485-489
reticulata	I	490-500
were	O	501-505
evoked	O	506-512
by	O	513-515
prolonged	O	516-525
pilocarpine	O	526-537
-	O	537-538
induced	O	538-545
status	B	546-552
epilepticus	I	553-564
.	O	564-565

Immunohistochemical	O	566-585
staining	O	586-594
for	O	595-598
NFs	O	599-602
showed	O	603-609
characteristic	O	610-624
terminal	O	625-633
clubs	O	634-639
of	O	640-642
axons	O	643-648
in	O	649-651
the	O	652-655
borderzone	O	656-666
of	O	667-669
lesions	O	670-677
.	O	677-678

Differences	O	679-690
in	O	691-693
the	O	694-697
labelling	O	698-707
pattern	O	708-715
occurred	O	716-724
with	O	725-729
different	O	730-739
antibodies	O	740-750
which	O	751-756
apparently	O	757-767
depended	O	768-776
on	O	777-779
molecular	O	780-789
weight	O	790-796
class	O	797-802
of	O	803-805
NFs	O	806-809
and	O	810-813
phosphorylation	O	814-829
state	O	830-835
.	O	835-836

These	O	837-842
immunohistochemical	O	843-862
changes	O	863-870
of	O	871-873
NFs	O	874-877
can	O	878-881
serve	O	882-887
as	O	888-890
a	O	891-892
marker	O	893-899
for	O	900-903
axonal	B	904-910
damage	I	911-917
in	O	918-920
various	O	921-928
experimental	O	929-941
traumatic	B	942-951
or	O	952-954
ischemic	O	955-963
lesions	O	964-971
.	O	971-972

Increase	O	0-8
of	O	9-11
Parkinson	B	12-21
disability	I	22-32
after	O	33-38
fluoxetine	O	39-49
medication	O	50-60
.	O	60-61

Depression	B	62-72
is	O	73-75
a	O	76-77
major	O	78-83
clinical	O	84-92
feature	O	93-100
of	O	101-103
Parkinson	B	104-113
'	I	113-114
s	I	110-111
disease	I	116-123
.	O	123-124

We	O	125-127
report	O	128-134
the	O	135-138
increased	O	139-148
amount	O	149-155
of	O	156-158
motor	B	159-164
disability	I	165-175
in	O	176-178
four	O	179-183
patients	O	184-192
with	O	193-197
idiopathic	B	198-208
Parkinson	I	209-218
'	I	218-219
s	I	215-216
disease	I	221-228
after	O	229-234
exposure	O	235-243
to	O	244-246
the	O	247-250
antidepressant	O	251-265
fluoxetine	O	266-276
.	O	276-277

The	O	278-281
possibility	O	282-293
of	O	294-296
a	O	297-298
clinically	O	299-309
relevant	O	310-318
dopamine	O	319-327
-	O	327-328
antagonistic	O	328-340
capacity	O	341-349
of	O	350-352
fluoxetine	O	353-363
in	O	364-366
Parkinson	B	367-376
'	I	376-377
s	I	373-374
disease	I	379-386
patients	O	387-395
must	O	396-400
be	O	401-403
considered	O	404-414
.	O	414-415

Acetaminophen	O	0-13
-	O	13-14
induced	O	14-21
hypotension	B	22-33
.	O	33-34

Through	O	35-42
30	O	43-45
years	O	46-51
of	O	52-54
widespread	O	55-65
use	O	66-69
,	O	69-70
acetaminophen	O	71-84
has	O	85-88
been	O	89-93
shown	O	94-99
to	O	100-102
be	O	103-105
a	O	106-107
remarkably	O	108-118
safe	O	119-123
medication	O	124-134
in	O	135-137
therapeutic	O	138-149
dosages	O	150-157
.	O	157-158

The	O	159-162
potential	O	163-172
for	O	173-176
acetaminophen	O	177-190
to	O	191-193
produce	O	194-201
cardiovascular	B	202-216
toxicities	I	217-227
is	O	228-230
very	O	231-235
low	O	236-239
.	O	239-240

However	O	241-248
,	O	248-249
acetaminophen	O	250-263
has	O	264-267
been	O	268-272
demonstrated	O	273-285
to	O	286-288
produce	O	289-296
symptoms	O	297-305
of	O	306-308
anaphylaxis	B	309-320
,	O	320-321
including	O	322-331
hypotension	B	332-343
,	O	343-344
in	O	345-347
sensitive	O	348-357
individuals	O	358-369
.	O	369-370

This	O	371-375
article	O	376-383
describes	O	384-393
two	O	394-397
critically	B	398-408
ill	I	409-412
patients	O	413-421
in	O	422-424
whom	O	425-429
transient	O	430-439
episodes	O	440-448
of	O	449-451
hypotension	B	452-463
reproducibly	O	464-476
developed	O	477-486
after	O	487-492
administration	O	493-507
of	O	508-510
acetaminophen	O	511-524
.	O	524-525

Other	O	526-531
symptoms	O	532-540
of	O	541-543
allergic	B	544-552
reactions	I	553-562
were	O	563-567
not	O	568-571
clinically	O	572-582
detectable	O	583-593
.	O	593-594

The	O	595-598
hypotensive	B	599-610
episodes	O	611-619
were	O	620-624
severe	O	625-631
enough	O	632-638
to	O	639-641
require	O	642-649
vasopressor	O	650-661
administration	O	662-676
.	O	676-677

The	O	678-681
reports	O	682-689
illustrate	O	690-700
the	O	701-704
need	O	705-709
for	O	710-713
clinicians	O	714-724
to	O	725-727
consider	O	728-736
acetaminophen	O	737-750
in	O	751-753
patients	O	754-762
with	O	763-767
hypotension	B	768-779
of	O	780-782
unknown	O	783-790
origin	O	791-797
.	O	797-798

Acute	O	0-5
hepatitis	B	6-15
,	O	15-16
autoimmune	B	17-27
hemolytic	I	28-37
anemia	I	38-44
,	O	44-45
and	O	46-49
erythroblastocytopenia	B	50-72
induced	O	73-80
by	O	81-83
ceftriaxone	O	84-95
.	O	95-96

An	O	97-99
80	O	100-102
-	O	102-103
yr	O	103-105
-	O	102-103
old	O	106-109
man	O	110-113
developed	O	114-123
acute	O	124-129
hepatitis	B	130-139
shortly	O	140-147
after	O	148-153
ingesting	O	154-163
oral	O	164-168
ceftriaxone	O	169-180
.	O	180-181

Although	O	182-190
the	O	191-194
transaminases	O	195-208
gradually	O	209-218
returned	O	219-227
to	O	228-230
baseline	O	231-239
after	O	240-245
withholding	O	246-257
the	O	258-261
beta	O	262-266
lactam	O	267-273
antibiotic	O	274-284
,	O	284-285
there	O	286-291
was	O	292-295
a	O	296-297
gradual	O	298-305
increase	O	306-314
in	O	315-317
serum	O	318-323
bilirubin	O	324-333
and	O	334-337
a	O	338-339
decrease	O	340-348
in	O	349-351
hemoglobin	O	352-362
concentration	O	363-376
caused	O	377-383
by	O	384-386
an	O	387-389
autoimmune	B	390-400
hemolytic	I	401-410
anemia	I	411-417
and	O	418-421
erythroblastocytopenia	B	422-444
.	O	444-445

These	O	446-451
responded	O	452-461
to	O	462-464
systemic	O	465-473
steroids	O	474-482
and	O	483-486
immunoglobulins	O	487-502
.	O	502-503

Despite	O	504-511
the	O	512-515
widespread	O	516-526
use	O	527-530
of	O	531-533
these	O	534-539
agents	O	540-546
this	O	547-551
triad	O	552-557
of	O	558-560
side	O	561-565
effects	O	566-573
has	O	574-577
not	O	578-581
previously	O	582-592
been	O	593-597
reported	O	598-606
in	O	607-609
connection	O	610-620
with	O	621-625
beta	O	626-630
lactam	O	631-637
antibiotics	O	638-649
.	O	649-650

Adverse	O	0-7
effects	O	8-15
of	O	16-18
the	O	19-22
atypical	O	23-31
antipsychotics	O	32-46
.	O	46-47

Collaborative	O	48-61
Working	O	62-69
Group	O	70-75
on	O	76-78
Clinical	O	79-87
Trial	O	88-93
Evaluations	O	94-105
.	O	105-106

Adverse	O	107-114
effects	O	115-122
of	O	123-125
antipsychotics	O	126-140
often	O	141-146
lead	O	147-151
to	O	152-154
noncompliance	O	155-168
.	O	168-169

Thus	O	170-174
,	O	174-175
clinicians	O	176-186
should	O	187-193
address	O	194-201
patients	O	202-210
'	O	210-211
concerns	O	212-220
about	O	221-226
adverse	O	227-234
effects	O	235-242
and	O	243-246
attempt	O	247-254
to	O	255-257
choose	O	258-264
medications	O	265-276
that	O	277-281
will	O	282-286
improve	O	287-294
their	O	295-300
patients	O	301-309
'	O	309-310
quality	O	311-318
of	O	319-321
life	O	322-326
as	O	327-329
well	O	330-334
as	O	335-337
overall	O	338-345
health	O	346-352
.	O	352-353

The	O	354-357
side	O	358-362
effect	O	363-369
profiles	O	370-378
of	O	379-381
the	O	382-385
atypical	O	386-394
antipsychotics	O	395-409
are	O	410-413
more	O	414-418
advantageous	O	419-431
than	O	432-436
those	O	437-442
of	O	443-445
the	O	446-449
conventional	O	450-462
neuroleptics	O	463-475
.	O	475-476

Conventional	O	477-489
agents	O	490-496
are	O	497-500
associated	O	501-511
with	O	512-516
unwanted	O	517-525
central	O	526-533
nervous	O	534-541
system	O	542-548
effects	O	549-556
,	O	556-557
including	O	558-567
extrapyramidal	B	568-582
symptoms	I	583-591
(	O	592-593
EPS	B	593-596
)	O	596-597
,	O	597-598
tardive	B	599-606
dyskinesia	I	607-617
,	O	617-618
sedation	O	619-627
,	O	627-628
and	O	629-632
possible	O	633-641
impairment	O	642-652
of	O	653-655
some	O	656-660
cognitive	O	661-670
measures	O	671-679
,	O	679-680
as	O	681-683
well	O	684-688
as	O	689-691
cardiac	O	692-699
effects	O	700-707
,	O	707-708
orthostatic	B	709-720
hypotension	I	721-732
,	O	732-733
hepatic	O	734-741
changes	O	742-749
,	O	749-750
anticholinergic	O	751-766
side	O	767-771
effects	O	772-779
,	O	779-780
sexual	B	781-787
dysfunction	I	788-799
,	O	799-800
and	O	801-804
weight	B	805-811
gain	I	812-816
.	O	816-817

The	O	818-821
newer	O	822-827
atypical	O	828-836
agents	O	837-843
have	O	844-848
a	O	849-850
lower	O	851-856
risk	O	857-861
of	O	862-864
EPS	B	865-868
,	O	868-869
but	O	870-873
are	O	874-877
associated	O	878-888
in	O	889-891
varying	O	892-899
degrees	O	900-907
with	O	908-912
sedation	O	913-921
,	O	921-922
cardiovascular	O	923-937
effects	O	938-945
,	O	945-946
anticholinergic	O	947-962
effects	O	963-970
,	O	970-971
weight	B	972-978
gain	I	979-983
,	O	983-984
sexual	B	985-991
dysfunction	I	992-1003
,	O	1003-1004
hepatic	O	1005-1012
effects	O	1013-1020
,	O	1020-1021
lowered	O	1022-1029
seizure	B	1030-1037
threshold	O	1038-1047
(	O	1048-1049
primarily	O	1049-1058
clozapine	O	1059-1068
)	O	1068-1069
,	O	1069-1070
and	O	1071-1074
agranulocytosis	B	1075-1090
(	O	1091-1092
clozapine	O	1092-1101
only	O	1102-1106
)	O	1106-1107
.	O	1107-1108

Since	O	1109-1114
the	O	1115-1118
incidence	O	1119-1128
and	O	1129-1132
severity	O	1133-1141
of	O	1142-1144
specific	O	1145-1153
adverse	O	1154-1161
effects	O	1162-1169
differ	O	1170-1176
among	O	1177-1182
the	O	1183-1186
various	O	1187-1194
atypicals	O	1195-1204
,	O	1204-1205
the	O	1206-1209
clinician	O	1210-1219
should	O	1220-1226
carefully	O	1227-1236
consider	O	1237-1245
which	O	1246-1251
side	O	1252-1256
effects	O	1257-1264
are	O	1265-1268
most	O	1269-1273
likely	O	1274-1280
to	O	1281-1283
lead	O	1284-1288
to	O	1289-1291
the	O	1292-1295
individual	O	1296-1306
'	O	1306-1307
s	O	1307-1308
dissatisfaction	O	1309-1324
and	O	1325-1328
noncompliance	O	1329-1342
before	O	1343-1349
choosing	O	1350-1358
an	O	1359-1361
antipsychotic	O	1362-1375
for	O	1376-1379
a	O	1380-1381
particular	O	1382-1392
patient	O	1393-1400
.	O	1400-1401

Effects	O	0-7
of	O	8-10
tetrandrine	O	11-22
and	O	23-26
fangchinoline	O	27-40
on	O	41-43
experimental	O	44-56
thrombosis	B	57-67
in	O	68-70
mice	O	71-75
and	O	76-79
human	O	80-85
platelet	B	86-94
aggregation	I	95-106
.	O	106-107

Tetrandrine	O	108-119
(	O	120-121
TET	O	121-124
)	O	124-125
and	O	126-129
fangchinoline	O	130-143
(	O	144-145
FAN	O	145-148
)	O	148-149
are	O	150-153
two	O	154-157
naturally	O	158-167
occurring	O	168-177
analogues	O	178-187
with	O	188-192
a	O	193-194
bisbenzylisoquinoline	O	195-216
structure	O	217-226
.	O	226-227

The	O	228-231
present	O	232-239
study	O	240-245
was	O	246-249
undertaken	O	250-260
to	O	261-263
investigate	O	264-275
the	O	276-279
effects	O	280-287
of	O	288-290
TET	O	291-294
and	O	295-298
FAN	O	299-302
on	O	303-305
the	O	306-309
experimental	O	310-322
thrombosis	B	323-333
induced	O	334-341
by	O	342-344
collagen	O	345-353
plus	O	354-358
epinephrine	O	359-370
(	O	371-372
EP	O	372-374
)	O	374-375
in	O	376-378
mice	O	379-383
,	O	383-384
and	O	385-388
platelet	B	389-397
aggregation	I	398-409
and	O	410-413
blood	B	414-419
coagulation	I	420-431
in	O	432-434
vitro	O	435-440
.	O	440-441

In	O	442-444
the	O	445-448
in	O	449-451
vivo	O	452-456
study	O	457-462
,	O	462-463
the	O	464-467
administration	O	468-482
(	O	483-484
50	O	484-486
mg	O	487-489
/	O	489-490
kg	O	490-492
,	O	492-493
i	O	494-495
.	O	495-496
p	O	496-497
.	O	495-496
)	O	498-499
of	O	500-502
TET	O	503-506
and	O	507-510
FAN	O	511-514
in	O	515-517
mice	O	518-522
showed	O	523-529
the	O	530-533
inhibition	O	534-544
of	O	545-547
thrombosis	B	548-558
by	O	559-561
55	O	562-564
%	O	564-565
and	O	566-569
35	O	570-572
%	O	572-573
,	O	573-574
respectively	O	575-587
,	O	587-588
while	O	589-594
acetylsalicylic	O	595-610
acid	O	611-615
(	O	616-617
ASA	O	617-620
,	O	620-621
50	O	622-624
mg	O	625-627
/	O	627-628
kg	O	628-630
,	O	630-631
i	O	632-633
.	O	633-634
p	O	634-635
.	O	633-634
)	O	636-637
,	O	637-638
a	O	639-640
positive	O	641-649
control	O	650-657
,	O	657-658
showed	O	659-665
only	O	666-670
30	O	671-673
%	O	673-674
inhibition	O	675-685
.	O	685-686

In	O	687-689
the	O	690-693
vitro	O	694-699
human	O	700-705
platelet	B	706-714
aggregations	I	715-727
induced	O	728-735
by	O	736-738
the	O	739-742
agonists	O	743-751
used	O	752-756
in	O	757-759
tests	O	760-765
,	O	765-766
TET	O	767-770
and	O	771-774
FAN	O	775-778
showed	O	779-785
the	O	786-789
inhibitions	O	790-801
dose	O	802-806
dependently	O	807-818
.	O	818-819

In	O	820-822
addition	O	823-831
,	O	831-832
neither	O	833-840
TET	O	841-844
nor	O	845-848
FAN	O	849-852
showed	O	853-859
any	O	860-863
anticoagulation	O	864-879
activities	O	880-890
in	O	891-893
the	O	894-897
measurement	O	898-909
of	O	910-912
the	O	913-916
activated	O	917-926
partial	O	927-934
thromboplastin	O	935-949
time	O	950-954
(	O	955-956
APTT	O	956-960
)	O	960-961
,	O	961-962
prothrombin	O	963-974
time	O	975-979
(	O	980-981
PT	O	981-983
)	O	983-984
and	O	985-988
thrombin	O	989-997
time	O	998-1002
(	O	1003-1004
TT	O	1004-1006
)	O	1006-1007
using	O	1008-1013
human	O	1014-1019
-	O	1019-1020
citrated	O	1020-1028
plasma	O	1029-1035
.	O	1035-1036

These	O	1037-1042
results	O	1043-1050
suggest	O	1051-1058
that	O	1059-1063
antithrombosis	O	1064-1078
of	O	1079-1081
TET	O	1082-1085
and	O	1086-1089
FAN	O	1090-1093
in	O	1094-1096
mice	O	1097-1101
may	O	1102-1105
be	O	1106-1108
mainly	O	1109-1115
related	O	1116-1123
to	O	1124-1126
the	O	1127-1130
antiplatelet	O	1131-1143
aggregation	O	1144-1155
activities	O	1156-1166
.	O	1166-1167

Gemcitabine	O	0-11
plus	O	12-16
vinorelbine	O	17-28
in	O	29-31
nonsmall	B	32-40
cell	I	41-45
lung	I	46-50
carcinoma	I	51-60
patients	O	61-69
age	O	70-73
70	O	74-76
years	O	77-82
or	O	83-85
older	O	86-91
or	O	92-94
patients	O	95-103
who	O	104-107
cannot	O	108-114
receive	O	115-122
cisplatin	O	123-132
.	O	132-133

Oncopaz	O	134-141
Cooperative	O	142-153
Group	O	154-159
.	O	159-160

BACKGROUND	O	161-171
:	O	171-172
Although	O	173-181
the	O	182-185
prevalence	O	186-196
of	O	197-199
nonsmall	B	200-208
cell	I	209-213
lung	I	214-218
carcinoma	I	219-228
(	O	229-230
NSCLC	B	230-235
)	O	235-236
is	O	237-239
high	O	240-244
among	O	245-250
elderly	O	251-258
patients	O	259-267
,	O	267-268
few	O	269-272
data	O	273-277
are	O	278-281
available	O	282-291
regarding	O	292-301
the	O	302-305
efficacy	O	306-314
and	O	315-318
toxicity	B	319-327
of	O	328-330
chemotherapy	O	331-343
in	O	344-346
this	O	347-351
group	O	352-357
of	O	358-360
patients	O	361-369
.	O	369-370

Recent	O	371-377
reports	O	378-385
indicate	O	386-394
that	O	395-399
single	O	400-406
agent	O	407-412
therapy	O	413-420
with	O	421-425
vinorelbine	O	426-437
(	O	438-439
VNB	O	439-442
)	O	442-443
or	O	444-446
gemcitabine	O	447-458
(	O	459-460
GEM	O	460-463
)	O	463-464
may	O	465-468
obtain	O	469-475
a	O	476-477
response	O	478-486
rate	O	487-491
of	O	492-494
20	O	495-497
-	O	497-498
30	O	498-500
%	O	500-501
in	O	502-504
elderly	O	505-512
patients	O	513-521
,	O	521-522
with	O	523-527
acceptable	O	528-538
toxicity	B	539-547
and	O	548-551
improvement	O	552-563
in	O	564-566
symptoms	O	567-575
and	O	576-579
quality	O	580-587
of	O	588-590
life	O	591-595
.	O	595-596

In	O	597-599
the	O	600-603
current	O	604-611
study	O	612-617
the	O	618-621
efficacy	O	622-630
and	O	631-634
toxicity	B	635-643
of	O	644-646
the	O	647-650
combination	O	651-662
of	O	663-665
GEM	O	666-669
and	O	670-673
VNB	O	674-677
in	O	678-680
elderly	O	681-688
patients	O	689-697
with	O	698-702
advanced	O	703-711
NSCLC	B	712-717
or	O	718-720
those	O	721-726
with	O	727-731
some	O	732-736
contraindication	O	737-753
to	O	754-756
receiving	O	757-766
cisplatin	O	767-776
were	O	777-781
assessed	O	782-790
.	O	790-791

METHODS	O	792-799
:	O	799-800
Forty	O	801-806
-	O	806-807
nine	O	807-811
patients	O	812-820
with	O	821-825
advanced	O	826-834
NSCLC	B	835-840
were	O	841-845
included	O	846-854
,	O	854-855
38	O	856-858
of	O	859-861
whom	O	862-866
were	O	867-871
age	O	872-875
>	O	876-877
/	O	877-878
=	O	878-879
70	O	880-882
years	O	883-888
and	O	889-892
11	O	893-895
were	O	896-900
age	O	901-904
<	O	905-906
70	O	907-909
years	O	910-915
but	O	916-919
who	O	920-923
had	O	924-927
some	O	928-932
contraindication	O	933-949
to	O	950-952
receiving	O	953-962
cisplatin	O	963-972
.	O	972-973

All	O	974-977
patients	O	978-986
were	O	987-991
evaluable	O	992-1001
for	O	1002-1005
response	O	1006-1014
and	O	1015-1018
toxicity	B	1019-1027
.	O	1027-1028

Treatment	O	1029-1038
was	O	1039-1042
comprised	O	1043-1052
of	O	1053-1055
VNB	O	1056-1059
,	O	1059-1060
25	O	1061-1063
mg	O	1064-1066
/	O	1066-1067
m	O	1064-1065
(	O	1068-1069
2	O	1069-1070
)	O	1070-1071
,	O	1071-1072
plus	O	1073-1077
GEM	O	1078-1081
,	O	1081-1082
1000	O	1083-1087
mg	O	1088-1090
/	O	1090-1091
m	O	1088-1089
(	O	1092-1093
2	O	1093-1094
)	O	1094-1095
,	O	1095-1096
both	O	1097-1101
on	O	1102-1104
Days	O	1105-1109
1	O	1110-1111
,	O	1111-1112
8	O	1113-1114
,	O	1114-1115
and	O	1116-1119
15	O	1120-1122
every	O	1123-1128
28	O	1129-1131
days	O	1132-1136
.	O	1136-1137

Patients	O	1138-1146
received	O	1147-1155
a	O	1156-1157
minimum	O	1158-1165
of	O	1166-1168
three	O	1169-1174
courses	O	1175-1182
unless	O	1183-1189
progressive	O	1190-1201
disease	O	1202-1209
was	O	1210-1213
detected	O	1214-1222
.	O	1222-1223

RESULTS	O	1224-1231
:	O	1231-1232
One	O	1233-1236
hundred	O	1237-1244
sixty	O	1245-1250
-	O	1250-1251
five	O	1251-1255
courses	O	1256-1263
were	O	1264-1268
administered	O	1269-1281
,	O	1281-1282
with	O	1283-1287
a	O	1288-1289
median	O	1290-1296
of	O	1297-1299
3	O	1300-1301
.	O	1301-1302
6	O	1303-1304
courses	O	1305-1312
per	O	1313-1316
patient	O	1317-1324
.	O	1324-1325

The	O	1326-1329
overall	O	1330-1337
response	O	1338-1346
rate	O	1347-1351
was	O	1352-1355
26	O	1356-1358
%	O	1358-1359
(	O	1360-1361
95	O	1361-1363
%	O	1363-1364
confidence	O	1365-1375
interval	O	1376-1384
,	O	1384-1385
15	O	1386-1388
-	O	1388-1389
41	O	1389-1391
%	O	1391-1392
)	O	1392-1393
.	O	1393-1394

Two	O	1395-1398
patients	O	1399-1407
attained	O	1408-1416
a	O	1417-1418
complete	O	1419-1427
response	O	1428-1436
(	O	1437-1438
4	O	1438-1439
%	O	1439-1440
)	O	1440-1441
and	O	1442-1445
11	O	1446-1448
patients	O	1449-1457
(	O	1458-1459
22	O	1459-1461
%	O	1461-1462
)	O	1462-1463
achieved	O	1464-1472
a	O	1473-1474
partial	O	1475-1482
response	O	1483-1491
.	O	1491-1492

Eastern	O	1493-1500
Cooperative	O	1501-1512
Oncology	O	1513-1521
Group	O	1522-1527
performance	O	1528-1539
status	O	1540-1546
improved	O	1547-1555
in	O	1556-1558
35	O	1559-1561
%	O	1561-1562
of	O	1563-1565
those	O	1566-1571
patients	O	1572-1580
with	O	1581-1585
an	O	1586-1588
initial	O	1589-1596
value	O	1597-1602
>	O	1603-1604
0	O	1605-1606
,	O	1606-1607
whereas	O	1608-1615
relief	O	1616-1622
of	O	1623-1625
at	O	1626-1628
least	O	1629-1634
1	O	1635-1636
symptom	O	1637-1644
without	O	1645-1652
worsening	O	1653-1662
of	O	1663-1665
other	O	1666-1671
symptoms	O	1672-1680
was	O	1681-1684
noted	O	1685-1690
in	O	1691-1693
27	O	1694-1696
patients	O	1697-1705
(	O	1706-1707
55	O	1707-1709
%	O	1709-1710
)	O	1710-1711
.	O	1711-1712

The	O	1713-1716
median	O	1717-1723
time	O	1724-1728
to	O	1729-1731
progression	O	1732-1743
was	O	1744-1747
16	O	1748-1750
weeks	O	1751-1756
and	O	1757-1760
the	O	1761-1764
1	O	1765-1766
-	O	1766-1767
year	O	1767-1771
survival	O	1772-1780
rate	O	1781-1785
was	O	1786-1789
33	O	1790-1792
%	O	1792-1793
.	O	1793-1794

Toxicity	B	1795-1803
was	O	1804-1807
mild	O	1808-1812
.	O	1812-1813

Six	O	1814-1817
patients	O	1818-1826
(	O	1827-1828
12	O	1828-1830
%	O	1830-1831
)	O	1831-1832
had	O	1833-1836
World	O	1837-1842
Health	O	1843-1849
Organization	O	1850-1862
Grade	O	1863-1868
3	O	1869-1870
-	O	1870-1871
4	O	1871-1872
neutropenia	B	1873-1884
,	O	1884-1885
2	O	1886-1887
patients	O	1888-1896
(	O	1897-1898
4	O	1898-1899
%	O	1899-1900
)	O	1900-1901
had	O	1902-1905
Grade	O	1906-1911
3	O	1912-1913
-	O	1913-1914
4	O	1914-1915
thrombocytopenia	B	1916-1932
,	O	1932-1933
and	O	1934-1937
2	O	1938-1939
patients	O	1940-1948
(	O	1949-1950
4	O	1950-1951
%	O	1951-1952
)	O	1952-1953
had	O	1954-1957
Grade	O	1958-1963
3	O	1964-1965
neurotoxicity	B	1966-1979
.	O	1979-1980

Three	O	1981-1986
patients	O	1987-1995
with	O	1996-2000
severe	O	2001-2007
neutropenia	B	2008-2019
(	O	2020-2021
6	O	2021-2022
%	O	2022-2023
)	O	2023-2024
died	O	2025-2029
of	O	2030-2032
sepsis	B	2033-2039
.	O	2039-2040

The	O	2041-2044
median	O	2045-2051
age	O	2052-2055
of	O	2056-2058
those	O	2059-2064
patients	O	2065-2073
developing	O	2074-2084
Grade	O	2085-2090
3	O	2091-2092
-	O	2092-2093
4	O	2093-2094
neutropenia	B	2095-2106
was	O	2107-2110
significantly	O	2111-2124
higher	O	2125-2131
than	O	2132-2136
that	O	2137-2141
of	O	2142-2144
the	O	2145-2148
remaining	O	2149-2158
patients	O	2159-2167
(	O	2168-2169
75	O	2169-2171
years	O	2172-2177
vs	O	2178-2180
.	O	2180-2181
72	O	2182-2184
years	O	2185-2190
;	O	2190-2191
P	O	2192-2193
=	O	2194-2195
0	O	2196-2197
.	O	2197-2198
047	O	2198-2201
)	O	2201-2202
.	O	2197-2198

CONCLUSIONS	O	2204-2215
:	O	2215-2216
The	O	2217-2220
combination	O	2221-2232
of	O	2233-2235
GEM	O	2236-2239
and	O	2240-2243
VNB	O	2244-2247
is	O	2248-2250
moderately	O	2251-2261
active	O	2262-2268
and	O	2269-2272
well	O	2273-2277
tolerated	O	2278-2287
except	O	2288-2294
in	O	2295-2297
patients	O	2298-2306
age	O	2307-2310
>	O	2311-2312
/	O	2312-2313
=	O	2313-2314
75	O	2315-2317
years	O	2318-2323
.	O	2323-2324

This	O	2325-2329
age	O	2330-2333
group	O	2334-2339
had	O	2340-2343
an	O	2344-2346
increased	O	2347-2356
risk	O	2357-2361
of	O	2362-2364
myelosuppression	B	2365-2381
.	O	2381-2382

Therefore	O	2383-2392
the	O	2393-2396
prophylactic	O	2397-2409
use	O	2410-2413
of	O	2414-2416
granulocyte	O	2417-2428
-	O	2428-2429
colony	O	2429-2435
stimulating	O	2436-2447
factor	O	2448-2454
should	O	2455-2461
be	O	2462-2464
considered	O	2465-2475
with	O	2476-2480
this	O	2481-2485
treatment	O	2486-2495
.	O	2495-2496

New	O	2497-2500
chemotherapy	O	2501-2513
combinations	O	2514-2526
with	O	2527-2531
higher	O	2532-2538
activity	O	2539-2547
and	O	2548-2551
lower	O	2552-2557
toxicity	B	2558-2566
are	O	2567-2570
needed	O	2571-2577
for	O	2578-2581
elderly	O	2582-2589
patients	O	2590-2598
with	O	2599-2603
advanced	O	2604-2612
NSCLC	B	2613-2618
.	O	2618-2619

Warfarin	O	0-8
-	O	8-9
induced	O	9-16
artery	B	17-23
calcification	I	24-37
is	O	38-40
accelerated	O	41-52
by	O	53-55
growth	O	56-62
and	O	63-66
vitamin	O	67-74
D	O	75-76
.	O	76-77
The	O	78-81
present	O	82-89
studies	O	90-97
demonstrate	O	98-109
that	O	110-114
growth	O	115-121
and	O	122-125
vitamin	O	126-133
D	O	134-135
treatment	O	136-145
enhance	O	146-153
the	O	154-157
extent	O	158-164
of	O	165-167
artery	B	168-174
calcification	I	175-188
in	O	189-191
rats	O	192-196
given	O	197-202
sufficient	O	203-213
doses	O	214-219
of	O	220-222
Warfarin	O	223-231
to	O	232-234
inhibit	O	235-242
gamma	O	243-248
-	O	248-249
carboxylation	O	249-262
of	O	263-265
matrix	O	266-272
Gla	O	273-276
protein	O	277-284
,	O	284-285
a	O	286-287
calcification	B	288-301
inhibitor	O	302-311
known	O	312-317
to	O	318-320
be	O	321-323
expressed	O	324-333
by	O	334-336
smooth	O	337-343
muscle	O	344-350
cells	O	351-356
and	O	357-360
macrophages	O	361-372
in	O	373-375
the	O	376-379
artery	O	380-386
wall	O	387-391
.	O	391-392

The	O	393-396
first	O	397-402
series	O	403-409
of	O	410-412
experiments	O	413-424
examined	O	425-433
the	O	434-437
influence	O	438-447
of	O	448-450
age	O	451-454
and	O	455-458
growth	O	459-465
status	O	466-472
on	O	473-475
artery	B	476-482
calcification	I	483-496
in	O	497-499
Warfarin	O	500-508
-	O	508-509
treated	O	509-516
rats	O	517-521
.	O	521-522

Treatment	O	523-532
for	O	533-536
2	O	537-538
weeks	O	539-544
with	O	545-549
Warfarin	O	550-558
caused	O	559-565
massive	O	566-573
focal	O	574-579
calcification	B	580-593
of	I	594-596
the	I	597-600
artery	I	601-607
media	O	608-613
in	O	614-616
20	O	617-619
-	O	619-620
day	O	620-623
-	O	619-620
old	O	624-627
rats	O	628-632
and	O	633-636
less	O	637-641
extensive	O	642-651
focal	O	652-657
calcification	B	658-671
in	O	672-674
42	O	675-677
-	O	677-678
day	O	678-681
-	O	677-678
old	O	682-685
rats	O	686-690
.	O	690-691

In	O	692-694
contrast	O	695-703
,	O	703-704
no	O	705-707
artery	B	708-714
calcification	I	715-728
could	O	729-734
be	O	735-737
detected	O	738-746
in	O	747-749
10	O	750-752
-	O	752-753
month	O	753-758
-	O	752-753
old	O	759-762
adult	O	763-768
rats	O	769-773
even	O	774-778
after	O	779-784
4	O	785-786
weeks	O	787-792
of	O	793-795
Warfarin	O	796-804
treatment	O	805-814
.	O	814-815

To	O	816-818
directly	O	819-827
examine	O	828-835
the	O	836-839
importance	O	840-850
of	O	851-853
growth	O	854-860
to	O	861-863
Warfarin	O	864-872
-	O	872-873
induced	O	873-880
artery	B	881-887
calcification	I	888-901
in	O	902-904
animals	O	905-912
of	O	913-915
the	O	916-919
same	O	920-924
age	O	925-928
,	O	928-929
20	O	930-932
-	O	932-933
day	O	933-936
-	O	932-933
old	O	937-940
rats	O	941-945
were	O	946-950
fed	O	951-954
for	O	955-958
2	O	959-960
weeks	O	961-966
either	O	967-973
an	O	974-976
ad	O	977-979
libitum	O	980-987
diet	O	988-992
or	O	993-995
a	O	996-997
6	O	998-999
-	O	999-1000
g	O	1000-1001
/	O	1001-1002
d	O	1002-1003
restricted	O	1004-1014
diet	O	1015-1019
that	O	1020-1024
maintains	O	1025-1034
weight	O	1035-1041
but	O	1042-1045
prevents	O	1046-1054
growth	O	1055-1061
.	O	1061-1062

Concurrent	O	1063-1073
treatment	O	1074-1083
of	O	1084-1086
both	O	1087-1091
dietary	O	1092-1099
groups	O	1100-1106
with	O	1107-1111
Warfarin	O	1112-1120
produced	O	1121-1129
massive	O	1130-1137
focal	O	1138-1143
calcification	B	1144-1157
of	I	1158-1160
the	I	1161-1164
artery	I	1165-1171
media	O	1172-1177
in	O	1178-1180
the	O	1181-1184
ad	O	1185-1187
libitum	O	1188-1195
-	O	1195-1196
fed	O	1196-1199
rats	O	1200-1204
but	O	1205-1208
no	O	1209-1211
detectable	O	1212-1222
artery	B	1223-1229
calcification	I	1230-1243
in	O	1244-1246
the	O	1247-1250
restricted	O	1251-1261
-	O	1261-1262
diet	O	1262-1266
,	O	1266-1267
growth	O	1268-1274
-	O	1274-1275
inhibited	O	1275-1284
group	O	1285-1290
.	O	1290-1291

Although	O	1292-1300
the	O	1301-1304
explanation	O	1305-1316
for	O	1317-1320
the	O	1321-1324
association	O	1325-1336
between	O	1337-1344
artery	B	1345-1351
calcification	I	1352-1365
and	O	1366-1369
growth	O	1370-1376
status	O	1377-1383
cannot	O	1384-1390
be	O	1391-1393
determined	O	1394-1404
from	O	1405-1409
the	O	1410-1413
present	O	1414-1421
study	O	1422-1427
,	O	1427-1428
there	O	1429-1434
was	O	1435-1438
a	O	1439-1440
relationship	O	1441-1453
between	O	1454-1461
higher	O	1462-1468
serum	O	1469-1474
phosphate	O	1475-1484
and	O	1485-1488
susceptibility	O	1489-1503
to	O	1504-1506
artery	B	1507-1513
calcification	I	1514-1527
,	O	1527-1528
with	O	1529-1533
30	O	1534-1536
%	O	1536-1537
higher	O	1538-1544
levels	O	1545-1551
of	O	1552-1554
serum	O	1555-1560
phosphate	O	1561-1570
in	O	1571-1573
young	O	1574-1579
,	O	1579-1580
ad	O	1581-1583
libitum	O	1584-1591
-	O	1591-1592
fed	O	1592-1595
rats	O	1596-1600
compared	O	1601-1609
with	O	1610-1614
either	O	1615-1621
of	O	1622-1624
the	O	1625-1628
groups	O	1629-1635
that	O	1636-1640
was	O	1641-1644
resistant	O	1645-1654
to	O	1655-1657
Warfarin	O	1658-1666
-	O	1666-1667
induced	O	1667-1674
artery	B	1675-1681
calcification	I	1682-1695
,	O	1695-1696
ie	O	1697-1699
,	O	1699-1700
the	O	1701-1704
10	O	1705-1707
-	O	1707-1708
month	O	1708-1713
-	O	1707-1708
old	O	1714-1717
rats	O	1718-1722
and	O	1723-1726
the	O	1727-1730
restricted	O	1731-1741
-	O	1741-1742
diet	O	1742-1746
,	O	1746-1747
growth	O	1748-1754
-	O	1754-1755
inhibited	O	1755-1764
young	O	1765-1770
rats	O	1771-1775
.	O	1775-1776

This	O	1777-1781
observation	O	1782-1793
suggests	O	1794-1802
that	O	1803-1807
increased	O	1808-1817
susceptibility	O	1818-1832
to	O	1833-1835
Warfarin	O	1836-1844
-	O	1844-1845
induced	O	1845-1852
artery	B	1853-1859
calcification	I	1860-1873
could	O	1874-1879
be	O	1880-1882
related	O	1883-1890
to	O	1891-1893
higher	O	1894-1900
serum	O	1901-1906
phosphate	O	1907-1916
levels	O	1917-1923
.	O	1923-1924

The	O	1925-1928
second	O	1929-1935
set	O	1936-1939
of	O	1940-1942
experiments	O	1943-1954
examined	O	1955-1963
the	O	1964-1967
possible	O	1968-1976
synergy	O	1977-1984
between	O	1985-1992
vitamin	O	1993-2000
D	O	2001-2002
and	O	2003-2006
Warfarin	O	2007-2015
in	O	2016-2018
artery	B	2019-2025
calcification	I	2026-2039
.	O	2039-2040

High	O	2041-2045
doses	O	2046-2051
of	O	2052-2054
vitamin	O	2055-2062
D	O	2063-2064
are	O	2065-2068
known	O	2069-2074
to	O	2075-2077
cause	O	2078-2083
calcification	B	2084-2097
of	I	2098-2100
the	I	2101-2104
artery	I	2105-2111
media	O	2112-2117
in	O	2118-2120
as	O	2121-2123
little	O	2124-2130
as	O	2131-2133
3	O	2134-2135
to	O	2136-2138
4	O	2139-2140
days	O	2141-2145
.	O	2145-2146

High	O	2147-2151
doses	O	2152-2157
of	O	2158-2160
the	O	2161-2164
vitamin	O	2165-2172
K	O	2173-2174
antagonist	O	2175-2185
Warfarin	O	2186-2194
are	O	2195-2198
also	O	2199-2203
known	O	2204-2209
to	O	2210-2212
cause	O	2213-2218
calcification	B	2219-2232
of	I	2233-2235
the	I	2236-2239
artery	I	2240-2246
media	O	2247-2252
,	O	2252-2253
but	O	2254-2257
at	O	2258-2260
treatment	O	2261-2270
times	O	2271-2276
of	O	2277-2279
2	O	2280-2281
weeks	O	2282-2287
or	O	2288-2290
longer	O	2291-2297
yet	O	2298-2301
not	O	2302-2305
at	O	2306-2308
1	O	2309-2310
week	O	2311-2315
.	O	2315-2316

In	O	2317-2319
the	O	2320-2323
current	O	2324-2331
study	O	2332-2337
,	O	2337-2338
we	O	2339-2341
investigated	O	2342-2354
the	O	2355-2358
synergy	O	2359-2366
between	O	2367-2374
these	O	2375-2380
2	O	2381-2382
treatments	O	2383-2393
and	O	2394-2397
found	O	2398-2403
that	O	2404-2408
concurrent	O	2409-2419
Warfarin	O	2420-2428
administration	O	2429-2443
dramatically	O	2444-2456
increased	O	2457-2466
the	O	2467-2470
extent	O	2471-2477
of	O	2478-2480
calcification	B	2481-2494
in	O	2495-2497
the	O	2498-2501
media	O	2502-2507
of	O	2508-2510
vitamin	O	2511-2518
D	O	2519-2520
-	O	2520-2521
treated	O	2521-2528
rats	O	2529-2533
at	O	2534-2536
3	O	2537-2538
and	O	2539-2542
4	O	2543-2544
days	O	2545-2549
.	O	2549-2550

There	O	2551-2556
was	O	2557-2560
a	O	2561-2562
close	O	2563-2568
parallel	O	2569-2577
between	O	2578-2585
the	O	2586-2589
effect	O	2590-2596
of	O	2597-2599
vitamin	O	2600-2607
D	O	2608-2609
dose	O	2610-2614
on	O	2615-2617
artery	B	2618-2624
calcification	I	2625-2638
and	O	2639-2642
the	O	2643-2646
effect	O	2647-2653
of	O	2654-2656
vitamin	O	2657-2664
D	O	2665-2666
dose	O	2667-2671
on	O	2672-2674
the	O	2675-2678
elevation	O	2679-2688
of	O	2689-2691
serum	O	2692-2697
calcium	O	2698-2705
,	O	2705-2706
which	O	2707-2712
suggests	O	2713-2721
that	O	2722-2726
vitamin	O	2727-2734
D	O	2735-2736
may	O	2737-2740
induce	O	2741-2747
artery	B	2748-2754
calcification	I	2755-2768
through	O	2769-2776
its	O	2777-2780
effect	O	2781-2787
on	O	2788-2790
serum	O	2791-2796
calcium	O	2797-2804
.	O	2804-2805

Because	O	2806-2813
Warfarin	O	2814-2822
treatment	O	2823-2832
had	O	2833-2836
no	O	2837-2839
effect	O	2840-2846
on	O	2847-2849
the	O	2850-2853
elevation	O	2854-2863
in	O	2864-2866
serum	O	2867-2872
calcium	O	2873-2880
produced	O	2881-2889
by	O	2890-2892
vitamin	O	2893-2900
D	O	2901-2902
,	O	2902-2903
the	O	2904-2907
synergy	O	2908-2915
between	O	2916-2923
Warfarin	O	2924-2932
and	O	2933-2936
vitamin	O	2937-2944
D	O	2945-2946
is	O	2947-2949
probably	O	2950-2958
best	O	2959-2963
explained	O	2964-2973
by	O	2974-2976
the	O	2977-2980
hypothesis	O	2981-2991
that	O	2992-2996
Warfarin	O	2997-3005
inhibits	O	3006-3014
the	O	3015-3018
activity	O	3019-3027
of	O	3028-3030
matrix	O	3031-3037
Gla	O	3038-3041
protein	O	3042-3049
as	O	3050-3052
a	O	3053-3054
calcification	B	3055-3068
inhibitor	O	3069-3078
.	O	3078-3079

High	O	3080-3084
levels	O	3085-3091
of	O	3092-3094
matrix	O	3095-3101
Gla	O	3102-3105
protein	O	3106-3113
are	O	3114-3117
found	O	3118-3123
at	O	3124-3126
sites	O	3127-3132
of	O	3133-3135
artery	B	3136-3142
calcification	I	3143-3156
in	O	3157-3159
rats	O	3160-3164
treated	O	3165-3172
with	O	3173-3177
vitamin	O	3178-3185
D	O	3186-3187
plus	O	3188-3192
Warfarin	O	3193-3201
,	O	3201-3202
and	O	3203-3206
chemical	O	3207-3215
analysis	O	3216-3224
showed	O	3225-3231
that	O	3232-3236
the	O	3237-3240
protein	O	3241-3248
that	O	3249-3253
accumulated	O	3254-3265
was	O	3266-3269
indeed	O	3270-3276
not	O	3277-3280
gamma	O	3281-3286
-	O	3286-3287
carboxylated	O	3287-3299
.	O	3299-3300

These	O	3301-3306
observations	O	3307-3319
indicate	O	3320-3328
that	O	3329-3333
although	O	3334-3342
the	O	3343-3346
gamma	O	3347-3352
-	O	3352-3353
carboxyglutamate	O	3353-3369
residues	O	3370-3378
of	O	3379-3381
matrix	O	3382-3388
Gla	O	3389-3392
protein	O	3393-3400
are	O	3401-3404
apparently	O	3405-3415
required	O	3416-3424
for	O	3425-3428
its	O	3429-3432
function	O	3433-3441
as	O	3442-3444
a	O	3445-3446
calcification	B	3447-3460
inhibitor	O	3461-3470
,	O	3470-3471
they	O	3472-3476
are	O	3477-3480
not	O	3481-3484
required	O	3485-3493
for	O	3494-3497
its	O	3498-3501
accumulation	O	3502-3514
at	O	3515-3517
calcification	B	3518-3531
sites	O	3532-3537
.	O	3537-3538

Antidepressant	O	0-14
-	O	14-15
induced	O	15-22
mania	B	23-28
in	O	29-31
bipolar	B	32-39
patients	O	40-48
:	O	48-49
identification	O	50-64
of	O	65-67
risk	O	68-72
factors	O	73-80
.	O	80-81

BACKGROUND	O	82-92
:	O	92-93
Concerns	O	94-102
about	O	103-108
possible	O	109-117
risks	O	118-123
of	O	124-126
switching	O	127-136
to	O	137-139
mania	B	140-145
associated	O	146-156
with	O	157-161
antidepressants	O	162-177
continue	O	178-186
to	O	187-189
interfere	O	190-199
with	O	200-204
the	O	205-208
establishment	O	209-222
of	O	223-225
an	O	226-228
optimal	O	229-236
treatment	O	237-246
paradigm	O	247-255
for	O	256-259
bipolar	B	260-267
depression	I	268-278
.	O	278-279

METHOD	O	280-286
:	O	286-287
The	O	288-291
response	O	292-300
of	O	301-303
44	O	304-306
patients	O	307-315
meeting	O	316-323
DSM	O	324-327
-	O	327-328
IV	O	328-330
criteria	O	331-339
for	O	340-343
bipolar	B	344-351
disorder	I	352-360
to	O	361-363
naturalistic	O	364-376
treatment	O	377-386
was	O	387-390
assessed	O	391-399
for	O	400-403
at	O	404-406
least	O	407-412
6	O	413-414
weeks	O	415-420
using	O	421-426
the	O	427-430
Montgomery	O	431-441
-	O	441-442
Asberg	O	442-448
Depression	O	449-459
Rating	O	460-466
Scale	O	467-472
and	O	473-476
the	O	477-480
Bech	O	481-485
-	O	485-486
Rafaelson	O	486-495
Mania	O	496-501
Rating	O	502-508
Scale	O	509-514
.	O	514-515

Patients	O	516-524
who	O	525-528
experienced	O	529-540
a	O	541-542
manic	B	543-548
or	O	549-551
hypomanic	B	552-561
switch	O	562-568
were	O	569-573
compared	O	574-582
with	O	583-587
those	O	588-593
who	O	594-597
did	O	598-601
not	O	602-605
on	O	606-608
several	O	609-616
variables	O	617-626
including	O	627-636
age	O	637-640
,	O	640-641
sex	O	642-645
,	O	645-646
diagnosis	O	647-656
(	O	657-658
DSM	B	658-661
-	I	661-662
IV	I	662-664
bipolar	I	665-672
I	I	673-674
vs	O	675-677
.	O	677-678
bipolar	B	679-686
II	I	687-689
)	O	689-690
,	O	690-691
number	O	692-698
of	O	699-701
previous	O	702-710
manic	B	711-716
episodes	O	717-725
,	O	725-726
type	O	727-731
of	O	732-734
antidepressant	O	735-749
therapy	O	750-757
used	O	758-762
(	O	763-764
electroconvulsive	O	764-781
therapy	O	782-789
vs	O	790-792
.	O	792-793
antidepressant	O	794-808
drugs	O	809-814
and	O	815-818
,	O	818-819
more	O	820-824
particularly	O	825-837
,	O	837-838
selective	O	839-848
serotonin	O	849-858
reuptake	O	859-867
inhibitors	O	868-878
[	O	879-880
SSRIs	O	880-885
]	O	885-886
)	O	886-887
,	O	887-888
use	O	889-892
and	O	893-896
type	O	897-901
of	O	902-904
mood	O	905-909
stabilizers	O	910-921
(	O	922-923
lithium	O	923-930
vs	O	931-933
.	O	933-934
anticonvulsants	O	935-950
)	O	950-951
,	O	951-952
and	O	953-956
temperament	O	957-968
of	O	969-971
the	O	972-975
patient	O	976-983
,	O	983-984
assessed	O	985-993
during	O	994-1000
a	O	1001-1002
normothymic	O	1003-1014
period	O	1015-1021
using	O	1022-1027
the	O	1028-1031
hyperthymia	O	1032-1043
component	O	1044-1053
of	O	1054-1056
the	O	1057-1060
Semi	O	1061-1065
-	O	1065-1066
structured	O	1066-1076
Affective	O	1077-1086
Temperament	O	1087-1098
Interview	O	1099-1108
.	O	1108-1109

RESULTS	O	1110-1117
:	O	1117-1118
Switches	O	1119-1127
to	O	1128-1130
hypomania	B	1131-1140
or	O	1141-1143
mania	B	1144-1149
occurred	O	1150-1158
in	O	1159-1161
27	O	1162-1164
%	O	1164-1165
of	O	1166-1168
all	O	1169-1172
patients	O	1173-1181
(	O	1182-1183
N	O	1183-1184
=	O	1185-1186
12	O	1187-1189
)	O	1189-1190
(	O	1191-1192
and	O	1192-1195
in	O	1196-1198
24	O	1199-1201
%	O	1201-1202
of	O	1203-1205
the	O	1206-1209
subgroup	O	1210-1218
of	O	1219-1221
patients	O	1222-1230
treated	O	1231-1238
with	O	1239-1243
SSRIs	O	1244-1249
[	O	1250-1251
8	O	1251-1252
/	O	1252-1253
33	O	1253-1255
]	O	1255-1256
)	O	1256-1257
;	O	1257-1258
16	O	1259-1261
%	O	1261-1262
(	O	1263-1264
N	O	1264-1265
=	O	1266-1267
7	O	1268-1269
)	O	1269-1270
experienced	O	1271-1282
manic	B	1283-1288
episodes	O	1289-1297
,	O	1297-1298
and	O	1299-1302
11	O	1303-1305
%	O	1305-1306
(	O	1307-1308
N	O	1308-1309
=	O	1310-1311
5	O	1312-1313
)	O	1313-1314
experienced	O	1315-1326
hypomanic	B	1327-1336
episodes	O	1337-1345
.	O	1345-1346

Sex	O	1347-1350
,	O	1350-1351
age	O	1352-1355
,	O	1355-1356
diagnosis	O	1357-1366
(	O	1367-1368
bipolar	B	1368-1375
I	I	1376-1377
vs	O	1378-1380
.	O	1380-1381
bipolar	B	1382-1389
II	I	1390-1392
)	O	1392-1393
,	O	1393-1394
and	O	1395-1398
additional	O	1399-1409
treatment	O	1410-1419
did	O	1420-1423
not	O	1424-1427
affect	O	1428-1434
the	O	1435-1438
risk	O	1439-1443
of	O	1444-1446
switching	O	1447-1456
.	O	1456-1457

The	O	1458-1461
incidence	O	1462-1471
of	O	1472-1474
mood	O	1475-1479
switches	O	1480-1488
seemed	O	1489-1495
not	O	1496-1499
to	O	1500-1502
differ	O	1503-1509
between	O	1510-1517
patients	O	1518-1526
receiving	O	1527-1536
an	O	1537-1539
anticonvulsant	O	1540-1554
and	O	1555-1558
those	O	1559-1564
receiving	O	1565-1574
no	O	1575-1577
mood	O	1578-1582
stabilizer	O	1583-1593
.	O	1593-1594

In	O	1595-1597
contrast	O	1598-1606
,	O	1606-1607
mood	O	1608-1612
switches	O	1613-1621
were	O	1622-1626
less	O	1627-1631
frequent	O	1632-1640
in	O	1641-1643
patients	O	1644-1652
receiving	O	1653-1662
lithium	O	1663-1670
(	O	1671-1672
15	O	1672-1674
%	O	1674-1675
,	O	1675-1676
4	O	1677-1678
/	O	1678-1679
26	O	1679-1681
)	O	1681-1682
than	O	1683-1687
in	O	1688-1690
patients	O	1691-1699
not	O	1700-1703
treated	O	1704-1711
with	O	1712-1716
lithium	O	1717-1724
(	O	1725-1726
44	O	1726-1728
%	O	1728-1729
,	O	1729-1730
8	O	1731-1732
/	O	1732-1733
18	O	1733-1735
;	O	1735-1736
p	O	1737-1738
=	O	1739-1740
.	O	1741-1742
04	O	1742-1744
)	O	1744-1745
.	O	1741-1742

The	O	1747-1750
number	O	1751-1757
of	O	1758-1760
previous	O	1761-1769
manic	B	1770-1775
episodes	O	1776-1784
did	O	1785-1788
not	O	1789-1792
affect	O	1793-1799
the	O	1800-1803
probability	O	1804-1815
of	O	1816-1818
switching	O	1819-1828
,	O	1828-1829
whereas	O	1830-1837
a	O	1838-1839
high	O	1840-1844
score	O	1845-1850
on	O	1851-1853
the	O	1854-1857
hyperthymia	O	1858-1869
component	O	1870-1879
of	O	1880-1882
the	O	1883-1886
Semistructured	O	1887-1901
Affective	O	1902-1911
Temperament	O	1912-1923
Interview	O	1924-1933
was	O	1934-1937
associated	O	1938-1948
with	O	1949-1953
a	O	1954-1955
greater	O	1956-1963
risk	O	1964-1968
of	O	1969-1971
switching	O	1972-1981
(	O	1982-1983
p	O	1983-1984
=	O	1985-1986
.	O	1987-1988
008	O	1988-1991
)	O	1991-1992
.	O	1987-1988

CONCLUSION	O	1994-2004
:	O	2004-2005
The	O	2006-2009
frequency	O	2010-2019
of	O	2020-2022
mood	O	2023-2027
switching	O	2028-2037
associated	O	2038-2048
with	O	2049-2053
acute	O	2054-2059
antidepressant	O	2060-2074
therapy	O	2075-2082
may	O	2083-2086
be	O	2087-2089
reduced	O	2090-2097
by	O	2098-2100
lithium	O	2101-2108
treatment	O	2109-2118
.	O	2118-2119

Particular	O	2120-2130
attention	O	2131-2140
should	O	2141-2147
be	O	2148-2150
paid	O	2151-2155
to	O	2156-2158
patients	O	2159-2167
with	O	2168-2172
a	O	2173-2174
hyperthymic	O	2175-2186
temperament	O	2187-2198
,	O	2198-2199
who	O	2200-2203
have	O	2204-2208
a	O	2209-2210
greater	O	2211-2218
risk	O	2219-2223
of	O	2224-2226
mood	O	2227-2231
switches	O	2232-2240
.	O	2240-2241

Caffeine	O	0-8
-	O	8-9
induced	O	9-16
cardiac	B	17-24
arrhythmia	I	25-35
:	O	35-36
an	O	37-39
unrecognised	O	40-52
danger	O	53-59
of	O	60-62
healthfood	O	63-73
products	O	74-82
.	O	82-83

We	O	84-86
describe	O	87-95
a	O	96-97
25	O	98-100
-	O	100-101
year	O	101-105
-	O	100-101
old	O	106-109
woman	O	110-115
with	O	116-120
pre	O	121-124
-	O	124-125
existing	O	125-133
mitral	B	134-140
valve	I	141-146
prolapse	I	147-155
who	O	156-159
developed	O	160-169
intractable	O	170-181
ventricular	B	182-193
fibrillation	I	194-206
after	O	207-212
consuming	O	213-222
a	O	223-224
"	O	225-226
natural	O	226-233
energy	O	234-240
"	O	240-241
guarana	O	242-249
health	O	250-256
drink	O	257-262
containing	O	263-273
a	O	274-275
high	O	276-280
concentration	O	281-294
of	O	295-297
caffeine	O	298-306
.	O	306-307

This	O	308-312
case	O	313-317
highlights	O	318-328
the	O	329-332
need	O	333-337
for	O	338-341
adequate	O	342-350
labelling	O	351-360
and	O	361-364
regulation	O	365-375
of	O	376-378
such	O	379-383
products	O	384-392
.	O	392-393

Bladder	O	0-7
retention	B	8-17
of	I	18-20
urine	I	21-26
as	O	27-29
a	O	30-31
result	O	32-38
of	O	39-41
continuous	O	42-52
intravenous	O	53-64
infusion	O	65-73
of	O	74-76
fentanyl	O	77-85
:	O	85-86
2	O	87-88
case	O	89-93
reports	O	94-101
.	O	101-102

Sedation	O	103-111
has	O	112-115
been	O	116-120
commonly	O	121-129
used	O	130-134
in	O	135-137
the	O	138-141
neonate	O	142-149
to	O	150-152
decrease	O	153-161
the	O	162-165
stress	O	166-172
and	O	173-176
pain	B	177-181
from	O	182-186
the	O	187-190
noxious	O	191-198
stimuli	O	199-206
and	O	207-210
invasive	O	211-219
procedures	O	220-230
in	O	231-233
the	O	234-237
neonatal	O	238-246
intensive	O	247-256
care	O	257-261
unit	O	262-266
,	O	266-267
as	O	268-270
well	O	271-275
as	O	276-278
to	O	279-281
facilitate	O	282-292
synchrony	O	293-302
between	O	303-310
ventilator	O	311-321
and	O	322-325
spontaneous	O	326-337
breaths	O	338-345
.	O	345-346

Fentanyl	O	347-355
,	O	355-356
an	O	357-359
opioid	O	360-366
analgesic	O	367-376
,	O	376-377
is	O	378-380
frequently	O	381-391
used	O	392-396
in	O	397-399
the	O	400-403
neonatal	O	404-412
intensive	O	413-422
care	O	423-427
unit	O	428-432
setting	O	433-440
for	O	441-444
these	O	445-450
very	O	451-455
purposes	O	456-464
.	O	464-465

Various	O	466-473
reported	O	474-482
side	O	483-487
effects	O	488-495
of	O	496-498
fentanyl	O	499-507
administration	O	508-522
include	O	523-530
chest	B	531-536
wall	I	537-541
rigidity	I	542-550
,	O	550-551
hypotension	B	552-563
,	O	563-564
respiratory	B	565-576
depression	I	577-587
,	O	587-588
and	O	589-592
bradycardia	B	593-604
.	O	604-605

Here	O	606-610
,	O	610-611
2	O	612-613
cases	O	614-619
of	O	620-622
urinary	B	623-630
bladder	I	631-638
retention	I	639-648
leading	O	649-656
to	O	657-659
renal	O	660-665
pelvocalyceal	O	666-679
dilatation	O	680-690
mimicking	O	691-700
hydronephrosis	B	701-715
as	O	716-718
a	O	719-720
result	O	721-727
of	O	728-730
continuous	O	731-741
infusion	O	742-750
of	O	751-753
fentanyl	O	754-762
are	O	763-766
reported	O	767-775
.	O	775-776

Combined	O	0-8
antiretroviral	O	9-23
therapy	O	24-31
causes	O	32-38
cardiomyopathy	B	39-53
and	O	54-57
elevates	O	58-66
plasma	O	67-73
lactate	O	74-81
in	O	82-84
transgenic	O	85-95
AIDS	B	96-100
mice	O	101-105
.	O	105-106

Highly	O	107-113
active	O	114-120
antiretroviral	O	121-135
therapy	O	136-143
(	O	144-145
HAART	O	145-150
)	O	150-151
is	O	152-154
implicated	O	155-165
in	O	166-168
cardiomyopathy	B	169-183
(	O	184-185
CM	B	185-187
)	O	187-188
and	O	189-192
in	O	193-195
elevated	O	196-204
plasma	O	205-211
lactate	O	212-219
(	O	220-221
LA	O	221-223
)	O	223-224
in	O	225-227
AIDS	B	228-232
through	O	233-240
mechanisms	O	241-251
of	O	252-254
mitochondrial	B	255-268
dysfunction	I	269-280
.	O	280-281

To	O	282-284
determine	O	285-294
mitochondrial	O	295-308
events	O	309-315
from	O	316-320
HAART	O	321-326
in	O	327-329
vivo	O	330-334
,	O	334-335
8	O	336-337
-	O	337-338
week	O	338-342
-	O	337-338
old	O	343-346
hemizygous	O	347-357
transgenic	O	358-368
AIDS	B	369-373
mice	O	374-378
(	O	379-380
NL4	O	380-383
-	O	383-384
3Delta	O	384-390
gag	O	391-394
/	O	394-395
pol	O	395-398
;	O	398-399
TG	O	400-402
)	O	402-403
and	O	404-407
wild	O	408-412
-	O	412-413
type	O	413-417
FVB	O	418-421
/	O	421-422
n	O	422-423
littermates	O	424-435
were	O	436-440
treated	O	441-448
with	O	449-453
the	O	454-457
HAART	O	458-463
combination	O	464-475
of	O	476-478
zidovudine	O	479-489
,	O	489-490
lamivudine	O	491-501
,	O	501-502
and	O	503-506
indinavir	O	507-516
or	O	517-519
vehicle	O	520-527
control	O	528-535
for	O	536-539
10	O	540-542
days	O	543-547
or	O	548-550
35	O	551-553
days	O	554-558
.	O	558-559

At	O	560-562
termination	O	563-574
of	O	575-577
the	O	578-581
experiments	O	582-593
,	O	593-594
mice	O	595-599
underwent	O	600-609
echocardiography	O	610-626
,	O	626-627
quantitation	O	628-640
of	O	641-643
abundance	O	644-653
of	O	654-656
molecular	O	657-666
markers	O	667-674
of	O	675-677
CM	B	678-680
(	O	681-682
ventricular	O	682-693
mRNA	O	694-698
encoding	O	699-707
atrial	O	708-714
natriuretic	O	715-726
factor	O	727-733
[	O	734-735
ANF	O	735-738
]	O	738-739
and	O	740-743
sarcoplasmic	O	744-756
calcium	O	757-764
ATPase	O	765-771
[	O	772-773
SERCA2	O	773-779
]	O	779-780
)	O	780-781
,	O	781-782
and	O	783-786
determination	O	787-800
of	O	801-803
plasma	O	804-810
LA	O	811-813
.	O	813-814

Myocardial	O	815-825
histologic	O	826-836
features	O	837-845
were	O	846-850
analyzed	O	851-859
semiquantitatively	O	860-878
and	O	879-882
results	O	883-890
were	O	891-895
confirmed	O	896-905
by	O	906-908
transmission	O	909-921
electron	O	922-930
microscopy	O	931-941
.	O	941-942

After	O	943-948
35	O	949-951
days	O	952-956
in	O	957-959
the	O	960-963
TG	O	964-966
+	O	967-968
HAART	O	969-974
cohort	O	975-981
,	O	981-982
left	O	983-987
ventricular	O	988-999
mass	O	1000-1004
increased	O	1005-1014
160	O	1015-1018
%	O	1018-1019
by	O	1020-1022
echocardiography	O	1023-1039
.	O	1039-1040

Molecularly	O	1041-1052
,	O	1052-1053
ANF	O	1054-1057
mRNA	O	1058-1062
increased	O	1063-1072
250	O	1073-1076
%	O	1076-1077
and	O	1078-1081
SERCA2	O	1082-1088
mRNA	O	1089-1093
decreased	O	1094-1103
57	O	1104-1106
%	O	1106-1107
.	O	1107-1108

Biochemically	O	1109-1122
,	O	1122-1123
LA	O	1124-1126
was	O	1127-1130
elevated	O	1131-1139
(	O	1140-1141
8	O	1141-1142
.	O	1142-1143
5	O	1143-1144
+	O	1145-1146
/	O	1146-1147
-	O	1147-1148
2	O	1149-1150
.	O	1150-1151
0	O	1151-1152
mM	O	1153-1155
)	O	1155-1156
.	O	1156-1157

Pathologically	O	1158-1172
,	O	1172-1173
granular	O	1174-1182
cytoplasmic	O	1183-1194
changes	O	1195-1202
were	O	1203-1207
found	O	1208-1213
in	O	1214-1216
cardiac	O	1217-1224
myocytes	O	1225-1233
,	O	1233-1234
indicating	O	1235-1245
enlarged	O	1246-1254
,	O	1254-1255
damaged	O	1256-1263
mitochondria	O	1264-1276
.	O	1276-1277

Findings	O	1278-1286
were	O	1287-1291
confirmed	O	1292-1301
ultrastructurally	O	1302-1319
.	O	1319-1320

No	O	1321-1323
changes	O	1324-1331
were	O	1332-1336
found	O	1337-1342
in	O	1343-1345
other	O	1346-1351
cohorts	O	1352-1359
.	O	1359-1360

After	O	1361-1366
10	O	1367-1369
days	O	1370-1374
,	O	1374-1375
only	O	1376-1380
ANF	O	1381-1384
was	O	1385-1388
elevated	O	1389-1397
,	O	1397-1398
and	O	1399-1402
only	O	1403-1407
in	O	1408-1410
the	O	1411-1414
TG	O	1415-1417
+	O	1418-1419
HAART	O	1420-1425
cohort	O	1426-1432
.	O	1432-1433

Results	O	1434-1441
show	O	1442-1446
that	O	1447-1451
cumulative	O	1452-1462
HAART	O	1463-1468
caused	O	1469-1475
mitochondrial	O	1476-1489
CM	B	1490-1492
with	O	1493-1497
elevated	O	1498-1506
LA	O	1507-1509
in	O	1510-1512
AIDS	B	1513-1517
transgenic	O	1518-1528
mice	O	1529-1533
.	O	1533-1534

Oral	O	0-4
contraceptives	O	5-19
and	O	20-23
the	O	24-27
risk	O	28-32
of	O	33-35
myocardial	B	36-46
infarction	I	47-57
.	O	57-58

BACKGROUND	O	59-69
:	O	69-70
An	O	71-73
association	O	74-85
between	O	86-93
the	O	94-97
use	O	98-101
of	O	102-104
oral	O	105-109
contraceptives	O	110-124
and	O	125-128
the	O	129-132
risk	O	133-137
of	O	138-140
myocardial	B	141-151
infarction	I	152-162
has	O	163-166
been	O	167-171
found	O	172-177
in	O	178-180
some	O	181-185
,	O	185-186
but	O	187-190
not	O	191-194
all	O	195-198
,	O	198-199
studies	O	200-207
.	O	207-208

We	O	209-211
investigated	O	212-224
this	O	225-229
association	O	230-241
,	O	241-242
according	O	243-252
to	O	253-255
the	O	256-259
type	O	260-264
of	O	265-267
progestagen	O	268-279
included	O	280-288
in	O	289-291
third	O	292-297
-	O	297-298
generation	O	298-308
(	O	309-310
i	O	310-311
.	O	311-312
e	O	312-313
.	O	311-312
,	O	314-315
desogestrel	O	316-327
or	O	328-330
gestodene	O	331-340
)	O	340-341
and	O	342-345
second	O	346-352
-	O	352-353
generation	O	353-363
(	O	364-365
i	O	365-366
.	O	366-367
e	O	367-368
.	O	366-367
,	O	369-370
levonorgestrel	O	371-385
)	O	385-386
oral	O	387-391
contraceptives	O	392-406
,	O	406-407
the	O	408-411
dose	O	412-416
of	O	417-419
estrogen	O	420-428
,	O	428-429
and	O	430-433
the	O	434-437
presence	O	438-446
or	O	447-449
absence	O	450-457
of	O	458-460
prothrombotic	O	461-474
mutations	O	475-484
METHODS	O	485-492
:	O	492-493
In	O	494-496
a	O	497-498
nationwide	O	499-509
,	O	509-510
population	O	511-521
-	O	521-522
based	O	522-527
,	O	527-528
case	O	529-533
-	O	533-534
control	O	534-541
study	O	542-547
,	O	547-548
we	O	549-551
identified	O	552-562
and	O	563-566
enrolled	O	567-575
248	O	576-579
women	O	580-585
18	O	586-588
through	O	589-596
49	O	597-599
years	O	600-605
of	O	606-608
age	O	609-612
who	O	613-616
had	O	617-620
had	O	621-624
a	O	625-626
first	O	627-632
myocardial	B	633-643
infarction	I	644-654
between	O	655-662
1990	O	663-667
and	O	668-671
1995	O	672-676
and	O	677-680
925	O	681-684
control	O	685-692
women	O	693-698
who	O	699-702
had	O	703-706
not	O	707-710
had	O	711-714
a	O	715-716
myocardial	B	717-727
infarction	I	728-738
and	O	739-742
who	O	743-746
were	O	747-751
matched	O	752-759
for	O	760-763
age	O	764-767
,	O	767-768
calendar	O	769-777
year	O	778-782
of	O	783-785
the	O	786-789
index	O	790-795
event	O	796-801
,	O	801-802
and	O	803-806
area	O	807-811
of	O	812-814
residence	O	815-824
.	O	824-825

Subjects	O	826-834
supplied	O	835-843
information	O	844-855
on	O	856-858
oral	O	859-863
-	O	863-864
contraceptive	O	864-877
use	O	878-881
and	O	882-885
major	O	886-891
cardiovascular	O	892-906
risk	O	907-911
factors	O	912-919
.	O	919-920

An	O	921-923
analysis	O	924-932
for	O	933-936
factor	O	937-943
V	O	944-945
Leiden	O	946-952
and	O	953-956
the	O	957-960
G20210A	O	961-968
mutation	O	969-977
in	O	978-980
the	O	981-984
prothrombin	O	985-996
gene	O	997-1001
was	O	1002-1005
conducted	O	1006-1015
in	O	1016-1018
217	O	1019-1022
patients	O	1023-1031
and	O	1032-1035
763	O	1036-1039
controls	O	1040-1048
RESULTS	O	1049-1056
:	O	1056-1057
The	O	1058-1061
odds	O	1062-1066
ratio	O	1067-1072
for	O	1073-1076
myocardial	B	1077-1087
infarction	I	1088-1098
among	O	1099-1104
women	O	1105-1110
who	O	1111-1114
used	O	1115-1119
any	O	1120-1123
type	O	1124-1128
of	O	1129-1131
combined	O	1132-1140
oral	O	1141-1145
contraceptive	O	1146-1159
,	O	1159-1160
as	O	1161-1163
compared	O	1164-1172
with	O	1173-1177
nonusers	O	1178-1186
,	O	1186-1187
was	O	1188-1191
2	O	1192-1193
.	O	1193-1194
0	O	1194-1195
(	O	1196-1197
95	O	1197-1199
percent	O	1200-1207
confidence	O	1208-1218
interval	O	1219-1227
,	O	1227-1228
1	O	1229-1230
.	O	1230-1231
5	O	1231-1232
to	O	1233-1235
2	O	1236-1237
.	O	1237-1238
8	O	1238-1239
)	O	1239-1240
.	O	1237-1238

The	O	1242-1245
adjusted	O	1246-1254
odds	O	1255-1259
ratio	O	1260-1265
was	O	1266-1269
2	O	1270-1271
.	O	1271-1272
5	O	1272-1273
(	O	1274-1275
95	O	1275-1277
percent	O	1278-1285
confidence	O	1286-1296
interval	O	1297-1305
,	O	1305-1306
1	O	1307-1308
.	O	1308-1309
5	O	1309-1310
to	O	1311-1313
4	O	1314-1315
.	O	1315-1316
1	O	1316-1317
)	O	1317-1318
among	O	1319-1324
women	O	1325-1330
who	O	1331-1334
used	O	1335-1339
second	O	1340-1346
-	O	1346-1347
generation	O	1347-1357
oral	O	1358-1362
contraceptives	O	1363-1377
and	O	1378-1381
1	O	1382-1383
.	O	1383-1384
3	O	1384-1385
(	O	1386-1387
95	O	1387-1389
percent	O	1390-1397
confidence	O	1398-1408
interval	O	1409-1417
,	O	1417-1418
0	O	1419-1420
.	O	1420-1421
7	O	1421-1422
to	O	1423-1425
2	O	1426-1427
.	O	1427-1428
5	O	1428-1429
)	O	1429-1430
among	O	1431-1436
those	O	1437-1442
who	O	1443-1446
used	O	1447-1451
third	O	1452-1457
-	O	1457-1458
generation	O	1458-1468
oral	O	1469-1473
contraceptives	O	1474-1488
.	O	1488-1489

Among	O	1490-1495
women	O	1496-1501
who	O	1502-1505
used	O	1506-1510
oral	O	1511-1515
contraceptives	O	1516-1530
,	O	1530-1531
the	O	1532-1535
odds	O	1536-1540
ratio	O	1541-1546
was	O	1547-1550
2	O	1551-1552
.	O	1552-1553
1	O	1553-1554
(	O	1555-1556
95	O	1556-1558
percent	O	1559-1566
confidence	O	1567-1577
interval	O	1578-1586
,	O	1586-1587
1	O	1588-1589
.	O	1589-1590
5	O	1590-1591
to	O	1592-1594
3	O	1595-1596
.	O	1596-1597
0	O	1597-1598
)	O	1598-1599
for	O	1600-1603
those	O	1604-1609
without	O	1610-1617
a	O	1618-1619
prothrombotic	O	1620-1633
mutation	O	1634-1642
and	O	1643-1646
1	O	1647-1648
.	O	1648-1649
9	O	1649-1650
(	O	1651-1652
95	O	1652-1654
percent	O	1655-1662
confidence	O	1663-1673
interval	O	1674-1682
,	O	1682-1683
0	O	1684-1685
.	O	1685-1686
6	O	1686-1687
to	O	1688-1690
5	O	1691-1692
.	O	1692-1693
5	O	1691-1692
)	O	1694-1695
for	O	1696-1699
those	O	1700-1705
with	O	1706-1710
a	O	1711-1712
mutation	O	1713-1721
CONCLUSIONS	O	1722-1733
:	O	1733-1734
The	O	1735-1738
risk	O	1739-1743
of	O	1744-1746
myocardial	B	1747-1757
infarction	I	1758-1768
was	O	1769-1772
increased	O	1773-1782
among	O	1783-1788
women	O	1789-1794
who	O	1795-1798
used	O	1799-1803
second	O	1804-1810
-	O	1810-1811
generation	O	1811-1821
oral	O	1822-1826
contraceptives	O	1827-1841
.	O	1841-1842

The	O	1843-1846
results	O	1847-1854
with	O	1855-1859
respect	O	1860-1867
to	O	1868-1870
the	O	1871-1874
use	O	1875-1878
of	O	1879-1881
third	O	1882-1887
-	O	1887-1888
generation	O	1888-1898
oral	O	1899-1903
contraceptives	O	1904-1918
were	O	1919-1923
inconclusive	O	1924-1936
but	O	1937-1940
suggested	O	1941-1950
that	O	1951-1955
the	O	1956-1959
risk	O	1960-1964
was	O	1965-1968
lower	O	1969-1974
than	O	1975-1979
the	O	1980-1983
risk	O	1984-1988
associated	O	1989-1999
with	O	2000-2004
second	O	2005-2011
-	O	2011-2012
generation	O	2012-2022
oral	O	2023-2027
contraceptives	O	2028-2042
.	O	2042-2043

The	O	2044-2047
risk	O	2048-2052
of	O	2053-2055
myocardial	B	2056-2066
infarction	I	2067-2077
was	O	2078-2081
similar	O	2082-2089
among	O	2090-2095
women	O	2096-2101
who	O	2102-2105
used	O	2106-2110
oral	O	2111-2115
contraceptives	O	2116-2130
whether	O	2131-2138
or	O	2139-2141
not	O	2142-2145
they	O	2146-2150
had	O	2151-2154
a	O	2155-2156
prothrombotic	O	2157-2170
mutation	O	2171-2179
.	O	2179-2180

Effects	O	0-7
of	O	8-10
5	O	11-12
-	O	12-13
HT1B	O	13-17
receptor	O	18-26
ligands	O	27-34
microinjected	O	35-48
into	O	49-53
the	O	54-57
accumbal	O	58-66
shell	O	67-72
or	O	73-75
core	O	76-80
on	O	81-83
the	O	84-87
cocaine	O	88-95
-	O	95-96
induced	O	96-103
locomotor	B	104-113
hyperactivity	I	114-127
in	O	128-130
rats	O	131-135
.	O	135-136

The	O	137-140
present	O	141-148
study	O	149-154
was	O	155-158
designed	O	159-167
to	O	168-170
examine	O	171-178
the	O	179-182
effect	O	183-189
of	O	190-192
5	O	193-194
-	O	194-195
HT1B	O	195-199
receptor	O	200-208
ligands	O	209-216
microinjected	O	217-230
into	O	231-235
the	O	236-239
subregions	O	240-250
of	O	251-253
the	O	254-257
nucleus	O	258-265
accumbens	O	266-275
(	O	276-277
the	O	277-280
shell	O	281-286
and	O	287-290
the	O	291-294
core	O	295-299
)	O	299-300
on	O	301-303
the	O	304-307
locomotor	B	308-317
hyperactivity	I	318-331
induced	O	332-339
by	O	340-342
cocaine	O	343-350
in	O	351-353
rats	O	354-358
.	O	358-359

Male	O	360-364
Wistar	O	365-371
rats	O	372-376
were	O	377-381
implanted	O	382-391
bilaterally	O	392-403
with	O	404-408
cannulae	O	409-417
into	O	418-422
the	O	423-426
accumbens	O	427-436
shell	O	437-442
or	O	443-445
core	O	446-450
,	O	450-451
and	O	452-455
then	O	456-460
were	O	461-465
locally	O	466-473
injected	O	474-482
with	O	483-487
GR	O	488-490
55562	O	491-496
(	O	497-498
an	O	498-500
antagonist	O	501-511
of	O	512-514
5	O	515-516
-	O	516-517
HT1B	O	517-521
receptors	O	522-531
)	O	531-532
or	O	533-535
CP	O	536-538
93129	O	539-544
(	O	545-546
an	O	546-548
agonist	O	549-556
of	O	557-559
5	O	560-561
-	O	561-562
HT1B	O	562-566
receptors	O	567-576
)	O	576-577
.	O	577-578

Given	O	579-584
alone	O	585-590
to	O	591-593
any	O	594-597
accumbal	O	598-606
subregion	O	607-616
,	O	616-617
GR	O	618-620
55562	O	621-626
(	O	627-628
0	O	628-629
.	O	629-630
1	O	630-631
-	O	631-632
10	O	632-634
microg	O	635-641
/	O	641-642
side	O	642-646
)	O	646-647
or	O	648-650
CP	O	651-653
93129	O	654-659
(	O	660-661
0	O	661-662
.	O	662-663
1	O	663-664
-	O	664-665
10	O	665-667
microg	O	668-674
/	O	674-675
side	O	675-679
)	O	679-680
did	O	681-684
not	O	685-688
change	O	689-695
basal	O	696-701
locomotor	O	702-711
activity	O	712-720
.	O	720-721

Systemic	O	722-730
cocaine	O	731-738
(	O	739-740
10	O	740-742
mg	O	743-745
/	O	745-746
kg	O	746-748
)	O	748-749
significantly	O	750-763
increased	O	764-773
the	O	774-777
locomotor	O	778-787
activity	O	788-796
of	O	797-799
rats	O	800-804
.	O	804-805

GR	O	806-808
55562	O	809-814
(	O	815-816
0	O	816-817
.	O	817-818
1	O	818-819
-	O	819-820
10	O	820-822
microg	O	823-829
/	O	829-830
side	O	830-834
)	O	834-835
,	O	835-836
administered	O	837-849
intra	O	850-855
-	O	855-856
accumbens	O	856-865
shell	O	866-871
prior	O	872-877
to	O	878-880
cocaine	O	881-888
,	O	888-889
dose	O	890-894
-	O	894-895
dependently	O	895-906
attenuated	O	907-917
the	O	918-921
psychostimulant	O	922-937
-	O	937-938
induced	O	938-945
locomotor	B	946-955
hyperactivity	I	956-969
.	O	969-970

Such	O	971-975
attenuation	O	976-987
was	O	988-991
not	O	992-995
found	O	996-1001
in	O	1002-1004
animals	O	1005-1012
which	O	1013-1018
had	O	1019-1022
been	O	1023-1027
injected	O	1028-1036
with	O	1037-1041
GR	O	1042-1044
55562	O	1045-1050
into	O	1051-1055
the	O	1056-1059
accumbens	O	1060-1069
core	O	1070-1074
.	O	1074-1075

When	O	1076-1080
injected	O	1081-1089
into	O	1090-1094
the	O	1095-1098
accumbens	O	1099-1108
shell	O	1109-1114
(	O	1115-1116
but	O	1116-1119
not	O	1120-1123
the	O	1124-1127
core	O	1128-1132
)	O	1132-1133
before	O	1134-1140
cocaine	O	1141-1148
,	O	1148-1149
CP	O	1150-1152
93129	O	1153-1158
(	O	1159-1160
0	O	1160-1161
.	O	1161-1162
1	O	1162-1163
-	O	1163-1164
10	O	1164-1166
microg	O	1167-1173
/	O	1173-1174
side	O	1174-1178
)	O	1178-1179
enhanced	O	1180-1188
the	O	1189-1192
locomotor	O	1193-1202
response	O	1203-1211
to	O	1212-1214
cocaine	O	1215-1222
;	O	1222-1223
the	O	1224-1227
maximum	O	1228-1235
effect	O	1236-1242
being	O	1243-1248
observed	O	1249-1257
after	O	1258-1263
10	O	1264-1266
microg	O	1267-1273
/	O	1273-1274
side	O	1274-1278
of	O	1279-1281
the	O	1282-1285
agonist	O	1286-1293
.	O	1293-1294

The	O	1295-1298
later	O	1299-1304
enhancement	O	1305-1316
was	O	1317-1320
attenuated	O	1321-1331
after	O	1332-1337
intra	O	1338-1343
-	O	1343-1344
accumbens	O	1344-1353
shell	O	1354-1359
treatment	O	1360-1369
with	O	1370-1374
GR	O	1375-1377
55562	O	1378-1383
(	O	1384-1385
1	O	1385-1386
microg	O	1387-1393
/	O	1393-1394
side	O	1394-1398
)	O	1398-1399
.	O	1399-1400

Our	O	1401-1404
findings	O	1405-1413
indicate	O	1414-1422
that	O	1423-1427
cocaine	O	1428-1435
induced	O	1436-1443
hyperlocomotion	B	1444-1459
is	O	1460-1462
modified	O	1463-1471
by	O	1472-1474
5	O	1475-1476
-	O	1476-1477
HT1B	O	1477-1481
receptor	O	1482-1490
ligands	O	1491-1498
microinjected	O	1499-1512
into	O	1513-1517
the	O	1518-1521
accumbens	O	1522-1531
shell	O	1532-1537
,	O	1537-1538
but	O	1539-1542
not	O	1543-1546
core	O	1547-1551
,	O	1551-1552
this	O	1553-1557
modification	O	1558-1570
consisting	O	1571-1581
in	O	1582-1584
inhibitory	O	1585-1595
and	O	1596-1599
facilitatory	O	1600-1612
effects	O	1613-1620
of	O	1621-1623
the	O	1624-1627
5	O	1628-1629
-	O	1629-1630
HT1B	O	1630-1634
receptor	O	1635-1643
antagonist	O	1644-1654
(	O	1655-1656
GR	O	1656-1658
55562	O	1659-1664
)	O	1664-1665
and	O	1666-1669
agonist	O	1670-1677
(	O	1678-1679
CP	O	1679-1681
93129	O	1682-1687
)	O	1687-1688
,	O	1688-1689
respectively	O	1690-1702
.	O	1702-1703

In	O	1704-1706
other	O	1707-1712
words	O	1713-1718
,	O	1718-1719
the	O	1720-1723
present	O	1724-1731
results	O	1732-1739
suggest	O	1740-1747
that	O	1748-1752
the	O	1753-1756
accumbal	O	1757-1765
shell	O	1766-1771
5	O	1772-1773
-	O	1773-1774
HT1B	O	1774-1778
receptors	O	1779-1788
play	O	1789-1793
a	O	1794-1795
permissive	O	1796-1806
role	O	1807-1811
in	O	1812-1814
the	O	1815-1818
behavioural	O	1819-1830
response	O	1831-1839
to	O	1840-1842
the	O	1843-1846
psychostimulant	O	1847-1862
.	O	1862-1863

Ticlopidine	O	0-11
-	O	11-12
induced	O	12-19
cholestatic	B	20-31
hepatitis	I	32-41
.	O	41-42

OBJECTIVE	O	43-52
:	O	52-53
To	O	54-56
report	O	57-63
2	O	64-65
cases	O	66-71
of	O	72-74
ticlopidine	O	75-86
-	O	86-87
induced	O	87-94
cholestatic	B	95-106
hepatitis	I	107-116
,	O	116-117
investigate	O	118-129
its	O	130-133
mechanism	O	134-143
,	O	143-144
and	O	145-148
compare	O	149-156
the	O	157-160
observed	O	161-169
main	O	170-174
characteristics	O	175-190
with	O	191-195
those	O	196-201
of	O	202-204
the	O	205-208
published	O	209-218
cases	O	219-224
.	O	224-225

CASE	O	226-230
SUMMARIES	O	231-240
:	O	240-241
Two	O	242-245
patients	O	246-254
developed	O	255-264
prolonged	O	265-274
cholestatic	B	275-286
hepatitis	I	287-296
after	O	297-302
receiving	O	303-312
ticlopidine	O	313-324
following	O	325-334
percutaneous	O	335-347
coronary	O	348-356
angioplasty	O	357-368
,	O	368-369
with	O	370-374
complete	O	375-383
remission	O	384-393
during	O	394-400
the	O	401-404
follow	O	405-411
-	O	411-412
up	O	412-414
period	O	415-421
.	O	421-422

T	O	423-424
-	O	424-425
cell	O	425-429
stimulation	O	430-441
by	O	442-444
therapeutic	O	445-456
concentration	O	457-470
of	O	471-473
ticlopidine	O	474-485
was	O	486-489
demonstrated	O	490-502
in	O	503-505
vitro	O	506-511
in	O	512-514
the	O	515-518
patients	O	519-527
,	O	527-528
but	O	529-532
not	O	533-536
in	O	537-539
healthy	O	540-547
controls	O	548-556
.	O	556-557

DISCUSSION	O	558-568
:	O	568-569
Cholestatic	B	570-581
hepatitis	I	582-591
is	O	592-594
a	O	595-596
rare	O	597-601
complication	O	602-614
of	O	615-617
the	O	618-621
antiplatelet	O	622-634
agent	O	635-640
ticlopidine	O	641-652
;	O	652-653
several	O	654-661
cases	O	662-667
have	O	668-672
been	O	673-677
reported	O	678-686
but	O	687-690
few	O	691-694
in	O	695-697
the	O	698-701
English	O	702-709
literature	O	710-720
.	O	720-721

Our	O	722-725
patients	O	726-734
developed	O	735-744
jaundice	B	745-753
following	O	754-763
treatment	O	764-773
with	O	774-778
ticlopidine	O	779-790
and	O	791-794
showed	O	795-801
the	O	802-805
clinical	O	806-814
and	O	815-818
laboratory	O	819-829
characteristics	O	830-845
of	O	846-848
cholestatic	B	849-860
hepatitis	I	861-870
,	O	870-871
which	O	872-877
resolved	O	878-886
after	O	887-892
discontinuation	O	893-908
of	O	909-911
the	O	912-915
drug	O	916-920
.	O	920-921

Hepatitis	B	922-931
may	O	932-935
develop	O	936-943
weeks	O	944-949
after	O	950-955
discontinuation	O	956-971
of	O	972-974
the	O	975-978
drug	O	979-983
and	O	984-987
may	O	988-991
run	O	992-995
a	O	996-997
prolonged	O	998-1007
course	O	1008-1014
,	O	1014-1015
but	O	1016-1019
complete	O	1020-1028
remission	O	1029-1038
was	O	1039-1042
observed	O	1043-1051
in	O	1052-1054
all	O	1055-1058
reported	O	1059-1067
cases	O	1068-1073
.	O	1073-1074

An	O	1075-1077
objective	O	1078-1087
causality	O	1088-1097
assessment	O	1098-1108
revealed	O	1109-1117
that	O	1118-1122
the	O	1123-1126
adverse	O	1127-1134
drug	O	1135-1139
event	O	1140-1145
was	O	1146-1149
probably	O	1150-1158
related	O	1159-1166
to	O	1167-1169
the	O	1170-1173
use	O	1174-1177
of	O	1178-1180
ticlopidine	O	1181-1192
.	O	1192-1193

The	O	1194-1197
mechanisms	O	1198-1208
of	O	1209-1211
this	O	1212-1216
ticlopidine	O	1217-1228
-	O	1228-1229
induced	O	1229-1236
cholestasis	B	1237-1248
are	O	1249-1252
unclear	O	1253-1260
.	O	1260-1261

Immune	O	1262-1268
mechanisms	O	1269-1279
may	O	1280-1283
be	O	1284-1286
involved	O	1287-1295
in	O	1296-1298
the	O	1299-1302
drug	O	1303-1307
'	O	1307-1308
s	O	1308-1309
hepatotoxicity	B	1310-1324
,	O	1324-1325
as	O	1326-1328
suggested	O	1329-1338
by	O	1339-1341
the	O	1342-1345
T	O	1346-1347
-	O	1347-1348
cell	O	1348-1352
stimulation	O	1353-1364
study	O	1365-1370
reported	O	1371-1379
here	O	1380-1384
.	O	1384-1385

CONCLUSIONS	O	1386-1397
:	O	1397-1398
Cholestatic	B	1399-1410
hepatitis	I	1411-1420
is	O	1421-1423
a	O	1424-1425
rare	O	1426-1430
adverse	O	1431-1438
effect	O	1439-1445
of	O	1446-1448
ticlopidine	O	1449-1460
that	O	1461-1465
may	O	1466-1469
be	O	1470-1472
immune	O	1473-1479
mediated	O	1480-1488
.	O	1488-1489

Patients	O	1490-1498
receiving	O	1499-1508
the	O	1509-1512
drug	O	1513-1517
should	O	1518-1524
be	O	1525-1527
monitored	O	1528-1537
with	O	1538-1542
liver	O	1543-1548
function	O	1549-1557
tests	O	1558-1563
along	O	1564-1569
with	O	1570-1574
complete	O	1575-1583
blood	O	1584-1589
cell	O	1590-1594
counts	O	1595-1601
.	O	1601-1602

This	O	1603-1607
complication	O	1608-1620
will	O	1621-1625
be	O	1626-1628
observed	O	1629-1637
even	O	1638-1642
less	O	1643-1647
often	O	1648-1653
in	O	1654-1656
the	O	1657-1660
future	O	1661-1667
as	O	1668-1670
ticlopidine	O	1671-1682
is	O	1683-1685
being	O	1686-1691
replaced	O	1692-1700
by	O	1701-1703
the	O	1704-1707
newer	O	1708-1713
antiplatelet	O	1714-1726
agent	O	1727-1732
clopidogrel	O	1733-1744
.	O	1744-1745

Epithelial	O	0-10
sodium	O	11-17
channel	O	18-25
(	O	26-27
ENaC	O	27-31
)	O	31-32
subunit	O	33-40
mRNA	O	41-45
and	O	46-49
protein	O	50-57
expression	O	58-68
in	O	69-71
rats	O	72-76
with	O	77-81
puromycin	O	82-91
aminonucleoside	O	92-107
-	O	107-108
induced	O	108-115
nephrotic	B	116-125
syndrome	I	126-134
.	O	134-135

In	O	136-138
experimental	O	139-151
nephrotic	B	152-161
syndrome	I	162-170
,	O	170-171
urinary	O	172-179
sodium	O	180-186
excretion	O	187-196
is	O	197-199
decreased	O	200-209
during	O	210-216
the	O	217-220
early	O	221-226
phase	O	227-232
of	O	233-235
the	O	236-239
disease	O	240-247
.	O	247-248

The	O	249-252
molecular	O	253-262
mechanism	O	263-272
(	O	272-273
s	O	270-271
)	O	274-275
leading	O	276-283
to	O	284-286
salt	O	287-291
retention	O	292-301
has	O	302-305
not	O	306-309
been	O	310-314
completely	O	315-325
elucidated	O	326-336
.	O	336-337

The	O	338-341
rate	O	342-346
-	O	346-347
limiting	O	347-355
constituent	O	356-367
of	O	368-370
collecting	O	371-381
duct	O	382-386
sodium	O	387-393
transport	O	394-403
is	O	404-406
the	O	407-410
epithelial	O	411-421
sodium	O	422-428
channel	O	429-436
(	O	437-438
ENaC	O	438-442
)	O	442-443
.	O	443-444

We	O	445-447
examined	O	448-456
the	O	457-460
abundance	O	461-470
of	O	471-473
ENaC	O	474-478
subunit	O	479-486
mRNAs	O	487-492
and	O	493-496
proteins	O	497-505
in	O	506-508
puromycin	O	509-518
aminonucleoside	O	519-534
(	O	535-536
PAN	O	536-539
)	O	539-540
-	O	540-541
induced	O	541-548
nephrotic	B	549-558
syndrome	I	559-567
.	O	567-568

The	O	569-572
time	O	573-577
courses	O	578-585
of	O	586-588
urinary	O	589-596
sodium	O	597-603
excretion	O	604-613
,	O	613-614
plasma	O	615-621
aldosterone	O	622-633
concentration	O	634-647
and	O	648-651
proteinuria	B	652-663
were	O	664-668
studied	O	669-676
in	O	677-679
male	O	680-684
Sprague	O	685-692
-	O	692-693
Dawley	O	693-699
rats	O	700-704
treated	O	705-712
with	O	713-717
a	O	718-719
single	O	720-726
dose	O	727-731
of	O	732-734
either	O	735-741
PAN	O	742-745
or	O	746-748
vehicle	O	749-756
.	O	756-757

The	O	758-761
relative	O	762-770
amounts	O	771-778
of	O	779-781
alphaENaC	O	782-791
,	O	791-792
betaENaC	O	793-801
and	O	802-805
gammaENaC	O	806-815
mRNAs	O	816-821
were	O	822-826
determined	O	827-837
in	O	838-840
kidneys	O	841-848
from	O	849-853
these	O	854-859
rats	O	860-864
by	O	865-867
real	O	868-872
-	O	872-873
time	O	873-877
quantitative	O	878-890
TaqMan	O	891-897
PCR	O	898-901
,	O	901-902
and	O	903-906
the	O	907-910
amounts	O	911-918
of	O	919-921
proteins	O	922-930
by	O	931-933
Western	O	934-941
blot	O	942-946
.	O	946-947

The	O	948-951
kinetics	O	952-960
of	O	961-963
urinary	O	964-971
sodium	O	972-978
excretion	O	979-988
and	O	989-992
the	O	993-996
appearance	O	997-1007
of	O	1008-1010
proteinuria	B	1011-1022
were	O	1023-1027
comparable	O	1028-1038
with	O	1039-1043
those	O	1044-1049
reported	O	1050-1058
previously	O	1059-1069
.	O	1069-1070

Sodium	O	1071-1077
retention	O	1078-1087
occurred	O	1088-1096
on	O	1097-1099
days	O	1100-1104
2	O	1105-1106
,	O	1106-1107
3	O	1108-1109
and	O	1110-1113
6	O	1114-1115
after	O	1116-1121
PAN	O	1122-1125
injection	O	1126-1135
.	O	1135-1136

A	O	1137-1138
significant	O	1139-1150
up	O	1151-1153
-	O	1153-1154
regulation	O	1154-1164
of	O	1165-1167
alphaENaC	O	1168-1177
and	O	1178-1181
betaENaC	O	1182-1190
mRNA	O	1191-1195
abundance	O	1196-1205
on	O	1206-1208
days	O	1209-1213
1	O	1214-1215
and	O	1216-1219
2	O	1220-1221
preceded	O	1222-1230
sodium	O	1231-1237
retention	O	1238-1247
on	O	1248-1250
days	O	1251-1255
2	O	1256-1257
and	O	1258-1261
3	O	1262-1263
.	O	1263-1264
Conversely	O	1265-1275
,	O	1275-1276
down	O	1277-1281
-	O	1281-1282
regulation	O	1282-1292
of	O	1293-1295
alphaENaC	O	1296-1305
,	O	1305-1306
betaENaC	O	1307-1315
and	O	1316-1319
gammaENaC	O	1320-1329
mRNA	O	1330-1334
expression	O	1335-1345
on	O	1346-1348
day	O	1349-1352
3	O	1353-1354
occurred	O	1355-1363
in	O	1364-1366
the	O	1367-1370
presence	O	1371-1379
of	O	1380-1382
high	O	1383-1387
aldosterone	O	1388-1399
concentrations	O	1400-1414
,	O	1414-1415
and	O	1416-1419
was	O	1420-1423
followed	O	1424-1432
by	O	1433-1435
a	O	1436-1437
return	O	1438-1444
of	O	1445-1447
sodium	O	1448-1454
excretion	O	1455-1464
to	O	1465-1467
control	O	1468-1475
values	O	1476-1482
.	O	1482-1483

The	O	1484-1487
amounts	O	1488-1495
of	O	1496-1498
alphaENaC	O	1499-1508
,	O	1508-1509
betaENaC	O	1510-1518
and	O	1519-1522
gammaENaC	O	1523-1532
proteins	O	1533-1541
were	O	1542-1546
not	O	1547-1550
increased	O	1551-1560
during	O	1561-1567
PAN	O	1568-1571
-	O	1571-1572
induced	O	1572-1579
sodium	O	1580-1586
retention	O	1587-1596
.	O	1596-1597

In	O	1598-1600
conclusion	O	1601-1611
,	O	1611-1612
ENaC	O	1613-1617
mRNA	O	1618-1622
expression	O	1623-1633
,	O	1633-1634
especially	O	1635-1645
alphaENaC	O	1646-1655
,	O	1655-1656
is	O	1657-1659
increased	O	1660-1669
in	O	1670-1672
the	O	1673-1676
very	O	1677-1681
early	O	1682-1687
phase	O	1688-1693
of	O	1694-1696
the	O	1697-1700
experimental	O	1701-1713
model	O	1714-1719
of	O	1720-1722
PAN	O	1723-1726
-	O	1726-1727
induced	O	1727-1734
nephrotic	B	1735-1744
syndrome	I	1745-1753
in	O	1754-1756
rats	O	1757-1761
,	O	1761-1762
but	O	1763-1766
appears	O	1767-1774
to	O	1775-1777
escape	O	1778-1784
from	O	1785-1789
the	O	1790-1793
regulation	O	1794-1804
by	O	1805-1807
aldosterone	O	1808-1819
after	O	1820-1825
day	O	1826-1829
3	O	1830-1831
.	O	1831-1832

NO	O	0-2
-	O	2-3
induced	O	3-10
migraine	B	11-19
attack	O	20-26
:	O	26-27
strong	O	28-34
increase	O	35-43
in	O	44-46
plasma	O	47-53
calcitonin	O	54-64
gene	O	65-69
-	O	69-70
related	O	70-77
peptide	O	78-85
(	O	86-87
CGRP	O	87-91
)	O	91-92
concentration	O	93-106
and	O	107-110
negative	O	111-119
correlation	O	120-131
with	O	132-136
platelet	O	137-145
serotonin	O	146-155
release	O	156-163
.	O	163-164

The	O	165-168
aim	O	169-172
of	O	173-175
the	O	176-179
present	O	180-187
study	O	188-193
was	O	194-197
to	O	198-200
investigate	O	201-212
changes	O	213-220
in	O	221-223
the	O	224-227
plasma	O	228-234
calcitonin	O	235-245
gene	O	246-250
-	O	250-251
related	O	251-258
peptide	O	259-266
(	O	267-268
CGRP	O	268-272
)	O	272-273
concentration	O	274-287
and	O	288-291
platelet	O	292-300
serotonin	O	301-310
(	O	311-312
5	O	312-313
-	O	313-314
hydroxytriptamine	O	314-331
,	O	331-332
5	O	333-334
-	O	334-335
HT	O	335-337
)	O	337-338
content	O	339-346
during	O	347-353
the	O	354-357
immediate	O	358-367
headache	B	368-376
and	O	377-380
the	O	381-384
delayed	O	385-392
genuine	O	393-400
migraine	B	401-409
attack	O	410-416
provoked	O	417-425
by	O	426-428
nitroglycerin	O	429-442
.	O	442-443

Fifteen	O	444-451
female	O	452-458
migraineurs	B	459-470
(	I	471-472
without	I	472-479
aura	I	480-484
)	I	484-485
and	O	486-489
eight	O	490-495
controls	O	496-504
participated	O	505-517
in	O	518-520
the	O	521-524
study	O	525-530
.	O	530-531

Sublingual	O	532-542
nitroglycerin	O	543-556
(	O	557-558
0	O	558-559
.	O	559-560
5	O	560-561
mg	O	562-564
)	O	564-565
was	O	566-569
administered	O	570-582
.	O	582-583

Blood	O	584-589
was	O	590-593
collected	O	594-603
from	O	604-608
the	O	609-612
antecubital	O	613-624
vein	O	625-629
four	O	630-634
times	O	635-640
:	O	640-641
60	O	642-644
min	O	645-648
before	O	649-655
and	O	656-659
after	O	660-665
the	O	666-669
nitroglycerin	O	670-683
application	O	684-695
,	O	695-696
and	O	697-700
60	O	701-703
and	O	704-707
120	O	708-711
min	O	712-715
after	O	716-721
the	O	722-725
beginning	O	726-735
of	O	736-738
the	O	739-742
migraine	B	743-751
attack	O	752-758
(	O	759-760
mean	O	760-764
344	O	765-768
and	O	769-772
404	O	773-776
min	O	777-780
;	O	780-781
12	O	782-784
subjects	O	785-793
)	O	793-794
.	O	794-795

In	O	796-798
those	O	799-804
subjects	O	805-813
who	O	814-817
had	O	818-821
no	O	822-824
migraine	B	825-833
attack	O	834-840
(	O	841-842
11	O	842-844
subjects	O	845-853
)	O	853-854
a	O	855-856
similar	O	857-864
time	O	865-869
schedule	O	870-878
was	O	879-882
used	O	883-887
.	O	887-888

Plasma	O	889-895
CGRP	O	896-900
concentration	O	901-914
increased	O	915-924
significantly	O	925-938
(	O	939-940
P	O	940-941
<	O	941-942
0	O	942-943
.	O	943-944
01	O	944-946
)	O	946-947

during	O	948-954
the	O	955-958
migraine	B	959-967
attack	O	968-974
and	O	975-978
returned	O	979-987
to	O	988-990
baseline	O	991-999
after	O	1000-1005
the	O	1006-1009
cessation	O	1010-1019
of	O	1020-1022
the	O	1023-1026
migraine	B	1027-1035
.	O	1035-1036

In	O	1037-1039
addition	O	1040-1048
,	O	1048-1049
both	O	1050-1054
change	O	1055-1061
and	O	1062-1065
peak	O	1066-1070
,	O	1070-1071
showed	O	1072-1078
significant	O	1079-1090
positive	O	1091-1099
correlations	O	1100-1112
with	O	1113-1117
migraine	B	1118-1126
headache	B	1127-1135
intensity	O	1136-1145
(	O	1146-1147
P	O	1147-1148
<	O	1148-1149
0	O	1149-1150
.	O	1150-1151
001	O	1151-1154
)	O	1154-1155
.	O	1150-1151

However	O	1157-1164
,	O	1164-1165
plasma	O	1166-1172
CGRP	O	1173-1177
concentrations	O	1178-1192
failed	O	1193-1199
to	O	1200-1202
change	O	1203-1209
during	O	1210-1216
immediate	O	1217-1226
headache	B	1227-1235
and	O	1236-1239
in	O	1240-1242
the	O	1243-1246
subjects	O	1247-1255
with	O	1256-1260
no	O	1261-1263
migraine	B	1264-1272
attack	O	1273-1279
.	O	1279-1280

Basal	O	1281-1286
CGRP	O	1287-1291
concentration	O	1292-1305
was	O	1306-1309
significantly	O	1310-1323
higher	O	1324-1330
and	O	1331-1334
platelet	O	1335-1343
5	O	1344-1345
-	O	1345-1346
HT	O	1346-1348
content	O	1349-1356
tended	O	1357-1363
to	O	1364-1366
be	O	1367-1369
lower	O	1370-1375
in	O	1376-1378
subjects	O	1379-1387
who	O	1388-1391
experienced	O	1392-1403
a	O	1404-1405
migraine	B	1406-1414
attack	O	1415-1421
.	O	1421-1422

Platelet	O	1423-1431
serotonin	O	1432-1441
content	O	1442-1449
decreased	O	1450-1459
significantly	O	1460-1473
(	O	1474-1475
P	O	1475-1476
<	O	1476-1477
0	O	1477-1478
.	O	1478-1479
01	O	1479-1481
)	O	1481-1482
after	O	1483-1488
nitroglycerin	O	1489-1502
in	O	1503-1505
subjects	O	1506-1514
with	O	1515-1519
no	O	1520-1522
migraine	B	1523-1531
attack	O	1532-1538
but	O	1539-1542
no	O	1543-1545
consistent	O	1546-1556
change	O	1557-1563
was	O	1564-1567
observed	O	1568-1576
in	O	1577-1579
patients	O	1580-1588
with	O	1589-1593
migraine	B	1594-1602
attack	O	1603-1609
.	O	1609-1610

In	O	1611-1613
conclusion	O	1614-1624
,	O	1624-1625
the	O	1626-1629
fact	O	1630-1634
that	O	1635-1639
plasma	O	1640-1646
CGRP	O	1647-1651
concentration	O	1652-1665
correlates	O	1666-1676
with	O	1677-1681
the	O	1682-1685
timing	O	1686-1692
and	O	1693-1696
severity	O	1697-1705
of	O	1706-1708
a	O	1709-1710
migraine	B	1711-1719
headache	B	1720-1728
suggests	O	1729-1737
a	O	1738-1739
direct	O	1740-1746
relationship	O	1747-1759
between	O	1760-1767
CGRP	O	1768-1772
and	O	1773-1776
migraine	B	1777-1785
.	O	1785-1786

In	O	1787-1789
contrast	O	1790-1798
,	O	1798-1799
serotonin	O	1800-1809
release	O	1810-1817
from	O	1818-1822
platelets	O	1823-1832
does	O	1833-1837
not	O	1838-1841
provoke	O	1842-1849
migraine	B	1850-1858
,	O	1858-1859
it	O	1860-1862
may	O	1863-1866
even	O	1867-1871
counteract	O	1872-1882
the	O	1883-1886
headache	B	1887-1895
and	O	1896-1899
the	O	1900-1903
concomitant	O	1904-1915
CGRP	O	1916-1920
release	O	1921-1928
in	O	1929-1931
this	O	1932-1936
model	O	1937-1942
.	O	1942-1943

Coronary	B	0-8
aneurysm	I	9-17
after	O	18-23
implantation	O	24-36
of	O	37-39
a	O	40-41
paclitaxel	O	42-52
-	O	52-53
eluting	O	53-60
stent	O	61-66
.	O	66-67

Formation	O	68-77
of	O	78-80
coronary	B	81-89
aneurysm	I	90-98
is	O	99-101
a	O	102-103
rare	O	104-108
complication	O	109-121
of	O	122-124
stenting	O	125-133
with	O	134-138
bare	O	139-143
metal	O	144-149
stents	O	150-156
,	O	156-157
but	O	158-161
based	O	162-167
on	O	168-170
experimental	O	171-183
studies	O	184-191
drug	O	192-196
-	O	196-197
eluting	O	197-204
stents	O	205-211
may	O	212-215
induce	O	216-222
toxic	O	223-228
effects	O	229-236
on	O	237-239
the	O	240-243
vessel	O	244-250
wall	O	251-255
with	O	256-260
incomplete	O	261-271
stent	O	272-277
apposition	O	278-288
,	O	288-289
aneurysm	B	290-298
formation	O	299-308
and	O	309-312
with	O	313-317
the	O	318-321
potential	O	322-331
of	O	332-334
stent	O	335-340
thrombosis	B	341-351
or	O	352-354
vessel	B	355-361
rupture	I	362-369
.	O	369-370

We	O	371-373
present	O	374-381
a	O	382-383
43	O	384-386
-	O	386-387
year	O	387-391
-	O	386-387
old	O	392-395
man	O	396-399
who	O	400-403
developed	O	404-413
a	O	414-415
coronary	B	416-424
aneurysm	I	425-433
in	O	434-436
the	O	437-440
right	O	441-446
coronary	O	447-455
artery	O	456-462
6	O	463-464
months	O	465-471
after	O	472-477
receiving	O	478-487
a	O	488-489
paclitaxel	O	490-500
-	O	500-501
eluting	O	501-508
stent	O	509-514
.	O	514-515

The	O	516-519
patient	O	520-527
was	O	528-531
asymptomatic	O	532-544
and	O	545-548
the	O	549-552
aneurysm	B	553-561
was	O	562-565
detected	O	566-574
in	O	575-577
a	O	578-579
routine	O	580-587
control	O	588-595
.	O	595-596

Angiography	O	597-608
and	O	609-612
intracoronary	O	613-626
ultrasound	O	627-637
demonstrated	O	638-650
lack	O	651-655
of	O	656-658
contact	O	659-666
between	O	667-674
stent	O	675-680
and	O	681-684
vessel	O	685-691
wall	O	692-696
in	O	697-699
a	O	700-701
15	O	702-704
-	O	704-705
mm	O	705-707
long	O	708-712
segment	O	713-720
with	O	721-725
maximal	O	726-733
aneurysm	B	734-742
diameter	O	743-751
of	O	752-754
6	O	755-756
.	O	756-757
0	O	757-758
mm	O	759-761
.	O	761-762

The	O	763-766
patient	O	767-774
was	O	775-778
successfully	O	779-791
treated	O	792-799
with	O	800-804
a	O	805-806
graft	O	807-812
stent	O	813-818
.	O	818-819

Behavioral	O	0-10
effects	O	11-18
of	O	19-21
urotensin	O	22-31
-	O	31-32
II	O	32-34
centrally	O	35-44
administered	O	45-57
in	O	58-60
mice	O	61-65
.	O	65-66

Urotensin	O	67-76
-	O	76-77
II	O	77-79
(	O	80-81
U	O	81-82
-	O	82-83
II	O	83-85
)	O	85-86
receptors	O	87-96
are	O	97-100
widely	O	101-107
distributed	O	108-119
in	O	120-122
the	O	123-126
central	O	127-134
nervous	O	135-142
system	O	143-149
.	O	149-150

Intracerebroventricular	O	151-174
(	O	175-176
i	O	176-177
.	O	177-178
c	O	178-179
.	O	177-178
v	O	180-181
.	O	177-178
)	O	182-183
injection	O	184-193
of	O	194-196
U	O	197-198
-	O	198-199
II	O	199-201
causes	O	202-208
hypertension	B	209-221
and	O	222-225
bradycardia	B	226-237
and	O	238-241
stimulates	O	242-252
prolactin	O	253-262
and	O	263-266
thyrotropin	O	267-278
secretion	O	279-288
.	O	288-289

However	O	290-297
,	O	297-298
the	O	299-302
behavioral	O	303-313
effects	O	314-321
of	O	322-324
centrally	O	325-334
administered	O	335-347
U	O	348-349
-	O	349-350
II	O	350-352
have	O	353-357
received	O	358-366
little	O	367-373
attention	O	374-383
.	O	383-384

In	O	385-387
the	O	388-391
present	O	392-399
study	O	400-405
,	O	405-406
we	O	407-409
tested	O	410-416
the	O	417-420
effects	O	421-428
of	O	429-431
i	O	432-433
.	O	433-434
c	O	434-435
.	O	433-434
v	O	436-437
.	O	433-434

injections	O	439-449
of	O	450-452
U	O	453-454
-	O	454-455
II	O	455-457
on	O	458-460
behavioral	O	461-471
,	O	471-472
metabolic	O	473-482
,	O	482-483
and	O	484-487
endocrine	O	488-497
responses	O	498-507
in	O	508-510
mice	O	511-515
.	O	515-516

Administration	O	517-531
of	O	532-534
graded	O	535-541
doses	O	542-547
of	O	548-550
U	O	551-552
-	O	552-553
II	O	553-555
(	O	556-557
1	O	557-558
-	O	558-559
10	O	559-561
,	O	561-562
000	O	562-565
ng	O	566-568
/	O	568-569
mouse	O	569-574
)	O	574-575
provoked	O	576-584
:	O	584-585
(	O	586-587
1	O	587-588
)	O	588-589
a	O	590-591
dose	O	592-596
-	O	596-597
dependent	O	597-606
reduction	O	607-616
in	O	617-619
the	O	620-623
number	O	624-630
of	O	631-633
head	O	634-638
dips	O	639-643
in	O	644-646
the	O	647-650
hole	O	651-655
-	O	655-656
board	O	656-661
test	O	662-666
;	O	666-667
(	O	668-669
2	O	669-670
)	O	670-671
a	O	672-673
dose	O	674-678
-	O	678-679
dependent	O	679-688
reduction	O	689-698
in	O	699-701
the	O	702-705
number	O	706-712
of	O	713-715
entries	O	716-723
in	O	724-726
the	O	727-730
white	O	731-736
chamber	O	737-744
in	O	745-747
the	O	748-751
black	O	752-757
-	O	757-758
and	O	758-761
-	O	757-758
white	O	762-767
compartment	O	768-779
test	O	780-784
,	O	784-785
and	O	786-789
in	O	790-792
the	O	793-796
number	O	797-803
of	O	804-806
entries	O	807-814
in	O	815-817
the	O	818-821
central	O	822-829
platform	O	830-838
and	O	839-842
open	O	843-847
arms	O	848-852
in	O	853-855
the	O	856-859
plus	O	860-864
-	O	864-865
maze	O	865-869
test	O	870-874
;	O	874-875
and	O	876-879
(	O	880-881
3	O	881-882
)	O	882-883
a	O	884-885
dose	O	886-890
-	O	890-891
dependent	O	891-900
increase	O	901-909
in	O	910-912
the	O	913-916
duration	O	917-925
of	O	926-928
immobility	O	929-939
in	O	940-942
the	O	943-946
forced	O	947-953
-	O	953-954
swimming	O	954-962
test	O	963-967
and	O	968-971
tail	O	972-976
suspension	O	977-987
test	O	988-992
.	O	992-993

Intracerebroventricular	O	994-1017
injection	O	1018-1027
of	O	1028-1030
U	O	1031-1032
-	O	1032-1033
II	O	1033-1035
also	O	1036-1040
caused	O	1041-1047
an	O	1048-1050
increase	O	1051-1059
in	O	1060-1062
:	O	1062-1063
food	O	1064-1068
intake	O	1069-1075
at	O	1076-1078
doses	O	1079-1084
of	O	1085-1087
100	O	1088-1091
and	O	1092-1095
1	O	1096-1097
,	O	1097-1098
000	O	1098-1101
ng	O	1102-1104
/	O	1104-1105
mouse	O	1105-1110
,	O	1110-1111
water	O	1112-1117
intake	O	1118-1124
at	O	1125-1127
doses	O	1128-1133
of	O	1134-1136
100	O	1137-1140
-	O	1140-1141
10	O	1137-1139
,	O	1143-1144
000	O	1144-1147
ng	O	1148-1150
/	O	1150-1151
mouse	O	1151-1156
,	O	1156-1157
and	O	1158-1161
horizontal	O	1162-1172
locomotion	O	1173-1183
activity	O	1184-1192
at	O	1193-1195
a	O	1196-1197
dose	O	1198-1202
of	O	1203-1205
10	O	1206-1208
,	O	1208-1209
000	O	1209-1212
ng	O	1213-1215
/	O	1215-1216
mouse	O	1216-1221
.	O	1221-1222

Whatever	O	1223-1231
was	O	1232-1235
the	O	1236-1239
dose	O	1240-1244
,	O	1244-1245
the	O	1246-1249
central	O	1250-1257
administration	O	1258-1272
of	O	1273-1275
U	O	1276-1277
-	O	1277-1278
II	O	1278-1280
had	O	1281-1284
no	O	1285-1287
effect	O	1288-1294
on	O	1295-1297
body	O	1298-1302
temperature	O	1303-1314
,	O	1314-1315
nociception	O	1316-1327
,	O	1327-1328
apomorphine	O	1329-1340
-	O	1340-1341
induced	O	1341-1348
penile	B	1349-1355
erection	I	1356-1364
and	O	1365-1368
climbing	O	1369-1377
behavior	O	1378-1386
,	O	1386-1387
and	O	1388-1391
stress	O	1392-1398
-	O	1398-1399
induced	O	1399-1406
plasma	O	1407-1413
corticosterone	O	1414-1428
level	O	1429-1434
.	O	1434-1435

Taken	O	1436-1441
together	O	1442-1450
,	O	1450-1451
the	O	1452-1455
present	O	1456-1463
study	O	1464-1469
demonstrates	O	1470-1482
that	O	1483-1487
the	O	1488-1491
central	O	1492-1499
injection	O	1500-1509
of	O	1510-1512
U	O	1513-1514
-	O	1514-1515
II	O	1515-1517
at	O	1518-1520
doses	O	1521-1526
of	O	1527-1529
1	O	1530-1531
-	O	1531-1532
10	O	1532-1534
,	O	1534-1535
000	O	1535-1538
ng	O	1539-1541
/	O	1541-1542
mouse	O	1542-1547
induces	O	1548-1555
anxiogenic	O	1556-1566
-	O	1566-1567
and	O	1568-1571
depressant	O	1572-1582
-	O	1582-1583
like	O	1583-1587
effects	O	1588-1595
in	O	1596-1598
mouse	O	1599-1604
.	O	1604-1605

These	O	1606-1611
data	O	1612-1616
suggest	O	1617-1624
that	O	1625-1629
U	O	1630-1631
-	O	1631-1632
II	O	1632-1634
may	O	1635-1638
be	O	1639-1641
involved	O	1642-1650
in	O	1651-1653
some	O	1654-1658
aspects	O	1659-1666
of	O	1667-1669
psychiatric	B	1670-1681
disorders	I	1682-1691
.	O	1691-1692

Recurrent	O	0-9
dysphonia	B	10-19
and	O	20-23
acitretin	O	24-33
.	O	33-34

We	O	35-37
report	O	38-44
the	O	45-48
case	O	49-53
of	O	54-56
a	O	57-58
woman	O	59-64
complaining	O	65-76
of	O	77-79
dysphonia	B	80-89
while	O	90-95
she	O	96-99
was	O	100-103
treated	O	104-111
by	O	112-114
acitretin	O	115-124
.	O	124-125

Her	O	126-129
symptoms	O	130-138
totally	O	139-146
regressed	O	147-156
after	O	157-162
drug	O	163-167
withdrawal	O	168-178
and	O	179-182
reappeared	O	183-193
when	O	194-198
acitretin	O	199-208
was	O	209-212
reintroduced	O	213-225
.	O	225-226

To	O	227-229
our	O	230-233
knowledge	O	234-243
,	O	243-244
this	O	245-249
is	O	250-252
the	O	253-256
first	O	257-262
case	O	263-267
of	O	268-270
acitretin	O	271-280
-	O	280-281
induced	O	281-288
dysphonia	B	289-298
.	O	298-299

This	O	300-304
effect	O	305-311
may	O	312-315
be	O	316-318
related	O	319-326
to	O	327-329
the	O	330-333
pharmacological	O	334-349
effect	O	350-356
of	O	357-359
this	O	360-364
drug	O	365-369
on	O	370-372
mucous	O	373-379
membranes	O	380-389
.	O	389-390

Pharmacological	O	0-15
modulation	O	16-26
of	O	27-29
pain	B	30-34
-	O	34-35
related	O	35-42
brain	O	43-48
activity	O	49-57
during	O	58-64
normal	O	65-71
and	O	72-75
central	O	76-83
sensitization	O	84-97
states	O	98-104
in	O	105-107
humans	O	108-114
.	O	114-115

Abnormal	O	116-124
processing	O	125-135
of	O	136-138
somatosensory	O	139-152
inputs	O	153-159
in	O	160-162
the	O	163-166
central	O	167-174
nervous	O	175-182
system	O	183-189
(	O	190-191
central	O	191-198
sensitization	O	199-212
)	O	212-213
is	O	214-216
the	O	217-220
mechanism	O	221-230
accounting	O	231-241
for	O	242-245
the	O	246-249
enhanced	O	250-258
pain	B	259-263
sensitivity	O	264-275
in	O	276-278
the	O	279-282
skin	O	283-287
surrounding	O	288-299
tissue	B	300-306
injury	I	307-313
(	O	314-315
secondary	B	315-324
hyperalgesia	I	325-337
)	O	337-338
.	O	338-339

Secondary	B	340-349
hyperalgesia	I	350-362
shares	O	363-369
clinical	O	370-378
characteristics	O	379-394
with	O	395-399
neurogenic	B	400-410
hyperalgesia	I	411-423
in	O	424-426
patients	O	427-435
with	O	436-440
neuropathic	B	441-452
pain	I	453-457
.	O	457-458

Abnormal	O	459-467
brain	O	468-473
responses	O	474-483
to	O	484-486
somatosensory	O	487-500
stimuli	O	501-508
have	O	509-513
been	O	514-518
found	O	519-524
in	O	525-527
patients	O	528-536
with	O	537-541
hyperalgesia	B	542-554
as	O	555-557
well	O	558-562
as	O	563-565
in	O	566-568
normal	O	569-575
subjects	O	576-584
during	O	585-591
experimental	O	592-604
central	O	605-612
sensitization	O	613-626
.	O	626-627

The	O	628-631
aim	O	632-635
of	O	636-638
this	O	639-643
study	O	644-649
was	O	650-653
to	O	654-656
assess	O	657-663
the	O	664-667
effects	O	668-675
of	O	676-678
gabapentin	O	679-689
,	O	689-690
a	O	691-692
drug	O	693-697
effective	O	698-707
in	O	708-710
neuropathic	B	711-722
pain	I	723-727
patients	O	728-736
,	O	736-737
on	O	738-740
brain	O	741-746
processing	O	747-757
of	O	758-760
nociceptive	O	761-772
information	O	773-784
in	O	785-787
normal	O	788-794
and	O	795-798
central	O	799-806
sensitization	O	807-820
states	O	821-827
.	O	827-828

Using	O	829-834
functional	O	835-845
magnetic	O	846-854
resonance	O	855-864
imaging	O	865-872
(	O	873-874
fMRI	O	874-878
)	O	878-879
in	O	880-882
normal	O	883-889
volunteers	O	890-900
,	O	900-901
we	O	902-904
studied	O	905-912
the	O	913-916
gabapentin	O	917-927
-	O	927-928
induced	O	928-935
modulation	O	936-946
of	O	947-949
brain	O	950-955
activity	O	956-964
in	O	965-967
response	O	968-976
to	O	977-979
nociceptive	O	980-991
mechanical	O	992-1002
stimulation	O	1003-1014
of	O	1015-1017
normal	O	1018-1024
skin	O	1025-1029
and	O	1030-1033
capsaicin	O	1034-1043
-	O	1043-1044
induced	O	1044-1051
secondary	B	1052-1061
hyperalgesia	I	1062-1074
.	O	1074-1075

The	O	1076-1079
dose	O	1080-1084
of	O	1085-1087
gabapentin	O	1088-1098
was	O	1099-1102
1	O	1103-1104
,	O	1104-1105
800	O	1105-1108
mg	O	1109-1111
per	O	1112-1115
os	O	1116-1118
,	O	1118-1119
in	O	1120-1122
a	O	1123-1124
single	O	1125-1131
administration	O	1132-1146
.	O	1146-1147

We	O	1148-1150
found	O	1151-1156
that	O	1157-1161
(	O	1162-1163
i	O	1163-1164
)	O	1164-1165
gabapentin	O	1166-1176
reduced	O	1177-1184
the	O	1185-1188
activations	O	1189-1200
in	O	1201-1203
the	O	1204-1207
bilateral	O	1208-1217
operculoinsular	O	1218-1233
cortex	O	1234-1240
,	O	1240-1241
independently	O	1242-1255
of	O	1256-1258
the	O	1259-1262
presence	O	1263-1271
of	O	1272-1274
central	O	1275-1282
sensitization	O	1283-1296
;	O	1296-1297
(	O	1298-1299
ii	O	1299-1301
)	O	1301-1302
gabapentin	O	1303-1313
reduced	O	1314-1321
the	O	1322-1325
activation	O	1326-1336
in	O	1337-1339
the	O	1340-1343
brainstem	O	1344-1353
,	O	1353-1354
only	O	1355-1359
during	O	1360-1366
central	O	1367-1374
sensitization	O	1375-1388
;	O	1388-1389
(	O	1390-1391
iii	O	1391-1394
)	O	1394-1395
gabapentin	O	1396-1406
suppressed	O	1407-1417
stimulus	O	1418-1426
-	O	1426-1427
induced	O	1427-1434
deactivations	O	1435-1448
,	O	1448-1449
only	O	1450-1454
during	O	1455-1461
central	O	1462-1469
sensitization	O	1470-1483
;	O	1483-1484
this	O	1485-1489
effect	O	1490-1496
was	O	1497-1500
more	O	1501-1505
robust	O	1506-1512
than	O	1513-1517
the	O	1518-1521
effect	O	1522-1528
on	O	1529-1531
brain	O	1532-1537
activation	O	1538-1548
.	O	1548-1549

The	O	1550-1553
observed	O	1554-1562
drug	O	1563-1567
-	O	1567-1568
induced	O	1568-1575
effects	O	1576-1583
were	O	1584-1588
not	O	1589-1592
due	O	1593-1596
to	O	1597-1599
changes	O	1600-1607
in	O	1608-1610
the	O	1611-1614
baseline	O	1615-1623
fMRI	O	1624-1628
signal	O	1629-1635
.	O	1635-1636

These	O	1637-1642
findings	O	1643-1651
indicate	O	1652-1660
that	O	1661-1665
gabapentin	O	1666-1676
has	O	1677-1680
a	O	1681-1682
measurable	O	1683-1693
antinociceptive	O	1694-1709
effect	O	1710-1716
and	O	1717-1720
a	O	1721-1722
stronger	O	1723-1731
antihyperalgesic	O	1732-1748
effect	O	1749-1755
most	O	1756-1760
evident	O	1761-1768
in	O	1769-1771
the	O	1772-1775
brain	O	1776-1781
areas	O	1782-1787
undergoing	O	1788-1798
deactivation	O	1799-1811
,	O	1811-1812
thus	O	1813-1817
supporting	O	1818-1828
the	O	1829-1832
concept	O	1833-1840
that	O	1841-1845
gabapentin	O	1846-1856
is	O	1857-1859
more	O	1860-1864
effective	O	1865-1874
in	O	1875-1877
modulating	O	1878-1888
nociceptive	O	1889-1900
transmission	O	1901-1913
when	O	1914-1918
central	O	1919-1926
sensitization	O	1927-1940
is	O	1941-1943
present	O	1944-1951
.	O	1951-1952

MDMA	O	0-4
polydrug	O	5-13
users	O	14-19
show	O	20-24
process	O	25-32
-	O	32-33
specific	O	33-41
central	O	42-49
executive	O	50-59
impairments	O	60-71
coupled	O	72-79
with	O	80-84
impaired	B	85-93
social	I	94-100
and	I	101-104
emotional	I	105-114
judgement	I	115-124
processes	I	125-134
.	O	134-135

In	O	136-138
recent	O	139-145
years	O	146-151
working	O	152-159
memory	B	160-166
deficits	I	167-175
have	O	176-180
been	O	181-185
reported	O	186-194
in	O	195-197
users	O	198-203
of	O	204-206
MDMA	O	207-211
(	O	212-213
3	O	213-214
,	O	214-215
4	O	215-216
-	O	216-217
methylenedioxymethamphetamine	O	217-246
,	O	214-215
ecstasy	O	248-255
)	O	255-256
.	O	256-257

The	O	258-261
current	O	262-269
study	O	270-275
aimed	O	276-281
to	O	282-284
assess	O	285-291
the	O	292-295
impact	O	296-302
of	O	303-305
MDMA	O	306-310
use	O	311-314
on	O	315-317
three	O	318-323
separate	O	324-332
central	O	333-340
executive	O	341-350
processes	O	351-360
(	O	361-362
set	O	362-365
shifting	O	366-374
,	O	374-375
inhibition	O	376-386
and	O	387-390
memory	O	391-397
updating	O	398-406
)	O	406-407
and	O	408-411
also	O	412-416
on	O	417-419
"	O	420-421
prefrontal	O	421-431
"	O	420-421
mediated	O	433-441
social	O	442-448
and	O	449-452
emotional	O	453-462
judgement	O	463-472
processes	O	473-482
.	O	482-483

Fifteen	O	484-491
polydrug	O	492-500
ecstasy	O	501-508
users	O	509-514
and	O	515-518
15	O	519-521
polydrug	O	522-530
non	O	531-534
-	O	534-535
ecstasy	O	535-542
user	O	543-547
controls	O	548-556
completed	O	557-566
a	O	567-568
general	O	569-576
drug	O	577-581
use	O	582-585
questionnaire	O	586-599
,	O	599-600
the	O	601-604
Brixton	O	605-612
Spatial	O	613-620
Anticipation	O	621-633
task	O	634-638
(	O	639-640
set	O	640-643
shifting	O	644-652
)	O	652-653
,	O	653-654
Backward	O	655-663
Digit	O	664-669
Span	O	670-674
procedure	O	675-684
(	O	685-686
memory	O	686-692
updating	O	693-701
)	O	701-702
,	O	702-703
Inhibition	O	704-714
of	O	715-717
Return	O	718-724
(	O	725-726
inhibition	O	726-736
)	O	736-737
,	O	737-738
an	O	739-741
emotional	O	742-751
intelligence	O	752-764
scale	O	765-770
,	O	770-771
the	O	772-775
Tromso	O	776-782
Social	O	783-789
Intelligence	O	790-802
Scale	O	803-808
and	O	809-812
the	O	813-816
Dysexecutive	O	817-829
Questionnaire	O	830-843
(	O	844-845
DEX	O	845-848
)	O	848-849
.	O	849-850

Compared	O	851-859
with	O	860-864
MDMA	O	865-869
-	O	869-870
free	O	870-874
polydrug	O	875-883
controls	O	884-892
,	O	892-893
MDMA	O	894-898
polydrug	O	899-907
users	O	908-913
showed	O	914-920
impairments	O	921-932
in	O	933-935
set	O	936-939
shifting	O	940-948
and	O	949-952
memory	O	953-959
updating	O	960-968
,	O	968-969
and	O	970-973
also	O	974-978
in	O	979-981
social	O	982-988
and	O	989-992
emotional	O	993-1002
judgement	O	1003-1012
processes	O	1013-1022
.	O	1022-1023

The	O	1024-1027
latter	O	1028-1034
two	O	1035-1038
deficits	O	1039-1047
remained	O	1048-1056
significant	O	1057-1068
after	O	1069-1074
controlling	O	1075-1086
for	O	1087-1090
other	O	1091-1096
drug	O	1097-1101
use	O	1102-1105
.	O	1105-1106

These	O	1107-1112
data	O	1113-1117
lend	O	1118-1122
further	O	1123-1130
support	O	1131-1138
to	O	1139-1141
the	O	1142-1145
proposal	O	1146-1154
that	O	1155-1159
cognitive	O	1160-1169
processes	O	1170-1179
mediated	O	1180-1188
by	O	1189-1191
the	O	1192-1195
prefrontal	O	1196-1206
cortex	O	1207-1213
may	O	1214-1217
be	O	1218-1220
impaired	O	1221-1229
by	O	1230-1232
recreational	O	1233-1245
ecstasy	O	1246-1253
use	O	1254-1257
.	O	1257-1258

Severe	O	0-6
citrate	O	7-14
toxicity	B	15-23
complicating	O	24-36
volunteer	O	37-46
apheresis	O	47-56
platelet	O	57-65
donation	O	66-74
.	O	74-75

We	O	76-78
report	O	79-85
a	O	86-87
case	O	88-92
of	O	93-95
severe	O	96-102
citrate	O	103-110
toxicity	B	111-119
during	O	120-126
volunteer	O	127-136
donor	O	137-142
apheresis	O	143-152
platelet	O	153-161
collection	O	162-172
.	O	172-173

The	O	174-177
donor	O	178-183
was	O	184-187
a	O	188-189
40	O	190-192
-	O	192-193
year	O	193-197
-	O	192-193
old	O	198-201
female	O	202-208
,	O	208-209
first	O	210-215
-	O	215-216
time	O	216-220
apheresis	O	221-230
platelet	O	231-239
donor	O	240-245
.	O	245-246

Past	O	247-251
medical	O	252-259
history	O	260-267
was	O	268-271
remarkable	O	272-282
for	O	283-286
hypertension	B	287-299
,	O	299-300
hyperlipidemia	B	301-315
,	O	315-316
and	O	317-320
depression	B	321-331
.	O	331-332

Reported	O	333-341
medications	O	342-353
included	O	354-362
bumetanide	O	363-373
,	O	373-374
pravastatin	O	375-386
,	O	386-387
and	O	388-391
paroxetine	O	392-402
.	O	402-403

Thirty	O	404-410
minutes	O	411-418
from	O	419-423
the	O	424-427
start	O	428-433
of	O	434-436
the	O	437-440
procedure	O	441-450
,	O	450-451
the	O	452-455
donor	O	456-461
noted	O	462-467
tingling	O	468-476
around	O	477-483
the	O	484-487
mouth	O	488-493
,	O	493-494
hands	O	495-500
,	O	500-501
and	O	502-505
feet	O	506-510
.	O	510-511

She	O	512-515
then	O	516-520
very	O	521-525
rapidly	O	526-533
developed	O	534-543
acute	O	544-549
onset	O	550-555
of	O	556-558
severe	O	559-565
facial	O	566-572
and	O	573-576
extremity	O	577-586
tetany	B	587-593
.	O	593-594

Empirical	O	595-604
treatment	O	605-614
with	O	615-619
intravenous	O	620-631
calcium	O	632-639
gluconate	O	640-649
was	O	650-653
initiated	O	654-663
,	O	663-664
and	O	665-668
muscle	B	669-675
contractions	I	676-688
slowly	O	689-695
subsided	O	696-704
over	O	705-709
approximately	O	710-723
10	O	724-726
to	O	727-729
15	O	730-732
minutes	O	733-740
.	O	740-741

The	O	742-745
events	O	746-752
are	O	753-756
consistent	O	757-767
with	O	768-772
a	O	773-774
severe	O	775-781
reaction	O	782-790
to	O	791-793
calcium	O	794-801
chelation	O	802-811
by	O	812-814
sodium	O	815-821
citrate	O	822-829
anticoagulant	O	830-843
resulting	O	844-853
in	O	854-856
symptomatic	O	857-868
systemic	O	869-877
hypocalcemia	B	878-890
.	O	890-891

Upon	O	892-896
additional	O	897-907
retrospective	O	908-921
analysis	O	922-930
,	O	930-931
it	O	932-934
was	O	935-938
noted	O	939-944
that	O	945-949
bumetanide	O	950-960
is	O	961-963
a	O	964-965
loop	O	966-970
diuretic	O	971-979
that	O	980-984
may	O	985-988
cause	O	989-994
significant	O	995-1006
hypocalcemia	B	1007-1019
.	O	1019-1020

We	O	1021-1023
conclude	O	1024-1032
that	O	1033-1037
careful	O	1038-1045
screening	O	1046-1055
for	O	1056-1059
medications	O	1060-1071
and	O	1072-1075
underlying	O	1076-1086
conditions	O	1087-1097
predisposing	O	1098-1110
to	O	1111-1113
hypocalcemia	B	1114-1126
is	O	1127-1129
recommended	O	1130-1141
to	O	1142-1144
help	O	1145-1149
prevent	O	1150-1157
severe	O	1158-1164
reactions	O	1165-1174
due	O	1175-1178
to	O	1179-1181
citrate	O	1182-1189
toxicity	B	1190-1198
.	O	1198-1199

Laboratory	O	1200-1210
measurement	O	1211-1222
of	O	1223-1225
pre	O	1226-1229
-	O	1229-1230
procedure	O	1230-1239
serum	O	1240-1245
calcium	O	1246-1253
levels	O	1254-1260
in	O	1261-1263
selected	O	1264-1272
donors	O	1273-1279
may	O	1280-1283
identify	O	1284-1292
cases	O	1293-1298
requiring	O	1299-1308
heightened	O	1309-1319
vigilance	O	1320-1329
.	O	1329-1330

The	O	1331-1334
case	O	1335-1339
also	O	1340-1344
illustrates	O	1345-1356
the	O	1357-1360
importance	O	1361-1371
of	O	1372-1374
maintaining	O	1375-1386
preparedness	O	1387-1399
for	O	1400-1403
managing	O	1404-1412
rare	O	1413-1417
but	O	1418-1421
serious	O	1422-1429
reactions	O	1430-1439
in	O	1440-1442
volunteer	O	1443-1452
apheresis	O	1453-1462
blood	O	1463-1468
donors	O	1469-1475
.	O	1475-1476

Proteinuria	B	0-11
after	O	12-17
conversion	O	18-28
to	O	29-31
sirolimus	O	32-41
in	O	42-44
renal	O	45-50
transplant	O	51-61
recipients	O	62-72
.	O	72-73

Sirolimus	O	74-83
(	O	84-85
SRL	O	85-88
)	O	88-89
is	O	90-92
a	O	93-94
new	O	95-98
,	O	98-99
potent	O	100-106
immunosuppressive	O	107-124
agent	O	125-130
.	O	130-131

More	O	132-136
recently	O	137-145
,	O	145-146
proteinuria	B	147-158
has	O	159-162
been	O	163-167
reported	O	168-176
as	O	177-179
a	O	180-181
consequence	O	182-193
of	O	194-196
sirolimus	O	197-206
therapy	O	207-214
,	O	214-215
although	O	216-224
the	O	225-228
mechanism	O	229-238
has	O	239-242
remained	O	243-251
unclear	O	252-259
.	O	259-260

We	O	261-263
retrospectively	O	264-279
examined	O	280-288
the	O	289-292
records	O	293-300
of	O	301-303
25	O	304-306
renal	O	307-312
transplant	O	313-323
patients	O	324-332
,	O	332-333
who	O	334-337
developed	O	338-347
or	O	348-350
displayed	O	351-360
increased	O	361-370
proteinuria	B	371-382
after	O	383-388
SRL	O	389-392
conversion	O	393-403
.	O	403-404

The	O	405-408
patient	O	409-416
cohort	O	417-423
(	O	424-425
14	O	425-427
men	O	428-431
,	O	431-432
11	O	433-435
women	O	436-441
)	O	441-442
was	O	443-446
treated	O	447-454
with	O	455-459
SRL	O	460-463
as	O	464-466
conversion	O	467-477
therapy	O	478-485
,	O	485-486
due	O	487-490
to	O	491-493
chronic	B	494-501
allograft	I	502-511
nephropathy	I	512-523
(	O	524-525
CAN	B	525-528
)	O	528-529
(	O	530-531
n	O	531-532
=	O	533-534
15	O	535-537
)	O	537-538
neoplasia	B	539-548
(	O	549-550
n	O	550-551
=	O	552-553
8	O	554-555
)	O	555-556
;	O	556-557
Kaposi	B	558-564
'	I	564-565
s	I	562-563
sarcoma	I	567-574
,	O	574-575
Four	O	576-580
skin	B	581-585
cancers	I	586-593
,	O	593-594
One	O	595-598
intestinal	B	599-609
tumors	I	610-616
,	O	616-617
One	O	618-621
renal	B	622-627
cell	I	628-632
carsinom	I	633-641
)	O	641-642
or	O	643-645
BK	O	646-648
virus	O	649-654
nephropathy	B	655-666
(	O	667-668
n	O	668-669
=	O	670-671
2	O	672-673
)	O	673-674
.	O	674-675

SRL	O	676-679
was	O	680-683
started	O	684-691
at	O	692-694
a	O	695-696
mean	O	697-701
of	O	702-704
78	O	705-707
+	O	708-709
/	O	709-710
-	O	710-711
42	O	712-714
(	O	715-716
15	O	716-718
to	O	719-721
163	O	722-725
)	O	725-726
months	O	727-733
after	O	734-739
transplantation	O	740-755
.	O	755-756

Mean	O	757-761
follow	O	762-768
-	O	768-769
up	O	769-771
on	O	772-774
SRL	O	775-778
therapy	O	779-786
was	O	787-790
20	O	791-793
+	O	794-795
/	O	795-796
-	O	796-797
12	O	798-800
(	O	801-802
6	O	802-803
to	O	804-806
43	O	807-809
)	O	809-810
months	O	811-817
.	O	817-818

Proteinuria	B	819-830
increased	O	831-840
from	O	841-845
0	O	846-847
.	O	847-848
445	O	848-851
(	O	852-853
0	O	853-854
to	O	855-857
1	O	858-859
.	O	859-860
5	O	860-861
)	O	861-862
g	O	863-864
/	O	864-865
d	O	865-866
before	O	867-873
conversion	O	874-884
to	O	885-887
3	O	888-889
.	O	889-890
2	O	890-891
g	O	892-893
/	O	893-894
dL	O	894-896
(	O	897-898
0	O	898-899
.	O	899-900
2	O	900-901
to	O	902-904
12	O	905-907
)	O	907-908
after	O	909-914
conversion	O	915-925
(	O	926-927
P	O	927-928
=	O	929-930
0	O	931-932
.	O	932-933
001	O	933-936
)	O	936-937
.	O	932-933

Before	O	939-945
conversion	O	946-956
8	O	957-958
(	O	959-960
32	O	960-962
%	O	962-963
)	O	963-964
patients	O	965-973
had	O	974-977
no	O	978-980
proteinuria	B	981-992
,	O	992-993
whereas	O	994-1001
afterwards	O	1002-1012
all	O	1013-1016
patients	O	1017-1025
had	O	1026-1029
proteinuria	B	1030-1041
.	O	1041-1042

In	O	1043-1045
28	O	1046-1048
%	O	1048-1049
of	O	1050-1052
patients	O	1053-1061
proteinuria	B	1062-1073
remained	O	1074-1082
unchanged	O	1083-1092
,	O	1092-1093
whereas	O	1094-1101
it	O	1102-1104
increased	O	1105-1114
in	O	1115-1117
68	O	1118-1120
%	O	1120-1121
of	O	1122-1124
patients	O	1125-1133
.	O	1133-1134

In	O	1135-1137
40	O	1138-1140
%	O	1140-1141
it	O	1142-1144
increased	O	1145-1154
by	O	1155-1157
more	O	1158-1162
than	O	1163-1167
100	O	1168-1171
%	O	1171-1172
.	O	1172-1173

Twenty	O	1174-1180
-	O	1180-1181
eight	O	1181-1186
percent	O	1187-1194
of	O	1195-1197
patients	O	1198-1206
showed	O	1207-1213
increased	O	1214-1223
proteinuria	B	1224-1235
to	O	1236-1238
the	O	1239-1242
nephrotic	B	1243-1252
range	O	1253-1258
.	O	1258-1259

Biopsies	O	1260-1268
performed	O	1269-1278
in	O	1279-1281
five	O	1282-1286
patients	O	1287-1295
revealed	O	1296-1304
new	O	1305-1308
pathological	O	1309-1321
changes	O	1322-1329
:	O	1329-1330
One	O	1331-1334
membranoproliferative	B	1335-1356
glomerulopathy	I	1357-1371
and	O	1372-1375
interstitial	B	1376-1388
nephritis	I	1389-1398
.	O	1398-1399

These	O	1400-1405
patients	O	1406-1414
showed	O	1415-1421
persistently	O	1422-1434
good	O	1435-1439
graft	O	1440-1445
function	O	1446-1454
.	O	1454-1455

Serum	O	1456-1461
creatinine	O	1462-1472
values	O	1473-1479
did	O	1480-1483
not	O	1484-1487
change	O	1488-1494
significantly	O	1495-1508
:	O	1508-1509
1	O	1510-1511
.	O	1511-1512
98	O	1512-1514
+	O	1515-1516
/	O	1516-1517
-	O	1517-1518
0	O	1519-1520
.	O	1520-1521
8	O	1521-1522
mg	O	1523-1525
/	O	1525-1526
dL	O	1526-1528
before	O	1529-1535
SRL	O	1536-1539
therapy	O	1540-1547
and	O	1548-1551
2	O	1552-1553
.	O	1553-1554
53	O	1554-1556
+	O	1557-1558
/	O	1558-1559
-	O	1559-1560
1	O	1561-1562
.	O	1562-1563
9	O	1563-1564
mg	O	1565-1567
/	O	1567-1568
dL	O	1568-1570
at	O	1571-1573
last	O	1574-1578
follow	O	1579-1585
-	O	1585-1586
up	O	1586-1588
(	O	1589-1590
P	O	1590-1591
=	O	1592-1593
.	O	1594-1595
14	O	1595-1597
)	O	1597-1598
.	O	1594-1595

Five	O	1600-1604
grafts	O	1605-1611
were	O	1612-1616
lost	O	1617-1621
and	O	1622-1625
the	O	1626-1629
patients	O	1630-1638
returned	O	1639-1647
to	O	1648-1650
dialysis	O	1651-1659
.	O	1659-1660

Five	O	1661-1665
patients	O	1666-1674
displayed	O	1675-1684
CAN	B	1685-1688
and	O	1689-1692
Kaposi	B	1693-1699
'	I	1699-1700
s	I	1697-1698
sarcoma	I	1702-1709
.	O	1709-1710

Mean	O	1711-1715
urinary	O	1716-1723
protein	O	1724-1731
of	O	1732-1734
patients	O	1735-1743
who	O	1744-1747
returned	O	1748-1756
to	O	1757-1759
dialysis	O	1760-1768
was	O	1769-1772
1	O	1773-1774
.	O	1774-1775
26	O	1775-1777
(	O	1778-1779
0	O	1779-1780
.	O	1780-1781
5	O	1781-1782
to	O	1783-1785
3	O	1786-1787
.	O	1787-1788
5	O	1788-1789
)	O	1789-1790
g	O	1791-1792
/	O	1792-1793
d	O	1793-1794
before	O	1795-1801
and	O	1802-1805
4	O	1806-1807
.	O	1807-1808
7	O	1808-1809
(	O	1810-1811
3	O	1811-1812
to	O	1813-1815
12	O	1816-1818
)	O	1818-1819
g	O	1820-1821
/	O	1821-1822
d	O	1822-1823
after	O	1824-1829
conversion	O	1830-1840
(	O	1841-1842
P	O	1842-1843
=	O	1844-1845
.	O	1846-1847
01	O	1847-1849
)	O	1849-1850
.	O	1846-1847

Mean	O	1852-1856
serum	O	1857-1862
creatinine	O	1863-1873
level	O	1874-1879
before	O	1880-1886
conversion	O	1887-1897
was	O	1898-1901
2	O	1902-1903
.	O	1903-1904
21	O	1904-1906
mg	O	1907-1909
/	O	1909-1910
dL	O	1910-1912
and	O	1913-1916
thereafter	O	1917-1927
,	O	1927-1928
4	O	1929-1930
.	O	1930-1931
93	O	1931-1933
mg	O	1934-1936
/	O	1936-1937
dL	O	1937-1939
(	O	1940-1941
P	O	1941-1942
=	O	1943-1944
.	O	1945-1946
02	O	1946-1948
)	O	1948-1949
.	O	1945-1946

Heavy	O	1951-1956
proteinuria	B	1957-1968
was	O	1969-1972
common	O	1973-1979
after	O	1980-1985
the	O	1986-1989
use	O	1990-1993
of	O	1994-1996
SRL	O	1997-2000
as	O	2001-2003
rescue	O	2004-2010
therapy	O	2011-2018
for	O	2019-2022
renal	O	2023-2028
transplantation	O	2029-2044
.	O	2044-2045

Therefore	O	2046-2055
,	O	2055-2056
conversion	O	2057-2067
should	O	2068-2074
be	O	2075-2077
considered	O	2078-2088
for	O	2089-2092
patients	O	2093-2101
who	O	2102-2105
have	O	2106-2110
not	O	2111-2114
developed	O	2115-2124
advanced	O	2125-2133
CAN	B	2134-2137
and	O	2138-2141
proteinuria	B	2142-2153
.	O	2153-2154

The	O	2155-2158
possibility	O	2159-2170
of	O	2171-2173
de	O	2174-2176
novo	O	2177-2181
glomerular	O	2182-2192
pathology	O	2193-2202
under	O	2203-2208
SRL	O	2209-2212
treatment	O	2213-2222
requires	O	2223-2231
further	O	2232-2239
investigation	O	2240-2253
by	O	2254-2256
renal	O	2257-2262
biopsy	O	2263-2269
.	O	2269-2270

In	O	0-2
vitro	O	3-8
characterization	O	9-25
of	O	26-28
parasympathetic	O	29-44
and	O	45-48
sympathetic	O	49-60
responses	O	61-70
in	O	71-73
cyclophosphamide	O	74-90
-	O	90-91
induced	O	91-98
cystitis	B	99-107
in	O	108-110
the	O	111-114
rat	O	115-118
.	O	118-119

In	O	120-122
cyclophosphamide	O	123-139
-	O	139-140
induced	O	140-147
cystitis	B	148-156
in	O	157-159
the	O	160-163
rat	O	164-167
,	O	167-168
detrusor	O	169-177
function	O	178-186
is	O	187-189
impaired	O	190-198
and	O	199-202
the	O	203-206
expression	O	207-217
and	O	218-221
effects	O	222-229
of	O	230-232
muscarinic	O	233-243
receptors	O	244-253
altered	O	254-261
.	O	261-262

Whether	O	263-270
or	O	271-273
not	O	274-277
the	O	278-281
neuronal	O	282-290
transmission	O	291-303
may	O	304-307
be	O	308-310
affected	O	311-319
by	O	320-322
cystitis	B	323-331
was	O	332-335
presently	O	336-345
investigated	O	346-358
.	O	358-359

Responses	O	360-369
of	O	370-372
urinary	O	373-380
strip	O	381-386
preparations	O	387-399
from	O	400-404
control	O	405-412
and	O	413-416
cyclophosphamide	O	417-433
-	O	433-434
pretreated	O	434-444
rats	O	445-449
to	O	450-452
electrical	O	453-463
field	O	464-469
stimulation	O	470-481
and	O	482-485
to	O	486-488
agonists	O	489-497
were	O	498-502
assessed	O	503-511
in	O	512-514
the	O	515-518
absence	O	519-526
and	O	527-530
presence	O	531-539
of	O	540-542
muscarinic	O	543-553
,	O	553-554
adrenergic	O	555-565
and	O	566-569
purinergic	O	570-580
receptor	O	581-589
antagonists	O	590-601
.	O	601-602

Generally	O	603-612
,	O	612-613
atropine	O	614-622
reduced	O	623-630
contractions	O	631-643
,	O	643-644
but	O	645-648
in	O	649-651
contrast	O	652-660
to	O	661-663
controls	O	664-672
,	O	672-673
it	O	674-676
also	O	677-681
reduced	O	682-689
responses	O	690-699
to	O	700-702
low	O	703-706
electrical	O	707-717
field	O	718-723
stimulation	O	724-735
intensity	O	736-745
(	O	746-747
1	O	747-748
-	O	748-749
5	O	749-750
Hz	O	751-753
)	O	753-754
in	O	755-757
inflamed	O	758-766
preparations	O	767-779
.	O	779-780

In	O	781-783
both	O	784-788
types	O	789-794
,	O	794-795
purinoceptor	O	796-808
desensitization	O	809-824
with	O	825-829
alpha	O	830-835
,	O	835-836
beta	O	836-840
-	O	840-841
methylene	O	841-850
adenosine	O	851-860
-	O	860-861
5	O	861-862
'	O	862-863
-	O	860-861
triphosphate	O	864-876
(	O	877-878
alpha	O	878-883
,	O	883-884
beta	O	884-888
-	O	888-889
meATP	O	889-894
)	O	894-895
caused	O	896-902
further	O	903-910
reductions	O	911-921
at	O	922-924
low	O	925-928
frequencies	O	929-940
(	O	941-942
<	O	942-943
10	O	943-945
Hz	O	946-948
)	O	948-949
.	O	949-950

The	O	951-954
muscarinic	O	955-965
receptor	O	966-974
antagonists	O	975-986
atropine	O	987-995
,	O	995-996
4	O	997-998
-	O	998-999
diphenylacetoxy	O	999-1014
-	O	998-999
N	O	1015-1016
-	O	998-999
methylpiperidine	O	1017-1033
(	O	1034-1035
4	O	1035-1036
-	O	1036-1037
DAMP	O	1037-1041
)	O	1041-1042
(	O	1043-1044
'	O	1044-1045
M	O	1045-1046
(	O	1043-1044
1	O	1047-1048
)	O	1048-1049
/	O	1049-1050
M	O	1045-1046
(	O	1043-1044
3	O	1052-1053
)	O	1048-1049
/	O	1049-1050
M	O	1045-1046
(	O	1043-1044
5	O	1057-1058
)	O	1048-1049
-	O	1059-1060
selective	O	1060-1069
'	O	1044-1045
)	O	1048-1049
,	O	1071-1072
methoctramine	O	1073-1086
(	O	1087-1088
'	O	1088-1089
M	O	1089-1090
(	O	1087-1088
2	O	1091-1092
)	O	1092-1093
-	O	1093-1094
selective	O	1094-1103
'	O	1088-1089
)	O	1092-1093
and	O	1106-1109
pirenzepine	O	1110-1121
(	O	1122-1123
'	O	1123-1124
M	O	1124-1125
(	O	1122-1123
1	O	1126-1127
)	O	1127-1128
-	O	1128-1129
selective	O	1129-1138
'	O	1123-1124
)	O	1127-1128
antagonized	O	1141-1152
the	O	1153-1156
tonic	O	1157-1162
component	O	1163-1172
of	O	1173-1175
the	O	1176-1179
electrical	O	1180-1190
field	O	1191-1196
stimulation	O	1197-1208
-	O	1208-1209
evoked	O	1209-1215
contractile	O	1216-1227
response	O	1228-1236
more	O	1237-1241
potently	O	1242-1250
than	O	1251-1255
the	O	1256-1259
phasic	O	1260-1266
component	O	1267-1276
.	O	1276-1277

4	O	1278-1279
-	O	1279-1280
DAMP	O	1280-1284
inhibited	O	1285-1294
the	O	1295-1298
tonic	O	1299-1304
contractions	O	1305-1317
in	O	1318-1320
controls	O	1321-1329
more	O	1330-1334
potently	O	1335-1343
than	O	1344-1348
methoctramine	O	1349-1362
and	O	1363-1366
pirenzepine	O	1367-1378
.	O	1378-1379

In	O	1380-1382
inflamed	O	1383-1391
preparations	O	1392-1404
,	O	1404-1405
the	O	1406-1409
muscarinic	O	1410-1420
receptor	O	1421-1429
antagonism	O	1430-1440
on	O	1441-1443
the	O	1444-1447
phasic	O	1448-1454
component	O	1455-1464
of	O	1465-1467
the	O	1468-1471
electrical	O	1472-1482
field	O	1483-1488
stimulation	O	1489-1500
-	O	1500-1501
evoked	O	1501-1507
contraction	O	1508-1519
was	O	1520-1523
decreased	O	1524-1533
and	O	1534-1537
the	O	1538-1541
pirenzepine	O	1542-1553
and	O	1554-1557
4	O	1558-1559
-	O	1559-1560
DAMP	O	1560-1564
antagonism	O	1565-1575
on	O	1576-1578
the	O	1579-1582
tonic	O	1583-1588
component	O	1589-1598
was	O	1599-1602
much	O	1603-1607
less	O	1608-1612
efficient	O	1613-1622
than	O	1623-1627
in	O	1628-1630
controls	O	1631-1639
.	O	1639-1640

In	O	1641-1643
contrast	O	1644-1652
to	O	1653-1655
controls	O	1656-1664
,	O	1664-1665
methoctramine	O	1666-1679
increased	O	1680-1689
-	O	1690-1691
-	O	1690-1691
instead	O	1693-1700
of	O	1701-1703
decreased	O	1704-1713
-	O	1714-1715
-	O	1714-1715
the	O	1717-1720
tonic	O	1721-1726
responses	O	1727-1736
at	O	1737-1739
high	O	1740-1744
frequencies	O	1745-1756
.	O	1756-1757

While	O	1758-1763
contractions	O	1764-1776
to	O	1777-1779
carbachol	O	1780-1789
and	O	1790-1793
ATP	O	1794-1797
were	O	1798-1802
the	O	1803-1806
same	O	1807-1811
in	O	1812-1814
inflamed	O	1815-1823
and	O	1824-1827
in	O	1828-1830
control	O	1831-1838
strips	O	1839-1845
when	O	1846-1850
related	O	1851-1858
to	O	1859-1861
a	O	1862-1863
reference	O	1864-1873
potassium	O	1874-1883
response	O	1884-1892
,	O	1892-1893
isoprenaline	O	1894-1906
-	O	1906-1907
induced	O	1907-1914
relaxations	O	1915-1926
were	O	1927-1931
smaller	O	1932-1939
in	O	1940-1942
inflamed	O	1943-1951
strips	O	1952-1958
.	O	1958-1959

Thus	O	1960-1964
,	O	1964-1965
in	O	1966-1968
cystitis	B	1969-1977
substantial	O	1978-1989
changes	O	1990-1997
of	O	1998-2000
the	O	2001-2004
efferent	O	2005-2013
functional	O	2014-2024
responses	O	2025-2034
occur	O	2035-2040
.	O	2040-2041

While	O	2042-2047
postjunctional	O	2048-2062
beta	O	2063-2067
-	O	2067-2068
adrenoceptor	O	2068-2080
-	O	2067-2068
mediated	O	2081-2089
relaxations	O	2090-2101
are	O	2102-2105
reduced	O	2106-2113
,	O	2113-2114
effects	O	2115-2122
by	O	2123-2125
prejunctional	O	2126-2139
inhibitory	O	2140-2150
muscarinic	O	2151-2161
receptors	O	2162-2171
may	O	2172-2175
be	O	2176-2178
increased	O	2179-2188
.	O	2188-2189

Associations	O	0-12
between	O	13-20
use	O	21-24
of	O	25-27
benzodiazepines	O	28-43
or	O	44-46
related	O	47-54
drugs	O	55-60
and	O	61-64
health	O	65-71
,	O	71-72
physical	O	73-81
abilities	O	82-91
and	O	92-95
cognitive	O	96-105
function	O	106-114
:	O	114-115
a	O	116-117
non	O	118-121
-	O	121-122
randomised	O	122-132
clinical	O	133-141
study	O	142-147
in	O	148-150
the	O	151-154
elderly	O	155-162
.	O	162-163

OBJECTIVE	O	164-173
:	O	173-174
To	O	175-177
describe	O	178-186
associations	O	187-199
between	O	200-207
the	O	208-211
use	O	212-215
of	O	216-218
benzodiazepines	O	219-234
or	O	235-237
related	O	238-245
drugs	O	246-251
(	O	252-253
BZDs	O	253-257
/	O	257-258
RDs	O	258-261
)	O	261-262
and	O	263-266
health	O	267-273
,	O	273-274
functional	O	275-285
abilities	O	286-295
and	O	296-299
cognitive	O	300-309
function	O	310-318
in	O	319-321
the	O	322-325
elderly	O	326-333
.	O	333-334

METHODS	O	335-342
:	O	342-343
A	O	344-345
non	O	346-349
-	O	349-350
randomised	O	350-360
clinical	O	361-369
study	O	370-375
of	O	376-378
patients	O	379-387
aged	O	388-392
>	O	393-394
or	O	395-397
=	O	398-399
65	O	399-401
years	O	402-407
admitted	O	408-416
to	O	417-419
acute	O	420-425
hospital	O	426-434
wards	O	435-440
during	O	441-447
1	O	448-449
month	O	450-455
.	O	455-456

164	O	457-460
patients	O	461-469
(	O	470-471
mean	O	471-475
age	O	476-479
+	O	480-481
/	O	481-482
-	O	482-483
standard	O	484-492
deviation	O	493-502
[	O	503-504
SD	O	504-506
]	O	506-507
81	O	508-510
.	O	510-511
6	O	511-512
+	O	513-514
/	O	514-515
-	O	515-516
6	O	517-518
.	O	518-519
8	O	519-520
years	O	521-526
)	O	526-527
were	O	528-532
admitted	O	533-541
.	O	541-542

Of	O	543-545
these	O	546-551
,	O	551-552
nearly	O	553-559
half	O	560-564
(	O	565-566
n	O	566-567
=	O	568-569
78	O	570-572
)	O	572-573
had	O	574-577
used	O	578-582
BZDs	O	583-587
/	O	587-588
RDs	O	588-591
before	O	592-598
admission	O	599-608
,	O	608-609
and	O	610-613
the	O	614-617
remainder	O	618-627
(	O	628-629
n	O	629-630
=	O	631-632
86	O	633-635
)	O	635-636
were	O	637-641
non	O	642-645
-	O	645-646
users	O	646-651
.	O	651-652

Cognitive	O	653-662
ability	O	663-670
was	O	671-674
assessed	O	675-683
by	O	684-686
the	O	687-690
Mini	O	691-695
-	O	695-696
Mental	O	696-702
State	O	703-708
Examination	O	709-720
(	O	721-722
MMSE	O	722-726
)	O	726-727
.	O	727-728

Patients	O	729-737
scoring	O	738-745
>	O	746-747
or	O	748-750
=	O	751-752
20	O	752-754
MMSE	O	755-759
sum	O	760-763
points	O	764-770
were	O	771-775
interviewed	O	776-787
(	O	788-789
n	O	789-790
=	O	791-792
79	O	793-795
)	O	795-796
and	O	797-800
questioned	O	801-811
regarding	O	812-821
symptoms	O	822-830
and	O	831-834
functional	O	835-845
abilities	O	846-855
during	O	856-862
the	O	863-866
week	O	867-871
prior	O	872-877
to	O	878-880
admission	O	881-890
.	O	890-891

Data	O	892-896
on	O	897-899
use	O	900-903
of	O	904-906
BZDs	O	907-911
/	O	911-912
RDs	O	912-915
before	O	916-922
admission	O	923-932
,	O	932-933
current	O	934-941
medications	O	942-953
and	O	954-957
discharge	O	958-967
diagnoses	O	968-977
were	O	978-982
collected	O	983-992
from	O	993-997
medical	O	998-1005
records	O	1006-1013
.	O	1013-1014

Health	O	1015-1021
,	O	1021-1022
physical	O	1023-1031
abilities	O	1032-1041
and	O	1042-1045
cognitive	O	1046-1055
function	O	1056-1064
were	O	1065-1069
compared	O	1070-1078
between	O	1079-1086
BZD	O	1087-1090
/	O	1090-1091
RD	O	1091-1093
users	O	1094-1099
and	O	1100-1103
non	O	1104-1107
-	O	1107-1108
users	O	1108-1113
,	O	1113-1114
and	O	1115-1118
adjustments	O	1119-1130
were	O	1131-1135
made	O	1136-1140
for	O	1141-1144
confounding	O	1145-1156
variables	O	1157-1166
.	O	1166-1167

The	O	1168-1171
residual	O	1172-1180
serum	O	1181-1186
concentrations	O	1187-1201
of	O	1202-1204
oxazepam	O	1205-1213
,	O	1213-1214
temazepam	O	1215-1224
and	O	1225-1228
zopiclone	O	1229-1238
were	O	1239-1243
analysed	O	1244-1252
.	O	1252-1253

RESULTS	O	1254-1261
:	O	1261-1262
The	O	1263-1266
mean	O	1267-1271
+	O	1272-1273
/	O	1273-1274
-	O	1274-1275
SD	O	1276-1278
duration	O	1279-1287
of	O	1288-1290
BZD	O	1291-1294
/	O	1294-1295
RD	O	1295-1297
use	O	1298-1301
was	O	1302-1305
7	O	1306-1307
+	O	1308-1309
/	O	1309-1310
-	O	1310-1311
7	O	1312-1313
years	O	1314-1319
(	O	1320-1321
range	O	1321-1326
1	O	1327-1328
-	O	1328-1329
31	O	1329-1331
)	O	1331-1332
.	O	1332-1333

Two	O	1334-1337
or	O	1338-1340
three	O	1341-1346
BZDs	O	1347-1351
/	O	1351-1352
RDs	O	1352-1355
were	O	1356-1360
concomitantly	O	1361-1374
taken	O	1375-1380
by	O	1381-1383
26	O	1384-1386
%	O	1386-1387
of	O	1388-1390
users	O	1391-1396
(	O	1397-1398
n	O	1398-1399
=	O	1400-1401
20	O	1402-1404
)	O	1404-1405
.	O	1405-1406

Long	O	1407-1411
-	O	1411-1412
term	O	1412-1416
use	O	1417-1420
of	O	1421-1423
these	O	1424-1429
drugs	O	1430-1435
was	O	1436-1439
associated	O	1440-1450
with	O	1451-1455
female	O	1456-1462
sex	O	1463-1466
and	O	1467-1470
use	O	1471-1474
of	O	1475-1477
a	O	1478-1479
higher	O	1480-1486
number	O	1487-1493
of	O	1494-1496
drugs	O	1497-1502
with	O	1503-1507
effects	O	1508-1515
on	O	1516-1518
the	O	1519-1522
CNS	O	1523-1526
,	O	1526-1527
which	O	1528-1533
tended	O	1534-1540
to	O	1541-1543
be	O	1544-1546
related	O	1547-1554
to	O	1555-1557
diagnosed	O	1558-1567
dementia	B	1568-1576
.	O	1576-1577

After	O	1578-1583
adjustment	O	1584-1594
for	O	1595-1598
these	O	1599-1604
variables	O	1605-1614
as	O	1615-1617
confounders	O	1618-1629
,	O	1629-1630
use	O	1631-1634
of	O	1635-1637
BZDs	O	1638-1642
/	O	1642-1643
RDs	O	1643-1646
was	O	1647-1650
not	O	1651-1654
associated	O	1655-1665
with	O	1666-1670
cognitive	O	1671-1680
function	O	1681-1689
as	O	1690-1692
measured	O	1693-1701
by	O	1702-1704
the	O	1705-1708
MMSE	O	1709-1713
.	O	1713-1714

However	O	1715-1722
,	O	1722-1723
use	O	1724-1727
of	O	1728-1730
BZDs	O	1731-1735
/	O	1735-1736
RDs	O	1736-1739
was	O	1740-1743
associated	O	1744-1754
with	O	1755-1759
dizziness	B	1760-1769
,	O	1769-1770
inability	B	1771-1780
to	I	1781-1783
sleep	I	1784-1789
after	O	1790-1795
awaking	O	1796-1803
at	O	1804-1806
night	O	1807-1812
and	O	1813-1816
tiredness	B	1817-1826
in	O	1827-1829
the	O	1830-1833
mornings	O	1834-1842
during	O	1843-1849
the	O	1850-1853
week	O	1854-1858
prior	O	1859-1864
to	O	1865-1867
admission	O	1868-1877
and	O	1878-1881
with	O	1882-1886
stronger	O	1887-1895
depressive	B	1896-1906
symptoms	I	1907-1915
measured	O	1916-1924
at	O	1925-1927
the	O	1928-1931
beginning	O	1932-1941
of	O	1942-1944
the	O	1945-1948
hospital	O	1949-1957
stay	O	1958-1962
.	O	1962-1963

Use	O	1964-1967
of	O	1968-1970
BZDs	O	1971-1975
/	O	1975-1976
RDs	O	1976-1979
tended	O	1980-1986
to	O	1987-1989
be	O	1990-1992
associated	O	1993-2003
with	O	2004-2008
a	O	2009-2010
reduced	O	2011-2018
ability	O	2019-2026
to	O	2027-2029
walk	O	2030-2034
and	O	2035-2038
shorter	O	2039-2046
night	O	2047-2052
-	O	2052-2053
time	O	2053-2057
sleep	O	2058-2063
during	O	2064-2070
the	O	2071-2074
week	O	2075-2079
prior	O	2080-2085
to	O	2086-2088
admission	O	2089-2098
.	O	2098-2099

A	O	2100-2101
higher	O	2102-2108
residual	O	2109-2117
serum	O	2118-2123
concentration	O	2124-2137
of	O	2138-2140
temazepam	O	2141-2150
correlated	O	2151-2161
with	O	2162-2166
a	O	2167-2168
lower	O	2169-2174
MMSE	O	2175-2179
sum	O	2180-2183
score	O	2184-2189
after	O	2190-2195
adjustment	O	2196-2206
for	O	2207-2210
confounding	O	2211-2222
variables	O	2223-2232
.	O	2232-2233

CONCLUSIONS	O	2234-2245
:	O	2245-2246
Long	O	2247-2251
-	O	2251-2252
term	O	2252-2256
use	O	2257-2260
and	O	2261-2264
concomitant	O	2265-2276
use	O	2277-2280
of	O	2281-2283
more	O	2284-2288
than	O	2289-2293
one	O	2294-2297
BZD	O	2298-2301
/	O	2301-2302
RD	O	2302-2304
were	O	2305-2309
common	O	2310-2316
in	O	2317-2319
elderly	O	2320-2327
patients	O	2328-2336
hospitalised	O	2337-2349
because	O	2350-2357
of	O	2358-2360
acute	O	2361-2366
illnesses	O	2367-2376
.	O	2376-2377

Long	O	2378-2382
-	O	2382-2383
term	O	2383-2387
use	O	2388-2391
was	O	2392-2395
associated	O	2396-2406
with	O	2407-2411
daytime	O	2412-2419
and	O	2420-2423
night	O	2424-2429
-	O	2429-2430
time	O	2430-2434
symptoms	O	2435-2443
indicative	O	2444-2454
of	O	2455-2457
poorer	O	2458-2464
health	O	2465-2471
and	O	2472-2475
potentially	O	2476-2487
caused	O	2488-2494
by	O	2495-2497
the	O	2498-2501
adverse	O	2502-2509
effects	O	2510-2517
of	O	2518-2520
these	O	2521-2526
drugs	O	2527-2532
.	O	2532-2533

Acute	O	0-5
vocal	B	6-11
fold	I	12-16
palsy	I	17-22
after	O	23-28
acute	O	29-34
disulfiram	O	35-45
intoxication	O	46-58
.	O	58-59

Acute	O	60-65
peripheral	B	66-76
neuropathy	I	77-87
caused	O	88-94
by	O	95-97
a	O	98-99
disulfiram	O	100-110
overdose	B	111-119
is	O	120-122
very	O	123-127
rare	O	128-132
and	O	133-136
there	O	137-142
is	O	143-145
no	O	146-148
report	O	149-155
of	O	156-158
it	O	159-161
leading	O	162-169
to	O	170-172
vocal	B	173-178
fold	I	179-183
palsy	I	184-189
.	O	189-190

A	O	191-192
49	O	193-195
-	O	195-196
year	O	196-200
-	O	195-196
old	O	201-204
woman	O	205-210
was	O	211-214
transferred	O	215-226
to	O	227-229
our	O	230-233
department	O	234-244
because	O	245-252
of	O	253-255
quadriparesis	B	256-269
,	O	269-270
lancinating	O	271-282
pain	B	283-287
,	O	287-288
sensory	B	289-296
loss	I	297-301
,	O	301-302
and	O	303-306
paresthesia	B	307-318
of	O	319-321
the	O	322-325
distal	O	326-332
limbs	O	333-338
.	O	338-339

One	O	340-343
month	O	344-349
previously	O	350-360
,	O	360-361
she	O	362-365
had	O	366-369
taken	O	370-375
a	O	376-377
single	O	378-384
high	O	385-389
dose	O	390-394
of	O	395-397
disulfiram	O	398-408
(	O	409-410
130	O	410-413
tablets	O	414-421
of	O	422-424
ALCOHOL	O	425-432
STOP	O	433-437
TAB	O	438-441
,	O	441-442
Shin	O	443-447
-	O	447-448
Poong	O	448-453
Pharm	O	454-459
.	O	459-460

Co	O	461-463
.	O	463-464
,	O	464-465
Ansan	O	466-471
,	O	471-472
Korea	O	473-478
)	O	478-479
in	O	480-482
a	O	483-484
suicide	O	485-492
attempt	O	493-500
.	O	500-501

She	O	502-505
was	O	506-509
not	O	510-513
an	O	514-516
alcoholic	O	517-526
.	O	526-527

For	O	528-531
the	O	532-535
first	O	536-541
few	O	542-545
days	O	546-550
after	O	551-556
ingestion	O	557-566
,	O	566-567
she	O	568-571
was	O	572-575
in	O	576-578
a	O	579-580
confused	O	581-589
state	O	590-595
and	O	596-599
had	O	600-603
mild	O	604-608
to	O	609-611
moderate	O	612-620
ataxia	B	621-627
and	O	628-631
giddiness	B	632-641
.	O	641-642

She	O	643-646
noticed	O	647-654
hoarseness	B	655-665
and	O	666-669
distally	O	670-678
accentuated	O	679-690
motor	O	691-696
and	O	697-700
sensory	O	701-708
dysfunction	O	709-720
after	O	721-726
she	O	727-730
had	O	731-734
recovered	O	735-744
from	O	745-749
this	O	750-754
state	O	755-760
.	O	760-761

A	O	762-763
nerve	O	764-769
conduction	O	770-780
study	O	781-786
was	O	787-790
consistent	O	791-801
with	O	802-806
severe	O	807-813
sensorimotor	O	814-826
axonal	O	827-833
polyneuropathy	B	834-848
.	O	848-849

Laryngeal	O	850-859
electromyography	O	860-876
(	O	877-878
thyroarytenoid	O	878-892
muscle	O	893-899
)	O	899-900
showed	O	901-907
ample	O	908-913
denervation	O	914-925
potentials	O	926-936
.	O	936-937

Laryngoscopy	O	938-950
revealed	O	951-959
asymmetric	O	960-970
vocal	O	971-976
fold	O	977-981
movements	O	982-991
during	O	992-998
phonation	O	999-1008
.	O	1008-1009

Her	O	1010-1013
vocal	O	1014-1019
change	O	1020-1026
and	O	1027-1030
weakness	O	1031-1039
began	O	1040-1045
to	O	1046-1048
improve	O	1049-1056
spontaneously	O	1057-1070
about	O	1071-1076
3	O	1077-1078
weeks	O	1079-1084
after	O	1085-1090
transfer	O	1091-1099
.	O	1099-1100

This	O	1101-1105
was	O	1106-1109
a	O	1110-1111
case	O	1112-1116
of	O	1117-1119
acute	O	1120-1125
palsy	B	1126-1131
of	O	1132-1134
the	O	1135-1138
recurrent	O	1139-1148
laryngeal	O	1149-1158
nerve	O	1159-1164
and	O	1165-1168
superimposed	O	1169-1181
severe	O	1182-1188
acute	O	1189-1194
sensorimotor	O	1195-1207
axonal	O	1208-1214
polyneuropathy	B	1215-1229
caused	O	1230-1236
by	O	1237-1239
high	O	1240-1244
-	O	1244-1245
dose	O	1245-1249
disulfiram	O	1250-1260
intoxication	O	1261-1273
.	O	1273-1274

Higher	O	0-6
optical	O	7-14
density	O	15-22
of	O	23-25
an	O	26-28
antigen	O	29-36
assay	O	37-42
predicts	O	43-51
thrombosis	B	52-62
in	O	63-65
patients	O	66-74
with	O	75-79
heparin	O	80-87
-	O	87-88
induced	O	88-95
thrombocytopenia	B	96-112
.	O	112-113

OBJECTIVES	O	114-124
:	O	124-125
To	O	126-128
correlate	O	129-138
optical	O	139-146
density	O	147-154
and	O	155-158
percent	O	159-166
inhibition	O	167-177
of	O	178-180
a	O	181-182
two	O	183-186
-	O	186-187
step	O	187-191
heparin	O	192-199
-	O	199-200
induced	O	200-207
thrombocytopenia	B	208-224
(	O	225-226
HIT	B	226-229
)	O	229-230
antigen	O	231-238
assay	O	239-244
with	O	245-249
thrombosis	B	250-260
;	O	260-261
the	O	262-265
assay	O	266-271
utilizes	O	272-280
reaction	O	281-289
inhibition	O	290-300
characteristics	O	301-316
of	O	317-319
a	O	320-321
high	O	322-326
heparin	O	327-334
concentration	O	335-348
.	O	348-349

PATIENTS	O	350-358
AND	O	359-362
METHODS	O	363-370
:	O	370-371
Patients	O	372-380
with	O	381-385
more	O	386-390
than	O	391-395
50	O	396-398
%	O	398-399
decrease	O	400-408
in	O	409-411
platelet	O	412-420
count	O	421-426
or	O	427-429
thrombocytopenia	B	430-446
(	O	447-448
<	O	448-449
150	O	449-452
x	O	453-454
10	O	455-457
(	O	457-458
9	O	458-459
)	O	459-460
/	O	460-461
L	O	461-462
)	O	459-460
after	O	464-469
exposure	O	470-478
to	O	479-481
heparin	O	482-489
,	O	489-490
who	O	491-494
had	O	495-498
a	O	499-500
positive	O	501-509
two	O	510-513
-	O	513-514
step	O	514-518
antigen	O	519-526
assay	O	527-532
[	O	533-534
optical	O	534-541
density	O	542-549
(	O	550-551
OD	O	551-553
)	O	553-554
>	O	555-556
0	O	556-557
.	O	557-558
4	O	558-559
and	O	560-563
>	O	564-565
50	O	565-567
inhibition	O	568-578
with	O	579-583
high	O	584-588
concentration	O	589-602
of	O	603-605
heparin	O	606-613
]	O	613-614
were	O	615-619
included	O	620-628
in	O	629-631
the	O	632-635
study	O	636-641
.	O	641-642

RESULTS	O	643-650
:	O	650-651
Forty	O	652-657
of	O	658-660
94	O	661-663
HIT	B	664-667
patients	O	668-676
had	O	677-680
thrombosis	B	681-691
at	O	692-694
diagnosis	O	695-704
;	O	704-705
54	O	706-708
/	O	708-709
94	O	709-711
had	O	712-715
isolated	O	716-724
-	O	724-725
HIT	B	725-728
without	O	729-736
thrombosis	B	737-747
.	O	747-748

Eight	O	749-754
of	O	755-757
the	O	758-761
isolated	O	762-770
-	O	770-771
HIT	B	771-774
patients	O	775-783
developed	O	784-793
thrombosis	B	794-804
within	O	805-811
the	O	812-815
next	O	816-820
30	O	821-823
d	O	824-825
;	O	825-826
thus	O	827-831
,	O	831-832
a	O	833-834
total	O	835-840
of	O	841-843
48	O	844-846
patients	O	847-855
had	O	856-859
thrombosis	B	860-870
at	O	871-873
day	O	874-877
30	O	878-880
.	O	880-881

At	O	882-884
diagnosis	O	885-894
there	O	895-900
was	O	901-904
no	O	905-907
significant	O	908-919
difference	O	920-930
in	O	931-933
OD	O	934-936
between	O	937-944
HIT	B	945-948
patients	O	949-957
with	O	958-962
thrombosis	B	963-973
and	O	974-977
those	O	978-983
with	O	984-988
isolated	O	989-997
-	O	997-998
HIT	B	998-1001
.	O	1001-1002

However	O	1003-1010
,	O	1010-1011
OD	O	1012-1014
was	O	1015-1018
significantly	O	1019-1032
higher	O	1033-1039
in	O	1040-1042
all	O	1043-1046
patients	O	1047-1055
with	O	1056-1060
thrombosis	B	1061-1071
(	O	1072-1073
n	O	1073-1074
=	O	1075-1076
48	O	1077-1079
,	O	1079-1080
1	O	1081-1082
.	O	1082-1083
34	O	1083-1085
+	O	1086-1087
/	O	1087-1088
-	O	1088-1089
0	O	1090-1091
.	O	1091-1092
89	O	1092-1094
)	O	1094-1095
,	O	1095-1096
including	O	1097-1106
isolated	O	1107-1115
-	O	1115-1116
HIT	B	1116-1119
patients	O	1120-1128
who	O	1129-1132
later	O	1133-1138
developed	O	1139-1148
thrombosis	B	1149-1159
within	O	1160-1166
30	O	1167-1169
d	O	1170-1171
(	O	1172-1173
n	O	1173-1174
=	O	1175-1176
8	O	1177-1178
,	O	1178-1179
1	O	1180-1181
.	O	1181-1182
84	O	1182-1184
+	O	1185-1186
/	O	1186-1187
-	O	1187-1188
0	O	1189-1190
.	O	1190-1191
64	O	1191-1193
)	O	1193-1194
as	O	1195-1197
compared	O	1198-1206
to	O	1207-1209
isolated	O	1210-1218
-	O	1218-1219
HIT	B	1219-1222
patients	O	1223-1231
who	O	1232-1235
did	O	1236-1239
not	O	1240-1243
develop	O	1244-1251
thrombosis	B	1252-1262
(	O	1263-1264
0	O	1264-1265
.	O	1265-1266
96	O	1266-1268
+	O	1269-1270
/	O	1270-1271
-	O	1271-1272
0	O	1273-1274
.	O	1274-1275
75	O	1275-1277
;	O	1277-1278
P	O	1279-1280
=	O	1281-1282
0	O	1283-1284
.	O	1284-1285
011	O	1285-1288
and	O	1289-1292
P	O	1293-1294
=	O	1295-1296
0	O	1297-1298
.	O	1298-1299
008	O	1299-1302
)	O	1302-1303
.	O	1298-1299

The	O	1305-1308
Receiver	O	1309-1317
Operative	O	1318-1327
Characteristic	O	1328-1342
Curve	O	1343-1348
showed	O	1349-1355
that	O	1356-1360
OD	O	1361-1363
>	O	1364-1365
1	O	1365-1366
.	O	1366-1367
27	O	1367-1369
in	O	1370-1372
the	O	1373-1376
isolated	O	1377-1385
-	O	1385-1386
HIT	B	1386-1389
group	O	1390-1395
had	O	1396-1399
a	O	1400-1401
significantly	O	1402-1415
higher	O	1416-1422
chance	O	1423-1429
of	O	1430-1432
developing	O	1433-1443
thrombosis	B	1444-1454
by	O	1455-1457
day	O	1458-1461
30	O	1462-1464
.	O	1464-1465

None	O	1466-1470
of	O	1471-1473
these	O	1474-1479
groups	O	1480-1486
showed	O	1487-1493
significant	O	1494-1505
difference	O	1506-1516
in	O	1517-1519
percent	O	1520-1527
inhibition	O	1528-1538
.	O	1538-1539

Multivariate	O	1540-1552
analysis	O	1553-1561
showed	O	1562-1568
a	O	1569-1570
2	O	1571-1572
.	O	1572-1573
8	O	1573-1574
-	O	1574-1575
fold	O	1575-1579
increased	O	1580-1589
risk	O	1590-1594
of	O	1595-1597
thrombosis	B	1598-1608
in	O	1609-1611
females	O	1612-1619
.	O	1619-1620

Similarly	O	1621-1630
,	O	1630-1631
thrombotic	B	1632-1642
risk	O	1643-1647
increased	O	1648-1657
with	O	1658-1662
age	O	1663-1666
and	O	1667-1670
OD	O	1671-1673
values	O	1674-1680
.	O	1680-1681

CONCLUSION	O	1682-1692
:	O	1692-1693
Higher	O	1694-1700
OD	O	1701-1703
is	O	1704-1706
associated	O	1707-1717
with	O	1718-1722
significant	O	1723-1734
risk	O	1735-1739
of	O	1740-1742
subsequent	O	1743-1753
thrombosis	B	1754-1764
in	O	1765-1767
patients	O	1768-1776
with	O	1777-1781
isolated	O	1782-1790
-	O	1790-1791
HIT	B	1791-1794
;	O	1794-1795
percent	O	1796-1803
inhibition	O	1804-1814
,	O	1814-1815
however	O	1816-1823
,	O	1823-1824
was	O	1825-1828
not	O	1829-1832
predictive	O	1833-1843
.	O	1843-1844

Central	O	0-7
retinal	B	8-15
vein	I	16-20
occlusion	I	21-30
associated	O	31-41
with	O	42-46
clomiphene	O	47-57
-	O	57-58
induced	O	58-65
ovulation	O	66-75
.	O	75-76

OBJECTIVE	O	77-86
:	O	86-87
To	O	88-90
report	O	91-97
a	O	98-99
case	O	100-104
of	O	105-107
central	O	108-115
retinal	B	116-123
vein	I	124-128
occlusion	I	129-138
associated	O	139-149
with	O	150-154
clomiphene	O	155-165
citrate	O	166-173
(	O	174-175
CC	O	175-177
)	O	177-178
.	O	178-179

DESIGN	O	180-186
:	O	186-187
Case	O	188-192
study	O	193-198
.	O	198-199

SETTING	O	200-207
:	O	207-208
Ophthalmology	O	209-222
clinic	O	223-229
of	O	230-232
an	O	233-235
academic	O	236-244
hospital	O	245-253
.	O	253-254

PATIENT	O	255-262
(	O	262-263
S	O	263-264
)	O	264-265
:	O	265-266
A	O	267-268
36	O	269-271
-	O	271-272
year	O	272-276
-	O	271-272
old	O	277-280
woman	O	281-286
referred	O	287-295
from	O	296-300
the	O	301-304
infertility	B	305-316
clinic	O	317-323
for	O	324-327
blurred	B	328-335
vision	I	336-342
.	O	342-343

INTERVENTION	O	344-356
(	O	356-357
S	O	357-358
)	O	358-359
:	O	359-360
Ophthalmic	O	361-371
examination	O	372-383
after	O	384-389
CC	O	390-392
therapy	O	393-400
.	O	400-401

MAIN	O	402-406
OUTCOME	O	407-414
MEASURE	O	415-422
(	O	422-423
S	O	418-419
)	O	424-425
:	O	425-426
Central	O	427-434
retinal	B	435-442
vein	I	443-447
occlusion	I	448-457
after	O	458-463
ovulation	O	464-473
induction	O	474-483
with	O	484-488
CC	O	489-491
.	O	491-492

RESULT	O	493-499
(	O	499-500
S	O	495-496
)	O	501-502
:	O	502-503
A	O	504-505
36	O	506-508
-	O	508-509
year	O	509-513
-	O	508-509
old	O	514-517
Chinese	O	518-525
woman	O	526-531
developed	O	532-541
central	O	542-549
retinal	B	550-557
vein	I	558-562
occlusion	I	563-572
after	O	573-578
eight	O	579-584
courses	O	585-592
of	O	593-595
CC	O	596-598
.	O	598-599

A	O	600-601
search	O	602-608
of	O	609-611
the	O	612-615
literature	O	616-626
on	O	627-629
the	O	630-633
thromboembolic	B	634-648
complications	O	649-662
of	O	663-665
CC	O	666-668
does	O	669-673
not	O	674-677
include	O	678-685
this	O	686-690
severe	O	691-697
ophthalmic	O	698-708
complication	O	709-721
,	O	721-722
although	O	723-731
mild	O	732-736
visual	B	737-743
disturbance	I	744-755
after	O	756-761
CC	O	762-764
intake	O	765-771
is	O	772-774
not	O	775-778
uncommon	O	779-787
.	O	787-788

CONCLUSION	O	789-799
(	O	799-800
S	O	795-796
)	O	801-802
:	O	802-803
This	O	804-808
is	O	809-811
the	O	812-815
first	O	816-821
reported	O	822-830
case	O	831-835
of	O	836-838
central	O	839-846
retinal	B	847-854
vein	I	855-859
occlusion	I	860-869
after	O	870-875
treatment	O	876-885
with	O	886-890
CC	O	891-893
.	O	893-894

Extra	O	895-900
caution	O	901-908
is	O	909-911
warranted	O	912-921
in	O	922-924
treating	O	925-933
infertility	B	934-945
patients	O	946-954
with	O	955-959
CC	O	960-962
,	O	962-963
and	O	964-967
patients	O	968-976
should	O	977-983
be	O	984-986
well	O	987-991
informed	O	992-1000
of	O	1001-1003
this	O	1004-1008
side	O	1009-1013
effect	O	1014-1020
before	O	1021-1027
commencement	O	1028-1040
of	O	1041-1043
therapy	O	1044-1051
.	O	1051-1052

Nicotine	O	0-8
-	O	8-9
induced	O	9-16
nystagmus	B	17-26
correlates	O	27-37
with	O	38-42
midpontine	O	43-53
activation	O	54-64
.	O	64-65

The	O	66-69
pathomechanism	O	70-84
of	O	85-87
nicotine	O	88-96
-	O	96-97
induced	O	97-104
nystagmus	B	105-114
(	O	115-116
NIN	B	116-119
)	O	119-120
is	O	121-123
unknown	O	124-131
.	O	131-132

The	O	133-136
aim	O	137-140
of	O	141-143
this	O	144-148
study	O	149-154
was	O	155-158
to	O	159-161
delineate	O	162-171
brain	O	172-177
structures	O	178-188
that	O	189-193
are	O	194-197
involved	O	198-206
in	O	207-209
NIN	B	210-213
generation	O	214-224
.	O	224-225

Eight	O	226-231
healthy	O	232-239
volunteers	O	240-250
inhaled	O	251-258
nicotine	O	259-267
in	O	268-270
darkness	O	271-279
during	O	280-286
a	O	287-288
functional	O	289-299
magnetic	O	300-308
resonance	O	309-318
imaging	O	319-326
(	O	327-328
fMRI	O	328-332
)	O	332-333
experiment	O	334-344
;	O	344-345
eye	O	346-349
movements	O	350-359
were	O	360-364
registered	O	365-375
using	O	376-381
video	O	382-387
-	O	387-388
oculography	O	388-399
.	O	399-400

NIN	B	401-404
correlated	O	405-415
with	O	416-420
blood	O	421-426
oxygen	O	427-433
level	O	434-439
-	O	439-440
dependent	O	440-449
(	O	450-451
BOLD	O	451-455
)	O	455-456
activity	O	457-465
levels	O	466-472
in	O	473-475
a	O	476-477
midpontine	O	478-488
site	O	489-493
in	O	494-496
the	O	497-500
posterior	O	501-510
basis	O	511-516
pontis	O	517-523
.	O	523-524

NIN	B	525-528
-	O	528-529
induced	O	529-536
midpontine	O	537-547
activation	O	548-558
may	O	559-562
correspond	O	563-573
to	O	574-576
activation	O	577-587
of	O	588-590
the	O	591-594
dorsomedial	O	595-606
pontine	O	607-614
nuclei	O	615-621
and	O	622-625
the	O	626-629
nucleus	O	630-637
reticularis	O	638-649
tegmenti	O	650-658
pontis	O	659-665
,	O	665-666
structures	O	667-677
known	O	678-683
to	O	684-686
participate	O	687-698
in	O	699-701
the	O	702-705
generation	O	706-716
of	O	717-719
multidirectional	O	720-736
saccades	O	737-745
and	O	746-749
smooth	O	750-756
pursuit	O	757-764
eye	O	765-768
movements	O	769-778
.	O	778-779

Protective	O	0-10
effect	O	11-17
of	O	18-20
verapamil	O	21-30
on	O	31-33
gastric	B	34-41
hemorrhagic	I	42-53
ulcers	B	54-60
in	O	61-63
severe	O	64-70
atherosclerotic	B	71-86
rats	O	87-91
.	O	91-92

Studies	O	93-100
concerning	O	101-111
with	O	112-116
pathogenesis	O	117-129
of	O	130-132
gastric	B	133-140
hemorrhage	I	141-151
and	O	152-155
mucosal	O	156-163
ulceration	O	164-174
produced	O	175-183
in	O	184-186
atherosclerotic	B	187-202
rats	O	203-207
are	O	208-211
lacking	O	212-219
.	O	219-220

The	O	221-224
aim	O	225-228
of	O	229-231
this	O	232-236
study	O	237-242
is	O	243-245
to	O	246-248
examine	O	249-256
the	O	257-260
role	O	261-265
of	O	266-268
gastric	O	269-276
acid	O	277-281
back	O	282-286
-	O	286-287
diffusion	O	287-296
,	O	296-297
mast	O	298-302
cell	O	303-307
histamine	O	308-317
release	O	318-325
,	O	325-326
lipid	O	327-332
peroxide	O	333-341
(	O	342-343
LPO	O	343-346
)	O	346-347
generation	O	348-358
and	O	359-362
mucosal	O	363-370
microvascular	O	371-384
permeability	O	385-397
in	O	398-400
modulating	O	401-411
gastric	B	412-419
hemorrhage	I	420-430
and	O	431-434
ulcer	B	435-440
in	O	441-443
rats	O	444-448
with	O	449-453
atherosclerosis	B	454-469
induced	O	470-477
by	O	478-480
coadministration	O	481-497
of	O	498-500
vitamin	O	501-508
D2	O	509-511
and	O	512-515
cholesterol	O	516-527
.	O	527-528

Additionally	O	529-541
,	O	541-542
the	O	543-546
protective	O	547-557
effect	O	558-564
of	O	565-567
verapamil	O	568-577
on	O	578-580
this	O	581-585
ulcer	B	586-591
model	O	592-597
was	O	598-601
evaluated	O	602-611
.	O	611-612

Male	O	613-617
Wistar	O	618-624
rats	O	625-629
were	O	630-634
challenged	O	635-645
intragastrically	O	646-662
once	O	663-667
daily	O	668-673
for	O	674-677
9	O	678-679
days	O	680-684
with	O	685-689
1	O	690-691
.	O	691-692
0	O	692-693
ml	O	694-696
/	O	696-697
kg	O	697-699
of	O	700-702
corn	O	703-707
oil	O	708-711
containing	O	712-722
vitamin	O	723-730
D2	O	731-733
and	O	734-737
cholesterol	O	738-749
to	O	750-752
induce	O	753-759
atherosclerosis	B	760-775
.	O	775-776

Control	O	777-784
rats	O	785-789
received	O	790-798
corn	O	799-803
oil	O	804-807
only	O	808-812
.	O	812-813

After	O	814-819
gastric	O	820-827
surgery	O	828-835
,	O	835-836
rat	O	837-840
stomachs	O	841-849
were	O	850-854
irrigated	O	855-864
for	O	865-868
3	O	869-870
h	O	871-872
with	O	873-877
either	O	878-884
simulated	O	885-894
gastric	O	895-902
juice	O	903-908
or	O	909-911
normal	O	912-918
saline	O	919-925
.	O	925-926

Gastric	O	927-934
acid	O	935-939
back	O	940-944
-	O	944-945
diffusion	O	945-954
,	O	954-955
mucosal	O	956-963
LPO	O	964-967
generation	O	968-978
,	O	978-979
histamine	O	980-989
concentration	O	990-1003
,	O	1003-1004
microvascular	O	1005-1018
permeability	O	1019-1031
,	O	1031-1032
luminal	O	1033-1040
hemoglobin	O	1041-1051
content	O	1052-1059
and	O	1060-1063
ulcer	B	1064-1069
areas	O	1070-1075
were	O	1076-1080
determined	O	1081-1091
.	O	1091-1092

Elevated	O	1093-1101
atherosclerotic	B	1102-1117
parameters	O	1118-1128
,	O	1128-1129
such	O	1130-1134
as	O	1135-1137
serum	O	1138-1143
calcium	O	1144-1151
,	O	1151-1152
total	O	1153-1158
cholesterol	O	1159-1170
and	O	1171-1174
low	O	1175-1178
-	O	1178-1179
density	O	1179-1186
lipoprotein	O	1187-1198
concentration	O	1199-1212
were	O	1213-1217
obtained	O	1218-1226
in	O	1227-1229
atherosclerotic	B	1230-1245
rats	O	1246-1250
.	O	1250-1251

Severe	O	1252-1258
gastric	O	1259-1266
ulcers	B	1267-1273
accompanied	O	1274-1285
with	O	1286-1290
increased	O	1291-1300
ulcerogenic	O	1301-1312
factors	O	1313-1320
,	O	1320-1321
including	O	1322-1331
gastric	O	1332-1339
acid	O	1340-1344
back	O	1345-1349
-	O	1349-1350
diffusion	O	1350-1359
,	O	1359-1360
histamine	O	1361-1370
release	O	1371-1378
,	O	1378-1379
LPO	O	1380-1383
generation	O	1384-1394
and	O	1395-1398
luminal	O	1399-1406
hemoglobin	O	1407-1417
content	O	1418-1425
were	O	1426-1430
also	O	1431-1435
observed	O	1436-1444
in	O	1445-1447
these	O	1448-1453
rats	O	1454-1458
.	O	1458-1459

Moreover	O	1460-1468
,	O	1468-1469
a	O	1470-1471
positive	O	1472-1480
correlation	O	1481-1492
of	O	1493-1495
histamine	O	1496-1505
to	O	1506-1508
gastric	B	1509-1516
hemorrhage	I	1517-1527
and	O	1528-1531
to	O	1532-1534
ulcer	B	1535-1540
was	O	1541-1544
found	O	1545-1550
in	O	1551-1553
those	O	1554-1559
atherosclerotic	B	1560-1575
rats	O	1576-1580
.	O	1580-1581

This	O	1582-1586
hemorrhagic	B	1587-1598
ulcer	B	1599-1604
and	O	1605-1608
various	O	1609-1616
ulcerogenic	O	1617-1628
parameters	O	1629-1639
were	O	1640-1644
dose	O	1645-1649
-	O	1649-1650
dependently	O	1650-1661
ameliorated	O	1662-1673
by	O	1674-1676
daily	O	1677-1682
intragastric	O	1683-1695
verapamil	O	1696-1705
.	O	1705-1706

Atherosclerosis	B	1707-1722
could	O	1723-1728
produce	O	1729-1736
gastric	B	1737-1744
hemorrhagic	I	1745-1756
ulcer	B	1757-1762
via	O	1763-1766
aggravation	O	1767-1778
of	O	1779-1781
gastric	O	1782-1789
acid	O	1790-1794
back	O	1795-1799
-	O	1799-1800
diffusion	O	1800-1809
,	O	1809-1810
LPO	O	1811-1814
generation	O	1815-1825
,	O	1825-1826
histamine	O	1827-1836
release	O	1837-1844
and	O	1845-1848
microvascular	O	1849-1862
permeability	O	1863-1875
that	O	1876-1880
could	O	1881-1886
be	O	1887-1889
ameliorated	O	1890-1901
by	O	1902-1904
verapamil	O	1905-1914
in	O	1915-1917
rats	O	1918-1922
.	O	1922-1923

Adriamycin	O	0-10
-	O	10-11
induced	O	11-18
autophagic	O	19-29
cardiomyocyte	O	30-43
death	B	44-49
plays	O	50-55
a	O	56-57
pathogenic	O	58-68
role	O	69-73
in	O	74-76
a	O	77-78
rat	O	79-82
model	O	83-88
of	O	89-91
heart	B	92-97
failure	I	98-105
.	O	105-106

BACKGROUND	O	107-117
:	O	117-118
The	O	119-122
mechanisms	O	123-133
underlying	O	134-144
heart	B	145-150
failure	I	151-158
induced	O	159-166
by	O	167-169
adriamycin	O	170-180
are	O	181-184
very	O	185-189
complicated	O	190-201
and	O	202-205
still	O	206-211
unclear	O	212-219
.	O	219-220

The	O	221-224
aim	O	225-228
of	O	229-231
this	O	232-236
study	O	237-242
was	O	243-246
to	O	247-249
investigate	O	250-261
whether	O	262-269
autophagy	O	270-279
was	O	280-283
involved	O	284-292
in	O	293-295
the	O	296-299
progression	O	300-311
of	O	312-314
heart	B	315-320
failure	I	321-328
induced	O	329-336
by	O	337-339
adriamycin	O	340-350
,	O	350-351
so	O	352-354
that	O	355-359
we	O	360-362
can	O	363-366
develop	O	367-374
a	O	375-376
novel	O	377-382
treatment	O	383-392
strategy	O	393-401
for	O	402-405
heart	B	406-411
failure	I	412-419
.	O	419-420

METHODS	O	421-428
:	O	428-429
3	O	430-431
-	O	431-432
methyladenine	O	432-445
(	O	446-447
3MA	O	447-450
)	O	450-451
,	O	451-452
a	O	453-454
specific	O	455-463
inhibitor	O	464-473
on	O	474-476
autophagy	O	477-486
was	O	487-490
used	O	491-495
in	O	496-498
a	O	499-500
heart	B	501-506
failure	I	507-514
model	O	515-520
of	O	521-523
rats	O	524-528
induced	O	529-536
by	O	537-539
adriamycin	O	540-550
.	O	550-551

Neonatal	O	552-560
cardiomyocytes	O	561-575
were	O	576-580
isolated	O	581-589
from	O	590-594
Sprague	O	595-602
-	O	602-603
Dawley	O	603-609
rat	O	610-613
hearts	O	614-620
and	O	621-624
randomly	O	625-633
divided	O	634-641
into	O	642-646
controls	O	647-655
,	O	655-656
an	O	657-659
adriamycin	O	660-670
-	O	670-671
treated	O	671-678
group	O	679-684
,	O	684-685
and	O	686-689
a	O	690-691
3MA	O	692-695
plus	O	696-700
adriamycin	O	701-711
-	O	711-712
treated	O	712-719
group	O	720-725
.	O	725-726

We	O	727-729
then	O	730-734
examined	O	735-743
the	O	744-747
morphology	O	748-758
,	O	758-759
expression	O	760-770
of	O	771-773
beclin	O	774-780
1	O	781-782
gene	O	783-787
,	O	787-788
mitochondrial	O	789-802
permeability	O	803-815
transition	O	816-826
(	O	827-828
MPT	O	828-831
)	O	831-832
,	O	832-833
and	O	834-837
Na	O	838-840
+	O	840-841
-	O	841-842
K	O	842-843
+	O	840-841
ATPase	O	845-851
activity	O	852-860
in	O	861-863
vivo	O	864-868
.	O	868-869

We	O	870-872
also	O	873-877
assessed	O	878-886
cell	O	887-891
viability	O	892-901
,	O	901-902
mitochondrial	O	903-916
membrane	O	917-925
potential	O	926-935
changes	O	936-943
and	O	944-947
counted	O	948-955
autophagic	O	956-966
vacuoles	O	967-975
in	O	976-978
cultured	O	979-987
cardiomyocytes	O	988-1002
.	O	1002-1003

In	O	1004-1006
addition	O	1007-1015
,	O	1015-1016
we	O	1017-1019
analyzed	O	1020-1028
the	O	1029-1032
expression	O	1033-1043
of	O	1044-1046
autophagy	O	1047-1056
associated	O	1057-1067
gene	O	1068-1072
,	O	1072-1073
beclin	O	1074-1080
1	O	1081-1082
using	O	1083-1088
RT	O	1089-1091
-	O	1091-1092
PCR	O	1092-1095
and	O	1096-1099
Western	O	1100-1107
blotting	O	1108-1116
in	O	1117-1119
an	O	1120-1122
animal	O	1123-1129
model	O	1130-1135
.	O	1135-1136

RESULTS	O	1137-1144
:	O	1144-1145
3MA	O	1146-1149
significantly	O	1150-1163
improved	O	1164-1172
cardiac	O	1173-1180
function	O	1181-1189
and	O	1190-1193
reduced	O	1194-1201
mitochondrial	O	1202-1215
injury	O	1216-1222
.	O	1222-1223

Furthermore	O	1224-1235
,	O	1235-1236
adriamycin	O	1237-1247
induced	O	1248-1255
the	O	1256-1259
formation	O	1260-1269
of	O	1270-1272
autophagic	O	1273-1283
vacuoles	O	1284-1292
,	O	1292-1293
and	O	1294-1297
3MA	O	1298-1301
strongly	O	1302-1310
downregulated	O	1311-1324
the	O	1325-1328
expression	O	1329-1339
of	O	1340-1342
beclin	O	1343-1349
1	O	1350-1351
in	O	1352-1354
adriamycin	O	1355-1365
-	O	1365-1366
induced	O	1366-1373
failing	O	1374-1381
heart	O	1382-1387
and	O	1388-1391
inhibited	O	1392-1401
the	O	1402-1405
formation	O	1406-1415
of	O	1416-1418
autophagic	O	1419-1429
vacuoles	O	1430-1438
.	O	1438-1439

CONCLUSION	O	1440-1450
:	O	1450-1451
Autophagic	O	1452-1462
cardiomyocyte	O	1463-1476
death	B	1477-1482
plays	O	1483-1488
an	O	1489-1491
important	O	1492-1501
role	O	1502-1506
in	O	1507-1509
the	O	1510-1513
pathogenesis	O	1514-1526
of	O	1527-1529
heart	B	1530-1535
failure	I	1536-1543
in	O	1544-1546
rats	O	1547-1551
induced	O	1552-1559
by	O	1560-1562
adriamycin	O	1563-1573
.	O	1573-1574

Mitochondrial	O	1575-1588
injury	O	1589-1595
may	O	1596-1599
be	O	1600-1602
involved	O	1603-1611
in	O	1612-1614
the	O	1615-1618
progression	O	1619-1630
of	O	1631-1633
heart	B	1634-1639
failure	I	1640-1647
caused	O	1648-1654
by	O	1655-1657
adriamycin	O	1658-1668
via	O	1669-1672
the	O	1673-1676
autophagy	O	1677-1686
pathway	O	1687-1694
.	O	1694-1695

Confusion	B	0-9
,	O	9-10
a	O	11-12
rather	O	13-19
serious	O	20-27
adverse	O	28-35
drug	O	36-40
reaction	O	41-49
with	O	50-54
valproic	O	55-63
acid	O	64-68
:	O	68-69
a	O	70-71
review	O	72-78
of	O	79-81
the	O	82-85
French	O	86-92
Pharmacovigilance	O	93-110
database	O	111-119
.	O	119-120

INTRODUCTION	O	121-133
:	O	133-134
Confusion	B	135-144
is	O	145-147
an	O	148-150
adverse	O	151-158
drug	O	159-163
reaction	O	164-172
frequently	O	173-183
observed	O	184-192
with	O	193-197
valproic	O	198-206
acid	O	207-211
.	O	211-212

Some	O	213-217
case	O	218-222
reports	O	223-230
are	O	231-234
published	O	235-244
in	O	245-247
the	O	248-251
literature	O	252-262
but	O	263-266
no	O	267-269
systematic	O	270-280
study	O	281-286
from	O	287-291
a	O	292-293
sample	O	294-300
of	O	301-303
patients	O	304-312
has	O	313-316
been	O	317-321
published	O	322-331
.	O	331-332

We	O	333-335
performed	O	336-345
this	O	346-350
study	O	351-356
in	O	357-359
order	O	360-365
to	O	366-368
describe	O	369-377
the	O	378-381
main	O	382-386
characteristics	O	387-402
of	O	403-405
this	O	406-410
adverse	O	411-418
drug	O	419-423
reaction	O	424-432
.	O	432-433

METHODS	O	434-441
:	O	441-442
Using	O	443-448
the	O	449-452
French	O	453-459
Pharmacovigilance	O	460-477
database	O	478-486
,	O	486-487
we	O	488-490
selected	O	491-499
the	O	500-503
cases	O	504-509
of	O	510-512
confusion	B	513-522
reported	O	523-531
since	O	532-537
1985	O	538-542
with	O	543-547
valproic	O	548-556
acid	O	557-561
.	O	561-562

RESULTS	O	563-570
:	O	570-571
272	O	572-575
cases	O	576-581
of	O	582-584
confusion	B	585-594
were	O	595-599
reported	O	600-608
with	O	609-613
valproic	O	614-622
acid	O	623-627
:	O	627-628
153	O	629-632
women	O	633-638
and	O	639-642
119	O	643-646
men	O	647-650
.	O	650-651

Confusion	B	652-661
mostly	O	662-668
occurred	O	669-677
during	O	678-684
the	O	685-688
two	O	689-692
first	O	693-698
weeks	O	699-704
following	O	705-714
valproic	O	715-723
acid	O	724-728
exposure	O	729-737
(	O	738-739
39	O	739-741
.	O	741-742
7	O	742-743
%	O	743-744
)	O	744-745
.	O	741-742

It	O	747-749
was	O	750-753
"	O	754-755
serious	O	755-762
"	O	754-755
for	O	764-767
almost	O	768-774
2	O	775-776
/	O	776-777
3	O	777-778
of	O	779-781
the	O	782-785
patients	O	786-794
(	O	795-796
62	O	796-798
.	O	798-799
5	O	799-800
%	O	800-801
)	O	801-802
and	O	803-806
its	O	807-810
outcome	O	811-818
favourable	O	819-829
in	O	830-832
most	O	833-837
of	O	838-840
the	O	841-844
cases	O	845-850
(	O	851-852
82	O	852-854
%	O	854-855
)	O	855-856
.	O	856-857

The	O	858-861
occurrence	O	862-872
of	O	873-875
this	O	876-880
ADR	O	881-884
was	O	885-888
more	O	889-893
frequent	O	894-902
in	O	903-905
patients	O	906-914
aged	O	915-919
between	O	920-927
61	O	928-930
and	O	931-934
80	O	935-937
years	O	938-943
.	O	943-944

CONCLUSION	O	945-955
:	O	955-956
This	O	957-961
work	O	962-966
shows	O	967-972
that	O	973-977
confusion	B	978-987
with	O	988-992
valproic	O	993-1001
acid	O	1002-1006
is	O	1007-1009
a	O	1010-1011
serious	O	1012-1019
,	O	1019-1020
rather	O	1021-1027
frequent	O	1028-1036
but	O	1037-1040
reversible	O	1041-1051
adverse	O	1052-1059
drug	O	1060-1064
reaction	O	1065-1073
.	O	1073-1074

It	O	1075-1077
occurs	O	1078-1084
especially	O	1085-1095
in	O	1096-1098
older	O	1099-1104
patients	O	1105-1113
and	O	1114-1117
during	O	1118-1124
the	O	1125-1128
first	O	1129-1134
two	O	1135-1138
weeks	O	1139-1144
of	O	1145-1147
treatment	O	1148-1157
.	O	1157-1158

Learning	B	0-8
and	I	9-12
memory	I	13-19
deficits	I	20-28
in	O	29-31
ecstasy	O	32-39
users	O	40-45
and	O	46-49
their	O	50-55
neural	O	56-62
correlates	O	63-73
during	O	74-80
a	O	81-82
face	O	83-87
-	O	87-88
learning	O	88-96
task	O	97-101
.	O	101-102

It	O	103-105
has	O	106-109
been	O	110-114
consistently	O	115-127
shown	O	128-133
that	O	134-138
ecstasy	O	139-146
users	O	147-152
display	O	153-160
impairments	B	161-172
in	I	173-175
learning	I	176-184
and	I	185-188
memory	I	189-195
performance	O	196-207
.	O	207-208

In	O	209-211
addition	O	212-220
,	O	220-221
working	O	222-229
memory	O	230-236
processing	O	237-247
in	O	248-250
ecstasy	O	251-258
users	O	259-264
has	O	265-268
been	O	269-273
shown	O	274-279
to	O	280-282
be	O	283-285
associated	O	286-296
with	O	297-301
neural	O	302-308
alterations	O	309-320
in	O	321-323
hippocampal	O	324-335
and	O	336-339
/	O	339-340
or	O	340-342
cortical	O	343-351
regions	O	352-359
as	O	360-362
measured	O	363-371
by	O	372-374
functional	O	375-385
magnetic	O	386-394
resonance	O	395-404
imaging	O	405-412
(	O	413-414
fMRI	O	414-418
)	O	418-419
.	O	419-420

Using	O	421-426
functional	O	427-437
imaging	O	438-445
and	O	446-449
a	O	450-451
face	O	452-456
-	O	456-457
learning	O	457-465
task	O	466-470
,	O	470-471
we	O	472-474
investigated	O	475-487
neural	O	488-494
correlates	O	495-505
of	O	506-508
encoding	O	509-517
and	O	518-521
recalling	O	522-531
face	O	532-536
-	O	536-537
name	O	537-541
associations	O	542-554
in	O	555-557
20	O	558-560
recreational	O	561-573
drug	O	574-578
users	O	579-584
whose	O	585-590
predominant	O	591-602
drug	O	603-607
use	O	608-611
was	O	612-615
ecstasy	O	616-623
and	O	624-627
20	O	628-630
controls	O	631-639
.	O	639-640

To	O	641-643
address	O	644-651
the	O	652-655
potential	O	656-665
confounding	O	666-677
effects	O	678-685
of	O	686-688
the	O	689-692
cannabis	O	693-701
use	O	702-705
of	O	706-708
the	O	709-712
ecstasy	O	713-720
using	O	721-726
group	O	727-732
,	O	732-733
a	O	734-735
second	O	736-742
analysis	O	743-751
included	O	752-760
14	O	761-763
previously	O	764-774
tested	O	775-781
cannabis	O	782-790
users	O	791-796
(	O	797-798
Nestor	O	798-804
,	O	804-805
L	O	806-807
.	O	807-808
,	O	808-809
Roberts	O	810-817
,	O	817-818
G	O	819-820
.	O	820-821
,	O	821-822
Garavan	O	823-830
,	O	830-831
H	O	832-833
.	O	833-834
,	O	834-835
Hester	O	836-842
,	O	842-843
R	O	844-845
.	O	845-846
,	O	846-847
2008	O	848-852
.	O	852-853

Deficits	B	854-862
in	I	863-865
learning	I	866-874
and	I	875-878
memory	I	879-885
:	O	885-886
parahippocampal	O	887-902
hyperactivity	B	903-916
and	O	917-920
frontocortical	O	921-935
hypoactivity	O	936-948
in	O	949-951
cannabis	O	952-960
users	O	961-966
.	O	966-967

Neuroimage	O	968-978
40	O	979-981
,	O	981-982
1328	O	983-987
-	O	987-988
1339	O	988-992
)	O	992-993
.	O	993-994

Ecstasy	O	995-1002
users	O	1003-1008
performed	O	1009-1018
significantly	O	1019-1032
worse	O	1033-1038
in	O	1039-1041
learning	O	1042-1050
and	O	1051-1054
memory	O	1055-1061
compared	O	1062-1070
to	O	1071-1073
controls	O	1074-1082
and	O	1083-1086
cannabis	O	1087-1095
users	O	1096-1101
.	O	1101-1102

A	O	1103-1104
conjunction	O	1105-1116
analysis	O	1117-1125
of	O	1126-1128
the	O	1129-1132
encode	O	1133-1139
and	O	1140-1143
recall	O	1144-1150
phases	O	1151-1157
of	O	1158-1160
the	O	1161-1164
task	O	1165-1169
revealed	O	1170-1178
ecstasy	O	1179-1186
-	O	1186-1187
specific	O	1187-1195
hyperactivity	B	1196-1209
in	O	1210-1212
bilateral	O	1213-1222
frontal	O	1223-1230
regions	O	1231-1238
,	O	1238-1239
left	O	1240-1244
temporal	O	1245-1253
,	O	1253-1254
right	O	1255-1260
parietal	O	1261-1269
,	O	1269-1270
bilateral	O	1271-1280
temporal	O	1281-1289
,	O	1289-1290
and	O	1291-1294
bilateral	O	1295-1304
occipital	O	1305-1314
brain	O	1315-1320
regions	O	1321-1328
.	O	1328-1329

Ecstasy	O	1330-1337
-	O	1337-1338
specific	O	1338-1346
hypoactivity	O	1347-1359
was	O	1360-1363
evident	O	1364-1371
in	O	1372-1374
the	O	1375-1378
right	O	1379-1384
dorsal	O	1385-1391
anterior	O	1392-1400
cingulated	O	1401-1411
cortex	O	1412-1418
(	O	1419-1420
ACC	O	1420-1423
)	O	1423-1424
and	O	1425-1428
left	O	1429-1433
posterior	O	1434-1443
cingulated	O	1444-1454
cortex	O	1455-1461
.	O	1461-1462

In	O	1463-1465
both	O	1466-1470
ecstasy	O	1471-1478
and	O	1479-1482
cannabis	O	1483-1491
groups	O	1492-1498
brain	O	1499-1504
activation	O	1505-1515
was	O	1516-1519
decreased	O	1520-1529
in	O	1530-1532
the	O	1533-1536
right	O	1537-1542
medial	O	1543-1549
frontal	O	1550-1557
gyrus	O	1558-1563
,	O	1563-1564
left	O	1565-1569
parahippocampal	O	1570-1585
gyrus	O	1586-1591
,	O	1591-1592
left	O	1593-1597
dorsal	O	1598-1604
cingulate	O	1605-1614
gyrus	O	1615-1620
,	O	1620-1621
and	O	1622-1625
left	O	1626-1630
caudate	O	1631-1638
.	O	1638-1639

These	O	1640-1645
results	O	1646-1653
elucidated	O	1654-1664
ecstasy	O	1665-1672
-	O	1672-1673
related	O	1673-1680
deficits	O	1681-1689
,	O	1689-1690
only	O	1691-1695
some	O	1696-1700
of	O	1701-1703
which	O	1704-1709
might	O	1710-1715
be	O	1716-1718
attributed	O	1719-1729
to	O	1730-1732
cannabis	O	1733-1741
use	O	1742-1745
.	O	1745-1746

These	O	1747-1752
ecstasy	O	1753-1760
-	O	1760-1761
specific	O	1761-1769
effects	O	1770-1777
may	O	1778-1781
be	O	1782-1784
related	O	1785-1792
to	O	1793-1795
the	O	1796-1799
vulnerability	O	1800-1813
of	O	1814-1816
isocortical	O	1817-1828
and	O	1829-1832
allocortical	O	1833-1845
regions	O	1846-1853
to	O	1854-1856
the	O	1857-1860
neurotoxic	B	1861-1871
effects	O	1872-1879
of	O	1880-1882
ecstasy	O	1883-1890
.	O	1890-1891

Prolonged	O	0-9
elevation	O	10-19
of	O	20-22
plasma	O	23-29
argatroban	O	30-40
in	O	41-43
a	O	44-45
cardiac	O	46-53
transplant	O	54-64
patient	O	65-72
with	O	73-77
a	O	78-79
suspected	O	80-89
history	O	90-97
of	O	98-100
heparin	O	101-108
-	O	108-109
induced	O	109-116
thrombocytopenia	B	117-133
with	O	134-138
thrombosis	B	139-149
.	O	149-150

BACKGROUND	O	151-161
:	O	161-162
Direct	O	163-169
thrombin	O	170-178
inhibitors	O	179-189
(	O	190-191
DTIs	O	191-195
)	O	195-196
provide	O	197-204
an	O	205-207
alternative	O	208-219
method	O	220-226
of	O	227-229
anticoagulation	O	230-245
for	O	246-249
patients	O	250-258
with	O	259-263
a	O	264-265
history	O	266-273
of	O	274-276
heparin	O	277-284
-	O	284-285
induced	O	285-292
thrombocytopenia	B	293-309
(	O	310-311
HIT	B	311-314
)	O	314-315
or	O	316-318
HIT	B	319-322
with	O	323-327
thrombosis	B	328-338
(	O	339-340
HITT	B	340-344
)	O	344-345
undergoing	O	346-356
cardiopulmonary	O	357-372
bypass	O	373-379
(	O	380-381
CPB	O	381-384
)	O	384-385
.	O	385-386

In	O	387-389
the	O	390-393
following	O	394-403
report	O	404-410
,	O	410-411
a	O	412-413
65	O	414-416
-	O	416-417
year	O	417-421
-	O	416-417
old	O	422-425
critically	B	426-436
ill	I	437-440
patient	O	441-448
with	O	449-453
a	O	454-455
suspected	O	456-465
history	O	466-473
of	O	474-476
HITT	B	477-481
was	O	482-485
administered	O	486-498
argatroban	O	499-509
for	O	510-513
anticoagulation	O	514-529
on	O	530-532
bypass	O	533-539
during	O	540-546
heart	O	547-552
transplantation	O	553-568
.	O	568-569

The	O	570-573
patient	O	574-581
required	O	582-590
massive	O	591-598
transfusion	O	599-610
support	O	611-618
(	O	619-620
55	O	620-622
units	O	623-628
of	O	629-631
red	O	632-635
blood	O	636-641
cells	O	642-647
,	O	647-648
42	O	649-651
units	O	652-657
of	O	658-660
fresh	O	661-666
-	O	666-667
frozen	O	667-673
plasma	O	674-680
,	O	680-681
40	O	682-684
units	O	685-690
of	O	691-693
cryoprecipitate	O	694-709
,	O	709-710
40	O	711-713
units	O	714-719
of	O	720-722
platelets	O	723-732
,	O	732-733
and	O	734-737
three	O	738-743
doses	O	744-749
of	O	750-752
recombinant	O	753-764
Factor	O	765-771
VIIa	O	772-776
)	O	776-777
for	O	778-781
severe	O	782-788
intraoperative	B	789-803
and	I	804-807
postoperative	I	808-821
bleeding	I	822-830
.	O	830-831

STUDY	O	832-837
DESIGN	O	838-844
AND	O	845-848
METHODS	O	849-856
:	O	856-857
Plasma	O	858-864
samples	O	865-872
from	O	873-877
before	O	878-884
and	O	885-888
after	O	889-894
CPB	O	895-898
were	O	899-903
analyzed	O	904-912
postoperatively	O	913-928
for	O	929-932
argatroban	O	933-943
concentration	O	944-957
using	O	958-963
a	O	964-965
modified	O	966-974
ecarin	O	975-981
clotting	O	982-990
time	O	991-995
(	O	996-997
ECT	O	997-1000
)	O	1000-1001
assay	O	1002-1007
.	O	1007-1008

RESULTS	O	1009-1016
:	O	1016-1017
Unexpectedly	O	1018-1030
high	O	1031-1035
concentrations	O	1036-1050
of	O	1051-1053
argatroban	O	1054-1064
were	O	1065-1069
measured	O	1070-1078
in	O	1079-1081
these	O	1082-1087
samples	O	1088-1095
(	O	1096-1097
range	O	1097-1102
,	O	1102-1103
0	O	1104-1105
-	O	1105-1106
32	O	1106-1108
microg	O	1109-1115
/	O	1115-1116
mL	O	1116-1118
)	O	1118-1119
,	O	1119-1120
and	O	1121-1124
a	O	1125-1126
prolonged	O	1127-1136
plasma	O	1137-1143
argatroban	O	1144-1154
half	O	1155-1159
life	O	1160-1164
(	O	1165-1166
t	O	1166-1167
(	O	1165-1166
1	O	1168-1169
/	O	1169-1170
2	O	1170-1171
)	O	1171-1172
)	O	1171-1172
of	O	1174-1176
514	O	1177-1180
minutes	O	1181-1188
was	O	1189-1192
observed	O	1193-1201
(	O	1202-1203
published	O	1203-1212
elimination	O	1213-1224
t	O	1225-1226
(	O	1226-1227
1	O	1227-1228
/	O	1228-1229
2	O	1229-1230
)	O	1230-1231
is	O	1232-1234
39	O	1235-1237
-	O	1237-1238
51	O	1238-1240
minutes	O	1241-1248
[	O	1249-1250
<	O	1250-1251
or	O	1252-1254
=	O	1255-1256
181	O	1257-1260
minutes	O	1261-1268
with	O	1269-1273
hepatic	B	1274-1281
impairment	I	1282-1292
]	O	1292-1293
)	O	1293-1294
.	O	1294-1295

CONCLUSIONS	O	1296-1307
:	O	1307-1308
Correlation	O	1309-1320
of	O	1321-1323
plasma	O	1324-1330
argatroban	O	1331-1341
concentration	O	1342-1355
versus	O	1356-1362
the	O	1363-1366
patient	O	1367-1374
'	O	1374-1375
s	O	1375-1376
coagulation	O	1377-1388
variables	O	1389-1398
and	O	1399-1402
clinical	O	1403-1411
course	O	1412-1418
suggest	O	1419-1426
that	O	1427-1431
prolonged	O	1432-1441
elevated	O	1442-1450
levels	O	1451-1457
of	O	1458-1460
plasma	O	1461-1467
argatroban	O	1468-1478
may	O	1479-1482
have	O	1483-1487
contributed	O	1488-1499
to	O	1500-1502
the	O	1503-1506
patient	O	1507-1514
'	O	1514-1515
s	O	1515-1516
extended	O	1517-1525
coagulopathy	B	1526-1538
.	O	1538-1539

Because	O	1540-1547
DTIs	O	1548-1552
do	O	1553-1555
not	O	1556-1559
have	O	1560-1564
reversal	O	1565-1573
agents	O	1574-1580
,	O	1580-1581
surgical	O	1582-1590
teams	O	1591-1596
and	O	1597-1600
transfusion	O	1601-1612
services	O	1613-1621
should	O	1622-1628
remain	O	1629-1635
aware	O	1636-1641
of	O	1642-1644
the	O	1645-1648
possibility	O	1649-1660
of	O	1661-1663
massive	O	1664-1671
transfusion	O	1672-1683
events	O	1684-1690
during	O	1691-1697
anticoagulation	O	1698-1713
with	O	1714-1718
these	O	1719-1724
agents	O	1725-1731
.	O	1731-1732

This	O	1733-1737
is	O	1738-1740
the	O	1741-1744
first	O	1745-1750
report	O	1751-1757
to	O	1758-1760
measure	O	1761-1768
plasma	O	1769-1775
argatroban	O	1776-1786
concentration	O	1787-1800
in	O	1801-1803
the	O	1804-1807
context	O	1808-1815
of	O	1816-1818
CPB	O	1819-1822
and	O	1823-1826
extended	O	1827-1835
coagulopathy	B	1836-1848
.	O	1848-1849

Antituberculosis	O	0-16
therapy	O	17-24
-	O	24-25
induced	O	25-32
acute	B	33-38
liver	I	39-44
failure	I	45-52
:	O	52-53
magnitude	O	54-63
,	O	63-64
profile	O	65-72
,	O	72-73
prognosis	O	74-83
,	O	83-84
and	O	85-88
predictors	O	89-99
of	O	100-102
outcome	O	103-110
.	O	110-111

Antituberculosis	O	112-128
therapy	O	129-136
(	O	137-138
ATT	O	138-141
)	O	141-142
-	O	142-143
associated	O	143-153
acute	B	154-159
liver	I	160-165
failure	I	166-173
(	O	174-175
ATT	O	175-178
-	O	178-179
ALF	B	179-182
)	O	182-183
is	O	184-186
the	O	187-190
commonest	O	191-200
drug	O	201-205
-	O	205-206
induced	O	206-213
ALF	B	214-217
in	O	218-220
South	O	221-226
Asia	O	227-231
.	O	231-232

Prospective	O	233-244
studies	O	245-252
on	O	253-255
ATT	O	256-259
-	O	259-260
ALF	B	260-263
are	O	264-267
lacking	O	268-275
.	O	275-276

The	O	277-280
current	O	281-288
study	O	289-294
prospectively	O	295-308
evaluated	O	309-318
the	O	319-322
magnitude	O	323-332
,	O	332-333
clinical	O	334-342
course	O	343-349
,	O	349-350
outcome	O	351-358
,	O	358-359
and	O	360-363
prognostic	O	364-374
factors	O	375-382
in	O	383-385
ATT	O	386-389
-	O	389-390
ALF	B	390-393
.	O	393-394

From	O	395-399
January	O	400-407
1986	O	408-412
to	O	413-415
January	O	416-423
2009	O	424-428
,	O	428-429
1223	O	430-434
consecutive	O	435-446
ALF	B	447-450
patients	O	451-459
were	O	460-464
evaluated	O	465-474
:	O	474-475
ATT	O	476-479
alone	O	480-485
was	O	486-489
the	O	490-493
cause	O	494-499
in	O	500-502
70	O	503-505
(	O	506-507
5	O	507-508
.	O	508-509
7	O	509-510
%	O	510-511
)	O	511-512

patients	O	513-521
.	O	521-522

Another	O	523-530
15	O	531-533
(	O	534-535
1	O	535-536
.	O	536-537
2	O	537-538
%	O	538-539
)	O	539-540
had	O	541-544
ATT	O	545-548
and	O	549-552
simultaneous	O	553-565
hepatitis	B	566-575
virus	I	576-581
infection	I	582-591
.	O	591-592

In	O	593-595
44	O	596-598
(	O	599-600
62	O	600-602
.	O	602-603
8	O	603-604
%	O	604-605
)	O	605-606
patients	O	607-615
,	O	615-616
ATT	O	617-620
was	O	621-624
prescribed	O	625-635
empirically	O	636-647
without	O	648-655
definitive	O	656-666
evidence	O	667-675
of	O	676-678
tuberculosis	B	679-691
.	O	691-692

ATT	O	693-696
-	O	696-697
ALF	B	697-700
patients	O	701-709
were	O	710-714
younger	O	715-722
(	O	723-724
32	O	724-726
.	O	726-727
87	O	727-729
[	O	730-731
+	O	731-732
/	O	732-733
-	O	733-734
15	O	734-736
.	O	736-737
8	O	737-738
]	O	738-739

years	O	740-745
)	O	745-746
,	O	746-747
and	O	748-751
49	O	752-754
(	O	755-756
70	O	756-758
%	O	758-759
)	O	759-760
of	O	761-763
them	O	764-768
were	O	769-773
women	O	774-779
.	O	779-780

Most	O	781-785
had	O	786-789
hyperacute	O	790-800
presentation	O	801-813
;	O	813-814
the	O	815-818
median	O	819-825
icterus	B	826-833
encephalopathy	B	834-848
interval	O	849-857
was	O	858-861
4	O	862-863
.	O	863-864
5	O	864-865
(	O	866-867
0	O	867-868
-	O	868-869
30	O	869-871
)	O	871-872
days	O	873-877
.	O	877-878

The	O	879-882
median	O	883-889
duration	O	890-898
of	O	899-901
ATT	O	902-905
before	O	906-912
ALF	B	913-916
was	O	917-920
30	O	921-923
(	O	924-925
7	O	925-926
-	O	926-927
350	O	927-930
)	O	930-931
days	O	932-936
.	O	936-937

At	O	938-940
presentation	O	941-953
,	O	953-954
advanced	O	955-963
encephalopathy	B	964-978
and	O	979-982
cerebral	B	983-991
edema	I	992-997
were	O	998-1002
present	O	1003-1010
in	O	1011-1013
51	O	1014-1016
(	O	1017-1018
76	O	1018-1020
%	O	1020-1021
)	O	1021-1022
and	O	1023-1026
29	O	1027-1029
(	O	1030-1031
41	O	1031-1033
.	O	1033-1034
4	O	1031-1032
%	O	1035-1036
)	O	1036-1037

patients	O	1038-1046
,	O	1046-1047
respectively	O	1048-1060
.	O	1060-1061

Gastrointestinal	B	1062-1078
bleed	I	1079-1084
,	O	1084-1085
seizures	B	1086-1094
,	O	1094-1095
infection	B	1096-1105
,	O	1105-1106
and	O	1107-1110
acute	B	1111-1116
renal	I	1117-1122
failure	I	1123-1130
were	O	1131-1135
documented	O	1136-1146
in	O	1147-1149
seven	O	1150-1155
(	O	1156-1157
10	O	1157-1159
%	O	1159-1160
)	O	1160-1161
,	O	1161-1162
five	O	1163-1167
(	O	1168-1169
7	O	1169-1170
.	O	1170-1171
1	O	1171-1172
%	O	1172-1173
)	O	1173-1174
,	O	1174-1175
26	O	1176-1178
(	O	1179-1180
37	O	1180-1182
.	O	1182-1183
1	O	1183-1184
%	O	1184-1185
)	O	1185-1186
,	O	1186-1187
and	O	1188-1191
seven	O	1192-1197
(	O	1198-1199
10	O	1199-1201
%	O	1201-1202
)	O	1202-1203
patients	O	1204-1212
,	O	1212-1213
respectively	O	1214-1226
.	O	1226-1227

Compared	O	1228-1236
with	O	1237-1241
hepatitis	B	1242-1251
E	I	1252-1253
virus	O	1254-1259
(	O	1260-1261
HEV	O	1261-1264
)	O	1264-1265
and	O	1266-1269
non	O	1270-1273
-	O	1273-1274
A	O	1274-1275
non	O	1276-1279
-	O	1279-1280
E	O	1280-1281
-	O	1279-1280
induced	O	1282-1289
ALF	B	1290-1293
,	O	1293-1294
ATT	O	1295-1298
-	O	1298-1299
ALF	B	1299-1302
patients	O	1303-1311
had	O	1312-1315
nearly	O	1316-1322
similar	O	1323-1330
presentations	O	1331-1344
except	O	1345-1351
for	O	1352-1355
older	O	1356-1361
age	O	1362-1365
and	O	1366-1369
less	O	1370-1374
elevation	O	1375-1384
of	O	1385-1387
liver	O	1388-1393
enzymes	O	1394-1401
.	O	1401-1402

The	O	1403-1406
mortality	O	1407-1416
rate	O	1417-1421
among	O	1422-1427
patients	O	1428-1436
with	O	1437-1441
ATT	O	1442-1445
-	O	1445-1446
ALF	B	1446-1449
was	O	1450-1453
high	O	1454-1458
(	O	1459-1460
67	O	1460-1462
.	O	1462-1463
1	O	1463-1464
%	O	1464-1465
,	O	1465-1466

n	O	1467-1468
=	O	1469-1470
47	O	1471-1473
)	O	1473-1474
,	O	1474-1475
and	O	1476-1479
only	O	1480-1484
23	O	1485-1487
(	O	1488-1489
32	O	1489-1491
.	O	1491-1492
9	O	1492-1493
%	O	1493-1494
)	O	1494-1495
patients	O	1496-1504
recovered	O	1505-1514
with	O	1515-1519
medical	O	1520-1527
treatment	O	1528-1537
.	O	1537-1538

In	O	1539-1541
multivariate	O	1542-1554
analysis	O	1555-1563
,	O	1563-1564
three	O	1565-1570
factors	O	1571-1578
independently	O	1579-1592
predicted	O	1593-1602
mortality	O	1603-1612
:	O	1612-1613
serum	O	1614-1619
bilirubin	O	1620-1629
(	O	1630-1631
>	O	1631-1632
or	O	1632-1634
=	O	1634-1635
10	O	1635-1637
.	O	1637-1638
8	O	1638-1639

mg	O	1640-1642
/	O	1642-1643
dL	O	1643-1645
)	O	1645-1646
,	O	1646-1647
prothrombin	O	1648-1659
time	O	1660-1664
(	O	1665-1666
PT	O	1666-1668
)	O	1668-1669
prolongation	O	1670-1682
(	O	1683-1684
>	O	1684-1685
or	O	1685-1687
=	O	1687-1688
26	O	1688-1690
seconds	O	1691-1698
)	O	1698-1699
,	O	1699-1700
and	O	1701-1704
grade	O	1705-1710
III	O	1711-1714
/	O	1714-1715
IV	O	1715-1717
encephalopathy	B	1718-1732
at	O	1733-1735
presentation	O	1736-1748
.	O	1748-1749

CONCLUSION	O	1750-1760
:	O	1760-1761
ATT	O	1762-1765
-	O	1765-1766
ALF	B	1766-1769
constituted	O	1770-1781
5	O	1782-1783
.	O	1783-1784
7	O	1784-1785
%	O	1785-1786
of	O	1787-1789
ALF	B	1790-1793
at	O	1794-1796
our	O	1797-1800
center	O	1801-1807
and	O	1808-1811
had	O	1812-1815
a	O	1816-1817
high	O	1818-1822
mortality	O	1823-1832
rate	O	1833-1837
.	O	1837-1838

Because	O	1839-1846
the	O	1847-1850
mortality	O	1851-1860
rate	O	1861-1865
is	O	1866-1868
so	O	1869-1871
high	O	1872-1876
,	O	1876-1877
determining	O	1878-1889
which	O	1890-1895
factors	O	1896-1903
are	O	1904-1907
predictors	O	1908-1918
is	O	1919-1921
less	O	1922-1926
important	O	1927-1936
.	O	1936-1937

A	O	1938-1939
high	O	1940-1944
proportion	O	1945-1955
of	O	1956-1958
patients	O	1959-1967
had	O	1968-1971
consumed	O	1972-1980
ATT	O	1981-1984
empirically	O	1985-1996
,	O	1996-1997
which	O	1998-2003
could	O	2004-2009
have	O	2010-2014
been	O	2015-2019
prevented	O	2020-2029
.	O	2029-2030

Central	B	0-7
nervous	I	8-15
system	I	16-22
complications	I	23-36
during	O	37-43
treatment	O	44-53
of	O	54-56
acute	B	57-62
lymphoblastic	I	63-76
leukemia	I	77-85
in	O	86-88
a	O	89-90
single	O	91-97
pediatric	O	98-107
institution	O	108-119
.	O	119-120

Central	B	121-128
nervous	I	129-136
system	I	137-143
(	I	144-145
CNS	I	145-148
)	I	148-149
complications	I	150-163
during	O	164-170
treatment	O	171-180
of	O	181-183
childhood	O	184-193
acute	B	194-199
lymphoblastic	I	200-213
leukemia	I	214-222
(	O	223-224
ALL	B	224-227
)	O	227-228
remain	O	229-235
a	O	236-237
challenging	O	238-249
clinical	O	250-258
problem	O	259-266
.	O	266-267

Outcome	O	268-275
improvement	O	276-287
with	O	288-292
more	O	293-297
intensive	O	298-307
chemotherapy	O	308-320
has	O	321-324
significantly	O	325-338
increased	O	339-348
the	O	349-352
incidence	O	353-362
and	O	363-366
severity	O	367-375
of	O	376-378
adverse	O	379-386
events	O	387-393
.	O	393-394

This	O	395-399
study	O	400-405
analyzed	O	406-414
the	O	415-418
incidence	O	419-428
of	O	429-431
neurological	B	432-444
complications	I	445-458
during	O	459-465
ALL	B	466-469
treatment	O	470-479
in	O	480-482
a	O	483-484
single	O	485-491
pediatric	O	492-501
institution	O	502-513
,	O	513-514
focusing	O	515-523
on	O	524-526
clinical	O	527-535
,	O	535-536
radiological	O	537-549
,	O	549-550
and	O	551-554
electrophysiological	O	555-575
findings	O	576-584
.	O	584-585

Exclusion	O	586-595
criteria	O	596-604
included	O	605-613
CNS	O	614-617
leukemic	B	618-626
infiltration	I	627-639
at	O	640-642
diagnosis	O	643-652
,	O	652-653
therapy	O	654-661
-	O	661-662
related	O	662-669
peripheral	B	670-680
neuropathy	I	681-691
,	O	691-692
late	O	693-697
-	O	697-698
onset	O	698-703
encephalopathy	B	704-718
,	O	718-719
or	O	720-722
long	O	723-727
-	O	727-728
term	O	728-732
neurocognitive	B	733-747
defects	I	748-755
.	O	755-756

During	O	757-763
a	O	764-765
9	O	766-767
-	O	767-768
year	O	768-772
period	O	773-779
,	O	779-780
we	O	781-783
retrospectively	O	784-799
collected	O	800-809
27	O	810-812
neurological	O	813-825
events	O	826-832
(	O	833-834
11	O	834-836
%	O	836-837
)	O	837-838
in	O	839-841
as	O	842-844
many	O	845-849
patients	O	850-858
,	O	858-859
from	O	860-864
253	O	865-868
children	O	869-877
enrolled	O	878-886
in	O	887-889
the	O	890-893
ALL	B	894-897
front	O	898-903
-	O	903-904
line	O	904-908
protocol	O	909-917
.	O	917-918

CNS	O	919-922
complications	O	923-936
included	O	937-945
posterior	O	946-955
reversible	O	956-966
leukoencephalopathy	B	967-986
syndrome	O	987-995
(	O	996-997
n	O	997-998
=	O	999-1000
10	O	1001-1003
)	O	1003-1004
,	O	1004-1005
stroke	B	1006-1012
(	O	1013-1014
n	O	1014-1015
=	O	1016-1017
5	O	1018-1019
)	O	1019-1020
,	O	1020-1021
temporal	B	1022-1030
lobe	I	1031-1035
epilepsy	I	1036-1044
(	O	1045-1046
n	O	1046-1047
=	O	1048-1049
2	O	1050-1051
)	O	1051-1052
,	O	1052-1053
high	O	1054-1058
-	O	1058-1059
dose	O	1059-1063
methotrexate	O	1064-1076
toxicity	B	1077-1085
(	O	1086-1087
n	O	1087-1088
=	O	1089-1090
2	O	1091-1092
)	O	1092-1093
,	O	1093-1094
syndrome	O	1095-1103
of	O	1104-1106
inappropriate	B	1107-1120
antidiuretic	I	1121-1133
hormone	I	1134-1141
secretion	I	1142-1151
(	O	1152-1153
n	O	1153-1154
=	O	1155-1156
1	O	1157-1158
)	O	1158-1159
,	O	1159-1160
and	O	1161-1164
other	O	1165-1170
unclassified	O	1171-1183
events	O	1184-1190
(	O	1191-1192
n	O	1192-1193
=	O	1194-1195
7	O	1196-1197
)	O	1197-1198
.	O	1198-1199

In	O	1200-1202
conclusion	O	1203-1213
,	O	1213-1214
CNS	O	1215-1218
complications	O	1219-1232
are	O	1233-1236
frequent	O	1237-1245
events	O	1246-1252
during	O	1253-1259
ALL	B	1260-1263
therapy	O	1264-1271
,	O	1271-1272
and	O	1273-1276
require	O	1277-1284
rapid	O	1285-1290
detection	O	1291-1300
and	O	1301-1304
prompt	O	1305-1311
treatment	O	1312-1321
to	O	1322-1324
limit	O	1325-1330
permanent	O	1331-1340
damage	O	1341-1347
.	O	1347-1348

Safety	O	0-6
of	O	7-9
capecitabine	O	10-22
:	O	22-23
a	O	24-25
review	O	26-32
.	O	32-33

IMPORTANCE	O	34-44
OF	O	45-47
THE	O	48-51
FIELD	O	52-57
:	O	57-58
Fluoropyrimidines	O	59-76
,	O	76-77
in	O	78-80
particular	O	81-91
5	O	92-93
-	O	93-94
fluorouracil	O	94-106
(	O	107-108
5	O	108-109
-	O	109-110
FU	O	110-112
)	O	112-113
,	O	113-114
have	O	115-119
been	O	120-124
the	O	125-128
mainstay	O	129-137
of	O	138-140
treatment	O	141-150
for	O	151-154
several	O	155-162
solid	O	163-168
tumors	B	169-175
,	O	175-176
including	O	177-186
colorectal	B	187-197
,	I	197-198
breast	I	199-205
and	I	206-209
head	I	210-214
and	I	215-218
neck	I	219-223
cancers	I	224-231
,	O	231-232
for	O	233-236
>	O	237-238
40	O	239-241
years	O	242-247
.	O	247-248

AREAS	O	249-254
COVERED	O	255-262
IN	O	263-265
THIS	O	266-270
REVIEW	O	271-277
:	O	277-278
This	O	279-283
article	O	284-291
reviews	O	292-299
the	O	300-303
pharmacology	O	304-316
and	O	317-320
efficacy	O	321-329
of	O	330-332
capecitabine	O	333-345
with	O	346-350
a	O	351-352
special	O	353-360
emphasis	O	361-369
on	O	370-372
its	O	373-376
safety	O	377-383
.	O	383-384

WHAT	O	385-389
THE	O	390-393
READER	O	394-400
WILL	O	401-405
GAIN	O	406-410
:	O	410-411
The	O	412-415
reader	O	416-422
will	O	423-427
gain	O	428-432
better	O	433-439
insight	O	440-447
into	O	448-452
the	O	453-456
safety	O	457-463
of	O	464-466
capecitabine	O	467-479
in	O	480-482
special	O	483-490
populations	O	491-502
such	O	503-507
as	O	508-510
patients	O	511-519
with	O	520-524
advanced	O	525-533
age	O	534-537
,	O	537-538
renal	B	539-544
and	I	545-548
kidney	I	549-555
disease	I	556-563
.	O	563-564

We	O	565-567
also	O	568-572
explore	O	573-580
different	O	581-590
dosing	O	591-597
and	O	598-601
schedules	O	602-611
of	O	612-614
capecitabine	O	615-627
administration	O	628-642
.	O	642-643

TAKE	O	644-648
HOME	O	649-653
MESSAGE	O	654-661
:	O	661-662
Capecitabine	O	663-675
is	O	676-678
an	O	679-681
oral	O	682-686
prodrug	O	687-694
of	O	695-697
5	O	698-699
-	O	699-700
FU	O	700-702
and	O	703-706
was	O	707-710
developed	O	711-720
to	O	721-723
fulfill	O	724-731
the	O	732-735
need	O	736-740
for	O	741-744
a	O	745-746
more	O	747-751
convenient	O	752-762
therapy	O	763-770
and	O	771-774
provide	O	775-782
an	O	783-785
improved	O	786-794
safety	O	795-801
/	O	801-802
efficacy	O	802-810
profile	O	811-818
.	O	818-819

It	O	820-822
has	O	823-826
shown	O	827-832
promising	O	833-842
results	O	843-850
alone	O	851-856
or	O	857-859
in	O	860-862
combination	O	863-874
with	O	875-879
other	O	880-885
chemotherapeutic	O	886-902
agents	O	903-909
in	O	910-912
colorectal	B	913-923
,	I	923-924
breast	I	925-931
,	I	931-932
pancreaticobiliary	I	933-951
,	I	951-952
gastric	I	953-960
,	I	960-961
renal	I	962-967
cell	I	968-972
and	I	973-976
head	I	977-981
and	I	982-985
neck	I	986-990
cancers	I	991-998
.	O	998-999

The	O	1000-1003
most	O	1004-1008
commonly	O	1009-1017
reported	O	1018-1026
toxic	O	1027-1032
effects	O	1033-1040
of	O	1041-1043
capecitabine	O	1044-1056
are	O	1057-1060
diarrhea	B	1061-1069
,	O	1069-1070
nausea	B	1071-1077
,	O	1077-1078
vomiting	B	1079-1087
,	O	1087-1088
stomatitis	B	1089-1099
and	O	1100-1103
hand	B	1104-1108
-	I	1108-1109
foot	I	1109-1113
syndrome	I	1114-1122
.	O	1122-1123

Capecitabine	O	1124-1136
has	O	1137-1140
a	O	1141-1142
well	O	1143-1147
-	O	1147-1148
established	O	1148-1159
safety	O	1160-1166
profile	O	1167-1174
and	O	1175-1178
can	O	1179-1182
be	O	1183-1185
given	O	1186-1191
safely	O	1192-1198
to	O	1199-1201
patients	O	1202-1210
with	O	1211-1215
advanced	O	1216-1224
age	O	1225-1228
,	O	1228-1229
hepatic	B	1230-1237
and	I	1238-1241
renal	I	1242-1247
dysfunctions	I	1248-1260
.	O	1260-1261

Effects	O	0-7
of	O	8-10
pallidal	O	11-19
neurotensin	O	20-31
on	O	32-34
haloperidol	O	35-46
-	O	46-47
induced	O	47-54
parkinsonian	B	55-67
catalepsy	I	68-77
:	O	77-78
behavioral	O	79-89
and	O	90-93
electrophysiological	O	94-114
studies	O	115-122
.	O	122-123

OBJECTIVE	O	124-133
:	O	133-134
The	O	135-138
globus	O	139-145
pallidus	O	146-154
plays	O	155-160
a	O	161-162
critical	O	163-171
role	O	172-176
in	O	177-179
movement	O	180-188
regulation	O	189-199
.	O	199-200

Previous	O	201-209
studies	O	210-217
have	O	218-222
indicated	O	223-232
that	O	233-237
the	O	238-241
globus	O	242-248
pallidus	O	249-257
receives	O	258-266
neurotensinergic	O	267-283
innervation	O	284-295
from	O	296-300
the	O	301-304
striatum	O	305-313
,	O	313-314
and	O	315-318
systemic	O	319-327
administration	O	328-342
of	O	343-345
a	O	346-347
neurotensin	O	348-359
analog	O	360-366
could	O	367-372
produce	O	373-380
antiparkinsonian	O	381-397
effects	O	398-405
.	O	405-406

The	O	407-410
present	O	411-418
study	O	419-424
aimed	O	425-430
to	O	431-433
investigate	O	434-445
the	O	446-449
effects	O	450-457
of	O	458-460
pallidal	O	461-469
neurotensin	O	470-481
on	O	482-484
haloperidol	O	485-496
-	O	496-497
induced	O	497-504
parkinsonian	B	505-517
symptoms	I	518-526
.	O	526-527

METHODS	O	528-535
:	O	535-536
Behavioral	O	537-547
experiments	O	548-559
and	O	560-563
electrophysiological	O	564-584
recordings	O	585-595
were	O	596-600
performed	O	601-610
in	O	611-613
the	O	614-617
present	O	618-625
study	O	626-631
.	O	631-632

RESULTS	O	633-640
:	O	640-641
Bilateral	O	642-651
infusions	O	652-661
of	O	662-664
neurotensin	O	665-676
into	O	677-681
the	O	682-685
globus	O	686-692
pallidus	O	693-701
reversed	O	702-710
haloperidol	O	711-722
-	O	722-723
induced	O	723-730
parkinsonian	B	731-743
catalepsy	I	744-753
in	O	754-756
rats	O	757-761
.	O	761-762

Electrophysiological	O	763-783
recordings	O	784-794
showed	O	795-801
that	O	802-806
microinjection	O	807-821
of	O	822-824
neurotensin	O	825-836
induced	O	837-844
excitation	O	845-855
of	O	856-858
pallidal	O	859-867
neurons	O	868-875
in	O	876-878
the	O	879-882
presence	O	883-891
of	O	892-894
systemic	O	895-903
haloperidol	O	904-915
administration	O	916-930
.	O	930-931

The	O	932-935
neurotensin	O	936-947
type	O	948-952
-	O	952-953
1	O	953-954
receptor	O	955-963
antagonist	O	964-974
SR48692	O	975-982
blocked	O	983-990
both	O	991-995
the	O	996-999
behavioral	O	1000-1010
and	O	1011-1014
the	O	1015-1018
electrophysiological	O	1019-1039
effects	O	1040-1047
induced	O	1048-1055
by	O	1056-1058
neurotensin	O	1059-1070
.	O	1070-1071

CONCLUSION	O	1072-1082
:	O	1082-1083
Activation	O	1084-1094
of	O	1095-1097
pallidal	O	1098-1106
neurotensin	O	1107-1118
receptors	O	1119-1128
may	O	1129-1132
be	O	1133-1135
involved	O	1136-1144
in	O	1145-1147
neurotensin	O	1148-1159
-	O	1159-1160
induced	O	1160-1167
antiparkinsonian	O	1168-1184
effects	O	1185-1192
.	O	1192-1193

Antihypertensive	O	0-16
drugs	O	17-22
and	O	23-26
depression	B	27-37
:	O	37-38
a	O	39-40
reappraisal	O	41-52
.	O	52-53

Eighty	O	54-60
-	O	60-61
nine	O	61-65
new	O	66-69
referral	O	70-78
hypertensive	B	79-91
out	O	92-95
-	O	95-96
patients	O	96-104
and	O	105-108
46	O	109-111
new	O	112-115
referral	O	116-124
non	O	125-128
-	O	128-129
hypertensive	B	129-141
chronically	O	142-153
physically	O	154-164
ill	O	165-168
out	O	169-172
-	O	172-173
patients	O	173-181
completed	O	182-191
a	O	192-193
mood	O	194-198
rating	O	199-205
scale	O	206-211
at	O	212-214
regular	O	215-222
intervals	O	223-232
for	O	233-236
one	O	237-240
year	O	241-245
.	O	245-246

The	O	247-250
results	O	251-258
showed	O	259-265
a	O	266-267
high	O	268-272
prevalence	O	273-283
of	O	284-286
depression	B	287-297
in	O	298-300
both	O	301-305
groups	O	306-312
of	O	313-315
patients	O	316-324
,	O	324-325
with	O	326-330
no	O	331-333
preponderance	O	334-347
in	O	348-350
the	O	351-354
hypertensive	B	355-367
group	O	368-373
.	O	373-374

Hypertensive	B	375-387
patients	O	388-396
with	O	397-401
psychiatric	B	402-413
histories	O	414-423
had	O	424-427
a	O	428-429
higher	O	430-436
prevalence	O	437-447
of	O	448-450
depression	B	451-461
than	O	462-466
the	O	467-470
comparison	O	471-481
patients	O	482-490
.	O	490-491

This	O	492-496
was	O	497-500
accounted	O	501-510
for	O	511-514
by	O	515-517
a	O	518-519
significant	O	520-531
number	O	532-538
of	O	539-541
depressions	B	542-553
occurring	O	554-563
in	O	564-566
methyl	O	567-573
dopa	O	574-578
treated	O	579-586
patients	O	587-595
with	O	596-600
psychiatric	B	601-612
histories	O	613-622
.	O	622-623

Pulmonary	O	0-9
shunt	O	10-15
and	O	16-19
cardiovascular	O	20-34
responses	O	35-44
to	O	45-47
CPAP	O	48-52
during	O	53-59
nitroprusside	O	60-73
-	O	73-74
induced	O	74-81
hypotension	B	82-93
.	O	93-94

The	O	95-98
effects	O	99-106
of	O	107-109
continuous	O	110-120
positive	O	121-129
airway	O	130-136
pressure	O	137-145
(	O	146-147
CPAP	O	147-151
)	O	151-152
on	O	153-155
cardiovascular	O	156-170
dynamics	O	171-179
and	O	180-183
pulmonary	O	184-193
shunt	O	194-199
(	O	200-201
QS	O	201-203
/	O	203-204
QT	O	204-206
)	O	206-207
were	O	208-212
investigated	O	213-225
in	O	226-228
12	O	229-231
dogs	O	232-236
before	O	237-243
and	O	244-247
during	O	248-254
sodium	O	255-261
nitroprusside	O	262-275
infusion	O	276-284
that	O	285-289
decreased	O	290-299
mean	O	300-304
arterial	O	305-313
blood	O	314-319
pressure	O	320-328
40	O	329-331
-	O	331-332
50	O	332-334
per	O	335-338
cent	O	339-343
.	O	343-344

Before	O	345-351
nitroprusside	O	352-365
infusion	O	366-374
,	O	374-375
5	O	376-377
cm	O	378-380
H2O	O	381-384
CPAP	O	385-389
significantly	O	390-403
,	O	403-404
P	O	405-406
less	O	407-411
than	O	412-416
.	O	417-418
05	O	418-420
,	O	420-421

decreased	O	422-431
arterial	O	432-440
blood	O	441-446
pressure	O	447-455
,	O	455-456
but	O	457-460
did	O	461-464
not	O	465-468
significantly	O	469-482
alter	O	483-488
heart	O	489-494
rate	O	495-499
,	O	499-500
cardiac	O	501-508
output	O	509-515
,	O	515-516
systemic	O	517-525
vascular	O	526-534
resistance	O	535-545
,	O	545-546
or	O	547-549
QS	O	550-552
/	O	552-553
QT	O	553-555
.	O	555-556

Ten	O	557-560
cm	O	561-563
H2O	O	564-567
CPAP	O	568-572
before	O	573-579
nitroprusside	O	580-593
infusion	O	594-602
produced	O	603-611
a	O	612-613
further	O	614-621
decrease	B	622-630
in	I	631-633
arterial	I	634-642
blood	I	643-648
pressure	I	649-657
and	O	658-661
significantly	O	662-675
increased	O	676-685
heart	O	686-691
rate	O	692-696
and	O	697-700
decreased	B	701-710
cardiac	I	711-718
output	I	719-725
and	O	726-729
QS	O	730-732
/	O	732-733
QT	O	733-735
.	O	735-736

Nitroprusside	O	737-750
caused	O	751-757
significant	O	758-769
decreases	B	770-779
in	I	780-782
arterial	I	783-791
blood	I	792-797
pressure	I	798-806
and	O	807-810
systemic	O	811-819
vascular	O	820-828
resistance	O	829-839
and	O	840-843
increases	O	844-853
in	O	854-856
heart	O	857-862
rate	O	863-867
,	O	867-868
but	O	869-872
did	O	873-876
not	O	877-880
change	O	881-887
cardiac	O	888-895
output	O	896-902
or	O	903-905
QS	O	906-908
/	O	908-909
QT	O	909-911
.	O	911-912

Five	O	913-917
cm	O	918-920
H2O	O	921-924
CPAP	O	925-929
during	O	930-936
nitroprusside	O	937-950
did	O	951-954
not	O	955-958
further	O	959-966
alter	O	967-972
any	O	973-976
of	O	977-979
the	O	980-983
above	O	984-989
-	O	989-990
mentioned	O	990-999
variables	O	1000-1009
.	O	1009-1010

However	O	1011-1018
,	O	1018-1019
10	O	1020-1022
cm	O	1023-1025
H2O	O	1026-1029
CPAP	O	1030-1034
decreased	O	1035-1044
arterial	O	1045-1053
blood	O	1054-1059
pressure	O	1060-1068
,	O	1068-1069
cardiac	O	1070-1077
output	O	1078-1084
,	O	1084-1085
and	O	1086-1089
QS	O	1090-1092
/	O	1092-1093
QT	O	1093-1095
.	O	1095-1096

These	O	1097-1102
data	O	1103-1107
indicate	O	1108-1116
that	O	1117-1121
nitroprusside	O	1122-1135
infusion	O	1136-1144
rates	O	1145-1150
that	O	1151-1155
decrease	O	1156-1164
mean	O	1165-1169
arterial	O	1170-1178
blood	O	1179-1184
pressure	O	1185-1193
by	O	1194-1196
40	O	1197-1199
-	O	1199-1200
50	O	1200-1202
per	O	1203-1206
cent	O	1207-1211
do	O	1212-1214
not	O	1215-1218
change	O	1219-1225
cardiac	O	1226-1233
output	O	1234-1240
or	O	1241-1243
QS	O	1244-1246
/	O	1246-1247
QT	O	1247-1249
.	O	1249-1250

During	O	1251-1257
nitroprusside	O	1258-1271
infusion	O	1272-1280
low	O	1281-1284
levels	O	1285-1291
of	O	1292-1294
CPAP	O	1295-1299
do	O	1300-1302
not	O	1303-1306
markedly	O	1307-1315
alter	O	1316-1321
cardiovascular	O	1322-1336
dynamics	O	1337-1345
,	O	1345-1346
but	O	1347-1350
high	O	1351-1355
levels	O	1356-1362
of	O	1363-1365
CPAP	O	1366-1370
(	O	1371-1372
10	O	1372-1374
cm	O	1375-1377
H2O	O	1378-1381
)	O	1381-1382
,	O	1382-1383
while	O	1384-1389
decreasing	O	1390-1400
QS	O	1401-1403
/	O	1403-1404
QT	O	1404-1406
,	O	1406-1407
produce	O	1408-1415
marked	O	1416-1422
decreases	B	1423-1432
in	I	1433-1435
arterial	I	1436-1444
blood	I	1445-1450
pressure	I	1451-1459
and	I	1460-1463
cardiac	I	1464-1471
output	I	1472-1478
.	O	1478-1479

Mediation	O	0-9
of	O	10-12
enhanced	O	13-21
reflex	O	22-28
vagal	O	29-34
bradycardia	B	35-46
by	O	47-49
L	O	50-51
-	O	51-52
dopa	O	52-56
via	O	57-60
central	O	61-68
dopamine	O	69-77
formation	O	78-87
in	O	88-90
dogs	O	91-95
.	O	95-96

L	O	97-98
-	O	98-99
Dopa	O	99-103
(	O	104-105
5	O	105-106
mg	O	107-109
/	O	109-110
kg	O	110-112
i	O	113-114
.	O	114-115
v	O	115-116
.	O	114-115
)	O	117-118
decreased	O	119-128
blood	O	129-134
pressure	O	135-143
and	O	144-147
heart	O	148-153
rate	O	154-158
after	O	159-164
extracerebral	O	165-178
decarboxylase	O	179-192
inhibition	O	193-203
with	O	204-208
MK	O	209-211
-	O	211-212
486	O	212-215
(	O	216-217
25	O	217-219
mg	O	220-222
/	O	222-223
kg	O	223-225
i	O	226-227
.	O	227-228
v	O	228-229
.	O	227-228
)	O	230-231
in	O	232-234
anesthetize	O	235-246
MAO	O	247-250
-	O	250-251
inhibited	O	251-260
dogs	O	261-265
.	O	265-266

In	O	267-269
addition	O	270-278
,	O	278-279
reflex	O	280-286
bradycardia	B	287-298
caused	O	299-305
by	O	306-308
injected	O	309-317
norepinephrine	O	318-332
was	O	333-336
significantly	O	337-350
enhanced	O	351-359
by	O	360-362
L	O	363-364
-	O	364-365
dopa	O	365-369
,	O	369-370
DL	O	371-373
-	O	373-374
Threo	O	374-379
-	O	373-374
dihydroxyphenylserine	O	380-401
had	O	402-405
no	O	406-408
effect	O	409-415
on	O	416-418
blood	O	419-424
pressure	O	425-433
,	O	433-434
heart	O	435-440
rate	O	441-445
or	O	446-448
reflex	O	449-455
responses	O	456-465
to	O	466-468
norepinephrine	O	469-483
.	O	483-484

FLA	O	485-488
-	O	488-489
63	O	489-491
,	O	491-492
a	O	493-494
dopamine	O	495-503
-	O	503-504
beta	O	504-508
-	O	503-504
oxidase	O	509-516
inhibitor	O	517-526
,	O	526-527
did	O	528-531
not	O	532-535
have	O	536-540
any	O	541-544
effect	O	545-551
on	O	552-554
the	O	555-558
hypotension	B	559-570
,	O	570-571
bradycardia	B	572-583
or	O	584-586
reflex	O	587-593
-	O	593-594
enhancing	O	594-603
effect	O	604-610
of	O	611-613
L	O	614-615
-	O	615-616
dopa	O	616-620
.	O	620-621

Pimozide	O	622-630
did	O	631-634
not	O	635-638
affect	O	639-645
the	O	646-649
actions	O	650-657
of	O	658-660
L	O	661-662
-	O	662-663
dopa	O	663-667
on	O	668-670
blood	O	671-676
pressure	O	677-685
and	O	686-689
heart	O	690-695
rate	O	696-700
but	O	701-704
completely	O	705-715
blocked	O	716-723
the	O	724-727
enhancement	O	728-739
of	O	740-742
reflexes	O	743-751
.	O	751-752

Removal	O	753-760
of	O	761-763
the	O	764-767
carotid	O	768-775
sinuses	O	776-783
caused	O	784-790
an	O	791-793
elevation	O	794-803
blood	O	804-809
pressure	O	810-818
and	O	819-822
heart	O	823-828
rate	O	829-833
and	O	834-837
abolished	O	838-847
the	O	848-851
negative	O	852-860
chronotropic	O	861-873
effect	O	874-880
of	O	881-883
norepinephrine	O	884-898
.	O	898-899

However	O	900-907
,	O	907-908
L	O	909-910
-	O	910-911
dopa	O	911-915
restored	O	916-924
the	O	925-928
bradycardia	B	929-940
caused	O	941-947
by	O	948-950
norepinephrine	O	951-965
in	O	966-968
addition	O	969-977
to	O	978-980
decreasing	O	981-991
blood	O	992-997
pressure	O	998-1006
and	O	1007-1010
heart	O	1011-1016
rate	O	1017-1021
.	O	1021-1022

5	O	1023-1024
-	O	1024-1025
HTP	O	1025-1028
(	O	1029-1030
5	O	1030-1031
mg	O	1032-1034
/	O	1034-1035
kg	O	1035-1037
i	O	1038-1039
.	O	1039-1040
v	O	1040-1041
.	O	1039-1040
)	O	1042-1043
decreased	O	1044-1053
blood	O	1054-1059
pressure	O	1060-1068
and	O	1069-1072
heart	O	1073-1078
rate	O	1079-1083
and	O	1084-1087
decreased	O	1088-1097
the	O	1098-1101
reflex	O	1102-1108
bradycardia	B	1109-1120
to	O	1121-1123
norepinephrine	O	1124-1138
.	O	1138-1139

It	O	1140-1142
is	O	1143-1145
concluded	O	1146-1155
that	O	1156-1160
L	O	1161-1162
-	O	1162-1163
dopa	O	1163-1167
enhances	O	1168-1176
reflex	O	1177-1183
bradycardia	B	1184-1195
through	O	1196-1203
central	O	1204-1211
alpha	O	1212-1217
-	O	1217-1218
receptor	O	1218-1226
stimulation	O	1227-1238
.	O	1238-1239

Furthermore	O	1240-1251
,	O	1251-1252
the	O	1253-1256
effects	O	1257-1264
are	O	1265-1268
mediated	O	1269-1277
through	O	1278-1285
dopamine	O	1286-1294
rather	O	1295-1301
than	O	1302-1306
norepinephrine	O	1307-1321
and	O	1322-1325
do	O	1326-1328
not	O	1329-1332
require	O	1333-1340
the	O	1341-1344
carotid	O	1345-1352
sinus	O	1353-1358
baroreceptors	O	1359-1372
.	O	1372-1373

Cocaine	O	0-7
-	O	7-8
induced	O	8-15
myocardial	B	16-26
infarction	I	27-37
:	O	37-38
clinical	O	39-47
observations	O	48-60
and	O	61-64
pathogenetic	O	65-77
considerations	O	78-92
.	O	92-93

Clinical	O	94-102
and	O	103-106
experimental	O	107-119
data	O	120-124
published	O	125-134
to	O	135-137
date	O	138-142
suggest	O	143-150
several	O	151-158
possible	O	159-167
mechanisms	O	168-178
by	O	179-181
which	O	182-187
cocaine	O	188-195
may	O	196-199
result	O	200-206
in	O	207-209
acute	B	210-215
myocardial	I	216-226
infarction	I	227-237
.	O	237-238

In	O	239-241
individuals	O	242-253
with	O	254-258
preexisting	O	259-270
,	O	270-271
high	O	272-276
-	O	276-277
grade	O	277-282
coronary	O	283-291
arterial	O	292-300
narrowing	O	301-310
,	O	310-311
acute	B	312-317
myocardial	I	318-328
infarction	I	329-339
may	O	340-343
result	O	344-350
from	O	351-355
an	O	356-358
increase	O	359-367
in	O	368-370
myocardial	O	371-381
oxygen	O	382-388
demand	O	389-395
associated	O	396-406
with	O	407-411
cocaine	O	412-419
-	O	419-420
induced	O	420-427
increase	O	428-436
in	O	437-439
rate	O	440-444
-	O	444-445
pressure	O	445-453
product	O	454-461
.	O	461-462

In	O	463-465
other	O	466-471
individuals	O	472-483
with	O	484-488
no	O	489-491
underlying	O	492-502
atherosclerotic	B	503-518
obstruction	I	519-530
,	O	530-531
coronary	B	532-540
occlusion	I	541-550
may	O	551-554
be	O	555-557
due	O	558-561
to	O	562-564
spasm	B	565-570
,	O	570-571
thrombus	B	572-580
,	O	580-581
or	O	582-584
both	O	585-589
.	O	589-590

With	O	591-595
regard	O	596-602
to	O	603-605
spasm	B	606-611
,	O	611-612
the	O	613-616
clinical	O	617-625
findings	O	626-634
are	O	635-638
largely	O	639-646
circumstantial	O	647-661
,	O	661-662
and	O	663-666
the	O	667-670
locus	O	671-676
of	O	677-679
cocaine	O	680-687
-	O	687-688
induced	O	688-695
vasoconstriction	O	696-712
remains	O	713-720
speculative	O	721-732
.	O	732-733

Although	O	734-742
certain	O	743-750
clinical	O	751-759
and	O	760-763
experimental	O	764-776
findings	O	777-785
support	O	786-793
the	O	794-797
hypothesis	O	798-808
that	O	809-813
spasm	B	814-819
involves	O	820-828
the	O	829-832
epicardial	O	833-843
,	O	843-844
medium	O	845-851
-	O	851-852
size	O	852-856
vessels	O	857-864
,	O	864-865
other	O	866-871
data	O	872-876
suggest	O	877-884
intramural	O	885-895
vasoconstriction	O	896-912
.	O	912-913

Diffuse	O	914-921
intramural	O	922-932
vasoconstriction	O	933-949
is	O	950-952
not	O	953-956
consistent	O	957-967
with	O	968-972
reports	O	973-980
of	O	981-983
segmental	O	984-993
,	O	993-994
discrete	O	995-1003
infarction	B	1004-1014
.	O	1014-1015

Whereas	O	1016-1023
certain	O	1024-1031
in	O	1032-1034
vivo	O	1035-1039
data	O	1040-1044
suggest	O	1045-1052
that	O	1053-1057
these	O	1058-1063
effects	O	1064-1071
are	O	1072-1075
alpha	O	1076-1081
-	O	1081-1082
mediated	O	1082-1090
,	O	1090-1091
other	O	1092-1097
in	O	1098-1100
vitro	O	1101-1106
data	O	1107-1111
suggest	O	1112-1119
the	O	1120-1123
opposite	O	1124-1132
.	O	1132-1133

The	O	1134-1137
finding	O	1138-1145
of	O	1146-1148
cocaine	O	1149-1156
-	O	1156-1157
induced	O	1157-1164
vasoconstriction	O	1165-1181
in	O	1182-1184
segments	O	1185-1193
of	O	1194-1196
(	O	1197-1198
noninnervated	O	1198-1211
)	O	1211-1212
human	O	1213-1218
umbilical	O	1219-1228
artery	O	1229-1235
suggests	O	1236-1244
that	O	1245-1249
the	O	1250-1253
presence	O	1254-1262
or	O	1263-1265
absence	O	1266-1273
of	O	1274-1276
intact	O	1277-1283
innervation	O	1284-1295
is	O	1296-1298
not	O	1299-1302
sufficient	O	1303-1313
to	O	1314-1316
explain	O	1317-1324
the	O	1325-1328
discrepant	O	1329-1339
data	O	1340-1344
involving	O	1345-1354
the	O	1355-1358
possibility	O	1359-1370
of	O	1371-1373
alpha	O	1374-1379
-	O	1379-1380
mediated	O	1380-1388
effects	O	1389-1396
.	O	1396-1397

Finally	O	1398-1405
,	O	1405-1406
the	O	1407-1410
contribution	O	1411-1423
of	O	1424-1426
a	O	1427-1428
primary	O	1429-1436
,	O	1436-1437
thrombotic	B	1438-1448
effect	O	1449-1455
of	O	1456-1458
cocaine	O	1459-1466
has	O	1467-1470
not	O	1471-1474
been	O	1475-1479
excluded	O	1480-1488
.	O	1488-1489

Rabbit	B	0-6
syndrome	I	7-15
,	O	15-16
antidepressant	O	17-31
use	O	32-35
,	O	35-36
and	O	37-40
cerebral	O	41-49
perfusion	O	50-59
SPECT	O	60-65
scan	O	66-70
findings	O	71-79
.	O	79-80

The	O	81-84
rabbit	B	85-91
syndrome	I	92-100
is	O	101-103
an	O	104-106
extrapyramidal	O	107-121
side	O	122-126
effect	O	127-133
associated	O	134-144
with	O	145-149
chronic	O	150-157
neuroleptic	O	158-169
therapy	O	170-177
.	O	177-178

Its	O	179-182
occurrence	O	183-193
in	O	194-196
a	O	197-198
patient	O	199-206
being	O	207-212
treated	O	213-220
with	O	221-225
imipramine	O	226-236
is	O	237-239
described	O	240-249
,	O	249-250
representing	O	251-263
the	O	264-267
first	O	268-273
reported	O	274-282
case	O	283-287
of	O	288-290
this	O	291-295
syndrome	O	296-304
in	O	305-307
conjunction	O	308-319
with	O	320-324
antidepressants	O	325-340
.	O	340-341

Repeated	O	342-350
cerebral	O	351-359
perfusion	O	360-369
SPECT	O	370-375
scans	O	376-381
revealed	O	382-390
decreased	B	391-400
basal	I	401-406
ganglia	I	407-414
perfusion	I	415-424
while	O	425-430
the	O	431-434
movement	B	435-443
disorder	I	444-452
was	O	453-456
present	O	457-464
,	O	464-465
and	O	466-469
a	O	470-471
return	O	472-478
to	O	479-481
normal	O	482-488
perfusion	O	489-498
when	O	499-503
the	O	504-507
rabbit	B	508-514
syndrome	I	515-523
resolved	O	524-532
.	O	532-533

Acute	O	0-5
bronchodilating	O	6-21
effects	O	22-29
of	O	30-32
ipratropium	O	33-44
bromide	O	45-52
and	O	53-56
theophylline	O	57-69
in	O	70-72
chronic	B	73-80
obstructive	I	81-92
pulmonary	I	93-102
disease	I	103-110
.	O	110-111

The	O	112-115
bronchodilator	O	116-130
effects	O	131-138
of	O	139-141
a	O	142-143
single	O	144-150
dose	O	151-155
of	O	156-158
ipratropium	O	159-170
bromide	O	171-178
aerosol	O	179-186
(	O	187-188
36	O	188-190
micrograms	O	191-201
)	O	201-202
and	O	203-206
short	O	207-212
-	O	212-213
acting	O	213-219
theophylline	O	220-232
tablets	O	233-240
(	O	241-242
dose	O	242-246
titrated	O	247-255
to	O	256-258
produce	O	259-266
serum	O	267-272
levels	O	273-279
of	O	280-282
10	O	283-285
-	O	285-286
20	O	286-288
micrograms	O	289-299
/	O	299-300
mL	O	300-302
)	O	302-303
were	O	304-308
compared	O	309-317
in	O	318-320
a	O	321-322
double	O	323-329
-	O	329-330
blind	O	330-335
,	O	335-336
placebo	O	337-344
-	O	344-345
controlled	O	345-355
crossover	O	356-365
study	O	366-371
in	O	372-374
21	O	375-377
patients	O	378-386
with	O	387-391
stable	O	392-398
,	O	398-399
chronic	B	400-407
obstructive	I	408-419
pulmonary	I	420-429
disease	I	430-437
.	O	437-438

Mean	O	439-443
peak	O	444-448
forced	O	449-455
expiratory	O	456-466
volume	O	467-473
in	O	474-476
1	O	477-478
second	O	479-485
(	O	486-487
FEV1	O	487-491
)	O	491-492
increases	O	493-502
over	O	503-507
baseline	O	508-516
and	O	517-520
the	O	521-524
proportion	O	525-535
of	O	536-538
patients	O	539-547
attaining	O	548-557
at	O	558-560
least	O	561-566
a	O	567-568
15	O	569-571
%	O	571-572
increase	O	573-581
in	O	582-584
the	O	585-588
FEV1	O	589-593
(	O	594-595
responders	O	595-605
)	O	605-606
were	O	607-611
31	O	612-614
%	O	614-615
and	O	616-619
90	O	620-622
%	O	622-623
,	O	623-624
respectively	O	625-637
,	O	637-638
for	O	639-642
ipratropium	O	643-654
and	O	655-658
17	O	659-661
%	O	661-662
and	O	663-666
50	O	667-669
%	O	669-670
,	O	670-671
respectively	O	672-684
,	O	684-685
for	O	686-689
theophylline	O	690-702
.	O	702-703

The	O	704-707
average	O	708-715
FEV1	O	716-720
increases	O	721-730
during	O	731-737
the	O	738-741
6	O	742-743
-	O	743-744
hour	O	744-748
observation	O	749-760
period	O	761-767
were	O	768-772
18	O	773-775
%	O	775-776
for	O	777-780
ipratropium	O	781-792
and	O	793-796
8	O	797-798
%	O	798-799
for	O	800-803
theophylline	O	804-816
.	O	816-817

The	O	818-821
mean	O	822-826
duration	O	827-835
of	O	836-838
action	O	839-845
was	O	846-849
3	O	850-851
.	O	851-852
8	O	852-853
hours	O	854-859
with	O	860-864
ipratropium	O	865-876
and	O	877-880
2	O	881-882
.	O	882-883
4	O	883-884
hours	O	885-890
with	O	891-895
theophylline	O	896-908
.	O	908-909

While	O	910-915
side	O	916-920
effects	O	921-928
were	O	929-933
rare	O	934-938
,	O	938-939
those	O	940-945
experienced	O	946-957
after	O	958-963
theophylline	O	964-976
use	O	977-980
did	O	981-984
involve	O	985-992
the	O	993-996
cardiovascular	B	997-1011
and	I	1012-1015
gastrointestinal	I	1016-1032
systems	I	1033-1040
.	O	1040-1041

These	O	1042-1047
results	O	1048-1055
show	O	1056-1060
that	O	1061-1065
ipratropium	O	1066-1077
is	O	1078-1080
a	O	1081-1082
more	O	1083-1087
potent	O	1088-1094
bronchodilator	O	1095-1109
than	O	1110-1114
oral	O	1115-1119
theophylline	O	1120-1132
in	O	1133-1135
patients	O	1136-1144
with	O	1145-1149
chronic	B	1150-1157
airflow	I	1158-1165
obstruction	I	1166-1177
.	O	1177-1178

Irreversible	O	0-12
damage	O	13-19
to	O	20-22
the	O	23-26
medullary	O	27-36
interstitium	O	37-49
in	O	50-52
experimental	O	53-65
analgesic	O	66-75
nephropathy	B	76-87
in	O	88-90
F344	O	91-95
rats	O	96-100
.	O	100-101

Renal	B	102-107
papillary	I	108-117
necrosis	I	118-126
(	O	127-128
RPN	B	128-131
)	O	131-132
and	O	133-136
a	O	137-138
decreased	O	139-148
urinary	O	149-156
concentrating	O	157-170
ability	O	171-178
developed	O	179-188
during	O	189-195
continuous	O	196-206
long	O	207-211
-	O	211-212
term	O	212-216
treatment	O	217-226
with	O	227-231
aspirin	O	232-239
and	O	240-243
paracetamol	O	244-255
in	O	256-258
female	O	259-265
Fischer	O	266-273
344	O	274-277
rats	O	278-282
.	O	282-283

Renal	O	284-289
structure	O	290-299
and	O	300-303
concentrating	O	304-317
ability	O	318-325
were	O	326-330
examined	O	331-339
after	O	340-345
a	O	346-347
recovery	O	348-356
period	O	357-363
of	O	364-366
up	O	367-369
to	O	370-372
18	O	373-375
weeks	O	376-381
,	O	381-382
when	O	383-387
no	O	388-390
analgesics	O	391-401
were	O	402-406
given	O	407-412
,	O	412-413
to	O	414-416
investigate	O	417-428
whether	O	429-436
the	O	437-440
analgesic	O	441-450
-	O	450-451
induced	O	451-458
changes	O	459-466
were	O	467-471
reversible	O	472-482
.	O	482-483

There	O	484-489
was	O	490-493
no	O	494-496
evidence	O	497-505
of	O	506-508
repair	O	509-515
to	O	516-518
the	O	519-522
damaged	O	523-530
medullary	O	531-540
interstitial	O	541-553
matrix	O	554-560
,	O	560-561
or	O	562-564
proliferation	O	565-578
of	O	579-581
remaining	O	582-591
undamaged	O	592-601
type	O	602-606
1	O	607-608
medullary	O	609-618
interstitial	O	619-631
cells	O	632-637
after	O	638-643
the	O	644-647
recovery	O	648-656
period	O	657-663
following	O	664-673
analgesic	O	674-683
treatment	O	684-693
.	O	693-694

The	O	695-698
recovery	O	699-707
of	O	708-710
urinary	O	711-718
concentrating	O	719-732
ability	O	733-740
was	O	741-744
related	O	745-752
to	O	753-755
the	O	756-759
length	O	760-766
of	O	767-769
analgesic	O	770-779
treatment	O	780-789
and	O	790-793
the	O	794-797
extent	O	798-804
of	O	805-807
the	O	808-811
resulting	O	812-821
inner	O	822-827
medullary	O	828-837
structural	O	838-848
damage	O	849-855
.	O	855-856

During	O	857-863
the	O	864-867
early	O	868-873
stages	O	874-880
of	O	881-883
analgesic	O	884-893
treatment	O	894-903
,	O	903-904
the	O	905-908
changes	O	909-916
in	O	917-919
urinary	O	920-927
concentrating	O	928-941
ability	O	942-949
were	O	950-954
reversible	O	955-965
,	O	965-966
but	O	967-970
after	O	971-976
prolonged	O	977-986
analgesic	O	987-996
treatment	O	997-1006
,	O	1006-1007
maximum	O	1008-1015
urinary	O	1016-1023
concentrating	O	1024-1037
ability	O	1038-1045
failed	O	1046-1052
to	O	1053-1055
recover	O	1056-1063
.	O	1063-1064

This	O	1065-1069
study	O	1070-1075
shows	O	1076-1081
that	O	1082-1086
prolonged	O	1087-1096
analgesic	O	1097-1106
treatment	O	1107-1116
in	O	1117-1119
Fischer	O	1120-1127
344	O	1128-1131
rats	O	1132-1136
causes	O	1137-1143
progressive	O	1144-1155
and	O	1156-1159
irreversible	O	1160-1172
damage	O	1173-1179
to	O	1180-1182
the	O	1183-1186
interstitial	O	1187-1199
matrix	O	1200-1206
and	O	1207-1210
type	O	1211-1215
1	O	1216-1217
interstitial	O	1218-1230
cells	O	1231-1236
leading	O	1237-1244
to	O	1245-1247
RPN	B	1248-1251
.	O	1251-1252

The	O	1253-1256
associated	O	1257-1267
urinary	O	1268-1275
concentrating	O	1276-1289
defect	O	1290-1296
is	O	1297-1299
reversible	O	1300-1310
only	O	1311-1315
during	O	1316-1322
the	O	1323-1326
early	O	1327-1332
stages	O	1333-1339
of	O	1340-1342
structural	O	1343-1353
damage	O	1354-1360
to	O	1361-1363
the	O	1364-1367
inner	O	1368-1373
medulla	O	1374-1381
.	O	1381-1382

Less	O	0-4
frequent	O	5-13
lithium	O	14-21
administration	O	22-36
and	O	37-40
lower	O	41-46
urine	O	47-52
volume	O	53-59
.	O	59-60

OBJECTIVE	O	61-70
:	O	70-71
This	O	72-76
study	O	77-82
was	O	83-86
designed	O	87-95
to	O	96-98
determine	O	99-108
whether	O	109-116
patients	O	117-125
maintained	O	126-136
on	O	137-139
a	O	140-141
regimen	O	142-149
of	O	150-152
lithium	O	153-160
on	O	161-163
a	O	164-165
once	O	166-170
-	O	170-171
per	O	171-174
-	O	170-171
day	O	175-178
schedule	O	179-187
have	O	188-192
lower	O	193-198
urine	O	199-204
volumes	O	205-212
than	O	213-217
do	O	218-220
patients	O	221-229
receiving	O	230-239
multiple	O	240-248
doses	O	249-254
per	O	255-258
day	O	259-262
.	O	262-263

METHOD	O	264-270
:	O	270-271
This	O	272-276
was	O	277-280
a	O	281-282
cross	O	283-288
-	O	288-289
sectional	O	289-298
study	O	299-304
of	O	305-307
85	O	308-310
patients	O	311-319
from	O	320-324
a	O	325-326
lithium	O	327-334
clinic	O	335-341
who	O	342-345
received	O	346-354
different	O	355-364
dose	O	365-369
schedules	O	370-379
.	O	379-380

Patients	O	381-389
were	O	390-394
admitted	O	395-403
to	O	404-406
the	O	407-410
hospital	O	411-419
for	O	420-423
measurement	O	424-435
of	O	436-438
lithium	O	439-446
level	O	447-452
,	O	452-453
creatinine	O	454-464
clearance	O	465-474
,	O	474-475
urine	O	476-481
volume	O	482-488
,	O	488-489
and	O	490-493
maximum	O	494-501
osmolality	O	502-512
.	O	512-513

RESULTS	O	514-521
:	O	521-522
Multiple	O	523-531
daily	O	532-537
doses	O	538-543
of	O	544-546
lithium	O	547-554
were	O	555-559
associated	O	560-570
with	O	571-575
higher	O	576-582
urine	O	583-588
volumes	O	589-596
.	O	596-597

The	O	598-601
dosing	O	602-608
schedule	O	609-617
,	O	617-618
duration	O	619-627
of	O	628-630
lithium	O	631-638
treatment	O	639-648
,	O	648-649
and	O	650-653
daily	O	654-659
dose	O	660-664
of	O	665-667
lithium	O	668-675
did	O	676-679
not	O	680-683
affect	O	684-690
maximum	O	691-698
osmolality	O	699-709
or	O	710-712
creatinine	O	713-723
clearance	O	724-733
.	O	733-734

CONCLUSIONS	O	735-746
:	O	746-747
Urine	O	748-753
volume	O	754-760
can	O	761-764
be	O	765-767
reduced	O	768-775
by	O	776-778
giving	O	779-785
lithium	O	786-793
once	O	794-798
daily	O	799-804
and	O	805-808
/	O	808-809
or	O	809-811
by	O	812-814
lowering	O	815-823
the	O	824-827
total	O	828-833
daily	O	834-839
dose	O	840-844
.	O	844-845

Lithium	O	846-853
-	O	853-854
induced	O	854-861
polyuria	B	862-870
seems	O	871-876
to	O	877-879
be	O	880-882
related	O	883-890
to	O	891-893
extrarenal	O	894-904
as	O	905-907
well	O	908-912
as	O	913-915
to	O	916-918
renal	O	919-924
effects	O	925-932
.	O	932-933

Effect	O	0-6
of	O	7-9
adriamycin	O	10-20
combined	O	21-29
with	O	30-34
whole	O	35-40
body	O	41-45
hyperthermia	B	46-58
on	O	59-61
tumor	B	62-67
and	O	68-71
normal	O	72-78
tissues	O	79-86
.	O	86-87

Thermal	O	88-95
enhancement	O	96-107
of	O	108-110
Adriamycin	O	111-121
-	O	121-122
mediated	O	122-130
antitumor	O	131-140
activity	O	141-149
and	O	150-153
normal	O	154-160
tissue	O	161-167
toxicities	B	168-178
by	O	179-181
whole	O	182-187
body	O	188-192
hyperthermia	B	193-205
were	O	206-210
compared	O	211-219
using	O	220-225
a	O	226-227
F344	O	228-232
rat	O	233-236
model	O	237-242
.	O	242-243

Antitumor	O	244-253
activity	O	254-262
was	O	263-266
studied	O	267-274
using	O	275-280
a	O	281-282
tumor	B	283-288
growth	O	289-295
delay	O	296-301
assay	O	302-307
.	O	307-308

Acute	O	309-314
normal	O	315-321
tissue	O	322-328
toxicities	B	329-339
(	O	340-341
i	O	341-342
.	O	342-343
e	O	343-344
.	O	342-343
,	O	345-346
leukopenia	B	347-357
and	O	358-361
thrombocytopenia	B	362-378
)	O	378-379
and	O	380-383
late	O	384-388
normal	O	389-395
tissue	O	396-402
toxicities	B	403-413
(	O	414-415
i	O	415-416
.	O	416-417
e	O	417-418
.	O	416-417
,	O	419-420
myocardial	B	421-431
and	I	432-435
kidney	I	436-442
injury	I	443-449
)	O	449-450
were	O	451-455
evaluated	O	456-465
by	O	466-468
functional	O	469-479
/	O	479-480
physiological	O	480-493
assays	O	494-500
and	O	501-504
by	O	505-507
morphological	O	508-521
techniques	O	522-532
.	O	532-533

Whole	O	534-539
body	O	540-544
hyperthermia	B	545-557
(	O	558-559
120	O	559-562
min	O	563-566
at	O	567-569
41	O	570-572
.	O	572-573
5	O	573-574
degrees	O	575-582
C	O	583-584
)	O	584-585
enhanced	O	586-594
both	O	595-599
Adriamycin	O	600-610
-	O	610-611
mediated	O	611-619
antitumor	O	620-629
activity	O	630-638
and	O	639-642
toxic	O	643-648
side	O	649-653
effects	O	654-661
.	O	661-662

The	O	663-666
thermal	O	667-674
enhancement	O	675-686
ratio	O	687-692
calculated	O	693-703
for	O	704-707
antitumor	O	708-717
activity	O	718-726
was	O	727-730
1	O	731-732
.	O	732-733
6	O	733-734
.	O	732-733

Thermal	O	736-743
enhancement	O	744-755
ratios	O	756-762
estimated	O	763-772
for	O	773-776
"	O	777-778
acute	O	778-783
"	O	777-778
hematological	O	785-798
changes	O	799-806
were	O	807-811
1	O	812-813
.	O	813-814
3	O	814-815
,	O	815-816
whereas	O	817-824
those	O	825-830
estimated	O	831-840
for	O	841-844
"	O	845-846
late	O	846-850
"	O	845-846
damage	O	852-858
(	O	859-860
based	O	860-865
on	O	866-868
morphological	O	869-882
cardiac	B	883-890
and	I	891-894
renal	I	895-900
lesions	I	901-908
)	O	908-909
varied	O	910-916
between	O	917-924
2	O	925-926
.	O	926-927
4	O	927-928
and	O	929-932
4	O	933-934
.	O	934-935
3	O	935-936
.	O	934-935

Thus	O	938-942
,	O	942-943
while	O	944-949
whole	O	950-955
body	O	956-960
hyperthermia	B	961-973
enhances	O	974-982
Adriamycin	O	983-993
-	O	993-994
mediated	O	994-1002
antitumor	O	1003-1012
effect	O	1013-1019
,	O	1019-1020
normal	O	1021-1027
tissue	O	1028-1034
toxicity	B	1035-1043
is	O	1044-1046
also	O	1047-1051
increased	O	1052-1061
,	O	1061-1062
and	O	1063-1066
the	O	1067-1070
potential	O	1071-1080
therapeutic	O	1081-1092
gain	O	1093-1097
of	O	1098-1100
the	O	1101-1104
combined	O	1105-1113
modality	O	1114-1122
treatment	O	1123-1132
is	O	1133-1135
eroded	O	1136-1142
.	O	1142-1143

Prazosin	O	0-8
-	O	8-9
induced	O	9-16
stress	B	17-23
incontinence	I	24-36
.	O	36-37

A	O	38-39
case	O	40-44
of	O	45-47
genuine	O	48-55
stress	B	56-62
incontinence	I	63-75
due	O	76-79
to	O	80-82
prazosin	O	83-91
,	O	91-92
a	O	93-94
common	O	95-101
antihypertensive	O	102-118
drug	O	119-123
,	O	123-124
is	O	125-127
presented	O	128-137
.	O	137-138

Prazosin	O	139-147
exerts	O	148-154
its	O	155-158
antihypertensive	O	159-175
effects	O	176-183
through	O	184-191
vasodilatation	O	192-206
caused	O	207-213
by	O	214-216
selective	O	217-226
blockade	O	227-235
of	O	236-238
postsynaptic	O	239-251
alpha	O	252-257
-	O	257-258
1	O	258-259
adrenergic	O	260-270
receptors	O	271-280
.	O	280-281

As	O	282-284
an	O	285-287
alpha	O	288-293
-	O	293-294
blocker	O	294-301
,	O	301-302
it	O	303-305
also	O	306-310
exerts	O	311-317
a	O	318-319
significant	O	320-331
relaxant	O	332-340
effect	O	341-347
on	O	348-350
the	O	351-354
bladder	O	355-362
neck	O	363-367
and	O	368-371
urethra	O	372-379
.	O	379-380

The	O	381-384
patient	O	385-392
'	O	392-393
s	O	393-394
clinical	O	395-403
course	O	404-410
is	O	411-413
described	O	414-423
and	O	424-427
correlated	O	428-438
with	O	439-443
initial	O	444-451
urodynamic	O	452-462
studies	O	463-470
while	O	471-476
on	O	477-479
prazosin	O	480-488
and	O	489-492
subsequent	O	493-503
studies	O	504-511
while	O	512-517
taking	O	518-524
verapamil	O	525-534
.	O	534-535

Her	O	536-539
incontinence	B	540-552
resolved	O	553-561
with	O	562-566
the	O	567-570
change	O	571-577
of	O	578-580
medication	O	581-591
.	O	591-592

The	O	593-596
restoration	O	597-608
of	O	609-611
continence	O	612-622
was	O	623-626
accompanied	O	627-638
by	O	639-641
a	O	642-643
substantial	O	644-655
rise	O	656-660
in	O	661-663
maximum	O	664-671
urethral	O	672-680
pressure	O	681-689
,	O	689-690
maximum	O	691-698
urethral	O	699-707
closure	O	708-715
pressure	O	716-724
,	O	724-725
and	O	726-729
functional	O	730-740
urethral	O	741-749
length	O	750-756
.	O	756-757

Patients	O	758-766
who	O	767-770
present	O	771-778
with	O	779-783
stress	B	784-790
incontinence	I	791-803
while	O	804-809
taking	O	810-816
prazosin	O	817-825
should	O	826-832
change	O	833-839
their	O	840-845
antihypertensive	O	846-862
medication	O	863-873
before	O	874-880
considering	O	881-892
surgery	O	893-900
,	O	900-901
because	O	902-909
their	O	910-915
incontinence	B	916-928
may	O	929-932
resolve	O	933-940
spontaneously	O	941-954
with	O	955-959
a	O	960-961
change	O	962-968
in	O	969-971
drug	O	972-976
therapy	O	977-984
.	O	984-985

Myocardial	B	0-10
infarction	I	11-21
following	O	22-31
sublingual	O	32-42
administration	O	43-57
of	O	58-60
isosorbide	O	61-71
dinitrate	O	72-81
.	O	81-82

A	O	83-84
78	O	85-87
-	O	87-88
year	O	88-92
-	O	87-88
old	O	93-96
with	O	97-101
healed	O	102-108
septal	O	109-115
necrosis	B	116-124
suffered	O	125-133
a	O	134-135
recurrent	O	136-145
myocardial	B	146-156
infarction	I	157-167
of	O	168-170
the	O	171-174
anterior	O	175-183
wall	O	184-188
following	O	189-198
the	O	199-202
administration	O	203-217
of	O	218-220
isosorbide	O	221-231
dinitrate	O	232-241
5	O	242-243
mg	O	244-246
sublingually	O	247-259
.	O	259-260

After	O	261-266
detailing	O	267-276
the	O	277-280
course	O	281-287
of	O	288-290
events	O	291-297
,	O	297-298
we	O	299-301
discuss	O	302-309
the	O	310-313
role	O	314-318
of	O	319-321
paradoxical	O	322-333
coronary	O	334-342
spasm	B	343-348
and	O	349-352
hypotension	B	353-364
-	O	364-365
mediated	O	365-373
myocardial	B	374-384
ischemia	I	385-393
occurring	O	394-403
downstream	O	404-414
to	O	415-417
significant	O	418-429
coronary	B	430-438
arterial	I	439-447
stenosis	I	448-456
in	O	457-459
the	O	460-463
pathophysiology	O	464-479
of	O	480-482
acute	B	483-488
coronary	I	489-497
insufficiency	I	498-511
.	O	511-512

Fluoxetine	O	0-10
-	O	10-11
induced	O	11-18
akathisia	B	19-28
:	O	28-29
clinical	O	30-38
and	O	39-42
theoretical	O	43-54
implications	O	55-67
.	O	67-68

Five	O	69-73
patients	O	74-82
receiving	O	83-92
fluoxetine	O	93-103
for	O	104-107
the	O	108-111
treatment	O	112-121
of	O	122-124
obsessive	B	125-134
compulsive	I	135-145
disorder	I	146-154
or	O	155-157
major	B	158-163
depression	I	164-174
developed	O	175-184
akathisia	B	185-194
.	O	194-195

The	O	196-199
typical	O	200-207
fluoxetine	O	208-218
-	O	218-219
induced	O	219-226
symptoms	O	227-235
of	O	236-238
restlessness	O	239-251
,	O	251-252
constant	O	253-261
pacing	O	262-268
,	O	268-269
purposeless	O	270-281
movements	O	282-291
of	O	292-294
the	O	295-298
feet	O	299-303
and	O	304-307
legs	O	308-312
,	O	312-313
and	O	314-317
marked	O	318-324
anxiety	B	325-332
were	O	333-337
indistinguishable	O	338-355
from	O	356-360
those	O	361-366
of	O	367-369
neuroleptic	O	370-381
-	O	381-382
induced	O	382-389
akathisia	B	390-399
.	O	399-400

Three	O	401-406
patients	O	407-415
who	O	416-419
had	O	420-423
experienced	O	424-435
neuroleptic	O	436-447
-	O	447-448
induced	O	448-455
akathisia	B	456-465
in	O	466-468
the	O	469-472
past	O	473-477
reported	O	478-486
that	O	487-491
the	O	492-495
symptoms	O	496-504
of	O	505-507
fluoxetine	O	508-518
-	O	518-519
induced	O	519-526
akathisia	B	527-536
were	O	537-541
identical	O	542-551
,	O	551-552
although	O	553-561
somewhat	O	562-570
milder	O	571-577
.	O	577-578

Akathisia	B	579-588
appeared	O	589-597
to	O	598-600
be	O	601-603
a	O	604-605
common	O	606-612
side	O	613-617
effect	O	618-624
of	O	625-627
fluoxetine	O	628-638
and	O	639-642
generally	O	643-652
responded	O	653-662
well	O	663-667
to	O	668-670
treatment	O	671-680
with	O	681-685
the	O	686-689
beta	O	690-694
-	O	694-695
adrenergic	O	695-705
antagonist	O	706-716
propranolol	O	717-728
,	O	728-729
dose	O	730-734
reduction	O	735-744
,	O	744-745
or	O	746-748
both	O	749-753
.	O	753-754

The	O	755-758
authors	O	759-766
suggest	O	767-774
that	O	775-779
fluoxetine	O	780-790
-	O	790-791
induced	O	791-798
akathisia	B	799-808
may	O	809-812
be	O	813-815
caused	O	816-822
by	O	823-825
serotonergically	O	826-842
mediated	O	843-851
inhibition	O	852-862
of	O	863-865
dopaminergic	O	866-878
neurotransmission	O	879-896
and	O	897-900
that	O	901-905
the	O	906-909
pathophysiology	O	910-925
of	O	926-928
fluoxetine	O	929-939
-	O	939-940
induced	O	940-947
akathisia	B	948-957
and	O	958-961
tricyclic	O	962-971
antidepressant	O	972-986
-	O	986-987
induced	O	987-994
"	O	995-996
jitteriness	O	996-1007
"	O	995-996
may	O	1009-1012
be	O	1013-1015
identical	O	1016-1025
.	O	1025-1026

Chronic	B	0-7
active	I	8-14
hepatitis	I	15-24
associated	O	25-35
with	O	36-40
diclofenac	O	41-51
sodium	O	52-58
therapy	O	59-66
.	O	66-67

Diclofenac	O	68-78
sodium	O	79-85
(	O	86-87
Voltarol	O	87-95
,	O	95-96
Geigy	O	97-102
Pharmaceuticals	O	103-118
)	O	118-119
is	O	120-122
a	O	123-124
non	O	125-128
-	O	128-129
steroidal	O	129-138
anti	O	139-143
-	O	143-144
inflammatory	O	144-156
derivative	O	157-167
of	O	168-170
phenylacetic	O	171-183
acid	O	184-188
.	O	188-189

Although	O	190-198
generally	O	199-208
well	O	209-213
-	O	213-214
tolerated	O	214-223
,	O	223-224
asymptomatic	O	225-237
abnormalities	B	238-251
of	I	252-254
liver	I	255-260
function	I	261-269
have	O	270-274
been	O	275-279
recorded	O	280-288
and	O	289-292
,	O	292-293
less	O	294-298
commonly	O	299-307
,	O	307-308
severe	O	309-315
hepatitis	B	316-325
induced	O	326-333
by	O	334-336
diclofenac	O	337-347
.	O	347-348

The	O	349-352
patient	O	353-360
described	O	361-370
developed	O	371-380
chronic	B	381-388
active	I	389-395
hepatitis	I	396-405
after	O	406-411
six	O	412-415
months	O	416-422
therapy	O	423-430
with	O	431-435
diclofenac	O	436-446
sodium	O	447-453
which	O	454-459
progressed	O	460-470
despite	O	471-478
the	O	479-482
withdrawal	O	483-493
of	O	494-496
the	O	497-500
drug	O	501-505
,	O	505-506
a	O	507-508
finding	O	509-516
not	O	517-520
previously	O	521-531
reported	O	532-540
.	O	540-541

Stroke	B	0-6
associated	O	7-17
with	O	18-22
cocaine	O	23-30
use	O	31-34
.	O	34-35

We	O	36-38
describe	O	39-47
eight	O	48-53
patients	O	54-62
in	O	63-65
whom	O	66-70
cocaine	O	71-78
use	O	79-82
was	O	83-86
related	O	87-94
to	O	95-97
stroke	B	98-104
and	O	105-108
review	O	109-115
39	O	116-118
cases	O	119-124
from	O	125-129
the	O	130-133
literature	O	134-144
.	O	144-145

Among	O	146-151
these	O	152-157
47	O	158-160
patients	O	161-169
the	O	170-173
mean	O	174-178
(	O	179-180
+	O	180-181
/	O	181-182
-	O	182-183
SD	O	184-186
)	O	186-187
age	O	188-191
was	O	192-195
32	O	196-198
.	O	198-199
5	O	199-200
+	O	201-202
/	O	202-203
-	O	203-204
12	O	205-207
.	O	207-208
1	O	205-206
years	O	210-215
;	O	215-216
76	O	217-219
%	O	219-220
(	O	221-222
34	O	222-224
/	O	224-225
45	O	225-227
)	O	227-228
were	O	229-233
men	O	234-237
.	O	237-238

Stroke	B	239-245
followed	O	246-254
cocaine	O	255-262
use	O	263-266
by	O	267-269
inhalation	O	270-280
,	O	280-281
intranasal	O	282-292
,	O	292-293
intravenous	O	294-305
,	O	305-306
and	O	307-310
intramuscular	O	311-324
routes	O	325-331
.	O	331-332

Intracranial	B	333-345
aneurysms	I	346-355
or	O	356-358
arteriovenous	B	359-372
malformations	I	373-386
were	O	387-391
present	O	392-399
in	O	400-402
17	O	403-405
of	O	406-408
32	O	409-411
patients	O	412-420
studied	O	421-428
angiographically	O	429-445
or	O	446-448
at	O	449-451
autopsy	O	452-459
;	O	459-460
cerebral	B	461-469
vasculitis	I	470-480
was	O	481-484
present	O	485-492
in	O	493-495
two	O	496-499
patients	O	500-508
.	O	508-509

Cerebral	B	510-518
infarction	I	519-529
occurred	O	530-538
in	O	539-541
10	O	542-544
patients	O	545-553
(	O	554-555
22	O	555-557
%	O	557-558
)	O	558-559
,	O	559-560
intracerebral	B	561-574
hemorrhage	I	575-585
in	O	586-588
22	O	589-591
(	O	592-593
49	O	593-595
%	O	595-596
)	O	596-597
,	O	597-598
and	O	599-602
subarachnoid	B	603-615
hemorrhage	I	616-626
in	O	627-629
13	O	630-632
(	O	633-634
29	O	634-636
%	O	636-637
)	O	637-638
.	O	638-639

These	O	640-645
data	O	646-650
indicate	O	651-659
that	O	660-664
(	O	665-666
1	O	666-667
)	O	667-668
the	O	669-672
apparent	O	673-681
incidence	O	682-691
of	O	692-694
stroke	B	695-701
related	O	702-709
to	O	710-712
cocaine	O	713-720
use	O	721-724
is	O	725-727
increasing	O	728-738
;	O	738-739
(	O	740-741
2	O	741-742
)	O	742-743
cocaine	O	744-751
-	O	751-752
associated	O	752-762
stroke	B	763-769
occurs	O	770-776
primarily	O	777-786
in	O	787-789
young	O	790-795
adults	O	796-802
;	O	802-803
(	O	804-805
3	O	805-806
)	O	806-807
stroke	B	808-814
may	O	815-818
follow	O	819-825
any	O	826-829
route	O	830-835
of	O	836-838
cocaine	O	839-846
administration	O	847-861
;	O	861-862
(	O	863-864
4	O	864-865
)	O	865-866
stroke	B	867-873
after	O	874-879
cocaine	O	880-887
use	O	888-891
is	O	892-894
frequently	O	895-905
associated	O	906-916
with	O	917-921
intracranial	B	922-934
aneurysms	I	935-944
and	O	945-948
arteriovenous	B	949-962
malformations	I	963-976
;	O	976-977
and	O	978-981
(	O	982-983
5	O	983-984
)	O	984-985
in	O	986-988
cocaine	O	989-996
-	O	996-997
associated	O	997-1007
stroke	B	1008-1014
,	O	1014-1015
the	O	1016-1019
frequency	O	1020-1029
of	O	1030-1032
intracranial	B	1033-1045
hemorrhage	I	1046-1056
exceeds	O	1057-1064
that	O	1065-1069
of	O	1070-1072
cerebral	B	1073-1081
infarction	I	1082-1092
.	O	1092-1093

Glyburide	O	0-9
-	O	9-10
induced	O	10-17
hepatitis	B	18-27
.	O	27-28

Drug	O	29-33
-	O	33-34
induced	O	34-41
hepatotoxicity	B	42-56
,	O	56-57
although	O	58-66
common	O	67-73
,	O	73-74
has	O	75-78
been	O	79-83
reported	O	84-92
only	O	93-97
infrequently	O	98-110
with	O	111-115
sulfonylureas	O	116-129
.	O	129-130

For	O	131-134
glyburide	O	135-144
,	O	144-145
a	O	146-147
second	O	148-154
-	O	154-155
generation	O	155-165
sulfonylurea	O	166-178
,	O	178-179
only	O	180-184
two	O	185-188
brief	O	189-194
reports	O	195-202
of	O	203-205
hepatotoxicity	B	206-220
exist	O	221-226
.	O	226-227

Two	O	228-231
patients	O	232-240
with	O	241-245
type	B	246-250
II	I	251-253
diabetes	I	254-262
mellitus	I	263-271
developed	O	272-281
an	O	282-284
acute	B	285-290
hepatitis	I	291-300
-	I	300-301
like	I	301-305
syndrome	I	306-314
soon	O	315-319
after	O	320-325
initiation	O	326-336
of	O	337-339
glyburide	O	340-349
therapy	O	350-357
.	O	357-358

There	O	359-364
was	O	365-368
no	O	369-371
serologic	O	372-381
evidence	O	382-390
of	O	391-393
viral	B	394-399
infection	I	400-409
,	O	409-410
and	O	411-414
a	O	415-416
liver	O	417-422
biopsy	O	423-429
sample	O	430-436
showed	O	437-443
a	O	444-445
histologic	O	446-456
pattern	O	457-464
consistent	O	465-475
with	O	476-480
drug	B	481-485
-	I	485-486
induced	I	486-493
hepatitis	I	494-503
.	O	503-504

Both	O	505-509
patients	O	510-518
recovered	O	519-528
quickly	O	529-536
after	O	537-542
stopping	O	543-551
glyburide	O	552-561
therapy	O	562-569
and	O	570-573
have	O	574-578
remained	O	579-587
well	O	588-592
for	O	593-596
a	O	597-598
follow	O	599-605
-	O	605-606
up	O	606-608
period	O	609-615
of	O	616-618
1	O	619-620
year	O	621-625
.	O	625-626

Glyburide	O	627-636
can	O	637-640
produce	O	641-648
an	O	649-651
acute	B	652-657
hepatitis	I	658-667
-	I	667-668
like	I	668-672
illness	I	673-680
in	O	681-683
some	O	684-688
persons	O	689-696
.	O	696-697

Systolic	O	0-8
pressure	O	9-17
variation	O	18-27
is	O	28-30
greater	O	31-38
during	O	39-45
hemorrhage	B	46-56
than	O	57-61
during	O	62-68
sodium	O	69-75
nitroprusside	O	76-89
-	O	89-90
induced	O	90-97
hypotension	B	98-109
in	O	110-112
ventilated	O	113-123
dogs	O	124-128
.	O	128-129

The	O	130-133
systolic	O	134-142
pressure	O	143-151
variation	O	152-161
(	O	162-163
SPV	O	163-166
)	O	166-167
,	O	167-168
which	O	169-174
is	O	175-177
the	O	178-181
difference	O	182-192
between	O	193-200
the	O	201-204
maximal	O	205-212
and	O	213-216
minimal	O	217-224
values	O	225-231
of	O	232-234
the	O	235-238
systolic	O	239-247
blood	O	248-253
pressure	O	254-262
(	O	263-264
SBP	O	264-267
)	O	267-268
after	O	269-274
one	O	275-278
positive	O	279-287
-	O	287-288
pressure	O	288-296
breath	O	297-303
,	O	303-304
was	O	305-308
studied	O	309-316
in	O	317-319
ventilated	O	320-330
dogs	O	331-335
subjected	O	336-345
to	O	346-348
hypotension	B	349-360
.	O	360-361

Mean	O	362-366
arterial	O	367-375
pressure	O	376-384
was	O	385-388
decreased	O	389-398
to	O	399-401
50	O	402-404
mm	O	405-407
Hg	O	408-410
for	O	411-414
30	O	415-417
minutes	O	418-425
either	O	426-432
by	O	433-435
hemorrhage	B	436-446
(	O	447-448
HEM	B	448-451
,	O	451-452
n	O	453-454
=	O	455-456
7	O	457-458
)	O	458-459
or	O	460-462
by	O	463-465
continuous	O	466-476
infusion	O	477-485
of	O	486-488
sodium	O	489-495
nitroprusside	O	496-509
(	O	510-511
SNP	O	511-514
,	O	514-515
n	O	516-517
=	O	518-519
7	O	520-521
)	O	521-522
.	O	522-523

During	O	524-530
HEM	B	531-534
-	O	534-535
induced	O	535-542
hypotension	B	543-554
the	O	555-558
cardiac	O	559-566
output	O	567-573
was	O	574-577
significantly	O	578-591
lower	O	592-597
and	O	598-601
systemic	O	602-610
vascular	O	611-619
resistance	O	620-630
higher	O	631-637
compared	O	638-646
with	O	647-651
that	O	652-656
in	O	657-659
the	O	660-663
SNP	O	664-667
group	O	668-673
.	O	673-674

The	O	675-678
systemic	O	679-687
,	O	687-688
central	O	689-696
venous	O	697-703
,	O	703-704
pulmonary	O	705-714
capillary	O	715-724
wedge	O	725-730
pressures	O	731-740
,	O	740-741
and	O	742-745
heart	O	746-751
rates	O	752-757
,	O	757-758
were	O	759-763
similar	O	764-771
in	O	772-774
the	O	775-778
two	O	779-782
groups	O	783-789
.	O	789-790

Analysis	O	791-799
of	O	800-802
the	O	803-806
respiratory	O	807-818
changes	O	819-826
in	O	827-829
the	O	830-833
arterial	O	834-842
pressure	O	843-851
waveform	O	852-860
enabled	O	861-868
differentiation	O	869-884
between	O	885-892
the	O	893-896
two	O	897-900
groups	O	901-907
.	O	907-908

The	O	909-912
SPV	O	913-916
during	O	917-923
hypotension	B	924-935
was	O	936-939
15	O	940-942
.	O	942-943
7	O	943-944
+	O	945-946
/	O	946-947
-	O	947-948
6	O	949-950
.	O	950-951
7	O	951-952
mm	O	953-955
Hg	O	956-958
in	O	959-961
the	O	962-965
HEM	B	966-969
group	O	970-975
,	O	975-976
compared	O	977-985
with	O	986-990
9	O	991-992
.	O	992-993
1	O	993-994
+	O	995-996
/	O	996-997
-	O	997-998
2	O	999-1000
.	O	1000-1001
0	O	1001-1002
mm	O	1003-1005
Hg	O	1006-1008
in	O	1009-1011
the	O	1012-1015
SNP	O	1016-1019
group	O	1020-1025
(	O	1026-1027
P	O	1027-1028
less	O	1029-1033
than	O	1034-1038
0	O	1039-1040
.	O	1040-1041
02	O	1041-1043
)	O	1043-1044
.	O	1040-1041

The	O	1046-1049
delta	O	1050-1055
down	O	1056-1060
,	O	1060-1061
which	O	1062-1067
is	O	1068-1070
the	O	1071-1074
measure	O	1075-1082
of	O	1083-1085
decrease	O	1086-1094
of	O	1095-1097
SBP	O	1098-1101
after	O	1102-1107
a	O	1108-1109
mechanical	O	1110-1120
breath	O	1121-1127
,	O	1127-1128
was	O	1129-1132
20	O	1133-1135
.	O	1135-1136
3	O	1136-1137
+	O	1138-1139
/	O	1139-1140
-	O	1140-1141
8	O	1142-1143
.	O	1143-1144
4	O	1144-1145
and	O	1146-1149
10	O	1150-1152
.	O	1152-1153
1	O	1150-1151
+	O	1155-1156
/	O	1156-1157
-	O	1157-1158
3	O	1159-1160
.	O	1160-1161
8	O	1161-1162
mm	O	1163-1165
Hg	O	1166-1168
in	O	1169-1171
the	O	1172-1175
HEM	B	1176-1179
and	O	1180-1183
SNP	O	1184-1187
groups	O	1188-1194
,	O	1194-1195
respectively	O	1196-1208
,	O	1208-1209
during	O	1210-1216
hypotension	B	1217-1228
(	O	1229-1230
P	O	1230-1231
less	O	1232-1236
than	O	1237-1241
0	O	1242-1243
.	O	1243-1244
02	O	1244-1246
)	O	1246-1247
.	O	1243-1244

It	O	1249-1251
is	O	1252-1254
concluded	O	1255-1264
that	O	1265-1269
increases	O	1270-1279
in	O	1280-1282
the	O	1283-1286
SPV	O	1287-1290
and	O	1291-1294
the	O	1295-1298
delta	O	1299-1304
down	O	1305-1309
are	O	1310-1313
characteristic	O	1314-1328
of	O	1329-1331
a	O	1332-1333
hypotensive	B	1334-1345
state	O	1346-1351
due	O	1352-1355
to	O	1356-1358
a	O	1359-1360
predominant	O	1361-1372
decrease	O	1373-1381
in	O	1382-1384
preload	O	1385-1392
.	O	1392-1393

They	O	1394-1398
are	O	1399-1402
thus	O	1403-1407
more	O	1408-1412
important	O	1413-1422
during	O	1423-1429
absolute	O	1430-1438
hypovolemia	B	1439-1450
than	O	1451-1455
during	O	1456-1462
deliberate	O	1463-1473
hypotension	B	1474-1485
.	O	1485-1486

Drug	O	0-4
-	O	4-5
induced	O	5-12
arterial	O	13-21
spasm	B	22-27
relieved	O	28-36
by	O	37-39
lidocaine	O	40-49
.	O	49-50

Case	O	51-55
report	O	56-62
.	O	62-63

Following	O	64-73
major	O	74-79
intracranial	O	80-92
surgery	O	93-100
in	O	101-103
a	O	104-105
35	O	106-108
-	O	108-109
year	O	109-113
-	O	108-109
old	O	114-117
man	O	118-121
,	O	121-122
sodium	O	123-129
pentothal	O	130-139
was	O	140-143
intravenously	O	144-157
infused	O	158-165
to	O	166-168
minimize	O	169-177
cerebral	B	178-186
ischaemia	I	187-196
.	O	196-197

Intense	O	198-205
vasospasm	B	206-215
with	O	216-220
threatened	O	221-231
gangrene	B	232-240
arose	O	241-246
in	O	247-249
the	O	250-253
arm	O	254-257
used	O	258-262
for	O	263-266
the	O	267-270
infusion	O	271-279
.	O	279-280

Since	O	281-286
the	O	287-290
cranial	O	291-298
condition	O	299-308
precluded	O	309-318
use	O	319-322
of	O	323-325
more	O	326-330
usual	O	331-336
methods	O	337-344
,	O	344-345
lidocaine	O	346-355
was	O	356-359
given	O	360-365
intra	O	366-371
-	O	371-372
arterially	O	372-382
,	O	382-383
with	O	384-388
careful	O	389-396
cardiovascular	O	397-411
monitoring	O	412-422
,	O	422-423
to	O	424-426
counteract	O	427-437
the	O	438-441
vasospasm	B	442-451
.	O	451-452

The	O	453-456
treatment	O	457-466
was	O	467-470
rapidly	O	471-478
successful	O	479-489
.	O	489-490

Cerebral	O	0-8
blood	O	9-14
flow	O	15-19
and	O	20-23
metabolism	O	24-34
during	O	35-41
isoflurane	O	42-52
-	O	52-53
induced	O	53-60
hypotension	B	61-72
in	O	73-75
patients	O	76-84
subjected	O	85-94
to	O	95-97
surgery	O	98-105
for	O	106-109
cerebral	B	110-118
aneurysms	I	119-128
.	O	128-129

Cerebral	O	130-138
blood	O	139-144
flow	O	145-149
and	O	150-153
cerebral	O	154-162
metabolic	O	163-172
rate	O	173-177
for	O	178-181
oxygen	O	182-188
were	O	189-193
measured	O	194-202
during	O	203-209
isoflurane	O	210-220
-	O	220-221
induced	O	221-228
hypotension	B	229-240
in	O	241-243
10	O	244-246
patients	O	247-255
subjected	O	256-265
to	O	266-268
craniotomy	O	269-279
for	O	280-283
clipping	O	284-292
of	O	293-295
a	O	296-297
cerebral	B	298-306
aneurysm	I	307-315
.	O	315-316

Flow	O	317-321
and	O	322-325
metabolism	O	326-336
were	O	337-341
measured	O	342-350
5	O	351-352
-	O	352-353
13	O	353-355
days	O	356-360
after	O	361-366
the	O	367-370
subarachnoid	B	371-383
haemorrhage	I	384-395
by	O	396-398
a	O	399-400
modification	O	401-413
of	O	414-416
the	O	417-420
classical	O	421-430
Kety	O	431-435
-	O	435-436
Schmidt	O	436-443
technique	O	444-453
using	O	454-459
xenon	O	460-465
-	O	465-466
133	O	466-469
i	O	470-471
.	O	471-472
v	O	472-473
.	O	471-472

Anaesthesia	O	475-486
was	O	487-490
maintained	O	491-501
with	O	502-506
an	O	507-509
inspired	O	510-518
isoflurane	O	519-529
concentration	O	530-543
of	O	544-546
0	O	547-548
.	O	548-549
75	O	549-551
%	O	551-552
(	O	553-554
plus	O	554-558
67	O	559-561
%	O	561-562
nitrous	O	563-570
oxide	O	571-576
in	O	577-579
oxygen	O	580-586
)	O	586-587
,	O	587-588
during	O	589-595
which	O	596-601
CBF	O	602-605
and	O	606-609
CMRO2	O	610-615
were	O	616-620
34	O	621-623
.	O	623-624
3	O	621-622
+	O	626-627
/	O	627-628
-	O	628-629
2	O	630-631
.	O	631-632
1	O	632-633
ml	O	634-636
/	O	636-637
100	O	637-640
g	O	641-642
min	O	643-646
-	O	646-647
1	O	647-648
and	O	649-652
2	O	653-654
.	O	654-655
32	O	655-657
+	O	658-659
/	O	659-660
-	O	660-661
0	O	662-663
.	O	663-664
16	O	664-666
ml	O	667-669
/	O	669-670
100	O	670-673
g	O	674-675
min	O	676-679
-	O	679-680
1	O	680-681
at	O	682-684
PaCO2	O	685-690
4	O	691-692
.	O	692-693
1	O	693-694
+	O	695-696
/	O	696-697
-	O	697-698
0	O	699-700
.	O	700-701
1	O	701-702
kPa	O	703-706
(	O	707-708
mean	O	708-712
+	O	713-714
/	O	714-715
-	O	715-716
SEM	O	717-720
)	O	720-721
.	O	721-722

Controlled	O	723-733
hypotension	B	734-745
to	O	746-748
an	O	749-751
average	O	752-759
MAP	O	760-763
of	O	764-766
50	O	767-769
-	O	769-770
55	O	770-772
mm	O	773-775
Hg	O	776-778
was	O	779-782
induced	O	783-790
by	O	791-793
increasing	O	794-804
the	O	805-808
dose	O	809-813
of	O	814-816
isoflurane	O	817-827
,	O	827-828
and	O	829-832
maintained	O	833-843
at	O	844-846
an	O	847-849
inspired	O	850-858
concentration	O	859-872
of	O	873-875
2	O	876-877
.	O	877-878
2	O	876-877
+	O	880-881
/	O	881-882
-	O	882-883
0	O	884-885
.	O	885-886
2	O	886-887
%	O	887-888
.	O	885-886

This	O	890-894
resulted	O	895-903
in	O	904-906
a	O	907-908
significant	O	909-920
decrease	O	921-929
in	O	930-932
CMRO2	O	933-938
(	O	939-940
to	O	940-942
1	O	943-944
.	O	944-945
73	O	945-947
+	O	948-949
/	O	949-950
-	O	950-951
0	O	952-953
.	O	953-954
16	O	954-956
ml	O	957-959
/	O	959-960
100	O	960-963
g	O	964-965
min	O	966-969
-	O	969-970
1	O	970-971
)	O	971-972
,	O	972-973
while	O	974-979
CBF	O	980-983
was	O	984-987
unchanged	O	988-997
.	O	997-998

After	O	999-1004
the	O	1005-1008
clipping	O	1009-1017
of	O	1018-1020
the	O	1021-1024
aneurysm	B	1025-1033
the	O	1034-1037
isoflurane	O	1038-1048
concentration	O	1049-1062
was	O	1063-1066
reduced	O	1067-1074
to	O	1075-1077
0	O	1078-1079
.	O	1079-1080
75	O	1080-1082
%	O	1082-1083
.	O	1079-1080

There	O	1085-1090
was	O	1091-1094
a	O	1095-1096
significant	O	1097-1108
increase	O	1109-1117
in	O	1118-1120
CBF	O	1121-1124
,	O	1124-1125
although	O	1126-1134
CMRO2	O	1135-1140
was	O	1141-1144
unchanged	O	1145-1154
,	O	1154-1155
compared	O	1156-1164
with	O	1165-1169
pre	O	1170-1173
-	O	1173-1174
hypotensive	B	1174-1185
values	O	1186-1192
.	O	1192-1193

These	O	1194-1199
changes	O	1200-1207
might	O	1208-1213
offer	O	1214-1219
protection	O	1220-1230
to	O	1231-1233
brain	O	1234-1239
tissue	O	1240-1246
during	O	1247-1253
periods	O	1254-1261
of	O	1262-1264
induced	O	1265-1272
hypotension	B	1273-1284
.	O	1284-1285

Allergic	B	0-8
reaction	I	9-17
to	O	18-20
5	O	21-22
-	O	22-23
fluorouracil	O	23-35
infusion	O	36-44
.	O	44-45

An	O	46-48
allergic	B	49-57
reaction	I	58-66
consisting	O	67-77
of	O	78-80
angioneurotic	B	81-94
edema	I	95-100
secondary	O	101-110
to	O	111-113
continuous	O	114-124
infusion	O	125-133
5	O	134-135
-	O	135-136
fluorouracil	O	136-148
occurred	O	149-157
in	O	158-160
a	O	161-162
patient	O	163-170
with	O	171-175
recurrent	O	176-185
carcinoma	B	186-195
of	I	196-198
the	I	199-202
oral	I	203-207
cavity	I	208-214
,	O	214-215
cirrhosis	B	216-225
,	O	225-226
and	O	227-230
cisplatin	O	231-240
-	O	240-241
induced	O	241-248
impaired	B	249-257
renal	I	258-263
function	I	264-272
.	O	272-273

This	O	274-278
reaction	O	279-287
occurred	O	288-296
during	O	297-303
the	O	304-307
sixth	O	308-313
and	O	314-317
seventh	O	318-325
courses	O	326-333
of	O	334-336
infusional	O	337-347
chemotherapy	O	348-360
.	O	360-361

Oral	O	362-366
diphenhydramine	O	367-382
and	O	383-386
prednisone	O	387-397
were	O	398-402
ineffective	O	403-414
in	O	415-417
preventing	O	418-428
the	O	429-432
recurrence	O	433-443
of	O	444-446
the	O	447-450
allergic	B	451-459
reaction	I	460-468
.	O	468-469

Discontinuance	O	470-484
of	O	485-487
effective	O	488-497
chemotherapy	O	498-510
in	O	511-513
this	O	514-518
patient	O	519-526
during	O	527-533
partial	O	534-541
remission	O	542-551
resulted	O	552-560
in	O	561-563
fatal	O	564-569
disease	O	570-577
progression	O	578-589
.	O	589-590

Amiodarone	O	0-10
-	O	10-11
induced	O	11-18
sinoatrial	B	19-29
block	I	30-35
.	O	35-36

We	O	37-39
observed	O	40-48
sinoatrial	B	49-59
block	I	60-65
due	O	66-69
to	O	70-72
chronic	O	73-80
amiodarone	O	81-91
administration	O	92-106
in	O	107-109
a	O	110-111
5	O	112-113
-	O	113-114
year	O	114-118
-	O	113-114
old	O	119-122
boy	O	123-126
with	O	127-131
primary	B	132-139
cardiomyopathy	I	140-154
,	O	154-155
Wolff	B	156-161
-	I	161-162
Parkinson	I	162-171
-	I	161-162
White	I	172-177
syndrome	I	178-186
and	O	187-190
supraventricular	B	191-207
tachycardia	I	208-219
.	O	219-220

Reduction	O	221-230
in	O	231-233
the	O	234-237
dosage	O	238-244
of	O	245-247
amiodarone	O	248-258
resulted	O	259-267
in	O	268-270
the	O	271-274
disappearance	O	275-288
of	O	289-291
the	O	292-295
sinoatrial	B	296-306
block	I	307-312
and	O	313-316
the	O	317-320
persistence	O	321-332
of	O	333-335
asymptomatic	O	336-348
sinus	B	349-354
bradycardia	I	355-366
.	O	366-367

Possible	O	0-8
teratogenicity	O	9-23
of	O	24-26
sulphasalazine	O	27-41
.	O	41-42

Three	O	43-48
infants	O	49-56
,	O	56-57
born	O	58-62
of	O	63-65
two	O	66-69
mothers	O	70-77
with	O	78-82
inflammatory	B	83-95
bowel	I	96-101
disease	I	102-109
who	O	110-113
received	O	114-122
treatment	O	123-132
with	O	133-137
sulphasalazine	O	138-152
throughout	O	153-163
pregnancy	O	164-173
,	O	173-174
were	O	175-179
found	O	180-185
to	O	186-188
have	O	189-193
major	O	194-199
congenital	B	200-210
anomalies	I	211-220
.	O	220-221

In	O	222-224
the	O	225-228
singleton	O	229-238
pregnancy	O	239-248
,	O	248-249
the	O	250-253
mother	O	254-260
had	O	261-264
ulcerative	B	265-275
colitis	I	276-283
,	O	283-284
and	O	285-288
the	O	289-292
infant	O	293-299
,	O	299-300
a	O	301-302
male	O	303-307
,	O	307-308
had	O	309-312
coarctation	B	313-324
of	I	325-327
the	I	328-331
aorta	I	332-337
and	O	338-341
a	O	342-343
ventricular	B	344-355
septal	I	356-362
defect	I	363-369
.	O	369-370

In	O	371-373
the	O	374-377
twin	O	378-382
pregnancy	O	383-392
,	O	392-393
the	O	394-397
mother	O	398-404
had	O	405-408
Crohn	B	409-414
'	I	414-415
s	I	415-416
disease	I	417-424
.	O	424-425

The	O	426-429
first	O	430-435
twin	O	436-440
,	O	440-441
a	O	442-443
female	O	444-450
,	O	450-451
had	O	452-455
a	O	456-457
left	O	458-462
Potter	B	463-469
-	I	469-470
type	I	470-474
IIa	I	475-478
polycystic	I	479-489
kidney	I	490-496
and	O	497-500
a	O	501-502
rudimentary	B	503-514
left	I	515-519
uterine	I	520-527
cornu	I	528-533
.	O	533-534

The	O	535-538
second	O	539-545
twin	O	546-550
,	O	550-551
a	O	552-553
male	O	554-558
,	O	558-559
had	O	560-563
some	O	564-568
features	O	569-577
of	O	578-580
Potter	B	581-587
'	I	587-588
s	I	588-589
facies	I	590-596
,	O	596-597
hypoplastic	B	598-609
lungs	I	610-615
,	O	615-616
absent	B	617-623
kidneys	I	624-631
and	I	632-635
ureters	I	636-643
,	O	643-644
and	O	645-648
talipes	B	649-656
equinovarus	I	657-668
.	O	668-669

Despite	O	670-677
reports	O	678-685
to	O	686-688
the	O	689-692
contrary	O	693-701
,	O	701-702
it	O	703-705
is	O	706-708
suggested	O	709-718
that	O	719-723
sulphasalazine	O	724-738
may	O	739-742
be	O	743-745
teratogenic	O	746-757
.	O	757-758

Veno	B	0-4
-	I	4-5
occlusive	I	5-14
liver	I	15-20
disease	I	21-28
after	O	29-34
dacarbazine	O	35-46
therapy	O	47-54
(	O	55-56
DTIC	O	56-60
)	O	60-61
for	O	62-65
melanoma	B	66-74
.	O	74-75

A	O	76-77
case	O	78-82
of	O	83-85
veno	B	86-90
-	I	90-91
occlusive	I	91-100
disease	I	101-108
of	I	109-111
the	I	112-115
liver	I	116-121
with	O	122-126
fatal	O	127-132
outcome	O	133-140
after	O	141-146
dacarbazine	O	147-158
(	O	159-160
DTIC	O	160-164
)	O	164-165
therapy	O	166-173
for	O	174-177
melanoma	B	178-186
is	O	187-189
reported	O	190-198
.	O	198-199

There	O	200-205
was	O	206-209
a	O	210-211
fulminant	O	212-221
clinical	O	222-230
course	O	231-237
from	O	238-242
start	O	243-248
of	O	249-251
symptoms	O	252-260
until	O	261-266
death	B	267-272
.	O	272-273

At	O	274-276
autopsy	O	277-284
the	O	285-288
liver	O	289-294
was	O	295-298
enlarged	O	299-307
and	O	308-311
firm	O	312-316
with	O	317-321
signs	O	322-327
of	O	328-330
venous	B	331-337
congestion	I	338-348
.	O	348-349

Small	O	350-355
-	O	355-356
and	O	357-360
medium	O	361-367
-	O	367-368
sized	O	368-373
hepatic	O	374-381
veins	O	382-387
were	O	388-392
blocked	O	393-400
by	O	401-403
thrombosis	B	404-414
.	O	414-415

Eosinophilic	O	416-428
infiltrations	O	429-442
were	O	443-447
found	O	448-453
around	O	454-460
the	O	461-464
vessels	O	465-472
.	O	472-473

Published	O	474-483
cases	O	484-489
from	O	490-494
the	O	495-498
literature	O	499-509
are	O	510-513
reviewed	O	514-522
and	O	523-526
pertinent	O	527-536
features	O	537-545
discussed	O	546-555
.	O	555-556

A	O	0-1
case	O	2-6
of	O	7-9
tardive	B	10-17
dyskinesia	I	18-28
caused	O	29-35
by	O	36-38
metoclopramide	O	39-53
.	O	53-54

Abnormal	B	55-63
involuntary	I	64-75
movements	I	76-85
appeared	O	86-94
in	O	95-97
the	O	98-101
mouth	O	102-107
,	O	107-108
tongue	O	109-115
,	O	115-116
neck	O	117-121
and	O	122-125
abdomen	O	126-133
of	O	134-136
a	O	137-138
64	O	139-141
-	O	141-142
year	O	142-146
-	O	141-142
old	O	147-150
male	O	151-155
patient	O	156-163
after	O	164-169
he	O	170-172
took	O	173-177
metoclopramide	O	178-192
for	O	193-196
gastrointestinal	B	197-213
disorder	I	214-222
in	O	223-225
a	O	226-227
regimen	O	228-235
of	O	236-238
30	O	239-241
mg	O	242-244
per	O	245-248
day	O	249-252
for	O	253-256
a	O	257-258
total	O	259-264
of	O	265-267
about	O	268-273
260	O	274-277
days	O	278-282
.	O	282-283

The	O	284-287
symptoms	O	288-296
exacerbated	O	297-308
to	O	309-311
a	O	312-313
maximum	O	314-321
in	O	322-324
a	O	325-326
month	O	327-332
.	O	332-333

When	O	334-338
the	O	339-342
metoclopramide	O	343-357
administration	O	358-372
was	O	373-376
discontinued	O	377-389
,	O	389-390
the	O	391-394
abnormal	B	395-403
movements	I	404-413
gradually	O	414-423
improved	O	424-432
to	O	433-435
a	O	436-437
considerable	O	438-450
extent	O	451-457
.	O	457-458

Attention	O	459-468
to	O	469-471
the	O	472-475
possible	O	476-484
induction	O	485-494
of	O	495-497
specific	O	498-506
tardive	B	507-514
dyskinesia	I	515-525
is	O	526-528
called	O	529-535
for	O	536-539
in	O	540-542
the	O	543-546
use	O	547-550
of	O	551-553
this	O	554-558
drug	O	559-563
.	O	563-564

Further	O	0-7
observations	O	8-20
on	O	21-23
the	O	24-27
electrophysiologic	O	28-46
effects	O	47-54
of	O	55-57
oral	O	58-62
amiodarone	O	63-73
therapy	O	74-81
.	O	81-82

A	O	83-84
case	O	85-89
is	O	90-92
presented	O	93-102
of	O	103-105
a	O	106-107
reversible	O	108-118
intra	B	119-124
-	I	124-125
Hisian	I	125-131
block	I	132-137
occurring	O	138-147
under	O	148-153
amiodarone	O	154-164
treatment	O	165-174
for	O	175-178
atrial	B	179-185
tachycardia	I	186-197
in	O	198-200
a	O	201-202
patient	O	203-210
without	O	211-218
clear	O	219-224
intraventricular	B	225-241
conduction	I	242-252
abnormalities	I	253-266
.	O	266-267

His	O	268-271
bundle	O	272-278
recordings	O	279-289
showed	O	290-296
an	O	297-299
atrial	B	300-306
tachycardia	I	307-318
with	O	319-323
intermittent	O	324-336
exit	O	337-341
block	O	342-347
and	O	348-351
greatly	O	352-359
prolonged	O	360-369
BH	O	370-372
and	O	373-376
HV	O	377-379
intervals	O	380-389
(	O	390-391
40	O	391-393
and	O	394-397
100	O	398-401
msec	O	402-406
,	O	406-407
respectively	O	408-420
)	O	420-421
.	O	421-422

Thirty	O	423-429
days	O	430-434
after	O	435-440
amiodarone	O	441-451
discontinuation	O	452-467
,	O	467-468
His	O	469-472
bundle	O	473-479
electrograms	O	480-492
showed	O	493-499
atrial	B	500-506
flutter	I	507-514
without	O	515-522
intra	O	523-528
-	O	528-529
Hisian	O	529-535
or	O	536-538
infra	O	539-544
-	O	544-545
Hisian	O	545-551
delay	O	552-557
.	O	557-558

Amiodarone	O	559-569
should	O	570-576
be	O	577-579
used	O	580-584
with	O	585-589
caution	O	590-597
during	O	598-604
long	O	605-609
-	O	609-610
term	O	610-614
oral	O	615-619
therapy	O	620-627
in	O	628-630
patients	O	631-639
with	O	640-644
or	O	645-647
without	O	648-655
clear	O	656-661
intraventricular	O	662-678
conduction	O	679-689
defects	O	690-697
.	O	697-698

Busulfan	O	0-8
-	O	8-9
induced	O	9-16
hemorrhagic	B	17-28
cystitis	I	29-37
.	O	37-38

A	O	39-40
case	O	41-45
of	O	46-48
a	O	49-50
busulfan	O	51-59
-	O	59-60
induced	O	60-67
hemorrhage	B	68-78
cystitis	I	79-87
is	O	88-90
reported	O	91-99
.	O	99-100

Spontaneous	O	101-112
resolution	O	113-123
occurred	O	124-132
following	O	133-142
cessation	O	143-152
of	O	153-155
the	O	156-159
drug	O	160-164
.	O	164-165

The	O	166-169
similarity	O	170-180
between	O	181-188
the	O	189-192
histologic	O	193-203
appearances	O	204-215
of	O	216-218
busulfan	O	219-227
cystitis	B	228-236
and	O	237-240
both	O	241-245
radiation	O	246-255
and	O	256-259
cyclophosphamide	O	260-276
-	O	276-277
induced	O	277-284
cystitis	B	285-293
is	O	294-296
discussed	O	297-306
and	O	307-310
the	O	311-314
world	O	315-320
literature	O	321-331
reviewed	O	332-340
.	O	340-341

In	O	342-344
view	O	345-349
of	O	350-352
the	O	353-356
known	O	357-362
tendency	O	363-371
of	O	372-374
busulfan	O	375-383
to	O	384-386
induce	O	387-393
cellular	O	394-402
atypia	O	403-409
and	O	410-413
carcinoma	B	414-423
in	O	424-426
other	O	427-432
sites	O	433-438
,	O	438-439
periodic	O	440-448
urinary	O	449-456
cytology	O	457-465
is	O	466-468
suggested	O	469-478
in	O	479-481
patients	O	482-490
on	O	491-493
long	O	494-498
-	O	498-499
term	O	499-503
therapy	O	504-511
.	O	511-512

Rebound	O	0-7
hypertensive	B	8-20
after	O	21-26
sodium	O	27-33
nitroprusside	O	34-47
prevented	O	48-57
by	O	58-60
saralasin	O	61-70
in	O	71-73
rats	O	74-78
.	O	78-79

The	O	80-83
role	O	84-88
of	O	89-91
the	O	92-95
renin	O	96-101
-	O	101-102
-	O	101-102
angiotensin	O	103-114
system	O	115-121
in	O	122-124
the	O	125-128
maintenance	O	129-140
of	O	141-143
blood	O	144-149
pressure	O	150-158
during	O	159-165
halothane	O	166-175
anesthesia	O	176-186
and	O	187-190
sodium	O	191-197
nitroprusside	O	198-211
(	O	212-213
SNP	O	213-216
)	O	216-217
-	O	217-218
induced	O	218-225
hypotension	B	226-237
was	O	238-241
evaluated	O	242-251
.	O	251-252

Control	O	253-260
rats	O	261-265
received	O	266-274
halothane	O	275-284
anesthesia	O	285-295
(	O	296-297
1	O	297-298
MAC	O	299-302
)	O	302-303
for	O	304-307
one	O	308-311
hour	O	312-316
,	O	316-317
followed	O	318-326
by	O	327-329
SNP	O	330-333
infusion	O	334-342
,	O	342-343
40	O	344-346
microgram	O	347-356
/	O	356-357
kg	O	357-359
/	O	356-357
min	O	360-363
,	O	363-364
for	O	365-368
30	O	369-371
min	O	372-375
,	O	375-376
followed	O	377-385
by	O	386-388
a	O	389-390
30	O	391-393
-	O	393-394
min	O	394-397
recovery	O	398-406
period	O	407-413
.	O	413-414

A	O	415-416
second	O	417-423
group	O	424-429
of	O	430-432
rats	O	433-437
was	O	438-441
treated	O	442-449
identically	O	450-461
and	O	462-465
,	O	465-466
in	O	467-469
addition	O	470-478
,	O	478-479
received	O	480-488
an	O	489-491
infusion	O	492-500
of	O	501-503
saralasin	O	504-513
(	O	514-515
a	O	515-516
competitive	O	517-528
inhibitor	O	529-538
of	O	539-541
angiotensin	O	542-553
II	O	554-556
)	O	556-557
throughout	O	558-568
the	O	569-572
experimental	O	573-585
period	O	586-592
.	O	592-593

In	O	594-596
each	O	597-601
group	O	602-607
,	O	607-608
SNP	O	609-612
infusion	O	613-621
resulted	O	622-630
in	O	631-633
an	O	634-636
initial	O	637-644
decrease	O	645-653
in	O	654-656
blood	O	657-662
pressure	O	663-671
from	O	672-676
86	O	677-679
torr	O	680-684
and	O	685-688
83	O	689-691
torr	O	692-696
,	O	696-697
respectively	O	698-710
,	O	710-711
to	O	712-714
48	O	715-717
torr	O	718-722
.	O	722-723

During	O	724-730
the	O	731-734
SNP	O	735-738
infusion	O	739-747
the	O	748-751
control	O	752-759
animals	O	760-767
demonstrated	O	768-780
a	O	781-782
progressive	O	783-794
increase	B	795-803
in	I	804-806
blood	I	807-812
pressure	I	813-821
to	O	822-824
61	O	825-827
torr	O	828-832
,	O	832-833
whereas	O	834-841
the	O	842-845
saralasin	O	846-855
-	O	855-856
treated	O	856-863
animals	O	864-871
showed	O	872-878
no	O	879-881
change	O	882-888
.	O	888-889

Following	O	890-899
discontinuation	O	900-915
of	O	916-918
SNP	O	919-922
,	O	922-923
blood	O	924-929
pressure	O	930-938
in	O	939-941
the	O	942-945
control	O	946-953
animals	O	954-961
rebounded	O	962-971
to	O	972-974
94	O	975-977
torr	O	978-982
,	O	982-983
as	O	984-986
compared	O	987-995
with	O	996-1000
78	O	1001-1003
torr	O	1004-1008
in	O	1009-1011
the	O	1012-1015
saralasin	O	1016-1025
-	O	1025-1026
treated	O	1026-1033
rats	O	1034-1038
.	O	1038-1039

This	O	1040-1044
study	O	1045-1050
indicates	O	1051-1060
that	O	1061-1065
with	O	1066-1070
stable	O	1071-1077
halothane	O	1078-1087
anesthesia	O	1088-1098
,	O	1098-1099
the	O	1100-1103
partial	O	1104-1111
recovery	O	1112-1120
of	O	1121-1123
blood	O	1124-1129
pressure	O	1130-1138
during	O	1139-1145
SNP	O	1146-1149
infusion	O	1150-1158
and	O	1159-1162
the	O	1163-1166
post	O	1167-1171
-	O	1171-1172
SNP	O	1172-1175
rebound	O	1176-1183
of	O	1184-1186
blood	O	1187-1192
pressure	O	1193-1201
can	O	1202-1205
be	O	1206-1208
completely	O	1209-1219
blocked	O	1220-1227
by	O	1228-1230
saralasin	O	1231-1240
.	O	1240-1241

This	O	1242-1246
demonstrates	O	1247-1259
the	O	1260-1263
participation	O	1264-1277
of	O	1278-1280
the	O	1281-1284
renin	O	1285-1290
-	O	1290-1291
-	O	1290-1291
angiotensin	O	1292-1303
system	O	1304-1310
in	O	1311-1313
antagonizing	O	1314-1326
the	O	1327-1330
combined	O	1331-1339
hypotensive	B	1340-1351
effects	O	1352-1359
of	O	1360-1362
halothane	O	1363-1372
and	O	1373-1376
SNP	O	1377-1380
.	O	1380-1381

Toxic	B	0-5
hepatitis	I	6-15
induced	O	16-23
by	O	24-26
antithyroid	O	27-38
drugs	O	39-44
:	O	44-45
four	O	46-50
cases	O	51-56
including	O	57-66
one	O	67-70
with	O	71-75
cross	O	76-81
-	O	81-82
reactivity	O	82-92
between	O	93-100
carbimazole	O	101-112
and	O	113-116
benzylthiouracil	O	117-133
.	O	133-134

OBJECTIVE	O	135-144
:	O	144-145
This	O	146-150
study	O	151-156
was	O	157-160
conducted	O	161-170
to	O	171-173
assess	O	174-180
the	O	181-184
occurrence	O	185-195
of	O	196-198
hepatic	B	199-206
adverse	I	207-214
effects	I	215-222
encountered	O	223-234
with	O	235-239
antithyroid	O	240-251
drugs	O	252-257
.	O	257-258

METHODS	O	259-266
:	O	266-267
Retrospective	O	268-281
review	O	282-288
of	O	289-291
medical	O	292-299
records	O	300-307
of	O	308-310
236	O	311-314
patients	O	315-323
with	O	324-328
hyperthyroidism	B	329-344
admitted	O	345-353
in	O	354-356
our	O	357-360
department	O	361-371
(	O	372-373
in	O	373-375
-	O	375-376
or	O	377-379
out	O	380-383
-	O	383-384
patients	O	384-392
)	O	392-393
from	O	394-398
1986	O	399-403
to	O	404-406
1992	O	407-411
.	O	411-412

RESULTS	O	413-420
:	O	420-421
Four	O	422-426
patients	O	427-435
(	O	436-437
1	O	437-438
.	O	438-439
7	O	439-440
%	O	440-441
)	O	441-442
were	O	443-447
identified	O	448-458
with	O	459-463
toxic	B	464-469
hepatitis	I	470-479
which	O	480-485
could	O	486-491
reasonably	O	492-502
be	O	503-505
attributed	O	506-516
to	O	517-519
the	O	520-523
use	O	524-527
of	O	528-530
antithyroid	O	531-542
agent	O	543-548
.	O	548-549

Two	O	550-553
patients	O	554-562
had	O	563-566
a	O	567-568
cholestatic	B	569-580
hepatitis	I	581-590
induced	O	591-598
by	O	599-601
carbimazole	O	602-613
(	O	614-615
N	O	615-616
omercazole	O	618-628
)	O	628-629
.	O	629-630

Two	O	631-634
others	O	635-641
had	O	642-645
a	O	646-647
mixed	O	648-653
(	O	654-655
cholestatic	B	655-666
and	O	667-670
cytolytic	O	671-680
)	O	680-681
hepatitis	B	682-691
following	O	692-701
carbimazole	O	702-713
.	O	713-714

One	O	715-718
of	O	719-721
the	O	722-725
latter	O	726-732
two	O	733-736
patients	O	737-745
further	O	746-753
experienced	O	754-765
a	O	766-767
cytolytic	O	768-777
hepatitis	B	778-787
which	O	788-793
appeared	O	794-802
after	O	803-808
Benzylthiouracil	O	809-825
(	O	826-827
Basd	O	827-831
ne	O	833-835
)	O	835-836
had	O	837-840
replaced	O	841-849
carbimazole	O	850-861
.	O	861-862

Biological	O	863-873
features	O	874-882
of	O	883-885
hepatitis	B	886-895
disappeared	O	896-907
in	O	908-910
all	O	911-914
cases	O	915-920
after	O	921-926
cessation	O	927-936
of	O	937-939
the	O	940-943
incriminated	O	944-956
drug	O	957-961
,	O	961-962
while	O	963-968
biliary	O	969-976
,	O	976-977
viral	O	978-983
and	O	984-987
immunological	O	988-1001
searches	O	1002-1010
were	O	1011-1015
negative	O	1016-1024
.	O	1024-1025

Only	O	1026-1030
2	O	1031-1032
patients	O	1033-1041
of	O	1042-1044
our	O	1045-1048
retrospective	O	1049-1062
study	O	1063-1068
experienced	O	1069-1080
a	O	1081-1082
mild	O	1083-1087
or	O	1088-1090
severe	O	1091-1097
neutropenia	B	1098-1109
.	O	1109-1110

CONCLUSION	O	1111-1121
:	O	1121-1122
Toxic	B	1123-1128
hepatitis	I	1129-1138
is	O	1139-1141
a	O	1142-1143
potential	O	1144-1153
adverse	O	1154-1161
effect	O	1162-1168
of	O	1169-1171
antithyroid	O	1172-1183
drugs	O	1184-1189
which	O	1190-1195
warrants	O	1196-1204
,	O	1204-1205
as	O	1206-1208
for	O	1209-1212
haematological	O	1213-1227
disturbances	O	1228-1240
,	O	1240-1241
a	O	1242-1243
pre	O	1244-1247
-	O	1247-1248
therapeutic	O	1248-1259
determination	O	1260-1273
and	O	1274-1277
a	O	1278-1279
careful	O	1280-1287
follow	O	1288-1294
-	O	1294-1295
up	O	1295-1297
of	O	1298-1300
relevant	O	1301-1309
biological	O	1310-1320
markers	O	1321-1328
.	O	1328-1329

Moreover	O	1330-1338
,	O	1338-1339
hepatotoxicity	B	1340-1354
may	O	1355-1358
not	O	1359-1362
be	O	1363-1365
restricted	O	1366-1376
to	O	1377-1379
one	O	1380-1383
class	O	1384-1389
of	O	1390-1392
antithyroid	O	1393-1404
agents	O	1405-1411
.	O	1411-1412

Study	O	0-5
of	O	6-8
the	O	9-12
role	O	13-17
of	O	18-20
vitamin	O	21-28
B12	O	29-32
and	O	33-36
folinic	O	37-44
acid	O	45-49
supplementation	O	50-65
in	O	66-68
preventing	O	69-79
hematologic	O	80-91
toxicity	B	92-100
of	O	101-103
zidovudine	O	104-114
.	O	114-115

A	O	116-117
prospective	O	118-129
,	O	129-130
randomized	O	131-141
study	O	142-147
was	O	148-151
conducted	O	152-161
to	O	162-164
evaluate	O	165-173
the	O	174-177
role	O	178-182
of	O	183-185
vitamin	O	186-193
B12	O	194-197
and	O	198-201
folinic	O	202-209
acid	O	210-214
supplementation	O	215-230
in	O	231-233
preventing	O	234-244
zidovudine	O	245-255
(	O	256-257
ZDV	O	257-260
)	O	260-261
-	O	261-262
induced	O	262-269
bone	B	270-274
marrow	I	275-281
suppression	I	282-293
.	O	293-294

Seventy	O	295-302
-	O	302-303
five	O	303-307
human	B	308-313
immunodeficiency	I	314-330
virus	I	331-336
(	I	337-338
HIV	I	338-341
)	I	341-342
-	I	342-343
infected	I	343-351
patients	O	352-360
with	O	361-365
CD4	O	366-369
+	O	369-370
cell	O	371-375
counts	O	376-382
<	O	383-384
500	O	385-388
/	O	388-389
mm3	O	389-392
were	O	393-397
randomized	O	398-408
to	O	409-411
receive	O	412-419
either	O	420-426
ZDV	O	427-430
(	O	431-432
500	O	432-435
mg	O	436-438
daily	O	439-444
)	O	444-445
alone	O	446-451
(	O	452-453
group	O	453-458
I	O	459-460
,	O	460-461
n	O	462-463
=	O	464-465
38	O	466-468
)	O	468-469
or	O	470-472
in	O	473-475
combination	O	476-487
with	O	488-492
folinic	O	493-500
acid	O	501-505
(	O	506-507
15	O	507-509
mg	O	510-512
daily	O	513-518
)	O	518-519
and	O	520-523
intramascular	O	524-537
vitamin	O	538-545
B12	O	546-549
(	O	550-551
1000	O	551-555
micrograms	O	556-566
monthly	O	567-574
)	O	574-575
(	O	576-577
group	O	577-582
II	O	583-585
,	O	585-586
n	O	587-588
=	O	589-590
37	O	591-593
)	O	593-594
.	O	594-595

Finally	O	596-603
,	O	603-604
15	O	605-607
patients	O	608-616
were	O	617-621
excluded	O	622-630
from	O	631-635
the	O	636-639
study	O	640-645
(	O	646-647
noncompliance	O	647-660
14	O	661-663
,	O	663-664
death	B	665-670
1	O	671-672
)	O	672-673
;	O	673-674
thus	O	675-679
,	O	679-680
60	O	681-683
patients	O	684-692
(	O	693-694
31	O	694-696
in	O	697-699
group	O	700-705
I	O	706-707
and	O	708-711
29	O	712-714
in	O	715-717
group	O	718-723
II	O	724-726
)	O	726-727
were	O	728-732
eligible	O	733-741
for	O	742-745
analysis	O	746-754
.	O	754-755

No	O	756-758
significant	O	759-770
differences	O	771-782
between	O	783-790
groups	O	791-797
were	O	798-802
found	O	803-808
at	O	809-811
enrollment	O	812-822
.	O	822-823

During	O	824-830
the	O	831-834
study	O	835-840
,	O	840-841
vitamin	O	842-849
B12	O	850-853
and	O	854-857
folate	O	858-864
levels	O	865-871
were	O	872-876
significantly	O	877-890
higher	O	891-897
in	O	898-900
group	O	901-906
II	O	907-909
patients	O	910-918
;	O	918-919
however	O	920-927
,	O	927-928
no	O	929-931
differences	O	932-943
in	O	944-946
hemoglobin	O	947-957
,	O	957-958
hematocrit	O	959-969
,	O	969-970
mean	O	971-975
corpuscular	O	976-987
volume	O	988-994
,	O	994-995
and	O	996-999
white	O	1000-1005
-	O	1005-1006
cell	O	1006-1010
,	O	1010-1011
neutrophil	O	1012-1022
and	O	1023-1026
platelet	O	1027-1035
counts	O	1036-1042
were	O	1043-1047
observed	O	1048-1056
between	O	1057-1064
groups	O	1065-1071
at	O	1072-1074
3	O	1075-1076
,	O	1076-1077
6	O	1078-1079
,	O	1079-1080
9	O	1081-1082
and	O	1083-1086
12	O	1087-1089
months	O	1090-1096
.	O	1096-1097

Severe	O	1098-1104
hematologic	O	1105-1116
toxicity	B	1117-1125
(	O	1126-1127
neutrophil	O	1127-1137
count	O	1138-1143
<	O	1144-1145
1000	O	1146-1150
/	O	1150-1151
mm3	O	1151-1154
and	O	1155-1158
/	O	1158-1159
or	O	1159-1161
hemoglobin	O	1162-1172
<	O	1173-1174
8	O	1175-1176
g	O	1177-1178
/	O	1178-1179
dl	O	1179-1181
)	O	1181-1182
occurred	O	1183-1191
in	O	1192-1194
4	O	1195-1196
patients	O	1197-1205
assigned	O	1206-1214
to	O	1215-1217
group	O	1218-1223
I	O	1224-1225
and	O	1226-1229
7	O	1230-1231
assigned	O	1232-1240
to	O	1241-1243
group	O	1244-1249
II	O	1250-1252
.	O	1252-1253

There	O	1254-1259
was	O	1260-1263
no	O	1264-1266
correlation	O	1267-1278
between	O	1279-1286
vitamin	O	1287-1294
B12	O	1295-1298
or	O	1299-1301
folate	O	1302-1308
levels	O	1309-1315
and	O	1316-1319
development	O	1320-1331
of	O	1332-1334
myelosuppression	B	1335-1351
.	O	1351-1352

Vitamin	O	1353-1360
B12	O	1361-1364
and	O	1365-1368
folinic	O	1369-1376
acid	O	1377-1381
supplementation	O	1382-1397
of	O	1398-1400
ZDV	O	1401-1404
therapy	O	1405-1412
does	O	1413-1417
not	O	1418-1421
seem	O	1422-1426
useful	O	1427-1433
in	O	1434-1436
preventing	O	1437-1447
or	O	1448-1450
reducing	O	1451-1459
ZDV	O	1460-1463
-	O	1463-1464
induced	O	1464-1471
myelotoxicity	B	1472-1485
in	O	1486-1488
the	O	1489-1492
overall	O	1493-1500
treated	O	1501-1508
population	O	1509-1519
,	O	1519-1520
although	O	1521-1529
a	O	1530-1531
beneficial	O	1532-1542
effect	O	1543-1549
in	O	1550-1552
certain	O	1553-1560
subgroups	O	1561-1570
of	O	1571-1573
patients	O	1574-1582
cannot	O	1583-1589
be	O	1590-1592
excluded	O	1593-1601
.	O	1601-1602

Acute	O	0-5
confusion	B	6-15
induced	O	16-23
by	O	24-26
a	O	27-28
high	O	29-33
-	O	33-34
dose	O	34-38
infusion	O	39-47
of	O	48-50
5	O	51-52
-	O	52-53
fluorouracil	O	53-65
and	O	66-69
folinic	O	70-77
acid	O	78-82
.	O	82-83

A	O	84-85
61	O	86-88
-	O	88-89
year	O	89-93
-	O	88-89
old	O	94-97
man	O	98-101
was	O	102-105
treated	O	106-113
with	O	114-118
combination	O	119-130
chemotherapy	O	131-143
incorporating	O	144-157
cisplatinum	O	158-169
,	O	169-170
etoposide	O	171-180
,	O	180-181
high	O	182-186
-	O	186-187
dose	O	187-191
5	O	192-193
-	O	193-194
fluorouracil	O	194-206
(	O	207-208
2	O	208-209
,	O	209-210
250	O	210-213
mg	O	214-216
/	O	216-217
m2	O	217-219
/	O	216-217
24	O	220-222
hours	O	223-228
)	O	228-229
and	O	230-233
folinic	O	234-241
acid	O	242-246
for	O	247-250
an	O	251-253
inoperable	O	254-264
gastric	B	265-272
adenocarcinoma	I	273-287
.	O	287-288

He	O	289-291
developed	O	292-301
acute	O	302-307
neurologic	O	308-318
symptoms	O	319-327
of	O	328-330
mental	O	331-337
confusion	B	338-347
,	O	347-348
disorientation	B	349-363
and	O	364-367
irritability	B	368-380
,	O	380-381
and	O	382-385
then	O	386-390
lapsed	O	391-397
into	O	398-402
a	O	403-404
deep	O	405-409
coma	B	410-414
,	O	414-415
lasting	O	416-423
for	O	424-427
approximately	O	428-441
40	O	442-444
hours	O	445-450
during	O	451-457
the	O	458-461
first	O	462-467
dose	O	468-472
(	O	473-474
day	O	474-477
2	O	478-479
)	O	479-480
of	O	481-483
5	O	484-485
-	O	485-486
fluorouracil	O	486-498
and	O	499-502
folinic	O	503-510
acid	O	511-515
infusion	O	516-524
.	O	524-525

This	O	526-530
complication	O	531-543
reappeared	O	544-554
on	O	555-557
day	O	558-561
25	O	562-564
during	O	565-571
the	O	572-575
second	O	576-582
dose	O	583-587
of	O	588-590
5	O	591-592
-	O	592-593
fluorouracil	O	593-605
and	O	606-609
folinic	O	610-617
acid	O	618-622
,	O	622-623
which	O	624-629
were	O	630-634
then	O	635-639
the	O	640-643
only	O	644-648
drugs	O	649-654
given	O	655-660
.	O	660-661

Because	O	662-669
folinic	O	670-677
acid	O	678-682
was	O	683-686
unlikely	O	687-695
to	O	696-698
be	O	699-701
associated	O	702-712
with	O	713-717
this	O	718-722
condition	O	723-732
,	O	732-733
neurotoxicity	B	734-747
due	O	748-751
to	O	752-754
high	O	755-759
-	O	759-760
dose	O	760-764
5	O	765-766
-	O	766-767
fluorouracil	O	767-779
was	O	780-783
highly	O	784-790
suspected	O	791-800
.	O	800-801

The	O	802-805
pathogenesis	O	806-818
of	O	819-821
5	O	822-823
-	O	823-824
fluorouracil	O	824-836
neurotoxicity	B	837-850
may	O	851-854
be	O	855-857
due	O	858-861
to	O	862-864
a	O	865-866
Krebs	O	867-872
cycle	O	873-878
blockade	O	879-887
by	O	888-890
fluoroacetate	O	891-904
and	O	905-908
fluorocitrate	O	909-922
,	O	922-923
thiamine	O	924-932
deficiency	O	933-943
,	O	943-944
or	O	945-947
dihydrouracil	O	948-961
dehydrogenase	O	962-975
deficiency	O	976-986
.	O	986-987

High	O	988-992
-	O	992-993
dose	O	993-997
5	O	998-999
-	O	999-1000
fluorouracil	O	1000-1012
/	O	1012-1013
folinic	O	1013-1020
acid	O	1021-1025
infusion	O	1026-1034
therapy	O	1035-1042
has	O	1043-1046
recently	O	1047-1055
become	O	1056-1062
a	O	1063-1064
popular	O	1065-1072
regimen	O	1073-1080
for	O	1081-1084
various	O	1085-1092
cancers	B	1093-1100
.	O	1100-1101

It	O	1102-1104
is	O	1105-1107
necessary	O	1108-1117
that	O	1118-1122
both	O	1123-1127
oncologists	O	1128-1139
and	O	1140-1143
neurologists	O	1144-1156
be	O	1157-1159
fully	O	1160-1165
aware	O	1166-1171
of	O	1172-1174
this	O	1175-1179
unusual	O	1180-1187
complication	O	1188-1200
.	O	1200-1201

Effect	O	0-6
of	O	7-9
switching	O	10-19
carbamazepine	O	20-33
to	O	34-36
oxcarbazepine	O	37-50
on	O	51-53
the	O	54-57
plasma	O	58-64
levels	O	65-71
of	O	72-74
neuroleptics	O	75-87
.	O	87-88

A	O	89-90
case	O	91-95
report	O	96-102
.	O	102-103

Carbamazepine	O	104-117
was	O	118-121
switched	O	122-130
to	O	131-133
its	O	134-137
10	O	138-140
-	O	140-141
keto	O	141-145
analogue	O	146-154
oxcarbazepine	O	155-168
among	O	169-174
six	O	175-178
difficult	O	179-188
-	O	188-189
to	O	189-191
-	O	188-189
treat	O	192-197
schizophrenic	B	198-211
or	O	212-214
organic	B	215-222
psychotic	I	223-232
patients	O	233-241
using	O	242-247
concomitantly	O	248-261
haloperidol	O	262-273
,	O	273-274
chlorpromazine	O	275-289
or	O	290-292
clozapine	O	293-302
.	O	302-303

This	O	304-308
change	O	309-315
resulted	O	316-324
within	O	325-331
2	O	332-333
-	O	333-334
4	O	334-335
weeks	O	336-341
in	O	342-344
the	O	345-348
50	O	349-351
-	O	351-352
200	O	352-355
%	O	355-356
increase	O	357-365
in	O	366-368
the	O	369-372
plasma	O	373-379
levels	O	380-386
of	O	387-389
these	O	390-395
neuroleptics	O	396-408
and	O	409-412
the	O	413-416
appearance	O	417-427
of	O	428-430
extrapyramidal	B	431-445
symptoms	I	446-454
.	O	454-455

None	O	456-460
of	O	461-463
the	O	464-467
patients	O	468-476
showed	O	477-483
any	O	484-487
clinical	O	488-496
deteriotation	O	497-510
during	O	511-517
the	O	518-521
following	O	522-531
3	O	532-533
-	O	533-534
6	O	534-535
months	O	536-542
.	O	542-543

The	O	544-547
results	O	548-555
of	O	556-558
this	O	559-563
case	O	564-568
report	O	569-575
support	O	576-583
the	O	584-587
idea	O	588-592
that	O	593-597
in	O	598-600
contrast	O	601-609
with	O	610-614
carbamazepine	O	615-628
oxcarbazepine	O	629-642
does	O	643-647
not	O	648-651
induce	O	652-658
the	O	659-662
hepatic	O	663-670
microsomal	O	671-681
enzyme	O	682-688
systems	O	689-696
regulating	O	697-707
the	O	708-711
inactivation	O	712-724
of	O	725-727
antipsychotic	O	728-741
drugs	O	742-747
.	O	747-748

Erythema	B	0-8
multiforme	I	9-19
and	O	20-23
hypersensitivity	B	24-40
myocarditis	I	41-52
caused	O	53-59
by	O	60-62
ampicillin	O	63-73
.	O	73-74

OBJECTIVE	O	75-84
:	O	84-85
To	O	86-88
report	O	89-95
a	O	96-97
case	O	98-102
of	O	103-105
erythema	B	106-114
multiforme	I	115-125
and	O	126-129
hypersensitivity	B	130-146
myocarditis	I	147-158
caused	O	159-165
by	O	166-168
ampicillin	O	169-179
.	O	179-180

CASE	O	181-185
SUMMARY	O	186-193
:	O	193-194
A	O	195-196
13	O	197-199
-	O	199-200
year	O	200-204
-	O	199-200
old	O	205-208
boy	O	209-212
was	O	213-216
treated	O	217-224
with	O	225-229
ampicillin	O	230-240
and	O	241-244
gentamicin	O	245-255
because	O	256-263
of	O	264-266
suspected	O	267-276
septicemia	B	277-287
.	O	287-288

Medications	O	289-300
were	O	301-305
discontinued	O	306-318
when	O	319-323
erythema	B	324-332
multiforme	I	333-343
and	O	344-347
congestive	B	348-358
heart	I	359-364
failure	I	365-372
caused	O	373-379
by	O	380-382
myocarditis	B	383-394
occurred	O	395-403
.	O	403-404

The	O	405-408
patient	O	409-416
was	O	417-420
treated	O	421-428
with	O	429-433
methylprednisolone	O	434-452
and	O	453-456
gradually	O	457-466
improved	O	467-475
.	O	475-476

Macrophage	O	477-487
-	O	487-488
migration	O	488-497
inhibition	O	498-508
(	O	509-510
MIF	O	510-513
)	O	513-514
test	O	515-519
with	O	520-524
ampicillin	O	525-535
was	O	536-539
positive	O	540-548
.	O	548-549

DISCUSSION	O	550-560
:	O	560-561
After	O	562-567
most	O	568-572
infections	B	573-583
causing	O	584-591
erythema	B	592-600
multiforme	I	601-611
and	O	612-615
myocarditis	B	616-627
were	O	628-632
ruled	O	633-638
out	O	639-642
,	O	642-643
a	O	644-645
drug	B	646-650
-	I	650-651
induced	I	651-658
allergic	I	659-667
reaction	I	668-676
was	O	677-680
suspected	O	681-690
.	O	690-691

Positive	O	692-700
MIF	O	701-704
test	O	705-709
for	O	710-713
ampicillin	O	714-724
showed	O	725-731
sensitization	O	732-745
of	O	746-748
the	O	749-752
patient	O	753-760
'	O	760-761
s	O	761-762
lymphocytes	O	763-774
to	O	775-777
ampicillin	O	778-788
.	O	788-789

CONCLUSIONS	O	790-801
:	O	801-802
Hypersensitivity	B	803-819
myocarditis	I	820-831
is	O	832-834
a	O	835-836
rare	O	837-841
and	O	842-845
dangerous	O	846-855
manifestation	O	856-869
of	O	870-872
allergy	B	873-880
to	O	881-883
penicillins	O	884-895
.	O	895-896

Immediate	O	0-9
allergic	B	10-18
reactions	I	19-28
to	O	29-31
amoxicillin	O	32-43
.	O	43-44

A	O	45-46
large	O	47-52
group	O	53-58
of	O	59-61
patients	O	62-70
with	O	71-75
suspected	O	76-85
allergic	B	86-94
reactions	I	95-104
to	O	105-107
beta	O	108-112
-	O	112-113
lactam	O	113-119
antibiotics	O	120-131
was	O	132-135
evaluated	O	136-145
.	O	145-146

A	O	147-148
detailed	O	149-157
clinical	O	158-166
history	O	167-174
,	O	174-175
together	O	176-184
with	O	185-189
skin	O	190-194
tests	O	195-200
,	O	200-201
RAST	O	202-206
(	O	207-208
radioallergosorbent	O	208-227
test	O	228-232
)	O	232-233
,	O	233-234
and	O	235-238
controlled	O	239-249
challenge	O	250-259
tests	O	260-265
,	O	265-266
was	O	267-270
used	O	271-275
to	O	276-278
establish	O	279-288
whether	O	289-296
patients	O	297-305
allergic	B	306-314
to	O	315-317
beta	O	318-322
-	O	322-323
lactam	O	323-329
antibiotics	O	330-341
had	O	342-345
selective	O	346-355
immediate	O	356-365
allergic	B	366-374
responses	O	375-384
to	O	385-387
amoxicillin	O	388-399
(	O	400-401
AX	O	401-403
)	O	403-404
or	O	405-407
were	O	408-412
cross	O	413-418
-	O	418-419
reacting	O	419-427
with	O	428-432
other	O	433-438
penicillin	O	439-449
derivatives	O	450-461
.	O	461-462

Skin	O	463-467
tests	O	468-473
were	O	474-478
performed	O	479-488
with	O	489-493
benzylpenicilloyl	O	494-511
-	O	511-512
poly	O	512-516
-	O	511-512
L	O	517-518
-	O	511-512
lysine	O	519-525
(	O	526-527
BPO	O	527-530
-	O	530-531
PLL	O	531-534
)	O	534-535
,	O	535-536
benzylpenicilloate	O	537-555
,	O	555-556
benzylpenicillin	O	557-573
(	O	574-575
PG	O	575-577
)	O	577-578
,	O	578-579
ampicillin	O	580-590
(	O	591-592
AMP	O	592-595
)	O	595-596
,	O	596-597
and	O	598-601
AX	O	602-604
.	O	604-605

RAST	O	606-610
for	O	611-614
BPO	O	615-618
-	O	618-619
PLL	O	619-622
and	O	623-626
AX	O	627-629
-	O	629-630
PLL	O	630-633
was	O	634-637
done	O	638-642
.	O	642-643

When	O	644-648
both	O	649-653
skin	O	654-658
test	O	659-663
and	O	664-667
RAST	O	668-672
for	O	673-676
BPO	O	677-680
were	O	681-685
negative	O	686-694
,	O	694-695
single	O	696-702
-	O	702-703
blind	O	703-708
,	O	708-709
placebo	O	710-717
-	O	717-718
controlled	O	718-728
challenge	O	729-738
tests	O	739-744
were	O	745-749
done	O	750-754
to	O	755-757
ensure	O	758-764
tolerance	O	765-774
of	O	775-777
PG	O	778-780
or	O	781-783
sensitivity	O	784-795
to	O	796-798
AX	O	799-801
.	O	801-802

A	O	803-804
total	O	805-810
of	O	811-813
177	O	814-817
patients	O	818-826
were	O	827-831
diagnosed	O	832-841
as	O	842-844
allergic	B	845-853
to	O	854-856
beta	O	857-861
-	O	861-862
lactam	O	862-868
antibiotics	O	869-880
.	O	880-881

We	O	882-884
selected	O	885-893
the	O	894-897
54	O	898-900
(	O	901-902
30	O	902-904
.	O	904-905
5	O	905-906
%	O	906-907
)	O	907-908
cases	O	909-914
of	O	915-917
immediate	O	918-927
AX	O	928-930
allergy	B	931-938
with	O	939-943
good	O	944-948
tolerance	O	949-958
of	O	959-961
PG	O	962-964
.	O	964-965

Anaphylaxis	B	966-977
was	O	978-981
seen	O	982-986
in	O	987-989
37	O	990-992
patients	O	993-1001
(	O	1002-1003
69	O	1003-1005
%	O	1005-1006
)	O	1006-1007
,	O	1007-1008
the	O	1009-1012
other	O	1013-1018
17	O	1019-1021
(	O	1022-1023
31	O	1023-1025
%	O	1025-1026
)	O	1026-1027
having	O	1028-1034
urticaria	B	1035-1044
and	O	1045-1048
/	O	1048-1049
or	O	1049-1051
angioedema	B	1052-1062
.	O	1062-1063

All	O	1064-1067
the	O	1068-1071
patients	O	1072-1080
were	O	1081-1085
skin	O	1086-1090
test	O	1091-1095
negative	O	1096-1104
to	O	1105-1107
BPO	O	1108-1111
;	O	1111-1112
49	O	1113-1115
of	O	1116-1118
51	O	1119-1121
(	O	1122-1123
96	O	1123-1125
%	O	1125-1126
)	O	1126-1127
were	O	1128-1132
also	O	1133-1137
negative	O	1138-1146
to	O	1147-1149
MDM	B	1150-1153
,	O	1153-1154
and	O	1155-1158
44	O	1159-1161
of	O	1162-1164
46	O	1165-1167
(	O	1168-1169
96	O	1169-1171
%	O	1171-1172
)	O	1172-1173
to	O	1174-1176
PG	O	1177-1179
.	O	1179-1180
Skin	O	1181-1185
tests	O	1186-1191
with	O	1192-1196
AX	O	1197-1199
were	O	1200-1204
positive	O	1205-1213
in	O	1214-1216
34	O	1217-1219
(	O	1220-1221
63	O	1221-1223
%	O	1223-1224
)	O	1224-1225
patients	O	1226-1234
.	O	1234-1235

RAST	O	1236-1240
was	O	1241-1244
positive	O	1245-1253
for	O	1254-1257
AX	O	1258-1260
in	O	1261-1263
22	O	1264-1266
patients	O	1267-1275
(	O	1276-1277
41	O	1277-1279
%	O	1279-1280
)	O	1280-1281
and	O	1282-1285
to	O	1286-1288
BPO	O	1289-1292
in	O	1293-1295
just	O	1296-1300
5	O	1301-1302
(	O	1303-1304
9	O	1304-1305
%	O	1305-1306
)	O	1306-1307
.	O	1307-1308

None	O	1309-1313
of	O	1314-1316
the	O	1317-1320
sera	O	1321-1325
with	O	1326-1330
negative	O	1331-1339
RAST	O	1340-1344
for	O	1345-1348
AX	O	1349-1351
were	O	1352-1356
positive	O	1357-1365
to	O	1366-1368
BPO	O	1369-1372
.	O	1372-1373

Challenge	O	1374-1383
tests	O	1384-1389
with	O	1390-1394
AX	O	1395-1397
were	O	1398-1402
performed	O	1403-1412
in	O	1413-1415
23	O	1416-1418
subjects	O	1419-1427
(	O	1428-1429
43	O	1429-1431
%	O	1431-1432
)	O	1432-1433
to	O	1434-1436
establish	O	1437-1446
the	O	1447-1450
diagnosis	O	1451-1460
of	O	1461-1463
immediate	O	1464-1473
allergic	B	1474-1482
reaction	I	1483-1491
to	O	1492-1494
AX	O	1495-1497
,	O	1497-1498
and	O	1499-1502
in	O	1503-1505
15	O	1506-1508
cases	O	1509-1514
(	O	1515-1516
28	O	1516-1518
%	O	1518-1519
)	O	1519-1520
both	O	1521-1525
skin	O	1526-1530
test	O	1531-1535
and	O	1536-1539
RAST	O	1540-1544
for	O	1545-1548
AX	O	1549-1551
were	O	1552-1556
negative	O	1557-1565
.	O	1565-1566

PG	O	1567-1569
was	O	1570-1573
well	O	1574-1578
tolerated	O	1579-1588
by	O	1589-1591
all	O	1592-1595
54	O	1596-1598
patients	O	1599-1607
.	O	1607-1608

We	O	1609-1611
describe	O	1612-1620
the	O	1621-1624
largest	O	1625-1632
group	O	1633-1638
of	O	1639-1641
AX	O	1642-1644
-	O	1644-1645
allergic	B	1645-1653
patients	O	1654-1662
who	O	1663-1666
have	O	1667-1671
tolerated	O	1672-1681
PG	O	1682-1684
reported	O	1685-1693
so	O	1694-1696
far	O	1697-1700
.	O	1700-1701

Diagnosis	O	1702-1711
of	O	1712-1714
these	O	1715-1720
patients	O	1721-1729
can	O	1730-1733
be	O	1734-1736
achieved	O	1737-1745
only	O	1746-1750
if	O	1751-1753
specific	O	1754-1762
AX	O	1763-1765
-	O	1765-1766
related	O	1766-1773
reagents	O	1774-1782
are	O	1783-1786
employed	O	1787-1795
.	O	1795-1796

Further	O	1797-1804
studies	O	1805-1812
are	O	1813-1816
necessary	O	1817-1826
to	O	1827-1829
determine	O	1830-1839
the	O	1840-1843
exact	O	1844-1849
extent	O	1850-1856
of	O	1857-1859
this	O	1860-1864
problem	O	1865-1872
and	O	1873-1876
to	O	1877-1879
improve	O	1880-1887
the	O	1888-1891
efficacy	O	1892-1900
of	O	1901-1903
diagnostic	O	1904-1914
methods	O	1915-1922
.	O	1922-1923

Persistent	O	0-10
paralysis	B	11-20
after	O	21-26
prolonged	O	27-36
use	O	37-40
of	O	41-43
atracurium	O	44-54
in	O	55-57
the	O	58-61
absence	O	62-69
of	O	70-72
corticosteroids	O	73-88
.	O	88-89

Neuromuscular	O	90-103
blocking	O	104-112
agents	O	113-119
(	O	120-121
NMBAs	O	121-126
)	O	126-127
are	O	128-131
often	O	132-137
used	O	138-142
for	O	143-146
patients	O	147-155
requiring	O	156-165
prolonged	O	166-175
mechanical	O	176-186
ventilation	O	187-198
.	O	198-199

Reports	O	200-207
of	O	208-210
persistent	O	211-221
paralysis	B	222-231
after	O	232-237
the	O	238-241
discontinuance	O	242-256
of	O	257-259
these	O	260-265
drugs	O	266-271
have	O	272-276
most	O	277-281
often	O	282-287
involved	O	288-296
aminosteroid	O	297-309
-	O	309-310
based	O	310-315
NMBAs	O	316-321
such	O	322-326
as	O	327-329
vecuronium	O	330-340
bromide	O	341-348
,	O	348-349
especially	O	350-360
when	O	361-365
used	O	366-370
in	O	371-373
conjunction	O	374-385
with	O	386-390
corticosteroids	O	391-406
.	O	406-407

Atracurium	O	408-418
besylate	O	419-427
,	O	427-428
a	O	429-430
short	O	431-436
-	O	436-437
acting	O	437-443
benzylisoquinolinium	O	444-464
NMBA	O	465-469
that	O	470-474
is	O	475-477
eliminated	O	478-488
independently	O	489-502
of	O	503-505
renal	O	506-511
or	O	512-514
hepatic	O	515-522
function	O	523-531
,	O	531-532
has	O	533-536
also	O	537-541
been	O	542-546
associated	O	547-557
with	O	558-562
persistent	O	563-573
paralysis	B	574-583
,	O	583-584
but	O	585-588
only	O	589-593
when	O	594-598
used	O	599-603
with	O	604-608
corticosteroids	O	609-624
.	O	624-625

We	O	626-628
report	O	629-635
a	O	636-637
case	O	638-642
of	O	643-645
atracurium	O	646-656
-	O	656-657
related	O	657-664
paralysis	B	665-674
persisting	O	675-685
for	O	686-689
approximately	O	690-703
50	O	704-706
hours	O	707-712
in	O	713-715
a	O	716-717
patient	O	718-725
who	O	726-729
was	O	730-733
not	O	734-737
treated	O	738-745
with	O	746-750
corticosteroids	O	751-766
.	O	766-767

Habitual	O	0-8
use	O	9-12
of	O	13-15
acetaminophen	O	16-29
as	O	30-32
a	O	33-34
risk	O	35-39
factor	O	40-46
for	O	47-50
chronic	B	51-58
renal	I	59-64
failure	I	65-72
:	O	72-73
a	O	74-75
comparison	O	76-86
with	O	87-91
phenacetin	O	92-102
.	O	102-103

Six	O	104-107
epidemiologic	O	108-121
studies	O	122-129
in	O	130-132
the	O	133-136
United	O	137-143
States	O	144-150
and	O	151-154
Europe	O	155-161
indicate	O	162-170
that	O	171-175
habitual	O	176-184
use	O	185-188
of	O	189-191
phenacetin	O	192-202
is	O	203-205
associated	O	206-216
with	O	217-221
the	O	222-225
development	O	226-237
of	O	238-240
chronic	B	241-248
renal	I	249-254
failure	I	255-262
and	O	263-266
end	B	267-270
-	I	270-271
stage	I	271-276
renal	I	277-282
disease	I	283-290
(	O	291-292
ESRD	B	292-296
)	O	296-297
,	O	297-298
with	O	299-303
a	O	304-305
relative	O	306-314
risk	O	315-319
in	O	320-322
the	O	323-326
range	O	327-332
of	O	333-335
4	O	336-337
to	O	338-340
19	O	341-343
.	O	343-344

As	O	345-347
a	O	348-349
result	O	350-356
of	O	357-359
these	O	360-365
and	O	366-369
other	O	370-375
studies	O	376-383
,	O	383-384
phenacetin	O	385-395
has	O	396-399
now	O	400-403
been	O	404-408
withdrawn	O	409-418
from	O	419-423
the	O	424-427
market	O	428-434
in	O	435-437
most	O	438-442
countries	O	443-452
.	O	452-453

However	O	454-461
,	O	461-462
three	O	463-468
case	O	469-473
control	O	474-481
studies	O	482-489
,	O	489-490
one	O	491-494
each	O	495-499
in	O	500-502
North	O	503-508
Carolina	O	509-517
,	O	517-518
northern	O	519-527
Maryland	O	528-536
,	O	536-537
and	O	538-541
West	O	542-546
Berlin	O	547-553
,	O	553-554
Germany	O	555-562
,	O	562-563
showed	O	564-570
that	O	571-575
habitual	O	576-584
use	O	585-588
of	O	589-591
acetaminophen	O	592-605
is	O	606-608
also	O	609-613
associated	O	614-624
with	O	625-629
chronic	B	630-637
renal	I	638-643
failure	I	644-651
and	O	652-655
ESRD	B	656-660
,	O	660-661
with	O	662-666
a	O	667-668
relative	O	669-677
risk	O	678-682
in	O	683-685
the	O	686-689
range	O	690-695
of	O	696-698
2	O	699-700
to	O	701-703
4	O	704-705
.	O	705-706
These	O	707-712
studies	O	713-720
suggest	O	721-728
that	O	729-733
both	O	734-738
phenacetin	O	739-749
and	O	750-753
acetaminophen	O	754-767
may	O	768-771
contribute	O	772-782
to	O	783-785
the	O	786-789
burden	O	790-796
of	O	797-799
ESRD	B	800-804
,	O	804-805
with	O	806-810
the	O	811-814
risk	O	815-819
of	O	820-822
the	O	823-826
latter	O	827-833
being	O	834-839
somewhat	O	840-848
less	O	849-853
than	O	854-858
that	O	859-863
of	O	864-866
the	O	867-870
former	O	871-877
.	O	877-878

This	O	879-883
apparent	O	884-892
difference	O	893-903
in	O	904-906
risk	O	907-911
may	O	912-915
not	O	916-919
be	O	920-922
due	O	923-926
to	O	927-929
differences	O	930-941
in	O	942-944
nephrotoxic	B	945-956
potential	O	957-966
of	O	967-969
the	O	970-973
drugs	O	974-979
themselves	O	980-990
.	O	990-991

A	O	992-993
lower	O	994-999
relative	O	1000-1008
risk	O	1009-1013
would	O	1014-1019
be	O	1020-1022
expected	O	1023-1031
for	O	1032-1035
acetaminophen	O	1036-1049
if	O	1050-1052
the	O	1053-1056
risk	O	1057-1061
of	O	1062-1064
both	O	1065-1069
drugs	O	1070-1075
in	O	1076-1078
combination	O	1079-1090
with	O	1091-1095
other	O	1096-1101
analgesics	O	1102-1112
was	O	1113-1116
higher	O	1117-1123
than	O	1124-1128
the	O	1129-1132
risk	O	1133-1137
of	O	1138-1140
either	O	1141-1147
agent	O	1148-1153
alone	O	1154-1159
.	O	1159-1160

Thus	O	1161-1165
,	O	1165-1166
acetaminophen	O	1167-1180
has	O	1181-1184
been	O	1185-1189
used	O	1190-1194
both	O	1195-1199
as	O	1200-1202
a	O	1203-1204
single	O	1205-1211
agent	O	1212-1217
and	O	1218-1221
in	O	1222-1224
combination	O	1225-1236
with	O	1237-1241
other	O	1242-1247
analgesics	O	1248-1258
,	O	1258-1259
whereas	O	1260-1267
phenacetin	O	1268-1278
was	O	1279-1282
available	O	1283-1292
only	O	1293-1297
in	O	1298-1300
combinations	O	1301-1313
.	O	1313-1314

The	O	1315-1318
possibility	O	1319-1330
that	O	1331-1335
habitual	O	1336-1344
use	O	1345-1348
of	O	1349-1351
acetaminophen	O	1352-1365
alone	O	1366-1371
increases	O	1372-1381
the	O	1382-1385
risk	O	1386-1390
of	O	1391-1393
ESRD	B	1394-1398
has	O	1399-1402
not	O	1403-1406
been	O	1407-1411
clearly	O	1412-1419
demonstrated	O	1420-1432
,	O	1432-1433
but	O	1434-1437
cannot	O	1438-1444
be	O	1445-1447
dismissed	O	1448-1457
.	O	1457-1458

Reduction	O	0-9
of	O	10-12
heparan	O	13-20
sulphate	O	21-29
-	O	29-30
associated	O	30-40
anionic	O	41-48
sites	O	49-54
in	O	55-57
the	O	58-61
glomerular	O	62-72
basement	O	73-81
membrane	O	82-90
of	O	91-93
rats	O	94-98
with	O	99-103
streptozotocin	O	104-118
-	O	118-119
induced	O	119-126
diabetic	B	127-135
nephropathy	I	136-147
.	O	147-148

Heparan	O	149-156
sulphate	O	157-165
-	O	165-166
associated	O	166-176
anionic	O	177-184
sites	O	185-190
in	O	191-193
the	O	194-197
glomerular	O	198-208
basement	O	209-217
membrane	O	218-226
were	O	227-231
studied	O	232-239
in	O	240-242
rats	O	243-247
8	O	248-249
months	O	250-256
after	O	257-262
induction	O	263-272
of	O	273-275
diabetes	B	276-284
by	O	285-287
streptozotocin	O	288-302
and	O	303-306
in	O	307-309
age	O	310-313
-	O	313-314
adn	O	315-318
sex	O	319-322
-	O	322-323
matched	O	323-330
control	O	331-338
rats	O	339-343
,	O	343-344
employing	O	345-354
the	O	355-358
cationic	O	359-367
dye	O	368-371
cuprolinic	O	372-382
blue	O	383-387
.	O	387-388

Morphometric	O	389-401
analysis	O	402-410
at	O	411-413
the	O	414-417
ultrastructural	O	418-433
level	O	434-439
was	O	440-443
performed	O	444-453
using	O	454-459
a	O	460-461
computerized	O	462-474
image	O	475-480
processor	O	481-490
.	O	490-491

The	O	492-495
heparan	O	496-503
sulphate	O	504-512
specificity	O	513-524
of	O	525-527
the	O	528-531
cuprolinic	O	532-542
blue	O	543-547
staining	O	548-556
was	O	557-560
demonstrated	O	561-573
by	O	574-576
glycosaminoglycan	O	577-594
-	O	594-595
degrading	O	595-604
enzymes	O	605-612
,	O	612-613
showing	O	614-621
that	O	622-626
pretreatment	O	627-639
of	O	640-642
the	O	643-646
sections	O	647-655
with	O	656-660
heparitinase	O	661-673
abolished	O	674-683
all	O	684-687
staining	O	688-696
,	O	696-697
whereas	O	698-705
chondroitinase	O	706-720
ABC	O	721-724
had	O	725-728
no	O	729-731
effect	O	732-738
.	O	738-739

The	O	740-743
majority	O	744-752
of	O	753-755
anionic	O	756-763
sites	O	764-769
(	O	770-771
74	O	771-773
%	O	773-774
in	O	775-777
diabetic	B	778-786
and	O	787-790
81	O	791-793
%	O	793-794
in	O	795-797
control	O	798-805
rats	O	806-810
)	O	810-811
were	O	812-816
found	O	817-822
within	O	823-829
the	O	830-833
lamina	O	834-840
rara	O	841-845
externa	O	846-853
of	O	854-856
the	O	857-860
glomerular	O	861-871
basement	O	872-880
membrane	O	881-889
.	O	889-890

A	O	891-892
minority	O	893-901
of	O	902-904
anionic	O	905-912
sites	O	913-918
were	O	919-923
scattered	O	924-933
throughout	O	934-944
the	O	945-948
lamina	O	949-955
densa	O	956-961
and	O	962-965
lamina	O	966-972
rara	O	973-977
interna	O	978-985
,	O	985-986
and	O	987-990
were	O	991-995
significantly	O	996-1009
smaller	O	1010-1017
than	O	1018-1022
those	O	1023-1028
in	O	1029-1031
the	O	1032-1035
lamina	O	1036-1042
rara	O	1043-1047
externa	O	1048-1055
of	O	1056-1058
the	O	1059-1062
glomerular	O	1063-1073
basement	O	1074-1082
membrane	O	1083-1091
(	O	1092-1093
p	O	1093-1094
<	O	1094-1095
0	O	1095-1096
.	O	1096-1097
001	O	1097-1100

and	O	1101-1104
p	O	1105-1106
<	O	1106-1107
0	O	1107-1108
.	O	1108-1109
01	O	1109-1111
for	O	1112-1115
diabetic	B	1116-1124
and	O	1125-1128
control	O	1129-1136
rats	O	1137-1141
,	O	1141-1142
respectively	O	1143-1155
)	O	1155-1156
.	O	1156-1157

Diabetic	B	1158-1166
rats	O	1167-1171
progressively	O	1172-1185
developed	O	1186-1195
albuminuria	B	1196-1207
reaching	O	1208-1216
40	O	1217-1219
.	O	1219-1220
3	O	1220-1221
(	O	1222-1223
32	O	1223-1225
.	O	1225-1226
2	O	1224-1225
-	O	1227-1228
62	O	1228-1230
.	O	1225-1226
0	O	1231-1232
)	O	1232-1233

mg	O	1234-1236
/	O	1236-1237
24	O	1237-1239
h	O	1240-1241
after	O	1242-1247
8	O	1248-1249
months	O	1250-1256
in	O	1257-1259
contrast	O	1260-1268
to	O	1269-1271
the	O	1272-1275
control	O	1276-1283
animals	O	1284-1291
(	O	1292-1293
0	O	1293-1294
.	O	1294-1295
8	O	1295-1296
(	O	1297-1298
0	O	1298-1299
.	O	1299-1300
2	O	1300-1301
-	O	1301-1302
0	O	1298-1299
.	O	1299-1300
9	O	1304-1305
)	O	1305-1306
mg	O	1307-1309
/	O	1309-1310
24	O	1310-1312
h	O	1313-1314
,	O	1314-1315
p	O	1316-1317
<	O	1317-1318
0	O	1318-1319
.	O	1319-1320
002	O	1320-1323
)	O	1323-1324
.	O	1319-1320

At	O	1326-1328
the	O	1329-1332
same	O	1333-1337
time	O	1338-1342
,	O	1342-1343
the	O	1344-1347
number	O	1348-1354
of	O	1355-1357
heparan	O	1358-1365
sulphate	O	1366-1374
anionic	O	1375-1382
sites	O	1383-1388
and	O	1389-1392
the	O	1393-1396
total	O	1397-1402
anionic	O	1403-1410
site	O	1411-1415
surface	O	1416-1423
(	O	1424-1425
number	O	1425-1431
of	O	1432-1434
anionic	O	1435-1442
sites	O	1443-1448
x	O	1449-1450
mean	O	1451-1455
anionic	O	1456-1463
site	O	1464-1468
surface	O	1469-1476
)	O	1476-1477
in	O	1478-1480
the	O	1481-1484
lamina	O	1485-1491
rara	O	1492-1496
externa	O	1497-1504
of	O	1505-1507
the	O	1508-1511
glomerular	O	1512-1522
basement	O	1523-1531
membrane	O	1532-1540
was	O	1541-1544
reduced	O	1545-1552
by	O	1553-1555
19	O	1556-1558
%	O	1558-1559
(	O	1560-1561
p	O	1561-1562
<	O	1562-1563
0	O	1563-1564
.	O	1564-1565
021	O	1565-1568
)	O	1568-1569
and	O	1570-1573
by	O	1574-1576
26	O	1577-1579
%	O	1579-1580
(	O	1581-1582
p	O	1582-1583
<	O	1583-1584
0	O	1584-1585
.	O	1585-1586
02	O	1586-1588
)	O	1588-1589
,	O	1589-1590

respectively	O	1591-1603
.	O	1603-1604

Number	O	1605-1611
and	O	1612-1615
total	O	1616-1621
anionic	O	1622-1629
site	O	1630-1634
surface	O	1635-1642
in	O	1643-1645
the	O	1646-1649
remaining	O	1650-1659
part	O	1660-1664
of	O	1665-1667
the	O	1668-1671
glomerular	O	1672-1682
basement	O	1683-1691
membrane	O	1692-1700
(	O	1701-1702
lamina	O	1702-1708
densa	O	1709-1714
and	O	1715-1718
lamina	O	1719-1725
rara	O	1726-1730
interna	O	1731-1738
)	O	1738-1739
were	O	1740-1744
not	O	1745-1748
significantly	O	1749-1762
changed	O	1763-1770
.	O	1770-1771

We	O	1772-1774
conclude	O	1775-1783
that	O	1784-1788
in	O	1789-1791
streptozotocin	O	1792-1806
-	O	1806-1807
diabetic	B	1807-1815
rats	O	1816-1820
with	O	1821-1825
an	O	1826-1828
increased	O	1829-1838
urinary	O	1839-1846
albumin	O	1847-1854
excretion	O	1855-1864
,	O	1864-1865
a	O	1866-1867
reduced	O	1868-1875
heparan	O	1876-1883
sulphate	O	1884-1892
charge	O	1893-1899
barrier	O	1900-1907
/	O	1907-1908
density	O	1908-1915
is	O	1916-1918
found	O	1919-1924
at	O	1925-1927
the	O	1928-1931
lamina	O	1932-1938
rara	O	1939-1943
externa	O	1944-1951
of	O	1952-1954
the	O	1955-1958
glomerular	O	1959-1969
basement	O	1970-1978
membrane	O	1979-1987
.	O	1987-1988

Effect	O	0-6
of	O	7-9
some	O	10-14
anticancer	O	15-25
drugs	O	26-31
and	O	32-35
combined	O	36-44
chemotherapy	O	45-57
on	O	58-60
renal	B	61-66
toxicity	I	67-75
.	O	75-76

The	O	77-80
nephrotoxic	B	81-92
action	O	93-99
of	O	100-102
anticancer	O	103-113
drugs	O	114-119
such	O	120-124
as	O	125-127
nitrogranulogen	O	128-143
(	O	144-145
NG	O	145-147
)	O	147-148
,	O	148-149
methotrexate	O	150-162
(	O	163-164
MTX	O	164-167
)	O	167-168
,	O	168-169
5	O	170-171
-	O	171-172
fluorouracil	O	172-184
(	O	185-186
5	O	186-187
-	O	187-188
FU	O	188-190
)	O	190-191
and	O	192-195
cyclophosphamide	O	196-212
(	O	213-214
CY	O	214-216
)	O	216-217
administered	O	218-230
alone	O	231-236
or	O	237-239
in	O	240-242
combination	O	243-254
[	O	255-256
MTX	O	256-259
+	O	260-261
5	O	262-263
-	O	263-264
FU	O	264-266
+	O	267-268
CY	O	269-271
(	O	272-273
CMF	O	273-276
)	O	276-277
]	O	277-278
was	O	279-282
evaluated	O	283-292
in	O	293-295
experiments	O	296-307
on	O	308-310
Wistar	O	311-317
rats	O	318-322
.	O	322-323

After	O	324-329
drug	O	330-334
administration	O	335-349
,	O	349-350
creatinine	O	351-361
concentrations	O	362-376
in	O	377-379
the	O	380-383
plasma	O	384-390
and	O	391-394
in	O	395-397
the	O	398-401
urine	O	402-407
of	O	408-410
the	O	411-414
rats	O	415-419
were	O	420-424
determined	O	425-435
,	O	435-436
as	O	437-439
well	O	440-444
as	O	445-447
creatinine	O	448-458
clearance	O	459-468
.	O	468-469

Histopathologic	O	470-485
evaluation	O	486-496
of	O	497-499
the	O	500-503
kidneys	O	504-511
was	O	512-515
also	O	516-520
performed	O	521-530
.	O	530-531

After	O	532-537
MTX	O	538-541
administration	O	542-556
a	O	557-558
significant	O	559-570
increase	O	571-579
(	O	580-581
p	O	581-582
=	O	583-584
0	O	585-586
.	O	586-587
0228	O	587-591
)	O	591-592
in	O	593-595
the	O	596-599
plasma	O	600-606
creatinine	O	607-617
concentration	O	618-631
and	O	632-635
a	O	636-637
significant	O	638-649
(	O	650-651
p	O	651-652
=	O	653-654
0	O	655-656
.	O	656-657
0001	O	657-661
)	O	661-662
decrease	O	663-671
in	O	672-674
creatinine	O	675-685
clearance	O	686-695
was	O	696-699
noted	O	700-705
compared	O	706-714
to	O	715-717
controls	O	718-726
.	O	726-727

After	O	728-733
the	O	734-737
administration	O	738-752
of	O	753-755
NG	O	756-758
,	O	758-759
5	O	760-761
-	O	761-762
FU	O	762-764
and	O	765-768
CY	O	769-771
neither	O	772-779
a	O	780-781
statistically	O	782-795
significant	O	796-807
increase	O	808-816
in	O	817-819
creatinine	O	820-830
concentration	O	831-844
nor	O	845-848
an	O	849-851
increase	O	852-860
in	O	861-863
creatinine	O	864-874
clearance	O	875-884
was	O	885-888
observed	O	889-897
compared	O	898-906
to	O	907-909
the	O	910-913
group	O	914-919
receiving	O	920-929
no	O	930-932
cytostatics	O	933-944
.	O	944-945

Following	O	946-955
polytherapy	O	956-967
according	O	968-977
to	O	978-980
the	O	981-984
CMF	O	985-988
regimen	O	989-996
,	O	996-997
a	O	998-999
statistically	O	1000-1013
significant	O	1014-1025
decrease	O	1026-1034
(	O	1035-1036
p	O	1036-1037
=	O	1038-1039
0	O	1040-1041
.	O	1041-1042
0343	O	1042-1046
)	O	1046-1047
in	O	1048-1050
creatinine	O	1051-1061
clearance	O	1062-1071
was	O	1072-1075
found	O	1076-1081
,	O	1081-1082
but	O	1083-1086
creatinine	O	1087-1097
concentration	O	1098-1111
did	O	1112-1115
not	O	1116-1119
increase	O	1120-1128
significantly	O	1129-1142
compared	O	1143-1151
to	O	1152-1154
controls	O	1155-1163
.	O	1163-1164

CY	O	1165-1167
caused	O	1168-1174
hemorrhagic	B	1175-1186
cystitis	I	1187-1195
in	O	1196-1198
40	O	1199-1201
%	O	1201-1202
of	O	1203-1205
rats	O	1206-1210
,	O	1210-1211
but	O	1212-1215
it	O	1216-1218
did	O	1219-1222
not	O	1223-1226
cause	O	1227-1232
this	O	1233-1237
complication	O	1238-1250
when	O	1251-1255
combined	O	1256-1264
with	O	1265-1269
5	O	1270-1271
-	O	1271-1272
FU	O	1272-1274
and	O	1275-1278
MTX	O	1279-1282
.	O	1282-1283

Histologic	O	1284-1294
changes	O	1295-1302
were	O	1303-1307
found	O	1308-1313
in	O	1314-1316
rat	O	1317-1320
kidneys	O	1321-1328
after	O	1329-1334
administration	O	1335-1349
of	O	1350-1352
MTX	O	1353-1356
,	O	1356-1357
CY	O	1358-1360
and	O	1361-1364
NG	O	1365-1367
,	O	1367-1368
while	O	1369-1374
no	O	1375-1377
such	O	1378-1382
change	O	1383-1389
was	O	1390-1393
observed	O	1394-1402
after	O	1403-1408
5	O	1409-1410
-	O	1410-1411
FU	O	1411-1413
and	O	1414-1417
joint	O	1418-1423
administration	O	1424-1438
of	O	1439-1441
MTX	O	1442-1445
+	O	1446-1447
5	O	1448-1449
-	O	1449-1450
FU	O	1450-1452
+	O	1453-1454
CY	O	1455-1457
compared	O	1458-1466
to	O	1467-1469
controls	O	1470-1478
.	O	1478-1479

Our	O	1480-1483
studies	O	1484-1491
indicate	O	1492-1500
that	O	1501-1505
nephrotoxicity	B	1506-1520
of	O	1521-1523
MTX	O	1524-1527
+	O	1528-1529
5	O	1530-1531
-	O	1531-1532
FU	O	1532-1534
+	O	1535-1536
CY	O	1537-1539
administered	O	1540-1552
jointly	O	1553-1560
is	O	1561-1563
lower	O	1564-1569
than	O	1570-1574
in	O	1575-1577
monotherapy	O	1578-1589
.	O	1589-1590

Lithium	O	0-7
-	O	7-8
associated	O	8-18
cognitive	B	19-28
and	I	29-32
functional	I	33-43
deficits	I	44-52
reduced	O	53-60
by	O	61-63
a	O	64-65
switch	O	66-72
to	O	73-75
divalproex	O	76-86
sodium	O	87-93
:	O	93-94
a	O	95-96
case	O	97-101
series	O	102-108
.	O	108-109

BACKGROUND	O	110-120
:	O	120-121
Lithium	O	122-129
remains	O	130-137
a	O	138-139
first	O	140-145
-	O	145-146
line	O	146-150
treatment	O	151-160
for	O	161-164
the	O	165-168
acute	O	169-174
and	O	175-178
maintenance	O	179-190
treatment	O	191-200
of	O	201-203
bipolar	B	204-211
disorder	I	212-220
.	O	220-221

Although	O	222-230
much	O	231-235
has	O	236-239
been	O	240-244
written	O	245-252
about	O	253-258
the	O	259-262
management	O	263-273
of	O	274-276
the	O	277-280
more	O	281-285
common	O	286-292
adverse	O	293-300
effects	O	301-308
of	O	309-311
lithium	O	312-319
,	O	319-320
such	O	321-325
as	O	326-328
polyuria	B	329-337
and	O	338-341
tremor	B	342-348
,	O	348-349
more	O	350-354
subtle	O	355-361
lithium	O	362-369
side	O	370-374
effects	O	375-382
such	O	383-387
as	O	388-390
cognitive	B	391-400
deficits	I	401-409
,	O	409-410
loss	B	411-415
of	I	416-418
creativity	I	419-429
,	O	429-430
and	O	431-434
functional	B	435-445
impairments	I	446-457
remain	O	458-464
understudied	O	465-477
.	O	477-478

This	O	479-483
report	O	484-490
summarizes	O	491-501
our	O	502-505
experience	O	506-516
in	O	517-519
switching	O	520-529
bipolar	B	530-537
patients	O	538-546
from	O	547-551
lithium	O	552-559
to	O	560-562
divalproex	O	563-573
sodium	O	574-580
to	O	581-583
alleviate	O	584-593
such	O	594-598
cognitive	B	599-608
and	I	609-612
functional	I	613-623
impairments	I	624-635
.	O	635-636

METHOD	O	637-643
:	O	643-644
Open	O	645-649
,	O	649-650
case	O	651-655
series	O	656-662
design	O	663-669
.	O	669-670

RESULTS	O	671-678
:	O	678-679
We	O	680-682
report	O	683-689
seven	O	690-695
cases	O	696-701
where	O	702-707
substitution	O	708-720
of	O	721-723
lithium	O	724-731
,	O	731-732
either	O	733-739
fully	O	740-745
or	O	746-748
partially	O	749-758
,	O	758-759
with	O	760-764
divalproex	O	765-775
sodium	O	776-782
was	O	783-786
extremely	O	787-796
helpful	O	797-804
in	O	805-807
reducing	O	808-816
the	O	817-820
cognitive	B	821-830
,	I	830-831
motivational	I	832-844
,	I	844-845
or	I	846-848
creative	I	849-857
deficits	I	858-866
attributed	O	867-877
to	O	878-880
lithium	O	881-888
in	O	889-891
our	O	892-895
bipolar	B	896-903
patients	O	904-912
.	O	912-913

CONCLUSION	O	914-924
:	O	924-925
In	O	926-928
this	O	929-933
preliminary	O	934-945
report	O	946-952
,	O	952-953
divalproex	O	954-964
sodium	O	965-971
was	O	972-975
a	O	976-977
superior	O	978-986
alternative	O	987-998
to	O	999-1001
lithium	O	1002-1009
in	O	1010-1012
bipolar	B	1013-1020
patients	O	1021-1029
experiencing	O	1030-1042
cognitive	B	1043-1052
deficits	I	1053-1061
,	O	1061-1062
loss	B	1063-1067
of	I	1068-1070
creativity	I	1071-1081
,	O	1081-1082
and	O	1083-1086
functional	B	1087-1097
impairments	I	1098-1109
.	O	1109-1110

Treatment	O	0-9
of	O	10-12
previously	O	13-23
treated	O	24-31
metastatic	O	32-42
breast	B	43-49
cancer	I	50-56
by	O	57-59
mitoxantrone	O	60-72
and	O	73-76
48	O	77-79
-	O	79-80
hour	O	80-84
continuous	O	85-95
infusion	O	96-104
of	O	105-107
high	O	108-112
-	O	112-113
dose	O	113-117
5	O	118-119
-	O	119-120
FU	O	120-122
and	O	123-126
leucovorin	O	127-137
(	O	138-139
MFL	O	139-142
)	O	142-143
:	O	143-144
low	O	145-148
palliative	O	149-159
benefit	O	160-167
and	O	168-171
high	O	172-176
treatment	O	177-186
-	O	186-187
related	O	187-194
toxicity	B	195-203
.	O	203-204

For	O	205-208
previously	O	209-219
treated	O	220-227
advanced	O	228-236
breast	B	237-243
cancer	I	244-250
,	O	250-251
there	O	252-257
is	O	258-260
no	O	261-263
standard	O	264-272
second	O	273-279
-	O	279-280
line	O	280-284
therapy	O	285-292
.	O	292-293

Combination	O	294-305
chemotherapy	O	306-318
with	O	319-323
mitoxantrone	O	324-336
,	O	336-337
high	O	338-342
-	O	342-343
dose	O	343-347
5	O	348-349
-	O	349-350
fluorouracil	O	350-362
(	O	363-364
5	O	364-365
-	O	365-366
FU	O	366-368
)	O	368-369
and	O	370-373
leucovorin	O	374-384
(	O	385-386
MFL	O	386-389
regimen	O	390-397
)	O	397-398
had	O	399-402
been	O	403-407
reported	O	408-416
as	O	417-419
an	O	420-422
effective	O	423-432
and	O	433-436
well	O	437-441
tolerated	O	442-451
regimen	O	452-459
.	O	459-460

From	O	461-465
October	O	466-473
1993	O	474-478
to	O	479-481
November	O	482-490
1995	O	491-495
,	O	495-496
we	O	497-499
treated	O	500-507
13	O	508-510
patients	O	511-519
with	O	520-524
previously	O	525-535
chemotherapy	O	536-548
-	O	548-549
treated	O	549-556
metastatic	O	557-567
breast	B	568-574
cancer	I	575-581
by	O	582-584
mitoxantrone	O	585-597
,	O	597-598
12	O	599-601
mg	O	602-604
/	O	604-605
m2	O	605-607
,	O	607-608
on	O	609-611
day	O	612-615
1	O	616-617
and	O	618-621
continuous	O	622-632
infusion	O	633-641
of	O	642-644
5	O	645-646
-	O	646-647
FU	O	647-649
,	O	649-650
3000	O	651-655
mg	O	656-658
/	O	658-659
m2	O	659-661
,	O	661-662
together	O	663-671
with	O	672-676
leucovorin	O	677-687
,	O	687-688
300	O	689-692
mg	O	693-695
/	O	695-696
m2	O	696-698
,	O	698-699
for	O	700-703
48	O	704-706
h	O	707-708
from	O	709-713
day	O	714-717
1	O	718-719
to	O	720-722
2	O	723-724
.	O	724-725
Each	O	726-730
course	O	731-737
of	O	738-740
chemotherapy	O	741-753
was	O	754-757
given	O	758-763
every	O	764-769
4	O	770-771
weeks	O	772-777
.	O	777-778

Most	O	779-783
of	O	784-786
these	O	787-792
patients	O	793-801
had	O	802-805
more	O	806-810
than	O	811-815
two	O	816-819
metastatic	O	820-830
sites	O	831-836
,	O	836-837
with	O	838-842
lung	O	843-847
metastasis	O	848-858
predominant	O	859-870
.	O	870-871

Seven	O	872-877
patients	O	878-886
had	O	887-890
been	O	891-895
treated	O	896-903
with	O	904-908
anthracycline	O	909-922
.	O	922-923

Seven	O	924-929
patients	O	930-938
had	O	939-942
previously	O	943-953
received	O	954-962
radiotherapy	O	963-975
and	O	976-979
seven	O	980-985
had	O	986-989
received	O	990-998
hormone	O	999-1006
therapy	O	1007-1014
.	O	1014-1015

Median	O	1016-1022
number	O	1023-1029
of	O	1030-1032
courses	O	1033-1040
of	O	1041-1043
MFL	O	1044-1047
regimen	O	1048-1055
given	O	1056-1061
was	O	1062-1065
six	O	1066-1069
and	O	1070-1073
the	O	1074-1077
median	O	1078-1084
cumulative	O	1085-1095
dose	O	1096-1100
of	O	1101-1103
mitoxantrone	O	1104-1116
was	O	1117-1120
68	O	1121-1123
.	O	1123-1124
35	O	1124-1126
mg	O	1127-1129
/	O	1129-1130
m2	O	1130-1132
.	O	1132-1133

One	O	1134-1137
patient	O	1138-1145
had	O	1146-1149
complete	O	1150-1158
response	O	1159-1167
,	O	1167-1168
seven	O	1169-1174
had	O	1175-1178
stable	O	1179-1185
disease	O	1186-1193
,	O	1193-1194
none	O	1195-1199
had	O	1200-1203
partial	O	1204-1211
response	O	1212-1220
and	O	1221-1224
five	O	1225-1229
had	O	1230-1233
progressive	O	1234-1245
disease	O	1246-1253
.	O	1253-1254

The	O	1255-1258
overall	O	1259-1266
objective	O	1267-1276
response	O	1277-1285
rate	O	1286-1290
was	O	1291-1294
7	O	1295-1296
.	O	1296-1297
6	O	1297-1298
%	O	1298-1299
.	O	1296-1297

The	O	1301-1304
median	O	1305-1311
follow	O	1312-1318
-	O	1318-1319
up	O	1319-1321
period	O	1322-1328
was	O	1329-1332
14	O	1333-1335
months	O	1336-1342
.	O	1342-1343

Median	O	1344-1350
survival	O	1351-1359
was	O	1360-1363
16	O	1364-1366
months	O	1367-1373
.	O	1373-1374

Median	O	1375-1381
progression	O	1382-1393
-	O	1393-1394
free	O	1394-1398
survival	O	1399-1407
was	O	1408-1411
5	O	1412-1413
months	O	1414-1420
.	O	1420-1421

A	O	1422-1423
complete	O	1424-1432
responder	O	1433-1442
had	O	1443-1446
relapse	O	1447-1454
-	O	1454-1455
free	O	1455-1459
survival	O	1460-1468
up	O	1469-1471
to	O	1472-1474
17	O	1475-1477
months	O	1478-1484
.	O	1484-1485

Major	O	1486-1491
toxicities	B	1492-1502
were	O	1503-1507
cardiotoxicity	B	1508-1522
and	O	1523-1526
leukopenia	B	1527-1537
.	O	1537-1538

Eight	O	1539-1544
patients	O	1545-1553
were	O	1554-1558
dead	O	1559-1563
in	O	1564-1566
the	O	1567-1570
last	O	1571-1575
follow	O	1576-1582
-	O	1582-1583
up	O	1583-1585
;	O	1585-1586
two	O	1587-1590
of	O	1591-1593
them	O	1594-1598
died	O	1599-1603
of	O	1604-1606
treatment	O	1607-1616
-	O	1616-1617
related	O	1617-1624
toxicity	B	1625-1633
.	O	1633-1634

The	O	1635-1638
MFL	O	1639-1642
regimen	O	1643-1650
achieves	O	1651-1659
little	O	1660-1666
palliative	O	1667-1677
benefit	O	1678-1685
and	O	1686-1689
induces	O	1690-1697
severe	O	1698-1704
toxicity	B	1705-1713
at	O	1714-1716
a	O	1717-1718
fairly	O	1719-1725
high	O	1726-1730
rate	O	1731-1735
.	O	1735-1736

Administration	O	1737-1751
of	O	1752-1754
this	O	1755-1759
regimen	O	1760-1767
to	O	1768-1770
breast	B	1771-1777
cancer	I	1778-1784
patients	O	1785-1793
who	O	1794-1797
have	O	1798-1802
been	O	1803-1807
treated	O	1808-1815
by	O	1816-1818
chemotherapy	O	1819-1831
and	O	1832-1835
those	O	1836-1841
with	O	1842-1846
impaired	B	1847-1855
heart	I	1856-1861
function	I	1862-1870
requires	O	1871-1879
careful	O	1880-1887
attention	O	1888-1897
.	O	1897-1898

Upregulation	O	0-12
of	O	13-15
the	O	16-19
expression	O	20-30
of	O	31-33
vasopressin	O	34-45
gene	O	46-50
in	O	51-53
the	O	54-57
paraventricular	O	58-73
and	O	74-77
supraoptic	O	78-88
nuclei	O	89-95
of	O	96-98
the	O	99-102
lithium	O	103-110
-	O	110-111
induced	O	111-118
diabetes	B	119-127
insipidus	I	128-137
rat	O	138-141
.	O	141-142

The	O	143-146
expression	O	147-157
of	O	158-160
arginine	O	161-169
vasopressin	O	170-181
(	O	182-183
AVP	O	183-186
)	O	186-187
gene	O	188-192
in	O	193-195
the	O	196-199
paraventricular	O	200-215
(	O	216-217
PVN	O	217-220
)	O	220-221
and	O	222-225
supraoptic	O	226-236
nuclei	O	237-243
(	O	244-245
SON	O	245-248
)	O	248-249
was	O	250-253
investigated	O	254-266
in	O	267-269
rats	O	270-274
with	O	275-279
lithium	O	280-287
(	O	288-289
Li	O	289-291
)	O	291-292
-	O	292-293
induced	O	293-300
polyuria	B	301-309
,	O	309-310
using	O	311-316
in	O	317-319
situ	O	320-324
hybridization	O	325-338
histochemistry	O	339-353
and	O	354-357
radioimmunoassay	O	358-374
.	O	374-375

The	O	376-379
male	O	380-384
Wistar	O	385-391
rats	O	392-396
consuming	O	397-406
a	O	407-408
diet	O	409-413
that	O	414-418
contained	O	419-428
LiCl	O	429-433
(	O	434-435
60	O	435-437
mmol	O	438-442
/	O	442-443
kg	O	443-445
)	O	445-446
for	O	447-450
4	O	451-452
weeks	O	453-458
developed	O	459-468
marked	O	469-475
polyuria	B	476-484
.	O	484-485

The	O	486-489
Li	O	490-492
-	O	492-493
treated	O	493-500
rats	O	501-505
produced	O	506-514
a	O	515-516
large	O	517-522
volume	O	523-529
of	O	530-532
hypotonic	O	533-542
urine	O	543-548
with	O	549-553
low	O	554-557
ionic	O	558-563
concentrations	O	564-578
.	O	578-579

Plasma	O	580-586
sodium	O	587-593
concentrations	O	594-608
were	O	609-613
found	O	614-619
to	O	620-622
be	O	623-625
slightly	O	626-634
increased	O	635-644
in	O	645-647
the	O	648-651
Li	O	652-654
-	O	654-655
treated	O	655-662
rats	O	663-667
compared	O	668-676
with	O	677-681
those	O	682-687
in	O	688-690
controls	O	691-699
.	O	699-700

Plasma	O	701-707
concentration	O	708-721
of	O	722-724
AVP	O	725-728
and	O	729-732
transcripts	O	733-744
of	O	745-747
AVP	O	748-751
gene	O	752-756
in	O	757-759
the	O	760-763
PVN	O	764-767
and	O	768-771
SON	O	772-775
were	O	776-780
significantly	O	781-794
increased	O	795-804
in	O	805-807
the	O	808-811
Li	O	812-814
-	O	814-815
treated	O	815-822
rats	O	823-827
compared	O	828-836
with	O	837-841
controls	O	842-850
.	O	850-851

These	O	852-857
results	O	858-865
suggest	O	866-873
that	O	874-878
dehydration	B	879-890
and	O	891-894
/	O	894-895
or	O	895-897
the	O	898-901
activation	O	902-912
of	O	913-915
visceral	O	916-924
afferent	O	925-933
inputs	O	934-940
may	O	941-944
contribute	O	945-955
to	O	956-958
the	O	959-962
elevation	O	963-972
of	O	973-975
plasma	O	976-982
AVP	O	983-986
and	O	987-990
the	O	991-994
upregulation	O	995-1007
of	O	1008-1010
AVP	O	1011-1014
gene	O	1015-1019
expression	O	1020-1030
in	O	1031-1033
the	O	1034-1037
PVN	O	1038-1041
and	O	1042-1045
the	O	1046-1049
SON	O	1050-1053
of	O	1054-1056
the	O	1057-1060
Li	O	1061-1063
-	O	1063-1064
induced	O	1064-1071
diabetes	B	1072-1080
insipidus	I	1081-1090
rat	O	1091-1094
.	O	1094-1095

Suxamethonium	O	0-13
-	O	13-14
induced	O	14-21
cardiac	B	22-29
arrest	I	30-36
and	O	37-40
death	B	41-46
following	O	47-56
5	O	57-58
days	O	59-63
of	O	64-66
immobilization	O	67-81
.	O	81-82

The	O	83-86
present	O	87-94
report	O	95-101
describes	O	102-111
a	O	112-113
case	O	114-118
of	O	119-121
cardiac	B	122-129
arrest	I	130-136
and	O	137-140
subsequent	O	141-151
death	B	152-157
as	O	158-160
a	O	161-162
result	O	163-169
of	O	170-172
hyperkalaemia	B	173-186
following	O	187-196
the	O	197-200
use	O	201-204
of	O	205-207
suxamethonium	O	208-221
in	O	222-224
a	O	225-226
23	O	227-229
-	O	229-230
year	O	230-234
-	O	229-230
old	O	235-238
Malawian	O	239-247
woman	O	248-253
.	O	253-254

Five	O	255-259
days	O	260-264
after	O	265-270
the	O	271-274
onset	O	275-280
of	O	281-283
the	O	284-287
symptoms	O	288-296
of	O	297-299
meningitis	B	300-310
,	O	310-311
the	O	312-315
patient	O	316-323
aspirated	O	324-333
stomach	O	334-341
contents	O	342-350
and	O	351-354
needed	O	355-361
endotracheal	O	362-374
intubation	O	375-385
.	O	385-386

Forty	O	387-392
seconds	O	393-400
after	O	401-406
injection	O	407-416
of	O	417-419
suxamethonium	O	420-433
,	O	433-434
bradycardia	B	435-446
and	O	447-450
cardiac	B	451-458
arrest	I	459-465
occurred	O	466-474
.	O	474-475

Attempts	O	476-484
to	O	485-487
resuscitate	O	488-499
the	O	500-503
patient	O	504-511
were	O	512-516
not	O	517-520
successful	O	521-531
.	O	531-532

The	O	533-536
serum	O	537-542
level	O	543-548
of	O	549-551
potassium	O	552-561
was	O	562-565
observed	O	566-574
to	O	575-577
be	O	578-580
8	O	581-582
.	O	582-583
4	O	583-584
mequiv	O	585-591
L	O	592-593
-	O	593-594
1	O	594-595
.	O	595-596

Apart	O	597-602
from	O	603-607
the	O	608-611
reduction	O	612-621
in	O	622-624
the	O	625-628
patient	O	629-636
'	O	636-637
s	O	637-638
level	O	639-644
of	O	645-647
consciousness	O	648-661
,	O	661-662
there	O	663-668
were	O	669-673
no	O	674-676
signs	O	677-682
of	O	683-685
motor	O	686-691
neurone	O	692-699
damage	O	700-706
or	O	707-709
of	O	710-712
any	O	713-716
of	O	717-719
the	O	720-723
other	O	724-729
known	O	730-735
predisposing	O	736-748
conditions	O	749-759
for	O	760-763
hyperkalaemia	B	764-777
following	O	778-787
the	O	788-791
administration	O	792-806
of	O	807-809
suxamethonium	O	810-823
.	O	823-824

It	O	825-827
is	O	828-830
postulated	O	831-841
that	O	842-846
her	O	847-850
death	B	851-856
was	O	857-860
caused	O	861-867
by	O	868-870
hypersensitivity	B	871-887
to	O	888-890
suxamethonium	O	891-904
,	O	904-905
associated	O	906-916
with	O	917-921
her	O	922-925
5	O	926-927
-	O	927-928
day	O	928-931
immobilization	O	932-946
.	O	946-947

An	O	0-2
unusual	O	3-10
toxic	O	11-16
reaction	O	17-25
to	O	26-28
axillary	O	29-37
block	O	38-43
by	O	44-46
mepivacaine	O	47-58
with	O	59-63
adrenaline	O	64-74
.	O	74-75

An	O	76-78
increase	B	79-87
in	I	88-90
blood	I	91-96
pressure	I	97-105
,	O	105-106
accompanied	O	107-118
by	O	119-121
atrial	B	122-128
fibrillation	I	129-141
,	O	141-142
agitation	B	143-152
,	O	152-153
incomprehensible	B	154-170
shouts	I	171-177
and	O	178-181
loss	B	182-186
of	I	187-189
consciousness	I	190-203
,	O	203-204
was	O	205-208
observed	O	209-217
in	O	218-220
an	O	221-223
elderly	O	224-231
,	O	231-232
ASA	O	233-236
classification	O	237-251
group	O	252-257
II	O	258-260
,	O	260-261
cardiovascularly	O	262-278
medicated	O	279-288
male	O	289-293
,	O	293-294
12	O	295-297
min	O	298-301
after	O	302-307
performance	O	308-319
of	O	320-322
axillary	O	323-331
block	O	332-337
with	O	338-342
mepivacaine	O	343-354
850	O	355-358
mg	O	359-361
containing	O	362-372
adrenaline	O	373-383
0	O	384-385
.	O	385-386
225	O	386-389
mg	O	390-392
,	O	392-393
for	O	394-397
correction	O	398-408
of	O	409-411
Dupuytren	B	412-421
'	I	421-422
s	I	422-423
contracture	I	424-435
.	O	435-436

After	O	437-442
intravenous	O	443-454
administration	O	455-469
of	O	470-472
labetalol	O	473-482
,	O	482-483
metoprolol	O	484-494
and	O	495-498
midazolam	O	499-508
the	O	509-512
patient	O	513-520
'	O	520-521
s	O	521-522
condition	O	523-532
improved	O	533-541
,	O	541-542
and	O	543-546
15	O	547-549
min	O	550-553
later	O	554-559
he	O	560-562
woke	O	563-567
up	O	568-570
.	O	570-571

The	O	572-575
block	O	576-581
was	O	582-585
successful	O	586-596
and	O	597-600
surgery	O	601-608
was	O	609-612
conducted	O	613-622
as	O	623-625
scheduled	O	626-635
despite	O	636-643
persisting	O	644-654
atrial	B	655-661
fibrillation	I	662-674
.	O	674-675

Postoperatively	O	676-691
,	O	691-692
the	O	693-696
patient	O	697-704
refused	O	705-712
DC	O	713-715
cardioversion	O	716-729
and	O	730-733
was	O	734-737
treated	O	738-745
medically	O	746-755
.	O	755-756

Both	O	757-761
the	O	762-765
temporal	O	766-774
relationship	O	775-787
of	O	788-790
events	O	791-797
and	O	798-801
the	O	802-805
response	O	806-814
to	O	815-817
treatment	O	818-827
suggest	O	828-835
that	O	836-840
a	O	841-842
rapid	O	843-848
systemic	O	849-857
absorption	O	858-868
of	O	869-871
mepivacaine	O	872-883
with	O	884-888
adrenaline	O	889-899
and	O	900-903
/	O	903-904
or	O	904-906
interaction	O	907-918
of	O	919-921
these	O	922-927
drugs	O	928-933
with	O	934-938
the	O	939-942
patient	O	943-950
'	O	950-951
s	O	951-952
cardiovascular	O	953-967
medications	O	968-979
were	O	980-984
responsible	O	985-996
for	O	997-1000
the	O	1001-1004
perioperative	O	1005-1018
complications	O	1019-1032
.	O	1032-1033

Clinical	O	0-8
and	O	9-12
histopathologic	O	13-28
examination	O	29-40
of	O	41-43
renal	O	44-49
allografts	O	50-60
treated	O	61-68
with	O	69-73
tacrolimus	O	74-84
(	O	85-86
FK506	O	86-91
)	O	91-92
for	O	93-96
at	O	97-99
least	O	100-105
one	O	106-109
year	O	110-114
.	O	114-115

BACKGROUND	O	116-126
:	O	126-127
We	O	128-130
clinically	O	131-141
and	O	142-145
pathologically	O	146-160
analyzed	O	161-169
renal	O	170-175
allografts	O	176-186
from	O	187-191
1	O	192-193
9	O	194-195
renal	O	196-201
transplant	O	202-212
patients	O	213-221
treated	O	222-229
with	O	230-234
tacrolimus	O	235-245
(	O	246-247
FK506	O	247-252
)	O	252-253
for	O	254-257
more	O	258-262
than	O	263-267
1	O	268-269
year	O	270-274
.	O	274-275

METHODS	O	276-283
:	O	283-284
Twenty	O	285-291
-	O	291-292
six	O	292-295
renal	O	296-301
allograft	O	302-311
biopsy	O	312-318
specimens	O	319-328
from	O	329-333
1	O	334-335
9	O	336-337
renal	O	338-343
transplant	O	344-354
patients	O	355-363
who	O	364-367
underwent	O	368-377
transplantations	O	378-394
between	O	395-402
1991	O	403-407
and	O	408-411
1993	O	412-416
were	O	417-421
evaluated	O	422-431
.	O	431-432

Thirteen	O	433-441
biopsies	O	442-450
were	O	451-455
performed	O	456-465
from	O	466-470
stable	O	471-477
functioning	O	478-489
renal	O	490-495
allografts	O	496-506
with	O	507-511
informed	O	512-520
consent	O	521-528
(	O	529-530
nonepisode	O	530-540
biopsy	O	541-547
)	O	547-548
and	O	549-552
the	O	553-556
other	O	557-562
13	O	563-565
were	O	566-570
from	O	571-575
dysfunctional	O	576-589
renal	O	590-595
allografts	O	596-606
with	O	607-611
a	O	612-613
clinical	O	614-622
indication	O	623-633
for	O	634-637
biopsy	O	638-644
(	O	645-646
episode	O	646-653
biopsy	O	654-660
)	O	660-661
.	O	661-662

RESULTS	O	663-670
:	O	670-671
The	O	672-675
main	O	676-680
pathologic	O	681-691
diagnoses	O	692-701
(	O	702-703
some	O	703-707
overlap	O	708-715
)	O	715-716
were	O	717-721
acute	O	722-727
rejection	O	728-737
(	O	738-739
AR	O	739-741
;	O	741-742
n	O	743-744
=	O	745-746
4	O	747-748
)	O	748-749
,	O	749-750
chronic	O	751-758
rejection	O	759-768
(	O	769-770
CR	O	770-772
;	O	772-773
n	O	774-775
=	O	775-776
5	O	776-777
)	O	777-778
,	O	778-779
AR	O	780-782
+	O	782-783
CR	O	783-785
(	O	786-787
n	O	787-788
=	O	789-790
4	O	790-791
)	O	791-792
,	O	792-793
recurrent	O	794-803
IgA	B	804-807
nephropathy	I	808-819
(	O	820-821
n	O	821-822
=	O	823-824
5	O	824-825
)	O	825-826
,	O	826-827
normal	O	828-834
findings	O	835-843
(	O	844-845
n	O	845-846
=	O	847-848
2	O	848-849
)	O	849-850
,	O	850-851
minimal	O	852-859
-	O	859-860
type	O	860-864
chronic	O	865-872
FK506	O	873-878
nephropathy	B	879-890
(	O	891-892
n	O	892-893
=	O	894-895
9	O	896-897
)	O	897-898
,	O	898-899
and	O	900-903
mild	O	904-908
-	O	908-909
type	O	909-913
FK506	O	914-919
nephropathy	B	920-931
(	O	932-933
n	O	933-934
=	O	935-936
11	O	937-939
)	O	939-940
.	O	940-941

Of	O	942-944
the	O	945-948
nonepisode	O	949-959
biopsies	O	960-968
,	O	968-969
7	O	970-971
and	O	972-975
4	O	976-977
biopsies	O	978-986
showed	O	987-993
minimal	O	994-1001
-	O	1001-1002
type	O	1002-1006
and	O	1007-1010
mild	O	1011-1015
-	O	1015-1016
type	O	1016-1020
chronic	O	1021-1028
FK506	O	1029-1034
nephropathy	B	1035-1046
,	O	1046-1047
respectively	O	1048-1060
.	O	1060-1061

Chronic	O	1062-1069
FK506	O	1070-1075
nephropathy	B	1076-1087
consisted	O	1088-1097
of	O	1098-1100
rough	O	1101-1106
and	O	1107-1110
foamy	O	1111-1116
tubular	O	1117-1124
vacuolization	O	1125-1138
(	O	1139-1140
5	O	1140-1141
biopsies	O	1142-1150
)	O	1150-1151
,	O	1151-1152
arteriolopathy	O	1153-1167
(	O	1168-1169
angiodegeneration	O	1169-1186
of	O	1187-1189
the	O	1190-1193
arteriolar	O	1194-1204
wall	O	1205-1209
;	O	1209-1210
20	O	1211-1213
biopsies	O	1214-1222
)	O	1222-1223
,	O	1223-1224
focal	B	1225-1230
segmental	I	1231-1240
glomerulosclerosis	I	1241-1259
(	O	1260-1261
4	O	1261-1262
biopsies	O	1263-1271
)	O	1271-1272
and	O	1273-1276
the	O	1277-1280
striped	O	1281-1288
form	O	1289-1293
of	O	1294-1296
interstitial	B	1297-1309
fibrosis	I	1310-1318
(	O	1319-1320
11	O	1320-1322
biopsies	O	1323-1331
)	O	1331-1332
.	O	1332-1333

The	O	1334-1337
serum	O	1338-1343
creatinine	O	1344-1354
levels	O	1355-1361
of	O	1362-1364
patients	O	1365-1373
in	O	1374-1376
the	O	1377-1380
mild	O	1381-1385
-	O	1385-1386
type	O	1386-1390
chronic	O	1391-1398
FK506	O	1399-1404
nephropathy	B	1405-1416
group	O	1417-1422
,	O	1422-1423
which	O	1424-1429
included	O	1430-1438
7	O	1439-1440
episode	O	1441-1448
biopsies	O	1449-1457
,	O	1457-1458
were	O	1459-1463
statistically	O	1464-1477
higher	O	1478-1484
than	O	1485-1489
those	O	1490-1495
in	O	1496-1498
the	O	1499-1502
minimum	O	1503-1510
-	O	1510-1511
type	O	1511-1515
chronic	O	1516-1523
FK506	O	1524-1529
-	O	1529-1530
nephropathy	B	1530-1541
group	O	1542-1547
(	O	1548-1549
P	O	1549-1550
<	O	1550-1551
0	O	1552-1553
.	O	1553-1554
001	O	1554-1557
)	O	1557-1558
.	O	1553-1554

CONCLUSIONS	O	1560-1571
:	O	1571-1572
This	O	1573-1577
study	O	1578-1583
demonstrates	O	1584-1596
that	O	1597-1601
chronic	O	1602-1609
FK506	O	1610-1615
nephropathy	B	1616-1627
consists	O	1628-1636
primarily	O	1637-1646
of	O	1647-1649
arteriolopathy	O	1650-1664
manifesting	O	1665-1676
as	O	1677-1679
insudative	O	1680-1690
hyalinosis	O	1691-1701
of	O	1702-1704
the	O	1705-1708
arteriolar	O	1709-1719
wall	O	1720-1724
,	O	1724-1725
and	O	1726-1729
suggests	O	1730-1738
that	O	1739-1743
mild	O	1744-1748
-	O	1748-1749
type	O	1749-1753
chronic	O	1754-1761
FK506	O	1762-1767
nephropathy	B	1768-1779
is	O	1780-1782
a	O	1783-1784
condition	O	1785-1794
which	O	1795-1800
may	O	1801-1804
lead	O	1805-1809
to	O	1810-1812
deterioration	O	1813-1826
of	O	1827-1829
renal	O	1830-1835
allograft	O	1836-1845
function	O	1846-1854
.	O	1854-1855

Memory	O	0-6
facilitation	O	7-19
and	O	20-23
stimulation	O	24-35
of	O	36-38
endogenous	O	39-49
nerve	O	50-55
growth	O	56-62
factor	O	63-69
synthesis	O	70-79
by	O	80-82
the	O	83-86
acetylcholine	O	87-100
releaser	O	101-109
PG	O	110-112
-	O	112-113
9	O	113-114
.	O	114-115

The	O	116-119
effects	O	120-127
of	O	128-130
PG	O	131-133
-	O	133-134
9	O	134-135
(	O	136-137
3alpha	O	137-143
-	O	143-144
tropyl	O	144-150
2	O	151-152
-	O	152-153
(	O	153-154
p	O	154-155
-	O	152-153
bromophenyl	O	156-167
)	O	167-168
propionate	O	168-178
)	O	167-168
,	O	179-180
the	O	181-184
acetylcholine	O	185-198
releaser	O	199-207
,	O	207-208
on	O	209-211
memory	O	212-218
processes	O	219-228
and	O	229-232
nerve	O	233-238
growth	O	239-245
factor	O	246-252
(	O	253-254
NGF	O	254-257
)	O	257-258
synthesis	O	259-268
were	O	269-273
evaluated	O	274-283
.	O	283-284

In	O	285-287
the	O	288-291
mouse	O	292-297
passive	O	298-305
-	O	305-306
avoidance	O	306-315
test	O	316-320
,	O	320-321
PG	O	322-324
-	O	324-325
9	O	325-326
(	O	327-328
10	O	328-330
-	O	330-331
30	O	331-333
mg	O	334-336
/	O	336-337
kg	O	337-339
,	O	339-340
i	O	341-342
.	O	342-343
p	O	343-344
.	O	342-343
)	O	345-346
,	O	346-347
administered	O	348-360
20	O	361-363
min	O	364-367
before	O	368-374
the	O	375-378
training	O	379-387
session	O	388-395
,	O	395-396
prevented	O	397-406
amnesia	B	407-414
induced	O	415-422
by	O	423-425
both	O	426-430
the	O	431-434
non	O	435-438
selective	O	439-448
antimuscarinic	O	449-463
drug	O	464-468
scopolamine	O	469-480
and	O	481-484
the	O	485-488
M1	O	489-491
-	O	491-492
selective	O	492-501
antagonist	O	502-512
S	O	513-514
-	O	514-515
(	O	515-516
-	O	514-515
)	O	517-518
-	O	514-515
ET	O	519-521
-	O	514-515
126	O	522-525
.	O	525-526

In	O	527-529
the	O	530-533
same	O	534-538
experimental	O	539-551
conditions	O	552-562
,	O	562-563
PG	O	564-566
-	O	566-567
9	O	567-568
(	O	569-570
5	O	570-571
-	O	571-572
20	O	572-574
microg	O	575-581
per	O	582-585
mouse	O	586-591
,	O	591-592
i	O	593-594
.	O	594-595
c	O	595-596
.	O	594-595
v	O	597-598
.	O	594-595
)	O	599-600
was	O	601-604
also	O	605-609
able	O	610-614
to	O	615-617
prevent	O	618-625
antimuscarine	O	626-639
-	O	639-640
induced	O	640-647
amnesia	B	648-655
,	O	655-656
demonstrating	O	657-670
a	O	671-672
central	O	673-680
localization	O	681-693
of	O	694-696
the	O	697-700
activity	O	701-709
.	O	709-710

At	O	711-713
the	O	714-717
highest	O	718-725
effective	O	726-735
doses	O	736-741
,	O	741-742
PG	O	743-745
-	O	745-746
9	O	746-747
did	O	748-751
not	O	752-755
produce	O	756-763
any	O	764-767
collateral	O	768-778
symptoms	O	779-787
as	O	788-790
revealed	O	791-799
by	O	800-802
the	O	803-806
Irwin	O	807-812
test	O	813-817
,	O	817-818
and	O	819-822
it	O	823-825
did	O	826-829
not	O	830-833
modify	O	834-840
spontaneous	O	841-852
motility	O	853-861
and	O	862-865
inspection	O	866-876
activity	O	877-885
,	O	885-886
as	O	887-889
revealed	O	890-898
by	O	899-901
the	O	902-905
hole	O	906-910
-	O	910-911
board	O	911-916
test	O	917-921
.	O	921-922

PG	O	923-925
-	O	925-926
9	O	926-927
was	O	928-931
also	O	932-936
able	O	937-941
to	O	942-944
increase	O	945-953
the	O	954-957
amount	O	958-964
of	O	965-967
NGF	O	968-971
secreted	O	972-980
in	O	981-983
vitro	O	984-989
by	O	990-992
astrocytes	O	993-1003
in	O	1004-1006
a	O	1007-1008
dose	O	1009-1013
-	O	1013-1014
dependent	O	1014-1023
manner	O	1024-1030
.	O	1030-1031

The	O	1032-1035
maximal	O	1036-1043
NGF	O	1044-1047
contents	O	1048-1056
obtained	O	1057-1065
by	O	1066-1068
PG	O	1069-1071
-	O	1071-1072
9	O	1072-1073
were	O	1074-1078
17	O	1079-1081
.	O	1081-1082
6	O	1082-1083
-	O	1083-1084
fold	O	1084-1088
of	O	1089-1091
the	O	1092-1095
control	O	1096-1103
value	O	1104-1109
.	O	1109-1110

During	O	1111-1117
culture	O	1118-1125
,	O	1125-1126
no	O	1127-1129
morphological	O	1130-1143
changes	O	1144-1151
were	O	1152-1156
found	O	1157-1162
at	O	1163-1165
effective	O	1166-1175
concentrations	O	1176-1190
of	O	1191-1193
PG	O	1194-1196
-	O	1196-1197
9	O	1197-1198
.	O	1198-1199

The	O	1200-1203
current	O	1204-1211
work	O	1212-1216
indicates	O	1217-1226
the	O	1227-1230
ability	O	1231-1238
of	O	1239-1241
PG	O	1242-1244
-	O	1244-1245
9	O	1245-1246
to	O	1247-1249
induce	O	1250-1256
beneficial	O	1257-1267
effects	O	1268-1275
on	O	1276-1278
cognitive	O	1279-1288
processes	O	1289-1298
and	O	1299-1302
stimulate	O	1303-1312
activity	O	1313-1321
of	O	1322-1324
NGF	O	1325-1328
synthesis	O	1329-1338
in	O	1339-1341
astroglial	O	1342-1352
cells	O	1353-1358
.	O	1358-1359

Therefore	O	1360-1369
,	O	1369-1370
PG	O	1371-1373
-	O	1373-1374
9	O	1374-1375
could	O	1376-1381
represent	O	1382-1391
a	O	1392-1393
potential	O	1394-1403
useful	O	1404-1410
drug	O	1411-1415
able	O	1416-1420
to	O	1421-1423
improve	O	1424-1431
the	O	1432-1435
function	O	1436-1444
of	O	1445-1447
impaired	O	1448-1456
cognitive	O	1457-1466
processes	O	1467-1476
.	O	1476-1477

Angioedema	B	0-10
due	O	11-14
to	O	15-17
ACE	O	18-21
inhibitors	O	22-32
:	O	32-33
common	O	34-40
and	O	41-44
inadequately	O	45-57
diagnosed	O	58-67
.	O	67-68

The	O	69-72
estimated	O	73-82
incidence	O	83-92
of	O	93-95
angioedema	B	96-106
during	O	107-113
angiotensin	O	114-125
-	O	125-126
converting	O	126-136
enzyme	O	137-143
(	O	144-145
ACE	O	145-148
)	O	148-149
inhibitor	O	150-159
treatment	O	160-169
is	O	170-172
between	O	173-180
1	O	181-182
and	O	183-186
7	O	187-188
per	O	189-192
thousand	O	193-201
patients	O	202-210
.	O	210-211

This	O	212-216
potentially	O	217-228
serious	O	229-236
adverse	O	237-244
effect	O	245-251
is	O	252-254
often	O	255-260
preceded	O	261-269
by	O	270-272
minor	O	273-278
manifestations	O	279-293
that	O	294-298
may	O	299-302
serve	O	303-308
as	O	309-311
a	O	312-313
warning	O	314-321
.	O	321-322

Recurarization	O	0-14
in	O	15-17
the	O	18-21
recovery	O	22-30
room	O	31-35
.	O	35-36

A	O	37-38
case	O	39-43
of	O	44-46
recurarization	O	47-61
in	O	62-64
the	O	65-68
recovery	O	69-77
room	O	78-82
is	O	83-85
reported	O	86-94
.	O	94-95

Accumulation	O	96-108
of	O	109-111
atracurium	O	112-122
in	O	123-125
the	O	126-129
intravenous	O	130-141
line	O	142-146
led	O	147-150
to	O	151-153
recurarization	O	154-168
after	O	169-174
flushing	O	175-183
the	O	184-187
line	O	188-192
in	O	193-195
the	O	196-199
recovery	O	200-208
room	O	209-213
.	O	213-214

A	O	215-216
respiratory	B	217-228
arrest	I	229-235
with	O	236-240
severe	O	241-247
desaturation	B	248-260
and	O	261-264
bradycardia	B	265-276
occurred	O	277-285
.	O	285-286

Circumstances	O	287-300
leading	O	301-308
to	O	309-311
this	O	312-316
event	O	317-322
and	O	323-326
the	O	327-330
mechanisms	O	331-341
enabling	O	342-350
a	O	351-352
neuromuscular	B	353-366
blockade	I	367-375
to	O	376-378
occur	O	379-384
,	O	384-385
following	O	386-395
the	O	396-399
administration	O	400-414
of	O	415-417
a	O	418-419
small	O	420-425
dose	O	426-430
of	O	431-433
relaxant	O	434-442
,	O	442-443
are	O	444-447
discussed	O	448-457
.	O	457-458

Recurrent	O	0-9
use	O	10-13
of	O	14-16
newer	O	17-22
oral	O	23-27
contraceptives	O	28-42
and	O	43-46
the	O	47-50
risk	O	51-55
of	O	56-58
venous	B	59-65
thromboembolism	I	66-81
.	O	81-82

The	O	83-86
epidemiological	O	87-102
studies	O	103-110
that	O	111-115
assessed	O	116-124
the	O	125-128
risk	O	129-133
of	O	134-136
venous	B	137-143
thromboembolism	I	144-159
(	O	160-161
VTE	B	161-164
)	O	164-165
associated	O	166-176
with	O	177-181
newer	O	182-187
oral	O	188-192
contraceptives	O	193-207
(	O	208-209
OC	O	209-211
)	O	211-212
did	O	213-216
not	O	217-220
distinguish	O	221-232
between	O	233-240
patterns	O	241-249
of	O	250-252
OC	O	253-255
use	O	256-259
,	O	259-260
namely	O	261-267
first	O	268-273
-	O	273-274
time	O	274-278
users	O	279-284
,	O	284-285
repeaters	O	286-295
and	O	296-299
switchers	O	300-309
.	O	309-310

Data	O	311-315
from	O	316-320
a	O	321-322
Transnational	O	323-336
case	O	337-341
-	O	341-342
control	O	342-349
study	O	350-355
were	O	356-360
used	O	361-365
to	O	366-368
assess	O	369-375
the	O	376-379
risk	O	380-384
of	O	385-387
VTE	B	388-391
for	O	392-395
the	O	396-399
latter	O	400-406
patterns	O	407-415
of	O	416-418
use	O	419-422
,	O	422-423
while	O	424-429
accounting	O	430-440
for	O	441-444
duration	O	445-453
of	O	454-456
use	O	457-460
.	O	460-461

Over	O	462-466
the	O	467-470
period	O	471-477
1993	O	478-482
-	O	482-483
1996	O	483-487
,	O	487-488
551	O	489-492
cases	O	493-498
of	O	499-501
VTE	B	502-505
were	O	506-510
identified	O	511-521
in	O	522-524
Germany	O	525-532
and	O	533-536
the	O	537-540
UK	O	541-543
along	O	544-549
with	O	550-554
2066	O	555-559
controls	O	560-568
.	O	568-569

Totals	O	570-576
of	O	577-579
128	O	580-583
cases	O	584-589
and	O	590-593
650	O	594-597
controls	O	598-606
were	O	607-611
analysed	O	612-620
for	O	621-624
repeat	O	625-631
use	O	632-635
and	O	636-639
135	O	640-643
cases	O	644-649
and	O	650-653
622	O	654-657
controls	O	658-666
for	O	667-670
switching	O	671-680
patterns	O	681-689
.	O	689-690

The	O	691-694
adjusted	O	695-703
rate	O	704-708
ratio	O	709-714
of	O	715-717
VTE	B	718-721
for	O	722-725
repeat	O	726-732
users	O	733-738
of	O	739-741
third	O	742-747
generation	O	748-758
OC	O	759-761
was	O	762-765
0	O	766-767
.	O	767-768
6	O	768-769
(	O	770-771
95	O	771-773
%	O	773-774
CI	O	775-777
:	O	777-778
0	O	778-779
.	O	779-780
3	O	780-781
-	O	781-782
1	O	782-783
.	O	779-780
2	O	784-785
)	O	785-786
relative	O	787-795
to	O	796-798
repeat	O	799-805
users	O	806-811
of	O	812-814
second	O	815-821
generation	O	822-832
pills	O	833-838
,	O	838-839
whereas	O	840-847
it	O	848-850
was	O	851-854
1	O	855-856
.	O	856-857
3	O	857-858
(	O	859-860
95	O	860-862
%	O	862-863
CI	O	864-866
:	O	866-867
0	O	867-868
.	O	868-869
7	O	869-870
-	O	870-871
2	O	871-872
.	O	868-869
4	O	873-874
)	O	874-875
for	O	876-879
switchers	O	880-889
from	O	890-894
second	O	895-901
to	O	902-904
third	O	905-910
generation	O	911-921
pills	O	922-927
relative	O	928-936
to	O	937-939
switchers	O	940-949
from	O	950-954
third	O	955-960
to	O	961-963
second	O	964-970
generation	O	971-981
pills	O	982-987
.	O	987-988

We	O	989-991
conclude	O	992-1000
that	O	1001-1005
second	O	1006-1012
and	O	1013-1016
third	O	1017-1022
generation	O	1023-1033
agents	O	1034-1040
are	O	1041-1044
associated	O	1045-1055
with	O	1056-1060
equivalent	O	1061-1071
risks	O	1072-1077
of	O	1078-1080
VTE	B	1081-1084
when	O	1085-1089
the	O	1090-1093
same	O	1094-1098
agent	O	1099-1104
is	O	1105-1107
used	O	1108-1112
repeatedly	O	1113-1123
after	O	1124-1129
interruption	O	1130-1142
periods	O	1143-1150
or	O	1151-1153
when	O	1154-1158
users	O	1159-1164
are	O	1165-1168
switched	O	1169-1177
between	O	1178-1185
the	O	1186-1189
two	O	1190-1193
generations	O	1194-1205
of	O	1206-1208
pills	O	1209-1214
.	O	1214-1215

These	O	1216-1221
analyses	O	1222-1230
suggest	O	1231-1238
that	O	1239-1243
the	O	1244-1247
higher	O	1248-1254
risk	O	1255-1259
observed	O	1260-1268
for	O	1269-1272
the	O	1273-1276
newer	O	1277-1282
OC	O	1283-1285
in	O	1286-1288
other	O	1289-1294
studies	O	1295-1302
may	O	1303-1306
be	O	1307-1309
the	O	1310-1313
result	O	1314-1320
of	O	1321-1323
inadequate	O	1324-1334
comparisons	O	1335-1346
of	O	1347-1349
pill	O	1350-1354
users	O	1355-1360
with	O	1361-1365
different	O	1366-1375
patterns	O	1376-1384
of	O	1385-1387
pill	O	1388-1392
use	O	1393-1396
.	O	1396-1397

Development	O	0-11
of	O	12-14
apomorphine	O	15-26
-	O	26-27
induced	O	27-34
aggressive	B	35-45
behavior	I	46-54
:	O	54-55
comparison	O	56-66
of	O	67-69
adult	O	70-75
male	O	76-80
and	O	81-84
female	O	85-91
Wistar	O	92-98
rats	O	99-103
.	O	103-104

The	O	105-108
development	O	109-120
of	O	121-123
apomorphine	O	124-135
-	O	135-136
induced	O	136-143
(	O	144-145
1	O	145-146
.	O	146-147
0	O	147-148
mg	O	149-151
/	O	151-152
kg	O	152-154
s	O	155-156
.	O	156-157
c	O	157-158
.	O	156-157

once	O	160-164
daily	O	165-170
)	O	170-171
aggressive	B	172-182
behavior	I	183-191
of	O	192-194
adult	O	195-200
male	O	201-205
and	O	206-209
female	O	210-216
Wistar	O	217-223
rats	O	224-228
obtained	O	229-237
from	O	238-242
the	O	243-246
same	O	247-251
breeder	O	252-259
was	O	260-263
studied	O	264-271
in	O	272-274
two	O	275-278
consecutive	O	279-290
sets	O	291-295
.	O	295-296

In	O	297-299
male	O	300-304
animals	O	305-312
,	O	312-313
repeated	O	314-322
apomorphine	O	323-334
treatment	O	335-344
induced	O	345-352
a	O	353-354
gradual	O	355-362
development	O	363-374
of	O	375-377
aggressive	B	378-388
behavior	I	389-397
as	O	398-400
evidenced	O	401-410
by	O	411-413
the	O	414-417
increased	O	418-427
intensity	O	428-437
of	O	438-440
aggressiveness	B	441-455
and	O	456-459
shortened	O	460-469
latency	O	470-477
before	O	478-484
the	O	485-488
first	O	489-494
attack	O	495-501
toward	O	502-508
the	O	509-512
opponent	O	513-521
.	O	521-522

In	O	523-525
female	O	526-532
rats	O	533-537
,	O	537-538
only	O	539-543
a	O	544-545
weak	O	546-550
tendency	O	551-559
toward	O	560-566
aggressiveness	B	567-581
was	O	582-585
found	O	586-591
.	O	591-592

In	O	593-595
conclusion	O	596-606
,	O	606-607
the	O	608-611
present	O	612-619
study	O	620-625
demonstrates	O	626-638
gender	O	639-645
differences	O	646-657
in	O	658-660
the	O	661-664
development	O	665-676
of	O	677-679
the	O	680-683
apomorphine	O	684-695
-	O	695-696
induced	O	696-703
aggressive	B	704-714
behavior	I	715-723
and	O	724-727
indicates	O	728-737
that	O	738-742
the	O	743-746
female	O	747-753
rats	O	754-758
do	O	759-761
not	O	762-765
fill	O	766-770
the	O	771-774
validation	O	775-785
criteria	O	786-794
for	O	795-798
use	O	799-802
in	O	803-805
this	O	806-810
method	O	811-817
.	O	817-818

Serotonergic	O	0-12
antidepressants	O	13-28
and	O	29-32
urinary	B	33-40
incontinence	I	41-53
.	O	53-54

Many	O	55-59
new	O	60-63
serotonergic	O	64-76
antidepressants	O	77-92
have	O	93-97
been	O	98-102
introduced	O	103-113
over	O	114-118
the	O	119-122
past	O	123-127
decade	O	128-134
.	O	134-135

Although	O	136-144
urinary	B	145-152
incontinence	I	153-165
is	O	166-168
listed	O	169-175
as	O	176-178
one	O	179-182
side	O	183-187
effect	O	188-194
of	O	195-197
these	O	198-203
drugs	O	204-209
in	O	210-212
their	O	213-218
package	O	219-226
inserts	O	227-234
there	O	235-240
is	O	241-243
only	O	244-248
one	O	249-252
report	O	253-259
in	O	260-262
the	O	263-266
literature	O	267-277
.	O	277-278

This	O	279-283
concerns	O	284-292
2	O	293-294
male	O	295-299
patients	O	300-308
who	O	309-312
experienced	O	313-324
incontinence	B	325-337
while	O	338-343
taking	O	344-350
venlafaxine	O	351-362
.	O	362-363

In	O	364-366
the	O	367-370
present	O	371-378
paper	O	379-384
the	O	385-388
authors	O	389-396
describe	O	397-405
2	O	406-407
female	O	408-414
patients	O	415-423
who	O	424-427
developed	O	428-437
incontinence	B	438-450
secondary	O	451-460
to	O	461-463
the	O	464-467
selective	O	468-477
serotonin	O	478-487
reuptake	O	488-496
inhibitors	O	497-507
paroxetine	O	508-518
and	O	519-522
sertraline	O	523-533
,	O	533-534
as	O	535-537
well	O	538-542
as	O	543-545
a	O	546-547
third	O	548-553
who	O	554-557
developed	O	558-567
this	O	568-572
side	O	573-577
effect	O	578-584
on	O	585-587
venlafaxine	O	588-599
.	O	599-600

In	O	601-603
2	O	604-605
of	O	606-608
the	O	609-612
3	O	613-614
cases	O	615-620
the	O	621-624
patients	O	625-633
were	O	634-638
also	O	639-643
taking	O	644-650
lithium	O	651-658
carbonate	O	659-668
and	O	669-672
beta	O	673-677
-	O	677-678
blockers	O	678-686
,	O	686-687
both	O	688-692
of	O	693-695
which	O	696-701
could	O	702-707
have	O	708-712
contributed	O	713-724
to	O	725-727
the	O	728-731
incontinence	B	732-744
.	O	744-745

Animal	O	746-752
studies	O	753-760
suggest	O	761-768
that	O	769-773
incontinence	B	774-786
secondary	O	787-796
to	O	797-799
serotonergic	O	800-812
antidepressants	O	813-828
could	O	829-834
be	O	835-837
mediated	O	838-846
by	O	847-849
the	O	850-853
5HT4	O	854-858
receptors	O	859-868
found	O	869-874
on	O	875-877
the	O	878-881
bladder	O	882-889
.	O	889-890

Further	O	891-898
research	O	899-907
is	O	908-910
needed	O	911-917
to	O	918-920
delineate	O	921-930
the	O	931-934
frequency	O	935-944
of	O	945-947
this	O	948-952
troubling	O	953-962
side	O	963-967
effect	O	968-974
and	O	975-978
how	O	979-982
best	O	983-987
to	O	988-990
treat	O	991-996
it	O	997-999
.	O	999-1000

Hypotension	B	0-11
following	O	12-21
the	O	22-25
initiation	O	26-36
of	O	37-39
tizanidine	O	40-50
in	O	51-53
a	O	54-55
patient	O	56-63
treated	O	64-71
with	O	72-76
an	O	77-79
angiotensin	O	80-91
converting	O	92-102
enzyme	O	103-109
inhibitor	O	110-119
for	O	120-123
chronic	O	124-131
hypertension	B	132-144
.	O	144-145

Centrally	O	146-155
acting	O	156-162
alpha	O	163-168
-	O	168-169
2	O	169-170
adrenergic	O	171-181
agonists	O	182-190
are	O	191-194
one	O	195-198
of	O	199-201
several	O	202-209
pharmacologic	O	210-223
agents	O	224-230
used	O	231-235
in	O	236-238
the	O	239-242
treatment	O	243-252
of	O	253-255
spasticity	B	256-266
related	O	267-274
to	O	275-277
disorders	B	278-287
of	I	288-290
the	I	291-294
central	I	295-302
nervous	I	303-310
system	I	311-317
.	O	317-318

In	O	319-321
addition	O	322-330
to	O	331-333
their	O	334-339
effects	O	340-347
on	O	348-350
spasticity	B	351-361
,	O	361-362
certain	O	363-370
adverse	O	371-378
cardiorespiratory	O	379-396
effects	O	397-404
have	O	405-409
been	O	410-414
reported	O	415-423
.	O	423-424

Adults	O	425-431
chronically	O	432-443
treated	O	444-451
with	O	452-456
angiotensin	O	457-468
converting	O	469-479
enzyme	O	480-486
inhibitors	O	487-497
may	O	498-501
have	O	502-506
a	O	507-508
limited	O	509-516
ability	O	517-524
to	O	525-527
respond	O	528-535
to	O	536-538
hypotension	B	539-550
when	O	551-555
the	O	556-559
sympathetic	O	560-571
response	O	572-580
is	O	581-583
simultaneously	O	584-598
blocked	O	599-606
.	O	606-607

The	O	608-611
authors	O	612-619
present	O	620-627
a	O	628-629
10	O	630-632
-	O	632-633
year	O	633-637
-	O	632-633
old	O	638-641
boy	O	642-645
chronically	O	646-657
treated	O	658-665
with	O	666-670
lisinopril	O	671-681
,	O	681-682
an	O	683-685
angiotensin	O	686-697
converting	O	698-708
enzyme	O	709-715
inhibitor	O	716-725
,	O	725-726
to	O	727-729
control	O	730-737
hypertension	B	738-750
who	O	751-754
developed	O	755-764
hypotension	B	765-776
following	O	777-786
the	O	787-790
addition	O	791-799
of	O	800-802
tizanidine	O	803-813
,	O	813-814
an	O	815-817
alpha	O	818-823
-	O	823-824
2	O	824-825
agonist	O	826-833
,	O	833-834
for	O	835-838
the	O	839-842
treatment	O	843-852
of	O	853-855
spasticity	B	856-866
.	O	866-867

The	O	868-871
possible	O	872-880
interaction	O	881-892
of	O	893-895
tizanidine	O	896-906
and	O	907-910
other	O	911-916
antihypertensive	O	917-933
agents	O	934-940
should	O	941-947
be	O	948-950
kept	O	951-955
in	O	956-958
mind	O	959-963
when	O	964-968
prescribing	O	969-980
therapy	O	981-988
to	O	989-991
treat	O	992-997
either	O	998-1004
hypertension	B	1005-1017
or	O	1018-1020
spasticity	B	1021-1031
in	O	1032-1034
such	O	1035-1039
patients	O	1040-1048
.	O	1048-1049

Peritubular	O	0-11
capillary	O	12-21
basement	O	22-30
membrane	O	31-39
reduplication	O	40-53
in	O	54-56
allografts	O	57-67
and	O	68-71
native	O	72-78
kidney	B	79-85
disease	I	86-93
:	O	93-94
a	O	95-96
clinicopathologic	O	97-114
study	O	115-120
of	O	121-123
278	O	124-127
consecutive	O	128-139
renal	O	140-145
specimens	O	146-155
.	O	155-156

BACKGROUND	O	157-167
:	O	167-168
An	O	169-171
association	O	172-183
has	O	184-187
been	O	188-192
found	O	193-198
between	O	199-206
transplant	B	207-217
glomerulopathy	I	218-232
(	O	233-234
TG	B	234-236
)	O	236-237
and	O	238-241
reduplication	O	242-255
of	O	256-258
peritubular	O	259-270
capillary	O	271-280
basement	O	281-289
membranes	O	290-299
(	O	300-301
PTCR	O	301-305
)	O	305-306
.	O	306-307

Although	O	308-316
such	O	317-321
an	O	322-324
association	O	325-336
is	O	337-339
of	O	340-342
practical	O	343-352
and	O	353-356
theoretical	O	357-368
importance	O	369-379
,	O	379-380
only	O	381-385
one	O	386-389
prospective	O	390-401
study	O	402-407
has	O	408-411
tried	O	412-417
to	O	418-420
confirm	O	421-428
it	O	429-431
.	O	431-432

METHODS	O	433-440
:	O	440-441
We	O	442-444
examined	O	445-453
278	O	454-457
consecutive	O	458-469
renal	O	470-475
specimens	O	476-485
(	O	486-487
from	O	487-491
135	O	492-495
transplants	O	496-507
and	O	508-511
143	O	512-515
native	O	516-522
kidneys	O	523-530
)	O	530-531
for	O	532-535
ultrastructural	O	536-551
evidence	O	552-560
of	O	561-563
PTCR	O	564-568
.	O	568-569

In	O	570-572
addition	O	573-581
to	O	582-584
renal	O	585-590
allografts	O	591-601
with	O	602-606
TG	B	607-609
,	O	609-610
we	O	611-613
also	O	614-618
examined	O	619-627
grafts	O	628-634
with	O	635-639
acute	O	640-645
rejection	O	646-655
,	O	655-656
recurrent	O	657-666
glomerulonephritis	B	667-685
,	O	685-686
chronic	B	687-694
allograft	I	695-704
nephropathy	I	705-716
and	O	717-720
stable	O	721-727
grafts	O	728-734
(	O	735-736
"	O	736-737
protocol	O	737-745
biopsies	O	746-754
"	O	754-755
)	O	755-756
.	O	756-757

Native	O	758-764
kidney	O	765-771
specimens	O	772-781
included	O	782-790
a	O	791-792
wide	O	793-797
range	O	798-803
of	O	804-806
glomerulopathies	B	807-823
as	O	824-826
well	O	827-831
as	O	832-834
cases	O	835-840
of	O	841-843
thrombotic	B	844-854
microangiopathy	I	855-870
,	O	870-871
malignant	B	872-881
hypertension	I	882-894
,	O	894-895
acute	O	896-901
interstitial	B	902-914
nephritis	I	915-924
,	O	924-925
and	O	926-929
acute	B	930-935
tubular	I	936-943
necrosis	I	944-952
.	O	952-953

RESULTS	O	954-961
:	O	961-962
We	O	963-965
found	O	966-971
PTCR	O	972-976
in	O	977-979
14	O	980-982
of	O	983-985
15	O	986-988
cases	O	989-994
of	O	995-997
TG	B	998-1000
,	O	1000-1001
in	O	1002-1004
7	O	1005-1006
transplant	O	1007-1017
biopsy	O	1018-1024
specimens	O	1025-1034
without	O	1035-1042
TG	B	1043-1045
,	O	1045-1046
and	O	1047-1050
in	O	1051-1053
13	O	1054-1056
of	O	1057-1059
143	O	1060-1063
native	O	1064-1070
kidney	O	1071-1077
biopsy	O	1078-1084
specimens	O	1085-1094
.	O	1094-1095

These	O	1096-1101
13	O	1102-1104
included	O	1105-1113
cases	O	1114-1119
of	O	1120-1122
malignant	B	1123-1132
hypertension	I	1133-1145
,	O	1145-1146
thrombotic	B	1147-1157
microangiopathy	I	1158-1173
,	O	1173-1174
lupus	B	1175-1180
nephritis	I	1181-1190
,	O	1190-1191
Henoch	B	1192-1198
-	I	1198-1199
Schonlein	I	1199-1208
nephritis	I	1209-1218
,	O	1218-1219
crescentic	O	1220-1230
glomerulonephritis	B	1231-1249
,	O	1249-1250
and	O	1251-1254
cocaine	O	1255-1262
-	O	1262-1263
related	O	1263-1270
acute	B	1271-1276
renal	I	1277-1282
failure	I	1283-1290
.	O	1290-1291

Mild	O	1292-1296
PTCR	O	1297-1301
in	O	1302-1304
allografts	O	1305-1315
without	O	1316-1323
TG	B	1324-1326
did	O	1327-1330
not	O	1331-1334
predict	O	1335-1342
renal	B	1343-1348
failure	I	1349-1356
or	O	1357-1359
significant	O	1360-1371
proteinuria	B	1372-1383
after	O	1384-1389
follow	O	1390-1396
-	O	1396-1397
up	O	1397-1399
periods	O	1400-1407
of	O	1408-1410
between	O	1411-1418
3	O	1419-1420
months	O	1421-1427
and	O	1428-1431
1	O	1432-1433
year	O	1434-1438
.	O	1438-1439

CONCLUSIONS	O	1440-1451
:	O	1451-1452
We	O	1453-1455
conclude	O	1456-1464
that	O	1465-1469
in	O	1470-1472
transplants	O	1473-1484
,	O	1484-1485
there	O	1486-1491
is	O	1492-1494
a	O	1495-1496
strong	O	1497-1503
association	O	1504-1515
between	O	1516-1523
well	O	1524-1528
-	O	1528-1529
developed	O	1529-1538
PTCR	O	1539-1543
and	O	1544-1547
TG	B	1548-1550
,	O	1550-1551
while	O	1552-1557
the	O	1558-1561
significance	O	1562-1574
of	O	1575-1577
mild	O	1578-1582
PTCR	O	1583-1587
and	O	1588-1591
its	O	1592-1595
predictive	O	1596-1606
value	O	1607-1612
in	O	1613-1615
the	O	1616-1619
absence	O	1620-1627
of	O	1628-1630
TG	B	1631-1633
is	O	1634-1636
unclear	O	1637-1644
.	O	1644-1645

PTCR	O	1646-1650
also	O	1651-1655
occurs	O	1656-1662
in	O	1663-1665
certain	O	1666-1673
native	O	1674-1680
kidney	B	1681-1687
diseases	I	1688-1696
,	O	1696-1697
though	O	1698-1704
the	O	1705-1708
association	O	1709-1720
is	O	1721-1723
not	O	1724-1727
as	O	1728-1730
strong	O	1731-1737
as	O	1738-1740
that	O	1741-1745
for	O	1746-1749
TG	B	1750-1752
.	O	1752-1753

We	O	1754-1756
suggest	O	1757-1764
that	O	1765-1769
repeated	O	1770-1778
endothelial	B	1779-1790
injury	I	1791-1797
,	O	1797-1798
including	O	1799-1808
immunologic	B	1809-1820
injury	I	1821-1827
,	O	1827-1828
may	O	1829-1832
be	O	1833-1835
the	O	1836-1839
cause	O	1840-1845
of	O	1846-1848
this	O	1849-1853
lesion	O	1854-1860
both	O	1861-1865
in	O	1866-1868
allografts	O	1869-1879
and	O	1880-1883
native	O	1884-1890
kidneys	O	1891-1898
.	O	1898-1899

Conformationally	O	0-16
restricted	O	17-27
analogs	O	28-35
of	O	36-38
BD1008	O	39-45
and	O	46-49
an	O	50-52
antisense	O	53-62
oligodeoxynucleotide	O	63-83
targeting	O	84-93
sigma1	O	94-100
receptors	O	101-110
produce	O	111-118
anti	O	119-123
-	O	123-124
cocaine	O	124-131
effects	O	132-139
in	O	140-142
mice	O	143-147
.	O	147-148

Cocaine	O	149-156
'	O	156-157
s	O	157-158
ability	O	159-166
to	O	167-169
interact	O	170-178
with	O	179-183
sigma	O	184-189
receptors	O	190-199
suggests	O	200-208
that	O	209-213
these	O	214-219
proteins	O	220-228
mediate	O	229-236
some	O	237-241
of	O	242-244
its	O	245-248
behavioral	O	249-259
effects	O	260-267
.	O	267-268

Therefore	O	269-278
,	O	278-279
three	O	280-285
novel	O	286-291
sigma	O	292-297
receptor	O	298-306
ligands	O	307-314
with	O	315-319
antagonist	O	320-330
activity	O	331-339
were	O	340-344
evaluated	O	345-354
in	O	355-357
Swiss	O	358-363
Webster	O	364-371
mice	O	372-376
:	O	376-377
BD1018	O	378-384
(	O	385-386
3S	O	386-388
-	O	388-389
1	O	389-390
-	O	388-389
[	O	391-392
2	O	392-393
-	O	388-389
(	O	385-386
3	O	386-387
,	O	396-397
4	O	397-398
-	O	388-389
dichlorophenyl	O	399-413
)	O	413-414
ethyl	O	414-419
]	O	419-420
-	O	388-389
1	O	389-390
,	O	396-397
4	O	397-398
-	O	388-389
diazabicyclo	O	425-437
[	O	391-392
4	O	397-398
.	O	439-440
3	O	386-387
.	O	439-440
0	O	442-443
]	O	419-420
nonane	O	444-450
)	O	413-414
,	O	396-397

BD1063	O	453-459
(	O	460-461
1	O	461-462
-	O	462-463
[	O	463-464
2	O	464-465
-	O	462-463
(	O	460-461
3	O	467-468
,	O	468-469
4	O	469-470
-	O	462-463
dichlorophenyl	O	471-485
)	O	485-486
ethyl	O	486-491
]	O	491-492
-	O	462-463
4	O	469-470
-	O	462-463
methylpiperazine	O	495-511
)	O	485-486
,	O	468-469
and	O	514-517
LR132	O	518-523
(	O	524-525
1R	O	525-527
,	O	527-528
2S	O	528-530
-	O	530-531
(	O	524-525
+	O	532-533
)	O	533-534
-	O	530-531
cis	O	535-538
-	O	530-531
N	O	539-540
-	O	530-531
[	O	541-542
2	O	528-529
-	O	530-531
(	O	524-525
3	O	545-546
,	O	527-528
4	O	547-548
-	O	530-531
dichlorophenyl	O	549-563
)	O	533-534
ethyl	O	564-569
]	O	569-570
-	O	530-531
2	O	528-529
-	O	530-531
(	O	524-525
1	O	525-526
-	O	530-531
pyrrolidinyl	O	576-588
)	O	533-534
cyclohexylamine	O	589-604
)	O	533-534
.	O	605-606

Competition	O	607-618
binding	O	619-626
assays	O	627-633
demonstrated	O	634-646
that	O	647-651
all	O	652-655
three	O	656-661
compounds	O	662-671
have	O	672-676
high	O	677-681
affinities	O	682-692
for	O	693-696
sigma1	O	697-703
receptors	O	704-713
.	O	713-714

The	O	715-718
three	O	719-724
compounds	O	725-734
vary	O	735-739
in	O	740-742
their	O	743-748
affinities	O	749-759
for	O	760-763
sigma2	O	764-770
receptors	O	771-780
and	O	781-784
exhibit	O	785-792
negligible	O	793-803
affinities	O	804-814
for	O	815-818
dopamine	O	819-827
,	O	827-828
opioid	O	829-835
,	O	835-836
GABA	O	837-841
(	O	841-842
A	O	838-839
)	O	843-844
and	O	845-848
NMDA	O	849-853
receptors	O	854-863
.	O	863-864

In	O	865-867
behavioral	O	868-878
studies	O	879-886
,	O	886-887
pre	O	888-891
-	O	891-892
treatment	O	892-901
of	O	902-904
mice	O	905-909
with	O	910-914
BD1018	O	915-921
,	O	921-922
BD1063	O	923-929
,	O	929-930
or	O	931-933
LR132	O	934-939
significantly	O	940-953
attenuated	O	954-964
cocaine	O	965-972
-	O	972-973
induced	O	973-980
convulsions	B	981-992
and	O	993-996
lethality	O	997-1006
.	O	1006-1007

Moreover	O	1008-1016
,	O	1016-1017
post	O	1018-1022
-	O	1022-1023
treatment	O	1023-1032
with	O	1033-1037
LR132	O	1038-1043
prevented	O	1044-1053
cocaine	O	1054-1061
-	O	1061-1062
induced	O	1062-1069
lethality	O	1070-1079
in	O	1080-1082
a	O	1083-1084
significant	O	1085-1096
proportion	O	1097-1107
of	O	1108-1110
animals	O	1111-1118
.	O	1118-1119

In	O	1120-1122
contrast	O	1123-1131
to	O	1132-1134
the	O	1135-1138
protection	O	1139-1149
provided	O	1150-1158
by	O	1159-1161
the	O	1162-1165
putative	O	1166-1174
antagonists	O	1175-1186
,	O	1186-1187
the	O	1188-1191
well	O	1192-1196
-	O	1196-1197
characterized	O	1197-1210
sigma	O	1211-1216
receptor	O	1217-1225
agonist	O	1226-1233
di	O	1234-1236
-	O	1236-1237
o	O	1237-1238
-	O	1236-1237
tolylguanidine	O	1239-1253
(	O	1254-1255
DTG	O	1255-1258
)	O	1258-1259
and	O	1260-1263
the	O	1264-1267
novel	O	1268-1273
sigma	O	1274-1279
receptor	O	1280-1288
agonist	O	1289-1296
BD1031	O	1297-1303
(	O	1304-1305
3R	O	1305-1307
-	O	1307-1308
1	O	1308-1309
-	O	1307-1308
[	O	1310-1311
2	O	1311-1312
-	O	1307-1308
(	O	1304-1305
3	O	1305-1306
,	O	1315-1316
4	O	1316-1317
-	O	1307-1308
dichlorophenyl	O	1318-1332
)	O	1332-1333
ethyl	O	1333-1338
]	O	1338-1339
-	O	1307-1308
1	O	1308-1309
,	O	1315-1316
4	O	1316-1317
-	O	1307-1308
diazabicyclo	O	1344-1356
[	O	1310-1311
4	O	1316-1317
.	O	1358-1359
3	O	1305-1306
.	O	1358-1359
0	O	1361-1362
]	O	1338-1339
nonane	O	1363-1369
)	O	1332-1333
each	O	1371-1375
worsened	O	1376-1384
the	O	1385-1388
behavioral	O	1389-1399
toxicity	B	1400-1408
of	O	1409-1411
cocaine	O	1412-1419
.	O	1419-1420

At	O	1421-1423
doses	O	1424-1429
where	O	1430-1435
alone	O	1436-1441
,	O	1441-1442
they	O	1443-1447
produced	O	1448-1456
no	O	1457-1459
significant	O	1460-1471
effects	O	1472-1479
on	O	1480-1482
locomotion	O	1483-1493
,	O	1493-1494
BD1018	O	1495-1501
,	O	1501-1502
BD1063	O	1503-1509
and	O	1510-1513
LR132	O	1514-1519
significantly	O	1520-1533
attenuated	O	1534-1544
the	O	1545-1548
locomotor	O	1549-1558
stimulatory	O	1559-1570
effects	O	1571-1578
of	O	1579-1581
cocaine	O	1582-1589
.	O	1589-1590

To	O	1591-1593
further	O	1594-1601
validate	O	1602-1610
the	O	1611-1614
hypothesis	O	1615-1625
that	O	1626-1630
the	O	1631-1634
anti	O	1635-1639
-	O	1639-1640
cocaine	O	1640-1647
effects	O	1648-1655
of	O	1656-1658
the	O	1659-1662
novel	O	1663-1668
ligands	O	1669-1676
involved	O	1677-1685
antagonism	O	1686-1696
of	O	1697-1699
sigma	O	1700-1705
receptors	O	1706-1715
,	O	1715-1716
an	O	1717-1719
antisense	O	1720-1729
oligodeoxynucleotide	O	1730-1750
against	O	1751-1758
sigma1	O	1759-1765
receptors	O	1766-1775
was	O	1776-1779
also	O	1780-1784
shown	O	1785-1790
to	O	1791-1793
significantly	O	1794-1807
attenuate	O	1808-1817
the	O	1818-1821
convulsive	B	1822-1832
and	O	1833-1836
locomotor	O	1837-1846
stimulatory	O	1847-1858
effects	O	1859-1866
of	O	1867-1869
cocaine	O	1870-1877
.	O	1877-1878

Together	O	1879-1887
,	O	1887-1888
the	O	1889-1892
data	O	1893-1897
suggests	O	1898-1906
that	O	1907-1911
functional	O	1912-1922
antagonism	O	1923-1933
of	O	1934-1936
sigma	O	1937-1942
receptors	O	1943-1952
is	O	1953-1955
capable	O	1956-1963
of	O	1964-1966
attenuating	O	1967-1978
a	O	1979-1980
number	O	1981-1987
of	O	1988-1990
cocaine	O	1991-1998
-	O	1998-1999
induced	O	1999-2006
behaviors	O	2007-2016
.	O	2016-2017

Pharmacokinetic	O	0-15
/	O	15-16
pharmacodynamic	O	16-31
assessment	O	32-42
of	O	43-45
the	O	46-49
effects	O	50-57
of	O	58-60
E4031	O	61-66
,	O	66-67
cisapride	O	68-77
,	O	77-78
terfenadine	O	79-90
and	O	91-94
terodiline	O	95-105
on	O	106-108
monophasic	O	109-119
action	O	120-126
potential	O	127-136
duration	O	137-145
in	O	146-148
dog	O	149-152
.	O	152-153
1	O	154-155
.	O	155-156
Torsades	B	157-165
de	I	166-168
pointes	I	169-176
(	O	177-178
TDP	B	178-181
)	O	181-182
is	O	183-185
a	O	186-187
potentially	O	188-199
fatal	O	200-205
ventricular	B	206-217
tachycardia	I	218-229
associated	O	230-240
with	O	241-245
increases	O	246-255
in	O	256-258
QT	O	259-261
interval	O	262-270
and	O	271-274
monophasic	O	275-285
action	O	286-292
potential	O	293-302
duration	O	303-311
(	O	312-313
MAPD	O	313-317
)	O	317-318
.	O	318-319

TDP	B	320-323
is	O	324-326
a	O	327-328
side	O	329-333
-	O	333-334
effect	O	334-340
that	O	341-345
has	O	346-349
led	O	350-353
to	O	354-356
withdrawal	O	357-367
of	O	368-370
several	O	371-378
drugs	O	379-384
from	O	385-389
the	O	390-393
market	O	394-400
(	O	401-402
e	O	402-403
.	O	403-404
g	O	404-405
.	O	403-404

terfenadine	O	407-418
and	O	419-422
terodiline	O	423-433
)	O	433-434
.	O	434-435

2	O	436-437
.	O	437-438
The	O	439-442
potential	O	443-452
of	O	453-455
compounds	O	456-465
to	O	466-468
cause	O	469-474
TDP	B	475-478
was	O	479-482
evaluated	O	483-492
by	O	493-495
monitoring	O	496-506
their	O	507-512
effects	O	513-520
on	O	521-523
MAPD	O	524-528
in	O	529-531
dog	O	532-535
.	O	535-536

Four	O	537-541
compounds	O	542-551
known	O	552-557
to	O	558-560
increase	O	561-569
QT	O	570-572
interval	O	573-581
and	O	582-585
cause	O	586-591
TDP	B	592-595
were	O	596-600
investigated	O	601-613
:	O	613-614
terfenadine	O	615-626
,	O	626-627
terodiline	O	628-638
,	O	638-639
cisapride	O	640-649
and	O	650-653
E4031	O	654-659
.	O	659-660

On	O	661-663
the	O	664-667
basis	O	668-673
that	O	674-678
only	O	679-683
free	O	684-688
drug	O	689-693
in	O	694-696
the	O	697-700
systemic	O	701-709
circulation	O	710-721
will	O	722-726
elicit	O	727-733
a	O	734-735
pharmacological	O	736-751
response	O	752-760
target	O	761-767
,	O	767-768
free	O	769-773
concentrations	O	774-788
in	O	789-791
plasma	O	792-798
were	O	799-803
selected	O	804-812
to	O	813-815
mimic	O	816-821
the	O	822-825
free	O	826-830
drug	O	831-835
exposures	O	836-845
in	O	846-848
man	O	849-852
.	O	852-853

Infusion	O	854-862
regimens	O	863-871
were	O	872-876
designed	O	877-885
that	O	886-890
rapidly	O	891-898
achieved	O	899-907
and	O	908-911
maintained	O	912-922
target	O	923-929
-	O	929-930
free	O	930-934
concentrations	O	935-949
of	O	950-952
these	O	953-958
drugs	O	959-964
in	O	965-967
plasma	O	968-974
and	O	975-978
data	O	979-983
on	O	984-986
the	O	987-990
relationship	O	991-1003
between	O	1004-1011
free	O	1012-1016
concentration	O	1017-1030
and	O	1031-1034
changes	O	1035-1042
in	O	1043-1045
MAPD	O	1046-1050
were	O	1051-1055
obtained	O	1056-1064
for	O	1065-1068
these	O	1069-1074
compounds	O	1075-1084
.	O	1084-1085

3	O	1086-1087
.	O	1087-1088

These	O	1089-1094
data	O	1095-1099
indicate	O	1100-1108
that	O	1109-1113
the	O	1114-1117
free	O	1118-1122
ED50	O	1123-1127
in	O	1128-1130
plasma	O	1131-1137
for	O	1138-1141
terfenadine	O	1142-1153
(	O	1154-1155
1	O	1155-1156
.	O	1156-1157
9	O	1157-1158
nM	O	1159-1161
)	O	1161-1162
,	O	1162-1163
terodiline	O	1164-1174
(	O	1175-1176
76	O	1176-1178
nM	O	1179-1181
)	O	1181-1182
,	O	1182-1183
cisapride	O	1184-1193
(	O	1194-1195
11	O	1195-1197
nM	O	1198-1200
)	O	1200-1201
and	O	1202-1205
E4031	O	1206-1211
(	O	1212-1213
1	O	1213-1214
.	O	1214-1215
9	O	1215-1216
nM	O	1217-1219
)	O	1219-1220
closely	O	1221-1228
correlate	O	1229-1238
with	O	1239-1243
the	O	1244-1247
free	O	1248-1252
concentration	O	1253-1266
in	O	1267-1269
man	O	1270-1273
causing	O	1274-1281
QT	O	1282-1284
effects	O	1285-1292
.	O	1292-1293

For	O	1294-1297
compounds	O	1298-1307
that	O	1308-1312
have	O	1313-1317
shown	O	1318-1323
TDP	B	1324-1327
in	O	1328-1330
the	O	1331-1334
clinic	O	1335-1341
(	O	1342-1343
terfenadine	O	1343-1354
,	O	1354-1355
terodiline	O	1356-1366
,	O	1366-1367
cisapride	O	1368-1377
)	O	1377-1378
there	O	1379-1384
is	O	1385-1387
little	O	1388-1394
differentiation	O	1395-1410
between	O	1411-1418
the	O	1419-1422
dog	O	1423-1426
ED50	O	1427-1431
and	O	1432-1435
the	O	1436-1439
efficacious	O	1440-1451
free	O	1452-1456
plasma	O	1457-1463
concentrations	O	1464-1478
in	O	1479-1481
man	O	1482-1485
(	O	1486-1487
<	O	1487-1488
10	O	1489-1491
-	O	1491-1492
fold	O	1492-1496
)	O	1496-1497
reflecting	O	1498-1508
their	O	1509-1514
limited	O	1515-1522
safety	O	1523-1529
margins	O	1530-1537
.	O	1537-1538

These	O	1539-1544
data	O	1545-1549
underline	O	1550-1559
the	O	1560-1563
need	O	1564-1568
to	O	1569-1571
maximize	O	1572-1580
the	O	1581-1584
therapeutic	O	1585-1596
ratio	O	1597-1602
with	O	1603-1607
respect	O	1608-1615
to	O	1616-1618
TDP	B	1619-1622
in	O	1623-1625
potential	O	1626-1635
development	O	1636-1647
candidates	O	1648-1658
and	O	1659-1662
the	O	1663-1666
importance	O	1667-1677
of	O	1678-1680
using	O	1681-1686
free	O	1687-1691
drug	O	1692-1696
concentrations	O	1697-1711
in	O	1712-1714
pharmacokinetic	O	1715-1730
/	O	1730-1731
pharmacodynamic	O	1731-1746
studies	O	1747-1754
.	O	1754-1755

Fatal	O	0-5
myeloencephalopathy	B	6-25
due	O	26-29
to	O	30-32
accidental	O	33-43
intrathecal	O	44-55
vincristin	O	56-66
administration	O	67-81
:	O	81-82
a	O	83-84
report	O	85-91
of	O	92-94
two	O	95-98
cases	O	99-104
.	O	104-105

We	O	106-108
report	O	109-115
on	O	116-118
two	O	119-122
fatal	O	123-128
cases	O	129-134
of	O	135-137
accidental	O	138-148
intrathecal	O	149-160
vincristine	O	161-172
instillation	O	173-185
in	O	186-188
a	O	189-190
5	O	191-192
-	O	192-193
year	O	193-197
old	O	198-201
girl	O	202-206
with	O	207-211
recurrent	O	212-221
acute	B	222-227
lymphoblastic	I	228-241
leucemia	I	242-250
and	O	251-254
a	O	255-256
57	O	257-259
-	O	259-260
year	O	260-264
old	O	265-268
man	O	269-272
with	O	273-277
lymphoblastic	B	278-291
lymphoma	I	292-300
.	O	300-301

The	O	302-305
girl	O	306-310
died	O	311-315
seven	O	316-321
days	O	322-326
,	O	326-327
the	O	328-331
man	O	332-335
four	O	336-340
weeks	O	341-346
after	O	347-352
intrathecal	O	353-364
injection	O	365-374
of	O	375-377
vincristine	O	378-389
.	O	389-390

Clinically	O	391-401
,	O	401-402
the	O	403-406
onset	O	407-412
was	O	413-416
characterized	O	417-430
by	O	431-433
the	O	434-437
signs	O	438-443
of	O	444-446
opistothonus	B	447-459
,	I	459-460
sensory	I	461-468
and	I	469-472
motor	I	473-478
dysfunction	I	479-490
and	O	491-494
ascending	O	495-504
paralysis	B	505-514
.	O	514-515

Histological	O	516-528
and	O	529-532
immunohistochemical	O	533-552
investigations	O	553-567
(	O	568-569
HE	O	569-571
-	O	571-572
LFB	O	572-575
,	O	575-576
CD	O	577-579
-	O	579-580
68	O	580-582
,	O	582-583
Neurofilament	O	584-597
)	O	597-598
revealed	O	599-607
degeneration	B	608-620
of	I	621-623
myelin	I	624-630
and	I	631-634
axons	I	635-640
as	O	641-643
well	O	644-648
as	O	649-651
pseudocystic	B	652-664
transformation	I	665-679
in	O	680-682
areas	O	683-688
exposed	O	689-696
to	O	697-699
vincristine	O	700-711
,	O	711-712
accompanied	O	713-724
by	O	725-727
secondary	O	728-737
changes	O	738-745
with	O	746-750
numerous	O	751-759
prominent	O	760-769
macrophages	O	770-781
.	O	781-782

The	O	783-786
clinical	O	787-795
course	O	796-802
and	O	803-806
histopathological	O	807-824
results	O	825-832
of	O	833-835
the	O	836-839
two	O	840-843
cases	O	844-849
are	O	850-853
presented	O	854-863
.	O	863-864

A	O	865-866
review	O	867-873
of	O	874-876
all	O	877-880
reported	O	881-889
cases	O	890-895
in	O	896-898
the	O	899-902
literature	O	903-913
is	O	914-916
given	O	917-922
.	O	922-923

A	O	924-925
better	O	926-932
controlled	O	933-943
regimen	O	944-951
for	O	952-955
administering	O	956-969
vincristine	O	970-981
and	O	982-985
intrathecal	O	986-997
chemotherapy	O	998-1010
is	O	1011-1013
recommended	O	1014-1025
.	O	1025-1026

Intravenous	O	0-11
administration	O	12-26
of	O	27-29
prochlorperazine	O	30-46
by	O	47-49
15	O	50-52
-	O	52-53
minute	O	53-59
infusion	O	60-68
versus	O	69-75
2	O	76-77
-	O	77-78
minute	O	78-84
bolus	O	85-90
does	O	91-95
not	O	96-99
affect	O	100-106
the	O	107-110
incidence	O	111-120
of	O	121-123
akathisia	B	124-133
:	O	133-134
a	O	135-136
prospective	O	137-148
,	O	148-149
randomized	O	150-160
,	O	160-161
controlled	O	162-172
trial	O	173-178
.	O	178-179

STUDY	O	180-185
OBJECTIVE	O	186-195
:	O	195-196
We	O	197-199
sought	O	200-206
to	O	207-209
compare	O	210-217
the	O	218-221
rate	O	222-226
of	O	227-229
akathisia	B	230-239
after	O	240-245
administration	O	246-260
of	O	261-263
intravenous	O	264-275
prochlorperazine	O	276-292
as	O	293-295
a	O	296-297
2	O	298-299
-	O	299-300
minute	O	300-306
bolus	O	307-312
or	O	313-315
15	O	316-318
-	O	318-319
minute	O	319-325
infusion	O	326-334
.	O	334-335

METHODS	O	336-343
:	O	343-344
We	O	345-347
conducted	O	348-357
a	O	358-359
prospective	O	360-371
,	O	371-372
randomized	O	373-383
,	O	383-384
double	O	385-391
-	O	391-392
blind	O	392-397
study	O	398-403
in	O	404-406
the	O	407-410
emergency	O	411-420
department	O	421-431
of	O	432-434
a	O	435-436
central	O	437-444
-	O	444-445
city	O	445-449
teaching	O	450-458
hospital	O	459-467
.	O	467-468

Patients	O	469-477
aged	O	478-482
18	O	483-485
years	O	486-491
or	O	492-494
older	O	495-500
treated	O	501-508
with	O	509-513
prochlorperazine	O	514-530
for	O	531-534
headache	B	535-543
,	O	543-544
nausea	B	545-551
,	O	551-552
or	O	553-555
vomiting	B	556-564
were	O	565-569
eligible	O	570-578
for	O	579-582
inclusion	O	583-592
.	O	592-593

Study	O	594-599
participants	O	600-612
were	O	613-617
randomized	O	618-628
to	O	629-631
receive	O	632-639
10	O	640-642
mg	O	643-645
of	O	646-648
prochlorperazine	O	649-665
administered	O	666-678
intravenously	O	679-692
by	O	693-695
means	O	696-701
of	O	702-704
2	O	705-706
-	O	706-707
minute	O	707-713
push	O	714-718
(	O	719-720
bolus	O	720-725
group	O	726-731
)	O	731-732
or	O	733-735
10	O	736-738
mg	O	739-741
diluted	O	742-749
in	O	750-752
50	O	753-755
mL	O	756-758
of	O	759-761
normal	O	762-768
saline	O	769-775
solution	O	776-784
administered	O	785-797
by	O	798-800
means	O	801-806
of	O	807-809
intravenous	O	810-821
infusion	O	822-830
during	O	831-837
a	O	838-839
15	O	840-842
-	O	842-843
minute	O	843-849
period	O	850-856
(	O	857-858
infusion	O	858-866
group	O	867-872
)	O	872-873
.	O	873-874

The	O	875-878
main	O	879-883
outcome	O	884-891
was	O	892-895
the	O	896-899
number	O	900-906
of	O	907-909
study	O	910-915
participants	O	916-928
experiencing	O	929-941
akathisia	B	942-951
within	O	952-958
60	O	959-961
minutes	O	962-969
of	O	970-972
administration	O	973-987
.	O	987-988

Akathisia	O	989-998
was	O	999-1002
defined	O	1003-1010
as	O	1011-1013
either	O	1014-1020
a	O	1021-1022
spontaneous	O	1023-1034
report	O	1035-1041
of	O	1042-1044
restlessness	O	1045-1057
or	O	1058-1060
agitation	B	1061-1070
or	O	1071-1073
a	O	1074-1075
change	O	1076-1082
of	O	1083-1085
2	O	1086-1087
or	O	1088-1090
more	O	1091-1095
in	O	1096-1098
the	O	1099-1102
patient	O	1103-1110
-	O	1110-1111
reported	O	1111-1119
akathisia	B	1120-1129
rating	O	1130-1136
scale	O	1137-1142
and	O	1143-1146
a	O	1147-1148
change	O	1149-1155
of	O	1156-1158
at	O	1159-1161
least	O	1162-1167
1	O	1168-1169
in	O	1170-1172
the	O	1173-1176
investigator	O	1177-1189
-	O	1189-1190
observed	O	1190-1198
akathisia	B	1199-1208
rating	O	1209-1215
scale	O	1216-1221
.	O	1221-1222

The	O	1223-1226
intensity	O	1227-1236
of	O	1237-1239
headache	B	1240-1248
and	O	1249-1252
nausea	B	1253-1259
was	O	1260-1263
measured	O	1264-1272
with	O	1273-1277
a	O	1278-1279
100	O	1280-1283
-	O	1283-1284
mm	O	1284-1286
visual	O	1287-1293
analog	O	1294-1300
scale	O	1301-1306
.	O	1306-1307

RESULTS	O	1308-1315
:	O	1315-1316
One	O	1317-1320
hundred	O	1321-1328
patients	O	1329-1337
were	O	1338-1342
enrolled	O	1343-1351
.	O	1351-1352

One	O	1353-1356
study	O	1357-1362
participant	O	1363-1374
was	O	1375-1378
excluded	O	1379-1387
after	O	1388-1393
protocol	O	1394-1402
violation	O	1403-1412
.	O	1412-1413

Seventy	O	1414-1421
-	O	1421-1422
three	O	1422-1427
percent	O	1428-1435
(	O	1436-1437
73	O	1437-1439
/	O	1439-1440
99	O	1440-1442
)	O	1442-1443
of	O	1444-1446
the	O	1447-1450
study	O	1451-1456
participants	O	1457-1469
were	O	1470-1474
treated	O	1475-1482
for	O	1483-1486
headache	B	1487-1495
and	O	1496-1499
70	O	1500-1502
%	O	1502-1503
(	O	1504-1505
70	O	1505-1507
/	O	1507-1508
99	O	1508-1510
)	O	1510-1511
for	O	1512-1515
nausea	B	1516-1522
.	O	1522-1523

In	O	1524-1526
the	O	1527-1530
bolus	O	1531-1536
group	O	1537-1542
,	O	1542-1543
26	O	1544-1546
.	O	1546-1547
0	O	1547-1548
%	O	1548-1549
(	O	1550-1551
13	O	1551-1553
/	O	1553-1554
50	O	1554-1556
)	O	1556-1557
had	O	1558-1561
akathisia	B	1562-1571
compared	O	1572-1580
with	O	1581-1585
32	O	1586-1588
.	O	1588-1589
7	O	1589-1590
%	O	1590-1591
(	O	1592-1593
16	O	1593-1595
/	O	1595-1596
49	O	1596-1598
)	O	1598-1599
in	O	1600-1602
the	O	1603-1606
infusion	O	1607-1615
group	O	1616-1621
(	O	1622-1623
Delta	O	1623-1628
=	O	1628-1629
-	O	1629-1630
6	O	1630-1631
.	O	1631-1632
7	O	1632-1633
%	O	1633-1634
;	O	1634-1635

95	O	1636-1638
%	O	1638-1639
confidence	O	1640-1650
interval	O	1651-1659
[	O	1660-1661
CI	O	1661-1663
]	O	1663-1664
-	O	1665-1666
24	O	1666-1668
.	O	1668-1669
6	O	1669-1670
%	O	1670-1671
to	O	1672-1674
11	O	1675-1677
.	O	1677-1678
2	O	1678-1679
%	O	1679-1680
)	O	1680-1681
.	O	1677-1678

The	O	1683-1686
difference	O	1687-1697
between	O	1698-1705
the	O	1706-1709
bolus	O	1710-1715
and	O	1716-1719
infusion	O	1720-1728
groups	O	1729-1735
in	O	1736-1738
the	O	1739-1742
percentage	O	1743-1753
of	O	1754-1756
participants	O	1757-1769
who	O	1770-1773
saw	O	1774-1777
a	O	1778-1779
50	O	1780-1782
%	O	1782-1783
reduction	O	1784-1793
in	O	1794-1796
their	O	1797-1802
headache	B	1803-1811
intensity	O	1812-1821
within	O	1822-1828
30	O	1829-1831
minutes	O	1832-1839
was	O	1840-1843
11	O	1844-1846
.	O	1846-1847
8	O	1847-1848
%	O	1848-1849
(	O	1850-1851
95	O	1851-1853
%	O	1853-1854
CI	O	1855-1857
-	O	1858-1859
9	O	1859-1860
.	O	1860-1861
6	O	1861-1862
%	O	1862-1863
to	O	1864-1866
33	O	1867-1869
.	O	1869-1870
3	O	1867-1868
%	O	1871-1872
)	O	1872-1873
.	O	1869-1870

The	O	1875-1878
difference	O	1879-1889
in	O	1890-1892
the	O	1893-1896
percentage	O	1897-1907
of	O	1908-1910
patients	O	1911-1919
with	O	1920-1924
a	O	1925-1926
50	O	1927-1929
%	O	1929-1930
reduction	O	1931-1940
in	O	1941-1943
their	O	1944-1949
nausea	B	1950-1956
was	O	1957-1960
12	O	1961-1963
.	O	1963-1964
6	O	1964-1965
%	O	1965-1966
(	O	1967-1968
95	O	1968-1970
%	O	1970-1971
CI	O	1972-1974
-	O	1975-1976
4	O	1976-1977
.	O	1977-1978
6	O	1978-1979
%	O	1979-1980
to	O	1981-1983
29	O	1984-1986
.	O	1986-1987
8	O	1987-1988
%	O	1988-1989
)	O	1989-1990
.	O	1986-1987

CONCLUSION	O	1992-2002
:	O	2002-2003
A	O	2004-2005
50	O	2006-2008
%	O	2008-2009
reduction	O	2010-2019
in	O	2020-2022
the	O	2023-2026
incidence	O	2027-2036
of	O	2037-2039
akathisia	B	2040-2049
when	O	2050-2054
prochlorperazine	O	2055-2071
was	O	2072-2075
administered	O	2076-2088
by	O	2089-2091
means	O	2092-2097
of	O	2098-2100
15	O	2101-2103
-	O	2103-2104
minute	O	2104-2110
intravenous	O	2111-2122
infusion	O	2123-2131
versus	O	2132-2138
a	O	2139-2140
2	O	2141-2142
-	O	2142-2143
minute	O	2143-2149
intravenous	O	2150-2161
push	O	2162-2166
was	O	2167-2170
not	O	2171-2174
detected	O	2175-2183
.	O	2183-2184

The	O	2185-2188
efficacy	O	2189-2197
of	O	2198-2200
prochlorperazine	O	2201-2217
in	O	2218-2220
the	O	2221-2224
treatment	O	2225-2234
of	O	2235-2237
headache	B	2238-2246
and	O	2247-2250
nausea	B	2251-2257
likewise	O	2258-2266
did	O	2267-2270
not	O	2271-2274
appear	O	2275-2281
to	O	2282-2284
be	O	2285-2287
affected	O	2288-2296
by	O	2297-2299
the	O	2300-2303
rate	O	2304-2308
of	O	2309-2311
administration	O	2312-2326
,	O	2326-2327
although	O	2328-2336
no	O	2337-2339
formal	O	2340-2346
statistical	O	2347-2358
comparisons	O	2359-2370
were	O	2371-2375
made	O	2376-2380
.	O	2380-2381

Antithymocyte	O	0-13
globulin	O	14-22
in	O	23-25
the	O	26-29
treatment	O	30-39
of	O	40-42
D	O	43-44
-	O	44-45
penicillamine	O	45-58
-	O	44-45
induced	O	59-66
aplastic	B	67-75
anemia	I	76-82
.	O	82-83

A	O	84-85
patient	O	86-93
who	O	94-97
received	O	98-106
antithymocyte	O	107-120
globulin	O	121-129
therapy	O	130-137
for	O	138-141
aplastic	B	142-150
anemia	I	151-157
due	O	158-161
to	O	162-164
D	O	165-166
-	O	166-167
penicillamine	O	167-180
therapy	O	181-188
is	O	189-191
described	O	192-201
.	O	201-202

Bone	O	203-207
marrow	O	208-214
recovery	O	215-223
and	O	224-227
peripheral	O	228-238
blood	O	239-244
recovery	O	245-253
were	O	254-258
complete	O	259-267
1	O	268-269
month	O	270-275
and	O	276-279
3	O	280-281
months	O	282-288
,	O	288-289
respectively	O	290-302
,	O	302-303
after	O	304-309
treatment	O	310-319
,	O	319-320
and	O	321-324
blood	O	325-330
transfusion	O	331-342
or	O	343-345
other	O	346-351
therapies	O	352-361
were	O	362-366
not	O	367-370
necessary	O	371-380
in	O	381-383
a	O	384-385
follow	O	386-392
-	O	392-393
up	O	393-395
period	O	396-402
of	O	403-405
more	O	406-410
than	O	411-415
2	O	416-417
years	O	418-423
.	O	423-424

Use	O	425-428
of	O	429-431
antithymocyte	O	432-445
globulin	O	446-454
may	O	455-458
be	O	459-461
the	O	462-465
optimal	O	466-473
treatment	O	474-483
of	O	484-486
D	O	487-488
-	O	488-489
penicillamine	O	489-502
-	O	488-489
induced	O	503-510
aplastic	B	511-519
anemia	I	520-526
.	O	526-527

The	O	0-3
relationship	O	4-16
between	O	17-24
hippocampal	O	25-36
acetylcholine	O	37-50
release	O	51-58
and	O	59-62
cholinergic	O	63-74
convulsant	O	75-85
sensitivity	O	86-97
in	O	98-100
withdrawal	O	101-111
seizure	B	112-119
-	O	119-120
prone	O	120-125
and	O	126-129
withdrawal	O	130-140
seizure	B	141-148
-	O	148-149
resistant	O	149-158
selected	O	159-167
mouse	O	168-173
lines	O	174-179
.	O	179-180

BACKGROUND	O	181-191
:	O	191-192
The	O	193-196
septo	O	197-202
-	O	202-203
hippocampal	O	203-214
cholinergic	O	215-226
pathway	O	227-234
has	O	235-238
been	O	239-243
implicated	O	244-254
in	O	255-257
epileptogenesis	O	258-273
,	O	273-274
and	O	275-278
genetic	O	279-286
factors	O	287-294
influence	O	295-304
the	O	305-308
response	O	309-317
to	O	318-320
cholinergic	O	321-332
agents	O	333-339
,	O	339-340
but	O	341-344
limited	O	345-352
data	O	353-357
are	O	358-361
available	O	362-371
on	O	372-374
cholinergic	O	375-386
involvement	O	387-398
in	O	399-401
alcohol	O	402-409
withdrawal	O	410-420
severity	O	421-429
.	O	429-430

Thus	O	431-435
,	O	435-436
the	O	437-440
relationship	O	441-453
between	O	454-461
cholinergic	O	462-473
activity	O	474-482
and	O	483-486
responsiveness	O	487-501
and	O	502-505
alcohol	O	506-513
withdrawal	O	514-524
was	O	525-528
investigated	O	529-541
in	O	542-544
a	O	545-546
genetic	O	547-554
animal	O	555-561
model	O	562-567
of	O	568-570
ethanol	O	571-578
withdrawal	O	579-589
severity	O	590-598
.	O	598-599

METHODS	O	600-607
:	O	607-608
Cholinergic	O	609-620
convulsant	O	621-631
sensitivity	O	632-643
was	O	644-647
examined	O	648-656
in	O	657-659
alcohol	O	660-667
-	O	667-668
na	O	668-670
ve	O	672-674
Withdrawal	O	675-685
Seizure	B	686-693
-	O	693-694
Prone	O	694-699
(	O	700-701
WSP	O	701-704
)	O	704-705
and	O	706-709
-	O	709-710
Resistant	O	710-719
(	O	720-721
WSR	O	721-724
)	O	724-725
mice	O	726-730
.	O	730-731

Animals	O	732-739
were	O	740-744
administered	O	745-757
nicotine	O	758-766
,	O	766-767
carbachol	O	768-777
,	O	777-778
or	O	779-781
neostigmine	O	782-793
via	O	794-797
timed	O	798-803
tail	O	804-808
vein	O	809-813
infusion	O	814-822
,	O	822-823
and	O	824-827
the	O	828-831
latencies	O	832-841
to	O	842-844
onset	O	845-850
of	O	851-853
tremor	B	854-860
and	O	861-864
clonus	O	865-871
were	O	872-876
recorded	O	877-885
and	O	886-889
converted	O	890-899
to	O	900-902
threshold	O	903-912
dose	O	913-917
.	O	917-918

We	O	919-921
also	O	922-926
used	O	927-931
microdialysis	O	932-945
to	O	946-948
measure	O	949-956
basal	O	957-962
and	O	963-966
potassium	O	967-976
-	O	976-977
stimulated	O	977-987
acetylcholine	O	988-1001
(	O	1002-1003
ACh	O	1003-1006
)	O	1006-1007
release	O	1008-1015
in	O	1016-1018
the	O	1019-1022
CA1	O	1023-1026
region	O	1027-1033
of	O	1034-1036
the	O	1037-1040
hippocampus	O	1041-1052
.	O	1052-1053

Potassium	O	1054-1063
was	O	1064-1067
applied	O	1068-1075
by	O	1076-1078
reverse	O	1079-1086
dialysis	O	1087-1095
twice	O	1096-1101
,	O	1101-1102
separated	O	1103-1112
by	O	1113-1115
75	O	1116-1118
min	O	1119-1122
.	O	1122-1123

Hippocampal	O	1124-1135
ACh	O	1136-1139
also	O	1140-1144
was	O	1145-1148
measured	O	1149-1157
during	O	1158-1164
testing	O	1165-1172
for	O	1173-1176
handling	O	1177-1185
-	O	1185-1186
induced	O	1186-1193
convulsions	B	1194-1205
.	O	1205-1206

RESULTS	O	1207-1214
:	O	1214-1215
Sensitivity	O	1216-1227
to	O	1228-1230
several	O	1231-1238
convulsion	B	1239-1249
endpoints	O	1250-1259
induced	O	1260-1267
by	O	1268-1270
nicotine	O	1271-1279
,	O	1279-1280
carbachol	O	1281-1290
,	O	1290-1291
and	O	1292-1295
neostigmine	O	1296-1307
were	O	1308-1312
significantly	O	1313-1326
greater	O	1327-1334
in	O	1335-1337
WSR	O	1338-1341
versus	O	1342-1348
WSP	O	1349-1352
mice	O	1353-1357
.	O	1357-1358

In	O	1359-1361
microdialysis	O	1362-1375
experiments	O	1376-1387
,	O	1387-1388
the	O	1389-1392
lines	O	1393-1398
did	O	1399-1402
not	O	1403-1406
differ	O	1407-1413
in	O	1414-1416
basal	O	1417-1422
release	O	1423-1430
of	O	1431-1433
ACh	O	1434-1437
,	O	1437-1438
and	O	1439-1442
50	O	1443-1445
mM	O	1446-1448
KCl	O	1449-1452
increased	O	1453-1462
ACh	O	1463-1466
output	O	1467-1473
in	O	1474-1476
both	O	1477-1481
lines	O	1482-1487
of	O	1488-1490
mice	O	1491-1495
.	O	1495-1496

However	O	1497-1504
,	O	1504-1505
the	O	1506-1509
increase	O	1510-1518
in	O	1519-1521
release	O	1522-1529
of	O	1530-1532
ACh	O	1533-1536
produced	O	1537-1545
by	O	1546-1548
the	O	1549-1552
first	O	1553-1558
application	O	1559-1570
of	O	1571-1573
KCl	O	1574-1577
was	O	1578-1581
2	O	1582-1583
-	O	1583-1584
fold	O	1584-1588
higher	O	1589-1595
in	O	1596-1598
WSP	O	1599-1602
versus	O	1603-1609
WSR	O	1610-1613
mice	O	1614-1618
.	O	1618-1619

When	O	1620-1624
hippocampal	O	1625-1636
ACh	O	1637-1640
was	O	1641-1644
measured	O	1645-1653
during	O	1654-1660
testing	O	1661-1668
for	O	1669-1672
handling	O	1673-1681
-	O	1681-1682
induced	O	1682-1689
convulsions	B	1690-1701
,	O	1701-1702
extracellular	O	1703-1716
ACh	O	1717-1720
was	O	1721-1724
significantly	O	1725-1738
elevated	O	1739-1747
(	O	1748-1749
192	O	1749-1752
%	O	1752-1753
)	O	1753-1754
in	O	1755-1757
WSP	O	1758-1761
mice	O	1762-1766
,	O	1766-1767
but	O	1768-1771
was	O	1772-1775
nonsignificantly	O	1776-1792
elevated	O	1793-1801
(	O	1802-1803
59	O	1803-1805
%	O	1805-1806
)	O	1806-1807
in	O	1808-1810
WSR	O	1811-1814
mice	O	1815-1819
.	O	1819-1820

CONCLUSIONS	O	1821-1832
:	O	1832-1833
These	O	1834-1839
results	O	1840-1847
suggest	O	1848-1855
that	O	1856-1860
differences	O	1861-1872
in	O	1873-1875
cholinergic	O	1876-1887
activity	O	1888-1896
and	O	1897-1900
postsynaptic	O	1901-1913
sensitivity	O	1914-1925
to	O	1926-1928
cholinergic	O	1929-1940
convulsants	B	1941-1952
may	O	1953-1956
be	O	1957-1959
associated	O	1960-1970
with	O	1971-1975
ethanol	O	1976-1983
withdrawal	O	1984-1994
severity	O	1995-2003
and	O	2004-2007
implicate	O	2008-2017
cholinergic	O	2018-2029
mechanisms	O	2030-2040
in	O	2041-2043
alcohol	O	2044-2051
withdrawal	O	2052-2062
.	O	2062-2063

Specifically	O	2064-2076
,	O	2076-2077
WSP	O	2078-2081
mice	O	2082-2086
may	O	2087-2090
have	O	2091-2095
lower	O	2096-2101
sensitivity	O	2102-2113
to	O	2114-2116
cholinergic	O	2117-2128
convulsants	B	2129-2140
compared	O	2141-2149
with	O	2150-2154
WSR	O	2155-2158
because	O	2159-2166
of	O	2167-2169
postsynaptic	O	2170-2182
receptor	O	2183-2191
desensitization	O	2192-2207
brought	O	2208-2215
on	O	2216-2218
by	O	2219-2221
higher	O	2222-2228
activity	O	2229-2237
of	O	2238-2240
cholinergic	O	2241-2252
neurons	O	2253-2260
.	O	2260-2261

Prenatal	O	0-8
dexamethasone	O	9-22
programs	O	23-31
hypertension	B	32-44
and	O	45-48
renal	B	49-54
injury	I	55-61
in	O	62-64
the	O	65-68
rat	O	69-72
.	O	72-73

Dexamethasone	O	74-87
is	O	88-90
frequently	O	91-101
administered	O	102-114
to	O	115-117
the	O	118-121
developing	O	122-132
fetus	O	133-138
to	O	139-141
accelerate	O	142-152
pulmonary	O	153-162
development	O	163-174
.	O	174-175

The	O	176-179
purpose	O	180-187
of	O	188-190
the	O	191-194
present	O	195-202
study	O	203-208
was	O	209-212
to	O	213-215
determine	O	216-225
if	O	226-228
prenatal	O	229-237
dexamethasone	O	238-251
programmed	O	252-262
a	O	263-264
progressive	O	265-276
increase	B	277-285
in	I	286-288
blood	I	289-294
pressure	I	295-303
and	O	304-307
renal	B	308-313
injury	I	314-320
in	O	321-323
rats	O	324-328
.	O	328-329

Pregnant	O	330-338
rats	O	339-343
were	O	344-348
given	O	349-354
either	O	355-361
vehicle	O	362-369
or	O	370-372
2	O	373-374
daily	O	375-380
intraperitoneal	O	381-396
injections	O	397-407
of	O	408-410
dexamethasone	O	411-424
(	O	425-426
0	O	426-427
.	O	427-428
2	O	428-429
mg	O	430-432
/	O	432-433
kg	O	433-435
body	O	436-440
weight	O	441-447
)	O	447-448
on	O	449-451
gestational	O	452-463
days	O	464-468
11	O	469-471
and	O	472-475
12	O	476-478
,	O	478-479
13	O	480-482
and	O	483-486
14	O	487-489
,	O	489-490
15	O	491-493
and	O	494-497
16	O	498-500
,	O	500-501
17	O	502-504
and	O	505-508
18	O	509-511
,	O	511-512
or	O	513-515
19	O	516-518
and	O	519-522
20	O	523-525
.	O	525-526

Offspring	O	527-536
of	O	537-539
rats	O	540-544
administered	O	545-557
dexamethasone	O	558-571
on	O	572-574
days	O	575-579
15	O	580-582
and	O	583-586
16	O	587-589
gestation	O	590-599
had	O	600-603
a	O	604-605
20	O	606-608
%	O	608-609
reduction	B	610-619
in	I	620-622
glomerular	I	623-633
number	I	634-640
compared	O	641-649
with	O	650-654
control	O	655-662
at	O	663-665
6	O	666-667
to	O	668-670
9	O	671-672
months	O	673-679
of	O	680-682
age	O	683-686
(	O	687-688
22	O	688-690
527	O	691-694
+	O	694-695
/	O	695-696
-	O	696-697
509	O	697-700
versus	O	701-707
28	O	708-710
050	O	711-714
+	O	714-715
/	O	715-716
-	O	716-717
561	O	717-720
,	O	720-721
P	O	722-723
<	O	723-724
0	O	724-725
.	O	725-726
05	O	726-728
)	O	728-729
,	O	729-730
which	O	731-736
was	O	737-740
comparable	O	741-751
to	O	752-754
the	O	755-758
percent	O	759-766
reduction	O	767-776
in	O	777-779
glomeruli	O	780-789
measured	O	790-798
at	O	799-801
3	O	802-803
weeks	O	804-809
of	O	810-812
age	O	813-816
.	O	816-817

Six	O	818-821
-	O	821-822
to	O	823-825
9	O	826-827
-	O	827-828
month	O	828-833
old	O	834-837
rats	O	838-842
receiving	O	843-852
prenatal	O	853-861
dexamethasone	O	862-875
on	O	876-878
days	O	879-883
17	O	884-886
and	O	887-890
18	O	891-893
of	O	894-896
gestation	O	897-906
had	O	907-910
a	O	911-912
17	O	913-915
%	O	915-916
reduction	O	917-926
in	O	927-929
glomeruli	O	930-939
(	O	940-941
23	O	941-943
380	O	944-947
+	O	947-948
/	O	948-949
-	O	949-950
587	O	950-953
)	O	953-954
compared	O	955-963
with	O	964-968
control	O	969-976
rats	O	977-981
(	O	982-983
P	O	983-984
<	O	984-985
0	O	985-986
.	O	986-987
05	O	987-989
)	O	989-990
.	O	986-987

Male	O	992-996
rats	O	997-1001
that	O	1002-1006
received	O	1007-1015
prenatal	O	1016-1024
dexamethasone	O	1025-1038
on	O	1039-1041
days	O	1042-1046
15	O	1047-1049
and	O	1050-1053
16	O	1054-1056
,	O	1056-1057
17	O	1058-1060
and	O	1061-1064
18	O	1065-1067
,	O	1067-1068
and	O	1069-1072
13	O	1073-1075
and	O	1076-1079
14	O	1080-1082
of	O	1083-1085
gestation	O	1086-1095
had	O	1096-1099
elevated	B	1100-1108
blood	I	1109-1114
pressures	I	1115-1124
at	O	1125-1127
6	O	1128-1129
months	O	1130-1136
of	O	1137-1139
age	O	1140-1143
;	O	1143-1144
the	O	1145-1148
latter	O	1149-1155
group	O	1156-1161
did	O	1162-1165
not	O	1166-1169
have	O	1170-1174
a	O	1175-1176
reduction	B	1177-1186
in	I	1187-1189
glomerular	I	1190-1200
number	I	1201-1207
.	O	1207-1208

Adult	O	1209-1214
rats	O	1215-1219
given	O	1220-1225
dexamethasone	O	1226-1239
on	O	1240-1242
days	O	1243-1247
15	O	1248-1250
and	O	1251-1254
16	O	1255-1257
of	O	1258-1260
gestation	O	1261-1270
had	O	1271-1274
more	O	1275-1279
glomeruli	O	1280-1289
with	O	1290-1294
glomerulosclerosis	B	1295-1313
than	O	1314-1318
control	O	1319-1326
rats	O	1327-1331
.	O	1331-1332

This	O	1333-1337
study	O	1338-1343
shows	O	1344-1349
that	O	1350-1354
prenatal	O	1355-1363
dexamethasone	O	1364-1377
in	O	1378-1380
rats	O	1381-1385
results	O	1386-1393
in	O	1394-1396
a	O	1397-1398
reduction	B	1399-1408
in	I	1409-1411
glomerular	I	1412-1422
number	I	1423-1429
,	O	1429-1430
glomerulosclerosis	B	1431-1449
,	O	1449-1450
and	O	1451-1454
hypertension	B	1455-1467
when	O	1468-1472
administered	O	1473-1485
at	O	1486-1488
specific	O	1489-1497
points	O	1498-1504
during	O	1505-1511
gestation	O	1512-1521
.	O	1521-1522

Hypertension	B	1523-1535
was	O	1536-1539
observed	O	1540-1548
in	O	1549-1551
animals	O	1552-1559
that	O	1560-1564
had	O	1565-1568
a	O	1569-1570
reduction	O	1571-1580
in	O	1581-1583
glomeruli	O	1584-1593
as	O	1594-1596
well	O	1597-1601
as	O	1602-1604
in	O	1605-1607
a	O	1608-1609
group	O	1610-1615
that	O	1616-1620
did	O	1621-1624
not	O	1625-1628
have	O	1629-1633
a	O	1634-1635
reduction	B	1636-1645
in	I	1646-1648
glomerular	I	1649-1659
number	I	1660-1666
,	O	1666-1667
suggesting	O	1668-1678
that	O	1679-1683
a	O	1684-1685
reduction	B	1686-1695
in	I	1696-1698
glomerular	I	1699-1709
number	I	1710-1716
is	O	1717-1719
not	O	1720-1723
the	O	1724-1727
sole	O	1728-1732
cause	O	1733-1738
for	O	1739-1742
the	O	1743-1746
development	O	1747-1758
of	O	1759-1761
hypertension	B	1762-1774
.	O	1774-1775

The	O	0-3
risk	O	4-8
of	O	9-11
venous	B	12-18
thromboembolism	I	19-34
in	O	35-37
women	O	38-43
prescribed	O	44-54
cyproterone	O	55-66
acetate	O	67-74
in	O	75-77
combination	O	78-89
with	O	90-94
ethinyl	O	95-102
estradiol	O	103-112
:	O	112-113
a	O	114-115
nested	O	116-122
cohort	O	123-129
analysis	O	130-138
and	O	139-142
case	O	143-147
-	O	147-148
control	O	148-155
study	O	156-161
.	O	161-162

BACKGROUND	O	163-173
:	O	173-174
Cyproterone	O	175-186
acetate	O	187-194
combined	O	195-203
with	O	204-208
ethinyl	O	209-216
estradiol	O	217-226
(	O	227-228
CPA	O	228-231
/	O	231-232
EE	O	232-234
)	O	234-235
is	O	236-238
licensed	O	239-247
in	O	248-250
the	O	251-254
UK	O	255-257
for	O	258-261
the	O	262-265
treatment	O	266-275
of	O	276-278
women	O	279-284
with	O	285-289
acne	B	290-294
and	O	295-298
hirsutism	B	299-308
and	O	309-312
is	O	313-315
also	O	316-320
a	O	321-322
treatment	O	323-332
option	O	333-339
for	O	340-343
polycystic	B	344-354
ovary	I	355-360
syndrome	I	361-369
(	O	370-371
PCOS	B	371-375
)	O	375-376
.	O	376-377

Previous	O	378-386
studies	O	387-394
have	O	395-399
demonstrated	O	400-412
an	O	413-415
increased	O	416-425
risk	O	426-430
of	O	431-433
venous	B	434-440
thromboembolism	I	441-456
(	O	457-458
VTE	B	458-461
)	O	461-462
associated	O	463-473
with	O	474-478
CPA	O	479-482
/	O	482-483
EE	O	483-485
compared	O	486-494
with	O	495-499
conventional	O	500-512
combined	O	513-521
oral	O	522-526
contraceptives	O	527-541
(	O	542-543
COCs	O	543-547
)	O	547-548
.	O	548-549

We	O	550-552
believe	O	553-560
the	O	561-564
results	O	565-572
of	O	573-575
those	O	576-581
studies	O	582-589
may	O	590-593
have	O	594-598
been	O	599-603
affected	O	604-612
by	O	613-615
residual	O	616-624
confounding	O	625-636
.	O	636-637

METHODS	O	638-645
:	O	645-646
Using	O	647-652
the	O	653-656
General	O	657-664
Practice	O	665-673
Research	O	674-682
Database	O	683-691
we	O	692-694
conducted	O	695-704
a	O	705-706
cohort	O	707-713
analysis	O	714-722
and	O	723-726
case	O	727-731
-	O	731-732
control	O	732-739
study	O	740-745
nested	O	746-752
within	O	753-759
a	O	760-761
population	O	762-772
of	O	773-775
women	O	776-781
aged	O	782-786
between	O	787-794
15	O	795-797
and	O	798-801
39	O	802-804
years	O	805-810
with	O	811-815
acne	B	816-820
,	O	820-821
hirsutism	B	822-831
or	O	832-834
PCOS	B	835-839
to	O	840-842
estimate	O	843-851
the	O	852-855
risk	O	856-860
of	O	861-863
VTE	B	864-867
associated	O	868-878
with	O	879-883
CPA	O	884-887
/	O	887-888
EE	O	888-890
.	O	890-891

RESULTS	O	892-899
:	O	899-900
The	O	901-904
age	O	905-908
-	O	908-909
adjusted	O	909-917
incidence	O	918-927
rate	O	928-932
ratio	O	933-938
for	O	939-942
CPA	O	943-946
/	O	946-947
EE	O	947-949
versus	O	950-956
conventional	O	957-969
COCs	O	970-974
was	O	975-978
2	O	979-980
.	O	980-981
20	O	981-983
[	O	984-985
95	O	985-987
%	O	987-988
confidence	O	989-999
interval	O	1000-1008
(	O	1009-1010
CI	O	1010-1012
)	O	1012-1013
1	O	1014-1015
.	O	1015-1016
35	O	1016-1018
-	O	1018-1019
3	O	1016-1017
.	O	1015-1016
58	O	1021-1023
]	O	1023-1024
.	O	1015-1016

Using	O	1026-1031
as	O	1032-1034
the	O	1035-1038
reference	O	1039-1048
group	O	1049-1054
women	O	1055-1060
who	O	1061-1064
were	O	1065-1069
not	O	1070-1073
using	O	1074-1079
oral	O	1080-1084
contraception	O	1085-1098
,	O	1098-1099
had	O	1100-1103
no	O	1104-1106
recent	O	1107-1113
pregnancy	O	1114-1123
or	O	1124-1126
menopausal	O	1127-1137
symptoms	O	1138-1146
,	O	1146-1147
the	O	1148-1151
case	O	1152-1156
-	O	1156-1157
control	O	1157-1164
analysis	O	1165-1173
gave	O	1174-1178
an	O	1179-1181
adjusted	O	1182-1190
odds	O	1191-1195
ratio	O	1196-1201
(	O	1202-1203
OR	O	1203-1205
(	O	1202-1203
adj	O	1206-1209
)	O	1209-1210
)	O	1209-1210
of	O	1212-1214
7	O	1215-1216
.	O	1216-1217
44	O	1217-1219
(	O	1220-1221
95	O	1221-1223
%	O	1223-1224
CI	O	1225-1227
3	O	1228-1229
.	O	1229-1230
67	O	1230-1232
-	O	1232-1233
15	O	1233-1235
.	O	1229-1230
08	O	1236-1238
)	O	1238-1239

for	O	1240-1243
CPA	O	1244-1247
/	O	1247-1248
EE	O	1248-1250
use	O	1251-1254
compared	O	1255-1263
with	O	1264-1268
an	O	1269-1271
OR	O	1272-1274
(	O	1274-1275
adj	O	1275-1278
)	O	1278-1279
of	O	1280-1282
2	O	1283-1284
.	O	1284-1285
58	O	1285-1287
(	O	1288-1289
95	O	1289-1291
%	O	1291-1292
CI	O	1293-1295
1	O	1296-1297
.	O	1297-1298
60	O	1298-1300
-	O	1300-1301
4	O	1301-1302
.	O	1297-1298
18	O	1303-1305
)	O	1305-1306

for	O	1307-1310
use	O	1311-1314
of	O	1315-1317
conventional	O	1318-1330
COCs	O	1331-1335
.	O	1335-1336

CONCLUSIONS	O	1337-1348
:	O	1348-1349
We	O	1350-1352
have	O	1353-1357
demonstrated	O	1358-1370
an	O	1371-1373
increased	O	1374-1383
risk	O	1384-1388
of	O	1389-1391
VTE	B	1392-1395
associated	O	1396-1406
with	O	1407-1411
the	O	1412-1415
use	O	1416-1419
of	O	1420-1422
CPA	O	1423-1426
/	O	1426-1427
EE	O	1427-1429
in	O	1430-1432
women	O	1433-1438
with	O	1439-1443
acne	B	1444-1448
,	O	1448-1449
hirsutism	B	1450-1459
or	O	1460-1462
PCOS	B	1463-1467
although	O	1468-1476
residual	O	1477-1485
confounding	O	1486-1497
by	O	1498-1500
indication	O	1501-1511
cannot	O	1512-1518
be	O	1519-1521
excluded	O	1522-1530
.	O	1530-1531

Pseudoacromegaly	B	0-16
induced	O	17-24
by	O	25-27
the	O	28-31
long	O	32-36
-	O	36-37
term	O	37-41
use	O	42-45
of	O	46-48
minoxidil	O	49-58
.	O	58-59

Acromegaly	B	60-70
is	O	71-73
an	O	74-76
endocrine	B	77-86
disorder	I	87-95
caused	O	96-102
by	O	103-105
chronic	O	106-113
excessive	O	114-123
growth	O	124-130
hormone	O	131-138
secretion	O	139-148
from	O	149-153
the	O	154-157
anterior	O	158-166
pituitary	O	167-176
gland	O	177-182
.	O	182-183

Significant	O	184-195
disfiguring	O	196-207
changes	O	208-215
occur	O	216-221
as	O	222-224
a	O	225-226
result	O	227-233
of	O	234-236
bone	O	237-241
,	O	241-242
cartilage	O	243-252
,	O	252-253
and	O	254-257
soft	O	258-262
tissue	O	263-269
hypertrophy	B	270-281
,	O	281-282
including	O	283-292
the	O	293-296
thickening	O	297-307
of	O	308-310
the	O	311-314
skin	O	315-319
,	O	319-320
coarsening	O	321-331
of	O	332-334
facial	O	335-341
features	O	342-350
,	O	350-351
and	O	352-355
cutis	B	356-361
verticis	I	362-370
gyrata	I	371-377
.	O	377-378

Pseudoacromegaly	B	379-395
,	O	395-396
on	O	397-399
the	O	400-403
other	O	404-409
hand	O	410-414
,	O	414-415
is	O	416-418
the	O	419-422
presence	O	423-431
of	O	432-434
similar	O	435-442
acromegaloid	O	443-455
features	O	456-464
in	O	465-467
the	O	468-471
absence	O	472-479
of	O	480-482
elevated	O	483-491
growth	O	492-498
hormone	O	499-506
or	O	507-509
insulin	O	510-517
-	O	517-518
like	O	518-522
growth	O	523-529
factor	O	530-536
levels	O	537-543
.	O	543-544

We	O	545-547
present	O	548-555
a	O	556-557
patient	O	558-565
with	O	566-570
pseudoacromegaly	B	571-587
that	O	588-592
resulted	O	593-601
from	O	602-606
the	O	607-610
long	O	611-615
-	O	615-616
term	O	616-620
use	O	621-624
of	O	625-627
minoxidil	O	628-637
at	O	638-640
an	O	641-643
unusually	O	644-653
high	O	654-658
dose	O	659-663
.	O	663-664

This	O	665-669
is	O	670-672
the	O	673-676
first	O	677-682
case	O	683-687
report	O	688-694
of	O	695-697
pseudoacromegaly	B	698-714
as	O	715-717
a	O	718-719
side	O	720-724
effect	O	725-731
of	O	732-734
minoxidil	O	735-744
use	O	745-748
.	O	748-749

Combined	O	0-8
androgen	O	9-17
blockade	O	18-26
-	O	26-27
induced	O	27-34
anemia	B	35-41
in	O	42-44
prostate	B	45-53
cancer	I	54-60
patients	O	61-69
without	O	70-77
bone	O	78-82
involvement	O	83-94
.	O	94-95

BACKGROUND	O	96-106
:	O	106-107
To	O	108-110
determine	O	111-120
the	O	121-124
onset	O	125-130
and	O	131-134
extent	O	135-141
of	O	142-144
combined	O	145-153
androgen	O	154-162
blockade	O	163-171
(	O	172-173
CAB	O	173-176
)	O	176-177
-	O	177-178
induced	O	178-185
anemia	B	186-192
in	O	193-195
prostate	B	196-204
cancer	I	205-211
patients	O	212-220
without	O	221-228
bone	O	229-233
involvement	O	234-245
.	O	245-246

PATIENTS	O	247-255
AND	O	256-259
METHODS	O	260-267
:	O	267-268
Forty	O	269-274
-	O	274-275
two	O	275-278
patients	O	279-287
with	O	288-292
biopsy	O	293-299
-	O	299-300
proven	O	300-306
prostatic	B	307-316
adenocarcinoma	I	317-331
[	O	332-333
26	O	333-335
with	O	336-340
stage	O	341-346
C	O	347-348
(	O	349-350
T3N0M0	O	350-356
)	O	356-357
and	O	358-361
16	O	362-364
with	O	365-369
stage	O	370-375
D1	O	376-378
(	O	379-380
T3N1M0	O	380-386
)	O	386-387
]	O	387-388
were	O	389-393
included	O	394-402
in	O	403-405
this	O	406-410
study	O	411-416
.	O	416-417

All	O	418-421
patients	O	422-430
received	O	431-439
CAB	O	440-443
[	O	444-445
leuprolide	O	445-455
acetate	O	456-463
(	O	464-465
LHRH	O	465-469
-	O	469-470
A	O	470-471
)	O	471-472
3	O	473-474
.	O	474-475
75	O	475-477
mg	O	478-480
,	O	480-481
intramuscularly	O	482-497
,	O	497-498
every	O	499-504
28	O	505-507
days	O	508-512
plus	O	513-517
250	O	518-521
mg	O	522-524
flutamide	O	525-534
,	O	534-535
tid	O	536-539
,	O	539-540
per	O	541-544
Os	O	545-547
]	O	547-548
and	O	549-552
were	O	553-557
evaluated	O	558-567
for	O	568-571
anemia	B	572-578
by	O	579-581
physical	O	582-590
examination	O	591-602
and	O	603-606
laboratory	O	607-617
tests	O	618-623
at	O	624-626
baseline	O	627-635
and	O	636-639
4	O	640-641
subsequent	O	642-652
intervals	O	653-662
(	O	663-664
1	O	664-665
,	O	665-666
2	O	667-668
,	O	668-669
3	O	670-671
and	O	672-675
6	O	676-677
months	O	678-684
post	O	685-689
-	O	689-690
CAB	O	690-693
)	O	693-694
.	O	694-695

Hb	O	696-698
,	O	698-699
PSA	O	700-703
and	O	704-707
Testosterone	O	708-720
measurements	O	721-733
were	O	734-738
recorded	O	739-747
.	O	747-748

Patients	O	749-757
with	O	758-762
stage	O	763-768
D2	O	769-771
-	O	771-772
3	O	772-773
disease	O	774-781
,	O	781-782
abnormal	O	783-791
hemoglobin	O	792-802
level	O	803-808
or	O	809-811
renal	O	812-817
and	O	818-821
liver	O	822-827
function	O	828-836
tests	O	837-842
that	O	843-847
were	O	848-852
higher	O	853-859
than	O	860-864
the	O	865-868
upper	O	869-874
limits	O	875-881
were	O	882-886
excluded	O	887-895
from	O	896-900
the	O	901-904
study	O	905-910
.	O	910-911

The	O	912-915
duration	O	916-924
of	O	925-927
the	O	928-931
study	O	932-937
was	O	938-941
six	O	942-945
months	O	946-952
.	O	952-953

RESULTS	O	954-961
:	O	961-962
The	O	963-966
mean	O	967-971
hemoglobin	O	972-982
(	O	983-984
Hb	O	984-986
)	O	986-987
levels	O	988-994
were	O	995-999
significantly	O	1000-1013
declined	O	1014-1022
in	O	1023-1025
all	O	1026-1029
patients	O	1030-1038
from	O	1039-1043
baseline	O	1044-1052
of	O	1053-1055
14	O	1056-1058
.	O	1058-1059
2	O	1059-1060
g	O	1061-1062
/	O	1062-1063
dl	O	1063-1065
to	O	1066-1068
14	O	1069-1071
.	O	1071-1072
0	O	1072-1073
g	O	1074-1075
/	O	1075-1076
dl	O	1076-1078
,	O	1078-1079
13	O	1080-1082
.	O	1082-1083
5	O	1083-1084
g	O	1085-1086
/	O	1086-1087
dl	O	1087-1089
,	O	1089-1090
13	O	1091-1093
.	O	1093-1094
2	O	1094-1095
g	O	1096-1097
/	O	1097-1098
dl	O	1098-1100
and	O	1101-1104
12	O	1105-1107
.	O	1107-1108
7	O	1108-1109
g	O	1110-1111
/	O	1111-1112
dl	O	1112-1114
at	O	1115-1117
1	O	1118-1119
,	O	1119-1120
2	O	1121-1122
,	O	1122-1123
3	O	1124-1125
and	O	1126-1129
6	O	1130-1131
months	O	1132-1138
post	O	1139-1143
-	O	1143-1144
CAB	O	1144-1147
,	O	1147-1148
respectively	O	1149-1161
.	O	1161-1162

Severe	O	1163-1169
and	O	1170-1173
clinically	O	1174-1184
evident	O	1185-1192
anemia	B	1193-1199
of	O	1200-1202
Hb	O	1203-1205
<	O	1206-1207
11	O	1208-1210
g	O	1211-1212
/	O	1212-1213
dl	O	1213-1215
with	O	1216-1220
clinical	O	1221-1229
symptoms	O	1230-1238
was	O	1239-1242
detected	O	1243-1251
in	O	1252-1254
6	O	1255-1256
patients	O	1257-1265
(	O	1266-1267
14	O	1267-1269
.	O	1269-1270
3	O	1270-1271
%	O	1271-1272
)	O	1272-1273
.	O	1269-1270

This	O	1275-1279
CAB	O	1280-1283
-	O	1283-1284
induced	O	1284-1291
anemia	B	1292-1298
was	O	1299-1302
normochromic	O	1303-1315
and	O	1316-1319
normocytic	O	1320-1330
.	O	1330-1331

At	O	1332-1334
six	O	1335-1338
months	O	1339-1345
post	O	1346-1350
-	O	1350-1351
CAB	O	1351-1354
,	O	1354-1355
patients	O	1356-1364
with	O	1365-1369
severe	O	1370-1376
anemia	B	1377-1383
had	O	1384-1387
a	O	1388-1389
Hb	O	1390-1392
mean	O	1393-1397
value	O	1398-1403
of	O	1404-1406
10	O	1407-1409
.	O	1409-1410
2	O	1410-1411
+	O	1412-1413
/	O	1413-1414
-	O	1414-1415
0	O	1416-1417
.	O	1417-1418
1	O	1418-1419
g	O	1420-1421
/	O	1421-1422
dl	O	1422-1424
(	O	1425-1426
X	O	1426-1427
+	O	1428-1429
/	O	1429-1430
-	O	1430-1431
SE	O	1432-1434
)	O	1434-1435
,	O	1435-1436
whereas	O	1437-1444
the	O	1445-1448
other	O	1449-1454
patients	O	1455-1463
had	O	1464-1467
mild	O	1468-1472
anemia	B	1473-1479
with	O	1480-1484
Hb	O	1485-1487
mean	O	1488-1492
value	O	1493-1498
of	O	1499-1501
13	O	1502-1504
.	O	1504-1505
2	O	1505-1506
+	O	1507-1508
/	O	1508-1509
-	O	1509-1510
0	O	1511-1512
.	O	1512-1513
17	O	1513-1515
(	O	1516-1517
X	O	1517-1518
+	O	1519-1520
/	O	1520-1521
-	O	1521-1522
SE	O	1523-1525
)	O	1525-1526
.	O	1526-1527

The	O	1528-1531
development	O	1532-1543
of	O	1544-1546
severe	O	1547-1553
anemia	B	1554-1560
at	O	1561-1563
6	O	1564-1565
months	O	1566-1572
post	O	1573-1577
-	O	1577-1578
CAB	O	1578-1581
was	O	1582-1585
predictable	O	1586-1597
by	O	1598-1600
the	O	1601-1604
reduction	O	1605-1614
of	O	1615-1617
Hb	O	1618-1620
baseline	O	1621-1629
value	O	1630-1635
of	O	1636-1638
more	O	1639-1643
than	O	1644-1648
2	O	1649-1650
.	O	1650-1651
5	O	1651-1652
g	O	1653-1654
/	O	1654-1655
dl	O	1655-1657
after	O	1658-1663
3	O	1664-1665
months	O	1666-1672
of	O	1673-1675
CAB	O	1676-1679
(	O	1680-1681
p	O	1681-1682
=	O	1683-1684
0	O	1685-1686
.	O	1686-1687
01	O	1687-1689
)	O	1689-1690
.	O	1686-1687

The	O	1692-1695
development	O	1696-1707
of	O	1708-1710
severe	O	1711-1717
CAB	O	1718-1721
-	O	1721-1722
induced	O	1722-1729
anemia	B	1730-1736
in	O	1737-1739
prostate	B	1740-1748
cancer	I	1749-1755
patients	O	1756-1764
did	O	1765-1768
not	O	1769-1772
correlate	O	1773-1782
with	O	1783-1787
T	O	1788-1789
baseline	O	1790-1798
values	O	1799-1805
(	O	1806-1807
T	O	1807-1808
<	O	1809-1810
3	O	1811-1812
ng	O	1813-1815
/	O	1815-1816
ml	O	1816-1818
versus	O	1819-1825
T	O	1826-1827
>	O	1828-1829
or	O	1830-1832
=	O	1833-1834
3	O	1835-1836
ng	O	1837-1839
/	O	1839-1840
ml	O	1840-1842
)	O	1842-1843
,	O	1843-1844
with	O	1845-1849
age	O	1850-1853
(	O	1854-1855
<	O	1855-1856
76	O	1857-1859
yrs	O	1860-1863
versus	O	1864-1870
>	O	1871-1872
or	O	1873-1875
=	O	1876-1877
76	O	1878-1880
yrs	O	1881-1884
)	O	1884-1885
,	O	1885-1886
and	O	1887-1890
clinical	O	1891-1899
stage	O	1900-1905
(	O	1906-1907
stage	O	1907-1912
C	O	1913-1914
versus	O	1915-1921
stage	O	1922-1927
D1	O	1928-1930
)	O	1930-1931
.	O	1931-1932

Severe	O	1933-1939
and	O	1940-1943
clinically	O	1944-1954
evident	O	1955-1962
anemia	B	1963-1969
was	O	1970-1973
easily	O	1974-1980
corrected	O	1981-1990
by	O	1991-1993
subcutaneous	O	1994-2006
injections	O	2007-2017
(	O	2018-2019
3	O	2019-2020
times	O	2021-2026
/	O	2026-2027
week	O	2027-2031
for	O	2032-2035
1	O	2036-2037
month	O	2038-2043
)	O	2043-2044
of	O	2045-2047
recombinant	O	2048-2059
erythropoietin	O	2060-2074
(	O	2075-2076
rHuEPO	O	2076-2082
-	O	2082-2083
beta	O	2083-2087
)	O	2087-2088
.	O	2088-2089

CONCLUSION	O	2090-2100
:	O	2100-2101
Our	O	2102-2105
data	O	2106-2110
suggest	O	2111-2118
that	O	2119-2123
rHuEPO	O	2124-2130
-	O	2130-2131
beta	O	2131-2135
correctable	O	2136-2147
CAB	O	2148-2151
-	O	2151-2152
induced	O	2152-2159
anemia	B	2160-2166
occurs	O	2167-2173
in	O	2174-2176
14	O	2177-2179
.	O	2179-2180
3	O	2180-2181
%	O	2181-2182
of	O	2183-2185
prostate	B	2186-2194
cancer	I	2195-2201
patients	O	2202-2210
after	O	2211-2216
6	O	2217-2218
months	O	2219-2225
of	O	2226-2228
therapy	O	2229-2236
.	O	2236-2237

Reversible	O	0-10
dilated	B	11-18
cardiomyopathy	I	19-33
related	O	34-41
to	O	42-44
amphotericin	O	45-57
B	O	58-59
therapy	O	60-67
.	O	67-68

We	O	69-71
describe	O	72-80
a	O	81-82
patient	O	83-90
who	O	91-94
developed	O	95-104
dilated	B	105-112
cardiomyopathy	I	113-127
and	O	128-131
clinical	O	132-140
congestive	O	141-151
heart	B	152-157
failure	I	158-165
after	O	166-171
2	O	172-173
months	O	174-180
of	O	181-183
therapy	O	184-191
with	O	192-196
amphotericin	O	197-209
B	O	210-211
(	O	212-213
AmB	O	213-216
)	O	216-217
for	O	218-221
disseminated	O	222-234
coccidioidomycosis	B	235-253
.	O	253-254

His	O	255-258
echocardiographic	O	259-276
abnormalities	O	277-290
and	O	291-294
heart	B	295-300
failure	I	301-308
resolved	O	309-317
after	O	318-323
posaconazole	O	324-336
was	O	337-340
substituted	O	341-352
for	O	353-356
AmB	O	357-360
.	O	360-361

It	O	362-364
is	O	365-367
important	O	368-377
to	O	378-380
recognize	O	381-390
the	O	391-394
rare	O	395-399
and	O	400-403
potentially	O	404-415
reversible	O	416-426
toxicity	B	427-435
of	O	436-438
AmB	O	439-442
.	O	442-443

Risks	O	0-5
of	O	6-8
the	O	9-12
consumption	O	13-24
of	O	25-27
beverages	O	28-37
containing	O	38-48
quinine	O	49-56
.	O	56-57

Although	O	58-66
the	O	67-70
United	O	71-77
States	O	78-84
Food	O	85-89
and	O	90-93
Drug	O	94-98
Administration	O	99-113
banned	O	114-120
its	O	121-124
use	O	125-128
for	O	129-132
nocturnal	B	133-142
leg	I	143-146
cramps	I	147-153
due	O	154-157
to	O	158-160
lack	O	161-165
of	O	166-168
safety	O	169-175
and	O	176-179
efficacy	O	180-188
,	O	188-189
quinine	O	190-197
is	O	198-200
widely	O	201-207
available	O	208-217
in	O	218-220
beverages	O	221-230
including	O	231-240
tonic	O	241-246
water	O	247-252
and	O	253-256
bitter	O	257-263
lemon	O	264-269
.	O	269-270

Numerous	O	271-279
anecdotal	O	280-289
reports	O	290-297
suggest	O	298-305
that	O	306-310
products	O	311-319
containing	O	320-330
quinine	O	331-338
may	O	339-342
produce	O	343-350
neurological	B	351-363
complications	I	364-377
,	O	377-378
including	O	379-388
confusion	B	389-398
,	O	398-399
altered	O	400-407
mental	O	408-414
status	O	415-421
,	O	421-422
seizures	B	423-431
,	O	431-432
and	O	433-436
coma	B	437-441
,	O	441-442
particularly	O	443-455
in	O	456-458
older	O	459-464
women	O	465-470
.	O	470-471

Psychologists	O	472-485
need	O	486-490
to	O	491-493
inquire	O	494-501
about	O	502-507
consumption	O	508-519
of	O	520-522
quinine	O	523-530
-	O	530-531
containing	O	531-541
beverages	O	542-551
as	O	552-554
part	O	555-559
of	O	560-562
an	O	563-565
evaluation	O	566-576
process	O	577-584
.	O	584-585

Organophosphate	O	0-15
-	O	15-16
induced	O	16-23
convulsions	B	24-35
and	O	36-39
prevention	O	40-50
of	O	51-53
neuropathological	B	54-71
damages	I	72-79
.	O	79-80

Such	O	81-85
organophosphorus	O	86-102
(	O	103-104
OP	O	104-106
)	O	106-107
compounds	O	108-117
as	O	118-120
diisopropylfluorophosphate	O	121-147
(	O	148-149
DFP	O	149-152
)	O	152-153
,	O	153-154
sarin	O	155-160
and	O	161-164
soman	O	165-170
are	O	171-174
potent	O	175-181
inhibitors	O	182-192
of	O	193-195
acetylcholinesterases	O	196-217
(	O	218-219
AChEs	O	219-224
)	O	224-225
and	O	226-229
butyrylcholinesterases	O	230-252
(	O	253-254
BChEs	O	254-259
)	O	259-260
.	O	260-261

The	O	262-265
acute	O	266-271
toxicity	B	272-280
of	O	281-283
OPs	O	284-287
is	O	288-290
the	O	291-294
result	O	295-301
of	O	302-304
their	O	305-310
irreversible	O	311-323
binding	O	324-331
with	O	332-336
AChEs	O	337-342
in	O	343-345
the	O	346-349
central	O	350-357
nervous	O	358-365
system	O	366-372
(	O	373-374
CNS	O	374-377
)	O	377-378
,	O	378-379
which	O	380-385
elevates	O	386-394
acetylcholine	O	395-408
(	O	409-410
ACh	O	410-413
)	O	413-414
levels	O	415-421
.	O	421-422

The	O	423-426
protective	O	427-437
action	O	438-444
of	O	445-447
subcutaneously	O	448-462
(	O	463-464
SC	O	464-466
)	O	466-467
administered	O	468-480
antidotes	O	481-490
or	O	491-493
their	O	494-499
combinations	O	500-512
in	O	513-515
DFP	O	516-519
(	O	520-521
2	O	521-522
.	O	522-523
0	O	523-524
mg	O	525-527
/	O	527-528
kg	O	528-530
BW	O	531-533
)	O	533-534
intoxication	O	535-547
was	O	548-551
studied	O	552-559
in	O	560-562
9	O	563-564
-	O	564-565
10	O	565-567
-	O	564-565
weeks	O	568-573
-	O	564-565
old	O	574-577
Han	O	578-581
-	O	581-582
Wistar	O	582-588
male	O	589-593
rats	O	594-598
.	O	598-599

The	O	600-603
rats	O	604-608
received	O	609-617
AChE	O	618-622
reactivator	O	623-634
pralidoxime	O	635-646
-	O	646-647
2	O	647-648
-	O	646-647
chloride	O	649-657
(	O	658-659
2PAM	O	659-663
)	O	663-664
(	O	665-666
30	O	666-668
.	O	668-669
0	O	667-668
mg	O	671-673
/	O	673-674
kg	O	674-676
BW	O	677-679
)	O	679-680
,	O	680-681
anticonvulsant	O	682-696
diazepam	O	697-705
(	O	706-707
2	O	707-708
.	O	708-709
0	O	709-710
mg	O	711-713
/	O	713-714
kg	O	714-716
BW	O	717-719
)	O	719-720
,	O	720-721
A	O	722-723
(	O	723-724
1	O	724-725
)	O	725-726
-	O	726-727
adenosine	O	727-736
receptor	O	737-745
agonist	O	746-753
N	O	754-755
(	O	755-756
6	O	756-757
)	O	757-758
-	O	758-759
cyclopentyl	O	759-770
adenosine	O	771-780
(	O	781-782
CPA	O	782-785
)	O	785-786
(	O	787-788
2	O	788-789
.	O	789-790
0	O	790-791
mg	O	792-794
/	O	794-795
kg	O	795-797
BW	O	798-800
)	O	800-801
,	O	801-802
NMDA	O	803-807
-	O	807-808
receptor	O	808-816
antagonist	O	817-827
dizocilpine	O	828-839
maleate	O	840-847
(	O	848-849
+	O	849-850
-	O	850-851
MK801	O	851-856
hydrogen	O	857-865
maleate	O	866-873
)	O	873-874
(	O	875-876
2	O	876-877
.	O	877-878
0	O	878-879
mg	O	880-882
/	O	882-883
kg	O	883-885
BW	O	886-888
)	O	888-889
or	O	890-892
their	O	893-898
combinations	O	899-911
with	O	912-916
cholinolytic	O	917-929
drug	O	930-934
atropine	O	935-943
sulfate	O	944-951
(	O	952-953
50	O	953-955
.	O	955-956
0	O	954-955
mg	O	958-960
/	O	960-961
kg	O	961-963
BW	O	964-966
)	O	966-967
immediately	O	968-979
or	O	980-982
30	O	983-985
min	O	986-989
after	O	990-995
the	O	996-999
single	O	1000-1006
SC	O	1007-1009
injection	O	1010-1019
of	O	1020-1022
DFP	O	1023-1026
.	O	1026-1027

The	O	1028-1031
control	O	1032-1039
rats	O	1040-1044
received	O	1045-1053
atropine	O	1054-1062
sulfate	O	1063-1070
,	O	1070-1071
but	O	1072-1075
also	O	1076-1080
saline	O	1081-1087
and	O	1088-1091
olive	O	1092-1097
oil	O	1098-1101
instead	O	1102-1109
of	O	1110-1112
other	O	1113-1118
antidotes	O	1119-1128
and	O	1129-1132
DFP	O	1133-1136
,	O	1136-1137
respectively	O	1138-1150
.	O	1150-1151

All	O	1152-1155
rats	O	1156-1160
were	O	1161-1165
terminated	O	1166-1176
either	O	1177-1183
24	O	1184-1186
h	O	1187-1188
or	O	1189-1191
3	O	1192-1193
weeks	O	1194-1199
after	O	1200-1205
the	O	1206-1209
DFP	O	1210-1213
injection	O	1214-1223
.	O	1223-1224

The	O	1225-1228
rats	O	1229-1233
treated	O	1234-1241
with	O	1242-1246
DFP	O	1247-1250
-	O	1250-1251
atropine	O	1251-1259
showed	O	1260-1266
severe	O	1267-1273
typical	O	1274-1281
OP	O	1282-1284
-	O	1284-1285
induced	O	1285-1292
toxicity	B	1293-1301
signs	O	1302-1307
.	O	1307-1308

When	O	1309-1313
CPA	O	1314-1317
,	O	1317-1318
diazepam	O	1319-1327
or	O	1328-1330
2PAM	O	1331-1335
was	O	1336-1339
given	O	1340-1345
immediately	O	1346-1357
after	O	1358-1363
DFP	O	1364-1367
-	O	1367-1368
atropine	O	1368-1376
,	O	1376-1377
these	O	1378-1383
treatments	O	1384-1394
prevented	O	1395-1404
,	O	1404-1405
delayed	O	1406-1413
or	O	1414-1416
shortened	O	1417-1426
the	O	1427-1430
occurrence	O	1431-1441
of	O	1442-1444
serious	O	1445-1452
signs	O	1453-1458
of	O	1459-1461
poisoning	B	1462-1471
.	O	1471-1472

Atropine	O	1473-1481
-	O	1481-1482
MK801	O	1482-1487
did	O	1488-1491
not	O	1492-1495
offer	O	1496-1501
any	O	1502-1505
additional	O	1506-1516
protection	O	1517-1527
against	O	1528-1535
DFP	O	1536-1539
toxicity	B	1540-1548
.	O	1548-1549

In	O	1550-1552
conclusion	O	1553-1563
,	O	1563-1564
CPA	O	1565-1568
,	O	1568-1569
diazepam	O	1570-1578
and	O	1579-1582
2PAM	O	1583-1587
in	O	1588-1590
combination	O	1591-1602
with	O	1603-1607
atropine	O	1608-1616
prevented	O	1617-1626
the	O	1627-1630
occurrence	O	1631-1641
of	O	1642-1644
serious	O	1645-1652
signs	O	1653-1658
of	O	1659-1661
poisoning	B	1662-1671
and	O	1672-1675
thus	O	1676-1680
reduced	O	1681-1688
the	O	1689-1692
toxicity	B	1693-1701
of	O	1702-1704
DFP	O	1705-1708
in	O	1709-1711
rat	O	1712-1715
.	O	1715-1716

Differential	O	0-12
modulation	O	13-23
by	O	24-26
estrogen	O	27-35
of	O	36-38
alpha2	O	39-45
-	O	45-46
adrenergic	O	46-56
and	O	57-60
I1	O	61-63
-	O	63-64
imidazoline	O	64-75
receptor	O	76-84
-	O	84-85
mediated	O	85-93
hypotension	B	94-105
in	O	106-108
female	O	109-115
rats	O	116-120
.	O	120-121

We	O	122-124
have	O	125-129
recently	O	130-138
shown	O	139-144
that	O	145-149
estrogen	O	150-158
negatively	O	159-169
modulates	O	170-179
the	O	180-183
hypotensive	B	184-195
effect	O	196-202
of	O	203-205
clonidine	O	206-215
(	O	216-217
mixed	O	217-222
alpha2	O	223-229
-	O	229-230
/	O	230-231
I1	O	231-233
-	O	229-230
receptor	O	234-242
agonist	O	243-250
)	O	250-251
in	O	252-254
female	O	255-261
rats	O	262-266
and	O	267-270
implicates	O	271-281
the	O	282-285
cardiovascular	O	286-300
autonomic	O	301-310
control	O	311-318
in	O	319-321
this	O	322-326
interaction	O	327-338
.	O	338-339

The	O	340-343
present	O	344-351
study	O	352-357
investigated	O	358-370
whether	O	371-378
this	O	379-383
effect	O	384-390
of	O	391-393
estrogen	O	394-402
involves	O	403-411
interaction	O	412-423
with	O	424-428
alpha2	O	429-435
-	O	435-436
and	O	437-440
/	O	440-441
or	O	441-443
I1	O	444-446
-	O	446-447
receptors	O	447-456
.	O	456-457

Changes	O	458-465
evoked	O	466-472
by	O	473-475
a	O	476-477
single	O	478-484
intraperitoneal	O	485-500
injection	O	501-510
of	O	511-513
rilmenidine	O	514-525
(	O	526-527
600	O	527-530
microg	O	531-537
/	O	537-538
kg	O	538-540
)	O	540-541
or	O	542-544
alpha	O	545-550
-	O	550-551
methyldopa	O	551-561
(	O	562-563
100	O	563-566
mg	O	567-569
/	O	569-570
kg	O	570-572
)	O	572-573
,	O	573-574
selective	O	575-584
I1	O	585-587
-	O	587-588
and	O	589-592
alpha2	O	593-599
-	O	599-600
receptor	O	600-608
agonists	O	609-617
,	O	617-618
respectively	O	619-631
,	O	631-632
in	O	633-635
blood	O	636-641
pressure	O	642-650
,	O	650-651
hemodynamic	O	652-663
variability	O	664-675
,	O	675-676
and	O	677-680
locomotor	O	681-690
activity	O	691-699
were	O	700-704
assessed	O	705-713
in	O	714-716
radiotelemetered	O	717-733
sham	O	734-738
-	O	738-739
operated	O	739-747
and	O	748-751
ovariectomized	O	752-766
(	O	767-768
Ovx	O	768-771
)	O	771-772
Sprague	O	773-780
-	O	780-781
Dawley	O	781-787
female	O	788-794
rats	O	795-799
with	O	800-804
or	O	805-807
without	O	808-815
12	O	816-818
-	O	818-819
wk	O	819-821
estrogen	O	822-830
replacement	O	831-842
.	O	842-843

Three	O	844-849
time	O	850-854
domain	O	855-861
indexes	O	862-869
of	O	870-872
hemodynamic	O	873-884
variability	O	885-896
were	O	897-901
employed	O	902-910
:	O	910-911
the	O	912-915
standard	O	916-924
deviation	O	925-934
of	O	935-937
mean	O	938-942
arterial	O	943-951
pressure	O	952-960
as	O	961-963
a	O	964-965
measure	O	966-973
of	O	974-976
blood	O	977-982
pressure	O	983-991
variability	O	992-1003
and	O	1004-1007
the	O	1008-1011
standard	O	1012-1020
deviation	O	1021-1030
of	O	1031-1033
beat	O	1034-1038
-	O	1038-1039
to	O	1039-1041
-	O	1038-1039
beat	O	1034-1038
intervals	O	1047-1056
(	O	1057-1058
SDRR	O	1058-1062
)	O	1062-1063
and	O	1064-1067
the	O	1068-1071
root	O	1072-1076
mean	O	1077-1081
square	O	1082-1088
of	O	1089-1091
successive	O	1092-1102
differences	O	1103-1114
in	O	1115-1117
R	O	1118-1119
-	O	1119-1120
wave	O	1120-1124
-	O	1119-1120
to	O	1125-1127
-	O	1119-1120
R	O	1118-1119
-	O	1119-1120
wave	O	1120-1124
intervals	O	1135-1144
as	O	1145-1147
measures	O	1148-1156
of	O	1157-1159
heart	O	1160-1165
rate	O	1166-1170
variability	O	1171-1182
.	O	1182-1183

In	O	1184-1186
sham	O	1187-1191
-	O	1191-1192
operated	O	1192-1200
rats	O	1201-1205
,	O	1205-1206
rilmenidine	O	1207-1218
or	O	1219-1221
alpha	O	1222-1227
-	O	1227-1228
methyldopa	O	1228-1238
elicited	O	1239-1247
similar	O	1248-1255
hypotension	B	1256-1267
that	O	1268-1272
lasted	O	1273-1279
at	O	1280-1282
least	O	1283-1288
5	O	1289-1290
h	O	1291-1292
and	O	1293-1296
was	O	1297-1300
associated	O	1301-1311
with	O	1312-1316
reductions	O	1317-1327
in	O	1328-1330
standard	O	1331-1339
deviation	O	1340-1349
of	O	1350-1352
mean	O	1353-1357
arterial	O	1358-1366
pressure	O	1367-1375
.	O	1375-1376

SDRR	O	1377-1381
was	O	1382-1385
reduced	O	1386-1393
only	O	1394-1398
by	O	1399-1401
alpha	O	1402-1407
-	O	1407-1408
methyldopa	O	1408-1418
.	O	1418-1419

Ovx	O	1420-1423
significantly	O	1424-1437
enhanced	O	1438-1446
the	O	1447-1450
hypotensive	B	1451-1462
response	O	1463-1471
to	O	1472-1474
alpha	O	1475-1480
-	O	1480-1481
methyldopa	O	1481-1491
,	O	1491-1492
in	O	1493-1495
contrast	O	1496-1504
to	O	1505-1507
no	O	1508-1510
effect	O	1511-1517
on	O	1518-1520
rilmenidine	O	1521-1532
hypotension	B	1533-1544
.	O	1544-1545

The	O	1546-1549
enhanced	O	1550-1558
alpha	O	1559-1564
-	O	1564-1565
methyldopa	O	1565-1575
hypotension	B	1576-1587
in	O	1588-1590
Ovx	O	1591-1594
rats	O	1595-1599
was	O	1600-1603
paralleled	O	1604-1614
with	O	1615-1619
further	O	1620-1627
reduction	O	1628-1637
in	O	1638-1640
SDRR	O	1641-1645
and	O	1646-1649
a	B	1650-1651
reduced	I	1652-1659
locomotor	I	1660-1669
activity	I	1670-1678
.	O	1678-1679

Estrogen	O	1680-1688
replacement	O	1689-1700
(	O	1701-1702
17beta	O	1702-1708
-	O	1708-1709
estradiol	O	1709-1718
subcutaneous	O	1719-1731
pellet	O	1732-1738
,	O	1738-1739
14	O	1740-1742
.	O	1742-1743
2	O	1743-1744
microg	O	1745-1751
/	O	1751-1752
day	O	1752-1755
,	O	1755-1756
12	O	1757-1759
wk	O	1760-1762
)	O	1762-1763
of	O	1764-1766
Ovx	O	1767-1770
rats	O	1771-1775
restored	O	1776-1784
the	O	1785-1788
hemodynamic	O	1789-1800
and	O	1801-1804
locomotor	O	1805-1814
effects	O	1815-1822
of	O	1823-1825
alpha	O	1826-1831
-	O	1831-1832
methyldopa	O	1832-1842
to	O	1843-1845
sham	O	1846-1850
-	O	1850-1851
operated	O	1851-1859
levels	O	1860-1866
.	O	1866-1867

These	O	1868-1873
findings	O	1874-1882
suggest	O	1883-1890
that	O	1891-1895
estrogen	O	1896-1904
downregulates	O	1905-1918
alpha2	O	1919-1925
-	O	1925-1926
but	O	1927-1930
not	O	1931-1934
I1	O	1935-1937
-	O	1937-1938
receptor	O	1938-1946
-	O	1937-1938
mediated	O	1947-1955
hypotension	B	1956-1967
and	O	1968-1971
highlight	O	1972-1981
a	O	1982-1983
role	O	1984-1988
for	O	1989-1992
the	O	1993-1996
cardiac	O	1997-2004
autonomic	O	2005-2014
control	O	2015-2022
in	O	2023-2025
alpha	O	2026-2031
-	O	2031-2032
methyldopa	O	2032-2042
-	O	2031-2032
estrogen	O	2043-2051
interaction	O	2052-2063
.	O	2063-2064

Cardioprotective	O	0-16
effect	O	17-23
of	O	24-26
tincture	O	27-35
of	O	36-38
Crataegus	O	39-48
on	O	49-51
isoproterenol	O	52-65
-	O	65-66
induced	O	66-73
myocardial	B	74-84
infarction	I	85-95
in	O	96-98
rats	O	99-103
.	O	103-104

Tincture	O	105-113
of	O	114-116
Crataegus	O	117-126
(	O	127-128
TCR	O	128-131
)	O	131-132
,	O	132-133
an	O	134-136
alcoholic	O	137-146
extract	O	147-154
of	O	155-157
the	O	158-161
berries	O	162-169
of	O	170-172
hawthorn	O	173-181
(	O	182-183
Crataegus	O	183-192
oxycantha	O	193-202
)	O	202-203
,	O	203-204
is	O	205-207
used	O	208-212
in	O	213-215
herbal	O	216-222
and	O	223-226
homeopathic	O	227-238
medicine	O	239-247
.	O	247-248

The	O	249-252
present	O	253-260
study	O	261-266
was	O	267-270
done	O	271-275
to	O	276-278
investigate	O	279-290
the	O	291-294
protective	O	295-305
effect	O	306-312
of	O	313-315
TCR	O	316-319
on	O	320-322
experimentally	O	323-337
induced	O	338-345
myocardial	B	346-356
infarction	I	357-367
in	O	368-370
rats	O	371-375
.	O	375-376

Pretreatment	O	377-389
of	O	390-392
TCR	O	393-396
,	O	396-397
at	O	398-400
a	O	401-402
dose	O	403-407
of	O	408-410
0	O	411-412
.	O	412-413
5	O	413-414
mL	O	415-417
/	O	417-418
100	O	418-421
g	O	422-423
bodyweight	O	424-434
per	O	435-438
day	O	439-442
,	O	442-443
orally	O	444-450
for	O	451-454
30	O	455-457
days	O	458-462
,	O	462-463
prevented	O	464-473
the	O	474-477
increase	O	478-486
in	O	487-489
lipid	O	490-495
peroxidation	O	496-508
and	O	509-512
activity	O	513-521
of	O	522-524
marker	O	525-531
enzymes	O	532-539
observed	O	540-548
in	O	549-551
isoproterenol	O	552-565
-	O	565-566
induced	O	566-573
rats	O	574-578
(	O	579-580
85	O	580-582
mg	O	583-585
kg	O	586-588
(	O	588-589
-	O	589-590
1	O	590-591
)	O	591-592
s	O	593-594
.	O	594-595
c	O	596-597
.	O	597-598
for	O	599-602
2	O	603-604
days	O	605-609
at	O	610-612
an	O	613-615
interval	O	616-624
of	O	625-627
24	O	628-630
h	O	631-632
)	O	632-633
.	O	633-634

TCR	O	635-638
prevented	O	639-648
the	O	649-652
isoproterenol	O	653-666
-	O	666-667
induced	O	667-674
decrease	O	675-683
in	O	684-686
antioxidant	O	687-698
enzymes	O	699-706
in	O	707-709
the	O	710-713
heart	O	714-719
and	O	720-723
increased	O	724-733
the	O	734-737
rate	O	738-742
of	O	743-745
ADP	O	746-749
-	O	749-750
stimulated	O	750-760
oxygen	O	761-767
uptake	O	768-774
and	O	775-778
respiratory	O	779-790
coupling	O	791-799
ratio	O	800-805
.	O	805-806

TCR	O	807-810
protected	O	811-820
against	O	821-828
pathological	O	829-841
changes	O	842-849
induced	O	850-857
by	O	858-860
isoproterenol	O	861-874
in	O	875-877
rat	O	878-881
heart	O	882-887
.	O	887-888

The	O	889-892
results	O	893-900
show	O	901-905
that	O	906-910
pretreatment	O	911-923
with	O	924-928
TCR	O	929-932
may	O	933-936
be	O	937-939
useful	O	940-946
in	O	947-949
preventing	O	950-960
the	O	961-964
damage	O	965-971
induced	O	972-979
by	O	980-982
isoproterenol	O	983-996
in	O	997-999
rat	O	1000-1003
heart	O	1004-1009
.	O	1009-1010

Safety	O	0-6
and	O	7-10
adverse	O	11-18
effects	O	19-26
associated	O	27-37
with	O	38-42
raloxifene	O	43-53
:	O	53-54
multiple	O	55-63
outcomes	O	64-72
of	O	73-75
raloxifene	O	76-86
evaluation	O	87-97
.	O	97-98

OBJECTIVE	O	99-108
:	O	108-109
To	O	110-112
examine	O	113-120
the	O	121-124
effect	O	125-131
of	O	132-134
raloxifene	O	135-145
on	O	146-148
major	O	149-154
adverse	O	155-162
events	O	163-169
that	O	170-174
occur	O	175-180
with	O	181-185
postmenopausal	O	186-200
estrogen	O	201-209
therapy	O	210-217
or	O	218-220
tamoxifen	O	221-230
.	O	230-231

METHODS	O	232-239
:	O	239-240
The	O	241-244
Multiple	O	245-253
Outcomes	O	254-262
of	O	263-265
Raloxifene	O	266-276
Evaluation	O	277-287
,	O	287-288
a	O	289-290
multicenter	O	291-302
,	O	302-303
randomized	O	304-314
,	O	314-315
double	O	316-322
-	O	322-323
blind	O	323-328
trial	O	329-334
,	O	334-335
enrolled	O	336-344
7	O	345-346
,	O	346-347
705	O	347-350
postmenopausal	O	351-365
women	O	366-371
with	O	372-376
osteoporosis	B	377-389
.	O	389-390

Women	O	391-396
were	O	397-401
randomly	O	402-410
assigned	O	411-419
to	O	420-422
raloxifene	O	423-433
60	O	434-436
mg	O	437-439
/	O	439-440
d	O	440-441
or	O	442-444
120	O	445-448
mg	O	449-451
/	O	451-452
d	O	452-453
or	O	454-456
placebo	O	457-464
.	O	464-465

Outcomes	O	466-474
included	O	475-483
venous	B	484-490
thromboembolism	I	491-506
,	O	506-507
cataracts	B	508-517
,	O	517-518
gallbladder	B	519-530
disease	I	531-538
,	O	538-539
and	O	540-543
endometrial	B	544-555
hyperplasia	I	556-567
or	I	568-570
cancer	I	571-577
.	O	577-578

RESULTS	O	579-586
:	O	586-587
During	O	588-594
a	O	595-596
mean	O	597-601
follow	O	602-608
-	O	608-609
up	O	609-611
of	O	612-614
3	O	615-616
.	O	616-617
3	O	615-616
years	O	619-624
,	O	624-625
raloxifene	O	626-636
was	O	637-640
associated	O	641-651
with	O	652-656
an	O	657-659
increased	O	660-669
risk	O	670-674
for	O	675-678
venous	B	679-685
thromboembolism	I	686-701
(	O	702-703
relative	O	703-711
risk	O	712-716
[	O	717-718
RR	O	718-720
]	O	720-721
2	O	722-723
.	O	723-724
1	O	724-725
;	O	725-726
95	O	727-729
%	O	729-730
confidence	O	731-741
interval	O	742-750
[	O	751-752
CI	O	752-754
]	O	754-755
1	O	756-757
.	O	757-758
2	O	758-759
-	O	759-760
3	O	760-761
.	O	757-758
8	O	762-763
)	O	763-764
.	O	757-758

The	O	766-769
excess	O	770-776
event	O	777-782
rate	O	783-787
was	O	788-791
1	O	792-793
.	O	793-794
8	O	794-795
per	O	796-799
1	O	800-801
,	O	801-802
000	O	802-805
woman	O	806-811
-	O	811-812
years	O	812-817
(	O	818-819
95	O	819-821
%	O	821-822
CI	O	823-825
-	O	826-827
0	O	827-828
.	O	828-829
5	O	829-830
-	O	826-827
4	O	831-832
.	O	828-829
1	O	833-834
)	O	834-835
,	O	835-836
and	O	837-840
the	O	841-844
number	O	845-851
needed	O	852-858
to	O	859-861
treat	O	862-867
to	O	868-870
cause	O	871-876
1	O	877-878
event	O	879-884
was	O	885-888
170	O	889-892
(	O	893-894
95	O	894-896
%	O	896-897
CI	O	898-900
100	O	901-904
-	O	904-905
582	O	905-908
)	O	908-909
over	O	910-914
3	O	915-916
.	O	916-917
3	O	915-916
years	O	919-924
.	O	924-925

Risk	O	926-930
in	O	931-933
the	O	934-937
raloxifene	O	938-948
group	O	949-954
was	O	955-958
higher	O	959-965
than	O	966-970
in	O	971-973
the	O	974-977
placebo	O	978-985
group	O	986-991
for	O	992-995
the	O	996-999
first	O	1000-1005
2	O	1006-1007
years	O	1008-1013
,	O	1013-1014
but	O	1015-1018
decreased	O	1019-1028
to	O	1029-1031
about	O	1032-1037
the	O	1038-1041
same	O	1042-1046
rate	O	1047-1051
as	O	1052-1054
in	O	1055-1057
the	O	1058-1061
placebo	O	1062-1069
group	O	1070-1075
thereafter	O	1076-1086
.	O	1086-1087

Raloxifene	O	1088-1098
did	O	1099-1102
not	O	1103-1106
increase	O	1107-1115
risk	O	1116-1120
for	O	1121-1124
cataracts	B	1125-1134
(	O	1135-1136
RR	O	1136-1138
0	O	1139-1140
.	O	1140-1141
9	O	1141-1142
;	O	1142-1143
95	O	1144-1146
%	O	1146-1147
CI	O	1148-1150
0	O	1151-1152
.	O	1152-1153
8	O	1153-1154
-	O	1154-1155
1	O	1155-1156
.	O	1152-1153
1	O	1155-1156
)	O	1158-1159
,	O	1159-1160

gallbladder	B	1161-1172
disease	I	1173-1180
(	O	1181-1182
RR	O	1182-1184
1	O	1185-1186
.	O	1186-1187
0	O	1187-1188
;	O	1188-1189
95	O	1190-1192
%	O	1192-1193
CI	O	1194-1196
0	O	1197-1198
.	O	1198-1199
7	O	1199-1200
-	O	1200-1201
1	O	1201-1202
.	O	1198-1199
3	O	1203-1204
)	O	1204-1205
,	O	1205-1206

endometrial	B	1207-1218
hyperplasia	I	1219-1230
(	O	1231-1232
RR	O	1232-1234
1	O	1235-1236
.	O	1236-1237
3	O	1237-1238
;	O	1238-1239
95	O	1240-1242
%	O	1242-1243
CI	O	1244-1246
0	O	1247-1248
.	O	1248-1249
4	O	1249-1250
-	O	1250-1251
5	O	1251-1252
.	O	1248-1249
1	O	1253-1254
)	O	1254-1255
,	O	1255-1256

or	O	1257-1259
endometrial	B	1260-1271
cancer	I	1272-1278
(	O	1279-1280
RR	O	1280-1282
0	O	1283-1284
.	O	1284-1285
9	O	1285-1286
;	O	1286-1287
95	O	1288-1290
%	O	1290-1291
CI	O	1292-1294
0	O	1295-1296
.	O	1296-1297
3	O	1297-1298
-	O	1298-1299
2	O	1299-1300
.	O	1296-1297
7	O	1301-1302
)	O	1302-1303
.	O	1296-1297

CONCLUSION	O	1305-1315
:	O	1315-1316
Raloxifene	O	1317-1327
was	O	1328-1331
associated	O	1332-1342
with	O	1343-1347
an	O	1348-1350
increased	O	1351-1360
risk	O	1361-1365
for	O	1366-1369
venous	B	1370-1376
thromboembolism	I	1377-1392
,	O	1392-1393
but	O	1394-1397
there	O	1398-1403
was	O	1404-1407
no	O	1408-1410
increased	O	1411-1420
risk	O	1421-1425
for	O	1426-1429
cataracts	B	1430-1439
,	O	1439-1440
gallbladder	B	1441-1452
disease	I	1453-1460
,	O	1460-1461
endometrial	B	1462-1473
hyperplasia	I	1474-1485
,	O	1485-1486
or	O	1487-1489
endometrial	B	1490-1501
cancer	I	1502-1508
.	O	1508-1509

LEVEL	O	1510-1515
OF	O	1516-1518
EVIDENCE	O	1519-1527
:	O	1527-1528
I	O	1529-1530

Ceftriaxone	O	0-11
-	O	11-12
associated	O	12-22
biliary	B	23-30
pseudolithiasis	I	31-46
in	O	47-49
paediatric	O	50-60
surgical	O	61-69
patients	O	70-78
.	O	78-79

It	O	80-82
is	O	83-85
well	O	86-90
known	O	91-96
that	O	97-101
ceftriaxone	O	102-113
leads	O	114-119
to	O	120-122
pseudolithiasis	B	123-138
in	O	139-141
some	O	142-146
patients	O	147-155
.	O	155-156

Clinical	O	157-165
and	O	166-169
experimental	O	170-182
studies	O	183-190
also	O	191-195
suggest	O	196-203
that	O	204-208
situations	O	209-219
causing	O	220-227
gallbladder	B	228-239
dysfunction	I	240-251
,	O	251-252
such	O	253-257
as	O	258-260
fasting	O	261-268
,	O	268-269
may	O	270-273
have	O	274-278
a	O	279-280
role	O	281-285
for	O	286-289
the	O	290-293
development	O	294-305
of	O	306-308
pseudolithiasis	B	309-324
.	O	324-325

In	O	326-328
this	O	329-333
study	O	334-339
,	O	339-340
we	O	341-343
prospectively	O	344-357
evaluated	O	358-367
the	O	368-371
incidence	O	372-381
and	O	382-385
clinical	O	386-394
importance	O	395-405
of	O	406-408
pseudolithiasis	B	409-424
in	O	425-427
paediatric	O	428-438
surgical	O	439-447
patients	O	448-456
receiving	O	457-466
ceftriaxone	O	467-478
treatment	O	479-488
,	O	488-489
who	O	490-493
often	O	494-499
had	O	500-503
to	O	504-506
fast	O	507-511
in	O	512-514
the	O	515-518
post	O	519-523
-	O	523-524
operative	O	524-533
period	O	534-540
.	O	540-541

Fifty	O	542-547
children	O	548-556
who	O	557-560
were	O	561-565
given	O	566-571
ceftriaxone	O	572-583
were	O	584-588
evaluated	O	589-598
by	O	599-601
serial	O	602-608
abdominal	O	609-618
sonograms	O	619-628
.	O	628-629

Of	O	630-632
those	O	633-638
,	O	638-639
13	O	640-642
(	O	643-644
26	O	644-646
%	O	646-647
)	O	647-648
developed	O	649-658
biliary	O	659-666
pathology	O	667-676
.	O	676-677

Comparison	O	678-688
of	O	689-691
the	O	692-695
patients	O	696-704
with	O	705-709
or	O	710-712
without	O	713-720
pseudolithiasis	B	721-736
revealed	O	737-745
no	O	746-748
significant	O	749-760
difference	O	761-771
with	O	772-776
respect	O	777-784
to	O	785-787
age	O	788-791
,	O	791-792
sex	O	793-796
,	O	796-797
duration	O	798-806
of	O	807-809
the	O	810-813
treatment	O	814-823
and	O	824-827
starvation	O	828-838
variables	O	839-848
.	O	848-849

After	O	850-855
cessation	O	856-865
of	O	866-868
the	O	869-872
treatment	O	873-882
,	O	882-883
pseudolithiasis	B	884-899
resolved	O	900-908
spontaneously	O	909-922
within	O	923-929
a	O	930-931
short	O	932-937
period	O	938-944
.	O	944-945

The	O	946-949
incidence	O	950-959
of	O	960-962
pseudolithiasis	B	963-978
is	O	979-981
not	O	982-985
affected	O	986-994
by	O	995-997
fasting	O	998-1005
.	O	1005-1006

Evaluation	O	0-10
of	O	11-13
the	O	14-17
anticocaine	O	18-29
monoclonal	O	30-40
antibody	O	41-49
GNC92H2	O	50-57
as	O	58-60
an	O	61-63
immunotherapy	O	64-77
for	O	78-81
cocaine	B	82-89
overdose	I	90-98
.	O	98-99

The	O	100-103
illicit	O	104-111
use	O	112-115
of	O	116-118
cocaine	O	119-126
continues	O	127-136
in	O	137-139
epidemic	O	140-148
proportions	O	149-160
and	O	161-164
treatment	O	165-174
for	O	175-178
cocaine	B	179-186
overdose	I	187-195
remains	O	196-203
elusive	O	204-211
.	O	211-212

Current	O	213-220
protein	O	221-228
-	O	228-229
based	O	229-234
technology	O	235-245
offers	O	246-252
a	O	253-254
new	O	255-258
therapeutic	O	259-270
venue	O	271-276
by	O	277-279
which	O	280-285
antibodies	O	286-296
bind	O	297-301
the	O	302-305
drug	O	306-310
in	O	311-313
the	O	314-317
blood	O	318-323
stream	O	324-330
,	O	330-331
inactivating	O	332-344
its	O	345-348
toxic	O	349-354
effects	O	355-362
.	O	362-363

The	O	364-367
therapeutic	O	368-379
potential	O	380-389
of	O	390-392
the	O	393-396
anticocaine	O	397-408
antibody	O	409-417
GNC92H2	O	418-425
was	O	426-429
examined	O	430-438
using	O	439-444
a	O	445-446
model	O	447-452
of	O	453-455
cocaine	B	456-463
overdose	I	464-472
.	O	472-473

Swiss	O	474-479
albino	O	480-486
mice	O	487-491
prepared	O	492-500
with	O	501-505
intrajugular	O	506-518
catheters	O	519-528
were	O	529-533
tested	O	534-540
in	O	541-543
photocell	O	544-553
cages	O	554-559
after	O	560-565
administration	O	566-580
of	O	581-583
93	O	584-586
mg	O	587-589
/	O	589-590
kg	O	590-592
(	O	593-594
LD50	O	594-598
)	O	598-599
of	O	600-602
cocaine	O	603-610
and	O	611-614
GNC92H2	O	615-622
infusions	O	623-632
ranging	O	633-640
from	O	641-645
30	O	646-648
to	O	649-651
190	O	652-655
mg	O	656-658
/	O	658-659
kg	O	659-661
.	O	661-662

GNC92H2	O	663-670
was	O	671-674
delivered	O	675-684
30	O	685-687
min	O	688-691
before	O	692-698
,	O	698-699
concomitantly	O	700-713
or	O	714-716
3	O	717-718
min	O	719-722
after	O	723-728
cocaine	O	729-736
treatment	O	737-746
.	O	746-747

Significant	O	748-759
blockade	O	760-768
of	O	769-771
cocaine	O	772-779
toxicity	B	780-788
was	O	789-792
observed	O	793-801
with	O	802-806
the	O	807-810
higher	O	811-817
dose	O	818-822
of	O	823-825
GNC92H2	O	826-833
(	O	834-835
190	O	835-838
mg	O	839-841
/	O	841-842
kg	O	842-844
)	O	844-845
,	O	845-846
where	O	847-852
premorbid	O	853-862
behaviors	O	863-872
were	O	873-877
reduced	O	878-885
up	O	886-888
to	O	889-891
40	O	892-894
%	O	894-895
,	O	895-896
seizures	B	897-905
up	O	906-908
to	O	909-911
77	O	912-914
%	O	914-915
and	O	916-919
death	B	920-925
by	O	926-928
72	O	929-931
%	O	931-932
.	O	932-933

Importantly	O	934-945
,	O	945-946
GNC92H2	O	947-954
prevented	O	955-964
death	B	965-970
even	O	971-975
post	O	976-980
-	O	980-981
cocaine	O	981-988
injection	O	989-998
.	O	998-999

The	O	1000-1003
results	O	1004-1011
support	O	1012-1019
the	O	1020-1023
important	O	1024-1033
potential	O	1034-1043
of	O	1044-1046
GNC92H2	O	1047-1054
as	O	1055-1057
a	O	1058-1059
therapeutic	O	1060-1071
tool	O	1072-1076
against	O	1077-1084
cocaine	B	1085-1092
overdose	I	1093-1101
.	O	1101-1102

The	O	0-3
effects	O	4-11
of	O	12-14
short	O	15-20
-	O	20-21
term	O	21-25
raloxifene	O	26-36
therapy	O	37-44
on	O	45-47
fibrinolysis	O	48-60
markers	O	61-68
:	O	68-69
TAFI	O	70-74
,	O	74-75
tPA	O	76-79
,	O	79-80
and	O	81-84
PAI	O	85-88
-	O	88-89
1	O	89-90
.	O	90-91

BACKGROUND	O	92-102
:	O	102-103
Markers	O	104-111
of	O	112-114
fibrinolysis	O	115-127
,	O	127-128
thrombin	O	129-137
-	O	137-138
activatable	O	138-149
fibrinolysis	O	150-162
inhibitor	O	163-172
(	O	173-174
TAFI	O	174-178
)	O	178-179
,	O	179-180
tissue	O	181-187
-	O	187-188
type	O	188-192
plasminogen	O	193-204
activator	O	205-214
(	O	215-216
tPA	O	216-219
)	O	219-220
,	O	220-221
and	O	222-225
plasminogen	O	226-237
activator	O	238-247
inhibitor	O	248-257
-	O	257-258
1	O	258-259
(	O	260-261
PAI	O	261-264
-	O	264-265
1	O	265-266
)	O	266-267
levels	O	268-274
were	O	275-279
studied	O	280-287
for	O	288-291
the	O	292-295
evaluation	O	296-306
of	O	307-309
short	O	310-315
-	O	315-316
term	O	316-320
effects	O	321-328
of	O	329-331
raloxifene	O	332-342
administration	O	343-357
in	O	358-360
postmenopausal	O	361-375
women	O	376-381
.	O	381-382

METHODS	O	383-390
:	O	390-391
Thirty	O	392-398
-	O	398-399
nine	O	399-403
postmenopausal	O	404-418
women	O	419-424
with	O	425-429
osteopenia	B	430-440
or	O	441-443
osteoporosis	B	444-456
were	O	457-461
included	O	462-470
in	O	471-473
this	O	474-478
prospective	O	479-490
,	O	490-491
controlled	O	492-502
clinical	O	503-511
study	O	512-517
.	O	517-518

Twenty	O	519-525
-	O	525-526
five	O	526-530
women	O	531-536
were	O	537-541
given	O	542-547
raloxifene	O	548-558
hydrochloride	O	559-572
(	O	573-574
60	O	574-576
mg	O	577-579
/	O	579-580
day	O	580-583
)	O	583-584
plus	O	585-589
calcium	O	590-597
(	O	598-599
500	O	599-602
mg	O	603-605
/	O	605-606
day	O	606-609
)	O	609-610
.	O	610-611

Age	O	612-615
-	O	615-616
matched	O	616-623
controls	O	624-632
(	O	633-634
n	O	634-635
=	O	636-637
14	O	638-640
)	O	640-641
were	O	642-646
given	O	647-652
only	O	653-657
calcium	O	658-665
.	O	665-666

Plasma	O	667-673
TAFI	O	674-678
,	O	678-679
tPA	O	680-683
,	O	683-684
and	O	685-688
PAI	O	689-692
-	O	692-693
1	O	693-694
antigen	O	695-702
levels	O	703-709
were	O	710-714
measured	O	715-723
at	O	724-726
baseline	O	727-735
and	O	736-739
after	O	740-745
3	O	746-747
months	O	748-754
of	O	755-757
treatment	O	758-767
by	O	768-770
commercially	O	771-783
available	O	784-793
ELISA	O	794-799
kits	O	800-804
.	O	804-805

Variations	O	806-816
of	O	817-819
individuals	O	820-831
were	O	832-836
assessed	O	837-845
by	O	846-848
Wilcoxon	O	849-857
'	O	857-858
s	O	858-859
test	O	860-864
.	O	864-865

Relationship	O	866-878
between	O	879-886
those	O	887-892
markers	O	893-900
and	O	901-904
demographic	O	905-916
characteristics	O	917-932
were	O	933-937
investigated	O	938-950
.	O	950-951

RESULTS	O	952-959
:	O	959-960
Three	O	961-966
months	O	967-973
of	O	974-976
raloxifene	O	977-987
treatment	O	988-997
was	O	998-1001
associated	O	1002-1012
with	O	1013-1017
a	O	1018-1019
significant	O	1020-1031
decrease	O	1032-1040
in	O	1041-1043
the	O	1044-1047
plasma	O	1048-1054
TAFI	O	1055-1059
antigen	O	1060-1067
concentrations	O	1068-1082
(	O	1083-1084
16	O	1084-1086
%	O	1086-1087
change	O	1088-1094
,	O	1094-1095
P	O	1096-1097
<	O	1098-1099
0	O	1100-1101
.	O	1101-1102
01	O	1102-1104
)	O	1104-1105
,	O	1105-1106
and	O	1107-1110
a	O	1111-1112
significant	O	1113-1124
increase	O	1125-1133
in	O	1134-1136
tPA	O	1137-1140
antigen	O	1141-1148
concentrations	O	1149-1163
(	O	1164-1165
25	O	1165-1167
%	O	1167-1168
change	O	1169-1175
,	O	1175-1176
P	O	1177-1178
<	O	1179-1180
0	O	1181-1182
.	O	1182-1183
05	O	1183-1185
)	O	1185-1186
.	O	1182-1183

A	O	1188-1189
significant	O	1190-1201
correlation	O	1202-1213
was	O	1214-1217
found	O	1218-1223
between	O	1224-1231
baseline	O	1232-1240
TAFI	O	1241-1245
antigen	O	1246-1253
concentrations	O	1254-1268
and	O	1269-1272
the	O	1273-1276
duration	O	1277-1285
of	O	1286-1288
amenorrhea	B	1289-1299
(	O	1300-1301
P	O	1301-1302
<	O	1303-1304
0	O	1305-1306
.	O	1306-1307
05	O	1307-1309
;	O	1309-1310
r	O	1311-1312
=	O	1313-1314
0	O	1315-1316
.	O	1316-1317
33	O	1317-1319
)	O	1319-1320
.	O	1316-1317

CONCLUSION	O	1322-1332
:	O	1332-1333
We	O	1334-1336
suggest	O	1337-1344
that	O	1345-1349
the	O	1350-1353
increased	O	1354-1363
risk	O	1364-1368
of	O	1369-1371
venous	B	1372-1378
thromboembolism	I	1379-1394
due	O	1395-1398
to	O	1399-1401
raloxifene	O	1402-1412
treatment	O	1413-1422
may	O	1423-1426
be	O	1427-1429
related	O	1430-1437
to	O	1438-1440
increased	O	1441-1450
tPA	O	1451-1454
levels	O	1455-1461
,	O	1461-1462
but	O	1463-1466
not	O	1467-1470
TAFI	O	1471-1475
levels	O	1476-1482
.	O	1482-1483

Ketoconazole	O	0-12
induced	O	13-20
torsades	B	21-29
de	I	30-32
pointes	I	33-40
without	O	41-48
concomitant	O	49-60
use	O	61-64
of	O	65-67
QT	O	68-70
interval	O	71-79
-	O	79-80
prolonging	O	80-90
drug	O	91-95
.	O	95-96

Ketoconazole	O	97-109
is	O	110-112
not	O	113-116
known	O	117-122
to	O	123-125
be	O	126-128
proarrhythmic	O	129-142
without	O	143-150
concomitant	O	151-162
use	O	163-166
of	O	167-169
QT	O	170-172
interval	O	173-181
-	O	181-182
prolonging	O	182-192
drugs	O	193-198
.	O	198-199

We	O	200-202
report	O	203-209
a	O	210-211
woman	O	212-217
with	O	218-222
coronary	B	223-231
artery	I	232-238
disease	I	239-246
who	O	247-250
developed	O	251-260
a	O	261-262
markedly	O	263-271
prolonged	B	272-281
QT	I	282-284
interval	I	285-293
and	O	294-297
torsades	B	298-306
de	I	307-309
pointes	I	310-317
(	O	318-319
TdP	B	319-322
)	O	322-323
after	O	324-329
taking	O	330-336
ketoconazole	O	337-349
for	O	350-353
treatment	O	354-363
of	O	364-366
fungal	B	367-373
infection	I	374-383
.	O	383-384

Her	O	385-388
QT	O	389-391
interval	O	392-400
returned	O	401-409
to	O	410-412
normal	O	413-419
upon	O	420-424
withdrawal	O	425-435
of	O	436-438
ketoconazole	O	439-451
.	O	451-452

Genetic	O	453-460
study	O	461-466
did	O	467-470
not	O	471-474
find	O	475-479
any	O	480-483
mutation	O	484-492
in	O	493-495
her	O	496-499
genes	O	500-505
that	O	506-510
encode	O	511-517
cardiac	O	518-525
IKr	O	526-529
channel	O	530-537
proteins	O	538-546
.	O	546-547

We	O	548-550
postulate	O	551-560
that	O	561-565
by	O	566-568
virtue	O	569-575
of	O	576-578
its	O	579-582
direct	O	583-589
blocking	O	590-598
action	O	599-605
on	O	606-608
IKr	O	609-612
,	O	612-613
ketoconazole	O	614-626
alone	O	627-632
may	O	633-636
prolong	O	637-644
QT	O	645-647
interval	O	648-656
and	O	657-660
induce	O	661-667
TdP	B	668-671
.	O	671-672

This	O	673-677
calls	O	678-683
for	O	684-687
attention	O	688-697
when	O	698-702
ketoconazole	O	703-715
is	O	716-718
administered	O	719-731
to	O	732-734
patients	O	735-743
with	O	744-748
risk	O	749-753
factors	O	754-761
for	O	762-765
acquired	O	766-774
long	B	775-779
QT	I	780-782
syndrome	I	783-791
.	O	791-792

Pharmacological	O	0-15
evidence	O	16-24
for	O	25-28
the	O	29-32
potential	O	33-42
of	O	43-45
Daucus	O	46-52
carota	O	53-59
in	O	60-62
the	O	63-66
management	O	67-77
of	O	78-80
cognitive	B	81-90
dysfunctions	I	91-103
.	O	103-104

The	O	105-108
present	O	109-116
study	O	117-122
was	O	123-126
aimed	O	127-132
at	O	133-135
investigating	O	136-149
the	O	150-153
effects	O	154-161
of	O	162-164
Daucus	O	165-171
carota	O	172-178
seeds	O	179-184
on	O	185-187
cognitive	O	188-197
functions	O	198-207
,	O	207-208
total	O	209-214
serum	O	215-220
cholesterol	O	221-232
levels	O	233-239
and	O	240-243
brain	O	244-249
cholinesterase	O	250-264
activity	O	265-273
in	O	274-276
mice	O	277-281
.	O	281-282

The	O	283-286
ethanolic	O	287-296
extract	O	297-304
of	O	305-307
Daucus	O	308-314
carota	O	315-321
seeds	O	322-327
(	O	328-329
DCE	O	329-332
)	O	332-333
was	O	334-337
administered	O	338-350
orally	O	351-357
in	O	358-360
three	O	361-366
doses	O	367-372
(	O	373-374
100	O	374-377
,	O	377-378
200	O	379-382
,	O	382-383
400	O	384-387
mg	O	388-390
/	O	390-391
kg	O	391-393
)	O	393-394
for	O	395-398
seven	O	399-404
successive	O	405-415
days	O	416-420
to	O	421-423
different	O	424-433
groups	O	434-440
of	O	441-443
young	O	444-449
and	O	450-453
aged	O	454-458
mice	O	459-463
.	O	463-464

Elevated	O	465-473
plus	O	474-478
maze	O	479-483
and	O	484-487
passive	O	488-495
avoidance	O	496-505
apparatus	O	506-515
served	O	516-522
as	O	523-525
the	O	526-529
exteroceptive	O	530-543
behavioral	O	544-554
models	O	555-561
for	O	562-565
testing	O	566-573
memory	O	574-580
.	O	580-581

Diazepam	O	582-590
-	O	590-591
,	O	591-592
scopolamine	O	593-604
-	O	604-605
and	O	606-609
ageing	O	610-616
-	O	616-617
induced	O	617-624
amnesia	B	625-632
served	O	633-639
as	O	640-642
the	O	643-646
interoceptive	O	647-660
behavioral	O	661-671
models	O	672-678
.	O	678-679

DCE	O	680-683
(	O	684-685
200	O	685-688
,	O	688-689
400	O	690-693
mg	O	694-696
/	O	696-697
kg	O	697-699
,	O	699-700
p	O	701-702
.	O	702-703
o	O	703-704
.	O	702-703
)	O	705-706
showed	O	707-713
significant	O	714-725
improvement	O	726-737
in	O	738-740
memory	O	741-747
scores	O	748-754
of	O	755-757
young	O	758-763
and	O	764-767
aged	O	768-772
mice	O	773-777
.	O	777-778

The	O	779-782
extent	O	783-789
of	O	790-792
memory	O	793-799
improvement	O	800-811
evoked	O	812-818
by	O	819-821
DCE	O	822-825
was	O	826-829
23	O	830-832
%	O	832-833
at	O	834-836
the	O	837-840
dose	O	841-845
of	O	846-848
200	O	849-852
mg	O	853-855
/	O	855-856
kg	O	856-858
and	O	859-862
35	O	863-865
%	O	865-866
at	O	867-869
the	O	870-873
dose	O	874-878
of	O	879-881
400	O	882-885
mg	O	886-888
/	O	888-889
kg	O	889-891
in	O	892-894
young	O	895-900
mice	O	901-905
using	O	906-911
elevated	O	912-920
plus	O	921-925
maze	O	926-930
.	O	930-931

Similarly	O	932-941
,	O	941-942
significant	O	943-954
improvements	O	955-967
in	O	968-970
memory	O	971-977
scores	O	978-984
were	O	985-989
observed	O	990-998
using	O	999-1004
passive	O	1005-1012
avoidance	O	1013-1022
apparatus	O	1023-1032
and	O	1033-1036
aged	O	1037-1041
mice	O	1042-1046
.	O	1046-1047

Furthermore	O	1048-1059
,	O	1059-1060
DCE	O	1061-1064
reversed	O	1065-1073
the	O	1074-1077
amnesia	B	1078-1085
induced	O	1086-1093
by	O	1094-1096
scopolamine	O	1097-1108
(	O	1109-1110
0	O	1110-1111
.	O	1111-1112
4	O	1112-1113
mg	O	1114-1116
/	O	1116-1117
kg	O	1117-1119
,	O	1119-1120
i	O	1121-1122
.	O	1122-1123
p	O	1123-1124
.	O	1122-1123
)	O	1125-1126
and	O	1127-1130
diazepam	O	1131-1139
(	O	1140-1141
1	O	1141-1142
mg	O	1143-1145
/	O	1145-1146
kg	O	1146-1148
,	O	1148-1149
i	O	1150-1151
.	O	1151-1152
p	O	1152-1153
.	O	1151-1152
)	O	1154-1155
.	O	1151-1152

Daucus	O	1157-1163
carota	O	1164-1170
extract	O	1171-1178
(	O	1179-1180
200	O	1180-1183
,	O	1183-1184
400	O	1185-1188
mg	O	1189-1191
/	O	1191-1192
kg	O	1192-1194
,	O	1194-1195
p	O	1196-1197
.	O	1197-1198
o	O	1198-1199
.	O	1197-1198
)	O	1200-1201
reduced	O	1202-1209
significantly	O	1210-1223
the	O	1224-1227
brain	O	1228-1233
acetylcholinesterase	O	1234-1254
activity	O	1255-1263
and	O	1264-1267
cholesterol	O	1268-1279
levels	O	1280-1286
in	O	1287-1289
young	O	1290-1295
and	O	1296-1299
aged	O	1300-1304
mice	O	1305-1309
.	O	1309-1310

The	O	1311-1314
extent	O	1315-1321
of	O	1322-1324
inhibition	O	1325-1335
of	O	1336-1338
brain	O	1339-1344
cholinesterase	O	1345-1359
activity	O	1360-1368
evoked	O	1369-1375
by	O	1376-1378
DCE	O	1379-1382
at	O	1383-1385
the	O	1386-1389
dose	O	1390-1394
of	O	1395-1397
400	O	1398-1401
mg	O	1402-1404
/	O	1404-1405
kg	O	1405-1407
was	O	1408-1411
22	O	1412-1414
%	O	1414-1415
in	O	1416-1418
young	O	1419-1424
and	O	1425-1428
19	O	1429-1431
%	O	1431-1432
in	O	1433-1435
aged	O	1436-1440
mice	O	1441-1445
.	O	1445-1446

There	O	1447-1452
was	O	1453-1456
a	O	1457-1458
remarkable	O	1459-1469
reduction	O	1470-1479
in	O	1480-1482
total	O	1483-1488
cholesterol	O	1489-1500
level	O	1501-1506
as	O	1507-1509
well	O	1510-1514
,	O	1514-1515
to	O	1516-1518
the	O	1519-1522
extent	O	1523-1529
of	O	1530-1532
23	O	1533-1535
%	O	1535-1536
in	O	1537-1539
young	O	1540-1545
and	O	1546-1549
21	O	1550-1552
%	O	1552-1553
in	O	1554-1556
aged	O	1557-1561
animals	O	1562-1569
with	O	1570-1574
this	O	1575-1579
dose	O	1580-1584
of	O	1585-1587
DCE	O	1588-1591
.	O	1591-1592

Therefore	O	1593-1602
,	O	1602-1603
DCE	O	1604-1607
may	O	1608-1611
prove	O	1612-1617
to	O	1618-1620
be	O	1621-1623
a	O	1624-1625
useful	O	1626-1632
remedy	O	1633-1639
for	O	1640-1643
the	O	1644-1647
management	O	1648-1658
of	O	1659-1661
cognitive	B	1662-1671
dysfunctions	I	1672-1684
on	O	1685-1687
account	O	1688-1695
of	O	1696-1698
its	O	1699-1702
multifarious	O	1703-1715
beneficial	O	1716-1726
effects	O	1727-1734
such	O	1735-1739
as	O	1740-1742
,	O	1742-1743
memory	O	1744-1750
improving	O	1751-1760
property	O	1761-1769
,	O	1769-1770
cholesterol	O	1771-1782
lowering	O	1783-1791
property	O	1792-1800
and	O	1801-1804
anticholinesterase	O	1805-1823
activity	O	1824-1832
.	O	1832-1833

Cauda	B	0-5
equina	I	6-12
syndrome	I	13-21
after	O	22-27
epidural	O	28-36
steroid	O	37-44
injection	O	45-54
:	O	54-55
a	O	56-57
case	O	58-62
report	O	63-69
.	O	69-70

OBJECTIVE	O	71-80
:	O	80-81
Conventional	O	82-94
treatment	O	95-104
methods	O	105-112
of	O	113-115
lumbusacral	O	116-127
radiculopathy	B	128-141
are	O	142-145
physical	O	146-154
therapy	O	155-162
,	O	162-163
epidural	O	164-172
steroid	O	173-180
injections	O	181-191
,	O	191-192
oral	O	193-197
medications	O	198-209
,	O	209-210
and	O	211-214
spinal	O	215-221
manipulative	O	222-234
therapy	O	235-242
.	O	242-243

Cauda	B	244-249
equina	I	250-256
syndrome	I	257-265
is	O	266-268
a	O	269-270
rare	O	271-275
complication	O	276-288
of	O	289-291
epidural	O	292-300
anesthesia	O	301-311
.	O	311-312

The	O	313-316
following	O	317-326
case	O	327-331
is	O	332-334
a	O	335-336
report	O	337-343
of	O	344-346
cauda	B	347-352
equina	I	353-359
syndrome	I	360-368
possibly	O	369-377
caused	O	378-384
by	O	385-387
epidural	O	388-396
injection	O	397-406
of	O	407-409
triamcinolone	O	410-423
and	O	424-427
bupivacaine	O	428-439
.	O	439-440

CLINICAL	O	441-449
FEATURES	O	450-458
:	O	458-459
A	O	460-461
50	O	462-464
-	O	464-465
year	O	465-469
-	O	464-465
old	O	470-473
woman	O	474-479
with	O	480-484
low	B	485-488
back	I	489-493
and	I	494-497
right	I	498-503
leg	I	504-507
pain	I	508-512
was	O	513-516
scheduled	O	517-526
for	O	527-530
epidural	O	531-539
steroid	O	540-547
injection	O	548-557
.	O	557-558

INTERVENTION	O	559-571
AND	O	572-575
OUTCOME	O	576-583
:	O	583-584
An	O	585-587
18	O	588-590
-	O	590-591
gauge	O	591-596
Touhy	O	597-602
needle	O	603-609
was	O	610-613
inserted	O	614-622
until	O	623-628
loss	O	629-633
of	O	634-636
resistance	O	637-647
occurred	O	648-656
at	O	657-659
the	O	660-663
L4	O	664-666
-	O	666-667
5	O	667-668
level	O	669-674
.	O	674-675

Spread	O	676-682
of	O	683-685
the	O	686-689
contrast	O	690-698
medium	O	699-705
within	O	706-712
the	O	713-716
epidural	O	717-725
space	O	726-731
was	O	732-735
determined	O	736-746
by	O	747-749
radiographic	O	750-762
imaging	O	763-770
.	O	770-771

After	O	772-777
verifying	O	778-787
the	O	788-791
epidural	O	792-800
space	O	801-806
,	O	806-807
bupivacaine	O	808-819
and	O	820-823
triamcinolone	O	824-837
diacetate	O	838-847
were	O	848-852
injected	O	853-861
.	O	861-862

After	O	863-868
the	O	869-872
injection	O	873-882
,	O	882-883
there	O	884-889
was	O	890-893
a	O	894-895
reduction	O	896-905
in	O	906-908
radicular	O	909-918
symptoms	O	919-927
.	O	927-928

Three	O	929-934
hours	O	935-940
later	O	941-946
,	O	946-947
she	O	948-951
complained	O	952-962
of	O	963-965
perineal	O	966-974
numbness	B	975-983
and	O	984-987
lower	B	988-993
extremity	I	994-1003
weakness	I	1004-1012
.	O	1012-1013

The	O	1014-1017
neurologic	O	1018-1028
evaluation	O	1029-1039
revealed	O	1040-1048
loss	B	1049-1053
of	I	1054-1056
sensation	I	1057-1066
in	O	1067-1069
the	O	1070-1073
saddle	O	1074-1080
area	O	1081-1085
and	O	1086-1089
medial	O	1090-1096
aspect	O	1097-1103
of	O	1104-1106
her	O	1107-1110
right	O	1111-1116
leg	O	1117-1120
.	O	1120-1121

There	O	1122-1127
was	O	1128-1131
a	O	1132-1133
decrease	O	1134-1142
in	O	1143-1145
the	O	1146-1149
perception	O	1150-1160
of	O	1161-1163
pinprick	O	1164-1172
test	O	1173-1177
.	O	1177-1178

Deep	O	1179-1183
-	O	1183-1184
tendon	O	1184-1190
reflexes	O	1191-1199
were	O	1200-1204
decreased	O	1205-1214
especially	O	1215-1225
in	O	1226-1228
the	O	1229-1232
right	O	1233-1238
leg	O	1239-1242
.	O	1242-1243

She	O	1244-1247
was	O	1248-1251
unable	O	1252-1258
to	O	1259-1261
urinate	O	1262-1269
.	O	1269-1270

The	O	1271-1274
patient	O	1275-1282
'	O	1282-1283
s	O	1283-1284
symptoms	O	1285-1293
improved	O	1294-1302
slightly	O	1303-1311
over	O	1312-1316
the	O	1317-1320
next	O	1321-1325
few	O	1326-1329
hours	O	1330-1335
.	O	1335-1336

She	O	1337-1340
had	O	1341-1344
a	O	1345-1346
gradual	O	1347-1354
return	O	1355-1361
of	O	1362-1364
motor	O	1365-1370
function	O	1371-1379
and	O	1380-1383
ability	O	1384-1391
of	O	1392-1394
feeling	O	1395-1402
Foley	O	1403-1408
catheter	O	1409-1417
.	O	1417-1418

All	O	1419-1422
of	O	1423-1425
the	O	1426-1429
symptoms	O	1430-1438
were	O	1439-1443
completely	O	1444-1454
resolved	O	1455-1463
over	O	1464-1468
the	O	1469-1472
next	O	1473-1477
8	O	1478-1479
hours	O	1480-1485
.	O	1485-1486

CONCLUSION	O	1487-1497
:	O	1497-1498
Complications	O	1499-1512
associated	O	1513-1523
with	O	1524-1528
epidural	O	1529-1537
steroid	O	1538-1545
injections	O	1546-1556
are	O	1557-1560
rare	O	1561-1565
.	O	1565-1566

Clinical	O	1567-1575
examination	O	1576-1587
and	O	1588-1591
continued	O	1592-1601
vigilance	O	1602-1611
for	O	1612-1615
neurologic	B	1616-1626
deterioration	I	1627-1640
after	O	1641-1646
epidural	O	1647-1655
steroid	O	1656-1663
injections	O	1664-1674
is	O	1675-1677
important	O	1678-1687
.	O	1687-1688

High	O	0-4
-	O	4-5
dose	O	5-9
testosterone	O	10-22
is	O	23-25
associated	O	26-36
with	O	37-41
atherosclerosis	B	42-57
in	O	58-60
postmenopausal	O	61-75
women	O	76-81
.	O	81-82

OBJECTIVES	O	83-93
:	O	93-94
To	O	95-97
study	O	98-103
the	O	104-107
long	O	108-112
-	O	112-113
term	O	113-117
effects	O	118-125
of	O	126-128
androgen	O	129-137
treatment	O	138-147
on	O	148-150
atherosclerosis	B	151-166
in	O	167-169
postmenopausal	O	170-184
women	O	185-190
.	O	190-191

METHODS	O	192-199
:	O	199-200
In	O	201-203
a	O	204-205
population	O	206-216
-	O	216-217
based	O	217-222
study	O	223-228
in	O	229-231
513	O	232-235
naturally	O	236-245
postmenopausal	O	246-260
women	O	261-266
aged	O	267-271
54	O	272-274
-	O	274-275
67	O	275-277
years	O	278-283
,	O	283-284
we	O	285-287
studied	O	288-295
the	O	296-299
association	O	300-311
between	O	312-319
self	O	320-324
-	O	324-325
reported	O	325-333
intramuscularly	O	334-349
administered	O	350-362
high	O	363-367
-	O	367-368
dose	O	368-372
estrogen	O	373-381
-	O	381-382
testosterone	O	382-394
therapy	O	395-402
(	O	403-404
estradiol	O	404-413
-	O	413-414
and	O	415-418
testosterone	O	419-431
esters	O	432-438
)	O	438-439
and	O	440-443
aortic	O	444-450
atherosclerosis	B	451-466
.	O	466-467

Aortic	O	468-474
atherosclerosis	B	475-490
was	O	491-494
diagnosed	O	495-504
by	O	505-507
radiographic	O	508-520
detection	O	521-530
of	O	531-533
calcified	O	534-543
deposits	O	544-552
in	O	553-555
the	O	556-559
abdominal	O	560-569
aorta	O	570-575
,	O	575-576
which	O	577-582
have	O	583-587
been	O	588-592
shown	O	593-598
to	O	599-601
reflect	O	602-609
intima	O	610-616
atherosclerosis	B	617-632
.	O	632-633

Hormone	O	634-641
therapy	O	642-649
users	O	650-655
were	O	656-660
compared	O	661-669
with	O	670-674
never	O	675-680
users	O	681-686
.	O	686-687

RESULTS	O	688-695
:	O	695-696
Intramuscular	O	697-710
hormone	O	711-718
therapy	O	719-726
use	O	727-730
for	O	731-734
1	O	735-736
year	O	737-741
or	O	742-744
longer	O	745-751
was	O	752-755
reported	O	756-764
by	O	765-767
25	O	768-770
women	O	771-776
.	O	776-777

In	O	778-780
almost	O	781-787
half	O	788-792
of	O	793-795
these	O	796-801
women	O	802-807
severe	O	808-814
atherosclerosis	B	815-830
of	O	831-833
the	O	834-837
aorta	O	838-843
was	O	844-847
present	O	848-855
(	O	856-857
n	O	857-858
=	O	858-859
11	O	859-861
)	O	861-862
,	O	862-863
while	O	864-869
in	O	870-872
women	O	873-878
without	O	879-886
hormone	O	887-894
use	O	895-898
severe	O	899-905
atherosclerosis	B	906-921
of	O	922-924
the	O	925-928
aorta	O	929-934
was	O	935-938
present	O	939-946
in	O	947-949
less	O	950-954
than	O	955-959
20	O	960-962
%	O	962-963
(	O	964-965
OR	O	965-967
3	O	968-969
.	O	969-970
1	O	970-971
;	O	971-972
95	O	973-975
%	O	975-976
CI	O	977-979
,	O	979-980
1	O	981-982
.	O	982-983
1	O	981-982
-	O	984-985
8	O	985-986
.	O	982-983
5	O	987-988
,	O	988-989
adjusted	O	990-998
for	O	999-1002
age	O	1003-1006
,	O	1006-1007
years	O	1008-1013
since	O	1014-1019
menopause	O	1020-1029
,	O	1029-1030
smoking	O	1031-1038
,	O	1038-1039
and	O	1040-1043
body	O	1044-1048
mass	O	1049-1053
index	O	1054-1059
)	O	1059-1060
.	O	1060-1061

The	O	1062-1065
association	O	1066-1077
remained	O	1078-1086
after	O	1087-1092
additional	O	1093-1103
adjustment	O	1104-1114
for	O	1115-1118
diabetes	B	1119-1127
,	O	1127-1128
cholesterol	O	1129-1140
level	O	1141-1146
,	O	1146-1147
systolic	O	1148-1156
blood	O	1157-1162
pressure	O	1163-1171
,	O	1171-1172
or	O	1173-1175
alcohol	O	1176-1183
use	O	1184-1187
.	O	1187-1188

No	O	1189-1191
association	O	1192-1203
was	O	1204-1207
found	O	1208-1213
for	O	1214-1217
hormone	O	1218-1225
use	O	1226-1229
less	O	1230-1234
than	O	1235-1239
1	O	1240-1241
year	O	1242-1246
.	O	1246-1247

CONCLUSION	O	1248-1258
:	O	1258-1259
Our	O	1260-1263
results	O	1264-1271
suggest	O	1272-1279
that	O	1280-1284
high	O	1285-1289
-	O	1289-1290
dose	O	1290-1294
testosterone	O	1295-1307
therapy	O	1308-1315
may	O	1316-1319
adversely	O	1320-1329
affect	O	1330-1336
atherosclerosis	B	1337-1352
in	O	1353-1355
postmenopausal	O	1356-1370
women	O	1371-1376
and	O	1377-1380
indicate	O	1381-1389
that	O	1390-1394
androgen	O	1395-1403
replacement	O	1404-1415
in	O	1416-1418
these	O	1419-1424
women	O	1425-1430
may	O	1431-1434
not	O	1435-1438
be	O	1439-1441
harmless	O	1442-1450
.	O	1450-1451

Sirolimus	O	0-9
-	O	9-10
associated	O	10-20
proteinuria	B	21-32
and	O	33-36
renal	B	37-42
dysfunction	I	43-54
.	O	54-55

Sirolimus	O	56-65
is	O	66-68
a	O	69-70
novel	O	71-76
immunosuppressant	O	77-94
with	O	95-99
potent	O	100-106
antiproliferative	O	107-124
actions	O	125-132
through	O	133-140
its	O	141-144
ability	O	145-152
to	O	153-155
inhibit	O	156-163
the	O	164-167
raptor	O	168-174
-	O	174-175
containing	O	175-185
mammalian	O	186-195
target	O	196-202
of	O	203-205
rapamycin	O	206-215
protein	O	216-223
kinase	O	224-230
.	O	230-231

Sirolimus	O	232-241
represents	O	242-252
a	O	253-254
major	O	255-260
therapeutic	O	261-272
advance	O	273-280
in	O	281-283
the	O	284-287
prevention	O	288-298
of	O	299-301
acute	O	302-307
renal	O	308-313
allograft	O	314-323
rejection	O	324-333
and	O	334-337
chronic	O	338-345
allograft	O	346-355
nephropathy	B	356-367
.	O	367-368

Its	O	369-372
role	O	373-377
in	O	378-380
the	O	381-384
therapy	O	385-392
of	O	393-395
glomerulonephritis	B	396-414
,	O	414-415
autoimmunity	B	416-428
,	O	428-429
cystic	B	430-436
renal	I	437-442
diseases	I	443-451
and	O	452-455
renal	B	456-461
cancer	I	462-468
is	O	469-471
under	O	472-477
investigation	O	478-491
.	O	491-492

Because	O	493-500
sirolimus	O	501-510
does	O	511-515
not	O	516-519
share	O	520-525
the	O	526-529
vasomotor	O	530-539
renal	O	540-545
adverse	O	546-553
effects	O	554-561
exhibited	O	562-571
by	O	572-574
calcineurin	O	575-586
inhibitors	O	587-597
,	O	597-598
it	O	599-601
has	O	602-605
been	O	606-610
designated	O	611-621
a	O	622-623
'	O	624-625
non	O	625-628
-	O	628-629
nephrotoxic	B	629-640
drug	O	641-645
'	O	645-646
.	O	646-647

However	O	648-655
,	O	655-656
clinical	O	657-665
reports	O	666-673
suggest	O	674-681
that	O	682-686
,	O	686-687
under	O	688-693
some	O	694-698
circumstances	O	699-712
,	O	712-713
sirolimus	O	714-723
is	O	724-726
associated	O	727-737
with	O	738-742
proteinuria	B	743-754
and	O	755-758
acute	B	759-764
renal	I	765-770
dysfunction	I	771-782
.	O	782-783

A	O	784-785
common	O	786-792
risk	O	793-797
factor	O	798-804
appears	O	805-812
to	O	813-815
be	O	816-818
presence	O	819-827
of	O	828-830
pre	O	831-834
-	O	834-835
existing	O	835-843
chronic	B	844-851
renal	I	852-857
damage	I	858-864
.	O	864-865

The	O	866-869
mechanisms	O	870-880
of	O	881-883
sirolimus	O	884-893
-	O	893-894
associated	O	894-904
proteinuria	B	905-916
are	O	917-920
multifactorial	O	921-935
and	O	936-939
may	O	940-943
be	O	944-946
due	O	947-950
to	O	951-953
an	O	954-956
increase	O	957-965
in	O	966-968
glomerular	O	969-979
capillary	O	980-989
pressure	O	990-998
following	O	999-1008
calcineurin	O	1009-1020
inhibitor	O	1021-1030
withdrawal	O	1031-1041
.	O	1041-1042

It	O	1043-1045
has	O	1046-1049
also	O	1050-1054
been	O	1055-1059
suggested	O	1060-1069
that	O	1070-1074
sirolimus	O	1075-1084
directly	O	1085-1093
causes	O	1094-1100
increased	O	1101-1110
glomerular	O	1111-1121
permeability	O	1122-1134
/	O	1134-1135
injury	O	1135-1141
,	O	1141-1142
but	O	1143-1146
evidence	O	1147-1155
for	O	1156-1159
this	O	1160-1164
mechanism	O	1165-1174
is	O	1175-1177
currently	O	1178-1187
inconclusive	O	1188-1200
.	O	1200-1201

The	O	1202-1205
acute	B	1206-1211
renal	I	1212-1217
dysfunction	I	1218-1229
associated	O	1230-1240
with	O	1241-1245
sirolimus	O	1246-1255
(	O	1256-1257
such	O	1257-1261
as	O	1262-1264
in	O	1265-1267
delayed	O	1268-1275
graft	O	1276-1281
function	O	1282-1290
)	O	1290-1291
may	O	1292-1295
be	O	1296-1298
due	O	1299-1302
to	O	1303-1305
suppression	O	1306-1317
of	O	1318-1320
compensatory	O	1321-1333
renal	O	1334-1339
cell	O	1340-1344
proliferation	O	1345-1358
and	O	1359-1362
survival	O	1363-1371
/	O	1371-1372
repair	O	1372-1378
processes	O	1379-1388
.	O	1388-1389

Although	O	1390-1398
these	O	1399-1404
adverse	O	1405-1412
effects	O	1413-1420
occur	O	1421-1426
in	O	1427-1429
some	O	1430-1434
patients	O	1435-1443
,	O	1443-1444
their	O	1445-1450
occurrence	O	1451-1461
could	O	1462-1467
be	O	1468-1470
minimised	O	1471-1480
by	O	1481-1483
knowledge	O	1484-1493
of	O	1494-1496
the	O	1497-1500
molecular	O	1501-1510
effects	O	1511-1518
of	O	1519-1521
sirolimus	O	1522-1531
on	O	1532-1534
the	O	1535-1538
kidney	O	1539-1545
,	O	1545-1546
the	O	1547-1550
use	O	1551-1554
of	O	1555-1557
sirolimus	O	1558-1567
in	O	1568-1570
appropriate	O	1571-1582
patient	O	1583-1590
populations	O	1591-1602
,	O	1602-1603
close	O	1604-1609
monitoring	O	1610-1620
of	O	1621-1623
proteinuria	B	1624-1635
and	O	1636-1639
renal	O	1640-1645
function	O	1646-1654
,	O	1654-1655
use	O	1656-1659
of	O	1660-1662
angiotensin	O	1663-1674
-	O	1674-1675
converting	O	1675-1685
enzyme	O	1686-1692
inhibitors	O	1693-1703
or	O	1704-1706
angiotensin	O	1707-1718
II	O	1719-1721
receptor	O	1722-1730
blockers	O	1731-1739
if	O	1740-1742
proteinuria	B	1743-1754
occurs	O	1755-1761
and	O	1762-1765
withdrawal	O	1766-1776
if	O	1777-1779
needed	O	1780-1786
.	O	1786-1787

Further	O	1788-1795
long	O	1796-1800
-	O	1800-1801
term	O	1801-1805
analysis	O	1806-1814
of	O	1815-1817
renal	O	1818-1823
allograft	O	1824-1833
studies	O	1834-1841
using	O	1842-1847
sirolimus	O	1848-1857
as	O	1858-1860
de	O	1861-1863
novo	O	1864-1868
immunosuppression	O	1869-1886
along	O	1887-1892
with	O	1893-1897
clinical	O	1898-1906
and	O	1907-1910
laboratory	O	1911-1921
studies	O	1922-1929
will	O	1930-1934
refine	O	1935-1941
these	O	1942-1947
issues	O	1948-1954
in	O	1955-1957
the	O	1958-1961
future	O	1962-1968
.	O	1968-1969

Progressive	O	0-11
myopathy	B	12-20
with	O	21-25
up	O	26-28
-	O	28-29
regulation	O	29-39
of	O	40-42
MHC	O	43-46
-	O	46-47
I	O	47-48
associated	O	49-59
with	O	60-64
statin	O	65-71
therapy	O	72-79
.	O	79-80

Statins	O	81-88
can	O	89-92
cause	O	93-98
a	O	99-100
necrotizing	O	101-112
myopathy	B	113-121
and	O	122-125
hyperCKaemia	B	126-138
which	O	139-144
is	O	145-147
reversible	O	148-158
on	O	159-161
cessation	O	162-171
of	O	172-174
the	O	175-178
drug	O	179-183
.	O	183-184

What	O	185-189
is	O	190-192
less	O	193-197
well	O	198-202
known	O	203-208
is	O	209-211
a	O	212-213
phenomenon	O	214-224
whereby	O	225-232
statins	O	233-240
may	O	241-244
induce	O	245-251
a	O	252-253
myopathy	B	254-262
,	O	262-263
which	O	264-269
persists	O	270-278
or	O	279-281
may	O	282-285
progress	O	286-294
after	O	295-300
stopping	O	301-309
the	O	310-313
drug	O	314-318
.	O	318-319

We	O	320-322
investigated	O	323-335
the	O	336-339
muscle	O	340-346
pathology	O	347-356
in	O	357-359
8	O	360-361
such	O	362-366
cases	O	367-372
.	O	372-373

All	O	374-377
had	O	378-381
myofibre	O	382-390
necrosis	B	391-399
but	O	400-403
only	O	404-408
3	O	409-410
had	O	411-414
an	O	415-417
inflammatory	O	418-430
infiltrate	O	431-441
.	O	441-442

In	O	443-445
all	O	446-449
cases	O	450-455
there	O	456-461
was	O	462-465
diffuse	O	466-473
or	O	474-476
multifocal	O	477-487
up	O	488-490
-	O	490-491
regulation	O	491-501
of	O	502-504
MHC	O	505-508
-	O	508-509
I	O	509-510
expression	O	511-521
even	O	522-526
in	O	527-529
non	O	530-533
-	O	533-534
necrotic	B	534-542
fibres	O	543-549
.	O	549-550

Progressive	O	551-562
improvement	O	563-574
occurred	O	575-583
in	O	584-586
7	O	587-588
cases	O	589-594
after	O	595-600
commencement	O	601-613
of	O	614-616
prednisolone	O	617-629
and	O	630-633
methotrexate	O	634-646
,	O	646-647
and	O	648-651
in	O	652-654
one	O	655-658
case	O	659-663
spontaneously	O	664-677
.	O	677-678

These	O	679-684
observations	O	685-697
suggest	O	698-705
that	O	706-710
statins	O	711-718
may	O	719-722
initiate	O	723-731
an	O	732-734
immune	O	735-741
-	O	741-742
mediated	O	742-750
myopathy	B	751-759
that	O	760-764
persists	O	765-773
after	O	774-779
withdrawal	O	780-790
of	O	791-793
the	O	794-797
drug	O	798-802
and	O	803-806
responds	O	807-815
to	O	816-818
immunosuppressive	O	819-836
therapy	O	837-844
.	O	844-845

The	O	846-849
mechanism	O	850-859
of	O	860-862
this	O	863-867
myopathy	B	868-876
is	O	877-879
uncertain	O	880-889
but	O	890-893
may	O	894-897
involve	O	898-905
the	O	906-909
induction	O	910-919
by	O	920-922
statins	O	923-930
of	O	931-933
an	O	934-936
endoplasmic	O	937-948
reticulum	O	949-958
stress	O	959-965
response	O	966-974
with	O	975-979
associated	O	980-990
up	O	991-993
-	O	993-994
regulation	O	994-1004
of	O	1005-1007
MHC	O	1008-1011
-	O	1011-1012
I	O	1012-1013
expression	O	1014-1024
and	O	1025-1028
antigen	O	1029-1036
presentation	O	1037-1049
by	O	1050-1052
muscle	O	1053-1059
fibres	O	1060-1066
.	O	1066-1067

Direct	O	0-6
inhibition	O	7-17
of	O	18-20
cardiac	O	21-28
hyperpolarization	O	29-46
-	O	46-47
activated	O	47-56
cyclic	O	57-63
nucleotide	O	64-74
-	O	74-75
gated	O	75-80
pacemaker	O	81-90
channels	O	91-99
by	O	100-102
clonidine	O	103-112
.	O	112-113

BACKGROUND	O	114-124
:	O	124-125
Inhibition	O	126-136
of	O	137-139
cardiac	O	140-147
sympathetic	O	148-159
tone	O	160-164
represents	O	165-175
an	O	176-178
important	O	179-188
strategy	O	189-197
for	O	198-201
treatment	O	202-211
of	O	212-214
cardiovascular	B	215-229
disease	I	230-237
,	O	237-238
including	O	239-248
arrhythmia	B	249-259
,	O	259-260
coronary	B	261-269
heart	I	270-275
disease	I	276-283
,	O	283-284
and	O	285-288
chronic	O	289-296
heart	B	297-302
failure	I	303-310
.	O	310-311

Activation	O	312-322
of	O	323-325
presynaptic	O	326-337
alpha2	O	338-344
-	O	344-345
adrenoceptors	O	345-358
is	O	359-361
the	O	362-365
most	O	366-370
widely	O	371-377
accepted	O	378-386
mechanism	O	387-396
of	O	397-399
action	O	400-406
of	O	407-409
the	O	410-413
antisympathetic	O	414-429
drug	O	430-434
clonidine	O	435-444
;	O	444-445
however	O	446-453
,	O	453-454
other	O	455-460
target	O	461-467
proteins	O	468-476
have	O	477-481
been	O	482-486
postulated	O	487-497
to	O	498-500
contribute	O	501-511
to	O	512-514
the	O	515-518
in	O	519-521
vivo	O	522-526
actions	O	527-534
of	O	535-537
clonidine	O	538-547
.	O	547-548

METHODS	O	549-556
AND	O	557-560
RESULTS	O	561-568
:	O	568-569
To	O	570-572
test	O	573-577
whether	O	578-585
clonidine	O	586-595
elicits	O	596-603
pharmacological	O	604-619
effects	O	620-627
independent	O	628-639
of	O	640-642
alpha2	O	643-649
-	O	649-650
adrenoceptors	O	650-663
,	O	663-664
we	O	665-667
have	O	668-672
generated	O	673-682
mice	O	683-687
with	O	688-692
a	O	693-694
targeted	O	695-703
deletion	O	704-712
of	O	713-715
all	O	716-719
3	O	720-721
alpha2	O	722-728
-	O	728-729
adrenoceptor	O	729-741
subtypes	O	742-750
(	O	751-752
alpha2ABC	O	752-761
-	O	761-762
/	O	762-763
-	O	761-762
)	O	764-765
.	O	765-766

Alpha2ABC	O	767-776
-	O	776-777
/	O	777-778
-	O	776-777
mice	O	780-784
were	O	785-789
completely	O	790-800
unresponsive	O	801-813
to	O	814-816
the	O	817-820
analgesic	O	821-830
and	O	831-834
hypnotic	O	835-843
effects	O	844-851
of	O	852-854
clonidine	O	855-864
;	O	864-865
however	O	866-873
,	O	873-874
clonidine	O	875-884
significantly	O	885-898
lowered	O	899-906
heart	O	907-912
rate	O	913-917
in	O	918-920
alpha2ABC	O	921-930
-	O	930-931
/	O	931-932
-	O	930-931
mice	O	934-938
by	O	939-941
up	O	942-944
to	O	945-947
150	O	948-951
bpm	O	952-955
.	O	955-956

Clonidine	O	957-966
-	O	966-967
induced	O	967-974
bradycardia	B	975-986
in	O	987-989
conscious	O	990-999
alpha2ABC	O	1000-1009
-	O	1009-1010
/	O	1010-1011
-	O	1009-1010
mice	O	1013-1017
was	O	1018-1021
32	O	1022-1024
.	O	1024-1025
3	O	1022-1023
%	O	1026-1027
(	O	1028-1029
10	O	1029-1031
microg	O	1032-1038
/	O	1038-1039
kg	O	1039-1041
)	O	1041-1042
and	O	1043-1046
26	O	1047-1049
.	O	1049-1050
6	O	1048-1049
%	O	1051-1052
(	O	1053-1054
100	O	1054-1057
microg	O	1058-1064
/	O	1064-1065
kg	O	1065-1067
)	O	1067-1068
of	O	1069-1071
the	O	1072-1075
effect	O	1076-1082
in	O	1083-1085
wild	O	1086-1090
-	O	1090-1091
type	O	1091-1095
mice	O	1096-1100
.	O	1100-1101

A	O	1102-1103
similar	O	1104-1111
bradycardic	O	1112-1123
effect	O	1124-1130
of	O	1131-1133
clonidine	O	1134-1143
was	O	1144-1147
observed	O	1148-1156
in	O	1157-1159
isolated	O	1160-1168
spontaneously	O	1169-1182
beating	O	1183-1190
right	O	1191-1196
atria	O	1197-1202
from	O	1203-1207
alpha2ABC	O	1208-1217
-	O	1217-1218
knockout	O	1218-1226
and	O	1227-1230
wild	O	1231-1235
-	O	1235-1236
type	O	1236-1240
mice	O	1241-1245
.	O	1245-1246

Clonidine	O	1247-1256
inhibited	O	1257-1266
the	O	1267-1270
native	O	1271-1277
pacemaker	O	1278-1287
current	O	1288-1295
(	O	1296-1297
I	O	1297-1298
(	O	1296-1297
f	O	1299-1300
)	O	1300-1301
)	O	1300-1301
in	O	1303-1305
isolated	O	1306-1314
sinoatrial	O	1315-1325
node	O	1326-1330
pacemaker	O	1331-1340
cells	O	1341-1346
and	O	1347-1350
the	O	1351-1354
I	O	1355-1356
(	O	1356-1357
f	O	1357-1358
)	O	1358-1359
-	O	1359-1360
generating	O	1360-1370
hyperpolarization	O	1371-1388
-	O	1388-1389
activated	O	1389-1398
cyclic	O	1399-1405
nucleotide	O	1406-1416
-	O	1416-1417
gated	O	1417-1422
(	O	1423-1424
HCN	O	1424-1427
)	O	1427-1428
2	O	1429-1430
and	O	1431-1434
HCN4	O	1435-1439
channels	O	1440-1448
in	O	1449-1451
transfected	O	1452-1463
HEK293	O	1464-1470
cells	O	1471-1476
.	O	1476-1477

As	O	1478-1480
a	O	1481-1482
consequence	O	1483-1494
of	O	1495-1497
blocking	O	1498-1506
I	O	1507-1508
(	O	1508-1509
f	O	1509-1510
)	O	1510-1511
,	O	1511-1512
clonidine	O	1513-1522
reduced	O	1523-1530
the	O	1531-1534
slope	O	1535-1540
of	O	1541-1543
the	O	1544-1547
diastolic	O	1548-1557
depolarization	O	1558-1572
and	O	1573-1576
the	O	1577-1580
frequency	O	1581-1590
of	O	1591-1593
pacemaker	O	1594-1603
potentials	O	1604-1614
in	O	1615-1617
sinoatrial	O	1618-1628
node	O	1629-1633
cells	O	1634-1639
from	O	1640-1644
wild	O	1645-1649
-	O	1649-1650
type	O	1650-1654
and	O	1655-1658
alpha2ABC	O	1659-1668
-	O	1668-1669
knockout	O	1669-1677
mice	O	1678-1682
.	O	1682-1683

CONCLUSIONS	O	1684-1695
:	O	1695-1696
Direct	O	1697-1703
inhibition	O	1704-1714
of	O	1715-1717
cardiac	O	1718-1725
HCN	O	1726-1729
pacemaker	O	1730-1739
channels	O	1740-1748
contributes	O	1749-1760
to	O	1761-1763
the	O	1764-1767
bradycardic	O	1768-1779
effects	O	1780-1787
of	O	1788-1790
clonidine	O	1791-1800
gene	O	1801-1805
-	O	1805-1806
targeted	O	1806-1814
mice	O	1815-1819
in	O	1820-1822
vivo	O	1823-1827
,	O	1827-1828
and	O	1829-1832
thus	O	1833-1837
,	O	1837-1838
clonidine	O	1839-1848
-	O	1848-1849
like	O	1849-1853
drugs	O	1854-1859
represent	O	1860-1869
novel	O	1870-1875
structures	O	1876-1886
for	O	1887-1890
future	O	1891-1897
HCN	O	1898-1901
channel	O	1902-1909
inhibitors	O	1910-1920
.	O	1920-1921

Influence	O	0-9
of	O	10-12
smoking	O	13-20
on	O	21-23
developing	O	24-34
cochlea	O	35-42
.	O	42-43

Does	O	44-48
smoking	O	49-56
during	O	57-63
pregnancy	O	64-73
affect	O	74-80
the	O	81-84
amplitudes	O	85-95
of	O	96-98
transient	O	99-108
evoked	O	109-115
otoacoustic	O	116-127
emissions	O	128-137
in	O	138-140
newborns	O	141-149
?	O	149-150

OBJECTIVE	O	151-160
:	O	160-161
Maternal	O	162-170
tobacco	O	171-178
smoking	O	179-186
has	O	187-190
negative	O	191-199
effects	O	200-207
on	O	208-210
fetal	O	211-216
growth	O	217-223
.	O	223-224

The	O	225-228
influence	O	229-238
of	O	239-241
smoking	O	242-249
during	O	250-256
pregnancy	O	257-266
on	O	267-269
the	O	270-273
developing	O	274-284
cochlea	O	285-292
has	O	293-296
not	O	297-300
been	O	301-305
estimated	O	306-315
,	O	315-316
although	O	317-325
smoking	O	326-333
has	O	334-337
been	O	338-342
positively	O	343-353
associated	O	354-364
with	O	365-369
hearing	B	370-377
loss	I	378-382
in	O	383-385
adults	O	386-392
.	O	392-393

The	O	394-397
objective	O	398-407
of	O	408-410
this	O	411-415
study	O	416-421
was	O	422-425
to	O	426-428
determine	O	429-438
the	O	439-442
effects	O	443-450
of	O	451-453
maternal	O	454-462
smoking	O	463-470
on	O	471-473
transient	O	474-483
evoked	O	484-490
otoacoustic	O	491-502
emissions	O	503-512
(	O	513-514
TEOAEs	O	514-520
)	O	520-521
of	O	522-524
healthy	O	525-532
neonates	O	533-541
.	O	541-542

METHODS	O	543-550
:	O	550-551
This	O	552-556
study	O	557-562
was	O	563-566
undertaken	O	567-577
as	O	578-580
part	O	581-585
of	O	586-588
neonatal	O	589-597
screening	O	598-607
for	O	608-611
hearing	B	612-619
impairment	I	620-630
and	O	631-634
involved	O	635-643
both	O	644-648
ears	O	649-653
of	O	654-656
200	O	657-660
newborns	O	661-669
.	O	669-670

Newborns	O	671-679
whose	O	680-685
mothers	O	686-693
reported	O	694-702
smoking	O	703-710
during	O	711-717
pregnancy	O	718-727
(	O	728-729
n	O	729-730
=	O	730-731
200	O	731-734
ears	O	735-739
)	O	739-740
were	O	741-745
compared	O	746-754
to	O	755-757
a	O	758-759
control	O	760-767
group	O	768-773
of	O	774-776
newborns	O	777-785
(	O	786-787
n	O	787-788
=	O	788-789
200	O	789-792
ears	O	793-797
)	O	797-798
,	O	798-799
whose	O	800-805
mothers	O	806-813
were	O	814-818
non	O	819-822
-	O	822-823
smokers	O	823-830
.	O	830-831

Exposure	O	832-840
to	O	841-843
tobacco	O	844-851
was	O	852-855
characterized	O	856-869
as	O	870-872
low	O	873-876
(	O	877-878
<	O	878-879
5	O	879-880
cigarettes	O	881-891
per	O	892-895
day	O	896-899
,	O	899-900
n	O	901-902
=	O	902-903
88	O	903-905
ears	O	906-910
)	O	910-911
,	O	911-912
moderate	O	913-921
(	O	922-923
5	O	923-924
<	O	924-925
or	O	926-928
=	O	929-930
cigarettes	O	930-940
per	O	941-944
day	O	945-948
<	O	948-949
10	O	949-951
,	O	951-952
n	O	953-954
=	O	954-955
76	O	955-957
)	O	957-958
or	O	959-961
high	O	962-966
(	O	967-968
>	O	968-969
or	O	970-972
=	O	973-974
10	O	974-976
cigarettes	O	977-987
per	O	988-991
day	O	992-995
,	O	995-996
n	O	997-998
=	O	998-999
36	O	999-1001
)	O	1001-1002
.	O	1002-1003

RESULTS	O	1004-1011
:	O	1011-1012
In	O	1013-1015
exposed	O	1016-1023
neonates	O	1024-1032
,	O	1032-1033
TEOAEs	O	1034-1040
mean	O	1041-1045
response	O	1046-1054
(	O	1055-1056
across	O	1056-1062
frequency	O	1063-1072
)	O	1072-1073
and	O	1074-1077
mean	O	1078-1082
amplitude	O	1083-1092
at	O	1093-1095
4000Hz	O	1096-1102
was	O	1103-1106
significantly	O	1107-1120
lower	O	1121-1126
than	O	1127-1131
in	O	1132-1134
non	O	1135-1138
-	O	1138-1139
exposed	O	1139-1146
neonates	O	1147-1155
.	O	1155-1156

Comparisons	O	1157-1168
between	O	1169-1176
exposed	O	1177-1184
newborns	O	1185-1193
'	O	1193-1194
subgroups	O	1195-1204
revealed	O	1205-1213
no	O	1214-1216
significant	O	1217-1228
differences	O	1229-1240
.	O	1240-1241

However	O	1242-1249
,	O	1249-1250
by	O	1251-1253
comparing	O	1254-1263
each	O	1264-1268
subgroup	O	1269-1277
to	O	1278-1280
control	O	1281-1288
group	O	1289-1294
,	O	1294-1295
we	O	1296-1298
found	O	1299-1304
statistically	O	1305-1318
significant	O	1319-1330
decreases	B	1331-1340
of	I	1341-1343
TEOAEs	I	1344-1350
amplitudes	I	1351-1361
at	O	1362-1364
4000Hz	O	1365-1371
for	O	1372-1375
all	O	1376-1379
three	O	1380-1385
groups	O	1386-1392
.	O	1392-1393

Mean	O	1394-1398
TEOAEs	O	1399-1405
responses	O	1406-1415
of	O	1416-1418
highly	O	1419-1425
exposed	O	1426-1433
newborns	O	1434-1442
were	O	1443-1447
also	O	1448-1452
significantly	O	1453-1466
lower	O	1467-1472
in	O	1473-1475
comparison	O	1476-1486
to	O	1487-1489
our	O	1490-1493
control	O	1494-1501
group	O	1502-1507
.	O	1507-1508

CONCLUSION	O	1509-1519
:	O	1519-1520
In	O	1521-1523
utero	O	1524-1529
,	O	1529-1530
exposure	O	1531-1539
to	O	1540-1542
tobacco	O	1543-1550
smoking	O	1551-1558
seems	O	1559-1564
to	O	1565-1567
have	O	1568-1572
a	O	1573-1574
small	O	1575-1580
impact	O	1581-1587
on	O	1588-1590
outer	O	1591-1596
hair	O	1597-1601
cells	O	1602-1607
.	O	1607-1608

These	O	1609-1614
effects	O	1615-1622
seem	O	1623-1627
to	O	1628-1630
be	O	1631-1633
equally	O	1634-1641
true	O	1642-1646
for	O	1647-1650
all	O	1651-1654
exposed	O	1655-1662
newborns	O	1663-1671
,	O	1671-1672
regardless	O	1673-1683
of	O	1684-1686
the	O	1687-1690
degree	O	1691-1697
of	O	1698-1700
exposure	O	1701-1709
.	O	1709-1710

Further	O	1711-1718
studies	O	1719-1726
are	O	1727-1730
needed	O	1731-1737
in	O	1738-1740
order	O	1741-1746
to	O	1747-1749
establish	O	1750-1759
a	O	1760-1761
potential	O	1762-1771
negative	O	1772-1780
effect	O	1781-1787
of	O	1788-1790
maternal	O	1791-1799
smoking	O	1800-1807
on	O	1808-1810
the	O	1811-1814
neonate	O	1815-1822
'	O	1822-1823
s	O	1823-1824
hearing	O	1825-1832
acuity	O	1833-1839
.	O	1839-1840

Neuroinflammation	B	0-17
and	O	18-21
behavioral	B	22-32
abnormalities	I	33-46
after	O	47-52
neonatal	O	53-61
terbutaline	O	62-73
treatment	O	74-83
in	O	84-86
rats	O	87-91
:	O	91-92
implications	O	93-105
for	O	106-109
autism	B	110-116
.	O	116-117

Autism	B	118-124
is	O	125-127
a	O	128-129
neurodevelopmental	B	130-148
disorder	I	149-157
presenting	O	158-168
before	O	169-175
3	O	176-177
years	O	178-183
of	O	184-186
age	O	187-190
with	O	191-195
deficits	B	196-204
in	I	205-207
communication	I	208-221
and	I	222-225
social	I	226-232
skills	I	233-239
and	O	240-243
repetitive	B	244-254
behaviors	I	255-264
.	O	264-265

In	O	266-268
addition	O	269-277
to	O	278-280
genetic	O	281-288
influences	O	289-299
,	O	299-300
recent	O	301-307
studies	O	308-315
suggest	O	316-323
that	O	324-328
prenatal	O	329-337
drug	O	338-342
or	O	343-345
chemical	O	346-354
exposures	O	355-364
are	O	365-368
risk	O	369-373
factors	O	374-381
for	O	382-385
autism	B	386-392
.	O	392-393

Terbutaline	O	394-405
,	O	405-406
a	O	407-408
beta2	O	409-414
-	O	414-415
adrenoceptor	O	415-427
agonist	O	428-435
used	O	436-440
to	O	441-443
arrest	O	444-450
preterm	B	451-458
labor	I	459-464
,	O	464-465
has	O	466-469
been	O	470-474
associated	O	475-485
with	O	486-490
increased	O	491-500
concordance	O	501-512
for	O	513-516
autism	B	517-523
in	O	524-526
dizygotic	O	527-536
twins	O	537-542
.	O	542-543

We	O	544-546
studied	O	547-554
the	O	555-558
effects	O	559-566
of	O	567-569
terbutaline	O	570-581
on	O	582-584
microglial	O	585-595
activation	O	596-606
in	O	607-609
different	O	610-619
brain	O	620-625
regions	O	626-633
and	O	634-637
behavioral	O	638-648
outcomes	O	649-657
in	O	658-660
developing	O	661-671
rats	O	672-676
.	O	676-677

Newborn	O	678-685
rats	O	686-690
were	O	691-695
given	O	696-701
terbutaline	O	702-713
(	O	714-715
10	O	715-717
mg	O	718-720
/	O	720-721
kg	O	721-723
)	O	723-724
daily	O	725-730
on	O	731-733
postnatal	O	734-743
days	O	744-748
(	O	749-750
PN	O	750-752
)	O	752-753
2	O	754-755
to	O	756-758
5	O	759-760
or	O	761-763
PN	O	764-766
11	O	767-769
to	O	770-772
14	O	773-775
and	O	776-779
examined	O	780-788
24	O	789-791
h	O	792-793
after	O	794-799
the	O	800-803
last	O	804-808
dose	O	809-813
and	O	814-817
at	O	818-820
PN	O	821-823
30	O	824-826
.	O	826-827

Immunohistochemical	O	828-847
studies	O	848-855
showed	O	856-862
that	O	863-867
administration	O	868-882
of	O	883-885
terbutaline	O	886-897
on	O	898-900
PN	O	901-903
2	O	904-905
to	O	906-908
5	O	909-910
produced	O	911-919
a	O	920-921
robust	O	922-928
increase	O	929-937
in	O	938-940
microglial	O	941-951
activation	O	952-962
on	O	963-965
PN	O	966-968
30	O	969-971
in	O	972-974
the	O	975-978
cerebral	O	979-987
cortex	O	988-994
,	O	994-995
as	O	996-998
well	O	999-1003
as	O	1004-1006
in	O	1007-1009
cerebellar	O	1010-1020
and	O	1021-1024
cerebrocortical	O	1025-1040
white	O	1041-1046
matter	O	1047-1053
.	O	1053-1054

None	O	1055-1059
of	O	1060-1062
these	O	1063-1068
effects	O	1069-1076
occurred	O	1077-1085
in	O	1086-1088
animals	O	1089-1096
given	O	1097-1102
terbutaline	O	1103-1114
on	O	1115-1117
PN	O	1118-1120
11	O	1121-1123
to	O	1124-1126
14	O	1127-1129
.	O	1129-1130

In	O	1131-1133
behavioral	O	1134-1144
tests	O	1145-1150
,	O	1150-1151
animals	O	1152-1159
treated	O	1160-1167
with	O	1168-1172
terbutaline	O	1173-1184
on	O	1185-1187
PN	O	1188-1190
2	O	1191-1192
to	O	1193-1195
5	O	1196-1197
showed	O	1198-1204
consistent	O	1205-1215
patterns	O	1216-1224
of	O	1225-1227
hyper	O	1228-1233
-	O	1233-1234
reactivity	O	1234-1244
to	O	1245-1247
novelty	O	1248-1255
and	O	1256-1259
aversive	O	1260-1268
stimuli	O	1269-1276
when	O	1277-1281
assessed	O	1282-1290
in	O	1291-1293
a	O	1294-1295
novel	O	1296-1301
open	O	1302-1306
field	O	1307-1312
,	O	1312-1313
as	O	1314-1316
well	O	1317-1321
as	O	1322-1324
in	O	1325-1327
the	O	1328-1331
acoustic	O	1332-1340
startle	O	1341-1348
response	O	1349-1357
test	O	1358-1362
.	O	1362-1363

Our	O	1364-1367
findings	O	1368-1376
indicate	O	1377-1385
that	O	1386-1390
beta2	O	1391-1396
-	O	1396-1397
adrenoceptor	O	1397-1409
overstimulation	O	1410-1425
during	O	1426-1432
an	O	1433-1435
early	O	1436-1441
critical	O	1442-1450
period	O	1451-1457
results	O	1458-1465
in	O	1466-1468
microglial	O	1469-1479
activation	O	1480-1490
associated	O	1491-1501
with	O	1502-1506
innate	O	1507-1513
neuroinflammatory	O	1514-1531
pathways	O	1532-1540
and	O	1541-1544
behavioral	B	1545-1555
abnormalities	I	1556-1569
,	O	1569-1570
similar	O	1571-1578
to	O	1579-1581
those	O	1582-1587
described	O	1588-1597
in	O	1598-1600
autism	B	1601-1607
.	O	1607-1608

This	O	1609-1613
study	O	1614-1619
provides	O	1620-1628
a	O	1629-1630
useful	O	1631-1637
animal	O	1638-1644
model	O	1645-1650
for	O	1651-1654
understanding	O	1655-1668
the	O	1669-1672
neuropathological	O	1673-1690
processes	O	1691-1700
underlying	O	1701-1711
autism	B	1712-1718
spectrum	I	1719-1727
disorders	I	1728-1737
.	O	1737-1738

Acute	O	0-5
myocarditis	B	6-17
associated	O	18-28
with	O	29-33
clozapine	O	34-43
.	O	43-44

OBJECTIVE	O	45-54
:	O	54-55
A	O	56-57
case	O	58-62
of	O	63-65
acute	O	66-71
myocarditis	B	72-83
associated	O	84-94
with	O	95-99
the	O	100-103
commencement	O	104-116
of	O	117-119
clozapine	O	120-129
is	O	130-132
described	O	133-142
,	O	142-143
highlighting	O	144-156
the	O	157-160
onset	O	161-166
,	O	166-167
course	O	168-174
and	O	175-178
possible	O	179-187
contributing	O	188-200
factors	O	201-208
.	O	208-209

There	O	210-215
is	O	216-218
an	O	219-221
urgent	O	222-228
need	O	229-233
to	O	234-236
raise	O	237-242
awareness	O	243-252
about	O	253-258
this	O	259-263
potentially	O	264-275
fatal	O	276-281
complication	O	282-294
of	O	295-297
clozapine	O	298-307
use	O	308-311
.	O	311-312

RESULTS	O	313-320
:	O	320-321
A	O	322-323
20	O	324-326
-	O	326-327
year	O	327-331
-	O	326-327
old	O	332-335
male	O	336-340
with	O	341-345
schizophrenia	B	346-359
developed	O	360-369
a	O	370-371
sudden	O	372-378
onset	O	379-384
of	O	385-387
myocarditis	B	388-399
after	O	400-405
commencement	O	406-418
of	O	419-421
clozapine	O	422-431
.	O	431-432

The	O	433-436
patient	O	437-444
recovered	O	445-454
with	O	455-459
intensive	O	460-469
medical	O	470-477
support	O	478-485
.	O	485-486

The	O	487-490
symptoms	O	491-499
occurred	O	500-508
around	O	509-515
2	O	516-517
weeks	O	518-523
after	O	524-529
starting	O	530-538
clozapine	O	539-548
in	O	549-551
an	O	552-554
inpatient	O	555-564
setting	O	565-572
.	O	572-573

Possible	O	574-582
contributing	O	583-595
factors	O	596-603
may	O	604-607
have	O	608-612
been	O	613-617
concomitant	O	618-629
antidepressant	O	630-644
use	O	645-648
and	O	649-652
unaccustomed	O	653-665
physical	O	666-674
activity	O	675-683
.	O	683-684

CONCLUSIONS	O	685-696
:	O	696-697
Myocarditis	B	698-709
is	O	710-712
an	O	713-715
increasingly	O	716-728
recognized	O	729-739
complication	O	740-752
associated	O	753-763
with	O	764-768
the	O	769-772
use	O	773-776
of	O	777-779
clozapine	O	780-789
.	O	789-790

It	O	791-793
can	O	794-797
be	O	798-800
fatal	O	801-806
if	O	807-809
not	O	810-813
recognized	O	814-824
and	O	825-828
treated	O	829-836
early	O	837-842
.	O	842-843

Considering	O	844-855
that	O	856-860
clozapine	O	861-870
remains	O	871-878
the	O	879-882
gold	O	883-887
standard	O	888-896
in	O	897-899
treatment	O	900-909
of	O	910-912
resistant	O	913-922
psychosis	B	923-932
,	O	932-933
there	O	934-939
is	O	940-942
an	O	943-945
urgent	O	946-952
need	O	953-957
to	O	958-960
raise	O	961-966
awareness	O	967-976
among	O	977-982
medical	O	983-990
and	O	991-994
paramedical	O	995-1006
staff	O	1007-1012
involved	O	1013-1021
in	O	1022-1024
the	O	1025-1028
care	O	1029-1033
of	O	1034-1036
these	O	1037-1042
patients	O	1043-1051
.	O	1051-1052

There	O	1053-1058
are	O	1059-1062
also	O	1063-1067
implications	O	1068-1080
for	O	1081-1084
recommendations	O	1085-1100
and	O	1101-1104
regulations	O	1105-1116
regarding	O	1117-1126
the	O	1127-1130
use	O	1131-1134
of	O	1135-1137
clozapine	O	1138-1147
.	O	1147-1148

Encephalopathy	B	0-14
induced	O	15-22
by	O	23-25
levetiracetam	O	26-39
added	O	40-45
to	O	46-48
valproate	O	49-58
.	O	58-59

BACKGROUND	O	60-70
:	O	70-71
We	O	72-74
report	O	75-81
on	O	82-84
the	O	85-88
manifestation	O	89-102
of	O	103-105
a	O	106-107
levetiracetam	O	108-121
(	O	122-123
LEV	O	123-126
)	O	126-127
-	O	127-128
induced	O	128-135
encephalopathy	B	136-150
.	O	150-151

FINDINGS	O	152-160
:	O	160-161
A	O	162-163
28	O	164-166
-	O	166-167
year	O	167-171
-	O	166-167
old	O	172-175
man	O	176-179
suffering	O	180-189
from	O	190-194
idiopathic	B	195-205
epilepsy	I	206-214
with	O	215-219
generalized	O	220-231
seizures	B	232-240
was	O	241-244
treated	O	245-252
with	O	253-257
LEV	O	258-261
(	O	262-263
3000	O	263-267
mg	O	268-270
)	O	270-271
added	O	272-277
to	O	278-280
valproate	O	281-290
(	O	291-292
VPA	O	292-295
)	O	295-296
(	O	297-298
2000	O	298-302
mg	O	303-305
)	O	305-306
.	O	306-307

Frequency	O	308-317
of	O	318-320
generalized	O	321-332
tonic	B	333-338
-	I	338-339
clonic	I	339-345
seizures	I	346-354
increased	O	355-364
from	O	365-369
one	O	370-373
per	O	374-377
6	O	378-379
months	O	380-386
to	O	387-389
two	O	390-393
per	O	394-397
month	O	398-403
.	O	403-404

Neuropsychological	O	405-423
testing	O	424-431
showed	O	432-438
impaired	B	439-447
word	I	448-452
fluency	I	453-460
,	I	460-461
psychomotor	I	462-473
speed	I	474-479
and	I	480-483
working	I	484-491
memory	I	492-498
.	O	498-499

The	O	500-503
interictal	O	504-514
electroencephalogram	O	515-535
(	O	536-537
EEG	O	537-540
)	O	540-541
showed	O	542-548
a	O	549-550
generalized	O	551-562
slowing	O	563-570
to	O	571-573
5	O	574-575
per	O	576-579
second	O	580-586
theta	O	587-592
rhythms	O	593-600
with	O	601-605
bilateral	O	606-615
generalized	O	616-627
high	O	628-632
-	O	632-633
amplitude	O	633-642
discharges	O	643-653
.	O	653-654

OUTCOME	O	655-662
:	O	662-663
Following	O	664-673
discontinuation	O	674-689
of	O	690-692
LEV	O	693-696
,	O	696-697
EEG	O	698-701
and	O	702-705
neuropsychological	O	706-724
findings	O	725-733
improved	O	734-742
and	O	743-746
seizure	B	747-754
frequency	O	755-764
decreased	O	765-774
.	O	774-775

Norepinephrine	O	0-14
signaling	O	15-24
through	O	25-32
beta	O	33-37
-	O	37-38
adrenergic	O	38-48
receptors	O	49-58
is	O	59-61
critical	O	62-70
for	O	71-74
expression	O	75-85
of	O	86-88
cocaine	O	89-96
-	O	96-97
induced	O	97-104
anxiety	B	105-112
.	O	112-113

BACKGROUND	O	114-124
:	O	124-125
Cocaine	O	126-133
is	O	134-136
a	O	137-138
widely	O	139-145
abused	O	146-152
psychostimulant	O	153-168
that	O	169-173
has	O	174-177
both	O	178-182
rewarding	O	183-192
and	O	193-196
aversive	O	197-205
properties	O	206-216
.	O	216-217

While	O	218-223
the	O	224-227
mechanisms	O	228-238
underlying	O	239-249
cocaine	O	250-257
'	O	257-258
s	O	258-259
rewarding	O	260-269
effects	O	270-277
have	O	278-282
been	O	283-287
studied	O	288-295
extensively	O	296-307
,	O	307-308
less	O	309-313
attention	O	314-323
has	O	324-327
been	O	328-332
paid	O	333-337
to	O	338-340
the	O	341-344
unpleasant	O	345-355
behavioral	O	356-366
states	O	367-373
induced	O	374-381
by	O	382-384
cocaine	O	385-392
,	O	392-393
such	O	394-398
as	O	399-401
anxiety	B	402-409
.	O	409-410

METHODS	O	411-418
:	O	418-419
In	O	420-422
this	O	423-427
study	O	428-433
,	O	433-434
we	O	435-437
evaluated	O	438-447
the	O	448-451
performance	O	452-463
of	O	464-466
dopamine	O	467-475
beta	O	476-480
-	O	480-481
hydroxylase	O	481-492
knockout	O	493-501
(	O	502-503
Dbh	O	503-506
-	O	507-508
/	O	508-509
-	O	507-508
)	O	510-511
mice	O	512-516
,	O	516-517
which	O	518-523
lack	O	524-528
norepinephrine	O	529-543
(	O	544-545
NE	O	545-547
)	O	547-548
,	O	548-549
in	O	550-552
the	O	553-556
elevated	O	557-565
plus	O	566-570
maze	O	571-575
(	O	576-577
EPM	O	577-580
)	O	580-581
to	O	582-584
examine	O	585-592
the	O	593-596
contribution	O	597-609
of	O	610-612
noradrenergic	O	613-626
signaling	O	627-636
to	O	637-639
cocaine	O	640-647
-	O	647-648
induced	O	648-655
anxiety	B	656-663
.	O	663-664

RESULTS	O	665-672
:	O	672-673
We	O	674-676
found	O	677-682
that	O	683-687
cocaine	O	688-695
dose	O	696-700
-	O	700-701
dependently	O	701-712
increased	O	713-722
anxiety	B	723-730
-	O	730-731
like	O	731-735
behavior	O	736-744
in	O	745-747
control	O	748-755
(	O	756-757
Dbh	O	757-760
+	O	761-762
/	O	762-763
-	O	763-764
)	O	764-765
mice	O	766-770
,	O	770-771
as	O	772-774
measured	O	775-783
by	O	784-786
a	O	787-788
decrease	O	789-797
in	O	798-800
open	O	801-805
arm	O	806-809
exploration	O	810-821
.	O	821-822

The	O	823-826
Dbh	O	827-830
-	O	831-832
/	O	832-833
-	O	831-832
mice	O	835-839
had	O	840-843
normal	O	844-850
baseline	O	851-859
performance	O	860-871
in	O	872-874
the	O	875-878
EPM	O	879-882
but	O	883-886
were	O	887-891
completely	O	892-902
resistant	O	903-912
to	O	913-915
the	O	916-919
anxiogenic	O	920-930
effects	O	931-938
of	O	939-941
cocaine	O	942-949
.	O	949-950

Cocaine	O	951-958
-	O	958-959
induced	O	959-966
anxiety	B	967-974
was	O	975-978
also	O	979-983
attenuated	O	984-994
in	O	995-997
Dbh	O	998-1001
+	O	1002-1003
/	O	1003-1004
-	O	1004-1005
mice	O	1006-1010
following	O	1011-1020
administration	O	1021-1035
of	O	1036-1038
disulfiram	O	1039-1049
,	O	1049-1050
a	O	1051-1052
dopamine	O	1053-1061
beta	O	1062-1066
-	O	1066-1067
hydroxylase	O	1067-1078
(	O	1079-1080
DBH	O	1080-1083
)	O	1083-1084
inhibitor	O	1085-1094
.	O	1094-1095

In	O	1096-1098
experiments	O	1099-1110
using	O	1111-1116
specific	O	1117-1125
adrenergic	O	1126-1136
antagonists	O	1137-1148
,	O	1148-1149
we	O	1150-1152
found	O	1153-1158
that	O	1159-1163
pretreatment	O	1164-1176
with	O	1177-1181
the	O	1182-1185
beta	O	1186-1190
-	O	1190-1191
adrenergic	O	1191-1201
receptor	O	1202-1210
antagonist	O	1211-1221
propranolol	O	1222-1233
blocked	O	1234-1241
cocaine	O	1242-1249
-	O	1249-1250
induced	O	1250-1257
anxiety	B	1258-1265
-	O	1265-1266
like	O	1266-1270
behavior	O	1271-1279
in	O	1280-1282
Dbh	O	1283-1286
+	O	1287-1288
/	O	1288-1289
-	O	1289-1290
and	O	1291-1294
wild	O	1295-1299
-	O	1299-1300
type	O	1300-1304
C57BL6	O	1305-1311
/	O	1311-1312
J	O	1312-1313
mice	O	1314-1318
,	O	1318-1319
while	O	1320-1325
the	O	1326-1329
alpha	O	1330-1335
(	O	1335-1336
1	O	1336-1337
)	O	1337-1338
antagonist	O	1339-1349
prazosin	O	1350-1358
and	O	1359-1362
the	O	1363-1366
alpha	O	1367-1372
(	O	1372-1373
2	O	1373-1374
)	O	1374-1375
antagonist	O	1376-1386
yohimbine	O	1387-1396
had	O	1397-1400
no	O	1401-1403
effect	O	1404-1410
.	O	1410-1411

CONCLUSIONS	O	1412-1423
:	O	1423-1424
These	O	1425-1430
results	O	1431-1438
indicate	O	1439-1447
that	O	1448-1452
noradrenergic	O	1453-1466
signaling	O	1467-1476
via	O	1477-1480
beta	O	1481-1485
-	O	1485-1486
adrenergic	O	1486-1496
receptors	O	1497-1506
is	O	1507-1509
required	O	1510-1518
for	O	1519-1522
cocaine	O	1523-1530
-	O	1530-1531
induced	O	1531-1538
anxiety	B	1539-1546
in	O	1547-1549
mice	O	1550-1554
.	O	1554-1555

Clonidine	O	0-9
for	O	10-13
attention	B	14-23
-	I	23-24
deficit	I	24-31
/	I	31-32
hyperactivity	I	32-45
disorder	I	46-54
:	O	54-55
II	O	56-58
.	O	58-59

ECG	O	60-63
changes	O	64-71
and	O	72-75
adverse	O	76-83
events	O	84-90
analysis	O	91-99
.	O	99-100

OBJECTIVE	O	101-110
:	O	110-111
To	O	112-114
examine	O	115-122
the	O	123-126
safety	O	127-133
and	O	134-137
tolerability	O	138-150
of	O	151-153
clonidine	O	154-163
used	O	164-168
alone	O	169-174
or	O	175-177
with	O	178-182
methylphenidate	O	183-198
in	O	199-201
children	O	202-210
with	O	211-215
attention	B	216-225
-	I	225-226
deficit	I	226-233
/	I	233-234
hyperactivity	I	234-247
disorder	I	248-256
(	O	257-258
ADHD	B	258-262
)	O	262-263
.	O	263-264

METHOD	O	265-271
:	O	271-272
In	O	273-275
a	O	276-277
16	O	278-280
-	O	280-281
week	O	281-285
multicenter	O	286-297
,	O	297-298
double	O	299-305
-	O	305-306
blind	O	306-311
trial	O	312-317
,	O	317-318
122	O	319-322
children	O	323-331
with	O	332-336
ADHD	B	337-341
were	O	342-346
randomly	O	347-355
assigned	O	356-364
to	O	365-367
clonidine	O	368-377
(	O	378-379
n	O	379-380
=	O	381-382
31	O	383-385
)	O	385-386
,	O	386-387
methylphenidate	O	388-403
(	O	404-405
n	O	405-406
=	O	407-408
29	O	409-411
)	O	411-412
,	O	412-413
clonidine	O	414-423
and	O	424-427
methylphenidate	O	428-443
(	O	444-445
n	O	445-446
=	O	447-448
32	O	449-451
)	O	451-452
,	O	452-453
or	O	454-456
placebo	O	457-464
(	O	465-466
n	O	466-467
=	O	468-469
30	O	470-472
)	O	472-473
.	O	473-474

Doses	O	475-480
were	O	481-485
flexibly	O	486-494
titrated	O	495-503
up	O	504-506
to	O	507-509
0	O	510-511
.	O	511-512
6	O	512-513
mg	O	514-516
/	O	516-517
day	O	517-520
for	O	521-524
clonidine	O	525-534
and	O	535-538
60	O	539-541
mg	O	542-544
/	O	544-545
day	O	545-548
for	O	549-552
methylphenidate	O	553-568
(	O	569-570
both	O	570-574
with	O	575-579
divided	O	580-587
dosing	O	588-594
)	O	594-595
.	O	595-596

Groups	O	597-603
were	O	604-608
compared	O	609-617
regarding	O	618-627
adverse	O	628-635
events	O	636-642
and	O	643-646
changes	O	647-654
from	O	655-659
baseline	O	660-668
to	O	669-671
week	O	672-676
16	O	677-679
in	O	680-682
electrocardiograms	O	683-701
and	O	702-705
vital	O	706-711
signs	O	712-717
.	O	717-718

RESULTS	O	719-726
:	O	726-727
There	O	728-733
were	O	734-738
more	O	739-743
incidents	O	744-753
of	O	754-756
bradycardia	B	757-768
in	O	769-771
subjects	O	772-780
treated	O	781-788
with	O	789-793
clonidine	O	794-803
compared	O	804-812
with	O	813-817
those	O	818-823
not	O	824-827
treated	O	828-835
with	O	836-840
clonidine	O	841-850
(	O	851-852
17	O	852-854
.	O	854-855
5	O	855-856
%	O	856-857
versus	O	858-864
3	O	865-866
.	O	866-867
4	O	867-868
%	O	868-869
;	O	869-870
p	O	871-872
=	O	873-874
.	O	874-875
02	O	875-877
)	O	877-878
,	O	878-879
but	O	880-883
no	O	884-886
other	O	887-892
significant	O	893-904
group	O	905-910
differences	O	911-922
regarding	O	923-932
electrocardiogram	O	933-950
and	O	951-954
other	O	955-960
cardiovascular	O	961-975
outcomes	O	976-984
.	O	984-985

There	O	986-991
were	O	992-996
no	O	997-999
suggestions	O	1000-1011
of	O	1012-1014
interactions	O	1015-1027
between	O	1028-1035
clonidine	O	1036-1045
and	O	1046-1049
methylphenidate	O	1050-1065
regarding	O	1066-1075
cardiovascular	O	1076-1090
outcomes	O	1091-1099
.	O	1099-1100

Moderate	O	1101-1109
or	O	1110-1112
severe	O	1113-1119
adverse	O	1120-1127
events	O	1128-1134
were	O	1135-1139
more	O	1140-1144
common	O	1145-1151
in	O	1152-1154
subjects	O	1155-1163
on	O	1164-1166
clonidine	O	1167-1176
(	O	1177-1178
79	O	1178-1180
.	O	1180-1181
4	O	1181-1182
%	O	1182-1183
versus	O	1184-1190
49	O	1191-1193
.	O	1193-1194
2	O	1194-1195
%	O	1195-1196
;	O	1196-1197
p	O	1198-1199
=	O	1200-1201
.	O	1201-1202
0006	O	1202-1206
)	O	1206-1207
but	O	1208-1211
not	O	1212-1215
associated	O	1216-1226
with	O	1227-1231
higher	O	1232-1238
rates	O	1239-1244
of	O	1245-1247
early	O	1248-1253
study	O	1254-1259
withdrawal	O	1260-1270
.	O	1270-1271

Drowsiness	B	1272-1282
was	O	1283-1286
common	O	1287-1293
on	O	1294-1296
clonidine	O	1297-1306
,	O	1306-1307
but	O	1308-1311
generally	O	1312-1321
resolved	O	1322-1330
by	O	1331-1333
6	O	1334-1335
to	O	1336-1338
8	O	1339-1340
weeks	O	1341-1346
.	O	1346-1347

CONCLUSIONS	O	1348-1359
:	O	1359-1360
Clonidine	O	1361-1370
,	O	1370-1371
used	O	1372-1376
alone	O	1377-1382
or	O	1383-1385
with	O	1386-1390
methylphenidate	O	1391-1406
,	O	1406-1407
appears	O	1408-1415
safe	O	1416-1420
and	O	1421-1424
well	O	1425-1429
tolerated	O	1430-1439
in	O	1440-1442
childhood	O	1443-1452
ADHD	B	1453-1457
.	O	1457-1458

Physicians	O	1459-1469
prescribing	O	1470-1481
clonidine	O	1482-1491
should	O	1492-1498
monitor	O	1499-1506
for	O	1507-1510
bradycardia	B	1511-1522
and	O	1523-1526
advise	O	1527-1533
patients	O	1534-1542
about	O	1543-1548
the	O	1549-1552
high	O	1553-1557
likelihood	O	1558-1568
of	O	1569-1571
initial	O	1572-1579
drowsiness	B	1580-1590
.	O	1590-1591

Thalidomide	O	0-11
has	O	12-15
limited	O	16-23
single	O	24-30
-	O	30-31
agent	O	31-36
activity	O	37-45
in	O	46-48
relapsed	O	49-57
or	O	58-60
refractory	O	61-71
indolent	O	72-80
non	B	81-84
-	I	84-85
Hodgkin	I	85-92
lymphomas	I	93-102
:	O	102-103
a	O	104-105
phase	O	106-111
II	O	112-114
trial	O	115-120
of	O	121-123
the	O	124-127
Cancer	B	128-134
and	O	135-138
Leukemia	B	139-147
Group	O	148-153
B	O	154-155
.	O	155-156
Thalidomide	O	157-168
is	O	169-171
an	O	172-174
immunomodulatory	O	175-191
agent	O	192-197
with	O	198-202
demonstrated	O	203-215
activity	O	216-224
in	O	225-227
multiple	B	228-236
myeloma	I	237-244
,	O	244-245
mantle	B	246-252
cell	I	253-257
lymphoma	I	258-266
and	O	267-270
lymphoplasmacytic	B	271-288
lymphoma	I	289-297
.	O	297-298

Its	O	299-302
activity	O	303-311
is	O	312-314
believed	O	315-323
to	O	324-326
be	O	327-329
due	O	330-333
modulation	O	334-344
of	O	345-347
the	O	348-351
tumour	B	352-358
milieu	O	359-365
,	O	365-366
including	O	367-376
downregulation	O	377-391
of	O	392-394
angiogenesis	O	395-407
and	O	408-411
inflammatory	O	412-424
cytokines	O	425-434
.	O	434-435

Between	O	436-443
July	O	444-448
2001	O	449-453
and	O	454-457
April	O	458-463
2004	O	464-468
,	O	468-469
24	O	470-472
patients	O	473-481
with	O	482-486
relapsed	O	487-495
/	O	495-496
refractory	O	496-506
indolent	O	507-515
lymphomas	B	516-525
received	O	526-534
thalidomide	O	535-546
200	O	547-550
mg	O	551-553
daily	O	554-559
with	O	560-564
escalation	O	565-575
by	O	576-578
100	O	579-582
mg	O	583-585
daily	O	586-591
every	O	592-597
1	O	598-599
-	O	599-600
2	O	600-601
weeks	O	602-607
as	O	608-610
tolerated	O	611-620
,	O	620-621
up	O	622-624
to	O	625-627
a	O	628-629
maximum	O	630-637
of	O	638-640
800	O	641-644
mg	O	645-647
daily	O	648-653
.	O	653-654

Patients	O	655-663
had	O	664-667
received	O	668-676
a	O	677-678
median	O	679-685
of	O	686-688
2	O	689-690
(	O	691-692
range	O	692-697
,	O	697-698
1	O	699-700
-	O	700-701
4	O	701-702
)	O	702-703
prior	O	704-709
regimens	O	710-718
.	O	718-719

Of	O	720-722
24	O	723-725
evaluable	O	726-735
patients	O	736-744
,	O	744-745
two	O	746-749
achieved	O	750-758
a	O	759-760
complete	O	761-769
remission	O	770-779
and	O	780-783
one	O	784-787
achieved	O	788-796
a	O	797-798
partial	O	799-806
remission	O	807-816
for	O	817-820
an	O	821-823
overall	O	824-831
response	O	832-840
rate	O	841-845
of	O	846-848
12	O	849-851
.	O	851-852
5	O	852-853
%	O	853-854
(	O	855-856
95	O	856-858
%	O	858-859
confidence	O	860-870
interval	O	871-879
:	O	879-880
2	O	881-882
.	O	882-883
6	O	883-884
-	O	884-885
32	O	885-887
.	O	882-883
4	O	888-889
%	O	889-890
)	O	890-891
.	O	882-883

Eleven	O	893-899
patients	O	900-908
progressed	O	909-919
during	O	920-926
therapy	O	927-934
.	O	934-935

Grade	O	936-941
3	O	942-943
-	O	943-944
4	O	944-945
adverse	O	946-953
effects	O	954-961
included	O	962-970
myelosuppression	B	971-987
,	O	987-988
fatigue	B	989-996
,	O	996-997
somnolence	B	998-1008
/	O	1008-1009
depressed	B	1009-1018
mood	I	1019-1023
,	O	1023-1024
neuropathy	B	1025-1035
and	O	1036-1039
dyspnea	B	1040-1047
.	O	1047-1048

Of	O	1049-1051
concern	O	1052-1059
was	O	1060-1063
the	O	1064-1067
occurrence	O	1068-1078
of	O	1079-1081
four	O	1082-1086
thromboembolic	B	1087-1101
events	O	1102-1108
.	O	1108-1109

Our	O	1110-1113
results	O	1114-1121
failed	O	1122-1128
to	O	1129-1131
demonstrate	O	1132-1143
an	O	1144-1146
important	O	1147-1156
response	O	1157-1165
rate	O	1166-1170
to	O	1171-1173
single	O	1174-1180
agent	O	1181-1186
thalidomide	O	1187-1198
in	O	1199-1201
indolent	O	1202-1210
lymphomas	B	1211-1220
and	O	1221-1224
contrast	O	1225-1233
with	O	1234-1238
the	O	1239-1242
higher	O	1243-1249
activity	O	1250-1258
level	O	1259-1264
reported	O	1265-1273
with	O	1274-1278
the	O	1279-1282
second	O	1283-1289
generation	O	1290-1300
immunomodulatory	O	1301-1317
agent	O	1318-1323
,	O	1323-1324
lenalidomide	O	1325-1337
.	O	1337-1338

Intracavernous	O	0-14
epinephrine	O	15-26
:	O	26-27
a	O	28-29
minimally	O	30-39
invasive	O	40-48
treatment	O	49-58
for	O	59-62
priapism	B	63-71
in	O	72-74
the	O	75-78
emergency	O	79-88
department	O	89-99
.	O	99-100

Priapism	B	101-109
is	O	110-112
the	O	113-116
prolonged	O	117-126
erection	O	127-135
of	O	136-138
the	O	139-142
penis	O	143-148
in	O	149-151
the	O	152-155
absence	O	156-163
of	O	164-166
sexual	O	167-173
arousal	O	174-181
.	O	181-182

A	O	183-184
45	O	185-187
-	O	187-188
year	O	188-192
-	O	187-188
old	O	193-196
man	O	197-200
,	O	200-201
an	O	202-204
admitted	O	205-213
frequent	O	214-222
cocaine	O	223-230
user	O	231-235
,	O	235-236
presented	O	237-246
to	O	247-249
the	O	250-253
Emergency	O	254-263
Department	O	264-274
(	O	275-276
ED	O	276-278
)	O	278-279
on	O	280-282
two	O	283-286
separate	O	287-295
occasions	O	296-305
with	O	306-310
a	O	311-312
history	O	313-320
of	O	321-323
priapism	B	324-332
after	O	333-338
cocaine	O	339-346
use	O	347-350
.	O	350-351

The	O	352-355
management	O	356-366
options	O	367-374
in	O	375-377
the	O	378-381
ED	O	382-384
,	O	384-385
as	O	386-388
exemplified	O	389-400
by	O	401-403
four	O	404-408
individual	O	409-419
case	O	420-424
reports	O	425-432
,	O	432-433
in	O	434-436
particular	O	437-447
the	O	448-451
use	O	452-455
of	O	456-458
a	O	459-460
minimally	O	461-470
invasive	O	471-479
method	O	480-486
of	O	487-489
intracorporal	O	490-503
epinephrine	O	504-515
instillation	O	516-528
,	O	528-529
are	O	530-533
discussed	O	534-543
.	O	543-544

Effect	O	0-6
of	O	7-9
green	O	10-15
tea	O	16-19
and	O	20-23
vitamin	O	24-31
E	O	32-33
combination	O	34-45
in	O	46-48
isoproterenol	O	49-62
induced	O	63-70
myocardial	B	71-81
infarction	I	82-92
in	O	93-95
rats	O	96-100
.	O	100-101

The	O	102-105
present	O	106-113
study	O	114-119
was	O	120-123
aimed	O	124-129
to	O	130-132
investigate	O	133-144
the	O	145-148
combined	O	149-157
effects	O	158-165
of	O	166-168
green	O	169-174
tea	O	175-178
and	O	179-182
vitamin	O	183-190
E	O	191-192
on	O	193-195
heart	O	196-201
weight	O	202-208
,	O	208-209
body	O	210-214
weight	O	215-221
,	O	221-222
serum	O	223-228
marker	O	229-235
enzymes	O	236-243
,	O	243-244
lipid	O	245-250
peroxidation	O	251-263
,	O	263-264
endogenous	O	265-275
antioxidants	O	276-288
and	O	289-292
membrane	O	293-301
bound	O	302-307
ATPases	O	308-315
in	O	316-318
isoproterenol	O	319-332
(	O	333-334
ISO	O	334-337
)	O	337-338
-	O	338-339
induced	O	339-346
myocardial	B	347-357
infarction	I	358-368
in	O	369-371
rats	O	372-376
.	O	376-377

Adult	O	378-383
male	O	384-388
albino	O	389-395
rats	O	396-400
,	O	400-401
treated	O	402-409
with	O	410-414
ISO	O	415-418
(	O	419-420
200	O	420-423
mg	O	424-426
/	O	426-427
kg	O	427-429
,	O	429-430
s	O	431-432
.	O	432-433
c	O	433-434
.	O	432-433
)	O	435-436
for	O	437-440
2	O	441-442
days	O	443-447
at	O	448-450
an	O	451-453
interval	O	454-462
of	O	463-465
24	O	466-468
h	O	469-470
caused	O	471-477
a	O	478-479
significant	O	480-491
(	O	492-493
P	O	493-494
<	O	494-495
0	O	495-496
.	O	496-497
05	O	497-499
)	O	499-500

elevation	O	501-510
of	O	511-513
heart	O	514-519
weight	O	520-526
,	O	526-527
serum	O	528-533
marker	O	534-540
enzymes	O	541-548
,	O	548-549
lipid	O	550-555
peroxidation	O	556-568
and	O	569-572
Ca	O	573-575
+	O	575-576
2	O	576-577
ATPase	O	578-584
level	O	585-590
whereas	O	591-598
there	O	599-604
was	O	605-608
a	O	609-610
significant	O	611-622
(	O	623-624
P	O	624-625
<	O	625-626
0	O	626-627
.	O	627-628
05	O	628-630
)	O	630-631

decrease	O	632-640
in	O	641-643
body	O	644-648
weight	O	649-655
,	O	655-656
endogenous	O	657-667
antioxidants	O	668-680
,	O	680-681
Na	O	682-684
+	O	684-685
/	O	685-686
K	O	687-688
+	O	688-689
ATPase	O	690-696
and	O	697-700
Mg	O	701-703
+	O	703-704
2	O	704-705
ATPase	O	706-712
levels	O	713-719
.	O	719-720

Administration	O	721-735
of	O	736-738
green	O	739-744
tea	O	745-748
(	O	749-750
100	O	750-753
mg	O	754-756
/	O	756-757
kg	O	757-759
/	O	756-757
day	O	760-763
,	O	763-764
p	O	765-766
.	O	766-767
o	O	767-768
.	O	766-767
)	O	769-770
and	O	771-774
vitamin	O	775-782
E	O	783-784
(	O	785-786
100	O	786-789
mg	O	790-792
/	O	792-793
kg	O	793-795
/	O	792-793
day	O	796-799
,	O	799-800
p	O	801-802
.	O	802-803
o	O	803-804
.	O	802-803
)	O	805-806
together	O	807-815
for	O	816-819
30	O	820-822
consecutive	O	823-834
days	O	835-839
and	O	840-843
challenged	O	844-854
with	O	855-859
ISO	O	860-863
on	O	864-866
the	O	867-870
day	O	871-874
29th	O	875-879
and	O	880-883
30th	O	884-888
,	O	888-889
showed	O	890-896
a	O	897-898
significant	O	899-910
(	O	911-912
P	O	912-913
<	O	913-914
0	O	914-915
.	O	915-916
05	O	916-918
)	O	918-919

decrease	O	920-928
in	O	929-931
heart	O	932-937
weight	O	938-944
,	O	944-945
serum	O	946-951
marker	O	952-958
enzymes	O	959-966
,	O	966-967
lipid	O	968-973
peroxidation	O	974-986
,	O	986-987
Ca	O	988-990
+	O	990-991
2	O	991-992
ATPase	O	993-999
and	O	1000-1003
a	O	1004-1005
significant	O	1006-1017
increase	O	1018-1026
in	O	1027-1029
the	O	1030-1033
body	O	1034-1038
weight	O	1039-1045
,	O	1045-1046
endogenous	O	1047-1057
antioxidants	O	1058-1070
,	O	1070-1071
Na	O	1072-1074
+	O	1074-1075
/	O	1075-1076
K	O	1076-1077
+	O	1074-1075
ATPase	O	1079-1085
and	O	1086-1089
Mg	O	1090-1092
+	O	1092-1093
2	O	1093-1094
ATPase	O	1095-1101
when	O	1102-1106
compared	O	1107-1115
with	O	1116-1120
ISO	O	1121-1124
treated	O	1125-1132
group	O	1133-1138
and	O	1139-1142
green	O	1143-1148
tea	O	1149-1152
or	O	1153-1155
vitamin	O	1156-1163
E	O	1164-1165
alone	O	1166-1171
treated	O	1172-1179
groups	O	1180-1186
.	O	1186-1187

These	O	1188-1193
findings	O	1194-1202
indicate	O	1203-1211
the	O	1212-1215
synergistic	O	1216-1227
protective	O	1228-1238
effect	O	1239-1245
of	O	1246-1248
green	O	1249-1254
tea	O	1255-1258
and	O	1259-1262
vitamin	O	1263-1270
E	O	1271-1272
during	O	1273-1279
ISO	O	1280-1283
induced	O	1284-1291
myocardial	B	1292-1302
infarction	I	1303-1313
in	O	1314-1316
rats	O	1317-1321
.	O	1321-1322

Development	O	0-11
of	O	12-14
ocular	B	15-21
myasthenia	I	22-32
during	O	33-39
pegylated	O	40-49
interferon	O	50-60
and	O	61-64
ribavirin	O	65-74
treatment	O	75-84
for	O	85-88
chronic	B	89-96
hepatitis	I	97-106
C	I	107-108
.	O	108-109
A	O	110-111
63	O	112-114
-	O	114-115
year	O	115-119
-	O	114-115
old	O	120-123
male	O	124-128
experienced	O	129-140
sudden	O	141-147
diplopia	B	148-156
after	O	157-162
9	O	163-164
weeks	O	165-170
of	O	171-173
administration	O	174-188
of	O	189-191
pegylated	O	192-201
interferon	O	202-212
(	O	213-214
IFN	O	214-217
)	O	217-218
alpha	O	219-224
-	O	224-225
2b	O	225-227
and	O	228-231
ribavirin	O	232-241
for	O	242-245
chronic	B	246-253
hepatitis	I	254-263
C	I	264-265
(	O	266-267
CHC	B	267-270
)	O	270-271
.	O	271-272

Ophthalmologic	O	273-287
examinations	O	288-300
showed	O	301-307
ptosis	B	308-314
on	I	315-317
the	I	318-321
right	I	322-327
upper	I	328-333
lid	I	334-337
and	O	338-341
restricted	B	342-352
right	I	353-358
eye	I	359-362
movement	I	363-371
without	O	372-379
any	O	380-383
other	O	384-389
neurological	O	390-402
signs	O	403-408
.	O	408-409

A	O	410-411
brain	O	412-417
imaging	O	418-425
study	O	426-431
and	O	432-435
repetitive	O	436-446
nerve	O	447-452
stimulation	O	453-464
test	O	465-469
indicated	O	470-479
no	O	480-482
abnormality	O	483-494
.	O	494-495

The	O	496-499
acetylcholine	O	500-513
receptor	O	514-522
antibody	O	523-531
titer	O	532-537
and	O	538-541
response	O	542-550
to	O	551-553
acetylcholinesterase	O	554-574
inhibitors	O	575-585
were	O	586-590
negative	O	591-599
,	O	599-600
and	O	601-604
the	O	605-608
results	O	609-616
of	O	617-619
thyroid	O	620-627
function	O	628-636
tests	O	637-642
were	O	643-647
normal	O	648-654
.	O	654-655

The	O	656-659
patient	O	660-667
'	O	667-668
s	O	668-669
ophthalmological	O	670-686
symptoms	O	687-695
improved	O	696-704
rapidly	O	705-712
3	O	713-714
weeks	O	715-720
after	O	721-726
discontinuation	O	727-742
of	O	743-745
pegylated	O	746-755
IFN	O	756-759
alpha	O	760-765
-	O	765-766
2b	O	766-768
and	O	769-772
ribavirin	O	773-782
.	O	782-783

The	O	784-787
ocular	B	788-794
myasthenia	I	795-805
associated	O	806-816
with	O	817-821
combination	O	822-833
therapy	O	834-841
of	O	842-844
pegylated	O	845-854
IFN	O	855-858
alpha	O	859-864
-	O	864-865
2b	O	865-867
and	O	868-871
ribavirin	O	872-881
for	O	882-885
CHC	B	886-889
is	O	890-892
very	O	893-897
rarely	O	898-904
reported	O	905-913
;	O	913-914
therefore	O	915-924
,	O	924-925
we	O	926-928
present	O	929-936
this	O	937-941
case	O	942-946
with	O	947-951
a	O	952-953
review	O	954-960
of	O	961-963
the	O	964-967
various	O	968-975
eye	O	976-979
complications	O	980-993
of	O	994-996
IFN	O	997-1000
therapy	O	1001-1008
.	O	1008-1009

The	O	0-3
glycine	O	4-11
transporter	O	12-23
-	O	23-24
1	O	24-25
inhibitor	O	26-35
SSR103800	O	36-45
displays	O	46-54
a	O	55-56
selective	O	57-66
and	O	67-70
specific	O	71-79
antipsychotic	O	80-93
-	O	93-94
like	O	94-98
profile	O	99-106
in	O	107-109
normal	O	110-116
and	O	117-120
transgenic	O	121-131
mice	O	132-136
.	O	136-137

Schizophrenia	B	138-151
has	O	152-155
been	O	156-160
initially	O	161-170
associated	O	171-181
with	O	182-186
dysfunction	O	187-198
in	O	199-201
dopamine	O	202-210
neurotransmission	O	211-228
.	O	228-229

However	O	230-237
,	O	237-238
the	O	239-242
observation	O	243-254
that	O	255-259
antagonists	O	260-271
of	O	272-274
the	O	275-278
glutamate	O	279-288
N	O	289-290
-	O	290-291
methyl	O	291-297
-	O	290-291
D	O	298-299
-	O	290-291
aspartate	O	300-309
(	O	310-311
NMDA	O	311-315
)	O	315-316
receptor	O	317-325
produce	O	326-333
schizophrenic	B	334-347
-	O	347-348
like	O	348-352
symptoms	O	353-361
in	O	362-364
humans	O	365-371
has	O	372-375
led	O	376-379
to	O	380-382
the	O	383-386
idea	O	387-391
of	O	392-394
a	O	395-396
dysfunctioning	O	397-411
of	O	412-414
the	O	415-418
glutamatergic	O	419-432
system	O	433-439
via	O	440-443
its	O	444-447
NMDA	O	448-452
receptor	O	453-461
.	O	461-462

As	O	463-465
a	O	466-467
result	O	468-474
,	O	474-475
there	O	476-481
is	O	482-484
a	O	485-486
growing	O	487-494
interest	O	495-503
in	O	504-506
the	O	507-510
development	O	511-522
of	O	523-525
pharmacological	O	526-541
agents	O	542-548
with	O	549-553
potential	O	554-563
antipsychotic	O	564-577
properties	O	578-588
that	O	589-593
enhance	O	594-601
the	O	602-605
activity	O	606-614
of	O	615-617
the	O	618-621
glutamatergic	O	622-635
system	O	636-642
via	O	643-646
a	O	647-648
modulation	O	649-659
of	O	660-662
the	O	663-666
NMDA	O	667-671
receptor	O	672-680
.	O	680-681

Among	O	682-687
them	O	688-692
are	O	693-696
glycine	O	697-704
transporter	O	705-716
-	O	716-717
1	O	717-718
(	O	719-720
GlyT1	O	720-725
)	O	725-726
inhibitors	O	727-737
such	O	738-742
as	O	743-745
SSR103800	O	746-755
,	O	755-756
which	O	757-762
indirectly	O	763-773
enhance	O	774-781
NMDA	O	782-786
receptor	O	787-795
function	O	796-804
by	O	805-807
increasing	O	808-818
the	O	819-822
glycine	O	823-830
(	O	831-832
a	O	832-833
co	O	834-836
-	O	836-837
agonist	O	837-844
for	O	845-848
the	O	849-852
NMDA	O	853-857
receptor	O	858-866
)	O	866-867
levels	O	868-874
in	O	875-877
the	O	878-881
synapse	O	882-889
.	O	889-890

This	O	891-895
study	O	896-901
aimed	O	902-907
at	O	908-910
investigating	O	911-924
the	O	925-928
potential	O	929-938
antipsychotic	O	939-952
-	O	952-953
like	O	953-957
properties	O	958-968
of	O	969-971
SSR103800	O	972-981
,	O	981-982
with	O	983-987
a	O	988-989
particular	O	990-1000
focus	O	1001-1006
on	O	1007-1009
models	O	1010-1016
of	O	1017-1019
hyperactivity	B	1020-1033
,	O	1033-1034
involving	O	1035-1044
either	O	1045-1051
drug	O	1052-1056
challenge	O	1057-1066
(	O	1067-1068
ie	O	1068-1070
,	O	1070-1071
amphetamine	O	1072-1083
and	O	1084-1087
MK	O	1088-1090
-	O	1090-1091
801	O	1091-1094
)	O	1094-1095
or	O	1096-1098
transgenic	O	1099-1109
mice	O	1110-1114
(	O	1115-1116
ie	O	1116-1118
,	O	1118-1119
NMDA	O	1120-1124
Nr1	O	1125-1128
(	O	1128-1129
neo	O	1129-1132
-	O	1132-1133
/	O	1133-1134
-	O	1132-1133
)	O	1135-1136
and	O	1137-1140
DAT	O	1141-1144
(	O	1144-1145
-	O	1145-1146
/	O	1146-1147
-	O	1145-1146
)	O	1148-1149
)	O	1148-1149
.	O	1150-1151

Results	O	1152-1159
showed	O	1160-1166
that	O	1167-1171
SSR103800	O	1172-1181
(	O	1182-1183
10	O	1183-1185
-	O	1185-1186
30	O	1186-1188
mg	O	1189-1191
/	O	1191-1192
kg	O	1192-1194
p	O	1195-1196
.	O	1196-1197
o	O	1197-1198
.	O	1196-1197
)	O	1199-1200
blocked	O	1201-1208
hyperactivity	B	1209-1222
induced	O	1223-1230
by	O	1231-1233
the	O	1234-1237
non	O	1238-1241
-	O	1241-1242
competitive	O	1242-1253
NMDA	O	1254-1258
receptor	O	1259-1267
antagonist	O	1268-1278
,	O	1278-1279
MK	O	1280-1282
-	O	1282-1283
801	O	1283-1286
and	O	1287-1290
partially	O	1291-1300
reversed	O	1301-1309
spontaneous	O	1310-1321
hyperactivity	B	1322-1335
of	O	1336-1338
NMDA	O	1339-1343
Nr1	O	1344-1347
(	O	1347-1348
neo	O	1348-1351
-	O	1351-1352
/	O	1352-1353
-	O	1351-1352
)	O	1354-1355
mice	O	1356-1360
.	O	1360-1361

In	O	1362-1364
contrast	O	1365-1373
,	O	1373-1374
SSR103800	O	1375-1384
failed	O	1385-1391
to	O	1392-1394
affect	O	1395-1401
hyperactivity	B	1402-1415
induced	O	1416-1423
by	O	1424-1426
amphetamine	O	1427-1438
or	O	1439-1441
naturally	O	1442-1451
observed	O	1452-1460
in	O	1461-1463
dopamine	O	1464-1472
transporter	O	1473-1484
(	O	1485-1486
DAT	O	1486-1489
(	O	1485-1486
-	O	1490-1491
/	O	1491-1492
-	O	1490-1491
)	O	1493-1494
)	O	1493-1494
knockout	O	1496-1504
mice	O	1505-1509
(	O	1510-1511
10	O	1511-1513
-	O	1513-1514
30	O	1514-1516
mg	O	1517-1519
/	O	1519-1520
kg	O	1520-1522
p	O	1523-1524
.	O	1524-1525
o	O	1525-1526
.	O	1524-1525
)	O	1527-1528
.	O	1524-1525

Importantly	O	1530-1541
,	O	1541-1542
both	O	1543-1547
classical	O	1548-1557
(	O	1558-1559
haloperidol	O	1559-1570
)	O	1570-1571
and	O	1572-1575
atypical	O	1576-1584
(	O	1585-1586
olanzapine	O	1586-1596
,	O	1596-1597
clozapine	O	1598-1607
and	O	1608-1611
aripiprazole	O	1612-1624
)	O	1624-1625
antipsychotics	O	1626-1640
were	O	1641-1645
effective	O	1646-1655
in	O	1656-1658
all	O	1659-1662
these	O	1663-1668
models	O	1669-1675
of	O	1676-1678
hyperactivity	B	1679-1692
.	O	1692-1693

However	O	1694-1701
,	O	1701-1702
unlike	O	1703-1709
these	O	1710-1715
latter	O	1716-1722
,	O	1722-1723
SSR103800	O	1724-1733
did	O	1734-1737
not	O	1738-1741
produce	O	1742-1749
catalepsy	B	1750-1759
(	O	1760-1761
retention	O	1761-1770
on	O	1771-1773
the	O	1774-1777
bar	O	1778-1781
test	O	1782-1786
)	O	1786-1787
up	O	1788-1790
to	O	1791-1793
30	O	1794-1796
mg	O	1797-1799
/	O	1799-1800
kg	O	1800-1802
p	O	1803-1804
.	O	1804-1805
o	O	1805-1806
.	O	1804-1805
Together	O	1808-1816
these	O	1817-1822
findings	O	1823-1831
show	O	1832-1836
that	O	1837-1841
the	O	1842-1845
GlyT1	O	1846-1851
inhibitor	O	1852-1861
,	O	1861-1862
SSR103800	O	1863-1872
,	O	1872-1873
produces	O	1874-1882
antipsychotic	O	1883-1896
-	O	1896-1897
like	O	1897-1901
effects	O	1902-1909
,	O	1909-1910
which	O	1911-1916
differ	O	1917-1923
from	O	1924-1928
those	O	1929-1934
observed	O	1935-1943
with	O	1944-1948
compounds	O	1949-1958
primarily	O	1959-1968
targeting	O	1969-1978
the	O	1979-1982
dopaminergic	O	1983-1995
system	O	1996-2002
,	O	2002-2003
and	O	2004-2007
has	O	2008-2011
a	O	2012-2013
reduced	O	2014-2021
side	O	2022-2026
-	O	2026-2027
effect	O	2027-2033
potential	O	2034-2043
as	O	2044-2046
compared	O	2047-2055
with	O	2056-2060
these	O	2061-2066
latter	O	2067-2073
drugs	O	2074-2079
.	O	2079-2080

Phenylephrine	O	0-13
but	O	14-17
not	O	18-21
ephedrine	O	22-31
reduces	B	32-39
frontal	I	40-47
lobe	I	48-52
oxygenation	I	53-64
following	O	65-74
anesthesia	O	75-85
-	O	85-86
induced	O	86-93
hypotension	B	94-105
.	O	105-106

BACKGROUND	O	107-117
:	O	117-118
Vasopressor	O	119-130
agents	O	131-137
are	O	138-141
used	O	142-146
to	O	147-149
correct	O	150-157
anesthesia	O	158-168
-	O	168-169
induced	O	169-176
hypotension	B	177-188
.	O	188-189

We	O	190-192
describe	O	193-201
the	O	202-205
effect	O	206-212
of	O	213-215
phenylephrine	O	216-229
and	O	230-233
ephedrine	O	234-243
on	O	244-246
frontal	O	247-254
lobe	O	255-259
oxygenation	O	260-271
(	O	272-273
S	O	273-274
(	O	272-273
c	O	275-276
)	O	276-277
O	O	277-278
(	O	272-273
2	O	279-280
)	O	276-277
)	O	276-277
following	O	283-292
anesthesia	O	293-303
-	O	303-304
induced	O	304-311
hypotension	B	312-323
.	O	323-324

METHODS	O	325-332
:	O	332-333
Following	O	334-343
induction	O	344-353
of	O	354-356
anesthesia	O	357-367
by	O	368-370
fentanyl	O	371-379
(	O	380-381
0	O	381-382
.	O	382-383
15	O	383-385
mg	O	386-388
kg	O	389-391
(	O	391-392
-	O	392-393
1	O	393-394
)	O	394-395
)	O	394-395
and	O	397-400
propofol	O	401-409
(	O	410-411
2	O	411-412
.	O	412-413
0	O	413-414
mg	O	415-417
kg	O	418-420
(	O	420-421
-	O	421-422
1	O	422-423
)	O	423-424
)	O	423-424
,	O	425-426
13	O	427-429
patients	O	430-438
received	O	439-447
phenylephrine	O	448-461
(	O	462-463
0	O	463-464
.	O	464-465
1	O	465-466
mg	O	467-469
iv	O	470-472
)	O	472-473
and	O	474-477
12	O	478-480
patients	O	481-489
received	O	490-498
ephedrine	O	499-508
(	O	509-510
10	O	510-512
mg	O	513-515
iv	O	516-518
)	O	518-519
to	O	520-522
restore	O	523-530
mean	O	531-535
arterial	O	536-544
pressure	O	545-553
(	O	554-555
MAP	O	555-558
)	O	558-559
.	O	559-560

Heart	O	561-566
rate	O	567-571
(	O	572-573
HR	O	573-575
)	O	575-576
,	O	576-577
MAP	O	578-581
,	O	581-582
stroke	B	583-589
volume	O	590-596
(	O	597-598
SV	O	598-600
)	O	600-601
,	O	601-602
cardiac	O	603-610
output	O	611-617
(	O	618-619
CO	O	619-621
)	O	621-622
,	O	622-623
and	O	624-627
frontal	O	628-635
lobe	O	636-640
oxygenation	O	641-652
(	O	653-654
S	O	654-655
(	O	653-654
c	O	656-657
)	O	657-658
O	O	658-659
(	O	653-654
2	O	660-661
)	O	657-658
)	O	657-658
were	O	664-668
registered	O	669-679
.	O	679-680

RESULTS	O	681-688
:	O	688-689
Induction	O	690-699
of	O	700-702
anesthesia	O	703-713
was	O	714-717
followed	O	718-726
by	O	727-729
a	B	730-731
decrease	I	732-740
in	I	741-743
MAP	I	744-747
,	I	747-748
HR	I	749-751
,	I	751-752
SV	I	753-755
,	I	755-756
and	I	757-760
CO	I	761-763
concomitant	O	764-775
with	O	776-780
an	O	781-783
elevation	O	784-793
in	O	794-796
S	O	797-798
(	O	798-799
c	O	799-800
)	O	800-801
O	O	801-802
(	O	798-799
2	O	803-804
)	O	800-801
.	O	805-806

After	O	807-812
administration	O	813-827
of	O	828-830
phenylephrine	O	831-844
,	O	844-845
MAP	O	846-849
increased	O	850-859
(	O	860-861
51	O	861-863
+	O	864-865
/	O	865-866
-	O	866-867
12	O	868-870
to	O	871-873
81	O	874-876
+	O	877-878
/	O	878-879
-	O	879-880
13	O	881-883
mmHg	O	884-888
;	O	888-889
P	O	890-891
<	O	892-893
0	O	894-895
.	O	895-896
001	O	896-899
;	O	899-900
mean	O	901-905
+	O	906-907
/	O	907-908
-	O	908-909
SD	O	910-912
)	O	912-913
.	O	913-914

However	O	915-922
,	O	922-923
a	O	924-925
14	O	926-928
%	O	928-929
(	O	930-931
from	O	931-935
70	O	936-938
+	O	939-940
/	O	940-941
-	O	941-942
8	O	943-944
%	O	944-945
to	O	946-948
60	O	949-951
+	O	952-953
/	O	953-954
-	O	954-955
7	O	956-957
%	O	957-958
)	O	958-959
reduction	O	960-969
in	O	970-972
S	O	973-974
(	O	974-975
c	O	975-976
)	O	976-977
O	O	977-978
(	O	974-975
2	O	979-980
)	O	976-977
(	O	982-983
P	O	983-984
<	O	985-986
0	O	987-988
.	O	988-989
05	O	989-991
)	O	991-992
followed	O	993-1001
with	O	1002-1006
no	O	1007-1009
change	O	1010-1016
in	O	1017-1019
CO	O	1020-1022
(	O	1023-1024
3	O	1024-1025
.	O	1025-1026
7	O	1026-1027
+	O	1028-1029
/	O	1029-1030
-	O	1030-1031
1	O	1032-1033
.	O	1033-1034
1	O	1032-1033
to	O	1036-1038
3	O	1039-1040
.	O	1040-1041
4	O	1041-1042
+	O	1043-1044
/	O	1044-1045
-	O	1045-1046
0	O	1047-1048
.	O	1048-1049
9	O	1049-1050
l	O	1051-1052
min	O	1053-1056
(	O	1056-1057
-	O	1057-1058
1	O	1058-1059
)	O	1059-1060
)	O	1059-1060
.	O	1061-1062

The	O	1063-1066
administration	O	1067-1081
of	O	1082-1084
ephedrine	O	1085-1094
led	O	1095-1098
to	O	1099-1101
a	O	1102-1103
similar	O	1104-1111
increase	O	1112-1120
in	O	1121-1123
MAP	O	1124-1127
(	O	1128-1129
53	O	1129-1131
+	O	1132-1133
/	O	1133-1134
-	O	1134-1135
9	O	1136-1137
to	O	1138-1140
79	O	1141-1143
+	O	1144-1145
/	O	1145-1146
-	O	1146-1147
8	O	1148-1149
mmHg	O	1150-1154
;	O	1154-1155
P	O	1156-1157
<	O	1158-1159
0	O	1160-1161
.	O	1161-1162
001	O	1162-1165
)	O	1165-1166
,	O	1166-1167
restored	O	1168-1176
CO	O	1177-1179
(	O	1180-1181
3	O	1181-1182
.	O	1182-1183
2	O	1183-1184
+	O	1185-1186
/	O	1186-1187
-	O	1187-1188
1	O	1189-1190
.	O	1190-1191
2	O	1191-1192
to	O	1193-1195
5	O	1196-1197
.	O	1197-1198
0	O	1198-1199
+	O	1200-1201
/	O	1201-1202
-	O	1202-1203
1	O	1204-1205
.	O	1205-1206
3	O	1206-1207
l	O	1208-1209
min	O	1210-1213
(	O	1213-1214
-	O	1214-1215
1	O	1215-1216
)	O	1216-1217
)	O	1216-1217
,	O	1218-1219
and	O	1220-1223
preserved	O	1224-1233
S	O	1234-1235
(	O	1235-1236
c	O	1236-1237
)	O	1237-1238
O	O	1238-1239
(	O	1235-1236
2	O	1240-1241
)	O	1237-1238
.	O	1242-1243

CONCLUSIONS	O	1244-1255
:	O	1255-1256
The	O	1257-1260
utilization	O	1261-1272
of	O	1273-1275
phenylephrine	O	1276-1289
to	O	1290-1292
correct	O	1293-1300
hypotension	B	1301-1312
induced	O	1313-1320
by	O	1321-1323
anesthesia	O	1324-1334
has	O	1335-1338
a	O	1339-1340
negative	O	1341-1349
impact	O	1350-1356
on	O	1357-1359
S	O	1360-1361
(	O	1361-1362
c	O	1362-1363
)	O	1363-1364
O	O	1364-1365
(	O	1361-1362
2	O	1366-1367
)	O	1363-1364
while	O	1369-1374
ephedrine	O	1375-1384
maintains	O	1385-1394
frontal	O	1395-1402
lobe	O	1403-1407
oxygenation	O	1408-1419
potentially	O	1420-1431
related	O	1432-1439
to	O	1440-1442
an	O	1443-1445
increase	O	1446-1454
in	O	1455-1457
CO	O	1458-1460
.	O	1460-1461

A	O	0-1
novel	O	2-7
,	O	7-8
multiple	O	9-17
symptom	O	18-25
model	O	26-31
of	O	32-34
obsessive	B	35-44
-	I	44-45
compulsive	I	45-55
-	I	44-45
like	I	56-60
behaviors	I	61-70
in	O	71-73
animals	O	74-81
.	O	81-82

BACKGROUND	O	83-93
:	O	93-94
Current	O	95-102
animal	O	103-109
models	O	110-116
of	O	117-119
obsessive	B	120-129
-	I	129-130
compulsive	I	130-140
disorder	I	141-149
(	O	150-151
OCD	B	151-154
)	O	154-155
typically	O	156-165
involve	O	166-173
acute	O	174-179
,	O	179-180
drug	O	181-185
-	O	185-186
induced	O	186-193
symptom	O	194-201
provocation	O	202-213
or	O	214-216
a	O	217-218
genetic	O	219-226
association	O	227-238
with	O	239-243
stereotypies	O	244-256
or	O	257-259
anxiety	B	260-267
.	O	267-268

None	O	269-273
of	O	274-276
these	O	277-282
current	O	283-290
models	O	291-297
demonstrate	O	298-309
multiple	O	310-318
OCD	B	319-322
-	O	322-323
like	O	323-327
behaviors	O	328-337
.	O	337-338

METHODS	O	339-346
:	O	346-347
Neonatal	O	348-356
rats	O	357-361
were	O	362-366
treated	O	367-374
with	O	375-379
the	O	380-383
tricyclic	O	384-393
antidepressant	O	394-408
clomipramine	O	409-421
or	O	422-424
vehicle	O	425-432
between	O	433-440
days	O	441-445
9	O	446-447
and	O	448-451
16	O	452-454
twice	O	455-460
daily	O	461-466
and	O	467-470
behaviorally	O	471-483
tested	O	484-490
in	O	491-493
adulthood	O	494-503
.	O	503-504

RESULTS	O	505-512
:	O	512-513
Clomipramine	O	514-526
exposure	O	527-535
in	O	536-538
immature	O	539-547
rats	O	548-552
produced	O	553-561
significant	O	562-573
behavioral	O	574-584
and	O	585-588
biochemical	O	589-600
changes	O	601-608
that	O	609-613
include	O	614-621
enhanced	O	622-630
anxiety	B	631-638
(	O	639-640
elevated	O	640-648
plus	O	649-653
maze	O	654-658
and	O	659-662
marble	O	663-669
burying	O	670-677
)	O	677-678
,	O	678-679
behavioral	B	680-690
inflexibility	I	691-704
(	O	705-706
perseveration	O	706-719
in	O	720-722
the	O	723-726
spontaneous	O	727-738
alternation	O	739-750
task	O	751-755
and	O	756-759
impaired	O	760-768
reversal	O	769-777
learning	O	778-786
)	O	786-787
,	O	787-788
working	O	789-796
memory	B	797-803
impairment	I	804-814
(	O	815-816
e	O	816-817
.	O	817-818
g	O	818-819
.	O	817-818
,	O	820-821
win	O	822-825
-	O	825-826
shift	O	826-831
paradigm	O	832-840
)	O	840-841
,	O	841-842
hoarding	B	843-851
,	O	851-852
and	O	853-856
corticostriatal	B	857-872
dysfunction	I	873-884
.	O	884-885

Dopamine	O	886-894
D2	O	895-897
receptors	O	898-907
were	O	908-912
elevated	O	913-921
in	O	922-924
the	O	925-928
striatum	O	929-937
,	O	937-938
whereas	O	939-946
serotonin	O	947-956
2C	O	957-959
,	O	959-960
but	O	961-964
not	O	965-968
serotonin	O	969-978
1A	O	979-981
,	O	981-982
receptors	O	983-992
were	O	993-997
elevated	O	998-1006
in	O	1007-1009
the	O	1010-1013
orbital	O	1014-1021
frontal	O	1022-1029
cortex	O	1030-1036
.	O	1036-1037

CONCLUSIONS	O	1038-1049
:	O	1049-1050
This	O	1051-1055
is	O	1056-1058
the	O	1059-1062
first	O	1063-1068
demonstration	O	1069-1082
of	O	1083-1085
multiple	O	1086-1094
symptoms	O	1095-1103
consistent	O	1104-1114
with	O	1115-1119
an	O	1120-1122
OCD	B	1123-1126
-	O	1126-1127
like	O	1127-1131
profile	O	1132-1139
in	O	1140-1142
animals	O	1143-1150
.	O	1150-1151

Moreover	O	1152-1160
,	O	1160-1161
these	O	1162-1167
behaviors	O	1168-1177
are	O	1178-1181
accompanied	O	1182-1193
by	O	1194-1196
biochemical	O	1197-1208
changes	O	1209-1216
in	O	1217-1219
brain	O	1220-1225
regions	O	1226-1233
previously	O	1234-1244
identified	O	1245-1255
as	O	1256-1258
relevant	O	1259-1267
to	O	1268-1270
OCD	B	1271-1274
.	O	1274-1275

This	O	1276-1280
novel	O	1281-1286
model	O	1287-1292
of	O	1293-1295
OCD	B	1296-1299
demonstrates	O	1300-1312
that	O	1313-1317
drug	O	1318-1322
exposure	O	1323-1331
during	O	1332-1338
a	O	1339-1340
sensitive	O	1341-1350
period	O	1351-1357
can	O	1358-1361
program	O	1362-1369
disease	O	1370-1377
-	O	1377-1378
like	O	1378-1382
systems	O	1383-1390
permanently	O	1391-1402
,	O	1402-1403
which	O	1404-1409
could	O	1410-1415
have	O	1416-1420
implications	O	1421-1433
for	O	1434-1437
current	O	1438-1445
and	O	1446-1449
future	O	1450-1456
therapeutic	O	1457-1468
strategies	O	1469-1479
for	O	1480-1483
this	O	1484-1488
and	O	1489-1492
other	O	1493-1498
psychiatric	B	1499-1510
disorders	I	1511-1520
.	O	1520-1521

Late	O	0-4
recovery	O	5-13
of	O	14-16
renal	O	17-22
function	O	23-31
in	O	32-34
a	O	35-36
woman	O	37-42
with	O	43-47
the	O	48-51
hemolytic	B	52-61
uremic	I	62-68
syndrome	I	69-77
.	O	77-78

A	O	79-80
case	O	81-85
is	O	86-88
reported	O	89-97
of	O	98-100
the	O	101-104
hemolytic	B	105-114
uremic	I	115-121
syndrome	I	122-130
(	O	131-132
HUS	B	132-135
)	O	135-136
in	O	137-139
a	O	140-141
woman	O	142-147
taking	O	148-154
oral	O	155-159
contraceptives	O	160-174
.	O	174-175

She	O	176-179
was	O	180-183
treated	O	184-191
with	O	192-196
heparin	O	197-204
,	O	204-205
dipyridamole	O	206-218
and	O	219-222
hemodialysis	O	223-235
;	O	235-236
and	O	237-240
after	O	241-246
more	O	247-251
than	O	252-256
three	O	257-262
months	O	263-269
,	O	269-270
her	O	271-274
urinary	O	275-282
output	O	283-289
rose	O	290-294
above	O	295-300
500	O	301-304
ml	O	305-307
;	O	307-308
and	O	309-312
six	O	313-316
months	O	317-323
after	O	324-329
the	O	330-333
onset	O	334-339
of	O	340-342
anuria	B	343-349
,	O	349-350
dialysis	O	351-359
treatment	O	360-369
was	O	370-373
stopped	O	374-381
.	O	381-382

This	O	383-387
case	O	388-392
emphasizes	O	393-403
the	O	404-407
possibility	O	408-419
that	O	420-424
HUS	B	425-428
in	O	429-431
adults	O	432-438
is	O	439-441
not	O	442-445
invariably	O	446-456
irreversible	O	457-469
and	O	470-473
that	O	474-478
,	O	478-479
despite	O	480-487
prolonged	O	488-497
oliguria	B	498-506
,	O	506-507
recovery	O	508-516
of	O	517-519
renal	O	520-525
function	O	526-534
can	O	535-538
be	O	539-541
obtained	O	542-550
.	O	550-551

Therefore	O	552-561
,	O	561-562
in	O	563-565
adult	O	566-571
patients	O	572-580
affected	O	581-589
by	O	590-592
HUS	B	593-596
,	O	596-597
dialysis	O	598-606
should	O	607-613
not	O	614-617
be	O	618-620
discontinued	O	621-633
prematurely	O	634-645
;	O	645-646
moreover	O	647-655
,	O	655-656
bilateral	O	657-666
nephrectomy	O	667-678
,	O	678-679
for	O	680-683
treatment	O	684-693
of	O	694-696
severe	O	697-703
hypertension	B	704-716
and	O	717-720
microangiopathic	B	721-737
hemolytic	I	738-747
anemia	I	748-754
,	O	754-755
should	O	756-762
be	O	763-765
performed	O	766-775
with	O	776-780
caution	O	781-788
.	O	788-789

Effects	O	0-7
of	O	8-10
acetylsalicylic	O	11-26
acid	O	27-31
,	O	31-32
dipyridamole	O	33-45
,	O	45-46
and	O	47-50
hydrocortisone	O	51-65
on	O	66-68
epinephrine	O	69-80
-	O	80-81
induced	O	81-88
myocardial	B	89-99
injury	I	100-106
in	O	107-109
dogs	O	110-114
.	O	114-115

A	O	116-117
reproducible	O	118-130
model	O	131-136
for	O	137-140
producing	O	141-150
diffuse	O	151-158
myocardial	B	159-169
injury	I	170-176
(	O	177-178
epinephrine	O	178-189
infusion	O	190-198
)	O	198-199
has	O	200-203
been	O	204-208
developed	O	209-218
to	O	219-221
study	O	222-227
the	O	228-231
cardioprotective	O	232-248
effects	O	249-256
of	O	257-259
agents	O	260-266
or	O	267-269
maneuvers	O	270-279
which	O	280-285
might	O	286-291
alter	O	292-297
the	O	298-301
evolution	O	302-311
of	O	312-314
acute	O	315-320
myocardial	B	321-331
infarction	I	332-342
.	O	342-343

Infusions	O	344-353
of	O	354-356
epinephrine	O	357-368
(	O	369-370
4	O	370-371
mug	O	372-375
per	O	376-379
kilogram	O	380-388
per	O	389-392
minute	O	393-399
for	O	400-403
6	O	404-405
hours	O	406-411
)	O	411-412
increased	O	413-422
radiocalcium	O	423-435
uptakes	O	436-443
into	O	444-448
intact	O	449-455
myocardium	O	456-466
and	O	467-470
each	O	471-475
of	O	476-478
its	O	479-482
subcellular	O	483-494
components	O	495-505
with	O	506-510
the	O	511-514
mitochondrial	O	515-528
fraction	O	529-537
showing	O	538-545
the	O	546-549
most	O	550-554
consistent	O	555-565
changes	O	566-573
when	O	574-578
compared	O	579-587
to	O	588-590
saline	O	591-597
-	O	597-598
infused	O	598-605
control	O	606-613
animals	O	614-621
(	O	622-623
4	O	623-624
,	O	624-625
957	O	625-628
vs	O	629-631
.	O	631-632
827	O	633-636
counts	O	637-643
per	O	644-647
minute	O	648-654
per	O	655-658
gram	O	659-663
of	O	664-666
dried	O	667-672
tissue	O	673-679
or	O	680-682
fraction	O	683-691
)	O	691-692
.	O	692-693

Myocardial	O	694-704
concentrations	O	705-719
of	O	720-722
calcium	O	723-730
also	O	731-735
increased	O	736-745
significantly	O	746-759
(	O	760-761
12	O	761-763
.	O	763-764
0	O	764-765
vs	O	766-768
.	O	768-769
5	O	770-771
.	O	771-772
0	O	772-773
mg	O	774-776
.	O	776-777
per	O	777-780
100	O	781-784
Gm	O	785-787
.	O	787-788
of	O	789-791
fat	O	792-795
-	O	795-796
free	O	796-800
dry	O	801-804
weight	O	805-811
)	O	811-812
.	O	812-813

Infusions	O	814-823
of	O	824-826
calcium	O	827-834
chloride	O	835-843
sufficient	O	844-854
to	O	855-857
raise	O	858-863
serum	O	864-869
calcium	O	870-877
concentrations	O	878-892
2	O	893-894
mEq	O	895-898
.	O	898-899

per	O	900-903
liter	O	904-909
failed	O	910-916
to	O	917-919
increase	O	920-928
calcium	O	929-936
influx	O	937-943
into	O	944-948
the	O	949-952
myocardial	O	953-963
cell	O	964-968
.	O	968-969

Mitochondrial	O	970-983
radiocalcium	O	984-996
uptakes	O	997-1004
were	O	1005-1009
significantly	O	1010-1023
decreased	O	1024-1033
in	O	1034-1036
animals	O	1037-1044
pretreated	O	1045-1055
with	O	1056-1060
acetylsalicylic	O	1061-1076
acid	O	1077-1081
or	O	1082-1084
dipyridamole	O	1085-1097
or	O	1098-1100
when	O	1101-1105
hydrocortisone	O	1106-1120
was	O	1121-1124
added	O	1125-1130
to	O	1131-1133
the	O	1134-1137
epinephrine	O	1138-1149
infusion	O	1150-1158
(	O	1159-1160
2	O	1160-1161
,	O	1161-1162
682	O	1162-1165
,	O	1161-1162
2	O	1160-1161
,	O	1161-1162
803	O	1168-1171
,	O	1161-1162
and	O	1173-1176
3	O	1177-1178
,	O	1178-1179
424	O	1179-1182
counts	O	1183-1189
per	O	1190-1193
minute	O	1194-1200
per	O	1201-1204
gram	O	1205-1209
of	O	1210-1212
dried	O	1213-1218
fraction	O	1219-1227
,	O	1227-1228
respectively	O	1229-1241
)	O	1241-1242
.	O	1242-1243

Myocardial	O	1244-1254
calcium	O	1255-1262
concentrations	O	1263-1277
also	O	1278-1282
were	O	1283-1287
decreased	O	1288-1297
(	O	1298-1299
11	O	1299-1301
.	O	1301-1302
2	O	1302-1303
,	O	1303-1304
8	O	1305-1306
.	O	1306-1307
3	O	1307-1308
,	O	1308-1309
and	O	1310-1313
8	O	1314-1315
.	O	1315-1316
9	O	1316-1317
mg	O	1318-1320
.	O	1320-1321
per	O	1322-1325
100	O	1326-1329
Gm	O	1330-1332
.	O	1332-1333
of	O	1334-1336
fat	O	1337-1340
-	O	1340-1341
free	O	1341-1345
dry	O	1346-1349
weight	O	1350-1356
,	O	1356-1357
respectively	O	1358-1370
)	O	1370-1371
in	O	1372-1374
the	O	1375-1378
three	O	1379-1384
treatment	O	1385-1394
groups	O	1395-1401
,	O	1401-1402
being	O	1403-1408
significantly	O	1409-1422
decreased	O	1423-1432
only	O	1433-1437
in	O	1438-1440
the	O	1441-1444
last	O	1445-1449
two	O	1450-1453
.	O	1453-1454

Evidence	O	1455-1463
of	O	1464-1466
microscopic	O	1467-1478
damage	O	1479-1485
was	O	1486-1489
graded	O	1490-1496
as	O	1497-1499
less	O	1500-1504
severe	O	1505-1511
in	O	1512-1514
the	O	1515-1518
three	O	1519-1524
treatment	O	1525-1534
groups	O	1535-1541
.	O	1541-1542

Acetylsalicylic	O	1543-1558
acid	O	1559-1563
,	O	1563-1564
dipyridamole	O	1565-1577
,	O	1577-1578
and	O	1579-1582
hydrocortisone	O	1583-1597
all	O	1598-1601
appear	O	1602-1608
to	O	1609-1611
have	O	1612-1616
cardioprotective	O	1617-1633
effects	O	1634-1641
when	O	1642-1646
tested	O	1647-1653
in	O	1654-1656
this	O	1657-1661
model	O	1662-1667
.	O	1667-1668

Changes	O	0-7
in	O	8-10
depressive	B	11-21
status	O	22-28
associated	O	29-39
with	O	40-44
topical	O	45-52
beta	O	53-57
-	O	57-58
blockers	O	58-66
.	O	66-67

Depression	B	68-78
and	O	79-82
sexual	B	83-89
dysfunction	I	90-101
have	O	102-106
been	O	107-111
related	O	112-119
to	O	120-122
side	O	123-127
effects	O	128-135
of	O	136-138
topical	O	139-146
beta	O	147-151
-	O	151-152
blockers	O	152-160
.	O	160-161

We	O	162-164
performed	O	165-174
a	O	175-176
preliminary	O	177-188
study	O	189-194
in	O	195-197
order	O	198-203
to	O	204-206
determine	O	207-216
any	O	217-220
difference	O	221-231
between	O	232-239
a	O	240-241
non	O	242-245
selective	O	246-255
beta	O	256-260
-	O	260-261
blocker	O	261-268
(	O	269-270
timolol	O	270-277
)	O	277-278
and	O	279-282
a	O	283-284
selective	O	285-294
beta	O	295-299
-	O	299-300
blocker	O	300-307
(	O	308-309
betaxolol	O	309-318
)	O	318-319
regarding	O	320-329
CNS	O	330-333
side	O	334-338
effects	O	339-346
.	O	346-347

Eight	O	348-353
glaucomatous	B	354-366
patients	O	367-375
chronically	O	376-387
treated	O	388-395
with	O	396-400
timolol	O	401-408
0	O	409-410
.	O	410-411
5	O	411-412
%	O	412-413
/	O	413-414
12h	O	414-417
,	O	417-418
suffering	O	419-428
from	O	429-433
depression	B	434-444
diagnosed	O	445-454
through	O	455-462
DMS	O	463-466
-	O	466-467
III	O	467-470
-	O	466-467
R	O	471-472
criteria	O	473-481
,	O	481-482
were	O	483-487
included	O	488-496
in	O	497-499
the	O	500-503
study	O	504-509
.	O	509-510

During	O	511-517
the	O	518-521
six	O	522-525
-	O	525-526
month	O	526-531
follow	O	532-538
up	O	539-541
,	O	541-542
depression	B	543-553
was	O	554-557
quantified	O	558-568
through	O	569-576
the	O	577-580
Beck	O	581-585
and	O	586-589
Zung	O	590-594
-	O	594-595
Conde	O	595-600
scales	O	601-607
every	O	608-613
two	O	614-617
months	O	618-624
.	O	624-625

In	O	626-628
a	O	629-630
double	O	631-637
blind	O	638-643
cross	O	644-649
-	O	649-650
over	O	650-654
study	O	655-660
with	O	661-665
control	O	666-673
group	O	674-679
,	O	679-680
the	O	681-684
patients	O	685-693
under	O	694-699
timolol	O	700-707
treatment	O	708-717
presented	O	718-727
higher	O	728-734
depression	B	735-745
values	O	746-752
measured	O	753-761
through	O	762-769
the	O	770-773
Beck	O	774-778
and	O	779-782
the	O	783-786
Zung	O	787-791
-	O	791-792
Conde	O	792-797
scales	O	798-804
(	O	805-806
p	O	806-807
<	O	808-809
0	O	810-811
.	O	811-812
001	O	812-815
vs	O	816-818
control	O	819-826
)	O	826-827
.	O	827-828

These	O	829-834
results	O	835-842
suggest	O	843-850
that	O	851-855
betaxolol	O	856-865
could	O	866-871
be	O	872-874
less	O	875-879
of	O	880-882
a	O	883-884
depression	B	885-895
-	O	895-896
inducer	O	896-903
than	O	904-908
timolol	O	909-916
in	O	917-919
predisposed	O	920-931
patients	O	932-940
.	O	940-941

Long	O	0-4
-	O	4-5
term	O	5-9
follow	O	10-16
-	O	16-17
up	O	17-19
of	O	20-22
ifosfamide	O	23-33
renal	B	34-39
toxicity	I	40-48
in	O	49-51
children	O	52-60
treated	O	61-68
for	O	69-72
malignant	B	73-82
mesenchymal	I	83-94
tumors	I	95-101
:	O	101-102
an	O	103-105
International	O	106-119
Society	O	120-127
of	O	128-130
Pediatric	O	131-140
Oncology	O	141-149
report	O	150-156
.	O	156-157

The	O	158-161
renal	O	162-167
function	O	168-176
of	O	177-179
74	O	180-182
children	O	183-191
with	O	192-196
malignant	B	197-206
mesenchymal	I	207-218
tumors	I	219-225
in	O	226-228
complete	O	229-237
remission	O	238-247
and	O	248-251
who	O	252-255
have	O	256-260
received	O	261-269
the	O	270-273
same	O	274-278
ifosfamide	O	279-289
chemotherapy	O	290-302
protocol	O	303-311
(	O	312-313
International	O	313-326
Society	O	327-334
of	O	335-337
Pediatric	O	338-347
Oncology	O	348-356
Malignant	B	357-366
Mesenchymal	I	367-378
Tumor	I	379-384
Study	O	385-390
84	O	391-393
[	O	394-395
SIOP	O	395-399
MMT	O	400-403
84	O	404-406
]	O	406-407
)	O	407-408
were	O	409-413
studied	O	414-421
1	O	422-423
year	O	424-428
after	O	429-434
the	O	435-438
completion	O	439-449
of	O	450-452
treatment	O	453-462
.	O	462-463

Total	O	464-469
cumulative	O	470-480
doses	O	481-486
were	O	487-491
36	O	492-494
or	O	495-497
60	O	498-500
g	O	501-502
/	O	502-503
m2	O	503-505
of	O	506-508
ifosfamide	O	509-519
(	O	520-521
six	O	521-524
or	O	525-527
10	O	528-530
cycles	O	531-537
of	O	538-540
ifosfamide	O	541-551
,	O	551-552
vincristine	O	553-564
,	O	564-565
and	O	566-569
dactinomycin	O	570-582
[	O	583-584
IVA	O	584-587
]	O	587-588
)	O	588-589
.	O	589-590

None	O	591-595
of	O	596-598
them	O	599-603
had	O	604-607
received	O	608-616
cisplatin	O	617-626
chemotherapy	O	627-639
.	O	639-640

Ages	O	641-645
ranged	O	646-652
from	O	653-657
4	O	658-659
months	O	660-666
to	O	667-669
17	O	670-672
years	O	673-678
;	O	678-679
58	O	680-682
patients	O	683-691
were	O	692-696
males	O	697-702
and	O	703-706
42	O	707-709
females	O	710-717
.	O	717-718

The	O	719-722
most	O	723-727
common	O	728-734
primary	O	735-742
tumor	B	743-748
site	O	749-753
was	O	754-757
the	O	758-761
head	O	762-766
and	O	767-770
neck	O	771-775
.	O	775-776

Renal	O	777-782
function	O	783-791
was	O	792-795
investigated	O	796-808
by	O	809-811
measuring	O	812-821
plasma	O	822-828
and	O	829-832
urinary	O	833-840
electrolytes	O	841-853
,	O	853-854
glucosuria	B	855-865
,	O	865-866
proteinuria	B	867-878
,	O	878-879
aminoaciduria	B	880-893
,	O	893-894
urinary	O	895-902
pH	O	903-905
,	O	905-906
osmolarity	O	907-917
,	O	917-918
creatinine	O	919-929
clearance	O	930-939
,	O	939-940
phosphate	O	941-950
tubular	O	951-958
reabsorption	O	959-971
,	O	971-972
beta	O	973-977
2	O	978-979
microglobulinuria	O	980-997
,	O	997-998
and	O	999-1002
lysozymuria	O	1003-1014
.	O	1014-1015

Fifty	O	1016-1021
-	O	1021-1022
eight	O	1022-1027
patients	O	1028-1036
(	O	1037-1038
78	O	1038-1040
%	O	1040-1041
)	O	1041-1042
had	O	1043-1046
normal	O	1047-1053
renal	O	1054-1059
tests	O	1060-1065
,	O	1065-1066
whereas	O	1067-1074
16	O	1075-1077
patients	O	1078-1086
(	O	1087-1088
22	O	1088-1090
%	O	1090-1091
)	O	1091-1092
had	O	1093-1096
renal	B	1097-1102
abnormalities	I	1103-1116
.	O	1116-1117

Two	O	1118-1121
subsets	O	1122-1129
of	O	1130-1132
patients	O	1133-1141
were	O	1142-1146
identified	O	1147-1157
from	O	1158-1162
this	O	1163-1167
latter	O	1168-1174
group	O	1175-1180
:	O	1180-1181
the	O	1182-1185
first	O	1186-1191
included	O	1192-1200
four	O	1201-1205
patients	O	1206-1214
(	O	1215-1216
5	O	1216-1217
%	O	1217-1218
of	O	1219-1221
the	O	1222-1225
total	O	1226-1231
population	O	1232-1242
)	O	1242-1243
who	O	1244-1247
developed	O	1248-1257
major	O	1258-1263
toxicity	B	1264-1272
resulting	O	1273-1282
in	O	1283-1285
Fanconi	B	1286-1293
'	I	1293-1294
s	I	1294-1295
syndrome	I	1296-1304
(	O	1305-1306
TDFS	B	1306-1310
)	O	1310-1311
;	O	1311-1312
and	O	1313-1316
the	O	1317-1320
second	O	1321-1327
group	O	1328-1333
included	O	1334-1342
five	O	1343-1347
patients	O	1348-1356
with	O	1357-1361
elevated	O	1362-1370
beta	O	1371-1375
2	O	1376-1377
microglobulinuria	O	1378-1395
and	O	1396-1399
low	O	1400-1403
phosphate	O	1404-1413
reabsorption	O	1414-1426
.	O	1426-1427

The	O	1428-1431
remaining	O	1432-1441
seven	O	1442-1447
patients	O	1448-1456
had	O	1457-1460
isolated	O	1461-1469
beta	O	1470-1474
2	O	1475-1476
microglobulinuria	O	1477-1494
.	O	1494-1495

Severe	O	1496-1502
toxicity	B	1503-1511
was	O	1512-1515
correlated	O	1516-1526
with	O	1527-1531
the	O	1532-1535
higher	O	1536-1542
cumulative	O	1543-1553
dose	O	1554-1558
of	O	1559-1561
60	O	1562-1564
g	O	1565-1566
/	O	1566-1567
m2	O	1567-1569
of	O	1570-1572
ifosfamide	O	1573-1583
,	O	1583-1584
a	O	1585-1586
younger	O	1587-1594
age	O	1595-1598
(	O	1599-1600
less	O	1600-1604
than	O	1605-1609
2	O	1610-1611
1	O	1612-1613
/	O	1613-1614
2	O	1614-1615
years	O	1616-1621
old	O	1622-1625
)	O	1625-1626
,	O	1626-1627
and	O	1628-1631
a	O	1632-1633
predominance	O	1634-1646
of	O	1647-1649
vesicoprostatic	O	1650-1665
tumor	B	1666-1671
involvement	O	1672-1683
.	O	1683-1684

This	O	1685-1689
low	O	1690-1693
percentage	O	1694-1704
(	O	1705-1706
5	O	1706-1707
%	O	1707-1708
)	O	1708-1709
of	O	1710-1712
TDFS	O	1713-1717
must	O	1718-1722
be	O	1723-1725
evaluated	O	1726-1735
with	O	1736-1740
respect	O	1741-1748
to	O	1749-1751
the	O	1752-1755
efficacy	O	1756-1764
of	O	1765-1767
ifosfamide	O	1768-1778
in	O	1779-1781
the	O	1782-1785
treatment	O	1786-1795
of	O	1796-1798
mesenchymal	B	1799-1810
tumors	I	1811-1817
in	O	1818-1820
children	O	1821-1829
.	O	1829-1830

Evidence	O	0-8
for	O	9-12
an	O	13-15
involvement	O	16-27
of	O	28-30
D1	O	31-33
and	O	34-37
D2	O	38-40
dopamine	O	41-49
receptors	O	50-59
in	O	60-62
mediating	O	63-72
nicotine	O	73-81
-	O	81-82
induced	O	82-89
hyperactivity	B	90-103
in	O	104-106
rats	O	107-111
.	O	111-112

Previous	O	113-121
studies	O	122-129
have	O	130-134
suggested	O	135-144
that	O	145-149
repeated	O	150-158
exposure	O	159-167
of	O	168-170
rats	O	171-175
to	O	176-178
the	O	179-182
drug	O	183-187
or	O	188-190
to	O	191-193
the	O	194-197
experimental	O	198-210
environment	O	211-222
is	O	223-225
necessary	O	226-235
to	O	236-238
observe	O	239-246
nicotine	O	247-255
-	O	255-256
induced	O	256-263
locomotor	O	264-273
stimulation	O	274-285
.	O	285-286

In	O	287-289
the	O	290-293
present	O	294-301
study	O	302-307
the	O	308-311
role	O	312-316
of	O	317-319
habituation	O	320-331
to	O	332-334
the	O	335-338
experimental	O	339-351
environment	O	352-363
on	O	364-366
the	O	367-370
stimulant	O	371-380
effect	O	381-387
of	O	388-390
nicotine	O	391-399
in	O	400-402
rats	O	403-407
was	O	408-411
examined	O	412-420
.	O	420-421

In	O	422-424
addition	O	425-433
,	O	433-434
the	O	435-438
role	O	439-443
of	O	444-446
dopamine	O	447-455
receptors	O	456-465
in	O	466-468
mediating	O	469-478
nicotine	O	479-487
-	O	487-488
induced	O	488-495
locomotor	O	496-505
stimulation	O	506-517
was	O	518-521
investigated	O	522-534
by	O	535-537
examining	O	538-547
the	O	548-551
effects	O	552-559
of	O	560-562
selective	O	563-572
D1	O	573-575
and	O	576-579
D2	O	580-582
dopamine	O	583-591
receptor	O	592-600
antagonists	O	601-612
on	O	613-615
activity	O	616-624
induced	O	625-632
by	O	633-635
nicotine	O	636-644
.	O	644-645

Locomotor	O	646-655
activity	O	656-664
was	O	665-668
assessed	O	669-677
in	O	678-680
male	O	681-685
Sprague	O	686-693
-	O	693-694
Dawley	O	694-700
rats	O	701-705
tested	O	706-712
in	O	713-715
photocell	O	716-725
cages	O	726-731
.	O	731-732

Nicotine	O	733-741
(	O	742-743
1	O	743-744
.	O	744-745
0	O	745-746
mg	O	747-749
/	O	749-750
kg	O	750-752
)	O	752-753
caused	O	754-760
a	O	761-762
significant	O	763-774
increase	B	775-783
in	I	784-786
locomotor	I	787-796
activity	I	797-805
in	O	806-808
rats	O	809-813
that	O	814-818
were	O	819-823
habituated	O	824-834
to	O	835-837
the	O	838-841
test	O	842-846
environment	O	847-858
,	O	858-859
but	O	860-863
had	O	864-867
only	O	868-872
a	O	873-874
weak	O	875-879
and	O	880-883
delayed	O	884-891
stimulant	O	892-901
action	O	902-908
in	O	909-911
rats	O	912-916
that	O	917-921
were	O	922-926
unfamiliar	O	927-937
with	O	938-942
the	O	943-946
test	O	947-951
environment	O	952-963
.	O	963-964

The	O	965-968
stimulant	O	969-978
action	O	979-985
of	O	986-988
nicotine	O	989-997
was	O	998-1001
blocked	O	1002-1009
by	O	1010-1012
the	O	1013-1016
central	O	1017-1024
nicotinic	O	1025-1034
antagonist	O	1035-1045
mecamylamine	O	1046-1058
but	O	1059-1062
not	O	1063-1066
by	O	1067-1069
the	O	1070-1073
peripheral	O	1074-1084
nicotinic	O	1085-1094
blocker	O	1095-1102
hexamethonium	O	1103-1116
,	O	1116-1117
indicating	O	1118-1128
that	O	1129-1133
the	O	1134-1137
response	O	1138-1146
is	O	1147-1149
probably	O	1150-1158
mediated	O	1159-1167
by	O	1168-1170
central	O	1171-1178
nicotinic	O	1179-1188
receptors	O	1189-1198
.	O	1198-1199

Nicotine	O	1200-1208
-	O	1208-1209
induced	O	1209-1216
hyperactivity	B	1217-1230
was	O	1231-1234
blocked	O	1235-1242
by	O	1243-1245
the	O	1246-1249
selective	O	1250-1259
D1	O	1260-1262
antagonist	O	1263-1273
SCH	O	1274-1277
23390	O	1278-1283
,	O	1283-1284
the	O	1285-1288
selective	O	1289-1298
D2	O	1299-1301
antagonist	O	1302-1312
raclopride	O	1313-1323
and	O	1324-1327
the	O	1328-1331
D1	O	1332-1334
/	O	1334-1335
D2	O	1335-1337
antagonist	O	1338-1348
fluphenazine	O	1349-1361
.	O	1361-1362

Pretreatment	O	1363-1375
with	O	1376-1380
the	O	1381-1384
D2	O	1385-1387
agonist	O	1388-1395
PHNO	O	1396-1400
enhanced	O	1401-1409
nicotine	O	1410-1418
-	O	1418-1419
induced	O	1419-1426
hyperactivity	B	1427-1440
,	O	1440-1441
whereas	O	1442-1449
the	O	1450-1453
D1	O	1454-1456
agonist	O	1457-1464
SKF	O	1465-1468
38393	O	1469-1474
had	O	1475-1478
no	O	1479-1481
effect	O	1482-1488
.	O	1488-1489

The	O	1490-1493
results	O	1494-1501
indicate	O	1502-1510
that	O	1511-1515
acute	O	1516-1521
nicotine	O	1522-1530
injection	O	1531-1540
induces	O	1541-1548
a	O	1549-1550
pronounced	O	1551-1561
hyperactivity	B	1562-1575
in	O	1576-1578
rats	O	1579-1583
habituated	O	1584-1594
to	O	1595-1597
the	O	1598-1601
test	O	1602-1606
environment	O	1607-1618
.	O	1618-1619

The	O	1620-1623
effect	O	1624-1630
appears	O	1631-1638
to	O	1639-1641
be	O	1642-1644
mediated	O	1645-1653
by	O	1654-1656
central	O	1657-1664
nicotine	O	1665-1673
receptors	O	1674-1683
,	O	1683-1684
possibly	O	1685-1693
located	O	1694-1701
on	O	1702-1704
dopaminergic	O	1705-1717
neurons	O	1718-1725
,	O	1725-1726
and	O	1727-1730
also	O	1731-1735
requires	O	1736-1744
the	O	1745-1748
activation	O	1749-1759
of	O	1760-1762
both	O	1763-1767
D1	O	1768-1770
and	O	1771-1774
D2	O	1775-1777
dopamine	O	1778-1786
receptors	O	1787-1796
.	O	1796-1797

Neuropsychiatric	O	0-16
side	O	17-21
effects	O	22-29
after	O	30-35
the	O	36-39
use	O	40-43
of	O	44-46
mefloquine	O	47-57
.	O	57-58

This	O	59-63
study	O	64-69
describes	O	70-79
neuropsychiatric	O	80-96
side	O	97-101
effects	O	102-109
in	O	110-112
patients	O	113-121
after	O	122-127
treatment	O	128-137
with	O	138-142
mefloquine	O	143-153
.	O	153-154

Reactions	O	155-164
consisted	O	165-174
mainly	O	175-181
of	O	182-184
seizures	B	185-193
,	O	193-194
acute	O	195-200
psychoses	B	201-210
,	O	210-211
anxiety	B	212-219
neurosis	I	220-228
,	O	228-229
and	O	230-233
major	O	234-239
disturbances	B	240-252
of	I	253-255
sleep	I	256-261
-	I	261-262
wake	I	262-266
rhythm	I	267-273
.	O	273-274

Side	O	275-279
effects	O	280-287
occurred	O	288-296
after	O	297-302
both	O	303-307
therapeutic	O	308-319
and	O	320-323
prophylactic	O	324-336
intake	O	337-343
and	O	344-347
were	O	348-352
graded	O	353-359
from	O	360-364
moderate	O	365-373
to	O	374-376
severe	O	377-383
.	O	383-384

In	O	385-387
a	O	388-389
risk	O	390-394
analysis	O	395-403
of	O	404-406
neuropsychiatric	O	407-423
side	O	424-428
effects	O	429-436
in	O	437-439
Germany	O	440-447
,	O	447-448
it	O	449-451
is	O	452-454
estimated	O	455-464
that	O	465-469
one	O	470-473
of	O	474-476
8	O	477-478
,	O	478-479
000	O	479-482
mefloquine	O	483-493
users	O	494-499
suffers	O	500-507
from	O	508-512
such	O	513-517
reactions	O	518-527
.	O	527-528

The	O	529-532
incidence	O	533-542
calculation	O	543-554
revealed	O	555-563
that	O	564-568
one	O	569-572
of	O	573-575
215	O	576-579
therapeutic	O	580-591
users	O	592-597
had	O	598-601
reactions	O	602-611
,	O	611-612
compared	O	613-621
with	O	622-626
one	O	627-630
of	O	631-633
13	O	634-636
,	O	636-637
000	O	637-640
in	O	641-643
the	O	644-647
prophylaxis	O	648-659
group	O	660-665
,	O	665-666
making	O	667-673
the	O	674-677
risk	O	678-682
of	O	683-685
neuropsychiatric	O	686-702
reactions	O	703-712
after	O	713-718
mefloquine	O	719-729
treatment	O	730-739
60	O	740-742
times	O	743-748
higher	O	749-755
than	O	756-760
after	O	761-766
prophylaxis	O	767-778
.	O	778-779

Therefore	O	780-789
,	O	789-790
certain	O	791-798
limitations	O	799-810
for	O	811-814
malaria	B	815-822
prophylaxis	O	823-834
and	O	835-838
treatment	O	839-848
with	O	849-853
mefloquine	O	854-864
are	O	865-868
recommended	O	869-880
.	O	880-881

Reduction	O	0-9
in	O	10-12
injection	O	13-22
pain	B	23-27
using	O	28-33
buffered	O	34-42
lidocaine	O	43-52
as	O	53-55
a	O	56-57
local	O	58-63
anesthetic	O	64-74
before	O	75-81
cardiac	O	82-89
catheterization	O	90-105
.	O	105-106

Previous	O	107-115
reports	O	116-123
have	O	124-128
suggested	O	129-138
that	O	139-143
pain	B	144-148
associated	O	149-159
with	O	160-164
the	O	165-168
injection	O	169-178
of	O	179-181
lidocaine	O	182-191
is	O	192-194
related	O	195-202
to	O	203-205
the	O	206-209
acidic	O	210-216
pH	O	217-219
of	O	220-222
the	O	223-226
solution	O	227-235
.	O	235-236

To	O	237-239
determine	O	240-249
if	O	250-252
the	O	253-256
addition	O	257-265
of	O	266-268
a	O	269-270
buffering	O	271-280
solution	O	281-289
to	O	290-292
adjust	O	293-299
the	O	300-303
pH	O	304-306
of	O	307-309
lidocaine	O	310-319
into	O	320-324
the	O	325-328
physiologic	O	329-340
range	O	341-346
would	O	347-352
reduce	O	353-359
pain	B	360-364
during	O	365-371
injection	O	372-381
,	O	381-382
we	O	383-385
performed	O	386-395
a	O	396-397
blinded	O	398-405
randomized	O	406-416
study	O	417-422
in	O	423-425
patients	O	426-434
undergoing	O	435-445
cardiac	O	446-453
catheterization	O	454-469
.	O	469-470

Twenty	O	471-477
patients	O	478-486
were	O	487-491
asked	O	492-497
to	O	498-500
quantify	O	501-509
the	O	510-513
severity	O	514-522
of	O	523-525
pain	B	526-530
after	O	531-536
receiving	O	537-546
standard	O	547-555
lidocaine	O	556-565
in	O	566-568
one	O	569-572
femoral	O	573-580
area	O	581-585
and	O	586-589
buffered	O	590-598
lidocaine	O	599-608
in	O	609-611
the	O	612-615
opposite	O	616-624
femoral	O	625-632
area	O	633-637
.	O	637-638

The	O	639-642
mean	O	643-647
pain	B	648-652
score	O	653-658
for	O	659-662
buffered	O	663-671
lidocaine	O	672-681
was	O	682-685
significantly	O	686-699
lower	O	700-705
than	O	706-710
the	O	711-714
mean	O	715-719
score	O	720-725
for	O	726-729
standard	O	730-738
lidocaine	O	739-748
(	O	749-750
2	O	750-751
.	O	751-752
7	O	752-753
+	O	754-755
/	O	755-756
-	O	756-757
1	O	758-759
.	O	759-760
9	O	760-761
vs	O	762-764
.	O	764-765
3	O	766-767
.	O	767-768
8	O	768-769
+	O	770-771
/	O	771-772
-	O	772-773
2	O	774-775
.	O	775-776
2	O	774-775
,	O	777-778
P	O	779-780
=	O	781-782
0	O	783-784
.	O	784-785
03	O	785-787
)	O	787-788
.	O	784-785

The	O	790-793
pH	O	794-796
adjustment	O	797-807
of	O	808-810
standard	O	811-819
lidocaine	O	820-829
can	O	830-833
be	O	834-836
accomplished	O	837-849
easily	O	850-856
in	O	857-859
the	O	860-863
catheterization	O	864-879
laboratory	O	880-890
before	O	891-897
injection	O	898-907
and	O	908-911
results	O	912-919
in	O	920-922
a	O	923-924
reduction	O	925-934
of	O	935-937
the	O	938-941
pain	B	942-946
occurring	O	947-956
during	O	957-963
the	O	964-967
infiltration	O	968-980
of	O	981-983
tissues	O	984-991
.	O	991-992

Randomized	O	0-10
,	O	10-11
double	O	12-18
-	O	18-19
blind	O	19-24
trial	O	25-30
of	O	31-33
mazindol	O	34-42
in	O	43-45
Duchenne	B	46-54
dystrophy	I	55-64
.	O	64-65

There	O	66-71
is	O	72-74
evidence	O	75-83
that	O	84-88
growth	O	89-95
hormone	O	96-103
may	O	104-107
be	O	108-110
related	O	111-118
to	O	119-121
the	O	122-125
progression	O	126-137
of	O	138-140
weakness	B	141-149
in	O	150-152
Duchenne	B	153-161
dystrophy	I	162-171
.	O	171-172

We	O	173-175
conducted	O	176-185
a	O	186-187
12	O	188-190
-	O	190-191
month	O	191-196
controlled	O	197-207
trial	O	208-213
of	O	214-216
mazindol	O	217-225
,	O	225-226
a	O	227-228
putative	O	229-237
growth	O	238-244
hormone	O	245-252
secretion	O	253-262
inhibitor	O	263-272
,	O	272-273
in	O	274-276
83	O	277-279
boys	O	280-284
with	O	285-289
Duchenne	B	290-298
dystrophy	I	299-308
.	O	308-309

Muscle	O	310-316
strength	O	317-325
,	O	325-326
contractures	O	327-339
,	O	339-340
functional	O	341-351
ability	O	352-359
and	O	360-363
pulmonary	O	364-373
function	O	374-382
were	O	383-387
tested	O	388-394
at	O	395-397
baseline	O	398-406
,	O	406-407
and	O	408-411
6	O	412-413
and	O	414-417
12	O	418-420
months	O	421-427
after	O	428-433
treatment	O	434-443
with	O	444-448
mazindol	O	449-457
(	O	458-459
3	O	459-460
mg	O	461-463
/	O	463-464
d	O	464-465
)	O	465-466
or	O	467-469
placebo	O	470-477
.	O	477-478

The	O	479-482
study	O	483-488
was	O	489-492
designed	O	493-501
to	O	502-504
have	O	505-509
a	O	510-511
power	O	512-517
of	O	518-520
greater	O	521-528
than	O	529-533
0	O	534-535
.	O	535-536
90	O	536-538
to	O	539-541
detect	O	542-548
a	O	549-550
slowing	O	551-558
to	O	559-561
25	O	562-564
%	O	564-565
of	O	566-568
the	O	569-572
expected	O	573-581
rate	O	582-586
of	O	587-589
progression	O	590-601
of	O	602-604
weakness	B	605-613
at	O	614-616
P	O	617-618
less	O	619-623
than	O	624-628
0	O	629-630
.	O	630-631
05	O	631-633
.	O	630-631

Mazindol	O	635-643
did	O	644-647
not	O	648-651
benefit	O	652-659
strength	O	660-668
at	O	669-671
any	O	672-675
point	O	676-681
in	O	682-684
the	O	685-688
study	O	689-694
.	O	694-695

Side	O	696-700
effects	O	701-708
attributable	O	709-721
to	O	722-724
mazindol	O	725-733
included	O	734-742
decreased	B	743-752
appetite	I	753-761
(	O	762-763
36	O	763-765
%	O	765-766
)	O	766-767
,	O	767-768
dry	B	769-772
mouth	I	773-778
(	O	779-780
10	O	780-782
%	O	782-783
)	O	783-784
,	O	784-785
behavioral	O	786-796
change	O	797-803
(	O	804-805
22	O	805-807
%	O	807-808
)	O	808-809
,	O	809-810
and	O	811-814
gastrointestinal	B	815-831
symptoms	I	832-840
(	O	841-842
18	O	842-844
%	O	844-845
)	O	845-846
;	O	846-847
mazindol	O	848-856
dosage	O	857-863
was	O	864-867
reduced	O	868-875
in	O	876-878
43	O	879-881
%	O	881-882
of	O	883-885
patients	O	886-894
.	O	894-895

The	O	896-899
effect	O	900-906
of	O	907-909
mazindol	O	910-918
on	O	919-921
GH	O	922-924
secretion	O	925-934
was	O	935-938
estimated	O	939-948
indirectly	O	949-959
by	O	960-962
comparing	O	963-972
the	O	973-976
postabsorptive	O	977-991
IGF	O	992-995
-	O	995-996
I	O	992-993
levels	O	998-1004
obtained	O	1005-1013
following	O	1014-1023
3	O	1024-1025
,	O	1025-1026
6	O	1027-1028
,	O	1028-1029
9	O	1030-1031
,	O	1031-1032
and	O	1033-1036
12	O	1037-1039
months	O	1040-1046
in	O	1047-1049
the	O	1050-1053
mazindol	O	1054-1062
treated	O	1063-1070
to	O	1071-1073
those	O	1074-1079
in	O	1080-1082
the	O	1083-1086
placebo	O	1087-1094
groups	O	1095-1101
.	O	1101-1102

Although	O	1103-1111
mazindol	O	1112-1120
-	O	1120-1121
treated	O	1121-1128
patients	O	1129-1137
gained	O	1138-1144
less	O	1145-1149
weight	O	1150-1156
and	O	1157-1160
height	O	1161-1167
than	O	1168-1172
placebo	O	1173-1180
-	O	1180-1181
treated	O	1181-1188
patients	O	1189-1197
,	O	1197-1198
no	O	1199-1201
significant	O	1202-1213
effect	O	1214-1220
on	O	1221-1223
IGF	O	1224-1227
-	O	1227-1228
I	O	1224-1225
levels	O	1230-1236
was	O	1237-1240
observed	O	1241-1249
.	O	1249-1250

Mazindol	O	1251-1259
doses	O	1260-1265
not	O	1266-1269
slow	O	1270-1274
the	O	1275-1278
progression	O	1279-1290
of	O	1291-1293
weakness	B	1294-1302
in	O	1303-1305
Duchenne	B	1306-1314
dystrophy	I	1315-1324
.	O	1324-1325

Pentoxifylline	O	0-14
(	O	15-16
Trental	O	16-23
)	O	23-24
does	O	25-29
not	O	30-33
inhibit	O	34-41
dipyridamole	O	42-54
-	O	54-55
induced	O	55-62
coronary	O	63-71
hyperemia	B	72-81
:	O	81-82
implications	O	83-95
for	O	96-99
dipyridamole	O	100-112
-	O	112-113
thallium	O	113-121
-	O	112-113
201	O	122-125
myocardial	O	126-136
imaging	O	137-144
.	O	144-145

Dipyridamole	O	146-158
-	O	158-159
thallium	O	159-167
-	O	158-159
201	O	168-171
imaging	O	172-179
is	O	180-182
often	O	183-188
performed	O	189-198
in	O	199-201
patients	O	202-210
unable	O	211-217
to	O	218-220
exercise	O	221-229
because	O	230-237
of	O	238-240
peripheral	B	241-251
vascular	I	252-260
disease	I	261-268
.	O	268-269

Many	O	270-274
of	O	275-277
these	O	278-283
patients	O	284-292
are	O	293-296
taking	O	297-303
pentoxifylline	O	304-318
(	O	319-320
Trental	O	320-327
)	O	327-328
,	O	328-329
a	O	330-331
methylxanthine	O	332-346
derivative	O	347-357
which	O	358-363
may	O	364-367
improve	O	368-375
intermittent	B	376-388
claudication	I	389-401
.	O	401-402

Whether	O	403-410
pentoxifylline	O	411-425
inhibits	O	426-434
dipyridamole	O	435-447
-	O	447-448
induced	O	448-455
coronary	O	456-464
hyperemia	B	465-474
like	O	475-479
other	O	480-485
methylxanthines	O	486-501
such	O	502-506
as	O	507-509
theophylline	O	510-522
and	O	523-526
should	O	527-533
be	O	534-536
stopped	O	537-544
prior	O	545-550
to	O	551-553
dipyridamole	O	554-566
-	O	566-567
thallium	O	567-575
-	O	566-567
201	O	576-579
imaging	O	580-587
is	O	588-590
unknown	O	591-598
.	O	598-599

Therefore	O	600-609
,	O	609-610
we	O	611-613
studied	O	614-621
the	O	622-625
hyperemic	O	626-635
response	O	636-644
to	O	645-647
dipyridamole	O	648-660
in	O	661-663
seven	O	664-669
open	O	670-674
-	O	674-675
chest	O	675-680
anesthetized	O	681-693
dogs	O	694-698
after	O	699-704
pretreatment	O	705-717
with	O	718-722
either	O	723-729
pentoxifylline	O	730-744
(	O	745-746
0	O	746-747
,	O	747-748
7	O	749-750
.	O	750-751
5	O	751-752
,	O	752-753
or	O	754-756
15	O	757-759
mg	O	760-762
/	O	762-763
kg	O	763-765
i	O	766-767
.	O	767-768
v	O	768-769
.	O	767-768
)	O	770-771
or	O	772-774
theophylline	O	775-787
(	O	788-789
3	O	789-790
mg	O	791-793
/	O	793-794
kg	O	794-796
i	O	797-798
.	O	798-799
v	O	799-800
.	O	798-799
)	O	801-802
.	O	798-799

Baseline	O	804-812
circumflex	O	813-823
coronary	O	824-832
blood	O	833-838
flows	O	839-844
did	O	845-848
not	O	849-852
differ	O	853-859
significantly	O	860-873
among	O	874-879
treatment	O	880-889
groups	O	890-896
.	O	896-897

Dipyridamole	O	898-910
significantly	O	911-924
increased	O	925-934
coronary	O	935-943
blood	O	944-949
flow	O	950-954
before	O	955-961
and	O	962-965
after	O	966-971
7	O	972-973
.	O	973-974
5	O	974-975
or	O	976-978
15	O	979-981
mm	O	982-984
/	O	984-985
kg	O	985-987
i	O	988-989
.	O	989-990
v	O	990-991
.	O	989-990

pentoxifylline	O	993-1007
(	O	1008-1009
p	O	1009-1010
less	O	1011-1015
than	O	1016-1020
0	O	1021-1022
.	O	1022-1023
002	O	1023-1026
)	O	1026-1027
.	O	1022-1023

Neither	O	1029-1036
dose	O	1037-1041
of	O	1042-1044
pentoxifylline	O	1045-1059
significantly	O	1060-1073
decreased	O	1074-1083
the	O	1084-1087
dipyridamole	O	1088-1100
-	O	1100-1101
induced	O	1101-1108
hyperemia	B	1109-1118
,	O	1118-1119
while	O	1120-1125
peak	O	1126-1130
coronary	O	1131-1139
blood	O	1140-1145
flow	O	1146-1150
was	O	1151-1154
significantly	O	1155-1168
lower	O	1169-1174
after	O	1175-1180
theophylline	O	1181-1193
(	O	1194-1195
p	O	1195-1196
less	O	1197-1201
than	O	1202-1206
0	O	1207-1208
.	O	1208-1209
01	O	1209-1211
)	O	1211-1212
.	O	1208-1209

We	O	1214-1216
conclude	O	1217-1225
that	O	1226-1230
pentoxyifylline	O	1231-1246
does	O	1247-1251
not	O	1252-1255
inhibit	O	1256-1263
dipyridamole	O	1264-1276
-	O	1276-1277
induced	O	1277-1284
coronary	O	1285-1293
hyperemia	B	1294-1303
even	O	1304-1308
at	O	1309-1311
high	O	1312-1316
doses	O	1317-1322
.	O	1322-1323

Cause	O	0-5
of	O	6-8
death	B	9-14
among	O	15-20
patients	O	21-29
with	O	30-34
Parkinson	B	35-44
'	I	44-45
s	I	41-42
disease	I	47-54
:	O	54-55
a	O	56-57
rare	O	58-62
mortality	O	63-72
due	O	73-76
to	O	77-79
cerebral	B	80-88
haemorrhage	I	89-100
.	O	100-101

Causes	O	102-108
of	O	109-111
death	B	112-117
,	O	117-118
with	O	119-123
special	O	124-131
reference	O	132-141
to	O	142-144
cerebral	B	145-153
haemorrhage	I	154-165
,	O	165-166
among	O	167-172
240	O	173-176
patients	O	177-185
with	O	186-190
pathologically	O	191-205
verified	O	206-214
Parkinson	B	215-224
'	I	224-225
s	I	221-222
disease	I	227-234
were	O	235-239
investigated	O	240-252
using	O	253-258
the	O	259-262
Annuals	O	263-270
of	O	271-273
the	O	274-277
Pathological	O	278-290
Autopsy	O	291-298
Cases	O	299-304
in	O	305-307
Japan	O	308-313
from	O	314-318
1981	O	319-323
to	O	324-326
1985	O	327-331
.	O	331-332

The	O	333-336
leading	O	337-344
causes	O	345-351
of	O	352-354
death	B	355-360
were	O	361-365
pneumonia	B	366-375
and	O	376-379
bronchitis	B	380-390
(	O	391-392
44	O	392-394
.	O	394-395
1	O	395-396
%	O	396-397
)	O	397-398
,	O	398-399
malignant	O	400-409
neoplasms	B	410-419
(	O	420-421
11	O	421-423
.	O	423-424
6	O	424-425
%	O	425-426
)	O	426-427
,	O	427-428
heart	B	429-434
diseases	I	435-443
(	O	444-445
4	O	445-446
.	O	446-447
1	O	447-448
%	O	448-449
)	O	449-450
,	O	450-451
cerebral	B	452-460
infarction	I	461-471
(	O	472-473
3	O	473-474
.	O	474-475
7	O	475-476
%	O	476-477
)	O	477-478
and	O	479-482
septicaemia	B	483-494
(	O	495-496
3	O	496-497
.	O	497-498
3	O	496-497
%	O	499-500
)	O	500-501
.	O	497-498

Cerebral	B	503-511
haemorrhage	I	512-523
was	O	524-527
the	O	528-531
11th	O	532-536
most	O	537-541
frequent	O	542-550
cause	O	551-556
of	O	557-559
death	B	560-565
,	O	565-566
accounting	O	567-577
for	O	578-581
only	O	582-586
0	O	587-588
.	O	588-589
8	O	589-590
%	O	590-591
of	O	592-594
deaths	B	595-601
among	O	602-607
the	O	608-611
patients	O	612-620
,	O	620-621
whereas	O	622-629
it	O	630-632
was	O	633-636
the	O	637-640
5th	O	641-644
most	O	645-649
common	O	650-656
cause	O	657-662
of	O	663-665
death	B	666-671
among	O	672-677
the	O	678-681
Japanese	O	682-690
general	O	691-698
population	O	699-709
in	O	710-712
1985	O	713-717
.	O	717-718

The	O	719-722
low	O	723-726
incidence	O	727-736
of	O	737-739
cerebral	B	740-748
haemorrhage	I	749-760
as	O	761-763
a	O	764-765
cause	O	766-771
of	O	772-774
death	B	775-780
in	O	781-783
patients	O	784-792
with	O	793-797
Parkinson	B	798-807
'	I	807-808
s	I	804-805
disease	I	810-817
may	O	818-821
reflect	O	822-829
the	O	830-833
hypotensive	B	834-845
effect	O	846-852
of	O	853-855
levodopa	O	856-864
and	O	865-868
a	O	869-870
hypotensive	B	871-882
mechanism	O	883-892
due	O	893-896
to	O	897-899
reduced	O	900-907
noradrenaline	O	908-921
levels	O	922-928
in	O	929-931
the	O	932-935
parkinsonian	B	936-948
brain	O	949-954
.	O	954-955

Tolerance	O	0-9
and	O	10-13
antiviral	O	14-23
effect	O	24-30
of	O	31-33
ribavirin	O	34-43
in	O	44-46
patients	O	47-55
with	O	56-60
Argentine	B	61-70
hemorrhagic	I	71-82
fever	I	83-88
.	O	88-89

Tolerance	O	90-99
and	O	100-103
antiviral	O	104-113
effect	O	114-120
of	O	121-123
ribavirin	O	124-133
was	O	134-137
studied	O	138-145
in	O	146-148
6	O	149-150
patients	O	151-159
with	O	160-164
Argentine	B	165-174
hemorrhagic	I	175-186
fever	I	187-192
(	O	193-194
AHF	B	194-197
)	O	197-198
of	O	199-201
more	O	202-206
than	O	207-211
8	O	212-213
days	O	214-218
of	O	219-221
evolution	O	222-231
.	O	231-232

Administration	O	233-247
of	O	248-250
ribavirin	O	251-260
resulted	O	261-269
in	O	270-272
a	O	273-274
neutralization	O	275-289
of	O	290-292
viremia	B	293-300
and	O	301-304
a	O	305-306
drop	O	307-311
of	O	312-314
endogenous	O	315-325
interferon	O	326-336
titers	O	337-343
.	O	343-344

The	O	345-348
average	O	349-356
time	O	357-361
of	O	362-364
death	B	365-370
was	O	371-374
delayed	O	375-382
.	O	382-383

A	O	384-385
reversible	O	386-396
anemia	B	397-403
was	O	404-407
the	O	408-411
only	O	412-416
adverse	O	417-424
effect	O	425-431
observed	O	432-440
.	O	440-441

From	O	442-446
these	O	447-452
results	O	453-460
,	O	460-461
we	O	462-464
conclude	O	465-473
that	O	474-478
ribavirin	O	479-488
has	O	489-492
an	O	493-495
antiviral	O	496-505
effect	O	506-512
in	O	513-515
advanced	O	516-524
cases	O	525-530
of	O	531-533
AHF	B	534-537
,	O	537-538
and	O	539-542
that	O	543-547
anemia	B	548-554
,	O	554-555
the	O	556-559
only	O	560-564
secondary	O	565-574
reaction	O	575-583
observed	O	584-592
,	O	592-593
can	O	594-597
be	O	598-600
easily	O	601-607
managed	O	608-615
.	O	615-616

The	O	617-620
possible	O	621-629
beneficial	O	630-640
effect	O	641-647
of	O	648-650
ribavirin	O	651-660
during	O	661-667
the	O	668-671
initial	O	672-679
days	O	680-684
of	O	685-687
AHF	B	688-691
is	O	692-694
discussed	O	695-704
.	O	704-705

Dipyridamole	O	0-12
-	O	12-13
induced	O	13-20
myocardial	B	21-31
ischemia	I	32-40
.	O	40-41

Angina	B	42-48
and	O	49-52
ischemic	O	53-61
electrocardiographic	O	62-82
changes	O	83-90
occurred	O	91-99
after	O	100-105
administration	O	106-120
of	O	121-123
oral	O	124-128
dipyridamole	O	129-141
in	O	142-144
four	O	145-149
patients	O	150-158
awaiting	O	159-167
urgent	O	168-174
myocardial	O	175-185
revascularization	O	186-203
procedures	O	204-214
.	O	214-215

To	O	216-218
our	O	219-222
knowledge	O	223-232
,	O	232-233
this	O	234-238
has	O	239-242
not	O	243-246
previously	O	247-257
been	O	258-262
reported	O	263-271
as	O	272-274
a	O	275-276
side	O	277-281
effect	O	282-288
of	O	289-291
preoperative	O	292-304
dipyridamole	O	305-317
therapy	O	318-325
,	O	325-326
although	O	327-335
dipyridamole	O	336-348
-	O	348-349
induced	O	349-356
myocardial	B	357-367
ischemia	I	368-376
has	O	377-380
been	O	381-385
demonstrated	O	386-398
to	O	399-401
occur	O	402-407
in	O	408-410
animals	O	411-418
and	O	419-422
humans	O	423-429
with	O	430-434
coronary	B	435-443
artery	I	444-450
disease	I	451-458
.	O	458-459

Epicardial	O	460-470
coronary	O	471-479
collateral	O	480-490
vessels	O	491-498
were	O	499-503
demonstrated	O	504-516
in	O	517-519
all	O	520-523
four	O	524-528
patients	O	529-537
;	O	537-538
a	O	539-540
coronary	O	541-549
"	O	550-551
steal	O	551-556
"	O	550-551
phenomenon	O	558-568
may	O	569-572
be	O	573-575
the	O	576-579
mechanism	O	580-589
of	O	590-592
the	O	593-596
dipyridamole	O	597-609
-	O	609-610
induced	O	610-617
ischemia	B	618-626
observed	O	627-635
.	O	635-636

Inhibition	O	0-10
of	O	11-13
immunoreactive	O	14-28
corticotropin	O	29-42
-	O	42-43
releasing	O	43-52
factor	O	53-59
secretion	O	60-69
into	O	70-74
the	O	75-78
hypophysial	O	79-90
-	O	90-91
portal	O	91-97
circulation	O	98-109
by	O	110-112
delayed	O	113-120
glucocorticoid	O	121-135
feedback	O	136-144
.	O	144-145

Nitroprusside	O	146-159
-	O	159-160
induced	O	160-167
hypotension	B	168-179
evokes	O	180-186
ACTH	O	187-191
secretion	O	192-201
which	O	202-207
is	O	208-210
primarily	O	211-220
mediated	O	221-229
by	O	230-232
enhanced	O	233-241
secretion	O	242-251
of	O	252-254
immunoreactive	O	255-269
corticotropin	O	270-283
-	O	283-284
releasing	O	284-293
factor	O	294-300
(	O	301-302
irCRF	O	302-307
)	O	307-308
into	O	309-313
the	O	314-317
hypophysial	O	318-329
-	O	329-330
portal	O	330-336
circulation	O	337-348
.	O	348-349

Portal	O	350-356
plasma	O	357-363
concentrations	O	364-378
of	O	379-381
neither	O	382-389
arginine	O	390-398
vasopressin	O	399-410
nor	O	411-414
oxytocin	O	415-423
are	O	424-427
significantly	O	428-441
altered	O	442-449
in	O	450-452
this	O	453-457
paradigm	O	458-466
.	O	466-467

Application	O	468-479
of	O	480-482
a	O	483-484
delayed	O	485-492
feedback	O	493-501
signal	O	502-508
,	O	508-509
in	O	510-512
the	O	513-516
form	O	517-521
of	O	522-524
a	O	525-526
2	O	527-528
-	O	528-529
h	O	529-530
systemic	O	531-539
corticosterone	O	540-554
infusion	O	555-563
in	O	564-566
urethane	O	567-575
-	O	575-576
anesthetized	O	576-588
rats	O	589-593
with	O	594-598
pharmacological	O	599-614
blockade	O	615-623
of	O	624-626
glucocorticoid	O	627-641
synthesis	O	642-651
,	O	651-652
is	O	653-655
without	O	656-663
effect	O	664-670
on	O	671-673
the	O	674-677
resting	O	678-685
secretion	O	686-695
of	O	696-698
arginine	O	699-707
vasopressin	O	708-719
and	O	720-723
oxytocin	O	724-732
at	O	733-735
any	O	736-739
corticosterone	O	740-754
feedback	O	755-763
dose	O	764-768
tested	O	769-775
.	O	775-776

Resting	O	777-784
irCRF	O	785-790
levels	O	791-797
are	O	798-801
suppressed	O	802-812
only	O	813-817
at	O	818-820
the	O	821-824
highest	O	825-832
corticosterone	O	833-847
infusion	O	848-856
rate	O	857-861
,	O	861-862
which	O	863-868
resulted	O	869-877
in	O	878-880
systemic	O	881-889
corticosterone	O	890-904
levels	O	905-911
of	O	912-914
40	O	915-917
micrograms	O	918-928
/	O	928-929
dl	O	929-931
.	O	931-932

Suppression	O	933-944
of	O	945-947
irCRF	O	948-953
secretion	O	954-963
in	O	964-966
response	O	967-975
to	O	976-978
nitroprusside	O	979-992
-	O	992-993
induced	O	993-1000
hypotension	B	1001-1012
is	O	1013-1015
observed	O	1016-1024
and	O	1025-1028
occurs	O	1029-1035
at	O	1036-1038
a	O	1039-1040
plasma	O	1041-1047
corticosterone	O	1048-1062
level	O	1063-1068
between	O	1069-1076
8	O	1077-1078
-	O	1078-1079
12	O	1079-1081
micrograms	O	1082-1092
/	O	1092-1093
dl	O	1093-1095
.	O	1095-1096

These	O	1097-1102
studies	O	1103-1110
provide	O	1111-1118
further	O	1119-1126
evidence	O	1127-1135
for	O	1136-1139
a	O	1140-1141
strong	O	1142-1148
central	O	1149-1156
component	O	1157-1166
of	O	1167-1169
the	O	1170-1173
delayed	O	1174-1181
feedback	O	1182-1190
process	O	1191-1198
which	O	1199-1204
is	O	1205-1207
mediated	O	1208-1216
by	O	1217-1219
modulation	O	1220-1230
of	O	1231-1233
irCRF	O	1234-1239
release	O	1240-1247
.	O	1247-1248

Noradrenergic	O	0-13
involvement	O	14-25
in	O	26-28
catalepsy	B	29-38
induced	O	39-46
by	O	47-49
delta	O	50-55
9	O	56-57
-	O	57-58
tetrahydrocannabinol	O	58-78
.	O	78-79

In	O	80-82
order	O	83-88
to	O	89-91
elucidate	O	92-101
the	O	102-105
role	O	106-110
of	O	111-113
the	O	114-117
catecholaminergic	O	118-135
system	O	136-142
in	O	143-145
the	O	146-149
cataleptogenic	O	150-164
effect	O	165-171
of	O	172-174
delta	O	175-180
9	O	181-182
-	O	182-183
tetrahydrocannabinol	O	183-203
(	O	204-205
THC	O	205-208
)	O	208-209
,	O	209-210
the	O	211-214
effect	O	215-221
of	O	222-224
pretreatment	O	225-237
with	O	238-242
6	O	243-244
-	O	244-245
hydroxydopamine	O	245-260
(	O	261-262
6	O	262-263
-	O	263-264
OHDA	O	264-268
)	O	268-269
or	O	270-272
with	O	273-277
desipramine	O	278-289
and	O	290-293
6	O	294-295
-	O	295-296
OHDA	O	296-300
and	O	301-304
lesions	O	305-312
of	O	313-315
the	O	316-319
locus	O	320-325
coeruleus	O	326-335
were	O	336-340
investigated	O	341-353
in	O	354-356
rats	O	357-361
.	O	361-362

The	O	363-366
cataleptogenic	O	367-381
effect	O	382-388
of	O	389-391
THC	O	392-395
was	O	396-399
significantly	O	400-413
reduced	O	414-421
in	O	422-424
rats	O	425-429
treated	O	430-437
with	O	438-442
6	O	443-444
-	O	444-445
OHDA	O	445-449
and	O	450-453
in	O	454-456
rats	O	457-461
with	O	462-466
lesions	O	467-474
of	O	475-477
the	O	478-481
locus	O	482-487
coeruleus	O	488-497
but	O	498-501
not	O	502-505
in	O	506-508
rats	O	509-513
treated	O	514-521
with	O	522-526
desipramine	O	527-538
and	O	539-542
6	O	543-544
-	O	544-545
OHDA	O	545-549
,	O	549-550
as	O	551-553
compared	O	554-562
with	O	563-567
control	O	568-575
rats	O	576-580
.	O	580-581

On	O	582-584
the	O	585-588
contrary	O	589-597
,	O	597-598
the	O	599-602
cataleptogenic	O	603-617
effect	O	618-624
of	O	625-627
haloperidol	O	628-639
was	O	640-643
significantly	O	644-657
reduced	O	658-665
in	O	666-668
rats	O	669-673
treated	O	674-681
with	O	682-686
desipramine	O	687-698
and	O	699-702
6	O	703-704
-	O	704-705
OHDA	O	705-709
but	O	710-713
not	O	714-717
in	O	718-720
rats	O	721-725
treated	O	726-733
with	O	734-738
6	O	739-740
-	O	740-741
OHDA	O	741-745
or	O	746-748
in	O	749-751
rats	O	752-756
with	O	757-761
lesions	O	762-769
of	O	770-772
the	O	773-776
locus	O	777-782
coeruleus	O	783-792
.	O	792-793

These	O	794-799
results	O	800-807
indicate	O	808-816
that	O	817-821
noradrenergic	O	822-835
neurons	O	836-843
have	O	844-848
an	O	849-851
important	O	852-861
role	O	862-866
in	O	867-869
the	O	870-873
manifestation	O	874-887
of	O	888-890
catalepsy	B	891-900
induced	O	901-908
by	O	909-911
THC	O	912-915
,	O	915-916
whereas	O	917-924
dopaminergic	O	925-937
neurons	O	938-945
are	O	946-949
important	O	950-959
in	O	960-962
catalepsy	B	963-972
induced	O	973-980
by	O	981-983
haloperidol	O	984-995
.	O	995-996

Intracranial	O	0-12
pressure	O	13-21
increases	O	22-31
during	O	32-38
alfentanil	O	39-49
-	O	49-50
induced	O	50-57
rigidity	B	58-66
.	O	66-67

Intracranial	O	68-80
pressure	O	81-89
(	O	90-91
ICP	O	91-94
)	O	94-95
was	O	96-99
measured	O	100-108
during	O	109-115
alfentanil	O	116-126
-	O	126-127
induced	O	127-134
rigidity	B	135-143
in	O	144-146
rats	O	147-151
.	O	151-152

Ten	O	153-156
rats	O	157-161
had	O	162-165
arterial	O	166-174
,	O	174-175
central	O	176-183
venous	O	184-190
(	O	191-192
CVP	O	192-195
)	O	195-196
,	O	196-197
and	O	198-201
subdural	O	202-210
cannulae	O	211-219
inserted	O	220-228
under	O	229-234
halothane	O	235-244
anesthesia	O	245-255
.	O	255-256

The	O	257-260
animals	O	261-268
were	O	269-273
mechanically	O	274-286
ventilated	O	287-297
to	O	298-300
achieve	O	301-308
normocarbia	O	309-320
(	O	321-322
PCO2	O	322-326
=	O	327-328
42	O	329-331
+	O	332-333
/	O	333-334
-	O	334-335
1	O	336-337
mmHg	O	338-342
,	O	342-343
mean	O	344-348
+	O	349-350
/	O	350-351
-	O	351-352
SE	O	353-355
)	O	355-356
.	O	356-357

Following	O	358-367
instrumentation	O	368-383
,	O	383-384
halothane	O	385-394
was	O	395-398
discontinued	O	399-411
and	O	412-415
alfentanil	O	416-426
(	O	427-428
125	O	428-431
mu	O	432-434
/	O	434-435
kg	O	435-437
)	O	437-438
administered	O	439-451
iv	O	452-454
during	O	455-461
emergence	O	462-471
from	O	472-476
halothane	O	477-486
anesthesia	O	487-497
.	O	497-498

In	O	499-501
the	O	502-505
five	O	506-510
rats	O	511-515
that	O	516-520
developed	O	521-530
somatic	B	531-538
rigidity	I	539-547
,	O	547-548
ICP	O	549-552
and	O	553-556
CVP	O	557-560
increased	O	561-570
significantly	O	571-584
above	O	585-590
baseline	O	591-599
(	O	600-601
delta	O	601-606
ICP	O	607-610
7	O	611-612
.	O	612-613
5	O	613-614
+	O	615-616
/	O	616-617
-	O	617-618
1	O	619-620
.	O	620-621
0	O	621-622
mmHg	O	623-627
,	O	627-628
delta	O	629-634
CVP	O	635-638
5	O	639-640
.	O	640-641
9	O	641-642
+	O	643-644
/	O	644-645
-	O	645-646
1	O	647-648
.	O	648-649
3	O	649-650
mmHg	O	651-655
)	O	655-656
.	O	656-657

These	O	658-663
variables	O	664-673
returned	O	674-682
to	O	683-685
baseline	O	686-694
when	O	695-699
rigidity	B	700-708
was	O	709-712
abolished	O	713-722
with	O	723-727
metocurine	O	728-738
.	O	738-739

In	O	740-742
five	O	743-747
rats	O	748-752
that	O	753-757
did	O	758-761
not	O	762-765
become	O	766-772
rigid	O	773-778
,	O	778-779
ICP	O	780-783
and	O	784-787
CVP	O	788-791
did	O	792-795
not	O	796-799
change	O	800-806
following	O	807-816
alfentanil	O	817-827
.	O	827-828

These	O	829-834
observations	O	835-847
suggest	O	848-855
that	O	856-860
rigidity	B	861-869
should	O	870-876
be	O	877-879
prevented	O	880-889
when	O	890-894
alfentanil	O	895-905
,	O	905-906
and	O	907-910
,	O	910-911
presumably	O	912-922
,	O	922-923
other	O	924-929
opiates	O	930-937
,	O	937-938
are	O	939-942
used	O	943-947
in	O	948-950
the	O	951-954
anesthetic	O	955-965
management	O	966-976
of	O	977-979
patients	O	980-988
with	O	989-993
ICP	O	994-997
problems	O	998-1006
.	O	1006-1007

Adverse	O	0-7
cardiac	O	8-15
effects	O	16-23
during	O	24-30
induction	O	31-40
chemotherapy	O	41-53
treatment	O	54-63
with	O	64-68
cis	O	69-72
-	O	72-73
platin	O	73-79
and	O	80-83
5	O	84-85
-	O	85-86
fluorouracil	O	86-98
.	O	98-99

Survival	O	100-108
for	O	109-112
patients	O	113-121
with	O	122-126
advanced	O	127-135
head	B	136-140
and	I	141-144
neck	I	145-149
carcinoma	I	150-159
and	O	160-163
esophageal	B	164-174
carcinoma	I	175-184
is	O	185-187
poor	O	188-192
with	O	193-197
radiotherapy	O	198-210
and	O	211-214
/	O	214-215
or	O	215-217
surgery	O	218-225
.	O	225-226

Obviously	O	227-236
,	O	236-237
there	O	238-243
is	O	244-246
a	O	247-248
need	O	249-253
for	O	254-257
effective	O	258-267
chemotherapy	O	268-280
.	O	280-281

In	O	282-284
the	O	285-288
present	O	289-296
study	O	297-302
,	O	302-303
cis	O	304-307
-	O	307-308
platin	O	308-314
(	O	315-316
80	O	316-318
-	O	318-319
120	O	319-322
mg	O	323-325
/	O	325-326
m2BSA	O	326-331
)	O	331-332
and	O	333-336
5	O	337-338
-	O	338-339
FU	O	339-341
(	O	342-343
1000	O	343-347
mg	O	348-350
/	O	350-351
m2BSA	O	351-356
daily	O	357-362
as	O	363-365
a	O	366-367
continuous	O	368-378
infusion	O	379-387
during	O	388-394
5	O	395-396
days	O	397-401
)	O	401-402
were	O	403-407
given	O	408-413
to	O	414-416
76	O	417-419
patients	O	420-428
before	O	429-435
radiotherapy	O	436-448
and	O	449-452
surgery	O	453-460
.	O	460-461

The	O	462-465
aim	O	466-469
of	O	470-472
the	O	473-476
study	O	477-482
was	O	483-486
to	O	487-489
clarify	O	490-497
the	O	498-501
incidence	O	502-511
and	O	512-515
severity	O	516-524
of	O	525-527
adverse	O	528-535
cardiac	O	536-543
effects	O	544-551
to	O	552-554
this	O	555-559
treatment	O	560-569
.	O	569-570

Before	O	571-577
treatment	O	578-587
all	O	588-591
patients	O	592-600
had	O	601-604
a	O	605-606
cardiac	O	607-614
evaluation	O	615-625
and	O	626-629
during	O	630-636
treatment	O	637-646
serial	O	647-653
ECG	O	654-657
recordings	O	658-668
were	O	669-673
performed	O	674-683
.	O	683-684

In	O	685-687
the	O	688-691
pre	O	692-695
-	O	695-696
treatment	O	696-705
evaluation	O	706-716
,	O	716-717
signs	O	718-723
of	O	724-726
cardiovascular	B	727-741
disease	I	742-749
were	O	750-754
found	O	755-760
in	O	761-763
33	O	764-766
patients	O	767-775
(	O	776-777
43	O	777-779
%	O	779-780
)	O	780-781
.	O	781-782

During	O	783-789
treatment	O	790-799
,	O	799-800
adverse	O	801-808
cardiac	O	809-816
effects	O	817-824
were	O	825-829
observed	O	830-838
in	O	839-841
14	O	842-844
patients	O	845-853
(	O	854-855
18	O	855-857
%	O	857-858
)	O	858-859
.	O	859-860

The	O	861-864
mean	O	865-869
age	O	870-873
of	O	874-876
these	O	877-882
patients	O	883-891
was	O	892-895
the	O	896-899
same	O	900-904
as	O	905-907
for	O	908-911
the	O	912-915
entire	O	916-922
group	O	923-928
,	O	928-929
64	O	930-932
years	O	933-938
.	O	938-939

The	O	940-943
incidence	O	944-953
of	O	954-956
cardiotoxicity	B	957-971
was	O	972-975
not	O	976-979
higher	O	980-986
in	O	987-989
patients	O	990-998
with	O	999-1003
signs	O	1004-1009
of	O	1010-1012
cardiovascular	B	1013-1027
disease	I	1028-1035
than	O	1036-1040
in	O	1041-1043
those	O	1044-1049
without	O	1050-1057
in	O	1058-1060
the	O	1061-1064
pre	O	1065-1068
-	O	1068-1069
treatment	O	1069-1078
evaluation	O	1079-1089
.	O	1089-1090

The	O	1091-1094
most	O	1095-1099
common	O	1100-1106
signs	O	1107-1112
of	O	1113-1115
cardiotoxicity	B	1116-1130
were	O	1131-1135
chest	B	1136-1141
pain	I	1142-1146
,	O	1146-1147
ST	O	1148-1150
-	O	1150-1151
T	O	1149-1150
wave	O	1153-1157
changes	O	1158-1165
and	O	1166-1169
atrial	B	1170-1176
fibrillation	I	1177-1189
.	O	1189-1190

This	O	1191-1195
was	O	1196-1199
followed	O	1200-1208
by	O	1209-1211
ventricular	B	1212-1223
fibrillation	I	1224-1236
in	O	1237-1239
one	O	1240-1243
patient	O	1244-1251
and	O	1252-1255
sudden	B	1256-1262
death	I	1263-1268
in	O	1269-1271
another	O	1272-1279
.	O	1279-1280

It	O	1281-1283
is	O	1284-1286
concluded	O	1287-1296
that	O	1297-1301
patients	O	1302-1310
on	O	1311-1313
5	O	1314-1315
-	O	1315-1316
FU	O	1316-1318
treatment	O	1319-1328
should	O	1329-1335
be	O	1336-1338
under	O	1339-1344
close	O	1345-1350
supervision	O	1351-1362
and	O	1363-1366
that	O	1367-1371
the	O	1372-1375
treatment	O	1376-1385
should	O	1386-1392
be	O	1393-1395
discontinued	O	1396-1408
if	O	1409-1411
chest	B	1412-1417
pain	I	1418-1422
or	O	1423-1425
tachyarrhythmia	B	1426-1441
is	O	1442-1444
observed	O	1445-1453
.	O	1453-1454

Verapamil	O	0-9
-	O	9-10
induced	O	10-17
carbamazepine	O	18-31
neurotoxicity	B	32-45
.	O	45-46

A	O	47-48
report	O	49-55
of	O	56-58
two	O	59-62
cases	O	63-68
.	O	68-69

Two	O	70-73
patients	O	74-82
with	O	83-87
signs	O	88-93
of	O	94-96
carbamazepine	O	97-110
neurotoxicity	B	111-124
after	O	125-130
combined	O	131-139
treatment	O	140-149
with	O	150-154
verapamil	O	155-164
showed	O	165-171
complete	O	172-180
recovery	O	181-189
after	O	190-195
discontinuation	O	196-211
of	O	212-214
the	O	215-218
calcium	O	219-226
entry	O	227-232
blocker	O	233-240
.	O	240-241

Use	O	242-245
of	O	246-248
verapamil	O	249-258
in	O	259-261
combination	O	262-273
with	O	274-278
carbamazepine	O	279-292
should	O	293-299
either	O	300-306
be	O	307-309
avoided	O	310-317
or	O	318-320
prescribed	O	321-331
only	O	332-336
with	O	337-341
appropriate	O	342-353
adjustment	O	354-364
of	O	365-367
the	O	368-371
carbamazepine	O	372-385
dose	O	386-390
(	O	391-392
usually	O	392-399
reduction	O	400-409
of	O	410-412
the	O	413-416
carbamazepine	O	417-430
dose	O	431-435
by	O	436-438
one	O	439-442
half	O	443-447
)	O	447-448
.	O	448-449

Serial	O	0-6
studies	O	7-14
of	O	15-17
auditory	B	18-26
neurotoxicity	I	27-40
in	O	41-43
patients	O	44-52
receiving	O	53-62
deferoxamine	O	63-75
therapy	O	76-83
.	O	83-84

Visual	B	85-91
and	I	92-95
auditory	I	96-104
neurotoxicity	I	105-118
was	O	119-122
previously	O	123-133
documented	O	134-144
in	O	145-147
42	O	148-150
of	O	151-153
89	O	154-156
patients	O	157-165
with	O	166-170
transfusion	O	171-182
-	O	182-183
dependent	O	183-192
anemia	B	193-199
who	O	200-203
were	O	204-208
receiving	O	209-218
iron	O	219-223
chelation	O	224-233
therapy	O	234-241
with	O	242-246
daily	O	247-252
subcutaneous	O	253-265
deferoxamine	O	266-278
.	O	278-279

Twenty	O	280-286
-	O	286-287
two	O	287-290
patients	O	291-299
in	O	300-302
the	O	303-306
affected	O	307-315
group	O	316-321
had	O	322-325
abnormal	B	326-334
audiograms	I	335-345
with	I	346-350
deficits	I	351-359
mostly	I	360-366
in	I	367-369
the	I	370-373
high	I	374-378
frequency	I	379-388
range	I	389-394
of	I	395-397
4	I	398-399
,	I	399-400
000	I	400-403
to	I	404-406
8	I	407-408
,	I	408-409
000	I	409-412
Hz	I	413-415
and	O	416-419
in	O	420-422
the	O	423-426
hearing	O	427-434
threshold	O	435-444
levels	O	445-451
of	O	452-454
30	O	455-457
to	O	458-460
100	O	461-464
decibels	O	465-473
.	O	473-474

When	O	475-479
deferoxamine	O	480-492
therapy	O	493-500
was	O	501-504
discontinued	O	505-517
and	O	518-521
serial	O	522-528
studies	O	529-536
were	O	537-541
performed	O	542-551
,	O	551-552
audiograms	O	553-563
in	O	564-566
seven	O	567-572
cases	O	573-578
reverted	O	579-587
to	O	588-590
normal	O	591-597
or	O	598-600
near	O	601-605
normal	O	606-612
within	O	613-619
two	O	620-623
to	O	624-626
three	O	627-632
weeks	O	633-638
,	O	638-639
and	O	640-643
nine	O	644-648
of	O	649-651
13	O	652-654
patients	O	655-663
with	O	664-668
symptoms	O	669-677
became	O	678-684
asymptomatic	O	685-697
.	O	697-698

Audiograms	O	699-709
from	O	710-714
15	O	715-717
patients	O	718-726
remained	O	727-735
abnormal	O	736-744
and	O	745-748
four	O	749-753
patients	O	754-762
required	O	763-771
hearing	O	772-779
aids	O	780-784
because	O	785-792
of	O	793-795
permanent	B	796-805
disability	I	806-816
.	O	816-817

Since	O	818-823
18	O	824-826
of	O	827-829
the	O	830-833
22	O	834-836
patients	O	837-845
were	O	846-850
initially	O	851-860
receiving	O	861-870
deferoxamine	O	871-883
doses	O	884-889
in	O	890-892
excess	O	893-899
of	O	900-902
the	O	903-906
commonly	O	907-915
recommended	O	916-927
50	O	928-930
mg	O	931-933
/	O	933-934
kg	O	934-936
per	O	937-940
dose	O	941-945
,	O	945-946
therapy	O	947-954
was	O	955-958
restarted	O	959-968
with	O	969-973
lower	O	974-979
doses	O	980-985
,	O	985-986
usually	O	987-994
50	O	995-997
mg	O	998-1000
/	O	1000-1001
kg	O	1001-1003
per	O	1004-1007
dose	O	1008-1012
or	O	1013-1015
less	O	1016-1020
depending	O	1021-1030
on	O	1031-1033
the	O	1034-1037
degree	O	1038-1044
of	O	1045-1047
auditory	B	1048-1056
abnormality	I	1057-1068
,	O	1068-1069
and	O	1070-1073
with	O	1074-1078
the	O	1079-1082
exception	O	1083-1092
of	O	1093-1095
two	O	1096-1099
cases	O	1100-1105
no	O	1106-1108
further	O	1109-1116
toxicity	B	1117-1125
was	O	1126-1129
demonstrated	O	1130-1142
.	O	1142-1143

Auditory	O	1144-1152
deterioration	O	1153-1166
and	O	1167-1170
improvement	O	1171-1182
,	O	1182-1183
demonstrated	O	1184-1196
serially	O	1197-1205
in	O	1206-1208
individual	O	1209-1219
patients	O	1220-1228
receiving	O	1229-1238
and	O	1239-1242
not	O	1243-1246
receiving	O	1247-1256
deferoxamine	O	1257-1269
,	O	1269-1270
respectively	O	1271-1283
,	O	1283-1284
provided	O	1285-1293
convincing	O	1294-1304
evidence	O	1305-1313
for	O	1314-1317
a	O	1318-1319
cause	O	1320-1325
-	O	1325-1326
and	O	1326-1329
-	O	1325-1326
effect	O	1330-1336
relation	O	1337-1345
between	O	1346-1353
deferoxamine	O	1354-1366
administration	O	1367-1381
and	O	1382-1385
ototoxicity	B	1386-1397
.	O	1397-1398

Based	O	1399-1404
on	O	1405-1407
these	O	1408-1413
data	O	1414-1418
,	O	1418-1419
a	O	1420-1421
plan	O	1422-1426
of	O	1427-1429
management	O	1430-1440
was	O	1441-1444
developed	O	1445-1454
that	O	1455-1459
allows	O	1460-1466
effective	O	1467-1476
yet	O	1477-1480
safe	O	1481-1485
administration	O	1486-1500
of	O	1501-1503
deferoxamine	O	1504-1516
.	O	1516-1517

A	O	1518-1519
dose	O	1520-1524
of	O	1525-1527
50	O	1528-1530
mg	O	1531-1533
/	O	1533-1534
kg	O	1534-1536
is	O	1537-1539
recommended	O	1540-1551
in	O	1552-1554
those	O	1555-1560
without	O	1561-1568
audiogram	O	1569-1578
abnormalities	O	1579-1592
.	O	1592-1593

With	O	1594-1598
mild	O	1599-1603
toxicity	B	1604-1612
,	O	1612-1613
a	O	1614-1615
reduction	O	1616-1625
to	O	1626-1628
30	O	1629-1631
or	O	1632-1634
40	O	1635-1637
mg	O	1638-1640
/	O	1640-1641
kg	O	1641-1643
per	O	1644-1647
dose	O	1648-1652
should	O	1653-1659
result	O	1660-1666
in	O	1667-1669
a	O	1670-1671
reversal	O	1672-1680
of	O	1681-1683
the	O	1684-1687
abnormal	O	1688-1696
results	O	1697-1704
to	O	1705-1707
normal	O	1708-1714
within	O	1715-1721
four	O	1722-1726
weeks	O	1727-1732
.	O	1732-1733

Moderate	O	1734-1742
abnormalities	O	1743-1756
require	O	1757-1764
a	O	1765-1766
reduction	O	1767-1776
of	O	1777-1779
deferoxamine	O	1780-1792
to	O	1793-1795
25	O	1796-1798
mg	O	1799-1801
/	O	1801-1802
kg	O	1802-1804
per	O	1805-1808
dose	O	1809-1813
with	O	1814-1818
careful	O	1819-1826
monitoring	O	1827-1837
.	O	1837-1838

In	O	1839-1841
those	O	1842-1847
with	O	1848-1852
symptoms	O	1853-1861
of	O	1862-1864
hearing	B	1865-1872
loss	I	1873-1877
,	O	1877-1878
the	O	1879-1882
drug	O	1883-1887
should	O	1888-1894
be	O	1895-1897
stopped	O	1898-1905
for	O	1906-1909
four	O	1910-1914
weeks	O	1915-1920
,	O	1920-1921
and	O	1922-1925
when	O	1926-1930
the	O	1931-1934
audiogram	O	1935-1944
is	O	1945-1947
stable	O	1948-1954
or	O	1955-1957
improved	O	1958-1966
,	O	1966-1967
therapy	O	1968-1975
should	O	1976-1982
be	O	1983-1985
restarted	O	1986-1995
at	O	1996-1998
10	O	1999-2001
to	O	2002-2004
25	O	2005-2007
mg	O	2008-2010
/	O	2010-2011
kg	O	2011-2013
per	O	2014-2017
dose	O	2018-2022
.	O	2022-2023

Serial	O	2024-2030
audiograms	O	2031-2041
should	O	2042-2048
be	O	2049-2051
performed	O	2052-2061
every	O	2062-2067
six	O	2068-2071
months	O	2072-2078
in	O	2079-2081
those	O	2082-2087
without	O	2088-2095
problems	O	2096-2104
and	O	2105-2108
more	O	2109-2113
frequently	O	2114-2124
in	O	2125-2127
young	O	2128-2133
patients	O	2134-2142
with	O	2143-2147
normal	O	2148-2154
serum	O	2155-2160
ferritin	O	2161-2169
values	O	2170-2176
and	O	2177-2180
in	O	2181-2183
those	O	2184-2189
with	O	2190-2194
auditory	B	2195-2203
dysfunction	I	2204-2215
.	O	2215-2216

Flurbiprofen	O	0-12
in	O	13-15
the	O	16-19
treatment	O	20-29
of	O	30-32
juvenile	B	33-41
rheumatoid	I	42-52
arthritis	I	53-62
.	O	62-63

Thirty	O	64-70
-	O	70-71
four	O	71-75
patients	O	76-84
with	O	85-89
juvenile	B	90-98
rheumatoid	I	99-109
arthritis	I	110-119
,	O	119-120
who	O	121-124
were	O	125-129
treated	O	130-137
with	O	138-142
flurbiprofen	O	143-155
at	O	156-158
a	O	159-160
maximum	O	161-168
dose	O	169-173
of	O	174-176
4	O	177-178
mg	O	179-181
/	O	181-182
kg	O	182-184
/	O	181-182
day	O	185-188
,	O	188-189
had	O	190-193
statistically	O	194-207
significant	O	208-219
decreases	O	220-229
from	O	230-234
baseline	O	235-243
in	O	244-246
6	O	247-248
arthritis	B	249-258
indices	O	259-266
after	O	267-272
12	O	273-275
weeks	O	276-281
of	O	282-284
treatment	O	285-294
.	O	294-295

Improvements	O	296-308
were	O	309-313
seen	O	314-318
in	O	319-321
the	O	322-325
number	O	326-332
of	O	333-335
tender	B	336-342
joints	I	343-349
,	O	349-350
the	O	351-354
severity	O	355-363
of	O	364-366
swelling	B	367-375
and	O	376-379
tenderness	B	380-390
,	O	390-391
the	O	392-395
time	O	396-400
of	O	401-403
walk	O	404-408
50	O	409-411
feet	O	412-416
,	O	416-417
the	O	418-421
duration	O	422-430
of	O	431-433
morning	B	434-441
stiffness	I	442-451
and	O	452-455
the	O	456-459
circumference	O	460-473
of	O	474-476
the	O	477-480
left	O	481-485
knee	O	486-490
.	O	490-491

The	O	492-495
most	O	496-500
frequently	O	501-511
observed	O	512-520
side	O	521-525
effect	O	526-532
was	O	533-536
fecal	B	537-542
occult	I	543-549
blood	I	550-555
(	O	556-557
25	O	557-559
%	O	559-560
of	O	561-563
patients	O	564-572
)	O	572-573
;	O	573-574
however	O	575-582
,	O	582-583
there	O	584-589
was	O	590-593
no	O	594-596
other	O	597-602
evidence	O	603-611
of	O	612-614
gastrointestinal	B	615-631
(	I	632-633
GI	I	633-635
)	I	635-636
bleeding	I	637-645
in	O	646-648
these	O	649-654
patients	O	655-663
.	O	663-664

One	O	665-668
patient	O	669-676
was	O	677-680
prematurely	O	681-692
discontinued	O	693-705
from	O	706-710
the	O	711-714
study	O	715-720
for	O	721-724
severe	O	725-731
headache	B	732-740
and	O	741-744
abdominal	B	745-754
pain	I	755-759
.	O	759-760

Most	O	761-765
side	O	766-770
effects	O	771-778
were	O	779-783
mild	O	784-788
and	O	789-792
related	O	793-800
to	O	801-803
the	O	804-807
GI	O	808-810
tract	O	811-816
.	O	816-817

The	O	0-3
correlation	O	4-15
between	O	16-23
neurotoxic	B	24-34
esterase	O	35-43
inhibition	O	44-54
and	O	55-58
mipafox	O	59-66
-	O	66-67
induced	O	67-74
neuropathic	B	75-86
damage	I	87-93
in	O	94-96
rats	O	97-101
.	O	101-102

The	O	103-106
correlation	O	107-118
between	O	119-126
neuropathic	B	127-138
damage	I	139-145
and	O	146-149
inhibition	O	150-160
of	O	161-163
neurotoxic	B	164-174
esterase	O	175-183
or	O	184-186
neuropathy	B	187-197
target	O	198-204
enzyme	O	205-211
(	O	212-213
NTE	O	213-216
)	O	216-217
was	O	218-221
examined	O	222-230
in	O	231-233
rats	O	234-238
acutely	O	239-246
exposed	O	247-254
to	O	255-257
Mipafox	O	258-265
(	O	266-267
N	O	267-268
,	O	268-269
N	O	270-271
'	O	271-272
-	O	272-273
diisopropylphosphorodiamidofluoridate	O	273-310
)	O	310-311
,	O	311-312
a	O	313-314
neurotoxic	B	315-325
organophosphate	O	326-341
.	O	341-342

Brain	O	343-348
and	O	349-352
spinal	O	353-359
cord	O	360-364
NTE	O	365-368
activities	O	369-379
were	O	380-384
measured	O	385-393
in	O	394-396
Long	O	397-401
-	O	401-402
Evans	O	402-407
male	O	408-412
rats	O	413-417
1	O	418-419
hr	O	420-422
post	O	423-427
-	O	427-428
exposure	O	428-436
to	O	437-439
various	O	440-447
dosages	O	448-455
of	O	456-458
Mipafox	O	459-466
(	O	467-468
ip	O	468-470
,	O	470-471
1	O	472-473
-	O	473-474
15	O	474-476
mg	O	477-479
/	O	479-480
kg	O	480-482
)	O	482-483
.	O	483-484

These	O	485-490
data	O	491-495
were	O	496-500
correlated	O	501-511
with	O	512-516
histologically	O	517-531
scored	O	532-538
cervical	O	539-547
cord	B	548-552
damage	I	553-559
in	O	560-562
a	O	563-564
separate	O	565-573
group	O	574-579
of	O	580-582
similarly	O	583-592
dosed	O	593-598
rats	O	599-603
sampled	O	604-611
14	O	612-614
-	O	614-615
21	O	615-617
days	O	618-622
post	O	623-627
-	O	627-628
exposure	O	628-636
.	O	636-637

Those	O	638-643
dosages	O	644-651
(	O	652-653
greater	O	653-660
than	O	661-665
or	O	666-668
equal	O	669-674
to	O	675-677
10	O	678-680
mg	O	681-683
/	O	683-684
kg	O	684-686
)	O	686-687
that	O	688-692
inhibited	O	693-702
mean	O	703-707
NTE	O	708-711
activity	O	712-720
in	O	721-723
the	O	724-727
spinal	O	728-734
cord	O	735-739
greater	O	740-747
than	O	748-752
or	O	753-755
equal	O	756-761
to	O	762-764
73	O	765-767
%	O	767-768
and	O	769-772
brain	O	773-778
greater	O	779-786
than	O	787-791
or	O	792-794
equal	O	795-800
to	O	801-803
67	O	804-806
%	O	806-807
of	O	808-810
control	O	811-818
values	O	819-825
produced	O	826-834
severe	O	835-841
(	O	842-843
greater	O	843-850
than	O	851-855
or	O	856-858
equal	O	859-864
to	O	865-867
3	O	868-869
)	O	869-870
cervical	O	871-879
cord	O	880-884
pathology	O	885-894
in	O	895-897
85	O	898-900
%	O	900-901
of	O	902-904
the	O	905-908
rats	O	909-913
.	O	913-914

In	O	915-917
contrast	O	918-926
,	O	926-927
dosages	O	928-935
of	O	936-938
Mipafox	O	939-946
(	O	947-948
less	O	948-952
than	O	953-957
or	O	958-960
equal	O	961-966
to	O	967-969
5	O	970-971
mg	O	972-974
/	O	974-975
kg	O	975-977
)	O	977-978
which	O	979-984
inhibited	O	985-994
mean	O	995-999
NTE	O	1000-1003
activity	O	1004-1012
in	O	1013-1015
spinal	O	1016-1022
cord	O	1023-1027
less	O	1028-1032
than	O	1033-1037
or	O	1038-1040
equal	O	1041-1046
to	O	1047-1049
61	O	1050-1052
%	O	1052-1053
and	O	1054-1057
brain	O	1058-1063
less	O	1064-1068
than	O	1069-1073
or	O	1074-1076
equal	O	1077-1082
to	O	1083-1085
60	O	1086-1088
%	O	1088-1089
produced	O	1090-1098
this	O	1099-1103
degree	O	1104-1110
of	O	1111-1113
cord	B	1114-1118
damage	I	1119-1125
in	O	1126-1128
only	O	1129-1133
9	O	1134-1135
%	O	1135-1136
of	O	1137-1139
the	O	1140-1143
animals	O	1144-1151
.	O	1151-1152

These	O	1153-1158
data	O	1159-1163
indicate	O	1164-1172
that	O	1173-1177
a	O	1178-1179
critical	O	1180-1188
percentage	O	1189-1199
of	O	1200-1202
NTE	O	1203-1206
inhibition	O	1207-1217
in	O	1218-1220
brain	O	1221-1226
and	O	1227-1230
spinal	O	1231-1237
cord	O	1238-1242
sampled	O	1243-1250
shortly	O	1251-1258
after	O	1259-1264
Mipafox	O	1265-1272
exposure	O	1273-1281
can	O	1282-1285
predict	O	1286-1293
neuropathic	B	1294-1305
damage	I	1306-1312
in	O	1313-1315
rats	O	1316-1320
several	O	1321-1328
weeks	O	1329-1334
later	O	1335-1340
.	O	1340-1341

Cerebral	B	0-8
infarction	I	9-19
with	O	20-24
a	O	25-26
single	O	27-33
oral	O	34-38
dose	O	39-43
of	O	44-46
phenylpropanolamine	O	47-66
.	O	66-67

Phenylpropanolamine	O	68-87
(	O	88-89
PPA	O	89-92
)	O	92-93
,	O	93-94
a	O	95-96
synthetic	O	97-106
sympathomimetic	O	107-122
that	O	123-127
is	O	128-130
structurally	O	131-143
similar	O	144-151
to	O	152-154
amphetamine	O	155-166
,	O	166-167
is	O	168-170
available	O	171-180
over	O	181-185
the	O	186-189
counter	O	190-197
in	O	198-200
anorectics	O	201-211
,	O	211-212
nasal	O	213-218
congestants	O	219-230
,	O	230-231
and	O	232-235
cold	O	236-240
preparations	O	241-253
.	O	253-254

Its	O	255-258
prolonged	O	259-268
use	O	269-272
or	O	273-275
overuse	O	276-283
has	O	284-287
been	O	288-292
associated	O	293-303
with	O	304-308
seizures	B	309-317
,	O	317-318
intracerebral	B	319-332
hemorrhage	I	333-343
,	O	343-344
neuropsychiatric	B	345-361
symptoms	I	362-370
,	O	370-371
and	O	372-375
nonhemorrhagic	O	376-390
cerebral	B	391-399
infarction	I	400-410
.	O	410-411

We	O	412-414
report	O	415-421
the	O	422-425
case	O	426-430
of	O	431-433
a	O	434-435
young	O	436-441
woman	O	442-447
who	O	448-451
suffered	O	452-460
a	O	461-462
cerebral	B	463-471
infarction	I	472-482
after	O	483-488
taking	O	489-495
a	O	496-497
single	O	498-504
oral	O	505-509
dose	O	510-514
of	O	515-517
PPA	O	518-521
.	O	521-522

Treatment	O	0-9
of	O	10-12
psoriasis	B	13-22
with	O	23-27
azathioprine	O	28-40
.	O	40-41

Azathioprine	O	42-54
treatment	O	55-64
benefited	O	65-74
19	O	75-77
(	O	78-79
66	O	79-81
%	O	81-82
)	O	82-83
out	O	84-87
of	O	88-90
29	O	91-93
patients	O	94-102
suffering	O	103-112
from	O	113-117
severe	O	118-124
psoriasis	B	125-134
.	O	134-135

Haematological	O	136-150
complications	O	151-164
were	O	165-169
not	O	170-173
troublesome	O	174-185
and	O	186-189
results	O	190-197
of	O	198-200
biochemical	O	201-212
liver	O	213-218
function	O	219-227
tests	O	228-233
remained	O	234-242
normal	O	243-249
.	O	249-250

Minimal	O	251-258
cholestasis	B	259-270
was	O	271-274
seen	O	275-279
in	O	280-282
two	O	283-286
cases	O	287-292
and	O	293-296
portal	O	297-303
fibrosis	B	304-312
of	O	313-315
a	O	316-317
reversible	O	318-328
degree	O	329-335
in	O	336-338
eight	O	339-344
.	O	344-345

Liver	O	346-351
biopsies	O	352-360
should	O	361-367
be	O	368-370
undertaken	O	371-381
at	O	382-384
regular	O	385-392
intervals	O	393-402
if	O	403-405
azathioprine	O	406-418
therapy	O	419-426
is	O	427-429
continued	O	430-439
so	O	440-442
that	O	443-447
structural	O	448-458
liver	B	459-464
damage	I	465-471
may	O	472-475
be	O	476-478
detected	O	479-487
at	O	488-490
an	O	491-493
early	O	494-499
and	O	500-503
reversible	O	504-514
stage	O	515-520
.	O	520-521

Maternal	O	0-8
lithium	O	9-16
and	O	17-20
neonatal	O	21-29
Ebstein	B	30-37
'	I	37-38
s	I	32-33
anomaly	I	40-47
:	O	47-48
evaluation	O	49-59
with	O	60-64
cross	O	65-70
-	O	70-71
sectional	O	71-80
echocardiography	O	81-97
.	O	97-98

Cross	O	99-104
-	O	104-105
sectional	O	105-114
echocardiography	O	115-131
was	O	132-135
used	O	136-140
to	O	141-143
evaluate	O	144-152
two	O	153-156
neonates	O	157-165
whose	O	166-171
mothers	O	172-179
ingested	O	180-188
lithium	O	189-196
during	O	197-203
pregnancy	O	204-213
.	O	213-214

In	O	215-217
one	O	218-221
infant	O	222-228
,	O	228-229
Ebstein	B	230-237
'	I	237-238
s	I	232-233
anomaly	I	240-247
of	O	248-250
the	O	251-254
tricuspid	O	255-264
valve	O	265-270
was	O	271-274
identified	O	275-285
.	O	285-286

In	O	287-289
the	O	290-293
other	O	294-299
infant	O	300-306
cross	O	307-312
-	O	312-313
sectional	O	313-322
echocardiography	O	323-339
provided	O	340-348
reassurance	O	349-360
that	O	361-365
the	O	366-369
infant	O	370-376
did	O	377-380
not	O	381-384
have	O	385-389
Ebstein	B	390-397
'	I	397-398
s	I	392-393
anomaly	I	400-407
.	O	407-408

Cross	O	409-414
-	O	414-415
sectional	O	415-424
echocardiographic	O	425-442
screening	O	443-452
of	O	453-455
newborns	O	456-464
exposed	O	465-472
to	O	473-475
lithium	O	476-483
during	O	484-490
gestation	O	491-500
can	O	501-504
provide	O	505-512
highly	O	513-519
accurate	O	520-528
,	O	528-529
noninvasive	O	530-541
assessment	O	542-552
of	O	553-555
the	O	556-559
presence	O	560-568
or	O	569-571
absence	O	572-579
of	O	580-582
lithium	O	583-590
-	O	590-591
induced	O	591-598
cardiac	B	599-606
malformations	I	607-620
.	O	620-621

Effects	O	0-7
of	O	8-10
training	O	11-19
on	O	20-22
the	O	23-26
extent	O	27-33
of	O	34-36
experimental	O	37-49
myocardial	B	50-60
infarction	I	61-71
in	O	72-74
aging	O	75-80
rats	O	81-85
.	O	85-86

The	O	87-90
effects	O	91-98
of	O	99-101
exercise	O	102-110
on	O	111-113
the	O	114-117
severity	O	118-126
of	O	127-129
isoproterenol	O	130-143
-	O	143-144
induced	O	144-151
myocardial	B	152-162
infarction	I	163-173
were	O	174-178
studied	O	179-186
in	O	187-189
female	O	190-196
albino	O	197-203
rats	O	204-208
of	O	209-211
20	O	212-214
,	O	214-215
40	O	215-217
,	O	214-215
60	O	218-220
and	O	221-224
80	O	225-227
weeks	O	228-233
of	O	234-236
age	O	237-240
.	O	240-241

The	O	242-245
rats	O	246-250
were	O	251-255
trained	O	256-263
to	O	264-266
swim	O	267-271
for	O	272-275
a	O	276-277
specific	O	278-286
duration	O	287-295
and	O	296-299
for	O	300-303
a	O	304-305
particular	O	306-316
period	O	317-323
.	O	323-324

The	O	325-328
occurrence	O	329-339
of	O	340-342
infarcts	B	343-351
were	O	352-356
confirmed	O	357-366
by	O	367-369
histological	O	370-382
methods	O	383-390
.	O	390-391

Elevations	O	392-402
in	O	403-405
the	O	406-409
serum	O	410-415
GOT	O	416-419
and	O	420-423
GPT	O	424-427
were	O	428-432
maximum	O	433-440
in	O	441-443
the	O	444-447
sedentary	O	448-457
-	O	457-458
isoproterenols	O	458-472
and	O	473-476
minimum	O	477-484
in	O	485-487
the	O	488-491
exercise	O	492-500
-	O	500-501
controls	O	501-509
.	O	509-510

These	O	511-516
changes	O	517-524
in	O	525-527
the	O	528-531
serum	O	532-537
transaminases	O	538-551
were	O	552-556
associated	O	557-567
with	O	568-572
corresponding	O	573-586
depletions	O	587-597
in	O	598-600
the	O	601-604
cardiac	O	605-612
GOT	O	613-616
and	O	617-620
GPT	O	621-624
.	O	624-625

However	O	626-633
,	O	633-634
age	O	635-638
was	O	639-642
seen	O	643-647
to	O	648-650
interfere	O	651-660
with	O	661-665
the	O	666-669
responses	O	670-679
exhibited	O	680-689
by	O	690-692
the	O	693-696
young	O	697-702
and	O	703-706
old	O	707-710
rats	O	711-715
.	O	715-716

Studies	O	717-724
dealing	O	725-732
with	O	733-737
myocardial	B	738-748
infarction	I	749-759
are	O	760-763
more	O	764-768
informative	O	769-780
when	O	781-785
dealt	O	786-791
with	O	792-796
age	O	797-800
.	O	800-801

Effect	O	0-6
of	O	7-9
polyethylene	O	10-22
glycol	O	23-29
400	O	30-33
on	O	34-36
adriamycin	O	37-47
toxicity	B	48-56
in	O	57-59
mice	O	60-64
.	O	64-65

The	O	66-69
effect	O	70-76
of	O	77-79
a	O	80-81
widely	O	82-88
used	O	89-93
organic	O	94-101
solvent	O	102-109
,	O	109-110
polyethylene	O	111-123
glycol	O	124-130
400	O	131-134
(	O	135-136
PEG	O	136-139
400	O	140-143
)	O	143-144
,	O	144-145
on	O	146-148
the	O	149-152
toxic	O	153-158
action	O	159-165
of	O	166-168
an	O	169-171
acute	O	172-177
or	O	178-180
chronic	O	181-188
treatment	O	189-198
with	O	199-203
adriamycin	O	204-214
(	O	215-216
ADR	O	216-219
)	O	219-220
was	O	221-224
evaluated	O	225-234
in	O	235-237
mice	O	238-242
.	O	242-243

PEG	O	244-247
400	O	248-251
impressively	O	252-264
decreased	O	265-274
both	O	275-279
acute	O	280-285
high	O	286-290
-	O	290-291
dose	O	291-295
and	O	296-299
chronic	O	300-307
low	O	308-311
-	O	311-312
dose	O	312-316
-	O	311-312
ADR	O	317-320
-	O	311-312
associated	O	321-331
lethality	O	332-341
.	O	341-342

Light	O	343-348
microscopic	O	349-360
analysis	O	361-369
showed	O	370-376
a	O	377-378
significant	O	379-390
protection	O	391-401
against	O	402-409
ADR	O	410-413
-	O	413-414
induced	O	414-421
cardiac	B	422-429
morphological	I	430-443
alterations	I	444-455
.	O	455-456

Such	O	457-461
treatment	O	462-471
did	O	472-475
not	O	476-479
diminish	O	480-488
the	O	489-492
ADR	O	493-496
antitumor	O	497-506
activity	O	507-515
in	O	516-518
L1210	B	519-524
leukemia	I	525-533
and	O	534-537
in	O	538-540
Ehrlich	B	541-548
ascites	I	549-556
tumor	I	557-562
.	O	562-563

Intra	O	0-5
-	O	5-6
arterial	O	6-14
BCNU	O	15-19
chemotherapy	O	20-32
for	O	33-36
treatment	O	37-46
of	O	47-49
malignant	B	50-59
gliomas	I	60-67
of	O	68-70
the	O	71-74
central	O	75-82
nervous	O	83-90
system	O	91-97
.	O	97-98

Because	O	99-106
of	O	107-109
the	O	110-113
rapid	O	114-119
systemic	O	120-128
clearance	O	129-138
of	O	139-141
BCNU	O	142-146
(	O	147-148
1	O	148-149
,	O	149-150
3	O	150-151
-	O	151-152
bis	O	152-155
-	O	151-152
(	O	147-148
2	O	157-158
-	O	151-152
chloroethyl	O	159-170
)	O	170-171
-	O	151-152
1	O	148-149
-	O	151-152
nitrosourea	O	174-185
)	O	170-171
,	O	149-150
intra	O	188-193
-	O	193-194
arterial	O	194-202
administration	O	203-217
should	O	218-224
provide	O	225-232
a	O	233-234
substantial	O	235-246
advantage	O	247-256
over	O	257-261
intravenous	O	262-273
administration	O	274-288
for	O	289-292
the	O	293-296
treatment	O	297-306
of	O	307-309
malignant	B	310-319
gliomas	I	320-327
.	O	327-328

Thirty	O	329-335
-	O	335-336
six	O	336-339
patients	O	340-348
were	O	349-353
treated	O	354-361
with	O	362-366
BCNU	O	367-371
every	O	372-377
6	O	378-379
to	O	380-382
8	O	383-384
weeks	O	385-390
,	O	390-391
either	O	392-398
by	O	399-401
transfemoral	O	402-414
catheterization	O	415-430
of	O	431-433
the	O	434-437
internal	O	438-446
carotid	O	447-454
or	O	455-457
vertebral	O	458-467
artery	O	468-474
or	O	475-477
through	O	478-485
a	O	486-487
fully	O	488-493
implantable	O	494-505
intracarotid	O	506-518
drug	O	519-523
delivery	O	524-532
system	O	533-539
,	O	539-540
beginning	O	541-550
with	O	551-555
a	O	556-557
dose	O	558-562
of	O	563-565
200	O	566-569
mg	O	570-572
/	O	572-573
sq	O	573-575
m	O	576-577
body	O	578-582
surface	O	583-590
area	O	591-595
.	O	595-596

Twelve	O	597-603
patients	O	604-612
with	O	613-617
Grade	O	618-623
III	O	624-627
or	O	628-630
IV	O	631-633
astrocytomas	B	634-646
were	O	647-651
treated	O	652-659
after	O	660-665
partial	O	666-673
resection	O	674-683
of	O	684-686
the	O	687-690
tumor	B	691-696
without	O	697-704
prior	O	705-710
radiation	O	711-720
therapy	O	721-728
.	O	728-729

After	O	730-735
two	O	736-739
to	O	740-742
seven	O	743-748
cycles	O	749-755
of	O	756-758
chemotherapy	O	759-771
,	O	771-772
nine	O	773-777
patients	O	778-786
showed	O	787-793
a	O	794-795
decrease	O	796-804
in	O	805-807
tumor	B	808-813
size	O	814-818
and	O	819-822
surrounding	O	823-834
edema	B	835-840
on	O	841-843
contrast	O	844-852
-	O	852-853
enhanced	O	853-861
computerized	O	862-874
tomography	O	875-885
scans	O	886-891
.	O	891-892

In	O	893-895
the	O	896-899
nine	O	900-904
responders	O	905-915
,	O	915-916
median	O	917-923
duration	O	924-932
of	O	933-935
chemotherapy	O	936-948
response	O	949-957
from	O	958-962
the	O	963-966
time	O	967-971
of	O	972-974
operation	O	975-984
was	O	985-988
25	O	989-991
weeks	O	992-997
(	O	998-999
range	O	999-1004
12	O	1005-1007
to	O	1008-1010
more	O	1011-1015
than	O	1016-1020
91	O	1021-1023
weeks	O	1024-1029
)	O	1029-1030
.	O	1030-1031

The	O	1032-1035
median	O	1036-1042
duration	O	1043-1051
of	O	1052-1054
survival	O	1055-1063
in	O	1064-1066
the	O	1067-1070
12	O	1071-1073
patients	O	1074-1082
was	O	1083-1086
54	O	1087-1089
weeks	O	1090-1095
(	O	1096-1097
range	O	1097-1102
21	O	1103-1105
to	O	1106-1108
more	O	1109-1113
than	O	1114-1118
156	O	1119-1122
weeks	O	1123-1128
)	O	1128-1129
,	O	1129-1130
with	O	1131-1135
an	O	1136-1138
18	O	1139-1141
-	O	1141-1142
month	O	1142-1147
survival	O	1148-1156
rate	O	1157-1161
of	O	1162-1164
42	O	1165-1167
%	O	1167-1168
.	O	1168-1169

Twenty	O	1170-1176
-	O	1176-1177
four	O	1177-1181
patients	O	1182-1190
with	O	1191-1195
recurrent	O	1196-1205
Grade	O	1206-1211
I	O	1212-1213
to	O	1214-1216
IV	O	1217-1219
astrocytomas	B	1220-1232
,	O	1232-1233
whose	O	1234-1239
resection	O	1240-1249
and	O	1250-1253
irradiation	O	1254-1265
therapy	O	1266-1273
had	O	1274-1277
failed	O	1278-1284
,	O	1284-1285
received	O	1286-1294
two	O	1295-1298
to	O	1299-1301
eight	O	1302-1307
courses	O	1308-1315
of	O	1316-1318
intra	O	1319-1324
-	O	1324-1325
arterial	O	1325-1333
BCNU	O	1334-1338
therapy	O	1339-1346
.	O	1346-1347

Seventeen	O	1348-1357
of	O	1358-1360
these	O	1361-1366
had	O	1367-1370
a	O	1371-1372
response	O	1373-1381
or	O	1382-1384
were	O	1385-1389
stable	O	1390-1396
for	O	1397-1400
a	O	1401-1402
median	O	1403-1409
of	O	1410-1412
20	O	1413-1415
weeks	O	1416-1421
(	O	1422-1423
range	O	1423-1428
6	O	1429-1430
to	O	1431-1433
more	O	1434-1438
than	O	1439-1443
66	O	1444-1446
weeks	O	1447-1452
)	O	1452-1453
.	O	1453-1454

The	O	1455-1458
catheterization	O	1459-1474
procedure	O	1475-1484
is	O	1485-1487
safe	O	1488-1492
,	O	1492-1493
with	O	1494-1498
no	O	1499-1501
immediate	O	1502-1511
complication	O	1512-1524
in	O	1525-1527
111	O	1528-1531
infusions	O	1532-1541
of	O	1542-1544
BCNU	O	1545-1549
.	O	1549-1550

A	O	1551-1552
delayed	O	1553-1560
complication	O	1561-1573
in	O	1574-1576
nine	O	1577-1581
patients	O	1582-1590
has	O	1591-1594
been	O	1595-1599
unilateral	O	1600-1610
loss	B	1611-1615
of	I	1616-1618
vision	I	1619-1625
secondary	O	1626-1635
to	O	1636-1638
a	O	1639-1640
retinal	B	1641-1648
vasculitis	I	1649-1659
.	O	1659-1660

The	O	1661-1664
frequency	O	1665-1674
of	O	1675-1677
visual	B	1678-1684
loss	I	1685-1689
decreased	O	1690-1699
after	O	1700-1705
the	O	1706-1709
concentration	O	1710-1723
of	O	1724-1726
the	O	1727-1730
ethanol	O	1731-1738
diluent	O	1739-1746
was	O	1747-1750
lowered	O	1751-1758
.	O	1758-1759

Blood	O	0-5
pressure	O	6-14
response	O	15-23
to	O	24-26
chronic	O	27-34
low	O	35-38
-	O	38-39
dose	O	39-43
intrarenal	O	44-54
noradrenaline	O	55-68
infusion	O	69-77
in	O	78-80
conscious	O	81-90
rats	O	91-95
.	O	95-96

Sodium	O	97-103
chloride	O	104-112
solution	O	113-121
(	O	122-123
0	O	123-124
.	O	124-125
9	O	125-126
%	O	126-127
)	O	127-128
or	O	129-131
noradrenaline	O	132-145
in	O	146-148
doses	O	149-154
of	O	155-157
4	O	158-159
,	O	159-160
12	O	161-163
and	O	164-167
36	O	168-170
micrograms	O	171-181
h	O	182-183
-	O	183-184
1	O	184-185
kg	O	186-188
-	O	188-189
1	O	189-190
was	O	191-194
infused	O	195-202
for	O	203-206
five	O	207-211
consecutive	O	212-223
days	O	224-228
,	O	228-229
either	O	230-236
intrarenally	O	237-249
(	O	250-251
by	O	251-253
a	O	254-255
new	O	256-259
technique	O	260-269
)	O	269-270
or	O	271-273
intravenously	O	274-287
into	O	288-292
rats	O	293-297
with	O	298-302
one	O	303-306
kidney	O	307-313
removed	O	314-321
.	O	321-322

Intrarenal	O	323-333
infusion	O	334-342
of	O	343-345
noradrenaline	O	346-359
caused	O	360-366
hypertension	B	367-379
at	O	380-382
doses	O	383-388
which	O	389-394
did	O	395-398
not	O	399-402
do	O	403-405
so	O	406-408
when	O	409-413
infused	O	414-421
intravenously	O	422-435
.	O	435-436

Intrarenal	O	437-447
compared	O	448-456
with	O	457-461
intravenous	O	462-473
infusion	O	474-482
of	O	483-485
noradrenaline	O	486-499
caused	O	500-506
higher	O	507-513
plasma	O	514-520
noradrenaline	O	521-534
concentrations	O	535-549
and	O	550-553
a	O	554-555
shift	O	556-561
of	O	562-564
the	O	565-568
plasma	O	569-575
noradrenaline	O	576-589
concentration	O	590-603
-	O	603-604
blood	O	604-609
pressure	O	610-618
effect	O	619-625
curve	O	626-631
towards	O	632-639
lower	O	640-645
plasma	O	646-652
noradrenaline	O	653-666
levels	O	667-673
.	O	673-674

These	O	675-680
results	O	681-688
suggest	O	689-696
that	O	697-701
hypertension	B	702-714
after	O	715-720
chronic	O	721-728
intrarenal	O	729-739
noradrenaline	O	740-753
infusion	O	754-762
is	O	763-765
produced	O	766-774
by	O	775-777
relatively	O	778-788
higher	O	789-795
levels	O	796-802
of	O	803-805
circulating	O	806-817
noradrenaline	O	818-831
and	O	832-835
by	O	836-838
triggering	O	839-849
of	O	850-852
an	O	853-855
additional	O	856-866
intrarenal	O	867-877
pressor	O	878-885
mechanism	O	886-895
.	O	895-896

Age	O	0-3
and	O	4-7
renal	O	8-13
clearance	O	14-23
of	O	24-26
cimetidine	O	27-37
.	O	37-38

In	O	39-41
35	O	42-44
patients	O	45-53
(	O	54-55
ages	O	55-59
20	O	60-62
to	O	63-65
86	O	66-68
yr	O	69-71
)	O	71-72
receiving	O	73-82
cimetidine	O	83-93
therapeutically	O	94-109
two	O	110-113
serum	O	114-119
samples	O	120-127
and	O	128-131
all	O	132-135
urine	O	136-141
formed	O	142-148
in	O	149-151
the	O	152-155
interim	O	156-163
were	O	164-168
collected	O	169-178
for	O	179-182
analysis	O	183-191
of	O	192-194
cimetidine	O	195-205
by	O	206-208
high	O	209-213
-	O	213-214
pressure	O	214-222
liquid	O	223-229
chromatography	O	230-244
and	O	245-248
for	O	249-252
creatinine	O	253-263
.	O	263-264

Cimetidine	O	265-275
clearance	O	276-285
decreased	O	286-295
with	O	296-300
age	O	301-304
.	O	304-305

The	O	306-309
extrapolated	O	310-322
6	O	323-324
-	O	324-325
hr	O	325-327
serum	O	328-333
concentration	O	334-347
of	O	348-350
cimetidine	O	351-361
per	O	362-365
unit	O	366-370
dose	O	371-375
,	O	375-376
after	O	377-382
intravenous	O	383-394
cimetidine	O	395-405
,	O	405-406
increased	O	407-416
with	O	417-421
age	O	422-425
of	O	426-428
the	O	429-432
patients	O	433-441
.	O	441-442

The	O	443-446
ratio	O	447-452
of	O	453-455
cimetidine	O	456-466
clearance	O	467-476
to	O	477-479
creatinine	O	480-490
clearance	O	491-500
(	O	501-502
Rc	O	502-504
)	O	504-505
averaged	O	506-514
4	O	515-516
.	O	516-517
8	O	517-518
+	O	519-520
/	O	520-521
-	O	521-522
2	O	523-524
.	O	524-525
0	O	525-526
,	O	526-527
indicating	O	528-538
net	O	539-542
tubular	O	543-550
secretion	O	551-560
for	O	561-564
cimetidine	O	565-575
.	O	575-576

Rc	O	577-579
seemed	O	580-586
to	O	587-589
be	O	590-592
independent	O	593-604
of	O	605-607
age	O	608-611
and	O	612-615
decreased	O	616-625
with	O	626-630
increasing	O	631-641
serum	O	642-647
concentration	O	648-661
of	O	662-664
cimetidine	O	665-675
,	O	675-676
suggesting	O	677-687
that	O	688-692
secretion	O	693-702
of	O	703-705
cimetidine	O	706-716
is	O	717-719
a	O	720-721
saturable	O	722-731
process	O	732-739
.	O	739-740

There	O	741-746
was	O	747-750
only	O	751-755
one	O	756-759
case	O	760-764
of	O	765-767
dementia	B	768-776
possibly	O	777-785
due	O	786-789
to	O	790-792
cimetidine	O	793-803
(	O	804-805
with	O	805-809
a	O	810-811
drug	O	812-816
level	O	817-822
of	O	823-825
1	O	826-827
.	O	827-828
9	O	828-829
microgram	O	830-839
/	O	839-840
ml	O	840-842
6	O	843-844
hr	O	845-847
after	O	848-853
a	O	854-855
dose	O	856-860
)	O	860-861
in	O	862-864
a	O	865-866
group	O	867-872
of	O	873-875
13	O	876-878
patients	O	879-887
without	O	888-895
liver	B	896-901
or	I	902-904
kidney	I	905-911
disease	I	912-919
who	O	920-923
had	O	924-927
cimetidine	O	928-938
levels	O	939-945
above	O	946-951
1	O	952-953
.	O	953-954
25	O	954-956
microgram	O	957-966
/	O	966-967
ml	O	967-969
.	O	969-970

Thus	O	971-975
,	O	975-976
high	O	977-981
cimetidine	O	982-992
levels	O	993-999
alone	O	1000-1005
do	O	1006-1008
not	O	1009-1012
always	O	1013-1019
induce	O	1020-1026
dementia	B	1027-1035
.	O	1035-1036

Development	O	0-11
of	O	12-14
clear	B	15-20
cell	I	21-25
adenocarcinoma	I	26-40
in	O	41-43
DES	O	44-47
-	O	47-48
exposed	O	48-55
offspring	O	56-65
under	O	66-71
observation	O	72-83
.	O	83-84

Two	O	85-88
cases	O	89-94
of	O	95-97
clear	B	98-103
cell	I	104-108
adenocarcinoma	I	109-123
of	I	124-126
the	I	127-130
vagina	I	131-137
detected	O	138-146
at	O	147-149
follow	O	150-156
-	O	156-157
up	O	157-159
in	O	160-162
young	O	163-168
women	O	169-174
exposed	O	175-182
in	O	183-185
utero	O	186-191
to	O	192-194
diethylstilbestrol	O	195-213
are	O	214-217
reported	O	218-226
.	O	226-227

One	O	228-231
patient	O	232-239
,	O	239-240
aged	O	241-245
23	O	246-248
,	O	248-249
had	O	250-253
been	O	254-258
followed	O	259-267
for	O	268-271
2	O	272-273
years	O	274-279
before	O	280-286
carcinoma	B	287-296
was	O	297-300
diagnosed	O	301-310
;	O	310-311
the	O	312-315
second	O	316-322
patient	O	323-330
,	O	330-331
aged	O	332-336
22	O	337-339
,	O	339-340
had	O	341-344
been	O	345-349
seen	O	350-354
on	O	355-357
a	O	358-359
regular	O	360-367
basis	O	368-373
for	O	374-377
5	O	378-379
years	O	380-385
,	O	385-386
8	O	387-388
months	O	389-395
.	O	395-396

In	O	397-399
both	O	400-404
instances	O	405-414
,	O	414-415
suspicion	O	416-425
of	O	426-428
the	O	429-432
presence	O	433-441
of	O	442-444
carcinoma	B	445-454
was	O	455-458
aroused	O	459-466
by	O	467-469
the	O	470-473
palpation	O	474-483
of	O	484-486
a	O	487-488
small	O	489-494
nodule	O	495-501
in	O	502-504
the	O	505-508
vaginal	O	509-516
fornix	O	517-523
.	O	523-524

Hysterosalpingography	O	525-546
was	O	547-550
performed	O	551-560
on	O	561-563
both	O	564-568
patients	O	569-577
and	O	578-581
,	O	581-582
in	O	583-585
1	O	586-587
instance	O	588-596
,	O	596-597
an	O	598-600
abnormal	O	601-609
x	O	610-611
-	O	611-612
ray	O	612-615
film	O	616-620
was	O	621-624
reflected	O	625-634
by	O	635-637
the	O	638-641
gross	O	642-647
appearance	O	648-658
of	O	659-661
the	O	662-665
uterine	O	666-673
cavity	O	674-680
found	O	681-686
in	O	687-689
the	O	690-693
surgical	O	694-702
specimen	O	703-711
.	O	711-712

Phenobarbitone	O	0-14
-	O	14-15
induced	O	15-22
enlargement	B	23-34
of	I	35-37
the	I	38-41
liver	I	42-47
in	O	48-50
the	O	51-54
rat	O	55-58
:	O	58-59
its	O	60-63
relationship	O	64-76
to	O	77-79
carbon	O	80-86
tetrachloride	O	87-100
-	O	100-101
induced	O	101-108
cirrhosis	B	109-118
.	O	118-119

The	O	120-123
yield	O	124-129
of	O	130-132
severe	O	133-139
cirrhosis	B	140-149
of	I	150-152
the	I	153-156
liver	I	157-162
(	O	163-164
defined	O	164-171
as	O	172-174
a	O	175-176
shrunken	O	177-185
finely	O	186-192
nodular	O	193-200
liver	O	201-206
with	O	207-211
micronodular	O	212-224
histology	O	225-234
,	O	234-235
ascites	B	236-243
greater	O	244-251
than	O	252-256
30	O	257-259
ml	O	260-262
,	O	262-263
plasma	O	264-270
albumin	O	271-278
less	O	279-283
than	O	284-288
2	O	289-290
.	O	290-291
2	O	289-290
g	O	293-294
/	O	294-295
dl	O	295-297
,	O	297-298
splenomegaly	B	299-311
2	O	312-313
-	O	313-314
3	O	314-315
times	O	316-321
normal	O	322-328
,	O	328-329
and	O	330-333
testicular	O	334-344
atrophy	B	345-352
approximately	O	353-366
half	O	367-371
normal	O	372-378
weight	O	379-385
)	O	385-386
after	O	387-392
12	O	393-395
doses	O	396-401
of	O	402-404
carbon	O	405-411
tetrachloride	O	412-425
given	O	426-431
intragastrically	O	432-448
in	O	449-451
the	O	452-455
phenobarbitone	O	456-470
-	O	470-471
primed	O	471-477
rat	O	478-481
was	O	482-485
increased	O	486-495
from	O	496-500
25	O	501-503
%	O	503-504
to	O	505-507
56	O	508-510
%	O	510-511
by	O	512-514
giving	O	515-521
the	O	522-525
initial	O	526-533
"	O	534-535
calibrating	O	535-546
"	O	534-535
dose	O	548-552
of	O	553-555
carbon	O	556-562
tetrachloride	O	563-576
at	O	577-579
the	O	580-583
peak	O	584-588
of	O	589-591
the	O	592-595
phenobarbitone	O	596-610
-	O	610-611
induced	O	611-618
enlargement	B	619-630
of	I	631-633
the	I	634-637
liver	I	638-643
.	O	643-644

At	O	645-647
this	O	648-652
point	O	653-658
it	O	659-661
was	O	662-665
assumed	O	666-673
that	O	674-678
the	O	679-682
cytochrome	O	683-693
P450	O	694-698
/	O	698-699
CCl4	O	699-703
toxic	O	704-709
state	O	710-715
was	O	716-719
both	O	720-724
maximal	O	725-732
and	O	733-736
stable	O	737-743
.	O	743-744

The	O	745-748
optimal	O	749-756
rat	O	757-760
size	O	761-765
to	O	766-768
begin	O	769-774
phenobarbitone	O	775-789
was	O	790-793
determined	O	794-804
as	O	805-807
100	O	808-811
g	O	812-813
,	O	813-814
and	O	815-818
this	O	819-823
size	O	824-828
as	O	829-831
a	O	832-833
group	O	834-839
had	O	840-843
a	O	844-845
mean	O	846-850
maximum	O	851-858
relative	O	859-867
liver	O	868-873
weight	O	874-880
increase	O	881-889
47	O	890-892
%	O	892-893
greater	O	894-901
than	O	902-906
normal	O	907-913
rats	O	914-918
of	O	919-921
the	O	922-925
same	O	926-930
body	O	931-935
weight	O	936-942
.	O	942-943

The	O	944-947
optimal	O	948-955
time	O	956-960
for	O	961-964
the	O	965-968
initial	O	969-976
dose	O	977-981
of	O	982-984
carbon	O	985-991
tetrachloride	O	992-1005
was	O	1006-1009
after	O	1010-1015
14	O	1016-1018
days	O	1019-1023
on	O	1024-1026
phenobarbitone	O	1027-1041
.	O	1041-1042

Attenuation	O	0-11
of	O	12-14
the	O	15-18
lithium	O	19-26
-	O	26-27
induced	O	27-34
diabetes	B	35-43
-	I	43-44
insipidus	I	44-53
-	I	43-44
like	I	54-58
syndrome	I	59-67
by	O	68-70
amiloride	O	71-80
in	O	81-83
rats	O	84-88
.	O	88-89

The	O	90-93
effect	O	94-100
of	O	101-103
amiloride	O	104-113
on	O	114-116
lithium	O	117-124
-	O	124-125
induced	O	125-132
polydipsia	B	133-143
and	O	144-147
polyuria	B	148-156
and	O	157-160
on	O	161-163
the	O	164-167
lithium	O	168-175
concentration	O	176-189
in	O	190-192
the	O	193-196
plasma	O	197-203
,	O	203-204
brain	O	205-210
,	O	210-211
kidney	O	212-218
,	O	218-219
thyroid	O	220-227
and	O	228-231
red	O	232-235
blood	O	236-241
cells	O	242-247
was	O	248-251
investigated	O	252-264
in	O	265-267
rats	O	268-272
,	O	272-273
chronically	O	274-285
treated	O	286-293
with	O	294-298
LiCl	O	299-303
.	O	303-304

Amiloride	O	305-314
reduced	O	315-322
the	O	323-326
drinking	O	327-335
and	O	336-339
urine	O	340-345
volume	O	346-352
of	O	353-355
rats	O	356-360
in	O	361-363
an	O	364-366
acute	O	367-372
(	O	373-374
6	O	374-375
or	O	376-378
12	O	379-381
h	O	382-383
)	O	383-384
and	O	385-388
a	O	389-390
subacute	O	391-399
(	O	400-401
3	O	401-402
days	O	403-407
)	O	407-408
experiment	O	409-419
.	O	419-420

6	O	421-422
h	O	423-424
after	O	425-430
the	O	431-434
administration	O	435-449
of	O	450-452
amiloride	O	453-462
,	O	462-463
a	O	464-465
reduction	O	466-475
was	O	476-479
observed	O	480-488
in	O	489-491
the	O	492-495
lithium	O	496-503
content	O	504-511
of	O	512-514
the	O	515-518
renal	O	519-524
medulla	O	525-532
but	O	533-536
not	O	537-540
in	O	541-543
the	O	544-547
other	O	548-553
organs	O	554-560
studied	O	561-568
.	O	568-569

At	O	570-572
12	O	573-575
h	O	576-577
,	O	577-578
all	O	579-582
the	O	583-586
tissues	O	587-594
showed	O	595-601
a	O	602-603
slight	O	604-610
increase	O	611-619
in	O	620-622
lithium	O	623-630
levels	O	631-637
.	O	637-638

After	O	639-644
3	O	645-646
days	O	647-651
of	O	652-654
combined	O	655-663
treatment	O	664-673
,	O	673-674
a	O	675-676
marked	O	677-683
elevation	O	684-693
in	O	694-696
plasma	O	697-703
and	O	704-707
tissue	O	708-714
lithium	O	715-722
levels	O	723-729
accompanied	O	730-741
a	O	742-743
reduction	O	744-753
in	O	754-756
water	O	757-762
intake	O	763-769
.	O	769-770

In	O	771-773
all	O	774-777
the	O	778-781
experiments	O	782-793
,	O	793-794
the	O	795-798
attenuation	O	799-810
of	O	811-813
the	O	814-817
lithium	O	818-825
-	O	825-826
induced	O	826-833
diabetes	B	834-842
-	I	842-843
insipidus	I	843-852
-	I	842-843
like	I	853-857
syndrome	I	858-866
by	O	867-869
amiloride	O	870-879
was	O	880-883
accompanied	O	884-895
by	O	896-898
a	O	899-900
reduction	O	901-910
of	O	911-913
the	O	914-917
ratio	O	918-923
between	O	924-931
the	O	932-935
lithium	O	936-943
concentration	O	944-957
in	O	958-960
the	O	961-964
renal	O	965-970
medulla	O	971-978
and	O	979-982
its	O	983-986
levels	O	987-993
in	O	994-996
the	O	997-1000
blood	O	1001-1006
and	O	1007-1010
an	O	1011-1013
elevation	O	1014-1023
in	O	1024-1026
the	O	1027-1030
plasma	O	1031-1037
potassium	O	1038-1047
level	O	1048-1053
.	O	1053-1054

It	O	1055-1057
is	O	1058-1060
concluded	O	1061-1070
that	O	1071-1075
acute	O	1076-1081
amiloride	O	1082-1091
administration	O	1092-1106
to	O	1107-1109
lithium	O	1110-1117
-	O	1117-1118
treated	O	1118-1125
patients	O	1126-1134
suffering	O	1135-1144
from	O	1145-1149
polydipsia	B	1150-1160
and	O	1161-1164
polyuria	B	1165-1173
might	O	1174-1179
relieve	O	1180-1187
these	O	1188-1193
patients	O	1194-1202
but	O	1203-1206
prolonged	O	1207-1216
amiloride	O	1217-1226
supplementation	O	1227-1242
would	O	1243-1248
result	O	1249-1255
in	O	1256-1258
elevated	O	1259-1267
lithium	O	1268-1275
levels	O	1276-1282
and	O	1283-1286
might	O	1287-1292
be	O	1293-1295
hazardous	O	1296-1305
.	O	1305-1306

Safety	O	0-6
and	O	7-10
side	O	11-15
-	O	15-16
effects	O	16-23
of	O	24-26
alprazolam	O	27-37
.	O	37-38

Controlled	O	39-49
study	O	50-55
in	O	56-58
agoraphobia	B	59-70
with	O	71-75
panic	B	76-81
disorder	I	82-90
.	O	90-91

BACKGROUND	O	92-102
:	O	102-103
The	O	104-107
widespread	O	108-118
use	O	119-122
of	O	123-125
benzodiazepines	O	126-141
has	O	142-145
led	O	146-149
to	O	150-152
increasing	O	153-163
recognition	O	164-175
of	O	176-178
their	O	179-184
unwanted	O	185-193
effects	O	194-201
.	O	201-202

The	O	203-206
efficacy	O	207-215
of	O	216-218
alprazolam	O	219-229
and	O	230-233
placebo	O	234-241
in	O	242-244
panic	B	245-250
disorder	I	251-259
with	O	260-264
agoraphobia	B	265-276
,	O	276-277
and	O	278-281
the	O	282-285
side	O	286-290
-	O	290-291
effect	O	291-297
and	O	298-301
adverse	O	302-309
effect	O	310-316
profiles	O	317-325
of	O	326-328
both	O	329-333
drug	O	334-338
groups	O	339-345
were	O	346-350
measured	O	351-359
.	O	359-360

METHOD	O	361-367
:	O	367-368
In	O	369-371
London	O	372-378
and	O	379-382
Toronto	O	383-390
154	O	391-394
patients	O	395-403
who	O	404-407
met	O	408-411
DSM	O	412-415
-	O	415-416
III	O	416-419
criteria	O	420-428
for	O	429-432
panic	B	433-438
disorder	I	439-447
with	O	448-452
agoraphobia	B	453-464
were	O	465-469
randomised	O	470-480
to	O	481-483
alprazolam	O	484-494
or	O	495-497
placebo	O	498-505
.	O	505-506

Subjects	O	507-515
in	O	516-518
each	O	519-523
drug	O	524-528
group	O	529-534
also	O	535-539
received	O	540-548
either	O	549-555
exposure	O	556-564
or	O	565-567
relaxation	O	568-578
.	O	578-579

Treatment	O	580-589
was	O	590-593
from	O	594-598
weeks	O	599-604
0	O	605-606
to	O	607-609
8	O	610-611
and	O	612-615
was	O	616-619
then	O	620-624
tapered	O	625-632
from	O	633-637
weeks	O	638-643
8	O	644-645
to	O	646-648
16	O	649-651
.	O	651-652
RESULTS	O	653-660
:	O	660-661
Mean	O	662-666
alprazolam	O	667-677
dose	O	678-682
was	O	683-686
5	O	687-688
mg	O	689-691
daily	O	692-697
.	O	697-698

Compared	O	699-707
with	O	708-712
placebo	O	713-720
subjects	O	721-729
,	O	729-730
alprazolam	O	731-741
patients	O	742-750
developed	O	751-760
more	O	761-765
adverse	O	766-773
reactions	O	774-783
(	O	784-785
21	O	785-787
%	O	787-788
v	O	789-790
.	O	790-791
0	O	792-793
%	O	793-794
)	O	794-795
of	O	796-798
depression	B	799-809
,	O	809-810
enuresis	B	811-819
,	O	819-820
disinhibition	O	821-834
and	O	835-838
aggression	B	839-849
;	O	849-850
and	O	851-854
more	O	855-859
side	O	860-864
-	O	864-865
effects	O	865-872
,	O	872-873
particularly	O	874-886
sedation	O	887-895
,	O	895-896
irritability	B	897-909
,	O	909-910
impaired	B	911-919
memory	I	920-926
,	O	926-927
weight	B	928-934
loss	I	935-939
and	O	940-943
ataxia	B	944-950
.	O	950-951

Side	O	952-956
-	O	956-957
effects	O	957-964
tended	O	965-971
to	O	972-974
diminish	O	975-983
during	O	984-990
treatment	O	991-1000
but	O	1001-1004
remained	O	1005-1013
significant	O	1014-1025
at	O	1026-1028
week	O	1029-1033
8	O	1034-1035
.	O	1035-1036

Despite	O	1037-1044
this	O	1045-1049
,	O	1049-1050
the	O	1051-1054
drop	O	1055-1059
-	O	1059-1060
out	O	1060-1063
rate	O	1064-1068
was	O	1069-1072
low	O	1073-1076
.	O	1076-1077

CONCLUSIONS	O	1078-1089
:	O	1089-1090
Alprazolam	O	1091-1101
caused	O	1102-1108
side	O	1109-1113
-	O	1113-1114
effects	O	1114-1121
and	O	1122-1125
adverse	O	1126-1133
effects	O	1134-1141
during	O	1142-1148
treatment	O	1149-1158
but	O	1159-1162
many	O	1163-1167
patients	O	1168-1176
were	O	1177-1181
willing	O	1182-1189
to	O	1190-1192
accept	O	1193-1199
these	O	1200-1205
.	O	1205-1206

Dup	O	0-3
753	O	4-7
prevents	O	8-16
the	O	17-20
development	O	21-32
of	O	33-35
puromycin	O	36-45
aminonucleoside	O	46-61
-	O	61-62
induced	O	62-69
nephrosis	B	70-79
.	O	79-80

The	O	81-84
appearance	O	85-95
of	O	96-98
nephrotic	B	99-108
syndromes	I	109-118
such	O	119-123
as	O	124-126
proteinuria	B	127-138
,	O	138-139
hypoalbuminemia	B	140-155
,	O	155-156
hypercholesterolemia	B	157-177
and	O	178-181
increase	O	182-190
in	O	191-193
blood	O	194-199
nitrogen	O	200-208
urea	O	209-213
,	O	213-214
induced	O	215-222
in	O	223-225
rats	O	226-230
by	O	231-233
injection	O	234-243
of	O	244-246
puromycin	O	247-256
aminonucleoside	O	257-272
was	O	273-276
markedly	O	277-285
inhibited	O	286-295
by	O	296-298
oral	O	299-303
administration	O	304-318
of	O	319-321
Dup	O	322-325
753	O	326-329
(	O	330-331
losartan	O	331-339
)	O	339-340
,	O	340-341
a	O	342-343
novel	O	344-349
angiotensin	O	350-361
II	O	362-364
receptor	O	365-373
antagonist	O	374-384
,	O	384-385
at	O	386-388
a	O	389-390
dose	O	391-395
of	O	396-398
1	O	399-400
or	O	401-403
2	O	404-405
mg	O	406-408
/	O	408-409
kg	O	409-411
per	O	412-415
day	O	416-419
.	O	419-420

The	O	421-424
results	O	425-432
suggest	O	433-440
a	O	441-442
possible	O	443-451
involvement	O	452-463
of	O	464-466
the	O	467-470
renin	O	471-476
-	O	476-477
angiotensin	O	477-488
system	O	489-495
in	O	496-498
the	O	499-502
development	O	503-514
of	O	515-517
puromycin	O	518-527
aminonucleoside	O	528-543
-	O	543-544
induced	O	544-551
nephrosis	B	552-561
.	O	561-562

Sodium	O	0-6
bicarbonate	O	7-18
alleviates	O	19-29
penile	B	30-36
pain	I	37-41
induced	O	42-49
by	O	50-52
intracavernous	O	53-67
injections	O	68-78
for	O	79-82
erectile	B	83-91
dysfunction	I	92-103
.	O	103-104

In	O	105-107
an	O	108-110
attempt	O	111-118
to	O	119-121
determine	O	122-131
whether	O	132-139
penile	B	140-146
pain	I	147-151
associated	O	152-162
with	O	163-167
intracorporeal	O	168-182
injections	O	183-193
could	O	194-199
be	O	200-202
due	O	203-206
to	O	207-209
the	O	210-213
acidity	O	214-221
of	O	222-224
the	O	225-228
medication	O	229-239
,	O	239-240
we	O	241-243
performed	O	244-253
a	O	254-255
randomized	O	256-266
study	O	267-272
comparing	O	273-282
the	O	283-286
incidence	O	287-296
of	O	297-299
penile	B	300-306
pain	I	307-311
following	O	312-321
intracorporeal	O	322-336
injections	O	337-347
with	O	348-352
or	O	353-355
without	O	356-363
the	O	364-367
addition	O	368-376
of	O	377-379
sodium	O	380-386
bicarbonate	O	387-398
to	O	399-401
the	O	402-405
intracorporeal	O	406-420
medications	O	421-432
.	O	432-433

A	O	434-435
total	O	436-441
of	O	442-444
38	O	445-447
consecutive	O	448-459
patients	O	460-468
who	O	469-472
presented	O	473-482
to	O	483-485
our	O	486-489
clinic	O	490-496
with	O	497-501
impotence	B	502-511
received	O	512-520
0	O	521-522
.	O	522-523
2	O	523-524
ml	O	525-527
.	O	527-528
of	O	529-531
a	O	532-533
combination	O	534-545
of	O	546-548
3	O	549-550
drugs	O	551-556
:	O	556-557
6	O	558-559
mg	O	560-562
.	O	562-563

papaverine	O	564-574
,	O	574-575
100	O	576-579
micrograms	O	580-590
.	O	590-591

phentolamine	O	592-604
and	O	605-608
10	O	609-611
micrograms	O	612-622
.	O	622-623

prostaglandin	O	624-637
E1	O	638-640
with	O	641-645
(	O	646-647
pH	O	647-649
7	O	650-651
.	O	651-652
05	O	652-654
)	O	654-655
or	O	656-658
without	O	659-666
(	O	667-668
pH	O	668-670
4	O	671-672
.	O	672-673
17	O	673-675
)	O	675-676
the	O	677-680
addition	O	681-689
of	O	690-692
sodium	O	693-699
bicarbonate	O	700-711
(	O	712-713
0	O	713-714
.	O	714-715
03	O	715-717
mEq	O	718-721
.	O	721-722
)	O	722-723
.	O	721-722

Of	O	725-727
the	O	728-731
19	O	732-734
patients	O	735-743
without	O	744-751
sodium	O	752-758
bicarbonate	O	759-770
added	O	771-776
to	O	777-779
the	O	780-783
medication	O	784-794
11	O	795-797
(	O	798-799
58	O	799-801
%	O	801-802
)	O	802-803
complained	O	804-814
of	O	815-817
penile	B	818-824
pain	I	825-829
due	O	830-833
to	O	834-836
the	O	837-840
medication	O	841-851
,	O	851-852
while	O	853-858
only	O	859-863
1	O	864-865
of	O	866-868
the	O	869-872
19	O	873-875
men	O	876-879
(	O	880-881
5	O	881-882
%	O	882-883
)	O	883-884
who	O	885-888
received	O	889-897
sodium	O	898-904
bicarbonate	O	905-916
complained	O	917-927
of	O	928-930
penile	B	931-937
pain	I	938-942
.	O	942-943

From	O	944-948
these	O	949-954
data	O	955-959
we	O	960-962
conclude	O	963-971
that	O	972-976
the	O	977-980
penile	B	981-987
pain	I	988-992
following	O	993-1002
intracorporeal	O	1003-1017
injections	O	1018-1028
is	O	1029-1031
most	O	1032-1036
likely	O	1037-1043
due	O	1044-1047
to	O	1048-1050
the	O	1051-1054
acidity	O	1055-1062
of	O	1063-1065
the	O	1066-1069
medication	O	1070-1080
,	O	1080-1081
which	O	1082-1087
can	O	1088-1091
be	O	1092-1094
overcome	O	1095-1103
by	O	1104-1106
elevating	O	1107-1116
the	O	1117-1120
pH	O	1121-1123
to	O	1124-1126
a	O	1127-1128
neutral	O	1129-1136
level	O	1137-1142
.	O	1142-1143

Prospective	O	0-11
study	O	12-17
of	O	18-20
the	O	21-24
long	O	25-29
-	O	29-30
term	O	30-34
effects	O	35-42
of	O	43-45
somatostatin	O	46-58
analog	O	59-65
(	O	66-67
octreotide	O	67-77
)	O	77-78
on	O	79-81
gallbladder	O	82-93
function	O	94-102
and	O	103-106
gallstone	B	107-116
formation	O	117-126
in	O	127-129
Chinese	O	130-137
acromegalic	B	138-149
patients	O	150-158
.	O	158-159

This	O	160-164
article	O	165-172
reports	O	173-180
the	O	181-184
changes	O	185-192
in	O	193-195
gallbladder	O	196-207
function	O	208-216
examined	O	217-225
by	O	226-228
ultrasonography	O	229-244
in	O	245-247
20	O	248-250
Chinese	O	251-258
patients	O	259-267
with	O	268-272
active	O	273-279
acromegaly	B	280-290
treated	O	291-298
with	O	299-303
sc	O	304-306
injection	O	307-316
of	O	317-319
the	O	320-323
somatostatin	O	324-336
analog	O	337-343
octreotide	O	344-354
in	O	355-357
dosages	O	358-365
of	O	366-368
300	O	369-372
-	O	372-373
1500	O	373-377
micrograms	O	378-388
/	O	388-389
day	O	389-392
for	O	393-396
a	O	397-398
mean	O	399-403
of	O	404-406
24	O	407-409
.	O	409-410
2	O	407-408
+	O	412-413
/	O	413-414
-	O	414-415
13	O	416-418
.	O	418-419
9	O	419-420
months	O	421-427
.	O	427-428

During	O	429-435
treatment	O	436-445
with	O	446-450
octreotide	O	451-461
,	O	461-462
17	O	463-465
patients	O	466-474
developed	O	475-484
sludge	O	485-491
,	O	491-492
10	O	493-495
had	O	496-499
gallstones	B	500-510
,	O	510-511
and	O	512-515
1	O	516-517
developed	O	518-527
acute	B	528-533
cholecystitis	I	534-547
requiring	O	548-557
surgery	O	558-565
.	O	565-566

In	O	567-569
all	O	570-573
of	O	574-576
7	O	577-578
patients	O	579-587
examined	O	588-596
acutely	O	597-604
,	O	604-605
gallbladder	O	606-617
contractility	O	618-631
was	O	632-635
inhibited	O	636-645
after	O	646-651
a	O	652-653
single	O	654-660
100	O	661-664
-	O	664-665
micrograms	O	665-675
injection	O	676-685
.	O	685-686

In	O	687-689
8	O	690-691
patients	O	692-700
followed	O	701-709
for	O	710-713
24	O	714-716
weeks	O	717-722
,	O	722-723
gallbladder	O	724-735
contractility	O	736-749
remained	O	750-758
depressed	B	759-768
throughout	O	769-779
therapy	O	780-787
.	O	787-788

After	O	789-794
withdrawal	O	795-805
of	O	806-808
octreotide	O	809-819
in	O	820-822
10	O	823-825
patients	O	826-834
without	O	835-842
gallstones	B	843-853
,	O	853-854
8	O	855-856
patients	O	857-865
assessed	O	866-874
had	O	875-878
return	O	879-885
of	O	886-888
normal	O	889-895
gallbladder	O	896-907
contractility	O	908-921
within	O	922-928
1	O	929-930
month	O	931-936
.	O	936-937

In	O	938-940
8	O	941-942
of	O	943-945
the	O	946-949
remaining	O	950-959
10	O	960-962
patients	O	963-971
who	O	972-975
developed	O	976-985
gallstones	B	986-996
during	O	997-1003
treatment	O	1004-1013
,	O	1013-1014
gallbladder	O	1015-1026
contractility	O	1027-1040
normalized	O	1041-1051
in	O	1052-1054
5	O	1055-1056
patients	O	1057-1065
(	O	1066-1067
3	O	1067-1068
of	O	1069-1071
whom	O	1072-1076
has	O	1077-1080
disappearance	O	1081-1094
of	O	1095-1097
their	O	1098-1103
stones	O	1104-1110
within	O	1111-1117
3	O	1118-1119
weeks	O	1120-1125
)	O	1125-1126
,	O	1126-1127
and	O	1128-1131
remained	O	1132-1140
depressed	B	1141-1150
in	O	1151-1153
3	O	1154-1155
(	O	1156-1157
2	O	1157-1158
of	O	1159-1161
whom	O	1162-1166
had	O	1167-1170
stones	O	1171-1177
present	O	1178-1185
at	O	1186-1188
6	O	1189-1190
months	O	1191-1197
)	O	1197-1198
.	O	1198-1199

Our	O	1200-1203
results	O	1204-1211
suggest	O	1212-1219
that	O	1220-1224
the	O	1225-1228
suppression	O	1229-1240
of	O	1241-1243
gallbladder	O	1244-1255
contractility	O	1256-1269
is	O	1270-1272
the	O	1273-1276
cause	O	1277-1282
of	O	1283-1285
the	O	1286-1289
successive	O	1290-1300
formation	O	1301-1310
of	O	1311-1313
bile	O	1314-1318
sludge	O	1319-1325
,	O	1325-1326
gallstones	B	1327-1337
,	O	1337-1338
and	O	1339-1342
cholecystitis	B	1343-1356
during	O	1357-1363
octreotide	O	1364-1374
therapy	O	1375-1382
in	O	1383-1385
Chinese	O	1386-1393
acromegalic	B	1394-1405
patients	O	1406-1414
.	O	1414-1415

It	O	1416-1418
is	O	1419-1421
therefore	O	1422-1431
very	O	1432-1436
important	O	1437-1446
to	O	1447-1449
follow	O	1450-1456
the	O	1457-1460
changes	O	1461-1468
of	O	1469-1471
gallbladder	O	1472-1483
function	O	1484-1492
during	O	1493-1499
long	O	1500-1504
-	O	1504-1505
term	O	1505-1509
octreotide	O	1510-1520
therapy	O	1521-1528
of	O	1529-1531
acromegalic	B	1532-1543
patients	O	1544-1552
.	O	1552-1553

Improvement	O	0-11
of	O	12-14
levodopa	O	15-23
-	O	23-24
induced	O	24-31
dyskinesia	B	32-42
by	O	43-45
propranolol	O	46-57
in	O	58-60
Parkinson	B	61-70
'	I	70-71
s	I	67-68
disease	I	73-80
.	O	80-81

Seven	O	82-87
patients	O	88-96
suffering	O	97-106
from	O	107-111
Parkinson	B	112-121
'	I	121-122
s	I	118-119
disease	I	124-131
(	O	132-133
PD	B	133-135
)	O	135-136
with	O	137-141
severely	O	142-150
disabling	O	151-160
dyskinesia	B	161-171
received	O	172-180
low	O	181-184
-	O	184-185
dose	O	185-189
propranolol	O	190-201
as	O	202-204
an	O	205-207
adjunct	O	208-215
to	O	216-218
the	O	219-222
currently	O	223-232
used	O	233-237
medical	O	238-245
treatment	O	246-255
.	O	255-256

There	O	257-262
was	O	263-266
a	O	267-268
significant	O	269-280
40	O	281-283
%	O	283-284
improvement	O	285-296
in	O	297-299
the	O	300-303
dyskinesia	B	304-314
score	O	315-320
without	O	321-328
increase	O	329-337
of	O	338-340
parkinsonian	B	341-353
motor	B	354-359
disability	I	360-370
.	O	370-371

Ballistic	O	372-381
and	O	382-385
choreic	O	386-393
dyskinesia	B	394-404
were	O	405-409
markedly	O	410-418
ameliorated	O	419-430
,	O	430-431
whereas	O	432-439
dystonia	B	440-448
was	O	449-452
not	O	453-456
.	O	456-457

This	O	458-462
study	O	463-468
suggests	O	469-477
that	O	478-482
administration	O	483-497
of	O	498-500
low	O	501-504
doses	O	505-510
of	O	511-513
beta	O	514-518
-	O	518-519
blockers	O	519-527
may	O	528-531
improve	O	532-539
levodopa	O	540-548
-	O	548-549
induced	O	549-556
ballistic	O	557-566
and	O	567-570
choreic	O	571-578
dyskinesia	B	579-589
in	O	590-592
PD	B	593-595
.	O	595-596

Morphological	O	0-13
features	O	14-22
of	O	23-25
encephalopathy	B	26-40
after	O	41-46
chronic	O	47-54
administration	O	55-69
of	O	70-72
the	O	73-76
antiepileptic	O	77-90
drug	O	91-95
valproate	O	96-105
to	O	106-108
rats	O	109-113
.	O	113-114

A	O	115-116
transmission	O	117-129
electron	O	130-138
microscopic	O	139-150
study	O	151-156
of	O	157-159
capillaries	O	160-171
in	O	172-174
the	O	175-178
cerebellar	O	179-189
cortex	O	190-196
.	O	196-197

Long	O	198-202
-	O	202-203
term	O	203-207
intragastric	O	208-220
application	O	221-232
of	O	233-235
the	O	236-239
antiepileptic	O	240-253
drug	O	254-258
sodium	O	259-265
valproate	O	266-275
(	O	276-277
Vupral	O	277-283
"	O	284-285
Polfa	O	285-290
"	O	284-285
)	O	291-292
at	O	293-295
the	O	296-299
effective	O	300-309
dose	O	310-314
of	O	315-317
200	O	318-321
mg	O	322-324
/	O	324-325
kg	O	325-327
b	O	328-329
.	O	329-330
w	O	331-332
.	O	332-333
once	O	334-338
daily	O	339-344
to	O	345-347
rats	O	348-352
for	O	353-356
1	O	357-358
,	O	358-359
3	O	360-361
,	O	361-362
6	O	363-364
,	O	364-365
9	O	366-367
and	O	368-371
12	O	372-374
months	O	375-381
revealed	O	382-390
neurological	B	391-403
disorders	I	404-413
indicating	O	414-424
cerebellum	B	425-435
damage	I	436-442
(	O	443-444
"	O	444-445
valproate	O	445-454
encephalopathy	B	455-469
"	O	469-470
)	O	470-471
.	O	471-472

The	O	473-476
first	O	477-482
ultrastructural	O	483-498
changes	O	499-506
in	O	507-509
structural	O	510-520
elements	O	521-529
of	O	530-532
the	O	533-536
blood	O	537-542
-	O	542-543
brain	O	543-548
-	O	542-543
barrier	O	549-556
(	O	557-558
BBB	O	558-561
)	O	561-562
in	O	563-565
the	O	566-569
cerebellar	O	570-580
cortex	O	581-587
were	O	588-592
detectable	O	593-603
after	O	604-609
3	O	610-611
months	O	612-618
of	O	619-621
the	O	622-625
experiment	O	626-636
.	O	636-637

They	O	638-642
became	O	643-649
more	O	650-654
severe	O	655-661
in	O	662-664
the	O	665-668
later	O	669-674
months	O	675-681
of	O	682-684
the	O	685-688
experiment	O	689-699
,	O	699-700
and	O	701-704
were	O	705-709
most	O	710-714
severe	O	715-721
after	O	722-727
12	O	728-730
months	O	731-737
,	O	737-738
located	O	739-746
mainly	O	747-753
in	O	754-756
the	O	757-760
molecular	O	761-770
layer	O	771-776
of	O	777-779
the	O	780-783
cerebellar	O	784-794
cortex	O	795-801
.	O	801-802

Lesions	O	803-810
of	O	811-813
the	O	814-817
capillary	O	818-827
included	O	828-836
necrosis	B	837-845
of	O	846-848
endothelial	O	849-860
cells	O	861-866
.	O	866-867

Organelles	O	868-878
of	O	879-881
these	O	882-887
cells	O	888-893
,	O	893-894
in	O	895-897
particular	O	898-908
the	O	909-912
mitochondria	O	913-925
(	O	926-927
increased	O	927-936
number	O	937-943
and	O	944-947
size	O	948-952
,	O	952-953
distinct	O	954-962
degeneration	O	963-975
of	O	976-978
their	O	979-984
matrix	O	985-991
and	O	992-995
cristae	O	996-1003
)	O	1003-1004
and	O	1005-1008
Golgi	O	1009-1014
apparatus	O	1015-1024
were	O	1025-1029
altered	O	1030-1037
.	O	1037-1038

Reduced	O	1039-1046
size	O	1047-1051
of	O	1052-1054
capillary	O	1055-1064
lumen	O	1065-1070
and	O	1071-1074
occlusion	O	1075-1084
were	O	1085-1089
caused	O	1090-1096
by	O	1097-1099
swollen	O	1100-1107
endothelial	O	1108-1119
cells	O	1120-1125
which	O	1126-1131
had	O	1132-1135
luminal	O	1136-1143
protrusions	O	1144-1155
and	O	1156-1159
swollen	O	1160-1167
microvilli	O	1168-1178
.	O	1178-1179

Pressure	O	1180-1188
on	O	1189-1191
the	O	1192-1195
vessel	O	1196-1202
wall	O	1203-1207
was	O	1208-1211
produced	O	1212-1220
by	O	1221-1223
enlarged	O	1224-1232
perivascular	O	1233-1245
astrocytic	O	1246-1256
processes	O	1257-1266
.	O	1266-1267

Fragments	O	1268-1277
of	O	1278-1280
necrotic	B	1281-1289
endothelial	O	1290-1301
cells	O	1302-1307
were	O	1308-1312
in	O	1313-1315
the	O	1316-1319
vascular	O	1320-1328
lumens	O	1329-1335
and	O	1336-1339
in	O	1340-1342
these	O	1343-1348
there	O	1349-1354
was	O	1355-1358
loosening	O	1359-1368
and	O	1369-1372
breaking	O	1373-1381
of	O	1382-1384
tight	O	1385-1390
cellular	O	1391-1399
junctions	O	1400-1409
.	O	1409-1410

Damage	O	1411-1417
to	O	1418-1420
the	O	1421-1424
vascular	O	1425-1433
basement	O	1434-1442
lamina	O	1443-1449
was	O	1450-1453
also	O	1454-1458
observed	O	1459-1467
.	O	1467-1468

Damage	O	1469-1475
to	O	1476-1478
the	O	1479-1482
capillary	O	1483-1492
was	O	1493-1496
accompanied	O	1497-1508
by	O	1509-1511
marked	O	1512-1518
damage	O	1519-1525
to	O	1526-1528
neuroglial	O	1529-1539
cells	O	1540-1545
,	O	1545-1546
mainly	O	1547-1553
to	O	1554-1556
perivascular	O	1557-1569
processes	O	1570-1579
of	O	1580-1582
astrocytes	O	1583-1593
.	O	1593-1594

The	O	1595-1598
proliferation	O	1599-1612
of	O	1613-1615
astrocytes	O	1616-1626
(	O	1627-1628
Bergmann	O	1628-1636
'	O	1636-1637
s	O	1637-1638
in	O	1639-1641
particular	O	1642-1652
)	O	1652-1653
and	O	1654-1657
occasionally	O	1658-1670
of	O	1671-1673
oligodendrocytes	O	1674-1690
was	O	1691-1694
found	O	1695-1700
.	O	1700-1701

Alterations	O	1702-1713
in	O	1714-1716
the	O	1717-1720
structural	O	1721-1731
elements	O	1732-1740
of	O	1741-1743
the	O	1744-1747
BBB	O	1748-1751
coexisted	O	1752-1761
with	O	1762-1766
marked	O	1767-1773
lesions	O	1774-1781
of	O	1782-1784
neurons	O	1785-1792
of	O	1793-1795
the	O	1796-1799
cerebellum	O	1800-1810
(	O	1811-1812
Purkinje	O	1812-1820
cells	O	1821-1826
are	O	1827-1830
earliest	O	1831-1839
)	O	1839-1840
.	O	1840-1841

In	O	1842-1844
electron	O	1845-1853
micrographs	O	1854-1865
both	O	1866-1870
luminal	O	1871-1878
and	O	1879-1882
antiluminal	O	1883-1894
sides	O	1895-1900
of	O	1901-1903
the	O	1904-1907
BBB	O	1908-1911
of	O	1912-1914
the	O	1915-1918
cerebellar	O	1919-1929
cortex	O	1930-1936
had	O	1937-1940
similar	O	1941-1948
lesions	O	1949-1956
.	O	1956-1957

The	O	1958-1961
possible	O	1962-1970
influence	O	1971-1980
of	O	1981-1983
the	O	1984-1987
hepatic	B	1988-1995
damage	I	1996-2002
,	O	2002-2003
mainly	O	2004-2010
hyperammonemia	B	2011-2025
,	O	2025-2026
upon	O	2027-2031
the	O	2032-2035
development	O	2036-2047
of	O	2048-2050
valproate	O	2051-2060
encephalopathy	B	2061-2075
is	O	2076-2078
discussed	O	2079-2088
.	O	2088-2089

Macula	O	0-6
toxicity	B	7-15
after	O	16-21
intravitreal	O	22-34
amikacin	O	35-43
.	O	43-44

BACKGROUND	O	45-55
:	O	55-56
Although	O	57-65
intravitreal	O	66-78
aminoglycosides	O	79-94
have	O	95-99
substantially	O	100-113
improved	O	114-122
visual	O	123-129
prognosis	O	130-139
in	O	140-142
endophthalmitis	B	143-158
,	O	158-159
macular	O	160-167
infarction	B	168-178
may	O	179-182
impair	O	183-189
full	O	190-194
visual	O	195-201
recovery	O	202-210
.	O	210-211

METHODS	O	212-219
:	O	219-220
We	O	221-223
present	O	224-231
a	O	232-233
case	O	234-238
of	O	239-241
presumed	O	242-250
amikacin	O	251-259
retinal	B	260-267
toxicity	I	268-276
following	O	277-286
treatment	O	287-296
with	O	297-301
amikacin	O	302-310
and	O	311-314
vancomycin	O	315-325
for	O	326-329
alpha	O	330-335
-	O	335-336
haemolytic	O	336-346
streptococcal	B	347-360
endophthalmitis	I	361-376
.	O	376-377

RESULTS	O	378-385
:	O	385-386
Endophthalmitis	B	387-402
resolved	O	403-411
with	O	412-416
improvement	O	417-428
in	O	429-431
visual	O	432-438
acuity	O	439-445
to	O	446-448
6	O	449-450
/	O	450-451
24	O	451-453
at	O	454-456
three	O	457-462
months	O	463-469
.	O	469-470

Fundus	O	471-477
fluorescein	O	478-489
angiography	O	490-501
confirmed	O	502-511
macular	O	512-519
capillary	O	520-529
closure	O	530-537
and	O	538-541
telangiectasis	B	542-556
.	O	556-557

CONCLUSIONS	O	558-569
:	O	569-570
Currently	O	571-580
accepted	O	581-589
intravitreal	O	590-602
antibiotic	O	603-613
regimens	O	614-622
may	O	623-626
cause	O	627-632
retinal	B	633-640
toxicity	I	641-649
and	O	650-653
macular	O	654-661
ischaemia	B	662-671
.	O	671-672

Treatment	O	673-682
strategies	O	683-693
aimed	O	694-699
at	O	700-702
avoiding	O	703-711
retinal	B	712-719
toxicity	I	720-728
are	O	729-732
discussed	O	733-742
.	O	742-743

Iatrogenically	O	0-14
induced	O	15-22
intractable	O	23-34
atrioventricular	B	35-51
reentrant	I	52-61
tachycardia	I	62-73
after	O	74-79
verapamil	O	80-89
and	O	90-93
catheter	O	94-102
ablation	O	103-111
in	O	112-114
a	O	115-116
patient	O	117-124
with	O	125-129
Wolff	B	130-135
-	I	135-136
Parkinson	I	136-145
-	I	135-136
White	I	146-151
syndrome	I	152-160
and	O	161-164
idiopathic	B	165-175
dilated	I	176-183
cardiomyopathy	I	184-198
.	O	198-199

In	O	200-202
a	O	203-204
patient	O	205-212
with	O	213-217
WPW	B	218-221
syndrome	I	222-230
and	O	231-234
idiopathic	B	235-245
dilated	I	246-253
cardiomyopathy	I	254-268
,	O	268-269
intractable	O	270-281
atrioventricular	B	282-298
reentrant	I	299-308
tachycardia	I	309-320
(	O	321-322
AVRT	B	322-326
)	O	326-327
was	O	328-331
iatrogenically	O	332-346
induced	O	347-354
.	O	354-355

QRS	O	356-359
without	O	360-367
preexcitation	O	368-381
,	O	381-382
caused	O	383-389
by	O	390-392
junctional	O	393-403
escape	O	404-410
beats	O	411-416
after	O	417-422
verapamil	O	423-432
or	O	433-435
unidirectional	O	436-450
antegrade	O	451-460
block	O	461-466
of	O	467-469
accessory	O	470-479
pathway	O	480-487
after	O	488-493
catheter	O	494-502
ablation	O	503-511
,	O	511-512
established	O	513-524
frequent	O	525-533
AVRT	B	534-538
attack	O	539-545
.	O	545-546

Epidemic	O	0-8
of	O	9-11
liver	B	12-17
disease	I	18-25
caused	O	26-32
by	O	33-35
hydrochlorofluorocarbons	O	36-60
used	O	61-65
as	O	66-68
ozone	O	69-74
-	O	74-75
sparing	O	75-82
substitutes	O	83-94
of	O	95-97
chlorofluorocarbons	O	98-117
.	O	117-118

BACKGROUND	O	119-129
:	O	129-130
Hydrochlorofluorocarbons	O	131-155
(	O	156-157
HCFCs	O	157-162
)	O	162-163
are	O	164-167
used	O	168-172
increasingly	O	173-185
in	O	186-188
industry	O	189-197
as	O	198-200
substitutes	O	201-212
for	O	213-216
ozone	O	217-222
-	O	222-223
depleting	O	223-232
chlorofluorocarbons	O	233-252
(	O	253-254
CFCs	O	254-258
)	O	258-259
.	O	259-260

Limited	O	261-268
studies	O	269-276
in	O	277-279
animals	O	280-287
indicate	O	288-296
potential	O	297-306
hepatotoxicity	B	307-321
of	O	322-324
some	O	325-329
of	O	330-332
these	O	333-338
compounds	O	339-348
.	O	348-349

We	O	350-352
investigated	O	353-365
an	O	366-368
epidemic	O	369-377
of	O	378-380
liver	B	381-386
disease	I	387-394
in	O	395-397
nine	O	398-402
industrial	O	403-413
workers	O	414-421
who	O	422-425
had	O	426-429
had	O	430-433
repeated	O	434-442
accidental	O	443-453
exposure	O	454-462
to	O	463-465
a	O	466-467
mixture	O	468-475
of	O	476-478
1	O	479-480
,	O	480-481
1	O	479-480
-	O	482-483
dichloro	O	483-491
-	O	482-483
2	O	492-493
,	O	480-481
2	O	492-493
,	O	480-481
2	O	492-493
-	O	482-483
trifluoroethane	O	498-513
(	O	514-515
HCFC	O	515-519
123	O	520-523
)	O	523-524
and	O	525-528
1	O	529-530
-	O	530-531
chloro	O	531-537
-	O	530-531
1	O	529-530
,	O	539-540
2	O	540-541
,	O	539-540
2	O	540-541
,	O	539-540
2	O	540-541
-	O	530-531
tetrafluoroethane	O	546-563
(	O	564-565
HCFC	O	565-569
124	O	570-573
)	O	573-574
.	O	574-575

All	O	576-579
nine	O	580-584
exposed	O	585-592
workers	O	593-600
were	O	601-605
affected	O	606-614
to	O	615-617
various	O	618-625
degrees	O	626-633
.	O	633-634

Both	O	635-639
compounds	O	640-649
are	O	650-653
metabolised	O	654-665
in	O	666-668
the	O	669-672
same	O	673-677
way	O	678-681
as	O	682-684
1	O	685-686
-	O	686-687
bromo	O	687-692
-	O	686-687
1	O	685-686
-	O	686-687
chloro	O	695-701
-	O	686-687
2	O	702-703
,	O	703-704
2	O	702-703
,	O	703-704
2	O	702-703
-	O	686-687
trifluoroethane	O	708-723
(	O	724-725
halothane	O	725-734
)	O	734-735
to	O	736-738
form	O	739-743
reactive	O	744-752
trifluoroacetyl	O	753-768
halide	O	769-775
intermediates	O	776-789
,	O	789-790
which	O	791-796
have	O	797-801
been	O	802-806
implicated	O	807-817
in	O	818-820
the	O	821-824
hepatotoxicity	B	825-839
of	O	840-842
halothane	O	843-852
.	O	852-853

We	O	854-856
aimed	O	857-862
to	O	863-865
test	O	866-870
whether	O	871-878
HCFCs	O	879-884
123	O	885-888
and	O	889-892
124	O	893-896
can	O	897-900
result	O	901-907
in	O	908-910
serious	O	911-918
liver	B	919-924
disease	I	925-932
.	O	932-933

METHODS	O	934-941
:	O	941-942
For	O	943-946
one	O	947-950
severely	O	951-959
affected	O	960-968
worker	O	969-975
liver	O	976-981
biopsy	O	982-988
and	O	989-992
immunohistochemical	O	993-1012
stainings	O	1013-1022
for	O	1023-1026
the	O	1027-1030
presence	O	1031-1039
of	O	1040-1042
trifluoroacetyl	O	1043-1058
protein	O	1059-1066
adducts	O	1067-1074
were	O	1075-1079
done	O	1080-1084
.	O	1084-1085

The	O	1086-1089
serum	O	1090-1095
of	O	1096-1098
six	O	1099-1102
affected	O	1103-1111
workers	O	1112-1119
and	O	1120-1123
five	O	1124-1128
controls	O	1129-1137
was	O	1138-1141
tested	O	1142-1148
for	O	1149-1152
autoantibodies	O	1153-1167
that	O	1168-1172
react	O	1173-1178
with	O	1179-1183
human	O	1184-1189
liver	O	1190-1195
cytochrome	O	1196-1206
-	O	1206-1207
P450	O	1207-1211
2E1	O	1212-1215
(	O	1216-1217
P450	O	1217-1221
2E1	O	1222-1225
)	O	1225-1226
and	O	1227-1230
P58	O	1231-1234
protein	O	1235-1242
disulphide	O	1243-1253
isomerase	O	1254-1263
isoform	O	1264-1271
(	O	1272-1273
P58	O	1273-1276
)	O	1276-1277
.	O	1277-1278

FINDINGS	O	1279-1287
:	O	1287-1288
The	O	1289-1292
liver	O	1293-1298
biopsy	O	1299-1305
sample	O	1306-1312
showed	O	1313-1319
hepatocellular	O	1320-1334
necrosis	B	1335-1343
which	O	1344-1349
was	O	1350-1353
prominent	O	1354-1363
in	O	1364-1366
perivenular	O	1367-1378
zone	O	1379-1383
three	O	1384-1389
and	O	1390-1393
extended	O	1394-1402
focally	O	1403-1410
from	O	1411-1415
portal	O	1416-1422
tracts	O	1423-1429
to	O	1430-1432
portal	O	1433-1439
tracts	O	1440-1446
and	O	1447-1450
centrilobular	O	1451-1464
areas	O	1465-1470
(	O	1471-1472
bridging	O	1472-1480
necrosis	B	1481-1489
)	O	1489-1490
.	O	1490-1491

Trifluoroacetyl	O	1492-1507
-	O	1507-1508
adducted	O	1508-1516
proteins	O	1517-1525
were	O	1526-1530
detected	O	1531-1539
in	O	1540-1542
surviving	O	1543-1552
hepatocytes	O	1553-1564
.	O	1564-1565

Autoantibodies	O	1566-1580
against	O	1581-1588
P450	O	1589-1593
2E1	O	1594-1597
or	O	1598-1600
P58	O	1601-1604
,	O	1604-1605
previously	O	1606-1616
associated	O	1617-1627
with	O	1628-1632
halothane	B	1633-1642
hepatitis	I	1643-1652
,	O	1652-1653
were	O	1654-1658
detected	O	1659-1667
in	O	1668-1670
the	O	1671-1674
serum	O	1675-1680
of	O	1681-1683
five	O	1684-1688
affected	O	1689-1697
workers	O	1698-1705
.	O	1705-1706

INTERPRETATION	O	1707-1721
:	O	1721-1722
Repeated	O	1723-1731
exposure	O	1732-1740
of	O	1741-1743
human	O	1744-1749
beings	O	1750-1756
to	O	1757-1759
HCFCs	O	1760-1765
123	O	1766-1769
and	O	1770-1773
124	O	1774-1777
can	O	1778-1781
result	O	1782-1788
in	O	1789-1791
serious	O	1792-1799
liver	B	1800-1805
injury	I	1806-1812
in	O	1813-1815
a	O	1816-1817
large	O	1818-1823
proportion	O	1824-1834
of	O	1835-1837
the	O	1838-1841
exposed	O	1842-1849
population	O	1850-1860
.	O	1860-1861

Although	O	1862-1870
the	O	1871-1874
exact	O	1875-1880
mechanism	O	1881-1890
of	O	1891-1893
hepatotoxicity	B	1894-1908
of	O	1909-1911
these	O	1912-1917
agents	O	1918-1924
is	O	1925-1927
not	O	1928-1931
known	O	1932-1937
,	O	1937-1938
the	O	1939-1942
results	O	1943-1950
suggest	O	1951-1958
that	O	1959-1963
trifluoroacetyl	O	1964-1979
-	O	1979-1980
altered	O	1980-1987
liver	O	1988-1993
proteins	O	1994-2002
are	O	2003-2006
involved	O	2007-2015
.	O	2015-2016

In	O	2017-2019
view	O	2020-2024
of	O	2025-2027
the	O	2028-2031
potentially	O	2032-2043
widespread	O	2044-2054
use	O	2055-2058
of	O	2059-2061
these	O	2062-2067
compounds	O	2068-2077
,	O	2077-2078
there	O	2079-2084
is	O	2085-2087
an	O	2088-2090
urgent	O	2091-2097
need	O	2098-2102
to	O	2103-2105
develop	O	2106-2113
safer	O	2114-2119
alternatives	O	2120-2132
.	O	2132-2133

The	O	0-3
effect	O	4-10
of	O	11-13
different	O	14-23
anaesthetic	O	24-35
agents	O	36-42
in	O	43-45
hearing	B	46-53
loss	I	54-58
following	O	59-68
spinal	O	69-75
anaesthesia	O	76-87
.	O	87-88

The	O	89-92
cause	O	93-98
of	O	99-101
hearing	B	102-109
loss	I	110-114
after	O	115-120
spinal	O	121-127
anaesthesia	O	128-139
is	O	140-142
unknown	O	143-150
.	O	150-151

Up	O	152-154
until	O	155-160
now	O	161-164
,	O	164-165
the	O	166-169
only	O	170-174
factor	O	175-181
studied	O	182-189
has	O	190-193
been	O	194-198
the	O	199-202
effect	O	203-209
of	O	210-212
the	O	213-216
diameter	O	217-225
of	O	226-228
the	O	229-232
spinal	O	233-239
needle	O	240-246
on	O	247-249
post	O	250-254
-	O	254-255
operative	O	255-264
sensorineural	B	265-278
hearing	I	279-286
loss	I	287-291
.	O	291-292

The	O	293-296
aim	O	297-300
of	O	301-303
this	O	304-308
study	O	309-314
was	O	315-318
to	O	319-321
describe	O	322-330
this	O	331-335
hearing	B	336-343
loss	I	344-348
and	O	349-352
to	O	353-355
investigate	O	356-367
other	O	368-373
factors	O	374-381
influencing	O	382-393
the	O	394-397
degree	O	398-404
of	O	405-407
hearing	B	408-415
loss	I	416-420
.	O	420-421

Two	O	422-425
groups	O	426-432
of	O	433-435
22	O	436-438
similar	O	439-446
patients	O	447-455
were	O	456-460
studied	O	461-468
:	O	468-469
one	O	470-473
group	O	474-479
received	O	480-488
6	O	489-490
mL	O	491-493
prilocaine	O	494-504
2	O	505-506
%	O	506-507
;	O	507-508
and	O	509-512
the	O	513-516
other	O	517-522
received	O	523-531
3	O	532-533
mL	O	534-536
bupivacaine	O	537-548
0	O	549-550
.	O	550-551
5	O	551-552
%	O	552-553
.	O	550-551

Patients	O	555-563
given	O	564-569
prilocaine	O	570-580
were	O	581-585
more	O	586-590
likely	O	591-597
to	O	598-600
develop	O	601-608
hearing	B	609-616
loss	I	617-621
(	O	622-623
10	O	623-625
out	O	626-629
of	O	630-632
22	O	633-635
)	O	635-636
than	O	637-641
those	O	642-647
given	O	648-653
bupivacaine	O	654-665
(	O	666-667
4	O	667-668
out	O	669-672
of	O	673-675
22	O	676-678
)	O	678-679
(	O	680-681
P	O	681-682
<	O	683-684
0	O	685-686
.	O	686-687
05	O	687-689
)	O	689-690
.	O	686-687

The	O	692-695
average	O	696-703
hearing	B	704-711
loss	I	712-716
for	O	717-720
speech	O	721-727
frequencies	O	728-739
was	O	740-743
about	O	744-749
10	O	750-752
dB	O	753-755
after	O	756-761
prilocaine	O	762-772
and	O	773-776
15	O	777-779
dB	O	780-782
after	O	783-788
bupivacaine	O	789-800
.	O	800-801

None	O	802-806
of	O	807-809
the	O	810-813
patients	O	814-822
complained	O	823-833
of	O	834-836
subjective	O	837-847
hearing	B	848-855
loss	I	856-860
.	O	860-861

Long	O	862-866
-	O	866-867
term	O	867-871
follow	O	872-878
-	O	878-879
up	O	879-881
of	O	882-884
the	O	885-888
patients	O	889-897
was	O	898-901
not	O	902-905
possible	O	906-914
.	O	914-915

A	O	0-1
transient	O	2-11
neurological	B	12-24
deficit	I	25-32
following	O	33-42
intrathecal	O	43-54
injection	O	55-64
of	O	65-67
1	O	68-69
%	O	69-70
hyperbaric	O	71-81
bupivacaine	O	82-93
for	O	94-97
unilateral	O	98-108
spinal	O	109-115
anaesthesia	O	116-127
.	O	127-128

We	O	129-131
describe	O	132-140
a	O	141-142
case	O	143-147
of	O	148-150
transient	O	151-160
neurological	B	161-173
deficit	I	174-181
that	O	182-186
occurred	O	187-195
after	O	196-201
unilateral	O	202-212
spinal	O	213-219
anaesthesia	O	220-231
with	O	232-236
8	O	237-238
mg	O	239-241
of	O	242-244
1	O	245-246
%	O	246-247
hyperbaric	O	248-258
bupivacaine	O	259-270
slowly	O	271-277
injected	O	278-286
through	O	287-294
a	O	295-296
25	O	297-299
-	O	299-300
gauge	O	300-305
pencil	O	306-312
-	O	312-313
point	O	313-318
spinal	O	319-325
needle	O	326-332
.	O	332-333

The	O	334-337
surgery	O	338-345
and	O	346-349
anaesthesia	O	350-361
were	O	362-366
uneventful	O	367-377
,	O	377-378
but	O	379-382
3	O	383-384
days	O	385-389
after	O	390-395
surgery	O	396-403
,	O	403-404
the	O	405-408
patient	O	409-416
reported	O	417-425
an	O	426-428
area	O	429-433
of	O	434-436
hypoaesthesia	O	437-450
over	O	451-455
L3	O	456-458
-	O	458-459
L4	O	459-461
dermatomes	O	462-472
of	O	473-475
the	O	476-479
leg	O	480-483
which	O	484-489
had	O	490-493
been	O	494-498
operated	O	499-507
on	O	508-510
(	O	511-512
loss	B	512-516
of	I	517-519
pinprick	I	520-528
sensation	I	529-538
)	O	538-539
without	O	540-547
reduction	O	548-557
in	O	558-560
muscular	O	561-569
strength	O	570-578
.	O	578-579

Sensation	O	580-589
in	O	590-592
this	O	593-597
area	O	598-602
returned	O	603-611
to	O	612-614
normal	O	615-621
over	O	622-626
the	O	627-630
following	O	631-640
2	O	641-642
weeks	O	643-648
.	O	648-649

Prospective	O	650-661
multicentre	O	662-673
studies	O	674-681
with	O	682-686
a	O	687-688
large	O	689-694
population	O	695-705
and	O	706-709
a	O	710-711
long	O	712-716
follow	O	717-723
-	O	723-724
up	O	724-726
should	O	727-733
be	O	734-736
performed	O	737-746
in	O	747-749
order	O	750-755
to	O	756-758
evaluate	O	759-767
the	O	768-771
incidence	O	772-781
of	O	782-784
this	O	785-789
unusual	O	790-797
side	O	798-802
effect	O	803-809
.	O	809-810

However	O	811-818
,	O	818-819
we	O	820-822
suggest	O	823-830
that	O	831-835
a	O	836-837
low	O	838-841
solution	O	842-850
concentration	O	851-864
should	O	865-871
be	O	872-874
preferred	O	875-884
for	O	885-888
unilateral	O	889-899
spinal	O	900-906
anaesthesia	O	907-918
with	O	919-923
a	O	924-925
hyperbaric	O	926-936
anaesthetic	O	937-948
solution	O	949-957
(	O	958-959
if	O	959-961
pencil	O	962-968
-	O	968-969
point	O	969-974
needle	O	975-981
and	O	982-985
slow	O	986-990
injection	O	991-1000
rate	O	1001-1005
are	O	1006-1009
employed	O	1010-1018
)	O	1018-1019
,	O	1019-1020
in	O	1021-1023
order	O	1024-1029
to	O	1030-1032
minimize	O	1033-1041
the	O	1042-1045
risk	O	1046-1050
of	O	1051-1053
a	O	1054-1055
localized	O	1056-1065
high	O	1066-1070
peak	O	1071-1075
anaesthetic	O	1076-1087
concentration	O	1088-1101
,	O	1101-1102
which	O	1103-1108
might	O	1109-1114
lead	O	1115-1119
to	O	1120-1122
a	O	1123-1124
transient	O	1125-1134
neurological	B	1135-1147
deficit	I	1148-1155
.	O	1155-1156

Pethidine	O	0-9
-	O	9-10
associated	O	10-20
seizure	B	21-28
in	O	29-31
a	O	32-33
healthy	O	34-41
adolescent	O	42-52
receiving	O	53-62
pethidine	O	63-72
for	O	73-76
postoperative	B	77-90
pain	I	91-95
control	O	96-103
.	O	103-104

A	O	105-106
healthy	O	107-114
17	O	115-117
-	O	117-118
year	O	118-122
-	O	117-118
old	O	123-126
male	O	127-131
received	O	132-140
standard	O	141-149
intermittent	O	150-162
doses	O	163-168
of	O	169-171
pethidine	O	172-181
via	O	182-185
a	O	186-187
patient	O	188-195
-	O	195-196
controlled	O	196-206
analgesia	O	207-216
(	O	217-218
PCA	O	218-221
)	O	221-222
pump	O	223-227
for	O	228-231
management	O	232-242
of	O	243-245
postoperative	B	246-259
pain	I	260-264
control	O	265-272
.	O	272-273

Twenty	O	274-280
-	O	280-281
three	O	281-286
h	O	287-288
postoperatively	O	289-304
he	O	305-307
developed	O	308-317
a	O	318-319
brief	O	320-325
self	O	326-330
-	O	330-331
limited	O	331-338
seizure	B	339-346
.	O	346-347

Both	O	348-352
plasma	O	353-359
pethidine	O	360-369
and	O	370-373
norpethidine	O	374-386
were	O	387-391
elevated	O	392-400
in	O	401-403
the	O	404-407
range	O	408-413
associated	O	414-424
with	O	425-429
clinical	O	430-438
manifestations	O	439-453
of	O	454-456
central	O	457-464
nervous	O	465-472
system	O	473-479
excitation	O	480-490
.	O	490-491

No	O	492-494
other	O	495-500
risk	O	501-505
factors	O	506-513
for	O	514-517
CNS	O	518-521
toxicity	B	522-530
were	O	531-535
identified	O	536-546
.	O	546-547

This	O	548-552
method	O	553-559
allowed	O	560-567
frequent	O	568-576
self	O	577-581
-	O	581-582
dosing	O	582-588
of	O	589-591
pethidine	O	592-601
at	O	602-604
short	O	605-610
time	O	611-615
intervals	O	616-625
and	O	626-629
rapid	O	630-635
accumulation	O	636-648
of	O	649-651
pethidine	O	652-661
and	O	662-665
norpethidine	O	666-678
.	O	678-679

The	O	680-683
routine	O	684-691
use	O	692-695
of	O	696-698
pethidine	O	699-708
via	O	709-712
PCA	O	713-716
even	O	717-721
for	O	722-725
a	O	726-727
brief	O	728-733
postoperative	O	734-747
analgesia	O	748-757
should	O	758-764
be	O	765-767
reconsidered	O	768-780
.	O	780-781

Drug	O	0-4
-	O	4-5
associated	O	5-15
acute	O	16-21
-	O	21-22
onset	O	22-27
vanishing	B	28-37
bile	I	38-42
duct	I	43-47
and	O	48-51
Stevens	B	52-59
-	I	59-60
Johnson	I	60-67
syndromes	I	68-77
in	O	78-80
a	O	81-82
child	O	83-88
.	O	88-89

Acute	O	90-95
vanishing	B	96-105
bile	I	106-110
duct	I	111-115
syndrome	O	116-124
is	O	125-127
a	O	128-129
rare	O	130-134
but	O	135-138
established	O	139-150
cause	O	151-156
of	O	157-159
progressive	O	160-171
cholestasis	B	172-183
in	O	184-186
adults	O	187-193
,	O	193-194
is	O	195-197
most	O	198-202
often	O	203-208
drug	O	209-213
or	O	214-216
toxin	O	217-222
related	O	223-230
,	O	230-231
and	O	232-235
is	O	236-238
of	O	239-241
unknown	O	242-249
pathogenesis	O	250-262
.	O	262-263

It	O	264-266
has	O	267-270
not	O	271-274
been	O	275-279
reported	O	280-288
previously	O	289-299
in	O	300-302
children	O	303-311
.	O	311-312

Stevens	B	313-320
-	I	320-321
Johnson	I	321-328
syndrome	I	329-337
is	O	338-340
a	O	341-342
well	O	343-347
-	O	347-348
recognized	O	348-358
immune	O	359-365
complex	O	366-373
-	O	373-374
mediated	O	374-382
hypersensitivity	B	383-399
reaction	O	400-408
that	O	409-413
affects	O	414-421
all	O	422-425
age	O	426-429
groups	O	430-436
,	O	436-437
is	O	438-440
drug	O	441-445
or	O	446-448
infection	B	449-458
induced	O	459-466
,	O	466-467
and	O	468-471
has	O	472-475
classic	O	476-483
systemic	O	484-492
,	O	492-493
mucosal	O	494-501
,	O	501-502
and	O	503-506
dermatologic	O	507-519
manifestations	O	520-534
.	O	534-535

A	O	536-537
previously	O	538-548
healthy	O	549-556
child	O	557-562
who	O	563-566
developed	O	567-576
acute	O	577-582
,	O	582-583
severe	O	584-590
,	O	590-591
rapidly	O	592-599
progressive	O	600-611
vanishing	B	612-621
bile	I	622-626
duct	I	627-631
syndrome	I	632-640
shortly	O	641-648
after	O	649-654
Stevens	B	655-662
-	I	662-663
Johnson	I	663-670
syndrome	I	671-679
is	O	680-682
described	O	683-692
;	O	692-693
this	O	694-698
was	O	699-702
temporally	O	703-713
associated	O	714-724
with	O	725-729
ibuprofen	O	730-739
use	O	740-743
.	O	743-744

Despite	O	745-752
therapy	O	753-760
with	O	761-765
ursodeoxycholic	O	766-781
acid	O	782-786
,	O	786-787
prednisone	O	788-798
,	O	798-799
and	O	800-803
then	O	804-808
tacrolimus	O	809-819
,	O	819-820
her	O	821-824
cholestatic	B	825-836
disease	I	837-844
was	O	845-848
unrelenting	O	849-860
,	O	860-861
with	O	862-866
cirrhosis	B	867-876
shown	O	877-882
by	O	883-885
biopsy	O	886-892
6	O	893-894
months	O	895-901
after	O	902-907
presentation	O	908-920
.	O	920-921

This	O	922-926
case	O	927-931
documents	O	932-941
acute	O	942-947
drug	O	948-952
-	O	952-953
related	O	953-960
vanishing	B	961-970
bile	I	971-975
duct	I	976-980
syndrome	I	981-989
in	O	990-992
the	O	993-996
pediatric	O	997-1006
age	O	1007-1010
group	O	1011-1016
and	O	1017-1020
suggests	O	1021-1029
shared	O	1030-1036
immune	O	1037-1043
mechanisms	O	1044-1054
in	O	1055-1057
the	O	1058-1061
pathogenesis	O	1062-1074
of	O	1075-1077
both	O	1078-1082
Stevens	B	1083-1090
-	I	1090-1091
Johnson	I	1091-1098
syndrome	I	1099-1107
and	O	1108-1111
vanishing	B	1112-1121
bile	I	1122-1126
duct	I	1127-1131
syndrome	I	1132-1140
.	O	1140-1141

High	O	0-4
incidence	O	5-14
of	O	15-17
primary	B	18-25
pulmonary	I	26-35
hypertension	I	36-48
associated	O	49-59
with	O	60-64
appetite	O	65-73
suppressants	O	74-86
in	O	87-89
Belgium	O	90-97
.	O	97-98

Primary	B	99-106
pulmonary	I	107-116
hypertension	I	117-129
is	O	130-132
a	O	133-134
rare	O	135-139
,	O	139-140
progressive	O	141-152
and	O	153-156
incurable	O	157-166
disease	O	167-174
,	O	174-175
which	O	176-181
has	O	182-185
been	O	186-190
associated	O	191-201
with	O	202-206
the	O	207-210
intake	O	211-217
of	O	218-220
appetite	O	221-229
suppressant	O	230-241
drugs	O	242-247
.	O	247-248

The	O	249-252
importance	O	253-263
of	O	264-266
this	O	267-271
association	O	272-283
was	O	284-287
evaluated	O	288-297
in	O	298-300
Belgium	O	301-308
while	O	309-314
this	O	315-319
country	O	320-327
still	O	328-333
had	O	334-337
no	O	338-340
restriction	O	341-352
on	O	353-355
the	O	356-359
prescription	O	360-372
of	O	373-375
appetite	O	376-384
suppressants	O	385-397
.	O	397-398

Thirty	O	399-405
-	O	405-406
five	O	406-410
patients	O	411-419
with	O	420-424
primary	B	425-432
pulmonary	I	433-442
hypertension	I	443-455
and	O	456-459
85	O	460-462
matched	O	463-470
controls	O	471-479
were	O	480-484
recruited	O	485-494
over	O	495-499
32	O	500-502
months	O	503-509
(	O	510-511
1992	O	511-515
-	O	515-516
1994	O	516-520
)	O	520-521
in	O	522-524
Belgium	O	525-532
.	O	532-533

Exposure	O	534-542
to	O	543-545
appetite	O	546-554
-	O	554-555
suppressants	O	555-567
was	O	568-571
assessed	O	572-580
on	O	581-583
the	O	584-587
basis	O	588-593
of	O	594-596
hospital	O	597-605
records	O	606-613
and	O	614-617
standardized	O	618-630
interview	O	631-640
.	O	640-641

Twenty	O	642-648
-	O	648-649
three	O	649-654
of	O	655-657
the	O	658-661
patients	O	662-670
had	O	671-674
previously	O	675-685
taken	O	686-691
appetite	O	692-700
suppressants	O	701-713
,	O	713-714
mainly	O	715-721
fenfluramines	O	722-735
,	O	735-736
as	O	737-739
compared	O	740-748
with	O	749-753
only	O	754-758
5	O	759-760
of	O	761-763
the	O	764-767
controls	O	768-776
(	O	777-778
66	O	778-780
versus	O	781-787
6	O	788-789
%	O	789-790
,	O	790-791
p	O	792-793
<	O	793-794
0	O	794-795
.	O	795-796
0001	O	796-800
)	O	800-801
.	O	795-796

Five	O	803-807
patients	O	808-816
died	O	817-821
before	O	822-828
the	O	829-832
interview	O	833-842
,	O	842-843
all	O	844-847
of	O	848-850
them	O	851-855
had	O	856-859
taken	O	860-865
appetite	O	866-874
suppressants	O	875-887
.	O	887-888

In	O	889-891
8	O	892-893
patients	O	894-902
the	O	903-906
diagnosis	O	907-916
of	O	917-919
primary	B	920-927
pulmonary	I	928-937
hypertension	I	938-950
was	O	951-954
uncertain	O	955-964
,	O	964-965
5	O	966-967
of	O	968-970
them	O	971-975
had	O	976-979
taken	O	980-985
appetite	O	986-994
suppressants	O	995-1007
.	O	1007-1008

The	O	1009-1012
patients	O	1013-1021
who	O	1022-1025
had	O	1026-1029
been	O	1030-1034
exposed	O	1035-1042
to	O	1043-1045
appetite	O	1046-1054
suppressants	O	1055-1067
tended	O	1068-1074
to	O	1075-1077
be	O	1078-1080
on	O	1081-1083
average	O	1084-1091
more	O	1092-1096
severely	O	1097-1105
ill	O	1106-1109
,	O	1109-1110
and	O	1111-1114
to	O	1115-1117
have	O	1118-1122
a	O	1123-1124
shorter	O	1125-1132
median	O	1133-1139
delay	O	1140-1145
between	O	1146-1153
onset	O	1154-1159
of	O	1160-1162
symptoms	O	1163-1171
and	O	1172-1175
diagnosis	O	1176-1185
.	O	1185-1186

A	O	1187-1188
policy	O	1189-1195
of	O	1196-1198
unrestricted	O	1199-1211
prescription	O	1212-1224
of	O	1225-1227
appetite	O	1228-1236
suppressants	O	1237-1249
may	O	1250-1253
lead	O	1254-1258
to	O	1259-1261
a	O	1262-1263
high	O	1264-1268
incidence	O	1269-1278
of	O	1279-1281
associated	O	1282-1292
primary	B	1293-1300
pulmonary	I	1301-1310
hypertension	I	1311-1323
.	O	1323-1324

Intake	O	1325-1331
of	O	1332-1334
appetite	O	1335-1343
suppressants	O	1344-1356
may	O	1357-1360
accelerate	O	1361-1371
the	O	1372-1375
progression	O	1376-1387
of	O	1388-1390
the	O	1391-1394
disease	O	1395-1402
.	O	1402-1403

Choreoathetoid	B	0-14
movements	I	15-24
associated	O	25-35
with	O	36-40
rapid	O	41-46
adjustment	O	47-57
to	O	58-60
methadone	O	61-70
.	O	70-71

Choreatiform	B	72-84
hyperkinesias	I	85-98
are	O	99-102
known	O	103-108
to	O	109-111
be	O	112-114
occasional	O	115-125
movement	B	126-134
abnormalities	I	135-148
during	O	149-155
intoxications	O	156-169
with	O	170-174
cocaine	O	175-182
but	O	183-186
not	O	187-190
opiates	O	191-198
.	O	198-199

This	O	200-204
is	O	205-207
a	O	208-209
case	O	210-214
report	O	215-221
of	O	222-224
euphoria	O	225-233
and	O	234-237
choreoathetoid	B	238-252
movements	I	253-262
both	O	263-267
transiently	O	268-279
induced	O	280-287
by	O	288-290
rapid	O	291-296
adjustment	O	297-307
to	O	308-310
the	O	311-314
selective	O	315-324
mu	O	325-327
-	O	327-328
opioid	O	328-334
receptor	O	335-343
agonist	O	344-351
methadone	O	352-361
in	O	362-364
an	O	365-367
inpatient	O	368-377
previously	O	378-388
abusing	O	389-396
heroine	O	397-404
and	O	405-408
cocaine	O	409-416
.	O	416-417

In	O	418-420
addition	O	421-429
,	O	429-430
minor	O	431-436
EEG	O	437-440
abnormalities	O	441-454
occurred	O	455-463
.	O	463-464

Possible	O	465-473
underlying	O	474-484
neurobiological	O	485-500
phenomena	O	501-510
are	O	511-514
discussed	O	515-524
.	O	524-525

Cocaine	O	0-7
-	O	7-8
induced	O	8-15
mood	B	16-20
disorder	I	21-29
:	O	29-30
prevalence	O	31-41
rates	O	42-47
and	O	48-51
psychiatric	B	52-63
symptoms	O	64-72
in	O	73-75
an	O	76-78
outpatient	O	79-89
cocaine	O	90-97
-	O	97-98
dependent	O	98-107
sample	O	108-114
.	O	114-115

This	O	116-120
paper	O	121-126
attempts	O	127-135
to	O	136-138
examine	O	139-146
and	O	147-150
compare	O	151-158
prevalence	O	159-169
rates	O	170-175
and	O	176-179
symptom	O	180-187
patterns	O	188-196
of	O	197-199
DSM	O	200-203
substance	O	204-213
-	O	213-214
induced	O	214-221
and	O	222-225
other	O	226-231
mood	B	232-236
disorders	I	237-246
.	O	246-247

243	O	248-251
cocaine	O	252-259
-	O	259-260
dependent	O	260-269
outpatients	O	270-281
with	O	282-286
cocaine	O	287-294
-	O	294-295
induced	O	295-302
mood	B	303-307
disorder	I	308-316
(	O	317-318
CIMD	B	318-322
)	O	322-323
,	O	323-324
other	O	325-330
mood	B	331-335
disorders	I	336-345
,	O	345-346
or	O	347-349
no	O	350-352
mood	B	353-357
disorder	I	358-366
were	O	367-371
compared	O	372-380
on	O	381-383
measures	O	384-392
of	O	393-395
psychiatric	B	396-407
symptoms	O	408-416
.	O	416-417

The	O	418-421
prevalence	O	422-432
rate	O	433-437
for	O	438-441
CIMD	B	442-446
was	O	447-450
12	O	451-453
%	O	453-454
at	O	455-457
baseline	O	458-466
.	O	466-467

Introduction	O	468-480
of	O	481-483
the	O	484-487
DSM	O	488-491
-	O	491-492
IV	O	492-494
diagnosis	O	495-504
of	O	505-507
CIMD	B	508-512
did	O	513-516
not	O	517-520
substantially	O	521-534
affect	O	535-541
rates	O	542-547
of	O	548-550
the	O	551-554
other	O	555-560
depressive	B	561-571
disorders	I	572-581
.	O	581-582

Patients	O	583-591
with	O	592-596
CIMD	B	597-601
had	O	602-605
symptom	O	606-613
severity	O	614-622
levels	O	623-629
between	O	630-637
those	O	638-643
of	O	644-646
patients	O	647-655
with	O	656-660
and	O	661-664
without	O	665-672
a	O	673-674
mood	B	675-679
disorder	I	680-688
.	O	688-689

These	O	690-695
findings	O	696-704
suggest	O	705-712
some	O	713-717
validity	O	718-726
for	O	727-730
the	O	731-734
new	O	735-738
DSM	O	739-742
-	O	742-743
IV	O	743-745
diagnosis	O	746-755
of	O	756-758
CIMD	B	759-763
,	O	763-764
but	O	765-768
also	O	769-773
suggest	O	774-781
that	O	782-786
it	O	787-789
requires	O	790-798
further	O	799-806
specification	O	807-820
and	O	821-824
replication	O	825-836
.	O	836-837

Hemolysis	B	0-9
of	O	10-12
human	O	13-18
erythrocytes	O	19-31
induced	O	32-39
by	O	40-42
tamoxifen	O	43-52
is	O	53-55
related	O	56-63
to	O	64-66
disruption	O	67-77
of	O	78-80
membrane	O	81-89
structure	O	90-99
.	O	99-100

Tamoxifen	O	101-110
(	O	111-112
TAM	O	112-115
)	O	115-116
,	O	116-117
the	O	118-121
antiestrogenic	O	122-136
drug	O	137-141
most	O	142-146
widely	O	147-153
prescribed	O	154-164
in	O	165-167
the	O	168-171
chemotherapy	O	172-184
of	O	185-187
breast	B	188-194
cancer	I	195-201
,	O	201-202
induces	O	203-210
changes	O	211-218
in	O	219-221
normal	O	222-228
discoid	O	229-236
shape	O	237-242
of	O	243-245
erythrocytes	O	246-258
and	O	259-262
hemolytic	B	263-272
anemia	I	273-279
.	O	279-280

This	O	281-285
work	O	286-290
evaluates	O	291-300
the	O	301-304
effects	O	305-312
of	O	313-315
TAM	O	316-319
on	O	320-322
isolated	O	323-331
human	O	332-337
erythrocytes	O	338-350
,	O	350-351
attempting	O	352-362
to	O	363-365
identify	O	366-374
the	O	375-378
underlying	O	379-389
mechanisms	O	390-400
on	O	401-403
TAM	O	404-407
-	O	407-408
induced	O	408-415
hemolytic	B	416-425
anemia	I	426-432
and	O	433-436
the	O	437-440
involvement	O	441-452
of	O	453-455
biomembranes	O	456-468
in	O	469-471
its	O	472-475
cytostatic	O	476-486
action	O	487-493
mechanisms	O	494-504
.	O	504-505

TAM	O	506-509
induces	O	510-517
hemolysis	B	518-527
of	O	528-530
erythrocytes	O	531-543
as	O	544-546
a	O	547-548
function	O	549-557
of	O	558-560
concentration	O	561-574
.	O	574-575

The	O	576-579
extension	O	580-589
of	O	590-592
hemolysis	B	593-602
is	O	603-605
variable	O	606-614
with	O	615-619
erythrocyte	O	620-631
samples	O	632-639
,	O	639-640
but	O	641-644
12	O	645-647
.	O	647-648
5	O	648-649
microM	O	650-656
TAM	O	657-660
induces	O	661-668
total	O	669-674
hemolysis	B	675-684
of	O	685-687
all	O	688-691
tested	O	692-698
suspensions	O	699-710
.	O	710-711

Despite	O	712-719
inducing	O	720-728
extensive	O	729-738
erythrocyte	O	739-750
lysis	O	751-756
,	O	756-757
TAM	O	758-761
does	O	762-766
not	O	767-770
shift	O	771-776
the	O	777-780
osmotic	O	781-788
fragility	O	789-798
curves	O	799-805
of	O	806-808
erythrocytes	O	809-821
.	O	821-822

The	O	823-826
hemolytic	B	827-836
effect	O	837-843
of	O	844-846
TAM	O	847-850
is	O	851-853
prevented	O	854-863
by	O	864-866
low	O	867-870
concentrations	O	871-885
of	O	886-888
alpha	O	889-894
-	O	894-895
tocopherol	O	895-905
(	O	906-907
alpha	O	907-912
-	O	912-913
T	O	913-914
)	O	914-915
and	O	916-919
alpha	O	920-925
-	O	925-926
tocopherol	O	926-936
acetate	O	937-944
(	O	945-946
alpha	O	946-951
-	O	951-952
TAc	O	952-955
)	O	955-956
(	O	957-958
inactivated	O	958-969
functional	O	970-980
hydroxyl	O	981-989
)	O	989-990
indicating	O	991-1001
that	O	1002-1006
TAM	O	1007-1010
-	O	1010-1011
induced	O	1011-1018
hemolysis	B	1019-1028
is	O	1029-1031
not	O	1032-1035
related	O	1036-1043
to	O	1044-1046
oxidative	O	1047-1056
membrane	O	1057-1065
damage	O	1066-1072
.	O	1072-1073

This	O	1074-1078
was	O	1079-1082
further	O	1083-1090
evidenced	O	1091-1100
by	O	1101-1103
absence	O	1104-1111
of	O	1112-1114
oxygen	O	1115-1121
consumption	O	1122-1133
and	O	1134-1137
hemoglobin	O	1138-1148
oxidation	O	1149-1158
both	O	1159-1163
determined	O	1164-1174
in	O	1175-1177
parallel	O	1178-1186
with	O	1187-1191
TAM	O	1192-1195
-	O	1195-1196
induced	O	1196-1203
hemolysis	B	1204-1213
.	O	1213-1214

Furthermore	O	1215-1226
,	O	1226-1227
it	O	1228-1230
was	O	1231-1234
observed	O	1235-1243
that	O	1244-1248
TAM	O	1249-1252
inhibits	O	1253-1261
the	O	1262-1265
peroxidation	O	1266-1278
of	O	1279-1281
human	O	1282-1287
erythrocytes	O	1288-1300
induced	O	1301-1308
by	O	1309-1311
AAPH	O	1312-1316
,	O	1316-1317
thus	O	1318-1322
ruling	O	1323-1329
out	O	1330-1333
TAM	O	1334-1337
-	O	1337-1338
induced	O	1338-1345
cell	O	1346-1350
oxidative	O	1351-1360
stress	O	1361-1367
.	O	1367-1368

Hemolysis	B	1369-1378
caused	O	1379-1385
by	O	1386-1388
TAM	O	1389-1392
was	O	1393-1396
not	O	1397-1400
preceded	O	1401-1409
by	O	1410-1412
the	O	1413-1416
leakage	O	1417-1424
of	O	1425-1427
K	O	1428-1429
(	O	1429-1430
+	O	1430-1431
)	O	1431-1432
from	O	1433-1437
the	O	1438-1441
cells	O	1442-1447
,	O	1447-1448
also	O	1449-1453
excluding	O	1454-1463
a	O	1464-1465
colloid	O	1466-1473
-	O	1473-1474
osmotic	O	1474-1481
type	O	1482-1486
mechanism	O	1487-1496
of	O	1497-1499
hemolysis	B	1500-1509
,	O	1509-1510
according	O	1511-1520
to	O	1521-1523
the	O	1524-1527
effects	O	1528-1535
on	O	1536-1538
osmotic	O	1539-1546
fragility	O	1547-1556
curves	O	1557-1563
.	O	1563-1564

However	O	1565-1572
,	O	1572-1573
TAM	O	1574-1577
induces	O	1578-1585
release	O	1586-1593
of	O	1594-1596
peripheral	O	1597-1607
proteins	O	1608-1616
of	O	1617-1619
membrane	O	1620-1628
-	O	1628-1629
cytoskeleton	O	1629-1641
and	O	1642-1645
cytosol	O	1646-1653
proteins	O	1654-1662
essentially	O	1663-1674
bound	O	1675-1680
to	O	1681-1683
band	O	1684-1688
3	O	1689-1690
.	O	1690-1691
Either	O	1692-1698
alpha	O	1699-1704
-	O	1704-1705
T	O	1705-1706
or	O	1707-1709
alpha	O	1710-1715
-	O	1715-1716
TAc	O	1716-1719
increases	O	1720-1729
membrane	O	1730-1738
packing	O	1739-1746
and	O	1747-1750
prevents	O	1751-1759
TAM	O	1760-1763
partition	O	1764-1773
into	O	1774-1778
model	O	1779-1784
membranes	O	1785-1794
.	O	1794-1795

These	O	1796-1801
effects	O	1802-1809
suggest	O	1810-1817
that	O	1818-1822
the	O	1823-1826
protection	O	1827-1837
from	O	1838-1842
hemolysis	B	1843-1852
by	O	1853-1855
tocopherols	O	1856-1867
is	O	1868-1870
related	O	1871-1878
to	O	1879-1881
a	O	1882-1883
decreased	O	1884-1893
TAM	O	1894-1897
incorporation	O	1898-1911
in	O	1912-1914
condensed	O	1915-1924
membranes	O	1925-1934
and	O	1935-1938
the	O	1939-1942
structural	O	1943-1953
damage	O	1954-1960
of	O	1961-1963
the	O	1964-1967
erythrocyte	O	1968-1979
membrane	O	1980-1988
is	O	1989-1991
consequently	O	1992-2004
avoided	O	2005-2012
.	O	2012-2013

Therefore	O	2014-2023
,	O	2023-2024
TAM	O	2025-2028
-	O	2028-2029
induced	O	2029-2036
hemolysis	B	2037-2046
results	O	2047-2054
from	O	2055-2059
a	O	2060-2061
structural	O	2062-2072
perturbation	O	2073-2085
of	O	2086-2088
red	O	2089-2092
cell	O	2093-2097
membrane	O	2098-2106
,	O	2106-2107
leading	O	2108-2115
to	O	2116-2118
changes	O	2119-2126
in	O	2127-2129
the	O	2130-2133
framework	O	2134-2143
of	O	2144-2146
the	O	2147-2150
erythrocyte	O	2151-2162
membrane	O	2163-2171
and	O	2172-2175
its	O	2176-2179
cytoskeleton	O	2180-2192
caused	O	2193-2199
by	O	2200-2202
its	O	2203-2206
high	O	2207-2211
partition	O	2212-2221
in	O	2222-2224
the	O	2225-2228
membrane	O	2229-2237
.	O	2237-2238

These	O	2239-2244
defects	O	2245-2252
explain	O	2253-2260
the	O	2261-2264
abnormal	O	2265-2273
erythrocyte	O	2274-2285
shape	O	2286-2291
and	O	2292-2295
decreased	O	2296-2305
mechanical	O	2306-2316
stability	O	2317-2326
promoted	O	2327-2335
by	O	2336-2338
TAM	O	2339-2342
,	O	2342-2343
resulting	O	2344-2353
in	O	2354-2356
hemolytic	B	2357-2366
anemia	I	2367-2373
.	O	2373-2374

Additionally	O	2375-2387
,	O	2387-2388
since	O	2389-2394
membrane	O	2395-2403
leakage	O	2404-2411
is	O	2412-2414
a	O	2415-2416
final	O	2417-2422
stage	O	2423-2428
of	O	2429-2431
cytotoxicity	O	2432-2444
,	O	2444-2445
the	O	2446-2449
disruption	O	2450-2460
of	O	2461-2463
the	O	2464-2467
structural	O	2468-2478
characteristics	O	2479-2494
of	O	2495-2497
biomembranes	O	2498-2510
by	O	2511-2513
TAM	O	2514-2517
may	O	2518-2521
contribute	O	2522-2532
to	O	2533-2535
the	O	2536-2539
multiple	O	2540-2548
mechanisms	O	2549-2559
of	O	2560-2562
its	O	2563-2566
anticancer	O	2567-2577
action	O	2578-2584
.	O	2584-2585

Changes	O	0-7
of	O	8-10
sodium	O	11-17
and	O	18-21
ATP	O	22-25
affinities	O	26-36
of	O	37-39
the	O	40-43
cardiac	O	44-51
(	O	52-53
Na	O	53-55
,	O	55-56
K	O	56-57
)	O	57-58
-	O	58-59
ATPase	O	59-65
during	O	66-72
and	O	73-76
after	O	77-82
nitric	O	83-89
oxide	O	90-95
deficient	O	96-105
hypertension	B	106-118
.	O	118-119

In	O	120-122
the	O	123-126
cardiovascular	O	127-141
system	O	142-148
,	O	148-149
NO	O	150-152
is	O	153-155
involved	O	156-164
in	O	165-167
the	O	168-171
regulation	O	172-182
of	O	183-185
a	O	186-187
variety	O	188-195
of	O	196-198
functions	O	199-208
.	O	208-209

Inhibition	O	210-220
of	O	221-223
NO	O	224-226
synthesis	O	227-236
induces	O	237-244
sustained	O	245-254
hypertension	B	255-267
.	O	267-268

In	O	269-271
several	O	272-279
models	O	280-286
of	O	287-289
hypertension	B	290-302
,	O	302-303
elevation	O	304-313
of	O	314-316
intracellular	O	317-330
sodium	O	331-337
level	O	338-343
was	O	344-347
documented	O	348-358
in	O	359-361
cardiac	O	362-369
tissue	O	370-376
.	O	376-377

To	O	378-380
assess	O	381-387
the	O	388-391
molecular	O	392-401
basis	O	402-407
of	O	408-410
disturbances	O	411-423
in	O	424-426
transmembraneous	O	427-443
transport	O	444-453
of	O	454-456
Na	O	457-459
+	O	459-460
,	O	460-461
we	O	462-464
studied	O	465-472
the	O	473-476
response	O	477-485
of	O	486-488
cardiac	O	489-496
(	O	497-498
Na	O	498-500
,	O	500-501
K	O	501-502
)	O	502-503
-	O	503-504
ATPase	O	504-510
to	O	511-513
NO	O	514-516
-	O	516-517
deficient	O	517-526
hypertension	B	527-539
induced	O	540-547
in	O	548-550
rats	O	551-555
by	O	556-558
NO	O	559-561
-	O	561-562
synthase	O	562-570
inhibition	O	571-581
with	O	582-586
40	O	587-589
mg	O	590-592
/	O	592-593
kg	O	593-595
/	O	592-593
day	O	596-599
N	O	600-601
(	O	601-602
G	O	602-603
)	O	603-604
-	O	604-605
nitro	O	605-610
-	O	604-605
L	O	611-612
-	O	604-605
arginine	O	613-621
methyl	O	622-628
ester	O	629-634
(	O	635-636
L	O	636-637
-	O	637-638
NAME	O	638-642
)	O	642-643
for	O	644-647
4	O	648-649
four	O	650-654
weeks	O	655-660
.	O	660-661

After	O	662-667
4	O	668-669
-	O	669-670
week	O	670-674
administration	O	675-689
of	O	690-692
L	O	693-694
-	O	694-695
NAME	O	695-699
,	O	699-700
the	O	701-704
systolic	O	705-713
blood	O	714-719
pressure	O	720-728
(	O	729-730
SBP	O	730-733
)	O	733-734
increased	O	735-744
by	O	745-747
36	O	748-750
%	O	750-751
.	O	751-752

Two	O	753-756
weeks	O	757-762
after	O	763-768
terminating	O	769-780
the	O	781-784
treatment	O	785-794
,	O	794-795
the	O	796-799
SBP	O	800-803
recovered	O	804-813
to	O	814-816
control	O	817-824
value	O	825-830
.	O	830-831

When	O	832-836
activating	O	837-847
the	O	848-851
(	O	852-853
Na	O	853-855
,	O	855-856
K	O	856-857
)	O	857-858
-	O	858-859
ATPase	O	859-865
with	O	866-870
its	O	871-874
substrate	O	875-884
ATP	O	885-888
,	O	888-889
no	O	890-892
changes	O	893-900
in	O	901-903
Km	O	904-906
and	O	907-910
Vmax	O	911-915
values	O	916-922
were	O	923-927
observed	O	928-936
in	O	937-939
NO	O	940-942
-	O	942-943
deficient	O	943-952
rats	O	953-957
.	O	957-958

During	O	959-965
activation	O	966-976
with	O	977-981
Na	O	982-984
+	O	984-985
,	O	985-986
the	O	987-990
Vmax	O	991-995
remained	O	996-1004
unchanged	O	1005-1014
,	O	1014-1015
however	O	1016-1023
the	O	1024-1027
K	O	1028-1029
(	O	1029-1030
Na	O	1030-1032
)	O	1032-1033
increased	O	1034-1043
by	O	1044-1046
50	O	1047-1049
%	O	1049-1050
,	O	1050-1051
indicating	O	1052-1062
a	O	1063-1064
profound	O	1065-1073
decrease	O	1074-1082
in	O	1083-1085
the	O	1086-1089
affinity	O	1090-1098
of	O	1099-1101
the	O	1102-1105
Na	O	1106-1108
+	O	1108-1109
-	O	1109-1110
binding	O	1110-1117
site	O	1118-1122
in	O	1123-1125
NO	O	1126-1128
-	O	1128-1129
deficient	O	1129-1138
rats	O	1139-1143
.	O	1143-1144

After	O	1145-1150
recovery	O	1151-1159
from	O	1160-1164
hypertension	B	1165-1177
,	O	1177-1178
the	O	1179-1182
activity	O	1183-1191
of	O	1192-1194
(	O	1195-1196
Na	O	1196-1198
,	O	1198-1199
K	O	1199-1200
)	O	1200-1201
-	O	1201-1202
ATPase	O	1202-1208
increased	O	1209-1218
,	O	1218-1219
due	O	1220-1223
to	O	1224-1226
higher	O	1227-1233
affinity	O	1234-1242
of	O	1243-1245
the	O	1246-1249
ATP	O	1250-1253
-	O	1253-1254
binding	O	1254-1261
site	O	1262-1266
,	O	1266-1267
as	O	1268-1270
revealed	O	1271-1279
from	O	1280-1284
the	O	1285-1288
lowered	O	1289-1296
Km	O	1297-1299
value	O	1300-1305
for	O	1306-1309
ATP	O	1310-1313
.	O	1313-1314

The	O	1315-1318
K	O	1319-1320
(	O	1320-1321
Na	O	1321-1323
)	O	1323-1324
value	O	1325-1330
for	O	1331-1334
Na	O	1335-1337
+	O	1337-1338
returned	O	1339-1347
to	O	1348-1350
control	O	1351-1358
value	O	1359-1364
.	O	1364-1365

Inhibition	O	1366-1376
of	O	1377-1379
NO	O	1380-1382
-	O	1382-1383
synthase	O	1383-1391
induced	O	1392-1399
a	O	1400-1401
reversible	O	1402-1412
hypertension	B	1413-1425
accompanied	O	1426-1437
by	O	1438-1440
depressed	B	1441-1450
Na	O	1451-1453
+	O	1453-1454
-	O	1454-1455
extrusion	O	1455-1464
from	O	1465-1469
cardiac	O	1470-1477
cells	O	1478-1483
as	O	1484-1486
a	O	1487-1488
consequence	O	1489-1500
of	O	1501-1503
deteriorated	O	1504-1516
Na	O	1517-1519
+	O	1519-1520
-	O	1520-1521
binding	O	1521-1528
properties	O	1529-1539
of	O	1540-1542
the	O	1543-1546
(	O	1547-1548
Na	O	1548-1550
,	O	1550-1551
K	O	1551-1552
)	O	1552-1553
-	O	1553-1554
ATPase	O	1554-1560
.	O	1560-1561

After	O	1562-1567
recovery	O	1568-1576
of	O	1577-1579
blood	O	1580-1585
pressure	O	1586-1594
to	O	1595-1597
control	O	1598-1605
values	O	1606-1612
,	O	1612-1613
the	O	1614-1617
extrusion	O	1618-1627
of	O	1628-1630
Na	O	1631-1633
+	O	1633-1634
from	O	1635-1639
cardiac	O	1640-1647
cells	O	1648-1653
was	O	1654-1657
normalized	O	1658-1668
,	O	1668-1669
as	O	1670-1672
revealed	O	1673-1681
by	O	1682-1684
restoration	O	1685-1696
of	O	1697-1699
the	O	1700-1703
(	O	1704-1705
Na	O	1705-1707
,	O	1707-1708
K	O	1708-1709
)	O	1709-1710
-	O	1710-1711
ATPase	O	1711-1717
activity	O	1718-1726
.	O	1726-1727

Effects	O	0-7
of	O	8-10
long	O	11-15
-	O	15-16
term	O	16-20
pretreatment	O	21-33
with	O	34-38
isoproterenol	O	39-52
on	O	53-55
bromocriptine	O	56-69
-	O	69-70
induced	O	70-77
tachycardia	B	78-89
in	O	90-92
conscious	O	93-102
rats	O	103-107
.	O	107-108

It	O	109-111
has	O	112-115
been	O	116-120
shown	O	121-126
that	O	127-131
bromocriptine	O	132-145
-	O	145-146
induced	O	146-153
tachycardia	B	154-165
,	O	165-166
which	O	167-172
persisted	O	173-182
after	O	183-188
adrenalectomy	O	189-202
,	O	202-203
is	O	204-206
(	O	207-208
i	O	208-209
)	O	209-210
mediated	O	211-219
by	O	220-222
central	O	223-230
dopamine	O	231-239
D2	O	240-242
receptor	O	243-251
activation	O	252-262
and	O	263-266
(	O	267-268
ii	O	268-270
)	O	270-271
reduced	O	272-279
by	O	280-282
5	O	283-284
-	O	284-285
day	O	285-288
isoproterenol	O	289-302
pretreatment	O	303-315
,	O	315-316
supporting	O	317-327
therefore	O	328-337
the	O	338-341
hypothesis	O	342-352
that	O	353-357
this	O	358-362
effect	O	363-369
is	O	370-372
dependent	O	373-382
on	O	383-385
sympathetic	O	386-397
outflow	O	398-405
to	O	406-408
the	O	409-412
heart	O	413-418
.	O	418-419

This	O	420-424
study	O	425-430
was	O	431-434
conducted	O	435-444
to	O	445-447
examine	O	448-455
whether	O	456-463
prolonged	O	464-473
pretreatment	O	474-486
with	O	487-491
isoproterenol	O	492-505
could	O	506-511
abolish	O	512-519
bromocriptine	O	520-533
-	O	533-534
induced	O	534-541
tachycardia	B	542-553
in	O	554-556
conscious	O	557-566
rats	O	567-571
.	O	571-572

Isoproterenol	O	573-586
pretreatment	O	587-599
for	O	600-603
15	O	604-606
days	O	607-611
caused	O	612-618
cardiac	B	619-626
hypertrophy	I	627-638
without	O	639-646
affecting	O	647-656
baseline	O	657-665
blood	O	666-671
pressure	O	672-680
and	O	681-684
heart	O	685-690
rate	O	691-695
.	O	695-696

In	O	697-699
control	O	700-707
rats	O	708-712
,	O	712-713
intravenous	O	714-725
bromocriptine	O	726-739
(	O	740-741
150	O	741-744
microg	O	745-751
/	O	751-752
kg	O	752-754
)	O	754-755
induced	O	756-763
significant	O	764-775
hypotension	B	776-787
and	O	788-791
tachycardia	B	792-803
.	O	803-804

Bromocriptine	O	805-818
-	O	818-819
induced	O	819-826
hypotension	B	827-838
was	O	839-842
unaffected	O	843-853
by	O	854-856
isoproterenol	O	857-870
pretreatment	O	871-883
,	O	883-884
while	O	885-890
tachycardia	B	891-902
was	O	903-906
reversed	O	907-915
to	O	916-918
significant	O	919-930
bradycardia	B	931-942
,	O	942-943
an	O	944-946
effect	O	947-953
that	O	954-958
was	O	959-962
partly	O	963-969
reduced	O	970-977
by	O	978-980
i	O	981-982
.	O	982-983
v	O	983-984
.	O	982-983

domperidone	O	986-997
(	O	998-999
0	O	999-1000
.	O	1000-1001
5	O	1001-1002
mg	O	1003-1005
/	O	1005-1006
kg	O	1006-1008
)	O	1008-1009
.	O	1009-1010

Neither	O	1011-1018
cardiac	O	1019-1026
vagal	O	1027-1032
nor	O	1033-1036
sympathetic	O	1037-1048
tone	O	1049-1053
was	O	1054-1057
altered	O	1058-1065
by	O	1066-1068
isoproterenol	O	1069-1082
pretreatment	O	1083-1095
.	O	1095-1096

In	O	1097-1099
isolated	O	1100-1108
perfused	O	1109-1117
heart	O	1118-1123
preparations	O	1124-1136
from	O	1137-1141
isoproterenol	O	1142-1155
-	O	1155-1156
pretreated	O	1156-1166
rats	O	1167-1171
,	O	1171-1172
the	O	1173-1176
isoproterenol	O	1177-1190
-	O	1190-1191
induced	O	1191-1198
maximal	O	1199-1206
increase	O	1207-1215
in	O	1216-1218
left	O	1219-1223
ventricular	O	1224-1235
systolic	O	1236-1244
pressure	O	1245-1253
was	O	1254-1257
significantly	O	1258-1271
reduced	O	1272-1279
,	O	1279-1280
compared	O	1281-1289
with	O	1290-1294
saline	O	1295-1301
-	O	1301-1302
pretreated	O	1302-1312
rats	O	1313-1317
(	O	1318-1319
the	O	1319-1322
EC50	O	1323-1327
of	O	1328-1330
the	O	1331-1334
isoproterenol	O	1335-1348
-	O	1348-1349
induced	O	1349-1356
increase	O	1357-1365
in	O	1366-1368
left	O	1369-1373
ventricular	O	1374-1385
systolic	O	1386-1394
pressure	O	1395-1403
was	O	1404-1407
enhanced	O	1408-1416
approximately	O	1417-1430
22	O	1431-1433
-	O	1433-1434
fold	O	1434-1438
)	O	1438-1439
.	O	1439-1440

These	O	1441-1446
results	O	1447-1454
show	O	1455-1459
that	O	1460-1464
15	O	1465-1467
-	O	1467-1468
day	O	1468-1471
isoproterenol	O	1472-1485
pretreatment	O	1486-1498
not	O	1499-1502
only	O	1503-1507
abolished	O	1508-1517
but	O	1518-1521
reversed	O	1522-1530
bromocriptine	O	1531-1544
-	O	1544-1545
induced	O	1545-1552
tachycardia	B	1553-1564
to	O	1565-1567
bradycardia	B	1568-1579
,	O	1579-1580
an	O	1581-1583
effect	O	1584-1590
that	O	1591-1595
is	O	1596-1598
mainly	O	1599-1605
related	O	1606-1613
to	O	1614-1616
further	O	1617-1624
cardiac	O	1625-1632
beta	O	1633-1637
-	O	1637-1638
adrenoceptor	O	1638-1650
desensitization	O	1651-1666
rather	O	1667-1673
than	O	1674-1678
to	O	1679-1681
impairment	O	1682-1692
of	O	1693-1695
autonomic	O	1696-1705
regulation	O	1706-1716
of	O	1717-1719
the	O	1720-1723
heart	O	1724-1729
.	O	1729-1730

They	O	1731-1735
suggest	O	1736-1743
that	O	1744-1748
,	O	1748-1749
in	O	1750-1752
normal	O	1753-1759
conscious	O	1760-1769
rats	O	1770-1774
,	O	1774-1775
the	O	1776-1779
central	O	1780-1787
tachycardia	B	1788-1799
of	O	1800-1802
bromocriptine	O	1803-1816
appears	O	1817-1824
to	O	1825-1827
predominate	O	1828-1839
and	O	1840-1843
to	O	1844-1846
mask	O	1847-1851
the	O	1852-1855
bradycardia	B	1856-1867
of	O	1868-1870
this	O	1871-1875
agonist	O	1876-1883
at	O	1884-1886
peripheral	O	1887-1897
dopamine	O	1898-1906
D2	O	1907-1909
receptors	O	1910-1919
.	O	1919-1920

A	O	0-1
developmental	O	2-15
analysis	O	16-24
of	O	25-27
clonidine	O	28-37
'	O	37-38
s	O	38-39
effects	O	40-47
on	O	48-50
cardiac	O	51-58
rate	O	59-63
and	O	64-67
ultrasound	O	68-78
production	O	79-89
in	O	90-92
infant	O	93-99
rats	O	100-104
.	O	104-105

Under	O	106-111
controlled	O	112-122
conditions	O	123-133
,	O	133-134
infant	O	135-141
rats	O	142-146
emit	O	147-151
ultrasonic	O	152-162
vocalizations	O	163-176
during	O	177-183
extreme	O	184-191
cold	O	192-196
exposure	O	197-205
and	O	206-209
after	O	210-215
administration	O	216-230
of	O	231-233
the	O	234-237
alpha	O	238-243
(	O	243-244
2	O	244-245
)	O	245-246
adrenoceptor	O	247-259
agonist	O	260-267
,	O	267-268
clonidine	O	269-278
.	O	278-279

Previous	O	280-288
investigations	O	289-303
have	O	304-308
determined	O	309-319
that	O	320-324
,	O	324-325
in	O	326-328
response	O	329-337
to	O	338-340
clonidine	O	341-350
,	O	350-351
ultrasound	O	352-362
production	O	363-373
increases	O	374-383
through	O	384-391
the	O	392-395
2nd	O	396-399
-	O	399-400
week	O	400-404
postpartum	O	405-415
and	O	416-419
decreases	O	420-429
thereafter	O	430-440
.	O	440-441

Given	O	442-447
that	O	448-452
sympathetic	O	453-464
neural	O	465-471
dominance	O	472-481
exhibits	O	482-490
a	O	491-492
similar	O	493-500
developmental	O	501-514
pattern	O	515-522
,	O	522-523
and	O	524-527
given	O	528-533
that	O	534-538
clonidine	O	539-548
induces	O	549-556
sympathetic	O	557-568
withdrawal	O	569-579
and	O	580-583
bradycardia	B	584-595
,	O	595-596
we	O	597-599
hypothesized	O	600-612
that	O	613-617
clonidine	O	618-627
'	O	627-628
s	O	628-629
developmental	O	630-643
effects	O	644-651
on	O	652-654
cardiac	O	655-662
rate	O	663-667
and	O	668-671
ultrasound	O	672-682
production	O	683-693
would	O	694-699
mirror	O	700-706
each	O	707-711
other	O	712-717
.	O	717-718

Therefore	O	719-728
,	O	728-729
in	O	730-732
the	O	733-736
present	O	737-744
experiment	O	745-755
,	O	755-756
the	O	757-760
effects	O	761-768
of	O	769-771
clonidine	O	772-781
administration	O	782-796
(	O	797-798
0	O	798-799
.	O	799-800
5	O	800-801
mg	O	802-804
/	O	804-805
kg	O	805-807
)	O	807-808
on	O	809-811
cardiac	O	812-819
rate	O	820-824
and	O	825-828
ultrasound	O	829-839
production	O	840-850
were	O	851-855
examined	O	856-864
in	O	865-867
2	O	868-869
-	O	869-870
,	O	870-871
8	O	872-873
-	O	873-874
,	O	874-875
15	O	876-878
-	O	878-879
,	O	879-880
and	O	881-884
20	O	885-887
-	O	887-888
day	O	888-891
-	O	887-888
old	O	892-895
rats	O	896-900
.	O	900-901

Age	O	902-905
-	O	905-906
related	O	906-913
changes	O	914-921
in	O	922-924
ultrasound	O	925-935
production	O	936-946
corresponded	O	947-959
with	O	960-964
changes	O	965-972
in	O	973-975
cardiovascular	O	976-990
variables	O	991-1000
,	O	1000-1001
including	O	1002-1011
baseline	O	1012-1020
cardiac	O	1021-1028
rate	O	1029-1033
and	O	1034-1037
clonidine	O	1038-1047
-	O	1047-1048
induced	O	1048-1055
bradycardia	B	1056-1067
.	O	1067-1068

This	O	1069-1073
experiment	O	1074-1084
is	O	1085-1087
discussed	O	1088-1097
with	O	1098-1102
regard	O	1103-1109
to	O	1110-1112
the	O	1113-1116
hypothesis	O	1117-1127
that	O	1128-1132
ultrasound	O	1133-1143
production	O	1144-1154
is	O	1155-1157
the	O	1158-1161
acoustic	O	1162-1170
by	O	1171-1173
-	O	1173-1174
product	O	1174-1181
of	O	1182-1184
a	O	1185-1186
physiological	O	1187-1200
maneuver	O	1201-1209
that	O	1210-1214
compensates	O	1215-1226
for	O	1227-1230
clonidine	O	1231-1240
'	O	1240-1241
s	O	1241-1242
detrimental	O	1243-1254
effects	O	1255-1262
on	O	1263-1265
cardiovascular	O	1266-1280
function	O	1281-1289
.	O	1289-1290

Differential	O	0-12
effects	O	13-20
of	O	21-23
systemically	O	24-36
administered	O	37-49
ketamine	O	50-58
and	O	59-62
lidocaine	O	63-72
on	O	73-75
dynamic	O	76-83
and	O	84-87
static	O	88-94
hyperalgesia	B	95-107
induced	O	108-115
by	O	116-118
intradermal	O	119-130
capsaicin	O	131-140
in	O	141-143
humans	O	144-150
.	O	150-151

We	O	152-154
have	O	155-159
examined	O	160-168
the	O	169-172
effect	O	173-179
of	O	180-182
systemic	O	183-191
administration	O	192-206
of	O	207-209
ketamine	O	210-218
and	O	219-222
lidocaine	O	223-232
on	O	233-235
brush	O	236-241
-	O	241-242
evoked	O	242-248
(	O	249-250
dynamic	O	250-257
)	O	257-258
pain	B	259-263
and	O	264-267
punctate	O	268-276
-	O	276-277
evoked	O	277-283
(	O	284-285
static	O	285-291
)	O	291-292
hyperalgesia	B	293-305
induced	O	306-313
by	O	314-316
capsaicin	O	317-326
.	O	326-327

In	O	328-330
a	O	331-332
randomized	O	333-343
,	O	343-344
double	O	345-351
-	O	351-352
blind	O	352-357
,	O	357-358
placebo	O	359-366
-	O	366-367
controlled	O	367-377
,	O	377-378
crossover	O	379-388
study	O	389-394
,	O	394-395
we	O	396-398
studied	O	399-406
12	O	407-409
volunteers	O	410-420
in	O	421-423
three	O	424-429
experiments	O	430-441
.	O	441-442

Capsaicin	O	443-452
100	O	453-456
micrograms	O	457-467
was	O	468-471
injected	O	472-480
intradermally	O	481-494
on	O	495-497
the	O	498-501
volar	O	502-507
forearm	O	508-515
followed	O	516-524
by	O	525-527
an	O	528-530
i	O	531-532
.	O	532-533
v	O	533-534
.	O	532-533

infusion	O	536-544
of	O	545-547
ketamine	O	548-556
(	O	557-558
bolus	O	558-563
0	O	564-565
.	O	565-566
1	O	566-567
mg	O	568-570
kg	O	571-573
-	O	573-574
1	O	574-575
over	O	576-580
10	O	581-583
min	O	584-587
followed	O	588-596
by	O	597-599
infusion	O	600-608
of	O	609-611
7	O	612-613
micrograms	O	614-624
kg	O	625-627
-	O	627-628
1	O	628-629
min	O	630-633
-	O	633-634
1	O	634-635
)	O	635-636
,	O	636-637
lidocaine	O	638-647
5	O	648-649
mg	O	650-652
kg	O	653-655
-	O	655-656
1	O	656-657
or	O	658-660
saline	O	661-667
for	O	668-671
50	O	672-674
min	O	675-678
.	O	678-679

Infusion	O	680-688
started	O	689-696
15	O	697-699
min	O	700-703
after	O	704-709
injection	O	710-719
of	O	720-722
capsaicin	O	723-732
.	O	732-733

The	O	734-737
following	O	738-747
were	O	748-752
measured	O	753-761
:	O	761-762
spontaneous	O	763-774
pain	B	775-779
,	O	779-780
pain	B	781-785
evoked	O	786-792
by	O	793-795
punctate	O	796-804
and	O	805-808
brush	O	809-814
stimuli	O	815-822
(	O	823-824
VAS	O	824-827
)	O	827-828
,	O	828-829
and	O	830-833
areas	O	834-839
of	O	840-842
brush	O	843-848
-	O	848-849
evoked	O	849-855
and	O	856-859
punctate	O	860-868
-	O	868-869
evoked	O	869-875
hyperalgesia	B	876-888
.	O	888-889

Ketamine	O	890-898
reduced	O	899-906
both	O	907-911
the	O	912-915
area	O	916-920
of	O	921-923
brush	O	924-929
-	O	929-930
evoked	O	930-936
and	O	937-940
punctate	O	941-949
-	O	949-950
evoked	O	950-956
hyperalgesia	B	957-969
significantly	O	970-983
and	O	984-987
it	O	988-990
tended	O	991-997
to	O	998-1000
reduce	O	1001-1007
brush	O	1008-1013
-	O	1013-1014
evoked	O	1014-1020
pain	B	1021-1025
.	O	1025-1026

Lidocaine	O	1027-1036
reduced	O	1037-1044
the	O	1045-1048
area	O	1049-1053
of	O	1054-1056
punctate	O	1057-1065
-	O	1065-1066
evoked	O	1066-1072
hyperalgesia	B	1073-1085
significantly	O	1086-1099
.	O	1099-1100

It	O	1101-1103
tended	O	1104-1110
to	O	1111-1113
reduce	O	1114-1120
VAS	O	1121-1124
scores	O	1125-1131
of	O	1132-1134
spontaneous	O	1135-1146
pain	B	1147-1151
but	O	1152-1155
had	O	1156-1159
no	O	1160-1162
effect	O	1163-1169
on	O	1170-1172
evoked	O	1173-1179
pain	B	1180-1184
.	O	1184-1185

The	O	1186-1189
differential	O	1190-1202
effects	O	1203-1210
of	O	1211-1213
ketamine	O	1214-1222
and	O	1223-1226
lidocaine	O	1227-1236
on	O	1237-1239
static	O	1240-1246
and	O	1247-1250
dynamic	O	1251-1258
hyperalgesia	B	1259-1271
suggest	O	1272-1279
that	O	1280-1284
the	O	1285-1288
two	O	1289-1292
types	O	1293-1298
of	O	1299-1301
hyperalgesia	B	1302-1314
are	O	1315-1318
mediated	O	1319-1327
by	O	1328-1330
separate	O	1331-1339
mechanisms	O	1340-1350
and	O	1351-1354
have	O	1355-1359
a	O	1360-1361
distinct	O	1362-1370
pharmacology	O	1371-1383
.	O	1383-1384

Cyclosporine	O	0-12
and	O	13-16
tacrolimus	O	17-27
-	O	27-28
associated	O	28-38
thrombotic	B	39-49
microangiopathy	I	50-65
.	O	65-66

The	O	67-70
development	O	71-82
of	O	83-85
thrombotic	B	86-96
microangiopathy	I	97-112
(	O	113-114
TMA	B	114-117
)	O	117-118
associated	O	119-129
with	O	130-134
the	O	135-138
use	O	139-142
of	O	143-145
cyclosporine	O	146-158
has	O	159-162
been	O	163-167
well	O	168-172
documented	O	173-183
.	O	183-184

Treatments	O	185-195
have	O	196-200
included	O	201-209
discontinuation	O	210-225
or	O	226-228
reduction	O	229-238
of	O	239-241
cyclosporine	O	242-254
dose	O	255-259
with	O	260-264
or	O	265-267
without	O	268-275
concurrent	O	276-286
plasma	O	287-293
exchange	O	294-302
,	O	302-303
plasma	O	304-310
infusion	O	311-319
,	O	319-320
anticoagulation	O	321-336
,	O	336-337
and	O	338-341
intravenous	O	342-353
immunoglobulin	O	354-368
G	O	369-370
infusion	O	371-379
.	O	379-380

However	O	381-388
,	O	388-389
for	O	390-393
recipients	O	394-404
of	O	405-407
organ	O	408-413
transplantation	O	414-429
,	O	429-430
removing	O	431-439
the	O	440-443
inciting	O	444-452
agent	O	453-458
is	O	459-461
not	O	462-465
without	O	466-473
the	O	474-477
attendant	O	478-487
risk	O	488-492
of	O	493-495
precipitating	O	496-509
acute	O	510-515
rejection	O	516-525
and	O	526-529
graft	O	530-535
loss	O	536-540
.	O	540-541

The	O	542-545
last	O	546-550
decade	O	551-557
has	O	558-561
seen	O	562-566
the	O	567-570
emergence	O	571-580
of	O	581-583
tacrolimus	O	584-594
as	O	595-597
a	O	598-599
potent	O	600-606
immunosuppressive	O	607-624
agent	O	625-630
with	O	631-635
mechanisms	O	636-646
of	O	647-649
action	O	650-656
virtually	O	657-666
identical	O	667-676
to	O	677-679
those	O	680-685
of	O	686-688
cyclosporine	O	689-701
.	O	701-702

As	O	703-705
a	O	706-707
result	O	708-714
,	O	714-715
switching	O	716-725
to	O	726-728
tacrolimus	O	729-739
has	O	740-743
been	O	744-748
reported	O	749-757
to	O	758-760
be	O	761-763
a	O	764-765
viable	O	766-772
therapeutic	O	773-784
option	O	785-791
in	O	792-794
the	O	795-798
setting	O	799-806
of	O	807-809
cyclosporine	O	810-822
-	O	822-823
induced	O	823-830
TMA	B	831-834
.	O	834-835

With	O	836-840
the	O	841-844
more	O	845-849
widespread	O	850-860
application	O	861-872
of	O	873-875
tacrolimus	O	876-886
in	O	887-889
organ	O	890-895
transplantation	O	896-911
,	O	911-912
tacrolimus	O	913-923
-	O	923-924
associated	O	924-934
TMA	B	935-938
has	O	939-942
also	O	943-947
been	O	948-952
recognized	O	953-963
.	O	963-964

However	O	965-972
,	O	972-973
literature	O	974-984
regarding	O	985-994
the	O	995-998
incidence	O	999-1008
of	O	1009-1011
the	O	1012-1015
recurrence	O	1016-1026
of	O	1027-1029
TMA	B	1030-1033
in	O	1034-1036
patients	O	1037-1045
exposed	O	1046-1053
sequentially	O	1054-1066
to	O	1067-1069
cyclosporine	O	1070-1082
and	O	1083-1086
tacrolimus	O	1087-1097
is	O	1098-1100
limited	O	1101-1108
.	O	1108-1109

We	O	1110-1112
report	O	1113-1119
a	O	1120-1121
case	O	1122-1126
of	O	1127-1129
a	O	1130-1131
living	O	1132-1138
donor	O	1139-1144
renal	O	1145-1150
transplant	O	1151-1161
recipient	O	1162-1171
who	O	1172-1175
developed	O	1176-1185
cyclosporine	O	1186-1198
-	O	1198-1199
induced	O	1199-1206
TMA	B	1207-1210
that	O	1211-1215
responded	O	1216-1225
to	O	1226-1228
the	O	1229-1232
withdrawal	O	1233-1243
of	O	1244-1246
cyclosporine	O	1247-1259
in	O	1260-1262
conjunction	O	1263-1274
with	O	1275-1279
plasmapheresis	O	1280-1294
and	O	1295-1298
fresh	O	1299-1304
frozen	O	1305-1311
plasma	O	1312-1318
replacement	O	1319-1330
therapy	O	1331-1338
.	O	1338-1339

Introduction	O	1340-1352
of	O	1353-1355
tacrolimus	O	1356-1366
as	O	1367-1369
an	O	1370-1372
alternative	O	1373-1384
immunosuppressive	O	1385-1402
agent	O	1403-1408
resulted	O	1409-1417
in	O	1418-1420
the	O	1421-1424
recurrence	O	1425-1435
of	O	1436-1438
TMA	B	1439-1442
and	O	1443-1446
the	O	1447-1450
subsequent	O	1451-1461
loss	O	1462-1466
of	O	1467-1469
the	O	1470-1473
renal	O	1474-1479
allograft	O	1480-1489
.	O	1489-1490

Patients	O	1491-1499
who	O	1500-1503
are	O	1504-1507
switched	O	1508-1516
from	O	1517-1521
cyclosporine	O	1522-1534
to	O	1535-1537
tacrolimus	O	1538-1548
or	O	1549-1551
vice	O	1552-1556
versa	O	1557-1562
should	O	1563-1569
be	O	1570-1572
closely	O	1573-1580
monitored	O	1581-1590
for	O	1591-1594
the	O	1595-1598
signs	O	1599-1604
and	O	1605-1608
symptoms	O	1609-1617
of	O	1618-1620
recurrent	O	1621-1630
TMA	B	1631-1634
.	O	1634-1635

Repeated	O	0-8
transient	O	9-18
anuria	B	19-25
following	O	26-35
losartan	O	36-44
administration	O	45-59
in	O	60-62
a	O	63-64
patient	O	65-72
with	O	73-77
a	O	78-79
solitary	O	80-88
kidney	O	89-95
.	O	95-96

We	O	97-99
report	O	100-106
the	O	107-110
case	O	111-115
of	O	116-118
a	O	119-120
70	O	121-123
-	O	123-124
year	O	124-128
-	O	123-124
old	O	129-132
hypertensive	B	133-145
man	O	146-149
with	O	150-154
a	O	155-156
solitary	O	157-165
kidney	O	166-172
and	O	173-176
chronic	B	177-184
renal	I	185-190
insufficiency	I	191-204
who	O	205-208
developed	O	209-218
two	O	219-222
episodes	O	223-231
of	O	232-234
transient	O	235-244
anuria	B	245-251
after	O	252-257
losartan	O	258-266
administration	O	267-281
.	O	281-282

He	O	283-285
was	O	286-289
hospitalized	O	290-302
for	O	303-306
a	O	307-308
myocardial	B	309-319
infarction	I	320-330
with	O	331-335
pulmonary	B	336-345
edema	I	346-351
,	O	351-352
treated	O	353-360
with	O	361-365
high	O	366-370
-	O	370-371
dose	O	371-375
diuretics	O	376-385
.	O	385-386

Due	O	387-390
to	O	391-393
severe	O	394-400
systolic	B	401-409
dysfunction	I	410-421
losartan	O	422-430
was	O	431-434
prescribed	O	435-445
.	O	445-446

Surprisingly	O	447-459
,	O	459-460
the	O	461-464
first	O	465-470
dose	O	471-475
of	O	476-478
50	O	479-481
mg	O	482-484
of	O	485-487
losartan	O	488-496
resulted	O	497-505
in	O	506-508
a	O	509-510
sudden	O	511-517
anuria	B	518-524
,	O	524-525
which	O	526-531
lasted	O	532-538
eight	O	539-544
hours	O	545-550
despite	O	551-558
high	O	559-563
-	O	563-564
dose	O	564-568
furosemide	O	569-579
and	O	580-583
amine	O	584-589
infusion	O	590-598
.	O	598-599

One	O	600-603
week	O	604-608
later	O	609-614
,	O	614-615
by	O	616-618
mistake	O	619-626
,	O	626-627
losartan	O	628-636
was	O	637-640
prescribed	O	641-651
again	O	652-657
and	O	658-661
after	O	662-667
the	O	668-671
second	O	672-678
dose	O	679-683
of	O	684-686
50	O	687-689
mg	O	690-692
,	O	692-693
the	O	694-697
patient	O	698-705
developed	O	706-715
a	O	716-717
second	O	718-724
episode	O	725-732
of	O	733-735
transient	O	736-745
anuria	B	746-752
lasting	O	753-760
10	O	761-763
hours	O	764-769
.	O	769-770

During	O	771-777
these	O	778-783
two	O	784-787
episodes	O	788-796
,	O	796-797
his	O	798-801
blood	O	802-807
pressure	O	808-816
diminished	O	817-827
but	O	828-831
no	O	832-834
severe	O	835-841
hypotension	B	842-853
was	O	854-857
noted	O	858-863
.	O	863-864

Ultimately	O	865-875
,	O	875-876
an	O	877-879
arteriography	O	880-893
showed	O	894-900
a	O	901-902
70	O	903-905
-	O	905-906
80	O	906-908
%	O	908-909
renal	B	910-915
artery	I	916-922
stenosis	I	923-931
.	O	931-932

In	O	933-935
this	O	936-940
patient	O	941-948
,	O	948-949
renal	B	950-955
artery	I	956-962
stenosis	I	963-971
combined	O	972-980
with	O	981-985
heart	B	986-991
failure	I	992-999
and	O	1000-1003
diuretic	O	1004-1012
therapy	O	1013-1020
certainly	O	1021-1030
resulted	O	1031-1039
in	O	1040-1042
a	O	1043-1044
strong	O	1045-1051
activation	O	1052-1062
of	O	1063-1065
the	O	1066-1069
renin	O	1070-1075
-	O	1075-1076
angiotensin	O	1076-1087
system	O	1088-1094
(	O	1095-1096
RAS	O	1096-1099
)	O	1099-1100
.	O	1100-1101

Under	O	1102-1107
such	O	1108-1112
conditions	O	1113-1123
,	O	1123-1124
angiotensin	O	1125-1136
II	O	1137-1139
receptor	O	1140-1148
blockade	O	1149-1157
by	O	1158-1160
losartan	O	1161-1169
probably	O	1170-1178
induced	O	1179-1186
a	O	1187-1188
critical	O	1189-1197
fall	O	1198-1202
in	O	1203-1205
glomerular	O	1206-1216
filtration	O	1217-1227
pressure	O	1228-1236
.	O	1236-1237

This	O	1238-1242
case	O	1243-1247
report	O	1248-1254
highlights	O	1255-1265
the	O	1266-1269
fact	O	1270-1274
that	O	1275-1279
the	O	1280-1283
angiotensin	O	1284-1295
II	O	1296-1298
receptor	O	1299-1307
antagonist	O	1308-1318
losartan	O	1319-1327
can	O	1328-1331
cause	O	1332-1337
serious	O	1338-1345
unexpected	O	1346-1356
complications	O	1357-1370
in	O	1371-1373
patients	O	1374-1382
with	O	1383-1387
renovascular	B	1388-1400
disease	I	1401-1408
and	O	1409-1412
should	O	1413-1419
be	O	1420-1422
used	O	1423-1427
with	O	1428-1432
extreme	O	1433-1440
caution	O	1441-1448
in	O	1449-1451
this	O	1452-1456
setting	O	1457-1464
.	O	1464-1465

In	O	0-2
vivo	O	3-7
protection	O	8-18
of	O	19-21
dna	O	22-25
damage	O	26-32
associated	O	33-43
apoptotic	O	44-53
and	O	54-57
necrotic	B	58-66
cell	O	67-71
deaths	O	72-78
during	O	79-85
acetaminophen	O	86-99
-	O	99-100
induced	O	100-107
nephrotoxicity	B	108-122
,	O	122-123
amiodarone	O	124-134
-	O	134-135
induced	O	135-142
lung	B	143-147
toxicity	I	148-156
and	O	157-160
doxorubicin	O	161-172
-	O	172-173
induced	O	173-180
cardiotoxicity	B	181-195
by	O	196-198
a	O	199-200
novel	O	201-206
IH636	O	207-212
grape	O	213-218
seed	O	219-223
proanthocyanidin	O	224-240
extract	O	241-248
.	O	248-249

Grape	O	250-255
seed	O	256-260
extract	O	261-268
,	O	268-269
primarily	O	270-279
a	O	280-281
mixture	O	282-289
of	O	290-292
proanthocyanidins	O	293-310
,	O	310-311
has	O	312-315
been	O	316-320
shown	O	321-326
to	O	327-329
modulate	O	330-338
a	O	339-340
wide	O	341-345
-	O	345-346
range	O	346-351
of	O	352-354
biological	O	355-365
,	O	365-366
pharmacological	O	367-382
and	O	383-386
toxicological	O	387-400
effects	O	401-408
which	O	409-414
are	O	415-418
mainly	O	419-425
cytoprotective	O	426-440
.	O	440-441

This	O	442-446
study	O	447-452
assessed	O	453-461
the	O	462-465
ability	O	466-473
of	O	474-476
IH636	O	477-482
grape	O	483-488
seed	O	489-493
proanthocyanidin	O	494-510
extract	O	511-518
(	O	519-520
GSPE	O	520-524
)	O	524-525
to	O	526-528
prevent	O	529-536
acetaminophen	O	537-550
(	O	551-552
AAP	O	552-555
)	O	555-556
-	O	556-557
induced	O	557-564
nephrotoxicity	B	565-579
,	O	579-580
amiodarone	O	581-591
(	O	592-593
AMI	O	593-596
)	O	596-597
-	O	597-598
induced	O	598-605
lung	B	606-610
toxicity	I	611-619
,	O	619-620
and	O	621-624
doxorubicin	O	625-636
(	O	637-638
DOX	O	638-641
)	O	641-642
-	O	642-643
induced	O	643-650
cardiotoxicity	B	651-665
in	O	666-668
mice	O	669-673
.	O	673-674

Experimental	O	675-687
design	O	688-694
consisted	O	695-704
of	O	705-707
four	O	708-712
groups	O	713-719
:	O	719-720
control	O	721-728
(	O	729-730
vehicle	O	730-737
alone	O	738-743
)	O	743-744
,	O	744-745
GSPE	O	746-750
alone	O	751-756
,	O	756-757
drug	O	758-762
alone	O	763-768
and	O	769-772
GSPE	O	773-777
+	O	777-778
drug	O	778-782
.	O	782-783

For	O	784-787
the	O	788-791
cytoprotection	O	792-806
study	O	807-812
,	O	812-813
animals	O	814-821
were	O	822-826
orally	O	827-833
gavaged	O	834-841
100	O	842-845
mg	O	846-848
/	O	848-849
Kg	O	849-851
GSPE	O	852-856
for	O	857-860
7	O	861-862
-	O	862-863
10	O	863-865
days	O	866-870
followed	O	871-879
by	O	880-882
i	O	883-884
.	O	884-885
p	O	885-886
.	O	884-885
injections	O	888-898
of	O	899-901
organ	O	902-907
specific	O	908-916
three	O	917-922
drugs	O	923-928
(	O	929-930
AAP	O	930-933
:	O	933-934
500	O	935-938
mg	O	939-941
/	O	941-942
Kg	O	942-944
for	O	945-948
24	O	949-951
h	O	952-953
;	O	953-954
AMI	O	955-958
:	O	958-959
50	O	960-962
mg	O	963-965
/	O	965-966
Kg	O	966-968
/	O	965-966
day	O	969-972
for	O	973-976
four	O	977-981
days	O	982-986
;	O	986-987
DOX	O	988-991
:	O	991-992
20	O	993-995
mg	O	996-998
/	O	998-999
Kg	O	999-1001
for	O	1002-1005
48	O	1006-1008
h	O	1009-1010
)	O	1010-1011
.	O	1011-1012

Parameters	O	1013-1023
of	O	1024-1026
study	O	1027-1032
included	O	1033-1041
analysis	O	1042-1050
of	O	1051-1053
serum	O	1054-1059
chemistry	O	1060-1069
(	O	1070-1071
ALT	O	1071-1074
,	O	1074-1075
BUN	O	1076-1079
and	O	1080-1083
CPK	O	1084-1087
)	O	1087-1088
,	O	1088-1089
and	O	1090-1093
orderly	O	1094-1101
fragmentation	O	1102-1115
of	O	1116-1118
genomic	O	1119-1126
DNA	O	1127-1130
(	O	1131-1132
both	O	1132-1136
endonuclease	O	1137-1149
-	O	1149-1150
dependent	O	1150-1159
and	O	1160-1163
independent	O	1164-1175
)	O	1175-1176
in	O	1177-1179
addition	O	1180-1188
to	O	1189-1191
microscopic	O	1192-1203
evaluation	O	1204-1214
of	O	1215-1217
damage	O	1218-1224
and	O	1225-1228
/	O	1228-1229
or	O	1229-1231
protection	O	1232-1242
in	O	1243-1245
corresponding	O	1246-1259
PAS	O	1260-1263
stained	O	1264-1271
tissues	O	1272-1279
.	O	1279-1280

Results	O	1281-1288
indicate	O	1289-1297
that	O	1298-1302
GSPE	O	1303-1307
preexposure	O	1308-1319
prior	O	1320-1325
to	O	1326-1328
AAP	O	1329-1332
,	O	1332-1333
AMI	O	1334-1337
and	O	1338-1341
DOX	O	1342-1345
,	O	1345-1346
provided	O	1347-1355
near	O	1356-1360
complete	O	1361-1369
protection	O	1370-1380
in	O	1381-1383
terms	O	1384-1389
of	O	1390-1392
serum	O	1393-1398
chemistry	O	1399-1408
changes	O	1409-1416
(	O	1417-1418
ALT	O	1418-1421
,	O	1421-1422
BUN	O	1423-1426
and	O	1427-1430
CPK	O	1431-1434
)	O	1434-1435
,	O	1435-1436
and	O	1437-1440
significantly	O	1441-1454
reduced	O	1455-1462
DNA	O	1463-1466
fragmentation	O	1467-1480
.	O	1480-1481

Histopathological	O	1482-1499
examination	O	1500-1511
of	O	1512-1514
kidney	O	1515-1521
,	O	1521-1522
heart	O	1523-1528
and	O	1529-1532
lung	O	1533-1537
sections	O	1538-1546
revealed	O	1547-1555
moderate	O	1556-1564
to	O	1565-1567
massive	O	1568-1575
tissue	B	1576-1582
damage	I	1583-1589
with	O	1590-1594
a	O	1595-1596
variety	O	1597-1604
of	O	1605-1607
morphological	O	1608-1621
aberrations	O	1622-1633
by	O	1634-1636
all	O	1637-1640
the	O	1641-1644
three	O	1645-1650
drugs	O	1651-1656
in	O	1657-1659
the	O	1660-1663
absence	O	1664-1671
of	O	1672-1674
GSPE	O	1675-1679
preexposure	O	1680-1691
than	O	1692-1696
in	O	1697-1699
its	O	1700-1703
presence	O	1704-1712
.	O	1712-1713

GSPE	O	1714-1718
+	O	1718-1719
drug	O	1719-1723
exposed	O	1724-1731
tissues	O	1732-1739
exhibited	O	1740-1749
minor	O	1750-1755
residual	O	1756-1764
damage	O	1765-1771
or	O	1772-1774
near	O	1775-1779
total	O	1780-1785
recovery	O	1786-1794
.	O	1794-1795

Additionally	O	1796-1808
,	O	1808-1809
histopathological	O	1810-1827
alterations	O	1828-1839
mirrored	O	1840-1848
both	O	1849-1853
serum	O	1854-1859
chemistry	O	1860-1869
changes	O	1870-1877
and	O	1878-1881
the	O	1882-1885
pattern	O	1886-1893
of	O	1894-1896
DNA	O	1897-1900
fragmentation	O	1901-1914
.	O	1914-1915

Interestingly	O	1916-1929
,	O	1929-1930
all	O	1931-1934
the	O	1935-1938
drugs	O	1939-1944
,	O	1944-1945
such	O	1946-1950
as	O	1951-1953
,	O	1953-1954
AAP	O	1955-1958
,	O	1958-1959
AMI	O	1960-1963
and	O	1964-1967
DOX	O	1968-1971
induced	O	1972-1979
apoptotic	O	1980-1989
death	O	1990-1995
in	O	1996-1998
addition	O	1999-2007
to	O	2008-2010
necrosis	B	2011-2019
in	O	2020-2022
the	O	2023-2026
respective	O	2027-2037
organs	O	2038-2044
which	O	2045-2050
was	O	2051-2054
very	O	2055-2059
effectively	O	2060-2071
blocked	O	2072-2079
by	O	2080-2082
GSPE	O	2083-2087
.	O	2087-2088

Since	O	2089-2094
AAP	O	2095-2098
,	O	2098-2099
AMI	O	2100-2103
and	O	2104-2107
DOX	O	2108-2111
undergo	O	2112-2119
biotransformation	O	2120-2137
and	O	2138-2141
are	O	2142-2145
known	O	2146-2151
to	O	2152-2154
produce	O	2155-2162
damaging	O	2163-2171
radicals	O	2172-2180
in	O	2181-2183
vivo	O	2184-2188
,	O	2188-2189
the	O	2190-2193
protection	O	2194-2204
by	O	2205-2207
GSPE	O	2208-2212
may	O	2213-2216
be	O	2217-2219
linked	O	2220-2226
to	O	2227-2229
both	O	2230-2234
inhibition	O	2235-2245
of	O	2246-2248
metabolism	O	2249-2259
and	O	2260-2263
/	O	2263-2264
or	O	2264-2266
detoxification	O	2267-2281
of	O	2282-2284
cytotoxic	O	2285-2294
radicals	O	2295-2303
.	O	2303-2304

In	O	2305-2307
addition	O	2308-2316
,	O	2316-2317
its	O	2318-2321
'	O	2321-2322
presumed	O	2323-2331
contribution	O	2332-2344
to	O	2345-2347
DNA	O	2348-2351
repair	O	2352-2358
may	O	2359-2362
be	O	2363-2365
another	O	2366-2373
important	O	2374-2383
attribute	O	2384-2393
,	O	2393-2394
which	O	2395-2400
played	O	2401-2407
a	O	2408-2409
role	O	2410-2414
in	O	2415-2417
the	O	2418-2421
chemoprevention	O	2422-2437
process	O	2438-2445
.	O	2445-2446

Additionally	O	2447-2459
,	O	2459-2460
this	O	2461-2465
may	O	2466-2469
have	O	2470-2474
been	O	2475-2479
the	O	2480-2483
first	O	2484-2489
report	O	2490-2496
on	O	2497-2499
AMI	O	2500-2503
-	O	2503-2504
induced	O	2504-2511
apoptotic	O	2512-2521
death	O	2522-2527
in	O	2528-2530
the	O	2531-2534
lung	O	2535-2539
tissue	O	2540-2546
.	O	2546-2547

Taken	O	2548-2553
together	O	2554-2562
,	O	2562-2563
these	O	2564-2569
events	O	2570-2576
undoubtedly	O	2577-2588
establish	O	2589-2598
GSPE	O	2599-2603
'	O	2603-2604
s	O	2604-2605
abundant	O	2606-2614
bioavailability	O	2615-2630
,	O	2630-2631
and	O	2632-2635
the	O	2636-2639
power	O	2640-2645
to	O	2646-2648
defend	O	2649-2655
multiple	O	2656-2664
target	O	2665-2671
organs	O	2672-2678
from	O	2679-2683
toxic	O	2684-2689
assaults	O	2690-2698
induced	O	2699-2706
by	O	2707-2709
structurally	O	2710-2722
diverse	O	2723-2730
and	O	2731-2734
functionally	O	2735-2747
different	O	2748-2757
entities	O	2758-2766
in	O	2767-2769
vivo	O	2770-2774
.	O	2774-2775

Palpebral	B	0-9
twitching	I	10-19
in	O	20-22
a	O	23-24
depressed	B	25-34
adolescent	O	35-45
on	O	46-48
citalopram	O	49-59
.	O	59-60

Current	O	61-68
estimates	O	69-78
suggest	O	79-86
that	O	87-91
between	O	92-99
0	O	100-101
.	O	101-102
4	O	102-103
%	O	103-104
and	O	105-108
8	O	109-110
.	O	110-111
3	O	111-112
%	O	112-113
of	O	114-116
children	O	117-125
and	O	126-129
adolescents	O	130-141
are	O	142-145
affected	O	146-154
by	O	155-157
major	B	158-163
depression	I	164-174
.	O	174-175

We	O	176-178
report	O	179-185
a	O	186-187
favorable	O	188-197
response	O	198-206
to	O	207-209
treatment	O	210-219
with	O	220-224
citalopram	O	225-235
by	O	236-238
a	O	239-240
15	O	241-243
-	O	243-244
year	O	244-248
-	O	243-244
old	O	249-252
boy	O	253-256
with	O	257-261
major	B	262-267
depression	I	268-278
who	O	279-282
exhibited	O	283-292
palpebral	B	293-302
twitching	I	303-312
during	O	313-319
his	O	320-323
first	O	324-329
2	O	330-331
weeks	O	332-337
of	O	338-340
treatment	O	341-350
.	O	350-351

This	O	352-356
may	O	357-360
have	O	361-365
been	O	366-370
a	O	371-372
side	O	373-377
effect	O	378-384
of	O	385-387
citalopram	O	388-398
as	O	399-401
it	O	402-404
remitted	O	405-413
with	O	414-418
redistribution	O	419-433
of	O	434-436
doses	O	437-442
.	O	442-443

Metamizol	O	0-9
potentiates	O	10-21
morphine	O	22-30
antinociception	O	31-46
but	O	47-50
not	O	51-54
constipation	B	55-67
after	O	68-73
chronic	O	74-81
treatment	O	82-91
.	O	91-92

This	O	93-97
work	O	98-102
evaluates	O	103-112
the	O	113-116
antinociceptive	O	117-132
and	O	133-136
constipating	B	137-149
effects	O	150-157
of	O	158-160
the	O	161-164
combination	O	165-176
of	O	177-179
3	O	180-181
.	O	181-182
2	O	182-183
mg	O	184-186
/	O	186-187
kg	O	187-189
s	O	190-191
.	O	191-192
c	O	192-193
.	O	191-192

morphine	O	195-203
with	O	204-208
177	O	209-212
.	O	212-213
8	O	213-214
mg	O	215-217
/	O	217-218
kg	O	218-220
s	O	221-222
.	O	222-223
c	O	223-224
.	O	222-223

metamizol	O	226-235
in	O	236-238
acutely	O	239-246
and	O	247-250
chronically	O	251-262
treated	O	263-270
(	O	271-272
once	O	272-276
a	O	277-278
day	O	279-282
for	O	283-286
12	O	287-289
days	O	290-294
)	O	294-295
rats	O	296-300
.	O	300-301

On	O	302-304
the	O	305-308
13th	O	309-313
day	O	314-317
,	O	317-318
antinociceptive	O	319-334
effects	O	335-342
were	O	343-347
assessed	O	348-356
using	O	357-362
a	O	363-364
model	O	365-370
of	O	371-373
inflammatory	O	374-386
nociception	O	387-398
,	O	398-399
pain	B	400-404
-	O	404-405
induced	O	405-412
functional	O	413-423
impairment	O	424-434
model	O	435-440
,	O	440-441
and	O	442-445
the	O	446-449
charcoal	O	450-458
meal	O	459-463
test	O	464-468
was	O	469-472
used	O	473-477
to	O	478-480
evaluate	O	481-489
the	O	490-493
intestinal	O	494-504
transit	O	505-512
.	O	512-513

Simultaneous	O	514-526
administration	O	527-541
of	O	542-544
morphine	O	545-553
with	O	554-558
metamizol	O	559-568
resulted	O	569-577
in	O	578-580
a	O	581-582
markedly	O	583-591
antinociceptive	O	592-607
potentiation	O	608-620
and	O	621-624
an	O	625-627
increasing	O	628-638
of	O	639-641
the	O	642-645
duration	O	646-654
of	O	655-657
action	O	658-664
after	O	665-670
a	O	671-672
single	O	673-679
(	O	680-681
298	O	681-684
+	O	684-685
/	O	685-686
-	O	686-687
7	O	687-688
vs	O	689-691
.	O	691-692
139	O	693-696
+	O	696-697
/	O	697-698
-	O	698-699
36	O	699-701
units	O	702-707
area	O	708-712
(	O	713-714
ua	O	714-716
)	O	716-717
;	O	717-718
P	O	719-720
<	O	720-721
0	O	721-722
.	O	722-723
001	O	723-726
)	O	726-727
and	O	728-731
repeated	O	732-740
administration	O	741-755
(	O	756-757
280	O	757-760
+	O	760-761
/	O	761-762
-	O	762-763
17	O	763-765
vs	O	766-768
.	O	768-769
131	O	770-773
+	O	773-774
/	O	774-775
-	O	775-776
22	O	776-778
ua	O	779-781
;	O	781-782
P	O	783-784
<	O	784-785
0	O	785-786
.	O	786-787
001	O	787-790
)	O	790-791
.	O	786-787

Antinociceptive	O	793-808
effect	O	809-815
of	O	816-818
morphine	O	819-827
was	O	828-831
reduced	O	832-839
in	O	840-842
chronically	O	843-854
treated	O	855-862
rats	O	863-867
(	O	868-869
39	O	869-871
+	O	871-872
/	O	872-873
-	O	873-874
10	O	874-876
vs	O	877-879
.	O	879-880
18	O	881-883
+	O	883-884
/	O	884-885
-	O	885-886
5	O	886-887
au	O	888-890
)	O	890-891
while	O	892-897
the	O	898-901
combination	O	902-913
-	O	913-914
induced	O	914-921
antinociception	O	922-937
was	O	938-941
remained	O	942-950
similar	O	951-958
as	O	959-961
an	O	962-964
acute	O	965-970
treatment	O	971-980
(	O	981-982
298	O	982-985
+	O	985-986
/	O	986-987
-	O	987-988
7	O	988-989
vs	O	990-992
.	O	992-993
280	O	994-997
+	O	997-998
/	O	998-999
-	O	999-1000
17	O	1000-1002
au	O	1003-1005
)	O	1005-1006
.	O	1006-1007

Acute	O	1008-1013
antinociceptive	O	1014-1029
effects	O	1030-1037
of	O	1038-1040
the	O	1041-1044
combination	O	1045-1056
were	O	1057-1061
partially	O	1062-1071
prevented	O	1072-1081
by	O	1082-1084
3	O	1085-1086
.	O	1086-1087
2	O	1087-1088
mg	O	1089-1091
/	O	1091-1092
kg	O	1092-1094
naloxone	O	1095-1103
s	O	1104-1105
.	O	1105-1106
c	O	1106-1107
.	O	1105-1106

(	O	1109-1110
P	O	1110-1111
<	O	1111-1112
0	O	1112-1113
.	O	1113-1114
05	O	1114-1116
)	O	1116-1117
,	O	1117-1118

suggesting	O	1119-1129
the	O	1130-1133
partial	O	1134-1141
involvement	O	1142-1153
of	O	1154-1156
the	O	1157-1160
opioidergic	O	1161-1172
system	O	1173-1179
in	O	1180-1182
the	O	1183-1186
synergism	O	1187-1196
observed	O	1197-1205
.	O	1205-1206

In	O	1207-1209
independent	O	1210-1221
groups	O	1222-1228
,	O	1228-1229
morphine	O	1230-1238
inhibited	O	1239-1248
the	O	1249-1252
intestinal	O	1253-1263
transit	O	1264-1271
in	O	1272-1274
48	O	1275-1277
+	O	1277-1278
/	O	1278-1279
-	O	1279-1280
4	O	1275-1276
%	O	1281-1282
and	O	1283-1286
38	O	1287-1289
+	O	1289-1290
/	O	1290-1291
-	O	1291-1292
4	O	1292-1293
%	O	1293-1294
after	O	1295-1300
acute	O	1301-1306
and	O	1307-1310
chronic	O	1311-1318
treatment	O	1319-1328
,	O	1328-1329
respectively	O	1330-1342
,	O	1342-1343
suggesting	O	1344-1354
that	O	1355-1359
tolerance	O	1360-1369
did	O	1370-1373
not	O	1374-1377
develop	O	1378-1385
to	O	1386-1388
the	O	1389-1392
constipating	B	1393-1405
effects	O	1406-1413
.	O	1413-1414

The	O	1415-1418
combination	O	1419-1430
inhibited	O	1431-1440
intestinal	O	1441-1451
transit	O	1452-1459
similar	O	1460-1467
to	O	1468-1470
that	O	1471-1475
produced	O	1476-1484
by	O	1485-1487
morphine	O	1488-1496
regardless	O	1497-1507
of	O	1508-1510
the	O	1511-1514
time	O	1515-1519
of	O	1520-1522
treatment	O	1523-1532
,	O	1532-1533
suggesting	O	1534-1544
that	O	1545-1549
metamizol	O	1550-1559
did	O	1560-1563
not	O	1564-1567
potentiate	O	1568-1578
morphine	O	1579-1587
-	O	1587-1588
induced	O	1588-1595
constipation	B	1596-1608
.	O	1608-1609

These	O	1610-1615
findings	O	1616-1624
show	O	1625-1629
a	O	1630-1631
significant	O	1632-1643
interaction	O	1644-1655
between	O	1656-1663
morphine	O	1664-1672
and	O	1673-1676
metamizol	O	1677-1686
in	O	1687-1689
chronically	O	1690-1701
treated	O	1702-1709
rats	O	1710-1714
,	O	1714-1715
suggesting	O	1716-1726
that	O	1727-1731
this	O	1732-1736
combination	O	1737-1748
could	O	1749-1754
be	O	1755-1757
useful	O	1758-1764
for	O	1765-1768
the	O	1769-1772
treatment	O	1773-1782
of	O	1783-1785
chronic	B	1786-1793
pain	I	1794-1798
.	O	1798-1799

Ifosfamide	O	0-10
encephalopathy	B	11-25
presenting	O	26-36
with	O	37-41
asterixis	B	42-51
.	O	51-52

CNS	O	53-56
toxic	O	57-62
effects	O	63-70
of	O	71-73
the	O	74-77
antineoplastic	O	78-92
agent	O	93-98
ifosfamide	O	99-109
(	O	110-111
IFX	O	111-114
)	O	114-115
are	O	116-119
frequent	O	120-128
and	O	129-132
include	O	133-140
a	O	141-142
variety	O	143-150
of	O	151-153
neurological	O	154-166
symptoms	O	167-175
that	O	176-180
can	O	181-184
limit	O	185-190
drug	O	191-195
use	O	196-199
.	O	199-200

We	O	201-203
report	O	204-210
a	O	211-212
case	O	213-217
of	O	218-220
a	O	221-222
51	O	223-225
-	O	225-226
year	O	226-230
-	O	225-226
old	O	231-234
man	O	235-238
who	O	239-242
developed	O	243-252
severe	O	253-259
,	O	259-260
disabling	O	261-270
negative	O	271-279
myoclonus	B	280-289
of	O	290-292
the	O	293-296
upper	O	297-302
and	O	303-306
lower	O	307-312
extremities	O	313-324
after	O	325-330
the	O	331-334
infusion	O	335-343
of	O	344-346
ifosfamide	O	347-357
for	O	358-361
plasmacytoma	B	362-374
.	O	374-375

He	O	376-378
was	O	379-382
awake	O	383-388
,	O	388-389
revealed	O	390-398
no	O	399-401
changes	O	402-409
of	O	410-412
mental	O	413-419
status	O	420-426
and	O	427-430
at	O	431-433
rest	O	434-438
there	O	439-444
were	O	445-449
no	O	450-452
further	O	453-460
motor	O	461-466
symptoms	O	467-475
.	O	475-476

Cranial	O	477-484
magnetic	O	485-493
resonance	O	494-503
imaging	O	504-511
and	O	512-515
extensive	O	516-525
laboratory	O	526-536
studies	O	537-544
failed	O	545-551
to	O	552-554
reveal	O	555-561
structural	B	562-572
lesions	I	573-580
of	I	581-583
the	I	584-587
brain	I	588-593
and	O	594-597
metabolic	B	598-607
abnormalities	I	608-621
.	O	621-622

An	O	623-625
electroencephalogram	O	626-646
showed	O	647-653
continuous	O	654-664
,	O	664-665
generalized	O	666-677
irregular	O	678-687
slowing	O	688-695
with	O	696-700
admixed	O	701-708
periodic	O	709-717
triphasic	O	718-727
waves	O	728-733
indicating	O	734-744
symptomatic	O	745-756
encephalopathy	B	757-771
.	O	771-772

The	O	773-776
administration	O	777-791
of	O	792-794
ifosfamide	O	795-805
was	O	806-809
discontinued	O	810-822
and	O	823-826
within	O	827-833
12	O	834-836
h	O	837-838
the	O	839-842
asterixis	B	843-852
resolved	O	853-861
completely	O	862-872
.	O	872-873

In	O	874-876
the	O	877-880
patient	O	881-888
described	O	889-898
,	O	898-899
the	O	900-903
presence	O	904-912
of	O	913-915
asterixis	B	916-925
during	O	926-932
infusion	O	933-941
of	O	942-944
ifosfamide	O	945-955
,	O	955-956
normal	O	957-963
laboratory	O	964-974
findings	O	975-983
and	O	984-987
imaging	O	988-995
studies	O	996-1003
and	O	1004-1007
the	O	1008-1011
resolution	O	1012-1022
of	O	1023-1025
symptoms	O	1026-1034
following	O	1035-1044
the	O	1045-1048
discontinuation	O	1049-1064
of	O	1065-1067
the	O	1068-1071
drug	O	1072-1076
suggest	O	1077-1084
that	O	1085-1089
negative	O	1090-1098
myoclonus	B	1099-1108
is	O	1109-1111
associated	O	1112-1122
with	O	1123-1127
the	O	1128-1131
use	O	1132-1135
of	O	1136-1138
IFX	O	1139-1142
.	O	1142-1143

Sub	O	0-3
-	O	3-4
chronic	O	4-11
low	O	12-15
dose	O	16-20
gamma	O	21-26
-	O	26-27
vinyl	O	27-32
GABA	O	33-37
(	O	38-39
vigabatrin	O	39-49
)	O	49-50
inhibits	O	51-59
cocaine	O	60-67
-	O	67-68
induced	O	68-75
increases	O	76-85
in	O	86-88
nucleus	O	89-96
accumbens	O	97-106
dopamine	O	107-115
.	O	115-116

RATIONALE	O	117-126
:	O	126-127
gamma	O	128-133
-	O	133-134
Vinyl	O	134-139
GABA	O	140-144
(	O	145-146
GVG	O	146-149
)	O	149-150
irreversibly	O	151-163
inhibits	O	164-172
GABA	O	173-177
-	O	177-178
transaminase	O	178-190
.	O	190-191

This	O	192-196
non	O	197-200
-	O	200-201
receptor	O	201-209
mediated	O	210-218
inhibition	O	219-229
requires	O	230-238
de	O	239-241
novo	O	242-246
synthesis	O	247-256
for	O	257-260
restoration	O	261-272
of	O	273-275
functional	O	276-286
GABA	O	287-291
catabolism	O	292-302
.	O	302-303

OBJECTIVES	O	304-314
:	O	314-315
Given	O	316-321
its	O	322-325
preclinical	O	326-337
success	O	338-345
for	O	346-349
treating	O	350-358
substance	B	359-368
abuse	I	369-374
and	O	375-378
the	O	379-382
increased	O	383-392
risk	O	393-397
of	O	398-400
visual	B	401-407
field	I	408-413
defects	I	414-421
(	O	422-423
VFD	B	423-426
)	O	426-427
associated	O	428-438
with	O	439-443
cumulative	O	444-454
lifetime	O	455-463
exposure	O	464-472
,	O	472-473
we	O	474-476
explored	O	477-485
the	O	486-489
effects	O	490-497
of	O	498-500
sub	O	501-504
-	O	504-505
chronic	O	505-512
low	O	513-516
dose	O	517-521
GVG	O	522-525
on	O	526-528
cocaine	O	529-536
-	O	536-537
induced	O	537-544
increases	O	545-554
in	O	555-557
nucleus	O	558-565
accumbens	O	566-575
(	O	576-577
NAcc	O	577-581
)	O	581-582
dopamine	O	583-591
(	O	592-593
DA	O	593-595
)	O	595-596
.	O	596-597

METHODS	O	598-605
:	O	605-606
Using	O	607-612
in	O	613-615
vivo	O	616-620
microdialysis	O	621-634
,	O	634-635
we	O	636-638
compared	O	639-647
acute	O	648-653
exposure	O	654-662
(	O	663-664
450	O	664-667
mg	O	668-670
/	O	670-671
kg	O	671-673
)	O	673-674
to	O	675-677
an	O	678-680
identical	O	681-690
sub	O	691-694
-	O	694-695
chronic	O	695-702
exposure	O	703-711
(	O	712-713
150	O	713-716
mg	O	717-719
/	O	719-720
kg	O	720-722
per	O	723-726
day	O	727-730
for	O	731-734
3	O	735-736
days	O	737-741
)	O	741-742
,	O	742-743
followed	O	744-752
by	O	753-755
1	O	756-757
-	O	757-758
or	O	759-761
3	O	762-763
-	O	763-764
day	O	764-767
washout	O	768-775
.	O	775-776

Finally	O	777-784
,	O	784-785
we	O	786-788
examined	O	789-797
the	O	798-801
low	O	802-805
dose	O	806-810
of	O	811-813
150	O	814-817
mg	O	818-820
/	O	820-821
kg	O	821-823
(	O	824-825
50	O	825-827
mg	O	828-830
/	O	830-831
kg	O	831-833
per	O	834-837
day	O	838-841
)	O	841-842
using	O	843-848
a	O	849-850
similar	O	851-858
washout	O	859-866
period	O	867-873
.	O	873-874

RESULTS	O	875-882
:	O	882-883
Sub	O	884-887
-	O	887-888
chronic	O	888-895
GVG	O	896-899
exposure	O	900-908
inhibited	O	909-918
the	O	919-922
effect	O	923-929
of	O	930-932
cocaine	O	933-940
for	O	941-944
3	O	945-946
days	O	947-951
,	O	951-952
which	O	953-958
exceeded	O	959-967
in	O	968-970
magnitude	O	971-980
and	O	981-984
duration	O	985-993
the	O	994-997
identical	O	998-1007
acute	O	1008-1013
dose	O	1014-1018
.	O	1018-1019

CONCLUSIONS	O	1020-1031
:	O	1031-1032
Sub	O	1033-1036
-	O	1036-1037
chronic	O	1037-1044
low	O	1045-1048
dose	O	1049-1053
GVG	O	1054-1057
potentiates	O	1058-1069
and	O	1070-1073
extends	O	1074-1081
the	O	1082-1085
inhibition	O	1086-1096
of	O	1097-1099
cocaine	O	1100-1107
-	O	1107-1108
induced	O	1108-1115
increases	O	1116-1125
in	O	1126-1128
dopamine	O	1129-1137
,	O	1137-1138
effectively	O	1139-1150
reducing	O	1151-1159
cumulative	O	1160-1170
exposures	O	1171-1180
and	O	1181-1184
the	O	1185-1188
risk	O	1189-1193
for	O	1194-1197
VFDS	O	1198-1202
.	O	1202-1203

Amount	O	0-6
of	O	7-9
bleeding	B	10-18
and	O	19-22
hematoma	B	23-31
size	O	32-36
in	O	37-39
the	O	40-43
collagenase	O	44-55
-	O	55-56
induced	O	56-63
intracerebral	B	64-77
hemorrhage	I	78-88
rat	O	89-92
model	O	93-98
.	O	98-99

The	O	100-103
aggravated	O	104-114
risk	O	115-119
on	O	120-122
intracerebral	B	123-136
hemorrhage	I	137-147
(	O	148-149
ICH	B	149-152
)	O	152-153
with	O	154-158
drugs	O	159-164
used	O	165-169
for	O	170-173
stroke	B	174-180
patients	O	181-189
should	O	190-196
be	O	197-199
estimated	O	200-209
carefully	O	210-219
.	O	219-220

We	O	221-223
therefore	O	224-233
established	O	234-245
sensitive	O	246-255
quantification	O	256-270
methods	O	271-278
and	O	279-282
provided	O	283-291
a	O	292-293
rat	O	294-297
ICH	B	298-301
model	O	302-307
for	O	308-311
detection	O	312-321
of	O	322-324
ICH	B	325-328
deterioration	O	329-342
.	O	342-343

In	O	344-346
ICH	B	347-350
intrastriatally	O	351-366
induced	O	367-374
by	O	375-377
0	O	378-379
.	O	379-380
014	O	380-383
-	O	383-384
unit	O	384-388
,	O	388-389
0	O	390-391
.	O	391-392
070	O	392-395
-	O	395-396
unit	O	396-400
,	O	400-401
and	O	402-405
0	O	406-407
.	O	407-408
350	O	408-411
-	O	411-412
unit	O	412-416
collagenase	O	417-428
,	O	428-429
the	O	430-433
amount	O	434-440
of	O	441-443
bleeding	B	444-452
was	O	453-456
measured	O	457-465
using	O	466-471
a	O	472-473
hemoglobin	O	474-484
assay	O	485-490
developed	O	491-500
in	O	501-503
the	O	504-507
present	O	508-515
study	O	516-521
and	O	522-525
was	O	526-529
compared	O	530-538
with	O	539-543
the	O	544-547
morphologically	O	548-563
determined	O	564-574
hematoma	B	575-583
volume	O	584-590
.	O	590-591

The	O	592-595
blood	O	596-601
amounts	O	602-609
and	O	610-613
hematoma	B	614-622
volumes	O	623-630
were	O	631-635
significantly	O	636-649
correlated	O	650-660
,	O	660-661
and	O	662-665
the	O	666-669
hematoma	B	670-678
induced	O	679-686
by	O	687-689
0	O	690-691
.	O	691-692
014	O	692-695
-	O	695-696
unit	O	696-700
collagenase	O	701-712
was	O	713-716
adequate	O	717-725
to	O	726-728
detect	O	729-735
ICH	B	736-739
deterioration	O	740-753
.	O	753-754

In	O	755-757
ICH	B	758-761
induction	O	762-771
using	O	772-777
0	O	778-779
.	O	779-780
014	O	780-783
-	O	783-784
unit	O	784-788
collagenase	O	789-800
,	O	800-801
heparin	O	802-809
enhanced	O	810-818
the	O	819-822
hematoma	B	823-831
volume	O	832-838
3	O	839-840
.	O	840-841
4	O	841-842
-	O	842-843
fold	O	843-847
over	O	848-852
that	O	853-857
seen	O	858-862
in	O	863-865
control	O	866-873
ICH	B	874-877
animals	O	878-885
and	O	886-889
the	O	890-893
bleeding	B	894-902
7	O	903-904
.	O	904-905
6	O	905-906
-	O	906-907
fold	O	907-911
.	O	904-905

Data	O	913-917
suggest	O	918-925
that	O	926-930
this	O	931-935
sensitive	O	936-945
hemoglobin	O	946-956
assay	O	957-962
is	O	963-965
useful	O	966-972
for	O	973-976
ICH	B	977-980
detection	O	981-990
,	O	990-991
and	O	992-995
that	O	996-1000
a	O	1001-1002
model	O	1003-1008
with	O	1009-1013
a	O	1014-1015
small	O	1016-1021
ICH	B	1022-1025
induced	O	1026-1033
with	O	1034-1038
a	O	1039-1040
low	O	1041-1044
-	O	1044-1045
dose	O	1045-1049
collagenase	O	1050-1061
should	O	1062-1068
be	O	1069-1071
used	O	1072-1076
for	O	1077-1080
evaluation	O	1081-1091
of	O	1092-1094
drugs	O	1095-1100
that	O	1101-1105
may	O	1106-1109
affect	O	1110-1116
ICH	B	1117-1120
.	O	1120-1121

Estradiol	O	0-9
reduces	O	10-17
seizure	B	18-25
-	O	25-26
induced	O	26-33
hippocampal	B	34-45
injury	I	46-52
in	O	53-55
ovariectomized	O	56-70
female	O	71-77
but	O	78-81
not	O	82-85
in	O	86-88
male	O	89-93
rats	O	94-98
.	O	98-99

Estrogens	O	100-109
protect	O	110-117
ovariectomized	O	118-132
rats	O	133-137
from	O	138-142
hippocampal	B	143-154
injury	I	155-161
induced	O	162-169
by	O	170-172
kainic	O	173-179
acid	O	180-184
-	O	184-185
induced	O	185-192
status	B	193-199
epilepticus	I	200-211
(	O	212-213
SE	B	213-215
)	O	215-216
.	O	216-217

We	O	218-220
compared	O	221-229
the	O	230-233
effects	O	234-241
of	O	242-244
17beta	O	245-251
-	O	251-252
estradiol	O	252-261
in	O	262-264
adult	O	265-270
male	O	271-275
and	O	276-279
ovariectomized	O	280-294
female	O	295-301
rats	O	302-306
subjected	O	307-316
to	O	317-319
lithium	O	320-327
-	O	327-328
pilocarpine	O	328-339
-	O	327-328
induced	O	340-347
SE	B	348-350
.	O	350-351

Rats	O	352-356
received	O	357-365
subcutaneous	O	366-378
injections	O	379-389
of	O	390-392
17beta	O	393-399
-	O	399-400
estradiol	O	400-409
(	O	410-411
2	O	411-412
microg	O	413-419
/	O	419-420
rat	O	420-423
)	O	423-424
or	O	425-427
oil	O	428-431
once	O	432-436
daily	O	437-442
for	O	443-446
four	O	447-451
consecutive	O	452-463
days	O	464-468
.	O	468-469

SE	B	470-472
was	O	473-476
induced	O	477-484
20	O	485-487
h	O	488-489
following	O	490-499
the	O	500-503
second	O	504-510
injection	O	511-520
and	O	521-524
terminated	O	525-535
3	O	536-537
h	O	538-539
later	O	540-545
.	O	545-546

The	O	547-550
extent	O	551-557
of	O	558-560
silver	O	561-567
-	O	567-568
stained	O	568-575
CA3	O	576-579
and	O	580-583
CA1	O	584-587
hippocampal	O	588-599
neurons	O	600-607
was	O	608-611
evaluated	O	612-621
2	O	622-623
days	O	624-628
after	O	629-634
SE	B	635-637
.	O	637-638
17beta	O	639-645
-	O	645-646
Estradiol	O	646-655
did	O	656-659
not	O	660-663
alter	O	664-669
the	O	670-673
onset	O	674-679
of	O	680-682
first	O	683-688
clonus	O	689-695
in	O	696-698
ovariectomized	O	699-713
rats	O	714-718
but	O	719-722
accelerated	O	723-734
it	O	735-737
in	O	738-740
males	O	741-746
.	O	746-747

17beta	O	748-754
-	O	754-755
Estradiol	O	755-764
reduced	O	765-772
the	O	773-776
argyrophilic	O	777-789
neurons	O	790-797
in	O	798-800
the	O	801-804
CA1	O	805-808
and	O	809-812
CA3	O	813-816
-	O	816-817
C	O	813-814
sectors	O	819-826
of	O	827-829
ovariectomized	O	830-844
rats	O	845-849
.	O	849-850

In	O	851-853
males	O	854-859
,	O	859-860
estradiol	O	861-870
increased	O	871-880
the	O	881-884
total	O	885-890
damage	O	891-897
score	O	898-903
.	O	903-904

These	O	905-910
findings	O	911-919
suggest	O	920-927
that	O	928-932
the	O	933-936
effects	O	937-944
of	O	945-947
estradiol	O	948-957
on	O	958-960
seizure	B	961-968
threshold	O	969-978
and	O	979-982
damage	O	983-989
may	O	990-993
be	O	994-996
altered	O	997-1004
by	O	1005-1007
sex	O	1008-1011
-	O	1011-1012
related	O	1012-1019
differences	O	1020-1031
in	O	1032-1034
the	O	1035-1038
hormonal	O	1039-1047
environment	O	1048-1059
.	O	1059-1060

Delirium	B	0-8
during	O	9-15
clozapine	O	16-25
treatment	O	26-35
:	O	35-36
incidence	O	37-46
and	O	47-50
associated	O	51-61
risk	O	62-66
factors	O	67-74
.	O	74-75

BACKGROUND	O	76-86
:	O	86-87
Incidence	O	88-97
and	O	98-101
risk	O	102-106
factors	O	107-114
for	O	115-118
delirium	B	119-127
during	O	128-134
clozapine	O	135-144
treatment	O	145-154
require	O	155-162
further	O	163-170
clarification	O	171-184
.	O	184-185

METHODS	O	186-193
:	O	193-194
We	O	195-197
used	O	198-202
computerized	O	203-215
pharmacy	O	216-224
records	O	225-232
to	O	233-235
identify	O	236-244
all	O	245-248
adult	O	249-254
psychiatric	B	255-266
inpatients	O	267-277
treated	O	278-285
with	O	286-290
clozapine	O	291-300
(	O	301-302
1995	O	302-306
-	O	306-307
96	O	307-309
)	O	309-310
,	O	310-311
reviewed	O	312-320
their	O	321-326
medical	O	327-334
records	O	335-342
to	O	343-345
score	O	346-351
incidence	O	352-361
and	O	362-365
severity	O	366-374
of	O	375-377
delirium	B	378-386
,	O	386-387
and	O	388-391
tested	O	392-398
associations	O	399-411
with	O	412-416
potential	O	417-426
risk	O	427-431
factors	O	432-439
.	O	439-440

RESULTS	O	441-448
:	O	448-449
Subjects	O	450-458
(	O	459-460
n	O	460-461
=	O	462-463
139	O	464-467
)	O	467-468
were	O	469-473
72	O	474-476
women	O	477-482
and	O	483-486
67	O	487-489
men	O	490-493
,	O	493-494
aged	O	495-499
40	O	500-502
.	O	502-503
8	O	503-504
+	O	505-506
/	O	506-507
-	O	507-508
12	O	509-511
.	O	511-512
1	O	509-510
years	O	514-519
,	O	519-520
hospitalized	O	521-533
for	O	534-537
24	O	538-540
.	O	540-541
9	O	541-542
+	O	543-544
/	O	544-545
-	O	545-546
23	O	547-549
.	O	549-550
3	O	548-549
days	O	552-556
,	O	556-557
and	O	558-561
given	O	562-567
clozapine	O	568-577
,	O	577-578
gradually	O	579-588
increased	O	589-598
to	O	599-601
an	O	602-604
average	O	605-612
daily	O	613-618
dose	O	619-623
of	O	624-626
282	O	627-630
+	O	631-632
/	O	632-633
-	O	633-634
203	O	635-638
mg	O	639-641
(	O	642-643
3	O	643-644
.	O	644-645
45	O	645-647
+	O	648-649
/	O	649-650
-	O	650-651
2	O	652-653
.	O	653-654
45	O	654-656
mg	O	657-659
/	O	659-660
kg	O	660-662
)	O	662-663
for	O	664-667
18	O	668-670
.	O	670-671
9	O	671-672
+	O	673-674
/	O	674-675
-	O	675-676
16	O	677-679
.	O	679-680
4	O	680-681
days	O	682-686
.	O	686-687

Delirium	B	688-696
was	O	697-700
diagnosed	O	701-710
in	O	711-713
14	O	714-716
(	O	717-718
10	O	718-720
.	O	720-721
1	O	718-719
%	O	723-724
incidence	O	725-734
,	O	734-735
or	O	736-738
1	O	739-740
.	O	740-741
48	O	741-743
cases	O	744-749
/	O	749-750
person	O	750-756
-	O	756-757
years	O	757-762
of	O	763-765
exposure	O	766-774
)	O	774-775
;	O	775-776
71	O	777-779
.	O	779-780
4	O	780-781
%	O	782-783
of	O	784-786
cases	O	787-792
were	O	793-797
moderate	O	798-806
or	O	807-809
severe	O	810-816
.	O	816-817

Associated	O	818-828
factors	O	829-836
were	O	837-841
co	O	842-844
-	O	844-845
treatment	O	845-854
with	O	855-859
other	O	860-865
centrally	O	866-875
antimuscarinic	O	876-890
agents	O	891-897
,	O	897-898
poor	O	899-903
clinical	O	904-912
outcome	O	913-920
,	O	920-921
older	O	922-927
age	O	928-931
,	O	931-932
and	O	933-936
longer	O	937-943
hospitalization	O	944-959
(	O	960-961
by	O	961-963
17	O	964-966
.	O	966-967
5	O	967-968
days	O	969-973
,	O	973-974
increasing	O	975-985
cost	O	986-990
)	O	990-991
;	O	991-992
sex	O	993-996
,	O	996-997
diagnosis	O	998-1007
or	O	1008-1010
medical	O	1011-1018
co	O	1019-1021
-	O	1021-1022
morbidity	O	1022-1031
,	O	1031-1032
and	O	1033-1036
daily	O	1037-1042
clozapine	O	1043-1052
dose	O	1053-1057
,	O	1057-1058
which	O	1059-1064
fell	O	1065-1069
with	O	1070-1074
age	O	1075-1078
,	O	1078-1079
were	O	1080-1084
unrelated	O	1085-1094
.	O	1094-1095

CONCLUSIONS	O	1096-1107
:	O	1107-1108
Delirium	B	1109-1117
was	O	1118-1121
found	O	1122-1127
in	O	1128-1130
10	O	1131-1133
%	O	1134-1135
of	O	1136-1138
clozapine	O	1139-1148
-	O	1148-1149
treated	O	1149-1156
inpatients	O	1157-1167
,	O	1167-1168
particularly	O	1169-1181
in	O	1182-1184
older	O	1185-1190
patients	O	1191-1199
exposed	O	1200-1207
to	O	1208-1210
other	O	1211-1216
central	O	1217-1224
anticholinergics	O	1225-1241
.	O	1241-1242

Delirium	B	1243-1251
was	O	1252-1255
inconsistently	O	1256-1270
recognized	O	1271-1281
clinically	O	1282-1292
in	O	1293-1295
milder	O	1296-1302
cases	O	1303-1308
and	O	1309-1312
was	O	1313-1316
associated	O	1317-1327
with	O	1328-1332
increased	O	1333-1342
length	O	1343-1349
-	O	1349-1350
of	O	1350-1352
-	O	1349-1350
stay	O	1353-1357
and	O	1358-1361
higher	O	1362-1368
costs	O	1369-1374
,	O	1374-1375
and	O	1376-1379
inferior	O	1380-1388
clinical	O	1389-1397
outcome	O	1398-1405
.	O	1405-1406

Ketoconazole	O	0-12
-	O	12-13
induced	O	13-20
neurologic	B	21-31
sequelae	I	32-40
.	O	40-41

A	O	42-43
77	O	44-46
-	O	46-47
y	O	47-48
-	O	46-47
old	O	49-52
patient	O	53-60
developed	O	61-70
weakness	B	71-79
of	I	80-82
extremities	I	83-94
,	O	94-95
legs	B	96-100
paralysis	I	101-110
,	O	110-111
dysarthria	B	112-122
and	O	123-126
tremor	B	127-133
1	O	134-135
h	O	136-137
after	O	138-143
ingestion	O	144-153
of	O	154-156
200	O	157-160
mg	O	161-163
ketoconazole	O	164-176
for	O	177-180
the	O	181-184
first	O	185-190
time	O	191-195
in	O	196-198
his	O	199-202
life	O	203-207
.	O	207-208

All	O	209-212
complaints	O	213-223
faded	O	224-229
away	O	230-234
within	O	235-241
24	O	242-244
h	O	245-246
.	O	246-247

Few	O	248-251
days	O	252-256
later	O	257-262
,	O	262-263
the	O	264-267
patient	O	268-275
used	O	276-280
another	O	281-288
200	O	289-292
mg	O	293-295
ketoconazole	O	296-308
tablet	O	309-315
,	O	315-316
and	O	317-320
within	O	321-327
an	O	328-330
hour	O	331-335
experienced	O	336-347
a	O	348-349
similar	O	350-357
clinical	O	358-366
picture	O	367-374
,	O	374-375
which	O	376-381
resolved	O	382-390
again	O	391-396
spontaneously	O	397-410
within	O	411-417
hours	O	418-423
.	O	423-424

Laboratory	O	425-435
evaluations	O	436-447
,	O	447-448
including	O	449-458
head	O	459-463
CT	O	464-466
scan	O	467-471
,	O	471-472
were	O	473-477
normal	O	478-484
.	O	484-485

This	O	486-490
case	O	491-495
illustrates	O	496-507
the	O	508-511
need	O	512-516
for	O	517-520
close	O	521-526
vigilance	O	527-536
in	O	537-539
adverse	B	540-547
drug	I	548-552
reactions	I	553-562
,	O	562-563
particularly	O	564-576
in	O	577-579
the	O	580-583
elderly	O	584-591
.	O	591-592

Noxious	O	0-7
chemical	O	8-16
stimulation	O	17-28
of	O	29-31
rat	O	32-35
facial	O	36-42
mucosa	O	43-49
increases	O	50-59
intracranial	O	60-72
blood	O	73-78
flow	O	79-83
through	O	84-91
a	O	92-93
trigemino	O	94-103
-	O	103-104
parasympathetic	O	104-119
reflex	O	120-126
-	O	126-127
-	O	126-127
an	O	128-130
experimental	O	131-143
model	O	144-149
for	O	150-153
vascular	B	154-162
dysfunctions	I	163-175
in	O	176-178
cluster	B	179-186
headache	I	187-195
.	O	195-196

Cluster	B	197-204
headache	I	205-213
is	O	214-216
characterized	O	217-230
by	O	231-233
typical	O	234-241
autonomic	O	242-251
dysfunctions	O	252-264
including	O	265-274
facial	O	275-281
and	O	282-285
intracranial	B	286-298
vascular	I	299-307
disturbances	I	308-320
.	O	320-321

Both	O	322-326
the	O	327-330
trigeminal	O	331-341
and	O	342-345
the	O	346-349
cranial	O	350-357
parasympathetic	O	358-373
systems	O	374-381
may	O	382-385
be	O	386-388
involved	O	389-397
in	O	398-400
mediating	O	401-410
these	O	411-416
dysfunctions	O	417-429
.	O	429-430

An	O	431-433
experimental	O	434-446
model	O	447-452
was	O	453-456
developed	O	457-466
in	O	467-469
the	O	470-473
rat	O	474-477
to	O	478-480
measure	O	481-488
changes	O	489-496
in	O	497-499
lacrimation	O	500-511
and	O	512-515
intracranial	O	516-528
blood	O	529-534
flow	O	535-539
following	O	540-549
noxious	O	550-557
chemical	O	558-566
stimulation	O	567-578
of	O	579-581
facial	O	582-588
mucosa	O	589-595
.	O	595-596

Blood	O	597-602
flow	O	603-607
was	O	608-611
monitored	O	612-621
in	O	622-624
arteries	O	625-633
of	O	634-636
the	O	637-640
exposed	O	641-648
cranial	O	649-656
dura	O	657-661
mater	O	662-667
and	O	668-671
the	O	672-675
parietal	O	676-684
cortex	O	685-691
using	O	692-697
laser	O	698-703
Doppler	O	704-711
flowmetry	O	712-721
.	O	721-722

Capsaicin	O	723-732
(	O	733-734
0	O	734-735
.	O	735-736
01	O	736-738
-	O	738-739
1	O	737-738
mm	O	741-743
)	O	743-744
applied	O	745-752
to	O	753-755
oral	O	756-760
or	O	761-763
nasal	O	764-769
mucosa	O	770-776
induced	O	777-784
increases	B	785-794
in	I	795-797
dural	I	798-803
and	I	804-807
cortical	I	808-816
blood	I	817-822
flow	I	823-827
and	O	828-831
provoked	O	832-840
lacrimation	O	841-852
.	O	852-853

These	O	854-859
responses	O	860-869
were	O	870-874
blocked	O	875-882
by	O	883-885
systemic	O	886-894
pre	O	895-898
-	O	898-899
administration	O	899-913
of	O	914-916
hexamethonium	O	917-930
chloride	O	931-939
(	O	940-941
20	O	941-943
mg	O	944-946
/	O	946-947
kg	O	947-949
)	O	949-950
.	O	950-951

The	O	952-955
evoked	O	956-962
increases	B	963-972
in	I	973-975
dural	I	976-981
blood	I	982-987
flow	I	988-992
were	O	993-997
also	O	998-1002
abolished	O	1003-1012
by	O	1013-1015
topical	O	1016-1023
pre	O	1024-1027
-	O	1027-1028
administration	O	1028-1042
of	O	1043-1045
atropine	O	1046-1054
(	O	1055-1056
1	O	1056-1057
mm	O	1058-1060
)	O	1060-1061
and	O	1062-1065
[	O	1066-1067
Lys1	O	1067-1071
,	O	1071-1072
Pro2	O	1073-1077
,	O	1077-1078
5	O	1078-1079
,	O	1077-1078
Arg3	O	1081-1085
,	O	1085-1086
4	O	1086-1087
,	O	1085-1086
Tyr6	O	1089-1093
]	O	1093-1094
-	O	1094-1095
VIP	O	1095-1098
(	O	1099-1100
0	O	1100-1101
.	O	1101-1102
1	O	1102-1103
mm	O	1104-1106
)	O	1106-1107
,	O	1107-1108
a	O	1109-1110
vasoactive	O	1111-1121
intestinal	O	1122-1132
polypeptide	O	1133-1144
(	O	1145-1146
VIP	O	1146-1149
)	O	1149-1150
antagonist	O	1151-1161
,	O	1161-1162
onto	O	1163-1167
the	O	1168-1171
exposed	O	1172-1179
dura	O	1180-1184
mater	O	1185-1190
.	O	1190-1191

We	O	1192-1194
conclude	O	1195-1203
that	O	1204-1208
noxious	O	1209-1216
stimulation	O	1217-1228
of	O	1229-1231
facial	O	1232-1238
mucosa	O	1239-1245
increases	O	1246-1255
intracranial	O	1256-1268
blood	O	1269-1274
flow	O	1275-1279
and	O	1280-1283
lacrimation	O	1284-1295
via	O	1296-1299
a	O	1300-1301
trigemino	O	1302-1311
-	O	1311-1312
parasympathetic	O	1312-1327
reflex	O	1328-1334
.	O	1334-1335

The	O	1336-1339
blood	O	1340-1345
flow	O	1346-1350
responses	O	1351-1360
seem	O	1361-1365
to	O	1366-1368
be	O	1369-1371
mediated	O	1372-1380
by	O	1381-1383
the	O	1384-1387
release	O	1388-1395
of	O	1396-1398
acetylcholine	O	1399-1412
and	O	1413-1416
VIP	O	1417-1420
within	O	1421-1427
the	O	1428-1431
meninges	O	1432-1440
.	O	1440-1441

Similar	O	1442-1449
mechanisms	O	1450-1460
may	O	1461-1464
be	O	1465-1467
involved	O	1468-1476
in	O	1477-1479
the	O	1480-1483
pathogenesis	O	1484-1496
of	O	1497-1499
cluster	B	1500-1507
headache	I	1508-1516
.	O	1516-1517

Recurrent	O	0-9
excitation	O	10-20
in	O	21-23
the	O	24-27
dentate	O	28-35
gyrus	O	36-41
of	O	42-44
a	O	45-46
murine	O	47-53
model	O	54-59
of	O	60-62
temporal	B	63-71
lobe	I	72-76
epilepsy	I	77-85
.	O	85-86

Similar	O	87-94
to	O	95-97
rats	O	98-102
,	O	102-103
systemic	O	104-112
pilocarpine	O	113-124
injection	O	125-134
causes	O	135-141
status	B	142-148
epilepticus	I	149-160
(	O	161-162
SE	B	162-164
)	O	164-165
and	O	166-169
the	O	170-173
eventual	O	174-182
development	O	183-194
of	O	195-197
spontaneous	O	198-209
seizures	B	210-218
and	O	219-222
mossy	O	223-228
fiber	O	229-234
sprouting	O	235-244
in	O	245-247
C57BL	O	248-253
/	O	253-254
6	O	254-255
and	O	256-259
CD1	O	260-263
mice	O	264-268
,	O	268-269
but	O	270-273
the	O	274-277
physiological	O	278-291
correlates	O	292-302
of	O	303-305
these	O	306-311
events	O	312-318
have	O	319-323
not	O	324-327
been	O	328-332
identified	O	333-343
in	O	344-346
mice	O	347-351
.	O	351-352

Population	O	353-363
responses	O	364-373
in	O	374-376
granule	O	377-384
cells	O	385-390
of	O	391-393
the	O	394-397
dentate	O	398-405
gyrus	O	406-411
were	O	412-416
examined	O	417-425
in	O	426-428
transverse	O	429-439
slices	O	440-446
of	O	447-449
the	O	450-453
ventral	O	454-461
hippocampus	O	462-473
from	O	474-478
pilocarpine	O	479-490
-	O	490-491
treated	O	491-498
and	O	499-502
untreated	O	503-512
mice	O	513-517
.	O	517-518

In	O	519-521
Mg	O	522-524
(	O	524-525
2	O	525-526
+	O	526-527
)	O	527-528
-	O	528-529
free	O	529-533
bathing	O	534-541
medium	O	542-548
containing	O	549-559
bicuculline	O	560-571
,	O	571-572
conditions	O	573-583
designed	O	584-592
to	O	593-595
increase	O	596-604
excitability	O	605-617
in	O	618-620
the	O	621-624
slices	O	625-631
,	O	631-632
electrical	O	633-643
stimulation	O	644-655
of	O	656-658
the	O	659-662
hilus	O	663-668
resulted	O	669-677
in	O	678-680
a	O	681-682
single	O	683-689
population	O	690-700
spike	O	701-706
in	O	707-709
granule	O	710-717
cells	O	718-723
from	O	724-728
control	O	729-736
mice	O	737-741
and	O	742-745
pilocarpine	O	746-757
-	O	757-758
treated	O	758-765
mice	O	766-770
that	O	771-775
did	O	776-779
not	O	780-783
experience	O	784-794
SE	B	795-797
.	O	797-798

In	O	799-801
SE	B	802-804
survivors	O	805-814
,	O	814-815
similar	O	816-823
stimulation	O	824-835
resulted	O	836-844
in	O	845-847
a	O	848-849
population	O	850-860
spike	O	861-866
followed	O	867-875
,	O	875-876
at	O	877-879
a	O	880-881
variable	O	882-890
latency	O	891-898
,	O	898-899
by	O	900-902
negative	O	903-911
DC	O	912-914
shifts	O	915-921
and	O	922-925
repetitive	O	926-936
afterdischarges	O	937-952
of	O	953-955
3	O	956-957
-	O	957-958
60	O	958-960
s	O	961-962
duration	O	963-971
,	O	971-972
which	O	973-978
were	O	979-983
blocked	O	984-991
by	O	992-994
ionotropic	O	995-1005
glutamate	O	1006-1015
receptor	O	1016-1024
antagonists	O	1025-1036
.	O	1036-1037

Focal	O	1038-1043
glutamate	O	1044-1053
photostimulation	O	1054-1070
of	O	1071-1073
the	O	1074-1077
granule	O	1078-1085
cell	O	1086-1090
layer	O	1091-1096
at	O	1097-1099
sites	O	1100-1105
distant	O	1106-1113
from	O	1114-1118
the	O	1119-1122
recording	O	1123-1132
pipette	O	1133-1140
resulted	O	1141-1149
in	O	1150-1152
population	O	1153-1163
responses	O	1164-1173
of	O	1174-1176
1	O	1177-1178
-	O	1178-1179
30	O	1179-1181
s	O	1182-1183
duration	O	1184-1192
in	O	1193-1195
slices	O	1196-1202
from	O	1203-1207
SE	B	1208-1210
survivors	O	1211-1220
but	O	1221-1224
not	O	1225-1228
other	O	1229-1234
groups	O	1235-1241
.	O	1241-1242

These	O	1243-1248
data	O	1249-1253
support	O	1254-1261
the	O	1262-1265
hypothesis	O	1266-1276
that	O	1277-1281
SE	B	1282-1284
-	O	1284-1285
induced	O	1285-1292
mossy	O	1293-1298
fiber	O	1299-1304
sprouting	O	1305-1314
and	O	1315-1318
synaptic	O	1319-1327
reorganization	O	1328-1342
are	O	1343-1346
relevant	O	1347-1355
characteristics	O	1356-1371
of	O	1372-1374
seizure	B	1375-1382
development	O	1383-1394
in	O	1395-1397
these	O	1398-1403
murine	O	1404-1410
strains	O	1411-1418
,	O	1418-1419
resembling	O	1420-1430
rat	O	1431-1434
models	O	1435-1441
of	O	1442-1444
human	O	1445-1450
temporal	B	1451-1459
lobe	I	1460-1464
epilepsy	I	1465-1473
.	O	1473-1474

The	O	0-3
alpha3	O	4-10
and	O	11-14
beta4	O	15-20
nicotinic	O	21-30
acetylcholine	O	31-44
receptor	O	45-53
subunits	O	54-62
are	O	63-66
necessary	O	67-76
for	O	77-80
nicotine	O	81-89
-	O	89-90
induced	O	90-97
seizures	B	98-106
and	O	107-110
hypolocomotion	B	111-125
in	O	126-128
mice	O	129-133
.	O	133-134

Binding	O	135-142
of	O	143-145
nicotine	O	146-154
to	O	155-157
nicotinic	O	158-167
acetylcholine	O	168-181
receptors	O	182-191
(	O	192-193
nAChRs	O	193-199
)	O	199-200
elicits	O	201-208
a	O	209-210
series	O	211-217
of	O	218-220
dose	O	221-225
-	O	225-226
dependent	O	226-235
behaviors	O	236-245
that	O	246-250
go	O	251-253
from	O	254-258
altered	O	259-266
exploration	O	267-278
,	O	278-279
sedation	O	280-288
,	O	288-289
and	O	290-293
tremors	B	294-301
,	O	301-302
to	O	303-305
seizures	B	306-314
and	O	315-318
death	B	319-324
.	O	324-325

nAChRs	O	326-332
are	O	333-336
pentameric	O	337-347
ion	O	348-351
channels	O	352-360
usually	O	361-368
composed	O	369-377
of	O	378-380
alpha	O	381-386
and	O	387-390
beta	O	391-395
subunits	O	396-404
.	O	404-405

A	O	406-407
gene	O	408-412
cluster	O	413-420
comprises	O	421-430
the	O	431-434
alpha3	O	435-441
,	O	441-442
alpha5	O	443-449
and	O	450-453
beta4	O	454-459
subunits	O	460-468
,	O	468-469
which	O	470-475
coassemble	O	476-486
to	O	487-489
form	O	490-494
functional	O	495-505
receptors	O	506-515
.	O	515-516

We	O	517-519
examined	O	520-528
the	O	529-532
role	O	533-537
of	O	538-540
the	O	541-544
beta4	O	545-550
subunits	O	551-559
in	O	560-562
nicotine	O	563-571
-	O	571-572
induced	O	572-579
seizures	B	580-588
and	O	589-592
hypolocomotion	B	593-607
in	O	608-610
beta4	O	611-616
homozygous	O	617-627
null	O	628-632
(	O	633-634
beta4	O	634-639
-	O	640-641
/	O	641-642
-	O	640-641
)	O	643-644
and	O	645-648
alpha3	O	649-655
heterozygous	O	656-668
(	O	669-670
+	O	670-671
/	O	671-672
-	O	672-673
)	O	673-674
mice	O	675-679
.	O	679-680

beta4	O	681-686
-	O	687-688
/	O	688-689
-	O	687-688
mice	O	691-695
were	O	696-700
less	O	701-705
sensitive	O	706-715
to	O	716-718
the	O	719-722
effects	O	723-730
of	O	731-733
nicotine	O	734-742
both	O	743-747
at	O	748-750
low	O	751-754
doses	O	755-760
,	O	760-761
measured	O	762-770
as	O	771-773
decreased	O	774-783
exploration	O	784-795
in	O	796-798
an	O	799-801
open	O	802-806
field	O	807-812
,	O	812-813
and	O	814-817
at	O	818-820
high	O	821-825
doses	O	826-831
,	O	831-832
measured	O	833-841
as	O	842-844
sensitivity	O	845-856
to	O	857-859
nicotine	O	860-868
-	O	868-869
induced	O	869-876
seizures	B	877-885
.	O	885-886

Using	O	887-892
in	O	893-895
situ	O	896-900
hybridization	O	901-914
probes	O	915-921
for	O	922-925
the	O	926-929
alpha3	O	930-936
and	O	937-940
alpha5	O	941-947
subunits	O	948-956
,	O	956-957
we	O	958-960
showed	O	961-967
that	O	968-972
alpha5	O	973-979
mRNA	O	980-984
levels	O	985-991
are	O	992-995
unchanged	O	996-1005
,	O	1005-1006
whereas	O	1007-1014
alpha3	O	1015-1021
mRNA	O	1022-1026
levels	O	1027-1033
are	O	1034-1037
selectively	O	1038-1049
decreased	O	1050-1059
in	O	1060-1062
the	O	1063-1066
mitral	O	1067-1073
cell	O	1074-1078
layer	O	1079-1084
of	O	1085-1087
the	O	1088-1091
olfactory	O	1092-1101
bulb	O	1102-1106
,	O	1106-1107
and	O	1108-1111
the	O	1112-1115
inferior	O	1116-1124
and	O	1125-1128
the	O	1129-1132
superior	O	1133-1141
colliculus	O	1142-1152
of	O	1153-1155
beta4	O	1156-1161
-	O	1162-1163
/	O	1163-1164
-	O	1162-1163
brains	O	1166-1172
.	O	1172-1173

alpha3	O	1174-1180
+	O	1181-1182
/	O	1182-1183
-	O	1183-1184
mice	O	1185-1189
were	O	1190-1194
partially	O	1195-1204
resistant	O	1205-1214
to	O	1215-1217
nicotine	O	1218-1226
-	O	1226-1227
induced	O	1227-1234
seizures	B	1235-1243
when	O	1244-1248
compared	O	1249-1257
to	O	1258-1260
wild	O	1261-1265
-	O	1265-1266
type	O	1266-1270
littermates	O	1271-1282
.	O	1282-1283

mRNA	O	1284-1288
levels	O	1289-1295
for	O	1296-1299
the	O	1300-1303
alpha5	O	1304-1310
and	O	1311-1314
the	O	1315-1318
beta4	O	1319-1324
subunits	O	1325-1333
were	O	1334-1338
unchanged	O	1339-1348
in	O	1349-1351
alpha3	O	1352-1358
+	O	1359-1360
/	O	1360-1361
-	O	1361-1362
brains	O	1363-1369
.	O	1369-1370

Together	O	1371-1379
,	O	1379-1380
these	O	1381-1386
results	O	1387-1394
suggest	O	1395-1402
that	O	1403-1407
the	O	1408-1411
beta4	O	1412-1417
and	O	1418-1421
the	O	1422-1425
alpha3	O	1426-1432
subunits	O	1433-1441
are	O	1442-1445
mediators	O	1446-1455
of	O	1456-1458
nicotine	O	1459-1467
-	O	1467-1468
induced	O	1468-1475
seizures	B	1476-1484
and	O	1485-1488
hypolocomotion	B	1489-1503
.	O	1503-1504

Recurrent	O	0-9
acute	O	10-15
interstitial	B	16-28
nephritis	I	29-38
induced	O	39-46
by	O	47-49
azithromycin	O	50-62
.	O	62-63

A	O	64-65
14	O	66-68
-	O	68-69
year	O	69-73
-	O	68-69
old	O	74-77
girl	O	78-82
is	O	83-85
reported	O	86-94
with	O	95-99
recurrent	O	100-109
,	O	109-110
azithromycin	O	111-123
-	O	123-124
induced	O	124-131
,	O	131-132
acute	O	133-138
interstitial	B	139-151
nephritis	I	152-161
.	O	161-162

The	O	163-166
second	O	167-173
episode	O	174-181
was	O	182-185
more	O	186-190
severe	O	191-197
than	O	198-202
the	O	203-206
first	O	207-212
;	O	212-213
and	O	214-217
although	O	218-226
both	O	227-231
were	O	232-236
treated	O	237-244
with	O	245-249
intensive	O	250-259
corticosteroid	O	260-274
therapy	O	275-282
,	O	282-283
renal	O	284-289
function	O	290-298
remained	O	299-307
impaired	O	308-316
.	O	316-317

Although	O	318-326
most	O	327-331
cases	O	332-337
of	O	338-340
antibiotic	O	341-351
induced	O	352-359
acute	O	360-365
interstitial	B	366-378
nephritis	I	379-388
are	O	389-392
benign	O	393-399
and	O	400-403
self	O	404-408
-	O	408-409
limited	O	409-416
,	O	416-417
some	O	418-422
patients	O	423-431
are	O	432-435
at	O	436-438
risk	O	439-443
for	O	444-447
permanent	O	448-457
renal	B	458-463
injury	I	464-470
.	O	470-471

Valproate	O	0-9
-	O	9-10
induced	O	10-17
encephalopathy	B	18-32
.	O	32-33

Valproate	O	34-43
-	O	43-44
induced	O	44-51
encephalopathy	B	52-66
is	O	67-69
a	O	70-71
rare	O	72-76
syndrome	O	77-85
that	O	86-90
may	O	91-94
manifest	O	95-103
in	O	104-106
otherwise	O	107-116
normal	O	117-123
epileptic	B	124-133
individuals	O	134-145
.	O	145-146

It	O	147-149
may	O	150-153
even	O	154-158
present	O	159-166
in	O	167-169
patients	O	170-178
who	O	179-182
have	O	183-187
tolerated	O	188-197
this	O	198-202
medicine	O	203-211
well	O	212-216
in	O	217-219
the	O	220-223
past	O	224-228
.	O	228-229

It	O	230-232
is	O	233-235
usually	O	236-243
but	O	244-247
not	O	248-251
necessarily	O	252-263
associated	O	264-274
with	O	275-279
hyperammonemia	B	280-294
.	O	294-295

The	O	296-299
EEG	O	300-303
shows	O	304-309
characteristic	O	310-324
triphasic	O	325-334
waves	O	335-340
in	O	341-343
most	O	344-348
patients	O	349-357
with	O	358-362
this	O	363-367
complication	O	368-380
.	O	380-381

A	O	382-383
case	O	384-388
of	O	389-391
valproate	O	392-401
-	O	401-402
induced	O	402-409
encephalopathy	B	410-424
is	O	425-427
presented	O	428-437
.	O	437-438

The	O	439-442
problems	O	443-451
in	O	452-454
diagnosing	O	455-465
this	O	466-470
condition	O	471-480
are	O	481-484
subsequently	O	485-497
discussed	O	498-507
.	O	507-508

Nitro	O	0-5
-	O	5-6
L	O	6-7
-	O	5-6
arginine	O	8-16
methyl	O	17-23
ester	O	24-29
:	O	29-30
a	O	31-32
potential	O	33-42
protector	O	43-52
against	O	53-60
gentamicin	O	61-71
ototoxicity	B	72-83
.	O	83-84

The	O	85-88
nitric	O	89-95
oxide	O	96-101
(	O	102-103
NO	O	103-105
)	O	105-106
inhibitor	O	107-116
nitro	O	117-122
-	O	122-123
L	O	123-124
-	O	122-123
arginine	O	125-133
methyl	O	134-140
ester	O	141-146
(	O	147-148
L	O	148-149
-	O	149-150
NAME	O	150-154
)	O	154-155
may	O	156-159
act	O	160-163
as	O	164-166
an	O	167-169
otoprotectant	O	170-183
against	O	184-191
high	B	192-196
-	I	196-197
frequency	I	197-206
hearing	I	207-214
loss	I	215-219
caused	O	220-226
by	O	227-229
gentamicin	O	230-240
,	O	240-241
but	O	242-245
further	O	246-253
studies	O	254-261
are	O	262-265
needed	O	266-272
to	O	273-275
confirm	O	276-283
this	O	284-288
.	O	288-289
Aminoglycoside	O	289-303
antibiotics	O	304-315
are	O	316-319
still	O	320-325
widely	O	326-332
used	O	333-337
by	O	338-340
virtue	O	341-347
of	O	348-350
their	O	351-356
efficacy	O	357-365
and	O	366-369
low	O	370-373
cost	O	374-378
.	O	378-379

Their	O	380-385
ototoxicity	B	386-397
is	O	398-400
a	O	401-402
serious	O	403-410
health	O	411-417
problem	O	418-425
and	O	426-429
,	O	429-430
as	O	431-433
their	O	434-439
ototoxic	B	440-448
mechanism	O	449-458
involves	O	459-467
the	O	468-471
production	O	472-482
of	O	483-485
NO	O	486-488
,	O	488-489
we	O	490-492
need	O	493-497
to	O	498-500
assess	O	501-507
the	O	508-511
use	O	512-515
of	O	516-518
NO	O	519-521
inhibitors	O	522-532
for	O	533-536
the	O	537-540
prevention	O	541-551
of	O	552-554
aminoglycoside	O	555-569
-	O	569-570
induced	O	570-577
sensorineural	B	578-591
hearing	I	592-599
loss	I	600-604
.	O	604-605

In	O	606-608
this	O	609-613
experimental	O	614-626
study	O	627-632
we	O	633-635
used	O	636-640
30	O	641-643
Sprague	O	644-651
-	O	651-652
Dawley	O	652-658
rats	O	659-663
,	O	663-664
27	O	665-667
of	O	668-670
which	O	671-676
had	O	677-680
gentamicin	O	681-691
instilled	O	692-701
into	O	702-706
the	O	707-710
middle	O	711-717
ear	O	718-721
.	O	721-722

The	O	723-726
otoprotectant	O	727-740
L	O	741-742
-	O	742-743
NAME	O	743-747
was	O	748-751
administered	O	752-764
topically	O	765-774
to	O	775-777
12	O	778-780
/	O	780-781
27	O	781-783
animals	O	784-791
.	O	791-792

Its	O	793-796
effect	O	797-803
was	O	804-807
determined	O	808-818
in	O	819-821
terms	O	822-827
of	O	828-830
attenuation	O	831-842
of	O	843-845
hearing	B	846-853
loss	I	854-858
,	O	858-859
measured	O	860-868
by	O	869-871
shifts	O	872-878
in	O	879-881
the	O	882-885
auditory	O	886-894
brainstem	O	895-904
response	O	905-913
threshold	O	914-923
.	O	923-924

L	O	925-926
-	O	926-927
NAME	O	927-931
reduced	O	932-939
gentamicin	O	940-950
-	O	950-951
induced	O	951-958
hearing	B	959-966
loss	I	967-971
in	O	972-974
the	O	975-978
high	O	979-983
-	O	983-984
frequency	O	984-993
range	O	994-999
,	O	999-1000
but	O	1001-1004
gave	O	1005-1009
no	O	1010-1012
protection	O	1013-1023
in	O	1024-1026
the	O	1027-1030
middle	O	1031-1037
or	O	1038-1040
low	O	1041-1044
frequencies	O	1045-1056
.	O	1056-1057

Cerebral	B	0-8
vasculitis	I	9-19
following	O	20-29
oral	O	30-34
methylphenidate	O	35-50
intake	O	51-57
in	O	58-60
an	O	61-63
adult	O	64-69
:	O	69-70
a	O	71-72
case	O	73-77
report	O	78-84
.	O	84-85

Methylphenidate	O	86-101
is	O	102-104
structurally	O	105-117
and	O	118-121
functionally	O	122-134
similar	O	135-142
to	O	143-145
amphetamine	O	146-157
.	O	157-158

Cerebral	B	159-167
vasculitis	I	168-178
associated	O	179-189
with	O	190-194
amphetamine	B	195-206
abuse	I	207-212
is	O	213-215
well	O	216-220
documented	O	221-231
,	O	231-232
and	O	233-236
in	O	237-239
rare	O	240-244
cases	O	245-250
ischaemic	B	251-260
stroke	I	261-267
has	O	268-271
been	O	272-276
reported	O	277-285
after	O	286-291
methylphenidate	O	292-307
intake	O	308-314
in	O	315-317
children	O	318-326
.	O	326-327

We	O	328-330
report	O	331-337
the	O	338-341
case	O	342-346
of	O	347-349
a	O	350-351
63	O	352-354
-	O	354-355
year	O	355-359
-	O	354-355
old	O	360-363
female	O	364-370
who	O	371-374
was	O	375-378
treated	O	379-386
with	O	387-391
methylphenidate	O	392-407
due	O	408-411
to	O	412-414
hyperactivity	B	415-428
and	O	429-432
suffered	O	433-441
from	O	442-446
multiple	O	447-455
ischaemic	B	456-465
strokes	I	466-473
.	O	473-474

We	O	475-477
consider	O	478-486
drug	O	487-491
-	O	491-492
induced	O	492-499
cerebral	B	500-508
vasculitis	I	509-519
as	O	520-522
the	O	523-526
most	O	527-531
likely	O	532-538
cause	O	539-544
of	O	545-547
recurrent	O	548-557
ischaemic	B	558-567
strokes	I	568-575
in	O	576-578
the	O	579-582
absence	O	583-590
of	O	591-593
any	O	594-597
pathological	O	598-610
findings	O	611-619
during	O	620-626
the	O	627-630
diagnostic	O	631-641
work	O	642-646
-	O	646-647
up	O	647-649
.	O	649-650

We	O	651-653
conclude	O	654-662
that	O	663-667
methylphenidate	O	668-683
mediated	O	684-692
vasculitis	B	693-703
should	O	704-710
be	O	711-713
considered	O	714-724
in	O	725-727
patients	O	728-736
with	O	737-741
neurological	O	742-754
symptoms	O	755-763
and	O	764-767
a	O	768-769
history	O	770-777
of	O	778-780
methylphenidate	O	781-796
therapy	O	797-804
.	O	804-805

This	O	806-810
potential	O	811-820
side	O	821-825
-	O	825-826
effect	O	826-832
,	O	832-833
though	O	834-840
very	O	841-845
rare	O	846-850
,	O	850-851
represents	O	852-862
one	O	863-866
more	O	867-871
reason	O	872-878
to	O	879-881
be	O	882-884
very	O	885-889
restrictive	O	890-901
in	O	902-904
the	O	905-908
use	O	909-912
of	O	913-915
methylphenidate	O	916-931
.	O	931-932

Cerebral	B	0-8
haemorrhage	I	9-20
induced	O	21-28
by	O	29-31
warfarin	O	32-40
-	O	41-42
the	O	43-46
influence	O	47-56
of	O	57-59
drug	O	60-64
-	O	64-65
drug	O	60-64
interactions	O	70-82
.	O	82-83

PURPOSE	O	84-91
:	O	91-92
To	O	93-95
evaluate	O	96-104
the	O	105-108
frequency	O	109-118
,	O	118-119
severity	O	120-128
and	O	129-132
preventability	O	133-147
of	O	148-150
warfarin	O	151-159
-	O	159-160
induced	O	160-167
cerebral	B	168-176
haemorrhages	I	177-189
due	O	190-193
to	O	194-196
warfarin	O	197-205
and	O	206-209
warfarin	O	210-218
-	O	218-219
drug	O	219-223
interactions	O	224-236
in	O	237-239
patients	O	240-248
living	O	249-255
in	O	256-258
the	O	259-262
county	O	263-269
of	O	270-272
Osterg	O	273-279
tland	O	281-286
,	O	286-287
Sweden	O	288-294
.	O	294-295

METHODS	O	296-303
:	O	303-304
All	O	305-308
patients	O	309-317
with	O	318-322
a	O	323-324
diagnosed	O	325-334
cerebral	B	335-343
haemorrhage	I	344-355
at	O	356-358
three	O	359-364
hospitals	O	365-374
during	O	375-381
the	O	382-385
period	O	386-392
2000	O	393-397
-	O	397-398
2002	O	398-402
were	O	403-407
identified	O	408-418
.	O	418-419

Medical	O	420-427
records	O	428-435
were	O	436-440
studied	O	441-448
retrospectively	O	449-464
to	O	465-467
evaluate	O	468-476
whether	O	477-484
warfarin	O	485-493
and	O	494-497
warfarin	O	498-506
-	O	506-507
drug	O	507-511
interactions	O	512-524
could	O	525-530
have	O	531-535
caused	O	536-542
the	O	543-546
cerebral	B	547-555
haemorrhage	I	556-567
.	O	567-568

The	O	569-572
proportion	O	573-583
of	O	584-586
possibly	O	587-595
avoidable	O	596-605
cases	O	606-611
due	O	612-615
to	O	616-618
drug	O	619-623
interactions	O	624-636
was	O	637-640
estimated	O	641-650
.	O	650-651

RESULTS	O	652-659
:	O	659-660
Among	O	661-666
593	O	667-670
patients	O	671-679
with	O	680-684
cerebral	B	685-693
haemorrhage	I	694-705
,	O	705-706
59	O	707-709
(	O	710-711
10	O	711-713
%	O	713-714
)	O	714-715
were	O	716-720
assessed	O	721-729
as	O	730-732
related	O	733-740
to	O	741-743
warfarin	O	744-752
treatment	O	753-762
.	O	762-763

This	O	764-768
imply	O	769-774
an	O	775-777
incidence	O	778-787
of	O	788-790
1	O	791-792
.	O	792-793
7	O	793-794
/	O	794-795
100	O	795-798
,	O	798-799
000	O	799-802
treatment	O	803-812
years	O	813-818
.	O	818-819

Of	O	820-822
the	O	823-826
59	O	827-829
cases	O	830-835
,	O	835-836
26	O	837-839
(	O	840-841
44	O	841-843
%	O	843-844
)	O	844-845
had	O	846-849
a	O	850-851
fatal	O	852-857
outcome	O	858-865
,	O	865-866
compared	O	867-875
to	O	876-878
136	O	879-882
(	O	883-884
25	O	884-886
%	O	886-887
)	O	887-888
among	O	889-894
the	O	895-898
non	O	899-902
-	O	902-903
warfarin	O	903-911
patients	O	912-920
(	O	921-922
p	O	922-923
<	O	924-925
0	O	926-927
.	O	927-928
01	O	928-930
)	O	930-931
.	O	927-928

A	O	933-934
warfarin	O	935-943
-	O	943-944
drug	O	944-948
interaction	O	949-960
could	O	961-966
have	O	967-971
contributed	O	972-983
to	O	984-986
the	O	987-990
haemorrhage	B	991-1002
in	O	1003-1005
24	O	1006-1008
(	O	1009-1010
41	O	1010-1012
%	O	1012-1013
)	O	1013-1014
of	O	1015-1017
the	O	1018-1021
warfarin	O	1022-1030
patients	O	1031-1039
and	O	1040-1043
in	O	1044-1046
7	O	1047-1048
of	O	1049-1051
these	O	1052-1057
(	O	1058-1059
12	O	1059-1061
%	O	1061-1062
)	O	1062-1063
the	O	1064-1067
bleeding	B	1068-1076
complication	O	1077-1089
was	O	1090-1093
considered	O	1094-1104
being	O	1105-1110
possible	O	1111-1119
to	O	1120-1122
avoid	O	1123-1128
.	O	1128-1129

CONCLUSIONS	O	1130-1141
:	O	1141-1142
Warfarin	O	1143-1151
-	O	1151-1152
induced	O	1152-1159
cerebral	B	1160-1168
haemorrhages	I	1169-1181
are	O	1182-1185
a	O	1186-1187
major	O	1188-1193
clinical	O	1194-1202
problem	O	1203-1210
with	O	1211-1215
a	O	1216-1217
high	O	1218-1222
fatality	O	1223-1231
rate	O	1232-1236
.	O	1236-1237

Almost	O	1238-1244
half	O	1245-1249
of	O	1250-1252
the	O	1253-1256
cases	O	1257-1262
was	O	1263-1266
related	O	1267-1274
to	O	1275-1277
a	O	1278-1279
warfarin	O	1280-1288
-	O	1288-1289
drug	O	1289-1293
interaction	O	1294-1305
.	O	1305-1306

A	O	1307-1308
significant	O	1309-1320
proportion	O	1321-1331
of	O	1332-1334
warfarin	O	1335-1343
-	O	1343-1344
related	O	1344-1351
cerebral	B	1352-1360
haemorrhages	I	1361-1373
might	O	1374-1379
have	O	1380-1384
been	O	1385-1389
prevented	O	1390-1399
if	O	1400-1402
greater	O	1403-1410
caution	O	1411-1418
had	O	1419-1422
been	O	1423-1427
taken	O	1428-1433
when	O	1434-1438
prescribing	O	1439-1450
drugs	O	1451-1456
known	O	1457-1462
to	O	1463-1465
interact	O	1466-1474
with	O	1475-1479
warfarin	O	1480-1488
.	O	1488-1489

Side	O	0-4
effects	O	5-12
of	O	13-15
postoperative	O	16-29
administration	O	30-44
of	O	45-47
methylprednisolone	O	48-66
and	O	67-70
gentamicin	O	71-81
into	O	82-86
the	O	87-90
posterior	O	91-100
sub	O	101-104
-	O	104-105
Tenon	O	105-110
'	O	110-111
s	O	101-102
space	O	113-118
.	O	118-119

PURPOSE	O	120-127
:	O	127-128
To	O	129-131
assess	O	132-138
the	O	139-142
incidence	O	143-152
of	O	153-155
postoperative	O	156-169
emetic	O	170-176
side	O	177-181
effects	O	182-189
after	O	190-195
the	O	196-199
administration	O	200-214
of	O	215-217
methylprednisolone	O	218-236
and	O	237-240
gentamicin	O	241-251
into	O	252-256
the	O	257-260
posterior	O	261-270
sub	O	271-274
-	O	274-275
Tenon	O	275-280
'	O	280-281
s	O	271-272
space	O	283-288
at	O	289-291
the	O	292-295
end	O	296-299
of	O	300-302
routine	O	303-310
cataract	B	311-319
surgery	O	320-327
.	O	327-328

SETTING	O	329-336
:	O	336-337
St	O	338-340
.	O	340-341
Luke	O	342-346
'	O	346-347
s	O	347-348
Hospital	O	349-357
,	O	357-358
Gwardamangia	O	359-371
,	O	371-372
Malta	O	373-378
.	O	378-379

METHODS	O	380-387
:	O	387-388
A	O	389-390
double	O	391-397
-	O	397-398
blind	O	398-403
double	O	404-410
-	O	410-411
armed	O	411-416
prospective	O	417-428
study	O	429-434
comprised	O	435-444
40	O	445-447
patients	O	448-456
who	O	457-460
had	O	461-464
uneventful	O	465-475
sutureless	O	476-486
phacoemulsification	O	487-506
under	O	507-512
sub	O	513-516
-	O	516-517
Tenon	O	517-522
'	O	522-523
s	O	513-514
local	O	525-530
infiltration	O	531-543
of	O	544-546
3	O	547-548
mL	O	549-551
of	O	552-554
plain	O	555-560
lignocaine	O	561-571
.	O	571-572

At	O	573-575
the	O	576-579
end	O	580-583
of	O	584-586
the	O	587-590
procedure	O	591-600
,	O	600-601
Group	O	602-607
A	O	608-609
(	O	610-611
n	O	611-612
=	O	613-614
20	O	615-617
)	O	617-618
had	O	619-622
20	O	623-625
mg	O	626-628
/	O	628-629
0	O	629-630
.	O	630-631
5	O	631-632
mL	O	633-635
of	O	636-638
methylprednisolone	O	639-657
and	O	658-661
10	O	662-664
mg	O	665-667
/	O	667-668
0	O	668-669
.	O	669-670
5	O	670-671
mL	O	672-674
of	O	675-677
gentamicin	O	678-688
injected	O	689-697
into	O	698-702
the	O	703-706
posterior	O	707-716
sub	O	717-720
-	O	720-721
Tenon	O	721-726
'	O	726-727
s	O	717-718
space	O	729-734
and	O	735-738
Group	O	739-744
B	O	745-746
(	O	747-748
n	O	748-749
=	O	750-751
20	O	752-754
)	O	754-755
had	O	756-759
the	O	760-763
same	O	764-768
combination	O	769-780
injected	O	781-789
into	O	790-794
the	O	795-798
anterior	O	799-807
sub	O	808-811
-	O	811-812
Tenon	O	812-817
'	O	817-818
s	O	808-809
space	O	820-825
.	O	825-826

Postoperatively	O	827-842
,	O	842-843
all	O	844-847
patients	O	848-856
were	O	857-861
assessed	O	862-870
for	O	871-874
symptoms	O	875-883
of	O	884-886
nausea	B	887-893
,	I	893-894
vomiting	I	895-903
,	O	903-904
and	O	905-908
headache	B	909-917
.	O	917-918

A	O	919-920
chi	O	921-924
-	O	924-925
square	O	925-931
test	O	932-936
was	O	937-940
used	O	941-945
to	O	946-948
assess	O	949-955
the	O	956-959
statistical	O	960-971
significance	O	972-984
of	O	985-987
results	O	988-995
.	O	995-996

RESULTS	O	997-1004
:	O	1004-1005
Sixty	O	1006-1011
percent	O	1012-1019
in	O	1020-1022
Group	O	1023-1028
A	O	1029-1030
developed	O	1031-1040
postoperative	B	1041-1054
emetic	I	1055-1061
symptoms	I	1062-1070
,	O	1070-1071
headache	B	1072-1080
,	O	1080-1081
or	O	1082-1084
both	O	1085-1089
;	O	1089-1090
1	O	1091-1092
patient	O	1093-1100
in	O	1101-1103
Group	O	1104-1109
B	O	1110-1111
developed	O	1112-1121
symptoms	O	1122-1130
.	O	1130-1131

CONCLUSIONS	O	1132-1143
:	O	1143-1144
The	O	1145-1148
administration	O	1149-1163
of	O	1164-1166
methylprednisolone	O	1167-1185
and	O	1186-1189
gentamicin	O	1190-1200
in	O	1201-1203
the	O	1204-1207
posterior	O	1208-1217
sub	O	1218-1221
-	O	1221-1222
Tenon	O	1222-1227
'	O	1227-1228
s	O	1218-1219
space	O	1230-1235
was	O	1236-1239
related	O	1240-1247
to	O	1248-1250
a	O	1251-1252
high	O	1253-1257
incidence	O	1258-1267
of	O	1268-1270
side	O	1271-1275
effects	O	1276-1283
including	O	1284-1293
nausea	B	1294-1300
,	I	1300-1301
vomiting	I	1302-1310
,	O	1310-1311
and	O	1312-1315
headache	B	1316-1324
.	O	1324-1325

All	O	1326-1329
adverse	O	1330-1337
effects	O	1338-1345
were	O	1346-1350
self	O	1351-1355
-	O	1355-1356
limiting	O	1356-1364
.	O	1364-1365

Cardiac	O	0-7
Angiography	O	8-19
in	O	20-22
Renally	O	23-30
Impaired	O	31-39
Patients	O	40-48
(	O	49-50
CARE	O	50-54
)	O	54-55
study	O	56-61
:	O	61-62
a	O	63-64
randomized	O	65-75
double	O	76-82
-	O	82-83
blind	O	83-88
trial	O	89-94
of	O	95-97
contrast	O	98-106
-	O	106-107
induced	O	107-114
nephropathy	B	115-126
in	O	127-129
patients	O	130-138
with	O	139-143
chronic	B	144-151
kidney	I	152-158
disease	I	159-166
.	O	166-167

BACKGROUND	O	168-178
:	O	178-179
No	O	180-182
direct	O	183-189
comparisons	O	190-201
exist	O	202-207
of	O	208-210
the	O	211-214
renal	O	215-220
tolerability	O	221-233
of	O	234-236
the	O	237-240
low	O	241-244
-	O	244-245
osmolality	O	245-255
contrast	O	256-264
medium	O	265-271
iopamidol	O	272-281
with	O	282-286
that	O	287-291
of	O	292-294
the	O	295-298
iso	O	299-302
-	O	302-303
osmolality	O	303-313
contrast	O	314-322
medium	O	323-329
iodixanol	O	330-339
in	O	340-342
high	O	343-347
-	O	347-348
risk	O	348-352
patients	O	353-361
.	O	361-362

METHODS	O	363-370
AND	O	371-374
RESULTS	O	375-382
:	O	382-383
The	O	384-387
present	O	388-395
study	O	396-401
is	O	402-404
a	O	405-406
multicenter	O	407-418
,	O	418-419
randomized	O	420-430
,	O	430-431
double	O	432-438
-	O	438-439
blind	O	439-444
comparison	O	445-455
of	O	456-458
iopamidol	O	459-468
and	O	469-472
iodixanol	O	473-482
in	O	483-485
patients	O	486-494
with	O	495-499
chronic	B	500-507
kidney	I	508-514
disease	I	515-522
(	O	523-524
estimated	O	524-533
glomerular	O	534-544
filtration	O	545-555
rate	O	556-560
,	O	560-561
20	O	562-564
to	O	565-567
59	O	568-570
mL	O	571-573
/	O	573-574
min	O	574-577
)	O	577-578
who	O	579-582
underwent	O	583-592
cardiac	O	593-600
angiography	O	601-612
or	O	613-615
percutaneous	O	616-628
coronary	O	629-637
interventions	O	638-651
.	O	651-652

Serum	O	653-658
creatinine	O	659-669
(	O	670-671
SCr	O	671-674
)	O	674-675
levels	O	676-682
and	O	683-686
estimated	O	687-696
glomerular	O	697-707
filtration	O	708-718
rate	O	719-723
were	O	724-728
assessed	O	729-737
at	O	738-740
baseline	O	741-749
and	O	750-753
2	O	754-755
to	O	756-758
5	O	759-760
days	O	761-765
after	O	766-771
receiving	O	772-781
medications	O	782-793
.	O	793-794

The	O	795-798
primary	O	799-806
outcome	O	807-814
was	O	815-818
a	O	819-820
postdose	O	821-829
SCr	O	830-833
increase	O	834-842
>	O	843-844
or	O	845-847
=	O	848-849
0	O	850-851
.	O	851-852
5	O	852-853
mg	O	854-856
/	O	856-857
dL	O	857-859
(	O	860-861
44	O	861-863
.	O	863-864
2	O	864-865
micromol	O	866-874
/	O	874-875
L	O	875-876
)	O	876-877
over	O	878-882
baseline	O	883-891
.	O	891-892

Secondary	O	893-902
outcomes	O	903-911
were	O	912-916
a	O	917-918
postdose	O	919-927
SCr	O	928-931
increase	O	932-940
>	O	941-942
or	O	943-945
=	O	946-947
25	O	948-950
%	O	950-951
,	O	951-952
a	O	953-954
postdose	O	955-963
estimated	O	964-973
glomerular	O	974-984
filtration	O	985-995
rate	O	996-1000
decrease	O	1001-1009
of	O	1010-1012
>	O	1013-1014
or	O	1015-1017
=	O	1018-1019
25	O	1020-1022
%	O	1022-1023
,	O	1023-1024
and	O	1025-1028
the	O	1029-1032
mean	O	1033-1037
peak	O	1038-1042
change	O	1043-1049
in	O	1050-1052
SCr	O	1053-1056
.	O	1056-1057

In	O	1058-1060
414	O	1061-1064
patients	O	1065-1073
,	O	1073-1074
contrast	O	1075-1083
volume	O	1084-1090
,	O	1090-1091
presence	O	1092-1100
of	O	1101-1103
diabetes	B	1104-1112
mellitus	I	1113-1121
,	O	1121-1122
use	O	1123-1126
of	O	1127-1129
N	O	1130-1131
-	O	1131-1132
acetylcysteine	O	1132-1146
,	O	1146-1147
mean	O	1148-1152
baseline	O	1153-1161
SCr	O	1162-1165
,	O	1165-1166
and	O	1167-1170
estimated	O	1171-1180
glomerular	O	1181-1191
filtration	O	1192-1202
rate	O	1203-1207
were	O	1208-1212
comparable	O	1213-1223
in	O	1224-1226
the	O	1227-1230
2	O	1231-1232
groups	O	1233-1239
.	O	1239-1240

SCr	O	1241-1244
increases	O	1245-1254
>	O	1255-1256
or	O	1257-1259
=	O	1260-1261
0	O	1262-1263
.	O	1263-1264
5	O	1264-1265
mg	O	1266-1268
/	O	1268-1269
dL	O	1269-1271
occurred	O	1272-1280
in	O	1281-1283
4	O	1284-1285
.	O	1285-1286
4	O	1284-1285
%	O	1287-1288
(	O	1289-1290
9	O	1290-1291
of	O	1292-1294
204	O	1295-1298
patients	O	1299-1307
)	O	1307-1308
after	O	1309-1314
iopamidol	O	1315-1324
and	O	1325-1328
6	O	1329-1330
.	O	1330-1331
7	O	1331-1332
%	O	1332-1333
(	O	1334-1335
14	O	1335-1337
of	O	1338-1340
210	O	1341-1344
patients	O	1345-1353
)	O	1353-1354
after	O	1355-1360
iodixanol	O	1361-1370
(	O	1371-1372
P	O	1372-1373
=	O	1373-1374
0	O	1374-1375
.	O	1375-1376
39	O	1376-1378
)	O	1378-1379
,	O	1379-1380

whereas	O	1381-1388
rates	O	1389-1394
of	O	1395-1397
SCr	O	1398-1401
increases	O	1402-1411
>	O	1412-1413
or	O	1414-1416
=	O	1417-1418
25	O	1419-1421
%	O	1421-1422
were	O	1423-1427
9	O	1428-1429
.	O	1429-1430
8	O	1430-1431
%	O	1431-1432
and	O	1433-1436
12	O	1437-1439
.	O	1439-1440
4	O	1440-1441
%	O	1441-1442
,	O	1442-1443
respectively	O	1444-1456
(	O	1457-1458
P	O	1458-1459
=	O	1459-1460
0	O	1460-1461
.	O	1461-1462
44	O	1462-1464
)	O	1464-1465
.	O	1461-1462

In	O	1467-1469
patients	O	1470-1478
with	O	1479-1483
diabetes	B	1484-1492
,	O	1492-1493
SCr	O	1494-1497
increases	O	1498-1507
>	O	1508-1509
or	O	1510-1512
=	O	1513-1514
0	O	1515-1516
.	O	1516-1517
5	O	1517-1518
mg	O	1519-1521
/	O	1521-1522
dL	O	1522-1524
were	O	1525-1529
5	O	1530-1531
.	O	1531-1532
1	O	1532-1533
%	O	1533-1534
(	O	1535-1536
4	O	1536-1537
of	O	1538-1540
78	O	1541-1543
patients	O	1544-1552
)	O	1552-1553
with	O	1554-1558
iopamidol	O	1559-1568
and	O	1569-1572
13	O	1573-1575
.	O	1575-1576
0	O	1576-1577
%	O	1577-1578
(	O	1579-1580
12	O	1580-1582
of	O	1583-1585
92	O	1586-1588
patients	O	1589-1597
)	O	1597-1598
with	O	1599-1603
iodixanol	O	1604-1613
(	O	1614-1615
P	O	1615-1616
=	O	1616-1617
0	O	1617-1618
.	O	1618-1619
11	O	1619-1621
)	O	1621-1622
,	O	1622-1623

whereas	O	1624-1631
SCr	O	1632-1635
increases	O	1636-1645
>	O	1646-1647
or	O	1648-1650
=	O	1651-1652
25	O	1653-1655
%	O	1655-1656
were	O	1657-1661
10	O	1662-1664
.	O	1664-1665
3	O	1665-1666
%	O	1666-1667
and	O	1668-1671
15	O	1672-1674
.	O	1674-1675
2	O	1675-1676
%	O	1676-1677
,	O	1677-1678
respectively	O	1679-1691
(	O	1692-1693
P	O	1693-1694
=	O	1694-1695
0	O	1695-1696
.	O	1696-1697
37	O	1697-1699
)	O	1699-1700
.	O	1696-1697

Mean	O	1702-1706
post	O	1707-1711
-	O	1711-1712
SCr	O	1712-1715
increases	O	1716-1725
were	O	1726-1730
significantly	O	1731-1744
less	O	1745-1749
with	O	1750-1754
iopamidol	O	1755-1764
(	O	1765-1766
all	O	1766-1769
patients	O	1770-1778
:	O	1778-1779
0	O	1780-1781
.	O	1781-1782
07	O	1782-1784
versus	O	1785-1791
0	O	1792-1793
.	O	1793-1794
12	O	1794-1796
mg	O	1797-1799
/	O	1799-1800
dL	O	1800-1802
,	O	1802-1803
6	O	1804-1805
.	O	1805-1806
2	O	1806-1807
versus	O	1808-1814
10	O	1815-1817
.	O	1817-1818
6	O	1818-1819
micromol	O	1820-1828
/	O	1828-1829
L	O	1829-1830
,	O	1830-1831
P	O	1832-1833
=	O	1833-1834
0	O	1834-1835
.	O	1835-1836
03	O	1836-1838
;	O	1838-1839
patients	O	1840-1848
with	O	1849-1853
diabetes	B	1854-1862
:	O	1862-1863
0	O	1864-1865
.	O	1865-1866
07	O	1866-1868
versus	O	1869-1875
0	O	1876-1877
.	O	1877-1878
16	O	1878-1880
mg	O	1881-1883
/	O	1883-1884
dL	O	1884-1886
,	O	1886-1887
6	O	1888-1889
.	O	1889-1890
2	O	1890-1891
versus	O	1892-1898
14	O	1899-1901
.	O	1901-1902
1	O	1899-1900
micromol	O	1904-1912
/	O	1912-1913
L	O	1913-1914
,	O	1914-1915
P	O	1916-1917
=	O	1917-1918
0	O	1918-1919
.	O	1919-1920
01	O	1920-1922
)	O	1922-1923
.	O	1919-1920

CONCLUSIONS	O	1925-1936
:	O	1936-1937
The	O	1938-1941
rate	O	1942-1946
of	O	1947-1949
contrast	O	1950-1958
-	O	1958-1959
induced	O	1959-1966
nephropathy	B	1967-1978
,	O	1978-1979
defined	O	1980-1987
by	O	1988-1990
multiple	O	1991-1999
end	O	2000-2003
points	O	2004-2010
,	O	2010-2011
is	O	2012-2014
not	O	2015-2018
statistically	O	2019-2032
different	O	2033-2042
after	O	2043-2048
the	O	2049-2052
intraarterial	O	2053-2066
administration	O	2067-2081
of	O	2082-2084
iopamidol	O	2085-2094
or	O	2095-2097
iodixanol	O	2098-2107
to	O	2108-2110
high	O	2111-2115
-	O	2115-2116
risk	O	2116-2120
patients	O	2121-2129
,	O	2129-2130
with	O	2131-2135
or	O	2136-2138
without	O	2139-2146
diabetes	B	2147-2155
mellitus	I	2156-2164
.	O	2164-2165

Any	O	2166-2169
true	O	2170-2174
difference	O	2175-2185
between	O	2186-2193
the	O	2194-2197
agents	O	2198-2204
is	O	2205-2207
small	O	2208-2213
and	O	2214-2217
not	O	2218-2221
likely	O	2222-2228
to	O	2229-2231
be	O	2232-2234
clinically	O	2235-2245
significant	O	2246-2257
.	O	2257-2258

A	O	0-1
novel	O	2-7
compound	O	8-16
,	O	16-17
maltolyl	O	18-26
p	O	27-28
-	O	28-29
coumarate	O	29-38
,	O	38-39
attenuates	O	40-50
cognitive	B	51-60
deficits	I	61-69
and	O	70-73
shows	O	74-79
neuroprotective	O	80-95
effects	O	96-103
in	O	104-106
vitro	O	107-112
and	O	113-116
in	O	117-119
vivo	O	120-124
dementia	B	125-133
models	O	134-140
.	O	140-141

To	O	142-144
develop	O	145-152
a	O	153-154
novel	O	155-160
and	O	161-164
effective	O	165-174
drug	O	175-179
that	O	180-184
could	O	185-190
enhance	O	191-198
cognitive	O	199-208
function	O	209-217
and	O	218-221
neuroprotection	O	222-237
,	O	237-238
we	O	239-241
newly	O	242-247
synthesized	O	248-259
maltolyl	O	260-268
p	O	269-270
-	O	270-271
coumarate	O	271-280
by	O	281-283
the	O	284-287
esterification	O	288-302
of	O	303-305
maltol	O	306-312
and	O	313-316
p	O	317-318
-	O	318-319
coumaric	O	319-327
acid	O	328-332
.	O	332-333

In	O	334-336
the	O	337-340
present	O	341-348
study	O	349-354
,	O	354-355
we	O	356-358
investigated	O	359-371
whether	O	372-379
maltolyl	O	380-388
p	O	389-390
-	O	390-391
coumarate	O	391-400
could	O	401-406
improve	O	407-414
cognitive	B	415-424
decline	I	425-432
in	O	433-435
scopolamine	O	436-447
-	O	447-448
injected	O	448-456
rats	O	457-461
and	O	462-465
in	O	466-468
amyloid	O	469-476
beta	O	477-481
peptide	O	482-489
(	O	489-490
1	O	490-491
-	O	491-492
42	O	492-494
)	O	494-495
-	O	491-492
infused	O	496-503
rats	O	504-508
.	O	508-509

Maltolyl	O	510-518
p	O	519-520
-	O	520-521
coumarate	O	521-530
was	O	531-534
found	O	535-540
to	O	541-543
attenuate	O	544-553
cognitive	B	554-563
deficits	I	564-572
in	O	573-575
both	O	576-580
rat	O	581-584
models	O	585-591
using	O	592-597
passive	O	598-605
avoidance	O	606-615
test	O	616-620
and	O	621-624
to	O	625-627
reduce	O	628-634
apoptotic	O	635-644
cell	O	645-649
death	O	650-655
observed	O	656-664
in	O	665-667
the	O	668-671
hippocampus	O	672-683
of	O	684-686
the	O	687-690
amyloid	O	691-698
beta	O	699-703
peptide	O	704-711
(	O	711-712
1	O	712-713
-	O	713-714
42	O	714-716
)	O	716-717
-	O	713-714
infused	O	718-725
rats	O	726-730
.	O	730-731

We	O	732-734
also	O	735-739
examined	O	740-748
the	O	749-752
neuroprotective	O	753-768
effects	O	769-776
of	O	777-779
maltolyl	O	780-788
p	O	789-790
-	O	790-791
coumarate	O	791-800
in	O	801-803
vitro	O	804-809
using	O	810-815
SH	O	816-818
-	O	818-819
SY5Y	O	819-823
cells	O	824-829
.	O	829-830

Cells	O	831-836
were	O	837-841
pretreated	O	842-852
with	O	853-857
maltolyl	O	858-866
p	O	867-868
-	O	868-869
coumarate	O	869-878
,	O	878-879
before	O	880-886
exposed	O	887-894
to	O	895-897
amyloid	O	898-905
beta	O	906-910
peptide	O	911-918
(	O	918-919
1	O	919-920
-	O	920-921
42	O	921-923
)	O	923-924
,	O	924-925
glutamate	O	926-935
or	O	936-938
H2O2	O	939-943
.	O	943-944

We	O	945-947
found	O	948-953
that	O	954-958
maltolyl	O	959-967
p	O	968-969
-	O	969-970
coumarate	O	970-979
significantly	O	980-993
decreased	O	994-1003
apoptotic	O	1004-1013
cell	O	1014-1018
death	O	1019-1024
and	O	1025-1028
reduced	O	1029-1036
reactive	O	1037-1045
oxygen	O	1046-1052
species	O	1053-1060
,	O	1060-1061
cytochrome	O	1062-1072
c	O	1073-1074
release	O	1075-1082
,	O	1082-1083
and	O	1084-1087
caspase	O	1088-1095
3	O	1096-1097
activation	O	1098-1108
.	O	1108-1109

Taking	O	1110-1116
these	O	1117-1122
in	O	1123-1125
vitro	O	1126-1131
and	O	1132-1135
in	O	1136-1138
vivo	O	1139-1143
results	O	1144-1151
together	O	1152-1160
,	O	1160-1161
our	O	1162-1165
study	O	1166-1171
suggests	O	1172-1180
that	O	1181-1185
maltolyl	O	1186-1194
p	O	1195-1196
-	O	1196-1197
coumarate	O	1197-1206
is	O	1207-1209
a	O	1210-1211
potentially	O	1212-1223
effective	O	1224-1233
candidate	O	1234-1243
against	O	1244-1251
Alzheimer	B	1252-1261
'	I	1261-1262
s	I	1262-1263
disease	I	1264-1271
that	O	1272-1276
is	O	1277-1279
characterized	O	1280-1293
by	O	1294-1296
wide	O	1297-1301
spread	O	1302-1308
neuronal	B	1309-1317
death	I	1318-1323
and	O	1324-1327
progressive	O	1328-1339
decline	B	1340-1347
of	I	1348-1350
cognitive	I	1351-1360
function	I	1361-1369
.	O	1369-1370

Interaction	O	0-11
between	O	12-19
warfarin	O	20-28
and	O	29-32
levofloxacin	O	33-45
:	O	45-46
case	O	47-51
series	O	52-58
.	O	58-59

Warfarin	O	60-68
is	O	69-71
the	O	72-75
most	O	76-80
widely	O	81-87
used	O	88-92
oral	O	93-97
anticoagulant	O	98-111
and	O	112-115
is	O	116-118
indicated	O	119-128
for	O	129-132
many	O	133-137
clinical	O	138-146
conditions	O	147-157
.	O	157-158

Levofloxacin	O	159-171
,	O	171-172
a	O	173-174
fluoroquinolone	O	175-190
,	O	190-191
is	O	192-194
one	O	195-198
of	O	199-201
the	O	202-205
most	O	206-210
commonly	O	211-219
prescribed	O	220-230
antibiotics	O	231-242
in	O	243-245
clinical	O	246-254
practice	O	255-263
and	O	264-267
is	O	268-270
effective	O	271-280
against	O	281-288
Gram	O	289-293
-	O	293-294
positive	O	294-302
,	O	302-303
Gram	O	304-308
-	O	308-309
negative	O	309-317
,	O	317-318
and	O	319-322
atypical	O	323-331
bacteria	O	332-340
.	O	340-341

While	O	342-347
small	O	348-353
prospective	O	354-365
studies	O	366-373
have	O	374-378
not	O	379-382
revealed	O	383-391
any	O	392-395
significant	O	396-407
drug	O	408-412
-	O	412-413
drug	O	408-412
interaction	O	418-429
between	O	430-437
warfarin	O	438-446
and	O	447-450
levofloxacin	O	451-463
,	O	463-464
several	O	465-472
case	O	473-477
reports	O	478-485
have	O	486-490
indicated	O	491-500
that	O	501-505
levofloxacin	O	506-518
may	O	519-522
significantly	O	523-536
potentiate	O	537-547
the	O	548-551
anticoagulation	O	552-567
effect	O	568-574
of	O	575-577
warfarin	O	578-586
.	O	586-587

We	O	588-590
report	O	591-597
3	O	598-599
cases	O	600-605
of	O	606-608
serious	O	609-616
bleeding	B	617-625
complications	O	626-639
that	O	640-644
appear	O	645-651
to	O	652-654
be	O	655-657
the	O	658-661
result	O	662-668
of	O	669-671
the	O	672-675
interaction	O	676-687
between	O	688-695
warfarin	O	696-704
and	O	705-708
levofloxacin	O	709-721
.	O	721-722

Physicians	O	723-733
should	O	734-740
be	O	741-743
aware	O	744-749
of	O	750-752
this	O	753-757
potential	O	758-767
interaction	O	768-779
and	O	780-783
use	O	784-787
caution	O	788-795
when	O	796-800
prescribing	O	801-812
levofloxacin	O	813-825
to	O	826-828
patients	O	829-837
taking	O	838-844
warfarin	O	845-853
.	O	853-854

Mutations	O	0-9
associated	O	10-20
with	O	21-25
lamivudine	O	26-36
-	O	36-37
resistance	O	37-47
in	O	48-50
therapy	O	51-58
-	O	58-59
na	O	59-61
ve	O	63-65
hepatitis	B	66-75
B	I	76-77
virus	I	78-83
(	I	84-85
HBV	I	85-88
)	I	88-89
infected	I	90-98
patients	O	99-107
with	O	108-112
and	O	113-116
without	O	117-124
HIV	B	125-128
co	I	129-131
-	I	131-132
infection	I	132-141
:	O	141-142
implications	O	143-155
for	O	156-159
antiretroviral	O	160-174
therapy	O	175-182
in	O	183-185
HBV	B	186-189
and	I	190-193
HIV	I	194-197
co	I	198-200
-	I	200-201
infected	I	201-209
South	O	210-215
African	O	216-223
patients	O	224-232
.	O	232-233

This	O	234-238
was	O	239-242
an	O	243-245
exploratory	O	246-257
study	O	258-263
to	O	264-266
investigate	O	267-278
lamivudine	O	279-289
-	O	289-290
resistant	O	290-299
hepatitis	B	300-309
B	I	310-311
virus	O	312-317
(	O	318-319
HBV	O	319-322
)	O	322-323
strains	O	324-331
in	O	332-334
selected	O	335-343
lamivudine	O	344-354
-	O	354-355
na	O	355-357
ve	O	359-361
HBV	O	362-365
carriers	O	366-374
with	O	375-379
and	O	380-383
without	O	384-391
human	B	392-397
immunodeficiency	I	398-414
virus	I	415-420
(	I	421-422
HIV	I	422-425
)	I	425-426
co	I	427-429
-	I	429-430
infection	I	430-439
in	O	440-442
South	O	443-448
African	O	449-456
patients	O	457-465
.	O	465-466

Thirty	O	467-473
-	O	473-474
five	O	474-478
lamivudine	O	479-489
-	O	489-490
na	O	490-492
ve	O	494-496
HBV	B	497-500
infected	I	501-509
patients	O	510-518
with	O	519-523
or	O	524-526
without	O	527-534
HIV	B	535-538
co	I	539-541
-	I	541-542
infection	I	542-551
were	O	552-556
studied	O	557-564
:	O	564-565
15	O	566-568
chronic	O	569-576
HBV	B	577-580
mono	I	581-585
-	I	585-586
infected	I	586-594
patients	O	595-603
and	O	604-607
20	O	608-610
HBV	B	611-614
-	I	614-615
HIV	I	615-618
co	I	619-621
-	I	621-622
infected	I	622-630
patients	O	631-639
.	O	639-640

The	O	641-644
latter	O	645-651
group	O	652-657
was	O	658-661
further	O	662-669
sub	O	670-673
-	O	673-674
divided	O	674-681
into	O	682-686
13	O	687-689
occult	O	690-696
HBV	O	697-700
(	O	701-702
HBsAg	O	702-707
-	O	707-708
negative	O	708-716
)	O	716-717
and	O	718-721
7	O	722-723
overt	O	724-729
HBV	O	730-733
(	O	734-735
HBsAg	O	735-740
-	O	740-741
positive	O	742-750
)	O	750-751
patients	O	752-760
.	O	760-761

HBsAg	O	762-767
,	O	767-768
anti	O	769-773
-	O	773-774
HBs	O	774-777
,	O	777-778
anti	O	779-783
-	O	783-784
HBc	O	784-787
,	O	787-788
and	O	789-792
anti	O	793-797
-	O	797-798
HIV	O	798-801
1	O	802-803
/	O	803-804
2	O	804-805
were	O	806-810
determined	O	811-821
as	O	822-824
part	O	825-829
of	O	830-832
routine	O	833-840
diagnosis	O	841-850
using	O	851-856
Axsym	O	857-862
assays	O	863-869
(	O	870-871
Abbott	O	871-877
Laboratories	O	878-890
,	O	890-891
North	O	892-897
Chicago	O	898-905
,	O	905-906
IL	O	907-909
)	O	909-910
.	O	910-911

Serum	O	912-917
samples	O	918-925
were	O	926-930
PCR	O	931-934
amplified	O	935-944
with	O	945-949
HBV	O	950-953
reverse	O	954-961
transcriptase	O	962-975
(	O	976-977
RT	O	977-979
)	O	979-980
primers	O	981-988
,	O	988-989
followed	O	990-998
by	O	999-1001
direct	O	1002-1008
sequencing	O	1009-1019
across	O	1020-1026
the	O	1027-1030
tyrosine	O	1031-1039
-	O	1039-1040
methionine	O	1040-1050
-	O	1039-1040
aspartate	O	1051-1060
-	O	1039-1040
aspartate	O	1051-1060
(	O	1071-1072
YMDD	O	1072-1076
)	O	1076-1077
motif	O	1078-1083
of	O	1084-1086
the	O	1087-1090
major	O	1091-1096
catalytic	O	1097-1106
region	O	1107-1113
in	O	1114-1116
the	O	1117-1120
C	O	1121-1122
domain	O	1123-1129
of	O	1130-1132
the	O	1133-1136
HBV	O	1137-1140
RT	O	1141-1143
enzyme	O	1144-1150
.	O	1150-1151

HBV	O	1152-1155
viral	O	1156-1161
load	O	1162-1166
was	O	1167-1170
performed	O	1171-1180
with	O	1181-1185
Amplicor	O	1186-1194
HBV	O	1195-1198
Monitor	O	1199-1206
test	O	1207-1211
v2	O	1212-1214
.	O	1214-1215
0	O	1215-1216
(	O	1217-1218
Roche	O	1218-1223
Diagnostics	O	1224-1235
,	O	1235-1236
Penzberg	O	1237-1245
,	O	1245-1246
Germany	O	1247-1254
)	O	1254-1255
.	O	1255-1256

HBV	O	1257-1260
lamivudine	O	1261-1271
-	O	1271-1272
resistant	O	1272-1281
strains	O	1282-1289
were	O	1290-1294
detected	O	1295-1303
in	O	1304-1306
3	O	1307-1308
of	O	1309-1311
15	O	1312-1314
mono	O	1315-1319
-	O	1319-1320
infected	O	1320-1328
chronic	O	1329-1336
hepatitis	B	1337-1346
B	I	1347-1348
patients	O	1349-1357
and	O	1358-1361
10	O	1362-1364
of	O	1365-1367
20	O	1368-1370
HBV	B	1371-1374
-	I	1374-1375
HIV	I	1375-1378
co	I	1379-1381
-	I	1381-1382
infected	I	1382-1390
patients	O	1391-1399
.	O	1399-1400

To	O	1401-1403
the	O	1404-1407
best	O	1408-1412
of	O	1413-1415
our	O	1416-1419
knowledge	O	1420-1429
,	O	1429-1430
this	O	1431-1435
constitutes	O	1436-1447
the	O	1448-1451
first	O	1452-1457
report	O	1458-1464
of	O	1465-1467
HBV	O	1468-1471
lamivudine	O	1472-1482
-	O	1482-1483
resistant	O	1483-1492
strains	O	1493-1500
in	O	1501-1503
therapy	O	1504-1511
-	O	1511-1512
na	O	1512-1514
ve	O	1516-1518
HBV	B	1519-1522
-	I	1522-1523
HIV	I	1523-1526
co	I	1527-1529
-	I	1529-1530
infected	I	1530-1538
patients	O	1539-1547
.	O	1547-1548

The	O	1549-1552
HBV	O	1553-1556
viral	O	1557-1562
loads	O	1563-1568
for	O	1569-1572
mono	O	1573-1577
-	O	1577-1578
infected	O	1578-1586
and	O	1587-1590
co	O	1591-1593
-	O	1593-1594
infected	O	1594-1602
patients	O	1603-1611
ranged	O	1612-1618
from	O	1619-1623
3	O	1624-1625
.	O	1625-1626
32	O	1626-1628
x	O	1629-1630
10	O	1631-1633
(	O	1633-1634
2	O	1634-1635
)	O	1635-1636
to	O	1637-1639
3	O	1640-1641
.	O	1641-1642
82	O	1642-1644
x	O	1645-1646
10	O	1647-1649
(	O	1649-1650
7	O	1650-1651
)	O	1651-1652
and	O	1653-1656
<	O	1657-1658
200	O	1658-1661
to	O	1662-1664
4	O	1665-1666
.	O	1666-1667
40	O	1667-1669
x	O	1670-1671
10	O	1672-1674
(	O	1674-1675
3	O	1675-1676
)	O	1676-1677
copies	O	1678-1684
/	O	1684-1685
ml	O	1685-1687
,	O	1687-1688
respectively	O	1689-1701
.	O	1701-1702

It	O	1703-1705
remains	O	1706-1713
to	O	1714-1716
be	O	1717-1719
seen	O	1720-1724
whether	O	1725-1732
such	O	1733-1737
pre	O	1738-1741
-	O	1741-1742
existing	O	1742-1750
antiviral	O	1751-1760
mutations	O	1761-1770
could	O	1771-1776
result	O	1777-1783
in	O	1784-1786
widespread	O	1787-1797
emergence	O	1798-1807
of	O	1808-1810
HBV	O	1811-1814
resistant	O	1815-1824
strains	O	1825-1832
when	O	1833-1837
lamivudine	O	1838-1848
-	O	1848-1849
containing	O	1849-1859
highly	O	1860-1866
active	O	1867-1873
antiretroviral	O	1874-1888
(	O	1889-1890
ARV	O	1890-1893
)	O	1893-1894
treatment	O	1895-1904
(	O	1905-1906
HAART	O	1906-1911
)	O	1911-1912
regimens	O	1913-1921
become	O	1922-1928
widely	O	1929-1935
applied	O	1936-1943
in	O	1944-1946
South	O	1947-1952
Africa	O	1953-1959
,	O	1959-1960
as	O	1961-1963
this	O	1964-1968
is	O	1969-1971
likely	O	1972-1978
to	O	1979-1981
have	O	1982-1986
potential	O	1987-1996
implications	O	1997-2009
in	O	2010-2012
the	O	2013-2016
management	O	2017-2027
of	O	2028-2030
HBV	B	2031-2034
-	I	2034-2035
HIV	I	2035-2038
co	I	2039-2041
-	I	2041-2042
infected	I	2042-2050
patients	O	2051-2059
.	O	2059-2060

Sex	O	0-3
differences	O	4-15
in	O	16-18
NMDA	O	19-23
antagonist	O	24-34
enhancement	O	35-46
of	O	47-49
morphine	O	50-58
antihyperalgesia	O	59-75
in	O	76-78
a	O	79-80
capsaicin	O	81-90
model	O	91-96
of	O	97-99
persistent	O	100-110
pain	B	111-115
:	O	115-116
comparisons	O	117-128
to	O	129-131
two	O	132-135
models	O	136-142
of	O	143-145
acute	B	146-151
pain	I	152-156
.	O	156-157

In	O	158-160
acute	B	161-166
pain	I	167-171
models	O	172-178
,	O	178-179
N	O	180-181
-	O	181-182
methyl	O	182-188
-	O	181-182
D	O	189-190
-	O	181-182
aspartate	O	191-200
(	O	201-202
NMDA	O	202-206
)	O	206-207
antagonists	O	208-219
enhance	O	220-227
the	O	228-231
antinociceptive	O	232-247
effects	O	248-255
of	O	256-258
morphine	O	259-267
to	O	268-270
a	O	271-272
greater	O	273-280
extent	O	281-287
in	O	288-290
males	O	291-296
than	O	297-301
females	O	302-309
.	O	309-310

The	O	311-314
purpose	O	315-322
of	O	323-325
this	O	326-330
investigation	O	331-344
was	O	345-348
to	O	349-351
extend	O	352-358
these	O	359-364
findings	O	365-373
to	O	374-376
a	O	377-378
persistent	O	379-389
pain	B	390-394
model	O	395-400
which	O	401-406
could	O	407-412
be	O	413-415
distinguished	O	416-429
from	O	430-434
acute	B	435-440
pain	I	441-445
models	O	446-452
on	O	453-455
the	O	456-459
basis	O	460-465
of	O	466-468
the	O	469-472
nociceptive	O	473-484
fibers	O	485-491
activated	O	492-501
,	O	501-502
neurochemical	O	503-516
substrates	O	517-527
,	O	527-528
and	O	529-532
duration	O	533-541
of	O	542-544
the	O	545-548
nociceptive	O	549-560
stimulus	O	561-569
.	O	569-570

To	O	571-573
this	O	574-578
end	O	579-582
,	O	582-583
persistent	O	584-594
hyperalgesia	B	595-607
was	O	608-611
induced	O	612-619
by	O	620-622
administration	O	623-637
of	O	638-640
capsaicin	O	641-650
in	O	651-653
the	O	654-657
tail	O	658-662
of	O	663-665
gonadally	O	666-675
intact	O	676-682
F344	O	683-687
rats	O	688-692
,	O	692-693
following	O	694-703
which	O	704-709
the	O	710-713
tail	O	714-718
was	O	719-722
immersed	O	723-731
in	O	732-734
a	O	735-736
mildly	O	737-743
noxious	O	744-751
thermal	O	752-759
stimulus	O	760-768
,	O	768-769
and	O	770-773
tail	O	774-778
-	O	778-779
withdrawal	O	779-789
latencies	O	790-799
measured	O	800-808
.	O	808-809

For	O	810-813
comparison	O	814-824
,	O	824-825
tests	O	826-831
were	O	832-836
conducted	O	837-846
in	O	847-849
two	O	850-853
acute	B	854-859
pain	I	860-864
models	O	865-871
,	O	871-872
the	O	873-876
hotplate	O	877-885
and	O	886-889
warm	O	890-894
water	O	895-900
tail	O	901-905
-	O	905-906
withdrawal	O	906-916
procedures	O	917-927
.	O	927-928

In	O	929-931
males	O	932-937
,	O	937-938
the	O	939-942
non	O	943-946
-	O	946-947
competitive	O	947-958
NMDA	O	959-963
antagonist	O	964-974
dextromethorphan	O	975-991
enhanced	O	992-1000
the	O	1001-1004
antihyperalgesic	O	1005-1021
effect	O	1022-1028
of	O	1029-1031
low	O	1032-1035
to	O	1036-1038
moderate	O	1039-1047
doses	O	1048-1053
of	O	1054-1056
morphine	O	1057-1065
in	O	1066-1068
a	O	1069-1070
dose	O	1071-1075
-	O	1075-1076
and	O	1076-1079
time	O	1080-1084
-	O	1084-1085
dependent	O	1085-1094
manner	O	1095-1101
.	O	1101-1102

Across	O	1103-1109
the	O	1110-1113
doses	O	1114-1119
and	O	1120-1123
pretreatment	O	1124-1136
times	O	1137-1142
examined	O	1143-1151
,	O	1151-1152
enhancement	O	1153-1164
was	O	1165-1168
not	O	1169-1172
observed	O	1173-1181
in	O	1182-1184
females	O	1185-1192
.	O	1192-1193

Enhancement	O	1194-1205
of	O	1206-1208
morphine	O	1209-1217
antinociception	O	1218-1233
by	O	1234-1236
dextromethorphan	O	1237-1253
was	O	1254-1257
seen	O	1258-1262
in	O	1263-1265
both	O	1266-1270
males	O	1271-1276
and	O	1277-1280
females	O	1281-1288
in	O	1289-1291
the	O	1292-1295
acute	B	1296-1301
pain	I	1302-1306
models	O	1307-1313
,	O	1313-1314
with	O	1315-1319
the	O	1320-1323
magnitude	O	1324-1333
of	O	1334-1336
this	O	1337-1341
effect	O	1342-1348
being	O	1349-1354
greater	O	1355-1362
in	O	1363-1365
males	O	1366-1371
.	O	1371-1372

These	O	1373-1378
findings	O	1379-1387
demonstrate	O	1388-1399
a	O	1400-1401
sexually	O	1402-1410
-	O	1410-1411
dimorphic	O	1411-1420
interaction	O	1421-1432
between	O	1433-1440
NMDA	O	1441-1445
antagonists	O	1446-1457
and	O	1458-1461
morphine	O	1462-1470
in	O	1471-1473
a	O	1474-1475
persistent	O	1476-1486
pain	B	1487-1491
model	O	1492-1497
that	O	1498-1502
can	O	1503-1506
be	O	1507-1509
distinguished	O	1510-1523
from	O	1524-1528
those	O	1529-1534
observed	O	1535-1543
in	O	1544-1546
acute	B	1547-1552
pain	I	1553-1557
models	O	1558-1564
.	O	1564-1565

Development	O	0-11
of	O	12-14
proteinuria	B	15-26
after	O	27-32
switch	O	33-39
to	O	40-42
sirolimus	O	43-52
-	O	52-53
based	O	53-58
immunosuppression	O	59-76
in	O	77-79
long	O	80-84
-	O	84-85
term	O	85-89
cardiac	O	90-97
transplant	O	98-108
patients	O	109-117
.	O	117-118

Calcineurin	O	119-130
-	O	130-131
inhibitor	O	131-140
therapy	O	141-148
can	O	149-152
lead	O	153-157
to	O	158-160
renal	B	161-166
dysfunction	I	167-178
in	O	179-181
heart	O	182-187
transplantation	O	188-203
patients	O	204-212
.	O	212-213

The	O	214-217
novel	O	218-223
immunosuppressive	O	224-241
(	O	242-243
IS	O	243-245
)	O	245-246
drug	O	247-251
sirolmus	O	252-260
(	O	261-262
Srl	O	262-265
)	O	265-266
lacks	O	267-272
nephrotoxic	B	273-284
effects	O	285-292
;	O	292-293
however	O	294-301
,	O	301-302
proteinuria	B	303-314
associated	O	315-325
with	O	326-330
Srl	O	331-334
has	O	335-338
been	O	339-343
reported	O	344-352
following	O	353-362
renal	O	363-368
transplantation	O	369-384
.	O	384-385

In	O	386-388
cardiac	O	389-396
transplantation	O	397-412
,	O	412-413
the	O	414-417
incidence	O	418-427
of	O	428-430
proteinuria	B	431-442
associated	O	443-453
with	O	454-458
Srl	O	459-462
is	O	463-465
unknown	O	466-473
.	O	473-474

In	O	475-477
this	O	478-482
study	O	483-488
,	O	488-489
long	O	490-494
-	O	494-495
term	O	495-499
cardiac	O	500-507
transplant	O	508-518
patients	O	519-527
were	O	528-532
switched	O	533-541
from	O	542-546
cyclosporine	O	547-559
to	O	560-562
Srl	O	563-566
-	O	566-567
based	O	567-572
IS	O	573-575
.	O	575-576

Concomitant	O	577-588
IS	O	589-591
consisted	O	592-601
of	O	602-604
mycophenolate	O	605-618
mofetil	O	619-626
+	O	627-628
/	O	628-629
-	O	629-630
steroids	O	631-639
.	O	639-640

Proteinuria	O	641-652
increased	O	653-662
significantly	O	663-676
from	O	677-681
a	O	682-683
median	O	684-690
of	O	691-693
0	O	694-695
.	O	695-696
13	O	696-698
g	O	699-700
/	O	700-701
day	O	701-704
(	O	705-706
range	O	706-711
0	O	712-713
-	O	713-714
5	O	714-715
.	O	715-716
7	O	716-717
)	O	717-718
preswitch	O	719-728
to	O	729-731
0	O	732-733
.	O	733-734
23	O	734-736
g	O	737-738
/	O	738-739
day	O	739-742
(	O	743-744
0	O	744-745
-	O	745-746
9	O	746-747
.	O	747-748
88	O	748-750
)	O	750-751
at	O	752-754
24	O	755-757
months	O	758-764
postswitch	O	765-775
(	O	776-777
p	O	777-778
=	O	779-780
0	O	781-782
.	O	782-783
0024	O	783-787
)	O	787-788
.	O	782-783

Before	O	790-796
the	O	797-800
switch	O	801-807
,	O	807-808
11	O	809-811
.	O	811-812
5	O	812-813
%	O	813-814
of	O	815-817
patients	O	818-826
had	O	827-830
high	O	831-835
-	O	835-836
grade	O	836-841
proteinuria	B	842-853
(	O	854-855
>	O	855-856
1	O	856-857
.	O	857-858
0	O	858-859
g	O	860-861
/	O	861-862
day	O	862-865
)	O	865-866
;	O	866-867
this	O	868-872
increased	O	873-882
to	O	883-885
22	O	886-888
.	O	888-889
9	O	889-890
%	O	890-891
postswitch	O	892-902
(	O	903-904
p	O	904-905
=	O	906-907
0	O	908-909
.	O	909-910
006	O	910-913
)	O	913-914
.	O	909-910

ACE	O	916-919
inhibitor	O	920-929
and	O	930-933
angiotensin	O	934-945
-	O	945-946
releasing	O	946-955
blocker	O	956-963
(	O	964-965
ARB	O	965-968
)	O	968-969
therapy	O	970-977
reduced	O	978-985
proteinuria	B	986-997
development	O	998-1009
.	O	1009-1010

Patients	O	1011-1019
without	O	1020-1027
proteinuria	B	1028-1039
had	O	1040-1043
increased	O	1044-1053
renal	O	1054-1059
function	O	1060-1068
(	O	1069-1070
median	O	1070-1076
42	O	1077-1079
.	O	1079-1080
5	O	1080-1081
vs	O	1082-1084
.	O	1084-1085
64	O	1086-1088
.	O	1088-1089
1	O	1089-1090
,	O	1090-1091

p	O	1092-1093
=	O	1094-1095
0	O	1096-1097
.	O	1097-1098
25	O	1098-1100
)	O	1100-1101
,	O	1101-1102
whereas	O	1103-1110
patients	O	1111-1119
who	O	1120-1123
developed	O	1124-1133
high	O	1134-1138
-	O	1138-1139
grade	O	1139-1144
proteinuria	B	1145-1156
showed	O	1157-1163
decreased	O	1164-1173
renal	O	1174-1179
function	O	1180-1188
at	O	1189-1191
the	O	1192-1195
end	O	1196-1199
of	O	1200-1202
follow	O	1203-1209
-	O	1209-1210
up	O	1210-1212
(	O	1213-1214
median	O	1214-1220
39	O	1221-1223
.	O	1223-1224
6	O	1224-1225
vs	O	1226-1228
.	O	1228-1229
29	O	1230-1232
.	O	1232-1233
2	O	1230-1231
,	O	1234-1235

p	O	1236-1237
=	O	1238-1239
0	O	1240-1241
.	O	1241-1242
125	O	1242-1245
)	O	1245-1246
.	O	1241-1242

Thus	O	1248-1252
,	O	1252-1253
proteinuria	B	1254-1265
may	O	1266-1269
develop	O	1270-1277
in	O	1278-1280
cardiac	O	1281-1288
transplant	O	1289-1299
patients	O	1300-1308
after	O	1309-1314
switch	O	1315-1321
to	O	1322-1324
Srl	O	1325-1328
,	O	1328-1329
which	O	1330-1335
may	O	1336-1339
have	O	1340-1344
an	O	1345-1347
adverse	O	1348-1355
effect	O	1356-1362
on	O	1363-1365
renal	O	1366-1371
function	O	1372-1380
in	O	1381-1383
these	O	1384-1389
patients	O	1390-1398
.	O	1398-1399

Srl	O	1400-1403
should	O	1404-1410
be	O	1411-1413
used	O	1414-1418
with	O	1419-1423
ACEi	O	1424-1428
/	O	1428-1429
ARB	O	1429-1432
therapy	O	1433-1440
and	O	1441-1444
patients	O	1445-1453
monitored	O	1454-1463
for	O	1464-1467
proteinuria	B	1468-1479
and	O	1480-1483
increased	O	1484-1493
renal	B	1494-1499
dysfunction	I	1500-1511
.	O	1511-1512

Synthesis	O	0-9
of	O	10-12
N	O	13-14
-	O	14-15
pyrimidinyl	O	15-26
-	O	14-15
2	O	27-28
-	O	14-15
phenoxyacetamides	O	29-46
as	O	47-49
adenosine	O	50-59
A2A	O	60-63
receptor	O	64-72
antagonists	O	73-84
.	O	84-85

A	O	86-87
series	O	88-94
of	O	95-97
N	O	98-99
-	O	99-100
pyrimidinyl	O	100-111
-	O	99-100
2	O	112-113
-	O	99-100
phenoxyacetamide	O	114-130
adenosine	O	131-140
A	O	141-142
(	O	142-143
2A	O	143-145
)	O	145-146
antagonists	O	147-158
is	O	159-161
described	O	162-171
.	O	171-172

SAR	O	173-176
studies	O	177-184
led	O	185-188
to	O	189-191
compound	O	192-200
14	O	201-203
with	O	204-208
excellent	O	209-218
potency	O	219-226
(	O	227-228
K	O	228-229
(	O	227-228
i	O	230-231
)	O	231-232
=	O	233-234
0	O	235-236
.	O	236-237
4	O	237-238
nM	O	239-241
)	O	241-242
,	O	242-243
selectivity	O	244-255
(	O	256-257
A	O	257-258
(	O	256-257
1	O	259-260
)	O	260-261
/	O	261-262
A	O	257-258
(	O	256-257
2A	O	264-266
)	O	260-261
>	O	268-269
100	O	270-273
)	O	273-274
,	O	274-275
and	O	276-279
efficacy	O	280-288
(	O	289-290
MED	O	290-293
10	O	294-296
mg	O	297-299
/	O	299-300
kg	O	300-302
p	O	303-304
.	O	304-305
o	O	305-306
.	O	304-305
)	O	307-308
in	O	309-311
the	O	312-315
rat	O	316-319
haloperidol	O	320-331
-	O	331-332
induced	O	332-339
catalepsy	B	340-349
model	O	350-355
for	O	356-359
Parkinson	B	360-369
'	I	369-370
s	I	366-367
disease	I	372-379
.	O	379-380

Methamphetamine	O	0-15
-	O	15-16
induced	O	16-23
neurotoxicity	B	24-37
and	O	38-41
microglial	O	42-52
activation	O	53-63
are	O	64-67
not	O	68-71
mediated	O	72-80
by	O	81-83
fractalkine	O	84-95
receptor	O	96-104
signaling	O	105-114
.	O	114-115

Methamphetamine	O	116-131
(	O	132-133
METH	O	133-137
)	O	137-138
damages	O	139-146
dopamine	O	147-155
(	O	156-157
DA	O	157-159
)	O	159-160
nerve	O	161-166
endings	O	167-174
by	O	175-177
a	O	178-179
process	O	180-187
that	O	188-192
has	O	193-196
been	O	197-201
linked	O	202-208
to	O	209-211
microglial	O	212-222
activation	O	223-233
but	O	234-237
the	O	238-241
signaling	O	242-251
pathways	O	252-260
that	O	261-265
mediate	O	266-273
this	O	274-278
response	O	279-287
have	O	288-292
not	O	293-296
yet	O	297-300
been	O	301-305
delineated	O	306-316
.	O	316-317

Cardona	O	318-325
et	O	326-328
al	O	329-331
.	O	331-332
[	O	333-334
Nat	O	334-337
.	O	337-338

Neurosci	O	339-347
.	O	347-348

9	O	349-350
(	O	351-352
2006	O	352-356
)	O	356-357
,	O	357-358
917	O	359-362
]	O	362-363
recently	O	364-372
identified	O	373-383
the	O	384-387
microglial	O	388-398
-	O	398-399
specific	O	399-407
fractalkine	O	408-419
receptor	O	420-428
(	O	429-430
CX3CR1	O	430-436
)	O	436-437
as	O	438-440
an	O	441-443
important	O	444-453
mediator	O	454-462
of	O	463-465
MPTP	O	466-470
-	O	470-471
induced	O	471-478
neurodegeneration	B	479-496
of	O	497-499
DA	O	500-502
neurons	O	503-510
.	O	510-511

Because	O	512-519
the	O	520-523
CNS	B	524-527
damage	I	528-534
caused	O	535-541
by	O	542-544
METH	O	545-549
and	O	550-553
MPTP	O	554-558
is	O	559-561
highly	O	562-568
selective	O	569-578
for	O	579-582
the	O	583-586
DA	O	587-589
neuronal	O	590-598
system	O	599-605
in	O	606-608
mouse	O	609-614
models	O	615-621
of	O	622-624
neurotoxicity	B	625-638
,	O	638-639
we	O	640-642
hypothesized	O	643-655
that	O	656-660
the	O	661-664
CX3CR1	O	665-671
plays	O	672-677
a	O	678-679
role	O	680-684
in	O	685-687
METH	O	688-692
-	O	692-693
induced	O	693-700
neurotoxicity	B	701-714
and	O	715-718
microglial	O	719-729
activation	O	730-740
.	O	740-741

Mice	O	742-746
in	O	747-749
which	O	750-755
the	O	756-759
CX3CR1	O	760-766
gene	O	767-771
has	O	772-775
been	O	776-780
deleted	O	781-788
and	O	789-792
replaced	O	793-801
with	O	802-806
a	O	807-808
cDNA	O	809-813
encoding	O	814-822
enhanced	O	823-831
green	O	832-837
fluorescent	O	838-849
protein	O	850-857
(	O	858-859
eGFP	O	859-863
)	O	863-864
were	O	865-869
treated	O	870-877
with	O	878-882
METH	O	883-887
and	O	888-891
examined	O	892-900
for	O	901-904
striatal	O	905-913
neurotoxicity	B	914-927
.	O	927-928

METH	O	929-933
depleted	O	934-942
DA	O	943-945
,	O	945-946
caused	O	947-953
microglial	O	954-964
activation	O	965-975
,	O	975-976
and	O	977-980
increased	O	981-990
body	O	991-995
temperature	O	996-1007
in	O	1008-1010
CX3CR1	O	1011-1017
knockout	O	1018-1026
mice	O	1027-1031
to	O	1032-1034
the	O	1035-1038
same	O	1039-1043
extent	O	1044-1050
and	O	1051-1054
over	O	1055-1059
the	O	1060-1063
same	O	1064-1068
time	O	1069-1073
course	O	1074-1080
seen	O	1081-1085
in	O	1086-1088
wild	O	1089-1093
-	O	1093-1094
type	O	1094-1098
controls	O	1099-1107
.	O	1107-1108

The	O	1109-1112
effects	O	1113-1120
of	O	1121-1123
METH	O	1124-1128
in	O	1129-1131
CX3CR1	O	1132-1138
knockout	O	1139-1147
mice	O	1148-1152
were	O	1153-1157
not	O	1158-1161
gender	O	1162-1168
-	O	1168-1169
dependent	O	1169-1178
and	O	1179-1182
did	O	1183-1186
not	O	1187-1190
extend	O	1191-1197
beyond	O	1198-1204
the	O	1205-1208
striatum	O	1209-1217
.	O	1217-1218

Striatal	O	1219-1227
microglia	O	1228-1237
expressing	O	1238-1248
eGFP	O	1249-1253
constitutively	O	1254-1268
show	O	1269-1273
morphological	O	1274-1287
changes	O	1288-1295
after	O	1296-1301
METH	O	1302-1306
that	O	1307-1311
are	O	1312-1315
characteristic	O	1316-1330
of	O	1331-1333
activation	O	1334-1344
.	O	1344-1345

This	O	1346-1350
response	O	1351-1359
was	O	1360-1363
restricted	O	1364-1374
to	O	1375-1377
the	O	1378-1381
striatum	O	1382-1390
and	O	1391-1394
contrasted	O	1395-1405
sharply	O	1406-1413
with	O	1414-1418
unresponsive	O	1419-1431
eGFP	O	1432-1436
-	O	1436-1437
microglia	O	1437-1446
in	O	1447-1449
surrounding	O	1450-1461
brain	O	1462-1467
areas	O	1468-1473
that	O	1474-1478
are	O	1479-1482
not	O	1483-1486
damaged	O	1487-1494
by	O	1495-1497
METH	O	1498-1502
.	O	1502-1503

We	O	1504-1506
conclude	O	1507-1515
from	O	1516-1520
these	O	1521-1526
studies	O	1527-1534
that	O	1535-1539
CX3CR1	O	1540-1546
signaling	O	1547-1556
does	O	1557-1561
not	O	1562-1565
modulate	O	1566-1574
METH	O	1575-1579
neurotoxicity	B	1580-1593
or	O	1594-1596
microglial	O	1597-1607
activation	O	1608-1618
.	O	1618-1619

Furthermore	O	1620-1631
,	O	1631-1632
it	O	1633-1635
appears	O	1636-1643
that	O	1644-1648
striatal	O	1649-1657
-	O	1657-1658
resident	O	1658-1666
microglia	O	1667-1676
respond	O	1677-1684
to	O	1685-1687
METH	O	1688-1692
with	O	1693-1697
an	O	1698-1700
activation	O	1701-1711
cascade	O	1712-1719
and	O	1720-1723
then	O	1724-1728
return	O	1729-1735
to	O	1736-1738
a	O	1739-1740
surveying	O	1741-1750
state	O	1751-1756
without	O	1757-1764
undergoing	O	1765-1775
apoptosis	O	1776-1785
or	O	1786-1788
migration	O	1789-1798
.	O	1798-1799

Recovery	O	0-8
of	O	9-11
tacrolimus	O	12-22
-	O	22-23
associated	O	23-33
brachial	B	34-42
neuritis	I	43-51
after	O	52-57
conversion	O	58-68
to	O	69-71
everolimus	O	72-82
in	O	83-85
a	O	86-87
pediatric	O	88-97
renal	O	98-103
transplant	O	104-114
recipient	O	115-124
-	O	124-125
-	O	124-125
case	O	126-130
report	O	131-137
and	O	138-141
review	O	142-148
of	O	149-151
the	O	152-155
literature	O	156-166
.	O	166-167

TAC	O	168-171
has	O	172-175
been	O	176-180
shown	O	181-186
to	O	187-189
be	O	190-192
a	O	193-194
potent	O	195-201
immunosuppressive	O	202-219
agent	O	220-225
for	O	226-229
solid	O	230-235
organ	O	236-241
transplantation	O	242-257
in	O	258-260
pediatrics	O	261-271
.	O	271-272

Neurotoxicity	B	273-286
is	O	287-289
a	O	290-291
potentially	O	292-303
serious	O	304-311
toxic	O	312-317
effect	O	318-324
.	O	324-325

It	O	326-328
is	O	329-331
characterized	O	332-345
by	O	346-348
encephalopathy	B	349-363
,	O	363-364
headaches	B	365-374
,	O	374-375
seizures	B	376-384
,	O	384-385
or	O	386-388
neurological	B	389-401
deficits	I	402-410
.	O	410-411

Here	O	412-416
,	O	416-417
we	O	418-420
describe	O	421-429
an	O	430-432
eight	O	433-438
-	O	438-439
and	O	439-442
-	O	438-439
a	O	439-440
-	O	438-439
half	O	445-449
-	O	438-439
yr	O	450-452
-	O	438-439
old	O	453-456
male	O	457-461
renal	O	462-467
transplant	O	468-478
recipient	O	479-488
with	O	489-493
right	O	494-499
BN	O	500-502
.	O	502-503
MRI	O	504-507
demonstrated	O	508-520
hyperintense	O	521-533
T2	O	534-536
signals	O	537-544
in	O	545-547
the	O	548-551
cervical	O	552-560
cord	O	561-565
and	O	566-569
right	O	570-575
brachial	O	576-584
plexus	O	585-591
roots	O	592-597
indicative	O	598-608
of	O	609-611
both	O	612-616
myelitis	B	617-625
and	O	626-629
right	O	630-635
brachial	B	636-644
plexitis	I	645-653
.	O	653-654

Symptoms	O	655-663
persisted	O	664-673
for	O	674-677
three	O	678-683
months	O	684-690
despite	O	691-698
TAC	O	699-702
dose	O	703-707
reduction	O	708-717
,	O	717-718
administration	O	719-733
of	O	734-736
IVIG	O	737-741
and	O	742-745
four	O	746-750
doses	O	751-756
of	O	757-759
methylprednisolone	O	760-778
pulse	O	779-784
therapy	O	785-792
.	O	792-793

Improvement	O	794-805
and	O	806-809
eventually	O	810-820
full	O	821-825
recovery	O	826-834
only	O	835-839
occurred	O	840-848
after	O	849-854
TAC	O	855-858
was	O	859-862
completely	O	863-873
discontinued	O	874-886
and	O	887-890
successfully	O	891-903
replaced	O	904-912
by	O	913-915
everolimus	O	916-926
.	O	926-927

Valvular	B	0-8
heart	I	9-14
disease	I	15-22
in	O	23-25
patients	O	26-34
with	O	35-39
Parkinson	B	40-49
'	I	49-50
s	I	46-47
disease	I	52-59
treated	O	60-67
with	O	68-72
pergolide	O	73-82
.	O	82-83

Course	O	84-90
following	O	91-100
treatment	O	101-110
modifications	O	111-124
.	O	124-125

Valvular	B	126-134
heart	I	135-140
abnormalities	I	141-154
have	O	155-159
been	O	160-164
reported	O	165-173
in	O	174-176
patients	O	177-185
with	O	186-190
Parkinson	B	191-200
'	I	200-201
s	I	197-198
disease	I	203-210
(	O	211-212
PD	B	212-214
)	O	214-215
treated	O	216-223
with	O	224-228
pergolide	O	229-238
.	O	238-239

However	O	240-247
,	O	247-248
the	O	249-252
incidence	O	253-262
and	O	263-266
severity	O	267-275
of	O	276-278
these	O	279-284
abnormalities	O	285-298
vary	O	299-303
from	O	304-308
study	O	309-314
to	O	315-317
study	O	318-323
and	O	324-327
their	O	328-333
course	O	334-340
after	O	341-346
drug	O	347-351
withdrawal	O	352-362
has	O	363-366
not	O	367-370
been	O	371-375
systematically	O	376-390
assessed	O	391-399
.	O	399-400

OBJECTIVES	O	401-411
:	O	411-412
To	O	413-415
estimate	O	416-424
the	O	425-428
frequency	O	429-438
and	O	439-442
severity	O	443-451
of	O	452-454
valvular	B	455-463
heart	I	464-469
abnormality	I	470-481
and	O	482-485
its	O	486-489
possible	O	490-498
reversibility	O	499-512
after	O	513-518
drug	O	519-523
withdrawal	O	524-534
in	O	535-537
a	O	538-539
case	O	540-544
-	O	544-545
control	O	545-552
study	O	553-558
.	O	558-559

METHODS	O	560-567
:	O	567-568
All	O	569-572
PD	B	573-575
patients	O	576-584
in	O	585-587
the	O	588-591
Amiens	O	592-598
area	O	599-603
treated	O	604-611
with	O	612-616
pergolide	O	617-626
were	O	627-631
invited	O	632-639
to	O	640-642
attend	O	643-649
a	O	650-651
cardiologic	O	652-663
assessment	O	664-674
including	O	675-684
transthoracic	O	685-698
echocardiography	O	699-715
.	O	715-716

Thirty	O	717-723
PD	B	724-726
patients	O	727-735
participated	O	736-748
in	O	749-751
the	O	752-755
study	O	756-761
.	O	761-762

A	O	763-764
second	O	765-771
echocardiography	O	772-788
was	O	789-792
performed	O	793-802
(	O	803-804
median	O	804-810
interval	O	811-819
:	O	819-820
13	O	821-823
months	O	824-830
)	O	830-831
after	O	832-837
pergolide	O	838-847
withdrawal	O	848-858
(	O	859-860
n	O	860-861
=	O	861-862
10	O	862-864
patients	O	865-873
)	O	873-874
.	O	874-875

Controls	O	876-884
were	O	885-889
age	O	890-893
-	O	893-894
and	O	895-898
sex	O	899-902
-	O	902-903
matched	O	903-910
non	O	911-914
-	O	914-915
PD	B	915-917
patients	O	918-926
referred	O	927-935
to	O	936-938
the	O	939-942
cardiology	O	943-953
department	O	954-964
.	O	964-965

RESULTS	O	966-973
:	O	973-974
Compared	O	975-983
to	O	984-986
controls	O	987-995
,	O	995-996
aortic	B	997-1003
regurgitation	I	1004-1017
(	O	1018-1019
OR	O	1019-1021
:	O	1021-1022
3	O	1023-1024
.	O	1024-1025
1	O	1025-1026
;	O	1026-1027
95	O	1028-1030
%	O	1030-1031
IC	O	1032-1034
:	O	1034-1035
1	O	1036-1037
.	O	1037-1038
1	O	1036-1037
-	O	1039-1040
8	O	1040-1041
.	O	1037-1038
8	O	1040-1041
)	O	1043-1044

and	O	1045-1048
mitral	B	1049-1055
regurgitation	I	1056-1069
(	O	1070-1071
OR	O	1071-1073
:	O	1073-1074
10	O	1075-1077
.	O	1077-1078
7	O	1078-1079
;	O	1079-1080
95	O	1081-1083
%	O	1083-1084
IC	O	1085-1087
:	O	1087-1088
2	O	1089-1090
.	O	1090-1091
1	O	1091-1092
-	O	1092-1093
53	O	1093-1095
)	O	1095-1096
were	O	1097-1101
more	O	1102-1106
frequent	O	1107-1115
in	O	1116-1118
PD	B	1119-1121
patients	O	1122-1130
(	O	1131-1132
tricuspid	O	1132-1141
:	O	1141-1142
NS	O	1143-1145
)	O	1145-1146
.	O	1146-1147

The	O	1148-1151
number	O	1152-1158
of	O	1159-1161
affected	O	1162-1170
valves	O	1171-1177
(	O	1178-1179
n	O	1179-1180
=	O	1180-1181
2	O	1181-1182
.	O	1182-1183
4	O	1183-1184
+	O	1184-1185
/	O	1185-1186
-	O	1186-1187
0	O	1187-1188
.	O	1182-1183
7	O	1189-1190
)	O	1190-1191

and	O	1192-1195
the	O	1196-1199
sum	O	1200-1203
of	O	1204-1206
regurgitation	O	1207-1220
grades	O	1221-1227
(	O	1228-1229
n	O	1229-1230
=	O	1230-1231
2	O	1231-1232
.	O	1232-1233
8	O	1233-1234
+	O	1234-1235
/	O	1235-1236
-	O	1236-1237
1	O	1237-1238
.	O	1232-1233
09	O	1239-1241
)	O	1241-1242

were	O	1243-1247
higher	O	1248-1254
(	O	1255-1256
p	O	1256-1257
=	O	1257-1258
0	O	1258-1259
.	O	1259-1260
008	O	1260-1263
and	O	1264-1267
p	O	1268-1269
=	O	1269-1270
0	O	1270-1271
.	O	1271-1272
006	O	1272-1275
,	O	1275-1276
respectively	O	1277-1289
)	O	1289-1290
in	O	1291-1293
the	O	1294-1297
pergolide	O	1298-1307
group	O	1308-1313
.	O	1313-1314

Severity	O	1315-1323
of	O	1324-1326
regurgitation	O	1327-1340
was	O	1341-1344
not	O	1345-1348
correlated	O	1349-1359
with	O	1360-1364
pergolide	O	1365-1374
cumulative	O	1375-1385
dose	O	1386-1390
.	O	1390-1391

A	O	1392-1393
restrictive	O	1394-1405
pattern	O	1406-1413
of	O	1414-1416
valvular	B	1417-1425
regurgitation	I	1426-1439
,	O	1439-1440
suggestive	O	1441-1451
of	O	1452-1454
the	O	1455-1458
role	O	1459-1463
of	O	1464-1466
pergolide	O	1467-1476
,	O	1476-1477
was	O	1478-1481
observed	O	1482-1490
in	O	1491-1493
12	O	1494-1496
/	O	1496-1497
30	O	1497-1499
(	O	1500-1501
40	O	1501-1503
%	O	1503-1504
)	O	1504-1505
patients	O	1506-1514
including	O	1515-1524
two	O	1525-1528
with	O	1529-1533
heart	B	1534-1539
failure	I	1540-1547
.	O	1547-1548

Pergolide	O	1549-1558
was	O	1559-1562
discontinued	O	1563-1575
in	O	1576-1578
10	O	1579-1581
patients	O	1582-1590
with	O	1591-1595
valvular	B	1596-1604
heart	I	1605-1610
disease	I	1611-1618
,	O	1618-1619
resulting	O	1620-1629
in	O	1630-1632
a	O	1633-1634
lower	O	1635-1640
regurgitation	O	1641-1654
grade	O	1655-1660
(	O	1661-1662
p	O	1662-1663
=	O	1663-1664
0	O	1664-1665
.	O	1665-1666
01	O	1666-1668
)	O	1668-1669
at	O	1670-1672
the	O	1673-1676
second	O	1677-1683
transthoracic	O	1684-1697
echocardiography	O	1698-1714
and	O	1715-1718
the	O	1719-1722
two	O	1723-1726
patients	O	1727-1735
with	O	1736-1740
heart	B	1741-1746
failure	I	1747-1754
returned	O	1755-1763
to	O	1764-1766
nearly	O	1767-1773
normal	O	1774-1780
clinical	O	1781-1789
examination	O	1790-1801
.	O	1801-1802

This	O	1803-1807
study	O	1808-1813
supports	O	1814-1822
the	O	1823-1826
high	O	1827-1831
frequency	O	1832-1841
of	O	1842-1844
restrictive	O	1845-1856
valve	B	1857-1862
regurgitation	I	1863-1876
in	O	1877-1879
PD	B	1880-1882
patients	O	1883-1891
treated	O	1892-1899
with	O	1900-1904
pergolide	O	1905-1914
and	O	1915-1918
reveals	O	1919-1926
that	O	1927-1931
a	O	1932-1933
significant	O	1934-1945
improvement	O	1946-1957
is	O	1958-1960
usual	O	1961-1966
when	O	1967-1971
the	O	1972-1975
treatment	O	1976-1985
is	O	1986-1988
converted	O	1989-1998
to	O	1999-2001
non	O	2002-2005
-	O	2005-2006
ergot	O	2006-2011
dopamine	O	2012-2020
agonists	O	2021-2029
.	O	2029-2030

Adverse	O	0-7
effects	O	8-15
of	O	16-18
topical	O	19-26
papaverine	O	27-37
on	O	38-40
auditory	O	41-49
nerve	O	50-55
function	O	56-64
.	O	64-65

BACKGROUND	O	66-76
:	O	76-77
Papaverine	O	78-88
hydrochloride	O	89-102
is	O	103-105
a	O	106-107
direct	O	108-114
-	O	114-115
acting	O	115-121
vasodilator	O	122-133
used	O	134-138
to	O	139-141
manage	O	142-148
vasospasm	B	149-158
during	O	159-165
various	O	166-173
neurosurgical	O	174-187
operations	O	188-198
.	O	198-199

Transient	O	200-209
cranial	B	210-217
nerve	I	218-223
dysfunction	I	224-235
has	O	236-239
been	O	240-244
described	O	245-254
in	O	255-257
a	O	258-259
few	O	260-263
cases	O	264-269
with	O	270-274
topical	O	275-282
papaverine	O	283-293
.	O	293-294

This	O	295-299
study	O	300-305
supports	O	306-314
previous	O	315-323
reports	O	324-331
and	O	332-335
provides	O	336-344
neurophysiological	O	345-363
evidence	O	364-372
of	O	373-375
an	O	376-378
adverse	O	379-386
effect	O	387-393
on	O	394-396
the	O	397-400
auditory	O	401-409
nerve	O	410-415
.	O	415-416

METHODS	O	417-424
:	O	424-425
We	O	426-428
conducted	O	429-438
a	O	439-440
retrospective	O	441-454
review	O	455-461
of	O	462-464
70	O	465-467
consecutive	O	468-479
microvascular	O	480-493
decompression	O	494-507
operations	O	508-518
and	O	519-522
studied	O	523-530
those	O	531-536
patients	O	537-545
who	O	546-549
received	O	550-558
topical	O	559-566
papaverine	O	567-577
for	O	578-581
vasospasm	B	582-591
.	O	591-592

Topical	O	593-600
papaverine	O	601-611
was	O	612-615
used	O	616-620
as	O	621-623
a	O	624-625
direct	O	626-632
therapeutic	O	633-644
action	O	645-651
to	O	652-654
manage	O	655-661
vasospasm	B	662-671
in	O	672-674
a	O	675-676
total	O	677-682
of	O	683-685
11	O	686-688
patients	O	689-697
.	O	697-698

The	O	699-702
timing	O	703-709
of	O	710-712
papaverine	O	713-723
application	O	724-735
and	O	736-739
ongoing	O	740-747
operative	O	748-757
events	O	758-764
was	O	765-768
reviewed	O	769-777
relative	O	778-786
to	O	787-789
changes	O	790-797
in	O	798-800
neurophysiological	O	801-819
recordings	O	820-830
.	O	830-831

Brainstem	O	832-841
auditory	O	842-850
evoked	O	851-857
potentials	O	858-868
(	O	869-870
BAEPs	O	870-875
)	O	875-876
were	O	877-881
routinely	O	882-891
used	O	892-896
to	O	897-899
monitor	O	900-907
cochlear	O	908-916
nerve	O	917-922
function	O	923-931
during	O	932-938
these	O	939-944
operations	O	945-955
.	O	955-956

FINDINGS	O	957-965
:	O	965-966
A	O	967-968
temporal	O	969-977
relationship	O	978-990
was	O	991-994
found	O	995-1000
between	O	1001-1008
topical	O	1009-1016
papaverine	O	1017-1027
and	O	1028-1031
BAEP	O	1032-1036
changes	O	1037-1044
leading	O	1045-1052
to	O	1053-1055
complete	O	1056-1064
waveform	O	1065-1073
loss	O	1074-1078
.	O	1078-1079

The	O	1080-1083
average	O	1084-1091
temporal	O	1092-1100
delay	O	1101-1106
between	O	1107-1114
papaverine	O	1115-1125
and	O	1126-1129
the	O	1130-1133
onset	O	1134-1139
of	O	1140-1142
an	O	1143-1145
adverse	O	1146-1153
BAEP	O	1154-1158
change	O	1159-1165
was	O	1166-1169
5	O	1170-1171
min	O	1172-1175
.	O	1175-1176

In	O	1177-1179
10	O	1180-1182
of	O	1183-1185
11	O	1186-1188
patients	O	1189-1197
,	O	1197-1198
BAEP	O	1199-1203
waves	O	1204-1209
II	O	1210-1212
/	O	1212-1213
III	O	1213-1216
-	O	1216-1217
V	O	1217-1218
completely	O	1219-1229
disappeared	O	1230-1241
within	O	1242-1248
2	O	1249-1250
to	O	1251-1253
25	O	1254-1256
min	O	1257-1260
after	O	1261-1266
papaverine	O	1267-1277
.	O	1277-1278

Eight	O	1279-1284
of	O	1285-1287
these	O	1288-1293
10	O	1294-1296
patients	O	1297-1305
had	O	1306-1309
complete	O	1310-1318
loss	O	1319-1323
of	O	1324-1326
BAEP	O	1327-1331
waveforms	O	1332-1341
within	O	1342-1348
10	O	1349-1351
min	O	1352-1355
.	O	1355-1356

One	O	1357-1360
patient	O	1361-1368
showed	O	1369-1375
no	O	1376-1378
recovery	O	1379-1387
of	O	1388-1390
later	O	1391-1396
waves	O	1397-1402
and	O	1403-1406
a	O	1407-1408
delayed	O	1409-1416
profound	O	1417-1425
sensorineural	B	1426-1439
hearing	I	1440-1447
loss	I	1448-1452
.	O	1452-1453

The	O	1454-1457
average	O	1458-1465
recovery	O	1466-1474
time	O	1475-1479
of	O	1480-1482
BAEP	O	1483-1487
waveforms	O	1488-1497
to	O	1498-1500
pre	O	1501-1504
-	O	1504-1505
papaverine	O	1505-1515
baseline	O	1516-1524
values	O	1525-1531
was	O	1532-1535
39	O	1536-1538
min	O	1539-1542
.	O	1542-1543

CONCLUSIONS	O	1544-1555
:	O	1555-1556
Topical	O	1557-1564
papaverine	O	1565-1575
for	O	1576-1579
the	O	1580-1583
treatment	O	1584-1593
of	O	1594-1596
vasospasm	B	1597-1606
was	O	1607-1610
associated	O	1611-1621
with	O	1622-1626
the	O	1627-1630
onset	O	1631-1636
of	O	1637-1639
a	O	1640-1641
transient	O	1642-1651
disturbance	O	1652-1663
in	O	1664-1666
neurophysiological	O	1667-1685
function	O	1686-1694
of	O	1695-1697
the	O	1698-1701
ascending	O	1702-1711
auditory	O	1712-1720
brainstem	O	1721-1730
pathway	O	1731-1738
.	O	1738-1739

The	O	1740-1743
complete	O	1744-1752
disappearance	O	1753-1766
of	O	1767-1769
BAEP	O	1770-1774
waveforms	O	1775-1784
with	O	1785-1789
a	O	1790-1791
consistent	O	1792-1802
temporal	O	1803-1811
delay	O	1812-1817
suggests	O	1818-1826
a	O	1827-1828
possible	O	1829-1837
adverse	B	1838-1845
effect	I	1846-1852
on	I	1853-1855
the	I	1856-1859
proximal	I	1860-1868
eighth	I	1869-1875
nerve	I	1876-1881
.	O	1881-1882

Recommendations	O	1883-1898
to	O	1899-1901
avoid	O	1902-1907
potential	O	1908-1917
cranial	B	1918-1925
nerve	I	1926-1931
deficits	I	1932-1940
from	O	1941-1945
papaverine	O	1946-1956
are	O	1957-1960
provided	O	1961-1969
.	O	1969-1970

Massive	O	0-7
proteinuria	B	8-19
and	O	20-23
acute	B	24-29
renal	I	30-35
failure	I	36-43
after	O	44-49
oral	O	50-54
bisphosphonate	O	55-69
(	O	70-71
alendronate	O	71-82
)	O	82-83
administration	O	84-98
in	O	99-101
a	O	102-103
patient	O	104-111
with	O	112-116
focal	B	117-122
segmental	I	123-132
glomerulosclerosis	I	133-151
.	O	151-152

A	O	153-154
61	O	155-157
-	O	157-158
year	O	158-162
-	O	157-158
old	O	163-166
Japanese	O	167-175
man	O	176-179
with	O	180-184
nephrotic	B	185-194
syndrome	I	195-203
due	O	204-207
to	O	208-210
focal	B	211-216
segmental	I	217-226
glomerulosclerosis	I	227-245
was	O	246-249
initially	O	250-259
responding	O	260-270
well	O	271-275
to	O	276-278
steroid	O	279-286
therapy	O	287-294
.	O	294-295

The	O	296-299
amount	O	300-306
of	O	307-309
daily	O	310-315
urinary	O	316-323
protein	O	324-331
decreased	O	332-341
from	O	342-346
15	O	347-349
.	O	349-350
6	O	350-351
to	O	352-354
2	O	355-356
.	O	356-357
8	O	357-358
g	O	359-360
.	O	360-361

Within	O	362-368
14	O	369-371
days	O	372-376
of	O	377-379
the	O	380-383
oral	O	384-388
bisphosphonate	O	389-403
(	O	404-405
alendronate	O	405-416
sodium	O	417-423
)	O	423-424
administration	O	425-439
,	O	439-440
the	O	441-444
amount	O	445-451
of	O	452-454
daily	O	455-460
urinary	O	461-468
protein	O	469-476
increased	O	477-486
rapidly	O	487-494
up	O	495-497
to	O	498-500
12	O	501-503
.	O	503-504
8	O	504-505
g	O	506-507
with	O	508-512
acute	B	513-518
renal	I	519-524
failure	I	525-532
.	O	532-533

After	O	534-539
discontinuing	O	540-553
the	O	554-557
oral	O	558-562
alendronate	O	563-574
,	O	574-575
the	O	576-579
patient	O	580-587
underwent	O	588-597
six	O	598-601
cycles	O	602-608
of	O	609-611
hemodialysis	O	612-624
and	O	625-628
four	O	629-633
cycles	O	634-640
of	O	641-643
LDL	O	644-647
apheresis	O	648-657
.	O	657-658

Urinary	O	659-666
volume	O	667-673
and	O	674-677
serum	O	678-683
creatinine	O	684-694
levels	O	695-701
recovered	O	702-711
to	O	712-714
the	O	715-718
normal	O	719-725
range	O	726-731
,	O	731-732
with	O	733-737
urinary	O	738-745
protein	O	746-753
disappearing	O	754-766
completely	O	767-777
within	O	778-784
40	O	785-787
days	O	788-792
.	O	792-793

This	O	794-798
report	O	799-805
demonstrates	O	806-818
that	O	819-823
not	O	824-827
only	O	828-832
intravenous	O	833-844
,	O	844-845
but	O	846-849
also	O	850-854
oral	O	855-859
bisphosphonates	O	860-875
can	O	876-879
aggravate	O	880-889
proteinuria	B	890-901
and	O	902-905
acute	B	906-911
renal	I	912-917
failure	I	918-925
.	O	925-926

Serum	O	0-5
-	O	5-6
and	O	7-10
glucocorticoid	O	11-25
-	O	25-26
inducible	O	26-35
kinase	O	36-42
1	O	43-44
in	O	45-47
doxorubicin	O	48-59
-	O	59-60
induced	O	60-67
nephrotic	B	68-77
syndrome	I	78-86
.	O	86-87

Doxorubicin	O	88-99
-	O	99-100
induced	O	100-107
nephropathy	B	108-119
leads	O	120-125
to	O	126-128
epithelial	O	129-139
sodium	O	140-146
channel	O	147-154
(	O	155-156
ENaC	O	156-160
)	O	160-161
-	O	161-162
dependent	O	162-171
volume	B	172-178
retention	I	179-188
and	O	189-192
renal	O	193-198
fibrosis	B	199-207
.	O	207-208

The	O	209-212
aldosterone	O	213-224
-	O	224-225
sensitive	O	225-234
serum	O	235-240
-	O	240-241
and	O	242-245
glucocorticoid	O	246-260
-	O	260-261
inducible	O	261-270
kinase	O	271-277
SGK1	O	278-282
has	O	283-286
been	O	287-291
shown	O	292-297
to	O	298-300
participate	O	301-312
in	O	313-315
the	O	316-319
stimulation	O	320-331
of	O	332-334
ENaC	O	335-339
and	O	340-343
to	O	344-346
mediate	O	347-354
renal	O	355-360
fibrosis	B	361-369
following	O	370-379
mineralocorticoid	O	380-397
and	O	398-401
salt	O	402-406
excess	O	407-413
.	O	413-414

The	O	415-418
present	O	419-426
study	O	427-432
was	O	433-436
performed	O	437-446
to	O	447-449
elucidate	O	450-459
the	O	460-463
role	O	464-468
of	O	469-471
SGK1	O	472-476
in	O	477-479
the	O	480-483
volume	B	484-490
retention	I	491-500
and	O	501-504
fibrosis	B	505-513
during	O	514-520
nephrotic	B	521-530
syndrome	I	531-539
.	O	539-540

To	O	541-543
this	O	544-548
end	O	549-552
,	O	552-553
doxorubicin	O	554-565
(	O	566-567
15	O	567-569
mug	O	570-573
/	O	573-574
g	O	572-573
body	O	576-580
wt	O	581-583
)	O	583-584
was	O	585-588
injected	O	589-597
intravenously	O	598-611
into	O	612-616
gene	O	617-621
-	O	621-622
targeted	O	622-630
mice	O	631-635
lacking	O	636-643
SGK1	O	644-648
(	O	649-650
sgk1	O	650-654
(	O	649-650
-	O	655-656
/	O	656-657
-	O	655-656
)	O	658-659
)	O	658-659
and	O	661-664
their	O	665-670
wild	O	671-675
-	O	675-676
type	O	676-680
littermates	O	681-692
(	O	693-694
sgk1	O	694-698
(	O	693-694
+	O	699-700
/	O	700-701
+	O	699-700
)	O	702-703
)	O	702-703
.	O	704-705

Doxorubicin	O	706-717
treatment	O	718-727
resulted	O	728-736
in	O	737-739
heavy	O	740-745
proteinuria	B	746-757
(	O	758-759
>	O	759-760
100	O	760-763
mg	O	764-766
protein	O	767-774
/	O	774-775
mg	O	775-777
crea	O	778-782
)	O	782-783
in	O	784-786
15	O	787-789
/	O	789-790
44	O	790-792
of	O	793-795
sgk1	O	796-800
(	O	800-801
+	O	801-802
/	O	802-803
+	O	801-802
)	O	804-805
and	O	806-809
15	O	810-812
/	O	812-813
44	O	813-815
of	O	816-818
sgk1	O	819-823
(	O	823-824
-	O	824-825
/	O	825-826
-	O	824-825
)	O	827-828
mice	O	829-833
leading	O	834-841
to	O	842-844
severe	O	845-851
nephrotic	B	852-861
syndrome	I	862-870
with	O	871-875
ascites	B	876-883
,	O	883-884
lipidemia	B	885-894
,	O	894-895
and	O	896-899
hypoalbuminemia	B	900-915
in	O	916-918
both	O	919-923
genotypes	O	924-933
.	O	933-934

Plasma	O	935-941
aldosterone	O	942-953
levels	O	954-960
increased	O	961-970
in	O	971-973
nephrotic	B	974-983
mice	O	984-988
of	O	989-991
both	O	992-996
genotypes	O	997-1006
and	O	1007-1010
was	O	1011-1014
followed	O	1015-1023
by	O	1024-1026
increased	O	1027-1036
SGK1	O	1037-1041
protein	O	1042-1049
expression	O	1050-1060
in	O	1061-1063
sgk1	O	1064-1068
(	O	1068-1069
+	O	1069-1070
/	O	1070-1071
+	O	1069-1070
)	O	1072-1073
mice	O	1074-1078
.	O	1078-1079

Urinary	O	1080-1087
sodium	O	1088-1094
excretion	O	1095-1104
reached	O	1105-1112
signficantly	O	1113-1125
lower	O	1126-1131
values	O	1132-1138
in	O	1139-1141
sgk1	O	1142-1146
(	O	1146-1147
+	O	1147-1148
/	O	1148-1149
+	O	1147-1148
)	O	1150-1151
mice	O	1152-1156
(	O	1157-1158
15	O	1158-1160
+	O	1161-1162
/	O	1162-1163
-	O	1163-1164
5	O	1165-1166
mumol	O	1167-1172
/	O	1172-1173
mg	O	1173-1175
crea	O	1176-1180
)	O	1180-1181
than	O	1182-1186
in	O	1187-1189
sgk1	O	1190-1194
(	O	1194-1195
-	O	1195-1196
/	O	1196-1197
-	O	1195-1196
)	O	1198-1199
mice	O	1200-1204
(	O	1205-1206
35	O	1206-1208
+	O	1209-1210
/	O	1210-1211
-	O	1211-1212
5	O	1213-1214
mumol	O	1215-1220
/	O	1220-1221
mg	O	1221-1223
crea	O	1224-1228
)	O	1228-1229
and	O	1230-1233
was	O	1234-1237
associated	O	1238-1248
with	O	1249-1253
a	O	1254-1255
significantly	O	1256-1269
higher	O	1270-1276
body	O	1277-1281
weight	B	1282-1288
gain	I	1289-1293
in	O	1294-1296
sgk1	O	1297-1301
(	O	1301-1302
+	O	1302-1303
/	O	1303-1304
+	O	1302-1303
)	O	1305-1306
compared	O	1307-1315
with	O	1316-1320
sgk1	O	1321-1325
(	O	1325-1326
-	O	1326-1327
/	O	1327-1328
-	O	1326-1327
)	O	1329-1330
mice	O	1331-1335
(	O	1336-1337
+	O	1337-1338
6	O	1338-1339
.	O	1339-1340
6	O	1338-1339
+	O	1342-1343
/	O	1343-1344
-	O	1344-1345
0	O	1346-1347
.	O	1347-1348
7	O	1348-1349
vs	O	1350-1352
.	O	1352-1353
+	O	1354-1355
4	O	1355-1356
.	O	1356-1357
1	O	1357-1358
+	O	1359-1360
/	O	1360-1361
-	O	1361-1362
0	O	1363-1364
.	O	1364-1365
8	O	1365-1366
g	O	1367-1368
)	O	1368-1369
.	O	1369-1370

During	O	1371-1377
the	O	1378-1381
course	O	1382-1388
of	O	1389-1391
nephrotic	B	1392-1401
syndrome	I	1402-1410
,	O	1410-1411
serum	O	1412-1417
urea	O	1418-1422
concentrations	O	1423-1437
increased	O	1438-1447
significantly	O	1448-1461
faster	O	1462-1468
in	O	1469-1471
sgk1	O	1472-1476
(	O	1476-1477
-	O	1477-1478
/	O	1478-1479
-	O	1477-1478
)	O	1480-1481
mice	O	1482-1486
than	O	1487-1491
in	O	1492-1494
sgk1	O	1495-1499
(	O	1499-1500
+	O	1500-1501
/	O	1501-1502
+	O	1500-1501
)	O	1503-1504
mice	O	1505-1509
leading	O	1510-1517
to	O	1518-1520
uremia	B	1521-1527
and	O	1528-1531
a	O	1532-1533
reduced	O	1534-1541
median	O	1542-1548
survival	O	1549-1557
in	O	1558-1560
sgk1	O	1561-1565
(	O	1565-1566
-	O	1566-1567
/	O	1567-1568
-	O	1566-1567
)	O	1569-1570
mice	O	1571-1575
(	O	1576-1577
29	O	1577-1579
vs	O	1580-1582
.	O	1582-1583
40	O	1584-1586
days	O	1587-1591
in	O	1592-1594
sgk1	O	1595-1599
(	O	1599-1600
+	O	1600-1601
/	O	1601-1602
+	O	1600-1601
)	O	1603-1604
mice	O	1605-1609
)	O	1609-1610
.	O	1610-1611

In	O	1612-1614
conclusion	O	1615-1625
,	O	1625-1626
gene	O	1627-1631
-	O	1631-1632
targeted	O	1632-1640
mice	O	1641-1645
lacking	O	1646-1653
SGK1	O	1654-1658
showed	O	1659-1665
blunted	O	1666-1673
volume	B	1674-1680
retention	I	1681-1690
,	O	1690-1691
yet	O	1692-1695
were	O	1696-1700
not	O	1701-1704
protected	O	1705-1714
against	O	1715-1722
renal	O	1723-1728
fibrosis	B	1729-1737
during	O	1738-1744
experimental	O	1745-1757
nephrotic	B	1758-1767
syndrome	I	1768-1776
.	O	1776-1777

Severe	O	0-6
and	O	7-10
long	O	11-15
lasting	O	16-23
cholestasis	B	24-35
after	O	36-41
high	O	42-46
-	O	46-47
dose	O	47-51
co	O	52-54
-	O	54-55
trimoxazole	O	55-66
treatment	O	67-76
for	O	77-80
Pneumocystis	B	81-93
pneumonia	I	94-103
in	O	104-106
HIV	B	107-110
-	I	110-111
infected	I	111-119
patients	O	120-128
-	O	128-129
-	O	128-129
a	O	121-122
report	O	132-138
of	O	139-141
two	O	142-145
cases	O	146-151
.	O	151-152

Pneumocystis	B	153-165
pneumonia	I	166-175
(	O	176-177
PCP	B	177-180
)	O	180-181
,	O	181-182
a	O	183-184
common	O	185-191
opportunistic	B	192-205
infection	I	206-215
in	O	216-218
HIV	B	219-222
-	I	222-223
infected	I	223-231
individuals	O	232-243
,	O	243-244
is	O	245-247
generally	O	248-257
treated	O	258-265
with	O	266-270
high	O	271-275
doses	O	276-281
of	O	282-284
co	O	285-287
-	O	287-288
trimoxazole	O	288-299
.	O	299-300

However	O	301-308
,	O	308-309
treatment	O	310-319
is	O	320-322
often	O	323-328
limited	O	329-336
by	O	337-339
adverse	O	340-347
effects	O	348-355
.	O	355-356

Here	O	357-361
,	O	361-362
we	O	363-365
report	O	366-372
two	O	373-376
cases	O	377-382
of	O	383-385
severely	O	386-394
immunocompromised	O	395-412
HIV	B	413-416
-	I	416-417
infected	I	417-425
patients	O	426-434
who	O	435-438
developed	O	439-448
severe	O	449-455
intrahepatic	B	456-468
cholestasis	I	469-480
,	O	480-481
and	O	482-485
in	O	486-488
one	O	489-492
patient	O	493-500
lesions	O	501-508
mimicking	O	509-518
liver	B	519-524
abscess	I	525-532
formation	O	533-542
on	O	543-545
radiologic	O	546-556
exams	O	557-562
,	O	562-563
during	O	564-570
co	O	571-573
-	O	573-574
trimoxazole	O	574-585
treatment	O	586-595
for	O	596-599
PCP	B	600-603
.	O	603-604

Whereas	O	605-612
patient	O	613-620
1	O	621-622
showed	O	623-629
lesions	O	630-637
of	O	638-640
up	O	641-643
to	O	644-646
1	O	647-648
cm	O	649-651
readily	O	652-659
detectable	O	660-670
on	O	671-673
magnetic	O	674-682
resonance	O	683-692
imaging	O	693-700
under	O	701-706
prolonged	O	707-716
co	O	717-719
-	O	719-720
trimoxazole	O	720-731
treatment	O	732-741
,	O	741-742
therapy	O	743-750
of	O	751-753
patient	O	754-761
2	O	762-763
was	O	764-767
switched	O	768-776
early	O	777-782
.	O	782-783

Clinically	O	0-10
significant	O	11-22
proteinuria	B	23-34
following	O	35-44
the	O	45-48
administration	O	49-63
of	O	64-66
sirolimus	O	67-76
to	O	77-79
renal	O	80-85
transplant	O	86-96
recipients	O	97-107
.	O	107-108

BACKGROUND	O	109-119
:	O	119-120
Sirolimus	O	121-130
is	O	131-133
the	O	134-137
latest	O	138-144
immunosuppressive	O	145-162
agent	O	163-168
used	O	169-173
to	O	174-176
prevent	O	177-184
rejection	O	185-194
,	O	194-195
and	O	196-199
may	O	200-203
have	O	204-208
less	O	209-213
nephrotoxicity	B	214-228
than	O	229-233
calcineurin	O	234-245
inhibitor	O	246-255
(	O	256-257
CNI	O	257-260
)	O	260-261
-	O	261-262
based	O	262-267
regimens	O	268-276
.	O	276-277

To	O	278-280
date	O	281-285
there	O	286-291
has	O	292-295
been	O	296-300
little	O	301-307
documentation	O	308-321
of	O	322-324
clinically	O	325-335
significant	O	336-347
proteinuria	B	348-359
linked	O	360-366
with	O	367-371
the	O	372-375
use	O	376-379
of	O	380-382
sirolimus	O	383-392
.	O	392-393

We	O	394-396
have	O	397-401
encountered	O	402-413
several	O	414-421
patients	O	422-430
who	O	431-434
developed	O	435-444
substantial	O	445-456
proteinuria	B	457-468
associated	O	469-479
with	O	480-484
sirolimus	O	485-494
use	O	495-498
.	O	498-499

In	O	500-502
each	O	503-507
patient	O	508-515
,	O	515-516
the	O	517-520
close	O	521-526
temporal	O	527-535
association	O	536-547
between	O	548-555
the	O	556-559
commencement	O	560-572
of	O	573-575
sirolimus	O	576-585
therapy	O	586-593
and	O	594-597
proteinuria	B	598-609
implicated	O	610-620
sirolimus	O	621-630
as	O	631-633
the	O	634-637
most	O	638-642
likely	O	643-649
etiology	O	650-658
of	O	659-661
the	O	662-665
proteinuria	B	666-677
.	O	677-678

METHODS	O	679-686
:	O	686-687
We	O	688-690
analyzed	O	691-699
the	O	700-703
clinical	O	704-712
and	O	713-716
laboratory	O	717-727
information	O	728-739
available	O	740-749
for	O	750-753
all	O	754-757
119	O	758-761
patients	O	762-770
transplanted	O	771-783
at	O	784-786
the	O	787-790
Washington	O	791-801
Hospital	O	802-810
Center	O	811-817
between	O	818-825
1999	O	826-830
-	O	830-831
2003	O	831-835
for	O	836-839
whom	O	840-844
sirolimus	O	845-854
was	O	855-858
a	O	859-860
component	O	861-870
of	O	871-873
their	O	874-879
immunosuppressant	O	880-897
regimen	O	898-905
.	O	905-906

In	O	907-909
these	O	910-915
patients	O	916-924
,	O	924-925
the	O	926-929
magnitude	O	930-939
of	O	940-942
proteinuria	B	943-954
was	O	955-958
assessed	O	959-967
on	O	968-970
morning	O	971-978
urine	O	979-984
samples	O	985-992
by	O	993-995
turbidometric	O	996-1009
measurement	O	1010-1021
or	O	1022-1024
random	O	1025-1031
urine	O	1032-1037
protein	O	1038-1045
:	O	1045-1046
creatinine	O	1046-1056
ratios	O	1057-1063
,	O	1063-1064
an	O	1065-1067
estimate	O	1068-1076
of	O	1077-1079
grams	O	1080-1085
of	O	1086-1088
proteinuria	B	1089-1100
/	O	1100-1101
day	O	1101-1104
.	O	1104-1105

Laboratory	O	1106-1116
results	O	1117-1124
were	O	1125-1129
compared	O	1130-1138
between	O	1139-1146
prior	O	1147-1152
,	O	1152-1153
during	O	1154-1160
and	O	1161-1164
following	O	1165-1174
sirolimus	O	1175-1184
use	O	1185-1188
.	O	1188-1189

RESULTS	O	1190-1197
:	O	1197-1198
Twenty	O	1199-1205
-	O	1205-1206
eight	O	1206-1211
patients	O	1212-1220
(	O	1221-1222
24	O	1222-1224
%	O	1224-1225
)	O	1225-1226
developed	O	1227-1236
increased	O	1237-1246
proteinuria	B	1247-1258
from	O	1259-1263
baseline	O	1264-1272
during	O	1273-1279
their	O	1280-1285
post	O	1286-1290
-	O	1290-1291
transplantation	O	1291-1306
course	O	1307-1313
.	O	1313-1314

In	O	1315-1317
21	O	1318-1320
patients	O	1321-1329
an	O	1330-1332
alternative	O	1333-1344
cause	O	1345-1350
of	O	1351-1353
proteinuria	B	1354-1365
was	O	1366-1369
either	O	1370-1376
obvious	O	1377-1384
or	O	1385-1387
insufficient	O	1388-1400
data	O	1401-1405
was	O	1406-1409
available	O	1410-1419
to	O	1420-1422
be	O	1423-1425
conclusive	O	1426-1436
.	O	1436-1437

In	O	1438-1440
7	O	1441-1442
of	O	1443-1445
the	O	1446-1449
28	O	1450-1452
patients	O	1453-1461
there	O	1462-1467
was	O	1468-1471
a	O	1472-1473
striking	O	1474-1482
temporal	O	1483-1491
association	O	1492-1503
between	O	1504-1511
the	O	1512-1515
initiation	O	1516-1526
of	O	1527-1529
sirolimus	O	1530-1539
and	O	1540-1543
the	O	1544-1547
development	O	1548-1559
of	O	1560-1562
nephrotic	B	1563-1572
-	O	1572-1573
range	O	1573-1578
proteinuria	B	1579-1590
.	O	1590-1591

Proteinuria	B	1592-1603
correlated	O	1604-1614
most	O	1615-1619
strongly	O	1620-1628
with	O	1629-1633
sirolimus	O	1634-1643
therapy	O	1644-1651
when	O	1652-1656
compared	O	1657-1665
to	O	1666-1668
other	O	1669-1674
demographic	O	1675-1686
and	O	1687-1690
clinical	O	1691-1699
variables	O	1700-1709
.	O	1709-1710

In	O	1711-1713
most	O	1714-1718
patients	O	1719-1727
,	O	1727-1728
discontinuation	O	1729-1744
of	O	1745-1747
sirolimus	O	1748-1757
resulted	O	1758-1766
in	O	1767-1769
a	O	1770-1771
decrease	O	1772-1780
,	O	1780-1781
but	O	1782-1785
not	O	1786-1789
resolution	O	1790-1800
,	O	1800-1801
of	O	1802-1804
proteinuria	B	1805-1816
.	O	1816-1817

CONCLUSIONS	O	1818-1829
:	O	1829-1830
Sirolimus	O	1831-1840
induces	O	1841-1848
or	O	1849-1851
aggravates	O	1852-1862
pre	O	1863-1866
-	O	1866-1867
existing	O	1867-1875
proteinuria	B	1876-1887
in	O	1888-1890
an	O	1891-1893
unpredictable	O	1894-1907
subset	O	1908-1914
of	O	1915-1917
renal	O	1918-1923
allograft	O	1924-1933
recipients	O	1934-1944
.	O	1944-1945

Proteinuria	B	1946-1957
may	O	1958-1961
improve	O	1962-1969
,	O	1969-1970
but	O	1971-1974
does	O	1975-1979
not	O	1980-1983
resolve	O	1984-1991
,	O	1991-1992
when	O	1993-1997
sirolimus	O	1998-2007
is	O	2008-2010
withdrawn	O	2011-2020
.	O	2020-2021

Comparative	O	0-11
cognitive	O	12-21
and	O	22-25
subjective	O	26-36
side	O	37-41
effects	O	42-49
of	O	50-52
immediate	O	53-62
-	O	62-63
release	O	63-70
oxycodone	O	71-80
in	O	81-83
healthy	O	84-91
middle	O	92-98
-	O	98-99
aged	O	99-103
and	O	104-107
older	O	108-113
adults	O	114-120
.	O	120-121

This	O	122-126
study	O	127-132
measured	O	133-141
the	O	142-145
objective	O	146-155
and	O	156-159
subjective	O	160-170
neurocognitive	O	171-185
effects	O	186-193
of	O	194-196
a	O	197-198
single	O	199-205
10	O	206-208
-	O	208-209
mg	O	209-211
dose	O	212-216
of	O	217-219
immediate	O	220-229
-	O	229-230
release	O	230-237
oxycodone	O	238-247
in	O	248-250
healthy	O	251-258
,	O	258-259
older	O	260-265
(	O	266-267
>	O	267-268
65	O	269-271
years	O	272-277
)	O	277-278
,	O	278-279
and	O	280-283
middle	O	284-290
-	O	290-291
aged	O	291-295
(	O	296-297
35	O	297-299
to	O	300-302
55	O	303-305
years	O	306-311
)	O	311-312
adults	O	313-319
who	O	320-323
were	O	324-328
not	O	329-332
suffering	O	333-342
from	O	343-347
chronic	O	348-355
or	O	356-358
significant	O	359-370
daily	O	371-376
pain	B	377-381
.	O	381-382

Seventy	O	383-390
-	O	390-391
one	O	391-394
participants	O	395-407
completed	O	408-417
2	O	418-419
separate	O	420-428
study	O	429-434
days	O	435-439
and	O	440-443
were	O	444-448
blind	O	449-454
to	O	455-457
medication	O	458-468
condition	O	469-478
(	O	479-480
placebo	O	480-487
,	O	487-488
10	O	489-491
-	O	491-492
mg	O	492-494
oxycodone	O	495-504
)	O	504-505
.	O	505-506

Plasma	O	507-513
oxycodone	O	514-523
concentration	O	524-537
peaked	O	538-544
between	O	545-552
60	O	553-555
and	O	556-559
90	O	560-562
minutes	O	563-570
postdose	O	571-579
(	O	580-581
P	O	581-582
<	O	583-584
.	O	585-586
01	O	586-588
)	O	588-589

and	O	590-593
pupil	O	594-599
size	O	600-604
,	O	604-605
an	O	606-608
indication	O	609-619
of	O	620-622
physiological	O	623-636
effects	O	637-644
of	O	645-647
the	O	648-651
medication	O	652-662
,	O	662-663
peaked	O	664-670
at	O	671-673
approximately	O	674-687
90	O	688-690
to	O	691-693
120	O	694-697
minutes	O	698-705
postdose	O	706-714
(	O	715-716
P	O	716-717
<	O	718-719
.	O	720-721
01	O	721-723
)	O	723-724
.	O	720-721

Significant	O	726-737
declines	B	738-746
in	I	747-749
simple	I	750-756
and	I	757-760
sustained	I	761-770
attention	I	771-780
,	I	780-781
working	I	782-789
memory	I	790-796
,	I	796-797
and	I	798-801
verbal	I	802-808
memory	I	809-815
were	O	816-820
observed	O	821-829
at	O	830-832
1	O	833-834
hour	O	835-839
postdose	O	840-848
compared	O	849-857
to	O	858-860
baseline	O	861-869
for	O	870-873
both	O	874-878
age	O	879-882
groups	O	883-889
with	O	890-894
a	O	895-896
trend	O	897-902
toward	O	903-909
return	O	910-916
to	O	917-919
baseline	O	920-928
by	O	929-931
5	O	932-933
hours	O	934-939
postdose	O	940-948
.	O	948-949

For	O	950-953
almost	O	954-960
all	O	961-964
cognitive	O	965-974
measures	O	975-983
,	O	983-984
there	O	985-990
were	O	991-995
no	O	996-998
medication	O	999-1009
by	O	1010-1012
age	O	1013-1016
-	O	1016-1017
interaction	O	1017-1028
effects	O	1029-1036
,	O	1036-1037
which	O	1038-1043
indicates	O	1044-1053
that	O	1054-1058
the	O	1059-1062
2	O	1063-1064
age	O	1065-1068
groups	O	1069-1075
exhibited	O	1076-1085
similar	O	1086-1093
responses	O	1094-1103
to	O	1104-1106
the	O	1107-1110
medication	O	1111-1121
challenge	O	1122-1131
.	O	1131-1132

This	O	1133-1137
study	O	1138-1143
suggests	O	1144-1152
that	O	1153-1157
for	O	1158-1161
healthy	O	1162-1169
older	O	1170-1175
adults	O	1176-1182
who	O	1183-1186
are	O	1187-1190
not	O	1191-1194
suffering	O	1195-1204
from	O	1205-1209
chronic	B	1210-1217
pain	I	1218-1222
,	O	1222-1223
neurocognitive	O	1224-1238
and	O	1239-1242
pharmacodynamic	O	1243-1258
changes	O	1259-1266
in	O	1267-1269
response	O	1270-1278
to	O	1279-1281
a	O	1282-1283
10	O	1284-1286
-	O	1286-1287
mg	O	1287-1289
dose	O	1290-1294
of	O	1295-1297
immediate	O	1298-1307
-	O	1307-1308
release	O	1308-1315
oxycodone	O	1316-1325
are	O	1326-1329
similar	O	1330-1337
to	O	1338-1340
those	O	1341-1346
observed	O	1347-1355
for	O	1356-1359
middle	O	1360-1366
-	O	1366-1367
aged	O	1367-1371
adults	O	1372-1378
.	O	1378-1379

PERSPECTIVE	O	1380-1391
:	O	1391-1392
Study	O	1393-1398
findings	O	1399-1407
indicate	O	1408-1416
that	O	1417-1421
the	O	1422-1425
metabolism	O	1426-1436
,	O	1436-1437
neurocognitive	O	1438-1452
effects	O	1453-1460
,	O	1460-1461
and	O	1462-1465
physical	O	1466-1474
side	O	1475-1479
effects	O	1480-1487
of	O	1488-1490
oral	O	1491-1495
oxycodone	O	1496-1505
are	O	1506-1509
similar	O	1510-1517
for	O	1518-1521
healthy	O	1522-1529
middle	O	1530-1536
-	O	1536-1537
aged	O	1537-1541
and	O	1542-1545
older	O	1546-1551
adults	O	1552-1558
.	O	1558-1559

Therefore	O	1560-1569
,	O	1569-1570
clinicians	O	1571-1581
should	O	1582-1588
not	O	1589-1592
avoid	O	1593-1598
prescribing	O	1599-1610
oral	O	1611-1615
opioids	O	1616-1623
to	O	1624-1626
older	O	1627-1632
adults	O	1633-1639
based	O	1640-1645
on	O	1646-1648
the	O	1649-1652
belief	O	1653-1659
that	O	1660-1664
older	O	1665-1670
adults	O	1671-1677
are	O	1678-1681
at	O	1682-1684
higher	O	1685-1691
risk	O	1692-1696
for	O	1697-1700
side	O	1701-1705
effects	O	1706-1713
than	O	1714-1718
younger	O	1719-1726
adults	O	1727-1733
.	O	1733-1734

Normalizing	O	0-11
effects	O	12-19
of	O	20-22
modafinil	O	23-32
on	O	33-35
sleep	O	36-41
in	O	42-44
chronic	O	45-52
cocaine	O	53-60
users	O	61-66
.	O	66-67

OBJECTIVE	O	68-77
:	O	77-78
The	O	79-82
purpose	O	83-90
of	O	91-93
the	O	94-97
present	O	98-105
study	O	106-111
was	O	112-115
to	O	116-118
determine	O	119-128
the	O	129-132
effect	O	133-139
of	O	140-142
morning	O	143-150
-	O	150-151
dosed	O	151-156
modafinil	O	157-166
on	O	167-169
sleep	O	170-175
and	O	176-179
daytime	B	180-187
sleepiness	I	188-198
in	O	199-201
chronic	O	202-209
cocaine	O	210-217
users	O	218-223
.	O	223-224

METHOD	O	225-231
:	O	231-232
Twenty	O	233-239
cocaine	O	240-247
-	O	247-248
dependent	O	248-257
participants	O	258-270
were	O	271-275
randomly	O	276-284
assigned	O	285-293
to	O	294-296
receive	O	297-304
modafinil	O	305-314
,	O	314-315
400	O	316-319
mg	O	320-322
(	O	323-324
N	O	324-325
=	O	325-326
10	O	326-328
)	O	328-329
,	O	329-330
or	O	331-333
placebo	O	334-341
(	O	342-343
N	O	343-344
=	O	344-345
10	O	345-347
)	O	347-348
every	O	349-354
morning	O	355-362
at	O	363-365
7	O	366-367
:	O	367-368
30	O	368-370
a	O	371-372
.	O	372-373
m	O	373-374
.	O	372-373
for	O	376-379
16	O	380-382
days	O	383-387
in	O	388-390
an	O	391-393
inpatient	O	394-403
,	O	403-404
double	O	405-411
-	O	411-412
blind	O	412-417
randomized	O	418-428
trial	O	429-434
.	O	434-435

Participants	O	436-448
underwent	O	449-458
polysomnographic	O	459-475
sleep	O	476-481
recordings	O	482-492
on	O	493-495
days	O	496-500
1	O	501-502
to	O	503-505
3	O	506-507
,	O	507-508
7	O	509-510
to	O	511-513
9	O	514-515
,	O	515-516
and	O	517-520
14	O	521-523
to	O	524-526
16	O	527-529
(	O	530-531
first	O	531-536
,	O	536-537
second	O	538-544
,	O	544-545
and	O	546-549
third	O	550-555
weeks	O	556-561
of	O	562-564
abstinence	O	565-575
)	O	575-576
.	O	576-577

The	O	578-581
Multiple	O	582-590
Sleep	O	591-596
Latency	O	597-604
Test	O	605-609
was	O	610-613
performed	O	614-623
at	O	624-626
11	O	627-629
:	O	629-630
30	O	630-632
a	O	633-634
.	O	634-635
m	O	635-636
.	O	634-635
,	O	637-638
2	O	639-640
:	O	640-641
00	O	641-643
p	O	644-645
.	O	645-646
m	O	646-647
.	O	645-646
,	O	648-649
and	O	650-653
4	O	654-655
:	O	655-656
30	O	656-658
p	O	659-660
.	O	660-661
m	O	661-662
.	O	660-661
on	O	664-666
days	O	667-671
2	O	672-673
,	O	673-674
8	O	675-676
,	O	676-677
and	O	678-681
15	O	682-684
.	O	684-685

For	O	686-689
comparison	O	690-700
of	O	701-703
sleep	O	704-709
architecture	O	710-722
variables	O	723-732
,	O	732-733
12	O	734-736
healthy	O	737-744
comparison	O	745-755
participants	O	756-768
underwent	O	769-778
a	O	779-780
single	O	781-787
night	O	788-793
of	O	794-796
experimental	O	797-809
polysomnography	O	810-825
that	O	826-830
followed	O	831-839
1	O	840-841
night	O	842-847
of	O	848-850
accommodation	O	851-864
polysomnography	O	865-880
.	O	880-881

RESULTS	O	882-889
:	O	889-890
Progressive	O	891-902
abstinence	O	903-913
from	O	914-918
cocaine	O	919-926
was	O	927-930
associated	O	931-941
with	O	942-946
worsening	O	947-956
of	O	957-959
all	O	960-963
measured	O	964-972
polysomnographic	O	973-989
sleep	O	990-995
outcomes	O	996-1004
.	O	1004-1005

Compared	O	1006-1014
with	O	1015-1019
placebo	O	1020-1027
,	O	1027-1028
modafinil	O	1029-1038
decreased	O	1039-1048
nighttime	O	1049-1058
sleep	O	1059-1064
latency	O	1065-1072
and	O	1073-1076
increased	O	1077-1086
slow	O	1087-1091
-	O	1091-1092
wave	O	1092-1096
sleep	O	1097-1102
time	O	1103-1107
in	O	1108-1110
cocaine	O	1111-1118
-	O	1118-1119
dependent	O	1119-1128
participants	O	1129-1141
.	O	1141-1142

The	O	1143-1146
effect	O	1147-1153
of	O	1154-1156
modafinil	O	1157-1166
interacted	O	1167-1177
with	O	1178-1182
the	O	1183-1186
abstinence	O	1187-1197
week	O	1198-1202
and	O	1203-1206
was	O	1207-1210
associated	O	1211-1221
with	O	1222-1226
longer	O	1227-1233
total	O	1234-1239
sleep	O	1240-1245
time	O	1246-1250
and	O	1251-1254
shorter	O	1255-1262
REM	O	1263-1266
sleep	O	1267-1272
latency	O	1273-1280
in	O	1281-1283
the	O	1284-1287
third	O	1288-1293
week	O	1294-1298
of	O	1299-1301
abstinence	O	1302-1312
.	O	1312-1313

Comparison	O	1314-1324
of	O	1325-1327
slow	O	1328-1332
-	O	1332-1333
wave	O	1333-1337
sleep	O	1338-1343
time	O	1344-1348
,	O	1348-1349
total	O	1350-1355
sleep	O	1356-1361
time	O	1362-1366
,	O	1366-1367
and	O	1368-1371
sleep	O	1372-1377
latency	O	1378-1385
in	O	1386-1388
cocaine	O	1389-1396
-	O	1396-1397
dependent	O	1397-1406
and	O	1407-1410
healthy	O	1411-1418
participants	O	1419-1431
revealed	O	1432-1440
a	O	1441-1442
normalizing	O	1443-1454
effect	O	1455-1461
of	O	1462-1464
modafinil	O	1465-1474
in	O	1475-1477
cocaine	O	1478-1485
-	O	1485-1486
dependent	O	1486-1495
participants	O	1496-1508
.	O	1508-1509

Modafinil	O	1510-1519
was	O	1520-1523
associated	O	1524-1534
with	O	1535-1539
increased	O	1540-1549
daytime	O	1550-1557
sleep	O	1558-1563
latency	O	1564-1571
,	O	1571-1572
as	O	1573-1575
measured	O	1576-1584
by	O	1585-1587
the	O	1588-1591
Multiple	O	1592-1600
Sleep	O	1601-1606
Latency	O	1607-1614
Test	O	1615-1619
,	O	1619-1620
and	O	1621-1624
a	O	1625-1626
nearly	O	1627-1633
significant	O	1634-1645
decrease	O	1646-1654
in	O	1655-1657
subjective	O	1658-1668
daytime	B	1669-1676
sleepiness	I	1677-1687
.	O	1687-1688

CONCLUSIONS	O	1689-1700
:	O	1700-1701
Morning	O	1702-1709
-	O	1709-1710
dosed	O	1710-1715
modafinil	O	1716-1725
promotes	O	1726-1734
nocturnal	O	1735-1744
sleep	O	1745-1750
,	O	1750-1751
normalizes	O	1752-1762
sleep	O	1763-1768
architecture	O	1769-1781
,	O	1781-1782
and	O	1783-1786
decreases	O	1787-1796
daytime	B	1797-1804
sleepiness	I	1805-1815
in	O	1816-1818
abstinent	O	1819-1828
cocaine	O	1829-1836
users	O	1837-1842
.	O	1842-1843

These	O	1844-1849
effects	O	1850-1857
may	O	1858-1861
be	O	1862-1864
relevant	O	1865-1873
in	O	1874-1876
the	O	1877-1880
treatment	O	1881-1890
of	O	1891-1893
cocaine	O	1894-1901
dependence	O	1902-1912
.	O	1912-1913

Efficacy	O	0-8
and	O	9-12
safety	O	13-19
of	O	20-22
asenapine	O	23-32
in	O	33-35
a	O	36-37
placebo	O	38-45
-	O	45-46
and	O	47-50
haloperidol	O	51-62
-	O	62-63
controlled	O	63-73
trial	O	74-79
in	O	80-82
patients	O	83-91
with	O	92-96
acute	O	97-102
exacerbation	O	103-115
of	O	116-118
schizophrenia	B	119-132
.	O	132-133

Asenapine	O	134-143
is	O	144-146
approved	O	147-155
by	O	156-158
the	O	159-162
Food	O	163-167
and	O	168-171
Drugs	O	172-177
Administration	O	178-192
in	O	193-195
adults	O	196-202
for	O	203-206
acute	O	207-212
treatment	O	213-222
of	O	223-225
schizophrenia	B	226-239
or	O	240-242
of	O	243-245
manic	B	246-251
or	O	252-254
mixed	O	255-260
episodes	O	261-269
associated	O	270-280
with	O	281-285
bipolar	B	286-293
I	I	294-295
disorder	I	296-304
with	O	305-309
or	O	310-312
without	O	313-320
psychotic	B	321-330
features	O	331-339
.	O	339-340

In	O	341-343
a	O	344-345
double	O	346-352
-	O	352-353
blind	O	353-358
6	O	359-360
-	O	360-361
week	O	361-365
trial	O	366-371
,	O	371-372
458	O	373-376
patients	O	377-385
with	O	386-390
acute	O	391-396
schizophrenia	B	397-410
were	O	411-415
randomly	O	416-424
assigned	O	425-433
to	O	434-436
fixed	O	437-442
-	O	442-443
dose	O	443-447
treatment	O	448-457
with	O	458-462
asenapine	O	463-472
at	O	473-475
5	O	476-477
mg	O	478-480
twice	O	481-486
daily	O	487-492
(	O	493-494
BID	O	494-497
)	O	497-498
,	O	498-499
asenapine	O	500-509
at	O	510-512
10	O	513-515
mg	O	516-518
BID	O	519-522
,	O	522-523
placebo	O	524-531
,	O	531-532
or	O	533-535
haloperidol	O	536-547
at	O	548-550
4	O	551-552
mg	O	553-555
BID	O	556-559
(	O	560-561
to	O	561-563
verify	O	564-570
assay	O	571-576
sensitivity	O	577-588
)	O	588-589
.	O	589-590

With	O	591-595
last	O	596-600
observations	O	601-613
carried	O	614-621
forward	O	622-629
(	O	630-631
LOCF	O	631-635
)	O	635-636
,	O	636-637
mean	O	638-642
Positive	O	643-651
and	O	652-655
Negative	O	656-664
Syndrome	O	665-673
Scale	O	674-679
total	O	680-685
score	O	686-691
reductions	O	692-702
from	O	703-707
baseline	O	708-716
to	O	717-719
endpoint	O	720-728
were	O	729-733
significantly	O	734-747
greater	O	748-755
with	O	756-760
asenapine	O	761-770
at	O	771-773
5	O	774-775
mg	O	776-778
BID	O	779-782
(	O	783-784
-	O	784-785
16	O	785-787
.	O	787-788
2	O	788-789
)	O	789-790
and	O	791-794
haloperidol	O	795-806
(	O	807-808
-	O	808-809
15	O	809-811
.	O	811-812
4	O	812-813
)	O	813-814

than	O	815-819
placebo	O	820-827
(	O	828-829
-	O	829-830
10	O	830-832
.	O	832-833
7	O	833-834
;	O	834-835

both	O	836-840
P	O	841-842
<	O	843-844
0	O	845-846
.	O	846-847
05	O	847-849
)	O	849-850
;	O	850-851
using	O	852-857
mixed	O	858-863
model	O	864-869
for	O	870-873
repeated	O	874-882
measures	O	883-891
(	O	892-893
MMRM	O	893-897
)	O	897-898
,	O	898-899
changes	O	900-907
at	O	908-910
day	O	911-914
42	O	915-917
were	O	918-922
significantly	O	923-936
greater	O	937-944
with	O	945-949
asenapine	O	950-959
at	O	960-962
5	O	963-964
and	O	965-968
10	O	969-971
mg	O	972-974
BID	O	975-978
(	O	979-980
-	O	980-981
21	O	981-983
.	O	983-984
3	O	984-985
and	O	986-989
-	O	990-991
19	O	991-993
.	O	993-994
4	O	994-995
,	O	995-996

respectively	O	997-1009
)	O	1009-1010
and	O	1011-1014
haloperidol	O	1015-1026
(	O	1027-1028
-	O	1028-1029
20	O	1029-1031
.	O	1031-1032
0	O	1030-1031
)	O	1033-1034

than	O	1035-1039
placebo	O	1040-1047
(	O	1048-1049
-	O	1049-1050
14	O	1050-1052
.	O	1052-1053
6	O	1053-1054
;	O	1054-1055

all	O	1056-1059
P	O	1060-1061
<	O	1062-1063
0	O	1064-1065
.	O	1065-1066
05	O	1066-1068
)	O	1068-1069
.	O	1065-1066

On	O	1071-1073
the	O	1074-1077
Positive	O	1078-1086
and	O	1087-1090
Negative	O	1091-1099
Syndrome	O	1100-1108
Scale	O	1109-1114
positive	O	1115-1123
subscale	O	1124-1132
,	O	1132-1133
all	O	1134-1137
treatments	O	1138-1148
were	O	1149-1153
superior	O	1154-1162
to	O	1163-1165
placebo	O	1166-1173
with	O	1174-1178
LOCF	O	1179-1183
and	O	1184-1187
MMRM	O	1188-1192
;	O	1192-1193
asenapine	O	1194-1203
at	O	1204-1206
5	O	1207-1208
mg	O	1209-1211
BID	O	1212-1215
was	O	1216-1219
superior	O	1220-1228
to	O	1229-1231
placebo	O	1232-1239
on	O	1240-1242
the	O	1243-1246
negative	O	1247-1255
subscale	O	1256-1264
with	O	1265-1269
MMRM	O	1270-1274
and	O	1275-1278
on	O	1279-1281
the	O	1282-1285
general	O	1286-1293
psychopathology	O	1294-1309
subscale	O	1310-1318
with	O	1319-1323
LOCF	O	1324-1328
and	O	1329-1332
MMRM	O	1333-1337
.	O	1337-1338

Treatment	O	1339-1348
-	O	1348-1349
related	O	1349-1356
adverse	O	1357-1364
events	O	1365-1371
(	O	1372-1373
AEs	O	1373-1376
)	O	1376-1377
occurred	O	1378-1386
in	O	1387-1389
44	O	1390-1392
%	O	1392-1393
and	O	1394-1397
52	O	1398-1400
%	O	1400-1401
,	O	1401-1402
57	O	1403-1405
%	O	1405-1406
,	O	1406-1407
and	O	1408-1411
41	O	1412-1414
%	O	1414-1415
of	O	1416-1418
the	O	1419-1422
asenapine	O	1423-1432
at	O	1433-1435
5	O	1436-1437
and	O	1438-1441
10	O	1442-1444
mg	O	1445-1447
BID	O	1448-1451
,	O	1451-1452
haloperidol	O	1453-1464
,	O	1464-1465
and	O	1466-1469
placebo	O	1470-1477
groups	O	1478-1484
,	O	1484-1485
respectively	O	1486-1498
.	O	1498-1499

Extrapyramidal	B	1500-1514
symptoms	I	1515-1523
reported	O	1524-1532
as	O	1533-1535
AEs	O	1536-1539
occurred	O	1540-1548
in	O	1549-1551
15	O	1552-1554
%	O	1554-1555
and	O	1556-1559
18	O	1560-1562
%	O	1562-1563
,	O	1563-1564
34	O	1565-1567
%	O	1567-1568
,	O	1568-1569
and	O	1570-1573
10	O	1574-1576
%	O	1576-1577
of	O	1578-1580
the	O	1581-1584
asenapine	O	1585-1594
at	O	1595-1597
5	O	1598-1599
and	O	1600-1603
10	O	1604-1606
mg	O	1607-1609
BID	O	1610-1613
,	O	1613-1614
haloperidol	O	1615-1626
,	O	1626-1627
and	O	1628-1631
placebo	O	1632-1639
groups	O	1640-1646
,	O	1646-1647
respectively	O	1648-1660
.	O	1660-1661

Across	O	1662-1668
all	O	1669-1672
groups	O	1673-1679
,	O	1679-1680
no	O	1681-1683
more	O	1684-1688
than	O	1689-1693
5	O	1694-1695
%	O	1695-1696
of	O	1697-1699
patients	O	1700-1708
had	O	1709-1712
clinically	O	1713-1723
significant	O	1724-1735
weight	O	1736-1742
change	O	1743-1749
.	O	1749-1750

Post	O	1751-1755
hoc	O	1756-1759
analyses	O	1760-1768
indicated	O	1769-1778
that	O	1779-1783
efficacy	O	1784-1792
was	O	1793-1796
similar	O	1797-1804
with	O	1805-1809
asenapine	O	1810-1819
and	O	1820-1823
haloperidol	O	1824-1835
;	O	1835-1836
greater	O	1837-1844
contrasts	O	1845-1854
were	O	1855-1859
seen	O	1860-1864
in	O	1865-1867
AEs	O	1868-1871
,	O	1871-1872
especially	O	1873-1883
extrapyramidal	B	1884-1898
symptoms	I	1899-1907
.	O	1907-1908

Permeability	O	0-12
,	O	12-13
ultrastructural	O	14-29
changes	O	30-37
,	O	37-38
and	O	39-42
distribution	O	43-55
of	O	56-58
novel	O	59-64
proteins	O	65-73
in	O	74-76
the	O	77-80
glomerular	O	81-91
barrier	O	92-99
in	O	100-102
early	O	103-108
puromycin	O	109-118
aminonucleoside	O	119-134
nephrosis	B	135-144
.	O	144-145

BACKGROUND	O	146-156
/	O	156-157
AIMS	O	157-161
:	O	161-162
It	O	163-165
is	O	166-168
still	O	169-174
unclear	O	175-182
what	O	183-187
happens	O	188-195
in	O	196-198
the	O	199-202
glomerulus	O	203-213
when	O	214-218
proteinuria	B	219-230
starts	O	231-237
.	O	237-238

Using	O	239-244
puromycin	O	245-254
aminonucleoside	O	255-270
nephrosis	B	271-280
(	O	281-282
PAN	O	282-285
)	O	285-286
rats	O	287-291
,	O	291-292
we	O	293-295
studied	O	296-303
early	O	304-309
ultrastructural	O	310-325
and	O	326-329
permeability	O	330-342
changes	O	343-350
in	O	351-353
relation	O	354-362
to	O	363-365
the	O	366-369
expression	O	370-380
of	O	381-383
the	O	384-387
podocyte	O	388-396
-	O	396-397
associated	O	397-407
molecules	O	408-417
nephrin	O	418-425
,	O	425-426
a	O	427-428
-	O	428-429
actinin	O	429-436
,	O	436-437
dendrin	O	438-445
,	O	445-446
and	O	447-450
plekhh2	O	451-458
,	O	458-459
the	O	460-463
last	O	464-468
two	O	469-472
of	O	473-475
which	O	476-481
were	O	482-486
only	O	487-491
recently	O	492-500
discovered	O	501-511
in	O	512-514
podocytes	O	515-524
.	O	524-525

METHODS	O	526-533
:	O	533-534
Using	O	535-540
immune	O	541-547
stainings	O	548-557
,	O	557-558
semiquantitative	O	559-575
measurement	O	576-587
was	O	588-591
performed	O	592-601
under	O	602-607
the	O	608-611
electron	O	612-620
microscope	O	621-631
.	O	631-632

Permeability	O	633-645
was	O	646-649
assessed	O	650-658
using	O	659-664
isolated	O	665-673
kidney	O	674-680
perfusion	O	681-690
with	O	691-695
tracers	O	696-703
.	O	703-704

Possible	O	705-713
effects	O	714-721
of	O	722-724
ACE	O	725-728
inhibition	O	729-739
were	O	740-744
tested	O	745-751
.	O	751-752

RESULTS	O	753-760
:	O	760-761
By	O	762-764
day	O	765-768
2	O	769-770
,	O	770-771
some	O	772-776
patchy	O	777-783
foot	O	784-788
process	O	789-796
effacement	O	797-807
,	O	807-808
but	O	809-812
no	O	813-815
proteinuria	B	816-827
,	O	827-828
appeared	O	829-837
.	O	837-838

The	O	839-842
amount	O	843-849
of	O	850-852
nephrin	O	853-860
was	O	861-864
reduced	O	865-872
in	O	873-875
both	O	876-880
diseased	O	881-889
and	O	890-893
normal	O	894-900
areas	O	901-906
.	O	906-907

The	O	908-911
other	O	912-917
proteins	O	918-926
showed	O	927-933
few	O	934-937
changes	O	938-945
,	O	945-946
which	O	947-952
were	O	953-957
limited	O	958-965
to	O	966-968
diseased	O	969-977
areas	O	978-983
.	O	983-984

By	O	985-987
day	O	988-991
4	O	992-993
,	O	993-994
foot	O	995-999
process	O	1000-1007
effacement	O	1008-1018
was	O	1019-1022
complete	O	1023-1031
and	O	1032-1035
proteinuria	B	1036-1047
appeared	O	1048-1056
in	O	1057-1059
parallel	O	1060-1068
with	O	1069-1073
signs	O	1074-1079
of	O	1080-1082
size	O	1083-1087
barrier	O	1088-1095
damage	O	1096-1102
.	O	1102-1103

Nephrin	O	1104-1111
decreased	O	1112-1121
further	O	1122-1129
,	O	1129-1130
while	O	1131-1136
dendrin	O	1137-1144
and	O	1145-1148
plekhh2	O	1149-1156
also	O	1157-1161
decreased	O	1162-1171
but	O	1172-1175
a	O	1176-1177
-	O	1177-1178
actinin	O	1178-1185
remained	O	1186-1194
unchanged	O	1195-1204
.	O	1204-1205

ACE	O	1206-1209
inhibition	O	1210-1220
had	O	1221-1224
no	O	1225-1227
significant	O	1228-1239
protective	O	1240-1250
effect	O	1251-1257
.	O	1257-1258

CONCLUSIONS	O	1259-1270
:	O	1270-1271
PAN	O	1272-1275
glomeruli	O	1276-1285
already	O	1286-1293
showed	O	1294-1300
significant	O	1301-1312
pathology	O	1313-1322
by	O	1323-1325
day	O	1326-1329
4	O	1330-1331
,	O	1331-1332
despite	O	1333-1340
relatively	O	1341-1351
mild	O	1352-1356
proteinuria	B	1357-1368
.	O	1368-1369

This	O	1370-1374
was	O	1375-1378
preceded	O	1379-1387
by	O	1388-1390
altered	O	1391-1398
nephrin	O	1399-1406
expression	O	1407-1417
,	O	1417-1418
supporting	O	1419-1429
its	O	1430-1433
pivotal	O	1434-1441
role	O	1442-1446
in	O	1447-1449
podocyte	O	1450-1458
morphology	O	1459-1469
.	O	1469-1470

The	O	1471-1474
novel	O	1475-1480
proteins	O	1481-1489
dendrin	O	1490-1497
and	O	1498-1501
plekhh2	O	1502-1509
were	O	1510-1514
both	O	1515-1519
reduced	O	1520-1527
,	O	1527-1528
suggesting	O	1529-1539
roles	O	1540-1545
in	O	1546-1548
PAN	O	1549-1552
,	O	1552-1553
whereas	O	1554-1561
a	O	1562-1563
-	O	1563-1564
actinin	O	1564-1571
was	O	1572-1575
unchanged	O	1576-1585
.	O	1585-1586

Twin	O	0-4
preterm	O	5-12
neonates	O	13-21
with	O	22-26
cardiac	B	27-34
toxicity	I	35-43
related	O	44-51
to	O	52-54
lopinavir	O	55-64
/	O	64-65
ritonavir	O	65-74
therapy	O	75-82
.	O	82-83

We	O	84-86
report	O	87-93
twin	O	94-98
neonates	O	99-107
who	O	108-111
were	O	112-116
born	O	117-121
prematurely	O	122-133
at	O	134-136
32	O	137-139
weeks	O	140-145
of	O	146-148
gestation	O	149-158
to	O	159-161
a	O	162-163
mother	O	164-170
with	O	171-175
human	B	176-181
immunodeficiency	I	182-198
virus	I	199-204
infection	I	205-214
.	O	214-215

One	O	216-219
of	O	220-222
the	O	223-226
twins	O	227-232
developed	O	233-242
complete	O	243-251
heart	B	252-257
block	I	258-263
and	O	264-267
dilated	B	268-275
cardiomyopathy	I	276-290
related	O	291-298
to	O	299-301
lopinavir	O	302-311
/	O	311-312
ritonavir	O	312-321
therapy	O	322-329
,	O	329-330
a	O	331-332
boosted	O	333-340
protease	O	341-349
-	O	349-350
inhibitor	O	350-359
agent	O	360-365
,	O	365-366
while	O	367-372
the	O	373-376
other	O	377-382
twin	O	383-387
developed	O	388-397
mild	O	398-402
bradycardia	B	403-414
.	O	414-415

We	O	416-418
recommend	O	419-428
caution	O	429-436
in	O	437-439
the	O	440-443
use	O	444-447
of	O	448-450
lopinavir	O	451-460
/	O	460-461
ritonavir	O	461-470
in	O	471-473
the	O	474-477
immediate	O	478-487
neonatal	O	488-496
period	O	497-503
.	O	503-504

Learning	O	0-8
of	O	9-11
rats	O	12-16
under	O	17-22
amnesia	B	23-30
caused	O	31-37
by	O	38-40
pentobarbital	O	41-54
.	O	54-55

Dissociated	O	56-67
learning	O	68-76
of	O	77-79
rats	O	80-84
in	O	85-87
the	O	88-91
normal	O	92-98
state	O	99-104
and	O	105-108
the	O	109-112
state	O	113-118
of	O	119-121
amnesia	B	122-129
produced	O	130-138
by	O	139-141
pentobarbital	O	142-155
(	O	156-157
15	O	157-159
mg	O	160-162
/	O	162-163
kg	O	163-165
,	O	165-166
ip	O	167-169
)	O	169-170
was	O	171-174
carried	O	175-182
out	O	183-186
.	O	186-187

Rats	O	188-192
were	O	193-197
trained	O	198-205
to	O	206-208
approach	O	209-217
a	O	218-219
shelf	O	220-225
where	O	226-231
they	O	232-236
received	O	237-245
food	O	246-250
reinforcement	O	251-264
.	O	264-265

In	O	266-268
Group	O	269-274
1	O	275-276
the	O	277-280
rats	O	281-285
were	O	286-290
trained	O	291-298
under	O	299-304
the	O	305-308
influence	O	309-318
of	O	319-321
pentobarbital	O	322-335
to	O	336-338
run	O	339-342
to	O	343-345
the	O	346-349
same	O	350-354
shelf	O	355-360
as	O	361-363
in	O	364-366
the	O	367-370
normal	O	371-377
state	O	378-383
.	O	383-384

In	O	385-387
Group	O	388-393
2	O	394-395
the	O	396-399
rats	O	400-404
were	O	405-409
trained	O	410-417
to	O	418-420
approach	O	421-429
different	O	430-439
shelves	O	440-447
in	O	448-450
different	O	451-460
drug	O	461-465
states	O	466-472
.	O	472-473

It	O	474-476
was	O	477-480
shown	O	481-486
that	O	487-491
memory	B	492-498
dissociation	I	499-511
occurred	O	512-520
in	O	521-523
both	O	524-528
groups	O	529-535
.	O	535-536

Differences	O	537-548
in	O	549-551
the	O	552-555
parameters	O	556-566
of	O	567-569
training	O	570-578
under	O	579-584
the	O	585-588
influence	O	589-598
of	O	599-601
pentobarbital	O	602-615
between	O	616-623
Groups	O	624-630
1	O	631-632
and	O	633-636
2	O	637-638
were	O	639-643
revealed	O	644-652
.	O	652-653

These	O	654-659
findings	O	660-668
show	O	669-673
that	O	674-678
the	O	679-682
brain	O	683-688
-	O	688-689
dissociated	O	689-700
state	O	701-706
induced	O	707-714
by	O	715-717
pentobarbital	O	718-731
is	O	732-734
formed	O	735-741
with	O	742-746
the	O	747-750
participation	O	751-764
of	O	765-767
the	O	768-771
mechanisms	O	772-782
of	O	783-785
information	O	786-797
perception	O	798-808
.	O	808-809

Angiosarcoma	B	0-12
of	I	13-15
the	I	16-19
liver	I	20-25
associated	O	26-36
with	O	37-41
diethylstilbestrol	O	42-60
.	O	60-61

Angiosarcoma	B	62-74
of	I	75-77
the	I	78-81
liver	I	82-87
occurred	O	88-96
in	O	97-99
a	O	100-101
76	O	102-104
-	O	104-105
year	O	105-109
-	O	104-105
old	O	110-113
man	O	114-117
who	O	118-121
had	O	122-125
been	O	126-130
treated	O	131-138
for	O	139-142
a	O	143-144
well	O	145-149
-	O	149-150
differentiated	O	150-164
adenocarcinoma	B	165-179
of	I	180-182
the	I	183-186
liver	I	187-192
with	O	193-197
diethylstilbestrol	O	198-216
for	O	217-220
13	O	221-223
years	O	224-229
.	O	229-230

Angiosarcoma	B	231-243
was	O	244-247
also	O	248-252
present	O	253-260
within	O	261-267
pulmonary	O	268-277
and	O	278-281
renal	O	282-287
arteries	O	288-296
.	O	296-297

The	O	298-301
possibility	O	302-313
that	O	314-318
the	O	319-322
intraarterial	B	323-336
lesions	I	337-344
might	O	345-350
represent	O	351-360
independent	O	361-372
primary	O	373-380
tumors	B	381-387
is	O	388-390
considered	O	391-401
.	O	401-402

Role	O	0-4
of	O	5-7
xanthine	O	8-16
oxidase	O	17-24
in	O	25-27
dexamethasone	O	28-41
-	O	41-42
induced	O	42-49
hypertension	B	50-62
in	O	63-65
rats	O	66-70
.	O	70-71
1	O	72-73
.	O	73-74
Glucocorticoid	O	75-89
-	O	89-90
induced	O	90-97
hypertension	B	98-110
(	O	111-112
GC	O	112-114
-	O	114-115
HT	B	115-117
)	O	117-118
in	O	119-121
the	O	122-125
rat	O	126-129
is	O	130-132
associated	O	133-143
with	O	144-148
nitric	O	149-155
oxide	O	156-161
-	O	161-162
redox	O	162-167
imbalance	O	168-177
.	O	177-178

2	O	179-180
.	O	180-181
We	O	182-184
studied	O	185-192
the	O	193-196
role	O	197-201
of	O	202-204
xanthine	O	205-213
oxidase	O	214-221
(	O	222-223
XO	O	223-225
)	O	225-226
,	O	226-227
which	O	228-233
is	O	234-236
implicated	O	237-247
in	O	248-250
the	O	251-254
production	O	255-265
of	O	266-268
reactive	O	269-277
oxygen	O	278-284
species	O	285-292
,	O	292-293
in	O	294-296
dexamethasone	O	297-310
-	O	310-311
induced	O	311-318
hypertension	B	319-331
(	O	332-333
dex	O	333-336
-	O	336-337
HT	B	337-339
)	O	339-340
.	O	340-341

3	O	342-343
.	O	343-344
Thirty	O	345-351
male	O	352-356
Sprague	O	357-364
-	O	364-365
Dawley	O	365-371
rats	O	372-376
were	O	377-381
divided	O	382-389
randomly	O	390-398
into	O	399-403
four	O	404-408
treatment	O	409-418
groups	O	419-425
:	O	425-426
saline	O	427-433
,	O	433-434
dexamethasone	O	435-448
(	O	449-450
dex	O	450-453
)	O	453-454
,	O	454-455
allopurinol	O	456-467
plus	O	468-472
saline	O	473-479
,	O	479-480
and	O	481-484
allopurinol	O	485-496
plus	O	497-501
dex	O	502-505
.	O	505-506
4	O	507-508
.	O	508-509
Systolic	O	510-518
blood	O	519-524
pressures	O	525-534
(	O	535-536
SBP	O	536-539
)	O	539-540
and	O	541-544
bodyweights	O	545-556
were	O	557-561
recorded	O	562-570
each	O	571-575
alternate	O	576-585
day	O	586-589
.	O	589-590

Thymus	O	591-597
weight	O	598-604
was	O	605-608
used	O	609-613
as	O	614-616
a	O	617-618
marker	O	619-625
of	O	626-628
glucocorticoid	O	629-643
activity	O	644-652
,	O	652-653
and	O	654-657
serum	O	658-663
urate	O	664-669
to	O	670-672
assess	O	673-679
XO	O	680-682
inhibition	O	683-693
.	O	693-694
5	O	695-696
.	O	696-697
Dex	O	698-701
increased	B	702-711
SBP	I	712-715
(	O	716-717
110	O	717-720
+	O	721-722
/	O	722-723
-	O	723-724
2	O	725-726
-	O	726-727
126	O	727-730
+	O	731-732
/	O	732-733
-	O	733-734
3	O	735-736
mmHg	O	737-741
;	O	741-742
P	O	743-744
<	O	745-746
0	O	747-748
.	O	748-749
001	O	749-752
)	O	752-753
and	O	754-757
decreased	B	758-767
thymus	I	768-774
(	I	775-776
P	I	776-777
<	I	778-779
0	I	780-781
.	I	781-782
001	I	782-785
)	I	785-786
and	I	787-790
bodyweights	I	791-802
(	O	803-804
P	O	804-805
"	O	805-806
<	O	807-808
0	O	809-810
.	O	810-811
01	O	811-813
)	O	813-814
.	O	810-811

Allopurinol	O	816-827
decreased	O	828-837
serum	O	838-843
urate	O	844-849
from	O	850-854
76	O	855-857
+	O	858-859
/	O	859-860
-	O	860-861
5	O	862-863
to	O	864-866
30	O	867-869
+	O	870-871
/	O	871-872
-	O	872-873
3	O	874-875
micromol	O	876-884
/	O	884-885
L	O	885-886
(	O	887-888
P	O	888-889
<	O	890-891
0	O	892-893
.	O	893-894
001	O	894-897
)	O	897-898
in	O	899-901
saline	O	902-908
and	O	909-912
from	O	913-917
84	O	918-920
+	O	921-922
/	O	922-923
-	O	923-924
13	O	925-927
to	O	928-930
28	O	931-933
+	O	934-935
/	O	935-936
-	O	936-937
2	O	938-939
micromol	O	940-948
/	O	948-949
L	O	949-950
in	O	951-953
dex	O	954-957
-	O	957-958
treated	O	958-965
(	O	966-967
P	O	967-968
<	O	969-970
0	O	971-972
.	O	972-973
01	O	973-975
)	O	975-976
groups	O	977-983
.	O	983-984

6	O	985-986
.	O	986-987
Allopurinol	O	988-999
did	O	1000-1003
not	O	1004-1007
prevent	O	1008-1015
dex	O	1016-1019
-	O	1019-1020
HT	B	1020-1022
.	O	1022-1023

This	O	1024-1028
,	O	1028-1029
together	O	1030-1038
with	O	1039-1043
our	O	1044-1047
previous	O	1048-1056
findings	O	1057-1065
that	O	1066-1070
allopurinol	O	1071-1082
failed	O	1083-1089
to	O	1090-1092
prevent	O	1093-1100
adrenocorticotrophic	O	1101-1121
hormone	O	1122-1129
induced	O	1130-1137
hypertension	B	1138-1150
,	O	1150-1151
suggests	O	1152-1160
that	O	1161-1165
XO	O	1166-1168
activity	O	1169-1177
is	O	1178-1180
not	O	1181-1184
a	O	1185-1186
major	O	1187-1192
determinant	O	1193-1204
of	O	1205-1207
GC	O	1208-1210
-	O	1210-1211
HT	B	1211-1213
in	O	1214-1216
the	O	1217-1220
rat	O	1221-1224
.	O	1224-1225

Extrapyramidal	O	0-14
side	O	15-19
effects	O	20-27
with	O	28-32
risperidone	O	33-44
and	O	45-48
haloperidol	O	49-60
at	O	61-63
comparable	O	64-74
D2	O	75-77
receptor	O	78-86
occupancy	O	87-96
levels	O	97-103
.	O	103-104

Risperidone	O	105-116
is	O	117-119
an	O	120-122
antipsychotic	O	123-136
drug	O	137-141
with	O	142-146
high	O	147-151
affinity	O	152-160
at	O	161-163
dopamine	O	164-172
D2	O	173-175
and	O	176-179
serotonin	O	180-189
5	O	190-191
-	O	191-192
HT2	O	192-195
receptors	O	196-205
.	O	205-206

Previous	O	207-215
clinical	O	216-224
studies	O	225-232
have	O	233-237
proposed	O	238-246
that	O	247-251
risperidone	O	252-263
'	O	263-264
s	O	254-255
pharmacologic	O	266-279
profile	O	280-287
may	O	288-291
produce	O	292-299
improved	O	300-308
efficacy	O	309-317
for	O	318-321
negative	O	322-330
psychotic	B	331-340
symptoms	I	341-349
and	O	350-353
decreased	O	354-363
propensity	O	364-374
for	O	375-378
extrapyramidal	O	379-393
side	O	394-398
effects	O	399-406
;	O	406-407
features	O	408-416
shared	O	417-423
by	O	424-426
so	O	427-429
-	O	429-430
called	O	430-436
'	O	437-438
atypical	O	438-446
'	O	437-438
neuroleptics	O	448-460
.	O	460-461

To	O	462-464
determine	O	465-474
if	O	475-477
routine	O	478-485
risperidone	O	486-497
treatment	O	498-507
is	O	508-510
associated	O	511-521
with	O	522-526
a	O	527-528
unique	O	529-535
degree	O	536-542
of	O	543-545
D2	O	546-548
receptor	O	549-557
occupancy	O	558-567
and	O	568-571
pattern	O	572-579
of	O	580-582
clinical	O	583-591
effects	O	592-599
,	O	599-600
we	O	601-603
used	O	604-608
[	O	609-610
123I	O	610-614
]	O	614-615
IBZM	O	615-619
SPECT	O	620-625
to	O	626-628
determine	O	629-638
D2	O	639-641
occupancy	O	642-651
in	O	652-654
subjects	O	655-663
treated	O	664-671
with	O	672-676
routine	O	677-684
clinical	O	685-693
doses	O	694-699
of	O	700-702
risperidone	O	703-714
(	O	715-716
n	O	716-717
=	O	718-719
12	O	720-722
)	O	722-723
or	O	724-726
haloperidol	O	727-738
(	O	739-740
n	O	740-741
=	O	742-743
7	O	744-745
)	O	745-746
.	O	746-747

Both	O	748-752
risperidone	O	753-764
and	O	765-768
haloperidol	O	769-780
produced	O	781-789
D2	O	790-792
occupancy	O	793-802
levels	O	803-809
between	O	810-817
approximately	O	818-831
60	O	832-834
and	O	835-838
90	O	839-841
%	O	841-842
at	O	843-845
standard	O	846-854
clinical	O	855-863
doses	O	864-869
.	O	869-870

There	O	871-876
was	O	877-880
no	O	881-883
significant	O	884-895
difference	O	896-906
between	O	907-914
occupancy	O	915-924
levels	O	925-931
obtained	O	932-940
with	O	941-945
haloperidol	O	946-957
or	O	958-960
risperidone	O	961-972
.	O	972-973

Drug	B	974-978
-	I	978-979
induced	I	979-986
parkinsonism	I	987-999
was	O	1000-1003
observed	O	1004-1012
in	O	1013-1015
subjects	O	1016-1024
treated	O	1025-1032
with	O	1033-1037
risperidone	O	1038-1049
(	O	1050-1051
42	O	1051-1053
%	O	1053-1054
)	O	1054-1055
and	O	1056-1059
haloperidol	O	1060-1071
(	O	1072-1073
29	O	1073-1075
%	O	1075-1076
)	O	1076-1077
and	O	1078-1081
was	O	1082-1085
observed	O	1086-1094
at	O	1095-1097
occupancy	O	1098-1107
levels	O	1108-1114
above	O	1115-1120
60	O	1121-1123
%	O	1123-1124
.	O	1124-1125

Based	O	1126-1131
on	O	1132-1134
these	O	1135-1140
observations	O	1141-1153
,	O	1153-1154
it	O	1155-1157
is	O	1158-1160
concluded	O	1161-1170
that	O	1171-1175
5	O	1176-1177
-	O	1177-1178
HT2	O	1178-1181
blockade	O	1182-1190
obtained	O	1191-1199
with	O	1200-1204
risperidone	O	1205-1216
at	O	1217-1219
D2	O	1220-1222
occupancy	O	1223-1232
rates	O	1233-1238
of	O	1239-1241
60	O	1242-1244
%	O	1244-1245
and	O	1246-1249
above	O	1250-1255
does	O	1256-1260
not	O	1261-1264
appear	O	1265-1271
to	O	1272-1274
protect	O	1275-1282
against	O	1283-1290
the	O	1291-1294
risk	O	1295-1299
for	O	1300-1303
extrapyramidal	O	1304-1318
side	O	1319-1323
effects	O	1324-1331
.	O	1331-1332

Simvastatin	O	0-11
-	O	11-12
ezetimibe	O	12-21
-	O	11-12
induced	O	22-29
hepatic	B	30-37
failure	I	38-45
necessitating	O	46-59
liver	O	60-65
transplantation	O	66-81
.	O	81-82

Abstract	O	83-91
Serum	O	92-97
aminotransferase	O	98-114
elevations	O	115-125
are	O	126-129
a	O	130-131
commonly	O	132-140
known	O	141-146
adverse	O	147-154
effect	O	155-161
of	O	162-164
3	O	165-166
-	O	166-167
hydroxy	O	167-174
-	O	166-167
3	O	165-166
-	O	166-167
methylglutaryl	O	177-191
coenzyme	O	192-200
A	O	201-202
reductase	O	203-212
inhibitor	O	213-222
(	O	223-224
statin	O	224-230
)	O	230-231
therapy	O	232-239
.	O	239-240

However	O	241-248
,	O	248-249
hepatotoxic	B	250-261
events	O	262-268
have	O	269-273
not	O	274-277
been	O	278-282
widely	O	283-289
published	O	290-299
with	O	300-304
ezetimibe	O	305-314
or	O	315-317
the	O	318-321
combination	O	322-333
agent	O	334-339
simvastatin	O	340-351
-	O	351-352
ezetimibe	O	352-361
.	O	361-362

We	O	363-365
describe	O	366-374
a	O	375-376
70	O	377-379
-	O	379-380
year	O	380-384
-	O	379-380
old	O	385-388
Hispanic	O	389-397
woman	O	398-403
who	O	404-407
developed	O	408-417
fulminant	B	418-427
hepatic	I	428-435
failure	I	436-443
necessitating	O	444-457
liver	O	458-463
transplantation	O	464-479
10	O	480-482
weeks	O	483-488
after	O	489-494
conversion	O	495-505
from	O	506-510
simvastatin	O	511-522
40	O	523-525
mg	O	526-528
/	O	528-529
day	O	529-532
to	O	533-535
simvastatin	O	536-547
10	O	548-550
mg	O	551-553
-	O	553-554
ezetimibe	O	554-563
40	O	564-566
mg	O	567-569
/	O	569-570
day	O	570-573
.	O	573-574

The	O	575-578
patient	O	579-586
'	O	586-587
s	O	587-588
lipid	O	589-594
panel	O	595-600
had	O	601-604
been	O	605-609
maintained	O	610-620
with	O	621-625
simvastatin	O	626-637
for	O	638-641
18	O	642-644
months	O	645-651
before	O	652-658
the	O	659-662
conversion	O	663-673
without	O	674-681
evidence	O	682-690
of	O	691-693
hepatotoxicity	B	694-708
.	O	708-709

A	O	710-711
routine	O	712-719
laboratory	O	720-730
work	O	731-735
-	O	735-736
up	O	736-738
10	O	739-741
weeks	O	742-747
after	O	748-753
conversion	O	754-764
revealed	O	765-773
elevated	O	774-782
serum	O	783-788
aminotransferase	O	789-805
levels	O	806-812
.	O	812-813

Simvastatinezetimibe	O	814-834
and	O	835-838
escitalopram	O	839-851
(	O	852-853
which	O	853-858
she	O	859-862
was	O	863-866
taking	O	867-873
for	O	874-877
depression	B	878-888
)	O	888-889
were	O	890-894
discontinued	O	895-907
,	O	907-908
and	O	909-912
other	O	913-918
potential	O	919-928
causes	O	929-935
of	O	936-938
hepatotoxicity	B	939-953
were	O	954-958
excluded	O	959-967
.	O	967-968

A	O	969-970
repeat	O	971-977
work	O	978-982
-	O	982-983
up	O	983-985
revealed	O	986-994
further	O	995-1002
elevations	O	1003-1013
in	O	1014-1016
aminotransferase	O	1017-1033
levels	O	1034-1040
,	O	1040-1041
and	O	1042-1045
liver	O	1046-1051
biopsy	O	1052-1058
revealed	O	1059-1067
evidence	O	1068-1076
of	O	1077-1079
moderate	O	1080-1088
-	O	1088-1089
to	O	1089-1091
-	O	1088-1089
severe	O	1092-1098
drug	B	1099-1103
toxicity	I	1104-1112
.	O	1112-1113

She	O	1114-1117
underwent	O	1118-1127
liver	O	1128-1133
transplantation	O	1134-1149
with	O	1150-1154
an	O	1155-1157
uneventful	O	1158-1168
postoperative	O	1169-1182
course	O	1183-1189
.	O	1189-1190

Her	O	1191-1194
aminotransferase	O	1195-1211
levels	O	1212-1218
returned	O	1219-1227
to	O	1228-1230
normal	O	1231-1237
by	O	1238-1240
postoperative	O	1241-1254
day	O	1255-1258
23	O	1259-1261
,	O	1261-1262
and	O	1263-1266
her	O	1267-1270
2	O	1271-1272
-	O	1272-1273
year	O	1273-1277
follow	O	1278-1284
-	O	1284-1285
up	O	1285-1287
showed	O	1288-1294
no	O	1295-1297
adverse	O	1298-1305
events	O	1306-1312
.	O	1312-1313

Ezetimibe	O	1314-1323
undergoes	O	1324-1333
extensive	O	1334-1343
glucuronidation	O	1344-1359
by	O	1360-1362
uridine	O	1363-1370
diphosphate	O	1371-1382
glucoronosyltransferases	O	1383-1407
(	O	1408-1409
UGT	O	1409-1412
)	O	1412-1413
in	O	1414-1416
the	O	1417-1420
intestine	O	1421-1430
and	O	1431-1434
liver	O	1435-1440
and	O	1441-1444
may	O	1445-1448
have	O	1449-1453
inhibited	O	1454-1463
the	O	1464-1467
glucuronidation	O	1468-1483
of	O	1484-1486
simvastatin	O	1487-1498
hydroxy	O	1499-1506
acid	O	1507-1511
,	O	1511-1512
resulting	O	1513-1522
in	O	1523-1525
increased	O	1526-1535
simvastatin	O	1536-1547
exposure	O	1548-1556
and	O	1557-1560
subsequent	O	1561-1571
hepatotoxicity	B	1572-1586
.	O	1586-1587

To	O	1588-1590
our	O	1591-1594
knowledge	O	1595-1604
,	O	1604-1605
this	O	1606-1610
is	O	1611-1613
the	O	1614-1617
first	O	1618-1623
case	O	1624-1628
report	O	1629-1635
of	O	1636-1638
simvastatin	O	1639-1650
-	O	1650-1651
ezetimibe	O	1651-1660
-	O	1650-1651
induced	O	1661-1668
liver	B	1669-1674
failure	I	1675-1682
that	O	1683-1687
resulted	O	1688-1696
in	O	1697-1699
liver	O	1700-1705
transplantation	O	1706-1721
.	O	1721-1722

We	O	1723-1725
postulate	O	1726-1735
that	O	1736-1740
the	O	1741-1744
mechanism	O	1745-1754
of	O	1755-1757
the	O	1758-1761
simvastatinezetimibe	O	1762-1782
-	O	1782-1783
induced	O	1783-1790
hepatotoxicity	B	1791-1805
is	O	1806-1808
the	O	1809-1812
increased	O	1813-1822
simvastatin	O	1823-1834
exposure	O	1835-1843
by	O	1844-1846
ezetimibe	O	1847-1856
inhibition	O	1857-1867
of	O	1868-1870
UGT	O	1871-1874
enzymes	O	1875-1882
.	O	1882-1883

Clinicians	O	1884-1894
should	O	1895-1901
be	O	1902-1904
aware	O	1905-1910
of	O	1911-1913
potential	O	1914-1923
hepatotoxicity	B	1924-1938
with	O	1939-1943
simvastatin	O	1944-1955
-	O	1955-1956
ezetimibe	O	1956-1965
especially	O	1966-1976
in	O	1977-1979
elderly	O	1980-1987
patients	O	1988-1996
and	O	1997-2000
should	O	2001-2007
carefully	O	2008-2017
monitor	O	2018-2025
serum	O	2026-2031
aminotransferase	O	2032-2048
levels	O	2049-2055
when	O	2056-2060
starting	O	2061-2069
therapy	O	2070-2077
and	O	2078-2081
titrating	O	2082-2091
the	O	2092-2095
dosage	O	2096-2102
.	O	2102-2103

Oral	O	0-4
manifestations	O	5-19
of	O	20-22
"	O	23-24
meth	B	24-28
mouth	I	29-34
"	O	34-35
:	O	35-36
a	O	37-38
case	O	39-43
report	O	44-50
.	O	50-51

AIM	O	52-55
:	O	55-56
The	O	57-60
aim	O	61-64
of	O	65-67
the	O	68-71
documentation	O	72-85
of	O	86-88
this	O	89-93
clinical	O	94-102
case	O	103-107
is	O	108-110
to	O	111-113
make	O	114-118
clinicians	O	119-129
aware	O	130-135
of	O	136-138
"	O	139-140
meth	B	140-144
mouth	I	145-150
"	O	150-151
and	O	152-155
the	O	156-159
medical	O	160-167
risks	O	168-173
associated	O	174-184
with	O	185-189
this	O	190-194
serious	O	195-202
condition	O	203-212
.	O	212-213

BACKGROUND	O	214-224
:	O	224-225
Methamphetamine	O	226-241
is	O	242-244
a	O	245-246
very	O	247-251
addictive	O	252-261
,	O	261-262
powerful	O	263-271
stimulant	O	272-281
that	O	282-286
increases	O	287-296
wakefulness	O	297-308
and	O	309-312
physical	O	313-321
activity	O	322-330
and	O	331-334
can	O	335-338
produce	O	339-346
other	O	347-352
effects	O	353-360
such	O	361-365
as	O	366-368
cardiac	B	369-376
dysrhythmias	I	377-389
,	O	389-390
hypertension	B	391-403
,	O	403-404
hallucinations	B	405-419
,	O	419-420
and	O	421-424
violent	B	425-432
behavior	I	433-441
.	O	441-442

Dental	O	443-449
patients	O	450-458
abusing	O	459-466
methamphetamine	O	467-482
can	O	483-486
present	O	487-494
with	O	495-499
poor	O	500-504
oral	O	505-509
hygiene	O	510-517
,	O	517-518
xerostomia	B	519-529
,	O	529-530
rampant	O	531-538
caries	B	539-545
(	O	546-547
"	O	547-548
meth	B	548-552
mouth	I	553-558
"	O	558-559
)	O	559-560
,	O	560-561
and	O	562-565
excessive	O	566-575
tooth	B	576-581
wear	I	582-586
.	O	586-587

Oral	O	588-592
rehabilitation	O	593-607
of	O	608-610
patients	O	611-619
using	O	620-625
methamphetamine	O	626-641
can	O	642-645
be	O	646-648
challenging	O	649-660
.	O	660-661

CASE	O	662-666
DESCRIPTION	O	667-678
:	O	678-679
A	O	680-681
30	O	682-684
-	O	684-685
year	O	685-689
-	O	684-685
old	O	690-693
Caucasian	O	694-703
woman	O	704-709
presented	O	710-719
with	O	720-724
dental	O	725-731
pain	B	732-736
,	O	736-737
bad	B	738-741
breath	I	742-748
,	O	748-749
and	O	750-753
self	O	754-758
-	O	758-759
reported	O	759-767
poor	O	768-772
esthetics	O	773-782
.	O	782-783

A	O	784-785
comprehensive	O	786-799
examination	O	800-811
including	O	812-821
her	O	822-825
medical	O	826-833
history	O	834-841
,	O	841-842
panoramic	O	843-852
radiograph	O	853-863
,	O	863-864
and	O	865-868
intraoral	O	869-878
examination	O	879-890
revealed	O	891-899
19	O	900-902
carious	B	903-910
lesions	I	911-918
,	O	918-919
which	O	920-925
is	O	926-928
not	O	929-932
very	O	933-937
common	O	938-944
for	O	945-948
a	O	949-950
healthy	O	951-958
adult	O	959-964
.	O	964-965

She	O	966-969
reported	O	970-978
her	O	979-982
use	O	983-986
of	O	987-989
methamphetamine	O	990-1005
for	O	1006-1009
five	O	1010-1014
years	O	1015-1020
and	O	1021-1024
had	O	1025-1028
not	O	1029-1032
experienced	O	1033-1044
any	O	1045-1048
major	O	1049-1054
carious	B	1055-1062
episodes	I	1063-1071
before	O	1072-1078
she	O	1079-1082
started	O	1083-1090
using	O	1091-1096
the	O	1097-1100
drug	O	1101-1105
.	O	1105-1106

SUMMARY	O	1107-1114
:	O	1114-1115
The	O	1116-1119
patient	O	1120-1127
'	O	1127-1128
s	O	1128-1129
medical	O	1130-1137
and	O	1138-1141
dental	O	1142-1148
histories	O	1149-1158
along	O	1159-1164
with	O	1165-1169
radiographic	O	1170-1182
and	O	1183-1186
clinical	O	1187-1195
findings	O	1196-1204
lead	O	1205-1209
to	O	1210-1212
a	O	1213-1214
diagnosis	O	1215-1224
of	O	1225-1227
"	O	1228-1229
meth	B	1229-1233
mouth	I	1234-1239
.	O	1239-1240
"	O	1240-1241

Although	O	1242-1250
three	O	1251-1256
different	O	1257-1266
dental	O	1267-1273
treatment	O	1274-1283
modalities	O	1284-1294
(	O	1295-1296
either	O	1296-1302
conventional	O	1303-1315
or	O	1316-1318
implant	O	1319-1326
-	O	1326-1327
supported	O	1327-1336
)	O	1336-1337
have	O	1338-1342
been	O	1343-1347
offered	O	1348-1355
to	O	1356-1358
the	O	1359-1362
patient	O	1363-1370
since	O	1371-1376
August	O	1377-1383
2007	O	1384-1388
,	O	1388-1389
the	O	1390-1393
patient	O	1394-1401
has	O	1402-1405
yet	O	1406-1409
to	O	1410-1412
initiate	O	1413-1421
any	O	1422-1425
treatment	O	1426-1435
.	O	1435-1436

CLINICAL	O	1437-1445
SIGNIFICANCE	O	1446-1458
:	O	1458-1459
This	O	1460-1464
clinical	O	1465-1473
case	O	1474-1478
showing	O	1479-1486
oral	O	1487-1491
manifestations	O	1492-1506
of	O	1507-1509
meth	B	1510-1514
mouth	I	1515-1520
was	O	1521-1524
presented	O	1525-1534
to	O	1535-1537
help	O	1538-1542
dental	O	1543-1549
practitioners	O	1550-1563
recognize	O	1564-1573
and	O	1574-1577
manage	O	1578-1584
patients	O	1585-1593
who	O	1594-1597
may	O	1598-1601
be	O	1602-1604
abusing	O	1605-1612
methamphetamines	O	1613-1629
.	O	1629-1630

Dental	O	1631-1637
practitioners	O	1638-1651
also	O	1652-1656
may	O	1657-1660
be	O	1661-1663
skeptical	O	1664-1673
about	O	1674-1679
the	O	1680-1683
reliability	O	1684-1695
of	O	1696-1698
appointment	O	1699-1710
keeping	O	1711-1718
by	O	1719-1721
these	O	1722-1727
patients	O	1728-1736
,	O	1736-1737
as	O	1738-1740
they	O	1741-1745
frequently	O	1746-1756
miss	O	1757-1761
their	O	1762-1767
appointments	O	1768-1780
without	O	1781-1788
reasonable	O	1789-1799
justification	O	1800-1813
.	O	1813-1814

Thyroxine	O	0-9
abuse	O	10-15
:	O	15-16
an	O	17-19
unusual	O	20-27
case	O	28-32
of	O	33-35
thyrotoxicosis	B	36-50
in	O	51-53
pregnancy	O	54-63
.	O	63-64

Eating	B	65-71
disorders	I	72-81
and	O	82-85
the	O	86-89
associated	O	90-100
behavioural	O	101-112
problems	O	113-121
and	O	122-125
drug	B	126-130
abuse	I	131-136
are	O	137-140
uncommon	O	141-149
in	O	150-152
pregnancy	O	153-162
.	O	162-163

When	O	164-168
they	O	169-173
do	O	174-176
occur	O	177-182
they	O	183-187
are	O	188-191
often	O	192-197
unrecognized	O	198-210
because	O	211-218
of	O	219-221
denial	O	222-228
but	O	229-232
when	O	233-237
significant	O	238-249
may	O	250-253
pose	O	254-258
a	O	259-260
risk	O	261-265
to	O	266-268
both	O	269-273
the	O	274-277
mother	O	278-284
and	O	285-288
her	O	289-292
fetus	O	293-298
.	O	298-299

This	O	300-304
case	O	305-309
illustrates	O	310-321
a	O	322-323
number	O	324-330
of	O	331-333
problems	O	334-342
that	O	343-347
may	O	348-351
be	O	352-354
encountered	O	355-366
in	O	367-369
women	O	370-375
with	O	376-380
eating	B	381-387
disorders	I	388-397
in	O	398-400
pregnancy	O	401-410
,	O	410-411
including	O	412-421
prolonged	O	422-431
and	O	432-435
recurrent	O	436-445
metabolic	O	446-455
disturbances	O	456-468
and	O	469-472
diuretic	O	473-481
abuse	O	482-487
.	O	487-488

In	O	489-491
particular	O	492-502
it	O	503-505
illustrates	O	506-517
the	O	518-521
derangements	O	522-534
of	O	535-537
thyroid	O	538-545
function	O	546-554
seen	O	555-559
in	O	560-562
pregnant	O	563-571
women	O	572-577
with	O	578-582
eating	B	583-589
disorders	I	590-599
and	O	600-603
reminds	O	604-611
us	O	612-614
that	O	615-619
when	O	620-624
a	O	625-626
cause	O	627-632
for	O	633-636
thyrotoxicosis	B	637-651
remains	O	652-659
obscure	O	660-667
,	O	667-668
thyroxine	O	669-678
abuse	O	679-684
should	O	685-691
be	O	692-694
considered	O	695-705
and	O	706-709
explored	O	710-718
.	O	718-719

Attenuation	O	0-11
of	O	12-14
methamphetamine	O	15-30
-	O	30-31
induced	O	31-38
nigrostriatal	O	39-52
dopaminergic	O	53-65
neurotoxicity	B	66-79
in	O	80-82
mice	O	83-87
by	O	88-90
lipopolysaccharide	O	91-109
pretreatment	O	110-122
.	O	122-123

Immunological	O	124-137
activation	O	138-148
has	O	149-152
been	O	153-157
proposed	O	158-166
to	O	167-169
play	O	170-174
a	O	175-176
role	O	177-181
in	O	182-184
methamphetamine	O	185-200
-	O	200-201
induced	O	201-208
dopaminergic	B	209-221
terminal	I	222-230
damage	I	231-237
.	O	237-238

In	O	239-241
this	O	242-246
study	O	247-252
,	O	252-253
we	O	254-256
examined	O	257-265
the	O	266-269
roles	O	270-275
of	O	276-278
lipopolysaccharide	O	279-297
,	O	297-298
a	O	299-300
pro	O	301-304
-	O	304-305
inflammatory	O	305-317
and	O	318-321
inflammatory	O	322-334
factor	O	335-341
,	O	341-342
treatment	O	343-352
in	O	353-355
modulating	O	356-366
the	O	367-370
methamphetamine	O	371-386
-	O	386-387
induced	O	387-394
nigrostriatal	O	395-408
dopamine	O	409-417
neurotoxicity	B	418-431
.	O	431-432

Lipopolysaccharide	O	433-451
pretreatment	O	452-464
did	O	465-468
not	O	469-472
affect	O	473-479
the	O	480-483
basal	O	484-489
body	O	490-494
temperature	O	495-506
or	O	507-509
methamphetamine	O	510-525
-	O	525-526
elicited	O	526-534
hyperthermia	B	535-547
three	O	548-553
days	O	554-558
later	O	559-564
.	O	564-565

Such	O	566-570
systemic	O	571-579
lipopolysaccharide	O	580-598
treatment	O	599-608
mitigated	O	609-618
methamphetamine	O	619-634
-	O	634-635
induced	O	635-642
striatal	O	643-651
dopamine	O	652-660
and	O	661-664
3	O	665-666
,	O	666-667
4	O	667-668
-	O	668-669
dihydroxyphenylacetic	O	669-690
acid	O	691-695
depletions	O	696-706
in	O	707-709
a	O	710-711
dose	O	712-716
-	O	716-717
dependent	O	717-726
manner	O	727-733
.	O	733-734

As	O	735-737
the	O	738-741
most	O	742-746
potent	O	747-753
dose	O	754-758
(	O	759-760
1	O	760-761
mg	O	762-764
/	O	764-765
kg	O	765-767
)	O	767-768
of	O	769-771
lipopolysaccharide	O	772-790
was	O	791-794
administered	O	795-807
two	O	808-811
weeks	O	812-817
,	O	817-818
one	O	819-822
day	O	823-826
before	O	827-833
or	O	834-836
after	O	837-842
the	O	843-846
methamphetamine	O	847-862
dosing	O	863-869
regimen	O	870-877
,	O	877-878
methamphetamine	O	879-894
-	O	894-895
induced	O	895-902
striatal	O	903-911
dopamine	O	912-920
and	O	921-924
3	O	925-926
,	O	926-927
4	O	927-928
-	O	928-929
dihydroxyphenylacetic	O	929-950
acid	O	951-955
depletions	O	956-966
remained	O	967-975
unaltered	O	976-985
.	O	985-986

Moreover	O	987-995
,	O	995-996
systemic	O	997-1005
lipopolysaccharide	O	1006-1024
pretreatment	O	1025-1037
(	O	1038-1039
1	O	1039-1040
mg	O	1041-1043
/	O	1043-1044
kg	O	1044-1046
)	O	1046-1047
attenuated	O	1048-1058
local	O	1059-1064
methamphetamine	O	1065-1080
infusion	O	1081-1089
-	O	1089-1090
produced	O	1090-1098
dopamine	O	1099-1107
and	O	1108-1111
3	O	1112-1113
,	O	1113-1114
4	O	1114-1115
-	O	1115-1116
dihydroxyphenylacetic	O	1116-1137
acid	O	1138-1142
depletions	O	1143-1153
in	O	1154-1156
the	O	1157-1160
striatum	O	1161-1169
,	O	1169-1170
indicating	O	1171-1181
that	O	1182-1186
the	O	1187-1190
protective	O	1191-1201
effect	O	1202-1208
of	O	1209-1211
lipopolysaccharide	O	1212-1230
is	O	1231-1233
less	O	1234-1238
likely	O	1239-1245
due	O	1246-1249
to	O	1250-1252
interrupted	O	1253-1264
peripheral	O	1265-1275
distribution	O	1276-1288
or	O	1289-1291
metabolism	O	1292-1302
of	O	1303-1305
methamphetamine	O	1306-1321
.	O	1321-1322

We	O	1323-1325
concluded	O	1326-1335
a	O	1336-1337
critical	O	1338-1346
time	O	1347-1351
window	O	1352-1358
for	O	1359-1362
systemic	O	1363-1371
lipopolysaccharide	O	1372-1390
pretreatment	O	1391-1403
in	O	1404-1406
exerting	O	1407-1415
effective	O	1416-1425
protection	O	1426-1436
against	O	1437-1444
methamphetamine	O	1445-1460
-	O	1460-1461
induced	O	1461-1468
nigrostriatal	O	1469-1482
dopamine	O	1483-1491
neurotoxicity	B	1492-1505
.	O	1505-1506

Effect	O	0-6
of	O	7-9
converting	O	10-20
enzyme	O	21-27
inhibition	O	28-38
on	O	39-41
the	O	42-45
course	O	46-52
of	O	53-55
adriamycin	O	56-66
-	O	66-67
induced	O	67-74
nephropathy	B	75-86
.	O	86-87

The	O	88-91
effect	O	92-98
of	O	99-101
the	O	102-105
converting	O	106-116
enzyme	O	117-123
inhibitor	O	124-133
(	O	134-135
CEI	O	135-138
)	O	138-139
enalapril	O	140-149
was	O	150-153
assessed	O	154-162
in	O	163-165
Munich	O	166-172
-	O	172-173
Wistar	O	173-179
rats	O	180-184
with	O	185-189
established	O	190-201
adriamycin	O	202-212
nephrosis	B	213-222
.	O	222-223

Rats	O	224-228
were	O	229-233
given	O	234-239
a	O	240-241
single	O	242-248
dose	O	249-253
of	O	254-256
adriamycin	O	257-267
and	O	268-271
one	O	272-275
month	O	276-281
later	O	282-287
divided	O	288-295
into	O	296-300
four	O	301-305
groups	O	306-312
matched	O	313-320
for	O	321-324
albuminuria	B	325-336
,	O	336-337
blood	O	338-343
pressure	O	344-352
,	O	352-353
and	O	354-357
plasma	O	358-364
albumin	O	365-372
concentration	O	373-386
.	O	386-387

Groups	O	388-394
1	O	395-396
and	O	397-400
3	O	401-402
remained	O	403-411
untreated	O	412-421
while	O	422-427
groups	O	428-434
2	O	435-436
and	O	437-440
4	O	441-442
received	O	443-451
enalapril	O	452-461
.	O	461-462

Groups	O	463-469
1	O	470-471
and	O	472-475
2	O	476-477
underwent	O	478-487
micropuncture	O	488-501
studies	O	502-509
after	O	510-515
10	O	516-518
days	O	519-523
.	O	523-524

These	O	525-530
short	O	531-536
-	O	536-537
term	O	537-541
studies	O	542-549
showed	O	550-556
that	O	557-561
enalapril	O	562-571
reduced	O	572-579
arterial	O	580-588
blood	O	589-594
pressure	O	595-603
(	O	604-605
101	O	605-608
+	O	609-610
/	O	610-611
-	O	611-612
2	O	613-614
vs	O	615-617
.	O	617-618
124	O	619-622
+	O	623-624
/	O	624-625
-	O	625-626
3	O	627-628
mm	O	629-631
Hg	O	632-634
,	O	634-635
group	O	636-641
2	O	642-643
vs	O	644-646
.	O	646-647
1	O	648-649
,	O	649-650
P	O	651-652
less	O	653-657
than	O	658-662
0	O	663-664
.	O	664-665
05	O	665-667
)	O	667-668
and	O	669-672
glomerular	O	673-683
capillary	O	684-693
pressure	O	694-702
(	O	703-704
54	O	704-706
+	O	707-708
/	O	708-709
-	O	709-710
1	O	711-712
vs	O	713-715
.	O	715-716
61	O	717-719
+	O	720-721
/	O	721-722
-	O	722-723
2	O	724-725
mm	O	726-728
Hg	O	729-731
,	O	731-732
P	O	733-734
less	O	735-739
than	O	740-744
0	O	745-746
.	O	746-747
05	O	747-749
)	O	749-750
without	O	751-758
reducing	O	759-767
albuminuria	B	768-779
(	O	780-781
617	O	781-784
+	O	785-786
/	O	786-787
-	O	787-788
50	O	789-791
vs	O	792-794
.	O	794-795

570	O	796-799
+	O	800-801
/	O	801-802
-	O	802-803
47	O	804-806
mg	O	807-809
/	O	809-810
day	O	810-813
)	O	813-814
or	O	815-817
GFR	O	818-821
(	O	822-823
1	O	823-824
.	O	824-825
03	O	825-827
+	O	828-829
/	O	829-830
-	O	830-831
0	O	832-833
.	O	833-834
04	O	834-836
vs	O	837-839
.	O	839-840
1	O	841-842
.	O	842-843
04	O	843-845
+	O	846-847
/	O	847-848
-	O	848-849
0	O	850-851
.	O	851-852
11	O	852-854
ml	O	855-857
/	O	857-858
min	O	858-861
)	O	861-862
.	O	862-863

Groups	O	864-870
3	O	871-872
and	O	873-876
4	O	877-878
were	O	879-883
studied	O	884-891
at	O	892-894
four	O	895-899
and	O	900-903
at	O	904-906
six	O	907-910
months	O	911-917
to	O	918-920
assess	O	921-927
the	O	928-931
effect	O	932-938
of	O	939-941
enalapril	O	942-951
on	O	952-954
progression	O	955-966
of	O	967-969
renal	B	970-975
injury	I	976-982
in	O	983-985
adriamycin	O	986-996
nephrosis	B	997-1006
.	O	1006-1007

Chronic	O	1008-1015
enalapril	O	1016-1025
treatment	O	1026-1035
reduced	O	1036-1043
blood	O	1044-1049
pressure	O	1050-1058
without	O	1059-1066
reducing	O	1067-1075
albuminuria	B	1076-1087
in	O	1088-1090
group	O	1091-1096
4	O	1097-1098
.	O	1098-1099
Untreated	O	1100-1109
group	O	1110-1115
3	O	1116-1117
rats	O	1118-1122
exhibited	O	1123-1132
a	O	1133-1134
progressive	O	1135-1146
reduction	O	1147-1156
in	O	1157-1159
GFR	O	1160-1163
(	O	1164-1165
0	O	1165-1166
.	O	1166-1167
35	O	1167-1169
+	O	1170-1171
/	O	1171-1172
-	O	1172-1173
0	O	1174-1175
.	O	1175-1176
08	O	1176-1178
ml	O	1179-1181
/	O	1181-1182
min	O	1182-1185
at	O	1186-1188
4	O	1189-1190
months	O	1191-1197
,	O	1197-1198
0	O	1199-1200
.	O	1200-1201
27	O	1201-1203
+	O	1204-1205
/	O	1205-1206
-	O	1206-1207
0	O	1208-1209
.	O	1209-1210
07	O	1210-1212
ml	O	1213-1215
/	O	1215-1216
min	O	1216-1219
at	O	1220-1222
6	O	1223-1224
months	O	1225-1231
)	O	1231-1232
.	O	1232-1233

Enalapril	O	1234-1243
treatment	O	1244-1253
blunted	O	1254-1261
but	O	1262-1265
did	O	1266-1269
not	O	1270-1273
prevent	O	1274-1281
reduction	O	1282-1291
in	O	1292-1294
GFR	O	1295-1298
in	O	1299-1301
group	O	1302-1307
4	O	1308-1309
(	O	1310-1311
0	O	1311-1312
.	O	1312-1313
86	O	1313-1315
+	O	1316-1317
/	O	1317-1318
-	O	1318-1319
0	O	1320-1321
.	O	1321-1322
15	O	1322-1324
ml	O	1325-1327
/	O	1327-1328
min	O	1328-1331
at	O	1332-1334
4	O	1335-1336
months	O	1337-1343
,	O	1343-1344
0	O	1345-1346
.	O	1346-1347
69	O	1347-1349
+	O	1350-1351
/	O	1351-1352
-	O	1352-1353
0	O	1354-1355
.	O	1355-1356
13	O	1356-1358
ml	O	1359-1361
/	O	1361-1362
min	O	1362-1365
at	O	1366-1368
6	O	1369-1370
months	O	1371-1377
,	O	1377-1378
both	O	1379-1383
P	O	1384-1385
less	O	1386-1390
than	O	1391-1395
0	O	1396-1397
.	O	1397-1398
05	O	1398-1400
vs	O	1401-1403
.	O	1403-1404
group	O	1405-1410
3	O	1411-1412
)	O	1412-1413
.	O	1413-1414

Reduction	O	1415-1424
in	O	1425-1427
GFR	O	1428-1431
was	O	1432-1435
associated	O	1436-1446
with	O	1447-1451
the	O	1452-1455
development	O	1456-1467
of	O	1468-1470
glomerular	B	1471-1481
sclerosis	I	1482-1491
in	O	1492-1494
both	O	1495-1499
treated	O	1500-1507
and	O	1508-1511
untreated	O	1512-1521
rats	O	1522-1526
.	O	1526-1527
(	O	1527-1528
ABSTRACT	O	1528-1536

TRUNCATED	O	1537-1546
AT	O	1547-1549
250	O	1550-1553
WORDS	O	1554-1559
)	O	1559-1560

Butyrylcholinesterase	O	0-21
gene	O	22-26
mutations	O	27-36
in	O	37-39
patients	O	40-48
with	O	49-53
prolonged	O	54-63
apnea	B	64-69
after	O	70-75
succinylcholine	O	76-91
for	O	92-95
electroconvulsive	O	96-113
therapy	O	114-121
.	O	121-122

BACKGROUND	O	123-133
:	O	133-134
patients	O	135-143
undergoing	O	144-154
electroconvulsive	O	155-172
therapy	O	173-180
(	O	181-182
ECT	O	182-185
)	O	185-186
often	O	187-192
receive	O	193-200
succinylcholine	O	201-216
as	O	217-219
part	O	220-224
of	O	225-227
the	O	228-231
anesthetic	O	232-242
procedure	O	243-252
.	O	252-253

The	O	254-257
duration	O	258-266
of	O	267-269
action	O	270-276
may	O	277-280
be	O	281-283
prolonged	O	284-293
in	O	294-296
patients	O	297-305
with	O	306-310
genetic	O	311-318
variants	O	319-327
of	O	328-330
the	O	331-334
butyrylcholinesterase	O	335-356
enzyme	O	357-363
(	O	364-365
BChE	O	365-369
)	O	369-370
,	O	370-371
the	O	372-375
most	O	376-380
common	O	381-387
being	O	388-393
the	O	394-397
K	O	398-399
-	O	399-400
and	O	401-404
the	O	405-408
A	O	409-410
-	O	410-411
variants	O	411-419
.	O	419-420

The	O	421-424
aim	O	425-428
of	O	429-431
the	O	432-435
study	O	436-441
was	O	442-445
to	O	446-448
assess	O	449-455
the	O	456-459
clinical	O	460-468
significance	O	469-481
of	O	482-484
genetic	O	485-492
variants	O	493-501
in	O	502-504
butyrylcholinesterase	O	505-526
gene	O	527-531
(	O	532-533
BCHE	O	533-537
)	O	537-538
in	O	539-541
patients	O	542-550
with	O	551-555
a	O	556-557
suspected	O	558-567
prolonged	O	568-577
duration	O	578-586
of	O	587-589
action	O	590-596
of	O	597-599
succinylcholine	O	600-615
after	O	616-621
ECT	O	622-625
.	O	625-626

METHODS	O	627-634
:	O	634-635
a	O	636-637
total	O	638-643
of	O	644-646
13	O	647-649
patients	O	650-658
were	O	659-663
referred	O	664-672
to	O	673-675
the	O	676-679
Danish	O	680-686
Cholinesterase	O	687-701
Research	O	702-710
Unit	O	711-715
after	O	716-721
ECT	O	722-725
during	O	726-732
38	O	733-735
months	O	736-742
.	O	742-743

We	O	744-746
determined	O	747-757
the	O	758-761
BChE	O	762-766
activity	O	767-775
and	O	776-779
the	O	780-783
BCHE	O	784-788
genotype	O	789-797
using	O	798-803
molecular	O	804-813
genetic	O	814-821
methods	O	822-829
,	O	829-830
the	O	831-834
duration	O	835-843
of	O	844-846
apnea	B	847-852
,	O	852-853
time	O	854-858
to	O	859-861
sufficient	O	862-872
spontaneous	O	873-884
ventilation	O	885-896
and	O	897-900
whether	O	901-908
neuromuscular	O	909-922
monitoring	O	923-933
was	O	934-937
used	O	938-942
.	O	942-943

The	O	944-947
duration	O	948-956
of	O	957-959
apnea	B	960-965
was	O	966-969
compared	O	970-978
with	O	979-983
published	O	984-993
data	O	994-998
on	O	999-1001
normal	O	1002-1008
subjects	O	1009-1017
.	O	1017-1018

RESULTS	O	1019-1026
:	O	1026-1027
in	O	1028-1030
11	O	1031-1033
patients	O	1034-1042
,	O	1042-1043
mutations	O	1044-1053
were	O	1054-1058
found	O	1059-1064
in	O	1065-1067
the	O	1068-1071
BCHE	O	1072-1076
gene	O	1077-1081
,	O	1081-1082
the	O	1083-1086
K	O	1087-1088
-	O	1088-1089
variant	O	1089-1096
being	O	1097-1102
the	O	1103-1106
most	O	1107-1111
frequent	O	1112-1120
.	O	1120-1121

The	O	1122-1125
duration	O	1126-1134
of	O	1135-1137
apnea	B	1138-1143
was	O	1144-1147
5	O	1148-1149
-	O	1149-1150
15	O	1150-1152
min	O	1153-1156
compared	O	1157-1165
with	O	1166-1170
3	O	1171-1172
-	O	1172-1173
5	O	1173-1174
.	O	1174-1175
3	O	1171-1172
min	O	1177-1180
from	O	1181-1185
the	O	1186-1189
literature	O	1190-1200
.	O	1200-1201

Severe	O	1202-1208
distress	O	1209-1217
was	O	1218-1221
noted	O	1222-1227
in	O	1228-1230
the	O	1231-1234
recovery	O	1235-1243
phase	O	1244-1249
in	O	1250-1252
two	O	1253-1256
patients	O	1257-1265
.	O	1265-1266

Neuromuscular	O	1267-1280
monitoring	O	1281-1291
was	O	1292-1295
used	O	1296-1300
in	O	1301-1303
two	O	1304-1307
patients	O	1308-1316
.	O	1316-1317

CONCLUSION	O	1318-1328
:	O	1328-1329
eleven	O	1330-1336
of	O	1337-1339
13	O	1340-1342
patients	O	1343-1351
with	O	1352-1356
a	O	1357-1358
prolonged	O	1359-1368
duration	O	1369-1377
of	O	1378-1380
action	O	1381-1387
of	O	1388-1390
succinylcholine	O	1391-1406
had	O	1407-1410
mutations	O	1411-1420
in	O	1421-1423
BCHE	O	1424-1428
,	O	1428-1429
indicating	O	1430-1440
that	O	1441-1445
this	O	1446-1450
is	O	1451-1453
the	O	1454-1457
possible	O	1458-1466
reason	O	1467-1473
for	O	1474-1477
a	O	1478-1479
prolonged	O	1480-1489
period	O	1490-1496
of	O	1497-1499
apnea	B	1500-1505
.	O	1505-1506

We	O	1507-1509
recommend	O	1510-1519
objective	O	1520-1529
neuromuscular	O	1530-1543
monitoring	O	1544-1554
during	O	1555-1561
the	O	1562-1565
first	O	1566-1571
ECT	O	1572-1575
.	O	1575-1576

Ketamine	O	0-8
sedation	O	9-17
for	O	18-21
the	O	22-25
reduction	O	26-35
of	O	36-38
children	O	39-47
'	O	47-48
s	O	48-49
fractures	B	50-59
in	O	60-62
the	O	63-66
emergency	O	67-76
department	O	77-87
.	O	87-88

BACKGROUND	O	89-99
:	O	99-100
There	O	101-106
recently	O	107-115
has	O	116-119
been	O	120-124
a	O	125-126
resurgence	O	127-137
in	O	138-140
the	O	141-144
utilization	O	145-156
of	O	157-159
ketamine	O	160-168
,	O	168-169
a	O	170-171
unique	O	172-178
anesthetic	O	179-189
,	O	189-190
for	O	191-194
emergency	O	195-204
-	O	204-205
department	O	205-215
procedures	O	216-226
requiring	O	227-236
sedation	O	237-245
.	O	245-246

The	O	247-250
purpose	O	251-258
of	O	259-261
the	O	262-265
present	O	266-273
study	O	274-279
was	O	280-283
to	O	284-286
examine	O	287-294
the	O	295-298
safety	O	299-305
and	O	306-309
efficacy	O	310-318
of	O	319-321
ketamine	O	322-330
for	O	331-334
sedation	O	335-343
in	O	344-346
the	O	347-350
treatment	O	351-360
of	O	361-363
children	O	364-372
'	O	372-373
s	O	373-374
fractures	B	375-384
in	O	385-387
the	O	388-391
emergency	O	392-401
department	O	402-412
.	O	412-413

METHODS	O	414-421
:	O	421-422
One	O	423-426
hundred	O	427-434
and	O	435-438
fourteen	O	439-447
children	O	448-456
(	O	457-458
average	O	458-465
age	O	466-469
,	O	469-470
5	O	471-472
.	O	472-473
3	O	473-474
years	O	475-480
;	O	480-481
range	O	482-487
,	O	487-488
twelve	O	489-495
months	O	496-502
to	O	503-505
ten	O	506-509
years	O	510-515
and	O	516-519
ten	O	520-523
months	O	524-530
)	O	530-531
who	O	532-535
underwent	O	536-545
closed	O	546-552
reduction	O	553-562
of	O	563-565
an	O	566-568
isolated	O	569-577
fracture	B	578-586
or	O	587-589
dislocation	B	590-601
in	O	602-604
the	O	605-608
emergency	O	609-618
department	O	619-629
at	O	630-632
a	O	633-634
level	O	635-640
-	O	640-641
I	O	641-642
trauma	B	643-649
center	O	650-656
were	O	657-661
prospectively	O	662-675
evaluated	O	676-685
.	O	685-686

Ketamine	O	687-695
hydrochloride	O	696-709
was	O	710-713
administered	O	714-726
intravenously	O	727-740
(	O	741-742
at	O	742-744
a	O	745-746
dose	O	747-751
of	O	752-754
two	O	755-758
milligrams	O	759-769
per	O	770-773
kilogram	O	774-782
of	O	783-785
body	O	786-790
weight	O	791-797
)	O	797-798
in	O	799-801
ninety	O	802-808
-	O	808-809
nine	O	802-806
of	O	814-816
the	O	817-820
patients	O	821-829
and	O	830-833
intramuscularly	O	834-849
(	O	850-851
at	O	851-853
a	O	854-855
dose	O	856-860
of	O	861-863
four	O	864-868
milligrams	O	869-879
per	O	880-883
kilogram	O	884-892
of	O	893-895
body	O	896-900
weight	O	901-907
)	O	907-908
in	O	909-911
the	O	912-915
other	O	916-921
fifteen	O	922-929
.	O	929-930

A	O	931-932
board	O	933-938
-	O	938-939
certified	O	939-948
emergency	O	949-958
physician	O	959-968
skilled	O	969-976
in	O	977-979
airway	O	980-986
management	O	987-997
supervised	O	998-1008
administration	O	1009-1023
of	O	1024-1026
the	O	1027-1030
anesthetic	O	1031-1041
,	O	1041-1042
and	O	1043-1046
the	O	1047-1050
patients	O	1051-1059
were	O	1060-1064
monitored	O	1065-1074
by	O	1075-1077
a	O	1078-1079
registered	O	1080-1090
nurse	O	1091-1096
.	O	1096-1097

Any	O	1098-1101
pain	B	1102-1106
during	O	1107-1113
the	O	1114-1117
reduction	O	1118-1127
was	O	1128-1131
rated	O	1132-1137
by	O	1138-1140
the	O	1141-1144
orthopaedic	O	1145-1156
surgeon	O	1157-1164
treating	O	1165-1173
the	O	1174-1177
patient	O	1178-1185
according	O	1186-1195
to	O	1196-1198
the	O	1199-1202
Children	O	1203-1211
'	O	1211-1212
s	O	1212-1213
Hospital	O	1214-1222
of	O	1223-1225
Eastern	O	1226-1233
Ontario	O	1234-1241
Pain	B	1242-1246
Scale	O	1247-1252
(	O	1253-1254
CHEOPS	O	1254-1260
)	O	1260-1261
.	O	1261-1262

RESULTS	O	1263-1270
:	O	1270-1271
The	O	1272-1275
average	O	1276-1283
time	O	1284-1288
from	O	1289-1293
intravenous	O	1294-1305
administration	O	1306-1320
of	O	1321-1323
ketamine	O	1324-1332
to	O	1333-1335
manipulation	O	1336-1348
of	O	1349-1351
the	O	1352-1355
fracture	B	1356-1364
or	O	1365-1367
dislocation	B	1368-1379
was	O	1380-1383
one	O	1384-1387
minute	O	1388-1394
and	O	1395-1398
thirty	O	1399-1405
-	O	1405-1406
six	O	1406-1409
seconds	O	1410-1417
(	O	1418-1419
range	O	1419-1424
,	O	1424-1425
twenty	O	1426-1432
seconds	O	1433-1440
to	O	1441-1443
five	O	1444-1448
minutes	O	1449-1456
)	O	1456-1457
,	O	1457-1458
and	O	1459-1462
the	O	1463-1466
average	O	1467-1474
time	O	1475-1479
from	O	1480-1484
intramuscular	O	1485-1498
administration	O	1499-1513
to	O	1514-1516
manipulation	O	1517-1529
was	O	1530-1533
four	O	1534-1538
minutes	O	1539-1546
and	O	1547-1550
forty	O	1551-1556
-	O	1556-1557
two	O	1557-1560
seconds	O	1561-1568
(	O	1569-1570
range	O	1570-1575
,	O	1575-1576
sixty	O	1577-1582
seconds	O	1583-1590
to	O	1591-1593
fifteen	O	1594-1601
minutes	O	1602-1609
)	O	1609-1610
.	O	1610-1611

The	O	1612-1615
average	O	1616-1623
score	O	1624-1629
according	O	1630-1639
to	O	1640-1642
the	O	1643-1646
Children	O	1647-1655
'	O	1655-1656
s	O	1656-1657
Hospital	O	1658-1666
of	O	1667-1669
Eastern	O	1670-1677
Ontario	O	1678-1685
Pain	B	1686-1690
Scale	O	1691-1696
was	O	1697-1700
6	O	1701-1702
.	O	1702-1703
4	O	1703-1704
points	O	1705-1711
(	O	1712-1713
range	O	1713-1718
,	O	1718-1719
5	O	1720-1721
to	O	1722-1724
10	O	1725-1727
points	O	1728-1734
)	O	1734-1735
,	O	1735-1736
reflecting	O	1737-1747
minimal	O	1748-1755
or	O	1756-1758
no	O	1759-1761
pain	B	1762-1766
during	O	1767-1773
fracture	B	1774-1782
reduction	O	1783-1792
.	O	1792-1793

Adequate	O	1794-1802
fracture	B	1803-1811
reduction	O	1812-1821
was	O	1822-1825
obtained	O	1826-1834
in	O	1835-1837
111	O	1838-1841
of	O	1842-1844
the	O	1845-1848
children	O	1849-1857
.	O	1857-1858

Ninety	O	1859-1865
-	O	1865-1866
nine	O	1866-1870
percent	O	1871-1878
(	O	1879-1880
sixty	O	1880-1885
-	O	1885-1886
eight	O	1886-1891
)	O	1891-1892
of	O	1893-1895
the	O	1896-1899
sixty	O	1900-1905
-	O	1905-1906
nine	O	1906-1910
parents	O	1911-1918
present	O	1919-1926
during	O	1927-1933
the	O	1934-1937
reduction	O	1938-1947
were	O	1948-1952
pleased	O	1953-1960
with	O	1961-1965
the	O	1966-1969
sedation	O	1970-1978
and	O	1979-1982
would	O	1983-1988
allow	O	1989-1994
it	O	1995-1997
to	O	1998-2000
be	O	2001-2003
used	O	2004-2008
again	O	2009-2014
in	O	2015-2017
a	O	2018-2019
similar	O	2020-2027
situation	O	2028-2037
.	O	2037-2038

Patency	O	2039-2046
of	O	2047-2049
the	O	2050-2053
airway	O	2054-2060
and	O	2061-2064
independent	O	2065-2076
respiration	O	2077-2088
were	O	2089-2093
maintained	O	2094-2104
in	O	2105-2107
all	O	2108-2111
of	O	2112-2114
the	O	2115-2118
patients	O	2119-2127
.	O	2127-2128

Blood	O	2129-2134
pressure	O	2135-2143
and	O	2144-2147
heart	O	2148-2153
rate	O	2154-2158
remained	O	2159-2167
stable	O	2168-2174
.	O	2174-2175

Minor	O	2176-2181
side	O	2182-2186
effects	O	2187-2194
included	O	2195-2203
nausea	B	2204-2210
(	O	2211-2212
thirteen	O	2212-2220
patients	O	2221-2229
)	O	2229-2230
,	O	2230-2231
emesis	B	2232-2238
(	O	2239-2240
eight	O	2240-2245
of	O	2246-2248
the	O	2249-2252
thirteen	O	2253-2261
patients	O	2262-2270
with	O	2271-2275
nausea	B	2276-2282
)	O	2282-2283
,	O	2283-2284
clumsiness	B	2285-2295
(	O	2296-2297
evident	O	2297-2304
as	O	2305-2307
ataxic	B	2308-2314
movements	I	2315-2324
in	O	2325-2327
ten	O	2328-2331
patients	O	2332-2340
)	O	2340-2341
,	O	2341-2342
and	O	2343-2346
dysphoric	B	2347-2356
reaction	I	2357-2365
(	O	2366-2367
one	O	2367-2370
patient	O	2371-2378
)	O	2378-2379
.	O	2379-2380

No	O	2381-2383
long	O	2384-2388
-	O	2388-2389
term	O	2389-2393
sequelae	O	2394-2402
were	O	2403-2407
noted	O	2408-2413
,	O	2413-2414
and	O	2415-2418
no	O	2419-2421
patients	O	2422-2430
had	O	2431-2434
hallucinations	B	2435-2449
or	O	2450-2452
nightmares	O	2453-2463
.	O	2463-2464

CONCLUSIONS	O	2465-2476
:	O	2476-2477
Ketamine	O	2478-2486
reliably	O	2487-2495
,	O	2495-2496
safely	O	2497-2503
,	O	2503-2504
and	O	2505-2508
quickly	O	2509-2516
provided	O	2517-2525
adequate	O	2526-2534
sedation	O	2535-2543
to	O	2544-2546
effectively	O	2547-2558
facilitate	O	2559-2569
the	O	2570-2573
reduction	O	2574-2583
of	O	2584-2586
children	O	2587-2595
'	O	2595-2596
s	O	2596-2597
fractures	B	2598-2607
in	O	2608-2610
the	O	2611-2614
emergency	O	2615-2624
department	O	2625-2635
at	O	2636-2638
our	O	2639-2642
institution	O	2643-2654
.	O	2654-2655

Ketamine	O	2656-2664
should	O	2665-2671
only	O	2672-2676
be	O	2677-2679
used	O	2680-2684
in	O	2685-2687
an	O	2688-2690
environment	O	2691-2702
such	O	2703-2707
as	O	2708-2710
the	O	2711-2714
emergency	O	2715-2724
department	O	2725-2735
,	O	2735-2736
where	O	2737-2742
proper	O	2743-2749
one	O	2750-2753
-	O	2753-2754
on	O	2750-2752
-	O	2753-2754
one	O	2750-2753
monitoring	O	2761-2771
is	O	2772-2774
used	O	2775-2779
and	O	2780-2783
board	O	2784-2789
-	O	2789-2790
certified	O	2790-2799
physicians	O	2800-2810
skilled	O	2811-2818
in	O	2819-2821
airway	O	2822-2828
management	O	2829-2839
are	O	2840-2843
directly	O	2844-2852
involved	O	2853-2861
in	O	2862-2864
the	O	2865-2868
care	O	2869-2873
of	O	2874-2876
the	O	2877-2880
patient	O	2881-2888
.	O	2888-2889

Prophylactic	O	0-12
use	O	13-16
of	O	17-19
lamivudine	O	20-30
with	O	31-35
chronic	O	36-43
immunosuppressive	O	44-61
therapy	O	62-69
for	O	70-73
rheumatologic	B	74-87
disorders	I	88-97
.	O	97-98

The	O	99-102
objective	O	103-112
of	O	113-115
this	O	116-120
study	O	121-126
was	O	127-130
to	O	131-133
report	O	134-140
our	O	141-144
experience	O	145-155
concerning	O	156-166
the	O	167-170
effectiveness	O	171-184
of	O	185-187
the	O	188-191
prophylactic	O	192-204
administration	O	205-219
of	O	220-222
lamivudine	O	223-233
in	O	234-236
hepatitis	O	237-246
B	O	247-248
virus	O	249-254
surface	O	255-262
antigen	O	263-270
(	O	271-272
HBs	O	272-275
Ag	O	276-278
)	O	278-279
positive	O	280-288
patients	O	289-297
with	O	298-302
rheumatologic	B	303-316
disease	I	317-324
.	O	324-325

From	O	326-330
June	O	331-335
2004	O	336-340
to	O	341-343
October	O	344-351
2006	O	352-356
,	O	356-357
11	O	358-360
HBs	O	361-364
Ag	O	365-367
positive	O	368-376
patients	O	377-385
with	O	386-390
rheumatologic	B	391-404
diseases	I	405-413
,	O	413-414
who	O	415-418
were	O	419-423
on	O	424-426
both	O	427-431
immunosuppressive	O	432-449
and	O	450-453
prophylactic	O	454-466
lamivudine	O	467-477
therapies	O	478-487
,	O	487-488
were	O	489-493
retrospectively	O	494-509
assessed	O	510-518
.	O	518-519

Liver	O	520-525
function	O	526-534
tests	O	535-540
,	O	540-541
hepatitis	B	542-551
B	I	552-553
virus	O	554-559
(	O	560-561
HBV	O	561-564
)	O	564-565
serologic	O	566-575
markers	O	576-583
,	O	583-584
and	O	585-588
HBV	O	589-592
DNA	O	593-596
levels	O	597-603
of	O	604-606
the	O	607-610
patients	O	611-619
during	O	620-626
follow	O	627-633
-	O	633-634
up	O	634-636
were	O	637-641
obtained	O	642-650
from	O	651-655
hospital	O	656-664
file	O	665-669
records	O	670-677
.	O	677-678

Eleven	O	679-685
patients	O	686-694
(	O	695-696
six	O	696-699
male	O	700-704
)	O	704-705
with	O	706-710
median	O	711-717
age	O	718-721
47	O	722-724
years	O	725-730
(	O	731-732
range	O	732-737
27	O	738-740
-	O	740-741
73	O	741-743
)	O	743-744
,	O	744-745
median	O	746-752
disease	O	753-760
duration	O	761-769
50	O	770-772
months	O	773-779
(	O	780-781
range	O	781-786
9	O	787-788
-	O	788-789
178	O	789-792
)	O	792-793
and	O	794-797
median	O	798-804
follow	O	805-811
-	O	811-812
up	O	812-814
period	O	815-821
of	O	822-824
patients	O	825-833
13	O	834-836
.	O	836-837
8	O	837-838
months	O	839-845
(	O	846-847
range	O	847-852
5	O	853-854
-	O	854-855
27	O	855-857
)	O	857-858
were	O	859-863
enrolled	O	864-872
in	O	873-875
this	O	876-880
study	O	881-886
.	O	886-887

Lamivudine	O	888-898
therapy	O	899-906
was	O	907-910
started	O	911-918
3	O	919-920
-	O	920-921
7	O	921-922
days	O	923-927
prior	O	928-933
to	O	934-936
immunosuppressive	O	937-954
therapy	O	955-962
in	O	963-965
all	O	966-969
patients	O	970-978
.	O	978-979

Baseline	O	980-988
,	O	988-989
liver	O	990-995
function	O	996-1004
tests	O	1005-1010
were	O	1011-1015
elevated	O	1016-1024
in	O	1025-1027
two	O	1028-1031
patients	O	1032-1040
(	O	1041-1042
fourth	O	1042-1048
patient	O	1049-1056
:	O	1056-1057
ALT	O	1058-1061
:	O	1061-1062
122	O	1062-1065
IU	O	1066-1068
/	O	1068-1069
l	O	1069-1070
,	O	1070-1071
AST	O	1072-1075
:	O	1075-1076
111	O	1076-1079
IU	O	1080-1082
/	O	1082-1083
l	O	1083-1084
,	O	1084-1085
tenth	O	1086-1091
patient	O	1092-1099
:	O	1099-1100
ALT	O	1100-1103
:	O	1099-1100
294	O	1104-1107
IU	O	1108-1110
/	O	1110-1111
l	O	1111-1112
,	O	1112-1113
AST	O	1114-1117
:	O	1117-1118
274	O	1118-1121
IU	O	1122-1124
/	O	1124-1125
l	O	1125-1126
,	O	1126-1127
with	O	1128-1132
minimal	O	1133-1140
changes	O	1141-1148
in	O	1149-1151
the	O	1152-1155
liver	O	1156-1161
biopsy	O	1162-1168
in	O	1169-1171
both	O	1172-1176
)	O	1176-1177
.	O	1177-1178

Shortly	O	1179-1186
after	O	1187-1192
treatment	O	1193-1202
their	O	1203-1208
tests	O	1209-1214
normalized	O	1215-1225
and	O	1226-1229
during	O	1230-1236
follow	O	1237-1243
-	O	1243-1244
up	O	1244-1246
period	O	1247-1253
none	O	1254-1258
of	O	1259-1261
the	O	1262-1265
patients	O	1266-1274
had	O	1275-1278
abnormal	B	1279-1287
liver	I	1288-1293
function	I	1294-1302
tests	O	1303-1308
.	O	1308-1309

In	O	1310-1312
four	O	1313-1317
patients	O	1318-1326
HBV	O	1327-1330
DNA	O	1331-1334
levels	O	1335-1341
were	O	1342-1346
higher	O	1347-1353
than	O	1354-1358
normal	O	1359-1365
at	O	1366-1368
baseline	O	1369-1377
.	O	1377-1378

Two	O	1379-1382
of	O	1383-1385
these	O	1386-1391
normalized	O	1392-1402
and	O	1403-1406
the	O	1407-1410
others	O	1411-1417
increased	O	1418-1427
later	O	1428-1433
.	O	1433-1434

In	O	1435-1437
three	O	1438-1443
additional	O	1444-1454
patients	O	1455-1463
,	O	1463-1464
HBV	O	1465-1468
DNA	O	1469-1472
levels	O	1473-1479
were	O	1480-1484
increased	O	1485-1494
during	O	1495-1501
follow	O	1502-1508
-	O	1508-1509
up	O	1509-1511
.	O	1511-1512

None	O	1513-1517
of	O	1518-1520
the	O	1521-1524
patients	O	1525-1533
had	O	1534-1537
significant	O	1538-1549
clinical	O	1550-1558
sings	O	1559-1564
of	O	1565-1567
HBV	O	1568-1571
activation	O	1572-1582
.	O	1582-1583

Lamivudine	O	1584-1594
was	O	1595-1598
well	O	1599-1603
tolerated	O	1604-1613
and	O	1614-1617
was	O	1618-1621
continued	O	1622-1631
in	O	1632-1634
all	O	1635-1638
patients	O	1639-1647
.	O	1647-1648

Prophylactic	O	1649-1661
administration	O	1662-1676
of	O	1677-1679
lamivudine	O	1680-1690
in	O	1691-1693
patients	O	1694-1702
who	O	1703-1706
required	O	1707-1715
immunosuppressive	O	1716-1733
therapy	O	1734-1741
seems	O	1742-1747
to	O	1748-1750
be	O	1751-1753
safe	O	1754-1758
,	O	1758-1759
well	O	1760-1764
tolerated	O	1765-1774
and	O	1775-1778
effective	O	1779-1788
in	O	1789-1791
preventing	O	1792-1802
HBV	O	1803-1806
reactivation	O	1807-1819
.	O	1819-1820

Safety	O	0-6
of	O	7-9
transesophageal	O	10-25
echocardiography	O	26-42
in	O	43-45
adults	O	46-52
:	O	52-53
study	O	54-59
in	O	60-62
a	O	63-64
multidisciplinary	O	65-82
hospital	O	83-91
.	O	91-92

BACKGROUND	O	93-103
:	O	103-104
TEE	O	105-108
is	O	109-111
a	O	112-113
semi	O	114-118
-	O	118-119
invasive	O	119-127
tool	O	128-132
broadly	O	133-140
used	O	141-145
and	O	146-149
its	O	150-153
utilization	O	154-165
associated	O	166-176
to	O	177-179
sedatives	O	180-189
drugs	O	190-195
might	O	196-201
to	O	202-204
affect	O	205-211
the	O	212-215
procedure	O	216-225
safety	O	226-232
.	O	232-233

OBJECTIVE	O	234-243
:	O	243-244
to	O	245-247
analyze	O	248-255
aspects	O	256-263
of	O	264-266
TEE	O	267-270
safety	O	271-277
associated	O	278-288
to	O	289-291
the	O	292-295
use	O	296-299
of	O	300-302
Midazolan	O	303-312
(	O	313-314
MZ	O	314-316
)	O	316-317
and	O	318-321
Flumazenil	O	322-332
(	O	333-334
FL	O	334-336
)	O	336-337
and	O	338-341
the	O	342-345
influence	O	346-355
of	O	356-358
the	O	359-362
clinical	O	363-371
variables	O	372-381
on	O	382-384
the	O	385-388
event	O	389-394
rate	O	395-399
.	O	399-400

METHOD	O	401-407
:	O	407-408
prospective	O	409-420
study	O	421-426
with	O	427-431
137	O	432-435
patients	O	436-444
that	O	445-449
underwent	O	450-459
TEE	O	460-463
with	O	464-468
MZ	O	469-471
associated	O	472-482
to	O	483-485
moderate	O	486-494
sedation	O	495-503
.	O	503-504

We	O	505-507
analyzed	O	508-516
the	O	517-520
following	O	521-530
events	O	531-537
:	O	537-538
complications	O	539-552
related	O	553-560
with	O	561-565
the	O	566-569
topical	O	570-577
anesthesia	O	578-588
,	O	588-589
with	O	590-594
MZ	O	595-597
use	O	598-601
and	O	602-605
with	O	606-610
the	O	611-614
procedure	O	615-624
.	O	624-625

Uni	O	626-629
-	O	629-630
and	O	631-634
multivariate	O	635-647
analyses	O	648-656
were	O	657-661
used	O	662-666
to	O	667-669
test	O	670-674
the	O	675-678
influence	O	679-688
of	O	689-691
the	O	692-695
clinical	O	696-704
variables	O	705-714
:	O	714-715
age	O	716-719
,	O	719-720
sex	O	721-724
,	O	724-725
stroke	B	726-732
,	O	732-733
myocardiopathy	B	734-748
(	O	749-750
MP	B	750-752
)	O	752-753
,	O	753-754
duration	O	755-763
of	O	764-766
the	O	767-770
test	O	771-775
,	O	775-776
mitral	B	777-783
regurgitation	I	784-797
(	O	798-799
MR	B	799-801
)	O	801-802
and	O	803-806
the	O	807-810
MZ	O	811-813
dose	O	814-818
.	O	818-819

RESULTS	O	820-827
:	O	827-828
All	O	829-832
patients	O	833-841
(	O	842-843
65	O	843-845
+	O	845-846
/	O	846-847
-	O	847-848
16	O	848-850
yrs	O	851-854
;	O	854-855
58	O	856-858
%	O	858-859
males	O	860-865
)	O	865-866
finished	O	867-875
the	O	876-879
examination	O	880-891
.	O	891-892

The	O	893-896
mean	O	897-901
doses	O	902-907
of	O	908-910
MZ	O	911-913
and	O	914-917
FL	O	918-920
were	O	921-925
4	O	926-927
.	O	927-928
3	O	928-929
+	O	929-930
/	O	930-931
-	O	931-932
1	O	932-933
.	O	927-928
9	O	934-935

mg	O	936-938
and	O	939-942
0	O	943-944
.	O	944-945
28	O	945-947
+	O	947-948
/	O	948-949
-	O	949-950
0	O	943-944
.	O	944-945
2	O	945-946

mg	O	954-956
,	O	956-957
respectively	O	958-970
.	O	970-971

The	O	972-975
duration	O	976-984
of	O	985-987
the	O	988-991
examination	O	992-1003
and	O	1004-1007
the	O	1008-1011
mean	O	1012-1016
ejection	O	1017-1025
fraction	O	1026-1034
(	O	1035-1036
EF	O	1036-1038
)	O	1038-1039
were	O	1040-1044
16	O	1045-1047
.	O	1047-1048
4	O	1048-1049
+	O	1049-1050
/	O	1050-1051
-	O	1051-1052
6	O	1046-1047
.	O	1047-1048
1	O	1045-1046

minutes	O	1056-1063
and	O	1064-1067
60	O	1068-1070
+	O	1070-1071
/	O	1071-1072
-	O	1072-1073
9	O	1073-1074
%	O	1074-1075
,	O	1075-1076
respectively	O	1077-1089
.	O	1089-1090

Mild	O	1091-1095
hypoxia	B	1096-1103
(	O	1104-1105
SO2	O	1105-1108
<	O	1108-1109
90	O	1109-1111
%	O	1111-1112
)	O	1112-1113
was	O	1114-1117
the	O	1118-1121
most	O	1122-1126
common	O	1127-1133
event	O	1134-1139
(	O	1140-1141
11	O	1141-1143
patients	O	1144-1152
)	O	1152-1153
;	O	1153-1154
3	O	1155-1156
patients	O	1157-1165
(	O	1166-1167
2	O	1167-1168
%	O	1168-1169
)	O	1169-1170
presented	O	1171-1180
transient	O	1181-1190
hypoxia	B	1191-1198
due	O	1199-1202
to	O	1203-1205
upper	O	1206-1211
airway	B	1212-1218
obstruction	I	1219-1230
by	O	1231-1233
probe	O	1234-1239
introduction	O	1240-1252
and	O	1253-1256
8	O	1257-1258
(	O	1259-1260
5	O	1260-1261
.	O	1261-1262
8	O	1262-1263
%	O	1263-1264
)	O	1264-1265
due	O	1266-1269
to	O	1270-1272
hypoxia	B	1273-1280
caused	O	1281-1287
by	O	1288-1290
MZ	O	1291-1293
use	O	1294-1297
.	O	1297-1298

Transient	O	1299-1308
hypotension	B	1309-1320
(	O	1321-1322
SAP	O	1322-1325
<	O	1325-1326
90mmHg	O	1326-1332
)	O	1332-1333
occurred	O	1334-1342
in	O	1343-1345
1	O	1346-1347
patient	O	1348-1355
(	O	1356-1357
0	O	1357-1358
.	O	1358-1359
7	O	1359-1360
%	O	1360-1361
)	O	1361-1362
.	O	1358-1359

The	O	1364-1367
multivariate	O	1368-1380
analysis	O	1381-1389
showed	O	1390-1396
that	O	1397-1401
severe	O	1402-1408
MR	B	1409-1411
,	O	1411-1412
MP	B	1413-1415
(	O	1416-1417
EF	O	1417-1419
<	O	1419-1420
45	O	1420-1422
%	O	1422-1423
)	O	1423-1424
and	O	1425-1428
high	O	1429-1433
doses	O	1434-1439
of	O	1440-1442
MZ	O	1443-1445
(	O	1446-1447
>	O	1447-1448
5mg	O	1448-1451
)	O	1451-1452
were	O	1453-1457
associated	O	1458-1468
with	O	1469-1473
events	O	1474-1480
(	O	1481-1482
p	O	1482-1483
<	O	1483-1484
0	O	1484-1485
.	O	1485-1486
001	O	1486-1489
)	O	1489-1490
.	O	1485-1486

The	O	1492-1495
EF	O	1496-1498
was	O	1499-1502
40	O	1503-1505
%	O	1505-1506
,	O	1506-1507
in	O	1508-1510
the	O	1511-1514
group	O	1515-1520
with	O	1521-1525
MP	B	1526-1528
and	O	1529-1532
44	O	1533-1535
%	O	1535-1536
in	O	1537-1539
the	O	1540-1543
group	O	1544-1549
with	O	1550-1554
severe	O	1555-1561
MR	B	1562-1564
and	O	1565-1568
it	O	1569-1571
can	O	1572-1575
be	O	1576-1578
a	O	1579-1580
factor	O	1581-1587
associated	O	1588-1598
with	O	1599-1603
clinical	O	1604-1612
events	O	1613-1619
in	O	1620-1622
the	O	1623-1626
last	O	1627-1631
group	O	1632-1637
.	O	1637-1638

CONCLUSION	O	1639-1649
:	O	1649-1650
TEE	O	1651-1654
with	O	1655-1659
sedation	O	1660-1668
presents	O	1669-1677
a	O	1678-1679
low	O	1680-1683
rate	O	1684-1688
of	O	1689-1691
events	O	1692-1698
.	O	1698-1699

There	O	1700-1705
were	O	1706-1710
no	O	1711-1713
severe	O	1714-1720
events	O	1721-1727
and	O	1728-1731
there	O	1732-1737
was	O	1738-1741
no	O	1742-1744
need	O	1745-1749
to	O	1750-1752
interrupt	O	1753-1762
the	O	1763-1766
examinations	O	1767-1779
.	O	1779-1780

Effects	O	0-7
of	O	8-10
calcium	O	11-18
channel	O	19-26
blockers	O	27-35
on	O	36-38
bupivacaine	O	39-50
-	O	50-51
induced	O	51-58
toxicity	B	59-67
.	O	67-68

The	O	69-72
purpose	O	73-80
of	O	81-83
this	O	84-88
study	O	89-94
was	O	95-98
to	O	99-101
investigate	O	102-113
the	O	114-117
influence	O	118-127
of	O	128-130
calcium	O	131-138
channel	O	139-146
blockers	O	147-155
on	O	156-158
bupivacaine	O	159-170
-	O	170-171
induced	O	171-178
acute	O	179-184
toxicity	B	185-193
.	O	193-194

For	O	195-198
each	O	199-203
of	O	204-206
the	O	207-210
three	O	211-216
tested	O	217-223
calcium	O	224-231
channel	O	232-239
blockers	O	240-248
(	O	249-250
diltiazem	O	250-259
,	O	259-260
verapamil	O	261-270
and	O	271-274
bepridil	O	275-283
)	O	283-284
6	O	285-286
groups	O	287-293
of	O	294-296
mice	O	297-301
were	O	302-306
treated	O	307-314
by	O	315-317
two	O	318-321
different	O	322-331
doses	O	332-337
,	O	337-338
i	O	339-340
.	O	340-341
e	O	341-342
.	O	340-341
2	O	344-345
and	O	346-349
10	O	350-352
mg	O	353-355
/	O	355-356
kg	O	356-358
/	O	355-356
i	O	359-360
.	O	360-361
p	O	361-362
.	O	360-361
,	O	363-364
or	O	365-367
an	O	368-370
equal	O	371-376
volume	O	377-383
of	O	384-386
saline	O	387-393
for	O	394-397
the	O	398-401
control	O	402-409
group	O	410-415
(	O	416-417
n	O	417-418
=	O	419-420
20	O	421-423
)	O	423-424
;	O	424-425
15	O	426-428
minutes	O	429-436
later	O	437-442
,	O	442-443
all	O	444-447
the	O	448-451
animals	O	452-459
were	O	460-464
injected	O	465-473
with	O	474-478
a	O	479-480
single	O	481-487
50	O	488-490
mg	O	491-493
/	O	493-494
kg	O	494-496
/	O	493-494
i	O	497-498
.	O	498-499
p	O	499-500
.	O	498-499
dose	O	502-506
of	O	507-509
bupivacaine	O	510-521
.	O	521-522

The	O	523-526
convulsant	O	527-537
activity	O	538-546
,	O	546-547
the	O	548-551
time	O	552-556
of	O	557-559
latency	O	560-567
to	O	568-570
convulse	O	571-579
and	O	580-583
the	O	584-587
mortality	O	588-597
rate	O	598-602
were	O	603-607
assessed	O	608-616
in	O	617-619
each	O	620-624
group	O	625-630
.	O	630-631

The	O	632-635
local	O	636-641
anesthetic	O	642-652
-	O	652-653
induced	O	653-660
mortality	O	661-670
was	O	671-674
significantly	O	675-688
increased	O	689-698
by	O	699-701
the	O	702-705
three	O	706-711
different	O	712-721
calcium	O	722-729
channel	O	730-737
blockers	O	738-746
.	O	746-747

The	O	748-751
convulsant	O	752-762
activity	O	763-771
of	O	772-774
bupivacaine	O	775-786
was	O	787-790
not	O	791-794
significantly	O	795-808
modified	O	809-817
but	O	818-821
calcium	O	822-829
channel	O	830-837
blockers	O	838-846
decreased	O	847-856
the	O	857-860
time	O	861-865
of	O	866-868
latency	O	869-876
to	O	877-879
obtain	O	880-886
bupivacaine	O	887-898
-	O	898-899
induced	O	899-906
convulsions	B	907-918
;	O	918-919
this	O	920-924
effect	O	925-931
was	O	932-935
less	O	936-940
pronounced	O	941-951
with	O	952-956
bepridil	O	957-965
.	O	965-966

Selegiline	O	0-10
-	O	10-11
induced	O	11-18
postural	B	19-27
hypotension	I	28-39
in	O	40-42
Parkinson	B	43-52
'	I	52-53
s	I	49-50
disease	I	55-62
:	O	62-63
a	O	64-65
longitudinal	O	66-78
study	O	79-84
on	O	85-87
the	O	88-91
effects	O	92-99
of	O	100-102
drug	O	103-107
withdrawal	O	108-118
.	O	118-119

OBJECTIVES	O	120-130
:	O	130-131
The	O	132-135
United	O	136-142
Kingdom	O	143-150
Parkinson	B	151-160
'	I	160-161
s	I	157-158
Disease	I	163-170
Research	O	171-179
Group	O	180-185
(	O	186-187
UKPDRG	O	187-193
)	O	193-194
trial	O	195-200
found	O	201-206
an	O	207-209
increased	O	210-219
mortality	O	220-229
in	O	230-232
patients	O	233-241
with	O	242-246
Parkinson	B	247-256
'	I	256-257
s	I	253-254
disease	I	259-266
(	O	267-268
PD	B	268-270
)	O	270-271
randomized	O	272-282
to	O	283-285
receive	O	286-293
10	O	294-296
mg	O	297-299
selegiline	O	300-310
per	O	311-314
day	O	315-318
and	O	319-322
L	O	323-324
-	O	324-325
dopa	O	325-329
compared	O	330-338
with	O	339-343
those	O	344-349
taking	O	350-356
L	O	357-358
-	O	358-359
dopa	O	359-363
alone	O	364-369
.	O	369-370

Recently	O	371-379
,	O	379-380
we	O	381-383
found	O	384-389
that	O	390-394
therapy	O	395-402
with	O	403-407
selegiline	O	408-418
and	O	419-422
L	O	423-424
-	O	424-425
dopa	O	425-429
was	O	430-433
associated	O	434-444
with	O	445-449
selective	O	450-459
systolic	B	460-468
orthostatic	I	469-480
hypotension	I	481-492
which	O	493-498
was	O	499-502
abolished	O	503-512
by	O	513-515
withdrawal	O	516-526
of	O	527-529
selegiline	O	530-540
.	O	540-541

This	O	542-546
unwanted	O	547-555
effect	O	556-562
on	O	563-565
postural	O	566-574
blood	O	575-580
pressure	O	581-589
was	O	590-593
not	O	594-597
the	O	598-601
result	O	602-608
of	O	609-611
underlying	O	612-622
autonomic	O	623-632
failure	O	633-640
.	O	640-641

The	O	642-645
aims	O	646-650
of	O	651-653
this	O	654-658
study	O	659-664
were	O	665-669
to	O	670-672
confirm	O	673-680
our	O	681-684
previous	O	685-693
findings	O	694-702
in	O	703-705
a	O	706-707
separate	O	708-716
cohort	O	717-723
of	O	724-726
patients	O	727-735
and	O	736-739
to	O	740-742
determine	O	743-752
the	O	753-756
time	O	757-761
course	O	762-768
of	O	769-771
the	O	772-775
cardiovascular	O	776-790
consequences	O	791-803
of	O	804-806
stopping	O	807-815
selegiline	O	816-826
in	O	827-829
the	O	830-833
expectation	O	834-845
that	O	846-850
this	O	851-855
might	O	856-861
shed	O	862-866
light	O	867-872
on	O	873-875
the	O	876-879
mechanisms	O	880-890
by	O	891-893
which	O	894-899
the	O	900-903
drug	O	904-908
causes	O	909-915
orthostatic	B	916-927
hypotension	I	928-939
.	O	939-940

METHODS	O	941-948
:	O	948-949
The	O	950-953
cardiovascular	O	954-968
responses	O	969-978
to	O	979-981
standing	O	982-990
and	O	991-994
head	O	995-999
-	O	999-1000
up	O	1000-1002
tilt	O	1003-1007
were	O	1008-1012
studied	O	1013-1020
repeatedly	O	1021-1031
in	O	1032-1034
PD	B	1035-1037
patients	O	1038-1046
receiving	O	1047-1056
selegiline	O	1057-1067
and	O	1068-1071
as	O	1072-1074
the	O	1075-1078
drug	O	1079-1083
was	O	1084-1087
withdrawn	O	1088-1097
.	O	1097-1098

RESULTS	O	1099-1106
:	O	1106-1107
Head	O	1108-1112
-	O	1112-1113
up	O	1113-1115
tilt	O	1116-1120
caused	O	1121-1127
systolic	B	1128-1136
orthostatic	I	1137-1148
hypotension	I	1149-1160
which	O	1161-1166
was	O	1167-1170
marked	O	1171-1177
in	O	1178-1180
six	O	1181-1184
of	O	1185-1187
20	O	1188-1190
PD	B	1191-1193
patients	O	1194-1202
on	O	1203-1205
selegiline	O	1206-1216
,	O	1216-1217
one	O	1218-1221
of	O	1222-1224
whom	O	1225-1229
lost	O	1230-1234
consciousness	O	1235-1248
with	O	1249-1253
unrecordable	O	1254-1266
blood	O	1267-1272
pressures	O	1273-1282
.	O	1282-1283

A	O	1284-1285
lesser	O	1286-1292
degree	O	1293-1299
of	O	1300-1302
orthostatic	B	1303-1314
hypotension	I	1315-1326
occurred	O	1327-1335
with	O	1336-1340
standing	O	1341-1349
.	O	1349-1350

Orthostatic	B	1351-1362
hypotension	I	1363-1374
was	O	1375-1378
ameliorated	O	1379-1390
4	O	1391-1392
days	O	1393-1397
after	O	1398-1403
withdrawal	O	1404-1414
of	O	1415-1417
selegiline	O	1418-1428
and	O	1429-1432
totally	O	1433-1440
abolished	O	1441-1450
7	O	1451-1452
days	O	1453-1457
after	O	1458-1463
discontinuation	O	1464-1479
of	O	1480-1482
the	O	1483-1486
drug	O	1487-1491
.	O	1491-1492

Stopping	O	1493-1501
selegiline	O	1502-1512
also	O	1513-1517
significantly	O	1518-1531
reduced	B	1532-1539
the	I	1540-1543
supine	I	1544-1550
systolic	I	1551-1559
and	I	1560-1563
diastolic	I	1564-1573
blood	I	1574-1579
pressures	I	1580-1589
consistent	O	1590-1600
with	O	1601-1605
a	O	1606-1607
previously	O	1608-1618
undescribed	O	1619-1630
supine	O	1631-1637
pressor	O	1638-1645
action	O	1646-1652
.	O	1652-1653

CONCLUSION	O	1654-1664
:	O	1664-1665
This	O	1666-1670
study	O	1671-1676
confirms	O	1677-1685
our	O	1686-1689
previous	O	1690-1698
finding	O	1699-1706
that	O	1707-1711
selegiline	O	1712-1722
in	O	1723-1725
combination	O	1726-1737
with	O	1738-1742
L	O	1743-1744
-	O	1744-1745
dopa	O	1745-1749
is	O	1750-1752
associated	O	1753-1763
with	O	1764-1768
selective	O	1769-1778
orthostatic	B	1779-1790
hypotension	I	1791-1802
.	O	1802-1803

The	O	1804-1807
possibilities	O	1808-1821
that	O	1822-1826
these	O	1827-1832
cardiovascular	O	1833-1847
findings	O	1848-1856
might	O	1857-1862
be	O	1863-1865
the	O	1866-1869
result	O	1870-1876
of	O	1877-1879
non	O	1880-1883
-	O	1883-1884
selective	O	1884-1893
inhibition	O	1894-1904
of	O	1905-1907
monoamine	O	1908-1917
oxidase	O	1918-1925
or	O	1926-1928
of	O	1929-1931
amphetamine	O	1932-1943
and	O	1944-1947
metamphetamine	O	1948-1962
are	O	1963-1966
discussed	O	1967-1976
.	O	1976-1977

Explicit	O	0-8
episodic	O	9-17
memory	O	18-24
for	O	25-28
sensory	O	29-36
-	O	36-37
discriminative	O	37-51
components	O	52-62
of	O	63-65
capsaicin	O	66-75
-	O	75-76
induced	O	76-83
pain	B	84-88
:	O	88-89
immediate	O	90-99
and	O	100-103
delayed	O	104-111
ratings	O	112-119
.	O	119-120

Pain	B	121-125
memory	O	126-132
is	O	133-135
thought	O	136-143
to	O	144-146
affect	O	147-153
future	O	154-160
pain	B	161-165
sensitivity	O	166-177
and	O	178-181
thus	O	182-186
contribute	O	187-197
to	O	198-200
clinical	O	201-209
pain	B	210-214
conditions	O	215-225
.	O	225-226

Systematic	O	227-237
investigations	O	238-252
of	O	253-255
the	O	256-259
human	O	260-265
capacity	O	266-274
to	O	275-277
remember	O	278-286
sensory	O	287-294
features	O	295-303
of	O	304-306
experimental	O	307-319
pain	B	320-324
are	O	325-328
sparse	O	329-335
.	O	335-336

In	O	337-339
order	O	340-345
to	O	346-348
address	O	349-356
long	O	357-361
-	O	361-362
term	O	362-366
pain	B	367-371
memory	O	372-378
,	O	378-379
nine	O	380-384
healthy	O	385-392
male	O	393-397
volunteers	O	398-408
received	O	409-417
intradermal	O	418-429
injections	O	430-440
of	O	441-443
three	O	444-449
doses	O	450-455
of	O	456-458
capsaicin	O	459-468
(	O	469-470
0	O	470-471
.	O	471-472
05	O	472-474
,	O	474-475
1	O	476-477
and	O	478-481
20	O	482-484
microg	O	485-491
,	O	491-492
separated	O	493-502
by	O	503-505
15	O	506-508
min	O	509-512
breaks	O	513-519
)	O	519-520
,	O	520-521
each	O	522-526
given	O	527-532
three	O	533-538
times	O	539-544
in	O	545-547
a	O	548-549
balanced	O	550-558
design	O	559-565
across	O	566-572
three	O	573-578
sessions	O	579-587
at	O	588-590
one	O	591-594
week	O	595-599
intervals	O	600-609
.	O	609-610

Pain	B	611-615
rating	O	616-622
was	O	623-626
performed	O	627-636
using	O	637-642
a	O	643-644
computerized	O	645-657
visual	O	658-664
analogue	O	665-673
scale	O	674-679
(	O	680-681
0	O	681-682
-	O	682-683
100	O	683-686
)	O	686-687
digitized	O	688-697
at	O	698-700
1	O	701-702
/	O	702-703
s	O	703-704
,	O	704-705
either	O	706-712
immediately	O	713-724
online	O	725-731
or	O	732-734
one	O	735-738
hour	O	739-743
or	O	744-746
one	O	747-750
day	O	751-754
after	O	755-760
injection	O	761-770
.	O	770-771

Subjects	O	772-780
also	O	781-785
recalled	O	786-794
their	O	795-800
pains	B	801-806
one	O	807-810
week	O	811-815
later	O	816-821
.	O	821-822

Capsaicin	O	823-832
injection	O	833-842
reliably	O	843-851
induced	O	852-859
a	O	860-861
dose	O	862-866
-	O	866-867
dependent	O	867-876
flare	O	877-882
(	O	883-884
p	O	884-885
<	O	885-886
0	O	886-887
.	O	887-888
001	O	888-891
)	O	891-892

without	O	893-900
any	O	901-904
difference	O	905-915
within	O	916-922
or	O	923-925
across	O	926-932
sessions	O	933-941
.	O	941-942

The	O	943-946
strong	O	947-953
burning	O	954-961
pain	B	962-966
decayed	O	967-974
exponentially	O	975-988
within	O	989-995
a	O	996-997
few	O	998-1001
minutes	O	1002-1009
.	O	1009-1010

Subjects	O	1011-1019
were	O	1020-1024
able	O	1025-1029
to	O	1030-1032
reliably	O	1033-1041
discriminate	O	1042-1054
pain	B	1055-1059
magnitude	O	1060-1069
and	O	1070-1073
duration	O	1074-1082
across	O	1083-1089
capsaicin	O	1090-1099
doses	O	1100-1105
(	O	1106-1107
both	O	1107-1111
p	O	1112-1113
<	O	1113-1114
0	O	1114-1115
.	O	1115-1116
001	O	1116-1119
)	O	1119-1120
,	O	1120-1121
regardless	O	1122-1132
of	O	1133-1135
whether	O	1136-1143
first	O	1144-1149
-	O	1149-1150
time	O	1150-1154
ratings	O	1155-1162
were	O	1163-1167
requested	O	1168-1177
immediately	O	1178-1189
,	O	1189-1190
after	O	1191-1196
one	O	1197-1200
hour	O	1201-1205
or	O	1206-1208
after	O	1209-1214
one	O	1215-1218
day	O	1219-1222
.	O	1222-1223

Pain	B	1224-1228
recall	O	1229-1235
after	O	1236-1241
one	O	1242-1245
week	O	1246-1250
was	O	1251-1254
similarly	O	1255-1264
precise	O	1265-1272
(	O	1273-1274
magnitude	O	1274-1283
:	O	1283-1284
p	O	1285-1286
<	O	1286-1287
0	O	1287-1288
.	O	1288-1289
01	O	1289-1291
,	O	1291-1292
duration	O	1293-1301
:	O	1301-1302
p	O	1303-1304
<	O	1304-1305
0	O	1305-1306
.	O	1306-1307
05	O	1307-1309
)	O	1309-1310
.	O	1306-1307

Correlation	O	1312-1323
with	O	1324-1328
rating	O	1329-1335
recall	O	1336-1342
after	O	1343-1348
one	O	1349-1352
week	O	1353-1357
was	O	1358-1361
best	O	1362-1366
when	O	1367-1371
first	O	1372-1377
-	O	1377-1378
time	O	1378-1382
ratings	O	1383-1390
were	O	1391-1395
requested	O	1396-1405
as	O	1406-1408
late	O	1409-1413
as	O	1414-1416
one	O	1417-1420
day	O	1421-1424
after	O	1425-1430
injection	O	1431-1440
(	O	1441-1442
R	O	1442-1443
(	O	1441-1442
2	O	1444-1445
)	O	1445-1446
=	O	1446-1447
0	O	1447-1448
.	O	1448-1449
79	O	1449-1451
)	O	1445-1446

indicating	O	1453-1463
that	O	1464-1468
both	O	1469-1473
rating	O	1474-1480
retrievals	O	1481-1491
utilized	O	1492-1500
similar	O	1501-1508
memory	O	1509-1515
traces	O	1516-1522
.	O	1522-1523

These	O	1524-1529
results	O	1530-1537
indicate	O	1538-1546
a	O	1547-1548
reliable	O	1549-1557
memory	O	1558-1564
for	O	1565-1568
magnitude	O	1569-1578
and	O	1579-1582
duration	O	1583-1591
of	O	1592-1594
experimentally	O	1595-1609
induced	O	1610-1617
pain	B	1618-1622
.	O	1622-1623

The	O	1624-1627
data	O	1628-1632
further	O	1633-1640
suggest	O	1641-1648
that	O	1649-1653
the	O	1654-1657
consolidation	O	1658-1671
of	O	1672-1674
this	O	1675-1679
memory	O	1680-1686
is	O	1687-1689
an	O	1690-1692
important	O	1693-1702
interim	O	1703-1710
stage	O	1711-1716
,	O	1716-1717
and	O	1718-1721
may	O	1722-1725
take	O	1726-1730
up	O	1731-1733
to	O	1734-1736
one	O	1737-1740
day	O	1741-1744
.	O	1744-1745

Reversibility	O	0-13
of	O	14-16
captopril	O	17-26
-	O	26-27
induced	O	27-34
renal	B	35-40
insufficiency	I	41-54
after	O	55-60
prolonged	O	61-70
use	O	71-74
in	O	75-77
an	O	78-80
unusual	O	81-88
case	O	89-93
of	O	94-96
renovascular	B	97-109
hypertension	I	110-122
.	O	122-123

We	O	124-126
report	O	127-133
a	O	134-135
case	O	136-140
of	O	141-143
severe	O	144-150
hypertension	B	151-163
with	O	164-168
an	O	169-171
occluded	O	172-180
renal	O	181-186
artery	O	187-193
to	O	194-196
a	O	197-198
solitary	O	199-207
kidney	O	208-214
,	O	214-215
who	O	216-219
developed	O	220-229
sudden	B	230-236
deterioration	I	237-250
of	I	251-253
renal	I	254-259
function	I	260-268
following	O	269-278
treatment	O	279-288
with	O	289-293
captopril	O	294-303
.	O	303-304

His	O	305-308
renal	O	309-314
function	O	315-323
remained	O	324-332
impaired	O	333-341
but	O	342-345
stable	O	346-352
during	O	353-359
2	O	360-361
years	O	362-367
'	O	367-368
treatment	O	369-378
with	O	379-383
captopril	O	384-393
but	O	394-397
returned	O	398-406
to	O	407-409
pre	O	410-413
-	O	413-414
treatment	O	414-423
levels	O	424-430
soon	O	431-435
after	O	436-441
cessation	O	442-451
of	O	452-454
the	O	455-458
drug	O	459-463
.	O	463-464

This	O	465-469
indicates	O	470-479
reversibility	O	480-493
in	O	494-496
captopril	O	497-506
-	O	506-507
induced	O	507-514
renal	B	515-520
failure	I	521-528
even	O	529-533
after	O	534-539
its	O	540-543
prolonged	O	544-553
use	O	554-557
and	O	558-561
suggests	O	562-570
that	O	571-575
no	O	576-578
organic	O	579-586
damage	O	587-593
occurs	O	594-600
to	O	601-603
glomerular	O	604-614
arterioles	O	615-625
following	O	626-635
chronic	O	636-643
ACE	O	644-647
inhibition	O	648-658
.	O	658-659

Liver	B	0-5
disease	I	6-13
caused	O	14-20
by	O	21-23
propylthiouracil	O	24-40
.	O	40-41

This	O	42-46
report	O	47-53
presents	O	54-62
the	O	63-66
clinical	O	67-75
,	O	75-76
laboratory	O	77-87
,	O	87-88
and	O	89-92
light	O	93-98
and	O	99-102
electron	O	103-111
microscopic	O	112-123
observations	O	124-136
on	O	137-139
a	O	140-141
patient	O	142-149
with	O	150-154
chronic	B	155-162
active	I	163-169
(	I	170-171
aggressive	I	171-181
)	I	181-182
hepatitis	I	183-192
caused	O	193-199
by	O	200-202
the	O	203-206
administration	O	207-221
of	O	222-224
propylthiouracil	O	225-241
.	O	241-242

This	O	243-247
is	O	248-250
an	O	251-253
addition	O	254-262
to	O	263-265
the	O	266-269
list	O	270-274
of	O	275-277
drugs	O	278-283
that	O	284-288
must	O	289-293
be	O	294-296
considered	O	297-307
in	O	308-310
the	O	311-314
evaluation	O	315-325
of	O	326-328
chronic	O	329-336
liver	B	337-342
disease	I	343-350
.	O	350-351

Capsaicin	O	0-9
-	O	9-10
induced	O	10-17
muscle	B	18-24
pain	I	25-29
alters	O	30-36
the	O	37-40
excitability	O	41-53
of	O	54-56
the	O	57-60
human	O	61-66
jaw	O	67-70
-	O	70-71
stretch	O	71-78
reflex	O	79-85
.	O	85-86

The	O	87-90
pathophysiology	O	91-106
of	O	107-109
painful	O	110-117
temporomandibular	B	118-135
disorders	I	136-145
is	O	146-148
not	O	149-152
fully	O	153-158
understood	O	159-169
,	O	169-170
but	O	171-174
evidence	O	175-183
suggests	O	184-192
that	O	193-197
muscle	B	198-204
pain	I	205-209
modulates	O	210-219
motor	O	220-225
function	O	226-234
in	O	235-237
characteristic	O	238-252
ways	O	253-257
.	O	257-258

This	O	259-263
study	O	264-269
tested	O	270-276
the	O	277-280
hypothesis	O	281-291
that	O	292-296
activation	O	297-307
of	O	308-310
nociceptive	B	311-322
muscle	I	323-329
afferent	O	330-338
fibers	O	339-345
would	O	346-351
be	O	352-354
linked	O	355-361
to	O	362-364
an	O	365-367
increased	O	368-377
excitability	O	378-390
of	O	391-393
the	O	394-397
human	O	398-403
jaw	O	404-407
-	O	407-408
stretch	O	408-415
reflex	O	416-422
and	O	423-426
whether	O	427-434
this	O	435-439
process	O	440-447
would	O	448-453
be	O	454-456
sensitive	O	457-466
to	O	467-469
length	O	470-476
and	O	477-480
velocity	O	481-489
of	O	490-492
the	O	493-496
stretch	O	497-504
.	O	504-505

Capsaicin	O	506-515
(	O	516-517
10	O	517-519
micro	O	520-525
g	O	526-527
)	O	527-528
was	O	529-532
injected	O	533-541
into	O	542-546
the	O	547-550
masseter	O	551-559
muscle	O	560-566
to	O	567-569
induce	O	570-576
pain	B	577-581
in	O	582-584
11	O	585-587
healthy	O	588-595
volunteers	O	596-606
.	O	606-607

Short	O	608-613
-	O	613-614
latency	O	614-621
reflex	O	622-628
responses	O	629-638
were	O	639-643
evoked	O	644-650
in	O	651-653
the	O	654-657
masseter	O	658-666
and	O	667-670
temporalis	O	671-681
muscles	O	682-689
by	O	690-692
a	O	693-694
stretch	O	695-702
device	O	703-709
with	O	710-714
different	O	715-724
velocities	O	725-735
and	O	736-739
displacements	O	740-753
before	O	754-760
,	O	760-761
during	O	762-768
,	O	768-769
and	O	770-773
after	O	774-779
the	O	780-783
pain	B	784-788
.	O	788-789

The	O	790-793
normalized	O	794-804
reflex	O	805-811
amplitude	O	812-821
increased	O	822-831
with	O	832-836
an	O	837-839
increase	O	840-848
in	O	849-851
velocity	O	852-860
at	O	861-863
a	O	864-865
given	O	866-871
displacement	O	872-884
,	O	884-885
but	O	886-889
remained	O	890-898
constant	O	899-907
with	O	908-912
different	O	913-922
displacements	O	923-936
at	O	937-939
a	O	940-941
given	O	942-947
velocity	O	948-956
.	O	956-957

The	O	958-961
normalized	O	962-972
reflex	O	973-979
amplitude	O	980-989
was	O	990-993
significantly	O	994-1007
higher	O	1008-1014
during	O	1015-1021
pain	B	1022-1026
,	O	1026-1027
but	O	1028-1031
only	O	1032-1036
at	O	1037-1039
faster	O	1040-1046
stretches	O	1047-1056
in	O	1057-1059
the	O	1060-1063
painful	B	1064-1071
muscle	I	1072-1078
.	O	1078-1079

Increased	O	1080-1089
sensitivity	O	1090-1101
of	O	1102-1104
the	O	1105-1108
fusimotor	O	1109-1118
system	O	1119-1125
during	O	1126-1132
acute	O	1133-1138
muscle	B	1139-1145
pain	I	1146-1150
could	O	1151-1156
be	O	1157-1159
one	O	1160-1163
likely	O	1164-1170
mechanism	O	1171-1180
to	O	1181-1183
explain	O	1184-1191
the	O	1192-1195
findings	O	1196-1204
.	O	1204-1205

Repetitive	O	0-10
transcranial	O	11-23
magnetic	O	24-32
stimulation	O	33-44
for	O	45-48
levodopa	O	49-57
-	O	57-58
induced	O	58-65
dyskinesias	B	66-77
in	O	78-80
Parkinson	B	81-90
'	I	90-91
s	I	87-88
disease	I	93-100
.	O	100-101

In	O	102-104
a	O	105-106
placebo	O	107-114
-	O	114-115
controlled	O	115-125
,	O	125-126
single	O	127-133
-	O	133-134
blinded	O	134-141
,	O	141-142
crossover	O	143-152
study	O	153-158
,	O	158-159
we	O	160-162
assessed	O	163-171
the	O	172-175
effect	O	176-182
of	O	183-185
"	O	186-187
real	O	187-191
"	O	186-187
repetitive	O	193-203
transcranial	O	204-216
magnetic	O	217-225
stimulation	O	226-237
(	O	238-239
rTMS	O	239-243
)	O	243-244
versus	O	245-251
"	O	252-253
sham	O	253-257
"	O	252-253
rTMS	O	259-263
(	O	264-265
placebo	O	265-272
)	O	272-273
on	O	274-276
peak	O	277-281
dose	O	282-286
dyskinesias	B	287-298
in	O	299-301
patients	O	302-310
with	O	311-315
Parkinson	B	316-325
'	I	325-326
s	I	322-323
disease	I	328-335
(	O	336-337
PD	B	337-339
)	O	339-340
.	O	340-341

Ten	O	342-345
patients	O	346-354
with	O	355-359
PD	B	360-362
and	O	363-366
prominent	O	367-376
dyskinesias	B	377-388
had	O	389-392
rTMS	O	393-397
(	O	398-399
1	O	399-400
,	O	400-401
800	O	401-404
pulses	O	405-411
;	O	411-412
1	O	413-414
Hz	O	415-417
rate	O	418-422
)	O	422-423
delivered	O	424-433
over	O	434-438
the	O	439-442
motor	O	443-448
cortex	O	449-455
for	O	456-459
4	O	460-461
consecutive	O	462-473
days	O	474-478
twice	O	479-484
,	O	484-485
once	O	486-490
real	O	491-495
stimuli	O	496-503
and	O	504-507
once	O	508-512
sham	O	513-517
stimulation	O	518-529
were	O	530-534
used	O	535-539
;	O	539-540
evaluations	O	541-552
were	O	553-557
done	O	558-562
at	O	563-565
the	O	566-569
baseline	O	570-578
and	O	579-582
1	O	583-584
day	O	585-588
after	O	589-594
the	O	595-598
end	O	599-602
of	O	603-605
each	O	606-610
of	O	611-613
the	O	614-617
treatment	O	618-627
series	O	628-634
.	O	634-635

Direct	O	636-642
comparison	O	643-653
between	O	654-661
sham	O	662-666
and	O	667-670
real	O	671-675
rTMS	O	676-680
effects	O	681-688
showed	O	689-695
no	O	696-698
significant	O	699-710
difference	O	711-721
in	O	722-724
clinician	O	725-734
-	O	734-735
assessed	O	735-743
dyskinesia	B	744-754
severity	O	755-763
.	O	763-764

However	O	765-772
,	O	772-773
comparison	O	774-784
with	O	785-789
the	O	790-793
baseline	O	794-802
showed	O	803-809
small	O	810-815
but	O	816-819
significant	O	820-831
reduction	O	832-841
in	O	842-844
dyskinesia	B	845-855
severity	O	856-864
following	O	865-874
real	O	875-879
rTMS	O	880-884
but	O	885-888
not	O	889-892
placebo	O	893-900
.	O	900-901

The	O	902-905
major	O	906-911
effect	O	912-918
was	O	919-922
on	O	923-925
dystonia	B	926-934
subscore	O	935-943
.	O	943-944

Similarly	O	945-954
,	O	954-955
in	O	956-958
patient	O	959-966
diaries	O	967-974
,	O	974-975
although	O	976-984
both	O	985-989
treatments	O	990-1000
caused	O	1001-1007
reduction	O	1008-1017
in	O	1018-1020
subjective	O	1021-1031
dyskinesia	B	1032-1042
scores	O	1043-1049
during	O	1050-1056
the	O	1057-1060
days	O	1061-1065
of	O	1066-1068
intervention	O	1069-1081
,	O	1081-1082
the	O	1083-1086
effect	O	1087-1093
was	O	1094-1097
sustained	O	1098-1107
for	O	1108-1111
3	O	1112-1113
days	O	1114-1118
after	O	1119-1124
the	O	1125-1128
intervention	O	1129-1141
for	O	1142-1145
the	O	1146-1149
real	O	1150-1154
rTMS	O	1155-1159
only	O	1160-1164
.	O	1164-1165

Following	O	1166-1175
rTMS	O	1176-1180
,	O	1180-1181
no	O	1182-1184
side	O	1185-1189
effects	O	1190-1197
and	O	1198-1201
no	O	1202-1204
adverse	O	1205-1212
effects	O	1213-1220
on	O	1221-1223
motor	O	1224-1229
function	O	1230-1238
and	O	1239-1242
PD	B	1243-1245
symptoms	O	1246-1254
were	O	1255-1259
noted	O	1260-1265
.	O	1265-1266

The	O	1267-1270
results	O	1271-1278
suggest	O	1279-1286
the	O	1287-1290
existence	O	1291-1300
of	O	1301-1303
residual	O	1304-1312
beneficial	O	1313-1323
clinical	O	1324-1332
aftereffects	O	1333-1345
of	O	1346-1348
consecutive	O	1349-1360
daily	O	1361-1366
applications	O	1367-1379
of	O	1380-1382
low	O	1383-1386
-	O	1386-1387
frequency	O	1387-1396
rTMS	O	1397-1401
on	O	1402-1404
dyskinesias	B	1405-1416
in	O	1417-1419
PD	B	1420-1422
.	O	1422-1423

The	O	1424-1427
effects	O	1428-1435
may	O	1436-1439
be	O	1440-1442
further	O	1443-1450
exploited	O	1451-1460
for	O	1461-1464
potential	O	1465-1474
therapeutic	O	1475-1486
uses	O	1487-1491
.	O	1491-1492

Disulfiram	O	0-10
-	O	10-11
like	O	11-15
syndrome	O	16-24
after	O	25-30
hydrogen	O	31-39
cyanamide	O	40-49
professional	O	50-62
skin	O	63-67
exposure	O	68-76
:	O	76-77
two	O	78-81
case	O	82-86
reports	O	87-94
in	O	95-97
France	O	98-104
.	O	104-105

Hydrogen	O	106-114
cyanamide	O	115-124
is	O	125-127
a	O	128-129
plant	O	130-135
growth	O	136-142
regulator	O	143-152
used	O	153-157
in	O	158-160
agriculture	O	161-172
to	O	173-175
induce	O	176-182
bud	O	183-186
break	O	187-192
in	O	193-195
fruit	O	196-201
trees	O	202-207
.	O	207-208

Contact	O	209-216
with	O	217-221
the	O	222-225
skin	O	226-230
can	O	231-234
result	O	235-241
in	O	242-244
percutaneous	O	245-257
absorption	O	258-268
of	O	269-271
the	O	272-275
substance	O	276-285
that	O	286-290
inhibits	O	291-299
aldehyde	O	300-308
dehydrogenase	O	309-322
and	O	323-326
can	O	327-330
induce	O	331-337
acetaldehyde	O	338-350
syndrome	O	351-359
in	O	360-362
case	O	363-367
of	O	368-370
alcohol	O	371-378
use	O	379-382
.	O	382-383

The	O	384-387
purpose	O	388-395
of	O	396-398
this	O	399-403
report	O	404-410
is	O	411-413
to	O	414-416
describe	O	417-425
two	O	426-429
cases	O	430-435
of	O	436-438
a	O	439-440
disulfiram	O	441-451
-	O	451-452
like	O	452-456
syndrome	O	457-465
following	O	466-475
occupational	O	476-488
exposure	O	489-497
to	O	498-500
hydrogen	O	501-509
cyanamide	O	510-519
.	O	519-520

The	O	521-524
first	O	525-530
case	O	531-535
involved	O	536-544
a	O	545-546
59	O	547-549
-	O	549-550
year	O	550-554
-	O	549-550
old	O	555-558
man	O	559-562
who	O	563-566
used	O	567-571
Dormex	O	572-578
,	O	578-579
which	O	580-585
contains	O	586-594
hydrogen	O	595-603
cyanamide	O	604-613
,	O	613-614
without	O	615-622
protection	O	623-633
after	O	634-639
consuming	O	640-649
a	O	650-651
large	O	652-657
amount	O	658-664
of	O	665-667
alcohol	O	668-675
during	O	676-682
a	O	683-684
meal	O	685-689
.	O	689-690

In	O	691-693
less	O	694-698
than	O	699-703
1	O	704-705
hour	O	706-710
after	O	711-716
the	O	717-720
ingestion	O	721-730
of	O	731-733
alcohol	O	734-741
,	O	741-742
he	O	743-745
developed	O	746-755
malaise	O	756-763
with	O	764-768
flushing	B	769-777
of	I	778-780
the	I	781-784
face	I	785-789
,	O	789-790
tachycardia	B	791-802
,	O	802-803
and	O	804-807
dyspnea	B	808-815
.	O	815-816

Manifestations	O	817-831
regressed	O	832-841
spontaneously	O	842-855
under	O	856-861
surveillance	O	862-874
in	O	875-877
the	O	878-881
hospital	O	882-890
.	O	890-891

The	O	892-895
second	O	896-902
case	O	903-907
occurred	O	908-916
in	O	917-919
a	O	920-921
55	O	922-924
-	O	924-925
year	O	925-929
-	O	924-925
old	O	930-933
farmer	O	934-940
following	O	941-950
cutaneous	O	951-960
contact	O	961-968
with	O	969-973
Dormex	O	974-980
.	O	980-981

Five	O	982-986
hours	O	987-992
after	O	993-998
exposure	O	999-1007
,	O	1007-1008
he	O	1009-1011
developed	O	1012-1021
disulfiram	O	1022-1032
-	O	1032-1033
like	O	1033-1037
syndrome	O	1038-1046
with	O	1047-1051
flushing	B	1052-1060
,	O	1060-1061
tachycardia	B	1062-1073
,	O	1073-1074
and	O	1075-1078
arterial	B	1079-1087
hypotension	I	1088-1099
after	O	1100-1105
consuming	O	1106-1115
three	O	1116-1121
glasses	O	1122-1129
of	O	1130-1132
wine	O	1133-1137
.	O	1137-1138

The	O	1139-1142
patient	O	1143-1150
recovered	O	1151-1160
spontaneously	O	1161-1174
in	O	1175-1177
3	O	1178-1179
hours	O	1180-1185
under	O	1186-1191
surveillance	O	1192-1204
in	O	1205-1207
the	O	1208-1211
hospital	O	1212-1220
.	O	1220-1221

These	O	1222-1227
cases	O	1228-1233
confirm	O	1234-1241
the	O	1242-1245
necessity	O	1246-1255
of	O	1256-1258
avoiding	O	1259-1267
alcohol	O	1268-1275
consumption	O	1276-1287
as	O	1288-1290
recommended	O	1291-1302
in	O	1303-1305
the	O	1306-1309
instructions	O	1310-1322
for	O	1323-1326
use	O	1327-1330
of	O	1331-1333
Dormex	O	1334-1340
and	O	1341-1344
of	O	1345-1347
preventing	O	1348-1358
cutaneous	O	1359-1368
contact	O	1369-1376
during	O	1377-1383
use	O	1384-1387
.	O	1387-1388

Repeated	O	0-8
trimipramine	O	9-21
induces	O	22-29
dopamine	O	30-38
D2	O	39-41
/	O	41-42
D3	O	42-44
and	O	45-48
alpha1	O	49-55
-	O	55-56
adrenergic	O	56-66
up	O	67-69
-	O	69-70
regulation	O	70-80
.	O	80-81

Trimipramine	O	82-94
(	O	95-96
TRI	O	96-99
)	O	99-100
,	O	100-101
which	O	102-107
shows	O	108-113
a	O	114-115
clinical	O	116-124
antidepressant	O	125-139
activity	O	140-148
,	O	148-149
is	O	150-152
chemically	O	153-163
related	O	164-171
to	O	172-174
imipramine	O	175-185
but	O	186-189
does	O	190-194
not	O	195-198
inhibit	O	199-206
the	O	207-210
reuptake	O	211-219
of	O	220-222
noradrenaline	O	223-236
and	O	237-240
5	O	241-242
-	O	242-243
hydroxytryptamine	O	243-260
,	O	260-261
nor	O	262-265
does	O	266-270
it	O	271-273
induce	O	274-280
beta	O	281-285
-	O	285-286
adrenergic	O	286-296
down	O	297-301
-	O	301-302
regulation	O	302-312
.	O	312-313

The	O	314-317
mechanism	O	318-327
of	O	328-330
its	O	331-334
antidepressant	O	335-349
activity	O	350-358
is	O	359-361
still	O	362-367
unknown	O	368-375
.	O	375-376

The	O	377-380
aim	O	381-384
of	O	385-387
the	O	388-391
present	O	392-399
study	O	400-405
was	O	406-409
to	O	410-412
find	O	413-417
out	O	418-421
whether	O	422-429
TRI	O	430-433
given	O	434-439
repeatedly	O	440-450
was	O	451-454
able	O	455-459
to	O	460-462
induce	O	463-469
adaptive	O	470-478
changes	O	479-486
in	O	487-489
the	O	490-493
dopaminergic	O	494-506
and	O	507-510
alpha1	O	511-517
-	O	517-518
adrenergic	O	518-528
systems	O	529-536
,	O	536-537
demonstrated	O	538-550
by	O	551-553
us	O	554-556
previously	O	557-567
for	O	568-571
various	O	572-579
antidepressants	O	580-595
.	O	595-596

TRI	O	597-600
was	O	601-604
given	O	605-610
to	O	611-613
male	O	614-618
Wistar	O	619-625
rats	O	626-630
and	O	631-634
male	O	635-639
Albino	O	640-646
Swiss	O	647-652
mice	O	653-657
perorally	O	658-667
twice	O	668-673
daily	O	674-679
for	O	680-683
14	O	684-686
days	O	687-691
.	O	691-692

In	O	693-695
the	O	696-699
acute	O	700-705
experiment	O	706-716
TRI	O	717-720
(	O	721-722
given	O	722-727
i	O	728-729
.	O	729-730
p	O	730-731
.	O	729-730
)	O	732-733
does	O	734-738
not	O	739-742
antagonize	O	743-753
the	O	754-757
reserpine	O	758-767
hypothermia	B	768-779
in	O	780-782
mice	O	783-787
and	O	788-791
does	O	792-796
not	O	797-800
potentiate	O	801-811
the	O	812-815
5	O	816-817
-	O	817-818
hydroxytryptophan	O	818-835
head	O	836-840
twitches	O	841-849
in	O	850-852
rats	O	853-857
.	O	857-858

TRI	O	859-862
given	O	863-868
repeatedly	O	869-879
to	O	880-882
rats	O	883-887
increases	O	888-897
the	O	898-901
locomotor	O	902-911
hyperactivity	B	912-925
induced	O	926-933
by	O	934-936
d	O	937-938
-	O	938-939
amphetamine	O	939-950
,	O	950-951
quinpirole	O	952-962
and	O	963-966
(	O	967-968
+	O	968-969
)	O	969-970
-	O	970-971
7	O	971-972
-	O	970-971
hydroxy	O	973-980
-	O	970-971
dipropyloaminotetralin	O	981-1003
(	O	1004-1005
dopamine	O	1005-1013
D2	O	1014-1016
and	O	1017-1020
D3	O	1021-1023
effects	O	1024-1031
)	O	1031-1032
.	O	1032-1033

The	O	1034-1037
stereotypies	O	1038-1050
induced	O	1051-1058
by	O	1059-1061
d	O	1062-1063
-	O	1063-1064
amphetamine	O	1064-1075
or	O	1076-1078
apomorphine	O	1079-1090
are	O	1091-1094
not	O	1095-1098
potentiated	O	1099-1110
by	O	1111-1113
TRI	O	1114-1117
.	O	1117-1118

It	O	1119-1121
increases	O	1122-1131
the	O	1132-1135
behaviour	O	1136-1145
stimulation	O	1146-1157
evoked	O	1158-1164
by	O	1165-1167
phenylephrine	O	1168-1181
(	O	1182-1183
given	O	1183-1188
intraventricularly	O	1189-1207
)	O	1207-1208
in	O	1209-1211
rats	O	1212-1216
,	O	1216-1217
evaluated	O	1218-1227
in	O	1228-1230
the	O	1231-1234
open	O	1235-1239
field	O	1240-1245
test	O	1246-1250
as	O	1251-1253
well	O	1254-1258
as	O	1259-1261
the	O	1262-1265
aggressiveness	B	1266-1280
evoked	O	1281-1287
by	O	1288-1290
clonidine	O	1291-1300
in	O	1301-1303
mice	O	1304-1308
,	O	1308-1309
both	O	1310-1314
these	O	1315-1320
effects	O	1321-1328
being	O	1329-1334
mediated	O	1335-1343
by	O	1344-1346
an	O	1347-1349
alpha1	O	1350-1356
-	O	1356-1357
adrenergic	O	1357-1367
receptor	O	1368-1376
.	O	1376-1377

It	O	1378-1380
may	O	1381-1384
be	O	1385-1387
concluded	O	1388-1397
that	O	1398-1402
,	O	1402-1403
like	O	1404-1408
other	O	1409-1414
tricyclic	O	1415-1424
antidepressants	O	1425-1440
studied	O	1441-1448
previously	O	1449-1459
,	O	1459-1460
TRI	O	1461-1464
given	O	1465-1470
repeatedly	O	1471-1481
increases	O	1482-1491
the	O	1492-1495
responsiveness	O	1496-1510
of	O	1511-1513
brain	O	1514-1519
dopamine	O	1520-1528
D2	O	1529-1531
and	O	1532-1535
D3	O	1536-1538
(	O	1539-1540
locomotor	O	1540-1549
activity	O	1550-1558
but	O	1559-1562
not	O	1563-1566
stereotypy	O	1567-1577
)	O	1577-1578
as	O	1579-1581
well	O	1582-1586
as	O	1587-1589
alpha1	O	1590-1596
-	O	1596-1597
adrenergic	O	1597-1607
receptors	O	1608-1617
to	O	1618-1620
their	O	1621-1626
agonists	O	1627-1635
.	O	1635-1636

A	O	1637-1638
question	O	1639-1647
arises	O	1648-1654
whether	O	1655-1662
the	O	1663-1666
reuptake	O	1667-1675
inhibition	O	1676-1686
is	O	1687-1689
of	O	1690-1692
any	O	1693-1696
importance	O	1697-1707
to	O	1708-1710
the	O	1711-1714
adaptive	O	1715-1723
changes	O	1724-1731
induced	O	1732-1739
by	O	1740-1742
repeated	O	1743-1751
antidepressants	O	1752-1767
,	O	1767-1768
suggested	O	1769-1778
to	O	1779-1781
be	O	1782-1784
responsible	O	1785-1796
for	O	1797-1800
the	O	1801-1804
antidepressant	O	1805-1819
activity	O	1820-1828
.	O	1828-1829

Ranitidine	O	0-10
-	O	10-11
induced	O	11-18
acute	O	19-24
interstitial	B	25-37
nephritis	I	38-47
in	O	48-50
a	O	51-52
cadaveric	O	53-62
renal	O	63-68
allograft	O	69-78
.	O	78-79

Ranitidine	O	80-90
frequently	O	91-101
is	O	102-104
used	O	105-109
for	O	110-113
preventing	O	114-124
peptic	O	125-131
ulceration	O	132-142
after	O	143-148
renal	O	149-154
transplantation	O	155-170
.	O	170-171

This	O	172-176
drug	O	177-181
occasionally	O	182-194
has	O	195-198
been	O	199-203
associated	O	204-214
with	O	215-219
acute	O	220-225
interstitial	B	226-238
nephritis	I	239-248
in	O	249-251
native	O	252-258
kidneys	O	259-266
.	O	266-267

There	O	268-273
are	O	274-277
no	O	278-280
similar	O	281-288
reports	O	289-296
with	O	297-301
renal	O	302-307
transplantation	O	308-323
.	O	323-324

We	O	325-327
report	O	328-334
a	O	335-336
case	O	337-341
of	O	342-344
ranitidine	O	345-355
-	O	355-356
induced	O	356-363
acute	O	364-369
interstitial	B	370-382
nephritis	I	383-392
in	O	393-395
a	O	396-397
recipient	O	398-407
of	O	408-410
a	O	411-412
cadaveric	O	413-422
renal	O	423-428
allograft	O	429-438
presenting	O	439-449
with	O	450-454
acute	O	455-460
allograft	O	461-470
dysfunction	O	471-482
within	O	483-489
48	O	490-492
hours	O	493-498
of	O	499-501
exposure	O	502-510
to	O	511-513
the	O	514-517
drug	O	518-522
.	O	522-523

The	O	524-527
biopsy	O	528-534
specimen	O	535-543
showed	O	544-550
pathognomonic	O	551-564
features	O	565-573
,	O	573-574
including	O	575-584
eosinophilic	O	585-597
infiltration	O	598-610
of	O	611-613
the	O	614-617
interstitial	O	618-630
compartment	O	631-642
.	O	642-643

Allograft	O	644-653
function	O	654-662
improved	O	663-671
rapidly	O	672-679
and	O	680-683
returned	O	684-692
to	O	693-695
baseline	O	696-704
after	O	705-710
stopping	O	711-719
the	O	720-723
drug	O	724-728
.	O	728-729

Late	O	0-4
,	O	4-5
late	O	6-10
doxorubicin	O	11-22
cardiotoxicity	B	23-37
.	O	37-38

Cardiac	B	39-46
toxicity	I	47-55
is	O	56-58
a	O	59-60
major	O	61-66
complication	O	67-79
which	O	80-85
limits	O	86-92
the	O	93-96
use	O	97-100
of	O	101-103
adriamycin	O	104-114
as	O	115-117
a	O	118-119
chemotherapeutic	O	120-136
agent	O	137-142
.	O	142-143

Cardiomyopathy	B	144-158
is	O	159-161
frequent	O	162-170
when	O	171-175
the	O	176-179
total	O	180-185
dose	O	186-190
exceeds	O	191-198
600	O	199-202
mg	O	203-205
/	O	205-206
m2	O	206-208
and	O	209-212
occurs	O	213-219
within	O	220-226
one	O	227-230
to	O	231-233
six	O	234-237
months	O	238-244
after	O	245-250
cessation	O	251-260
of	O	261-263
therapy	O	264-271
.	O	271-272

A	O	273-274
patient	O	275-282
is	O	283-285
reported	O	286-294
who	O	295-298
developed	O	299-308
progressive	O	309-320
cardiomyopathy	B	321-335
two	O	336-339
and	O	340-343
one	O	344-347
-	O	347-348
half	O	348-352
years	O	353-358
after	O	359-364
receiving	O	365-374
580	O	375-378
mg	O	379-381
/	O	381-382
m2	O	382-384
which	O	385-390
apparently	O	391-401
represents	O	402-412
late	O	413-417
,	O	417-418
late	O	419-423
cardiotoxicity	B	424-438
.	O	438-439

Acetazolamide	O	0-13
-	O	13-14
induced	O	14-21
nephrolithiasis	B	22-37
:	O	37-38
implications	O	39-51
for	O	52-55
treatment	O	56-65
of	O	66-68
neuromuscular	B	69-82
disorders	I	83-92
.	O	92-93

Carbonic	O	94-102
anhydrase	O	103-112
inhibitors	O	113-123
can	O	124-127
cause	O	128-133
nephrolithiasis	B	134-149
.	O	149-150

We	O	151-153
studied	O	154-161
20	O	162-164
patients	O	165-173
receiving	O	174-183
long	O	184-188
-	O	188-189
term	O	189-193
carbonic	O	194-202
anhydrase	O	203-212
inhibitor	O	213-222
treatment	O	223-232
for	O	233-236
periodic	O	237-245
paralysis	B	246-255
and	O	256-259
myotonia	B	260-268
.	O	268-269

Three	O	270-275
patients	O	276-284
on	O	285-287
acetazolamide	O	288-301
(	O	302-303
15	O	303-305
%	O	305-306
)	O	306-307
developed	O	308-317
renal	B	318-323
calculi	I	324-331
.	O	331-332

Extracorporeal	O	333-347
lithotripsy	O	348-359
successfully	O	360-372
removed	O	373-380
a	O	381-382
renal	B	383-388
calculus	I	389-397
in	O	398-400
one	O	401-404
patient	O	405-412
and	O	413-416
surgery	O	417-424
removed	O	425-432
a	O	433-434
staghorn	O	435-443
calculus	B	444-452
in	O	453-455
another	O	456-463
,	O	463-464
permitting	O	465-475
continued	O	476-485
treatment	O	486-495
.	O	495-496

Renal	O	497-502
function	O	503-511
remained	O	512-520
normal	O	521-527
in	O	528-530
all	O	531-534
patients	O	535-543
.	O	543-544

Nephrolithiasis	B	545-560
is	O	561-563
a	O	564-565
complication	O	566-578
of	O	579-581
acetazolamide	O	582-595
but	O	596-599
does	O	600-604
not	O	605-608
preclude	O	609-617
its	O	618-621
use	O	622-625
.	O	625-626

Is	O	0-2
the	O	3-6
treatment	O	7-16
of	O	17-19
scabies	B	20-27
hazardous	O	28-37
?	O	37-38

Treatment	O	39-48
for	O	49-52
scabies	B	53-60
is	O	61-63
usually	O	64-71
initiated	O	72-81
by	O	82-84
general	O	85-92
practitioners	O	93-106
;	O	106-107
most	O	108-112
consider	O	113-121
lindane	O	122-129
(	O	130-131
gamma	O	131-136
benzene	O	137-144
hexachloride	O	145-157
)	O	157-158
the	O	159-162
treatment	O	163-172
of	O	173-175
choice	O	176-182
.	O	182-183

Lindane	O	184-191
is	O	192-194
also	O	195-199
widely	O	200-206
used	O	207-211
as	O	212-214
an	O	215-217
agricultural	O	218-230
and	O	231-234
industrial	O	235-245
pesticide	O	246-255
,	O	255-256
and	O	257-260
as	O	261-263
a	O	264-265
result	O	266-272
the	O	273-276
toxic	O	277-282
profile	O	283-290
of	O	291-293
this	O	294-298
insecticide	O	299-310
is	O	311-313
well	O	314-318
understood	O	319-329
.	O	329-330

Evidence	O	331-339
is	O	340-342
accumulating	O	343-355
that	O	356-360
lindane	O	361-368
can	O	369-372
be	O	373-375
toxic	B	376-381
to	I	382-384
the	I	385-388
central	I	389-396
nervous	I	397-404
system	I	405-411
and	O	412-415
may	O	416-419
be	O	420-422
associated	O	423-433
with	O	434-438
aplastic	B	439-447
anaemia	I	448-455
.	O	455-456

Preparations	O	457-469
containing	O	470-480
lindane	O	481-488
continue	O	489-497
to	O	498-500
be	O	501-503
sold	O	504-508
over	O	509-513
the	O	514-517
counter	O	518-525
and	O	526-529
may	O	530-533
represent	O	534-543
a	O	544-545
hazard	O	546-552
to	O	553-555
poorly	O	556-562
informed	O	563-571
patients	O	572-580
.	O	580-581

This	O	582-586
literature	O	587-597
review	O	598-604
suggests	O	605-613
that	O	614-618
general	O	619-626
practitioners	O	627-640
should	O	641-647
prescribe	O	648-657
scabicides	O	658-668
with	O	669-673
increased	O	674-683
caution	O	684-691
for	O	692-695
certain	O	696-703
at	O	704-706
-	O	706-707
risk	O	707-711
groups	O	712-718
,	O	718-719
and	O	720-723
give	O	724-728
adequate	O	729-737
warnings	O	738-746
regarding	O	747-756
potential	O	757-766
toxicity	B	767-775
.	O	775-776

Anaesthetists	O	0-13
'	O	13-14
nightmare	O	15-24
:	O	24-25
masseter	B	26-34
spasm	I	35-40
after	O	41-46
induction	O	47-56
in	O	57-59
an	O	60-62
undiagnosed	O	63-74
case	O	75-79
of	O	80-82
myotonia	B	83-91
congenita	I	92-101
.	O	101-102

We	O	103-105
report	O	106-112
an	O	113-115
undiagnosed	O	116-127
case	O	128-132
of	O	133-135
myotonia	B	136-144
congenita	I	145-154
in	O	155-157
a	O	158-159
24	O	160-162
-	O	162-163
year	O	163-167
-	O	162-163
old	O	168-171
previously	O	172-182
healthy	O	183-190
primigravida	O	191-203
,	O	203-204
who	O	205-208
developed	O	209-218
life	O	219-223
threatening	O	224-235
masseter	B	236-244
spasm	I	245-250
following	O	251-260
a	O	261-262
standard	O	263-271
dose	O	272-276
of	O	277-279
intravenous	O	280-291
suxamethonium	O	292-305
for	O	306-309
induction	O	310-319
of	O	320-322
anaesthesia	O	323-334
.	O	334-335

Neither	O	336-343
the	O	344-347
patient	O	348-355
nor	O	356-359
the	O	360-363
anaesthetist	O	364-376
was	O	377-380
aware	O	381-386
of	O	387-389
the	O	390-393
diagnosis	O	394-403
before	O	404-410
this	O	411-415
potentially	O	416-427
lethal	O	428-434
complication	O	435-447
occurred	O	448-456
.	O	456-457

Toxicity	B	0-8
in	O	9-11
rhesus	O	12-18
monkeys	O	19-26
following	O	27-36
administration	O	37-51
of	O	52-54
the	O	55-58
8	O	59-60
-	O	60-61
aminoquinoline	O	61-75
8	O	76-77
-	O	77-78
[	O	78-79
(	O	79-80
4	O	80-81
-	O	77-78
amino	O	82-87
-	O	77-78
l	O	88-89
-	O	77-78
methylbutyl	O	90-101
)	O	101-102
amino	O	82-87
]	O	107-108
-	O	77-78
5	O	110-111
-	O	111-112
(	O	112-113
l	O	113-114
-	O	111-112
hexyloxy	O	115-123
)	O	123-124
-	O	111-112
6	O	125-126
-	O	111-112
methoxy	O	127-134
-	O	111-112
4	O	135-136
-	O	111-112
methylquinoline	O	137-152
(	O	153-154
WR242511	O	154-162
)	O	162-163
.	O	163-164

INTRODUCTION	O	165-177
:	O	177-178
Many	O	179-183
substances	O	184-194
that	O	195-199
form	O	200-204
methemoglobin	O	205-218
(	O	219-220
MHb	O	220-223
)	O	223-224
effectively	O	225-236
counter	O	237-244
cyanide	O	245-252
(	O	253-254
CN	O	254-256
)	O	256-257
toxicity	B	258-266
.	O	266-267

Although	O	268-276
MHb	O	277-280
formers	O	281-288
are	O	289-292
generally	O	293-302
applied	O	303-310
as	O	311-313
treatments	O	314-324
for	O	325-328
CN	O	329-331
poisoning	B	332-341
,	O	341-342
it	O	343-345
has	O	346-349
been	O	350-354
proposed	O	355-363
that	O	364-368
a	O	369-370
stable	O	371-377
,	O	377-378
long	O	379-383
-	O	383-384
acting	O	384-390
MHb	O	391-394
former	O	395-401
could	O	402-407
serve	O	408-413
as	O	414-416
a	O	417-418
CN	O	419-421
pretreatment	O	422-434
.	O	434-435

Using	O	436-441
this	O	442-446
rationale	O	447-456
,	O	456-457
the	O	458-461
8	O	462-463
-	O	463-464
aminoquinoline	O	464-478
WR242511	O	479-487
,	O	487-488
a	O	489-490
potent	O	491-497
long	O	498-502
-	O	502-503
lasting	O	503-510
MHb	O	511-514
former	O	515-521
in	O	522-524
rodents	O	525-532
and	O	533-536
beagle	O	537-543
dogs	O	544-548
,	O	548-549
was	O	550-553
studied	O	554-561
in	O	562-564
the	O	565-568
rhesus	O	569-575
monkey	O	576-582
for	O	583-586
advanced	O	587-595
development	O	596-607
as	O	608-610
a	O	611-612
potential	O	613-622
CN	O	623-625
pretreatment	O	626-638
.	O	638-639

METHODS	O	640-647
:	O	647-648
In	O	649-651
this	O	652-656
study	O	657-662
,	O	662-663
WR242511	O	664-672
was	O	673-676
administered	O	677-689
intravenously	O	690-703
(	O	704-705
IV	O	705-707
)	O	707-708
in	O	709-711
2	O	712-713
female	O	714-720
and	O	721-724
4	O	725-726
male	O	727-731
rhesus	O	732-738
monkeys	O	739-746
in	O	747-749
doses	O	750-755
of	O	756-758
3	O	759-760
.	O	760-761
5	O	761-762
and	O	763-766
/	O	766-767
or	O	767-769
7	O	770-771
.	O	771-772
0	O	772-773
mg	O	774-776
/	O	776-777
kg	O	777-779
;	O	779-780
a	O	781-782
single	O	783-789
male	O	790-794
also	O	795-799
received	O	800-808
WR242511	O	809-817
orally	O	818-824
(	O	825-826
PO	O	826-828
)	O	828-829
at	O	830-832
7	O	833-834
.	O	834-835
0	O	835-836
mg	O	837-839
/	O	839-840
kg	O	840-842
.	O	842-843

Health	O	844-850
status	O	851-857
and	O	858-861
MHb	O	862-865
levels	O	866-872
were	O	873-877
monitored	O	878-887
following	O	888-897
exposure	O	898-906
.	O	906-907

RESULTS	O	908-915
:	O	915-916
The	O	917-920
selected	O	921-929
doses	O	930-935
of	O	936-938
WR242511	O	939-947
,	O	947-948
which	O	949-954
produced	O	955-963
significant	O	964-975
methemoglobinemia	B	976-993
in	O	994-996
beagle	O	997-1003
dogs	O	1004-1008
in	O	1009-1011
earlier	O	1012-1019
studies	O	1020-1027
conducted	O	1028-1037
elsewhere	O	1038-1047
,	O	1047-1048
produced	O	1049-1057
very	O	1058-1062
little	O	1063-1069
MHb	O	1070-1073
(	O	1074-1075
mean	O	1075-1079
<	O	1080-1081
2	O	1082-1083
.	O	1083-1084
0	O	1084-1085
%	O	1085-1086
)	O	1086-1087
in	O	1088-1090
the	O	1091-1094
rhesus	O	1095-1101
monkey	O	1102-1108
.	O	1108-1109

Furthermore	O	1110-1121
,	O	1121-1122
transient	O	1123-1132
hemoglobinuria	B	1133-1147
was	O	1148-1151
noted	O	1152-1157
approximately	O	1158-1171
60	O	1172-1174
minutes	O	1175-1182
postinjection	O	1183-1196
of	O	1197-1199
WR242511	O	1200-1208
(	O	1209-1210
3	O	1210-1211
.	O	1211-1212
5	O	1212-1213
or	O	1214-1216
7	O	1217-1218
.	O	1218-1219
0	O	1219-1220
mg	O	1221-1223
/	O	1223-1224
kg	O	1224-1226
)	O	1226-1227
,	O	1227-1228
and	O	1229-1232
2	O	1233-1234
lethalities	O	1235-1246
occurred	O	1247-1255
(	O	1256-1257
one	O	1257-1260
IV	O	1261-1263
and	O	1264-1267
one	O	1268-1271
PO	O	1272-1274
)	O	1274-1275
following	O	1276-1285
the	O	1286-1289
7	O	1290-1291
.	O	1291-1292
0	O	1292-1293
mg	O	1294-1296
/	O	1296-1297
kg	O	1297-1299
dose	O	1300-1304
.	O	1304-1305

Myoglobinuria	B	1306-1319
was	O	1320-1323
also	O	1324-1328
observed	O	1329-1337
following	O	1338-1347
the	O	1348-1351
7	O	1352-1353
.	O	1353-1354
0	O	1354-1355
mg	O	1356-1358
/	O	1358-1359
kg	O	1359-1361
dose	O	1362-1366
.	O	1366-1367

Histopathology	O	1368-1382
analyses	O	1383-1391
in	O	1392-1394
the	O	1395-1398
2	O	1399-1400
animals	O	1401-1408
that	O	1409-1413
died	O	1414-1418
revealed	O	1419-1427
liver	B	1428-1433
and	I	1434-1437
kidney	I	1438-1444
toxicity	I	1445-1453
,	O	1453-1454
with	O	1455-1459
greater	O	1460-1467
severity	O	1468-1476
in	O	1477-1479
the	O	1480-1483
orally	O	1484-1490
-	O	1490-1491
treated	O	1491-1498
animal	O	1499-1505
.	O	1505-1506

CONCLUSIONS	O	1507-1518
:	O	1518-1519
These	O	1520-1525
data	O	1526-1530
demonstrate	O	1531-1542
direct	O	1543-1549
and	O	1550-1553
/	O	1553-1554
or	O	1554-1556
indirect	O	1557-1565
drug	O	1566-1570
-	O	1570-1571
induced	O	1571-1578
toxicity	B	1579-1587
.	O	1587-1588

It	O	1589-1591
is	O	1592-1594
concluded	O	1595-1604
that	O	1605-1609
WR242511	O	1610-1618
should	O	1619-1625
not	O	1626-1629
be	O	1630-1632
pursued	O	1633-1640
as	O	1641-1643
a	O	1644-1645
pretreatment	O	1646-1658
for	O	1659-1662
CN	O	1663-1665
poisoning	B	1666-1675
unless	O	1676-1682
the	O	1683-1686
anti	O	1687-1691
-	O	1691-1692
CN	O	1692-1694
characteristics	O	1695-1710
of	O	1711-1713
this	O	1714-1718
compound	O	1719-1727
can	O	1728-1731
be	O	1732-1734
successfully	O	1735-1747
dissociated	O	1748-1759
from	O	1760-1764
those	O	1765-1770
producing	O	1771-1780
undesirable	O	1781-1792
toxicity	B	1793-1801
.	O	1801-1802

Neuroplasticity	O	0-15
of	O	16-18
the	O	19-22
adult	O	23-28
primate	O	29-36
auditory	O	37-45
cortex	O	46-52
following	O	53-62
cochlear	O	63-71
hearing	B	72-79
loss	I	80-84
.	O	84-85

Tonotopic	O	86-95
organization	O	96-108
is	O	109-111
an	O	112-114
essential	O	115-124
feature	O	125-132
of	O	133-135
the	O	136-139
primary	O	140-147
auditory	O	148-156
area	O	157-161
(	O	162-163
A1	O	163-165
)	O	165-166
of	O	167-169
primate	O	170-177
cortex	O	178-184
.	O	184-185

In	O	186-188
A1	O	189-191
of	O	192-194
macaque	O	195-202
monkeys	O	203-210
,	O	210-211
low	O	212-215
frequencies	O	216-227
are	O	228-231
represented	O	232-243
rostrolaterally	O	244-259
and	O	260-263
high	O	264-268
frequencies	O	269-280
are	O	281-284
represented	O	285-296
caudomedially	O	297-310
.	O	310-311

The	O	312-315
purpose	O	316-323
of	O	324-326
this	O	327-331
study	O	332-337
was	O	338-341
to	O	342-344
determine	O	345-354
if	O	355-357
changes	O	358-365
occur	O	366-371
in	O	372-374
this	O	375-379
tonotopic	O	380-389
organization	O	390-402
following	O	403-412
cochlear	O	413-421
hearing	B	422-429
loss	I	430-434
.	O	434-435

Under	O	436-441
anesthesia	O	442-452
,	O	452-453
the	O	454-457
superior	O	458-466
temporal	O	467-475
gyrus	O	476-481
of	O	482-484
adult	O	485-490
macaque	O	491-498
monkeys	O	499-506
was	O	507-510
exposed	O	511-518
,	O	518-519
and	O	520-523
the	O	524-527
tonotopic	O	528-537
organization	O	538-550
of	O	551-553
A1	O	554-556
was	O	557-560
mapped	O	561-567
using	O	568-573
conventional	O	574-586
microelectrode	O	587-601
recording	O	602-611
techniques	O	612-622
.	O	622-623

Following	O	624-633
recovery	O	634-642
,	O	642-643
the	O	644-647
monkeys	O	648-655
were	O	656-660
selectively	O	661-672
deafened	O	673-681
for	O	682-685
high	O	686-690
frequencies	O	691-702
using	O	703-708
kanamycin	O	709-718
and	O	719-722
furosemide	O	723-733
.	O	733-734

The	O	735-738
actual	O	739-745
frequencies	O	746-757
deafened	O	758-766
were	O	767-771
determined	O	772-782
by	O	783-785
the	O	786-789
loss	O	790-794
of	O	795-797
tone	O	798-802
-	O	802-803
burst	O	803-808
elicited	O	809-817
auditory	O	818-826
brainstem	O	827-836
responses	O	837-846
.	O	846-847

Three	O	848-853
months	O	854-860
after	O	861-866
deafening	O	867-876
,	O	876-877
A1	O	878-880
was	O	881-884
remapped	O	885-893
.	O	893-894

Postmortem	O	895-905
cytoarchitectural	O	906-923
features	O	924-932
identifying	O	933-944
A1	O	945-947
were	O	948-952
correlated	O	953-963
with	O	964-968
the	O	969-972
electrophysiologic	O	973-991
data	O	992-996
.	O	996-997

The	O	998-1001
results	O	1002-1009
indicate	O	1010-1018
that	O	1019-1023
the	O	1024-1027
deprived	O	1028-1036
area	O	1037-1041
of	O	1042-1044
A1	O	1045-1047
undergoes	O	1048-1057
extensive	O	1058-1067
reorganization	O	1068-1082
and	O	1083-1086
becomes	O	1087-1094
responsive	O	1095-1105
to	O	1106-1108
intact	O	1109-1115
cochlear	O	1116-1124
frequencies	O	1125-1136
.	O	1136-1137

The	O	1138-1141
region	O	1142-1148
of	O	1149-1151
cortex	O	1152-1158
that	O	1159-1163
represents	O	1164-1174
the	O	1175-1178
low	O	1179-1182
frequencies	O	1183-1194
was	O	1195-1198
not	O	1199-1202
obviously	O	1203-1212
affected	O	1213-1221
by	O	1222-1224
the	O	1225-1228
cochlear	O	1229-1237
hearing	B	1238-1245
loss	I	1246-1250
.	O	1250-1251

The	O	0-3
site	O	4-8
of	O	9-11
common	O	12-18
side	O	19-23
effects	O	24-31
of	O	32-34
sumatriptan	O	35-46
.	O	46-47

Atypical	B	48-56
sensations	I	57-67
following	O	68-77
the	O	78-81
use	O	82-85
of	O	86-88
subcutaneous	O	89-101
sumatriptan	O	102-113
are	O	114-117
common	O	118-124
,	O	124-125
but	O	126-129
of	O	130-132
uncertain	O	133-142
origin	O	143-149
.	O	149-150

They	O	151-155
are	O	156-159
almost	O	160-166
always	O	167-173
benign	O	174-180
,	O	180-181
but	O	182-185
can	O	186-189
be	O	190-192
mistaken	O	193-201
for	O	202-205
a	O	206-207
serious	O	208-215
adverse	O	216-223
event	O	224-229
by	O	230-232
the	O	233-236
patient	O	237-244
.	O	244-245

Two	O	246-249
patients	O	250-258
are	O	259-262
presented	O	263-272
with	O	273-277
tingling	B	278-286
or	I	287-289
burning	I	290-297
sensations	I	298-308
limited	O	309-316
to	O	317-319
areas	O	320-325
of	O	326-328
heat	O	329-333
exposure	O	334-342
or	O	343-345
sunburn	B	346-353
.	O	353-354

In	O	355-357
these	O	358-363
individuals	O	364-375
,	O	375-376
side	O	377-381
effects	O	382-389
are	O	390-393
most	O	394-398
likely	O	399-405
generated	O	406-415
superficially	O	416-429
in	O	430-432
the	O	433-436
skin	O	437-441
.	O	441-442

Tremor	B	0-6
side	O	7-11
effects	O	12-19
of	O	20-22
salbutamol	O	23-33
,	O	33-34
quantified	O	35-45
by	O	46-48
a	O	49-50
laser	O	51-56
pointer	O	57-64
technique	O	65-74
.	O	74-75

OBJECTIVE	O	76-85
:	O	85-86
To	O	87-89
study	O	90-95
tremor	B	96-102
side	O	103-107
effects	O	108-115
of	O	116-118
salbutamol	O	119-129
an	O	130-132
easily	O	133-139
applicable	O	140-150
,	O	150-151
quick	O	152-157
and	O	158-161
low	O	162-165
-	O	165-166
priced	O	166-172
method	O	173-179
is	O	180-182
needed	O	183-189
.	O	189-190

A	O	191-192
new	O	193-196
method	O	197-203
using	O	204-209
a	O	210-211
commercially	O	212-224
available	O	225-234
,	O	234-235
pen	O	236-239
-	O	239-240
shaped	O	240-246
laser	O	247-252
pointer	O	253-260
was	O	261-264
developed	O	265-274
.	O	274-275

Aim	O	276-279
of	O	280-282
the	O	283-286
study	O	287-292
was	O	293-296
to	O	297-299
determine	O	300-309
sensitivity	O	310-321
,	O	321-322
reproducibility	O	323-338
,	O	338-339
reference	O	340-349
values	O	350-356
and	O	357-360
the	O	361-364
agreement	O	365-374
with	O	375-379
a	O	380-381
questionnaire	O	382-395
.	O	395-396

METHODS	O	397-404
:	O	404-405
Tremor	B	406-412
was	O	413-416
measured	O	417-425
using	O	426-431
a	O	432-433
laser	O	434-439
pointer	O	440-447
technique	O	448-457
.	O	457-458

To	O	459-461
determine	O	462-471
sensitivity	O	472-483
we	O	484-486
assessed	O	487-495
tremor	B	496-502
in	O	503-505
44	O	506-508
patients	O	509-517
with	O	518-522
obstructive	B	523-534
lung	I	535-539
disease	I	540-547
after	O	548-553
administration	O	554-568
of	O	569-571
cumulative	O	572-582
doses	O	583-588
of	O	589-591
salbutamol	O	592-602
.	O	602-603

Subjects	O	604-612
were	O	613-617
asked	O	618-623
to	O	624-626
aim	O	627-630
at	O	631-633
the	O	634-637
centre	O	638-644
of	O	645-647
a	O	648-649
target	O	650-656
,	O	656-657
subdivided	O	658-668
in	O	669-671
concentric	O	672-682
circles	O	683-690
,	O	690-691
from	O	692-696
5	O	697-698
m	O	699-700
distance	O	701-709
.	O	709-710

The	O	711-714
circle	O	715-721
in	O	722-724
which	O	725-730
the	O	731-734
participant	O	735-746
succeeded	O	747-756
to	O	757-759
aim	O	760-763
was	O	764-767
recorded	O	768-776
in	O	777-779
millimetres	O	780-791
radius	O	792-798
.	O	798-799

In	O	800-802
another	O	803-810
series	O	811-817
of	O	818-820
measurements	O	821-833
,	O	833-834
reproducibility	O	835-850
and	O	851-854
reference	O	855-864
values	O	865-871
of	O	872-874
the	O	875-878
tremor	B	879-885
was	O	886-889
assessed	O	890-898
in	O	899-901
65	O	902-904
healthy	O	905-912
subjects	O	913-921
in	O	922-924
three	O	925-930
sessions	O	931-939
,	O	939-940
at	O	941-943
9	O	944-945
a	O	946-947
.	O	947-948
m	O	948-949
.	O	947-948
,	O	950-951
4	O	952-953
p	O	954-955
.	O	955-956
m	O	956-957
.	O	955-956
and	O	959-962
9	O	963-964
a	O	965-966
.	O	966-967
m	O	967-968
.	O	966-967
,	O	969-970
respectively	O	971-983
,	O	983-984
1	O	985-986
week	O	987-991
later	O	992-997
.	O	997-998

Postural	O	999-1007
tremor	B	1008-1014
was	O	1015-1018
measured	O	1019-1027
with	O	1028-1032
the	O	1033-1036
arm	O	1037-1040
horizontally	O	1041-1053
outstretched	O	1054-1066
rest	O	1067-1071
tremor	B	1072-1078
with	O	1079-1083
the	O	1084-1087
arm	O	1088-1091
supported	O	1092-1101
by	O	1102-1104
an	O	1105-1107
armrest	O	1108-1115
and	O	1116-1119
finally	O	1120-1127
tremor	B	1128-1134
was	O	1135-1138
measured	O	1139-1147
after	O	1148-1153
holding	O	1154-1161
a	O	1162-1163
2	O	1164-1165
-	O	1165-1166
kg	O	1166-1168
weight	O	1169-1175
until	O	1176-1181
exhaustion	O	1182-1192
.	O	1192-1193

Inter	O	1194-1199
-	O	1199-1200
observer	O	1200-1208
variability	O	1209-1220
was	O	1221-1224
measured	O	1225-1233
in	O	1234-1236
a	O	1237-1238
series	O	1239-1245
of	O	1246-1248
10	O	1249-1251
healthy	O	1252-1259
subjects	O	1260-1268
.	O	1268-1269

Tremor	B	1270-1276
was	O	1277-1280
measured	O	1281-1289
simultaneously	O	1290-1304
by	O	1305-1307
two	O	1308-1311
independent	O	1312-1323
observers	O	1324-1333
.	O	1333-1334

RESULTS	O	1335-1342
:	O	1342-1343
Salbutamol	O	1344-1354
significantly	O	1355-1368
increased	O	1369-1378
tremor	B	1379-1385
severity	O	1386-1394
in	O	1395-1397
patients	O	1398-1406
in	O	1407-1409
a	O	1410-1411
dose	O	1412-1416
-	O	1416-1417
dependent	O	1417-1426
way	O	1427-1430
.	O	1430-1431

Within	O	1432-1438
healthy	O	1439-1446
adults	O	1447-1453
no	O	1454-1456
age	O	1457-1460
-	O	1460-1461
dependency	O	1461-1471
could	O	1472-1477
be	O	1478-1480
found	O	1481-1486
(	O	1487-1488
b	O	1488-1489
=	O	1490-1491
0	O	1492-1493
.	O	1493-1494
262	O	1494-1497
mm	O	1498-1500
/	O	1500-1501
year	O	1501-1505
;	O	1505-1506
P	O	1507-1508
=	O	1509-1510
0	O	1511-1512
.	O	1512-1513
72	O	1513-1515
)	O	1515-1516
.	O	1512-1513

There	O	1518-1523
was	O	1524-1527
no	O	1528-1530
agreement	O	1531-1540
between	O	1541-1548
the	O	1549-1552
questionnaire	O	1553-1566
and	O	1567-1570
tremor	B	1571-1577
severity	O	1578-1586
(	O	1587-1588
r	O	1588-1589
=	O	1590-1591
0	O	1592-1593
.	O	1593-1594
093	O	1594-1597
;	O	1597-1598
P	O	1599-1600
=	O	1601-1602
0	O	1603-1604
.	O	1604-1605
53	O	1605-1607
)	O	1607-1608
.	O	1604-1605

Postural	O	1610-1618
tremor	B	1619-1625
showed	O	1626-1632
no	O	1633-1635
significant	O	1636-1647
difference	O	1648-1658
between	O	1659-1666
the	O	1667-1670
first	O	1671-1676
and	O	1677-1680
third	O	1681-1686
session	O	1687-1694
(	O	1695-1696
P	O	1696-1697
=	O	1698-1699
0	O	1700-1701
.	O	1701-1702
07	O	1702-1704
)	O	1704-1705
.	O	1701-1702

Support	O	1707-1714
of	O	1715-1717
the	O	1718-1721
arm	O	1722-1725
decreased	O	1726-1735
tremor	B	1736-1742
severity	O	1743-1751
,	O	1751-1752
exhaustion	O	1753-1763
increased	O	1764-1773
tremor	B	1774-1780
severity	O	1781-1789
significantly	O	1790-1803
.	O	1803-1804

A	O	1805-1806
good	O	1807-1811
agreement	O	1812-1821
was	O	1822-1825
found	O	1826-1831
between	O	1832-1839
two	O	1840-1843
independent	O	1844-1855
observers	O	1856-1865
(	O	1866-1867
interclass	O	1867-1877
correlation	O	1878-1889
coefficient	O	1890-1901
0	O	1902-1903
.	O	1903-1904
72	O	1904-1906
)	O	1906-1907
.	O	1903-1904

DISCUSSION	O	1909-1919
:	O	1919-1920
Quantifying	O	1921-1932
tremor	B	1933-1939
by	O	1940-1942
using	O	1943-1948
an	O	1949-1951
inexpensive	O	1952-1963
laser	O	1964-1969
pointer	O	1970-1977
is	O	1978-1980
,	O	1980-1981
with	O	1982-1986
the	O	1987-1990
exception	O	1991-2000
of	O	2001-2003
children	O	2004-2012
(	O	2013-2014
<	O	2014-2015
12	O	2015-2017
years	O	2018-2023
)	O	2023-2024
a	O	2025-2026
sensitive	O	2027-2036
and	O	2037-2040
reproducible	O	2041-2053
method	O	2054-2060
.	O	2060-2061

Increased	O	0-9
frequency	O	10-19
of	O	20-22
venous	B	23-29
thromboembolism	I	30-45
with	O	46-50
the	O	51-54
combination	O	55-66
of	O	67-69
docetaxel	O	70-79
and	O	80-83
thalidomide	O	84-95
in	O	96-98
patients	O	99-107
with	O	108-112
metastatic	O	113-123
androgen	O	124-132
-	O	132-133
independent	O	133-144
prostate	B	145-153
cancer	I	154-160
.	O	160-161

STUDY	O	162-167
OBJECTIVE	O	168-177
:	O	177-178
To	O	179-181
evaluate	O	182-190
the	O	191-194
frequency	O	195-204
of	O	205-207
venous	B	208-214
thromboembolism	I	215-230
(	O	231-232
VTE	B	232-235
)	O	235-236
in	O	237-239
patients	O	240-248
with	O	249-253
advanced	O	254-262
androgen	O	263-271
-	O	271-272
independent	O	272-283
prostate	B	284-292
cancer	I	293-299
who	O	300-303
were	O	304-308
treated	O	309-316
with	O	317-321
docetaxel	O	322-331
alone	O	332-337
or	O	338-340
in	O	341-343
combination	O	344-355
with	O	356-360
thalidomide	O	361-372
.	O	372-373

DESIGN	O	374-380
:	O	380-381
Retrospective	O	382-395
analysis	O	396-404
of	O	405-407
a	O	408-409
randomized	O	410-420
phase	O	421-426
II	O	427-429
trial	O	430-435
.	O	435-436

SETTING	O	437-444
:	O	444-445
National	O	446-454
Institutes	O	455-465
of	O	466-468
Health	O	469-475
clinical	O	476-484
research	O	485-493
center	O	494-500
.	O	500-501

PATIENTS	O	502-510
:	O	510-511
Seventy	O	512-519
men	O	520-523
,	O	523-524
aged	O	525-529
50	O	530-532
-	O	532-533
80	O	533-535
years	O	536-541
,	O	541-542
with	O	543-547
advanced	O	548-556
androgen	O	557-565
-	O	565-566
independent	O	566-577
prostate	B	578-586
cancer	I	587-593
.	O	593-594

INTERVENTION	O	595-607
:	O	607-608
Each	O	609-613
patient	O	614-621
received	O	622-630
either	O	631-637
intravenous	O	638-649
docetaxel	O	650-659
30	O	660-662
mg	O	663-665
/	O	665-666
m2	O	666-668
/	O	665-666
week	O	669-673
for	O	674-677
3	O	678-679
consecutive	O	680-691
weeks	O	692-697
,	O	697-698
followed	O	699-707
by	O	708-710
1	O	711-712
week	O	713-717
off	O	718-721
,	O	721-722
or	O	723-725
the	O	726-729
combination	O	730-741
of	O	742-744
continuous	O	745-755
oral	O	756-760
thalidomide	O	761-772
200	O	773-776
mg	O	777-779
every	O	780-785
evening	O	786-793
plus	O	794-798
the	O	799-802
same	O	803-807
docetaxel	O	808-817
regimen	O	818-825
.	O	825-826

This	O	827-831
4	O	832-833
-	O	833-834
week	O	834-838
cycle	O	839-844
was	O	845-848
repeated	O	849-857
until	O	858-863
there	O	864-869
was	O	870-873
evidence	O	874-882
of	O	883-885
excessive	O	886-895
toxicity	B	896-904
or	O	905-907
disease	O	908-915
progression	O	916-927
.	O	927-928

MEASUREMENTS	O	929-941
AND	O	942-945
MAIN	O	946-950
RESULTS	O	951-958
:	O	958-959
None	O	960-964
of	O	965-967
23	O	968-970
patients	O	971-979
who	O	980-983
received	O	984-992
docetaxel	O	993-1002
alone	O	1003-1008
developed	O	1009-1018
VTE	B	1019-1022
,	O	1022-1023
whereas	O	1024-1031
9	O	1032-1033
of	O	1034-1036
47	O	1037-1039
patients	O	1040-1048
(	O	1049-1050
19	O	1050-1052
%	O	1052-1053
)	O	1053-1054
who	O	1055-1058
received	O	1059-1067
docetaxel	O	1068-1077
plus	O	1078-1082
thalidomide	O	1083-1094
developed	O	1095-1104
VTE	B	1105-1108
(	O	1109-1110
p	O	1110-1111
=	O	1111-1112
0	O	1112-1113
.	O	1113-1114
025	O	1114-1117
)	O	1117-1118
.	O	1113-1114

CONCLUSION	O	1120-1130
:	O	1130-1131
The	O	1132-1135
addition	O	1136-1144
of	O	1145-1147
thalidomide	O	1148-1159
to	O	1160-1162
docetaxel	O	1163-1172
in	O	1173-1175
the	O	1176-1179
treatment	O	1180-1189
of	O	1190-1192
prostate	B	1193-1201
cancer	I	1202-1208
significantly	O	1209-1222
increases	O	1223-1232
the	O	1233-1236
frequency	O	1237-1246
of	O	1247-1249
VTE	B	1250-1253
.	O	1253-1254

Clinicians	O	1255-1265
should	O	1266-1272
be	O	1273-1275
aware	O	1276-1281
of	O	1282-1284
this	O	1285-1289
potential	O	1290-1299
complication	O	1300-1312
when	O	1313-1317
adding	O	1318-1324
thalidomide	O	1325-1336
to	O	1337-1339
chemotherapeutic	O	1340-1356
regimens	O	1357-1365
.	O	1365-1366

Sublingual	O	0-10
absorption	O	11-21
of	O	22-24
the	O	25-28
quaternary	O	29-39
ammonium	O	40-48
antiarrhythmic	O	49-63
agent	O	64-69
,	O	69-70
UM	O	71-73
-	O	73-74
272	O	74-77
.	O	77-78

UM	O	79-81
-	O	81-82
272	O	82-85
(	O	86-87
N	O	87-88
,	O	88-89
N	O	87-88
-	O	90-91
dimethylpropranolol	O	91-110
)	O	110-111
,	O	88-89
a	O	113-114
quaternary	O	115-125
antiarrhythmic	O	126-140
agent	O	141-146
,	O	146-147
was	O	148-151
administered	O	152-164
sublingually	O	165-177
to	O	178-180
dogs	O	181-185
with	O	186-190
ouabain	O	191-198
-	O	198-199
induced	O	199-206
ventricular	B	207-218
tachycardias	I	219-231
.	O	231-232

Both	O	233-237
anti	O	238-242
-	O	242-243
arrhythmic	O	243-253
efficacy	O	254-262
and	O	263-266
bioavailability	O	267-282
were	O	283-287
compared	O	288-296
to	O	297-299
oral	O	300-304
drug	O	305-309
.	O	309-310

Sublingual	O	311-321
UM	O	322-324
-	O	324-325
272	O	325-328
converted	O	329-338
ventricular	B	339-350
tachycardia	I	351-362
to	O	363-365
sinus	O	366-371
rhythm	O	372-378
in	O	379-381
all	O	382-385
5	O	386-387
dogs	O	388-392
.	O	392-393

The	O	394-397
area	O	398-402
under	O	403-408
the	O	409-412
plasma	O	413-419
concentration	O	420-433
time	O	434-438
curve	O	439-444
at	O	445-447
90	O	448-450
min	O	451-454
was	O	455-458
4	O	459-460
-	O	460-461
12	O	461-463
times	O	464-469
greater	O	470-477
than	O	478-482
for	O	483-486
oral	O	487-491
drug	O	492-496
,	O	496-497
suggesting	O	498-508
the	O	509-512
existence	O	513-522
of	O	523-525
an	O	526-528
absorption	O	529-539
-	O	539-540
limiting	O	540-548
process	O	549-556
in	O	557-559
the	O	560-563
intestine	O	564-573
,	O	573-574
and	O	575-578
providing	O	579-588
an	O	589-591
alternate	O	592-601
form	O	602-606
of	O	607-609
administration	O	610-624
for	O	625-628
quaternary	O	629-639
drugs	O	640-645
.	O	645-646

Severe	O	0-6
thrombocytopenia	B	7-23
and	O	24-27
haemolytic	B	28-38
anaemia	I	39-46
associated	O	47-57
with	O	58-62
ciprofloxacin	O	63-76
:	O	76-77
a	O	78-79
case	O	80-84
report	O	85-91
with	O	92-96
fatal	O	97-102
outcome	O	103-110
.	O	110-111

Haematological	O	112-126
adverse	O	127-134
reactions	O	135-144
associated	O	145-155
with	O	156-160
fatal	O	161-166
outcome	O	167-174
are	O	175-178
rare	O	179-183
during	O	184-190
treatment	O	191-200
with	O	201-205
ciprofloxacin	O	206-219
.	O	219-220

A	O	221-222
30	O	223-225
-	O	225-226
year	O	226-230
old	O	231-234
Caucasian	O	235-244
man	O	245-248
reported	O	249-257
with	O	258-262
abdominal	B	263-272
pain	I	273-277
and	O	278-281
jaundice	B	282-290
after	O	291-296
3	O	297-298
-	O	298-299
day	O	299-302
administration	O	303-317
of	O	318-320
oral	O	321-325
ciprofloxacin	O	326-339
for	O	340-343
a	O	344-345
suspect	O	346-353
of	O	354-356
urinary	B	357-364
tract	I	365-370
infection	I	371-380
.	O	380-381

Clinical	O	382-390
evaluations	O	391-402
suggested	O	403-412
an	O	413-415
initial	O	416-423
diagnosis	O	424-433
of	O	434-436
severe	O	437-443
thrombocytopenia	B	444-460
and	O	461-464
haemolysis	B	465-475
.	O	475-476

The	O	477-480
patient	O	481-488
progressively	O	489-502
developed	O	503-512
petechiae	B	513-522
and	O	523-526
purpura	B	527-534
on	O	535-537
thorax	O	538-544
and	O	545-548
lower	O	549-554
limbs	O	555-560
.	O	560-561

Despite	O	562-569
pharmacological	O	570-585
and	O	586-589
supportive	O	590-600
interventions	O	601-614
,	O	614-615
laboratory	O	616-626
parameters	O	627-637
worsened	O	638-646
and	O	647-650
the	O	651-654
patient	O	655-662
died	O	663-667
17	O	668-670
hours	O	671-676
after	O	677-682
admission	O	683-692
.	O	692-693

An	O	694-696
accurate	O	697-705
autopsy	O	706-713
revealed	O	714-722
most	O	723-727
organs	O	728-734
with	O	735-739
diffuse	O	740-747
petechial	O	748-757
haemorrhages	B	758-770
.	O	770-771

No	O	772-774
signs	O	775-780
of	O	781-783
bone	B	784-788
marrow	I	789-795
depression	I	796-806
were	O	807-811
found	O	812-817
.	O	817-818

No	O	819-821
thrombi	B	822-829
or	O	830-832
signs	O	833-838
of	O	839-841
microangiopathies	B	842-859
were	O	860-864
observed	O	865-873
in	O	874-876
arterial	O	877-885
vessels	O	886-893
.	O	893-894

Blood	O	895-900
and	O	901-904
urine	O	905-910
cultures	O	911-919
did	O	920-923
not	O	924-927
show	O	928-932
any	O	933-936
bacterial	O	937-946
growth	O	947-953
.	O	953-954

This	O	955-959
case	O	960-964
report	O	965-971
shows	O	972-977
that	O	978-982
ciprofloxacin	O	983-996
may	O	997-1000
precipitate	O	1001-1012
life	O	1013-1017
-	O	1017-1018
threatening	O	1018-1029
thrombocytopenia	B	1030-1046
and	O	1047-1050
haemolytic	B	1051-1061
anaemia	I	1062-1069
,	O	1069-1070
even	O	1071-1075
in	O	1076-1078
the	O	1079-1082
early	O	1083-1088
phases	O	1089-1095
of	O	1096-1098
treatment	O	1099-1108
and	O	1109-1112
without	O	1113-1120
apparent	O	1121-1129
previous	O	1130-1138
exposures	O	1139-1148
.	O	1148-1149

Simvastatin	O	0-11
-	O	11-12
induced	O	12-19
bilateral	O	20-29
leg	O	30-33
compartment	B	34-45
syndrome	I	46-54
and	O	55-58
myonecrosis	B	59-70
associated	O	71-81
with	O	82-86
hypothyroidism	B	87-101
.	O	101-102

A	O	103-104
54	O	105-107
-	O	107-108
year	O	108-112
-	O	107-108
old	O	113-116
hypothyroid	B	117-128
male	O	129-133
taking	O	134-140
thyroxine	O	141-150
and	O	151-154
simvastatin	O	155-166
presented	O	167-176
with	O	177-181
bilateral	O	182-191
leg	O	192-195
compartment	B	196-207
syndrome	I	208-216
and	O	217-220
myonecrosis	B	221-232
.	O	232-233

Urgent	O	234-240
fasciotomies	O	241-253
were	O	254-258
performed	O	259-268
and	O	269-272
the	O	273-276
patient	O	277-284
made	O	285-289
an	O	290-292
uneventful	O	293-303
recovery	O	304-312
with	O	313-317
the	O	318-321
withdrawal	O	322-332
of	O	333-335
simvastatin	O	336-347
.	O	347-348

It	O	349-351
is	O	352-354
likely	O	355-361
that	O	362-366
this	O	367-371
complication	O	372-384
will	O	385-389
be	O	390-392
seen	O	393-397
more	O	398-402
often	O	403-408
with	O	409-413
the	O	414-417
increased	O	418-427
worldwide	O	428-437
use	O	438-441
of	O	442-444
this	O	445-449
drug	O	450-454
and	O	455-458
its	O	459-462
approval	O	463-471
for	O	472-475
all	O	476-479
arteriopathic	B	480-493
patients	O	494-502
.	O	502-503

Bile	B	0-4
duct	I	5-9
hamartoma	I	10-19
occurring	O	20-29
in	O	30-32
association	O	33-44
with	O	45-49
long	O	50-54
-	O	54-55
term	O	55-59
treatment	O	60-69
with	O	70-74
danazol	O	75-82
.	O	82-83

We	O	84-86
report	O	87-93
a	O	94-95
case	O	96-100
of	O	101-103
bile	B	104-108
duct	I	109-113
hamartoma	I	114-123
which	O	124-129
developed	O	130-139
in	O	140-142
a	O	143-144
patient	O	145-152
who	O	153-156
had	O	157-160
been	O	161-165
on	O	166-168
long	O	169-173
-	O	173-174
term	O	174-178
danazol	O	179-186
treatment	O	187-196
.	O	196-197

Such	O	198-202
patients	O	203-211
should	O	212-218
be	O	219-221
under	O	222-227
close	O	228-233
follow	O	234-240
-	O	240-241
up	O	241-243
,	O	243-244
preferably	O	245-255
with	O	256-260
periodic	O	261-269
ultrasound	O	270-280
examination	O	281-292
of	O	293-295
the	O	296-299
liver	O	300-305
.	O	305-306

If	O	307-309
the	O	310-313
patient	O	314-321
develops	O	322-330
a	O	331-332
liver	B	333-338
mass	I	339-343
,	O	343-344
because	O	345-352
of	O	353-355
non	O	356-359
-	O	359-360
specific	O	360-368
clinical	O	369-377
features	O	378-386
and	O	387-390
imaging	O	391-398
appearances	O	399-410
,	O	410-411
biopsy	O	412-418
may	O	419-422
be	O	423-425
the	O	426-429
only	O	430-434
way	O	435-438
to	O	439-441
achieve	O	442-449
a	O	450-451
definitive	O	452-462
diagnosis	O	463-472
.	O	472-473

Granulomatous	B	0-13
hepatitis	I	14-23
due	O	24-27
to	O	28-30
combination	O	31-42
of	O	43-45
amoxicillin	O	46-57
and	O	58-61
clavulanic	O	62-72
acid	O	73-77
.	O	77-78

We	O	79-81
report	O	82-88
the	O	89-92
case	O	93-97
of	O	98-100
a	O	101-102
patient	O	103-110
with	O	111-115
amoxicillin	O	116-127
-	O	127-128
clavulanic	O	128-138
acid	O	139-143
-	O	143-144
induced	O	144-151
hepatitis	B	152-161
with	O	162-166
histologic	O	167-177
multiple	O	178-186
granulomas	B	187-197
.	O	197-198

This	O	199-203
type	O	204-208
of	O	209-211
lesion	O	212-218
broadens	O	219-227
the	O	228-231
spectrum	O	232-240
of	O	241-243
liver	B	244-249
injury	I	250-256
due	O	257-260
to	O	261-263
this	O	264-268
drug	O	269-273
combination	O	274-285
,	O	285-286
mainly	O	287-293
represented	O	294-305
by	O	306-308
a	O	309-310
benign	O	311-317
cholestatic	B	318-329
syndrome	I	330-338
.	O	338-339

The	O	340-343
association	O	344-355
of	O	356-358
granulomas	B	359-369
and	O	370-373
eosinophilia	B	374-386
favor	O	387-392
an	O	393-395
immunoallergic	O	396-410
mechanism	O	411-420
.	O	420-421

As	O	422-424
penicillin	O	425-435
derivatives	O	436-447
and	O	448-451
amoxicillin	O	452-463
alone	O	464-469
are	O	470-473
known	O	474-479
to	O	480-482
induce	O	483-489
such	O	490-494
types	O	495-500
of	O	501-503
lesions	O	504-511
,	O	511-512
the	O	513-516
amoxicillin	O	517-528
component	O	529-538
,	O	538-539
with	O	540-544
or	O	545-547
without	O	548-555
a	O	556-557
potentiating	O	558-570
effect	O	571-577
of	O	578-580
clavulanic	O	581-591
acid	O	592-596
,	O	596-597
might	O	598-603
have	O	604-608
a	O	609-610
major	O	611-616
role	O	617-621
.	O	621-622

Intracranial	B	0-12
aneurysms	I	13-22
and	O	23-26
cocaine	B	27-34
abuse	I	35-40
:	O	40-41
analysis	O	42-50
of	O	51-53
prognostic	O	54-64
indicators	O	65-75
.	O	75-76

OBJECTIVE	O	77-86
:	O	86-87
The	O	88-91
outcome	O	92-99
of	O	100-102
subarachnoid	B	103-115
hemorrhage	I	116-126
associated	O	127-137
with	O	138-142
cocaine	B	143-150
abuse	I	151-156
is	O	157-159
reportedly	O	160-170
poor	O	171-175
.	O	175-176

However	O	177-184
,	O	184-185
no	O	186-188
study	O	189-194
in	O	195-197
the	O	198-201
literature	O	202-212
has	O	213-216
reported	O	217-225
the	O	226-229
use	O	230-233
of	O	234-236
a	O	237-238
statistical	O	239-250
model	O	251-256
to	O	257-259
analyze	O	260-267
the	O	268-271
variables	O	272-281
that	O	282-286
influence	O	287-296
outcome	O	297-304
.	O	304-305

METHODS	O	306-313
:	O	313-314
A	O	315-316
review	O	317-323
of	O	324-326
admissions	O	327-337
during	O	338-344
a	O	345-346
6	O	347-348
-	O	348-349
year	O	349-353
period	O	354-360
revealed	O	361-369
14	O	370-372
patients	O	373-381
with	O	382-386
cocaine	O	387-394
-	O	394-395
related	O	395-402
aneurysms	B	403-412
.	O	412-413

This	O	414-418
group	O	419-424
was	O	425-428
compared	O	429-437
with	O	438-442
a	O	443-444
control	O	445-452
group	O	453-458
of	O	459-461
135	O	462-465
patients	O	466-474
with	O	475-479
ruptured	B	480-488
aneurysms	I	489-498
and	O	499-502
no	O	503-505
history	O	506-513
of	O	514-516
cocaine	B	517-524
abuse	I	525-530
.	O	530-531

Age	O	532-535
at	O	536-538
presentation	O	539-551
,	O	551-552
time	O	553-557
of	O	558-560
ictus	O	561-566
after	O	567-572
intoxication	O	573-585
,	O	585-586
Hunt	O	587-591
and	O	592-595
Hess	O	596-600
grade	O	601-606
of	O	607-609
subarachnoid	B	610-622
hemorrhage	I	623-633
,	O	633-634
size	O	635-639
of	O	640-642
the	O	643-646
aneurysm	B	647-655
,	O	655-656
location	O	657-665
of	O	666-668
the	O	669-672
aneurysm	B	673-681
,	O	681-682
and	O	683-686
the	O	687-690
Glasgow	O	691-698
Outcome	O	699-706
Scale	O	707-712
score	O	713-718
were	O	719-723
assessed	O	724-732
and	O	733-736
compared	O	737-745
.	O	745-746

RESULTS	O	747-754
:	O	754-755
The	O	756-759
patients	O	760-768
in	O	769-771
the	O	772-775
study	O	776-781
group	O	782-787
were	O	788-792
significantly	O	793-806
younger	O	807-814
than	O	815-819
the	O	820-823
patients	O	824-832
in	O	833-835
the	O	836-839
control	O	840-847
group	O	848-853
(	O	854-855
P	O	855-856
<	O	857-858
0	O	859-860
.	O	860-861
002	O	861-864
)	O	864-865
.	O	860-861

In	O	867-869
patients	O	870-878
in	O	879-881
the	O	882-885
study	O	886-891
group	O	892-897
,	O	897-898
all	O	899-902
aneurysms	B	903-912
were	O	913-917
located	O	918-925
in	O	926-928
the	O	929-932
anterior	O	933-941
circulation	O	942-953
.	O	953-954

The	O	955-958
majority	O	959-967
of	O	968-970
these	O	971-976
aneurysms	B	977-986
were	O	987-991
smaller	O	992-999
than	O	1000-1004
those	O	1005-1010
of	O	1011-1013
the	O	1014-1017
control	O	1018-1025
group	O	1026-1031
(	O	1032-1033
8	O	1033-1034
+	O	1035-1036
/	O	1036-1037
-	O	1037-1038
6	O	1039-1040
.	O	1040-1041
08	O	1041-1043
mm	O	1044-1046
versus	O	1047-1053
11	O	1054-1056
+	O	1057-1058
/	O	1058-1059
-	O	1059-1060
5	O	1061-1062
.	O	1062-1063
4	O	1063-1064
mm	O	1065-1067
;	O	1067-1068
P	O	1069-1070
=	O	1071-1072
0	O	1073-1074
.	O	1074-1075
05	O	1075-1077
)	O	1077-1078
.	O	1074-1075

The	O	1080-1083
differences	O	1084-1095
in	O	1096-1098
mortality	O	1099-1108
and	O	1109-1112
morbidity	O	1113-1122
between	O	1123-1130
the	O	1131-1134
two	O	1135-1138
groups	O	1139-1145
were	O	1146-1150
not	O	1151-1154
significant	O	1155-1166
.	O	1166-1167

Hunt	O	1168-1172
and	O	1173-1176
Hess	O	1177-1181
grade	O	1182-1187
(	O	1188-1189
P	O	1189-1190
<	O	1191-1192
0	O	1193-1194
.	O	1194-1195
005	O	1195-1198
)	O	1198-1199
and	O	1200-1203
age	O	1204-1207
(	O	1208-1209
P	O	1209-1210
<	O	1211-1212
0	O	1213-1214
.	O	1214-1215
007	O	1215-1218
)	O	1218-1219
were	O	1220-1224
significant	O	1225-1236
predictors	O	1237-1247
of	O	1248-1250
outcome	O	1251-1258
for	O	1259-1262
the	O	1263-1266
patients	O	1267-1275
with	O	1276-1280
cocaine	O	1281-1288
-	O	1288-1289
related	O	1289-1296
aneurysms	B	1297-1306
.	O	1306-1307

CONCLUSION	O	1308-1318
:	O	1318-1319
Cocaine	O	1320-1327
use	O	1328-1331
predisposed	O	1332-1343
aneurysmal	B	1344-1354
rupture	I	1355-1362
at	O	1363-1365
a	O	1366-1367
significantly	O	1368-1381
earlier	O	1382-1389
age	O	1390-1393
and	O	1394-1397
in	O	1398-1400
much	O	1401-1405
smaller	O	1406-1413
aneurysms	B	1414-1423
.	O	1423-1424

Contrary	O	1425-1433
to	O	1434-1436
the	O	1437-1440
published	O	1441-1450
literature	O	1451-1461
,	O	1461-1462
this	O	1463-1467
group	O	1468-1473
did	O	1474-1477
reasonably	O	1478-1488
well	O	1489-1493
with	O	1494-1498
aggressive	O	1499-1509
management	O	1510-1520
.	O	1520-1521

Anti	O	0-4
-	O	4-5
epileptic	B	5-14
drugs	O	15-20
-	O	20-21
induced	O	21-28
de	O	29-31
novo	O	32-36
absence	B	37-44
seizures	I	45-53
.	O	53-54

The	O	55-58
authors	O	59-66
present	O	67-74
three	O	75-80
patients	O	81-89
with	O	90-94
de	O	95-97
novo	O	98-102
absence	B	103-110
epilepsy	I	111-119
after	O	120-125
administration	O	126-140
of	O	141-143
carbamazepine	O	144-157
and	O	158-161
vigabatrin	O	162-172
.	O	172-173

Despite	O	174-181
the	O	182-185
underlying	O	186-196
diseases	O	197-205
,	O	205-206
the	O	207-210
prognosis	O	211-220
for	O	221-224
drug	O	225-229
-	O	229-230
induced	O	230-237
de	O	238-240
novo	O	241-245
absence	B	246-253
seizure	I	254-261
is	O	262-264
good	O	265-269
because	O	270-277
it	O	278-280
subsides	O	281-289
rapidly	O	290-297
after	O	298-303
discontinuing	O	304-317
the	O	318-321
use	O	322-325
of	O	326-328
the	O	329-332
offending	O	333-342
drugs	O	343-348
.	O	348-349

The	O	350-353
gamma	O	354-359
-	O	359-360
aminobutyric	O	360-372
acid	O	373-377
-	O	377-378
transmitted	O	378-389
thalamocortical	O	390-405
circuitry	O	406-415
accounts	O	416-424
for	O	425-428
a	O	429-430
major	O	431-436
part	O	437-441
of	O	442-444
the	O	445-448
underlying	O	449-459
neurophysiology	O	460-475
of	O	476-478
the	O	479-482
absence	B	483-490
epilepsy	I	491-499
.	O	499-500

Because	O	501-508
drug	O	509-513
-	O	513-514
induced	O	514-521
de	O	522-524
novo	O	525-529
absence	B	530-537
seizure	I	538-545
is	O	546-548
rare	O	549-553
,	O	553-554
pro	O	555-558
-	O	558-559
absence	O	559-566
drugs	O	567-572
can	O	573-576
only	O	577-581
be	O	582-584
considered	O	585-595
a	O	596-597
promoting	O	598-607
factor	O	608-614
.	O	614-615

The	O	616-619
underlying	O	620-630
epileptogenecity	O	631-647
of	O	648-650
the	O	651-654
patients	O	655-663
or	O	664-666
the	O	667-670
synergistic	O	671-682
effects	O	683-690
of	O	691-693
the	O	694-697
accompanying	O	698-710
drugs	O	711-716
is	O	717-719
required	O	720-728
to	O	729-731
trigger	O	732-739
the	O	740-743
de	O	744-746
novo	O	747-751
absence	B	752-759
seizure	I	760-767
.	O	767-768

The	O	769-772
possibility	O	773-784
of	O	785-787
drug	O	788-792
-	O	792-793
induced	O	793-800
aggravation	O	801-812
should	O	813-819
be	O	820-822
considered	O	823-833
whenever	O	834-842
an	O	843-845
unexpected	O	846-856
increase	O	857-865
in	O	866-868
seizure	B	869-876
frequency	O	877-886
and	O	887-890
/	O	890-891
or	O	891-893
new	O	894-897
seizure	B	898-905
types	O	906-911
appear	O	912-918
following	O	919-928
a	O	929-930
change	O	931-937
in	O	938-940
drug	O	941-945
treatment	O	946-955
.	O	955-956

By	O	957-959
understanding	O	960-973
the	O	974-977
underlying	O	978-988
mechanism	O	989-998
of	O	999-1001
absence	B	1002-1009
epilepsy	I	1010-1018
,	O	1018-1019
we	O	1020-1022
can	O	1023-1026
avoid	O	1027-1032
the	O	1033-1036
inappropriate	O	1037-1050
use	O	1051-1054
of	O	1055-1057
anticonvulsants	O	1058-1073
in	O	1074-1076
children	O	1077-1085
with	O	1086-1090
epilepsy	B	1091-1099
and	O	1100-1103
prevent	O	1104-1111
drug	O	1112-1116
-	O	1116-1117
induced	O	1117-1124
absence	B	1125-1132
seizures	I	1133-1141
.	O	1141-1142

Procainamide	O	0-12
-	O	12-13
induced	O	13-20
polymorphous	O	21-33
ventricular	B	34-45
tachycardia	I	46-57
.	O	57-58

Seven	O	59-64
cases	O	65-70
of	O	71-73
procainamide	O	74-86
-	O	86-87
induced	O	87-94
polymorphous	O	95-107
ventricular	B	108-119
tachycardia	I	120-131
are	O	132-135
presented	O	136-145
.	O	145-146

In	O	147-149
four	O	150-154
patients	O	155-163
,	O	163-164
polymorphous	O	165-177
ventricular	B	178-189
tachycardia	I	190-201
appeared	O	202-210
after	O	211-216
intravenous	O	217-228
administration	O	229-243
of	O	244-246
200	O	247-250
to	O	251-253
400	O	254-257
mg	O	258-260
of	O	261-263
procainamide	O	264-276
for	O	277-280
the	O	281-284
treatment	O	285-294
of	O	295-297
sustained	O	298-307
ventricular	B	308-319
tachycardia	I	320-331
.	O	331-332

In	O	333-335
the	O	336-339
remaining	O	340-349
three	O	350-355
patients	O	356-364
,	O	364-365
procainamide	O	366-378
was	O	379-382
administered	O	383-395
orally	O	396-402
for	O	403-406
treatment	O	407-416
of	O	417-419
chronic	O	420-427
premature	B	428-437
ventricular	I	438-449
contractions	I	450-462
or	O	463-465
atrial	B	466-472
flutter	I	473-480
.	O	480-481

These	O	482-487
patients	O	488-496
had	O	497-500
Q	B	501-502
-	I	502-503
T	I	503-504
prolongation	I	505-517
and	O	518-521
recurrent	O	522-531
syncope	B	532-539
due	O	540-543
to	O	544-546
polymorphous	O	547-559
ventricular	B	560-571
tachycardia	I	572-583
.	O	583-584

In	O	585-587
four	O	588-592
patients	O	593-601
,	O	601-602
the	O	603-606
arrhythmia	B	607-617
was	O	618-621
rapidly	O	622-629
diagnosed	O	630-639
and	O	640-643
treated	O	644-651
with	O	652-656
disappearance	O	657-670
of	O	671-673
further	O	674-681
episodes	O	682-690
of	O	691-693
the	O	694-697
arrhythmia	B	698-708
.	O	708-709

In	O	710-712
two	O	713-716
patients	O	717-725
,	O	725-726
the	O	727-730
arrhythmia	B	731-741
degenerated	O	742-753
into	O	754-758
irreversible	O	759-771
ventricular	B	772-783
fibrillation	I	784-796
and	O	797-800
both	O	801-805
patients	O	806-814
died	O	815-819
.	O	819-820

In	O	821-823
the	O	824-827
seventh	O	828-835
patient	O	836-843
,	O	843-844
a	O	845-846
permanent	O	847-856
ventricular	O	857-868
pacemaker	O	869-878
was	O	879-882
inserted	O	883-891
and	O	892-895
,	O	895-896
despite	O	897-904
continuation	O	905-917
of	O	918-920
procainamide	O	921-933
therapy	O	934-941
,	O	941-942
polymorphous	O	943-955
ventricular	B	956-967
tachycardia	I	968-979
did	O	980-983
not	O	984-987
reoccur	O	988-995
.	O	995-996

These	O	997-1002
seven	O	1003-1008
cases	O	1009-1014
demonstrate	O	1015-1026
that	O	1027-1031
procainamide	O	1032-1044
can	O	1045-1048
produce	O	1049-1056
an	O	1057-1059
acquired	O	1060-1068
prolonged	B	1069-1078
Q	I	1079-1080
-	I	1080-1081
T	I	1081-1082
syndrome	I	1083-1091
with	O	1092-1096
polymorphous	O	1097-1109
ventricular	B	1110-1121
tachycardia	I	1122-1133
.	O	1133-1134

Role	O	0-4
of	O	5-7
activation	O	8-18
of	O	19-21
bradykinin	O	22-32
B2	O	33-35
receptors	O	36-45
in	O	46-48
disruption	O	49-59
of	O	60-62
the	O	63-66
blood	O	67-72
-	O	72-73
brain	O	73-78
barrier	O	79-86
during	O	87-93
acute	O	94-99
hypertension	B	100-112
.	O	112-113

Cellular	O	114-122
mechanisms	O	123-133
which	O	134-139
account	O	140-147
for	O	148-151
disruption	O	152-162
the	O	163-166
blood	O	167-172
-	O	172-173
brain	O	173-178
barrier	O	179-186
during	O	187-193
acute	O	194-199
hypertension	B	200-212
are	O	213-216
not	O	217-220
clear	O	221-226
.	O	226-227

The	O	228-231
goal	O	232-236
of	O	237-239
this	O	240-244
study	O	245-250
was	O	251-254
to	O	255-257
determine	O	258-267
the	O	268-271
role	O	272-276
of	O	277-279
synthesis	O	280-289
/	O	289-290
release	O	290-297
of	O	298-300
bradykinin	O	301-311
to	O	312-314
activate	O	315-323
B2	O	324-326
receptors	O	327-336
in	O	337-339
disruption	O	340-350
of	O	351-353
the	O	354-357
blood	O	358-363
-	O	363-364
brain	O	364-369
barrier	O	370-377
during	O	378-384
acute	O	385-390
hypertension	B	391-403
.	O	403-404

Permeability	O	405-417
of	O	418-420
the	O	421-424
blood	O	425-430
-	O	430-431
brain	O	431-436
barrier	O	437-444
was	O	445-448
quantitated	O	449-460
by	O	461-463
clearance	O	464-473
of	O	474-476
fluorescent	O	477-488
-	O	488-489
labeled	O	489-496
dextran	O	497-504
before	O	505-511
and	O	512-515
during	O	516-522
phenylephrine	O	523-536
-	O	536-537
induced	O	537-544
acute	O	545-550
hypertension	B	551-563
in	O	564-566
rats	O	567-571
treated	O	572-579
with	O	580-584
vehicle	O	585-592
and	O	593-596
Hoe	O	597-600
-	O	600-601
140	O	601-604
(	O	605-606
0	O	606-607
.	O	607-608
1	O	608-609
microM	O	610-616
)	O	616-617
.	O	617-618

Phenylephrine	O	619-632
infusion	O	633-641
increased	O	642-651
arterial	O	652-660
pressure	O	661-669
,	O	669-670
arteriolar	O	671-681
diameter	O	682-690
and	O	691-694
clearance	O	695-704
of	O	705-707
fluorescent	O	708-719
dextran	O	720-727
by	O	728-730
a	O	731-732
similar	O	733-740
magnitude	O	741-750
in	O	751-753
both	O	754-758
groups	O	759-765
.	O	765-766

These	O	767-772
findings	O	773-781
suggest	O	782-789
that	O	790-794
disruption	O	795-805
of	O	806-808
the	O	809-812
blood	O	813-818
-	O	818-819
brain	O	819-824
barrier	O	825-832
during	O	833-839
acute	O	840-845
hypertension	B	846-858
is	O	859-861
not	O	862-865
related	O	866-873
to	O	874-876
the	O	877-880
synthesis	O	881-890
/	O	890-891
release	O	891-898
of	O	899-901
bradykinin	O	902-912
to	O	913-915
activate	O	916-924
B2	O	925-927
receptors	O	928-937
.	O	937-938

5	O	0-1
-	O	1-2
azacytidine	O	2-13
potentiates	O	14-25
initiation	B	26-36
induced	I	37-44
by	I	45-47
carcinogens	I	48-59
in	O	60-62
rat	O	63-66
liver	O	67-72
.	O	72-73

To	O	74-76
test	O	77-81
the	O	82-85
validity	O	86-94
of	O	95-97
the	O	98-101
hypothesis	O	102-112
that	O	113-117
hypomethylation	O	118-133
of	O	134-136
DNA	O	137-140
plays	O	141-146
an	O	147-149
important	O	150-159
role	O	160-164
in	O	165-167
the	O	168-171
initiation	B	172-182
of	I	183-185
carcinogenic	I	186-198
process	I	199-206
,	O	206-207
5	O	208-209
-	O	209-210
azacytidine	O	210-221
(	O	222-223
5	O	223-224
-	O	224-225
AzC	O	225-228
)	O	228-229
(	O	230-231
10	O	231-233
mg	O	234-236
/	O	236-237
kg	O	237-239
)	O	239-240
,	O	240-241
an	O	242-244
inhibitor	O	245-254
of	O	255-257
DNA	O	258-261
methylation	O	262-273
,	O	273-274
was	O	275-278
given	O	279-284
to	O	285-287
rats	O	288-292
during	O	293-299
the	O	300-303
phase	O	304-309
of	O	310-312
repair	O	313-319
synthesis	O	320-329
induced	O	330-337
by	O	338-340
the	O	341-344
three	O	345-350
carcinogens	O	351-362
,	O	362-363
benzo	O	364-369
[	O	369-370
a	O	370-371
]	O	371-372
-	O	372-373
pyrene	O	373-379
(	O	380-381
200	O	381-384
mg	O	385-387
/	O	387-388
kg	O	388-390
)	O	390-391
,	O	391-392
N	O	393-394
-	O	394-395
methyl	O	395-401
-	O	394-395
N	O	393-394
-	O	394-395
nitrosourea	O	404-415
(	O	416-417
60	O	417-419
mg	O	420-422
/	O	422-423
kg	O	423-425
)	O	425-426
and	O	427-430
1	O	431-432
,	O	432-433
2	O	433-434
-	O	434-435
dimethylhydrazine	O	435-452
(	O	453-454
1	O	454-455
,	O	455-456
2	O	456-457
-	O	457-458
DMH	O	458-461
)	O	461-462
(	O	463-464
100	O	464-467
mg	O	468-470
/	O	470-471
kg	O	471-473
)	O	473-474
.	O	474-475

The	O	476-479
initiated	O	480-489
hepatocytes	O	490-501
in	O	502-504
the	O	505-508
liver	O	509-514
were	O	515-519
assayed	O	520-527
as	O	528-530
the	O	531-534
gamma	O	535-540
-	O	540-541
glutamyltransferase	O	541-560
(	O	561-562
gamma	O	562-567
-	O	567-568
GT	O	568-570
)	O	570-571
positive	O	572-580
foci	O	581-585
formed	O	586-592
following	O	593-602
a	O	603-604
2	O	605-606
-	O	606-607
week	O	607-611
selection	O	612-621
regimen	O	622-629
consisting	O	630-640
of	O	641-643
dietary	O	644-651
0	O	652-653
.	O	653-654
02	O	654-656
%	O	656-657
2	O	658-659
-	O	659-660
acetylaminofluorene	O	660-679
coupled	O	680-687
with	O	688-692
a	O	693-694
necrogenic	O	695-705
dose	O	706-710
of	O	711-713
CCl4	O	714-718
.	O	718-719

The	O	720-723
results	O	724-731
obtained	O	732-740
indicate	O	741-749
that	O	750-754
with	O	755-759
all	O	760-763
three	O	764-769
carcinogens	O	770-781
,	O	781-782
administration	O	783-797
of	O	798-800
5	O	801-802
-	O	802-803
AzC	O	803-806
during	O	807-813
repair	O	814-820
synthesis	O	821-830
increased	O	831-840
the	O	841-844
incidence	O	845-854
of	O	855-857
initiated	O	858-867
hepatocytes	O	868-879
,	O	879-880
for	O	881-884
example	O	885-892
10	O	893-895
-	O	895-896
20	O	896-898
foci	O	899-903
/	O	903-904
cm2	O	904-907
in	O	908-910
5	O	911-912
-	O	912-913
AzC	O	913-916
and	O	917-920
carcinogen	O	921-931
-	O	931-932
treated	O	932-939
rats	O	940-944
compared	O	945-953
with	O	954-958
3	O	959-960
-	O	960-961
5	O	961-962
foci	O	963-967
/	O	967-968
cm2	O	968-971
in	O	972-974
rats	O	975-979
treated	O	980-987
with	O	988-992
carcinogen	O	993-1003
only	O	1004-1008
.	O	1008-1009

Administration	O	1010-1024
of	O	1025-1027
[	O	1028-1029
3H	O	1029-1031
]	O	1031-1032
-	O	1032-1033
5	O	1033-1034
-	O	1032-1033
azadeoxycytidine	O	1035-1051
during	O	1052-1058
the	O	1059-1062
repair	O	1063-1069
synthesis	O	1070-1079
induced	O	1080-1087
by	O	1088-1090
1	O	1091-1092
,	O	1092-1093
2	O	1093-1094
-	O	1094-1095
DMH	O	1095-1098
further	O	1099-1106
showed	O	1107-1113
that	O	1114-1118
0	O	1119-1120
.	O	1120-1121
019	O	1121-1124
mol	O	1125-1128
%	O	1129-1130
of	O	1131-1133
cytosine	O	1134-1142
residues	O	1143-1151
in	O	1152-1154
DNA	O	1155-1158
were	O	1159-1163
substituted	O	1164-1175
by	O	1176-1178
the	O	1179-1182
analogue	O	1183-1191
,	O	1191-1192
indicating	O	1193-1203
that	O	1204-1208
incorporation	O	1209-1222
of	O	1223-1225
5	O	1226-1227
-	O	1227-1228
AzC	O	1228-1231
occurs	O	1232-1238
during	O	1239-1245
repair	O	1246-1252
synthesis	O	1253-1262
.	O	1262-1263

In	O	1264-1266
the	O	1267-1270
absence	O	1271-1278
of	O	1279-1281
the	O	1282-1285
carcinogen	O	1286-1296
,	O	1296-1297
5	O	1298-1299
-	O	1299-1300
AzC	O	1300-1303
given	O	1304-1309
after	O	1310-1315
a	O	1316-1317
two	O	1318-1321
thirds	O	1322-1328
partial	O	1329-1336
hepatectomy	O	1337-1348
,	O	1348-1349
when	O	1350-1354
its	O	1355-1358
incorporation	O	1359-1372
should	O	1373-1379
be	O	1380-1382
maximum	O	1383-1390
,	O	1390-1391
failed	O	1392-1398
to	O	1399-1401
induce	O	1402-1408
any	O	1409-1412
gamma	O	1413-1418
-	O	1418-1419
GT	O	1419-1421
positive	O	1422-1430
foci	O	1431-1435
.	O	1435-1436

The	O	1437-1440
results	O	1441-1448
suggest	O	1449-1456
that	O	1457-1461
hypomethylation	O	1462-1477
of	O	1478-1480
DNA	O	1481-1484
per	O	1485-1488
se	O	1489-1491
may	O	1492-1495
not	O	1496-1499
be	O	1500-1502
sufficient	O	1503-1513
for	O	1514-1517
initiation	O	1518-1528
.	O	1528-1529

Perhaps	O	1530-1537
two	O	1538-1541
events	O	1542-1548
might	O	1549-1554
be	O	1555-1557
necessary	O	1558-1567
for	O	1568-1571
initiation	O	1572-1582
,	O	1582-1583
the	O	1584-1587
first	O	1588-1593
caused	O	1594-1600
by	O	1601-1603
the	O	1604-1607
carcinogen	O	1608-1618
and	O	1619-1622
a	O	1623-1624
second	O	1625-1631
involving	O	1632-1641
hypomethylation	O	1642-1657
of	O	1658-1660
DNA	O	1661-1664
.	O	1664-1665

Withdrawal	B	0-10
-	I	10-11
emergent	I	11-19
rabbit	I	20-26
syndrome	I	27-35
during	O	36-42
dose	O	43-47
reduction	O	48-57
of	O	58-60
risperidone	O	61-72
.	O	72-73

Rabbit	B	74-80
syndrome	I	81-89
(	O	90-91
RS	B	91-93
)	O	93-94
is	O	95-97
a	O	98-99
rare	O	100-104
extrapyramidal	O	105-119
side	O	120-124
effect	O	125-131
caused	O	132-138
by	O	139-141
prolonged	O	142-151
neuroleptic	O	152-163
medication	O	164-174
.	O	174-175

Here	O	176-180
we	O	181-183
present	O	184-191
a	O	192-193
case	O	194-198
of	O	199-201
withdrawal	B	202-212
-	I	212-213
emergent	I	213-221
RS	I	222-224
,	O	224-225
which	O	226-231
is	O	232-234
the	O	235-238
first	O	239-244
of	O	245-247
its	O	248-251
kind	O	252-256
to	O	257-259
be	O	260-262
reported	O	263-271
.	O	271-272

The	O	273-276
patient	O	277-284
developed	O	285-294
RS	B	295-297
during	O	298-304
dose	O	305-309
reduction	O	310-319
of	O	320-322
risperidone	O	323-334
.	O	334-335

The	O	336-339
symptom	O	340-347
was	O	348-351
treated	O	352-359
successfully	O	360-372
with	O	373-377
trihexyphenidyl	O	378-393
anticholinergic	O	394-409
therapy	O	410-417
.	O	417-418

The	O	419-422
underlying	O	423-433
mechanism	O	434-443
of	O	444-446
withdrawal	B	447-457
-	I	457-458
emergent	I	458-466
RS	I	467-469
in	O	470-472
the	O	473-476
present	O	477-484
case	O	485-489
may	O	490-493
have	O	494-498
been	O	499-503
related	O	504-511
to	O	512-514
the	O	515-518
pharmacological	O	519-534
profile	O	535-542
of	O	543-545
risperidone	O	546-557
,	O	557-558
a	O	559-560
serotonin	O	561-570
-	O	570-571
dopamine	O	571-579
antagonist	O	580-590
,	O	590-591
suggesting	O	592-602
the	O	603-606
pathophysiologic	O	607-623
influence	O	624-633
of	O	634-636
the	O	637-640
serotonin	O	641-650
system	O	651-657
in	O	658-660
the	O	661-664
development	O	665-676
of	O	677-679
RS	B	680-682
.	O	682-683

Verapamil	O	0-9
withdrawal	O	10-20
as	O	21-23
a	O	24-25
possible	O	26-34
cause	O	35-40
of	O	41-43
myocardial	B	44-54
infarction	I	55-65
in	O	66-68
a	O	69-70
hypertensive	B	71-83
woman	O	84-89
with	O	90-94
a	O	95-96
normal	O	97-103
coronary	O	104-112
angiogram	O	113-122
.	O	122-123

Verapamil	O	124-133
is	O	134-136
an	O	137-139
effective	O	140-149
and	O	150-153
relatively	O	154-164
-	O	164-165
safe	O	165-169
antihypertensive	O	170-186
drug	O	187-191
.	O	191-192

Serious	O	193-200
adverse	O	201-208
effects	O	209-216
are	O	217-220
uncommon	O	221-229
and	O	230-233
mainly	O	234-240
have	O	241-245
been	O	246-250
related	O	251-258
to	O	259-261
the	O	262-265
depression	B	266-276
of	O	277-279
cardiac	O	280-287
contractility	O	288-301
and	O	302-305
conduction	O	306-316
,	O	316-317
especially	O	318-328
when	O	329-333
the	O	334-337
drug	O	338-342
is	O	343-345
combined	O	346-354
with	O	355-359
beta	O	360-364
-	O	364-365
blocking	O	365-373
agents	O	374-380
.	O	380-381

We	O	382-384
report	O	385-391
a	O	392-393
case	O	394-398
in	O	399-401
which	O	402-407
myocardial	B	408-418
infarction	I	419-429
coincided	O	430-439
with	O	440-444
the	O	445-448
introduction	O	449-461
of	O	462-464
captopril	O	465-474
and	O	475-478
the	O	479-482
withdrawal	O	483-493
of	O	494-496
verapamil	O	497-506
in	O	507-509
a	O	510-511
previously	O	512-522
asymptomatic	O	523-535
woman	O	536-541
with	O	542-546
severe	O	547-553
hypertension	B	554-566
.	O	566-567

Possible	O	568-576
mechanisms	O	577-587
that	O	588-592
involve	O	593-600
a	O	601-602
verapamil	O	603-612
-	O	612-613
related	O	613-620
increase	O	621-629
in	O	630-632
platelet	O	633-641
and	O	642-645
/	O	645-646
or	O	646-648
vascular	O	649-657
alpha	O	658-663
2	O	664-665
-	O	665-666
adrenoreceptor	O	666-680
affinity	O	681-689
for	O	690-693
catecholamines	O	694-708
are	O	709-712
discussed	O	713-722
.	O	722-723

Remission	O	0-9
induction	O	10-19
of	O	20-22
meningeal	B	23-32
leukemia	I	33-41
with	O	42-46
high	O	47-51
-	O	51-52
dose	O	52-56
intravenous	O	57-68
methotrexate	O	69-81
.	O	81-82

Twenty	O	83-89
children	O	90-98
with	O	99-103
acute	B	104-109
lymphoblastic	I	110-123
leukemia	I	124-132
who	O	133-136
developed	O	137-146
meningeal	B	147-156
disease	I	157-164
were	O	165-169
treated	O	170-177
with	O	178-182
a	O	183-184
high	O	185-189
-	O	189-190
dose	O	190-194
intravenous	O	195-206
methotrexate	O	207-219
regimen	O	220-227
that	O	228-232
was	O	233-236
designed	O	237-245
to	O	246-248
achieve	O	249-256
and	O	257-260
maintain	O	261-269
CSF	O	270-273
methotrexate	O	274-286
concentrations	O	287-301
of	O	302-304
10	O	305-307
(	O	307-308
-	O	308-309
5	O	309-310
)	O	310-311
mol	O	312-315
/	O	315-316
L	O	316-317
without	O	318-325
the	O	326-329
need	O	330-334
for	O	335-338
concomitant	O	339-350
intrathecal	O	351-362
dosing	O	363-369
.	O	369-370

The	O	371-374
methotrexate	O	375-387
was	O	388-391
administered	O	392-404
as	O	405-407
a	O	408-409
loading	O	410-417
dose	O	418-422
of	O	423-425
6	O	426-427
,	O	427-428
000	O	428-431
mg	O	432-434
/	O	434-435
m2	O	435-437
for	O	438-441
a	O	442-443
period	O	444-450
of	O	451-453
one	O	454-457
hour	O	458-462
followed	O	463-471
by	O	472-474
an	O	475-477
infusion	O	478-486
of	O	487-489
1	O	490-491
,	O	491-492
200	O	492-495
mg	O	496-498
/	O	498-499
m2	O	499-501
/	O	498-499
h	O	502-503
for	O	504-507
23	O	508-510
hours	O	511-516
.	O	516-517

Leucovorin	O	518-528
rescue	O	529-535
was	O	536-539
initiated	O	540-549
12	O	550-552
hours	O	553-558
after	O	559-564
the	O	565-568
end	O	569-572
of	O	573-575
the	O	576-579
infusion	O	580-588
with	O	589-593
a	O	594-595
loading	O	596-603
dose	O	604-608
of	O	609-611
200	O	612-615
mg	O	616-618
/	O	618-619
m2	O	619-621
followed	O	622-630
by	O	631-633
12	O	634-636
mg	O	637-639
/	O	639-640
m2	O	640-642
every	O	643-648
three	O	649-654
hours	O	655-660
for	O	661-664
six	O	665-668
doses	O	669-674
and	O	675-678
then	O	679-683
every	O	684-689
six	O	690-693
hours	O	694-699
until	O	700-705
the	O	706-709
plasma	O	710-716
methotrexate	O	717-729
level	O	730-735
decreased	O	736-745
to	O	746-748
less	O	749-753
than	O	754-758
1	O	759-760
X	O	761-762
10	O	763-765
(	O	765-766
-	O	766-767
7	O	767-768
)	O	768-769
mol	O	770-773
/	O	773-774
L	O	774-775
.	O	775-776

The	O	777-780
mean	O	781-785
steady	O	786-792
-	O	792-793
state	O	793-798
plasma	O	799-805
and	O	806-809
CSF	O	810-813
methotrexate	O	814-826
concentrations	O	827-841
achieved	O	842-850
were	O	851-855
1	O	856-857
.	O	857-858
1	O	856-857
X	O	860-861
10	O	862-864
(	O	864-865
-	O	865-866
3	O	866-867
)	O	867-868
mol	O	869-872
/	O	872-873
L	O	873-874
and	O	875-878
3	O	879-880
.	O	880-881
6	O	881-882
X	O	883-884
10	O	885-887
(	O	887-888
-	O	888-889
5	O	889-890
)	O	890-891
mol	O	892-895
/	O	895-896
L	O	896-897
,	O	897-898
respectively	O	899-911
.	O	911-912

All	O	913-916
20	O	917-919
patients	O	920-928
responded	O	929-938
to	O	939-941
this	O	942-946
regimen	O	947-954
,	O	954-955
16	O	956-958
/	O	958-959
20	O	959-961
(	O	962-963
80	O	963-965
%	O	965-966
)	O	966-967
achieved	O	968-976
a	O	977-978
complete	O	979-987
remission	O	988-997
,	O	997-998
and	O	999-1002
20	O	1003-1005
%	O	1005-1006
obtained	O	1007-1015
a	O	1016-1017
partial	O	1018-1025
remission	O	1026-1035
.	O	1035-1036

The	O	1037-1040
most	O	1041-1045
common	O	1046-1052
toxicities	B	1053-1063
encountered	O	1064-1075
were	O	1076-1080
transient	O	1081-1090
serum	O	1091-1096
transaminase	O	1097-1109
and	O	1110-1113
bilirubin	O	1114-1123
elevations	O	1124-1134
,	O	1134-1135
neutropenia	B	1136-1147
,	O	1147-1148
and	O	1149-1152
mucositis	B	1153-1162
.	O	1162-1163

One	O	1164-1167
patient	O	1168-1175
had	O	1176-1179
focal	O	1180-1185
seizures	B	1186-1194
and	O	1195-1198
transient	B	1199-1208
hemiparesis	I	1209-1220
but	O	1221-1224
recovered	O	1225-1234
completely	O	1235-1245
.	O	1245-1246

High	O	1247-1251
-	O	1251-1252
dose	O	1252-1256
intravenous	O	1257-1268
methotrexate	O	1269-1281
is	O	1282-1284
an	O	1285-1287
effective	O	1288-1297
treatment	O	1298-1307
for	O	1308-1311
the	O	1312-1315
induction	O	1316-1325
of	O	1326-1328
remission	O	1329-1338
after	O	1339-1344
meningeal	O	1345-1354
relapse	O	1355-1362
in	O	1363-1365
acute	B	1366-1371
lymphoblastic	I	1372-1385
leukemia	I	1386-1394
.	O	1394-1395

Hypersensitivity	B	0-16
to	O	17-19
carbamazepine	O	20-33
presenting	O	34-44
with	O	45-49
a	O	50-51
leukemoid	B	52-61
reaction	I	62-70
,	O	70-71
eosinophilia	B	72-84
,	O	84-85
erythroderma	B	86-98
,	O	98-99
and	O	100-103
renal	B	104-109
failure	I	110-117
.	O	117-118

We	O	119-121
report	O	122-128
a	O	129-130
patient	O	131-138
in	O	139-141
whom	O	142-146
hypersensitivity	B	147-163
to	O	164-166
carbamazepine	O	167-180
presented	O	181-190
with	O	191-195
generalized	O	196-207
erythroderma	B	208-220
,	O	220-221
a	O	222-223
severe	O	224-230
leukemoid	B	231-240
reaction	I	241-249
,	O	249-250
eosinophilia	B	251-263
,	O	263-264
hyponatremia	B	265-277
,	O	277-278
and	O	279-282
renal	B	283-288
failure	I	289-296
.	O	296-297

This	O	298-302
is	O	303-305
the	O	306-309
first	O	310-315
report	O	316-322
of	O	323-325
such	O	326-330
an	O	331-333
unusual	O	334-341
reaction	O	342-350
to	O	351-353
carbamazepine	O	354-367
.	O	367-368

The	O	0-3
interpeduncular	O	4-19
nucleus	O	20-27
regulates	O	28-37
nicotine	O	38-46
'	O	46-47
s	O	47-48
effects	O	49-56
on	O	57-59
free	O	60-64
-	O	64-65
field	O	65-70
activity	O	71-79
.	O	79-80

Partial	O	81-88
lesions	O	89-96
were	O	97-101
made	O	102-106
with	O	107-111
kainic	O	112-118
acid	O	119-123
in	O	124-126
the	O	127-130
interpeduncular	O	131-146
nucleus	O	147-154
of	O	155-157
the	O	158-161
ventral	O	162-169
midbrain	O	170-178
of	O	179-181
the	O	182-185
rat	O	186-189
.	O	189-190

Compared	O	191-199
with	O	200-204
sham	O	205-209
-	O	209-210
operated	O	210-218
controls	O	219-227
,	O	227-228
lesions	O	229-236
significantly	O	237-250
(	O	251-252
p	O	252-253
<	O	254-255
0	O	256-257
.	O	257-258
25	O	258-260
)	O	260-261
blunted	O	262-269
the	O	270-273
early	O	274-279
(	O	280-281
<	O	281-282
60	O	282-284
min	O	285-288
)	O	288-289
free	O	290-294
-	O	294-295
field	O	295-300
locomotor	B	301-310
hypoactivity	I	311-323
caused	O	324-330
by	O	331-333
nicotine	O	334-342
(	O	343-344
0	O	344-345
.	O	345-346
5	O	346-347
mg	O	348-350
kg	O	351-353
(	O	353-354
-	O	354-355
1	O	355-356
)	O	356-357
,	O	357-358
i	O	359-360
.	O	360-361
m	O	361-362
.	O	360-361
)	O	363-364
,	O	364-365
enhanced	O	366-374
the	O	375-378
later	O	379-384
(	O	385-386
60	O	386-388
-	O	388-389
120	O	389-392
min	O	393-396
)	O	396-397
nicotine	O	398-406
-	O	406-407
induced	O	407-414
hyperactivity	B	415-428
,	O	428-429
and	O	430-433
raised	O	434-440
spontaneous	O	441-452
nocturnal	O	453-462
activity	O	463-471
.	O	471-472

Lesions	O	473-480
reduced	O	481-488
the	O	489-492
extent	O	493-499
of	O	500-502
immunohistological	O	503-521
staining	O	522-530
for	O	531-534
choline	O	535-542
acetyltransferase	O	543-560
in	O	561-563
the	O	564-567
interpeduncular	O	568-583
nucleus	O	584-591
(	O	592-593
p	O	593-594
<	O	595-596
0	O	596-597
.	O	597-598
025	O	598-601
)	O	601-602
,	O	602-603
but	O	604-607
not	O	608-611
for	O	612-615
tyrosine	O	616-624
hydroxylase	O	625-636
in	O	637-639
the	O	640-643
surrounding	O	644-655
catecholaminergic	O	656-673
A10	O	674-677
region	O	678-684
.	O	684-685

We	O	686-688
conclude	O	689-697
that	O	698-702
the	O	703-706
interpeduncular	O	707-722
nucleus	O	723-730
mediates	O	731-739
nicotinic	O	740-749
depression	B	750-760
of	O	761-763
locomotor	O	764-773
activity	O	774-782
and	O	783-786
dampens	O	787-794
nicotinic	O	795-804
arousal	O	805-812
mechanisms	O	813-823
located	O	824-831
elsewhere	O	832-841
in	O	842-844
the	O	845-848
brain	O	849-854
.	O	854-855

Assessment	O	0-10
of	O	11-13
a	O	14-15
new	O	16-19
non	O	20-23
-	O	23-24
invasive	O	24-32
index	O	33-38
of	O	39-41
cardiac	O	42-49
performance	O	50-61
for	O	62-65
detection	O	66-75
of	O	76-78
dobutamine	O	79-89
-	O	89-90
induced	O	90-97
myocardial	B	98-108
ischemia	I	109-117
.	O	117-118

BACKGROUND	O	119-129
:	O	129-130
Electrocardiography	O	131-150
has	O	151-154
a	O	155-156
very	O	157-161
low	O	162-165
sensitivity	O	166-177
in	O	178-180
detecting	O	181-190
dobutamine	O	191-201
-	O	201-202
induced	O	202-209
myocardial	B	210-220
ischemia	I	221-229
.	O	229-230

OBJECTIVES	O	231-241
:	O	241-242
To	O	243-245
assess	O	246-252
the	O	253-256
added	O	257-262
diagnostic	O	263-273
value	O	274-279
of	O	280-282
a	O	283-284
new	O	285-288
cardiac	O	289-296
performance	O	297-308
index	O	309-314
(	O	315-316
dP	O	316-318
/	O	318-319
dtejc	O	319-324
)	O	324-325
measurement	O	326-337
,	O	337-338
based	O	339-344
on	O	345-347
brachial	O	348-356
artery	O	357-363
flow	O	364-368
changes	O	369-376
,	O	376-377
as	O	378-380
compared	O	381-389
to	O	390-392
standard	O	393-401
12	O	402-404
-	O	404-405
lead	O	405-409
ECG	O	410-413
,	O	413-414
for	O	415-418
detecting	O	419-428
dobutamine	O	429-439
-	O	439-440
induced	O	440-447
myocardial	B	448-458
ischemia	I	459-467
,	O	467-468
using	O	469-474
Tc99m	O	475-480
-	O	480-481
Sestamibi	O	481-490
single	O	491-497
-	O	497-498
photon	O	498-504
emission	O	505-513
computed	O	514-522
tomography	O	523-533
as	O	534-536
the	O	537-540
gold	O	541-545
standard	O	546-554
of	O	555-557
comparison	O	558-568
to	O	569-571
assess	O	572-578
the	O	579-582
presence	O	583-591
or	O	592-594
absence	O	595-602
of	O	603-605
ischemia	B	606-614
.	O	614-615

METHODS	O	616-623
:	O	623-624
The	O	625-628
study	O	629-634
group	O	635-640
comprised	O	641-650
40	O	651-653
patients	O	654-662
undergoing	O	663-673
Sestamibi	O	674-683
-	O	683-684
SPECT	O	684-689
/	O	689-690
dobutamine	O	690-700
stress	O	701-707
test	O	708-712
.	O	712-713

Simultaneous	O	714-726
measurements	O	727-739
of	O	740-742
ECG	O	743-746
and	O	747-750
brachial	O	751-759
artery	O	760-766
dP	O	767-769
/	O	769-770
dtejc	O	770-775
were	O	776-780
performed	O	781-790
at	O	791-793
each	O	794-798
dobutamine	O	799-809
level	O	810-815
.	O	815-816

In	O	817-819
19	O	820-822
of	O	823-825
the	O	826-829
40	O	830-832
patients	O	833-841
perfusion	O	842-851
defects	O	852-859
compatible	O	860-870
with	O	871-875
ischemia	B	876-884
were	O	885-889
detected	O	890-898
on	O	899-901
SPECT	O	902-907
.	O	907-908

The	O	909-912
increase	O	913-921
in	O	922-924
dP	O	925-927
/	O	927-928
dtejc	O	928-933
during	O	934-940
infusion	O	941-949
of	O	950-952
dobutamine	O	953-963
in	O	964-966
this	O	967-971
group	O	972-977
was	O	978-981
severely	O	982-990
impaired	O	991-999
as	O	1000-1002
compared	O	1003-1011
to	O	1012-1014
the	O	1015-1018
non	O	1019-1022
-	O	1022-1023
ischemic	O	1023-1031
group	O	1032-1037
.	O	1037-1038

dP	O	1039-1041
/	O	1041-1042
dtejc	O	1042-1047
outcome	O	1048-1055
was	O	1056-1059
combined	O	1060-1068
with	O	1069-1073
the	O	1074-1077
ECG	O	1078-1081
results	O	1082-1089
,	O	1089-1090
giving	O	1091-1097
an	O	1098-1100
ECG	O	1101-1104
-	O	1104-1105
enhanced	O	1105-1113
value	O	1114-1119
,	O	1119-1120
and	O	1121-1124
compared	O	1125-1133
to	O	1134-1136
ECG	O	1137-1140
alone	O	1141-1146
.	O	1146-1147

RESULTS	O	1148-1155
:	O	1155-1156
The	O	1157-1160
sensitivity	O	1161-1172
improved	O	1173-1181
dramatically	O	1182-1194
from	O	1195-1199
16	O	1200-1202
%	O	1202-1203
to	O	1204-1206
79	O	1207-1209
%	O	1209-1210
,	O	1210-1211
positive	O	1212-1220
predictive	O	1221-1231
value	O	1232-1237
increased	O	1238-1247
from	O	1248-1252
60	O	1253-1255
%	O	1255-1256
to	O	1257-1259
68	O	1260-1262
%	O	1262-1263
and	O	1264-1267
negative	O	1268-1276
predictive	O	1277-1287
value	O	1288-1293
from	O	1294-1298
54	O	1299-1301
%	O	1301-1302
to	O	1303-1305
78	O	1306-1308
%	O	1308-1309
,	O	1309-1310
and	O	1311-1314
specificity	O	1315-1326
decreased	O	1327-1336
from	O	1337-1341
90	O	1342-1344
%	O	1344-1345
to	O	1346-1348
67	O	1349-1351
%	O	1351-1352
.	O	1352-1353

CONCLUSIONS	O	1354-1365
:	O	1365-1366
If	O	1367-1369
ECG	O	1370-1373
alone	O	1374-1379
is	O	1380-1382
used	O	1383-1387
for	O	1388-1391
specificity	O	1392-1403
,	O	1403-1404
the	O	1405-1408
combination	O	1409-1420
with	O	1421-1425
dP	O	1426-1428
/	O	1428-1429
dtejc	O	1429-1434
improved	O	1435-1443
the	O	1444-1447
sensitivity	O	1448-1459
of	O	1460-1462
the	O	1463-1466
test	O	1467-1471
and	O	1472-1475
could	O	1476-1481
be	O	1482-1484
a	O	1485-1486
cost	O	1487-1491
-	O	1491-1492
savings	O	1492-1499
alternative	O	1500-1511
to	O	1512-1514
cardiac	O	1515-1522
imaging	O	1523-1530
or	O	1531-1533
perfusion	O	1534-1543
studies	O	1544-1551
to	O	1552-1554
detect	O	1555-1561
myocardial	B	1562-1572
ischemia	I	1573-1581
,	O	1581-1582
especially	O	1583-1593
in	O	1594-1596
patients	O	1597-1605
unable	O	1606-1612
to	O	1613-1615
exercise	O	1616-1624
.	O	1624-1625

Acute	B	0-5
liver	I	6-11
failure	I	12-19
in	O	20-22
two	O	23-26
patients	O	27-35
with	O	36-40
regular	O	41-48
alcohol	O	49-56
consumption	O	57-68
ingesting	O	69-78
paracetamol	O	79-90
at	O	91-93
therapeutic	O	94-105
dosage	O	106-112
.	O	112-113

BACKGROUND	O	114-124
:	O	124-125
The	O	126-129
possible	O	130-138
role	O	139-143
of	O	144-146
alcohol	O	147-154
in	O	155-157
the	O	158-161
development	O	162-173
of	O	174-176
hepatotoxicity	B	177-191
associated	O	192-202
with	O	203-207
therapeutic	O	208-219
doses	O	220-225
of	O	226-228
paracetamol	O	229-240
(	O	241-242
acetaminophen	O	242-255
)	O	255-256
is	O	257-259
currently	O	260-269
debated	O	270-277
.	O	277-278

CASE	O	279-283
REPORT	O	284-290
:	O	290-291
We	O	292-294
describe	O	295-303
2	O	304-305
patients	O	306-314
who	O	315-318
were	O	319-323
regular	O	324-331
consumers	O	332-341
of	O	342-344
alcohol	O	345-352
and	O	353-356
who	O	357-360
developed	O	361-370
liver	B	371-376
failure	I	377-384
within	O	385-391
3	O	392-393
-	O	393-394
5	O	394-395
days	O	396-400
after	O	401-406
hospitalization	O	407-422
and	O	423-426
stopping	O	427-435
alcohol	O	436-443
consumption	O	444-455
while	O	456-461
being	O	462-467
treated	O	468-475
with	O	476-480
4	O	481-482
g	O	483-484
paracetamol	O	485-496
/	O	496-497
day	O	497-500
.	O	500-501

A	O	502-503
paracetamol	O	504-515
serum	O	516-521
level	O	522-527
obtained	O	528-536
in	O	537-539
one	O	540-543
of	O	544-546
these	O	547-552
patients	O	553-561
was	O	562-565
not	O	566-569
in	O	570-572
the	O	573-576
toxic	O	577-582
range	O	583-588
.	O	588-589

Possible	O	590-598
risk	O	599-603
factors	O	604-611
for	O	612-615
the	O	616-619
development	O	620-631
of	O	632-634
hepatotoxicity	B	635-649
in	O	650-652
patients	O	653-661
treated	O	662-669
with	O	670-674
therapeutic	O	675-686
doses	O	687-692
of	O	693-695
paracetamol	O	696-707
are	O	708-711
discussed	O	712-721
.	O	721-722

CONCLUSION	O	723-733
:	O	733-734
In	O	735-737
patients	O	738-746
with	O	747-751
risk	O	752-756
factors	O	757-764
,	O	764-765
e	O	766-767
.	O	767-768
g	O	768-769
.	O	767-768

regular	O	771-778
consumption	O	779-790
of	O	791-793
alcohol	O	794-801
,	O	801-802
liver	B	803-808
failure	I	809-816
is	O	817-819
possible	O	820-828
when	O	829-833
therapeutic	O	834-845
doses	O	846-851
are	O	852-855
ingested	O	856-864
.	O	864-865

We	O	866-868
propose	O	869-876
that	O	877-881
the	O	882-885
paracetamol	O	886-897
dose	O	898-902
should	O	903-909
not	O	910-913
exceed	O	914-920
2	O	921-922
g	O	923-924
/	O	924-925
day	O	925-928
in	O	929-931
such	O	932-936
patients	O	937-945
and	O	946-949
that	O	950-954
their	O	955-960
liver	O	961-966
function	O	967-975
should	O	976-982
be	O	983-985
monitored	O	986-995
closely	O	996-1003
while	O	1004-1009
being	O	1010-1015
treated	O	1016-1023
with	O	1024-1028
paracetamol	O	1029-1040
.	O	1040-1041

Cocaine	O	0-7
related	O	8-15
chest	B	16-21
pain	I	22-26
:	O	26-27
are	O	28-31
we	O	32-34
seeing	O	35-41
the	O	42-45
tip	O	46-49
of	O	50-52
an	O	53-55
iceberg	O	56-63
?	O	63-64

The	O	65-68
recreational	O	69-81
use	O	82-85
of	O	86-88
cocaine	O	89-96
is	O	97-99
on	O	100-102
the	O	103-106
increase	O	107-115
.	O	115-116

The	O	117-120
emergency	O	121-130
nurse	O	131-136
ought	O	137-142
to	O	143-145
be	O	146-148
familiar	O	149-157
with	O	158-162
some	O	163-167
of	O	168-170
the	O	171-174
cardiovascular	O	175-189
consequences	O	190-202
of	O	203-205
cocaine	O	206-213
use	O	214-217
.	O	217-218

In	O	219-221
particular	O	222-232
,	O	232-233
the	O	234-237
tendency	O	238-246
of	O	247-249
cocaine	O	250-257
to	O	258-260
produce	O	261-268
chest	B	269-274
pain	I	275-279
ought	O	280-285
to	O	286-288
be	O	289-291
in	O	292-294
the	O	295-298
mind	O	299-303
of	O	304-306
the	O	307-310
emergency	O	311-320
nurse	O	321-326
when	O	327-331
faced	O	332-337
with	O	338-342
a	O	343-344
young	O	345-350
victim	O	351-357
of	O	358-360
chest	B	361-366
pain	I	367-371
who	O	372-375
is	O	376-378
otherwise	O	379-388
at	O	389-391
low	O	392-395
risk	O	396-400
.	O	400-401

The	O	402-405
mechanism	O	406-415
of	O	416-418
chest	B	419-424
pain	I	425-429
related	O	430-437
to	O	438-440
cocaine	O	441-448
use	O	449-452
is	O	453-455
discussed	O	456-465
and	O	466-469
treatment	O	470-479
dilemmas	O	480-488
are	O	489-492
discussed	O	493-502
.	O	502-503

Finally	O	504-511
,	O	511-512
moral	O	513-518
issues	O	519-525
relating	O	526-534
to	O	535-537
the	O	538-541
testing	O	542-549
of	O	550-552
potential	O	553-562
cocaine	O	563-570
users	O	571-576
will	O	577-581
be	O	582-584
addressed	O	585-594
.	O	594-595

Severe	O	0-6
rhabdomyolysis	B	7-21
and	O	22-25
acute	B	26-31
renal	I	32-37
failure	I	38-45
secondary	O	46-55
to	O	56-58
concomitant	O	59-70
use	O	71-74
of	O	75-77
simvastatin	O	78-89
,	O	89-90
amiodarone	O	91-101
,	O	101-102
and	O	103-106
atazanavir	O	107-117
.	O	117-118

OBJECTIVE	O	119-128
:	O	128-129
To	O	130-132
report	O	133-139
a	O	140-141
case	O	142-146
of	O	147-149
a	O	150-151
severe	O	152-158
interaction	O	159-170
between	O	171-178
simvastatin	O	179-190
,	O	190-191
amiodarone	O	192-202
,	O	202-203
and	O	204-207
atazanavir	O	208-218
resulting	O	219-228
in	O	229-231
rhabdomyolysis	B	232-246
and	O	247-250
acute	B	251-256
renal	I	257-262
failure	I	263-270
.	O	270-271

BACKGROUND	O	272-282
:	O	282-283
A	O	284-285
72	O	286-288
-	O	288-289
year	O	289-293
-	O	288-289
old	O	294-297
white	O	298-303
man	O	304-307
with	O	308-312
underlying	O	313-323
human	B	324-329
immunodeficiency	I	330-346
virus	I	347-352
,	O	352-353
atrial	B	354-360
fibrillation	I	361-373
,	O	373-374
coronary	B	375-383
artery	I	384-390
disease	I	391-398
,	O	398-399
and	O	400-403
hyperlipidemia	B	404-418
presented	O	419-428
with	O	429-433
generalized	O	434-445
pain	B	446-450
,	O	450-451
fatigue	B	452-459
,	O	459-460
and	O	461-464
dark	O	465-469
orange	O	470-476
urine	O	477-482
for	O	483-486
3	O	487-488
days	O	489-493
.	O	493-494

The	O	495-498
patient	O	499-506
was	O	507-510
taking	O	511-517
80	O	518-520
mg	O	521-523
simvastatin	O	524-535
at	O	536-538
bedtime	O	539-546
(	O	547-548
initiated	O	548-557
27	O	558-560
days	O	561-565
earlier	O	566-573
)	O	573-574
;	O	574-575
amiodarone	O	576-586
at	O	587-589
a	O	590-591
dose	O	592-596
of	O	597-599
400	O	600-603
mg	O	604-606
daily	O	607-612
for	O	613-616
7	O	617-618
days	O	619-623
,	O	623-624
then	O	625-629
200	O	630-633
mg	O	634-636
daily	O	637-642
(	O	643-644
initiated	O	644-653
19	O	654-656
days	O	657-661
earlier	O	662-669
)	O	669-670
;	O	670-671
and	O	672-675
400	O	676-679
mg	O	680-682
atazanavir	O	683-693
daily	O	694-699
(	O	700-701
initiated	O	701-710
at	O	711-713
least	O	714-719
2	O	720-721
years	O	722-727
previously	O	728-738
)	O	738-739
.	O	739-740

Laboratory	O	741-751
evaluation	O	752-762
revealed	O	763-771
66	O	772-774
,	O	774-775
680	O	775-778
U	O	779-780
/	O	780-781
L	O	781-782
creatine	O	783-791
kinase	O	792-798
,	O	798-799
93	O	800-802
mg	O	803-805
/	O	805-806
dL	O	806-808
blood	O	809-814
urea	O	815-819
nitrogen	O	820-828
,	O	828-829
4	O	830-831
.	O	831-832
6	O	832-833
mg	O	834-836
/	O	836-837
dL	O	837-839
creatinine	O	840-850
,	O	850-851
1579	O	852-856
U	O	857-858
/	O	858-859
L	O	859-860
aspartate	O	861-870
aminotransferase	O	871-887
,	O	887-888
and	O	889-892
738	O	893-896
U	O	897-898
/	O	898-899
L	O	899-900
alanine	O	901-908
aminotransferase	O	909-925
.	O	925-926

Simvastatin	O	927-938
,	O	938-939
amiodarone	O	940-950
,	O	950-951
and	O	952-955
the	O	956-959
patient	O	960-967
'	O	967-968
s	O	968-969
human	B	970-975
immunodeficiency	I	976-992
virus	I	993-998
medications	O	999-1010
were	O	1011-1015
all	O	1016-1019
temporarily	O	1020-1031
discontinued	O	1032-1044
and	O	1045-1048
the	O	1049-1052
patient	O	1053-1060
was	O	1061-1064
given	O	1065-1070
forced	O	1071-1077
alkaline	O	1078-1086
diuresis	O	1087-1095
and	O	1096-1099
started	O	1100-1107
on	O	1108-1110
dialysis	O	1111-1119
.	O	1119-1120

Nine	O	1121-1125
days	O	1126-1130
later	O	1131-1136
the	O	1137-1140
patient	O	1141-1148
'	O	1148-1149
s	O	1149-1150
creatine	O	1151-1159
kinase	O	1160-1166
had	O	1167-1170
dropped	O	1171-1178
to	O	1179-1181
1695	O	1182-1186
U	O	1187-1188
/	O	1188-1189
L	O	1189-1190
and	O	1191-1194
creatinine	O	1195-1205
was	O	1206-1209
3	O	1210-1211
.	O	1211-1212
3	O	1210-1211
mg	O	1214-1216
/	O	1216-1217
dL	O	1217-1219
.	O	1219-1220

The	O	1221-1224
patient	O	1225-1232
was	O	1233-1236
discharged	O	1237-1247
and	O	1248-1251
continued	O	1252-1261
outpatient	O	1262-1272
dialysis	O	1273-1281
for	O	1282-1285
1	O	1286-1287
month	O	1288-1293
until	O	1294-1299
his	O	1300-1303
renal	O	1304-1309
function	O	1310-1318
recovered	O	1319-1328
.	O	1328-1329

DISCUSSION	O	1330-1340
:	O	1340-1341
The	O	1342-1345
risk	O	1346-1350
of	O	1351-1353
rhabdomyolysis	B	1354-1368
is	O	1369-1371
increased	O	1372-1381
in	O	1382-1384
the	O	1385-1388
presence	O	1389-1397
of	O	1398-1400
concomitant	O	1401-1412
drugs	O	1413-1418
that	O	1419-1423
inhibit	O	1424-1431
simvastatin	O	1432-1443
metabolism	O	1444-1454
.	O	1454-1455

Simvastatin	O	1456-1467
is	O	1468-1470
metabolized	O	1471-1482
by	O	1483-1485
CYP3A4	O	1486-1492
.	O	1492-1493

Amiodarone	O	1494-1504
and	O	1505-1508
atazanavir	O	1509-1519
are	O	1520-1523
recognized	O	1524-1534
CYP3A4	O	1535-1541
inhibitors	O	1542-1552
.	O	1552-1553

CONCLUSIONS	O	1554-1565
:	O	1565-1566
Pharmacokinetic	O	1567-1582
differences	O	1583-1594
in	O	1595-1597
statins	O	1598-1605
are	O	1606-1609
an	O	1610-1612
important	O	1613-1622
consideration	O	1623-1636
for	O	1637-1640
assessing	O	1641-1650
the	O	1651-1654
risk	O	1655-1659
of	O	1660-1662
potential	O	1663-1672
drug	O	1673-1677
interactions	O	1678-1690
.	O	1690-1691

In	O	1692-1694
patients	O	1695-1703
requiring	O	1704-1713
the	O	1714-1717
concurrent	O	1718-1728
use	O	1729-1732
of	O	1733-1735
statins	O	1736-1743
and	O	1744-1747
CYP3A4	O	1748-1754
inhibitors	O	1755-1765
,	O	1765-1766
pravastatin	O	1767-1778
,	O	1778-1779
fluvastatin	O	1780-1791
,	O	1791-1792
and	O	1793-1796
rosuvastatin	O	1797-1809
carry	O	1810-1815
the	O	1816-1819
lowest	O	1820-1826
risk	O	1827-1831
of	O	1832-1834
drug	O	1835-1839
interactions	O	1840-1852
;	O	1852-1853
atorvastatin	O	1854-1866
carries	O	1867-1874
moderate	O	1875-1883
risk	O	1884-1888
,	O	1888-1889
whereas	O	1890-1897
simvastatin	O	1898-1909
and	O	1910-1913
lovastatin	O	1914-1924
have	O	1925-1929
the	O	1930-1933
highest	O	1934-1941
risk	O	1942-1946
and	O	1947-1950
should	O	1951-1957
be	O	1958-1960
avoided	O	1961-1968
in	O	1969-1971
patients	O	1972-1980
taking	O	1981-1987
concomitant	O	1988-1999
CYP3A4	O	2000-2006
inhibitors	O	2007-2017
.	O	2017-2018

Phase	O	0-5
II	O	6-8
trial	O	9-14
of	O	15-17
vinorelbine	O	18-29
in	O	30-32
metastatic	O	33-43
squamous	B	44-52
cell	I	53-57
esophageal	I	58-68
carcinoma	I	69-78
.	O	78-79

European	O	80-88
Organization	O	89-101
for	O	102-105
Research	O	106-114
and	O	115-118
Treatment	O	119-128
of	O	129-131
Cancer	B	132-138
Gastrointestinal	O	139-155
Treat	O	156-161
Cancer	B	162-168
Cooperative	O	169-180
Group	O	181-186
.	O	186-187

PURPOSE	O	188-195
:	O	195-196
To	O	197-199
evaluate	O	200-208
the	O	209-212
response	O	213-221
rate	O	222-226
and	O	227-230
toxic	O	231-236
effects	O	237-244
of	O	245-247
vinorelbine	O	248-259
(	O	260-261
VNB	O	261-264
)	O	264-265
administered	O	266-278
as	O	279-281
a	O	282-283
single	O	284-290
agent	O	291-296
in	O	297-299
metastatic	O	300-310
squamous	B	311-319
cell	I	320-324
esophageal	I	325-335
carcinoma	I	336-345
.	O	345-346

PATIENTS	O	347-355
AND	O	356-359
METHODS	O	360-367
:	O	367-368
Forty	O	369-374
-	O	374-375
six	O	375-378
eligible	O	379-387
patients	O	388-396
with	O	397-401
measurable	O	402-412
lesions	O	413-420
were	O	421-425
included	O	426-434
and	O	435-438
were	O	439-443
stratified	O	444-454
according	O	455-464
to	O	465-467
previous	O	468-476
chemotherapy	O	477-489
.	O	489-490

Thirty	O	491-497
patients	O	498-506
without	O	507-514
prior	O	515-520
chemotherapy	O	521-533
and	O	534-537
16	O	538-540
pretreated	O	541-551
with	O	552-556
cisplatin	O	557-566
-	O	566-567
based	O	567-572
chemotherapy	O	573-585
were	O	586-590
assessable	O	591-601
for	O	602-605
toxicity	B	606-614
and	O	615-618
response	O	619-627
.	O	627-628

VNB	O	629-632
was	O	633-636
administered	O	637-649
weekly	O	650-656
as	O	657-659
a	O	660-661
25	O	662-664
-	O	664-665
mg	O	665-667
/	O	667-668
m2	O	668-670
short	O	671-676
intravenous	O	677-688
(	O	689-690
i	O	690-691
.	O	691-692
v	O	692-693
.	O	691-692
)	O	694-695
infusion	O	696-704
.	O	704-705

RESULTS	O	706-713
:	O	713-714
Six	O	715-718
of	O	719-721
30	O	722-724
patients	O	725-733
(	O	734-735
20	O	735-737
%	O	737-738
)	O	738-739
without	O	740-747
prior	O	748-753
chemotherapy	O	754-766
achieved	O	767-775
a	O	776-777
partial	O	778-785
response	O	786-794
(	O	795-796
PR	O	796-798
)	O	798-799
(	O	800-801
95	O	801-803
%	O	803-804
confidence	O	805-815
interval	O	816-824
[	O	825-826
CI	O	826-828
]	O	828-829
,	O	829-830
8	O	831-832
%	O	832-833
to	O	834-836
39	O	837-839
%	O	839-840
)	O	840-841
.	O	841-842

The	O	843-846
median	O	847-853
duration	O	854-862
of	O	863-865
response	O	866-874
was	O	875-878
21	O	879-881
weeks	O	882-887
(	O	888-889
range	O	889-894
,	O	894-895
17	O	896-898
to	O	899-901
28	O	902-904
)	O	904-905
.	O	905-906

One	O	907-910
of	O	911-913
16	O	914-916
patients	O	917-925
(	O	926-927
6	O	927-928
%	O	928-929
)	O	929-930
with	O	931-935
prior	O	936-941
chemotherapy	O	942-954
had	O	955-958
a	O	959-960
complete	O	961-969
response	O	970-978
(	O	979-980
CR	O	980-982
)	O	982-983
of	O	984-986
31	O	987-989
weeks	O	990-995
'	O	995-996
duration	O	997-1005
(	O	1006-1007
95	O	1007-1009
%	O	1009-1010
CI	O	1011-1013
,	O	1013-1014
0	O	1015-1016
%	O	1016-1017
to	O	1018-1020
30	O	1021-1023
%	O	1023-1024
)	O	1024-1025
.	O	1025-1026

The	O	1027-1030
overall	O	1031-1038
response	O	1039-1047
rate	O	1048-1052
(	O	1053-1054
World	O	1054-1059
Health	O	1060-1066
Organization	O	1067-1079
[	O	1080-1081
WHO	O	1081-1084
]	O	1084-1085
criteria	O	1086-1094
)	O	1094-1095
was	O	1096-1099
15	O	1100-1102
%	O	1102-1103
(	O	1104-1105
CR	O	1105-1107
,	O	1107-1108
2	O	1109-1110
%	O	1110-1111
;	O	1111-1112
PR	O	1113-1115
13	O	1116-1118
%	O	1118-1119
;	O	1119-1120
95	O	1121-1123
%	O	1123-1124
CI	O	1125-1127
,	O	1127-1128
6	O	1129-1130
%	O	1130-1131
to	O	1132-1134
29	O	1135-1137
%	O	1137-1138
)	O	1138-1139
.	O	1139-1140

The	O	1141-1144
median	O	1145-1151
dose	O	1152-1156
-	O	1156-1157
intensity	O	1157-1166
(	O	1167-1168
DI	O	1168-1170
)	O	1170-1171
was	O	1172-1175
20	O	1176-1178
mg	O	1179-1181
/	O	1181-1182
m2	O	1182-1184
/	O	1181-1182
wk	O	1185-1187
.	O	1187-1188

VNB	O	1189-1192
was	O	1193-1196
well	O	1197-1201
tolerated	O	1202-1211
and	O	1212-1215
zero	O	1216-1220
instances	O	1221-1230
of	O	1231-1233
WHO	O	1234-1237
grade	O	1238-1243
4	O	1244-1245
nonhematologic	O	1246-1260
toxicity	B	1261-1269
occurred	O	1270-1278
.	O	1278-1279

At	O	1280-1282
least	O	1283-1288
one	O	1289-1292
episode	O	1293-1300
of	O	1301-1303
grade	O	1304-1309
3	O	1310-1311
or	O	1312-1314
4	O	1315-1316
granulocytopenia	B	1317-1333
was	O	1334-1337
seen	O	1338-1342
in	O	1343-1345
59	O	1346-1348
%	O	1348-1349
of	O	1350-1352
patients	O	1353-1361
.	O	1361-1362

A	O	1363-1364
grade	O	1365-1370
2	O	1371-1372
or	O	1373-1375
3	O	1376-1377
infection	B	1378-1387
occurred	O	1388-1396
in	O	1397-1399
16	O	1400-1402
%	O	1402-1403
of	O	1404-1406
patients	O	1407-1415
,	O	1415-1416
but	O	1417-1420
no	O	1421-1423
toxic	O	1424-1429
deaths	B	1430-1436
occurred	O	1437-1445
.	O	1445-1446

Other	O	1447-1452
side	O	1453-1457
effects	O	1458-1465
were	O	1466-1470
rare	O	1471-1475
,	O	1475-1476
and	O	1477-1480
peripheral	B	1481-1491
neurotoxicity	I	1492-1505
has	O	1506-1509
been	O	1510-1514
minor	O	1515-1520
(	O	1521-1522
26	O	1522-1524
%	O	1524-1525
grade	O	1526-1531
1	O	1532-1533
)	O	1533-1534
.	O	1534-1535

CONCLUSION	O	1536-1546
:	O	1546-1547
These	O	1548-1553
data	O	1554-1558
indicate	O	1559-1567
that	O	1568-1572
VNB	O	1573-1576
is	O	1577-1579
an	O	1580-1582
active	O	1583-1589
agent	O	1590-1595
in	O	1596-1598
metastatic	O	1599-1609
esophageal	B	1610-1620
squamous	I	1621-1629
cell	I	1630-1634
carcinoma	I	1635-1644
.	O	1644-1645

Given	O	1646-1651
its	O	1652-1655
excellent	O	1656-1665
tolerance	O	1666-1675
profile	O	1676-1683
and	O	1684-1687
low	O	1688-1691
toxicity	B	1692-1700
,	O	1700-1701
further	O	1702-1709
evaluation	O	1710-1720
of	O	1721-1723
VNB	O	1724-1727
in	O	1728-1730
combination	O	1731-1742
therapy	O	1743-1750
is	O	1751-1753
warranted	O	1754-1763
.	O	1763-1764

Paclitaxel	O	0-10
,	O	10-11
cisplatin	O	12-21
,	O	21-22
and	O	23-26
gemcitabine	O	27-38
combination	O	39-50
chemotherapy	O	51-63
within	O	64-70
a	O	71-72
multidisciplinary	O	73-90
therapeutic	O	91-102
approach	O	103-111
in	O	112-114
metastatic	O	115-125
nonsmall	B	126-134
cell	I	135-139
lung	I	140-144
carcinoma	I	145-154
.	O	154-155

BACKGROUND	O	156-166
:	O	166-167
Cisplatin	O	168-177
-	O	177-178
based	O	178-183
chemotherapy	O	184-196
combinations	O	197-209
improve	O	210-217
quality	O	218-225
of	O	226-228
life	O	229-233
and	O	234-237
survival	O	238-246
in	O	247-249
advanced	O	250-258
nonsmall	B	259-267
cell	I	268-272
lung	I	273-277
carcinoma	I	278-287
(	O	288-289
NSCLC	B	289-294
)	O	294-295
.	O	295-296

The	O	297-300
emergence	O	301-310
of	O	311-313
new	O	314-317
active	O	318-324
drugs	O	325-330
might	O	331-336
translate	O	337-346
into	O	347-351
more	O	352-356
effective	O	357-366
regimens	O	367-375
for	O	376-379
the	O	380-383
treatment	O	384-393
of	O	394-396
this	O	397-401
disease	O	402-409
.	O	409-410

METHODS	O	411-418
:	O	418-419
The	O	420-423
objective	O	424-433
of	O	434-436
this	O	437-441
study	O	442-447
was	O	448-451
to	O	452-454
determine	O	455-464
the	O	465-468
feasibility	O	469-480
,	O	480-481
response	O	482-490
rate	O	491-495
,	O	495-496
and	O	497-500
toxicity	B	501-509
of	O	510-512
a	O	513-514
paclitaxel	O	515-525
,	O	525-526
cisplatin	O	527-536
,	O	536-537
and	O	538-541
gemcitabine	O	542-553
combination	O	554-565
to	O	566-568
treat	O	569-574
metastatic	O	575-585
NSCLC	B	586-591
.	O	591-592

Thirty	O	593-599
-	O	599-600
five	O	600-604
consecutive	O	605-616
chemotherapy	O	617-629
-	O	629-630
naive	O	630-635
patients	O	636-644
with	O	645-649
Stage	O	650-655
IV	O	656-658
NSCLC	B	659-664
and	O	665-668
an	O	669-671
Eastern	O	672-679
Cooperative	O	680-691
Oncology	O	692-700
Group	O	701-706
performance	O	707-718
status	O	719-725
of	O	726-728
0	O	729-730
-	O	730-731
2	O	731-732
were	O	733-737
treated	O	738-745
with	O	746-750
a	O	751-752
combination	O	753-764
of	O	765-767
paclitaxel	O	768-778
(	O	779-780
135	O	780-783
mg	O	784-786
/	O	786-787
m	O	784-785
(	O	788-789
2	O	789-790
)	O	790-791
given	O	792-797
intravenously	O	798-811
in	O	812-814
3	O	815-816
hours	O	817-822
)	O	822-823
on	O	824-826
Day	O	827-830
1	O	831-832
,	O	832-833
cisplatin	O	834-843
(	O	844-845
120	O	845-848
mg	O	849-851
/	O	851-852
m	O	849-850
(	O	853-854
2	O	854-855
)	O	855-856
given	O	857-862
intravenously	O	863-876
in	O	877-879
6	O	880-881
hours	O	882-887
)	O	887-888
on	O	889-891
Day	O	892-895
1	O	896-897
,	O	897-898
and	O	899-902
gemcitabine	O	903-914
(	O	915-916
800	O	916-919
mg	O	920-922
/	O	922-923
m	O	920-921
(	O	924-925
2	O	925-926
)	O	926-927
given	O	928-933
intravenously	O	934-947
in	O	948-950
30	O	951-953
minutes	O	954-961
)	O	961-962
on	O	963-965
Days	O	966-970
1	O	971-972
and	O	973-976
8	O	977-978
,	O	978-979
every	O	980-985
4	O	986-987
weeks	O	988-993
.	O	993-994

Although	O	995-1003
responding	O	1004-1014
patients	O	1015-1023
were	O	1024-1028
scheduled	O	1029-1038
to	O	1039-1041
receive	O	1042-1049
consolidation	O	1050-1063
radiotherapy	O	1064-1076
and	O	1077-1080
24	O	1081-1083
patients	O	1084-1092
received	O	1093-1101
preplanned	O	1102-1112
second	O	1113-1119
-	O	1119-1120
line	O	1120-1124
chemotherapy	O	1125-1137
after	O	1138-1143
disease	O	1144-1151
progression	O	1152-1163
,	O	1163-1164
the	O	1165-1168
response	O	1169-1177
and	O	1178-1181
toxicity	B	1182-1190
rates	O	1191-1196
reported	O	1197-1205
refer	O	1206-1211
only	O	1212-1216
to	O	1217-1219
the	O	1220-1223
chemotherapy	O	1224-1236
regimen	O	1237-1244
given	O	1245-1250
.	O	1250-1251

RESULTS	O	1252-1259
:	O	1259-1260
All	O	1261-1264
the	O	1265-1268
patients	O	1269-1277
were	O	1278-1282
examined	O	1283-1291
for	O	1292-1295
toxicity	B	1296-1304
;	O	1304-1305
34	O	1306-1308
were	O	1309-1313
examinable	O	1314-1324
for	O	1325-1328
response	O	1329-1337
.	O	1337-1338

An	O	1339-1341
objective	O	1342-1351
response	O	1352-1360
was	O	1361-1364
observed	O	1365-1373
in	O	1374-1376
73	O	1377-1379
.	O	1379-1380
5	O	1380-1381
%	O	1381-1382
of	O	1383-1385
the	O	1386-1389
patients	O	1390-1398
(	O	1399-1400
95	O	1400-1402
%	O	1402-1403
confidence	O	1404-1414
interval	O	1415-1423
[	O	1424-1425
CI	O	1425-1427
]	O	1427-1428
,	O	1428-1429
55	O	1430-1432
.	O	1432-1433
6	O	1433-1434
-	O	1434-1435
87	O	1435-1437
.	O	1432-1433
1	O	1438-1439
%	O	1439-1440
)	O	1440-1441
,	O	1441-1442

including	O	1443-1452
4	O	1453-1454
complete	O	1455-1463
responses	O	1464-1473
(	O	1474-1475
11	O	1475-1477
.	O	1477-1478
7	O	1478-1479
%	O	1479-1480
)	O	1480-1481
.	O	1477-1478

According	O	1483-1492
to	O	1493-1495
intention	O	1496-1505
-	O	1505-1506
to	O	1506-1508
-	O	1505-1506
treat	O	1509-1514
,	O	1514-1515
the	O	1516-1519
overall	O	1520-1527
response	O	1528-1536
rate	O	1537-1541
was	O	1542-1545
71	O	1546-1548
.	O	1548-1549
4	O	1549-1550
%	O	1550-1551
(	O	1552-1553
95	O	1553-1555
%	O	1555-1556
CI	O	1557-1559
,	O	1559-1560
53	O	1561-1563
.	O	1563-1564

7	O	1565-1566
-	O	1566-1567
85	O	1567-1569
.	O	1569-1570
4	O	1570-1571
%	O	1571-1572
)	O	1572-1573
.	O	1569-1570

After	O	1575-1580
154	O	1581-1584
courses	O	1585-1592
of	O	1593-1595
therapy	O	1596-1603
,	O	1603-1604
the	O	1605-1608
median	O	1609-1615
dose	O	1616-1620
intensity	O	1621-1630
was	O	1631-1634
131	O	1635-1638
mg	O	1639-1641
/	O	1641-1642
m	O	1639-1640
(	O	1643-1644
2	O	1644-1645
)	O	1645-1646
for	O	1647-1650
paclitaxel	O	1651-1661
(	O	1662-1663
97	O	1663-1665
.	O	1665-1666
3	O	1666-1667
%	O	1667-1668
)	O	1668-1669
,	O	1669-1670
117	O	1671-1674
mg	O	1675-1677
/	O	1677-1678
m	O	1675-1676
(	O	1679-1680
2	O	1680-1681
)	O	1681-1682
for	O	1683-1686
cisplatin	O	1687-1696
(	O	1697-1698
97	O	1698-1700
.	O	1700-1701
3	O	1701-1702
%	O	1702-1703
)	O	1703-1704
,	O	1704-1705
and	O	1706-1709
1378	O	1710-1714
mg	O	1715-1717
/	O	1717-1718
m	O	1715-1716
(	O	1719-1720
2	O	1720-1721
)	O	1721-1722
for	O	1723-1726
gemcitabine	O	1727-1738
(	O	1739-1740
86	O	1740-1742
.	O	1742-1743
2	O	1743-1744
%	O	1744-1745
)	O	1745-1746
.	O	1742-1743

World	O	1748-1753
Health	O	1754-1760
Organization	O	1761-1773
Grade	O	1774-1779
3	O	1780-1781
-	O	1781-1782
4	O	1782-1783
neutropenia	B	1784-1795
and	O	1796-1799
thrombocytopenia	B	1800-1816
occurred	O	1817-1825
in	O	1826-1828
39	O	1829-1831
.	O	1831-1832
9	O	1830-1831
%	O	1833-1834
and	O	1835-1838
11	O	1839-1841
.	O	1841-1842
4	O	1842-1843
%	O	1843-1844
of	O	1845-1847
patients	O	1848-1856
,	O	1856-1857
respectively	O	1858-1870
.	O	1870-1871

There	O	1872-1877
was	O	1878-1881
one	O	1882-1885
treatment	O	1886-1895
-	O	1895-1896
related	O	1896-1903
death	B	1904-1909
.	O	1909-1910

Nonhematologic	O	1911-1925
toxicities	B	1926-1936
were	O	1937-1941
mild	O	1942-1946
.	O	1946-1947

After	O	1948-1953
a	O	1954-1955
median	O	1956-1962
follow	O	1963-1969
-	O	1969-1970
up	O	1970-1972
of	O	1973-1975
22	O	1976-1978
months	O	1979-1985
,	O	1985-1986
the	O	1987-1990
median	O	1991-1997
progression	O	1998-2009
free	O	2010-2014
survival	O	2015-2023
rate	O	2024-2028
was	O	2029-2032
7	O	2033-2034
months	O	2035-2041
,	O	2041-2042
and	O	2043-2046
the	O	2047-2050
median	O	2051-2057
survival	O	2058-2066
time	O	2067-2071
was	O	2072-2075
16	O	2076-2078
months	O	2079-2085
.	O	2085-2086

CONCLUSIONS	O	2087-2098
:	O	2098-2099
The	O	2100-2103
combination	O	2104-2115
of	O	2116-2118
paclitaxel	O	2119-2129
,	O	2129-2130
cisplatin	O	2131-2140
,	O	2140-2141
and	O	2142-2145
gemcitabine	O	2146-2157
is	O	2158-2160
well	O	2161-2165
tolerated	O	2166-2175
and	O	2176-2179
shows	O	2180-2185
high	O	2186-2190
activity	O	2191-2199
in	O	2200-2202
metastatic	O	2203-2213
NSCLC	B	2214-2219
.	O	2219-2220

This	O	2221-2225
treatment	O	2226-2235
merits	O	2236-2242
further	O	2243-2250
comparison	O	2251-2261
with	O	2262-2266
other	O	2267-2272
cisplatin	O	2273-2282
-	O	2282-2283
based	O	2283-2288
regimens	O	2289-2297
.	O	2297-2298

Evaluation	O	0-10
of	O	11-13
adverse	O	14-21
reactions	O	22-31
of	O	32-34
aponidine	O	35-44
hydrochloride	O	45-58
ophthalmic	O	59-69
solution	O	70-78
.	O	78-79

We	O	80-82
prospectively	O	83-96
evaluated	O	97-106
the	O	107-110
adverse	O	111-118
reactions	O	119-128
of	O	129-131
apraclonidine	O	132-145
in	O	146-148
20	O	149-151
normal	O	152-158
volunteers	O	159-169
by	O	170-172
instilling	O	173-183
a	O	184-185
single	O	186-192
drop	O	193-197
of	O	198-200
1	O	201-202
%	O	202-203
apraclonidine	O	204-217
in	O	218-220
their	O	221-226
right	O	227-232
eyes	O	233-237
.	O	237-238

Examinations	O	239-251
,	O	251-252
including	O	253-262
blood	O	263-268
pressure	O	269-277
,	O	277-278
pulse	O	279-284
rate	O	285-289
,	O	289-290
conjunctiva	O	291-302
and	O	303-306
cornea	O	307-313
,	O	313-314
intraocular	O	315-326
pressure	O	327-335
(	O	336-337
IOP	O	337-340
)	O	340-341
,	O	341-342
pupil	O	343-348
diameter	O	349-357
,	O	357-358
basal	O	359-364
tear	O	365-369
secretion	O	370-379
and	O	380-383
margin	O	384-390
reflex	O	391-397
distance	O	398-406
of	O	407-409
both	O	410-414
upper	O	415-420
and	O	421-424
lower	O	425-430
eyelids	O	431-438
,	O	438-439
were	O	440-444
performed	O	445-454
prior	O	455-460
to	O	461-463
entry	O	464-469
and	O	470-473
at	O	474-476
1	O	477-478
,	O	478-479
3	O	480-481
,	O	481-482
5	O	483-484
and	O	485-488
7	O	489-490
hours	O	491-496
after	O	497-502
instillation	O	503-515
.	O	515-516

The	O	517-520
ocular	B	521-527
hypotensive	I	528-539
effects	O	540-547
were	O	548-552
statistically	O	553-566
significant	O	567-578
for	O	579-582
apraclonidine	O	583-596
-	O	596-597
treated	O	597-604
eyes	O	605-609
throughout	O	610-620
the	O	621-624
study	O	625-630
and	O	631-634
also	O	635-639
statistically	O	640-653
significant	O	654-665
for	O	666-669
contralateral	O	670-683
eyes	O	684-688
from	O	689-693
three	O	694-699
hours	O	700-705
after	O	706-711
topical	O	712-719
administration	O	720-734
of	O	735-737
1	O	738-739
%	O	739-740
apraclonidine	O	741-754
.	O	754-755

Decreases	B	756-765
in	I	766-768
systolic	I	769-777
blood	I	778-783
pressure	I	784-792
were	O	793-797
statistically	O	798-811
,	O	811-812
but	O	813-816
not	O	817-820
clinically	O	821-831
,	O	831-832
significant	O	833-844
.	O	844-845

No	O	846-848
significant	O	849-860
changes	O	861-868
in	O	869-871
diastolic	O	872-881
blood	O	882-887
pressure	O	888-896
,	O	896-897
pulse	O	898-903
rate	O	904-908
and	O	909-912
basal	O	913-918
tear	O	919-923
secretion	O	924-933
were	O	934-938
noted	O	939-944
.	O	944-945

Conjunctival	B	946-958
blanching	I	959-968
and	O	969-972
mydriasis	B	973-982
were	O	983-987
commonly	O	988-996
found	O	997-1002
.	O	1002-1003

Upper	O	1004-1009
lid	O	1010-1013
retraction	O	1014-1024
was	O	1025-1028
frequently	O	1029-1039
noted	O	1040-1045
.	O	1045-1046

While	O	1047-1052
the	O	1053-1056
elevations	O	1057-1067
of	O	1068-1070
the	O	1071-1074
upper	O	1075-1080
lid	O	1081-1084
margin	O	1085-1091
in	O	1092-1094
most	O	1095-1099
subjects	O	1100-1108
were	O	1109-1113
not	O	1114-1117
more	O	1118-1122
than	O	1123-1127
2	O	1128-1129
mm	O	1130-1132
and	O	1133-1136
did	O	1137-1140
not	O	1141-1144
cause	O	1145-1150
noticeable	O	1151-1161
change	O	1162-1168
in	O	1169-1171
appearance	O	1172-1182
,	O	1182-1183
one	O	1184-1187
subject	O	1188-1195
suffered	O	1196-1204
from	O	1205-1209
mechanical	O	1210-1220
entropion	B	1221-1230
and	O	1231-1234
marked	O	1235-1241
corneal	B	1242-1249
abrasion	I	1250-1258
3	O	1259-1260
hours	O	1261-1266
after	O	1267-1272
instillation	O	1273-1285
of	O	1286-1288
the	O	1289-1292
medication	O	1293-1303
.	O	1303-1304

This	O	1305-1309
may	O	1310-1313
well	O	1314-1318
be	O	1319-1321
a	O	1322-1323
particularly	O	1324-1336
notable	O	1337-1344
finding	O	1345-1352
in	O	1353-1355
Asian	O	1356-1361
people	O	1362-1368
.	O	1368-1369

Carmofur	O	0-8
-	O	8-9
induced	O	9-16
organic	B	17-24
mental	I	25-31
disorders	I	32-41
.	O	41-42

Organic	B	43-50
mental	I	51-57
disorder	I	58-66
was	O	67-70
observed	O	71-79
in	O	80-82
a	O	83-84
29	O	85-87
-	O	87-88
year	O	88-92
-	O	87-88
old	O	93-96
female	O	97-103
in	O	104-106
the	O	107-110
prognostic	O	111-121
period	O	122-128
after	O	129-134
the	O	135-138
onset	O	139-144
of	O	145-147
carmofur	O	148-156
-	O	156-157
induced	O	157-164
leukoencephalopathy	B	165-184
.	O	184-185

Symptoms	O	186-194
such	O	195-199
as	O	200-202
euphoria	O	203-211
,	O	211-212
emotional	O	213-222
lability	O	223-231
and	O	232-235
puerile	O	236-243
attitude	O	244-252
noted	O	253-258
in	O	259-261
the	O	262-265
patient	O	266-273
were	O	274-278
diagnosed	O	279-288
as	O	289-291
organic	B	292-299
personality	I	300-311
syndrome	I	312-320
according	O	321-330
to	O	331-333
the	O	334-337
criteria	O	338-346
defined	O	347-354
in	O	355-357
the	O	358-361
DSM	O	362-365
-	O	365-366
III	O	366-369
-	O	365-366
R	O	370-371
.	O	371-372

It	O	373-375
is	O	376-378
referred	O	379-387
to	O	388-390
as	O	391-393
a	O	394-395
frontal	B	396-403
lobe	I	404-408
syndrome	I	409-417
.	O	417-418

Brain	O	419-424
CT	O	425-427
revealed	O	428-436
a	O	437-438
periventricular	O	439-454
low	O	455-458
density	O	459-466
area	O	467-471
in	O	472-474
the	O	475-478
frontal	O	479-486
white	O	487-492
matter	O	493-499
and	O	500-503
moderate	O	504-512
dilatation	O	513-523
of	O	524-526
the	O	527-530
lateral	O	531-538
ventricles	O	539-549
especially	O	550-560
at	O	561-563
the	O	564-567
bilateral	O	568-577
anterior	O	578-586
horns	O	587-592
.	O	592-593

Consequently	O	594-606
,	O	606-607
carmofur	O	608-616
-	O	616-617
induced	O	617-624
leukoencephalopathy	B	625-644
may	O	645-648
uncommonly	O	649-659
result	O	660-666
in	O	667-669
organic	B	670-677
personality	I	678-689
syndrome	I	690-698
in	O	699-701
the	O	702-705
residual	O	706-714
state	O	715-720
.	O	720-721

It	O	722-724
may	O	725-728
be	O	729-731
attributed	O	732-742
to	O	743-745
the	O	746-749
structural	B	750-760
damage	I	761-767
to	I	768-770
the	I	771-774
frontal	I	775-782
lobe	I	783-787
.	O	787-788

International	O	0-13
mexiletine	O	14-24
and	O	25-28
placebo	O	29-36
antiarrhythmic	O	37-51
coronary	O	52-60
trial	O	61-66
:	O	66-67
I	O	68-69
.	O	69-70
Report	O	71-77
on	O	78-80
arrhythmia	B	81-91
and	O	92-95
other	O	96-101
findings	O	102-110
.	O	110-111

Impact	O	112-118
Research	O	119-127
Group	O	128-133
.	O	133-134

The	O	135-138
antiarrhythmic	O	139-153
effects	O	154-161
of	O	162-164
the	O	165-168
sustained	O	169-178
release	O	179-186
form	O	187-191
of	O	192-194
mexiletine	O	195-205
(	O	206-207
Mexitil	O	207-214
-	O	214-215
Perlongets	O	215-225
)	O	225-226
were	O	227-231
evaluated	O	232-241
in	O	242-244
a	O	245-246
double	O	247-253
-	O	253-254
blind	O	254-259
placebo	O	260-267
trial	O	268-273
in	O	274-276
630	O	277-280
patients	O	281-289
with	O	290-294
recent	O	295-301
documented	O	302-312
myocardial	B	313-323
infarction	I	324-334
.	O	334-335

The	O	336-339
primary	O	340-347
response	O	348-356
variable	O	357-365
was	O	366-369
based	O	370-375
on	O	376-378
central	O	379-386
reading	O	387-394
of	O	395-397
24	O	398-400
hour	O	401-405
ambulatory	O	406-416
electrocardiographic	O	417-437
recordings	O	438-448
and	O	449-452
was	O	453-456
defined	O	457-464
as	O	465-467
the	O	468-471
occurrence	O	472-482
of	O	483-485
30	O	486-488
or	O	489-491
more	O	492-496
single	O	497-503
premature	O	504-513
ventricular	O	514-525
complexes	O	526-535
in	O	536-538
any	O	539-542
two	O	543-546
consecutive	O	547-558
30	O	559-561
minute	O	562-568
blocks	O	569-575
or	O	576-578
one	O	579-582
or	O	583-585
more	O	586-590
runs	O	591-595
of	O	596-598
two	O	599-602
or	O	603-605
more	O	606-610
premature	O	611-620
ventricular	O	621-632
complexes	O	633-642
in	O	643-645
the	O	646-649
entire	O	650-656
24	O	657-659
hour	O	660-664
electrocardiographic	O	665-685
recording	O	686-695
.	O	695-696

Large	O	697-702
differences	O	703-714
,	O	714-715
regarded	O	716-724
as	O	725-727
statistically	O	728-741
significant	O	742-753
,	O	753-754
between	O	755-762
the	O	763-766
mexiletine	O	767-777
and	O	778-781
placebo	O	782-789
groups	O	790-796
were	O	797-801
noted	O	802-807
in	O	808-810
that	O	811-815
end	O	816-819
point	O	820-825
at	O	826-828
months	O	829-835
1	O	836-837
and	O	838-841
4	O	842-843
,	O	843-844
but	O	845-848
only	O	849-853
trends	O	854-860
were	O	861-865
observed	O	866-874
at	O	875-877
month	O	878-883
12	O	884-886
.	O	886-887

These	O	888-893
differences	O	894-905
were	O	906-910
observed	O	911-919
even	O	920-924
though	O	925-931
the	O	932-935
serum	O	936-941
mexiletine	O	942-952
levels	O	953-959
obtained	O	960-968
in	O	969-971
this	O	972-976
study	O	977-982
were	O	983-987
generally	O	988-997
lower	O	998-1003
than	O	1004-1008
those	O	1009-1014
observed	O	1015-1023
in	O	1024-1026
studies	O	1027-1034
that	O	1035-1039
have	O	1040-1044
used	O	1045-1049
the	O	1050-1053
regular	O	1054-1061
form	O	1062-1066
of	O	1067-1069
the	O	1070-1073
drug	O	1074-1078
.	O	1078-1079

There	O	1080-1085
were	O	1086-1090
more	O	1091-1095
deaths	B	1096-1102
in	O	1103-1105
the	O	1106-1109
mexiletine	O	1110-1120
group	O	1121-1126
(	O	1127-1128
7	O	1128-1129
.	O	1129-1130
6	O	1130-1131
%	O	1131-1132
)	O	1132-1133
than	O	1134-1138
in	O	1139-1141
the	O	1142-1145
placebo	O	1146-1153
group	O	1154-1159
(	O	1160-1161
4	O	1161-1162
.	O	1162-1163
8	O	1163-1164
%	O	1164-1165
)	O	1165-1166
;	O	1166-1167
the	O	1168-1171
difference	O	1172-1182
was	O	1183-1186
not	O	1187-1190
statistically	O	1191-1204
significant	O	1205-1216
.	O	1216-1217

The	O	1218-1221
incidence	O	1222-1231
of	O	1232-1234
coronary	O	1235-1243
events	O	1244-1250
was	O	1251-1254
similar	O	1255-1262
in	O	1263-1265
both	O	1266-1270
groups	O	1271-1277
.	O	1277-1278

Previously	O	1279-1289
recognized	O	1290-1300
side	O	1301-1305
effects	O	1306-1313
,	O	1313-1314
particularly	O	1315-1327
tremor	B	1328-1334
and	O	1335-1338
gastrointestinal	B	1339-1355
problems	I	1356-1364
,	O	1364-1365
were	O	1366-1370
more	O	1371-1375
frequent	O	1376-1384
in	O	1385-1387
the	O	1388-1391
mexiletine	O	1392-1402
group	O	1403-1408
than	O	1409-1413
in	O	1414-1416
the	O	1417-1420
placebo	O	1421-1428
group	O	1429-1434
.	O	1434-1435

Regional	O	0-8
localization	O	9-21
of	O	22-24
the	O	25-28
antagonism	O	29-39
of	O	40-42
amphetamine	O	43-54
-	O	54-55
induced	O	55-62
hyperactivity	B	63-76
by	O	77-79
intracerebral	O	80-93
calcitonin	O	94-104
injections	O	105-115
.	O	115-116

Calcitonin	O	117-127
receptors	O	128-137
are	O	138-141
found	O	142-147
in	O	148-150
the	O	151-154
brain	O	155-160
,	O	160-161
and	O	162-165
intracerebral	O	166-179
infusions	O	180-189
of	O	190-192
calcitonin	O	193-203
can	O	204-207
produce	O	208-215
behavioral	O	216-226
effects	O	227-234
.	O	234-235

Among	O	236-241
these	O	242-247
behavioral	O	248-258
effects	O	259-266
are	O	267-270
decreases	O	271-280
in	O	281-283
food	O	284-288
intake	O	289-295
and	O	296-299
decreases	O	300-309
in	O	310-312
amphetamine	O	313-324
-	O	324-325
induced	O	325-332
locomotor	O	333-342
activity	O	343-351
.	O	351-352

In	O	353-355
previous	O	356-364
experiments	O	365-376
we	O	377-379
found	O	380-385
that	O	386-390
decreases	O	391-400
in	O	401-403
food	O	404-408
intake	O	409-415
were	O	416-420
induced	O	421-428
by	O	429-431
local	O	432-437
administration	O	438-452
of	O	453-455
calcitonin	O	456-466
into	O	467-471
several	O	472-479
hypothalamic	O	480-492
sites	O	493-498
and	O	499-502
into	O	503-507
the	O	508-511
nucleus	O	512-519
accumbens	O	520-529
.	O	529-530

In	O	531-533
the	O	534-537
present	O	538-545
experiment	O	546-556
calcitonin	O	557-567
decreased	O	568-577
locomotor	O	578-587
activity	O	588-596
when	O	597-601
locally	O	602-609
injected	O	610-618
into	O	619-623
the	O	624-627
same	O	628-632
sites	O	633-638
where	O	639-644
it	O	645-647
decreases	O	648-657
food	O	658-662
intake	O	663-669
.	O	669-670

The	O	671-674
areas	O	675-680
where	O	681-686
calcitonin	O	687-697
is	O	698-700
most	O	701-705
effective	O	706-715
in	O	716-718
decreasing	O	719-729
locomotor	O	730-739
activity	O	740-748
are	O	749-752
located	O	753-760
in	O	761-763
the	O	764-767
hypothalamus	O	768-780
and	O	781-784
nucleus	O	785-792
accumbens	O	793-802
,	O	802-803
suggesting	O	804-814
that	O	815-819
these	O	820-825
areas	O	826-831
are	O	832-835
the	O	836-839
major	O	840-845
sites	O	846-851
of	O	852-854
action	O	855-861
of	O	862-864
calcitonin	O	865-875
in	O	876-878
inhibiting	O	879-889
amphetamine	O	890-901
-	O	901-902
induced	O	902-909
locomotor	O	910-919
activity	O	920-928
.	O	928-929

Fatal	O	0-5
intracranial	B	6-18
bleeding	I	19-27
associated	O	28-38
with	O	39-43
prehospital	O	44-55
use	O	56-59
of	O	60-62
epinephrine	O	63-74
.	O	74-75

We	O	76-78
present	O	79-86
a	O	87-88
case	O	89-93
of	O	94-96
paramedic	O	97-106
misjudgment	O	107-118
in	O	119-121
the	O	122-125
execution	O	126-135
of	O	136-138
a	O	139-140
protocol	O	141-149
for	O	150-153
the	O	154-157
treatment	O	158-167
of	O	168-170
allergic	B	171-179
reaction	I	180-188
in	O	189-191
a	O	192-193
case	O	194-198
of	O	199-201
pulmonary	B	202-211
edema	I	212-217
with	O	218-222
wheezing	B	223-231
.	O	231-232

The	O	233-236
sudden	O	237-243
onset	O	244-249
of	O	250-252
respiratory	B	253-264
distress	I	265-273
,	O	273-274
rash	B	275-279
,	O	279-280
and	O	281-284
a	O	285-286
history	O	287-294
of	O	295-297
a	O	298-299
new	O	300-303
medicine	O	304-312
led	O	313-316
the	O	317-320
two	O	321-324
paramedics	O	325-335
on	O	336-338
the	O	339-342
scene	O	343-348
to	O	349-351
administer	O	352-362
subcutaneous	O	363-375
epinephrine	O	376-387
.	O	387-388

Subsequently	O	389-401
,	O	401-402
acute	O	403-408
cardiac	B	409-416
arrest	I	417-423
and	O	424-427
fatal	O	428-433
subarachnoid	B	434-446
hemorrhage	I	447-457
occurred	O	458-466
.	O	466-467

Epinephrine	O	468-479
has	O	480-483
a	O	484-485
proven	O	486-492
role	O	493-497
in	O	498-500
cardiac	B	501-508
arrest	I	509-515
in	O	516-518
prehospital	O	519-530
care	O	531-535
;	O	535-536
however	O	537-544
,	O	544-545
use	O	546-549
by	O	550-552
paramedics	O	553-563
in	O	564-566
patients	O	567-575
with	O	576-580
suspected	O	581-590
allergic	B	591-599
reaction	I	600-608
and	O	609-612
severe	O	613-619
hypertension	B	620-632
should	O	633-639
be	O	640-642
viewed	O	643-649
with	O	650-654
caution	O	655-662
.	O	662-663

A	O	0-1
case	O	2-6
of	O	7-9
massive	O	10-17
rhabdomyolysis	B	18-32
following	O	33-42
molindone	O	43-52
administration	O	53-67
.	O	67-68

Rhabdomyolysis	B	69-83
is	O	84-86
a	O	87-88
potentially	O	89-100
lethal	O	101-107
syndrome	O	108-116
that	O	117-121
psychiatric	B	122-133
patients	O	134-142
seem	O	143-147
predisposed	O	148-159
to	O	160-162
develop	O	163-170
.	O	170-171

The	O	172-175
clinical	O	176-184
signs	O	185-190
and	O	191-194
symptoms	O	195-203
,	O	203-204
typical	O	205-212
laboratory	O	213-223
features	O	224-232
,	O	232-233
and	O	234-237
complications	O	238-251
of	O	252-254
rhabdomyolysis	B	255-269
are	O	270-273
presented	O	274-283
.	O	283-284

The	O	285-288
case	O	289-293
of	O	294-296
a	O	297-298
schizophrenic	B	299-312
patient	O	313-320
is	O	321-323
reported	O	324-332
to	O	333-335
illustrate	O	336-346
massive	O	347-354
rhabdomyolysis	B	355-369
and	O	370-373
subsequent	O	374-384
acute	B	385-390
renal	I	391-396
failure	I	397-404
following	O	405-414
molindone	O	415-424
administration	O	425-439
.	O	439-440

Physicians	O	441-451
who	O	452-455
prescribe	O	456-465
molindone	O	466-475
should	O	476-482
be	O	483-485
aware	O	486-491
of	O	492-494
this	O	495-499
reaction	O	500-508
.	O	508-509

Cardiovascular	B	0-14
alterations	I	15-26
in	O	27-29
rat	O	30-33
fetuses	O	34-41
exposed	O	42-49
to	O	50-52
calcium	O	53-60
channel	O	61-68
blockers	O	69-77
.	O	77-78

Preclinical	O	79-90
toxicologic	O	91-102
investigation	O	103-116
suggested	O	117-126
that	O	127-131
a	O	132-133
new	O	134-137
calcium	O	138-145
channel	O	146-153
blocker	O	154-161
,	O	161-162
Ro	O	163-165
40	O	166-168
-	O	168-169
5967	O	169-173
,	O	173-174
induced	O	175-182
cardiovascular	B	183-197
alterations	I	198-209
in	O	210-212
rat	O	213-216
fetuses	O	217-224
exposed	O	225-232
to	O	233-235
this	O	236-240
agent	O	241-246
during	O	247-253
organogenesis	O	254-267
.	O	267-268

The	O	269-272
present	O	273-280
study	O	281-286
was	O	287-290
designed	O	291-299
to	O	300-302
investigate	O	303-314
the	O	315-318
hypothesis	O	319-329
that	O	330-334
calcium	O	335-342
channel	O	343-350
blockers	O	351-359
in	O	360-362
general	O	363-370
induce	O	371-377
cardiovascular	B	378-392
malformations	I	393-406
indicating	O	407-417
a	O	418-419
pharmacologic	O	420-433
class	O	434-439
effect	O	440-446
.	O	446-447

We	O	448-450
studied	O	451-458
three	O	459-464
calcium	O	465-472
channel	O	473-480
blockers	O	481-489
of	O	490-492
different	O	493-502
structure	O	503-512
,	O	512-513
nifedipine	O	514-524
,	O	524-525
diltiazem	O	526-535
,	O	535-536
and	O	537-540
verapamil	O	541-550
,	O	550-551
along	O	552-557
with	O	558-562
the	O	563-566
new	O	567-570
agent	O	571-576
.	O	576-577

Pregnant	O	578-586
rats	O	587-591
were	O	592-596
administered	O	597-609
one	O	610-613
of	O	614-616
these	O	617-622
calcium	O	623-630
channel	O	631-638
blockers	O	639-647
during	O	648-654
the	O	655-658
period	O	659-665
of	O	666-668
cardiac	O	669-676
morphogenesis	O	677-690
and	O	691-694
the	O	695-698
offspring	O	699-708
examined	O	709-717
on	O	718-720
day	O	721-724
20	O	725-727
of	O	728-730
gestation	O	731-740
for	O	741-744
cardiovascular	B	745-759
malformations	I	760-773
.	O	773-774

A	O	775-776
low	O	777-780
incidence	O	781-790
of	O	791-793
cardiovascular	B	794-808
malformations	I	809-822
was	O	823-826
observed	O	827-835
after	O	836-841
exposure	O	842-850
to	O	851-853
each	O	854-858
of	O	859-861
the	O	862-865
four	O	866-870
calcium	O	871-878
channel	O	879-886
blockers	O	887-895
,	O	895-896
but	O	897-900
this	O	901-905
incidence	O	906-915
was	O	916-919
statistically	O	920-933
significant	O	934-945
only	O	946-950
for	O	951-954
verapamil	O	955-964
and	O	965-968
nifedipine	O	969-979
.	O	979-980

All	O	981-984
four	O	985-989
agents	O	990-996
were	O	997-1001
associated	O	1002-1012
with	O	1013-1017
aortic	O	1018-1024
arch	O	1025-1029
branching	O	1030-1039
variants	O	1040-1048
,	O	1048-1049
although	O	1050-1058
significantly	O	1059-1072
increased	O	1073-1082
only	O	1083-1087
for	O	1088-1091
Ro	O	1092-1094
40	O	1095-1097
-	O	1097-1098
5967	O	1098-1102
and	O	1103-1106
verapamil	O	1107-1116
.	O	1116-1117

Differential	O	0-12
impact	O	13-19
of	O	20-22
immune	O	23-29
escape	O	30-36
mutations	O	37-46
G145R	O	47-52
and	O	53-56
P120T	O	57-62
on	O	63-65
the	O	66-69
replication	O	70-81
of	O	82-84
lamivudine	O	85-95
-	O	95-96
resistant	O	96-105
hepatitis	O	106-115
B	O	116-117
virus	O	118-123
e	O	124-125
antigen	O	126-133
-	O	133-134
positive	O	134-142
and	O	143-146
-	O	147-148
negative	O	148-156
strains	O	157-164
.	O	164-165

Immune	O	166-172
escape	O	173-179
variants	O	180-188
of	O	189-191
the	O	192-195
hepatitis	B	196-205
B	I	206-207
virus	O	208-213
(	O	214-215
HBV	O	215-218
)	O	218-219
represent	O	220-229
an	O	230-232
emerging	O	233-241
clinical	O	242-250
challenge	O	251-260
,	O	260-261
because	O	262-269
they	O	270-274
can	O	275-278
be	O	279-281
associated	O	282-292
with	O	293-297
vaccine	O	298-305
escape	O	306-312
,	O	312-313
HBV	O	314-317
reactivation	O	318-330
,	O	330-331
and	O	332-335
failure	O	336-343
of	O	344-346
diagnostic	O	347-357
tests	O	358-363
.	O	363-364

Recent	O	365-371
data	O	372-376
suggest	O	377-384
a	O	385-386
preferential	O	387-399
selection	O	400-409
of	O	410-412
immune	O	413-419
escape	O	420-426
mutants	O	427-434
in	O	435-437
distinct	O	438-446
peripheral	O	447-457
blood	O	458-463
leukocyte	O	464-473
compartments	O	474-486
of	O	487-489
infected	O	490-498
individuals	O	499-510
.	O	510-511

We	O	512-514
therefore	O	515-524
systematically	O	525-539
analyzed	O	540-548
the	O	549-552
functional	O	553-563
impact	O	564-570
of	O	571-573
the	O	574-577
most	O	578-582
prevalent	O	583-592
immune	O	593-599
escape	O	600-606
variants	O	607-615
,	O	615-616
the	O	617-620
sG145R	O	621-627
and	O	628-631
sP120T	O	632-638
mutants	O	639-646
,	O	646-647
on	O	648-650
the	O	651-654
viral	O	655-660
replication	O	661-672
efficacy	O	673-681
and	O	682-685
antiviral	O	686-695
drug	O	696-700
susceptibility	O	701-715
of	O	716-718
common	O	719-725
treatment	O	726-735
-	O	735-736
associated	O	736-746
mutants	O	747-754
with	O	755-759
resistance	O	760-770
to	O	771-773
lamivudine	O	774-784
(	O	785-786
LAM	O	786-789
)	O	789-790
and	O	791-794
/	O	794-795
or	O	795-797
HBeAg	O	798-803
negativity	O	804-814
.	O	814-815

Replication	O	816-827
-	O	827-828
competent	O	828-837
HBV	O	838-841
strains	O	842-849
with	O	850-854
sG145R	O	855-861
or	O	862-864
sP120T	O	865-871
and	O	872-875
LAM	O	876-879
resistance	O	880-890
(	O	891-892
rtM204I	O	892-899
or	O	900-902
rtL180M	O	903-910
/	O	910-911
rtM204V	O	911-918
)	O	918-919
were	O	920-924
generated	O	925-934
on	O	935-937
an	O	938-940
HBeAg	O	941-946
-	O	946-947
positive	O	947-955
and	O	956-959
an	O	960-962
HBeAg	O	963-968
-	O	968-969
negative	O	969-977
background	O	978-988
with	O	989-993
precore	O	994-1001
(	O	1002-1003
PC	O	1003-1005
)	O	1005-1006
and	O	1007-1010
basal	O	1011-1016
core	O	1017-1021
promoter	O	1022-1030
(	O	1031-1032
BCP	O	1032-1035
)	O	1035-1036
mutants	O	1037-1044
.	O	1044-1045

The	O	1046-1049
sG145R	O	1050-1056
mutation	O	1057-1065
strongly	O	1066-1074
reduced	O	1075-1082
HBsAg	O	1083-1088
levels	O	1089-1095
and	O	1096-1099
was	O	1100-1103
able	O	1104-1108
to	O	1109-1111
fully	O	1112-1117
restore	O	1118-1125
the	O	1126-1129
impaired	O	1130-1138
replication	O	1139-1150
of	O	1151-1153
LAM	O	1154-1157
-	O	1157-1158
resistant	O	1158-1167
HBV	O	1168-1171
mutants	O	1172-1179
to	O	1180-1182
the	O	1183-1186
levels	O	1187-1193
of	O	1194-1196
wild	O	1197-1201
-	O	1201-1202
type	O	1202-1206
HBV	O	1207-1210
,	O	1210-1211
and	O	1212-1215
PC	O	1216-1218
or	O	1219-1221
BCP	O	1222-1225
mutations	O	1226-1235
further	O	1236-1243
enhanced	O	1244-1252
viral	O	1253-1258
replication	O	1259-1270
.	O	1270-1271

Although	O	1272-1280
the	O	1281-1284
sP120T	O	1285-1291
substitution	O	1292-1304
also	O	1305-1309
impaired	O	1310-1318
HBsAg	O	1319-1324
secretion	O	1325-1334
,	O	1334-1335
it	O	1336-1338
did	O	1339-1342
not	O	1343-1346
enhance	O	1347-1354
the	O	1355-1358
replication	O	1359-1370
of	O	1371-1373
LAM	O	1374-1377
-	O	1377-1378
resistant	O	1378-1387
clones	O	1388-1394
.	O	1394-1395

However	O	1396-1403
,	O	1403-1404
the	O	1405-1408
concomitant	O	1409-1420
occurrence	O	1421-1431
of	O	1432-1434
HBeAg	O	1435-1440
negativity	O	1441-1451
(	O	1452-1453
PC	O	1453-1455
/	O	1455-1456
BCP	O	1456-1459
)	O	1459-1460
,	O	1460-1461
sP120T	O	1462-1468
,	O	1468-1469
and	O	1470-1473
LAM	O	1474-1477
resistance	O	1478-1488
resulted	O	1489-1497
in	O	1498-1500
the	O	1501-1504
restoration	O	1505-1516
of	O	1517-1519
replication	O	1520-1531
to	O	1532-1534
levels	O	1535-1541
of	O	1542-1544
wild	O	1545-1549
-	O	1549-1550
type	O	1550-1554
HBV	O	1555-1558
.	O	1558-1559

In	O	1560-1562
all	O	1563-1566
clones	O	1567-1573
with	O	1574-1578
combined	O	1579-1587
immune	O	1588-1594
escape	O	1595-1601
and	O	1602-1605
LAM	O	1606-1609
resistance	O	1610-1620
mutations	O	1621-1630
,	O	1630-1631
the	O	1632-1635
nucleotide	O	1636-1646
analogues	O	1647-1656
adefovir	O	1657-1665
and	O	1666-1669
tenofovir	O	1670-1679
remained	O	1680-1688
effective	O	1689-1698
in	O	1699-1701
suppressing	O	1702-1713
viral	O	1714-1719
replication	O	1720-1731
in	O	1732-1734
vitro	O	1735-1740
.	O	1740-1741

These	O	1742-1747
findings	O	1748-1756
reveal	O	1757-1763
the	O	1764-1767
differential	O	1768-1780
impact	O	1781-1787
of	O	1788-1790
immune	O	1791-1797
escape	O	1798-1804
variants	O	1805-1813
on	O	1814-1816
the	O	1817-1820
replication	O	1821-1832
and	O	1833-1836
drug	O	1837-1841
susceptibility	O	1842-1856
of	O	1857-1859
complex	O	1860-1867
HBV	O	1868-1871
mutants	O	1872-1879
,	O	1879-1880
supporting	O	1881-1891
the	O	1892-1895
need	O	1896-1900
of	O	1901-1903
close	O	1904-1909
surveillance	O	1910-1922
and	O	1923-1926
treatment	O	1927-1936
adjustment	O	1937-1947
in	O	1948-1950
response	O	1951-1959
to	O	1960-1962
the	O	1963-1966
selection	O	1967-1976
of	O	1977-1979
distinct	O	1980-1988
mutational	O	1989-1999
patterns	O	2000-2008
.	O	2008-2009

The	O	0-3
effects	O	4-11
of	O	12-14
sevoflurane	O	15-26
on	O	27-29
lidocaine	O	30-39
-	O	39-40
induced	O	40-47
convulsions	B	48-59
.	O	59-60

The	O	61-64
influence	O	65-74
of	O	75-77
sevoflurane	O	78-89
on	O	90-92
lidocaine	O	93-102
-	O	102-103
induced	O	103-110
convulsions	B	111-122
was	O	123-126
studied	O	127-134
in	O	135-137
cats	O	138-142
.	O	142-143

The	O	144-147
convulsive	B	148-158
threshold	O	159-168
(	O	169-170
mean	O	170-174
+	O	175-176
/	O	176-177
-	O	177-178
SD	O	179-181
)	O	181-182
was	O	183-186
41	O	187-189
.	O	189-190
4	O	187-188
+	O	192-193
/	O	193-194
-	O	194-195
6	O	196-197
.	O	197-198
5	O	198-199
mg	O	200-202
.	O	202-203

l	O	204-205
(	O	205-206
-	O	206-207
1	O	207-208
)	O	208-209
with	O	210-214
lidocaine	O	215-224
infusion	O	225-233
(	O	234-235
6	O	235-236
mg	O	237-239
.	O	239-240
kg	O	240-242
(	O	242-243
-	O	243-244
1	O	244-245
)	O	245-246
.	O	239-240
min	O	247-250
(	O	242-243
-	O	243-244
1	O	244-245
)	O	245-246
)	O	245-246
,	O	255-256

increasing	O	257-267
significantly	O	268-281
to	O	282-284
66	O	285-287
.	O	287-288
6	O	285-286
+	O	290-291
/	O	291-292
-	O	292-293
10	O	294-296
.	O	296-297
9	O	297-298
mg	O	299-301
.	O	301-302

l	O	303-304
(	O	304-305
-	O	305-306
1	O	306-307
)	O	307-308
when	O	309-313
the	O	314-317
end	O	318-321
-	O	321-322
tidal	O	322-327
concentration	O	328-341
of	O	342-344
sevoflurane	O	345-356
was	O	357-360
0	O	361-362
.	O	362-363
8	O	363-364
%	O	364-365
.	O	362-363

However	O	367-374
,	O	374-375
the	O	376-379
threshold	O	380-389
(	O	390-391
61	O	391-393
.	O	393-394
6	O	391-392
+	O	396-397
/	O	397-398
-	O	398-399
8	O	400-401
.	O	401-402
7	O	402-403
mg	O	404-406
.	O	406-407

l	O	408-409
(	O	409-410
-	O	410-411
1	O	411-412
)	O	412-413
)	O	412-413
during	O	415-421
1	O	422-423
.	O	423-424
6	O	424-425
%	O	425-426
sevoflurane	O	427-438
was	O	439-442
not	O	443-446
significant	O	447-458
from	O	459-463
that	O	464-468
during	O	469-475
0	O	476-477
.	O	477-478
8	O	478-479
%	O	479-480
sevoflurane	O	481-492
,	O	492-493
indicating	O	494-504
a	O	505-506
celling	O	507-514
effect	O	515-521
.	O	521-522

There	O	523-528
was	O	529-532
no	O	533-535
significant	O	536-547
difference	O	548-558
in	O	559-561
the	O	562-565
convulsive	B	566-576
threshold	O	577-586
between	O	587-594
sevoflurane	O	595-606
and	O	607-610
enflurane	O	611-620
.	O	620-621

The	O	622-625
rise	O	626-630
in	O	631-633
blood	O	634-639
pressure	O	640-648
became	O	649-655
less	O	656-660
marked	O	661-667
when	O	668-672
higher	O	673-679
concentrations	O	680-694
of	O	695-697
sevoflurane	O	698-709
or	O	710-712
enflurane	O	713-722
were	O	723-727
administered	O	728-740
and	O	741-744
the	O	745-748
blood	O	749-754
pressure	O	755-763
at	O	764-766
convulsions	B	767-778
decreased	O	779-788
significantly	O	789-802
in	O	803-805
1	O	806-807
.	O	807-808
6	O	808-809
%	O	809-810
sevoflurane	O	811-822
,	O	822-823
and	O	824-827
in	O	828-830
0	O	831-832
.	O	832-833
8	O	833-834
%	O	834-835
and	O	836-839
1	O	840-841
.	O	841-842
6	O	842-843
%	O	843-844
enflurane	O	845-854
.	O	854-855

However	O	856-863
,	O	863-864
there	O	865-870
was	O	871-874
no	O	875-877
significant	O	878-889
difference	O	890-900
in	O	901-903
the	O	904-907
lidocaine	O	908-917
concentrations	O	918-932
measured	O	933-941
when	O	942-946
the	O	947-950
systolic	O	951-959
blood	O	960-965
pressure	O	966-974
became	O	975-981
70	O	982-984
mmHg	O	985-989
.	O	989-990

Apamin	O	991-997
,	O	997-998
a	O	999-1000
selective	O	1001-1010
blocker	O	1011-1018
of	O	1019-1021
calcium	O	1022-1029
-	O	1029-1030
dependent	O	1030-1039
potassium	O	1040-1049
channels	O	1050-1058
,	O	1058-1059
was	O	1060-1063
administered	O	1064-1076
intracerebroventricularly	O	1077-1102
in	O	1103-1105
rats	O	1106-1110
anesthetized	O	1111-1123
with	O	1124-1128
0	O	1129-1130
.	O	1130-1131
8	O	1131-1132
%	O	1132-1133
sevoflurane	O	1134-1145
to	O	1146-1148
investigate	O	1149-1160
the	O	1161-1164
mechanism	O	1165-1174
of	O	1175-1177
the	O	1178-1181
anticonvulsive	O	1182-1196
effects	O	1197-1204
.	O	1204-1205

Apamin	O	1206-1212
(	O	1213-1214
10	O	1214-1216
ng	O	1217-1219
)	O	1219-1220
had	O	1221-1224
a	O	1225-1226
tendency	O	1227-1235
to	O	1236-1238
decrease	O	1239-1247
the	O	1248-1251
convulsive	B	1252-1262
threshold	O	1263-1272
(	O	1273-1274
21	O	1274-1276
.	O	1276-1277
6	O	1277-1278
+	O	1279-1280
/	O	1280-1281
-	O	1281-1282
2	O	1283-1284
.	O	1284-1285
2	O	1283-1284
to	O	1287-1289
19	O	1290-1292
.	O	1292-1293
9	O	1291-1292
+	O	1295-1296
/	O	1296-1297
-	O	1297-1298
2	O	1299-1300
.	O	1300-1301
5	O	1301-1302
mg	O	1303-1305
.	O	1305-1306

l	O	1307-1308
(	O	1308-1309
-	O	1309-1310
1	O	1310-1311
)	O	1311-1312
)	O	1311-1312
but	O	1314-1317
this	O	1318-1322
was	O	1323-1326
not	O	1327-1330
statistically	O	1331-1344
significant	O	1345-1356
.	O	1356-1357

It	O	1358-1360
is	O	1361-1363
suggested	O	1364-1373
that	O	1374-1378
sevoflurane	O	1379-1390
reduces	O	1391-1398
the	O	1399-1402
convulsive	B	1403-1413
effect	O	1414-1420
of	O	1421-1423
lidocaine	O	1424-1433
toxicity	B	1434-1442
but	O	1443-1446
carries	O	1447-1454
some	O	1455-1459
risk	O	1460-1464
due	O	1465-1468
to	O	1469-1471
circulatory	O	1472-1483
depression	B	1484-1494
.	O	1494-1495

Anti	O	0-4
-	O	4-5
oxidant	O	5-12
effects	O	13-20
of	O	21-23
atorvastatin	O	24-36
in	O	37-39
dexamethasone	O	40-53
-	O	53-54
induced	O	54-61
hypertension	B	62-74
in	O	75-77
the	O	78-81
rat	O	82-85
.	O	85-86
1	O	87-88
.	O	88-89
Dexamethasone	O	90-103
(	O	104-105
Dex	O	105-108
)	O	108-109
-	O	109-110
induced	O	110-117
hypertension	B	118-130
is	O	131-133
characterized	O	134-147
by	O	148-150
endothelial	O	151-162
dysfunction	O	163-174
associated	O	175-185
with	O	186-190
nitric	O	191-197
oxide	O	198-203
(	O	204-205
NO	O	205-207
)	O	207-208
deficiency	O	209-219
and	O	220-223
increased	O	224-233
superoxide	O	234-244
(	O	245-246
O2	O	246-248
-	O	248-249
)	O	249-250
production	O	251-261
.	O	261-262

Atorvastatin	O	263-275
(	O	276-277
Ato	O	277-280
)	O	280-281
possesses	O	282-291
pleiotropic	O	292-303
properties	O	304-314
that	O	315-319
have	O	320-324
been	O	325-329
reported	O	330-338
to	O	339-341
improve	O	342-349
endothelial	O	350-361
function	O	362-370
through	O	371-378
increased	O	379-388
availability	O	389-401
of	O	402-404
NO	O	405-407
and	O	408-411
reduced	O	412-419
O2	O	420-422
-	O	422-423
production	O	424-434
in	O	435-437
various	O	438-445
forms	O	446-451
of	O	452-454
hypertension	B	455-467
.	O	467-468

In	O	469-471
the	O	472-475
present	O	476-483
study	O	484-489
,	O	489-490
we	O	491-493
investigated	O	494-506
whether	O	507-514
50	O	515-517
mg	O	518-520
/	O	520-521
kg	O	521-523
per	O	524-527
day	O	528-531
,	O	531-532
p	O	533-534
.	O	534-535
o	O	535-536
.	O	534-535
,	O	537-538
Ato	O	539-542
could	O	543-548
prevent	O	549-556
endothelial	O	557-568
NO	O	569-571
synthase	O	572-580
(	O	581-582
eNOS	O	582-586
)	O	586-587
downregulation	O	588-602
and	O	603-606
the	O	607-610
increase	O	611-619
in	O	620-622
O2	O	623-625
-	O	625-626
in	O	627-629
Sprague	O	630-637
-	O	637-638
Dawley	O	638-644
(	O	645-646
SD	O	646-648
)	O	648-649
rats	O	650-654
,	O	654-655
thereby	O	656-663
reducing	O	664-672
blood	O	673-678
pressure	O	679-687
.	O	687-688

2	O	689-690
.	O	690-691
Male	O	692-696
SD	O	697-699
rats	O	700-704
(	O	705-706
n	O	706-707
=	O	708-709
30	O	710-712
)	O	712-713
were	O	714-718
treated	O	719-726
with	O	727-731
Ato	O	732-735
(	O	736-737
50	O	737-739
mg	O	740-742
/	O	742-743
kg	O	743-745
per	O	746-749
day	O	750-753
in	O	754-756
drinking	O	757-765
water	O	766-771
)	O	771-772
or	O	773-775
tap	O	776-779
water	O	780-785
for	O	786-789
15	O	790-792
days	O	793-797
.	O	797-798

Dexamethasone	O	799-812
(	O	813-814
10	O	814-816
microg	O	817-823
/	O	823-824
kg	O	824-826
per	O	827-830
day	O	831-834
,	O	834-835
s	O	836-837
.	O	837-838
c	O	838-839
.	O	837-838
)	O	840-841
or	O	842-844
saline	O	845-851
was	O	852-855
started	O	856-863
after	O	864-869
4	O	870-871
days	O	872-876
in	O	877-879
Ato	O	880-883
-	O	883-884
treated	O	884-891
and	O	892-895
non	O	896-899
-	O	899-900
treated	O	900-907
rats	O	908-912
and	O	913-916
continued	O	917-926
for	O	927-930
11	O	931-933
-	O	933-934
13	O	934-936
days	O	937-941
.	O	941-942

Systolic	O	943-951
blood	O	952-957
pressure	O	958-966
(	O	967-968
SBP	O	968-971
)	O	971-972
was	O	973-976
measured	O	977-985
on	O	986-988
alternate	O	989-998
days	O	999-1003
using	O	1004-1009
the	O	1010-1013
tail	O	1014-1018
-	O	1018-1019
cuff	O	1019-1023
method	O	1024-1030
.	O	1030-1031

Endothelial	O	1032-1043
function	O	1044-1052
was	O	1053-1056
assessed	O	1057-1065
by	O	1066-1068
acetylcholine	O	1069-1082
-	O	1082-1083
induced	O	1083-1090
vasorelaxation	O	1091-1105
and	O	1106-1109
phenylephrine	O	1110-1123
-	O	1123-1124
induced	O	1124-1131
vasoconstriction	O	1132-1148
in	O	1149-1151
aortic	O	1152-1158
segments	O	1159-1167
.	O	1167-1168

Vascular	O	1169-1177
eNOS	O	1178-1182
mRNA	O	1183-1187
was	O	1188-1191
assessed	O	1192-1200
by	O	1201-1203
semi	O	1204-1208
-	O	1208-1209
quantitative	O	1209-1221
reverse	O	1222-1229
transcription	O	1230-1243
-	O	1243-1244
polymerase	O	1244-1254
chain	O	1255-1260
reaction	O	1261-1269
.	O	1269-1270

3	O	1271-1272
.	O	1272-1273

In	O	1274-1276
rats	O	1277-1281
treated	O	1282-1289
with	O	1290-1294
Dex	O	1295-1298
alone	O	1299-1304
,	O	1304-1305
SBP	O	1306-1309
was	O	1310-1313
increased	O	1314-1323
from	O	1324-1328
109	O	1329-1332
+	O	1333-1334
/	O	1334-1335
-	O	1335-1336
2	O	1337-1338
to	O	1339-1341
133	O	1342-1345
+	O	1346-1347
/	O	1347-1348
-	O	1348-1349
2	O	1350-1351
mmHg	O	1352-1356
on	O	1357-1359
Days	O	1360-1364
4	O	1365-1366
and	O	1367-1370
Day	O	1371-1374
14	O	1375-1377
,	O	1377-1378
respectively	O	1379-1391
(	O	1392-1393
P	O	1393-1394
<	O	1395-1396
0	O	1397-1398
.	O	1398-1399
001	O	1399-1402
)	O	1402-1403
.	O	1398-1399

In	O	1405-1407
the	O	1408-1411
Ato	O	1412-1415
+	O	1416-1417
Dex	O	1418-1421
group	O	1422-1427
,	O	1427-1428
SBP	O	1429-1432
was	O	1433-1436
increased	O	1437-1446
from	O	1447-1451
113	O	1452-1455
+	O	1456-1457
/	O	1457-1458
-	O	1458-1459
2	O	1460-1461
to	O	1462-1464
119	O	1465-1468
+	O	1469-1470
/	O	1470-1471
-	O	1471-1472
2	O	1473-1474
mmHg	O	1475-1479
on	O	1480-1482
Days	O	1483-1487
4	O	1488-1489
to	O	1490-1492
14	O	1493-1495
,	O	1495-1496
respectively	O	1497-1509
(	O	1510-1511
P	O	1511-1512
<	O	1513-1514
0	O	1515-1516
.	O	1516-1517
001	O	1517-1520
)	O	1520-1521
,	O	1521-1522
but	O	1523-1526
was	O	1527-1530
significantly	O	1531-1544
lower	O	1545-1550
than	O	1551-1555
SBP	O	1556-1559
in	O	1560-1562
the	O	1563-1566
group	O	1567-1572
treated	O	1573-1580
with	O	1581-1585
Dex	O	1586-1589
alone	O	1590-1595
(	O	1596-1597
P	O	1597-1598
<	O	1599-1600
0	O	1601-1602
.	O	1602-1603
05	O	1603-1605
)	O	1605-1606
.	O	1602-1603

Endothelial	O	1608-1619
-	O	1619-1620
dependent	O	1620-1629
relaxation	O	1630-1640
and	O	1641-1644
eNOS	O	1645-1649
mRNA	O	1650-1654
expression	O	1655-1665
were	O	1666-1670
greater	O	1671-1678
in	O	1679-1681
the	O	1682-1685
Dex	O	1686-1689
+	O	1690-1691
Ato	O	1692-1695
group	O	1696-1701
than	O	1702-1706
in	O	1707-1709
the	O	1710-1713
Dex	O	1714-1717
only	O	1718-1722
group	O	1723-1728
(	O	1729-1730
P	O	1730-1731
<	O	1732-1733
0	O	1734-1735
.	O	1735-1736
05	O	1736-1738
and	O	1739-1742
P	O	1743-1744
<	O	1745-1746
0	O	1747-1748
.	O	1748-1749
0001	O	1749-1753
,	O	1753-1754
respectively	O	1755-1767
)	O	1767-1768
.	O	1768-1769

Aortic	O	1770-1776
superoxide	O	1777-1787
production	O	1788-1798
was	O	1799-1802
lower	O	1803-1808
in	O	1809-1811
the	O	1812-1815
Dex	O	1816-1819
+	O	1820-1821
Ato	O	1822-1825
group	O	1826-1831
compared	O	1832-1840
with	O	1841-1845
the	O	1846-1849
group	O	1850-1855
treated	O	1856-1863
with	O	1864-1868
Dex	O	1869-1872
alone	O	1873-1878
(	O	1879-1880
P	O	1880-1881
<	O	1882-1883
0	O	1884-1885
.	O	1885-1886
0001	O	1886-1890
)	O	1890-1891
.	O	1885-1886

4	O	1893-1894
.	O	1894-1895
Treatment	O	1896-1905
with	O	1906-1910
Ato	O	1911-1914
improved	O	1915-1923
endothelial	O	1924-1935
function	O	1936-1944
,	O	1944-1945
reduced	O	1946-1953
superoxide	O	1954-1964
production	O	1965-1975
and	O	1976-1979
reduced	O	1980-1987
SBP	O	1988-1991
in	O	1992-1994
Dex	O	1995-1998
-	O	1998-1999
treated	O	1999-2006
SD	O	2007-2009
rats	O	2010-2014
.	O	2014-2015

99mTc	O	0-5
-	O	5-6
glucarate	O	6-15
for	O	16-19
detection	O	20-29
of	O	30-32
isoproterenol	O	33-46
-	O	46-47
induced	O	47-54
myocardial	B	55-65
infarction	I	66-76
in	O	77-79
rats	O	80-84
.	O	84-85

Infarct	B	86-93
-	O	93-94
avid	O	94-98
radiopharmaceuticals	O	99-119
are	O	120-123
necessary	O	124-133
for	O	134-137
rapid	O	138-143
and	O	144-147
timely	O	148-154
diagnosis	O	155-164
of	O	165-167
acute	O	168-173
myocardial	B	174-184
infarction	I	185-195
.	O	195-196

The	O	197-200
animal	O	201-207
model	O	208-213
used	O	214-218
to	O	219-221
produce	O	222-229
infarction	B	230-240
implies	O	241-248
artery	O	249-255
ligation	O	256-264
but	O	265-268
chemical	O	269-277
induction	O	278-287
can	O	288-291
be	O	292-294
easily	O	295-301
obtained	O	302-310
with	O	311-315
isoproterenol	O	316-329
.	O	329-330

A	O	331-332
new	O	333-336
infarct	B	337-344
-	O	344-345
avid	O	345-349
radiopharmaceutical	O	350-369
based	O	370-375
on	O	376-378
glucaric	O	379-387
acid	O	388-392
was	O	393-396
prepared	O	397-405
in	O	406-408
the	O	409-412
hospital	O	413-421
radiopharmacy	O	422-435
of	O	436-438
the	O	439-442
INCMNSZ	O	443-450
.	O	450-451

99mTc	O	452-457
-	O	457-458
glucarate	O	458-467
was	O	468-471
easy	O	472-476
to	O	477-479
prepare	O	480-487
,	O	487-488
stable	O	489-495
for	O	496-499
96	O	500-502
h	O	503-504
and	O	505-508
was	O	509-512
used	O	513-517
to	O	518-520
study	O	521-526
its	O	527-530
biodistribution	O	531-546
in	O	547-549
rats	O	550-554
with	O	555-559
isoproterenol	O	560-573
-	O	573-574
induced	O	574-581
acute	O	582-587
myocardial	B	588-598
infarction	I	599-609
.	O	609-610

Histological	O	611-623
studies	O	624-631
demonstrated	O	632-644
that	O	645-649
the	O	650-653
rats	O	654-658
developed	O	659-668
an	O	669-671
infarct	B	672-679
18	O	680-682
h	O	683-684
after	O	685-690
isoproterenol	O	691-704
administration	O	705-719
.	O	719-720

The	O	721-724
rat	O	725-728
biodistribution	O	729-744
studies	O	745-752
showed	O	753-759
a	O	760-761
rapid	O	762-767
blood	O	768-773
clearance	O	774-783
via	O	784-787
the	O	788-791
kidneys	O	792-799
.	O	799-800

Thirty	O	801-807
minutes	O	808-815
after	O	816-821
99mTc	O	822-827
-	O	827-828
glucarate	O	828-837
administration	O	838-852
the	O	853-856
standardised	O	857-869
heart	O	870-875
uptake	O	876-882
value	O	883-888
S	O	889-890
(	O	890-891
h	O	891-892
)	O	892-893
UV	O	893-895
was	O	896-899
4	O	900-901
.	O	901-902
7	O	902-903
in	O	904-906
infarcted	O	907-916
rat	O	917-920
heart	O	921-926
which	O	927-932
is	O	933-935
six	O	936-939
times	O	940-945
more	O	946-950
than	O	951-955
in	O	956-958
normal	O	959-965
rats	O	966-970
.	O	970-971

ROIs	O	972-976
drawn	O	977-982
over	O	983-987
the	O	988-991
gamma	O	992-997
camera	O	998-1004
images	O	1005-1011
showed	O	1012-1018
a	O	1019-1020
ratio	O	1021-1026
of	O	1027-1029
4	O	1030-1031
.	O	1031-1032
4	O	1030-1031
.	O	1031-1032

The	O	1035-1038
high	O	1039-1043
image	O	1044-1049
quality	O	1050-1057
suggests	O	1058-1066
that	O	1067-1071
high	O	1072-1076
contrast	O	1077-1085
images	O	1086-1092
can	O	1093-1096
be	O	1097-1099
obtained	O	1100-1108
in	O	1109-1111
humans	O	1112-1118
and	O	1119-1122
the	O	1123-1126
96	O	1127-1129
h	O	1130-1131
stability	O	1132-1141
makes	O	1142-1147
it	O	1148-1150
an	O	1151-1153
ideal	O	1154-1159
agent	O	1160-1165
to	O	1166-1168
detect	O	1169-1175
,	O	1175-1176
in	O	1177-1179
patients	O	1180-1188
,	O	1188-1189
early	O	1190-1195
cardiac	B	1196-1203
infarction	I	1204-1214
.	O	1214-1215

A	O	0-1
randomized	O	2-12
,	O	12-13
placebo	O	14-21
-	O	21-22
controlled	O	22-32
dose	O	33-37
-	O	37-38
comparison	O	38-48
trial	O	49-54
of	O	55-57
haloperidol	O	58-69
for	O	70-73
psychosis	B	74-83
and	O	84-87
disruptive	B	88-98
behaviors	I	99-108
in	O	109-111
Alzheimer	B	112-121
'	I	121-122
s	I	122-123
disease	I	124-131
.	O	131-132

OBJECTIVE	O	133-142
:	O	142-143
The	O	144-147
goal	O	148-152
of	O	153-155
this	O	156-160
study	O	161-166
was	O	167-170
to	O	171-173
compare	O	174-181
the	O	182-185
efficacy	O	186-194
and	O	195-198
side	O	199-203
effects	O	204-211
of	O	212-214
two	O	215-218
doses	O	219-224
of	O	225-227
haloperidol	O	228-239
and	O	240-243
placebo	O	244-251
in	O	252-254
the	O	255-258
treatment	O	259-268
of	O	269-271
psychosis	B	272-281
and	O	282-285
disruptive	B	286-296
behaviors	I	297-306
in	O	307-309
patients	O	310-318
with	O	319-323
Alzheimer	B	324-333
'	I	333-334
s	I	334-335
disease	I	336-343
.	O	343-344

METHOD	O	345-351
:	O	351-352
In	O	353-355
a	O	356-357
6	O	358-359
-	O	359-360
week	O	360-364
random	O	365-371
-	O	371-372
assignment	O	372-382
,	O	382-383
double	O	384-390
-	O	390-391
blind	O	391-396
,	O	396-397
placebo	O	398-405
-	O	405-406
controlled	O	406-416
trial	O	417-422
(	O	423-424
phase	O	424-429
A	O	430-431
)	O	431-432
,	O	432-433
haloperidol	O	434-445
,	O	445-446
2	O	447-448
-	O	448-449
3	O	449-450
mg	O	451-453
/	O	453-454
day	O	454-457
(	O	458-459
standard	O	459-467
dose	O	468-472
)	O	472-473
,	O	473-474
and	O	475-478
haloperidol	O	479-490
,	O	490-491
0	O	492-493
.	O	493-494
50	O	494-496
-	O	496-497
0	O	492-493
.	O	493-494
75	O	499-501

mg	O	502-504
/	O	504-505
day	O	505-508
(	O	509-510
low	O	510-513
dose	O	514-518
)	O	518-519
,	O	519-520
were	O	521-525
compared	O	526-534
in	O	535-537
71	O	538-540
outpatients	O	541-552
with	O	553-557
Alzheimer	B	558-567
'	I	567-568
s	I	568-569
disease	I	570-577
.	O	577-578

For	O	579-582
the	O	583-586
subsequent	O	587-597
6	O	598-599
-	O	599-600
week	O	600-604
double	O	605-611
-	O	611-612
blind	O	612-617
crossover	O	618-627
phase	O	628-633
(	O	634-635
phase	O	635-640
B	O	641-642
)	O	642-643
,	O	643-644
patients	O	645-653
taking	O	654-660
standard	O	661-669
-	O	669-670
or	O	671-673
low	O	674-677
-	O	677-678
dose	O	678-682
haloperidol	O	683-694
were	O	695-699
switched	O	700-708
to	O	709-711
placebo	O	712-719
,	O	719-720
and	O	721-724
patients	O	725-733
taking	O	734-740
placebo	O	741-748
were	O	749-753
randomly	O	754-762
assigned	O	763-771
to	O	772-774
standard	O	775-783
-	O	783-784
or	O	785-787
low	O	788-791
-	O	791-792
dose	O	792-796
haloperidol	O	797-808
.	O	808-809

RESULTS	O	810-817
:	O	817-818
For	O	819-822
the	O	823-826
60	O	827-829
patients	O	830-838
who	O	839-842
completed	O	843-852
phase	O	853-858
A	O	859-860
,	O	860-861
standard	O	862-870
-	O	870-871
dose	O	871-875
haloperidol	O	876-887
was	O	888-891
efficacious	O	892-903
and	O	904-907
superior	O	908-916
to	O	917-919
both	O	920-924
low	O	925-928
-	O	928-929
dose	O	929-933
haloperidol	O	934-945
and	O	946-949
placebo	O	950-957
for	O	958-961
scores	O	962-968
on	O	969-971
the	O	972-975
Brief	O	976-981
Psychiatric	O	982-993
Rating	O	994-1000
Scale	O	1001-1006
psychosis	B	1007-1016
factor	O	1017-1023
and	O	1024-1027
on	O	1028-1030
psychomotor	B	1031-1042
agitation	I	1043-1052
.	O	1052-1053

Response	O	1054-1062
rates	O	1063-1068
according	O	1069-1078
to	O	1079-1081
three	O	1082-1087
sets	O	1088-1092
of	O	1093-1095
criteria	O	1096-1104
were	O	1105-1109
greater	O	1110-1117
with	O	1118-1122
the	O	1123-1126
standard	O	1127-1135
dose	O	1136-1140
(	O	1141-1142
55	O	1142-1144
%	O	1144-1145
-	O	1145-1146
60	O	1146-1148
%	O	1144-1145
)	O	1149-1150
than	O	1151-1155
the	O	1156-1159
low	O	1160-1163
dose	O	1164-1168
(	O	1169-1170
25	O	1170-1172
%	O	1172-1173
-	O	1173-1174
35	O	1174-1176
%	O	1172-1173
)	O	1177-1178
and	O	1179-1182
placebo	O	1183-1190
(	O	1191-1192
25	O	1192-1194
%	O	1194-1195
-	O	1195-1196
30	O	1196-1198
%	O	1194-1195
)	O	1199-1200
.	O	1200-1201

The	O	1202-1205
advantage	O	1206-1215
of	O	1216-1218
standard	O	1219-1227
dose	O	1228-1232
over	O	1233-1237
low	O	1238-1241
dose	O	1242-1246
was	O	1247-1250
replicated	O	1251-1261
in	O	1262-1264
phase	O	1265-1270
B	O	1271-1272
.	O	1272-1273
In	O	1274-1276
phase	O	1277-1282
A	O	1283-1284
,	O	1284-1285
extrapyramidal	B	1286-1300
signs	I	1301-1306
tended	O	1307-1313
to	O	1314-1316
be	O	1317-1319
greater	O	1320-1327
with	O	1328-1332
the	O	1333-1336
standard	O	1337-1345
dose	O	1346-1350
than	O	1351-1355
in	O	1356-1358
the	O	1359-1362
other	O	1363-1368
two	O	1369-1372
conditions	O	1373-1383
,	O	1383-1384
primarily	O	1385-1394
because	O	1395-1402
of	O	1403-1405
a	O	1406-1407
subgroup	O	1408-1416
(	O	1417-1418
20	O	1418-1420
%	O	1420-1421
)	O	1421-1422
who	O	1423-1426
developed	O	1427-1436
moderate	O	1437-1445
to	O	1446-1448
severe	O	1449-1455
signs	O	1456-1461
.	O	1461-1462

Low	O	1463-1466
-	O	1466-1467
dose	O	1467-1471
haloperidol	O	1472-1483
did	O	1484-1487
not	O	1488-1491
differ	O	1492-1498
from	O	1499-1503
placebo	O	1504-1511
on	O	1512-1514
any	O	1515-1518
measure	O	1519-1526
of	O	1527-1529
efficacy	O	1530-1538
or	O	1539-1541
side	O	1542-1546
effects	O	1547-1554
.	O	1554-1555

CONCLUSIONS	O	1556-1567
:	O	1567-1568
The	O	1569-1572
results	O	1573-1580
indicated	O	1581-1590
a	O	1591-1592
favorable	O	1593-1602
therapeutic	O	1603-1614
profile	O	1615-1622
for	O	1623-1626
haloperidol	O	1627-1638
in	O	1639-1641
doses	O	1642-1647
of	O	1648-1650
2	O	1651-1652
-	O	1652-1653
3	O	1653-1654
mg	O	1655-1657
/	O	1657-1658
day	O	1658-1661
,	O	1661-1662
although	O	1663-1671
a	O	1672-1673
subgroup	O	1674-1682
developed	O	1683-1692
moderate	O	1693-1701
to	O	1702-1704
severe	O	1705-1711
extrapyramidal	B	1712-1726
signs	I	1727-1732
.	O	1732-1733

A	O	1734-1735
starting	O	1736-1744
dose	O	1745-1749
of	O	1750-1752
1	O	1753-1754
mg	O	1755-1757
/	O	1757-1758
day	O	1758-1761
with	O	1762-1766
gradual	O	1767-1774
,	O	1774-1775
upward	O	1776-1782
dose	O	1783-1787
titration	O	1788-1797
is	O	1798-1800
recommended	O	1801-1812
.	O	1812-1813

The	O	1814-1817
narrow	O	1818-1824
therapeutic	O	1825-1836
window	O	1837-1843
observed	O	1844-1852
with	O	1853-1857
haloperidol	O	1858-1869
may	O	1870-1873
also	O	1874-1878
apply	O	1879-1884
to	O	1885-1887
other	O	1888-1893
neuroleptics	O	1894-1906
used	O	1907-1911
in	O	1912-1914
Alzheimer	B	1915-1924
'	I	1924-1925
s	I	1925-1926
disease	I	1927-1934
patients	O	1935-1943
with	O	1944-1948
psychosis	B	1949-1958
and	O	1959-1962
disruptive	B	1963-1973
behaviors	I	1974-1983
.	O	1983-1984

Individual	O	0-10
differences	O	11-22
in	O	23-25
renal	O	26-31
ACE	O	32-35
activity	O	36-44
in	O	45-47
healthy	O	48-55
rats	O	56-60
predict	O	61-68
susceptibility	O	69-83
to	O	84-86
adriamycin	O	87-97
-	O	97-98
induced	O	98-105
renal	B	106-111
damage	I	112-118
.	O	118-119

BACKGROUND	O	120-130
:	O	130-131
In	O	132-134
man	O	135-138
,	O	138-139
differences	O	140-151
in	O	152-154
angiotensin	O	155-166
-	O	166-167
converting	O	167-177
enzyme	O	178-184
(	O	185-186
ACE	O	186-189
)	O	189-190
levels	O	191-197
,	O	197-198
related	O	199-206
to	O	207-209
ACE	O	210-213
(	O	214-215
I	O	215-216
/	O	216-217
D	O	217-218
)	O	218-219
genotype	O	220-228
,	O	228-229
are	O	230-233
associated	O	234-244
with	O	245-249
renal	O	250-255
prognosis	O	256-265
.	O	265-266

This	O	267-271
raises	O	272-278
the	O	279-282
hypothesis	O	283-293
that	O	294-298
individual	O	299-309
differences	O	310-321
in	O	322-324
renal	O	325-330
ACE	O	331-334
activity	O	335-343
are	O	344-347
involved	O	348-356
in	O	357-359
renal	O	360-365
susceptibility	O	366-380
to	O	381-383
inflicted	O	384-393
damage	O	394-400
.	O	400-401

Therefore	O	402-411
,	O	411-412
we	O	413-415
studied	O	416-423
the	O	424-427
predictive	O	428-438
effect	O	439-445
of	O	446-448
renal	O	449-454
ACE	O	455-458
activity	O	459-467
for	O	468-471
the	O	472-475
severity	O	476-484
of	O	485-487
renal	B	488-493
damage	I	494-500
induced	O	501-508
by	O	509-511
a	O	512-513
single	O	514-520
injection	O	521-530
of	O	531-533
adriamycin	O	534-544
in	O	545-547
rats	O	548-552
.	O	552-553

METHODS	O	554-561
:	O	561-562
Renal	O	563-568
ACE	O	569-572
activity	O	573-581
(	O	582-583
Hip	O	583-586
-	O	586-587
His	O	587-590
-	O	586-587
Leu	O	591-594
cleavage	O	595-603
by	O	604-606
cortical	O	607-615
homogenates	O	616-627
)	O	627-628
was	O	629-632
determined	O	633-643
by	O	644-646
renal	O	647-652
biopsy	O	653-659
in	O	660-662
27	O	663-665
adult	O	666-671
male	O	672-676
Wistar	O	677-683
rats	O	684-688
.	O	688-689

After	O	690-695
1	O	696-697
week	O	698-702
of	O	703-705
recovery	O	706-714
,	O	714-715
proteinuria	B	716-727
was	O	728-731
induced	O	732-739
by	O	740-742
adriamycin	O	743-753
[	O	754-755
1	O	755-756
.	O	756-757
5	O	757-758
mg	O	759-761
/	O	761-762
kg	O	762-764
intravenously	O	765-778
(	O	779-780
i	O	780-781
.	O	781-782
v	O	782-783
.	O	781-782
)	O	784-785
n	O	786-787
=	O	788-789
18	O	790-792
;	O	792-793
controls	O	794-802
,	O	802-803
saline	O	804-810
i	O	811-812
.	O	812-813
v	O	813-814
.	O	812-813

n	O	816-817
=	O	818-819
9	O	820-821
]	O	821-822
.	O	822-823

Proteinuria	B	824-835
was	O	836-839
measured	O	840-848
every	O	849-854
2	O	855-856
weeks	O	857-862
.	O	862-863

After	O	864-869
12	O	870-872
weeks	O	873-878
,	O	878-879
rats	O	880-884
were	O	885-889
sacrificed	O	890-900
and	O	901-904
their	O	905-910
kidneys	O	911-918
harvested	O	919-928
.	O	928-929

RESULTS	O	930-937
:	O	937-938
As	O	939-941
anticipated	O	942-953
,	O	953-954
adriamycin	O	955-965
elicited	O	966-974
nephrotic	B	975-984
range	O	985-990
proteinuria	B	991-1002
,	O	1002-1003
renal	B	1004-1009
interstitial	I	1010-1022
damage	I	1023-1029
and	O	1030-1033
mild	O	1034-1038
focal	B	1039-1044
glomerulosclerosis	I	1045-1063
.	O	1063-1064

Baseline	O	1065-1073
renal	O	1074-1079
ACE	O	1080-1083
positively	O	1084-1094
correlated	O	1095-1105
with	O	1106-1110
the	O	1111-1114
relative	O	1115-1123
rise	O	1124-1128
in	O	1129-1131
proteinuria	B	1132-1143
after	O	1144-1149
adriamycin	O	1150-1160
(	O	1161-1162
r	O	1162-1163
=	O	1164-1165
0	O	1166-1167
.	O	1167-1168
62	O	1168-1170
,	O	1170-1171
P	O	1172-1173
<	O	1173-1174
0	O	1174-1175
.	O	1175-1176
01	O	1176-1178
)	O	1178-1179
,	O	1179-1180
renal	O	1181-1186
interstitial	O	1187-1199
alpha	O	1200-1205
-	O	1205-1206
smooth	O	1206-1212
muscle	O	1213-1219
actin	O	1220-1225
(	O	1226-1227
r	O	1227-1228
=	O	1229-1230
0	O	1231-1232
.	O	1232-1233
49	O	1233-1235
,	O	1235-1236
P	O	1237-1238
<	O	1238-1239
0	O	1239-1240
.	O	1240-1241
05	O	1241-1243
)	O	1243-1244
,	O	1244-1245
interstitial	O	1246-1258
macrophage	O	1259-1269
influx	O	1270-1276
(	O	1277-1278
r	O	1278-1279
=	O	1280-1281
0	O	1282-1283
.	O	1283-1284
56	O	1284-1286
,	O	1286-1287
P	O	1288-1289
<	O	1289-1290
0	O	1290-1291
.	O	1291-1292
05	O	1292-1294
)	O	1294-1295
,	O	1295-1296
interstitial	O	1297-1309
collagen	O	1310-1318
III	O	1319-1322
(	O	1323-1324
r	O	1324-1325
=	O	1326-1327
0	O	1328-1329
.	O	1329-1330
53	O	1330-1332
,	O	1332-1333
P	O	1334-1335
<	O	1335-1336
0	O	1336-1337
.	O	1337-1338
05	O	1338-1340
)	O	1340-1341
,	O	1341-1342
glomerular	O	1343-1353
alpha	O	1354-1359
-	O	1359-1360
smooth	O	1360-1366
muscle	O	1367-1373
actin	O	1374-1379
(	O	1380-1381
r	O	1381-1382
=	O	1383-1384
0	O	1385-1386
.	O	1386-1387
74	O	1387-1389
,	O	1389-1390
P	O	1391-1392
<	O	1392-1393
0	O	1393-1394
.	O	1394-1395
01	O	1395-1397
)	O	1397-1398
and	O	1399-1402
glomerular	O	1403-1413
desmin	O	1414-1420
(	O	1421-1422
r	O	1422-1423
=	O	1424-1425
0	O	1426-1427
.	O	1427-1428
48	O	1428-1430
,	O	1430-1431
P	O	1432-1433
<	O	1433-1434
0	O	1434-1435
.	O	1435-1436
05	O	1436-1438
)	O	1438-1439
.	O	1435-1436

Baseline	O	1441-1449
renal	O	1450-1455
ACE	O	1456-1459
did	O	1460-1463
not	O	1464-1467
correlate	O	1468-1477
with	O	1478-1482
focal	B	1483-1488
glomerulosclerosis	I	1489-1507
(	O	1508-1509
r	O	1509-1510
=	O	1511-1512
0	O	1513-1514
.	O	1514-1515
22	O	1515-1517
,	O	1517-1518
NS	O	1519-1521
)	O	1521-1522
.	O	1522-1523

In	O	1524-1526
controls	O	1527-1535
,	O	1535-1536
no	O	1537-1539
predictive	O	1540-1550
values	O	1551-1557
for	O	1558-1561
renal	O	1562-1567
parameters	O	1568-1578
were	O	1579-1583
observed	O	1584-1592
.	O	1592-1593

CONCLUSION	O	1594-1604
:	O	1604-1605
Individual	O	1606-1616
differences	O	1617-1628
in	O	1629-1631
renal	O	1632-1637
ACE	O	1638-1641
activity	O	1642-1650
predict	O	1651-1658
the	O	1659-1662
severity	O	1663-1671
of	O	1672-1674
adriamycin	O	1675-1685
-	O	1685-1686
induced	O	1686-1693
renal	B	1694-1699
damage	I	1700-1706
in	O	1707-1709
this	O	1710-1714
outbred	O	1715-1722
rat	O	1723-1726
strain	O	1727-1733
.	O	1733-1734

This	O	1735-1739
supports	O	1740-1748
the	O	1749-1752
assumption	O	1753-1763
that	O	1764-1768
differences	O	1769-1780
in	O	1781-1783
renal	O	1784-1789
ACE	O	1790-1793
activity	O	1794-1802
predispose	O	1803-1813
to	O	1814-1816
a	O	1817-1818
less	O	1819-1823
favourable	O	1824-1834
course	O	1835-1841
of	O	1842-1844
renal	B	1845-1850
damage	I	1851-1857
.	O	1857-1858

Clinical	O	0-8
nephrotoxicity	B	9-23
of	O	24-26
tobramycin	O	27-37
and	O	38-41
gentamicin	O	42-52
.	O	52-53

A	O	54-55
prospective	O	56-67
study	O	68-73
.	O	73-74

Nearly	O	75-81
3	O	82-83
.	O	83-84
2	O	84-85
million	O	86-93
people	O	94-100
in	O	101-103
this	O	104-108
country	O	109-116
receive	O	117-124
aminoglycoside	O	125-139
antibiotics	O	140-151
annually	O	152-160
.	O	160-161

Gentamicin	O	162-172
sulfate	O	173-180
and	O	181-184
tobramycin	O	185-195
sulfate	O	196-203
continue	O	204-212
to	O	213-215
demonstrate	O	216-227
ototoxicity	B	228-239
and	O	240-243
nephrotoxicity	B	244-258
in	O	259-261
both	O	262-266
animal	O	267-273
and	O	274-277
clinical	O	278-286
studies	O	287-294
.	O	294-295

In	O	296-298
this	O	299-303
study	O	304-309
,	O	309-310
62	O	311-313
patients	O	314-322
with	O	323-327
confirmed	O	328-337
initial	O	338-345
normal	O	346-352
renal	O	353-358
function	O	359-367
and	O	368-371
treated	O	372-379
with	O	380-384
2	O	385-386
to	O	387-389
5	O	390-391
mg	O	392-394
/	O	394-395
kg	O	395-397
/	O	394-395
day	O	398-401
of	O	402-404
gentamicin	O	405-415
sulfate	O	416-423
or	O	424-426
tobramycin	O	427-437
sulfate	O	438-445
for	O	446-449
a	O	450-451
minimum	O	452-459
of	O	460-462
seven	O	463-468
days	O	469-473
were	O	474-478
followed	O	479-487
up	O	488-490
prospectively	O	491-504
for	O	505-508
the	O	509-512
development	O	513-524
of	O	525-527
aminoglycoside	O	528-542
-	O	542-543
related	O	543-550
renal	B	551-556
failure	I	557-564
,	O	564-565
defined	O	566-573
as	O	574-576
at	O	577-579
least	O	580-585
a	O	586-587
one	O	588-591
-	O	591-592
third	O	592-597
reduction	O	598-607
in	O	608-610
renal	O	611-616
function	O	617-625
.	O	625-626

In	O	627-629
these	O	630-635
62	O	636-638
patients	O	639-647
,	O	647-648
no	O	649-651
other	O	652-657
causes	O	658-664
for	O	665-668
renal	B	669-674
failure	I	675-682
could	O	683-688
be	O	689-691
identified	O	692-702
.	O	702-703

Five	O	704-708
of	O	709-711
33	O	712-714
(	O	715-716
15	O	716-718
%	O	718-719
)	O	719-720
of	O	721-723
the	O	724-727
tobramycin	O	728-738
-	O	738-739
treated	O	739-746
patients	O	747-755
and	O	756-759
16	O	760-762
of	O	763-765
29	O	766-768
(	O	769-770
55	O	770-772
.	O	772-773
2	O	773-774
%	O	774-775
)	O	775-776
of	O	777-779
the	O	780-783
gentamicin	O	784-794
-	O	794-795
treated	O	795-802
patients	O	803-811
had	O	812-815
renal	B	816-821
failure	I	822-829
.	O	829-830

Thus	O	831-835
,	O	835-836
gentamicin	O	837-847
was	O	848-851
associated	O	852-862
with	O	863-867
renal	B	868-873
failure	I	874-881
more	O	882-886
than	O	887-891
three	O	892-897
times	O	898-903
as	O	904-906
often	O	907-912
as	O	913-915
was	O	916-919
tobramycin	O	920-930
.	O	930-931

Neuroprotective	O	0-15
action	O	16-22
of	O	23-25
MPEP	O	26-30
,	O	30-31
a	O	32-33
selective	O	34-43
mGluR5	O	44-50
antagonist	O	51-61
,	O	61-62
in	O	63-65
methamphetamine	O	66-81
-	O	81-82
induced	O	82-89
dopaminergic	O	90-102
neurotoxicity	B	103-116
is	O	117-119
associated	O	120-130
with	O	131-135
a	O	136-137
decrease	O	138-146
in	O	147-149
dopamine	O	150-158
outflow	O	159-166
and	O	167-170
inhibition	O	171-181
of	O	182-184
hyperthermia	B	185-197
in	O	198-200
rats	O	201-205
.	O	205-206

The	O	207-210
aim	O	211-214
of	O	215-217
this	O	218-222
study	O	223-228
was	O	229-232
to	O	233-235
examine	O	236-243
the	O	244-247
role	O	248-252
of	O	253-255
metabotropic	O	256-268
glutamate	O	269-278
receptor	O	279-287
5	O	288-289
(	O	290-291
mGluR5	O	291-297
)	O	297-298
in	O	299-301
the	O	302-305
toxic	O	306-311
action	O	312-318
of	O	319-321
methamphetamine	O	322-337
on	O	338-340
dopaminergic	O	341-353
neurones	O	354-362
in	O	363-365
rats	O	366-370
.	O	370-371

Methamphetamine	O	372-387
(	O	388-389
10	O	389-391
mg	O	392-394
/	O	394-395
kg	O	395-397
sc	O	398-400
)	O	400-401
,	O	401-402
administered	O	403-415
five	O	416-420
times	O	421-426
,	O	426-427
reduced	O	428-435
the	O	436-439
levels	O	440-446
of	O	447-449
dopamine	O	450-458
and	O	459-462
its	O	463-466
metabolites	O	467-478
in	O	479-481
striatal	O	482-490
tissue	O	491-497
when	O	498-502
measured	O	503-511
72	O	512-514
h	O	515-516
after	O	517-522
the	O	523-526
last	O	527-531
injection	O	532-541
.	O	541-542

A	O	543-544
selective	O	545-554
antagonist	O	555-565
of	O	566-568
mGluR5	O	569-575
,	O	575-576
2	O	577-578
-	O	578-579
methyl	O	579-585
-	O	578-579
6	O	586-587
-	O	578-579
(	O	588-589
phenylethynyl	O	589-602
)	O	602-603
pyridine	O	603-611
(	O	612-613
MPEP	O	613-617
;	O	617-618
5	O	619-620
mg	O	621-623
/	O	623-624
kg	O	624-626
ip	O	627-629
)	O	629-630
,	O	630-631
when	O	632-636
administered	O	637-649
five	O	650-654
times	O	655-660
immediately	O	661-672
before	O	673-679
each	O	680-684
methamphetamine	O	685-700
injection	O	701-710
reversed	O	711-719
the	O	720-723
above	O	724-729
-	O	729-730
mentioned	O	730-739
methamphetamine	O	740-755
effects	O	756-763
.	O	763-764

A	O	765-766
single	O	767-773
MPEP	O	774-778
(	O	779-780
5	O	780-781
mg	O	782-784
/	O	784-785
kg	O	785-787
ip	O	788-790
)	O	790-791
injection	O	792-801
reduced	O	802-809
the	O	810-813
basal	O	814-819
extracellular	O	820-833
dopamine	O	834-842
level	O	843-848
in	O	849-851
the	O	852-855
striatum	O	856-864
,	O	864-865
as	O	866-868
well	O	869-873
as	O	874-876
dopamine	O	877-885
release	O	886-893
stimulated	O	894-904
either	O	905-911
by	O	912-914
methamphetamine	O	915-930
(	O	931-932
10	O	932-934
mg	O	935-937
/	O	937-938
kg	O	938-940
sc	O	941-943
)	O	943-944
or	O	945-947
by	O	948-950
intrastriatally	O	951-966
administered	O	967-979
veratridine	O	980-991
(	O	992-993
100	O	993-996
microM	O	997-1003
)	O	1003-1004
.	O	1004-1005

Moreover	O	1006-1014
,	O	1014-1015
it	O	1016-1018
transiently	O	1019-1030
diminished	O	1031-1041
the	O	1042-1045
methamphetamine	O	1046-1061
(	O	1062-1063
10	O	1063-1065
mg	O	1066-1068
/	O	1068-1069
kg	O	1069-1071
sc	O	1072-1074
)	O	1074-1075
-	O	1075-1076
induced	O	1076-1083
hyperthermia	B	1084-1096
and	O	1097-1100
reduced	O	1101-1108
basal	O	1109-1114
body	O	1115-1119
temperature	O	1120-1131
.	O	1131-1132

MPEP	O	1133-1137
administered	O	1138-1150
into	O	1151-1155
the	O	1156-1159
striatum	O	1160-1168
at	O	1169-1171
high	O	1172-1176
concentrations	O	1177-1191
(	O	1192-1193
500	O	1193-1196
microM	O	1197-1203
)	O	1203-1204
increased	O	1205-1214
extracellular	O	1215-1228
dopamine	O	1229-1237
levels	O	1238-1244
,	O	1244-1245
while	O	1246-1251
lower	O	1252-1257
concentrations	O	1258-1272
(	O	1273-1274
50	O	1274-1276
-	O	1276-1277
100	O	1277-1280
microM	O	1281-1287
)	O	1287-1288
were	O	1289-1293
devoid	O	1294-1300
of	O	1301-1303
any	O	1304-1307
effect	O	1308-1314
.	O	1314-1315

The	O	1316-1319
results	O	1320-1327
of	O	1328-1330
this	O	1331-1335
study	O	1336-1341
suggest	O	1342-1349
that	O	1350-1354
the	O	1355-1358
blockade	O	1359-1367
of	O	1368-1370
mGluR5	O	1371-1377
by	O	1378-1380
MPEP	O	1381-1385
may	O	1386-1389
protect	O	1390-1397
dopaminergic	O	1398-1410
neurones	O	1411-1419
against	O	1420-1427
methamphetamine	O	1428-1443
-	O	1443-1444
induced	O	1444-1451
toxicity	B	1452-1460
.	O	1460-1461

Neuroprotection	O	1462-1477
rendered	O	1478-1486
by	O	1487-1489
MPEP	O	1490-1494
may	O	1495-1498
be	O	1499-1501
associated	O	1502-1512
with	O	1513-1517
the	O	1518-1521
reduction	O	1522-1531
of	O	1532-1534
the	O	1535-1538
methamphetamine	O	1539-1554
-	O	1554-1555
induced	O	1555-1562
dopamine	O	1563-1571
efflux	O	1572-1578
in	O	1579-1581
the	O	1582-1585
striatum	O	1586-1594
due	O	1595-1598
to	O	1599-1601
the	O	1602-1605
blockade	O	1606-1614
of	O	1615-1617
extrastriatal	O	1618-1631
mGluR5	O	1632-1638
,	O	1638-1639
and	O	1640-1643
with	O	1644-1648
a	O	1649-1650
decrease	O	1651-1659
in	O	1660-1662
hyperthermia	B	1663-1675
.	O	1675-1676

Pharmacokinetics	O	0-16
of	O	17-19
desipramine	O	20-31
HCl	O	32-35
when	O	36-40
administered	O	41-53
with	O	54-58
cinacalcet	O	59-69
HCl	O	70-73
.	O	73-74

OBJECTIVE	O	75-84
:	O	84-85
In	O	86-88
vitro	O	89-94
work	O	95-99
has	O	100-103
demonstrated	O	104-116
that	O	117-121
cinacalcet	O	122-132
is	O	133-135
a	O	136-137
strong	O	138-144
inhibitor	O	145-154
of	O	155-157
cytochrome	O	158-168
P450	O	169-173
isoenzyme	O	174-183
(	O	184-185
CYP	O	185-188
)	O	188-189
2D6	O	190-193
.	O	193-194

The	O	195-198
purpose	O	199-206
of	O	207-209
this	O	210-214
study	O	215-220
was	O	221-224
to	O	225-227
evaluate	O	228-236
the	O	237-240
effect	O	241-247
of	O	248-250
cinacalcet	O	251-261
on	O	262-264
CYP2D6	O	265-271
activity	O	272-280
,	O	280-281
using	O	282-287
desipramine	O	288-299
as	O	300-302
a	O	303-304
probe	O	305-310
substrate	O	311-320
,	O	320-321
in	O	322-324
healthy	O	325-332
subjects	O	333-341
.	O	341-342

METHODS	O	343-350
:	O	350-351
Seventeen	O	352-361
subjects	O	362-370
who	O	371-374
were	O	375-379
genotyped	O	380-389
as	O	390-392
CYP2D6	O	393-399
extensive	O	400-409
metabolizers	O	410-422
were	O	423-427
enrolled	O	428-436
in	O	437-439
this	O	440-444
randomized	O	445-455
,	O	455-456
open	O	457-461
-	O	461-462
label	O	462-467
,	O	467-468
crossover	O	469-478
study	O	479-484
to	O	485-487
receive	O	488-495
a	O	496-497
single	O	498-504
oral	O	505-509
dose	O	510-514
of	O	515-517
desipramine	O	518-529
(	O	530-531
50	O	531-533
mg	O	534-536
)	O	536-537
on	O	538-540
two	O	541-544
separate	O	545-553
occasions	O	554-563
,	O	563-564
once	O	565-569
alone	O	570-575
and	O	576-579
once	O	580-584
after	O	585-590
multiple	O	591-599
doses	O	600-605
of	O	606-608
cinacalcet	O	609-619
(	O	620-621
90	O	621-623
mg	O	624-626
for	O	627-630
7	O	631-632
days	O	633-637
)	O	637-638
.	O	638-639

Blood	O	640-645
samples	O	646-653
were	O	654-658
obtained	O	659-667
predose	O	668-675
and	O	676-679
up	O	680-682
to	O	683-685
72	O	686-688
h	O	689-690
postdose	O	691-699
.	O	699-700

RESULTS	O	701-708
:	O	708-709
Fourteen	O	710-718
subjects	O	719-727
completed	O	728-737
both	O	738-742
treatment	O	743-752
arms	O	753-757
.	O	757-758

Relative	O	759-767
to	O	768-770
desipramine	O	771-782
alone	O	783-788
,	O	788-789
mean	O	790-794
AUC	O	795-798
and	O	799-802
C	O	803-804
(	O	804-805
max	O	805-808
)	O	808-809
of	O	810-812
desipramine	O	813-824
increased	O	825-834
3	O	835-836
.	O	836-837
6	O	837-838
-	O	838-839
and	O	840-843
1	O	844-845
.	O	845-846
8	O	846-847
-	O	847-848
fold	O	848-852
when	O	853-857
coadministered	O	858-872
with	O	873-877
cinacalcet	O	878-888
.	O	888-889

The	O	890-893
t	O	894-895
(	O	896-897
1	O	897-898
/	O	898-899
2	O	899-900
,	O	900-901
z	O	901-902
)	O	902-903
of	O	904-906
desipramine	O	907-918
was	O	919-922
longer	O	923-929
when	O	930-934
desipramine	O	935-946
was	O	947-950
coadministered	O	951-965
with	O	966-970
cinacalcet	O	971-981
(	O	982-983
21	O	983-985
.	O	985-986
0	O	986-987
versus	O	988-994
43	O	995-997
.	O	997-998
3	O	996-997
hs	O	1000-1002
)	O	1002-1003
.	O	1003-1004

The	O	1005-1008
t	O	1009-1010
(	O	1011-1012
max	O	1012-1015
)	O	1015-1016
was	O	1017-1020
similar	O	1021-1028
between	O	1029-1036
the	O	1037-1040
regimens	O	1041-1049
.	O	1049-1050

Fewer	O	1051-1056
subjects	O	1057-1065
reported	O	1066-1074
adverse	O	1075-1082
events	O	1083-1089
following	O	1090-1099
treatment	O	1100-1109
with	O	1110-1114
desipramine	O	1115-1126
alone	O	1127-1132
than	O	1133-1137
when	O	1138-1142
receiving	O	1143-1152
desipramine	O	1153-1164
with	O	1165-1169
cinacalcet	O	1170-1180
(	O	1181-1182
33	O	1182-1184
versus	O	1185-1191
86	O	1192-1194
%	O	1194-1195
)	O	1195-1196
,	O	1196-1197
the	O	1198-1201
most	O	1202-1206
frequent	O	1207-1215
of	O	1216-1218
which	O	1219-1224
(	O	1225-1226
nausea	B	1226-1232
and	O	1233-1236
headache	B	1237-1245
)	O	1245-1246
have	O	1247-1251
been	O	1252-1256
reported	O	1257-1265
for	O	1266-1269
patients	O	1270-1278
treated	O	1279-1286
with	O	1287-1291
either	O	1292-1298
desipramine	O	1299-1310
or	O	1311-1313
cinacalcet	O	1314-1324
.	O	1324-1325

CONCLUSION	O	1326-1336
:	O	1336-1337
This	O	1338-1342
study	O	1343-1348
demonstrates	O	1349-1361
that	O	1362-1366
cinacalcet	O	1367-1377
is	O	1378-1380
a	O	1381-1382
strong	O	1383-1389
inhibitor	O	1390-1399
of	O	1400-1402
CYP2D6	O	1403-1409
.	O	1409-1410

These	O	1411-1416
data	O	1417-1421
suggest	O	1422-1429
that	O	1430-1434
during	O	1435-1441
concomitant	O	1442-1453
treatment	O	1454-1463
with	O	1464-1468
cinacalcet	O	1469-1479
,	O	1479-1480
dose	O	1481-1485
adjustment	O	1486-1496
may	O	1497-1500
be	O	1501-1503
necessary	O	1504-1513
for	O	1514-1517
drugs	O	1518-1523
that	O	1524-1528
demonstrate	O	1529-1540
a	O	1541-1542
narrow	O	1543-1549
therapeutic	O	1550-1561
index	O	1562-1567
and	O	1568-1571
are	O	1572-1575
metabolized	O	1576-1587
by	O	1588-1590
CYP2D6	O	1591-1597
.	O	1597-1598

Proteomic	O	0-9
analysis	O	10-18
of	O	19-21
striatal	O	22-30
proteins	O	31-39
in	O	40-42
the	O	43-46
rat	O	47-50
model	O	51-56
of	O	57-59
L	O	60-61
-	O	61-62
DOPA	O	62-66
-	O	61-62
induced	O	67-74
dyskinesia	B	75-85
.	O	85-86

L	O	87-88
-	O	88-89
DOPA	O	89-93
-	O	88-89
induced	O	94-101
dyskinesia	B	102-112
(	O	113-114
LID	B	114-117
)	O	117-118
is	O	119-121
among	O	122-127
the	O	128-131
motor	O	132-137
complications	O	138-151
that	O	152-156
arise	O	157-162
in	O	163-165
Parkinson	B	166-175
'	I	175-176
s	I	172-173
disease	I	178-185
(	O	186-187
PD	B	187-189
)	O	189-190
patients	O	191-199
after	O	200-205
a	O	206-207
prolonged	O	208-217
treatment	O	218-227
with	O	228-232
L	O	233-234
-	O	234-235
DOPA	O	235-239
.	O	239-240

To	O	241-243
this	O	244-248
day	O	249-252
,	O	252-253
transcriptome	O	254-267
analysis	O	268-276
has	O	277-280
been	O	281-285
performed	O	286-295
in	O	296-298
a	O	299-300
rat	O	301-304
model	O	305-310
of	O	311-313
LID	B	314-317
[	O	318-319
Neurobiol	O	319-328
.	O	328-329

Dis	O	330-333
.	O	333-334
,	O	334-335
17	O	336-338
(	O	339-340
2004	O	340-344
)	O	344-345
,	O	345-346
219	O	347-350
]	O	350-351
but	O	352-355
information	O	356-367
regarding	O	368-377
the	O	378-381
proteome	O	382-390
is	O	391-393
still	O	394-399
lacking	O	400-407
.	O	407-408

In	O	409-411
the	O	412-415
present	O	416-423
study	O	424-429
,	O	429-430
we	O	431-433
investigated	O	434-446
the	O	447-450
changes	O	451-458
occurring	O	459-468
at	O	469-471
the	O	472-475
protein	O	476-483
level	O	484-489
in	O	490-492
striatal	O	493-501
samples	O	502-509
obtained	O	510-518
from	O	519-523
the	O	524-527
unilaterally	O	528-540
6	O	541-542
-	O	542-543
hydroxydopamine	O	543-558
-	O	542-543
lesion	O	559-565
rat	O	566-569
model	O	570-575
of	O	576-578
PD	B	579-581
treated	O	582-589
with	O	590-594
saline	O	595-601
,	O	601-602
L	O	603-604
-	O	604-605
DOPA	O	605-609
or	O	610-612
bromocriptine	O	613-626
using	O	627-632
two	O	633-636
-	O	636-637
dimensional	O	637-648
difference	O	649-659
gel	O	660-663
electrophoresis	O	664-679
and	O	680-683
mass	O	684-688
spectrometry	O	689-701
(	O	702-703
MS	O	703-705
)	O	705-706
.	O	706-707

Rats	O	708-712
treated	O	713-720
with	O	721-725
L	O	726-727
-	O	727-728
DOPA	O	728-732
were	O	733-737
allocated	O	738-747
to	O	748-750
two	O	751-754
groups	O	755-761
based	O	762-767
on	O	768-770
the	O	771-774
presence	O	775-783
or	O	784-786
absence	O	787-794
of	O	795-797
LID	B	798-801
.	O	801-802

Among	O	803-808
the	O	809-812
2000	O	813-817
spots	O	818-823
compared	O	824-832
for	O	833-836
statistical	O	837-848
difference	O	849-859
,	O	859-860
67	O	861-863
spots	O	864-869
were	O	870-874
significantly	O	875-888
changed	O	889-896
in	O	897-899
abundance	O	900-909
and	O	910-913
identified	O	914-924
using	O	925-930
matrix	O	931-937
-	O	937-938
assisted	O	938-946
laser	O	947-952
desorption	O	953-963
/	O	963-964
ionization	O	964-974
time	O	975-979
-	O	979-980
of	O	980-982
-	O	979-980
flight	O	983-989
MS	O	990-992
,	O	992-993
atmospheric	O	994-1005
pressure	O	1006-1014
matrix	O	1015-1021
-	O	1021-1022
assisted	O	1022-1030
laser	O	1031-1036
desorption	O	1037-1047
/	O	1047-1048
ionization	O	1048-1058
and	O	1059-1062
HPLC	O	1063-1067
coupled	O	1068-1075
tandem	O	1076-1082
MS	O	1083-1085
(	O	1086-1087
LC	O	1087-1089
/	O	1089-1090
MS	O	1090-1092
/	O	1089-1090
MS	O	1090-1092
)	O	1095-1096
.	O	1096-1097

Out	O	1098-1101
of	O	1102-1104
these	O	1105-1110
67	O	1111-1113
proteins	O	1114-1122
,	O	1122-1123
LID	B	1124-1127
significantly	O	1128-1141
changed	O	1142-1149
the	O	1150-1153
expression	O	1154-1164
level	O	1165-1170
of	O	1171-1173
five	O	1174-1178
proteins	O	1179-1187
:	O	1187-1188
alphabeta	O	1189-1198
-	O	1198-1199
crystalin	O	1199-1208
,	O	1208-1209
gamma	O	1210-1215
-	O	1215-1216
enolase	O	1216-1223
,	O	1223-1224
guanidoacetate	O	1225-1239
methyltransferase	O	1240-1257
,	O	1257-1258
vinculin	O	1259-1267
,	O	1267-1268
and	O	1269-1272
proteasome	O	1273-1283
alpha	O	1284-1289
-	O	1289-1290
2	O	1290-1291
subunit	O	1292-1299
.	O	1299-1300

Complementary	O	1301-1314
techniques	O	1315-1325
such	O	1326-1330
as	O	1331-1333
western	O	1334-1341
immunoblotting	O	1342-1356
and	O	1357-1360
immunohistochemistry	O	1361-1381
were	O	1382-1386
performed	O	1387-1396
to	O	1397-1399
investigate	O	1400-1411
the	O	1412-1415
validity	O	1416-1424
of	O	1425-1427
the	O	1428-1431
data	O	1432-1436
obtained	O	1437-1445
using	O	1446-1451
the	O	1452-1455
proteomic	O	1456-1465
approach	O	1466-1474
.	O	1474-1475

In	O	1476-1478
conclusion	O	1479-1489
,	O	1489-1490
this	O	1491-1495
study	O	1496-1501
provides	O	1502-1510
new	O	1511-1514
insights	O	1515-1523
into	O	1524-1528
the	O	1529-1532
protein	O	1533-1540
changes	O	1541-1548
occurring	O	1549-1558
in	O	1559-1561
LID	B	1562-1565
.	O	1565-1566

Pseudo	O	0-6
-	O	6-7
allergic	B	7-15
reactions	I	16-25
to	O	26-28
corticosteroids	O	29-44
:	O	44-45
diagnosis	O	46-55
and	O	56-59
alternatives	O	60-72
.	O	72-73

Two	O	74-77
patients	O	78-86
treated	O	87-94
with	O	95-99
parenteral	O	100-110
paramethasone	O	111-124
(	O	125-126
Triniol	O	126-133
)	O	133-134
and	O	135-138
dexamethasone	O	139-152
(	O	153-154
Sedionbel	O	154-163
)	O	163-164
are	O	165-168
described	O	169-178
.	O	178-179

A	O	180-181
few	O	182-185
minutes	O	186-193
after	O	194-199
administration	O	200-214
of	O	215-217
the	O	218-221
drugs	O	222-227
,	O	227-228
they	O	229-233
presented	O	234-243
urticaria	B	244-253
(	O	254-255
patients	O	255-263
1	O	264-265
and	O	266-269
2	O	270-271
)	O	271-272
and	O	273-276
conjunctivitis	B	277-291
(	O	292-293
patient	O	293-300
1	O	301-302
)	O	302-303
.	O	303-304

The	O	305-308
purpose	O	309-316
of	O	317-319
our	O	320-323
study	O	324-329
was	O	330-333
to	O	334-336
determine	O	337-346
the	O	347-350
cause	O	351-356
of	O	357-359
the	O	360-363
patients	O	364-372
'	O	372-373
reactions	O	374-383
,	O	383-384
the	O	385-388
immunological	O	389-402
mechanisms	O	403-413
involved	O	414-422
and	O	423-426
whether	O	427-434
these	O	435-440
patients	O	441-449
would	O	450-455
be	O	456-458
able	O	459-463
to	O	464-466
tolerate	O	467-475
any	O	476-479
kind	O	480-484
of	O	485-487
corticoid	O	488-497
.	O	497-498

Clinical	O	499-507
examinations	O	508-520
and	O	521-524
skin	O	525-529
,	O	529-530
oral	O	531-535
and	O	536-539
parenteral	O	540-550
challenges	O	551-561
with	O	562-566
different	O	567-576
corticosteroids	O	577-592
and	O	593-596
ELISA	O	597-602
tests	O	603-608
were	O	609-613
performed	O	614-623
.	O	623-624

In	O	625-627
the	O	628-631
two	O	632-635
patients	O	636-644
,	O	644-645
skin	O	646-650
and	O	651-654
ELISA	O	655-660
tests	O	661-666
with	O	667-671
paramethasone	O	672-685
were	O	686-690
negative	O	691-699
,	O	699-700
as	O	701-703
was	O	704-707
the	O	708-711
prick	O	712-717
test	O	718-722
with	O	723-727
each	O	728-732
of	O	733-735
its	O	736-739
excipients	O	740-750
.	O	750-751

A	O	752-753
single	O	754-760
-	O	760-761
blind	O	761-766
parenteral	O	767-777
challenge	O	778-787
with	O	788-792
Triniol	O	793-800
was	O	801-804
positive	O	805-813
in	O	814-816
both	O	817-821
patients	O	822-830
after	O	831-836
the	O	837-840
administration	O	841-855
of	O	856-858
1	O	859-860
ml	O	861-863
of	O	864-866
the	O	867-870
drug	O	871-875
,	O	875-876
and	O	877-880
negative	O	881-889
with	O	890-894
its	O	895-898
excipients	O	899-909
.	O	909-910

We	O	911-913
also	O	914-918
carried	O	919-926
out	O	927-930
oral	O	931-935
and	O	936-939
parenteral	O	940-950
challenges	O	951-961
with	O	962-966
other	O	967-972
corticosteroids	O	973-988
and	O	989-992
found	O	993-998
intolerance	O	999-1010
to	O	1011-1013
some	O	1014-1018
of	O	1019-1021
them	O	1022-1026
.	O	1026-1027

These	O	1028-1033
results	O	1034-1041
suggest	O	1042-1049
that	O	1050-1054
paramethasone	O	1055-1068
caused	O	1069-1075
pseudoallergic	O	1076-1090
reactions	O	1091-1100
in	O	1101-1103
our	O	1104-1107
patients	O	1108-1116
.	O	1116-1117

Corticosteroids	O	1118-1133
different	O	1134-1143
from	O	1144-1148
paramethasone	O	1149-1162
also	O	1163-1167
produced	O	1168-1176
hypersensitivity	B	1177-1193
reactions	O	1194-1203
in	O	1204-1206
these	O	1207-1212
patients	O	1213-1221
;	O	1221-1222
however	O	1223-1230
,	O	1230-1231
a	O	1232-1233
few	O	1234-1237
of	O	1238-1240
them	O	1241-1245
were	O	1246-1250
tolerated	O	1251-1260
.	O	1260-1261

The	O	1262-1265
basic	O	1266-1271
mechanisms	O	1272-1282
of	O	1283-1285
those	O	1286-1291
reactions	O	1292-1301
are	O	1302-1305
not	O	1306-1309
yet	O	1310-1313
fully	O	1314-1319
understood	O	1320-1330
.	O	1330-1331

To	O	1332-1334
our	O	1335-1338
knowledge	O	1339-1348
,	O	1348-1349
this	O	1350-1354
is	O	1355-1357
the	O	1358-1361
first	O	1362-1367
report	O	1368-1374
of	O	1375-1377
a	O	1378-1379
pseudo	O	1380-1386
-	O	1386-1387
allergy	B	1387-1394
caused	O	1395-1401
by	O	1402-1404
paramethasone	O	1405-1418
.	O	1418-1419

Valproic	O	0-8
acid	O	9-13
induced	O	14-21
encephalopathy	B	22-36
-	O	36-37
-	O	36-37
19	O	38-40
new	O	41-44
cases	O	45-50
in	O	51-53
Germany	O	54-61
from	O	62-66
1994	O	67-71
to	O	72-74
2003	O	75-79
-	O	79-80
-	O	79-80
a	O	81-82
side	O	83-87
effect	O	88-94
associated	O	95-105
to	O	106-108
VPA	O	109-112
-	O	112-113
therapy	O	113-120
not	O	121-124
only	O	125-129
in	O	130-132
young	O	133-138
children	O	139-147
.	O	147-148

Valproic	O	149-157
acid	O	158-162
(	O	163-164
VPA	O	164-167
)	O	167-168
is	O	169-171
a	O	172-173
broad	O	174-179
-	O	179-180
spectrum	O	180-188
antiepileptic	O	189-202
drug	O	203-207
and	O	208-211
is	O	212-214
usually	O	215-222
well	O	223-227
-	O	227-228
tolerated	O	228-237
.	O	237-238

Rare	O	239-243
serious	O	244-251
complications	O	252-265
may	O	266-269
occur	O	270-275
in	O	276-278
some	O	279-283
patients	O	284-292
,	O	292-293
including	O	294-303
haemorrhagic	O	304-316
pancreatitis	B	317-329
,	O	329-330
bone	B	331-335
marrow	I	336-342
suppression	I	343-354
,	O	354-355
VPA	O	356-359
-	O	359-360
induced	O	360-367
hepatotoxicity	B	368-382
and	O	383-386
VPA	O	387-390
-	O	390-391
induced	O	391-398
encephalopathy	B	399-413
.	O	413-414

The	O	415-418
typical	O	419-426
signs	O	427-432
of	O	433-435
VPA	O	436-439
-	O	439-440
induced	O	440-447
encephalopathy	B	448-462
are	O	463-466
impaired	B	467-475
consciousness	I	476-489
,	O	489-490
sometimes	O	491-500
marked	O	501-507
EEG	O	508-511
background	O	512-522
slowing	O	523-530
,	O	530-531
increased	O	532-541
seizure	B	542-549
frequency	O	550-559
,	O	559-560
with	O	561-565
or	O	566-568
without	O	569-576
hyperammonemia	B	577-591
.	O	591-592

There	O	593-598
is	O	599-601
still	O	602-607
no	O	608-610
proof	O	611-616
of	O	617-619
causative	O	620-629
effect	O	630-636
of	O	637-639
VPA	O	640-643
in	O	644-646
patients	O	647-655
with	O	656-660
encephalopathy	B	661-675
,	O	675-676
but	O	677-680
only	O	681-685
of	O	686-688
an	O	689-691
association	O	692-703
with	O	704-708
an	O	709-711
assumed	O	712-719
causal	O	720-726
relation	O	727-735
.	O	735-736

We	O	737-739
report	O	740-746
19	O	747-749
patients	O	750-758
with	O	759-763
VPA	O	764-767
-	O	767-768
associated	O	768-778
encephalopathy	B	779-793
in	O	794-796
Germany	O	797-804
from	O	805-809
the	O	810-813
years	O	814-819
1994	O	820-824
to	O	825-827
2003	O	828-832
,	O	832-833
none	O	834-838
of	O	839-841
whom	O	842-846
had	O	847-850
been	O	851-855
published	O	856-865
previously	O	866-876
.	O	876-877

Haemolytic	B	0-10
-	I	10-11
uraemic	I	11-18
syndrome	I	19-27
after	O	28-33
treatment	O	34-43
with	O	44-48
metronidazole	O	49-62
.	O	62-63

This	O	64-68
paper	O	69-74
describes	O	75-84
the	O	85-88
clinical	O	89-97
features	O	98-106
of	O	107-109
six	O	110-113
children	O	114-122
who	O	123-126
developed	O	127-136
the	O	137-140
haemolytic	B	141-151
-	I	151-152
uraemic	I	152-159
syndrome	I	160-168
after	O	169-174
treatment	O	175-184
with	O	185-189
metronidazole	O	190-203
.	O	203-204

These	O	205-210
children	O	211-219
were	O	220-224
older	O	225-230
and	O	231-234
were	O	235-239
more	O	240-244
likely	O	245-251
to	O	252-254
have	O	255-259
undergone	O	260-269
recent	O	270-276
bowel	O	277-282
surgery	O	283-290
than	O	291-295
are	O	296-299
other	O	300-305
children	O	306-314
with	O	315-319
this	O	320-324
condition	O	325-334
.	O	334-335

While	O	336-341
the	O	342-345
involvement	O	346-357
of	O	358-360
metronidazole	O	361-374
in	O	375-377
the	O	378-381
aetiology	O	382-391
of	O	392-394
the	O	395-398
haemolytic	B	399-409
-	I	409-410
uraemic	I	410-417
syndrome	I	418-426
is	O	427-429
not	O	430-433
established	O	434-445
firmly	O	446-452
,	O	452-453
the	O	454-457
action	O	458-464
of	O	465-467
this	O	468-472
drug	O	473-477
in	O	478-480
sensitizing	O	481-492
tissues	O	493-500
to	O	501-503
oxidation	O	504-513
injury	O	514-520
and	O	521-524
the	O	525-528
reported	O	529-537
evidence	O	538-546
of	O	547-549
oxidation	O	550-559
changes	O	560-567
in	O	568-570
the	O	571-574
haemolytic	B	575-585
-	I	585-586
uraemic	I	586-593
syndrome	I	594-602
suggest	O	603-610
a	O	611-612
possible	O	613-621
link	O	622-626
between	O	627-634
metronidazole	O	635-648
treatment	O	649-658
and	O	659-662
some	O	663-667
cases	O	668-673
of	O	674-676
the	O	677-680
haemolytic	B	681-691
-	I	691-692
uraemic	I	692-699
syndrome	I	700-708
.	O	708-709

Risk	O	0-4
factors	O	5-12
of	O	13-15
sensorineural	B	16-29
hearing	I	30-37
loss	I	38-42
in	O	43-45
preterm	O	46-53
infants	O	54-61
.	O	61-62

Among	O	63-68
547	O	69-72
preterm	O	73-80
infants	O	81-88
of	O	89-91
<	O	92-93
or	O	94-96
=	O	97-98
34	O	99-101
weeks	O	102-107
gestation	O	108-117
born	O	118-122
between	O	123-130
1987	O	131-135
and	O	136-139
1991	O	140-144
,	O	144-145
8	O	146-147
children	O	148-156
(	O	157-158
1	O	158-159
.	O	159-160
46	O	160-162
%	O	162-163
)	O	163-164
developed	O	165-174
severe	O	175-181
progressive	O	182-193
and	O	194-197
bilateral	O	198-207
sensorineural	B	208-221
hearing	I	222-229
loss	I	230-234
.	O	234-235

Perinatal	O	236-245
risk	O	246-250
factors	O	251-258
of	O	259-261
infants	O	262-269
with	O	270-274
hearing	B	275-282
loss	I	283-287
were	O	288-292
compared	O	293-301
with	O	302-306
those	O	307-312
of	O	313-315
two	O	316-319
control	O	320-327
groups	O	328-334
matched	O	335-342
for	O	343-346
gestation	O	347-356
and	O	357-360
birth	O	361-366
weight	O	367-373
and	O	374-377
for	O	378-381
perinatal	O	382-391
complications	O	392-405
.	O	405-406

Our	O	407-410
observations	O	411-423
demonstrated	O	424-436
an	O	437-439
association	O	440-451
of	O	452-454
hearing	B	455-462
loss	I	463-467
with	O	468-472
a	O	473-474
higher	O	475-481
incidence	O	482-491
of	O	492-494
perinatal	O	495-504
complications	O	505-518
.	O	518-519

Ototoxicity	B	520-531
appeared	O	532-540
closely	O	541-548
related	O	549-556
to	O	557-559
a	O	560-561
prolonged	O	562-571
administration	O	572-586
and	O	587-590
higher	O	591-597
total	O	598-603
dose	O	604-608
of	O	609-611
ototoxic	B	612-620
drugs	O	621-626
,	O	626-627
particularly	O	628-640
aminoglycosides	O	641-656
and	O	657-660
furosemide	O	661-671
.	O	671-672

Finally	O	673-680
,	O	680-681
we	O	682-684
strongly	O	685-693
recommend	O	694-703
to	O	704-706
prospectively	O	707-720
and	O	721-724
regularly	O	725-734
perform	O	735-742
audiologic	O	743-753
assessment	O	754-764
in	O	765-767
sick	O	768-772
preterm	O	773-780
children	O	781-789
as	O	790-792
hearing	B	793-800
loss	I	801-805
is	O	806-808
of	O	809-811
delayed	O	812-819
onset	O	820-825
and	O	826-829
in	O	830-832
most	O	833-837
cases	O	838-843
bilateral	O	844-853
and	O	854-857
severe	O	858-864
.	O	864-865

Pharmacokinetic	O	0-15
and	O	16-19
clinical	O	20-28
studies	O	29-36
in	O	37-39
patients	O	40-48
with	O	49-53
cimetidine	O	54-64
-	O	64-65
associated	O	65-75
mental	O	76-82
confusion	B	83-92
.	O	92-93

15	O	94-96
cases	O	97-102
of	O	103-105
cimetidine	O	106-116
-	O	116-117
associated	O	117-127
mental	O	128-134
confusion	B	135-144
have	O	145-149
been	O	150-154
reported	O	155-163
.	O	163-164

In	O	165-167
order	O	168-173
that	O	174-178
this	O	179-183
syndrome	O	184-192
might	O	193-198
be	O	199-201
investigated	O	202-214
changes	O	215-222
in	O	223-225
mental	O	226-232
status	O	233-239
(	O	240-241
M	O	241-242
.	O	242-243
S	O	243-244
.	O	242-243
)	O	245-246
were	O	247-251
correlated	O	252-262
with	O	263-267
serum	O	268-273
concentrations	O	274-288
and	O	289-292
renal	O	293-298
and	O	299-302
hepatic	O	303-310
function	O	311-319
in	O	320-322
36	O	323-325
patients	O	326-334
,	O	334-335
30	O	336-338
patients	O	339-347
had	O	348-351
no	O	352-354
M	O	355-356
.	O	356-357
S	O	357-358
.	O	356-357
change	O	360-366
on	O	367-369
cimetidine	O	370-380
and	O	381-384
6	O	385-386
had	O	387-390
moderate	O	391-399
to	O	400-402
severe	O	403-409
changes	O	410-417
.	O	417-418

These	O	419-424
6	O	425-426
patients	O	427-435
had	O	436-439
both	O	440-444
renal	B	445-450
and	I	451-454
liver	I	455-460
dysfunction	I	461-472
(	O	473-474
P	O	474-475
less	O	476-480
than	O	481-485
0	O	486-487
.	O	487-488
05	O	488-490
)	O	490-491
,	O	491-492
as	O	493-495
well	O	496-500
as	O	501-503
cimetidine	O	504-514
trough	O	515-521
-	O	521-522
concentrations	O	522-536
of	O	537-539
more	O	540-544
than	O	545-549
1	O	550-551
.	O	551-552
25	O	552-554
microgram	O	555-564
/	O	564-565
ml	O	565-567
(	O	568-569
P	O	569-570
less	O	571-575
than	O	576-580
0	O	581-582
.	O	582-583
05	O	583-585
)	O	585-586
.	O	582-583

The	O	588-591
severity	O	592-600
of	O	601-603
M	O	604-605
.	O	605-606
S	O	606-607
.	O	605-606
changes	O	609-616
increased	O	617-626
as	O	627-629
trough	O	630-636
-	O	636-637
concentrations	O	637-651
rose	O	652-656
,	O	656-657
5	O	658-659
patients	O	660-668
had	O	669-672
lumbar	O	673-679
puncture	O	680-688
.	O	688-689

The	O	690-693
cerebrospinal	O	694-707
fluid	O	708-713
:	O	713-714
serum	O	715-720
ratio	O	721-726
of	O	727-729
cimetidine	O	730-740
concentrations	O	741-755
was	O	756-759
0	O	760-761
.	O	761-762
24	O	762-764
:	O	764-765
1	O	765-766
and	O	767-770
indicates	O	771-780
that	O	781-785
cimetidine	O	786-796
passes	O	797-803
the	O	804-807
blood	O	808-813
-	O	813-814
brain	O	814-819
barrier	O	820-827
;	O	827-828
it	O	829-831
also	O	832-836
raises	O	837-843
the	O	844-847
possibility	O	848-859
that	O	860-864
M	O	865-866
.	O	866-867
S	O	867-868
.	O	866-867
changes	O	870-877
are	O	878-881
due	O	882-885
to	O	886-888
blockade	O	889-897
of	O	898-900
histamine	O	901-910
H2	O	911-913
-	O	913-914
receptors	O	914-923
in	O	924-926
the	O	927-930
central	O	931-938
nervous	O	939-946
system	O	947-953
.	O	953-954

Patients	O	955-963
likely	O	964-970
to	O	971-973
have	O	974-978
both	O	979-983
raised	O	984-990
trough	O	991-997
-	O	997-998
concentrations	O	998-1012
and	O	1013-1016
mental	O	1017-1023
confusion	B	1024-1033
are	O	1034-1037
those	O	1038-1043
with	O	1044-1048
both	O	1049-1053
severe	O	1054-1060
renal	B	1061-1066
and	I	1067-1070
hepatic	I	1071-1078
dysfunction	I	1079-1090
.	O	1090-1091

They	O	1092-1096
should	O	1097-1103
be	O	1104-1106
closely	O	1107-1114
observed	O	1115-1123
and	O	1124-1127
should	O	1128-1134
be	O	1135-1137
given	O	1138-1143
reduced	O	1144-1151
doses	O	1152-1157
of	O	1158-1160
cimetidine	O	1161-1171
.	O	1171-1172

Different	O	0-9
lobular	O	10-17
distributions	O	18-31
of	O	32-34
altered	O	35-42
hepatocyte	O	43-53
tight	O	54-59
junctions	O	60-69
in	O	70-72
rat	O	73-76
models	O	77-83
of	O	84-86
intrahepatic	B	87-99
and	I	100-103
extrahepatic	I	104-116
cholestasis	I	117-128
.	O	128-129

Hepatocyte	O	130-140
tight	O	141-146
junctions	O	147-156
(	O	157-158
TJs	O	158-161
)	O	161-162
,	O	162-163
the	O	164-167
only	O	168-172
intercellular	O	173-186
barrier	O	187-194
between	O	195-202
the	O	203-206
sinusoidal	O	207-217
and	O	218-221
the	O	222-225
canalicular	O	226-237
spaces	O	238-244
,	O	244-245
play	O	246-250
a	O	251-252
key	O	253-256
role	O	257-261
in	O	262-264
bile	O	265-269
formation	O	270-279
.	O	279-280

Although	O	281-289
hepatocyte	O	290-300
TJs	O	301-304
are	O	305-308
impaired	O	309-317
in	O	318-320
cholestasis	B	321-332
,	O	332-333
attempts	O	334-342
to	O	343-345
localize	O	346-354
the	O	355-358
precise	O	359-366
site	O	367-371
of	O	372-374
hepatocyte	O	375-385
TJ	O	386-388
damage	O	389-395
by	O	396-398
freeze	O	399-405
-	O	405-406
fracture	O	406-414
electron	O	415-423
microscopy	O	424-434
have	O	435-439
produced	O	440-448
limited	O	449-456
information	O	457-468
.	O	468-469

Recently	O	470-478
,	O	478-479
several	O	480-487
TJ	O	488-490
-	O	490-491
associated	O	491-501
proteins	O	502-510
like	O	511-515
ZO	O	516-518
-	O	518-519
1	O	519-520
and	O	521-524
7H6	O	525-528
have	O	529-533
been	O	534-538
identified	O	539-549
and	O	550-553
characterized	O	554-567
.	O	567-568

Immunolocalization	O	569-587
of	O	588-590
7H6	O	591-594
appears	O	595-602
to	O	603-605
closely	O	606-613
correlate	O	614-623
with	O	624-628
paracellular	O	629-641
permeability	O	642-654
.	O	654-655

We	O	656-658
used	O	659-663
rat	O	664-667
models	O	668-674
of	O	675-677
intrahepatic	B	678-690
cholestasis	I	691-702
by	O	703-705
ethinyl	O	706-713
estradiol	O	714-723
(	O	724-725
EE	O	725-727
)	O	727-728
treatment	O	729-738
and	O	739-742
extrahepatic	B	743-755
cholestasis	I	756-767
by	O	768-770
bile	O	771-775
duct	O	776-780
ligation	O	781-789
(	O	790-791
BDL	O	791-794
)	O	794-795
to	O	796-798
precisely	O	799-808
determine	O	809-818
the	O	819-822
site	O	823-827
of	O	828-830
TJ	O	831-833
damage	O	834-840
.	O	840-841

Alterations	O	842-853
in	O	854-856
hepatocyte	O	857-867
TJs	O	868-871
were	O	872-876
assessed	O	877-885
by	O	886-888
double	O	889-895
-	O	895-896
immunolabeling	O	896-910
for	O	911-914
7H6	O	915-918
and	O	919-922
ZO	O	923-925
-	O	925-926
1	O	926-927
using	O	928-933
a	O	934-935
confocal	O	936-944
laser	O	945-950
scanning	O	951-959
microscope	O	960-970
.	O	970-971

In	O	972-974
control	O	975-982
rats	O	983-987
,	O	987-988
immunostaining	O	989-1003
for	O	1004-1007
7H6	O	1008-1011
and	O	1012-1015
ZO	O	1016-1018
-	O	1018-1019
1	O	1019-1020
colocalized	O	1021-1032
to	O	1033-1035
outline	O	1036-1043
bile	O	1044-1048
canaliculi	O	1049-1059
in	O	1060-1062
a	O	1063-1064
continuous	O	1065-1075
fashion	O	1076-1083
.	O	1083-1084

In	O	1085-1087
contrast	O	1088-1096
,	O	1096-1097
7H6	O	1098-1101
and	O	1102-1105
ZO	O	1106-1108
-	O	1108-1109
1	O	1109-1110
immunostaining	O	1111-1125
was	O	1126-1129
more	O	1130-1134
discontinuous	O	1135-1148
,	O	1148-1149
outlining	O	1150-1159
the	O	1160-1163
bile	O	1164-1168
canaliculi	O	1169-1179
after	O	1180-1185
BDL	O	1186-1189
.	O	1189-1190

Immunostaining	O	1191-1205
for	O	1206-1209
7H6	O	1210-1213
,	O	1213-1214
not	O	1215-1218
ZO	O	1219-1221
-	O	1221-1222
1	O	1222-1223
,	O	1223-1224
decreased	O	1225-1234
and	O	1235-1238
predominantly	O	1239-1252
appeared	O	1253-1261
as	O	1262-1264
discrete	O	1265-1273
signals	O	1274-1281
in	O	1282-1284
the	O	1285-1288
submembranous	O	1289-1302
cytoplasm	O	1303-1312
of	O	1313-1315
periportal	O	1316-1326
hepatocytes	O	1327-1338
after	O	1339-1344
BDL	O	1345-1348
.	O	1348-1349

After	O	1350-1355
EE	O	1356-1358
treatment	O	1359-1368
,	O	1368-1369
changes	O	1370-1377
in	O	1378-1380
immunostaining	O	1381-1395
for	O	1396-1399
7H6	O	1400-1403
and	O	1404-1407
ZO	O	1408-1410
-	O	1410-1411
1	O	1411-1412
were	O	1413-1417
similar	O	1418-1425
to	O	1426-1428
those	O	1429-1434
seen	O	1435-1439
in	O	1440-1442
periportal	O	1443-1453
hepatocytes	O	1454-1465
after	O	1466-1471
BDL	O	1472-1475
,	O	1475-1476
but	O	1477-1480
distributed	O	1481-1492
more	O	1493-1497
diffusely	O	1498-1507
throughout	O	1508-1518
the	O	1519-1522
lobule	O	1523-1529
.	O	1529-1530

This	O	1531-1535
study	O	1536-1541
is	O	1542-1544
the	O	1545-1548
first	O	1549-1554
to	O	1555-1557
demonstrate	O	1558-1569
that	O	1570-1574
impairment	O	1575-1585
of	O	1586-1588
hepatocyte	O	1589-1599
TJs	O	1600-1603
occurs	O	1604-1610
heterogenously	O	1611-1625
in	O	1626-1628
the	O	1629-1632
liver	O	1633-1638
lobule	O	1639-1645
after	O	1646-1651
BDL	O	1652-1655
and	O	1656-1659
suggests	O	1660-1668
that	O	1669-1673
BDL	O	1674-1677
and	O	1678-1681
EE	O	1682-1684
treatments	O	1685-1695
produce	O	1696-1703
different	O	1704-1713
lobular	O	1714-1721
distributions	O	1722-1735
of	O	1736-1738
increased	O	1739-1748
paracellular	O	1749-1761
permeability	O	1762-1774
.	O	1774-1775

Long	O	0-4
term	O	5-9
audiological	O	10-22
evaluation	O	23-33
of	O	34-36
beta	B	37-41
-	I	41-42
thalassemic	I	42-53
patients	O	54-62
.	O	62-63

OBJECTIVE	O	64-73
:	O	73-74
The	O	75-78
objective	O	79-88
of	O	89-91
this	O	92-96
study	O	97-102
was	O	103-106
to	O	107-109
identify	O	110-118
the	O	119-122
incidence	O	123-132
and	O	133-136
to	O	137-139
monitor	O	140-147
the	O	148-151
progression	O	152-163
of	O	164-166
hearing	B	167-174
loss	I	175-179
in	O	180-182
children	O	183-191
and	O	192-195
young	O	196-201
adults	O	202-208
with	O	209-213
beta	B	214-218
-	I	218-219
thalassemia	I	219-230
major	O	231-236
.	O	236-237

METHODS	O	238-245
:	O	245-246
One	O	247-250
hundred	O	251-258
and	O	259-262
four	O	263-267
(	O	268-269
104	O	269-272
)	O	272-273
patients	O	274-282
aged	O	283-287
6	O	288-289
-	O	289-290
35	O	290-292
years	O	293-298
(	O	299-300
mean	O	300-304
17	O	305-307
,	O	307-308
2	O	308-309
years	O	310-315
)	O	315-316
participated	O	317-329
in	O	330-332
the	O	333-336
study	O	337-342
.	O	342-343

All	O	344-347
patients	O	348-356
were	O	357-361
on	O	362-364
a	O	365-366
regular	O	367-374
transfusion	O	375-386
-	O	386-387
chelation	O	387-396
program	O	397-404
maintaining	O	405-416
a	O	417-418
mean	O	419-423
hemoglobin	O	424-434
level	O	435-440
of	O	441-443
9	O	444-445
.	O	445-446
5	O	446-447
gr	O	448-450
/	O	450-451
dl	O	451-453
.	O	453-454

Subjects	O	455-463
were	O	464-468
receiving	O	469-478
desferrioxamine	O	479-494
(	O	495-496
DFO	O	496-499
)	O	499-500
chelation	O	501-510
treatment	O	511-520
with	O	521-525
a	O	526-527
mean	O	528-532
daily	O	533-538
dose	O	539-543
of	O	544-546
50	O	547-549
-	O	549-550
60	O	550-552
mg	O	553-555
/	O	555-556
kg	O	556-558
,	O	558-559
5	O	560-561
-	O	561-562
6	O	562-563
days	O	564-568
a	O	569-570
week	O	571-575
during	O	576-582
the	O	583-586
first	O	587-592
six	O	593-596
years	O	597-602
of	O	603-605
the	O	606-609
study	O	610-615
,	O	615-616
which	O	617-622
was	O	623-626
then	O	627-631
reduced	O	632-639
to	O	640-642
40	O	643-645
-	O	645-646
50	O	646-648
mg	O	649-651
/	O	651-652
kg	O	652-654
for	O	655-658
the	O	659-662
following	O	663-672
eight	O	673-678
years	O	679-684
.	O	684-685

Patients	O	686-694
were	O	695-699
followed	O	700-708
for	O	709-712
8	O	713-714
-	O	714-715
14	O	715-717
years	O	718-723
.	O	723-724

RESULTS	O	725-732
:	O	732-733
Overall	O	734-741
,	O	741-742
21	O	743-745
out	O	746-749
of	O	750-752
104	O	753-756
patients	O	757-765
(	O	766-767
20	O	767-769
.	O	769-770
2	O	767-768
%	O	771-772
)	O	772-773
presented	O	774-783
with	O	784-788
high	O	789-793
frequency	O	794-803
sensorineural	B	804-817
hearing	I	818-825
loss	I	826-830
(	O	831-832
SNHL	B	832-836
)	O	836-837
,	O	837-838
either	O	839-845
unilateral	O	846-856
or	O	857-859
bilateral	O	860-869
.	O	869-870

No	O	871-873
ototoxic	B	874-882
factor	O	883-889
,	O	889-890
other	O	891-896
than	O	897-901
DFO	O	902-905
,	O	905-906
was	O	907-910
present	O	911-918
in	O	919-921
any	O	922-925
of	O	926-928
the	O	929-932
patients	O	933-941
.	O	941-942

Patients	O	943-951
with	O	952-956
SNHL	B	957-961
presented	O	962-971
with	O	972-976
relatively	O	977-987
lower	O	988-993
serum	O	994-999
ferritin	O	1000-1008
levels	O	1009-1015
than	O	1016-1020
those	O	1021-1026
with	O	1027-1031
normal	O	1032-1038
hearing	O	1039-1046
,	O	1046-1047
however	O	1048-1055
,	O	1055-1056
no	O	1057-1059
statistically	O	1060-1073
significant	O	1074-1085
difference	O	1086-1096
was	O	1097-1100
observed	O	1101-1109
.	O	1109-1110

Subjects	O	1111-1119
with	O	1120-1124
SNHL	B	1125-1129
were	O	1130-1134
submitted	O	1135-1144
to	O	1145-1147
DFO	O	1148-1151
reduction	O	1152-1161
or	O	1162-1164
temporary	O	1165-1174
withdrawal	O	1175-1185
.	O	1185-1186

Following	O	1187-1196
intervention	O	1197-1209
,	O	1209-1210
7	O	1211-1212
out	O	1213-1216
of	O	1217-1219
21	O	1220-1222
affected	O	1223-1231
patients	O	1232-1240
recovered	O	1241-1250
,	O	1250-1251
10	O	1252-1254
remained	O	1255-1263
stable	O	1264-1270
and	O	1271-1274
4	O	1275-1276
demonstrated	O	1277-1289
aggravation	O	1290-1301
.	O	1301-1302

CONCLUSION	O	1303-1313
:	O	1313-1314
The	O	1315-1318
findings	O	1319-1327
are	O	1328-1331
indicative	O	1332-1342
of	O	1343-1345
DFO	O	1346-1349
'	O	1349-1350
s	O	1350-1351
contributing	O	1352-1364
role	O	1365-1369
in	O	1370-1372
the	O	1373-1376
development	O	1377-1388
of	O	1389-1391
hearing	B	1392-1399
impairment	I	1400-1410
.	O	1410-1411

Regular	O	1412-1419
audiologic	O	1420-1430
evaluation	O	1431-1441
is	O	1442-1444
imperative	O	1445-1455
in	O	1456-1458
all	O	1459-1462
thalassemic	B	1463-1474
patients	O	1475-1483
so	O	1484-1486
that	O	1487-1491
early	O	1492-1497
changes	O	1498-1505
may	O	1506-1509
be	O	1510-1512
recognized	O	1513-1523
and	O	1524-1527
treatment	O	1528-1537
may	O	1538-1541
be	O	1542-1544
judiciously	O	1545-1556
adjusted	O	1557-1565
in	O	1566-1568
order	O	1569-1574
to	O	1575-1577
prevent	O	1578-1585
or	O	1586-1588
reverse	O	1589-1596
hearing	B	1597-1604
impairment	I	1605-1615
.	O	1615-1616

Design	O	0-6
and	O	7-10
analysis	O	11-19
of	O	20-22
the	O	23-26
HYPREN	O	27-33
-	O	33-34
trial	O	34-39
:	O	39-40
safety	O	41-47
of	O	48-50
enalapril	O	51-60
and	O	61-64
prazosin	O	65-73
in	O	74-76
the	O	77-80
initial	O	81-88
treatment	O	89-98
phase	O	99-104
of	O	105-107
patients	O	108-116
with	O	117-121
congestive	B	122-132
heart	I	133-138
failure	I	139-146
.	O	146-147

Since	O	148-153
the	O	154-157
introduction	O	158-170
of	O	171-173
angiotensin	O	174-185
converting	O	186-196
enzyme	O	197-203
(	O	204-205
ACE	O	205-208
)	O	208-209
inhibitors	O	210-220
into	O	221-225
the	O	226-229
adjunctive	O	230-240
treatment	O	241-250
of	O	251-253
patients	O	254-262
with	O	263-267
congestive	B	268-278
heart	I	279-284
failure	I	285-292
,	O	292-293
cases	O	294-299
of	O	300-302
severe	O	303-309
hypotension	B	310-321
,	O	321-322
especially	O	323-333
on	O	334-336
the	O	337-340
first	O	341-346
day	O	347-350
of	O	351-353
treatment	O	354-363
,	O	363-364
have	O	365-369
occasionally	O	370-382
been	O	383-387
reported	O	388-396
.	O	396-397

To	O	398-400
assess	O	401-407
the	O	408-411
safety	O	412-418
of	O	419-421
the	O	422-425
ACE	O	426-429
inhibitor	O	430-439
enalapril	O	440-449
a	O	450-451
multicenter	O	452-463
,	O	463-464
randomized	O	465-475
,	O	475-476
prazosin	O	477-485
-	O	485-486
controlled	O	486-496
trial	O	497-502
was	O	503-506
designed	O	507-515
that	O	516-520
compared	O	521-529
the	O	530-533
incidence	O	534-543
and	O	544-547
severity	O	548-556
of	O	557-559
symptomatic	O	560-571
hypotension	B	572-583
on	O	584-586
the	O	587-590
first	O	591-596
day	O	597-600
of	O	601-603
treatment	O	604-613
.	O	613-614

Trial	O	615-620
medication	O	621-631
was	O	632-635
2	O	636-637
.	O	637-638
5	O	638-639
mg	O	640-642
enalapril	O	643-652
or	O	653-655
0	O	656-657
.	O	657-658
5	O	658-659
prazosin	O	660-668
.	O	668-669

Subjects	O	670-678
were	O	679-683
1210	O	684-688
inpatients	O	689-699
with	O	700-704
New	O	705-708
York	O	709-713
Heart	O	714-719
Association	O	720-731
(	O	732-733
NYHA	O	733-737
)	O	737-738
functional	O	739-749
class	O	750-755
II	O	756-758
and	O	759-762
III	O	763-766
.	O	766-767

Patients	O	768-776
who	O	777-780
received	O	781-789
enalapril	O	790-799
experienced	O	800-811
clinically	O	812-822
and	O	823-826
statistically	O	827-840
significantly	O	841-854
less	O	855-859
symptomatic	O	860-871
hypotension	B	872-883
(	O	884-885
5	O	885-886
.	O	886-887
2	O	887-888
%	O	888-889
)	O	889-890
than	O	891-895
the	O	896-899
patients	O	900-908
who	O	909-912
received	O	913-921
prazosin	O	922-930
(	O	931-932
12	O	932-934
.	O	934-935
9	O	935-936
%	O	936-937
)	O	937-938
.	O	934-935

All	O	940-943
patients	O	944-952
recovered	O	953-962
.	O	962-963

It	O	964-966
was	O	967-970
concluded	O	971-980
that	O	981-985
treatment	O	986-995
with	O	996-1000
enalapril	O	1001-1010
was	O	1011-1014
well	O	1015-1019
tolerated	O	1020-1029
and	O	1030-1033
it	O	1034-1036
is	O	1037-1039
,	O	1039-1040
therefore	O	1041-1050
,	O	1050-1051
unreasonable	O	1052-1064
to	O	1065-1067
restrict	O	1068-1076
the	O	1077-1080
initiation	O	1081-1091
of	O	1092-1094
treatment	O	1095-1104
with	O	1105-1109
enalapril	O	1110-1119
to	O	1120-1122
inpatients	O	1123-1133
.	O	1133-1134

Antagonism	O	0-10
between	O	11-18
interleukin	O	19-30
3	O	31-32
and	O	33-36
erythropoietin	O	37-51
in	O	52-54
mice	O	55-59
with	O	60-64
azidothymidine	O	65-79
-	O	79-80
induced	O	80-87
anemia	B	88-94
and	O	95-98
in	O	99-101
bone	O	102-106
marrow	O	107-113
endothelial	O	114-125
cells	O	126-131
.	O	131-132

Azidothymidine	O	133-147
(	O	148-149
AZT	O	149-152
)	O	152-153
-	O	153-154
induced	O	154-161
anemia	B	162-168
in	O	169-171
mice	O	172-176
can	O	177-180
be	O	181-183
reversed	O	184-192
by	O	193-195
the	O	196-199
administration	O	200-214
of	O	215-217
IGF	O	218-221
-	O	221-222
IL	O	222-224
-	O	221-222
3	O	225-226
(	O	227-228
fusion	O	228-234
protein	O	235-242
of	O	243-245
insulin	O	246-253
-	O	253-254
like	O	254-258
growth	O	259-265
factor	O	266-272
II	O	273-275
(	O	276-277
IGF	O	277-280
II	O	281-283
)	O	283-284
and	O	285-288
interleukin	O	289-300
3	O	301-302
)	O	302-303
.	O	303-304

Although	O	305-313
interleukin	O	314-325
3	O	326-327
(	O	328-329
IL	O	329-331
-	O	331-332
3	O	332-333
)	O	333-334
and	O	335-338
erythropoietin	O	339-353
(	O	354-355
EPO	O	355-358
)	O	358-359
are	O	360-363
known	O	364-369
to	O	370-372
act	O	373-376
synergistically	O	377-392
on	O	393-395
hematopoietic	O	396-409
cell	O	410-414
proliferation	O	415-428
in	O	429-431
vitro	O	432-437
,	O	437-438
injection	O	439-448
of	O	449-451
IGF	O	452-455
-	O	455-456
IL	O	456-458
-	O	455-456
3	O	459-460
and	O	461-464
EPO	O	465-468
in	O	469-471
AZT	O	472-475
-	O	475-476
treated	O	476-483
mice	O	484-488
resulted	O	489-497
in	O	498-500
a	O	501-502
reduction	O	503-512
of	O	513-515
red	O	516-519
cells	O	520-525
and	O	526-529
an	O	530-532
increase	O	533-541
of	O	542-544
plasma	O	545-551
EPO	O	552-555
levels	O	556-562
as	O	563-565
compared	O	566-574
to	O	575-577
animals	O	578-585
treated	O	586-593
with	O	594-598
IGF	O	599-602
-	O	602-603
IL	O	603-605
-	O	602-603
3	O	606-607
or	O	608-610
EPO	O	611-614
alone	O	615-620
.	O	620-621

We	O	622-624
tested	O	625-631
the	O	632-635
hypothesis	O	636-646
that	O	647-651
the	O	652-655
antagonistic	O	656-668
effect	O	669-675
of	O	676-678
IL	O	679-681
-	O	681-682
3	O	682-683
and	O	684-687
EPO	O	688-691
on	O	692-694
erythroid	O	695-704
cells	O	705-710
may	O	711-714
be	O	715-717
mediated	O	718-726
by	O	727-729
endothelial	O	730-741
cells	O	742-747
.	O	747-748

Bovine	O	749-755
liver	O	756-761
erythroid	O	762-771
cells	O	772-777
were	O	778-782
cultured	O	783-791
on	O	792-794
monolayers	O	795-805
of	O	806-808
human	O	809-814
bone	O	815-819
marrow	O	820-826
endothelial	O	827-838
cells	O	839-844
previously	O	845-855
treated	O	856-863
with	O	864-868
EPO	O	869-872
and	O	873-876
IGF	O	877-880
-	O	880-881
IL	O	881-883
-	O	880-881
3	O	884-885
.	O	885-886

There	O	887-892
was	O	893-896
a	O	897-898
significant	O	899-910
reduction	O	911-920
of	O	921-923
thymidine	O	924-933
incorporation	O	934-947
into	O	948-952
both	O	953-957
erythroid	O	958-967
and	O	968-971
endothelial	O	972-983
cells	O	984-989
in	O	990-992
cultures	O	993-1001
pre	O	1002-1005
-	O	1005-1006
treated	O	1006-1013
with	O	1014-1018
IGF	O	1019-1022
-	O	1022-1023
IL	O	1023-1025
-	O	1022-1023
3	O	1026-1027
and	O	1028-1031
EPO	O	1032-1035
.	O	1035-1036

Endothelial	O	1037-1048
cell	O	1049-1053
culture	O	1054-1061
supernatants	O	1062-1074
separated	O	1075-1084
by	O	1085-1087
ultrafiltration	O	1088-1103
and	O	1104-1107
ultracentrifugation	O	1108-1127
from	O	1128-1132
cells	O	1133-1138
treated	O	1139-1146
with	O	1147-1151
EPO	O	1152-1155
and	O	1156-1159
IL	O	1160-1162
-	O	1162-1163
3	O	1163-1164
significantly	O	1165-1178
reduced	O	1179-1186
thymidine	O	1187-1196
incorporation	O	1197-1210
into	O	1211-1215
erythroid	O	1216-1225
cells	O	1226-1231
as	O	1232-1234
compared	O	1235-1243
to	O	1244-1246
identical	O	1247-1256
fractions	O	1257-1266
obtained	O	1267-1275
from	O	1276-1280
the	O	1281-1284
media	O	1285-1290
of	O	1291-1293
cells	O	1294-1299
cultured	O	1300-1308
with	O	1309-1313
EPO	O	1314-1317
alone	O	1318-1323
.	O	1323-1324

These	O	1325-1330
results	O	1331-1338
suggest	O	1339-1346
that	O	1347-1351
endothelial	O	1352-1363
cells	O	1364-1369
treated	O	1370-1377
simultaneously	O	1378-1392
with	O	1393-1397
EPO	O	1398-1401
and	O	1402-1405
IL	O	1406-1408
-	O	1408-1409
3	O	1409-1410
have	O	1411-1415
a	O	1416-1417
negative	O	1418-1426
effect	O	1427-1433
on	O	1434-1436
erythroid	O	1437-1446
cell	O	1447-1451
production	O	1452-1462
.	O	1462-1463

Interactive	O	0-11
effects	O	12-19
of	O	20-22
variations	O	23-33
in	O	34-36
[	O	37-38
Na	O	38-40
]	O	40-41
o	O	41-42
and	O	43-46
[	O	47-48
Ca	O	48-50
]	O	50-51
o	O	51-52
on	O	53-55
rat	O	56-59
atrial	O	60-66
spontaneous	O	67-78
frequency	O	79-88
.	O	88-89

The	O	90-93
effects	O	94-101
of	O	102-104
varying	O	105-112
the	O	113-116
extracellular	O	117-130
concentrations	O	131-145
of	O	146-148
Na	O	149-151
and	O	152-155
Ca	O	156-158
(	O	159-160
[	O	160-161
Na	O	161-163
]	O	163-164
o	O	164-165
and	O	166-169
[	O	170-171
Ca	O	171-173
]	O	173-174
o	O	174-175
)	O	175-176
on	O	177-179
both	O	180-184
,	O	184-185
the	O	186-189
spontaneous	O	190-201
beating	O	202-209
and	O	210-213
the	O	214-217
negative	O	218-226
chronotropic	O	227-239
action	O	240-246
of	O	247-249
verapamil	O	250-259
,	O	259-260
were	O	261-265
studied	O	266-273
in	O	274-276
the	O	277-280
isolated	O	281-289
rat	O	290-293
atria	O	294-299
.	O	299-300

Basal	O	301-306
frequency	O	307-316
(	O	317-318
BF	O	318-320
)	O	320-321
evaluated	O	322-331
by	O	332-334
surface	O	335-342
electrogram	O	343-354
was	O	355-358
223	O	359-362
+	O	363-364
/	O	364-365
-	O	365-366
4	O	367-368
beats	O	369-374
/	O	374-375
min	O	375-378
.	O	378-379

in	O	380-382
control	O	383-390
Krebs	O	391-396
-	O	396-397
Ringer	O	397-403
containing	O	404-414
137	O	415-418
mM	O	419-421
Na	O	422-424
and	O	425-428
1	O	429-430
.	O	430-431
35	O	431-433
mM	O	434-436
Ca	O	437-439
(	O	440-441
N	O	441-442
)	O	442-443
.	O	443-444

It	O	445-447
decreased	O	448-457
by	O	458-460
16	O	461-463
+	O	464-465
/	O	465-466
-	O	466-467
3	O	468-469
%	O	469-470
by	O	471-473
lowering	O	474-482
[	O	483-484
Na	O	484-486
]	O	486-487
o	O	487-488
to	O	489-491
78	O	492-494
mM	O	495-497
(	O	498-499
LNa	O	499-502
)	O	502-503
,	O	503-504
23	O	505-507
+	O	508-509
/	O	509-510
-	O	510-511
2	O	512-513
%	O	513-514
by	O	515-517
lowering	O	518-526
simultaneously	O	527-541
[	O	542-543
Na	O	543-545
]	O	545-546
o	O	546-547
to	O	548-550
78	O	551-553
mM	O	554-556
and	O	557-560
[	O	561-562
Ca	O	562-564
]	O	564-565
o	O	565-566
to	O	567-569
0	O	570-571
.	O	571-572
675	O	572-575
mM	O	576-578
(	O	579-580
LNa	O	580-583
+	O	583-584
LCa	O	584-587
)	O	587-588
and	O	589-592
31	O	593-595
+	O	596-597
/	O	597-598
-	O	598-599
5	O	600-601
%	O	601-602
by	O	603-605
lowering	O	606-614
[	O	615-616
Na	O	616-618
]	O	618-619
o	O	619-620
to	O	621-623
78	O	624-626
mM	O	627-629
plus	O	630-634
increasing	O	635-645
[	O	646-647
Ca	O	647-649
]	O	649-650
o	O	650-651
to	O	652-654
3	O	655-656
.	O	656-657
6	O	657-658
mM	O	659-661
(	O	662-663
LNa	O	663-666
+	O	666-667
HCa	O	667-670
)	O	670-671
.	O	671-672

At	O	673-675
normal	O	676-682
[	O	683-684
Na	O	684-686
]	O	686-687
o	O	687-688
,	O	688-689
decrease	O	690-698
(	O	699-700
0	O	700-701
.	O	701-702
675	O	702-705
mM	O	706-708
)	O	708-709
or	O	710-712
increase	O	713-721
(	O	722-723
3	O	723-724
.	O	724-725
6	O	725-726
mM	O	727-729
)	O	729-730
of	O	731-733
[	O	734-735
Ca	O	735-737
]	O	737-738
o	O	738-739
did	O	740-743
not	O	744-747
modify	O	748-754
BF	O	755-757
;	O	757-758
a	O	759-760
reduction	O	761-770
of	O	771-773
ten	O	774-777
times	O	778-783
(	O	784-785
0	O	785-786
.	O	786-787
135	O	787-790
mM	O	791-793
of	O	794-796
normal	O	797-803
[	O	804-805
Ca	O	805-807
]	O	807-808
o	O	808-809
was	O	810-813
effective	O	814-823
to	O	824-826
reduce	O	827-833
BF	O	834-836
by	O	837-839
40	O	840-842
+	O	843-844
/	O	844-845
-	O	845-846
13	O	847-849
%	O	849-850
.	O	850-851

All	O	852-855
negative	O	856-864
chronotropic	O	865-877
effects	O	878-885
were	O	886-890
BF	O	891-893
-	O	893-894
dependent	O	894-903
.	O	903-904

Dose	O	905-909
-	O	909-910
dependent	O	910-919
bradycardia	B	920-931
induced	O	932-939
by	O	940-942
verapamil	O	943-952
was	O	953-956
potentiated	O	957-968
by	O	969-971
LNa	O	972-975
,	O	975-976
LCa	O	977-980
,	O	980-981
and	O	982-985
HCa	O	986-989
.	O	989-990

Independent	O	991-1002
but	O	1003-1006
not	O	1007-1010
additive	O	1011-1019
effects	O	1020-1027
of	O	1028-1030
Na	O	1031-1033
and	O	1034-1037
Ca	O	1038-1040
are	O	1041-1044
shown	O	1045-1050
by	O	1051-1053
decreases	O	1054-1063
in	O	1064-1066
the	O	1067-1070
values	O	1071-1077
of	O	1078-1080
[	O	1081-1082
verapamil	O	1082-1091
]	O	1091-1092
o	O	1092-1093
needed	O	1094-1100
to	O	1101-1103
reduce	O	1104-1110
BF	O	1111-1113
by	O	1114-1116
30	O	1117-1119
%	O	1119-1120
(	O	1121-1122
IC30	O	1122-1126
)	O	1126-1127
with	O	1128-1132
the	O	1133-1136
following	O	1137-1146
order	O	1147-1152
of	O	1153-1155
inhibitory	O	1156-1166
potency	O	1167-1174
:	O	1174-1175
LNa	O	1176-1179
>	O	1180-1181
LCa	O	1182-1185
>	O	1186-1187
HCa	O	1188-1191
>	O	1192-1193
N	O	1194-1195
,	O	1195-1196
resulting	O	1197-1206
LNa	O	1207-1210
+	O	1210-1211
HCa	O	1211-1214
similar	O	1215-1222
to	O	1223-1225
LNa	O	1226-1229
.	O	1229-1230

The	O	1231-1234
[	O	1235-1236
verapamil	O	1236-1245
]	O	1245-1246
o	O	1246-1247
that	O	1248-1252
arrested	O	1253-1261
atrial	O	1262-1268
beating	O	1269-1276
(	O	1277-1278
AC	O	1278-1280
)	O	1280-1281
was	O	1282-1285
also	O	1286-1290
potentiated	O	1291-1302
with	O	1303-1307
the	O	1308-1311
order	O	1312-1317
LNa	O	1318-1321
=	O	1322-1323
LNa	O	1324-1327
+	O	1327-1328
LCa	O	1328-1331
=	O	1332-1333
LNa	O	1334-1337
+	O	1337-1338
HCa	O	1338-1341
=	O	1342-1343
LCa	O	1344-1347
>	O	1348-1349
HCa	O	1350-1353
=	O	1354-1355
N	O	1356-1357
.	O	1357-1358

The	O	1359-1362
results	O	1363-1370
indicate	O	1371-1379
that	O	1380-1384
rat	O	1385-1388
atrial	O	1389-1395
spontaneous	O	1396-1407
beating	O	1408-1415
is	O	1416-1418
more	O	1419-1423
dependent	O	1424-1433
on	O	1434-1436
[	O	1437-1438
Na	O	1438-1440
]	O	1440-1441
o	O	1441-1442
than	O	1443-1447
on	O	1448-1450
[	O	1451-1452
Ca	O	1452-1454
]	O	1454-1455
o	O	1455-1456
in	O	1457-1459
a	O	1460-1461
range	O	1462-1467
of	O	1468-1470
+	O	1471-1472
/	O	1472-1473
-	O	1473-1474
50	O	1475-1477
%	O	1477-1478
of	O	1479-1481
their	O	1482-1487
normal	O	1488-1494
concentration	O	1495-1508
.	O	1508-1509

Also	O	1510-1514
the	O	1515-1518
enhancement	O	1519-1530
of	O	1531-1533
verapamil	O	1534-1543
effects	O	1544-1551
on	O	1552-1554
atrial	O	1555-1561
beating	O	1562-1569
was	O	1570-1573
more	O	1574-1578
pronounced	O	1579-1589
at	O	1590-1592
LNa	O	1593-1596
than	O	1597-1601
at	O	1602-1604
LCa	O	1605-1608
.	O	1608-1609
(	O	1609-1610
ABSTRACT	O	1610-1618
TRUNCATED	O	1619-1628
AT	O	1629-1631
250	O	1632-1635
WORDS	O	1636-1641
)	O	1641-1642

Sodium	O	0-6
status	O	7-13
influences	O	14-24
chronic	O	25-32
amphotericin	O	33-45
B	O	46-47
nephrotoxicity	B	48-62
in	O	63-65
rats	O	66-70
.	O	70-71

The	O	72-75
nephrotoxic	B	76-87
potential	O	88-97
of	O	98-100
amphotericin	O	101-113
B	O	114-115
(	O	116-117
5	O	117-118
mg	O	119-121
/	O	121-122
kg	O	122-124
per	O	125-128
day	O	129-132
intraperitoneally	O	133-150
for	O	151-154
3	O	155-156
weeks	O	157-162
)	O	162-163
has	O	164-167
been	O	168-172
investigated	O	173-185
in	O	186-188
salt	O	189-193
-	O	193-194
depleted	O	194-202
,	O	202-203
normal	O	204-210
-	O	210-211
salt	O	211-215
,	O	215-216
and	O	217-220
salt	O	221-225
-	O	225-226
loaded	O	226-232
rats	O	233-237
.	O	237-238

In	O	239-241
salt	O	242-246
-	O	246-247
depleted	O	247-255
rats	O	256-260
,	O	260-261
amphotericin	O	262-274
B	O	275-276
decreased	O	277-286
creatinine	O	287-297
clearance	O	298-307
linearly	O	308-316
with	O	317-321
time	O	322-326
,	O	326-327
with	O	328-332
an	O	333-335
85	O	336-338
%	O	338-339
reduction	O	340-349
by	O	350-352
week	O	353-357
3	O	358-359
.	O	359-360

In	O	361-363
contrast	O	364-372
,	O	372-373
in	O	374-376
normal	O	377-383
-	O	383-384
salt	O	384-388
rats	O	389-393
creatinine	O	394-404
clearance	O	405-414
was	O	415-418
decreased	O	419-428
but	O	429-432
to	O	433-435
a	O	436-437
lesser	O	438-444
extent	O	445-451
at	O	452-454
week	O	455-459
2	O	460-461
and	O	462-465
3	O	466-467
,	O	467-468
and	O	469-472
in	O	473-475
salt	O	476-480
-	O	480-481
loaded	O	481-487
rats	O	488-492
creatinine	O	493-503
clearance	O	504-513
did	O	514-517
not	O	518-521
change	O	522-528
for	O	529-532
2	O	533-534
weeks	O	535-540
and	O	541-544
was	O	545-548
decreased	O	549-558
by	O	559-561
43	O	562-564
%	O	564-565
at	O	566-568
week	O	569-573
3	O	574-575
.	O	575-576

All	O	577-580
rats	O	581-585
in	O	586-588
the	O	589-592
sodium	O	593-599
-	O	599-600
depleted	O	600-608
group	O	609-614
had	O	615-618
histopathological	O	619-636
evidence	O	637-645
of	O	646-648
patchy	O	649-655
tubular	O	656-663
cytoplasmic	O	664-675
degeneration	O	676-688
in	O	689-691
tubules	O	692-699
that	O	700-704
was	O	705-708
not	O	709-712
observed	O	713-721
in	O	722-724
any	O	725-728
normal	O	729-735
-	O	735-736
salt	O	736-740
or	O	741-743
salt	O	744-748
-	O	748-749
loaded	O	749-755
rat	O	756-759
.	O	759-760

Concentrations	O	761-775
of	O	776-778
amphotericin	O	779-791
B	O	792-793
in	O	794-796
plasma	O	797-803
were	O	804-808
not	O	809-812
significantly	O	813-826
different	O	827-836
among	O	837-842
the	O	843-846
three	O	847-852
groups	O	853-859
at	O	860-862
any	O	863-866
time	O	867-871
during	O	872-878
the	O	879-882
study	O	883-888
.	O	888-889

However	O	890-897
,	O	897-898
at	O	899-901
the	O	902-905
end	O	906-909
of	O	910-912
3	O	913-914
weeks	O	915-920
,	O	920-921
amphotericin	O	922-934
B	O	935-936
levels	O	937-943
in	O	944-946
the	O	947-950
kidneys	O	951-958
and	O	959-962
liver	O	963-968
were	O	969-973
significantly	O	974-987
higher	O	988-994
in	O	995-997
salt	O	998-1002
-	O	1002-1003
depleted	O	1003-1011
and	O	1012-1015
normal	O	1016-1022
-	O	1022-1023
salt	O	1023-1027
rats	O	1028-1032
than	O	1033-1037
those	O	1038-1043
in	O	1044-1046
salt	O	1047-1051
-	O	1051-1052
loaded	O	1052-1058
rats	O	1059-1063
,	O	1063-1064
with	O	1065-1069
plasma	O	1070-1076
/	O	1076-1077
kidney	O	1077-1083
ratios	O	1084-1090
of	O	1091-1093
21	O	1094-1096
,	O	1096-1097
14	O	1098-1100
,	O	1100-1101
and	O	1102-1105
8	O	1106-1107
in	O	1108-1110
salt	O	1111-1115
-	O	1115-1116
depleted	O	1116-1124
,	O	1124-1125
normal	O	1126-1132
-	O	1132-1133
salt	O	1133-1137
,	O	1137-1138
and	O	1139-1142
salt	O	1143-1147
-	O	1147-1148
loaded	O	1148-1154
rats	O	1155-1159
,	O	1159-1160
respectively	O	1161-1173
.	O	1173-1174

In	O	1175-1177
conclusion	O	1178-1188
,	O	1188-1189
reductions	O	1190-1200
in	O	1201-1203
creatinine	O	1204-1214
clearance	O	1215-1224
and	O	1225-1228
renal	O	1229-1234
amphotericin	O	1235-1247
B	O	1248-1249
accumulation	O	1250-1262
after	O	1263-1268
chronic	O	1269-1276
amphotericin	O	1277-1289
B	O	1290-1291
administration	O	1292-1306
were	O	1307-1311
enhanced	O	1312-1320
by	O	1321-1323
salt	O	1324-1328
depletion	O	1329-1338
and	O	1339-1342
attenuated	O	1343-1353
by	O	1354-1356
sodium	O	1357-1363
loading	O	1364-1371
in	O	1372-1374
rats	O	1375-1379
.	O	1379-1380

Reversible	O	0-10
inferior	B	11-19
colliculus	I	20-30
lesion	I	31-37
in	O	38-40
metronidazole	O	41-54
-	O	54-55
induced	O	55-62
encephalopathy	B	63-77
:	O	77-78
magnetic	O	79-87
resonance	O	88-97
findings	O	98-106
on	O	107-109
diffusion	O	110-119
-	O	119-120
weighted	O	120-128
and	O	129-132
fluid	O	133-138
attenuated	O	139-149
inversion	O	150-159
recovery	O	160-168
imaging	O	169-176
.	O	176-177

OBJECTIVE	O	178-187
:	O	187-188
This	O	189-193
is	O	194-196
to	O	197-199
present	O	200-207
reversible	O	208-218
inferior	B	219-227
colliculus	I	228-238
lesions	I	239-246
in	O	247-249
metronidazole	O	250-263
-	O	263-264
induced	O	264-271
encephalopathy	B	272-286
,	O	286-287
to	O	288-290
focus	O	291-296
on	O	297-299
the	O	300-303
diffusion	O	304-313
-	O	313-314
weighted	O	314-322
imaging	O	323-330
(	O	331-332
DWI	O	332-335
)	O	335-336
and	O	337-340
fluid	O	341-346
attenuated	O	347-357
inversion	O	358-367
recovery	O	368-376
(	O	377-378
FLAIR	O	378-383
)	O	383-384
imaging	O	385-392
.	O	392-393

MATERIALS	O	394-403
AND	O	404-407
METHODS	O	408-415
:	O	415-416
From	O	417-421
November	O	422-430
2005	O	431-435
to	O	436-438
September	O	439-448
2007	O	449-453
,	O	453-454
8	O	455-456
patients	O	457-465
(	O	466-467
5	O	467-468
men	O	469-472
and	O	473-476
3	O	477-478
women	O	479-484
)	O	484-485
were	O	486-490
diagnosed	O	491-500
as	O	501-503
having	O	504-510
metronidazole	O	511-524
-	O	524-525
induced	O	525-532
encephalopathy	B	533-547
(	O	548-549
age	O	549-552
range	O	553-558
;	O	558-559
43	O	560-562
-	O	562-563
78	O	563-565
years	O	566-571
)	O	571-572
.	O	572-573

They	O	574-578
had	O	579-582
been	O	583-587
taking	O	588-594
metronidazole	O	595-608
(	O	609-610
total	O	610-615
dosage	O	616-622
,	O	622-623
45	O	624-626
-	O	626-627
120	O	627-630
g	O	631-632
;	O	632-633
duration	O	634-642
,	O	642-643
30	O	644-646
days	O	647-651
to	O	652-654
2	O	655-656
months	O	657-663
)	O	663-664
to	O	665-667
treat	O	668-673
the	O	674-677
infection	B	678-687
in	O	688-690
various	O	691-698
organs	O	699-705
.	O	705-706

Initial	O	707-714
brain	O	715-720
magnetic	O	721-729
resonance	O	730-739
imaging	O	740-747
(	O	748-749
MRI	O	749-752
)	O	752-753
were	O	754-758
obtained	O	759-767
after	O	768-773
the	O	774-777
hospitalization	O	778-793
,	O	793-794
including	O	795-804
DWI	O	805-808
(	O	809-810
8	O	810-811
/	O	811-812
8	O	810-811
)	O	813-814
,	O	814-815
apparent	O	816-824
diffusion	O	825-834
coefficient	O	835-846
(	O	847-848
ADC	O	848-851
)	O	851-852
map	O	853-856
(	O	857-858
4	O	858-859
/	O	859-860
8	O	860-861
)	O	861-862
,	O	862-863
FLAIR	O	864-869
(	O	870-871
7	O	871-872
/	O	872-873
8	O	873-874
)	O	874-875
,	O	875-876
and	O	877-880
T2	O	881-883
-	O	883-884
weighted	O	884-892
image	O	893-898
(	O	899-900
8	O	900-901
/	O	901-902
8	O	900-901
)	O	903-904
.	O	904-905

Follow	O	906-912
-	O	912-913
up	O	913-915
MRIs	O	916-920
were	O	921-925
performed	O	926-935
on	O	936-938
5	O	939-940
patients	O	941-949
from	O	950-954
third	O	955-960
to	O	961-963
14th	O	964-968
days	O	969-973
after	O	974-979
discontinuation	O	980-995
of	O	996-998
metronidazole	O	999-1012
administration	O	1013-1027
.	O	1027-1028

Findings	O	1029-1037
of	O	1038-1040
initial	O	1041-1048
and	O	1049-1052
follow	O	1053-1059
-	O	1059-1060
up	O	1060-1062
MRIs	O	1063-1067
were	O	1068-1072
retrospectively	O	1073-1088
evaluated	O	1089-1098
by	O	1099-1101
2	O	1102-1103
neuroradiologists	O	1104-1121
by	O	1122-1124
consensus	O	1125-1134
,	O	1134-1135
to	O	1136-1138
analyze	O	1139-1146
the	O	1147-1150
presence	O	1151-1159
of	O	1160-1162
abnormal	O	1163-1171
signal	O	1172-1178
intensities	O	1179-1190
,	O	1190-1191
their	O	1192-1197
locations	O	1198-1207
,	O	1207-1208
and	O	1209-1212
signal	O	1213-1219
changes	O	1220-1227
on	O	1228-1230
follow	O	1231-1237
-	O	1237-1238
up	O	1238-1240
images	O	1241-1247
.	O	1247-1248

RESULTS	O	1249-1256
:	O	1256-1257
Initial	O	1258-1265
MRIs	O	1266-1270
showed	O	1271-1277
abnormal	O	1278-1286
high	O	1287-1291
signal	O	1292-1298
intensities	O	1299-1310
on	O	1311-1313
DWI	O	1314-1317
and	O	1318-1321
FLAIR	O	1322-1327
(	O	1328-1329
or	O	1329-1331
T2	O	1332-1334
-	O	1334-1335
weighted	O	1335-1343
image	O	1344-1349
)	O	1349-1350
at	O	1351-1353
the	O	1354-1357
dentate	O	1358-1365
nucleus	O	1366-1373
(	O	1374-1375
8	O	1375-1376
/	O	1376-1377
8	O	1375-1376
)	O	1378-1379
,	O	1379-1380
inferior	O	1381-1389
colliculus	O	1390-1400
(	O	1401-1402
6	O	1402-1403
/	O	1403-1404
8	O	1404-1405
)	O	1405-1406
,	O	1406-1407
corpus	O	1408-1414
callosum	O	1415-1423
(	O	1424-1425
2	O	1425-1426
/	O	1426-1427
8	O	1427-1428
)	O	1428-1429
,	O	1429-1430
pons	O	1431-1435
(	O	1436-1437
2	O	1437-1438
/	O	1438-1439
8	O	1439-1440
)	O	1440-1441
,	O	1441-1442
medulla	O	1443-1450
(	O	1451-1452
1	O	1452-1453
/	O	1453-1454
8	O	1454-1455
)	O	1455-1456
,	O	1456-1457
and	O	1458-1461
bilateral	O	1462-1471
cerebral	O	1472-1480
white	O	1481-1486
matter	O	1487-1493
(	O	1494-1495
1	O	1495-1496
/	O	1496-1497
8	O	1497-1498
)	O	1498-1499
.	O	1499-1500

High	O	1501-1505
-	O	1505-1506
signal	O	1506-1512
intensity	O	1513-1522
lesions	O	1523-1530
on	O	1531-1533
DWI	O	1534-1537
tended	O	1538-1544
to	O	1545-1547
show	O	1548-1552
low	O	1553-1556
signal	O	1557-1563
intensity	O	1564-1573
on	O	1574-1576
ADC	O	1577-1580
map	O	1581-1584
(	O	1585-1586
3	O	1586-1587
/	O	1587-1588
4	O	1588-1589
)	O	1589-1590
,	O	1590-1591
but	O	1592-1595
in	O	1596-1598
one	O	1599-1602
patient	O	1603-1610
,	O	1610-1611
high	O	1612-1616
signal	O	1617-1623
intensity	O	1624-1633
was	O	1634-1637
shown	O	1638-1643
at	O	1644-1646
bilateral	O	1647-1656
dentate	O	1657-1664
nuclei	O	1665-1671
on	O	1672-1674
not	O	1675-1678
only	O	1679-1683
DWI	O	1684-1687
but	O	1688-1691
also	O	1692-1696
ADC	O	1697-1700
map	O	1701-1704
.	O	1704-1705

All	O	1706-1709
the	O	1710-1713
lesions	O	1714-1721
in	O	1722-1724
dentate	O	1725-1732
,	O	1732-1733
inferior	O	1734-1742
colliculus	O	1743-1753
,	O	1753-1754
pons	O	1755-1759
,	O	1759-1760
and	O	1761-1764
medullas	O	1765-1773
had	O	1774-1777
been	O	1778-1782
resolved	O	1783-1791
completely	O	1792-1802
on	O	1803-1805
follow	O	1806-1812
-	O	1812-1813
up	O	1813-1815
MRIs	O	1816-1820
in	O	1821-1823
5	O	1824-1825
patients	O	1826-1834
,	O	1834-1835
but	O	1836-1839
in	O	1840-1842
1	O	1843-1844
patient	O	1845-1852
of	O	1853-1855
them	O	1856-1860
,	O	1860-1861
corpus	O	1862-1868
callosal	B	1869-1877
lesion	I	1878-1884
persisted	O	1885-1894
.	O	1894-1895

CONCLUSIONS	O	1896-1907
:	O	1907-1908
Reversible	O	1909-1919
inferior	B	1920-1928
colliculus	I	1929-1939
lesions	I	1940-1947
could	O	1948-1953
be	O	1954-1956
considered	O	1957-1967
as	O	1968-1970
the	O	1971-1974
characteristic	O	1975-1989
for	O	1990-1993
metronidazole	O	1994-2007
-	O	2007-2008
induced	O	2008-2015
encephalopathy	B	2016-2030
,	O	2030-2031
next	O	2032-2036
to	O	2037-2039
the	O	2040-2043
dentate	O	2044-2051
nucleus	O	2052-2059
involvement	O	2060-2071
.	O	2071-2072

Comparison	O	0-10
of	O	11-13
the	O	14-17
respiratory	O	18-29
effects	O	30-37
of	O	38-40
i	O	41-42
.	O	42-43
v	O	43-44
.	O	42-43

infusions	O	46-55
of	O	56-58
morphine	O	59-67
and	O	68-71
regional	O	72-80
analgesia	O	81-90
by	O	91-93
extradural	O	94-104
block	O	105-110
.	O	110-111

The	O	112-115
incidence	O	116-125
of	O	126-128
postoperative	O	129-142
respiratory	O	143-154
apnoea	B	155-161
was	O	162-165
compared	O	166-174
between	O	175-182
five	O	183-187
patients	O	188-196
receiving	O	197-206
a	O	207-208
continuous	O	209-219
i	O	220-221
.	O	221-222
v	O	222-223
.	O	221-222

infusion	O	225-233
of	O	234-236
morphine	O	237-245
(	O	246-247
mean	O	247-251
73	O	252-254
.	O	254-255
6	O	255-256
mg	O	257-259
)	O	259-260
and	O	261-264
five	O	265-269
patients	O	270-278
receiving	O	279-288
a	O	289-290
continuous	O	291-301
extradural	O	302-312
infusion	O	313-321
of	O	322-324
0	O	325-326
.	O	326-327
25	O	327-329
%	O	329-330
bupivacaine	O	331-342
(	O	343-344
mean	O	344-348
192	O	349-352
mg	O	353-355
)	O	355-356
in	O	357-359
the	O	360-363
24	O	364-366
-	O	366-367
h	O	367-368
period	O	369-375
following	O	376-385
upper	O	386-391
abdominal	O	392-401
surgery	O	402-409
.	O	409-410

Monitoring	O	411-421
consisted	O	422-431
of	O	432-434
airflow	O	435-442
detection	O	443-452
by	O	453-455
a	O	456-457
carbon	O	458-464
dioxide	O	465-472
analyser	O	473-481
,	O	481-482
chest	O	483-488
wall	O	489-493
movement	O	494-502
detected	O	503-511
by	O	512-514
pneumatic	O	515-524
capsules	O	525-533
,	O	533-534
and	O	535-538
continuous	O	539-549
electrocardiograph	O	550-568
recorded	O	569-577
with	O	578-582
a	O	583-584
Holter	O	585-591
ambulatory	O	592-602
monitor	O	603-610
.	O	610-611

Both	O	612-616
obstructive	B	617-628
(	I	629-630
P	I	630-631
less	I	632-636
than	I	637-641
0	I	642-643
.	I	643-644
05	I	644-646
)	I	646-647
and	I	648-651
central	I	652-659
apnoea	I	660-666
(	O	667-668
P	O	668-669
less	O	670-674
than	O	675-679
0	O	680-681
.	O	681-682
05	O	682-684
)	O	684-685
occurred	O	686-694
more	O	695-699
frequently	O	700-710
in	O	711-713
patients	O	714-722
who	O	723-726
had	O	727-730
a	O	731-732
morphine	O	733-741
infusion	O	742-750
.	O	750-751

There	O	752-757
was	O	758-761
also	O	762-766
a	O	767-768
higher	O	769-775
incidence	O	776-785
of	O	786-788
tachyarrhythmias	B	789-805
(	O	806-807
P	O	807-808
less	O	809-813
than	O	814-818
0	O	819-820
.	O	820-821
05	O	821-823
)	O	823-824
and	O	825-828
ventricular	B	829-840
ectopic	I	841-848
beats	I	849-854
(	O	855-856
P	O	856-857
less	O	858-862
than	O	863-867
0	O	868-869
.	O	869-870
05	O	870-872
)	O	872-873
in	O	874-876
the	O	877-880
morphine	O	881-889
infusion	O	890-898
group	O	899-904
.	O	904-905

Magnetic	O	0-8
resonance	O	9-18
volumetry	O	19-28
of	O	29-31
the	O	32-35
cerebellum	O	36-46
in	O	47-49
epileptic	B	50-59
patients	O	60-68
after	O	69-74
phenytoin	O	75-84
overdosages	B	85-96
.	O	96-97

The	O	98-101
aim	O	102-105
of	O	106-108
this	O	109-113
study	O	114-119
was	O	120-123
to	O	124-126
evaluate	O	127-135
the	O	136-139
relationship	O	140-152
between	O	153-160
phenytoin	O	161-170
medication	O	171-181
and	O	182-185
cerebellar	B	186-196
atrophy	I	197-204
in	O	205-207
patients	O	208-216
who	O	217-220
had	O	221-224
experienced	O	225-236
clinical	O	237-245
intoxication	O	246-258
.	O	258-259

Five	O	260-264
females	O	265-272
and	O	273-276
6	O	277-278
males	O	279-284
,	O	284-285
21	O	286-288
-	O	288-289
59	O	289-291
years	O	292-297
of	O	298-300
age	O	301-304
,	O	304-305
were	O	306-310
examined	O	311-319
with	O	320-324
a	O	325-326
1	O	327-328
.	O	328-329
5	O	329-330
-	O	330-331
T	O	331-332
whole	O	333-338
-	O	338-339
body	O	339-343
system	O	344-350
using	O	351-356
a	O	357-358
circular	O	359-367
polarized	O	368-377
head	O	378-382
coil	O	383-387
.	O	387-388

Conventional	O	389-401
spin	O	402-406
echo	O	407-411
images	O	412-418
were	O	419-423
acquired	O	424-432
in	O	433-435
the	O	436-439
sagittal	O	440-448
and	O	449-452
transverse	O	453-463
orientation	O	464-475
.	O	475-476

In	O	477-479
addition	O	480-488
,	O	488-489
we	O	490-492
performed	O	493-502
a	O	503-504
high	O	505-509
-	O	509-510
resolution	O	510-520
3D	O	521-523
gradient	O	524-532
echo	O	533-537
,	O	537-538
T1	O	539-541
-	O	541-542
weighted	O	542-550
sequences	O	551-560
at	O	561-563
a	O	564-565
1	O	566-567
-	O	567-568
mm	O	568-570
slice	O	571-576
thickness	O	577-586
.	O	586-587

The	O	588-591
images	O	592-598
were	O	599-603
subsequently	O	604-616
processed	O	617-626
to	O	627-629
obtain	O	630-636
volumetric	O	637-647
data	O	648-652
for	O	653-656
the	O	657-660
cerebellum	O	661-671
.	O	671-672

Cerebellar	O	673-683
volume	O	684-690
for	O	691-694
the	O	695-698
patient	O	699-706
group	O	707-712
ranged	O	713-719
between	O	720-727
67	O	728-730
.	O	730-731
66	O	731-733
and	O	734-737
131	O	738-741
.	O	741-742
08	O	742-744
ml	O	745-747
(	O	748-749
mean	O	749-753
108	O	754-757
.	O	757-758
9	O	758-759
ml	O	760-762
)	O	762-763
.	O	763-764

In	O	765-767
addition	O	768-776
3D	O	777-779
gradient	O	780-788
echo	O	789-793
data	O	794-798
sets	O	799-803
from	O	804-808
10	O	809-811
healthy	O	812-819
male	O	820-824
and	O	825-828
10	O	829-831
healthy	O	832-839
female	O	840-846
age	O	847-850
-	O	850-851
matched	O	851-858
volunteers	O	859-869
were	O	870-874
used	O	875-879
to	O	880-882
compare	O	883-890
cerebellar	O	891-901
volumes	O	902-909
.	O	909-910

Using	O	911-916
linear	O	917-923
regression	O	924-934
we	O	935-937
found	O	938-943
that	O	944-948
no	O	949-951
correlation	O	952-963
exists	O	964-970
between	O	971-978
seizure	B	979-986
duration	O	987-995
,	O	995-996
elevation	O	997-1006
of	O	1007-1009
phenytoin	O	1010-1019
serum	O	1020-1025
levels	O	1026-1032
and	O	1033-1036
cerebellar	O	1037-1047
volume	O	1048-1054
.	O	1054-1055

However	O	1056-1063
,	O	1063-1064
multiple	O	1065-1073
regression	O	1074-1084
for	O	1085-1088
the	O	1089-1092
daily	O	1093-1098
dosage	O	1099-1105
,	O	1105-1106
duration	O	1107-1115
of	O	1116-1118
phenytoin	O	1119-1128
treatment	O	1129-1138
and	O	1139-1142
cerebellar	O	1143-1153
volume	O	1154-1160
revealed	O	1161-1169
a	O	1170-1171
correlation	O	1172-1183
of	O	1184-1186
these	O	1187-1192
parameters	O	1193-1203
.	O	1203-1204

We	O	1205-1207
conclude	O	1208-1216
that	O	1217-1221
phenytoin	O	1222-1231
overdosage	B	1232-1242
does	O	1243-1247
not	O	1248-1251
necessarily	O	1252-1263
result	O	1264-1270
in	O	1271-1273
cerebellar	B	1274-1284
atrophy	I	1285-1292
and	O	1293-1296
it	O	1297-1299
is	O	1300-1302
unlikely	O	1303-1311
that	O	1312-1316
phenytoin	O	1317-1326
medication	O	1327-1337
was	O	1338-1341
the	O	1342-1345
only	O	1346-1350
cause	O	1351-1356
of	O	1357-1359
cerebellar	B	1360-1370
atrophy	I	1371-1378
in	O	1379-1381
the	O	1382-1385
remaining	O	1386-1395
patients	O	1396-1404
.	O	1404-1405

Quantitative	O	1406-1418
morphometric	O	1419-1431
studies	O	1432-1439
of	O	1440-1442
the	O	1443-1446
cerebellum	O	1447-1457
provide	O	1458-1465
valuable	O	1466-1474
insights	O	1475-1483
into	O	1484-1488
the	O	1489-1492
pathogenesis	O	1493-1505
of	O	1506-1508
cerebellar	B	1509-1519
disorders	I	1520-1529
.	O	1529-1530

Evaluation	O	0-10
of	O	11-13
cardiac	O	14-21
troponin	O	22-30
I	O	31-32
and	O	33-36
T	O	37-38
levels	O	39-45
as	O	46-48
markers	O	49-56
of	O	57-59
myocardial	B	60-70
damage	I	71-77
in	O	78-80
doxorubicin	O	81-92
-	O	92-93
induced	O	93-100
cardiomyopathy	B	101-115
rats	O	116-120
,	O	120-121
and	O	122-125
their	O	126-131
relationship	O	132-144
with	O	145-149
echocardiographic	O	150-167
and	O	168-171
histological	O	172-184
findings	O	185-193
.	O	193-194

BACKGROUND	O	195-205
:	O	205-206
Cardiac	O	207-214
troponins	O	215-224
I	O	225-226
(	O	227-228
cTnI	O	228-232
)	O	232-233
and	O	234-237
T	O	238-239
(	O	240-241
cTnT	O	241-245
)	O	245-246
have	O	247-251
been	O	252-256
shown	O	257-262
to	O	263-265
be	O	266-268
highly	O	269-275
sensitive	O	276-285
and	O	286-289
specific	O	290-298
markers	O	299-306
of	O	307-309
myocardial	B	310-320
cell	I	321-325
injury	I	326-332
.	O	332-333

We	O	334-336
investigated	O	337-349
the	O	350-353
diagnostic	O	354-364
value	O	365-370
of	O	371-373
cTnI	O	374-378
and	O	379-382
cTnT	O	383-387
for	O	388-391
the	O	392-395
diagnosis	O	396-405
of	O	406-408
myocardial	B	409-419
damage	I	420-426
in	O	427-429
a	O	430-431
rat	O	432-435
model	O	436-441
of	O	442-444
doxorubicin	O	445-456
(	O	457-458
DOX	O	458-461
)	O	461-462
-	O	462-463
induced	O	463-470
cardiomyopathy	B	471-485
,	O	485-486
and	O	487-490
we	O	491-493
examined	O	494-502
the	O	503-506
relationship	O	507-519
between	O	520-527
serial	O	528-534
cTnI	O	535-539
and	O	540-543
cTnT	O	544-548
with	O	549-553
the	O	554-557
development	O	558-569
of	O	570-572
cardiac	B	573-580
disorders	I	581-590
monitored	O	591-600
by	O	601-603
echocardiography	O	604-620
and	O	621-624
histological	O	625-637
examinations	O	638-650
in	O	651-653
this	O	654-658
model	O	659-664
.	O	664-665

METHODS	O	666-673
:	O	673-674
Thirty	O	675-681
-	O	681-682
five	O	682-686
Wistar	O	687-693
rats	O	694-698
were	O	699-703
given	O	704-709
1	O	710-711
.	O	711-712
5	O	712-713
mg	O	714-716
/	O	716-717
kg	O	717-719
DOX	O	720-723
,	O	723-724
i	O	725-726
.	O	726-727
v	O	727-728
.	O	726-727
,	O	729-730
weekly	O	731-737
for	O	738-741
up	O	742-744
to	O	745-747
8	O	748-749
weeks	O	750-755
for	O	756-759
a	O	760-761
total	O	762-767
cumulative	O	768-778
dose	O	779-783
of	O	784-786
12	O	787-789
mg	O	790-792
/	O	792-793
kg	O	793-795
BW	O	796-798
.	O	798-799

Ten	O	800-803
rats	O	804-808
received	O	809-817
saline	O	818-824
as	O	825-827
a	O	828-829
control	O	830-837
group	O	838-843
.	O	843-844

cTnI	O	845-849
was	O	850-853
measured	O	854-862
with	O	863-867
Access	O	868-874
(	O	874-875
R	O	875-876
)	O	876-877
(	O	878-879
ng	O	879-881
/	O	881-882
ml	O	882-884
)	O	884-885
and	O	886-889
a	O	890-891
research	O	892-900
immunoassay	O	901-912
(	O	913-914
pg	O	914-916
/	O	916-917
ml	O	917-919
)	O	919-920
,	O	920-921
and	O	922-925
compared	O	926-934
with	O	935-939
cTnT	O	940-944
,	O	944-945
CK	O	946-948
-	O	948-949
MB	O	949-951
mass	O	952-956
and	O	957-960
CK	O	961-963
.	O	963-964

By	O	965-967
using	O	968-973
transthoracic	O	974-987
echocardiography	O	988-1004
,	O	1004-1005
anterior	O	1006-1014
and	O	1015-1018
posterior	O	1019-1028
wall	O	1029-1033
thickness	O	1034-1043
,	O	1043-1044
LV	O	1045-1047
diameters	O	1048-1057
and	O	1058-1061
LV	O	1062-1064
fractional	O	1065-1075
shortening	O	1076-1086
(	O	1087-1088
FS	O	1088-1090
)	O	1090-1091
were	O	1092-1096
measured	O	1097-1105
in	O	1106-1108
all	O	1109-1112
rats	O	1113-1117
before	O	1118-1124
DOX	O	1125-1128
or	O	1129-1131
saline	O	1132-1138
,	O	1138-1139
and	O	1140-1143
at	O	1144-1146
weeks	O	1147-1152
6	O	1153-1154
and	O	1155-1158
9	O	1159-1160
after	O	1161-1166
treatment	O	1167-1176
in	O	1177-1179
all	O	1180-1183
surviving	O	1184-1193
rats	O	1194-1198
.	O	1198-1199

Histology	O	1200-1209
was	O	1210-1213
performed	O	1214-1223
in	O	1224-1226
DOX	O	1227-1230
-	O	1230-1231
rats	O	1231-1235
at	O	1236-1238
6	O	1239-1240
and	O	1241-1244
9	O	1245-1246
weeks	O	1247-1252
after	O	1253-1258
the	O	1259-1262
last	O	1263-1267
DOX	O	1268-1271
dose	O	1272-1276
and	O	1277-1280
in	O	1281-1283
all	O	1284-1287
controls	O	1288-1296
.	O	1296-1297

RESULTS	O	1298-1305
:	O	1305-1306
Eighteen	O	1307-1315
of	O	1316-1318
the	O	1319-1322
DOX	O	1323-1326
rats	O	1327-1331
died	O	1332-1336
prematurely	O	1337-1348
of	O	1349-1351
general	O	1352-1359
toxicity	B	1360-1368
during	O	1369-1375
the	O	1376-1379
9	O	1380-1381
-	O	1381-1382
week	O	1382-1386
period	O	1387-1393
.	O	1393-1394

End	O	1395-1398
-	O	1398-1399
diastolic	O	1399-1408
(	O	1409-1410
ED	O	1410-1412
)	O	1412-1413
and	O	1414-1417
end	O	1418-1421
-	O	1421-1422
systolic	O	1422-1430
(	O	1431-1432
ES	O	1432-1434
)	O	1434-1435
LV	O	1436-1438
diameters	O	1439-1448
/	O	1448-1449
BW	O	1449-1451
significantly	O	1452-1465
increased	O	1466-1475
,	O	1475-1476
whereas	O	1477-1484
LV	O	1485-1487
FS	O	1488-1490
was	O	1491-1494
decreased	O	1495-1504
after	O	1505-1510
9	O	1511-1512
weeks	O	1513-1518
in	O	1519-1521
the	O	1522-1525
DOX	O	1526-1529
group	O	1530-1535
(	O	1536-1537
p	O	1537-1538
<	O	1538-1539
0	O	1539-1540
.	O	1540-1541
001	O	1541-1544
)	O	1544-1545
.	O	1540-1541

These	O	1547-1552
parameters	O	1553-1563
remained	O	1564-1572
unchanged	O	1573-1582
in	O	1583-1585
controls	O	1586-1594
.	O	1594-1595

Histological	O	1596-1608
evaluation	O	1609-1619
of	O	1620-1622
hearts	O	1623-1629
from	O	1630-1634
all	O	1635-1638
rats	O	1639-1643
given	O	1644-1649
DOX	O	1650-1653
revealed	O	1654-1662
significant	O	1663-1674
slight	O	1675-1681
degrees	O	1682-1689
of	O	1690-1692
perivascular	O	1693-1705
and	O	1706-1709
interstitial	O	1710-1722
fibrosis	B	1723-1731
.	O	1731-1732

In	O	1733-1735
7	O	1736-1737
of	O	1738-1740
the	O	1741-1744
18	O	1745-1747
rats	O	1748-1752
,	O	1752-1753
degeneration	O	1754-1766
and	O	1767-1770
myocyte	O	1771-1778
vacuolisation	O	1779-1792
were	O	1793-1797
found	O	1798-1803
.	O	1803-1804

Only	O	1805-1809
five	O	1810-1814
of	O	1815-1817
the	O	1818-1821
controls	O	1822-1830
exhibited	O	1831-1840
evidence	O	1841-1849
of	O	1850-1852
very	O	1853-1857
slight	O	1858-1864
perivascular	O	1865-1877
fibrosis	B	1878-1886
.	O	1886-1887

A	O	1888-1889
significant	O	1890-1901
rise	O	1902-1906
in	O	1907-1909
cTnT	O	1910-1914
was	O	1915-1918
found	O	1919-1924
in	O	1925-1927
DOX	O	1928-1931
rats	O	1932-1936
after	O	1937-1942
cumulative	O	1943-1953
doses	O	1954-1959
of	O	1960-1962
7	O	1963-1964
.	O	1964-1965
5	O	1965-1966
and	O	1967-1970
12	O	1971-1973
mg	O	1974-1976
/	O	1976-1977
kg	O	1977-1979
in	O	1980-1982
comparison	O	1983-1993
with	O	1994-1998
baseline	O	1999-2007
(	O	2008-2009
p	O	2009-2010
<	O	2010-2011
0	O	2011-2012
.	O	2012-2013
05	O	2013-2015
)	O	2015-2016
.	O	2012-2013

cTnT	O	2018-2022
found	O	2023-2028
in	O	2029-2031
rats	O	2032-2036
after	O	2037-2042
12	O	2043-2045
mg	O	2046-2048
/	O	2048-2049
kg	O	2049-2051
were	O	2052-2056
significantly	O	2057-2070
greater	O	2071-2078
than	O	2079-2083
that	O	2084-2088
found	O	2089-2094
after	O	2095-2100
7	O	2101-2102
.	O	2102-2103
5	O	2103-2104
mg	O	2105-2107
/	O	2107-2108
kg	O	2108-2110
DOX	O	2111-2114
.	O	2114-2115

Maximal	O	2116-2123
cTnI	O	2124-2128
(	O	2129-2130
pg	O	2130-2132
/	O	2132-2133
ml	O	2133-2135
)	O	2135-2136
and	O	2137-2140
cTnT	O	2141-2145
levels	O	2146-2152
were	O	2153-2157
significantly	O	2158-2171
increased	O	2172-2181
in	O	2182-2184
DOX	O	2185-2188
rats	O	2189-2193
compared	O	2194-2202
with	O	2203-2207
controls	O	2208-2216
(	O	2217-2218
p	O	2218-2219
=	O	2219-2220
0	O	2220-2221
.	O	2221-2222
006	O	2222-2225
,	O	2225-2226

0	O	2227-2228
.	O	2228-2229
007	O	2229-2232
)	O	2232-2233
.	O	2228-2229

cTnI	O	2235-2239
(	O	2240-2241
ng	O	2241-2243
/	O	2243-2244
ml	O	2244-2246
)	O	2246-2247
,	O	2247-2248
CK	O	2249-2251
-	O	2251-2252
MB	O	2252-2254
mass	O	2255-2259
and	O	2260-2263
CK	O	2264-2266
remained	O	2267-2275
unchanged	O	2276-2285
in	O	2286-2288
DOX	O	2289-2292
rats	O	2293-2297
compared	O	2298-2306
with	O	2307-2311
controls	O	2312-2320
.	O	2320-2321

All	O	2322-2325
markers	O	2326-2333
remained	O	2334-2342
stable	O	2343-2349
in	O	2350-2352
controls	O	2353-2361
.	O	2361-2362

Analysis	O	2363-2371
of	O	2372-2374
data	O	2375-2379
revealed	O	2380-2388
a	O	2389-2390
significant	O	2391-2402
correlation	O	2403-2414
between	O	2415-2422
maximal	O	2423-2430
cTnT	O	2431-2435
and	O	2436-2439
ED	O	2440-2442
and	O	2443-2446
ES	O	2447-2449
LV	O	2450-2452
diameters	O	2453-2462
/	O	2462-2463
BW	O	2463-2465
(	O	2466-2467
r	O	2467-2468
=	O	2468-2469
0	O	2469-2470
.	O	2470-2471
81	O	2471-2473
and	O	2474-2477
0	O	2478-2479
.	O	2479-2480
65	O	2480-2482
;	O	2482-2483
p	O	2484-2485
<	O	2485-2486
0	O	2486-2487
.	O	2487-2488
0001	O	2488-2492
)	O	2492-2493
.	O	2487-2488

A	O	2495-2496
significant	O	2497-2508
relationship	O	2509-2521
was	O	2522-2525
observed	O	2526-2534
between	O	2535-2542
maximal	O	2543-2550
cTnT	O	2551-2555
and	O	2556-2559
the	O	2560-2563
extent	O	2564-2570
of	O	2571-2573
myocardial	O	2574-2584
morphological	O	2585-2598
changes	O	2599-2606
,	O	2606-2607
and	O	2608-2611
between	O	2612-2619
LV	O	2620-2622
diameters	O	2623-2632
/	O	2632-2633
BW	O	2633-2635
and	O	2636-2639
histological	O	2640-2652
findings	O	2653-2661
.	O	2661-2662

CONCLUSIONS	O	2663-2674
:	O	2674-2675
Among	O	2676-2681
markers	O	2682-2689
of	O	2690-2692
ischemic	B	2693-2701
injury	I	2702-2708
after	O	2709-2714
DOX	O	2715-2718
in	O	2719-2721
rats	O	2722-2726
,	O	2726-2727
cTnT	O	2728-2732
showed	O	2733-2739
the	O	2740-2743
greatest	O	2744-2752
ability	O	2753-2760
to	O	2761-2763
detect	O	2764-2770
myocardial	B	2771-2781
damage	I	2782-2788
assessed	O	2789-2797
by	O	2798-2800
echocardiographic	O	2801-2818
detection	O	2819-2828
and	O	2829-2832
histological	O	2833-2845
changes	O	2846-2853
.	O	2853-2854

Although	O	2855-2863
there	O	2864-2869
was	O	2870-2873
a	O	2874-2875
discrepancy	O	2876-2887
between	O	2888-2895
the	O	2896-2899
amount	O	2900-2906
of	O	2907-2909
cTnI	O	2910-2914
and	O	2915-2918
cTnT	O	2919-2923
after	O	2924-2929
DOX	O	2930-2933
,	O	2933-2934
probably	O	2935-2943
due	O	2944-2947
to	O	2948-2950
heterogeneity	O	2951-2964
in	O	2965-2967
cross	O	2968-2973
-	O	2973-2974
reactivities	O	2974-2986
of	O	2987-2989
mAbs	O	2990-2994
to	O	2995-2997
various	O	2998-3005
cTnI	O	3006-3010
and	O	3011-3014
cTnT	O	3015-3019
forms	O	3020-3025
,	O	3025-3026
it	O	3027-3029
is	O	3030-3032
likely	O	3033-3039
that	O	3040-3044
cTnT	O	3045-3049
in	O	3050-3052
rats	O	3053-3057
after	O	3058-3063
DOX	O	3064-3067
indicates	O	3068-3077
cell	O	3078-3082
damage	O	3083-3089
determined	O	3090-3100
by	O	3101-3103
the	O	3104-3107
magnitude	O	3108-3117
of	O	3118-3120
injury	O	3121-3127
induced	O	3128-3135
and	O	3136-3139
that	O	3140-3144
cTnT	O	3145-3149
should	O	3150-3156
be	O	3157-3159
a	O	3160-3161
useful	O	3162-3168
marker	O	3169-3175
for	O	3176-3179
the	O	3180-3183
prediction	O	3184-3194
of	O	3195-3197
experimentally	O	3198-3212
induced	O	3213-3220
cardiotoxicity	B	3221-3235
and	O	3236-3239
possibly	O	3240-3248
for	O	3249-3252
cardioprotective	O	3253-3269
experiments	O	3270-3281
.	O	3281-3282

Calcineurin	O	0-11
-	O	11-12
inhibitor	O	12-21
induced	O	22-29
pain	B	30-34
syndrome	O	35-43
(	O	44-45
CIPS	B	45-49
)	O	49-50
:	O	50-51
a	O	52-53
severe	O	54-60
disabling	O	61-70
complication	O	71-83
after	O	84-89
organ	O	90-95
transplantation	O	96-111
.	O	111-112

Bone	O	113-117
pain	B	118-122
after	O	123-128
transplantation	O	129-144
is	O	145-147
a	O	148-149
frequent	O	150-158
complication	O	159-171
that	O	172-176
can	O	177-180
be	O	181-183
caused	O	184-190
by	O	191-193
several	O	194-201
diseases	O	202-210
.	O	210-211

Treatment	O	212-221
strategies	O	222-232
depend	O	233-239
on	O	240-242
the	O	243-246
correct	O	247-254
diagnosis	O	255-264
of	O	265-267
the	O	268-271
pain	B	272-276
.	O	276-277

Nine	O	278-282
patients	O	283-291
with	O	292-296
severe	O	297-303
pain	B	304-308
in	O	309-311
their	O	312-317
feet	O	318-322
,	O	322-323
which	O	324-329
was	O	330-333
registered	O	334-344
after	O	345-350
transplantation	O	351-366
,	O	366-367
were	O	368-372
investigated	O	373-385
.	O	385-386

Bone	O	387-391
scans	O	392-397
showed	O	398-404
an	O	405-407
increased	O	408-417
tracer	O	418-424
uptake	O	425-431
of	O	432-434
the	O	435-438
foot	O	439-443
bones	O	444-449
.	O	449-450

Magnetic	O	451-459
resonance	O	460-469
imaging	O	470-477
demonstrated	O	478-490
bone	B	491-495
marrow	I	496-502
oedema	I	503-509
in	O	510-512
the	O	513-516
painful	O	517-524
bones	O	525-530
.	O	530-531

Pain	B	532-536
was	O	537-540
not	O	541-544
explained	O	545-554
by	O	555-557
other	O	558-563
diseases	O	564-572
causing	O	573-580
foot	O	581-585
pain	B	586-590
,	O	590-591
like	O	592-596
reflex	B	597-603
sympathetic	I	604-615
dystrophy	I	616-625
,	O	625-626
polyneuropathy	B	627-641
,	O	641-642
Morton	B	643-649
'	I	649-650
s	I	650-651
neuralgia	I	652-661
,	O	661-662
gout	B	663-667
,	O	667-668
osteoporosis	B	669-681
,	O	681-682
avascular	B	683-692
necrosis	I	693-701
,	O	701-702
intermittent	B	703-715
claudication	I	716-728
,	O	728-729
orthopaedic	O	730-741
foot	B	742-746
deformities	I	747-758
,	O	758-759
stress	B	760-766
fractures	I	767-776
,	O	776-777
and	O	778-781
hyperparathyroidism	B	782-801
.	O	801-802

The	O	803-806
reduction	O	807-816
of	O	817-819
cyclosporine	O	820-832
-	O	832-833
or	O	834-836
tacrolimus	O	837-847
trough	O	848-854
levels	O	855-861
and	O	862-865
the	O	866-869
administration	O	870-884
of	O	885-887
calcium	O	888-895
channel	O	896-903
blockers	O	904-912
led	O	913-916
to	O	917-919
relief	O	920-926
of	O	927-929
pain	B	930-934
.	O	934-935

The	O	936-939
Calcineurin	O	940-951
-	O	951-952
inhibitor	O	952-961
Induced	O	962-969
Pain	B	970-974
Syndrome	O	975-983
(	O	984-985
CIPS	B	985-989
)	O	989-990
is	O	991-993
a	O	994-995
rare	O	996-1000
but	O	1001-1004
severe	O	1005-1011
side	O	1012-1016
effect	O	1017-1023
of	O	1024-1026
cyclosporine	O	1027-1039
or	O	1040-1042
tacrolimus	O	1043-1053
and	O	1054-1057
is	O	1058-1060
accurately	O	1061-1071
diagnosed	O	1072-1081
by	O	1082-1084
its	O	1085-1088
typical	O	1089-1096
presentation	O	1097-1109
,	O	1109-1110
magnetic	O	1111-1119
resonance	O	1120-1129
imaging	O	1130-1137
and	O	1138-1141
bone	O	1142-1146
scans	O	1147-1152
.	O	1152-1153

Incorrect	O	1154-1163
diagnosis	O	1164-1173
of	O	1174-1176
the	O	1177-1180
syndrome	O	1181-1189
will	O	1190-1194
lead	O	1195-1199
to	O	1200-1202
a	O	1203-1204
significant	O	1205-1216
reduction	O	1217-1226
of	O	1227-1229
life	O	1230-1234
quality	O	1235-1242
in	O	1243-1245
patients	O	1246-1254
suffering	O	1255-1264
from	O	1265-1269
CIPS	B	1270-1274
.	O	1274-1275

The	O	0-3
haemodynamic	O	4-16
effects	O	17-24
of	O	25-27
propofol	O	28-36
in	O	37-39
combination	O	40-51
with	O	52-56
ephedrine	O	57-66
in	O	67-69
elderly	O	70-77
patients	O	78-86
(	O	87-88
ASA	O	88-91
groups	O	92-98
3	O	99-100
and	O	101-104
4	O	105-106
)	O	106-107
.	O	107-108

The	O	109-112
marked	O	113-119
vasodilator	O	120-131
and	O	132-135
negative	O	136-144
inotropic	O	145-154
effects	O	155-162
of	O	163-165
propofol	O	166-174
are	O	175-178
disadvantages	O	179-192
in	O	193-195
frail	O	196-201
elderly	O	202-209
patients	O	210-218
.	O	218-219

We	O	220-222
investigated	O	223-235
the	O	236-239
safety	O	240-246
and	O	247-250
efficacy	O	251-259
of	O	260-262
adding	O	263-269
different	O	270-279
doses	O	280-285
of	O	286-288
ephedrine	O	289-298
to	O	299-301
propofol	O	302-310
in	O	311-313
order	O	314-319
to	O	320-322
obtund	O	323-329
the	O	330-333
hypotensive	B	334-345
response	O	346-354
.	O	354-355

The	O	356-359
haemodynamic	O	360-372
effects	O	373-380
of	O	381-383
adding	O	384-390
15	O	391-393
,	O	393-394
20	O	395-397
or	O	398-400
25	O	401-403
mg	O	404-406
of	O	407-409
ephedrine	O	410-419
to	O	420-422
200	O	423-426
mg	O	427-429
of	O	430-432
propofol	O	433-441
were	O	442-446
compared	O	447-455
to	O	456-458
control	O	459-466
in	O	467-469
40	O	470-472
ASA	O	473-476
3	O	477-478
/	O	478-479
4	O	479-480
patients	O	481-489
over	O	490-494
60	O	495-497
years	O	498-503
presenting	O	504-514
for	O	515-518
genito	O	519-525
-	O	525-526
urinary	O	526-533
surgery	O	534-541
.	O	541-542

The	O	543-546
addition	O	547-555
of	O	556-558
ephedrine	O	559-568
to	O	569-571
propofol	O	572-580
appears	O	581-588
to	O	589-591
be	O	592-594
an	O	595-597
effective	O	598-607
method	O	608-614
of	O	615-617
obtunding	O	618-627
the	O	628-631
hypotensive	B	632-643
response	O	644-652
to	O	653-655
propofol	O	656-664
at	O	665-667
all	O	668-671
doses	O	672-677
used	O	678-682
in	O	683-685
this	O	686-690
study	O	691-696
.	O	696-697

However	O	698-705
,	O	705-706
marked	O	707-713
tachycardia	B	714-725
associated	O	726-736
with	O	737-741
the	O	742-745
use	O	746-749
of	O	750-752
ephedrine	O	753-762
in	O	763-765
combination	O	766-777
with	O	778-782
propofol	O	783-791
occurred	O	792-800
in	O	801-803
the	O	804-807
majority	O	808-816
of	O	817-819
patients	O	820-828
,	O	828-829
occasionally	O	830-842
reaching	O	843-851
high	O	852-856
levels	O	857-863
in	O	864-866
individual	O	867-877
patients	O	878-886
.	O	886-887

Due	O	888-891
to	O	892-894
the	O	895-898
risk	O	899-903
of	O	904-906
this	O	907-911
tachycardia	B	912-923
inducing	O	924-932
myocardial	B	933-943
ischemia	I	944-952
,	O	952-953
we	O	954-956
would	O	957-962
not	O	963-966
recommend	O	967-976
the	O	977-980
use	O	981-984
in	O	985-987
elderly	O	988-995
patients	O	996-1004
of	O	1005-1007
any	O	1008-1011
of	O	1012-1014
the	O	1015-1018
ephedrine	O	1019-1028
/	O	1028-1029
propofol	O	1029-1037
/	O	1028-1029
mixtures	O	1038-1046
studied	O	1047-1054
.	O	1054-1055

Neurotoxicity	B	0-13
of	O	14-16
halogenated	O	17-28
hydroxyquinolines	O	29-46
:	O	46-47
clinical	O	48-56
analysis	O	57-65
of	O	66-68
cases	O	69-74
reported	O	75-83
outside	O	84-91
Japan	O	92-97
.	O	97-98

An	O	99-101
analysis	O	102-110
is	O	111-113
presented	O	114-123
of	O	124-126
220	O	127-130
cases	O	131-136
of	O	137-139
possible	O	140-148
neurotoxic	B	149-159
reactions	O	160-169
to	O	170-172
halogenated	O	173-184
hydroxyquinolines	O	185-202
reported	O	203-211
from	O	212-216
outside	O	217-224
Japan	O	225-230
.	O	230-231

In	O	232-234
80	O	235-237
cases	O	238-243
insufficient	O	244-256
information	O	257-268
was	O	269-272
available	O	273-282
for	O	283-286
adequate	O	287-295
comment	O	296-303
and	O	304-307
in	O	308-310
29	O	311-313
a	O	314-315
relationship	O	316-328
to	O	329-331
the	O	332-335
administration	O	336-350
of	O	351-353
clioquinol	O	354-364
could	O	365-370
be	O	371-373
excluded	O	374-382
.	O	382-383

Of	O	384-386
the	O	387-390
remainder	O	391-400
,	O	400-401
a	O	402-403
relationship	O	404-416
to	O	417-419
clioquinol	O	420-430
was	O	431-434
considered	O	435-445
probable	O	446-454
in	O	455-457
42	O	458-460
and	O	461-464
possible	O	465-473
in	O	474-476
69	O	477-479
cases	O	480-485
.	O	485-486

In	O	487-489
six	O	490-493
of	O	494-496
the	O	497-500
probable	O	501-509
cases	O	510-515
the	O	516-519
neurological	B	520-532
disturbance	I	533-544
consisted	O	545-554
of	O	555-557
an	O	558-560
acute	O	561-566
reversible	O	567-577
encephalopathy	B	578-592
usually	O	593-600
related	O	601-608
to	O	609-611
the	O	612-615
ingestion	O	616-625
of	O	626-628
a	O	629-630
high	O	631-635
dose	O	636-640
of	O	641-643
clioquinol	O	644-654
over	O	655-659
a	O	660-661
short	O	662-667
period	O	668-674
.	O	674-675

The	O	676-679
most	O	680-684
common	O	685-691
manifestation	O	692-705
,	O	705-706
observed	O	707-715
in	O	716-718
15	O	719-721
further	O	722-729
cases	O	730-735
,	O	735-736
was	O	737-740
isolated	O	741-749
optic	B	750-755
atrophy	I	756-763
.	O	763-764

This	O	765-769
was	O	770-773
most	O	774-778
frequently	O	779-789
found	O	790-795
in	O	796-798
children	O	799-807
,	O	807-808
many	O	809-813
of	O	814-816
whom	O	817-821
had	O	822-825
received	O	826-834
clioquinol	O	835-845
as	O	846-848
treatment	O	849-858
for	O	859-862
acrodermatitis	B	863-877
enteropathica	I	878-891
.	O	891-892

In	O	893-895
the	O	896-899
remaining	O	900-909
cases	O	910-915
,	O	915-916
a	O	917-918
combination	O	919-930
of	O	931-933
myelopathy	B	934-944
,	O	944-945
visual	B	946-952
disturbance	I	953-964
,	O	964-965
and	O	966-969
peripheral	B	970-980
neuropathy	I	981-991
was	O	992-995
the	O	996-999
most	O	1000-1004
common	O	1005-1011
manifestation	O	1012-1025
.	O	1025-1026

Isolated	O	1027-1035
myelopathy	B	1036-1046
or	O	1047-1049
peripheral	B	1050-1060
neuropathy	I	1061-1071
,	O	1071-1072
or	O	1073-1075
these	O	1076-1081
manifestations	O	1082-1096
occurring	O	1097-1106
together	O	1107-1115
,	O	1115-1116
were	O	1117-1121
infrequent	O	1122-1132
.	O	1132-1133

The	O	1134-1137
onset	O	1138-1143
of	O	1144-1146
all	O	1147-1150
manifestations	O	1151-1165
(	O	1166-1167
except	O	1167-1173
toxic	O	1174-1179
encephalopathy	B	1180-1194
)	O	1194-1195
was	O	1196-1199
usually	O	1200-1207
subacute	O	1208-1216
,	O	1216-1217
with	O	1218-1222
subsequent	O	1223-1233
partial	O	1234-1241
recovery	O	1242-1250
.	O	1250-1251

Older	O	1252-1257
subjects	O	1258-1266
tended	O	1267-1273
to	O	1274-1276
display	O	1277-1284
more	O	1285-1289
side	O	1290-1294
effects	O	1295-1302
.	O	1302-1303

The	O	1304-1307
full	O	1308-1312
syndrome	O	1313-1321
of	O	1322-1324
subacute	O	1325-1333
myelo	B	1334-1339
-	I	1339-1340
optic	I	1340-1345
neuropathy	I	1346-1356
was	O	1357-1360
more	O	1361-1365
frequent	O	1366-1374
in	O	1375-1377
women	O	1378-1383
,	O	1383-1384
but	O	1385-1388
they	O	1389-1393
tended	O	1394-1400
to	O	1401-1403
have	O	1404-1408
taken	O	1409-1414
greater	O	1415-1422
quantities	O	1423-1433
of	O	1434-1436
the	O	1437-1440
drug	O	1441-1445
.	O	1445-1446

Epileptic	B	0-9
seizures	I	10-18
following	O	19-28
cortical	O	29-37
application	O	38-49
of	O	50-52
fibrin	O	53-59
sealants	O	60-68
containing	O	69-79
tranexamic	O	80-90
acid	O	91-95
in	O	96-98
rats	O	99-103
.	O	103-104

BACKGROUND	O	105-115
:	O	115-116
Fibrin	O	117-123
sealants	O	124-132
(	O	133-134
FS	O	134-136
)	O	136-137
derived	O	138-145
from	O	146-150
human	O	151-156
plasma	O	157-163
are	O	164-167
frequently	O	168-178
used	O	179-183
in	O	184-186
neurosurgery	O	187-199
.	O	199-200

In	O	201-203
order	O	204-209
to	O	210-212
increase	O	213-221
clot	O	222-226
stability	O	227-236
,	O	236-237
FS	O	238-240
typically	O	241-250
contain	O	251-258
aprotinin	O	259-268
,	O	268-269
a	O	270-271
natural	O	272-279
fibrinolysis	O	280-292
inhibitor	O	293-302
.	O	302-303

Recently	O	304-312
,	O	312-313
synthetic	O	314-323
fibrinolysis	O	324-336
inhibitors	O	337-347
such	O	348-352
as	O	353-355
tranexamic	O	356-366
acid	O	367-371
(	O	372-373
tAMCA	O	373-378
)	O	378-379
have	O	380-384
been	O	385-389
considered	O	390-400
as	O	401-403
substitutes	O	404-415
for	O	416-419
aprotinin	O	420-429
.	O	429-430

However	O	431-438
,	O	438-439
tAMCA	O	440-445
has	O	446-449
been	O	450-454
shown	O	455-460
to	O	461-463
cause	O	464-469
epileptic	B	470-479
seizures	I	480-488
.	O	488-489

We	O	490-492
wanted	O	493-499
to	O	500-502
study	O	503-508
whether	O	509-516
tAMCA	O	517-522
retains	O	523-530
its	O	531-534
convulsive	B	535-545
action	O	546-552
if	O	553-555
incorporated	O	556-568
into	O	569-573
a	O	574-575
FS	O	576-578
.	O	578-579

METHOD	O	580-586
:	O	586-587
FS	O	588-590
containing	O	591-601
aprotinin	O	602-611
or	O	612-614
different	O	615-624
concentrations	O	625-639
of	O	640-642
tAMCA	O	643-648
(	O	649-650
0	O	650-651
.	O	651-652
5	O	652-653
-	O	653-654
47	O	654-656
.	O	651-652
5	O	652-653
mg	O	659-661
/	O	661-662
ml	O	662-664
)	O	664-665
were	O	666-670
applied	O	671-678
to	O	679-681
the	O	682-685
pial	O	686-690
surface	O	691-698
of	O	699-701
the	O	702-705
cortex	O	706-712
of	O	713-715
anaesthetized	O	716-729
rats	O	730-734
.	O	734-735

The	O	736-739
response	O	740-748
of	O	749-751
the	O	752-755
animals	O	756-763
was	O	764-767
evaluated	O	768-777
using	O	778-783
electroencephalography	O	784-806
and	O	807-810
by	O	811-813
monitoring	O	814-824
the	O	825-828
clinical	O	829-837
behaviour	O	838-847
during	O	848-854
and	O	855-858
after	O	859-864
recovery	O	865-873
from	O	874-878
anaesthesia	O	879-890
.	O	890-891

FINDINGS	O	892-900
:	O	900-901
FS	O	902-904
containing	O	905-915
tAMCA	O	916-921
caused	O	922-928
paroxysmal	O	929-939
brain	O	940-945
activity	O	946-954
which	O	955-960
was	O	961-964
associated	O	965-975
with	O	976-980
distinct	O	981-989
convulsive	B	990-1000
behaviours	O	1001-1011
.	O	1011-1012

The	O	1013-1016
degree	O	1017-1023
of	O	1024-1026
these	O	1027-1032
seizures	B	1033-1041
increased	O	1042-1051
with	O	1052-1056
increasing	O	1057-1067
concentration	O	1068-1081
of	O	1082-1084
tAMCA	O	1085-1090
.	O	1090-1091

Thus	O	1092-1096
,	O	1096-1097
FS	O	1098-1100
containing	O	1101-1111
47	O	1112-1114
.	O	1114-1115
5	O	1115-1116
mg	O	1117-1119
/	O	1119-1120
ml	O	1120-1122
tAMCA	O	1123-1128
evoked	O	1129-1135
generalized	B	1136-1147
seizures	I	1148-1156
in	O	1157-1159
all	O	1160-1163
tested	O	1164-1170
rats	O	1171-1175
(	O	1176-1177
n	O	1177-1178
=	O	1178-1179
6	O	1179-1180
)	O	1180-1181
while	O	1182-1187
the	O	1188-1191
lowest	O	1192-1198
concentration	O	1199-1212
of	O	1213-1215
tAMCA	O	1216-1221
(	O	1222-1223
0	O	1223-1224
.	O	1224-1225
5	O	1225-1226
mg	O	1227-1229
/	O	1229-1230
ml	O	1230-1232
)	O	1232-1233
only	O	1234-1238
evoked	O	1239-1245
brief	O	1246-1251
episodes	O	1252-1260
of	O	1261-1263
jerk	O	1264-1268
-	O	1268-1269
correlated	O	1269-1279
convulsive	B	1280-1290
potentials	O	1291-1301
in	O	1302-1304
1	O	1305-1306
of	O	1307-1309
6	O	1310-1311
rats	O	1312-1316
.	O	1316-1317

In	O	1318-1320
contrast	O	1321-1329
,	O	1329-1330
FS	O	1331-1333
containing	O	1334-1344
aprotinin	O	1345-1354
did	O	1355-1358
not	O	1359-1362
evoke	O	1363-1368
any	O	1369-1372
paroxysmal	O	1373-1383
activity	O	1384-1392
.	O	1392-1393

INTERPRETATION	O	1394-1408
:	O	1408-1409
Tranexamic	O	1410-1420
acid	O	1421-1425
retains	O	1426-1433
its	O	1434-1437
convulsive	B	1438-1448
action	O	1449-1455
within	O	1456-1462
FS	O	1463-1465
.	O	1465-1466

Thus	O	1467-1471
,	O	1471-1472
use	O	1473-1476
of	O	1477-1479
FS	O	1480-1482
containing	O	1483-1493
tAMCA	O	1494-1499
for	O	1500-1503
surgery	O	1504-1511
within	O	1512-1518
or	O	1519-1521
close	O	1522-1527
to	O	1528-1530
the	O	1531-1534
CNS	O	1535-1538
may	O	1539-1542
pose	O	1543-1547
a	O	1548-1549
substantial	O	1550-1561
risk	O	1562-1566
to	O	1567-1569
the	O	1570-1573
patient	O	1574-1581
.	O	1581-1582

A	O	0-1
diet	O	2-6
promoting	O	7-16
sugar	B	17-22
dependency	I	23-33
causes	O	34-40
behavioral	B	41-51
cross	I	52-57
-	I	57-58
sensitization	I	58-71
to	O	72-74
a	O	75-76
low	O	77-80
dose	O	81-85
of	O	86-88
amphetamine	O	89-100
.	O	100-101

Previous	O	102-110
research	O	111-119
in	O	120-122
this	O	123-127
laboratory	O	128-138
has	O	139-142
shown	O	143-148
that	O	149-153
a	O	154-155
diet	O	156-160
of	O	161-163
intermittent	O	164-176
excessive	O	177-186
sugar	O	187-192
consumption	O	193-204
produces	O	205-213
a	O	214-215
state	O	216-221
with	O	222-226
neurochemical	O	227-240
and	O	241-244
behavioral	O	245-255
similarities	O	256-268
to	O	269-271
drug	B	272-276
dependency	I	277-287
.	O	287-288

The	O	289-292
present	O	293-300
study	O	301-306
examined	O	307-315
whether	O	316-323
female	O	324-330
rats	O	331-335
on	O	336-338
various	O	339-346
regimens	O	347-355
of	O	356-358
sugar	O	359-364
access	O	365-371
would	O	372-377
show	O	378-382
behavioral	B	383-393
cross	I	394-399
-	I	399-400
sensitization	I	400-413
to	O	414-416
a	O	417-418
low	O	419-422
dose	O	423-427
of	O	428-430
amphetamine	O	431-442
.	O	442-443

After	O	444-449
a	O	450-451
30	O	452-454
-	O	454-455
min	O	455-458
baseline	O	459-467
measure	O	468-475
of	O	476-478
locomotor	O	479-488
activity	O	489-497
(	O	498-499
day	O	499-502
0	O	503-504
)	O	504-505
,	O	505-506
animals	O	507-514
were	O	515-519
maintained	O	520-530
on	O	531-533
a	O	534-535
cyclic	O	536-542
diet	O	543-547
of	O	548-550
12	O	551-553
-	O	553-554
h	O	554-555
deprivation	O	556-567
followed	O	568-576
by	O	577-579
12	O	580-582
-	O	582-583
h	O	583-584
access	O	585-591
to	O	592-594
10	O	595-597
%	O	597-598
sucrose	O	599-606
solution	O	607-615
and	O	616-619
chow	O	620-624
pellets	O	625-632
(	O	633-634
12	O	634-636
h	O	637-638
access	O	639-645
starting	O	646-654
4	O	655-656
h	O	657-658
after	O	659-664
onset	O	665-670
of	O	671-673
the	O	674-677
dark	O	678-682
period	O	683-689
)	O	689-690
for	O	691-694
21	O	695-697
days	O	698-702
.	O	702-703

Locomotor	O	704-713
activity	O	714-722
was	O	723-726
measured	O	727-735
again	O	736-741
for	O	742-745
30	O	746-748
min	O	749-752
at	O	753-755
the	O	756-759
beginning	O	760-769
of	O	770-772
days	O	773-777
1	O	778-779
and	O	780-783
21	O	784-786
of	O	787-789
sugar	O	790-795
access	O	796-802
.	O	802-803

Beginning	O	804-813
on	O	814-816
day	O	817-820
22	O	821-823
,	O	823-824
all	O	825-828
rats	O	829-833
were	O	834-838
maintained	O	839-849
on	O	850-852
ad	O	853-855
libitum	O	856-863
chow	O	864-868
.	O	868-869

Nine	O	870-874
days	O	875-879
later	O	880-885
locomotor	O	886-895
activity	O	896-904
was	O	905-908
measured	O	909-917
in	O	918-920
response	O	921-929
to	O	930-932
a	O	933-934
single	O	935-941
low	O	942-945
dose	O	946-950
of	O	951-953
amphetamine	O	954-965
(	O	966-967
0	O	967-968
.	O	968-969
5	O	969-970
mg	O	971-973
/	O	973-974
kg	O	974-976
)	O	976-977
.	O	977-978

The	O	979-982
animals	O	983-990
that	O	991-995
had	O	996-999
experienced	O	1000-1011
cyclic	O	1012-1018
sucrose	O	1019-1026
and	O	1027-1030
chow	O	1031-1035
were	O	1036-1040
hyperactive	B	1041-1052
in	O	1053-1055
response	O	1056-1064
to	O	1065-1067
amphetamine	O	1068-1079
compared	O	1080-1088
with	O	1089-1093
four	O	1094-1098
control	O	1099-1106
groups	O	1107-1113
(	O	1114-1115
ad	O	1115-1117
libitum	O	1118-1125
10	O	1126-1128
%	O	1128-1129
sucrose	O	1130-1137
and	O	1138-1141
chow	O	1142-1146
followed	O	1147-1155
by	O	1156-1158
amphetamine	O	1159-1170
injection	O	1171-1180
,	O	1180-1181
cyclic	O	1182-1188
chow	O	1189-1193
followed	O	1194-1202
by	O	1203-1205
amphetamine	O	1206-1217
injection	O	1218-1227
,	O	1227-1228
ad	O	1229-1231
libitum	O	1232-1239
chow	O	1240-1244
with	O	1245-1249
amphetamine	O	1250-1261
,	O	1261-1262
or	O	1263-1265
cyclic	O	1266-1272
10	O	1273-1275
%	O	1275-1276
sucrose	O	1277-1284
and	O	1285-1288
chow	O	1289-1293
with	O	1294-1298
a	O	1299-1300
saline	O	1301-1307
injection	O	1308-1317
)	O	1317-1318
.	O	1318-1319

These	O	1320-1325
results	O	1326-1333
suggest	O	1334-1341
that	O	1342-1346
a	O	1347-1348
diet	O	1349-1353
comprised	O	1354-1363
of	O	1364-1366
alternating	O	1367-1378
deprivation	O	1379-1390
and	O	1391-1394
access	O	1395-1401
to	O	1402-1404
a	O	1405-1406
sugar	O	1407-1412
solution	O	1413-1421
and	O	1422-1425
chow	O	1426-1430
produces	O	1431-1439
bingeing	O	1440-1448
on	O	1449-1451
sugar	O	1452-1457
that	O	1458-1462
leads	O	1463-1468
to	O	1469-1471
a	O	1472-1473
long	O	1474-1478
lasting	O	1479-1486
state	O	1487-1492
of	O	1493-1495
increased	O	1496-1505
sensitivity	O	1506-1517
to	O	1518-1520
amphetamine	O	1521-1532
,	O	1532-1533
possibly	O	1534-1542
due	O	1543-1546
to	O	1547-1549
a	O	1550-1551
lasting	O	1552-1559
alteration	O	1560-1570
in	O	1571-1573
the	O	1574-1577
dopamine	O	1578-1586
system	O	1587-1593
.	O	1593-1594

D	O	0-1
-	O	1-2
penicillamine	O	2-15
-	O	1-2
induced	O	16-23
angiopathy	B	24-34
in	O	35-37
rats	O	38-42
.	O	42-43

The	O	44-47
effect	O	48-54
of	O	55-57
high	O	58-62
dose	O	63-67
D	O	68-69
-	O	69-70
penicillamine	O	70-83
treatment	O	84-93
on	O	94-96
aortic	O	97-103
permeability	O	104-116
to	O	117-119
albumin	O	120-127
and	O	128-131
on	O	132-134
the	O	135-138
ultrastructure	O	139-153
of	O	154-156
the	O	157-160
vessel	O	161-167
.	O	167-168

Male	O	169-173
Sprague	O	174-181
-	O	181-182
Dawley	O	182-188
rats	O	189-193
were	O	194-198
treated	O	199-206
with	O	207-211
D	O	212-213
-	O	213-214
penicillamine	O	214-227
(	O	228-229
D	O	229-230
-	O	230-231
pen	O	231-234
)	O	234-235
500	O	236-239
mg	O	240-242
/	O	242-243
kg	O	243-245
/	O	242-243
day	O	246-249
for	O	250-253
10	O	254-256
or	O	257-259
42	O	260-262
days	O	263-267
.	O	267-268

Pair	O	269-273
fed	O	274-277
rats	O	278-282
served	O	283-289
as	O	290-292
controls	O	293-301
.	O	301-302

Changes	O	303-310
in	O	311-313
aortic	O	314-320
morphology	O	321-331
were	O	332-336
examined	O	337-345
by	O	346-348
light	O	349-354
-	O	354-355
and	O	356-359
transmission	O	360-372
-	O	372-373
electron	O	373-381
microscopy	O	382-392
(	O	393-394
TEM	O	394-397
)	O	397-398
.	O	398-399

In	O	400-402
addition	O	403-411
,	O	411-412
the	O	413-416
endothelial	O	417-428
permeability	O	429-441
and	O	442-445
the	O	446-449
penetration	O	450-461
through	O	462-469
the	O	470-473
aortic	O	474-480
wall	O	481-485
of	O	486-488
albumin	O	489-496
were	O	497-501
studied	O	502-509
10	O	510-512
minutes	O	513-520
,	O	520-521
24	O	522-524
and	O	525-528
48	O	529-531
hours	O	532-537
after	O	538-543
i	O	544-545
.	O	545-546
v	O	547-548
.	O	548-549
injection	O	550-559
of	O	560-562
human	O	563-568
serum	O	569-574
131I	O	575-579
-	O	579-580
albumin	O	580-587
(	O	588-589
131I	O	589-593
-	O	593-594
HSA	O	594-597
)	O	597-598
.	O	598-599

TEM	O	600-603
revealed	O	604-612
extensive	O	613-622
elastolysis	O	623-634
in	O	635-637
the	O	638-641
arterial	O	642-650
wall	O	651-655
of	O	656-658
D	O	659-660
-	O	660-661
pen	O	661-664
-	O	660-661
treated	O	665-672
rats	O	673-677
,	O	677-678
consistent	O	679-689
with	O	690-694
an	O	695-697
inhibitory	O	698-708
effect	O	709-715
on	O	716-718
crosslink	O	719-728
formation	O	729-738
.	O	738-739

In	O	740-742
experimental	O	743-755
animals	O	756-763
excess	O	764-770
deposition	O	771-781
of	O	782-784
collagen	O	785-793
and	O	794-797
glycoaminoglycans	O	798-815
was	O	816-819
observed	O	820-828
in	O	829-831
the	O	832-835
subendothelial	O	836-850
and	O	851-854
medial	O	855-861
layer	O	862-867
of	O	868-870
the	O	871-874
aortic	O	875-881
wall	O	882-886
,	O	886-887
together	O	888-896
with	O	897-901
prominent	O	902-911
basal	O	912-917
membrane	O	918-926
substance	O	927-936
around	O	937-943
aortic	O	944-950
smooth	O	951-957
muscle	O	958-964
cells	O	965-970
.	O	970-971

The	O	972-975
aorta	O	976-981
/	O	981-982
serum	O	982-987
-	O	987-988
ratio	O	988-993
and	O	994-997
the	O	998-1001
radioactive	O	1002-1013
build	O	1014-1019
-	O	1019-1020
up	O	1020-1022
24	O	1023-1025
and	O	1026-1029
48	O	1030-1032
hours	O	1033-1038
after	O	1039-1044
injection	O	1045-1054
of	O	1055-1057
131I	O	1058-1062
-	O	1062-1063
HSA	O	1063-1066
was	O	1067-1070
reduced	O	1071-1078
in	O	1079-1081
animals	O	1082-1089
treated	O	1090-1097
with	O	1098-1102
D	O	1103-1104
-	O	1104-1105
pen	O	1105-1108
for	O	1109-1112
42	O	1113-1115
days	O	1116-1120
,	O	1120-1121
indicating	O	1122-1132
an	O	1133-1135
impeded	O	1136-1143
transmural	O	1144-1154
transport	O	1155-1164
of	O	1165-1167
tracer	O	1168-1174
which	O	1175-1180
may	O	1181-1184
be	O	1185-1187
caused	O	1188-1194
by	O	1195-1197
a	O	1198-1199
steric	O	1200-1206
exclusion	O	1207-1216
effect	O	1217-1223
of	O	1224-1226
abundant	O	1227-1235
hyaluronate	O	1236-1247
.	O	1247-1248

The	O	1249-1252
endothelial	O	1253-1264
ultrastructure	O	1265-1279
was	O	1280-1283
unaffected	O	1284-1294
by	O	1295-1297
D	O	1298-1299
-	O	1299-1300
pen	O	1300-1303
,	O	1303-1304
and	O	1305-1308
no	O	1309-1311
differences	O	1312-1323
in	O	1324-1326
aortic	O	1327-1333
131I	O	1334-1338
-	O	1338-1339
HSA	O	1339-1342
radioactivity	O	1343-1356
or	O	1357-1359
aorta	O	1360-1365
/	O	1365-1366
serum	O	1366-1371
-	O	1371-1372
ratio	O	1372-1377
were	O	1378-1382
recorded	O	1383-1391
between	O	1392-1399
experimental	O	1400-1412
and	O	1413-1416
control	O	1417-1424
groups	O	1425-1431
10	O	1432-1434
minutes	O	1435-1442
after	O	1443-1448
tracer	O	1449-1455
injection	O	1456-1465
,	O	1465-1466
indicating	O	1467-1477
that	O	1478-1482
the	O	1483-1486
permeability	O	1487-1499
of	O	1500-1502
the	O	1503-1506
endothelial	O	1507-1518
barrier	O	1519-1526
to	O	1527-1529
albumin	O	1530-1537
remained	O	1538-1546
unaffected	O	1547-1557
by	O	1558-1560
D	O	1561-1562
-	O	1562-1563
pen	O	1563-1566
treatment	O	1567-1576
.	O	1576-1577

These	O	1578-1583
observations	O	1584-1596
support	O	1597-1604
the	O	1605-1608
hypothesis	O	1609-1619
that	O	1620-1624
treatment	O	1625-1634
with	O	1635-1639
high	O	1640-1644
doses	O	1645-1650
of	O	1651-1653
D	O	1654-1655
-	O	1655-1656
pen	O	1656-1659
may	O	1660-1663
induce	O	1664-1670
a	O	1671-1672
fibroproliferative	O	1673-1691
response	O	1692-1700
in	O	1701-1703
rat	O	1704-1707
aorta	O	1708-1713
,	O	1713-1714
possibly	O	1715-1723
by	O	1724-1726
an	O	1727-1729
inhibitory	O	1730-1740
effect	O	1741-1747
on	O	1748-1750
the	O	1751-1754
cross	O	1755-1760
-	O	1760-1761
linking	O	1761-1768
of	O	1769-1771
collagen	O	1772-1780
and	O	1781-1784
elastin	O	1785-1792
.	O	1792-1793

Brain	O	0-5
natriuretic	O	6-17
peptide	O	18-25
is	O	26-28
a	O	29-30
predictor	O	31-40
of	O	41-43
anthracycline	O	44-57
-	O	57-58
induced	O	58-65
cardiotoxicity	B	66-80
.	O	80-81

Anthracyclines	O	82-96
are	O	97-100
effective	O	101-110
antineoplastic	O	111-125
drugs	O	126-131
,	O	131-132
but	O	133-136
they	O	137-141
frequently	O	142-152
cause	O	153-158
dose	O	159-163
-	O	163-164
related	O	164-171
cardiotoxicity	B	172-186
.	O	186-187

The	O	188-191
cardiotoxicity	B	192-206
of	O	207-209
conventional	O	210-222
anthracycline	O	223-236
therapy	O	237-244
highlights	O	245-255
a	O	256-257
need	O	258-262
to	O	263-265
search	O	266-272
for	O	273-276
methods	O	277-284
that	O	285-289
are	O	290-293
highly	O	294-300
sensitive	O	301-310
and	O	311-314
capable	O	315-322
of	O	323-325
predicting	O	326-336
cardiac	B	337-344
dysfunction	I	345-356
.	O	356-357

We	O	358-360
measured	O	361-369
the	O	370-373
plasma	O	374-380
level	O	381-386
of	O	387-389
brain	O	390-395
natriuretic	O	396-407
peptide	O	408-415
(	O	416-417
BNP	O	417-420
)	O	420-421
to	O	422-424
determine	O	425-434
whether	O	435-442
BNP	O	443-446
might	O	447-452
serve	O	453-458
as	O	459-461
a	O	462-463
simple	O	464-470
diagnostic	O	471-481
indicator	O	482-491
of	O	492-494
anthracycline	O	495-508
-	O	508-509
induced	O	509-516
cardiotoxicity	B	517-531
in	O	532-534
patients	O	535-543
with	O	544-548
acute	B	549-554
leukemia	I	555-563
treated	O	564-571
with	O	572-576
a	O	577-578
daunorubicin	O	579-591
(	O	592-593
DNR	O	593-596
)	O	596-597
-	O	597-598
containing	O	598-608
regimen	O	609-616
.	O	616-617

Thirteen	O	618-626
patients	O	627-635
with	O	636-640
acute	B	641-646
leukemia	I	647-655
were	O	656-660
treated	O	661-668
with	O	669-673
a	O	674-675
DNR	O	676-679
-	O	679-680
containing	O	680-690
regimen	O	691-698
.	O	698-699

Cardiac	O	700-707
functions	O	708-717
were	O	718-722
evaluated	O	723-732
with	O	733-737
radionuclide	O	738-750
angiography	O	751-762
before	O	763-769
chemotherapies	O	770-784
.	O	784-785

The	O	786-789
plasma	O	790-796
levels	O	797-803
of	O	804-806
atrial	O	807-813
natriuretic	O	814-825
peptide	O	826-833
(	O	834-835
ANP	O	835-838
)	O	838-839
and	O	840-843
BNP	O	844-847
were	O	848-852
measured	O	853-861
at	O	862-864
the	O	865-868
time	O	869-873
of	O	874-876
radionuclide	O	877-889
angiography	O	890-901
.	O	901-902

Three	O	903-908
patients	O	909-917
developed	O	918-927
congestive	B	928-938
heart	I	939-944
failure	I	945-952
after	O	953-958
the	O	959-962
completion	O	963-973
of	O	974-976
chemotherapy	O	977-989
.	O	989-990

Five	O	991-995
patients	O	996-1004
were	O	1005-1009
diagnosed	O	1010-1019
as	O	1020-1022
having	O	1023-1029
subclinical	O	1030-1041
heart	B	1042-1047
failure	I	1048-1055
after	O	1056-1061
the	O	1062-1065
completion	O	1066-1076
of	O	1077-1079
chemotherapy	O	1080-1092
.	O	1092-1093

The	O	1094-1097
plasma	O	1098-1104
levels	O	1105-1111
of	O	1112-1114
BNP	O	1115-1118
in	O	1119-1121
all	O	1122-1125
the	O	1126-1129
patients	O	1130-1138
with	O	1139-1143
clinical	O	1144-1152
and	O	1153-1156
subclinical	O	1157-1168
heart	B	1169-1174
failure	I	1175-1182
increased	O	1183-1192
above	O	1193-1198
the	O	1199-1202
normal	O	1203-1209
limit	O	1210-1215
(	O	1216-1217
40	O	1217-1219
pg	O	1220-1222
/	O	1222-1223
ml	O	1223-1225
)	O	1225-1226
before	O	1227-1233
the	O	1234-1237
detection	O	1238-1247
of	O	1248-1250
clinical	O	1251-1259
or	O	1260-1262
subclinical	O	1263-1274
heart	B	1275-1280
failure	I	1281-1288
by	O	1289-1291
radionuclide	O	1292-1304
angiography	O	1305-1316
.	O	1316-1317

On	O	1318-1320
the	O	1321-1324
other	O	1325-1330
hand	O	1331-1335
,	O	1335-1336
BNP	O	1337-1340
did	O	1341-1344
not	O	1345-1348
increase	O	1349-1357
in	O	1358-1360
the	O	1361-1364
patients	O	1365-1373
without	O	1374-1381
heart	B	1382-1387
failure	I	1388-1395
given	O	1396-1401
DNR	O	1402-1405
,	O	1405-1406
even	O	1407-1411
at	O	1412-1414
more	O	1415-1419
than	O	1420-1424
700	O	1425-1428
mg	O	1429-1431
/	O	1431-1432
m	O	1429-1430
(	O	1433-1434
2	O	1434-1435
)	O	1435-1436
.	O	1436-1437

The	O	1438-1441
plasma	O	1442-1448
level	O	1449-1454
of	O	1455-1457
ANP	O	1458-1461
did	O	1462-1465
not	O	1466-1469
always	O	1470-1476
increase	O	1477-1485
in	O	1486-1488
all	O	1489-1492
the	O	1493-1496
patients	O	1497-1505
with	O	1506-1510
clinical	O	1511-1519
and	O	1520-1523
subclinical	O	1524-1535
heart	B	1536-1541
failure	I	1542-1549
.	O	1549-1550

These	O	1551-1556
preliminary	O	1557-1568
results	O	1569-1576
suggest	O	1577-1584
that	O	1585-1589
BNP	O	1590-1593
may	O	1594-1597
be	O	1598-1600
useful	O	1601-1607
as	O	1608-1610
an	O	1611-1613
early	O	1614-1619
and	O	1620-1623
sensitive	O	1624-1633
indicator	O	1634-1643
of	O	1644-1646
anthracycline	O	1647-1660
-	O	1660-1661
induced	O	1661-1668
cardiotoxicity	B	1669-1683
.	O	1683-1684

Antibacterial	O	0-13
medication	O	14-24
use	O	25-28
during	O	29-35
pregnancy	O	36-45
and	O	46-49
risk	O	50-54
of	O	55-57
birth	B	58-63
defects	I	64-71
:	O	71-72
National	O	73-81
Birth	B	82-87
Defects	I	88-95
Prevention	O	96-106
Study	O	107-112
.	O	112-113

OBJECTIVE	O	114-123
:	O	123-124
To	O	125-127
estimate	O	128-136
the	O	137-140
association	O	141-152
between	O	153-160
antibacterial	O	161-174
medications	O	175-186
and	O	187-190
selected	O	191-199
birth	B	200-205
defects	I	206-213
.	O	213-214

DESIGN	O	215-221
,	O	221-222
SETTING	O	223-230
,	O	230-231
AND	O	232-235
PARTICIPANTS	O	236-248
:	O	248-249
Population	O	250-260
-	O	260-261
based	O	261-266
,	O	266-267
multisite	O	268-277
,	O	277-278
case	O	279-283
-	O	283-284
control	O	284-291
study	O	292-297
of	O	298-300
women	O	301-306
who	O	307-310
had	O	311-314
pregnancies	O	315-326
affected	O	327-335
by	O	336-338
1	O	339-340
of	O	341-343
more	O	344-348
than	O	349-353
30	O	354-356
eligible	O	357-365
major	O	366-371
birth	B	372-377
defects	I	378-385
identified	O	386-396
via	O	397-400
birth	B	401-406
defect	I	407-413
surveillance	O	414-426
programs	O	427-435
in	O	436-438
10	O	439-441
states	O	442-448
(	O	449-450
n	O	450-451
=	O	452-453
13	O	454-456
155	O	457-460
)	O	460-461
and	O	462-465
control	O	466-473
women	O	474-479
randomly	O	480-488
selected	O	489-497
from	O	498-502
the	O	503-506
same	O	507-511
geographical	O	512-524
regions	O	525-532
(	O	533-534
n	O	534-535
=	O	536-537
4941	O	538-542
)	O	542-543
.	O	543-544

MAIN	O	545-549
EXPOSURE	O	550-558
:	O	558-559
Reported	O	560-568
maternal	O	569-577
use	O	578-581
of	O	582-584
antibacterials	O	585-599
(	O	600-601
1	O	601-602
month	O	603-608
before	O	609-615
pregnancy	O	616-625
through	O	626-633
the	O	634-637
end	O	638-641
of	O	642-644
the	O	645-648
first	O	649-654
trimester	O	655-664
)	O	664-665
.	O	665-666

MAIN	O	667-671
OUTCOME	O	672-679
MEASURE	O	680-687
:	O	687-688
Odds	O	689-693
ratios	O	694-700
(	O	701-702
ORs	O	702-705
)	O	705-706
measuring	O	707-716
the	O	717-720
association	O	721-732
between	O	733-740
antibacterial	O	741-754
use	O	755-758
and	O	759-762
selected	O	763-771
birth	B	772-777
defects	I	778-785
adjusted	O	786-794
for	O	795-798
potential	O	799-808
confounders	O	809-820
.	O	820-821

RESULTS	O	822-829
:	O	829-830
The	O	831-834
reported	O	835-843
use	O	844-847
of	O	848-850
antibacterials	O	851-865
increased	O	866-875
during	O	876-882
pregnancy	O	883-892
,	O	892-893
peaking	O	894-901
during	O	902-908
the	O	909-912
third	O	913-918
month	O	919-924
.	O	924-925

Sulfonamides	O	926-938
were	O	939-943
associated	O	944-954
with	O	955-959
anencephaly	B	960-971
(	O	972-973
adjusted	O	973-981
OR	O	982-984
[	O	985-986
AOR	O	986-989
]	O	989-990
=	O	991-992
3	O	993-994
.	O	994-995
4	O	995-996
;	O	996-997
95	O	998-1000
%	O	1000-1001
confidence	O	1002-1012
interval	O	1013-1021
[	O	1022-1023
CI	O	1023-1025
]	O	1025-1026
,	O	1026-1027
1	O	1028-1029
.	O	1029-1030
3	O	1030-1031
-	O	1031-1032
8	O	1032-1033
.	O	1029-1030
8	O	1032-1033
)	O	1035-1036
,	O	1036-1037

hypoplastic	B	1038-1049
left	I	1050-1054
heart	I	1055-1060
syndrome	I	1061-1069
(	O	1070-1071
AOR	O	1071-1074
=	O	1075-1076
3	O	1077-1078
.	O	1078-1079
2	O	1079-1080
;	O	1080-1081
95	O	1082-1084
%	O	1084-1085
CI	O	1086-1088
,	O	1088-1089
1	O	1090-1091
.	O	1091-1092
3	O	1092-1093
-	O	1093-1094
7	O	1094-1095
.	O	1091-1092
6	O	1096-1097
)	O	1097-1098
,	O	1098-1099

coarctation	B	1100-1111
of	I	1112-1114
the	I	1115-1118
aorta	I	1119-1124
(	O	1125-1126
AOR	O	1126-1129
=	O	1130-1131
2	O	1132-1133
.	O	1133-1134
7	O	1134-1135
;	O	1135-1136
95	O	1137-1139
%	O	1139-1140
CI	O	1141-1143
,	O	1143-1144
1	O	1145-1146
.	O	1146-1147
3	O	1147-1148
-	O	1148-1149
5	O	1149-1150
.	O	1146-1147
6	O	1151-1152
)	O	1152-1153
,	O	1153-1154

choanal	B	1155-1162
atresia	I	1163-1170
(	O	1171-1172
AOR	O	1172-1175
=	O	1176-1177
8	O	1178-1179
.	O	1179-1180
0	O	1180-1181
;	O	1181-1182
95	O	1183-1185
%	O	1185-1186
CI	O	1187-1189
,	O	1189-1190
2	O	1191-1192
.	O	1192-1193
7	O	1193-1194
-	O	1194-1195
23	O	1195-1197
.	O	1192-1193
5	O	1198-1199
)	O	1199-1200
,	O	1200-1201

transverse	B	1202-1212
limb	I	1213-1217
deficiency	I	1218-1228
(	O	1229-1230
AOR	O	1230-1233
=	O	1234-1235
2	O	1236-1237
.	O	1237-1238
5	O	1238-1239
;	O	1239-1240
95	O	1241-1243
%	O	1243-1244
CI	O	1245-1247
,	O	1247-1248
1	O	1249-1250
.	O	1250-1251
0	O	1251-1252
-	O	1252-1253
5	O	1253-1254
.	O	1250-1251
9	O	1255-1256
)	O	1256-1257
,	O	1257-1258

and	O	1259-1262
diaphragmatic	B	1263-1276
hernia	I	1277-1283
(	O	1284-1285
AOR	O	1285-1288
=	O	1289-1290
2	O	1291-1292
.	O	1292-1293
4	O	1293-1294
;	O	1294-1295
95	O	1296-1298
%	O	1298-1299
CI	O	1300-1302
,	O	1302-1303
1	O	1304-1305
.	O	1305-1306
1	O	1304-1305
-	O	1307-1308
5	O	1308-1309
.	O	1305-1306
4	O	1310-1311
)	O	1311-1312
.	O	1305-1306

Nitrofurantoins	O	1314-1329
were	O	1330-1334
associated	O	1335-1345
with	O	1346-1350
anophthalmia	B	1351-1363
or	O	1364-1366
microphthalmos	B	1367-1381
(	O	1382-1383
AOR	O	1383-1386
=	O	1387-1388
3	O	1389-1390
.	O	1390-1391
7	O	1391-1392
;	O	1392-1393
95	O	1394-1396
%	O	1396-1397
CI	O	1398-1400
,	O	1400-1401
1	O	1402-1403
.	O	1403-1404
1	O	1402-1403
-	O	1405-1406
12	O	1406-1408
.	O	1403-1404
2	O	1407-1408
)	O	1410-1411
,	O	1411-1412

hypoplastic	B	1413-1424
left	I	1425-1429
heart	I	1430-1435
syndrome	I	1436-1444
(	O	1445-1446
AOR	O	1446-1449
=	O	1450-1451
4	O	1452-1453
.	O	1453-1454
2	O	1454-1455
;	O	1455-1456
95	O	1457-1459
%	O	1459-1460
CI	O	1461-1463
,	O	1463-1464
1	O	1465-1466
.	O	1466-1467
9	O	1467-1468
-	O	1468-1469
9	O	1467-1468
.	O	1466-1467
1	O	1465-1466
)	O	1472-1473
,	O	1473-1474

atrial	B	1475-1481
septal	I	1482-1488
defects	I	1489-1496
(	O	1497-1498
AOR	O	1498-1501
=	O	1502-1503
1	O	1504-1505
.	O	1505-1506
9	O	1506-1507
;	O	1507-1508
95	O	1509-1511
%	O	1511-1512
CI	O	1513-1515
,	O	1515-1516
1	O	1517-1518
.	O	1518-1519
1	O	1517-1518
-	O	1520-1521
3	O	1521-1522
.	O	1518-1519
4	O	1523-1524
)	O	1524-1525
,	O	1525-1526

and	O	1527-1530
cleft	B	1531-1536
lip	I	1537-1540
with	O	1541-1545
cleft	B	1546-1551
palate	I	1552-1558
(	O	1559-1560
AOR	O	1560-1563
=	O	1564-1565
2	O	1566-1567
.	O	1567-1568
1	O	1568-1569
;	O	1569-1570
95	O	1571-1573
%	O	1573-1574
CI	O	1575-1577
,	O	1577-1578
1	O	1579-1580
.	O	1580-1581
2	O	1581-1582
-	O	1582-1583
3	O	1583-1584
.	O	1580-1581
9	O	1585-1586
)	O	1586-1587
.	O	1580-1581

Other	O	1589-1594
antibacterial	O	1595-1608
agents	O	1609-1615
that	O	1616-1620
showed	O	1621-1627
associations	O	1628-1640
included	O	1641-1649
erythromycins	O	1650-1663
(	O	1664-1665
2	O	1665-1666
defects	O	1667-1674
)	O	1674-1675
,	O	1675-1676
penicillins	O	1677-1688
(	O	1689-1690
1	O	1690-1691
defect	O	1692-1698
)	O	1698-1699
,	O	1699-1700
cephalosporins	O	1701-1715
(	O	1716-1717
1	O	1717-1718
defect	O	1719-1725
)	O	1725-1726
,	O	1726-1727
and	O	1728-1731
quinolones	O	1732-1742
(	O	1743-1744
1	O	1744-1745
defect	O	1746-1752
)	O	1752-1753
.	O	1753-1754

CONCLUSIONS	O	1755-1766
:	O	1766-1767
Reassuringly	O	1768-1780
,	O	1780-1781
penicillins	O	1782-1793
,	O	1793-1794
erythromycins	O	1795-1808
,	O	1808-1809
and	O	1810-1813
cephalosporins	O	1814-1828
,	O	1828-1829
although	O	1830-1838
used	O	1839-1843
commonly	O	1844-1852
by	O	1853-1855
pregnant	O	1856-1864
women	O	1865-1870
,	O	1870-1871
were	O	1872-1876
not	O	1877-1880
associated	O	1881-1891
with	O	1892-1896
many	O	1897-1901
birth	B	1902-1907
defects	I	1908-1915
.	O	1915-1916

Sulfonamides	O	1917-1929
and	O	1930-1933
nitrofurantoins	O	1934-1949
were	O	1950-1954
associated	O	1955-1965
with	O	1966-1970
several	O	1971-1978
birth	B	1979-1984
defects	I	1985-1992
,	O	1992-1993
indicating	O	1994-2004
a	O	2005-2006
need	O	2007-2011
for	O	2012-2015
additional	O	2016-2026
scrutiny	O	2027-2035
.	O	2035-2036

Incidence	O	0-9
of	O	10-12
neoplasms	B	13-22
in	O	23-25
patients	O	26-34
with	O	35-39
rheumatoid	B	40-50
arthritis	I	51-60
exposed	O	61-68
to	O	69-71
different	O	72-81
treatment	O	82-91
regimens	O	92-100
.	O	100-101

Immunosuppressive	O	102-119
drugs	O	120-125
have	O	126-130
been	O	131-135
used	O	136-140
during	O	141-147
the	O	148-151
last	O	152-156
30	O	157-159
years	O	160-165
in	O	166-168
treatment	O	169-178
of	O	179-181
patients	O	182-190
with	O	191-195
severe	O	196-202
rheumatoid	B	203-213
arthritis	I	214-223
.	O	223-224

The	O	225-228
drugs	O	229-234
commonly	O	235-243
used	O	244-248
are	O	249-252
cyclophosphamide	O	253-269
and	O	270-273
chlorambucil	O	274-286
(	O	287-288
alkylating	O	288-298
agents	O	299-305
)	O	305-306
,	O	306-307
azathioprine	O	308-320
(	O	321-322
purine	O	322-328
analogue	O	329-337
)	O	337-338
,	O	338-339
and	O	340-343
methotrexate	O	344-356
(	O	357-358
folic	O	358-363
acid	O	364-368
analogue	O	369-377
)	O	377-378
.	O	378-379

There	O	380-385
is	O	386-388
evidence	O	389-397
that	O	398-402
all	O	403-406
four	O	407-411
immunosuppressive	O	412-429
drugs	O	430-435
can	O	436-439
reduce	O	440-446
synovitis	B	447-456
,	O	456-457
but	O	458-461
disease	O	462-469
activity	O	470-478
almost	O	479-485
always	O	486-492
recurs	O	493-499
after	O	500-505
therapy	O	506-513
is	O	514-516
stopped	O	517-524
.	O	524-525

Since	O	526-531
adverse	O	532-539
reactions	O	540-549
are	O	550-553
frequent	O	554-562
,	O	562-563
less	O	564-568
than	O	569-573
50	O	574-576
percent	O	577-584
of	O	585-587
patients	O	588-596
are	O	597-600
able	O	601-605
to	O	606-608
continue	O	609-617
a	O	618-619
particular	O	620-630
drug	O	631-635
for	O	636-639
more	O	640-644
than	O	645-649
one	O	650-653
year	O	654-658
.	O	658-659

Since	O	660-665
it	O	666-668
takes	O	669-674
three	O	675-680
to	O	681-683
12	O	684-686
months	O	687-693
to	O	694-696
achieve	O	697-704
maximal	O	705-712
effects	O	713-720
,	O	720-721
those	O	722-727
patients	O	728-736
who	O	737-740
are	O	741-744
unable	O	745-751
to	O	752-754
continue	O	755-763
the	O	764-767
drug	O	768-772
receive	O	773-780
little	O	781-787
benefit	O	788-795
from	O	796-800
it	O	801-803
.	O	803-804

Patients	O	805-813
treated	O	814-821
with	O	822-826
alkylating	O	827-837
agents	O	838-844
have	O	845-849
an	O	850-852
increased	O	853-862
risk	O	863-867
of	O	868-870
development	O	871-882
of	O	883-885
acute	B	886-891
nonlymphocytic	I	892-906
leukemia	I	907-915
,	O	915-916
and	O	917-920
both	O	921-925
alkylating	O	926-936
agents	O	937-943
and	O	944-947
azathioprine	O	948-960
are	O	961-964
associated	O	965-975
with	O	976-980
the	O	981-984
development	O	985-996
of	O	997-999
non	B	1000-1003
-	I	1003-1004
Hodgkin	I	1004-1011
'	I	1011-1012
s	I	1012-1013
lymphoma	I	1014-1022
.	O	1022-1023

Cyclophosphamide	O	1024-1040
therapy	O	1041-1048
increases	O	1049-1058
the	O	1059-1062
risk	O	1063-1067
of	O	1068-1070
carcinoma	B	1071-1080
of	I	1081-1083
the	I	1084-1087
bladder	I	1088-1095
.	O	1095-1096

There	O	1097-1102
have	O	1103-1107
been	O	1108-1112
several	O	1113-1120
long	O	1121-1125
-	O	1125-1126
term	O	1126-1130
studies	O	1131-1138
of	O	1139-1141
patients	O	1142-1150
with	O	1151-1155
rheumatoid	B	1156-1166
arthritis	I	1167-1176
treated	O	1177-1184
with	O	1185-1189
azathioprine	O	1190-1202
and	O	1203-1206
cyclophosphamide	O	1207-1223
and	O	1224-1227
the	O	1228-1231
incidence	O	1232-1241
of	O	1242-1244
most	O	1245-1249
of	O	1250-1252
the	O	1253-1256
common	O	1257-1263
cancers	B	1264-1271
is	O	1272-1274
not	O	1275-1278
increased	O	1279-1288
.	O	1288-1289

Data	O	1290-1294
on	O	1295-1297
the	O	1298-1301
possible	O	1302-1310
increased	O	1311-1320
risk	O	1321-1325
of	O	1326-1328
malignancy	B	1329-1339
in	O	1340-1342
rheumatoid	B	1343-1353
arthritis	I	1354-1363
are	O	1364-1367
still	O	1368-1373
being	O	1374-1379
collected	O	1380-1389
,	O	1389-1390
and	O	1391-1394
until	O	1395-1400
further	O	1401-1408
information	O	1409-1420
is	O	1421-1423
available	O	1424-1433
,	O	1433-1434
the	O	1435-1438
use	O	1439-1442
of	O	1443-1445
immunosuppressive	O	1446-1463
drugs	O	1464-1469
,	O	1469-1470
particularly	O	1471-1483
alkylating	O	1484-1494
agents	O	1495-1501
,	O	1501-1502
in	O	1503-1505
the	O	1506-1509
treatment	O	1510-1519
of	O	1520-1522
rheumatoid	B	1523-1533
arthritis	I	1534-1543
should	O	1544-1550
be	O	1551-1553
reserved	O	1554-1562
for	O	1563-1566
patients	O	1567-1575
with	O	1576-1580
severe	O	1581-1587
progressive	O	1588-1599
disease	O	1600-1607
or	O	1608-1610
life	O	1611-1615
-	O	1615-1616
threatening	O	1616-1627
complications	O	1628-1641
.	O	1641-1642

Patterns	O	0-8
of	O	9-11
hepatic	B	12-19
injury	I	20-26
induced	O	27-34
by	O	35-37
methyldopa	O	38-48
.	O	48-49

Twelve	O	50-56
patients	O	57-65
with	O	66-70
liver	B	71-76
disease	I	77-84
related	O	85-92
to	O	93-95
methyldopa	O	96-106
were	O	107-111
seen	O	112-116
between	O	117-124
1967	O	125-129
and	O	130-133
1977	O	134-138
.	O	138-139

Illness	O	140-147
occurred	O	148-156
within	O	157-163
1	O	164-165
-	O	165-166
-	O	165-166
9	O	167-168
weeks	O	169-174
of	O	175-177
commencement	O	178-190
of	O	191-193
therapy	O	194-201
in	O	202-204
9	O	205-206
patients	O	207-215
,	O	215-216
the	O	217-220
remaining	O	221-230
3	O	231-232
patients	O	233-241
having	O	242-248
received	O	249-257
the	O	258-261
drug	O	262-266
for	O	267-270
13	O	271-273
months	O	274-280
,	O	280-281
15	O	282-284
months	O	285-291
and	O	292-295
7	O	296-297
years	O	298-303
before	O	304-310
experiencing	O	311-323
symptoms	O	324-332
.	O	332-333

Jaundice	B	334-342
with	O	343-347
tender	O	348-354
hepatomegaly	B	355-367
,	O	367-368
usually	O	369-376
preceded	O	377-385
by	O	386-388
symptoms	O	389-397
of	O	398-400
malaise	O	401-408
,	O	408-409
anorexia	B	410-418
,	O	418-419
nausea	B	420-426
and	O	427-430
vomiting	B	431-439
,	O	439-440
and	O	441-444
associated	O	445-455
with	O	456-460
upper	O	461-466
abdominal	B	467-476
pain	I	477-481
,	O	481-482
was	O	483-486
an	O	487-489
invariable	O	490-500
finding	O	501-508
in	O	509-511
all	O	512-515
patients	O	516-524
.	O	524-525

Biochemical	O	526-537
liver	O	538-543
function	O	544-552
tests	O	553-558
indicated	O	559-568
hepatocellular	O	569-583
necrosis	B	584-592
and	O	593-596
correlated	O	597-607
with	O	608-612
histopathological	O	613-630
evidence	O	631-639
of	O	640-642
hepatic	B	643-650
injury	I	651-657
,	O	657-658
the	O	659-662
spectrum	O	663-671
of	O	672-674
which	O	675-680
ranged	O	681-687
from	O	688-692
fatty	B	693-698
change	I	699-705
and	O	706-709
focal	O	710-715
hepatocellular	O	716-730
necrosis	B	731-739
to	O	740-742
massive	B	743-750
hepatic	I	751-758
necrosis	I	759-767
.	O	767-768

Most	O	769-773
patients	O	774-782
showed	O	783-789
moderate	O	790-798
to	O	799-801
severe	O	802-808
acute	B	809-814
hepatitis	I	815-824
or	O	825-827
chronic	B	828-835
active	I	836-842
hepatitis	I	843-852
with	O	853-857
associated	O	858-868
cholestasis	B	869-880
.	O	880-881

The	O	882-885
drug	O	886-890
was	O	891-894
withdrawn	O	895-904
on	O	905-907
presentation	O	908-920
to	O	921-923
hospital	O	924-932
in	O	933-935
11	O	936-938
patients	O	939-947
,	O	947-948
with	O	949-953
rapid	O	954-959
clinical	O	960-968
improvement	O	969-980
in	O	981-983
9	O	984-985
.	O	985-986

One	O	987-990
patient	O	991-998
died	O	999-1003
,	O	1003-1004
having	O	1005-1011
presented	O	1012-1021
in	O	1022-1024
hepatic	B	1025-1032
failure	I	1033-1040
,	O	1040-1041
and	O	1042-1045
another	O	1046-1053
,	O	1053-1054
who	O	1055-1058
had	O	1059-1062
been	O	1063-1067
taking	O	1068-1074
methyldopa	O	1075-1085
for	O	1086-1089
7	O	1090-1091
years	O	1092-1097
,	O	1097-1098
showed	O	1099-1105
slower	O	1106-1112
clinical	O	1113-1121
and	O	1122-1125
biochemical	O	1126-1137
resolution	O	1138-1148
over	O	1149-1153
a	O	1154-1155
period	O	1156-1162
of	O	1163-1165
several	O	1166-1173
months	O	1174-1180
.	O	1180-1181

The	O	1182-1185
remaining	O	1186-1195
patient	O	1196-1203
in	O	1204-1206
the	O	1207-1210
series	O	1211-1217
developed	O	1218-1227
fulminant	B	1228-1237
hepatitis	I	1238-1247
when	O	1248-1252
the	O	1253-1256
drug	O	1257-1261
was	O	1262-1265
accidentally	O	1266-1278
recommenced	O	1279-1290
1	O	1291-1292
year	O	1293-1297
after	O	1298-1303
a	O	1304-1305
prior	O	1306-1311
episode	O	1312-1319
of	O	1320-1322
methyldopa	O	1323-1333
-	O	1333-1334
induced	O	1334-1341
hepatitis	B	1342-1351
.	O	1351-1352

In	O	1353-1355
this	O	1356-1360
latter	O	1361-1367
patient	O	1368-1375
,	O	1375-1376
and	O	1377-1380
in	O	1381-1383
2	O	1384-1385
others	O	1386-1392
,	O	1392-1393
the	O	1394-1397
causal	O	1398-1404
relationship	O	1405-1417
between	O	1418-1425
methyldopa	O	1426-1436
and	O	1437-1440
hepatic	B	1441-1448
dysfunction	I	1449-1460
was	O	1461-1464
proved	O	1465-1471
with	O	1472-1476
the	O	1477-1480
recurrence	O	1481-1491
of	O	1492-1494
hepatitis	B	1495-1504
within	O	1505-1511
2	O	1512-1513
weeks	O	1514-1519
of	O	1520-1522
re	O	1523-1525
-	O	1525-1526
exposure	O	1526-1534
to	O	1535-1537
the	O	1538-1541
drug	O	1542-1546
.	O	1546-1547

A	O	0-1
phase	O	2-7
I	O	8-9
/	O	9-10
II	O	10-12
study	O	13-18
of	O	19-21
paclitaxel	O	22-32
plus	O	33-37
cisplatin	O	38-47
as	O	48-50
first	O	51-56
-	O	56-57
line	O	57-61
therapy	O	62-69
for	O	70-73
head	B	74-78
and	I	79-82
neck	I	83-87
cancers	I	88-95
:	O	95-96
preliminary	O	97-108
results	O	109-116
.	O	116-117

Improved	O	118-126
outcomes	O	127-135
among	O	136-141
patients	O	142-150
with	O	151-155
head	B	156-160
and	I	161-164
neck	I	165-169
carcinomas	I	170-180
require	O	181-188
investigations	O	189-203
of	O	204-206
new	O	207-210
drugs	O	211-216
for	O	217-220
induction	O	221-230
therapy	O	231-238
.	O	238-239

Preliminary	O	240-251
results	O	252-259
of	O	260-262
an	O	263-265
Eastern	O	266-273
Cooperative	O	274-285
Oncology	O	286-294
Group	O	295-300
study	O	301-306
of	O	307-309
single	O	310-316
-	O	316-317
agent	O	317-322
paclitaxel	O	323-333
(	O	334-335
Taxol	O	335-340
;	O	340-341
Bristol	O	342-349
-	O	349-350
Myers	O	350-355
Squibb	O	356-362
Company	O	363-370
,	O	370-371
Princeton	O	372-381
,	O	381-382
NJ	O	383-385
)	O	385-386
reported	O	387-395
a	O	396-397
37	O	398-400
%	O	400-401
response	O	402-410
rate	O	411-415
in	O	416-418
patients	O	419-427
with	O	428-432
head	B	433-437
and	I	438-441
neck	I	442-446
cancer	I	447-453
,	O	453-454
and	O	455-458
the	O	459-462
paclitaxel	O	463-473
/	O	473-474
cisplatin	O	474-483
combination	O	484-495
has	O	496-499
been	O	500-504
used	O	505-509
successfully	O	510-522
and	O	523-526
has	O	527-530
significantly	O	531-544
improved	O	545-553
median	O	554-560
response	O	561-569
duration	O	570-578
in	O	579-581
ovarian	B	582-589
cancer	I	590-596
patients	O	597-605
.	O	605-606

We	O	607-609
initiated	O	610-619
a	O	620-621
phase	O	622-627
I	O	628-629
/	O	629-630
II	O	630-632
trial	O	633-638
to	O	639-641
determine	O	642-651
the	O	652-655
response	O	656-664
and	O	665-668
toxicity	B	669-677
of	O	678-680
escalating	O	681-691
paclitaxel	O	692-702
doses	O	703-708
combined	O	709-717
with	O	718-722
fixed	O	723-728
-	O	728-729
dose	O	729-733
cisplatin	O	734-743
with	O	744-748
granulocyte	O	749-760
colony	O	761-767
-	O	767-768
stimulating	O	768-779
factor	O	780-786
support	O	787-794
in	O	795-797
patients	O	798-806
with	O	807-811
untreated	O	812-821
locally	O	822-829
advanced	O	830-838
inoperable	O	839-849
head	B	850-854
and	I	855-858
neck	I	859-863
carcinoma	I	864-873
.	O	873-874

To	O	875-877
date	O	878-882
,	O	882-883
23	O	884-886
men	O	887-890
with	O	891-895
a	O	896-897
median	O	898-904
age	O	905-908
of	O	909-911
50	O	912-914
years	O	915-920
and	O	921-924
good	O	925-929
performance	O	930-941
status	O	942-948
have	O	949-953
entered	O	954-961
the	O	962-965
trial	O	966-971
.	O	971-972

Primary	O	973-980
tumor	B	981-986
sites	O	987-992
were	O	993-997
oropharynx	O	998-1008
,	O	1008-1009
10	O	1010-1012
patients	O	1013-1021
;	O	1021-1022
hypopharynx	O	1023-1034
,	O	1034-1035
four	O	1036-1040
;	O	1040-1041
larynx	O	1042-1048
,	O	1048-1049
two	O	1050-1053
;	O	1053-1054
oral	O	1055-1059
cavity	O	1060-1066
,	O	1066-1067
three	O	1068-1073
;	O	1073-1074
unknown	O	1075-1082
primary	O	1083-1090
,	O	1090-1091
two	O	1092-1095
;	O	1095-1096
and	O	1097-1100
nasal	O	1101-1106
cavity	O	1107-1113
and	O	1114-1117
parotid	O	1118-1125
gland	O	1126-1131
,	O	1131-1132
one	O	1133-1136
each	O	1137-1141
.	O	1141-1142

Of	O	1143-1145
20	O	1146-1148
patients	O	1149-1157
evaluable	O	1158-1167
for	O	1168-1171
toxicity	B	1172-1180
,	O	1180-1181
four	O	1182-1186
had	O	1187-1190
stage	O	1191-1196
III	O	1197-1200
and	O	1201-1204
16	O	1205-1207
had	O	1208-1211
stage	O	1212-1217
IV	O	1218-1220
disease	O	1221-1228
.	O	1228-1229

Treatment	O	1230-1239
,	O	1239-1240
given	O	1241-1246
every	O	1247-1252
21	O	1253-1255
days	O	1256-1260
for	O	1261-1264
a	O	1265-1266
maximum	O	1267-1274
of	O	1275-1277
three	O	1278-1283
cycles	O	1284-1290
,	O	1290-1291
consisted	O	1292-1301
of	O	1302-1304
paclitaxel	O	1305-1315
by	O	1316-1318
3	O	1319-1320
-	O	1320-1321
hour	O	1321-1325
infusion	O	1326-1334
followed	O	1335-1343
the	O	1344-1347
next	O	1348-1352
day	O	1353-1356
by	O	1357-1359
a	O	1360-1361
fixed	O	1362-1367
dose	O	1368-1372
of	O	1373-1375
cisplatin	O	1376-1385
(	O	1386-1387
75	O	1387-1389
mg	O	1390-1392
/	O	1392-1393
m2	O	1393-1395
)	O	1395-1396
.	O	1396-1397

The	O	1398-1401
dose	O	1402-1406
levels	O	1407-1413
incorporate	O	1414-1425
escalating	O	1426-1436
paclitaxel	O	1437-1447
doses	O	1448-1453
,	O	1453-1454
and	O	1455-1458
intrapatient	O	1459-1471
escalations	O	1472-1483
within	O	1484-1490
a	O	1491-1492
given	O	1493-1498
dose	O	1499-1503
level	O	1504-1509
are	O	1510-1513
permitted	O	1514-1523
if	O	1524-1526
toxicity	B	1527-1535
permits	O	1536-1543
.	O	1543-1544

At	O	1545-1547
the	O	1548-1551
time	O	1552-1556
of	O	1557-1559
this	O	1560-1564
writing	O	1565-1572
,	O	1572-1573
dose	O	1574-1578
level	O	1579-1584
4	O	1585-1586
(	O	1587-1588
260	O	1588-1591
,	O	1591-1592
270	O	1593-1596
,	O	1596-1597
and	O	1598-1601
280	O	1602-1605
mg	O	1606-1608
/	O	1608-1609
m2	O	1609-1611
)	O	1611-1612
is	O	1613-1615
being	O	1616-1621
evaluated	O	1622-1631
;	O	1631-1632
three	O	1633-1638
patients	O	1639-1647
from	O	1648-1652
this	O	1653-1657
level	O	1658-1663
are	O	1664-1667
evaluable	O	1668-1677
.	O	1677-1678

With	O	1679-1683
paclitaxel	O	1684-1694
doses	O	1695-1700
of	O	1701-1703
200	O	1704-1707
mg	O	1708-1710
/	O	1710-1711
m2	O	1711-1713
and	O	1714-1717
higher	O	1718-1724
,	O	1724-1725
granulocyte	O	1726-1737
colony	O	1738-1744
-	O	1744-1745
stimulating	O	1745-1756
factor	O	1757-1763
5	O	1764-1765
micrograms	O	1766-1776
/	O	1776-1777
kg	O	1777-1779
/	O	1776-1777
d	O	1780-1781
is	O	1782-1784
given	O	1785-1790
(	O	1791-1792
days	O	1792-1796
4	O	1797-1798
through	O	1799-1806
12	O	1807-1809
)	O	1809-1810
.	O	1810-1811

Of	O	1812-1814
18	O	1815-1817
patients	O	1818-1826
evaluable	O	1827-1836
for	O	1837-1840
response	O	1841-1849
,	O	1849-1850
seven	O	1851-1856
(	O	1857-1858
39	O	1858-1860
%	O	1860-1861
)	O	1861-1862
achieved	O	1863-1871
a	O	1872-1873
complete	O	1874-1882
response	O	1883-1891
and	O	1892-1895
six	O	1896-1899
(	O	1900-1901
33	O	1901-1903
%	O	1903-1904
)	O	1904-1905
achieved	O	1906-1914
a	O	1915-1916
partial	O	1917-1924
response	O	1925-1933
.	O	1933-1934

Three	O	1935-1940
patients	O	1941-1949
had	O	1950-1953
no	O	1954-1956
change	O	1957-1963
and	O	1964-1967
disease	O	1968-1975
progressed	O	1976-1986
in	O	1987-1989
two	O	1990-1993
.	O	1993-1994

The	O	1995-1998
overall	O	1999-2006
response	O	2007-2015
rate	O	2016-2020
is	O	2021-2023
72	O	2024-2026
%	O	2026-2027
.	O	2027-2028

Eleven	O	2029-2035
responding	O	2036-2046
patients	O	2047-2055
had	O	2056-2059
subsequent	O	2060-2070
surgery	O	2071-2078
/	O	2078-2079
radiotherapy	O	2079-2091
or	O	2092-2094
radical	O	2095-2102
radiotherapy	O	2103-2115
.	O	2115-2116

Two	O	2117-2120
pathologic	O	2121-2131
complete	O	2132-2140
responses	O	2141-2150
were	O	2151-2155
observed	O	2156-2164
in	O	2165-2167
patients	O	2168-2176
who	O	2177-2180
had	O	2181-2184
achieved	O	2185-2193
clinical	O	2194-2202
complete	O	2203-2211
responses	O	2212-2221
.	O	2221-2222

Alopecia	B	2223-2231
,	O	2231-2232
paresthesias	B	2233-2245
,	O	2245-2246
and	O	2247-2250
arthralgias	B	2251-2262
/	O	2262-2263
myalgias	B	2263-2271
have	O	2272-2276
occurred	O	2277-2285
frequently	O	2286-2296
,	O	2296-2297
but	O	2298-2301
with	O	2302-2306
one	O	2307-2310
exception	O	2311-2320
(	O	2321-2322
a	O	2322-2323
grade	O	2324-2329
3	O	2330-2331
myalgia	B	2332-2339
)	O	2339-2340
they	O	2341-2345
have	O	2346-2350
been	O	2351-2355
grade	O	2356-2361
1	O	2362-2363
or	O	2364-2366
2	O	2367-2368
.	O	2368-2369
No	O	2370-2372
dose	O	2373-2377
-	O	2377-2378
limiting	O	2378-2386
hematologic	O	2387-2398
toxicity	B	2399-2407
has	O	2408-2411
been	O	2412-2416
seen	O	2417-2421
.	O	2421-2422

Paclitaxel	O	2423-2433
/	O	2433-2434
cisplatin	O	2434-2443
is	O	2444-2446
an	O	2447-2449
effective	O	2450-2459
first	O	2460-2465
-	O	2465-2466
line	O	2466-2470
regimen	O	2471-2478
for	O	2479-2482
locoregionally	O	2483-2497
advanced	O	2498-2506
head	B	2507-2511
and	I	2512-2515
neck	I	2516-2520
cancer	I	2521-2527
and	O	2528-2531
continued	O	2532-2541
study	O	2542-2547
is	O	2548-2550
warranted	O	2551-2560
.	O	2560-2561

Results	O	2562-2569
thus	O	2570-2574
far	O	2575-2578
suggest	O	2579-2586
no	O	2587-2589
dose	O	2590-2594
-	O	2594-2595
response	O	2595-2603
effect	O	2604-2610
for	O	2611-2614
paclitaxel	O	2615-2625
doses	O	2626-2631
above	O	2632-2637
200	O	2638-2641
mg	O	2642-2644
/	O	2644-2645
m2	O	2645-2647
.	O	2647-2648

A	O	0-1
phase	O	2-7
I	O	8-9
study	O	10-15
of	O	16-18
4	O	19-20
'	O	20-21
-	O	21-22
0	O	22-23
-	O	21-22
tetrahydropyranyladriamycin	O	24-51
.	O	51-52

Clinical	O	53-61
pharmacology	O	62-74
and	O	75-78
pharmacokinetics	O	79-95
.	O	95-96

A	O	97-98
Phase	O	99-104
I	O	105-106
study	O	107-112
of	O	113-115
intravenous	O	116-127
(	O	128-129
IV	O	129-131
)	O	131-132
bolus	O	133-138
4	O	139-140
'	O	140-141
-	O	141-142
0	O	142-143
-	O	141-142
tetrahydropyranyladriamycin	O	144-171
(	O	172-173
Pirarubicin	O	173-184
)	O	184-185
was	O	186-189
done	O	190-194
in	O	195-197
55	O	198-200
patients	O	201-209
in	O	210-212
good	O	213-217
performance	O	218-229
status	O	230-236
with	O	237-241
refractory	O	242-252
tumors	B	253-259
.	O	259-260

Twenty	O	261-267
-	O	267-268
six	O	268-271
had	O	272-275
minimal	O	276-283
prior	O	284-289
therapy	O	290-297
(	O	298-299
good	O	299-303
risk	O	304-308
)	O	308-309
,	O	309-310
23	O	311-313
had	O	314-317
extensive	O	318-327
prior	O	328-333
therapy	O	334-341
(	O	342-343
poor	O	343-347
risk	O	348-352
)	O	352-353
,	O	353-354
and	O	355-358
six	O	359-362
had	O	363-366
renal	B	367-372
and	I	373-376
/	I	376-377
or	I	377-379
hepatic	I	380-387
dysfunction	I	388-399
.	O	399-400

A	O	401-402
total	O	403-408
of	O	409-411
167	O	412-415
courses	O	416-423
at	O	424-426
doses	O	427-432
of	O	433-435
15	O	436-438
to	O	439-441
70	O	442-444
mg	O	445-447
/	O	447-448
m2	O	448-450
were	O	451-455
evaluable	O	456-465
.	O	465-466

Maximum	O	467-474
tolerated	O	475-484
dose	O	485-489
in	O	490-492
good	O	493-497
-	O	497-498
risk	O	498-502
patients	O	503-511
was	O	512-515
70	O	516-518
mg	O	519-521
/	O	521-522
m2	O	522-524
,	O	524-525
and	O	526-529
in	O	530-532
poor	O	533-537
-	O	537-538
risk	O	538-542
patients	O	543-551
,	O	551-552
60	O	553-555
mg	O	556-558
/	O	558-559
m2	O	559-561
.	O	561-562

The	O	563-566
dose	O	567-571
-	O	571-572
limiting	O	572-580
toxic	O	581-586
effect	O	587-593
was	O	594-597
transient	O	598-607
noncumulative	O	608-621
granulocytopenia	B	622-638
.	O	638-639

Granulocyte	O	640-651
nadir	O	652-657
was	O	658-661
on	O	662-664
day	O	665-668
14	O	669-671
(	O	672-673
range	O	673-678
,	O	678-679
4	O	680-681
-	O	681-682
22	O	682-684
)	O	684-685
.	O	685-686

Less	O	687-691
frequent	O	692-700
toxic	O	701-706
effects	O	707-714
included	O	715-723
thrombocytopenia	B	724-740
,	O	740-741
anemia	B	742-748
,	O	748-749
nausea	B	750-756
,	O	756-757
mild	O	758-762
alopecia	B	763-771
,	O	771-772
phlebitis	B	773-782
,	O	782-783
and	O	784-787
mucositis	B	788-797
.	O	797-798

Myelosuppression	B	799-815
was	O	816-819
more	O	820-824
in	O	825-827
patients	O	828-836
with	O	837-841
hepatic	B	842-849
dysfunction	I	850-861
.	O	861-862

Pharmacokinetic	O	863-878
analyses	O	879-887
in	O	888-890
21	O	891-893
patients	O	894-902
revealed	O	903-911
Pirarubicin	O	912-923
plasma	O	924-930
T	O	931-932
1	O	933-934
/	O	934-935
2	O	935-936
alpha	O	937-942
(	O	943-944
+	O	944-945
/	O	945-946
-	O	946-947
SE	O	948-950
)	O	950-951
of	O	952-954
2	O	955-956
.	O	956-957
5	O	957-958
+	O	959-960
/	O	960-961
-	O	961-962
0	O	963-964
.	O	964-965
85	O	965-967
minutes	O	968-975
,	O	975-976
T	O	977-978
beta	O	979-983
1	O	984-985
/	O	985-986
2	O	986-987
of	O	988-990
25	O	991-993
.	O	993-994
6	O	994-995
+	O	996-997
/	O	997-998
-	O	998-999
6	O	1000-1001
.	O	1001-1002
5	O	1002-1003
minutes	O	1004-1011
,	O	1011-1012
and	O	1013-1016
T	O	1017-1018
1	O	1019-1020
/	O	1020-1021
2	O	1021-1022
gamma	O	1023-1028
of	O	1029-1031
23	O	1032-1034
.	O	1034-1035
6	O	1035-1036
+	O	1037-1038
/	O	1038-1039
-	O	1039-1040
7	O	1041-1042
.	O	1042-1043
6	O	1043-1044
hours	O	1045-1050
.	O	1050-1051

The	O	1052-1055
area	O	1056-1060
under	O	1061-1066
the	O	1067-1070
curve	O	1071-1076
was	O	1077-1080
537	O	1081-1084
+	O	1085-1086
/	O	1086-1087
-	O	1087-1088
149	O	1089-1092
ng	O	1093-1095
/	O	1095-1096
ml	O	1096-1098
x	O	1099-1100
hours	O	1101-1106
,	O	1106-1107
volume	O	1108-1114
of	O	1115-1117
distribution	O	1118-1130
(	O	1131-1132
Vd	O	1132-1134
)	O	1134-1135
3504	O	1136-1140
+	O	1141-1142
/	O	1142-1143
-	O	1143-1144
644	O	1145-1148
l	O	1149-1150
/	O	1150-1151
m2	O	1151-1153
,	O	1153-1154
and	O	1155-1158
total	O	1159-1164
clearance	O	1165-1174
(	O	1175-1176
ClT	O	1176-1179
)	O	1179-1180
was	O	1181-1184
204	O	1185-1188
+	O	1189-1190
39	O	1191-1193
.	O	1193-1194
3	O	1191-1192
l	O	1196-1197
/	O	1197-1198
hour	O	1198-1202
/	O	1197-1198
m2	O	1203-1205
.	O	1205-1206

Adriamycinol	O	1207-1219
,	O	1219-1220
doxorubicin	O	1221-1232
,	O	1232-1233
adriamycinone	O	1234-1247
,	O	1247-1248
and	O	1249-1252
tetrahydropyranyladriamycinol	O	1253-1282
were	O	1283-1287
the	O	1288-1291
metabolites	O	1292-1303
detected	O	1304-1312
in	O	1313-1315
plasma	O	1316-1322
and	O	1323-1326
the	O	1327-1330
amount	O	1331-1337
of	O	1338-1340
doxorubicin	O	1341-1352
was	O	1353-1356
less	O	1357-1361
than	O	1362-1366
or	O	1367-1369
equal	O	1370-1375
to	O	1376-1378
10	O	1379-1381
%	O	1381-1382
of	O	1383-1385
the	O	1386-1389
total	O	1390-1395
metabolites	O	1396-1407
.	O	1407-1408

Urinary	O	1409-1416
excretion	O	1417-1426
of	O	1427-1429
Pirarubicin	O	1430-1441
in	O	1442-1444
the	O	1445-1448
first	O	1449-1454
24	O	1455-1457
hours	O	1458-1463
was	O	1464-1467
less	O	1468-1472
than	O	1473-1477
or	O	1478-1480
equal	O	1481-1486
to	O	1487-1489
10	O	1490-1492
%	O	1492-1493
.	O	1493-1494

Activity	O	1495-1503
was	O	1504-1507
noted	O	1508-1513
in	O	1514-1516
mesothelioma	B	1517-1529
,	O	1529-1530
leiomyosarcoma	B	1531-1545
,	O	1545-1546
and	O	1547-1550
basal	B	1551-1556
cell	I	1557-1561
carcinoma	I	1562-1571
.	O	1571-1572

The	O	1573-1576
recommended	O	1577-1588
starting	O	1589-1597
dose	O	1598-1602
for	O	1603-1606
Phase	O	1607-1612
II	O	1613-1615
trials	O	1616-1622
is	O	1623-1625
60	O	1626-1628
mg	O	1629-1631
/	O	1631-1632
m2	O	1632-1634
IV	O	1635-1637
bolus	O	1638-1643
every	O	1644-1649
3	O	1650-1651
weeks	O	1652-1657
.	O	1657-1658

Differential	O	0-12
effects	O	13-20
of	O	21-23
gamma	O	24-29
-	O	29-30
hexachlorocyclohexane	O	30-51
(	O	52-53
lindane	O	53-60
)	O	60-61
on	O	62-64
pharmacologically	O	65-82
-	O	82-83
induced	O	83-90
seizures	B	91-99
.	O	99-100

Gamma	O	101-106
-	O	106-107
hexachlorocyclohexane	O	107-128
(	O	129-130
gamma	O	130-135
-	O	135-136
HCH	O	136-139
)	O	139-140
,	O	140-141
the	O	142-145
active	O	146-152
ingredient	O	153-163
of	O	164-166
the	O	167-170
insecticide	O	171-182
lindane	O	183-190
,	O	190-191
has	O	192-195
been	O	196-200
shown	O	201-206
to	O	207-209
decrease	O	210-218
seizure	B	219-226
threshold	O	227-236
to	O	237-239
pentylenetrazol	O	240-255
(	O	256-257
PTZ	O	257-260
)	O	260-261
3	O	262-263
h	O	264-265
after	O	266-271
exposure	O	272-280
to	O	281-283
gamma	O	284-289
-	O	289-290
HCH	O	290-293
and	O	294-297
conversely	O	298-308
increase	O	309-317
threshold	O	318-327
to	O	328-330
PTZ	O	331-334
-	O	334-335
induced	O	335-342
seizures	B	343-351
24	O	352-354
h	O	355-356
after	O	357-362
exposure	O	363-371
to	O	372-374
gamma	O	375-380
-	O	380-381
HCH	O	381-384
(	O	385-386
Vohland	O	386-393
et	O	394-396
al	O	397-399
.	O	399-400
1981	O	401-405
)	O	405-406
.	O	406-407

In	O	408-410
this	O	411-415
study	O	416-421
,	O	421-422
the	O	423-426
severity	O	427-435
of	O	436-438
response	O	439-447
to	O	448-450
other	O	451-456
seizure	B	457-464
-	O	464-465
inducing	O	465-473
agents	O	474-480
was	O	481-484
tested	O	485-491
in	O	492-494
mice	O	495-499
1	O	500-501
and	O	502-505
24	O	506-508
h	O	509-510
after	O	511-516
intraperitoneal	O	517-532
administration	O	533-547
of	O	548-550
80	O	551-553
mg	O	554-556
/	O	556-557
kg	O	557-559
gamma	O	560-565
-	O	565-566
HCH	O	566-569
.	O	569-570

One	O	571-574
hour	O	575-579
after	O	580-585
the	O	586-589
administration	O	590-604
of	O	605-607
gamma	O	608-613
-	O	613-614
HCH	O	614-617
,	O	617-618
the	O	619-622
activity	O	623-631
of	O	632-634
seizure	B	635-642
-	O	642-643
inducing	O	643-651
agents	O	652-658
was	O	659-662
increased	O	663-672
,	O	672-673
regardless	O	674-684
of	O	685-687
their	O	688-693
mechanism	O	694-703
,	O	703-704
while	O	705-710
24	O	711-713
h	O	714-715
after	O	716-721
gamma	O	722-727
-	O	727-728
HCH	O	728-731
a	O	732-733
differential	O	734-746
response	O	747-755
was	O	756-759
observed	O	760-768
.	O	768-769

Seizure	B	770-777
activity	O	778-786
due	O	787-790
to	O	791-793
PTZ	O	794-797
and	O	798-801
picrotoxin	O	802-812
(	O	813-814
PTX	O	814-817
)	O	817-818
was	O	819-822
significantly	O	823-836
decreased	O	837-846
;	O	846-847
however	O	848-855
,	O	855-856
seizure	B	857-864
activity	O	865-873
due	O	874-877
to	O	878-880
3	O	881-882
-	O	882-883
mercaptopropionic	O	883-900
acid	O	901-905
(	O	906-907
MPA	O	907-910
)	O	910-911
,	O	911-912
bicuculline	O	913-924
(	O	925-926
BCC	O	926-929
)	O	929-930
,	O	930-931
methyl	O	932-938
6	O	939-940
,	O	940-941
7	O	941-942
-	O	942-943
dimethoxy	O	943-952
-	O	942-943
4	O	953-954
-	O	942-943
ethyl	O	955-960
-	O	942-943
B	O	961-962
-	O	942-943
carboline	O	963-972
-	O	942-943
3	O	973-974
-	O	942-943
carboxylate	O	975-986
(	O	987-988
DMCM	O	988-992
)	O	992-993
,	O	993-994
or	O	995-997
strychnine	O	998-1008
(	O	1009-1010
STR	O	1010-1013
)	O	1013-1014
was	O	1015-1018
not	O	1019-1022
different	O	1023-1032
from	O	1033-1037
control	O	1038-1045
.	O	1045-1046

In	O	1047-1049
vitro	O	1050-1055
,	O	1055-1056
gamma	O	1057-1062
-	O	1062-1063
HCH	O	1063-1066
,	O	1066-1067
pentylenetetrazol	O	1068-1085
and	O	1086-1089
picrotoxin	O	1090-1100
were	O	1101-1105
shown	O	1106-1111
to	O	1112-1114
inhibit	O	1115-1122
3H	O	1123-1125
-	O	1125-1126
TBOB	O	1126-1130
binding	O	1131-1138
in	O	1139-1141
mouse	O	1142-1147
whole	O	1148-1153
brain	O	1154-1159
,	O	1159-1160
with	O	1161-1165
IC50	O	1166-1170
values	O	1171-1177
of	O	1178-1180
4	O	1181-1182
.	O	1182-1183
6	O	1183-1184
,	O	1184-1185
404	O	1186-1189
and	O	1190-1193
9	O	1194-1195
.	O	1195-1196
4	O	1196-1197
microM	O	1198-1204
,	O	1204-1205
respectively	O	1206-1218
.	O	1218-1219

MPA	O	1220-1223
,	O	1223-1224
BCC	O	1225-1228
,	O	1228-1229
DMCM	O	1230-1234
,	O	1234-1235
and	O	1236-1239
STR	O	1240-1243
showed	O	1244-1250
no	O	1251-1253
inhibition	O	1254-1264
of	O	1265-1267
3H	O	1268-1270
-	O	1270-1271
TBOB	O	1271-1275
(	O	1276-1277
t	O	1277-1278
-	O	1278-1279
butyl	O	1279-1284
bicyclo	O	1285-1292
-	O	1292-1293
orthobenzoate	O	1293-1306
)	O	1306-1307
binding	O	1308-1315
at	O	1316-1318
concentrations	O	1319-1333
of	O	1334-1336
100	O	1337-1340
micron	O	1341-1347
.	O	1347-1348

The	O	1349-1352
pharmacological	O	1353-1368
challenge	O	1369-1378
data	O	1379-1383
suggest	O	1384-1391
that	O	1392-1396
tolerance	O	1397-1406
may	O	1407-1410
occur	O	1411-1416
to	O	1417-1419
seizure	B	1420-1427
activity	O	1428-1436
induced	O	1437-1444
by	O	1445-1447
PTZ	O	1448-1451
and	O	1452-1455
PTX	O	1456-1459
24	O	1460-1462
h	O	1463-1464
after	O	1465-1470
gamma	O	1471-1476
-	O	1476-1477
HCH	O	1477-1480
,	O	1480-1481
since	O	1482-1487
the	O	1488-1491
response	O	1492-1500
to	O	1501-1503
only	O	1504-1508
these	O	1509-1514
two	O	1515-1518
seizure	B	1519-1526
-	O	1526-1527
inducing	O	1527-1535
agents	O	1536-1542
is	O	1543-1545
decreased	O	1546-1555
.	O	1555-1556

The	O	1557-1560
in	O	1561-1563
vitro	O	1564-1569
data	O	1570-1574
suggest	O	1575-1582
that	O	1583-1587
the	O	1588-1591
site	O	1592-1596
responsible	O	1597-1608
for	O	1609-1612
the	O	1613-1616
decrease	O	1617-1625
in	O	1626-1628
seizure	B	1629-1636
activity	O	1637-1645
24	O	1646-1648
h	O	1649-1650
after	O	1651-1656
gamma	O	1657-1662
-	O	1662-1663
HCH	O	1663-1666
may	O	1667-1670
be	O	1671-1673
the	O	1674-1677
GABA	O	1678-1682
-	O	1682-1683
A	O	1679-1680
receptor	O	1685-1693
-	O	1693-1694
linked	O	1694-1700
chloride	O	1701-1709
channel	O	1710-1717
.	O	1717-1718

Severe	O	0-6
ocular	B	7-13
and	I	14-17
orbital	I	18-25
toxicity	I	26-34
after	O	35-40
intracarotid	O	41-53
injection	O	54-63
of	O	64-66
carboplatin	O	67-78
for	O	79-82
recurrent	O	83-92
glioblastomas	B	93-106
.	O	106-107

BACKGROUND	O	108-118
:	O	118-119
Glioblastoma	B	120-132
is	O	133-135
a	O	136-137
malignant	B	138-147
tumor	I	148-153
that	O	154-158
occurs	O	159-165
in	O	166-168
the	O	169-172
cerebrum	O	173-181
during	O	182-188
adulthood	O	189-198
.	O	198-199

With	O	200-204
current	O	205-212
treatment	O	213-222
regimens	O	223-231
including	O	232-241
combined	O	242-250
surgery	O	251-258
,	O	258-259
radiation	O	260-269
and	O	270-273
chemotherapy	O	274-286
,	O	286-287
the	O	288-291
average	O	292-299
life	O	300-304
expectancy	O	305-315
of	O	316-318
the	O	319-322
patients	O	323-331
is	O	332-334
limited	O	335-342
to	O	343-345
approximately	O	346-359
1	O	360-361
year	O	362-366
.	O	366-367

Therefore	O	368-377
,	O	377-378
patients	O	379-387
with	O	388-392
glioblastoma	B	393-405
sometimes	O	406-415
have	O	416-420
intracarotid	O	421-433
injection	O	434-443
of	O	444-446
carcinostatics	O	447-461
added	O	462-467
to	O	468-470
the	O	471-474
treatment	O	475-484
regimen	O	485-492
.	O	492-493

Generally	O	494-503
,	O	503-504
carboplatin	O	505-516
is	O	517-519
said	O	520-524
to	O	525-527
have	O	528-532
milder	O	533-539
side	O	540-544
effects	O	545-552
than	O	553-557
cisplatin	O	558-567
,	O	567-568
whose	O	569-574
ocular	B	575-581
and	I	582-585
orbital	I	586-593
toxicity	I	594-602
are	O	603-606
well	O	607-611
known	O	612-617
.	O	617-618

However	O	619-626
,	O	626-627
we	O	628-630
experienced	O	631-642
a	O	643-644
case	O	645-649
of	O	650-652
severe	O	653-659
ocular	B	660-666
and	I	667-670
orbital	I	671-678
toxicity	I	679-687
after	O	688-693
intracarotid	O	694-706
injection	O	707-716
of	O	717-719
carboplatin	O	720-731
,	O	731-732
which	O	733-738
is	O	739-741
infrequently	O	742-754
reported	O	755-763
.	O	763-764

CASE	O	765-769
:	O	769-770
A	O	771-772
58	O	773-775
-	O	775-776
year	O	776-780
-	O	775-776
old	O	781-784
man	O	785-788
received	O	789-797
an	O	798-800
intracarotid	O	801-813
injection	O	814-823
of	O	824-826
carboplatin	O	827-838
for	O	839-842
recurrent	O	843-852
glioblastomas	B	853-866
in	O	867-869
his	O	870-873
left	O	874-878
temporal	O	879-887
lobe	O	888-892
.	O	892-893

He	O	894-896
complained	O	897-907
of	O	908-910
pain	B	911-915
and	I	916-919
visual	I	920-926
disturbance	I	927-938
in	I	939-941
the	I	942-945
ipsilateral	I	946-957
eye	I	958-961
30	O	962-964
h	O	965-966
after	O	967-972
the	O	973-976
injection	O	977-986
.	O	986-987

Various	O	988-995
ocular	O	996-1002
symptoms	O	1003-1011
and	O	1012-1015
findings	O	1016-1024
caused	O	1025-1031
by	O	1032-1034
carboplatin	O	1035-1046
toxicity	B	1047-1055
were	O	1056-1060
seen	O	1061-1065
.	O	1065-1066

RESULTS	O	1067-1074
:	O	1074-1075
He	O	1076-1078
was	O	1079-1082
treated	O	1083-1090
with	O	1091-1095
intravenous	O	1096-1107
administration	O	1108-1122
of	O	1123-1125
corticosteroids	O	1126-1141
and	O	1142-1145
glycerin	O	1146-1154
for	O	1155-1158
6	O	1159-1160
days	O	1161-1165
after	O	1166-1171
the	O	1172-1175
injection	O	1176-1185
.	O	1185-1186

Although	O	1187-1195
the	O	1196-1199
intraocular	O	1200-1211
pressure	O	1212-1220
elevation	O	1221-1230
caused	O	1231-1237
by	O	1238-1240
secondary	O	1241-1250
acute	O	1251-1256
angle	O	1257-1262
-	O	1262-1263
closure	O	1263-1270
glaucoma	B	1271-1279
decreased	O	1280-1289
and	O	1290-1293
ocular	B	1294-1300
pain	I	1301-1305
diminished	O	1306-1316
,	O	1316-1317
inexorable	O	1318-1328
papilledema	B	1329-1340
and	O	1341-1344
exudative	O	1345-1354
retinal	B	1355-1362
detachment	I	1363-1373
continued	O	1374-1383
for	O	1384-1387
3	O	1388-1389
weeks	O	1390-1395
.	O	1395-1396

Finally	O	1397-1404
,	O	1404-1405
6	O	1406-1407
weeks	O	1408-1413
later	O	1414-1419
,	O	1419-1420
diffuse	O	1421-1428
chorioretinal	B	1429-1442
atrophy	I	1443-1450
with	O	1451-1455
optic	B	1456-1461
atrophy	I	1462-1469
occurred	O	1470-1478
and	O	1479-1482
the	O	1483-1486
vision	O	1487-1493
in	O	1494-1496
his	O	1497-1500
left	O	1501-1505
eye	O	1506-1509
was	O	1510-1513
lost	O	1514-1518
.	O	1518-1519

CONCLUSION	O	1520-1530
:	O	1530-1531
When	O	1532-1536
performing	O	1537-1547
intracarotid	O	1548-1560
injection	O	1561-1570
of	O	1571-1573
carboplatin	O	1574-1585
,	O	1585-1586
we	O	1587-1589
must	O	1590-1594
be	O	1595-1597
aware	O	1598-1603
of	O	1604-1606
its	O	1607-1610
potentially	O	1611-1622
blinding	O	1623-1631
ocular	B	1632-1638
toxicity	I	1639-1647
.	O	1647-1648

It	O	1649-1651
is	O	1652-1654
recommended	O	1655-1666
that	O	1667-1671
further	O	1672-1679
studies	O	1680-1687
and	O	1688-1691
investigations	O	1692-1706
are	O	1707-1710
undertaken	O	1711-1721
in	O	1722-1724
the	O	1725-1728
effort	O	1729-1735
to	O	1736-1738
minimize	O	1739-1747
such	O	1748-1752
severe	O	1753-1759
side	O	1760-1764
effects	O	1765-1772
.	O	1772-1773

Phase	O	0-5
II	O	6-8
study	O	9-14
of	O	15-17
the	O	18-21
amsacrine	O	22-31
analogue	O	32-40
CI	O	41-43
-	O	43-44
921	O	44-47
(	O	48-49
NSC	O	49-52
343499	O	53-59
)	O	59-60
in	O	61-63
non	B	64-67
-	I	67-68
small	I	68-73
cell	I	74-78
lung	I	79-83
cancer	I	84-90
.	O	90-91

CI	O	92-94
-	O	94-95
921	O	95-98
(	O	99-100
NSC	O	100-103
343499	O	104-110
;	O	110-111
9	O	112-113
-	O	113-114
[	O	114-115
[	O	114-115
2	O	116-117
-	O	113-114
methoxy	O	118-125
-	O	113-114
4	O	126-127
-	O	113-114
[	O	114-115
(	O	129-130
methylsulphonyl	O	130-145
)	O	145-146
amino	O	146-151
]	O	151-152
phenyl	O	152-158
]	O	151-152
amino	O	146-151
]	O	151-152
-	O	166-167
N	O	167-168
,	O	168-169
5	O	169-170
-	O	166-167
dimethyl	O	171-179
-	O	166-167
4	O	181-182
-	O	182-183
acridinecarboxamide	O	183-202
)	O	202-203
is	O	204-206
a	O	207-208
topoisomerase	O	209-222
II	O	223-225
poison	O	226-232
with	O	233-237
high	O	238-242
experimental	O	243-255
antitumour	O	256-266
activity	O	267-275
.	O	275-276

It	O	277-279
was	O	280-283
administered	O	284-296
by	O	297-299
15	O	300-302
min	O	303-306
infusion	O	307-315
to	O	316-318
16	O	319-321
evaluable	O	322-331
patients	O	332-340
with	O	341-345
non	B	346-349
-	I	349-350
small	I	350-355
cell	I	356-360
lung	I	361-365
cancer	I	366-372
(	O	373-374
NSCLC	B	374-379
)	O	379-380
(	O	381-382
7	O	382-383
with	O	384-388
no	O	389-391
prior	O	392-397
treatment	O	398-407
,	O	407-408
9	O	409-410
patients	O	411-419
in	O	420-422
relapse	O	423-430
following	O	431-440
surgery	O	441-448
/	O	448-449
radiotherapy	O	449-461
)	O	461-462
at	O	463-465
a	O	466-467
dose	O	468-472
(	O	473-474
648	O	474-477
mg	O	478-480
/	O	480-481
m2	O	481-483
divided	O	484-491
over	O	492-496
3	O	497-498
days	O	499-503
,	O	503-504
repeated	O	505-513
every	O	514-519
3	O	520-521
weeks	O	522-527
)	O	527-528
determined	O	529-539
by	O	540-542
phase	O	543-548
I	O	549-550
trial	O	551-556
.	O	556-557

Patients	O	558-566
had	O	567-570
a	O	571-572
median	O	573-579
performance	O	580-591
status	O	592-598
of	O	599-601
1	O	602-603
(	O	604-605
WHO	O	605-608
)	O	608-609
,	O	609-610
and	O	611-614
median	O	615-621
age	O	622-625
of	O	626-628
61	O	629-631
years	O	632-637
.	O	637-638

The	O	639-642
histology	O	643-652
comprised	O	653-662
squamous	B	663-671
carcinoma	I	672-681
(	O	682-683
11	O	683-685
)	O	685-686
,	O	686-687
adenocarcinoma	B	688-702
(	O	703-704
1	O	704-705
)	O	705-706
,	O	706-707
mixed	O	708-713
histology	O	714-723
(	O	724-725
2	O	725-726
)	O	726-727
,	O	727-728
bronchio	B	729-737
-	I	737-738
alveolar	I	738-746
carcinoma	I	747-756
(	O	757-758
1	O	758-759
)	O	759-760
and	O	761-764
large	O	765-770
cell	O	771-775
undifferentiated	B	776-792
carcinoma	I	793-802
(	O	803-804
1	O	804-805
)	O	805-806
.	O	806-807

Neutropenia	B	808-819
grade	O	820-825
greater	O	826-833
than	O	834-838
or	O	839-841
equal	O	842-847
to	O	848-850
3	O	851-852
was	O	853-856
seen	O	857-861
in	O	862-864
15	O	865-867
patients	O	868-876
,	O	876-877
infections	B	878-888
with	O	889-893
recovery	O	894-902
in	O	903-905
3	O	906-907
,	O	907-908
and	O	909-912
grand	O	913-918
mal	O	919-922
seizures	B	923-931
in	O	932-934
1	O	935-936
patient	O	937-944
.	O	944-945

Grade	O	946-951
less	O	952-956
than	O	957-961
or	O	962-964
equal	O	965-970
to	O	971-973
2	O	974-975
nausea	B	976-982
and	O	983-986
vomiting	B	987-995
occurred	O	996-1004
in	O	1005-1007
66	O	1008-1010
%	O	1010-1011
courses	O	1012-1019
and	O	1020-1023
phlebitis	B	1024-1033
in	O	1034-1036
the	O	1037-1040
infusion	O	1041-1049
arm	O	1050-1053
in	O	1054-1056
37	O	1057-1059
%	O	1059-1060
.	O	1060-1061
1	O	1062-1063
patient	O	1064-1071
with	O	1072-1076
squamous	B	1077-1085
cell	I	1086-1090
carcinoma	I	1091-1100
achieved	O	1101-1109
a	O	1110-1111
partial	O	1112-1119
response	O	1120-1128
lasting	O	1129-1136
5	O	1137-1138
months	O	1139-1145
.	O	1145-1146

Further	O	1147-1154
testing	O	1155-1162
in	O	1163-1165
this	O	1166-1170
and	O	1171-1174
other	O	1175-1180
tumour	B	1181-1187
types	O	1188-1193
using	O	1194-1199
multiple	O	1200-1208
daily	O	1209-1214
schedules	O	1215-1224
is	O	1225-1227
warranted	O	1228-1237
.	O	1237-1238

Alpha	O	0-5
-	O	5-6
lipoic	O	6-12
acid	O	13-17
prevents	O	18-26
mitochondrial	B	27-40
damage	I	41-47
and	O	48-51
neurotoxicity	B	52-65
in	O	66-68
experimental	O	69-81
chemotherapy	O	82-94
neuropathy	B	95-105
.	O	105-106

The	O	107-110
study	O	111-116
investigates	O	117-129
if	O	130-132
alpha	O	133-138
-	O	138-139
lipoic	O	139-145
acid	O	146-150
is	O	151-153
neuroprotective	O	154-169
against	O	170-177
chemotherapy	O	178-190
induced	O	191-198
neurotoxicity	B	199-212
,	O	212-213
if	O	214-216
mitochondrial	B	217-230
damage	I	231-237
plays	O	238-243
a	O	244-245
critical	O	246-254
role	O	255-259
in	O	260-262
toxic	B	263-268
neurodegenerative	I	269-286
cascade	I	287-294
,	O	294-295
and	O	296-299
if	O	300-302
neuroprotective	O	303-318
effects	O	319-326
of	O	327-329
alpha	O	330-335
-	O	335-336
lipoic	O	336-342
acid	O	343-347
depend	O	348-354
on	O	355-357
mitochondria	O	358-370
protection	O	371-381
.	O	381-382

We	O	383-385
used	O	386-390
an	O	391-393
in	O	394-396
vitro	O	397-402
model	O	403-408
of	O	409-411
chemotherapy	O	412-424
induced	O	425-432
peripheral	B	433-443
neuropathy	I	444-454
that	O	455-459
closely	O	460-467
mimic	O	468-473
the	O	474-477
in	O	478-480
vivo	O	481-485
condition	O	486-495
by	O	496-498
exposing	O	499-507
primary	O	508-515
cultures	O	516-524
of	O	525-527
dorsal	O	528-534
root	O	535-539
ganglion	O	540-548
(	O	549-550
DRG	O	550-553
)	O	553-554
sensory	O	555-562
neurons	O	563-570
to	O	571-573
paclitaxel	O	574-584
and	O	585-588
cisplatin	O	589-598
,	O	598-599
two	O	600-603
widely	O	604-610
used	O	611-615
and	O	616-619
highly	O	620-626
effective	O	627-636
chemotherapeutic	O	637-653
drugs	O	654-659
.	O	659-660

This	O	661-665
approach	O	666-674
allowed	O	675-682
investigating	O	683-696
the	O	697-700
efficacy	O	701-709
of	O	710-712
alpha	O	713-718
-	O	718-719
lipoic	O	719-725
acid	O	726-730
in	O	731-733
preventing	O	734-744
axonal	B	745-751
damage	I	752-758
and	O	759-762
apoptosis	O	763-772
and	O	773-776
the	O	777-780
function	O	781-789
and	O	790-793
ultrastructural	O	794-809
morphology	O	810-820
of	O	821-823
mitochondria	O	824-836
after	O	837-842
exposure	O	843-851
to	O	852-854
toxic	O	855-860
agents	O	861-867
and	O	868-871
alpha	O	872-877
-	O	877-878
lipoic	O	878-884
acid	O	885-889
.	O	889-890

Our	O	891-894
results	O	895-902
demonstrate	O	903-914
that	O	915-919
both	O	920-924
cisplatin	O	925-934
and	O	935-938
paclitaxel	O	939-949
cause	O	950-955
early	O	956-961
mitochondrial	B	962-975
impairment	I	976-986
with	O	987-991
loss	O	992-996
of	O	997-999
membrane	O	1000-1008
potential	O	1009-1018
and	O	1019-1022
induction	O	1023-1032
of	O	1033-1035
autophagic	O	1036-1046
vacuoles	O	1047-1055
in	O	1056-1058
neurons	O	1059-1066
.	O	1066-1067

Alpha	O	1068-1073
-	O	1073-1074
lipoic	O	1074-1080
acid	O	1081-1085
exerts	O	1086-1092
neuroprotective	O	1093-1108
effects	O	1109-1116
against	O	1117-1124
chemotherapy	O	1125-1137
induced	O	1138-1145
neurotoxicity	B	1146-1159
in	O	1160-1162
sensory	O	1163-1170
neurons	O	1171-1178
:	O	1178-1179
it	O	1180-1182
rescues	O	1183-1190
the	O	1191-1194
mitochondrial	B	1195-1208
toxicity	I	1209-1217
and	O	1218-1221
induces	O	1222-1229
the	O	1230-1233
expression	O	1234-1244
of	O	1245-1247
frataxin	O	1248-1256
,	O	1256-1257
an	O	1258-1260
essential	O	1261-1270
mitochondrial	O	1271-1284
protein	O	1285-1292
with	O	1293-1297
anti	O	1298-1302
-	O	1302-1303
oxidant	O	1303-1310
and	O	1311-1314
chaperone	O	1315-1324
properties	O	1325-1335
.	O	1335-1336

In	O	1337-1339
conclusion	O	1340-1350
mitochondrial	B	1351-1364
toxicity	I	1365-1373
is	O	1374-1376
an	O	1377-1379
early	O	1380-1385
common	O	1386-1392
event	O	1393-1398
both	O	1399-1403
in	O	1404-1406
paclitaxel	O	1407-1417
and	O	1418-1421
cisplatin	O	1422-1431
induced	O	1432-1439
neurotoxicity	B	1440-1453
.	O	1453-1454

Alpha	O	1455-1460
-	O	1460-1461
lipoic	O	1461-1467
acid	O	1468-1472
protects	O	1473-1481
sensory	O	1482-1489
neurons	O	1490-1497
through	O	1498-1505
its	O	1506-1509
anti	O	1510-1514
-	O	1514-1515
oxidant	O	1515-1522
and	O	1523-1526
mitochondrial	O	1527-1540
regulatory	O	1541-1551
functions	O	1552-1561
,	O	1561-1562
possibly	O	1563-1571
inducing	O	1572-1580
the	O	1581-1584
expression	O	1585-1595
of	O	1596-1598
frataxin	O	1599-1607
.	O	1607-1608

These	O	1609-1614
findings	O	1615-1623
suggest	O	1624-1631
that	O	1632-1636
alpha	O	1637-1642
-	O	1642-1643
lipoic	O	1643-1649
acid	O	1650-1654
might	O	1655-1660
reduce	O	1661-1667
the	O	1668-1671
risk	O	1672-1676
of	O	1677-1679
developing	O	1680-1690
peripheral	B	1691-1701
nerve	I	1702-1707
toxicity	I	1708-1716
in	O	1717-1719
patients	O	1720-1728
undergoing	O	1729-1739
chemotherapy	O	1740-1752
and	O	1753-1756
encourage	O	1757-1766
further	O	1767-1774
confirmatory	O	1775-1787
clinical	O	1788-1796
trials	O	1797-1803
.	O	1803-1804

Optimising	O	0-10
stroke	B	11-17
prevention	O	18-28
in	O	29-31
non	O	32-35
-	O	35-36
valvular	O	36-44
atrial	B	45-51
fibrillation	I	52-64
.	O	64-65

Atrial	B	66-72
fibrillation	I	73-85
is	O	86-88
associated	O	89-99
with	O	100-104
substantial	O	105-116
morbidity	O	117-126
and	O	127-130
mortality	O	131-140
.	O	140-141

Pooled	O	142-148
data	O	149-153
from	O	154-158
trials	O	159-165
comparing	O	166-175
antithrombotic	O	176-190
treatment	O	191-200
with	O	201-205
placebo	O	206-213
have	O	214-218
shown	O	219-224
that	O	225-229
warfarin	O	230-238
reduces	O	239-246
the	O	247-250
risk	O	251-255
of	O	256-258
stroke	B	259-265
by	O	266-268
62	O	269-271
%	O	271-272
,	O	272-273
and	O	274-277
that	O	278-282
aspirin	O	283-290
alone	O	291-296
reduces	O	297-304
the	O	305-308
risk	O	309-313
by	O	314-316
22	O	317-319
%	O	319-320
.	O	320-321

Overall	O	322-329
,	O	329-330
in	O	331-333
high	O	334-338
-	O	338-339
risk	O	339-343
patients	O	344-352
,	O	352-353
warfarin	O	354-362
is	O	363-365
superior	O	366-374
to	O	375-377
aspirin	O	378-385
in	O	386-388
preventing	O	389-399
strokes	B	400-407
,	O	407-408
with	O	409-413
a	O	414-415
relative	O	416-424
risk	O	425-429
reduction	O	430-439
of	O	440-442
36	O	443-445
%	O	445-446
.	O	446-447

Ximelagatran	O	448-460
,	O	460-461
an	O	462-464
oral	O	465-469
direct	O	470-476
thrombin	O	477-485
inhibitor	O	486-495
,	O	495-496
was	O	497-500
found	O	501-506
to	O	507-509
be	O	510-512
as	O	513-515
efficient	O	516-525
as	O	526-528
vitamin	O	529-536
K	O	537-538
antagonist	O	539-549
drugs	O	550-555
in	O	556-558
the	O	559-562
prevention	O	563-573
of	O	574-576
embolic	B	577-584
events	I	585-591
,	O	591-592
but	O	593-596
has	O	597-600
been	O	601-605
recently	O	606-614
withdrawn	O	615-624
because	O	625-632
of	O	633-635
abnormal	B	636-644
liver	I	645-650
function	I	651-659
tests	O	660-665
.	O	665-666

The	O	667-670
ACTIVE	O	671-677
-	O	677-678
W	O	678-679
(	O	680-681
Atrial	B	681-687
Fibrillation	I	688-700
Clopidogrel	O	701-712
Trial	O	713-718
with	O	719-723
Irbesartan	O	724-734
for	O	735-738
Prevention	O	739-749
of	O	750-752
Vascular	O	753-761
Events	O	762-768
)	O	768-769
study	O	770-775
has	O	776-779
demonstrated	O	780-792
that	O	793-797
warfarin	O	798-806
is	O	807-809
superior	O	810-818
to	O	819-821
platelet	O	822-830
therapy	O	831-838
(	O	839-840
clopidogrel	O	840-851
plus	O	852-856
aspirin	O	857-864
)	O	864-865
in	O	866-868
the	O	869-872
prevention	O	873-883
af	O	884-886
embolic	B	887-894
events	I	895-901
.	O	901-902

Idraparinux	O	903-914
,	O	914-915
a	O	916-917
Factor	O	918-924
Xa	O	925-927
inhibitor	O	928-937
,	O	937-938
is	O	939-941
being	O	942-947
evaluated	O	948-957
in	O	958-960
patients	O	961-969
with	O	970-974
atrial	B	975-981
fibrillation	I	982-994
.	O	994-995

Angiotensin	O	996-1007
-	O	1007-1008
converting	O	1008-1018
enzyme	O	1019-1025
inhibitors	O	1026-1036
and	O	1037-1040
angiotensin	O	1041-1052
II	O	1053-1055
receptor	O	1056-1064
-	O	1064-1065
blocking	O	1065-1073
drugs	O	1074-1079
hold	O	1080-1084
promise	O	1085-1092
in	O	1093-1095
atrial	B	1096-1102
fibrillation	I	1103-1115
through	O	1116-1123
cardiac	B	1124-1131
remodelling	I	1132-1143
.	O	1143-1144

Preliminary	O	1145-1156
studies	O	1157-1164
suggest	O	1165-1172
that	O	1173-1177
statins	O	1178-1185
could	O	1186-1191
interfere	O	1192-1201
with	O	1202-1206
the	O	1207-1210
risk	O	1211-1215
of	O	1216-1218
recurrence	O	1219-1229
after	O	1230-1235
electrical	O	1236-1246
cardioversion	O	1247-1260
.	O	1260-1261

Finally	O	1262-1269
,	O	1269-1270
percutaneous	O	1271-1283
methods	O	1284-1291
for	O	1292-1295
the	O	1296-1299
exclusion	O	1300-1309
of	O	1310-1312
left	O	1313-1317
atrial	O	1318-1324
appendage	O	1325-1334
are	O	1335-1338
under	O	1339-1344
investigation	O	1345-1358
in	O	1359-1361
high	O	1362-1366
-	O	1366-1367
risk	O	1367-1371
patients	O	1372-1380
.	O	1380-1381

Interaction	O	0-11
of	O	12-14
cyclosporin	O	15-26
A	O	27-28
with	O	29-33
antineoplastic	O	34-48
agents	O	49-55
.	O	55-56

A	O	57-58
synergistic	O	59-70
effect	O	71-77
of	O	78-80
etoposide	O	81-90
and	O	91-94
cyclosporin	O	95-106
A	O	107-108
was	O	109-112
observed	O	113-121
in	O	122-124
a	O	125-126
patient	O	127-134
with	O	135-139
acute	B	140-145
T	I	146-147
-	I	147-148
lymphocytic	I	148-159
leukemia	I	160-168
in	O	169-171
relapse	O	172-179
.	O	179-180

The	O	181-184
concomitant	O	185-196
administration	O	197-211
of	O	212-214
etoposide	O	215-224
and	O	225-228
cyclosporin	O	229-240
A	O	241-242
resulted	O	243-251
in	O	252-254
eradication	O	255-266
of	O	267-269
hitherto	O	270-278
refractory	O	279-289
leukemic	B	290-298
infiltration	I	299-311
of	O	312-314
bone	O	315-319
marrow	O	320-326
.	O	326-327

Severe	O	328-334
side	O	335-339
effects	O	340-347
in	O	348-350
terms	O	351-356
of	O	357-359
mental	O	360-366
confusion	B	367-376
and	O	377-380
progressive	O	381-392
hyperbilirubinemia	B	393-411
,	O	411-412
however	O	413-420
,	O	420-421
point	O	422-427
to	O	428-430
an	O	431-433
enhancement	O	434-445
not	O	446-449
only	O	450-454
of	O	455-457
antineoplastic	O	458-472
effects	O	473-480
but	O	481-484
also	O	485-489
of	O	490-492
toxicity	B	493-501
in	O	502-504
normal	O	505-511
tissues	O	512-519
.	O	519-520

This	O	521-525
report	O	526-532
demonstrates	O	533-545
for	O	546-549
the	O	550-553
first	O	554-559
time	O	560-564
that	O	565-569
the	O	570-573
pharmacodynamic	O	574-589
properties	O	590-600
of	O	601-603
cyclosporin	O	604-615
A	O	616-617
may	O	618-621
not	O	622-625
be	O	626-628
confined	O	629-637
strictly	O	638-646
to	O	647-649
suppression	O	650-661
of	O	662-664
normal	O	665-671
T	O	672-673
-	O	673-674
cell	O	674-678
functions	O	679-688
.	O	688-689

The	O	0-3
hematologic	O	4-15
effects	O	16-23
of	O	24-26
cefonicid	O	27-36
and	O	37-40
cefazedone	O	41-51
in	O	52-54
the	O	55-58
dog	O	59-62
:	O	62-63
a	O	64-65
potential	O	66-75
model	O	76-81
of	O	82-84
cephalosporin	O	85-98
hematotoxicity	B	99-113
in	O	114-116
man	O	117-120
.	O	120-121

Cephalosporin	O	122-135
antibiotics	O	136-147
cause	O	148-153
a	O	154-155
variety	O	156-163
of	O	164-166
hematologic	B	167-178
disturbances	I	179-191
in	O	192-194
man	O	195-198
,	O	198-199
the	O	200-203
pathogeneses	O	204-216
and	O	217-220
hematopathology	O	221-236
of	O	237-239
which	O	240-245
remain	O	246-252
poorly	O	253-259
characterized	O	260-273
.	O	273-274

There	O	275-280
is	O	281-283
a	O	284-285
need	O	286-290
for	O	291-294
a	O	295-296
well	O	297-301
-	O	301-302
defined	O	302-309
animal	O	310-316
model	O	317-322
in	O	323-325
which	O	326-331
these	O	332-337
blood	B	338-343
dyscrasias	I	344-354
can	O	355-358
be	O	359-361
studied	O	362-369
.	O	369-370

In	O	371-373
four	O	374-378
subacute	O	379-387
toxicity	B	388-396
studies	O	397-404
,	O	404-405
the	O	406-409
intravenous	O	410-421
administration	O	422-436
of	O	437-439
cefonicid	O	440-449
or	O	450-452
cefazedone	O	453-463
to	O	464-466
beagle	O	467-473
dogs	O	474-478
caused	O	479-485
a	O	486-487
dose	O	488-492
-	O	492-493
dependent	O	493-502
incidence	O	503-512
of	O	513-515
anemia	B	516-522
,	O	522-523
neutropenia	B	524-535
,	O	535-536
and	O	537-540
thrombocytopenia	B	541-557
after	O	558-563
1	O	564-565
-	O	565-566
3	O	566-567
months	O	568-574
of	O	575-577
treatment	O	578-587
.	O	587-588

A	O	589-590
nonregenerative	O	591-606
anemia	B	607-613
was	O	614-617
the	O	618-621
most	O	622-626
compromising	O	627-639
of	O	640-642
the	O	643-646
cytopenias	B	647-657
and	O	658-661
occurred	O	662-670
in	O	671-673
approximately	O	674-687
50	O	688-690
%	O	690-691
of	O	692-694
dogs	O	695-699
receiving	O	700-709
400	O	710-713
-	O	713-714
500	O	714-717
mg	O	718-720
/	O	720-721
kg	O	721-723
cefonicid	O	724-733
or	O	734-736
540	O	737-740
-	O	740-741
840	O	741-744
mg	O	745-747
/	O	747-748
kg	O	748-750
cefazedone	O	751-761
.	O	761-762

All	O	763-766
three	O	767-772
cytopenias	B	773-783
were	O	784-788
completely	O	789-799
reversible	O	800-810
following	O	811-820
cessation	O	821-830
of	O	831-833
treatment	O	834-843
;	O	843-844
the	O	845-848
time	O	849-853
required	O	854-862
for	O	863-866
recovery	O	867-875
of	O	876-878
the	O	879-882
erythron	O	883-891
(	O	892-893
approximately	O	893-906
1	O	907-908
month	O	909-914
)	O	914-915
was	O	916-919
considerably	O	920-932
longer	O	933-939
than	O	940-944
that	O	945-949
of	O	950-952
the	O	953-956
granulocytes	O	957-969
and	O	970-973
platelets	O	974-983
(	O	984-985
hours	O	985-990
to	O	991-993
a	O	994-995
few	O	996-999
days	O	1000-1004
)	O	1004-1005
.	O	1005-1006

Upon	O	1007-1011
rechallenge	O	1012-1023
with	O	1024-1028
either	O	1029-1035
cephalosporin	O	1036-1049
,	O	1049-1050
the	O	1051-1054
hematologic	B	1055-1066
syndrome	I	1067-1075
was	O	1076-1079
reproduced	O	1080-1090
in	O	1091-1093
most	O	1094-1098
dogs	O	1099-1103
tested	O	1104-1110
;	O	1110-1111
cefonicid	O	1112-1121
(	O	1122-1123
but	O	1123-1126
not	O	1127-1130
cefazedone	O	1131-1141
)	O	1141-1142
-	O	1142-1143
treated	O	1143-1150
dogs	O	1151-1155
showed	O	1156-1162
a	O	1163-1164
substantially	O	1165-1178
reduced	O	1179-1186
induction	O	1187-1196
period	O	1197-1203
(	O	1204-1205
15	O	1205-1207
+	O	1208-1209
/	O	1209-1210
-	O	1210-1211
5	O	1212-1213
days	O	1214-1218
)	O	1218-1219
compared	O	1220-1228
to	O	1229-1231
that	O	1232-1236
of	O	1237-1239
the	O	1240-1243
first	O	1244-1249
exposure	O	1250-1258
to	O	1259-1261
the	O	1262-1265
drug	O	1266-1270
(	O	1271-1272
61	O	1272-1274
+	O	1275-1276
/	O	1276-1277
-	O	1277-1278
24	O	1279-1281
days	O	1282-1286
)	O	1286-1287
.	O	1287-1288

This	O	1289-1293
observation	O	1294-1305
,	O	1305-1306
along	O	1307-1312
with	O	1313-1317
the	O	1318-1321
rapid	O	1322-1327
rate	O	1328-1332
of	O	1333-1335
decline	O	1336-1343
in	O	1344-1346
red	O	1347-1350
cell	O	1351-1355
mass	O	1356-1360
parameters	O	1361-1371
of	O	1372-1374
affected	O	1375-1383
dogs	O	1384-1388
,	O	1388-1389
suggests	O	1390-1398
that	O	1399-1403
a	O	1404-1405
hemolytic	B	1406-1415
component	O	1416-1425
complicated	O	1426-1437
the	O	1438-1441
red	O	1442-1445
cell	O	1446-1450
production	O	1451-1461
problem	O	1462-1469
and	O	1470-1473
that	O	1474-1478
multiple	O	1479-1487
toxicologic	O	1488-1499
mechanisms	O	1500-1510
contributed	O	1511-1522
to	O	1523-1525
the	O	1526-1529
cytopenia	B	1530-1539
.	O	1539-1540

We	O	1541-1543
conclude	O	1544-1552
that	O	1553-1557
the	O	1558-1561
administration	O	1562-1576
of	O	1577-1579
high	O	1580-1584
doses	O	1585-1590
of	O	1591-1593
cefonicid	O	1594-1603
or	O	1604-1606
cefazedone	O	1607-1617
to	O	1618-1620
dogs	O	1621-1625
can	O	1626-1629
induce	O	1630-1636
hematotoxicity	B	1637-1651
similar	O	1652-1659
to	O	1660-1662
the	O	1663-1666
cephalosporin	O	1667-1680
-	O	1680-1681
induced	O	1681-1688
blood	B	1689-1694
dyscrasias	I	1695-1705
described	O	1706-1715
in	O	1716-1718
man	O	1719-1722
and	O	1723-1726
thus	O	1727-1731
provides	O	1732-1740
a	O	1741-1742
useful	O	1743-1749
model	O	1750-1755
for	O	1756-1759
studying	O	1760-1768
the	O	1769-1772
mechanisms	O	1773-1783
of	O	1784-1786
these	O	1787-1792
disorders	O	1793-1802
.	O	1802-1803

A	O	0-1
pyridoxine	O	2-12
-	O	12-13
dependent	O	13-22
behavioral	B	23-33
disorder	I	34-42
unmasked	O	43-51
by	O	52-54
isoniazid	O	55-64
.	O	64-65

A	O	66-67
3	O	68-69
-	O	69-70
year	O	70-74
-	O	69-70
old	O	75-78
girl	O	79-83
had	O	84-87
behavioral	B	88-98
deterioration	I	99-112
,	O	112-113
with	O	114-118
hyperkinesis	B	119-131
,	O	131-132
irritability	B	133-145
,	O	145-146
and	O	147-150
sleeping	B	151-159
difficulties	I	160-172
after	O	173-178
the	O	179-182
therapeutic	O	183-194
administration	O	195-209
of	O	210-212
isoniazid	O	213-222
.	O	222-223

The	O	224-227
administration	O	228-242
of	O	243-245
pharmacologic	O	246-259
doses	O	260-265
of	O	266-268
pyridoxine	O	269-279
hydrochloride	O	280-293
led	O	294-297
to	O	298-300
a	O	301-302
disappearance	O	303-316
of	O	317-319
symptoms	O	320-328
.	O	328-329

After	O	330-335
discontinuing	O	336-349
isoniazid	O	350-359
therapy	O	360-367
a	O	368-369
similar	O	370-377
pattern	O	378-385
of	O	386-388
behavior	O	389-397
was	O	398-401
noted	O	402-407
that	O	408-412
was	O	413-416
controlled	O	417-427
by	O	428-430
pyridoxine	O	431-441
.	O	441-442

A	O	443-444
placebo	O	445-452
had	O	453-456
no	O	457-459
effect	O	460-466
,	O	466-467
but	O	468-471
niacinamide	O	472-483
was	O	484-487
as	O	488-490
effective	O	491-500
as	O	501-503
pyridoxine	O	504-514
.	O	514-515

Periodic	O	516-524
withdrawal	O	525-535
of	O	536-538
pyridoxine	O	539-549
was	O	550-553
associated	O	554-564
with	O	565-569
return	O	570-576
of	O	577-579
the	O	580-583
hyperkinesis	B	584-596
.	O	596-597

The	O	598-601
level	O	602-607
of	O	608-610
pyridoxal	O	611-620
in	O	621-623
the	O	624-627
blood	O	628-633
was	O	634-637
normal	O	638-644
during	O	645-651
the	O	652-655
periods	O	656-663
of	O	664-666
relapse	O	667-674
.	O	674-675

Metabolic	O	676-685
studies	O	686-693
suggested	O	694-703
a	O	704-705
block	O	706-711
in	O	712-714
the	O	715-718
kynurenine	O	719-729
pathway	O	730-737
of	O	738-740
tryptophan	O	741-751
metabolism	O	752-762
.	O	762-763

The	O	764-767
patient	O	768-775
has	O	776-779
been	O	780-784
followed	O	785-793
for	O	794-797
six	O	798-801
years	O	802-807
and	O	808-811
has	O	812-815
required	O	816-824
pharmacologic	O	825-838
doses	O	839-844
of	O	845-847
pyridoxine	O	848-858
to	O	859-861
control	O	862-869
her	O	870-873
behavior	O	874-882
.	O	882-883

A	O	0-1
selective	O	2-11
dopamine	O	12-20
D4	O	21-23
receptor	O	24-32
antagonist	O	33-43
,	O	43-44
NRA0160	O	45-52
:	O	52-53
a	O	54-55
preclinical	O	56-67
neuropharmacological	O	68-88
profile	O	89-96
.	O	96-97

NRA0160	O	98-105
,	O	105-106
5	O	107-108
-	O	109-110
[	O	111-112
2	O	112-113
-	O	113-114
(	O	115-116
4	O	117-118
-	O	118-119
(	O	120-121
3	O	122-123
-	O	124-125
fluorobenzylidene	O	126-143
)	O	143-144
piperidin	O	145-154
-	O	154-155
1	O	155-156
-	O	154-155
yl	O	157-159
)	O	159-160
ethyl	O	161-166
]	O	166-167
-	O	168-169
4	O	170-171
-	O	172-173
(	O	173-174
4	O	174-175
-	O	172-173
fluorophenyl	O	176-188
)	O	188-189
thiazole	O	190-198
-	O	198-199
2	O	199-200
-	O	198-199
carboxamide	O	201-212
,	O	212-213
has	O	214-217
a	O	218-219
high	O	220-224
affinity	O	225-233
for	O	234-237
human	O	238-243
cloned	O	244-250
dopamine	O	251-259
D4	O	260-262
.	O	262-263
2	O	263-264
,	O	264-265
D4	O	266-268
.	O	268-269
4	O	267-268
and	O	271-274
D4	O	275-277
.	O	277-278
7	O	278-279
receptors	O	280-289
,	O	289-290
with	O	291-295
Ki	O	296-298
values	O	299-305
of	O	306-308
0	O	309-310
.	O	310-311
5	O	311-312
,	O	312-313
0	O	314-315
.	O	315-316
9	O	316-317
and	O	318-321
2	O	322-323
.	O	323-324
7	O	324-325
nM	O	326-328
,	O	328-329
respectively	O	330-342
.	O	342-343

NRA0160	O	344-351
is	O	352-354
over	O	355-359
20	O	360-362
,	O	362-363
000fold	O	363-370
more	O	371-375
potent	O	376-382
at	O	383-385
the	O	386-389
dopamine	O	390-398
D4	O	399-401
.	O	401-402
2	O	402-403
receptor	O	404-412
compared	O	413-421
with	O	422-426
the	O	427-430
human	O	431-436
cloned	O	437-443
dopamine	O	444-452
D2L	O	453-456
receptor	O	457-465
.	O	465-466

NRA0160	O	467-474
has	O	475-478
negligible	O	479-489
affinity	O	490-498
for	O	499-502
the	O	503-506
human	O	507-512
cloned	O	513-519
dopamine	O	520-528
D3	O	529-531
receptor	O	532-540
(	O	541-542
Ki	O	542-544
=	O	544-545
39	O	545-547
nM	O	548-550
)	O	550-551
,	O	551-552
rat	O	553-556
serotonin	O	557-566
(	O	567-568
5	O	568-569
-	O	569-570
HT	O	570-572
)	O	572-573
2A	O	573-575
receptors	O	576-585
(	O	586-587
Ki	O	587-589
=	O	589-590
180	O	590-593
nM	O	594-596
)	O	596-597
and	O	598-601
rat	O	602-605
alpha1	O	606-612
adrenoceptor	O	613-625
(	O	626-627
Ki	O	627-629
=	O	629-630
237	O	630-633
nM	O	634-636
)	O	636-637
.	O	637-638

NRA0160	O	639-646
and	O	647-650
clozapine	O	651-660
antagonized	O	661-672
locomotor	O	673-682
hyperactivity	B	683-696
induced	O	697-704
by	O	705-707
methamphetamine	O	708-723
(	O	724-725
MAP	O	725-728
)	O	728-729
in	O	730-732
mice	O	733-737
.	O	737-738

NRA0160	O	739-746
and	O	747-750
clozapine	O	751-760
antagonized	O	761-772
MAP	O	773-776
-	O	776-777
induced	O	777-784
stereotyped	O	785-796
behavior	O	797-805
in	O	806-808
mice	O	809-813
,	O	813-814
although	O	815-823
their	O	824-829
effects	O	830-837
did	O	838-841
not	O	842-845
exceed	O	846-852
50	O	853-855
%	O	855-856
inhibition	O	857-867
,	O	867-868
even	O	869-873
at	O	874-876
the	O	877-880
highest	O	881-888
dose	O	889-893
given	O	894-899
.	O	899-900

NRA0160	O	901-908
and	O	909-912
clozapine	O	913-922
significantly	O	923-936
induced	O	937-944
catalepsy	B	945-954
in	O	955-957
rats	O	958-962
,	O	962-963
although	O	964-972
their	O	973-978
effects	O	979-986
did	O	987-990
not	O	991-994
exceed	O	995-1001
50	O	1002-1004
%	O	1004-1005
induction	O	1006-1015
even	O	1016-1020
at	O	1021-1023
the	O	1024-1027
highest	O	1028-1035
dose	O	1036-1040
given	O	1041-1046
.	O	1046-1047

NRA0160	O	1048-1055
and	O	1056-1059
clozapine	O	1060-1069
significantly	O	1070-1083
reversed	O	1084-1092
the	O	1093-1096
disruption	O	1097-1107
of	O	1108-1110
prepulse	O	1111-1119
inhibition	O	1120-1130
(	O	1131-1132
PPI	O	1132-1135
)	O	1135-1136
in	O	1137-1139
rats	O	1140-1144
produced	O	1145-1153
by	O	1154-1156
apomorphine	O	1157-1168
.	O	1168-1169

NRA0160	O	1170-1177
and	O	1178-1181
clozapine	O	1182-1191
significantly	O	1192-1205
shortened	O	1206-1215
the	O	1216-1219
phencyclidine	O	1220-1233
(	O	1234-1235
PCP	O	1235-1238
)	O	1238-1239
-	O	1239-1240
induced	O	1240-1247
prolonged	O	1248-1257
swimming	O	1258-1266
latency	O	1267-1274
in	O	1275-1277
rats	O	1278-1282
in	O	1283-1285
a	O	1286-1287
water	O	1288-1293
maze	O	1294-1298
task	O	1299-1303
.	O	1303-1304

These	O	1305-1310
findings	O	1311-1319
suggest	O	1320-1327
that	O	1328-1332
NRA0160	O	1333-1340
may	O	1341-1344
have	O	1345-1349
unique	O	1350-1356
antipsychotic	O	1357-1370
activities	O	1371-1381
without	O	1382-1389
the	O	1390-1393
liability	O	1394-1403
of	O	1404-1406
motor	O	1407-1412
side	O	1413-1417
effects	O	1418-1425
typical	O	1426-1433
of	O	1434-1436
classical	O	1437-1446
antipsychotics	O	1447-1461
.	O	1461-1462

Prolonged	O	0-9
cholestasis	B	10-21
after	O	22-27
troleandomycin	O	28-42
-	O	42-43
induced	O	43-50
acute	O	51-56
hepatitis	B	57-66
.	O	66-67

We	O	68-70
report	O	71-77
the	O	78-81
case	O	82-86
of	O	87-89
a	O	90-91
patient	O	92-99
in	O	100-102
whom	O	103-107
troleandomycin	O	108-122
-	O	122-123
induced	O	123-130
hepatitis	B	131-140
was	O	141-144
followed	O	145-153
by	O	154-156
prolonged	O	157-166
anicteric	O	167-176
cholestasis	B	177-188
.	O	188-189

Jaundice	B	190-198
occurred	O	199-207
after	O	208-213
administration	O	214-228
of	O	229-231
troleandomycin	O	232-246
for	O	247-250
7	O	251-252
days	O	253-257
and	O	258-261
was	O	262-265
associated	O	266-276
with	O	277-281
hypereosinophilia	B	282-299
.	O	299-300

Jaundice	B	301-309
disappeared	O	310-321
within	O	322-328
3	O	329-330
months	O	331-337
but	O	338-341
was	O	342-345
followed	O	346-354
by	O	355-357
prolonged	O	358-367
anicteric	O	368-377
cholestasis	B	378-389
marked	O	390-396
by	O	397-399
pruritus	B	400-408
and	O	409-412
high	O	413-417
levels	O	418-424
of	O	425-427
alkaline	O	428-436
phosphatase	O	437-448
and	O	449-452
gammaglutamyltransferase	O	453-477
activities	O	478-488
.	O	488-489

Finally	O	490-497
,	O	497-498
pruritus	B	499-507
disappeared	O	508-519
within	O	520-526
19	O	527-529
months	O	530-536
,	O	536-537
and	O	538-541
liver	O	542-547
tests	O	548-553
returned	O	554-562
to	O	563-565
normal	O	566-572
27	O	573-575
months	O	576-582
after	O	583-588
the	O	589-592
onset	O	593-598
of	O	599-601
hepatitis	B	602-611
.	O	611-612

This	O	613-617
observation	O	618-629
demonstrates	O	630-642
that	O	643-647
prolonged	O	648-657
cholestasis	B	658-669
can	O	670-673
follow	O	674-680
troleandomycin	O	681-695
-	O	695-696
induced	O	696-703
acute	O	704-709
hepatitis	B	710-719
.	O	719-720

HMG	O	0-3
CoA	O	4-7
reductase	O	8-17
inhibitors	O	18-28
.	O	28-29

Current	O	30-37
clinical	O	38-46
experience	O	47-57
.	O	57-58

Lovastatin	O	59-69
and	O	70-73
simvastatin	O	74-85
are	O	86-89
the	O	90-93
2	O	94-95
best	O	96-100
-	O	100-101
known	O	101-106
members	O	107-114
of	O	115-117
the	O	118-121
class	O	122-127
of	O	128-130
hypolipidaemic	O	131-145
agents	O	146-152
known	O	153-158
as	O	159-161
HMG	O	162-165
CoA	O	166-169
reductase	O	170-179
inhibitors	O	180-190
.	O	190-191

Clinical	O	192-200
experience	O	201-211
with	O	212-216
lovastatin	O	217-227
includes	O	228-236
over	O	237-241
5000	O	242-246
patients	O	247-255
,	O	255-256
700	O	257-260
of	O	261-263
whom	O	264-268
have	O	269-273
been	O	274-278
treated	O	279-286
for	O	287-290
2	O	291-292
years	O	293-298
or	O	299-301
more	O	302-306
,	O	306-307
and	O	308-311
experience	O	312-322
with	O	323-327
simvastatin	O	328-339
includes	O	340-348
over	O	349-353
3500	O	354-358
patients	O	359-367
,	O	367-368
of	O	369-371
whom	O	372-376
350	O	377-380
have	O	381-385
been	O	386-390
treated	O	391-398
for	O	399-402
18	O	403-405
months	O	406-412
or	O	413-415
more	O	416-420
.	O	420-421

Lovastatin	O	422-432
has	O	433-436
been	O	437-441
marketed	O	442-450
in	O	451-453
the	O	454-457
United	O	458-464
States	O	465-471
for	O	472-475
over	O	476-480
6	O	481-482
months	O	483-489
.	O	489-490

Both	O	491-495
agents	O	496-502
show	O	503-507
substantial	O	508-519
clinical	O	520-528
efficacy	O	529-537
,	O	537-538
with	O	539-543
reductions	O	544-554
in	O	555-557
total	O	558-563
cholesterol	O	564-575
of	O	576-578
over	O	579-583
30	O	584-586
%	O	586-587
and	O	588-591
in	O	592-594
LDL	O	595-598
-	O	598-599
cholesterol	O	599-610
of	O	611-613
40	O	614-616
%	O	616-617
in	O	618-620
clinical	O	621-629
studies	O	630-637
.	O	637-638

Modest	O	639-645
increases	O	646-655
in	O	656-658
HDL	O	659-662
-	O	662-663
cholesterol	O	663-674
levels	O	675-681
of	O	682-684
about	O	685-690
10	O	691-693
%	O	693-694
are	O	695-698
also	O	699-703
reported	O	704-712
.	O	712-713

Clinical	O	714-722
tolerability	O	723-735
of	O	736-738
both	O	739-743
agents	O	744-750
has	O	751-754
been	O	755-759
good	O	760-764
,	O	764-765
with	O	766-770
fewer	O	771-776
than	O	777-781
3	O	782-783
%	O	783-784
of	O	785-787
patients	O	788-796
withdrawn	O	797-806
from	O	807-811
treatment	O	812-821
because	O	822-829
of	O	830-832
clinical	O	833-841
adverse	O	842-849
experiences	O	850-861
.	O	861-862

Ophthalmological	O	863-879
examinations	O	880-892
in	O	893-895
over	O	896-900
1100	O	901-905
patients	O	906-914
treated	O	915-922
with	O	923-927
one	O	928-931
or	O	932-934
the	O	935-938
other	O	939-944
agent	O	945-950
have	O	951-955
revealed	O	956-964
no	O	965-967
evidence	O	968-976
of	O	977-979
significant	O	980-991
short	O	992-997
term	O	998-1002
(	O	1003-1004
up	O	1004-1006
to	O	1007-1009
2	O	1010-1011
years	O	1012-1017
)	O	1017-1018
cataractogenic	O	1019-1033
potential	O	1034-1043
.	O	1043-1044

One	O	1045-1048
to	O	1049-1051
2	O	1052-1053
%	O	1053-1054
of	O	1055-1057
patients	O	1058-1066
have	O	1067-1071
elevations	O	1072-1082
of	O	1083-1085
serum	O	1086-1091
transaminases	O	1092-1105
to	O	1106-1108
greater	O	1109-1116
than	O	1117-1121
3	O	1122-1123
times	O	1124-1129
the	O	1130-1133
upper	O	1134-1139
limit	O	1140-1145
of	O	1146-1148
normal	O	1149-1155
.	O	1155-1156

These	O	1157-1162
episodes	O	1163-1171
are	O	1172-1175
asymptomatic	O	1176-1188
and	O	1189-1192
reversible	O	1193-1203
when	O	1204-1208
therapy	O	1209-1216
is	O	1217-1219
discontinued	O	1220-1232
.	O	1232-1233

Minor	O	1234-1239
elevations	O	1240-1250
of	O	1251-1253
creatine	O	1254-1262
kinase	O	1263-1269
levels	O	1270-1276
are	O	1277-1280
reported	O	1281-1289
in	O	1290-1292
about	O	1293-1298
5	O	1299-1300
%	O	1300-1301
of	O	1302-1304
patients	O	1305-1313
.	O	1313-1314

Myopathy	B	1315-1323
,	O	1323-1324
associated	O	1325-1335
in	O	1336-1338
some	O	1339-1343
cases	O	1344-1349
with	O	1350-1354
myoglobinuria	B	1355-1368
,	O	1368-1369
and	O	1370-1373
in	O	1374-1376
2	O	1377-1378
cases	O	1379-1384
with	O	1385-1389
transient	O	1390-1399
renal	B	1400-1405
failure	I	1406-1413
,	O	1413-1414
has	O	1415-1418
been	O	1419-1423
rarely	O	1424-1430
reported	O	1431-1439
with	O	1440-1444
lovastatin	O	1445-1455
,	O	1455-1456
especially	O	1457-1467
in	O	1468-1470
patients	O	1471-1479
concomitantly	O	1480-1493
treated	O	1494-1501
with	O	1502-1506
cyclosporin	O	1507-1518
,	O	1518-1519
gemfibrozil	O	1520-1531
or	O	1532-1534
niacin	O	1535-1541
.	O	1541-1542

Lovastatin	O	1543-1553
and	O	1554-1557
simvastatin	O	1558-1569
are	O	1570-1573
both	O	1574-1578
effective	O	1579-1588
and	O	1589-1592
well	O	1593-1597
-	O	1597-1598
tolerated	O	1598-1607
agents	O	1608-1614
for	O	1615-1618
lowering	O	1619-1627
elevated	O	1628-1636
levels	O	1637-1643
of	O	1644-1646
serum	O	1647-1652
cholesterol	O	1653-1664
.	O	1664-1665

As	O	1666-1668
wider	O	1669-1674
use	O	1675-1678
confirms	O	1679-1687
their	O	1688-1693
safety	O	1694-1700
profile	O	1701-1708
,	O	1708-1709
they	O	1710-1714
will	O	1715-1719
gain	O	1720-1724
increasing	O	1725-1735
importance	O	1736-1746
in	O	1747-1749
the	O	1750-1753
therapeutic	O	1754-1765
approach	O	1766-1774
to	O	1775-1777
hypercholesterolaemia	B	1778-1799
and	O	1800-1803
its	O	1804-1807
consequences	O	1808-1820
.	O	1820-1821

Sulfasalazine	O	0-13
-	O	13-14
induced	O	14-21
lupus	B	22-27
erythematosus	I	28-41
.	O	41-42

Pneumonitis	B	43-54
,	O	54-55
bilateral	O	56-65
pleural	B	66-73
effusions	I	74-83
,	O	83-84
echocardiographic	O	85-102
evidence	O	103-111
of	O	112-114
cardiac	B	115-122
tamponade	I	123-132
,	O	132-133
and	O	134-137
positive	O	138-146
autoantibodies	O	147-161
developed	O	162-171
in	O	172-174
a	O	175-176
43	O	177-179
-	O	179-180
year	O	180-184
-	O	179-180
old	O	185-188
man	O	189-192
,	O	192-193
who	O	194-197
was	O	198-201
receiving	O	202-211
long	O	212-216
-	O	216-217
term	O	217-221
sulfasalazine	O	222-235
therapy	O	236-243
for	O	244-247
chronic	O	248-255
ulcerative	B	256-266
colitis	I	267-274
.	O	274-275

After	O	276-281
cessation	O	282-291
of	O	292-294
the	O	295-298
sulfasalazine	O	299-312
and	O	313-316
completion	O	317-327
of	O	328-330
a	O	331-332
six	O	333-336
-	O	336-337
week	O	337-341
course	O	342-348
of	O	349-351
corticosteroids	O	352-367
,	O	367-368
these	O	369-374
problems	O	375-383
resolved	O	384-392
over	O	393-397
a	O	398-399
period	O	400-406
of	O	407-409
four	O	410-414
to	O	415-417
six	O	418-421
months	O	422-428
.	O	428-429

It	O	430-432
is	O	433-435
suggested	O	436-445
that	O	446-450
the	O	451-454
patient	O	455-462
had	O	463-466
sulfasalazine	O	467-480
-	O	480-481
induced	O	481-488
lupus	B	489-494
,	O	494-495
which	O	496-501
manifested	O	502-512
with	O	513-517
serositis	B	518-527
and	O	528-531
pulmonary	O	532-541
parenchymal	O	542-553
involvement	O	554-565
in	O	566-568
the	O	569-572
absence	O	573-580
of	O	581-583
joint	O	584-589
symptoms	O	590-598
.	O	598-599

Physicians	O	600-610
who	O	611-614
use	O	615-618
sulfasalazine	O	619-632
to	O	633-635
treat	O	636-641
patients	O	642-650
with	O	651-655
inflammatory	B	656-668
bowel	I	669-674
disease	I	675-682
should	O	683-689
be	O	690-692
aware	O	693-698
of	O	699-701
the	O	702-705
signs	O	706-711
of	O	712-714
sulfasalazine	O	715-728
-	O	728-729
induced	O	729-736
lupus	B	737-742
syndrome	I	743-751
.	O	751-752

Optimization	O	0-12
of	O	13-15
levodopa	O	16-24
therapy	O	25-32
.	O	32-33

While	O	34-39
there	O	40-45
is	O	46-48
no	O	49-51
single	O	52-58
correct	O	59-66
starting	O	67-75
dose	O	76-80
for	O	81-84
levodopa	O	85-93
therapy	O	94-101
,	O	101-102
many	O	103-107
individuals	O	108-119
can	O	120-123
be	O	124-126
started	O	127-134
on	O	135-137
either	O	138-144
the	O	145-148
25	O	149-151
/	O	151-152
100	O	152-155
or	O	156-158
controlled	O	159-169
-	O	169-170
release	O	170-177
formula	O	178-185
,	O	185-186
following	O	187-196
the	O	197-200
general	O	201-208
rule	O	209-213
not	O	214-217
to	O	218-220
attempt	O	221-228
to	O	229-231
titrate	O	232-239
carbidopa	O	240-249
-	O	249-250
levodopa	O	250-258
to	O	259-261
the	O	262-265
point	O	266-271
of	O	272-274
"	O	275-276
normality	O	276-285
,	O	285-286
"	O	275-276
which	O	288-293
can	O	294-297
lead	O	298-302
to	O	303-305
toxicity	B	306-314
.	O	314-315

The	O	316-319
physician	O	320-329
should	O	330-336
also	O	337-341
determine	O	342-351
the	O	352-355
proper	O	356-362
use	O	363-366
of	O	367-369
any	O	370-373
adjunctive	O	374-384
medications	O	385-396
;	O	396-397
such	O	398-402
combined	O	403-411
therapy	O	412-419
has	O	420-423
become	O	424-430
the	O	431-434
standard	O	435-443
approach	O	444-452
to	O	453-455
treatment	O	456-465
.	O	465-466

Following	O	467-476
the	O	477-480
initial	O	481-488
period	O	489-495
of	O	496-498
therapy	O	499-506
,	O	506-507
emerging	O	508-516
difficulties	O	517-529
require	O	530-537
a	O	538-539
reassessment	O	540-552
of	O	553-555
therapeutic	O	556-567
approaches	O	568-578
,	O	578-579
such	O	580-584
as	O	585-587
dosage	O	588-594
adjustment	O	595-605
or	O	606-608
introduction	O	609-621
of	O	622-624
a	O	625-626
dopamine	O	627-635
agonist	O	636-643
.	O	643-644

Other	O	645-650
possible	O	651-659
adverse	O	660-667
effects	O	668-675
-	O	675-676
-	O	675-676
such	O	677-681
as	O	682-684
gastrointestinal	B	685-701
disorders	I	702-711
,	O	711-712
orthostatic	B	713-724
hypotension	I	725-736
,	O	736-737
levodopa	O	738-746
-	O	746-747
induced	O	747-754
psychosis	B	755-764
,	O	764-765
sleep	B	766-771
disturbances	I	772-784
or	O	785-787
parasomnias	B	788-799
,	O	799-800
or	O	801-803
drug	O	804-808
interactions	O	809-821
-	O	821-822
-	O	821-822
also	O	823-827
require	O	828-835
carefully	O	836-845
monitored	O	846-855
individual	O	856-866
treatment	O	867-876
.	O	876-877

Nonpharmacologic	O	878-894
concerns	O	895-903
can	O	904-907
help	O	908-912
the	O	913-916
Parkinson	B	917-926
'	I	926-927
s	I	923-924
disease	I	929-936
patient	O	937-944
achieve	O	945-952
and	O	953-956
maintain	O	957-965
optimal	O	966-973
functioning	O	974-985
,	O	985-986
including	O	987-996
daily	O	997-1002
exercise	O	1003-1011
,	O	1011-1012
physical	O	1013-1021
therapy	O	1022-1029
,	O	1029-1030
and	O	1031-1034
involvement	O	1035-1046
with	O	1047-1051
support	O	1052-1059
groups	O	1060-1066
.	O	1066-1067

Alpha	O	0-5
and	O	6-9
beta	O	10-14
coma	B	15-19
in	O	20-22
drug	O	23-27
intoxication	O	28-40
uncomplicated	O	41-54
by	O	55-57
cerebral	B	58-66
hypoxia	I	67-74
.	O	74-75

Four	O	76-80
patients	O	81-89
who	O	90-93
were	O	94-98
rendered	O	99-107
comatose	B	108-116
or	O	117-119
stuporous	B	120-129
by	O	130-132
drug	O	133-137
intoxication	O	138-150
,	O	150-151
but	O	152-155
who	O	156-159
were	O	160-164
not	O	165-168
hypoxic	O	169-176
,	O	176-177
are	O	178-181
described	O	182-191
.	O	191-192

Three	O	193-198
patients	O	199-207
received	O	208-216
high	O	217-221
doses	O	222-227
of	O	228-230
chlormethiazole	O	231-246
for	O	247-250
alcohol	O	251-258
withdrawal	B	259-269
symptoms	I	270-278
,	O	278-279
and	O	280-283
one	O	284-287
took	O	288-292
a	O	293-294
suicidal	O	295-303
overdose	B	304-312
of	O	313-315
nitrazepam	O	316-326
.	O	326-327

The	O	328-331
patient	O	332-339
with	O	340-344
nitrazepam	O	345-355
overdose	B	356-364
and	O	365-368
two	O	369-372
of	O	373-375
those	O	376-381
with	O	382-386
chlormethiazole	O	387-402
intoxication	O	403-415
conformed	O	416-425
to	O	426-428
the	O	429-432
criteria	O	433-441
of	O	442-444
'	O	445-446
alpha	O	446-451
coma	B	452-456
'	O	456-457
,	O	457-458
showing	O	459-466
non	O	467-470
-	O	470-471
reactive	O	471-479
generalized	O	480-491
or	O	492-494
frontally	O	495-504
predominant	O	505-516
alpha	O	517-522
activity	O	523-531
in	O	532-534
the	O	535-538
EEG	O	539-542
.	O	542-543

The	O	544-547
fourth	O	548-554
patient	O	555-562
who	O	563-566
was	O	567-570
unconscious	O	571-582
after	O	583-588
chlormethiazole	O	589-604
administration	O	605-619
exhibite	O	620-628
generalized	O	629-640
non	O	641-644
-	O	644-645
reactive	O	645-653
activity	O	654-662
in	O	663-665
the	O	666-669
slow	O	670-674
beta	O	675-679
range	O	680-685
.	O	685-686

All	O	687-690
four	O	691-695
recovered	O	696-705
completely	O	706-716
without	O	717-724
neurological	B	725-737
sequelae	I	738-746
following	O	747-756
the	O	757-760
withdrawal	O	761-771
of	O	772-774
the	O	775-778
offending	O	779-788
agents	O	789-795
.	O	795-796

The	O	797-800
similarities	O	801-813
between	O	814-821
the	O	822-825
effects	O	826-833
of	O	834-836
structural	O	837-847
lesions	O	848-855
and	O	856-859
pharmacological	O	860-875
depression	B	876-886
of	O	887-889
the	O	890-893
brain	O	894-899
stem	O	900-904
reticular	O	905-914
formation	O	915-924
are	O	925-928
discussed	O	929-938
.	O	938-939

It	O	940-942
is	O	943-945
suggested	O	946-955
that	O	956-960
in	O	961-963
both	O	964-968
situations	O	969-979
disturbed	O	980-989
reticulo	O	990-998
-	O	998-999
thalamic	O	999-1007
interactions	O	1008-1020
are	O	1021-1024
important	O	1025-1034
in	O	1035-1037
the	O	1038-1041
pathogenesis	O	1042-1054
of	O	1055-1057
alpha	O	1058-1063
coma	B	1064-1068
.	O	1068-1069

It	O	1070-1072
is	O	1073-1075
concluded	O	1076-1085
that	O	1086-1090
when	O	1091-1095
this	O	1096-1100
electroencephalographic	O	1101-1124
and	O	1125-1128
behavioural	O	1129-1140
picture	O	1141-1148
is	O	1149-1151
seen	O	1152-1156
in	O	1157-1159
drug	O	1160-1164
intoxication	O	1165-1177
,	O	1177-1178
in	O	1179-1181
the	O	1182-1185
absence	O	1186-1193
of	O	1194-1196
significant	O	1197-1208
hypoxaemia	B	1209-1219
,	O	1219-1220
a	O	1221-1222
favourable	O	1223-1233
outcome	O	1234-1241
may	O	1242-1245
be	O	1246-1248
anticipated	O	1249-1260
.	O	1260-1261

Omitting	O	0-8
fentanyl	O	9-17
reduces	O	18-25
nausea	B	26-32
and	O	33-36
vomiting	B	37-45
,	O	45-46
without	O	47-54
increasing	O	55-65
pain	B	66-70
,	O	70-71
after	O	72-77
sevoflurane	O	78-89
for	O	90-93
day	O	94-97
surgery	O	98-105
.	O	105-106

BACKGROUND	O	107-117
AND	O	118-121
OBJECTIVE	O	122-131
:	O	131-132
Despite	O	133-140
advantages	O	141-151
of	O	152-154
induction	O	155-164
and	O	165-168
maintenance	O	169-180
of	O	181-183
anaesthesia	O	184-195
with	O	196-200
sevoflurane	O	201-212
,	O	212-213
postoperative	B	214-227
nausea	I	228-234
and	I	235-238
vomiting	I	239-247
occurs	O	248-254
frequently	O	255-265
.	O	265-266

Fentanyl	O	267-275
is	O	276-278
a	O	279-280
commonly	O	281-289
used	O	290-294
supplement	O	295-305
that	O	306-310
may	O	311-314
contribute	O	315-325
to	O	326-328
this	O	329-333
,	O	333-334
although	O	335-343
it	O	344-346
may	O	347-350
also	O	351-355
improve	O	356-363
analgesia	O	364-373
.	O	373-374

METHODS	O	375-382
:	O	382-383
This	O	384-388
double	O	389-395
-	O	395-396
blind	O	396-401
study	O	402-407
examined	O	408-416
the	O	417-420
incidence	O	421-430
and	O	431-434
severity	O	435-443
of	O	444-446
postoperative	B	447-460
nausea	I	461-467
and	I	468-471
vomiting	I	472-480
and	O	481-484
pain	B	485-489
in	O	490-492
the	O	493-496
first	O	497-502
24	O	503-505
h	O	506-507
after	O	508-513
sevoflurane	O	514-525
anaesthesia	O	526-537
in	O	538-540
216	O	541-544
adult	O	545-550
day	O	551-554
surgery	O	555-562
patients	O	563-571
.	O	571-572

Patients	O	573-581
were	O	582-586
randomly	O	587-595
allocated	O	596-605
to	O	606-608
either	O	609-615
receive	O	616-623
or	O	624-626
not	O	627-630
receive	O	631-638
1	O	639-640
1	O	641-642
fentanyl	O	643-651
,	O	651-652
while	O	653-658
a	O	659-660
third	O	661-666
group	O	667-672
received	O	673-681
dexamethasone	O	682-695
in	O	696-698
addition	O	699-707
to	O	708-710
fentanyl	O	711-719
.	O	719-720

RESULTS	O	721-728
:	O	728-729
Omission	O	730-738
of	O	739-741
fentanyl	O	742-750
did	O	751-754
not	O	755-758
reduce	O	759-765
the	O	766-769
overall	O	770-777
incidence	O	778-787
of	O	788-790
postoperative	B	791-804
nausea	I	805-811
and	I	812-815
vomiting	I	816-824
,	O	824-825
but	O	826-829
did	O	830-833
reduce	O	834-840
the	O	841-844
incidence	O	845-854
of	O	855-857
vomiting	B	858-866
and	O	867-870
/	O	870-871
or	O	871-873
moderate	O	874-882
to	O	883-885
severe	O	886-892
nausea	B	893-899
prior	O	900-905
to	O	906-908
discharge	O	909-918
from	O	919-923
20	O	924-926
%	O	926-927
and	O	928-931
17	O	932-934
%	O	934-935
with	O	936-940
fentanyl	O	941-949
and	O	950-953
fentanyl	O	954-962
-	O	962-963
dexamethasone	O	963-976
,	O	976-977
respectively	O	978-990
,	O	990-991
to	O	992-994
5	O	995-996
%	O	996-997
(	O	998-999
P	O	999-1000
=	O	1001-1002
0	O	1003-1004
.	O	1004-1005
013	O	1005-1008
)	O	1008-1009
.	O	1004-1005

Antiemetic	O	1011-1021
requirements	O	1022-1034
were	O	1035-1039
reduced	O	1040-1047
from	O	1048-1052
24	O	1053-1055
%	O	1055-1056
and	O	1057-1060
31	O	1061-1063
%	O	1063-1064
to	O	1065-1067
7	O	1068-1069
%	O	1069-1070
(	O	1071-1072
P	O	1072-1073
=	O	1074-1075
0	O	1076-1077
.	O	1077-1078
0012	O	1078-1082
)	O	1082-1083
.	O	1077-1078

Dexamethasone	O	1085-1098
had	O	1099-1102
no	O	1103-1105
significant	O	1106-1117
effect	O	1118-1124
on	O	1125-1127
the	O	1128-1131
incidence	O	1132-1141
or	O	1142-1144
severity	O	1145-1153
of	O	1154-1156
postoperative	B	1157-1170
nausea	I	1171-1177
and	I	1178-1181
vomiting	I	1182-1190
.	O	1190-1191

Combining	O	1192-1201
the	O	1202-1205
two	O	1206-1209
fentanyl	O	1210-1218
groups	O	1219-1225
revealed	O	1226-1234
further	O	1235-1242
significant	O	1243-1254
benefits	O	1255-1263
from	O	1264-1268
the	O	1269-1272
avoidance	O	1273-1282
of	O	1283-1285
opioids	O	1286-1293
,	O	1293-1294
reducing	O	1295-1303
postoperative	B	1304-1317
nausea	I	1318-1324
and	I	1325-1328
vomiting	I	1329-1337
and	O	1338-1341
nausea	B	1342-1348
prior	O	1349-1354
to	O	1355-1357
discharge	O	1358-1367
from	O	1368-1372
35	O	1373-1375
%	O	1375-1376
and	O	1377-1380
33	O	1381-1383
%	O	1383-1384
to	O	1385-1387
22	O	1388-1390
%	O	1390-1391
and	O	1392-1395
19	O	1396-1398
%	O	1398-1399
(	O	1400-1401
P	O	1401-1402
=	O	1403-1404
0	O	1405-1406
.	O	1406-1407
049	O	1407-1410
and	O	1411-1414
P	O	1415-1416
=	O	1417-1418
0	O	1419-1420
.	O	1420-1421
035	O	1421-1424
)	O	1424-1425
,	O	1425-1426
respectively	O	1427-1439
,	O	1439-1440
while	O	1441-1446
nausea	B	1447-1453
in	O	1454-1456
the	O	1457-1460
first	O	1461-1466
24	O	1467-1469
h	O	1470-1471
was	O	1472-1475
decreased	O	1476-1485
from	O	1486-1490
42	O	1491-1493
%	O	1493-1494
to	O	1495-1497
27	O	1498-1500
%	O	1500-1501
(	O	1502-1503
P	O	1503-1504
=	O	1505-1506
0	O	1507-1508
.	O	1508-1509
034	O	1509-1512
)	O	1512-1513
.	O	1508-1509

Pain	B	1515-1519
severity	O	1520-1528
and	O	1529-1532
analgesic	O	1533-1542
requirements	O	1543-1555
were	O	1556-1560
unaffected	O	1561-1571
by	O	1572-1574
the	O	1575-1578
omission	O	1579-1587
of	O	1588-1590
fentanyl	O	1591-1599
.	O	1599-1600

Fentanyl	O	1601-1609
did	O	1610-1613
reduce	O	1614-1620
minor	O	1621-1626
intraoperative	O	1627-1641
movement	O	1642-1650
but	O	1651-1654
had	O	1655-1658
no	O	1659-1661
sevoflurane	O	1662-1673
-	O	1673-1674
sparing	O	1674-1681
effect	O	1682-1688
and	O	1689-1692
increased	O	1693-1702
respiratory	B	1703-1714
depression	I	1715-1725
,	O	1725-1726
hypotension	B	1727-1738
and	O	1739-1742
bradycardia	B	1743-1754
.	O	1754-1755

CONCLUSION	O	1756-1766
:	O	1766-1767
As	O	1768-1770
fentanyl	O	1771-1779
exacerbated	O	1780-1791
postoperative	B	1792-1805
nausea	I	1806-1812
and	I	1813-1816
vomiting	I	1817-1825
without	O	1826-1833
an	O	1834-1836
improvement	O	1837-1848
in	O	1849-1851
postoperative	B	1852-1865
pain	I	1866-1870
and	O	1871-1874
also	O	1875-1879
had	O	1880-1883
adverse	O	1884-1891
cardiorespiratory	O	1892-1909
effects	O	1910-1917
,	O	1917-1918
it	O	1919-1921
appears	O	1922-1929
to	O	1930-1932
be	O	1933-1935
an	O	1936-1938
unnecessary	O	1939-1950
and	O	1951-1954
possibly	O	1955-1963
detrimental	O	1964-1975
supplement	O	1976-1986
to	O	1987-1989
sevoflurane	O	1990-2001
in	O	2002-2004
day	O	2005-2008
surgery	O	2009-2016
.	O	2016-2017

Renal	B	0-5
Fanconi	I	6-13
syndrome	I	14-22
and	O	23-26
myopathy	B	27-35
after	O	36-41
liver	O	42-47
transplantation	O	48-63
:	O	63-64
drug	O	65-69
-	O	69-70
related	O	70-77
mitochondrial	B	78-91
cytopathy	I	92-101
?	O	101-102

Advances	O	103-111
in	O	112-114
the	O	115-118
field	O	119-124
of	O	125-127
transplantation	O	128-143
provide	O	144-151
a	O	152-153
better	O	154-160
quality	O	161-168
of	O	169-171
life	O	172-176
and	O	177-180
allow	O	181-186
more	O	187-191
favorable	O	192-201
conditions	O	202-212
for	O	213-216
growth	O	217-223
and	O	224-227
development	O	228-239
in	O	240-242
children	O	243-251
.	O	251-252

However	O	253-260
,	O	260-261
combinations	O	262-274
of	O	275-277
different	O	278-287
therapeutic	O	288-299
regimens	O	300-308
require	O	309-316
consideration	O	317-330
of	O	331-333
potential	O	334-343
adverse	O	344-351
reactions	O	352-361
.	O	361-362

We	O	363-365
describe	O	366-374
a	O	375-376
15	O	377-379
-	O	379-380
yr	O	380-382
-	O	379-380
old	O	383-386
girl	O	387-391
who	O	392-395
had	O	396-399
orthotopic	O	400-410
liver	O	411-416
transplantation	O	417-432
because	O	433-440
of	O	441-443
Wilson	B	444-450
'	I	450-451
s	I	447-448
disease	I	453-460
.	O	460-461

Tacrolimus	O	462-472
,	O	472-473
MMF	O	474-477
,	O	477-478
and	O	479-482
steroids	O	483-491
were	O	492-496
given	O	497-502
as	O	503-505
immunosuppressant	O	506-523
.	O	523-524

Lamivudine	O	525-535
was	O	536-539
added	O	540-545
because	O	546-553
of	O	554-556
de	O	557-559
nova	O	560-564
hepatitis	B	565-574
B	I	575-576
infection	I	577-586
during	O	587-593
her	O	594-597
follow	O	598-604
-	O	604-605
up	O	605-607
.	O	607-608

Three	O	609-614
yr	O	615-617
after	O	618-623
transplantation	O	624-639
she	O	640-643
developed	O	644-653
renal	B	654-659
Fanconi	I	660-667
syndrome	I	668-676
with	O	677-681
severe	O	682-688
metabolic	B	689-698
acidosis	I	699-707
,	O	707-708
hypophosphatemia	B	709-725
,	O	725-726
glycosuria	B	727-737
,	O	737-738
and	O	739-742
aminoaciduria	B	743-756
.	O	756-757

Although	O	758-766
tacrolimus	O	767-777
was	O	778-781
suspected	O	782-791
to	O	792-794
be	O	795-797
the	O	798-801
cause	O	802-807
of	O	808-810
late	O	811-815
post	O	816-820
-	O	820-821
transplant	O	821-831
renal	O	832-837
acidosis	B	838-846
and	O	847-850
was	O	851-854
replaced	O	855-863
by	O	864-866
sirolimus	O	867-876
,	O	876-877
acidosis	B	878-886
,	O	886-887
and	O	888-891
electrolyte	O	892-903
imbalance	O	904-913
got	O	914-917
worse	O	918-923
.	O	923-924

Proximal	O	925-933
muscle	B	934-940
weakness	I	941-949
has	O	950-953
developed	O	954-963
during	O	964-970
her	O	971-974
follow	O	975-981
-	O	981-982
up	O	982-984
.	O	984-985

Fanconi	B	986-993
syndrome	I	994-1002
,	O	1002-1003
as	O	1004-1006
well	O	1007-1011
as	O	1012-1014
myopathy	B	1015-1023
,	O	1023-1024
is	O	1025-1027
well	O	1028-1032
recognized	O	1033-1043
in	O	1044-1046
patients	O	1047-1055
with	O	1056-1060
mitochondrial	B	1061-1074
disorders	I	1075-1084
and	O	1085-1088
caused	O	1089-1095
by	O	1096-1098
depletion	O	1099-1108
of	O	1109-1111
mtDNA	O	1112-1117
.	O	1117-1118

We	O	1119-1121
suggest	O	1122-1129
that	O	1130-1134
our	O	1135-1138
patient	O	1139-1146
'	O	1146-1147
s	O	1147-1148
tubular	B	1149-1156
dysfunction	I	1157-1168
and	O	1169-1172
myopathy	B	1173-1181
may	O	1182-1185
have	O	1186-1190
resulted	O	1191-1199
from	O	1200-1204
mitochondrial	B	1205-1218
dysfunction	I	1219-1230
which	O	1231-1236
is	O	1237-1239
triggered	O	1240-1249
by	O	1250-1252
tacrolimus	O	1253-1263
and	O	1264-1267
augmented	O	1268-1277
by	O	1278-1280
lamivudine	O	1281-1291
.	O	1291-1292

Antipsychotic	O	0-13
-	O	13-14
like	O	14-18
profile	O	19-26
of	O	27-29
thioperamide	O	30-42
,	O	42-43
a	O	44-45
selective	O	46-55
H3	O	56-58
-	O	58-59
receptor	O	59-67
antagonist	O	68-78
in	O	79-81
mice	O	82-86
.	O	86-87

Experimental	O	88-100
and	O	101-104
clinical	O	105-113
evidence	O	114-122
points	O	123-129
to	O	130-132
a	O	133-134
role	O	135-139
of	O	140-142
central	O	143-150
histaminergic	O	151-164
system	O	165-171
in	O	172-174
the	O	175-178
pathogenesis	O	179-191
of	O	192-194
schizophrenia	B	195-208
.	O	208-209

The	O	210-213
present	O	214-221
study	O	222-227
was	O	228-231
designed	O	232-240
to	O	241-243
study	O	244-249
the	O	250-253
effect	O	254-260
of	O	261-263
histamine	O	264-273
H	O	274-275
(	O	275-276
3	O	276-277
)	O	277-278
-	O	278-279
receptor	O	279-287
ligands	O	288-295
on	O	296-298
neuroleptic	O	299-310
-	O	310-311
induced	O	311-318
catalepsy	B	319-328
,	O	328-329
apomorphine	O	330-341
-	O	341-342
induced	O	342-349
climbing	O	350-358
behavior	O	359-367
and	O	368-371
amphetamine	O	372-383
-	O	383-384
induced	O	384-391
locomotor	O	392-401
activities	O	402-412
in	O	413-415
mice	O	416-420
.	O	420-421

Catalepsy	B	422-431
was	O	432-435
induced	O	436-443
by	O	444-446
haloperidol	O	447-458
(	O	459-460
2	O	460-461
mg	O	462-464
/	O	464-465
kg	O	465-467
p	O	468-469
.	O	469-470
o	O	470-471
.	O	469-470
)	O	472-473
,	O	473-474
while	O	475-480
apomorphine	O	481-492
(	O	493-494
1	O	494-495
.	O	495-496
5	O	496-497
mg	O	498-500
/	O	500-501
kg	O	501-503
s	O	504-505
.	O	505-506
c	O	506-507
.	O	505-506
)	O	508-509
and	O	510-513
amphetamine	O	514-525
(	O	526-527
2	O	527-528
mg	O	529-531
/	O	531-532
kg	O	532-534
s	O	535-536
.	O	536-537
c	O	537-538
.	O	536-537
)	O	539-540
were	O	541-545
used	O	546-550
for	O	551-554
studying	O	555-563
climbing	O	564-572
behavior	O	573-581
and	O	582-585
locomotor	O	586-595
activities	O	596-606
,	O	606-607
respectively	O	608-620
.	O	620-621

(	O	622-623
R	O	623-624
)	O	624-625
-	O	625-626
alpha	O	626-631
-	O	625-626
methylhistamine	O	632-647
(	O	648-649
RAMH	O	649-653
)	O	653-654
(	O	655-656
5	O	656-657
microg	O	658-664
i	O	665-666
.	O	666-667
c	O	667-668
.	O	666-667
v	O	669-670
.	O	666-667
)	O	671-672
and	O	673-676
thioperamide	O	677-689
(	O	690-691
THP	O	691-694
)	O	694-695
(	O	696-697
15	O	697-699
mg	O	700-702
/	O	702-703
kg	O	703-705
i	O	706-707
.	O	707-708
p	O	708-709
.	O	707-708
)	O	710-711
,	O	711-712
per	O	713-716
se	O	717-719
did	O	720-723
not	O	724-727
cause	O	728-733
catalepsy	B	734-743
.	O	743-744

Administration	O	745-759
of	O	760-762
THP	O	763-766
(	O	767-768
3	O	768-769
.	O	769-770
75	O	770-772
,	O	772-773
7	O	774-775
.	O	775-776
5	O	776-777
and	O	778-781
15	O	782-784
mg	O	785-787
/	O	787-788
kg	O	788-790
i	O	791-792
.	O	792-793
p	O	793-794
.	O	792-793
)	O	795-796
1	O	797-798
h	O	799-800
prior	O	801-806
to	O	807-809
haloperidol	O	810-821
resulted	O	822-830
in	O	831-833
a	O	834-835
dose	O	836-840
-	O	840-841
dependent	O	841-850
increase	O	851-859
in	O	860-862
the	O	863-866
catalepsy	B	867-876
times	O	877-882
(	O	883-884
P	O	884-885
<	O	886-887
0	O	888-889
.	O	889-890
05	O	890-892
)	O	892-893
.	O	889-890

However	O	895-902
,	O	902-903
pretreatment	O	904-916
with	O	917-921
RAMH	O	922-926
significantly	O	927-940
reversed	O	941-949
such	O	950-954
an	O	955-957
effect	O	958-964
of	O	965-967
THP	O	968-971
(	O	972-973
15	O	973-975
mg	O	976-978
/	O	978-979
kg	O	979-981
i	O	982-983
.	O	983-984
p	O	984-985
.	O	983-984
)	O	986-987
.	O	983-984

RAMH	O	989-993
per	O	994-997
se	O	998-1000
showed	O	1001-1007
significant	O	1008-1019
reduction	O	1020-1029
in	O	1030-1032
locomotor	O	1033-1042
time	O	1043-1047
,	O	1047-1048
distance	O	1049-1057
traveled	O	1058-1066
and	O	1067-1070
average	O	1071-1078
speed	O	1079-1084
but	O	1085-1088
THP	O	1089-1092
(	O	1093-1094
15	O	1094-1096
mg	O	1097-1099
/	O	1099-1100
kg	O	1100-1102
i	O	1103-1104
.	O	1104-1105
p	O	1105-1106
.	O	1104-1105
)	O	1107-1108
per	O	1109-1112
se	O	1113-1115
had	O	1116-1119
no	O	1120-1122
effect	O	1123-1129
on	O	1130-1132
these	O	1133-1138
parameters	O	1139-1149
.	O	1149-1150

On	O	1151-1153
amphetamine	O	1154-1165
-	O	1165-1166
induced	O	1166-1173
hyperactivity	B	1174-1187
,	O	1187-1188
THP	O	1189-1192
(	O	1193-1194
3	O	1194-1195
.	O	1195-1196
75	O	1196-1198
and	O	1199-1202
7	O	1203-1204
.	O	1204-1205
5	O	1205-1206
mg	O	1207-1209
/	O	1209-1210
kg	O	1210-1212
i	O	1213-1214
.	O	1214-1215
p	O	1215-1216
.	O	1214-1215
)	O	1217-1218
reduced	O	1219-1226
locomotor	O	1227-1236
time	O	1237-1241
,	O	1241-1242
distance	O	1243-1251
traveled	O	1252-1260
and	O	1261-1264
average	O	1265-1272
speed	O	1273-1278
(	O	1279-1280
P	O	1280-1281
<	O	1282-1283
0	O	1284-1285
.	O	1285-1286
05	O	1286-1288
)	O	1288-1289
.	O	1285-1286

Pretreatment	O	1291-1303
with	O	1304-1308
RAMH	O	1309-1313
(	O	1314-1315
5	O	1315-1316
microg	O	1317-1323
i	O	1324-1325
.	O	1325-1326
c	O	1326-1327
.	O	1325-1326
v	O	1328-1329
.	O	1325-1326
)	O	1330-1331
could	O	1332-1337
partially	O	1338-1347
reverse	O	1348-1355
such	O	1356-1360
effects	O	1361-1368
of	O	1369-1371
THP	O	1372-1375
(	O	1376-1377
3	O	1377-1378
.	O	1378-1379
75	O	1379-1381
mg	O	1382-1384
/	O	1384-1385
kg	O	1385-1387
i	O	1388-1389
.	O	1389-1390
p	O	1390-1391
.	O	1389-1390
)	O	1392-1393
.	O	1389-1390

Climbing	O	1395-1403
behavior	O	1404-1412
induced	O	1413-1420
by	O	1421-1423
apomorphine	O	1424-1435
was	O	1436-1439
reduced	O	1440-1447
in	O	1448-1450
animals	O	1451-1458
treated	O	1459-1466
with	O	1467-1471
THP	O	1472-1475
.	O	1475-1476

Such	O	1477-1481
an	O	1482-1484
effect	O	1485-1491
was	O	1492-1495
,	O	1495-1496
however	O	1497-1504
,	O	1504-1505
reversed	O	1506-1514
in	O	1515-1517
presence	O	1518-1526
of	O	1527-1529
RAMH	O	1530-1534
.	O	1534-1535

THP	O	1536-1539
exhibited	O	1540-1549
an	O	1550-1552
antipsychotic	O	1553-1566
-	O	1566-1567
like	O	1567-1571
profile	O	1572-1579
by	O	1580-1582
potentiating	O	1583-1595
haloperidol	O	1596-1607
-	O	1607-1608
induced	O	1608-1615
catalepsy	B	1616-1625
,	O	1625-1626
reducing	O	1627-1635
amphetamine	O	1636-1647
-	O	1647-1648
induced	O	1648-1655
hyperactivity	B	1656-1669
and	O	1670-1673
reducing	O	1674-1682
apomorphine	O	1683-1694
-	O	1694-1695
induced	O	1695-1702
climbing	O	1703-1711
in	O	1712-1714
mice	O	1715-1719
.	O	1719-1720

Such	O	1721-1725
effects	O	1726-1733
of	O	1734-1736
THP	O	1737-1740
were	O	1741-1745
reversed	O	1746-1754
by	O	1755-1757
RAMH	O	1758-1762
indicating	O	1763-1773
the	O	1774-1777
involvement	O	1778-1789
of	O	1790-1792
histamine	O	1793-1802
H	O	1803-1804
(	O	1804-1805
3	O	1805-1806
)	O	1806-1807
-	O	1807-1808
receptors	O	1808-1817
.	O	1817-1818

Findings	O	1819-1827
suggest	O	1828-1835
a	O	1836-1837
potential	O	1838-1847
for	O	1848-1851
H	O	1852-1853
(	O	1853-1854
3	O	1854-1855
)	O	1855-1856
-	O	1856-1857
receptor	O	1857-1865
antagonists	O	1866-1877
in	O	1878-1880
improving	O	1881-1890
the	O	1891-1894
refractory	O	1895-1905
cases	O	1906-1911
of	O	1912-1914
schizophrenia	B	1915-1928
.	O	1928-1929

Transient	O	0-9
platypnea	B	10-19
-	I	19-20
orthodeoxia	I	20-31
-	I	19-20
like	I	32-36
syndrome	I	37-45
induced	O	46-53
by	O	54-56
propafenone	O	57-68
overdose	B	69-77
in	O	78-80
a	O	81-82
young	O	83-88
woman	O	89-94
with	O	95-99
Ebstein	B	100-107
'	I	107-108
s	I	102-103
anomaly	I	110-117
.	O	117-118

In	O	119-121
this	O	122-126
report	O	127-133
we	O	134-136
describe	O	137-145
the	O	146-149
case	O	150-154
of	O	155-157
a	O	158-159
37	O	160-162
-	O	162-163
year	O	163-167
-	O	162-163
old	O	168-171
white	O	172-177
woman	O	178-183
with	O	184-188
Ebstein	B	189-196
'	I	196-197
s	I	191-192
anomaly	I	199-206
,	O	206-207
who	O	208-211
developed	O	212-221
a	O	222-223
rare	O	224-228
syndrome	O	229-237
called	O	238-244
platypnea	B	245-254
-	I	254-255
orthodeoxia	I	255-266
,	O	266-267
characterized	O	268-281
by	O	282-284
massive	O	285-292
right	O	293-298
-	O	298-299
to	O	299-301
-	O	298-299
left	O	302-306
interatrial	O	307-318
shunting	O	319-327
with	O	328-332
transient	O	333-342
profound	O	343-351
hypoxia	B	352-359
and	O	360-363
cyanosis	B	364-372
.	O	372-373

This	O	374-378
shunt	O	379-384
of	O	385-387
blood	O	388-393
via	O	394-397
a	O	398-399
patent	B	400-406
foramen	I	407-414
ovale	I	415-420
occurred	O	421-429
in	O	430-432
the	O	433-436
presence	O	437-445
of	O	446-448
a	O	449-450
normal	O	451-457
pulmonary	O	458-467
artery	O	468-474
pressure	O	475-483
,	O	483-484
and	O	485-488
was	O	489-492
probably	O	493-501
precipitated	O	502-514
by	O	515-517
a	O	518-519
propafenone	O	520-531
overdose	B	532-540
.	O	540-541

This	O	542-546
drug	O	547-551
caused	O	552-558
biventricular	B	559-572
dysfunction	I	573-584
,	O	584-585
due	O	586-589
to	O	590-592
its	O	593-596
negative	O	597-605
inotropic	O	606-615
effect	O	616-622
,	O	622-623
and	O	624-627
hypotension	B	628-639
,	O	639-640
due	O	641-644
to	O	645-647
its	O	648-651
peripheral	O	652-662
vasodilatory	O	663-675
effect	O	676-682
.	O	682-683

These	O	684-689
effects	O	690-697
gave	O	698-702
rise	O	703-707
to	O	708-710
an	O	711-713
increase	O	714-722
in	O	723-725
the	O	726-729
right	O	730-735
atrial	O	736-742
pressure	O	743-751
and	O	752-755
a	O	756-757
decrease	O	758-766
in	O	767-769
the	O	770-773
left	O	774-778
one	O	779-782
with	O	783-787
a	O	788-789
consequent	O	790-800
stretching	O	801-811
of	O	812-814
the	O	815-818
foramen	O	819-826
ovale	O	827-832
and	O	833-836
the	O	837-840
creation	O	841-849
of	O	850-852
massive	O	853-860
right	O	861-866
-	O	866-867
to	O	867-869
-	O	866-867
left	O	870-874
shunting	O	875-883
.	O	883-884

In	O	885-887
our	O	888-891
case	O	892-896
this	O	897-901
interatrial	O	902-913
shunt	O	914-919
was	O	920-923
very	O	924-928
accurately	O	929-939
detected	O	940-948
at	O	949-951
bubble	O	952-958
contrast	O	959-967
echocardiography	O	968-984
.	O	984-985

A	O	0-1
Phase	O	2-7
II	O	8-10
trial	O	11-16
of	O	17-19
cisplatin	O	20-29
plus	O	30-34
WR	O	35-37
-	O	37-38
2721	O	38-42
(	O	43-44
amifostine	O	44-54
)	O	54-55
for	O	56-59
metastatic	O	60-70
breast	B	71-77
carcinoma	I	78-87
:	O	87-88
an	O	89-91
Eastern	O	92-99
Cooperative	O	100-111
Oncology	O	112-120
Group	O	121-126
Study	O	127-132
(	O	133-134
E8188	O	134-139
)	O	139-140
.	O	140-141

BACKGROUND	O	142-152
:	O	152-153
Cisplatin	O	154-163
has	O	164-167
minimal	O	168-175
antitumor	O	176-185
activity	O	186-194
when	O	195-199
used	O	200-204
as	O	205-207
second	O	208-214
-	O	214-215
or	O	216-218
third	O	219-224
-	O	224-225
line	O	225-229
treatment	O	230-239
of	O	240-242
metastatic	O	243-253
breast	B	254-260
carcinoma	I	261-270
.	O	270-271

Older	O	272-277
reports	O	278-285
suggest	O	286-293
an	O	294-296
objective	O	297-306
response	O	307-315
rate	O	316-320
of	O	321-323
8	O	324-325
%	O	325-326
when	O	327-331
60	O	332-334
-	O	334-335
120	O	335-338
mg	O	339-341
/	O	341-342
m2	O	342-344
of	O	345-347
cisplatin	O	348-357
is	O	358-360
administered	O	361-373
every	O	374-379
3	O	380-381
-	O	381-382
4	O	382-383
weeks	O	384-389
.	O	389-390

Although	O	391-399
a	O	400-401
dose	O	402-406
-	O	406-407
response	O	407-415
effect	O	416-422
has	O	423-426
been	O	427-431
observed	O	432-440
with	O	441-445
cisplatin	O	446-455
,	O	455-456
the	O	457-460
dose	O	461-465
-	O	465-466
limiting	O	466-474
toxicities	B	475-485
associated	O	486-496
with	O	497-501
cisplatin	O	502-511
(	O	512-513
e	O	513-514
.	O	514-515
g	O	515-516
.	O	514-515
,	O	517-518
nephrotoxicity	B	519-533
,	O	533-534
ototoxicity	B	535-546
,	O	546-547
and	O	548-551
neurotoxicity	B	552-565
)	O	565-566
have	O	567-571
limited	O	572-579
its	O	580-583
use	O	584-587
as	O	588-590
a	O	591-592
treatment	O	593-602
for	O	603-606
breast	B	607-613
carcinoma	I	614-623
.	O	623-624

WR	O	625-627
-	O	627-628
2721	O	628-632
or	O	633-635
amifostine	O	636-646
initially	O	647-656
was	O	657-660
developed	O	661-670
to	O	671-673
protect	O	674-681
military	O	682-690
personnel	O	691-700
in	O	701-703
the	O	704-707
event	O	708-713
of	O	714-716
nuclear	O	717-724
war	O	725-728
.	O	728-729

Amifostine	O	730-740
subsequently	O	741-753
was	O	754-757
shown	O	758-763
to	O	764-766
protect	O	767-774
normal	O	775-781
tissues	O	782-789
from	O	790-794
the	O	795-798
toxic	O	799-804
effects	O	805-812
of	O	813-815
alkylating	O	816-826
agents	O	827-833
and	O	834-837
cisplatin	O	838-847
without	O	848-855
decreasing	O	856-866
the	O	867-870
antitumor	O	871-880
effect	O	881-887
of	O	888-890
the	O	891-894
chemotherapy	O	895-907
.	O	907-908

Early	O	909-914
trials	O	915-921
of	O	922-924
cisplatin	O	925-934
and	O	935-938
amifostine	O	939-949
also	O	950-954
suggested	O	955-964
that	O	965-969
the	O	970-973
incidence	O	974-983
and	O	984-987
severity	O	988-996
of	O	997-999
cisplatin	O	1000-1009
-	O	1009-1010
induced	O	1010-1017
nephrotoxicity	B	1018-1032
,	O	1032-1033
ototoxicity	B	1034-1045
,	O	1045-1046
and	O	1047-1050
neuropathy	B	1051-1061
were	O	1062-1066
reduced	O	1067-1074
.	O	1074-1075

METHODS	O	1076-1083
:	O	1083-1084
A	O	1085-1086
Phase	O	1087-1092
II	O	1093-1095
study	O	1096-1101
of	O	1102-1104
the	O	1105-1108
combination	O	1109-1120
of	O	1121-1123
cisplatin	O	1124-1133
plus	O	1134-1138
amifostine	O	1139-1149
was	O	1150-1153
conducted	O	1154-1163
in	O	1164-1166
patients	O	1167-1175
with	O	1176-1180
progressive	O	1181-1192
metastatic	O	1193-1203
breast	B	1204-1210
carcinoma	I	1211-1220
who	O	1221-1224
had	O	1225-1228
received	O	1229-1237
one	O	1238-1241
,	O	1241-1242
but	O	1243-1246
not	O	1247-1250
more	O	1251-1255
than	O	1256-1260
one	O	1261-1264
,	O	1264-1265
chemotherapy	O	1266-1278
regimen	O	1279-1286
for	O	1287-1290
metastatic	O	1291-1301
disease	O	1302-1309
.	O	1309-1310

Patients	O	1311-1319
received	O	1320-1328
amifostine	O	1329-1339
,	O	1339-1340
910	O	1341-1344
mg	O	1345-1347
/	O	1347-1348
m2	O	1348-1350
intravenously	O	1351-1364
over	O	1365-1369
15	O	1370-1372
minutes	O	1373-1380
.	O	1380-1381

After	O	1382-1387
completion	O	1388-1398
of	O	1399-1401
the	O	1402-1405
amifostine	O	1406-1416
infusion	O	1417-1425
,	O	1425-1426
cisplatin	O	1427-1436
120	O	1437-1440
mg	O	1441-1443
/	O	1443-1444
m2	O	1444-1446
was	O	1447-1450
administered	O	1451-1463
over	O	1464-1468
30	O	1469-1471
minutes	O	1472-1479
.	O	1479-1480

Intravenous	O	1481-1492
hydration	O	1493-1502
and	O	1503-1506
mannitol	O	1507-1515
was	O	1516-1519
administered	O	1520-1532
before	O	1533-1539
and	O	1540-1543
after	O	1544-1549
cisplatin	O	1550-1559
.	O	1559-1560

Treatment	O	1561-1570
was	O	1571-1574
administered	O	1575-1587
every	O	1588-1593
3	O	1594-1595
weeks	O	1596-1601
until	O	1602-1607
disease	O	1608-1615
progression	O	1616-1627
.	O	1627-1628

RESULTS	O	1629-1636
:	O	1636-1637
Forty	O	1638-1643
-	O	1643-1644
four	O	1644-1648
patients	O	1649-1657
were	O	1658-1662
enrolled	O	1663-1671
in	O	1672-1674
the	O	1675-1678
study	O	1679-1684
of	O	1685-1687
which	O	1688-1693
7	O	1694-1695
(	O	1696-1697
16	O	1697-1699
%	O	1699-1700
)	O	1700-1701
were	O	1702-1706
ineligible	O	1707-1717
.	O	1717-1718

A	O	1719-1720
median	O	1721-1727
of	O	1728-1730
2	O	1731-1732
cycles	O	1733-1739
of	O	1740-1742
therapy	O	1743-1750
was	O	1751-1754
administered	O	1755-1767
to	O	1768-1770
the	O	1771-1774
37	O	1775-1777
eligible	O	1778-1786
patients	O	1787-1795
.	O	1795-1796

Six	O	1797-1800
partial	O	1801-1808
responses	O	1809-1818
were	O	1819-1823
observed	O	1824-1832
for	O	1833-1836
an	O	1837-1839
overall	O	1840-1847
response	O	1848-1856
rate	O	1857-1861
of	O	1862-1864
16	O	1865-1867
%	O	1867-1868
.	O	1868-1869

Most	O	1870-1874
patients	O	1875-1883
(	O	1884-1885
57	O	1885-1887
%	O	1887-1888
)	O	1888-1889
stopped	O	1890-1897
treatment	O	1898-1907
because	O	1908-1915
of	O	1916-1918
disease	O	1919-1926
progression	O	1927-1938
.	O	1938-1939

Neurologic	B	1940-1950
toxicity	I	1951-1959
was	O	1960-1963
reported	O	1964-1972
in	O	1973-1975
52	O	1976-1978
%	O	1978-1979
of	O	1980-1982
patients	O	1983-1991
.	O	1991-1992

Seven	O	1993-1998
different	O	1999-2008
life	O	2009-2013
-	O	2013-2014
threatening	O	2014-2025
toxicities	B	2026-2036
were	O	2037-2041
observed	O	2042-2050
in	O	2051-2053
patients	O	2054-2062
while	O	2063-2068
receiving	O	2069-2078
treatment	O	2079-2088
.	O	2088-2089

CONCLUSIONS	O	2090-2101
:	O	2101-2102
The	O	2103-2106
combination	O	2107-2118
of	O	2119-2121
cisplatin	O	2122-2131
and	O	2132-2135
amifostine	O	2136-2146
in	O	2147-2149
this	O	2150-2154
study	O	2155-2160
resulted	O	2161-2169
in	O	2170-2172
an	O	2173-2175
overall	O	2176-2183
response	O	2184-2192
rate	O	2193-2197
of	O	2198-2200
16	O	2201-2203
%	O	2203-2204
.	O	2204-2205

Neither	O	2206-2213
a	O	2214-2215
tumor	B	2216-2221
-	O	2221-2222
protective	O	2222-2232
effect	O	2233-2239
nor	O	2240-2243
reduced	O	2244-2251
toxicity	B	2252-2260
to	O	2261-2263
normal	O	2264-2270
tissues	O	2271-2278
was	O	2279-2282
observed	O	2283-2291
with	O	2292-2296
the	O	2297-2300
addition	O	2301-2309
of	O	2310-2312
amifostine	O	2313-2323
to	O	2324-2326
cisplatin	O	2327-2336
in	O	2337-2339
this	O	2340-2344
trial	O	2345-2350
.	O	2350-2351

Warfarin	O	0-8
-	O	8-9
induced	O	9-16
iliopsoas	O	17-26
hemorrhage	B	27-37
with	O	38-42
subsequent	O	43-53
femoral	B	54-61
nerve	I	62-67
palsy	I	68-73
.	O	73-74

We	O	75-77
present	O	78-85
the	O	86-89
case	O	90-94
of	O	95-97
a	O	98-99
28	O	100-102
-	O	102-103
year	O	103-107
-	O	102-103
old	O	108-111
man	O	112-115
on	O	116-118
chronic	O	119-126
warfarin	O	127-135
therapy	O	136-143
who	O	144-147
sustained	O	148-157
a	O	158-159
minor	O	160-165
muscle	B	166-172
tear	I	173-177
and	O	178-181
developed	O	182-191
increasing	O	192-202
pain	B	203-207
and	O	208-211
a	O	212-213
flexure	O	214-221
contracture	B	222-233
of	O	234-236
the	O	237-240
right	O	241-246
hip	O	247-250
.	O	250-251

Surgical	O	252-260
exploration	O	261-272
revealed	O	273-281
an	O	282-284
iliopsoas	O	285-294
hematoma	B	295-303
and	O	304-307
femoral	O	308-315
nerve	B	316-321
entrapment	I	322-332
,	O	332-333
resulting	O	334-343
in	O	344-346
a	O	347-348
femoral	B	349-356
nerve	I	357-362
palsy	I	363-368
and	O	369-372
partial	B	373-380
loss	I	381-385
of	I	386-388
quadriceps	I	389-399
functions	I	400-409
.	O	409-410

Anticoagulant	O	411-424
-	O	424-425
induced	O	425-432
femoral	B	433-440
nerve	I	441-446
palsy	I	447-452
represents	O	453-463
the	O	464-467
most	O	468-472
common	O	473-479
form	O	480-484
of	O	485-487
warfarin	O	488-496
-	O	496-497
induced	O	497-504
peripheral	B	505-515
neuropathy	I	516-526
;	O	526-527
it	O	528-530
is	O	531-533
characterized	O	534-547
by	O	548-550
severe	O	551-557
pain	B	558-562
in	O	563-565
the	O	566-569
inguinal	O	570-578
region	O	579-585
,	O	585-586
varying	O	587-594
degrees	O	595-602
of	O	603-605
motor	B	606-611
and	I	612-615
sensory	I	616-623
impairment	I	624-634
,	O	634-635
and	O	636-639
flexure	O	640-647
contracture	B	648-659
of	O	660-662
the	O	663-666
involved	O	667-675
extremity	O	676-685
.	O	685-686

Myasthenia	B	0-10
gravis	I	11-17
caused	O	18-24
by	O	25-27
penicillamine	O	28-41
and	O	42-45
chloroquine	O	46-57
therapy	O	58-65
for	O	66-69
rheumatoid	B	70-80
arthritis	I	81-90
.	O	90-91

We	O	92-94
have	O	95-99
described	O	100-109
a	O	110-111
unique	O	112-118
patient	O	119-126
who	O	127-130
had	O	131-134
reversible	O	135-145
and	O	146-149
dose	O	150-154
-	O	154-155
related	O	155-162
myasthenia	B	163-173
gravis	I	174-180
after	O	181-186
penicillamine	O	187-200
and	O	201-204
chloroquine	O	205-216
therapy	O	217-224
for	O	225-228
rheumatoid	B	229-239
arthritis	I	240-249
.	O	249-250

Although	O	251-259
acetylcholine	O	260-273
receptor	O	274-282
antibodies	O	283-293
were	O	294-298
not	O	299-302
detectable	O	303-313
,	O	313-314
the	O	315-318
time	O	319-323
course	O	324-330
was	O	331-334
consistent	O	335-345
with	O	346-350
an	O	351-353
autoimmune	O	354-364
process	O	365-372
.	O	372-373

Nephrotoxicity	B	0-14
of	O	15-17
combined	O	18-26
cephalothin	O	27-38
-	O	38-39
gentamicin	O	39-49
regimen	O	50-57
.	O	57-58

Two	O	59-62
patients	O	63-71
developed	O	72-81
acute	B	82-87
tubular	I	88-95
necrosis	I	96-104
,	O	104-105
characterized	O	106-119
clinically	O	120-130
by	O	131-133
acute	O	134-139
oliguric	B	140-148
renal	I	149-154
failure	I	155-162
,	O	162-163
while	O	164-169
they	O	170-174
were	O	175-179
receiving	O	180-189
a	O	190-191
combination	O	192-203
of	O	204-206
cephalothin	O	207-218
sodium	O	219-225
and	O	226-229
gentamicin	O	230-240
sulfate	O	241-248
therapy	O	249-256
.	O	256-257

Patients	O	258-266
who	O	267-270
are	O	271-274
given	O	275-280
this	O	281-285
drug	O	286-290
regimen	O	291-298
should	O	299-305
be	O	306-308
observed	O	309-317
very	O	318-322
carefully	O	323-332
for	O	333-336
early	O	337-342
signs	O	343-348
of	O	349-351
nephrotoxicity	B	352-366
.	O	366-367

High	O	368-372
doses	O	373-378
of	O	379-381
this	O	382-386
antibiotic	O	387-397
combination	O	398-409
should	O	410-416
be	O	417-419
avoided	O	420-427
especially	O	428-438
in	O	439-441
elderly	O	442-449
patients	O	450-458
.	O	458-459

Patients	O	460-468
with	O	469-473
renal	B	474-479
insufficiency	I	480-493
should	O	494-500
not	O	501-504
be	O	505-507
given	O	508-513
this	O	514-518
regimen	O	519-526
.	O	526-527

Components	O	0-10
of	O	11-13
lemon	O	14-19
essential	O	20-29
oil	O	30-33
attenuate	O	34-43
dementia	B	44-52
induced	O	53-60
by	O	61-63
scopolamine	O	64-75
.	O	75-76

The	O	77-80
anti	O	81-85
-	O	85-86
dementia	B	86-94
effects	O	95-102
of	O	103-105
s	O	106-107
-	O	107-108
limonene	O	108-116
and	O	117-120
s	O	121-122
-	O	122-123
perillyl	O	123-131
alcohol	O	132-139
were	O	140-144
observed	O	145-153
using	O	154-159
the	O	160-163
passive	O	164-171
avoidance	O	172-181
test	O	182-186
(	O	187-188
PA	O	188-190
)	O	190-191
and	O	192-195
the	O	196-199
open	O	200-204
field	O	205-210
habituation	O	211-222
test	O	223-227
(	O	228-229
OFH	O	229-232
)	O	232-233
.	O	233-234

These	O	235-240
lemon	O	241-246
essential	O	247-256
oils	O	257-261
showed	O	262-268
strong	O	269-275
ability	O	276-283
to	O	284-286
improve	O	287-294
memory	B	295-301
impaired	I	302-310
by	O	311-313
scopolamine	O	314-325
;	O	325-326
however	O	327-334
,	O	334-335
s	O	336-337
-	O	337-338
perillyl	O	338-346
alcohol	O	347-354
relieved	O	355-363
the	O	364-367
deficit	B	368-375
of	I	376-378
associative	I	379-390
memory	I	391-397
in	O	398-400
PA	O	401-403
only	O	404-408
,	O	408-409
and	O	410-413
did	O	414-417
not	O	418-421
improve	O	422-429
non	O	430-433
-	O	433-434
associative	O	434-445
memory	O	446-452
significantly	O	453-466
in	O	467-469
OFH	O	470-473
.	O	473-474

Analysis	O	475-483
of	O	484-486
neurotransmitter	O	487-503
concentration	O	504-517
in	O	518-520
some	O	521-525
brain	O	526-531
regions	O	532-539
on	O	540-542
the	O	543-546
test	O	547-551
day	O	552-555
showed	O	556-562
that	O	563-567
dopamine	O	568-576
concentration	O	577-590
of	O	591-593
the	O	594-597
vehicle	O	598-605
/	O	605-606
scopolamine	O	606-617
group	O	618-623
was	O	624-627
significantly	O	628-641
lower	O	642-647
than	O	648-652
that	O	653-657
of	O	658-660
the	O	661-664
vehicle	O	665-672
/	O	672-673
vehicle	O	665-672
group	O	681-686
,	O	686-687
but	O	688-691
this	O	692-696
phenomenon	O	697-707
was	O	708-711
reversed	O	712-720
when	O	721-725
s	O	726-727
-	O	727-728
limonene	O	728-736
or	O	737-739
s	O	740-741
-	O	741-742
perillyl	O	742-750
alcohol	O	751-758
were	O	759-763
administered	O	764-776
before	O	777-783
the	O	784-787
injection	O	788-797
of	O	798-800
scopolamine	O	801-812
.	O	812-813

Simultaneously	O	814-828
,	O	828-829
we	O	830-832
found	O	833-838
that	O	839-843
these	O	844-849
two	O	850-853
lemon	O	854-859
essential	O	860-869
oil	O	870-873
components	O	874-884
could	O	885-890
inhibit	O	891-898
acetylcholinesterase	O	899-919
activity	O	920-928
in	O	929-931
vitro	O	932-937
using	O	938-943
the	O	944-947
Ellman	O	948-954
method	O	955-961
.	O	961-962

The	O	0-3
selective	O	4-13
5	O	14-15
-	O	15-16
HT6	O	16-19
receptor	O	20-28
antagonist	O	29-39
Ro4368554	O	40-49
restores	O	50-58
memory	O	59-65
performance	O	66-77
in	O	78-80
cholinergic	O	81-92
and	O	93-96
serotonergic	O	97-109
models	O	110-116
of	O	117-119
memory	B	120-126
deficiency	I	127-137
in	O	138-140
the	O	141-144
rat	O	145-148
.	O	148-149

Antagonists	O	150-161
at	O	162-164
serotonin	O	165-174
type	O	175-179
6	O	180-181
(	O	182-183
5	O	183-184
-	O	184-185
HT	O	185-187
(	O	182-183
6	O	188-189
)	O	189-190
)	O	189-190
receptors	O	192-201
show	O	202-206
activity	O	207-215
in	O	216-218
models	O	219-225
of	O	226-228
learning	O	229-237
and	O	238-241
memory	O	242-248
.	O	248-249

Although	O	250-258
the	O	259-262
underlying	O	263-273
mechanism	O	274-283
(	O	283-284
s	O	281-282
)	O	285-286
are	O	287-290
not	O	291-294
well	O	295-299
understood	O	300-310
,	O	310-311
these	O	312-317
effects	O	318-325
may	O	326-329
involve	O	330-337
an	O	338-340
increase	O	341-349
in	O	350-352
acetylcholine	O	353-366
(	O	367-368
ACh	O	368-371
)	O	371-372
levels	O	373-379
.	O	379-380

The	O	381-384
present	O	385-392
study	O	393-398
sought	O	399-405
to	O	406-408
characterize	O	409-421
the	O	422-425
cognitive	O	426-435
-	O	435-436
enhancing	O	436-445
effects	O	446-453
of	O	454-456
the	O	457-460
5	O	461-462
-	O	462-463
HT	O	463-465
(	O	465-466
6	O	466-467
)	O	467-468
antagonist	O	469-479
Ro4368554	O	480-489
(	O	490-491
3	O	491-492
-	O	492-493
benzenesulfonyl	O	493-508
-	O	492-493
7	O	509-510
-	O	492-493
(	O	490-491
4	O	512-513
-	O	492-493
methyl	O	514-520
-	O	492-493
piperazin	O	521-530
-	O	492-493
1	O	531-532
-	O	492-493
yl	O	506-508
)	O	535-536
1H	O	536-538
-	O	492-493
indole	O	539-545
)	O	535-536
in	O	547-549
a	O	550-551
rat	O	552-555
object	O	556-562
recognition	O	563-574
task	O	575-579
employing	O	580-589
a	O	590-591
cholinergic	O	592-603
(	O	604-605
scopolamine	O	605-616
pretreatment	O	617-629
)	O	629-630
and	O	631-634
a	O	635-636
serotonergic	O	637-649
-	O	649-650
(	O	651-652
tryptophan	O	652-662
(	O	663-664
TRP	O	664-667
)	O	667-668
depletion	O	669-678
)	O	678-679
deficient	O	680-689
model	O	690-695
,	O	695-696
and	O	697-700
compared	O	701-709
its	O	710-713
pattern	O	714-721
of	O	722-724
action	O	725-731
with	O	732-736
that	O	737-741
of	O	742-744
the	O	745-748
acetylcholinesterase	O	749-769
inhibitor	O	770-779
metrifonate	O	780-791
.	O	791-792

Initial	O	793-800
testing	O	801-808
in	O	809-811
a	O	812-813
time	O	814-818
-	O	818-819
dependent	O	819-828
forgetting	O	829-839
task	O	840-844
employing	O	845-854
a	O	855-856
24	O	857-859
-	O	859-860
h	O	860-861
delay	O	862-867
between	O	868-875
training	O	876-884
and	O	885-888
testing	O	889-896
showed	O	897-903
that	O	904-908
metrifonate	O	909-920
improved	O	921-929
object	O	930-936
recognition	O	937-948
(	O	949-950
at	O	950-952
10	O	953-955
and	O	956-959
30	O	960-962
mg	O	963-965
/	O	965-966
kg	O	966-968
,	O	968-969
p	O	970-971
.	O	971-972
o	O	972-973
.	O	971-972
)	O	974-975
,	O	975-976
whereas	O	977-984
Ro4368554	O	985-994
was	O	995-998
inactive	O	999-1007
.	O	1007-1008

Both	O	1009-1013
,	O	1013-1014
Ro4368554	O	1015-1024
(	O	1025-1026
3	O	1026-1027
and	O	1028-1031
10	O	1032-1034
mg	O	1035-1037
/	O	1037-1038
kg	O	1038-1040
,	O	1040-1041
intraperitoneally	O	1042-1059
(	O	1060-1061
i	O	1061-1062
.	O	1062-1063
p	O	1063-1064
.	O	1062-1063
)	O	1065-1066
)	O	1065-1066
and	O	1068-1071
metrifonate	O	1072-1083
(	O	1084-1085
10	O	1085-1087
mg	O	1088-1090
/	O	1090-1091
kg	O	1091-1093
,	O	1093-1094
p	O	1095-1096
.	O	1096-1097
o	O	1097-1098
.	O	1096-1097
,	O	1099-1100
respectively	O	1101-1113
)	O	1113-1114
reversed	O	1115-1123
memory	B	1124-1130
deficits	I	1131-1139
induced	O	1140-1147
by	O	1148-1150
scopolamine	O	1151-1162
and	O	1163-1166
TRP	O	1167-1170
depletion	O	1171-1180
(	O	1181-1182
10	O	1182-1184
mg	O	1185-1187
/	O	1187-1188
kg	O	1188-1190
,	O	1190-1191
i	O	1192-1193
.	O	1193-1194
p	O	1194-1195
.	O	1193-1194
,	O	1196-1197
and	O	1198-1201
3	O	1202-1203
mg	O	1204-1206
/	O	1206-1207
kg	O	1207-1209
,	O	1209-1210
p	O	1211-1212
.	O	1212-1213
o	O	1213-1214
.	O	1212-1213
,	O	1215-1216
respectively	O	1217-1229
)	O	1229-1230
.	O	1230-1231

In	O	1232-1234
conclusion	O	1235-1245
,	O	1245-1246
although	O	1247-1255
Ro4368554	O	1256-1265
did	O	1266-1269
not	O	1270-1273
improve	O	1274-1281
a	O	1282-1283
time	O	1284-1288
-	O	1288-1289
related	O	1289-1296
retention	O	1297-1306
deficit	O	1307-1314
,	O	1314-1315
it	O	1316-1318
reversed	O	1319-1327
a	O	1328-1329
cholinergic	O	1330-1341
and	O	1342-1345
a	O	1346-1347
serotonergic	O	1348-1360
memory	B	1361-1367
deficit	I	1368-1375
,	O	1375-1376
suggesting	O	1377-1387
that	O	1388-1392
both	O	1393-1397
mechanisms	O	1398-1408
may	O	1409-1412
be	O	1413-1415
involved	O	1416-1424
in	O	1425-1427
the	O	1428-1431
facilitation	O	1432-1444
of	O	1445-1447
object	O	1448-1454
memory	O	1455-1461
by	O	1462-1464
Ro4368554	O	1465-1474
and	O	1475-1478
,	O	1478-1479
possibly	O	1480-1488
,	O	1488-1489
other	O	1490-1495
5	O	1496-1497
-	O	1497-1498
HT	O	1498-1500
(	O	1500-1501
6	O	1501-1502
)	O	1502-1503
receptor	O	1504-1512
antagonists	O	1513-1524
.	O	1524-1525

Lone	O	0-4
atrial	B	5-11
fibrillation	I	12-24
associated	O	25-35
with	O	36-40
creatine	O	41-49
monohydrate	O	50-61
supplementation	O	62-77
.	O	77-78

Atrial	B	79-85
fibrillation	I	86-98
in	O	99-101
young	O	102-107
patients	O	108-116
without	O	117-124
structural	O	125-135
heart	B	136-141
disease	I	142-149
is	O	150-152
rare	O	153-157
.	O	157-158

Therefore	O	159-168
,	O	168-169
when	O	170-174
the	O	175-178
arrhythmia	B	179-189
is	O	190-192
present	O	193-200
in	O	201-203
this	O	204-208
population	O	209-219
,	O	219-220
reversible	O	221-231
causes	O	232-238
must	O	239-243
be	O	244-246
identified	O	247-257
and	O	258-261
resolved	O	262-270
.	O	270-271

Thyroid	B	272-279
disorders	I	280-289
,	O	289-290
illicit	O	291-298
drug	O	299-303
or	O	304-306
stimulant	O	307-316
use	O	317-320
,	O	320-321
and	O	322-325
acute	B	326-331
alcohol	I	332-339
intoxication	I	340-352
are	O	353-356
among	O	357-362
these	O	363-368
causes	O	369-375
.	O	375-376

We	O	377-379
report	O	380-386
the	O	387-390
case	O	391-395
of	O	396-398
a	O	399-400
30	O	401-403
-	O	403-404
year	O	404-408
-	O	403-404
old	O	409-412
Caucasian	O	413-422
man	O	423-426
who	O	427-430
came	O	431-435
to	O	436-438
the	O	439-442
emergency	O	443-452
department	O	453-463
in	O	464-466
atrial	B	467-473
fibrillation	I	474-486
with	O	487-491
rapid	O	492-497
ventricular	O	498-509
response	O	510-518
.	O	518-519

His	O	520-523
medical	O	524-531
history	O	532-539
was	O	540-543
unremarkable	O	544-556
,	O	556-557
except	O	558-564
for	O	565-568
minor	O	569-574
fractures	B	575-584
of	O	585-587
the	O	588-591
fingers	O	592-599
and	O	600-603
foot	O	604-608
.	O	608-609

Thyroid	O	610-617
-	O	617-618
stimulating	O	618-629
hormone	O	630-637
,	O	637-638
magnesium	O	639-648
,	O	648-649
and	O	650-653
potassium	O	654-663
levels	O	664-670
were	O	671-675
within	O	676-682
normal	O	683-689
limits	O	690-696
,	O	696-697
urine	O	698-703
drug	O	704-708
screen	O	709-715
was	O	716-719
negative	O	720-728
,	O	728-729
and	O	730-733
alcohol	O	734-741
use	O	742-745
was	O	746-749
denied	O	750-756
.	O	756-757

However	O	758-765
,	O	765-766
when	O	767-771
the	O	772-775
patient	O	776-783
was	O	784-787
questioned	O	788-798
about	O	799-804
use	O	805-808
of	O	809-811
herbal	O	812-818
products	O	819-827
and	O	828-831
supplements	O	832-843
,	O	843-844
the	O	845-848
use	O	849-852
of	O	853-855
creatine	O	856-864
monohydrate	O	865-876
was	O	877-880
revealed	O	881-889
.	O	889-890

The	O	891-894
patient	O	895-902
was	O	903-906
admitted	O	907-915
to	O	916-918
the	O	919-922
hospital	O	923-931
,	O	931-932
anticoagulated	O	933-947
with	O	948-952
unfractionated	O	953-967
heparin	O	968-975
,	O	975-976
and	O	977-980
given	O	981-986
intravenous	O	987-998
diltiazem	O	999-1008
for	O	1009-1012
rate	O	1013-1017
control	O	1018-1025
and	O	1026-1029
intravenous	O	1030-1041
amiodarone	O	1042-1052
for	O	1053-1056
rate	O	1057-1061
and	O	1062-1065
rhythm	O	1066-1072
control	O	1073-1080
.	O	1080-1081

When	O	1082-1086
discharged	O	1087-1097
less	O	1098-1102
than	O	1103-1107
24	O	1108-1110
hours	O	1111-1116
later	O	1117-1122
,	O	1122-1123
he	O	1124-1126
was	O	1127-1130
receiving	O	1131-1140
metoprolol	O	1141-1151
and	O	1152-1155
aspirin	O	1156-1163
,	O	1163-1164
with	O	1165-1169
follow	O	1170-1176
-	O	1176-1177
up	O	1177-1179
plans	O	1180-1185
for	O	1186-1189
echocardiography	O	1190-1206
and	O	1207-1210
nuclear	O	1211-1218
imaging	O	1219-1226
to	O	1227-1229
assess	O	1230-1236
perfusion	O	1237-1246
.	O	1246-1247

Exogenous	O	1248-1257
creatine	O	1258-1266
is	O	1267-1269
used	O	1270-1274
by	O	1275-1277
athletes	O	1278-1286
to	O	1287-1289
theoretically	O	1290-1303
improve	O	1304-1311
exercise	O	1312-1320
performance	O	1321-1332
.	O	1332-1333

Vegetarians	O	1334-1345
may	O	1346-1349
also	O	1350-1354
take	O	1355-1359
creatine	O	1360-1368
to	O	1369-1371
replace	O	1372-1379
what	O	1380-1384
they	O	1385-1389
are	O	1390-1393
not	O	1394-1397
consuming	O	1398-1407
from	O	1408-1412
meat	O	1413-1417
,	O	1417-1418
fish	O	1419-1423
,	O	1423-1424
and	O	1425-1428
other	O	1429-1434
animal	O	1435-1441
products	O	1442-1450
.	O	1450-1451

Previous	O	1452-1460
anecdotal	O	1461-1470
reports	O	1471-1478
have	O	1479-1483
linked	O	1484-1490
creatine	O	1491-1499
to	O	1500-1502
the	O	1503-1506
development	O	1507-1518
of	O	1519-1521
arrhythmia	B	1522-1532
.	O	1532-1533

Clinicians	O	1534-1544
must	O	1545-1549
be	O	1550-1552
diligent	O	1553-1561
when	O	1562-1566
interviewing	O	1567-1579
patients	O	1580-1588
about	O	1589-1594
their	O	1595-1600
drug	O	1601-1605
therapy	O	1606-1613
histories	O	1614-1623
and	O	1624-1627
include	O	1628-1635
questions	O	1636-1645
about	O	1646-1651
their	O	1652-1657
use	O	1658-1661
of	O	1662-1664
herbal	O	1665-1671
products	O	1672-1680
and	O	1681-1684
dietary	O	1685-1692
supplements	O	1693-1704
.	O	1704-1705

In	O	1706-1708
addition	O	1709-1717
,	O	1717-1718
it	O	1719-1721
is	O	1722-1724
important	O	1725-1734
to	O	1735-1737
report	O	1738-1744
adverse	O	1745-1752
effects	O	1753-1760
associated	O	1761-1771
with	O	1772-1776
frequently	O	1777-1787
consumed	O	1788-1796
supplements	O	1797-1808
and	O	1809-1812
herbal	O	1813-1819
products	O	1820-1828
to	O	1829-1831
the	O	1832-1835
Food	O	1836-1840
and	O	1841-1844
Drug	O	1845-1849
Administration	O	1850-1864
and	O	1865-1868
in	O	1869-1871
the	O	1872-1875
literature	O	1876-1886
.	O	1886-1887

Comparison	O	0-10
of	O	11-13
developmental	O	14-27
toxicity	B	28-36
of	O	37-39
selective	O	40-49
and	O	50-53
non	O	54-57
-	O	57-58
selective	O	58-67
cyclooxygenase	O	68-82
-	O	82-83
2	O	83-84
inhibitors	O	85-95
in	O	96-98
CRL	O	99-102
:	O	102-103
(	O	103-104
WI	O	104-106
)	O	106-107
WUBR	O	107-111
Wistar	O	112-118
rats	O	119-123
-	O	123-124
-	O	123-124
DFU	O	125-128
and	O	129-132
piroxicam	O	133-142
study	O	143-148
.	O	148-149

BACKGROUND	O	150-160
:	O	160-161
Cyclooxygenase	O	162-176
(	O	177-178
COX	O	178-181
)	O	181-182
inhibitors	O	183-193
are	O	194-197
one	O	198-201
of	O	202-204
the	O	205-208
most	O	209-213
often	O	214-219
ingested	O	220-228
drugs	O	229-234
during	O	235-241
pregnancy	O	242-251
.	O	251-252

Unlike	O	253-259
general	O	260-267
toxicity	B	268-276
data	O	277-281
,	O	281-282
their	O	283-288
prenatal	O	289-297
toxic	O	298-303
effects	O	304-311
were	O	312-316
not	O	317-320
extensively	O	321-332
studied	O	333-340
before	O	341-347
.	O	347-348

The	O	349-352
aim	O	353-356
of	O	357-359
the	O	360-363
experiment	O	364-374
was	O	375-378
to	O	379-381
evaluate	O	382-390
the	O	391-394
developmental	O	395-408
toxicity	B	409-417
of	O	418-420
the	O	421-424
non	O	425-428
-	O	428-429
selective	O	429-438
(	O	439-440
piroxicam	O	440-449
)	O	449-450
and	O	451-454
selective	O	455-464
(	O	465-466
DFU	O	466-469
;	O	469-470
5	O	471-472
,	O	472-473
5	O	471-472
-	O	474-475
dimethyl	O	475-483
-	O	474-475
3	O	484-485
-	O	474-475
(	O	486-487
3	O	484-485
-	O	474-475
fluorophenyl	O	489-501
)	O	501-502
-	O	474-475
4	O	503-504
-	O	474-475
(	O	486-487
4	O	503-504
-	O	474-475
methylsulphonyl	O	508-523
)	O	501-502
phenyl	O	525-531
-	O	531-532
2	O	532-533
(	O	533-534
5H	O	534-536
)	O	536-537
-	O	531-532
furanon	O	538-545
)	O	536-537
COX	O	547-550
-	O	550-551
2	O	551-552
inhibitors	O	553-563
.	O	563-564

METHODS	O	565-572
:	O	572-573
Drugs	O	574-579
were	O	580-584
separately	O	585-595
,	O	595-596
orally	O	597-603
once	O	604-608
daily	O	609-614
dosed	O	615-620
to	O	621-623
pregnant	O	624-632
rats	O	633-637
from	O	638-642
day	O	643-646
8	O	647-648
to	O	649-651
21	O	652-654
(	O	655-656
GD1	O	656-659
=	O	659-660
plug	O	660-664
day	O	665-668
)	O	668-669
.	O	669-670

Doses	O	671-676
were	O	677-681
set	O	682-685
at	O	686-688
0	O	689-690
.	O	690-691
3	O	691-692
,	O	692-693
3	O	694-695
.	O	695-696
0	O	696-697
and	O	698-701
30	O	702-704
.	O	704-705
0mg	O	705-708
/	O	708-709
kg	O	709-711
for	O	712-715
piroxicam	O	716-725
and	O	726-729
0	O	730-731
.	O	731-732
2	O	732-733
,	O	733-734
2	O	735-736
.	O	736-737
0	O	737-738
and	O	739-742
20	O	743-745
.	O	745-746
0mg	O	746-749
/	O	749-750
kg	O	750-752
for	O	753-756
DFU	O	757-760
.	O	760-761

Fetuses	O	762-769
were	O	770-774
delivered	O	775-784
on	O	785-787
GD	O	788-790
21	O	791-793
and	O	794-797
routinely	O	798-807
examined	O	808-816
.	O	816-817

Comprehensive	O	818-831
clinical	O	832-840
and	O	841-844
developmental	O	845-858
measurements	O	859-871
were	O	872-876
done	O	877-881
.	O	881-882

The	O	883-886
pooled	O	887-893
statistical	O	894-905
analysis	O	906-914
for	O	915-918
ventricular	B	919-930
septal	I	931-937
(	I	938-939
VSD	I	939-942
)	I	942-943
and	I	944-947
midline	I	948-955
(	I	956-957
MD	I	957-959
)	I	959-960
defects	I	961-968
was	O	969-972
performed	O	973-982
for	O	983-986
rat	O	987-990
fetuses	O	991-998
exposed	O	999-1006
to	O	1007-1009
piroxicam	O	1010-1019
,	O	1019-1020
selective	O	1021-1030
and	O	1031-1034
non	O	1035-1038
-	O	1038-1039
selective	O	1039-1048
COX	O	1049-1052
-	O	1052-1053
2	O	1053-1054
inhibitor	O	1055-1064
based	O	1065-1070
on	O	1071-1073
present	O	1074-1081
and	O	1082-1085
historic	O	1086-1094
data	O	1095-1099
.	O	1099-1100

RESULTS	O	1101-1108
:	O	1108-1109
Maternal	O	1110-1118
toxicity	B	1119-1127
,	O	1127-1128
intrauterine	B	1129-1141
growth	I	1142-1148
retardation	I	1149-1160
,	O	1160-1161
and	O	1162-1165
increase	B	1166-1174
of	I	1175-1177
external	I	1178-1186
and	I	1187-1190
skeletal	I	1191-1199
variations	I	1200-1210
were	O	1211-1215
found	O	1216-1221
in	O	1222-1224
rats	O	1225-1229
treated	O	1230-1237
with	O	1238-1242
the	O	1243-1246
highest	O	1247-1254
dose	O	1255-1259
of	O	1260-1262
piroxicam	O	1263-1272
.	O	1272-1273

Decrease	O	1274-1282
of	O	1283-1285
fetal	O	1286-1291
length	O	1292-1298
was	O	1299-1302
the	O	1303-1306
only	O	1307-1311
signs	O	1312-1317
of	O	1318-1320
the	O	1321-1324
DFU	O	1325-1328
developmental	O	1329-1342
toxicity	B	1343-1351
observed	O	1352-1360
in	O	1361-1363
pups	O	1364-1368
exposed	O	1369-1376
to	O	1377-1379
the	O	1380-1383
highest	O	1384-1391
compound	O	1392-1400
dose	O	1401-1405
.	O	1405-1406

Lack	O	1407-1411
of	O	1412-1414
teratogenicity	O	1415-1429
was	O	1430-1433
found	O	1434-1439
in	O	1440-1442
piroxicam	O	1443-1452
and	O	1453-1456
DFU	O	1457-1460
-	O	1460-1461
exposed	O	1461-1468
groups	O	1469-1475
.	O	1475-1476

Prenatal	O	1477-1485
exposure	O	1486-1494
to	O	1495-1497
non	O	1498-1501
-	O	1501-1502
selective	O	1502-1511
COX	O	1512-1515
inhibitors	O	1516-1526
increases	O	1527-1536
the	O	1537-1540
risk	O	1541-1545
of	O	1546-1548
VSD	O	1549-1552
and	O	1553-1556
MD	O	1557-1559
when	O	1560-1564
compared	O	1565-1573
to	O	1574-1576
historic	O	1577-1585
control	O	1586-1593
but	O	1594-1597
not	O	1598-1601
with	O	1602-1606
selective	O	1607-1616
COX	O	1617-1620
-	O	1620-1621
2	O	1621-1622
inhibitors	O	1623-1633
.	O	1633-1634

CONCLUSION	O	1635-1645
:	O	1645-1646
Both	O	1647-1651
selective	O	1652-1661
and	O	1662-1665
non	O	1666-1669
-	O	1669-1670
selective	O	1670-1679
COX	O	1680-1683
-	O	1683-1684
2	O	1684-1685
inhibitors	O	1686-1696
were	O	1697-1701
toxic	O	1702-1707
for	O	1708-1711
rats	O	1712-1716
fetuses	O	1717-1724
when	O	1725-1729
administered	O	1730-1742
in	O	1743-1745
the	O	1746-1749
highest	O	1750-1757
dose	O	1758-1762
.	O	1762-1763

Unlike	O	1764-1770
DFU	O	1771-1774
,	O	1774-1775
piroxicam	O	1776-1785
was	O	1786-1789
also	O	1790-1794
highly	O	1795-1801
toxic	O	1802-1807
to	O	1808-1810
the	O	1811-1814
dams	O	1815-1819
.	O	1819-1820

Prenatal	O	1821-1829
exposure	O	1830-1838
to	O	1839-1841
selective	O	1842-1851
COX	O	1852-1855
-	O	1855-1856
2	O	1856-1857
inhibitors	O	1858-1868
does	O	1869-1873
not	O	1874-1877
increase	O	1878-1886
the	O	1887-1890
risk	O	1891-1895
of	O	1896-1898
ventricular	B	1899-1910
septal	I	1911-1917
and	I	1918-1921
midline	I	1922-1929
defects	I	1930-1937
in	O	1938-1940
rat	O	1941-1944
when	O	1945-1949
compared	O	1950-1958
to	O	1959-1961
non	O	1962-1965
-	O	1965-1966
selective	O	1966-1975
drugs	O	1976-1981
and	O	1982-1985
historic	O	1986-1994
control	O	1995-2002
.	O	2002-2003

Protective	O	0-10
efficacy	O	11-19
of	O	20-22
neuroactive	O	23-34
steroids	O	35-43
against	O	44-51
cocaine	O	52-59
kindled	O	60-67
-	O	67-68
seizures	B	68-76
in	O	77-79
mice	O	80-84
.	O	84-85

Neuroactive	O	86-97
steroids	O	98-106
demonstrate	O	107-118
pharmacological	O	119-134
actions	O	135-142
that	O	143-147
have	O	148-152
relevance	O	153-162
for	O	163-166
a	O	167-168
host	O	169-173
of	O	174-176
neurological	B	177-189
and	I	190-193
psychiatric	I	194-205
disorders	I	206-215
.	O	215-216

They	O	217-221
offer	O	222-227
protection	O	228-238
against	O	239-246
seizures	B	247-255
in	O	256-258
a	O	259-260
range	O	261-266
of	O	267-269
models	O	270-276
and	O	277-280
seem	O	281-285
to	O	286-288
inhibit	O	289-296
certain	O	297-304
stages	O	305-311
of	O	312-314
drug	B	315-319
dependence	I	320-330
in	O	331-333
preclinical	O	334-345
assessments	O	346-357
.	O	357-358

The	O	359-362
present	O	363-370
study	O	371-376
was	O	377-380
designed	O	381-389
to	O	390-392
evaluate	O	393-401
two	O	402-405
endogenous	O	406-416
and	O	417-420
one	O	421-424
synthetic	O	425-434
neuroactive	O	435-446
steroid	O	447-454
that	O	455-459
positively	O	460-470
modulate	O	471-479
the	O	480-483
gamma	O	484-489
-	O	489-490
aminobutyric	O	490-502
acid	O	503-507
(	O	508-509
GABA	O	509-513
(	O	508-509
A	O	510-511
)	O	515-516
)	O	515-516
receptor	O	518-526
against	O	527-534
the	O	535-538
increase	O	539-547
in	O	548-550
sensitivity	O	551-562
to	O	563-565
the	O	566-569
convulsant	O	570-580
effects	O	581-588
of	O	589-591
cocaine	O	592-599
engendered	O	600-610
by	O	611-613
repeated	O	614-622
cocaine	O	623-630
administration	O	631-645
(	O	646-647
seizure	B	647-654
kindling	O	655-663
)	O	663-664
.	O	664-665

Allopregnanolone	O	666-682
(	O	683-684
3alpha	O	684-690
-	O	690-691
hydroxy	O	691-698
-	O	690-691
5alpha	O	699-705
-	O	690-691
pregnan	O	706-713
-	O	690-691
20	O	714-716
-	O	690-691
one	O	717-720
)	O	720-721
,	O	721-722
pregnanolone	O	723-735
(	O	736-737
3alpha	O	737-743
-	O	743-744
hydroxy	O	744-751
-	O	743-744
5beta	O	752-757
-	O	743-744
pregnan	O	758-765
-	O	743-744
20	O	766-768
-	O	743-744
one	O	769-772
)	O	772-773
and	O	774-777
ganaxolone	O	778-788
(	O	789-790
a	O	790-791
synthetic	O	792-801
derivative	O	802-812
of	O	813-815
allopregnanolone	O	816-832
3alpha	O	833-839
-	O	839-840
hydroxy	O	840-847
-	O	839-840
3beta	O	848-853
-	O	839-840
methyl	O	854-860
-	O	839-840
5alpha	O	861-867
-	O	839-840
pregnan	O	868-875
-	O	839-840
20	O	876-878
-	O	839-840
one	O	879-882
)	O	882-883
were	O	884-888
tested	O	889-895
for	O	896-899
their	O	900-905
ability	O	906-913
to	O	914-916
suppress	O	917-925
the	O	926-929
expression	O	930-940
(	O	941-942
anticonvulsant	O	942-956
effect	O	957-963
)	O	963-964
and	O	965-968
development	O	969-980
(	O	981-982
antiepileptogenic	O	982-999
effect	O	1000-1006
)	O	1006-1007
of	O	1008-1010
cocaine	O	1011-1018
-	O	1018-1019
kindled	O	1019-1026
seizures	B	1027-1035
in	O	1036-1038
male	O	1039-1043
,	O	1043-1044
Swiss	O	1045-1050
-	O	1050-1051
Webster	O	1051-1058
mice	O	1059-1063
.	O	1063-1064

Kindled	O	1065-1072
seizures	B	1073-1081
were	O	1082-1086
induced	O	1087-1094
by	O	1095-1097
daily	O	1098-1103
administration	O	1104-1118
of	O	1119-1121
60	O	1122-1124
mg	O	1125-1127
/	O	1127-1128
kg	O	1128-1130
cocaine	O	1131-1138
for	O	1139-1142
5	O	1143-1144
days	O	1145-1149
.	O	1149-1150

All	O	1151-1154
of	O	1155-1157
these	O	1158-1163
positive	O	1164-1172
GABA	O	1173-1177
(	O	1177-1178
A	O	1174-1175
)	O	1179-1180
modulators	O	1181-1191
suppressed	O	1192-1202
the	O	1203-1206
expression	O	1207-1217
of	O	1218-1220
kindled	O	1221-1228
seizures	B	1229-1237
,	O	1237-1238
whereas	O	1239-1246
only	O	1247-1251
allopregnanolone	O	1252-1268
and	O	1269-1272
ganaxolone	O	1273-1283
inhibited	O	1284-1293
the	O	1294-1297
development	O	1298-1309
of	O	1310-1312
kindling	O	1313-1321
.	O	1321-1322

Allopregnanolone	O	1323-1339
and	O	1340-1343
pregnanolone	O	1344-1356
,	O	1356-1357
but	O	1358-1361
not	O	1362-1365
ganaxolone	O	1366-1376
,	O	1376-1377
also	O	1378-1382
reduced	O	1383-1390
cumulative	O	1391-1401
lethality	O	1402-1411
associated	O	1412-1422
with	O	1423-1427
kindling	O	1428-1436
.	O	1436-1437

These	O	1438-1443
findings	O	1444-1452
demonstrate	O	1453-1464
that	O	1465-1469
some	O	1470-1474
neuroactive	O	1475-1486
steroids	O	1487-1495
attenuate	O	1496-1505
convulsant	O	1506-1516
and	O	1517-1520
sensitizing	O	1521-1532
properties	O	1533-1543
of	O	1544-1546
cocaine	O	1547-1554
and	O	1555-1558
add	O	1559-1562
to	O	1563-1565
a	O	1566-1567
growing	O	1568-1575
literature	O	1576-1586
on	O	1587-1589
their	O	1590-1595
potential	O	1596-1605
use	O	1606-1609
in	O	1610-1612
the	O	1613-1616
modulation	O	1617-1627
of	O	1628-1630
effects	O	1631-1638
of	O	1639-1641
drugs	O	1642-1647
of	O	1648-1650
abuse	O	1651-1656
.	O	1656-1657

Kidney	O	0-6
function	O	7-15
and	O	16-19
morphology	O	20-30
after	O	31-36
short	O	37-42
-	O	42-43
term	O	43-47
combination	O	48-59
therapy	O	60-67
with	O	68-72
cyclosporine	O	73-85
A	O	86-87
,	O	87-88
tacrolimus	O	89-99
and	O	100-103
sirolimus	O	104-113
in	O	114-116
the	O	117-120
rat	O	121-124
.	O	124-125

BACKGROUND	O	126-136
:	O	136-137
Sirolimus	O	138-147
(	O	148-149
SRL	O	149-152
)	O	152-153
may	O	154-157
supplement	O	158-168
calcineurin	O	169-180
inhibitors	O	181-191
in	O	192-194
clinical	O	195-203
organ	O	204-209
transplantation	O	210-225
.	O	225-226

These	O	227-232
are	O	233-236
nephrotoxic	B	237-248
,	O	248-249
but	O	250-253
SRL	O	254-257
seems	O	258-263
to	O	264-266
act	O	267-270
differently	O	271-282
displaying	O	283-293
only	O	294-298
minor	O	299-304
nephrotoxic	B	305-316
effects	O	317-324
,	O	324-325
although	O	326-334
this	O	335-339
question	O	340-348
is	O	349-351
still	O	352-357
open	O	358-362
.	O	362-363

In	O	364-366
a	O	367-368
number	O	369-375
of	O	376-378
treatment	O	379-388
protocols	O	389-398
where	O	399-404
SRL	O	405-408
was	O	409-412
combined	O	413-421
with	O	422-426
a	O	427-428
calcineurin	O	429-440
inhibitor	O	441-450
indications	O	451-462
of	O	463-465
a	O	466-467
synergistic	O	468-479
nephrotoxic	B	480-491
effect	O	492-498
were	O	499-503
described	O	504-513
.	O	513-514

The	O	515-518
aim	O	519-522
of	O	523-525
this	O	526-530
study	O	531-536
was	O	537-540
to	O	541-543
examine	O	544-551
further	O	552-559
the	O	560-563
renal	O	564-569
function	O	570-578
,	O	578-579
including	O	580-589
morphological	O	590-603
analysis	O	604-612
of	O	613-615
the	O	616-619
kidneys	O	620-627
of	O	628-630
male	O	631-635
Sprague	O	636-643
-	O	643-644
Dawley	O	644-650
rats	O	651-655
treated	O	656-663
with	O	664-668
either	O	669-675
cyclosporine	O	676-688
A	O	689-690
(	O	691-692
CsA	O	692-695
)	O	695-696
,	O	696-697
tacrolimus	O	698-708
(	O	709-710
FK506	O	710-715
)	O	715-716
or	O	717-719
SRL	O	720-723
as	O	724-726
monotherapies	O	727-740
or	O	741-743
in	O	744-746
different	O	747-756
combinations	O	757-769
.	O	769-770

METHODS	O	771-778
:	O	778-779
For	O	780-783
a	O	784-785
period	O	786-792
of	O	793-795
2	O	796-797
weeks	O	798-803
,	O	803-804
CsA	O	805-808
15	O	809-811
mg	O	812-814
/	O	814-815
kg	O	815-817
/	O	814-815
day	O	818-821
(	O	822-823
given	O	823-828
orally	O	829-835
)	O	835-836
,	O	836-837
FK506	O	838-843
3	O	844-845
.	O	845-846
0	O	846-847
mg	O	848-850
/	O	850-851
kg	O	851-853
/	O	850-851
day	O	854-857
(	O	858-859
given	O	859-864
orally	O	865-871
)	O	871-872
or	O	873-875
SRL	O	876-879
0	O	880-881
.	O	881-882
4	O	882-883
mg	O	884-886
/	O	886-887
kg	O	887-889
/	O	886-887
day	O	890-893
(	O	894-895
given	O	895-900
intraperitoneally	O	901-918
)	O	918-919
was	O	920-923
administered	O	924-936
once	O	937-941
a	O	942-943
day	O	944-947
as	O	948-950
these	O	951-956
doses	O	957-962
have	O	963-967
earlier	O	968-975
been	O	976-980
found	O	981-986
to	O	987-989
achieve	O	990-997
a	O	998-999
significant	O	1000-1011
immunosuppressive	O	1012-1029
effect	O	1030-1036
in	O	1037-1039
Sprague	O	1040-1047
-	O	1047-1048
Dawley	O	1048-1054
rats	O	1055-1059
.	O	1059-1060

In	O	1061-1063
the	O	1064-1067
'	O	1068-1069
conscious	O	1069-1078
catheterized	O	1079-1091
rat	O	1092-1095
'	O	1095-1096
model	O	1097-1102
,	O	1102-1103
the	O	1104-1107
glomerular	O	1108-1118
filtration	O	1119-1129
rate	O	1130-1134
(	O	1135-1136
GFR	O	1136-1139
)	O	1139-1140
was	O	1141-1144
measured	O	1145-1153
as	O	1154-1156
the	O	1157-1160
clearance	O	1161-1170
of	O	1171-1173
Cr	O	1174-1176
(	O	1176-1177
EDTA	O	1177-1181
)	O	1181-1182
.	O	1182-1183

The	O	1184-1187
morphological	O	1188-1201
analysis	O	1202-1210
of	O	1211-1213
the	O	1214-1217
kidneys	O	1218-1225
included	O	1226-1234
a	O	1235-1236
semi	O	1237-1241
-	O	1241-1242
quantitative	O	1242-1254
scoring	O	1255-1262
system	O	1263-1269
analysing	O	1270-1279
the	O	1280-1283
degree	O	1284-1290
of	O	1291-1293
striped	O	1294-1301
fibrosis	B	1302-1310
,	O	1310-1311
subcapsular	O	1312-1323
fibrosis	B	1324-1332
and	O	1333-1336
the	O	1337-1340
number	O	1341-1347
of	O	1348-1350
basophilic	O	1351-1361
tubules	O	1362-1369
,	O	1369-1370
plus	O	1371-1375
an	O	1376-1378
additional	O	1379-1389
stereological	O	1390-1403
analysis	O	1404-1412
of	O	1413-1415
the	O	1416-1419
total	O	1420-1425
grade	O	1426-1431
of	O	1432-1434
fibrosis	B	1435-1443
in	O	1444-1446
the	O	1447-1450
cortex	O	1451-1457
stained	O	1458-1465
with	O	1466-1470
Sirius	O	1471-1477
Red	O	1478-1481
.	O	1481-1482

RESULTS	O	1483-1490
:	O	1490-1491
CsA	O	1492-1495
,	O	1495-1496
FK506	O	1497-1502
and	O	1503-1506
SRL	O	1507-1510
all	O	1511-1514
significantly	O	1515-1528
decreased	O	1529-1538
the	O	1539-1542
GFR	O	1543-1546
.	O	1546-1547

A	O	1548-1549
further	O	1550-1557
deterioration	O	1558-1571
was	O	1572-1575
seen	O	1576-1580
when	O	1581-1585
CsA	O	1586-1589
was	O	1590-1593
combined	O	1594-1602
with	O	1603-1607
either	O	1608-1614
FK506	O	1615-1620
or	O	1621-1623
SRL	O	1624-1627
,	O	1627-1628
whereas	O	1629-1636
the	O	1637-1640
GFR	O	1641-1644
remained	O	1645-1653
unchanged	O	1654-1663
in	O	1664-1666
the	O	1667-1670
group	O	1671-1676
treated	O	1677-1684
with	O	1685-1689
FK506	O	1690-1695
plus	O	1696-1700
SRL	O	1701-1704
when	O	1705-1709
compared	O	1710-1718
with	O	1719-1723
treatment	O	1724-1733
with	O	1734-1738
any	O	1739-1742
of	O	1743-1745
the	O	1746-1749
single	O	1750-1756
substances	O	1757-1767
.	O	1767-1768

The	O	1769-1772
morphological	O	1773-1786
changes	O	1787-1794
presented	O	1795-1804
a	O	1805-1806
similar	O	1807-1814
pattern	O	1815-1822
.	O	1822-1823

The	O	1824-1827
semi	O	1828-1832
-	O	1832-1833
quantitative	O	1833-1845
scoring	O	1846-1853
was	O	1854-1857
significantly	O	1858-1871
worst	O	1872-1877
in	O	1878-1880
the	O	1881-1884
group	O	1885-1890
treated	O	1891-1898
with	O	1899-1903
CsA	O	1904-1907
plus	O	1908-1912
SRL	O	1913-1916
(	O	1917-1918
P	O	1918-1919
<	O	1919-1920
0	O	1920-1921
.	O	1921-1922
001	O	1922-1925

compared	O	1926-1934
with	O	1935-1939
controls	O	1940-1948
)	O	1948-1949
and	O	1950-1953
the	O	1954-1957
analysis	O	1958-1966
of	O	1967-1969
the	O	1970-1973
total	O	1974-1979
grade	O	1980-1985
of	O	1986-1988
fibrosis	B	1989-1997
also	O	1998-2002
showed	O	2003-2009
the	O	2010-2013
highest	O	2014-2021
proportion	O	2022-2032
in	O	2033-2035
the	O	2036-2039
same	O	2040-2044
group	O	2045-2050
and	O	2051-2054
was	O	2055-2058
significantly	O	2059-2072
different	O	2073-2082
from	O	2083-2087
controls	O	2088-2096
(	O	2097-2098
P	O	2098-2099
<	O	2099-2100
0	O	2100-2101
.	O	2101-2102
02	O	2102-2104
)	O	2104-2105
.	O	2101-2102

The	O	2107-2110
FK506	O	2111-2116
plus	O	2117-2121
SRL	O	2122-2125
combination	O	2126-2137
showed	O	2138-2144
only	O	2145-2149
a	O	2150-2151
marginally	O	2152-2162
higher	O	2163-2169
degree	O	2170-2176
of	O	2177-2179
fibrosis	B	2180-2188
as	O	2189-2191
compared	O	2192-2200
with	O	2201-2205
controls	O	2206-2214
(	O	2215-2216
P	O	2216-2217
=	O	2217-2218
0	O	2218-2219
.	O	2219-2220
05	O	2220-2222
)	O	2222-2223
.	O	2219-2220

CONCLUSION	O	2225-2235
:	O	2235-2236
This	O	2237-2241
rat	O	2242-2245
study	O	2246-2251
demonstrated	O	2252-2264
a	O	2265-2266
synergistic	O	2267-2278
nephrotoxic	B	2279-2290
effect	O	2291-2297
of	O	2298-2300
CsA	O	2301-2304
plus	O	2305-2309
SRL	O	2310-2313
,	O	2313-2314
whereas	O	2315-2322
FK506	O	2323-2328
plus	O	2329-2333
SRL	O	2334-2337
was	O	2338-2341
better	O	2342-2348
tolerated	O	2349-2358
.	O	2358-2359

Effect	O	0-6
of	O	7-9
fucoidan	O	10-18
treatment	O	19-28
on	O	29-31
collagenase	O	32-43
-	O	43-44
induced	O	44-51
intracerebral	B	52-65
hemorrhage	I	66-76
in	O	77-79
rats	O	80-84
.	O	84-85

Inflammatory	O	86-98
cells	O	99-104
are	O	105-108
postulated	O	109-119
to	O	120-122
mediate	O	123-130
some	O	131-135
of	O	136-138
the	O	139-142
brain	B	143-148
damage	I	149-155
following	O	156-165
ischemic	B	166-174
stroke	I	175-181
.	O	181-182

Intracerebral	B	183-196
hemorrhage	I	197-207
is	O	208-210
associated	O	211-221
with	O	222-226
more	O	227-231
inflammation	B	232-244
than	O	245-249
ischemic	B	250-258
stroke	I	259-265
.	O	265-266

We	O	267-269
tested	O	270-276
the	O	277-280
sulfated	O	281-289
polysaccharide	O	290-304
fucoidan	O	305-313
,	O	313-314
which	O	315-320
has	O	321-324
been	O	325-329
reported	O	330-338
to	O	339-341
reduce	O	342-348
inflammatory	O	349-361
brain	B	362-367
damage	I	368-374
,	O	374-375
in	O	376-378
a	O	379-380
rat	O	381-384
model	O	385-390
of	O	391-393
intracerebral	B	394-407
hemorrhage	I	408-418
induced	O	419-426
by	O	427-429
injection	O	430-439
of	O	440-442
bacterial	O	443-452
collagenase	O	453-464
into	O	465-469
the	O	470-473
caudate	O	474-481
nucleus	O	482-489
.	O	489-490

Rats	O	491-495
were	O	496-500
treated	O	501-508
with	O	509-513
seven	O	514-519
day	O	520-523
intravenous	O	524-535
infusion	O	536-544
of	O	545-547
fucoidan	O	548-556
(	O	557-558
30	O	558-560
micrograms	O	561-571
h	O	572-573
-	O	573-574
1	O	574-575
)	O	575-576
or	O	577-579
vehicle	O	580-587
.	O	587-588

The	O	589-592
hematoma	B	593-601
was	O	602-605
assessed	O	606-614
in	O	615-617
vivo	O	618-622
by	O	623-625
magnetic	O	626-634
resonance	O	635-644
imaging	O	645-652
.	O	652-653

Motor	O	654-659
behavior	O	660-668
,	O	668-669
passive	O	670-677
avoidance	O	678-687
,	O	687-688
and	O	689-692
skilled	O	693-700
forelimb	O	701-709
function	O	710-718
were	O	719-723
tested	O	724-730
repeatedly	O	731-741
for	O	742-745
six	O	746-749
weeks	O	750-755
.	O	755-756

Fucoidan	O	757-765
-	O	765-766
treated	O	766-773
rats	O	774-778
exhibited	O	779-788
evidence	O	789-797
of	O	798-800
impaired	B	801-809
blood	I	810-815
clotting	I	816-824
and	O	825-828
hemodilution	B	829-841
,	O	841-842
had	O	843-846
larger	O	847-853
hematomas	B	854-863
,	O	863-864
and	O	865-868
tended	O	869-875
to	O	876-878
have	O	879-883
less	O	884-888
inflammation	B	889-901
in	O	902-904
the	O	905-908
vicinity	O	909-917
of	O	918-920
the	O	921-924
hematoma	B	925-933
after	O	934-939
three	O	940-945
days	O	946-950
.	O	950-951

They	O	952-956
showed	O	957-963
significantly	O	964-977
more	O	978-982
rapid	O	983-988
improvement	O	989-1000
of	O	1001-1003
motor	O	1004-1009
function	O	1010-1018
in	O	1019-1021
the	O	1022-1025
first	O	1026-1031
week	O	1032-1036
following	O	1037-1046
hemorrhage	B	1047-1057
and	O	1058-1061
better	O	1062-1068
memory	O	1069-1075
retention	O	1076-1085
in	O	1086-1088
the	O	1089-1092
passive	O	1093-1100
avoidance	O	1101-1110
test	O	1111-1115
.	O	1115-1116

Acute	O	1117-1122
white	B	1123-1128
matter	I	1129-1135
edema	I	1136-1141
and	O	1142-1145
eventual	O	1146-1154
neuronal	B	1155-1163
loss	I	1164-1168
in	O	1169-1171
the	O	1172-1175
striatum	O	1176-1184
adjacent	O	1185-1193
to	O	1194-1196
the	O	1197-1200
hematoma	B	1201-1209
did	O	1210-1213
not	O	1214-1217
differ	O	1218-1224
between	O	1225-1232
the	O	1233-1236
two	O	1237-1240
groups	O	1241-1247
.	O	1247-1248

Investigation	O	1249-1262
of	O	1263-1265
more	O	1266-1270
specific	O	1271-1279
anti	O	1280-1284
-	O	1284-1285
inflammatory	O	1285-1297
agents	O	1298-1304
and	O	1305-1308
hemodiluting	O	1309-1321
agents	O	1322-1328
are	O	1329-1332
warranted	O	1333-1342
in	O	1343-1345
intracerebral	B	1346-1359
hemorrhage	I	1360-1370
.	O	1370-1371

Paracetamol	O	0-11
-	O	11-12
associated	O	12-22
coma	B	23-27
,	O	27-28
metabolic	B	29-38
acidosis	I	39-47
,	O	47-48
renal	B	49-54
and	I	55-58
hepatic	I	59-66
failure	I	67-74
.	O	74-75

A	O	76-77
case	O	78-82
of	O	83-85
metabolic	B	86-95
acidosis	I	96-104
,	O	104-105
acute	B	106-111
renal	I	112-117
failure	I	118-125
and	I	126-129
hepatic	I	130-137
failure	I	138-145
following	O	146-155
paracetamol	O	156-167
ingestion	O	168-177
is	O	178-180
presented	O	181-190
.	O	190-191

The	O	192-195
diagnostic	O	196-206
difficulty	O	207-217
at	O	218-220
presentation	O	221-233
is	O	234-236
highlighted	O	237-248
.	O	248-249

Continuous	O	250-260
arteriovenous	O	261-274
haemofiltration	O	275-290
proved	O	291-297
a	O	298-299
valuable	O	300-308
means	O	309-314
of	O	315-317
maintaining	O	318-329
fluid	O	330-335
and	O	336-339
electrolyte	O	340-351
balance	O	352-359
.	O	359-360

The	O	361-364
patient	O	365-372
recovered	O	373-382
.	O	382-383

Hepatic	O	0-7
reactions	O	8-17
associated	O	18-28
with	O	29-33
ketoconazole	O	34-46
in	O	47-49
the	O	50-53
United	O	54-60
Kingdom	O	61-68
.	O	68-69

Ketoconazole	O	70-82
was	O	83-86
introduced	O	87-97
in	O	98-100
the	O	101-104
United	O	105-111
Kingdom	O	112-119
in	O	120-122
1981	O	123-127
.	O	127-128

By	O	129-131
November	O	132-140
1984	O	141-145
the	O	146-149
Committee	O	150-159
on	O	160-162
Safety	O	163-169
of	O	170-172
Medicines	O	173-182
had	O	183-186
received	O	187-195
82	O	196-198
reports	O	199-206
of	O	207-209
possible	O	210-218
hepatotoxicity	B	219-233
associated	O	234-244
with	O	245-249
the	O	250-253
drug	O	254-258
,	O	258-259
including	O	260-269
five	O	270-274
deaths	B	275-281
.	O	281-282

An	O	283-285
analysis	O	286-294
of	O	295-297
the	O	298-301
75	O	302-304
cases	O	305-310
that	O	311-315
had	O	316-319
been	O	320-324
adequately	O	325-335
followed	O	336-344
up	O	345-347
suggested	O	348-357
that	O	358-362
16	O	363-365
,	O	365-366
including	O	367-376
three	O	377-382
deaths	B	383-389
,	O	389-390
were	O	391-395
probably	O	396-404
related	O	405-412
to	O	413-415
treatment	O	416-425
with	O	426-430
the	O	431-434
drug	O	435-439
.	O	439-440

Of	O	441-443
the	O	444-447
remainder	O	448-457
,	O	457-458
48	O	459-461
were	O	462-466
possibly	O	467-475
related	O	476-483
to	O	484-486
treatment	O	487-496
,	O	496-497
five	O	498-502
were	O	503-507
unlikely	O	508-516
to	O	517-519
be	O	520-522
so	O	523-525
,	O	525-526
and	O	527-530
six	O	531-534
were	O	535-539
unclassifiable	O	540-554
.	O	554-555

The	O	556-559
mean	O	560-564
age	O	565-568
of	O	569-571
patients	O	572-580
in	O	581-583
the	O	584-587
16	O	588-590
probable	O	591-599
cases	O	600-605
was	O	606-609
57	O	610-612
.	O	612-613
9	O	613-614
,	O	614-615
with	O	616-620
hepatotoxicity	B	621-635
being	O	636-641
more	O	642-646
common	O	647-653
in	O	654-656
women	O	657-662
.	O	662-663

The	O	664-667
average	O	668-675
duration	O	676-684
of	O	685-687
treatment	O	688-697
before	O	698-704
the	O	705-708
onset	O	709-714
of	O	715-717
jaundice	B	718-726
was	O	727-730
61	O	731-733
days	O	734-738
.	O	738-739

None	O	740-744
of	O	745-747
these	O	748-753
well	O	754-758
validated	O	759-768
cases	O	769-774
occurred	O	775-783
within	O	784-790
the	O	791-794
first	O	795-800
10	O	801-803
days	O	804-808
after	O	809-814
treatment	O	815-824
.	O	824-825

The	O	826-829
results	O	830-837
of	O	838-840
serum	O	841-846
liver	O	847-852
function	O	853-861
tests	O	862-867
suggested	O	868-877
hepatocellular	B	878-892
injury	I	893-899
in	O	900-902
10	O	903-905
(	O	906-907
63	O	907-909
%	O	909-910
)	O	910-911
;	O	911-912
the	O	913-916
rest	O	917-921
showed	O	922-928
a	O	929-930
mixed	O	931-936
pattern	O	937-944
.	O	944-945

In	O	946-948
contrast	O	949-957
,	O	957-958
the	O	959-962
results	O	963-970
of	O	971-973
histological	O	974-986
examination	O	987-998
of	O	999-1001
the	O	1002-1005
liver	O	1006-1011
often	O	1012-1017
showed	O	1018-1024
evidence	O	1025-1033
of	O	1034-1036
cholestasis	B	1037-1048
.	O	1048-1049

The	O	1050-1053
characteristics	O	1054-1069
of	O	1070-1072
the	O	1073-1076
48	O	1077-1079
patients	O	1080-1088
in	O	1089-1091
the	O	1092-1095
possible	O	1096-1104
cases	O	1105-1110
were	O	1111-1115
similar	O	1116-1123
.	O	1123-1124

Allergic	O	1125-1133
manifestations	O	1134-1148
such	O	1149-1153
as	O	1154-1156
rash	B	1157-1161
and	O	1162-1165
eosinophilia	B	1166-1178
were	O	1179-1183
rare	O	1184-1188
.	O	1188-1189

Hepatitis	B	1190-1199
was	O	1200-1203
usually	O	1204-1211
reversible	O	1212-1222
when	O	1223-1227
treatment	O	1228-1237
was	O	1238-1241
stopped	O	1242-1249
,	O	1249-1250
with	O	1251-1255
the	O	1256-1259
results	O	1260-1267
of	O	1268-1270
liver	O	1271-1276
function	O	1277-1285
tests	O	1286-1291
returning	O	1292-1301
to	O	1302-1304
normal	O	1305-1311
after	O	1312-1317
an	O	1318-1320
average	O	1321-1328
of	O	1329-1331
3	O	1332-1333
.	O	1333-1334
1	O	1334-1335
months	O	1336-1342
.	O	1342-1343

In	O	1344-1346
two	O	1347-1350
of	O	1351-1353
the	O	1354-1357
three	O	1358-1363
deaths	B	1364-1370
probably	O	1371-1379
associated	O	1380-1390
with	O	1391-1395
ketoconazole	O	1396-1408
treatment	O	1409-1418
the	O	1419-1422
drug	O	1423-1427
had	O	1428-1431
been	O	1432-1436
continued	O	1437-1446
after	O	1447-1452
the	O	1453-1456
onset	O	1457-1462
of	O	1463-1465
jaundice	B	1466-1474
and	O	1475-1478
other	O	1479-1484
symptoms	O	1485-1493
of	O	1494-1496
hepatitis	B	1497-1506
.	O	1506-1507

Clinical	O	1508-1516
and	O	1517-1520
biochemical	O	1521-1532
monitoring	O	1533-1543
at	O	1544-1546
regular	O	1547-1554
intervals	O	1555-1564
for	O	1565-1568
evidence	O	1569-1577
of	O	1578-1580
hepatitis	B	1581-1590
is	O	1591-1593
advised	O	1594-1601
during	O	1602-1608
long	O	1609-1613
term	O	1614-1618
treatment	O	1619-1628
with	O	1629-1633
ketoconazole	O	1634-1646
to	O	1647-1649
prevent	O	1650-1657
possible	O	1658-1666
serious	O	1667-1674
hepatic	B	1675-1682
injury	I	1683-1689
.	O	1689-1690

Combined	O	0-8
effects	O	9-16
of	O	17-19
prolonged	O	20-29
prostaglandin	O	30-43
E1	O	44-46
-	O	46-47
induced	O	47-54
hypotension	B	55-66
and	O	67-70
haemodilution	B	71-84
on	O	85-87
human	O	88-93
hepatic	O	94-101
function	O	102-110
.	O	110-111

Combined	O	112-120
effects	O	121-128
of	O	129-131
prolonged	O	132-141
prostaglandin	O	142-155
E1	O	156-158
(	O	159-160
PGE1	O	160-164
)	O	164-165
-	O	165-166
induced	O	166-173
hypotension	B	174-185
and	O	186-189
haemodilution	B	190-203
on	O	204-206
hepatic	O	207-214
function	O	215-223
were	O	224-228
studied	O	229-236
in	O	237-239
30	O	240-242
patients	O	243-251
undergoing	O	252-262
hip	O	263-266
surgery	O	267-274
.	O	274-275

The	O	276-279
patients	O	280-288
were	O	289-293
randomly	O	294-302
allocated	O	303-312
to	O	313-315
one	O	316-319
of	O	320-322
three	O	323-328
groups	O	329-335
;	O	335-336
those	O	337-342
in	O	343-345
group	O	346-351
A	O	352-353
(	O	354-355
n	O	355-356
=	O	357-358
10	O	359-361
)	O	361-362
were	O	363-367
subjected	O	368-377
to	O	378-380
controlled	O	381-391
hypotension	B	392-403
alone	O	404-409
,	O	409-410
those	O	411-416
in	O	417-419
group	O	420-425
B	O	426-427
(	O	428-429
n	O	429-430
=	O	431-432
10	O	433-435
)	O	435-436
to	O	437-439
haemodilution	B	440-453
alone	O	454-459
and	O	460-463
those	O	464-469
in	O	470-472
group	O	473-478
C	O	479-480
(	O	481-482
n	O	482-483
=	O	484-485
10	O	486-488
)	O	488-489
to	O	490-492
both	O	493-497
controlled	O	498-508
hypotension	B	509-520
and	O	521-524
haemodilution	B	525-538
.	O	538-539

Haemodilution	B	540-553
in	O	554-556
groups	O	557-563
B	O	564-565
and	O	566-569
C	O	570-571
was	O	572-575
produced	O	576-584
by	O	585-587
withdrawing	O	588-599
approximately	O	600-613
1000	O	614-618
mL	O	619-621
of	O	622-624
blood	O	625-630
and	O	631-634
replacing	O	635-644
it	O	645-647
with	O	648-652
the	O	653-656
same	O	657-661
amount	O	662-668
of	O	669-671
dextran	O	672-679
solution	O	680-688
,	O	688-689
and	O	690-693
final	O	694-699
haematocrit	O	700-711
values	O	712-718
were	O	719-723
21	O	724-726
or	O	727-729
22	O	730-732
%	O	732-733
.	O	733-734

Controlled	O	735-745
hypotension	B	746-757
in	O	758-760
groups	O	761-767
A	O	768-769
and	O	770-773
C	O	774-775
was	O	776-779
induced	O	780-787
with	O	788-792
PGE1	O	793-797
to	O	798-800
maintain	O	801-809
mean	O	810-814
arterial	O	815-823
blood	O	824-829
pressure	O	830-838
at	O	839-841
55	O	842-844
mmHg	O	845-849
for	O	850-853
180	O	854-857
min	O	858-861
.	O	861-862

Measurements	O	863-875
included	O	876-884
arterial	O	885-893
ketone	O	894-900
body	O	901-905
ratio	O	906-911
(	O	912-913
AKBR	O	913-917
,	O	917-918
aceto	O	919-924
-	O	924-925
acetate	O	925-932
/	O	932-933
3	O	933-934
-	O	924-925
hydroxybutyrate	O	935-950
)	O	950-951
and	O	952-955
clinical	O	956-964
hepatic	O	965-972
function	O	973-981
parameters	O	982-992
.	O	992-993

AKBR	O	994-998
and	O	999-1002
biological	O	1003-1013
hepatic	O	1014-1021
function	O	1022-1030
tests	O	1031-1036
showed	O	1037-1043
no	O	1044-1046
change	O	1047-1053
throughout	O	1054-1064
the	O	1065-1068
time	O	1069-1073
course	O	1074-1080
in	O	1081-1083
groups	O	1084-1090
A	O	1091-1092
and	O	1093-1096
B	O	1097-1098
.	O	1098-1099
In	O	1100-1102
group	O	1103-1108
C	O	1109-1110
,	O	1110-1111
AKBR	O	1112-1116
showed	O	1117-1123
a	O	1124-1125
significant	O	1126-1137
decrease	O	1138-1146
at	O	1147-1149
120	O	1150-1153
min	O	1154-1157
(	O	1158-1159
-	O	1159-1160
40	O	1160-1162
%	O	1162-1163
)	O	1163-1164
and	O	1165-1168
at	O	1169-1171
180	O	1172-1175
min	O	1176-1179
(	O	1180-1181
-	O	1181-1182
49	O	1182-1184
%	O	1184-1185
)	O	1185-1186
after	O	1187-1192
the	O	1193-1196
start	O	1197-1202
of	O	1203-1205
hypotension	B	1206-1217
and	O	1218-1221
at	O	1222-1224
60	O	1225-1227
min	O	1228-1231
(	O	1232-1233
-	O	1233-1234
32	O	1234-1236
%	O	1236-1237
)	O	1237-1238
after	O	1239-1244
recovery	O	1245-1253
of	O	1254-1256
normotension	O	1257-1269
,	O	1269-1270
and	O	1271-1274
SGOT	O	1275-1279
,	O	1279-1280
SGPT	O	1281-1285
,	O	1285-1286
LDH	O	1287-1290
and	O	1291-1294
total	O	1295-1300
bilirubin	O	1301-1310
showed	O	1311-1317
significant	O	1318-1329
increases	O	1330-1339
after	O	1340-1345
operation	O	1346-1355
.	O	1355-1356

The	O	1357-1360
results	O	1361-1368
suggest	O	1369-1376
that	O	1377-1381
a	O	1382-1383
prolonged	O	1384-1393
combination	O	1394-1405
of	O	1406-1408
more	O	1409-1413
than	O	1414-1418
120	O	1419-1422
min	O	1423-1426
of	O	1427-1429
PGE1	O	1430-1434
-	O	1434-1435
induced	O	1435-1442
hypotension	B	1443-1454
and	O	1455-1458
moderate	O	1459-1467
haemodilution	B	1468-1481
would	O	1482-1487
cause	O	1488-1493
impairment	B	1494-1504
of	I	1505-1507
hepatic	I	1508-1515
function	I	1516-1524
.	O	1524-1525

Levodopa	O	0-8
-	O	8-9
induced	O	9-16
dyskinesias	B	17-28
in	O	29-31
patients	O	32-40
with	O	41-45
Parkinson	B	46-55
'	I	55-56
s	I	52-53
disease	I	58-65
:	O	65-66
filling	O	67-74
the	O	75-78
bench	O	79-84
-	O	84-85
to	O	85-87
-	O	84-85
bedside	O	88-95
gap	O	96-99
.	O	99-100

Levodopa	O	101-109
is	O	110-112
the	O	113-116
most	O	117-121
effective	O	122-131
drug	O	132-136
for	O	137-140
the	O	141-144
treatment	O	145-154
of	O	155-157
Parkinson	B	158-167
'	I	167-168
s	I	164-165
disease	I	170-177
.	O	177-178

However	O	179-186
,	O	186-187
the	O	188-191
long	O	192-196
-	O	196-197
term	O	197-201
use	O	202-205
of	O	206-208
this	O	209-213
dopamine	O	214-222
precursor	O	223-232
is	O	233-235
complicated	O	236-247
by	O	248-250
highly	O	251-257
disabling	O	258-267
fluctuations	O	268-280
and	O	281-284
dyskinesias	B	285-296
.	O	296-297

Although	O	298-306
preclinical	O	307-318
and	O	319-322
clinical	O	323-331
findings	O	332-340
suggest	O	341-348
pulsatile	O	349-358
stimulation	O	359-370
of	O	371-373
striatal	O	374-382
postsynaptic	O	383-395
receptors	O	396-405
as	O	406-408
a	O	409-410
key	O	411-414
mechanism	O	415-424
underlying	O	425-435
levodopa	O	436-444
-	O	444-445
induced	O	445-452
dyskinesias	B	453-464
,	O	464-465
their	O	466-471
pathogenesis	O	472-484
is	O	485-487
still	O	488-493
unclear	O	494-501
.	O	501-502

In	O	503-505
recent	O	506-512
years	O	513-518
,	O	518-519
evidence	O	520-528
from	O	529-533
animal	O	534-540
models	O	541-547
of	O	548-550
Parkinson	B	551-560
'	I	560-561
s	I	557-558
disease	I	563-570
has	O	571-574
provided	O	575-583
important	O	584-593
information	O	594-605
to	O	606-608
understand	O	609-619
the	O	620-623
effect	O	624-630
of	O	631-633
specific	O	634-642
receptor	O	643-651
and	O	652-655
post	O	656-660
-	O	660-661
receptor	O	661-669
molecular	O	670-679
mechanisms	O	680-690
underlying	O	691-701
the	O	702-705
development	O	706-717
of	O	718-720
dyskinetic	B	721-731
movements	I	732-741
.	O	741-742

Recent	O	743-749
preclinical	O	750-761
and	O	762-765
clinical	O	766-774
data	O	775-779
from	O	780-784
promising	O	785-794
lines	O	795-800
of	O	801-803
research	O	804-812
focus	O	813-818
on	O	819-821
the	O	822-825
differential	O	826-838
role	O	839-843
of	O	844-846
presynaptic	O	847-858
versus	O	859-865
postsynaptic	O	866-878
mechanisms	O	879-889
,	O	889-890
dopamine	O	891-899
receptor	O	900-908
subtypes	O	909-917
,	O	917-918
ionotropic	O	919-929
and	O	930-933
metabotropic	O	934-946
glutamate	O	947-956
receptors	O	957-966
,	O	966-967
and	O	968-971
non	O	972-975
-	O	975-976
dopaminergic	O	976-988
neurotransmitter	O	989-1005
systems	O	1006-1013
in	O	1014-1016
the	O	1017-1020
pathophysiology	O	1021-1036
of	O	1037-1039
levodopa	O	1040-1048
-	O	1048-1049
induced	O	1049-1056
dyskinesias	B	1057-1068
.	O	1068-1069

Prevention	O	0-10
of	O	11-13
seizures	B	14-22
and	O	23-26
reorganization	O	27-41
of	O	42-44
hippocampal	O	45-56
functions	O	57-66
by	O	67-69
transplantation	O	70-85
of	O	86-88
bone	O	89-93
marrow	O	94-100
cells	O	101-106
in	O	107-109
the	O	110-113
acute	O	114-119
phase	O	120-125
of	O	126-128
experimental	O	129-141
epilepsy	B	142-150
.	O	150-151

In	O	152-154
this	O	155-159
study	O	160-165
,	O	165-166
we	O	167-169
investigated	O	170-182
the	O	183-186
therapeutic	O	187-198
potential	O	199-208
of	O	209-211
bone	O	212-216
marrow	O	217-223
mononuclear	O	224-235
cells	O	236-241
(	O	242-243
BMCs	O	243-247
)	O	247-248
in	O	249-251
a	O	252-253
model	O	254-259
of	O	260-262
epilepsy	B	263-271
induced	O	272-279
by	O	280-282
pilocarpine	O	283-294
in	O	295-297
rats	O	298-302
.	O	302-303

BMCs	O	304-308
obtained	O	309-317
from	O	318-322
green	O	323-328
fluorescent	O	329-340
protein	O	341-348
(	O	349-350
GFP	O	350-353
)	O	353-354
transgenic	O	355-365
mice	O	366-370
or	O	371-373
rats	O	374-378
were	O	379-383
transplanted	O	384-396
intravenously	O	397-410
after	O	411-416
induction	O	417-426
of	O	427-429
status	B	430-436
epilepticus	I	437-448
(	O	449-450
SE	B	450-452
)	O	452-453
.	O	453-454

Spontaneous	B	455-466
recurrent	I	467-476
seizures	I	477-485
(	O	486-487
SRS	B	487-490
)	O	490-491
were	O	492-496
monitored	O	497-506
using	O	507-512
Racine	O	513-519
'	O	519-520
s	O	520-521
seizure	B	522-529
severity	O	530-538
scale	O	539-544
.	O	544-545

All	O	546-549
of	O	550-552
the	O	553-556
rats	O	557-561
in	O	562-564
the	O	565-568
saline	O	569-575
-	O	575-576
treated	O	576-583
epileptic	B	584-593
control	O	594-601
group	O	602-607
developed	O	608-617
SRS	B	618-621
,	O	621-622
whereas	O	623-630
none	O	631-635
of	O	636-638
the	O	639-642
BMC	O	643-646
-	O	646-647
treated	O	647-654
epileptic	B	655-664
animals	O	665-672
had	O	673-676
seizures	B	677-685
in	O	686-688
the	O	689-692
short	O	693-698
term	O	699-703
(	O	704-705
15	O	705-707
days	O	708-712
after	O	713-718
transplantation	O	719-734
)	O	734-735
,	O	735-736
regardless	O	737-747
of	O	748-750
the	O	751-754
BMC	O	755-758
source	O	759-765
.	O	765-766

Over	O	767-771
the	O	772-775
long	O	776-780
-	O	780-781
term	O	781-785
chronic	O	786-793
phase	O	794-799
(	O	800-801
120	O	801-804
days	O	805-809
after	O	810-815
transplantation	O	816-831
)	O	831-832
,	O	832-833
only	O	834-838
25	O	839-841
%	O	841-842
of	O	843-845
BMC	O	846-849
-	O	849-850
treated	O	850-857
epileptic	B	858-867
animals	O	868-875
had	O	876-879
seizures	B	880-888
,	O	888-889
but	O	890-893
with	O	894-898
a	O	899-900
lower	O	901-906
frequency	O	907-916
and	O	917-920
duration	O	921-929
compared	O	930-938
to	O	939-941
the	O	942-945
epileptic	B	946-955
control	O	956-963
group	O	964-969
.	O	969-970

The	O	971-974
density	O	975-982
of	O	983-985
hippocampal	O	986-997
neurons	O	998-1005
in	O	1006-1008
the	O	1009-1012
brains	O	1013-1019
of	O	1020-1022
animals	O	1023-1030
treated	O	1031-1038
with	O	1039-1043
BMCs	O	1044-1048
was	O	1049-1052
markedly	O	1053-1061
preserved	O	1062-1071
.	O	1071-1072

At	O	1073-1075
hippocampal	O	1076-1087
Schaeffer	O	1088-1097
collateral	O	1098-1108
-	O	1108-1109
CA1	O	1109-1112
synapses	O	1113-1121
,	O	1121-1122
long	O	1123-1127
-	O	1127-1128
term	O	1128-1132
potentiation	O	1133-1145
was	O	1146-1149
preserved	O	1150-1159
in	O	1160-1162
BMC	O	1163-1166
-	O	1166-1167
transplanted	O	1167-1179
rats	O	1180-1184
compared	O	1185-1193
to	O	1194-1196
epileptic	B	1197-1206
controls	O	1207-1215
.	O	1215-1216

The	O	1217-1220
donor	O	1221-1226
-	O	1226-1227
derived	O	1227-1234
GFP	O	1235-1238
(	O	1238-1239
+	O	1239-1240
)	O	1240-1241
cells	O	1242-1247
were	O	1248-1252
rarely	O	1253-1259
found	O	1260-1265
in	O	1266-1268
the	O	1269-1272
brains	O	1273-1279
of	O	1280-1282
transplanted	O	1283-1295
epileptic	B	1296-1305
rats	O	1306-1310
.	O	1310-1311

In	O	1312-1314
conclusion	O	1315-1325
,	O	1325-1326
treatment	O	1327-1336
with	O	1337-1341
BMCs	O	1342-1346
can	O	1347-1350
prevent	O	1351-1358
the	O	1359-1362
development	O	1363-1374
of	O	1375-1377
chronic	O	1378-1385
seizures	B	1386-1394
,	O	1394-1395
reduce	O	1396-1402
neuronal	B	1403-1411
loss	I	1412-1416
,	O	1416-1417
and	O	1418-1421
influence	O	1422-1431
the	O	1432-1435
reorganization	O	1436-1450
of	O	1451-1453
the	O	1454-1457
hippocampal	O	1458-1469
neuronal	O	1470-1478
network	O	1479-1486
.	O	1486-1487

Cardioprotective	O	0-16
effect	O	17-23
of	O	24-26
salvianolic	O	27-38
acid	O	39-43
A	O	44-45
on	O	46-48
isoproterenol	O	49-62
-	O	62-63
induced	O	63-70
myocardial	B	71-81
infarction	I	82-92
in	O	93-95
rats	O	96-100
.	O	100-101

The	O	102-105
present	O	106-113
study	O	114-119
was	O	120-123
designed	O	124-132
to	O	133-135
evaluate	O	136-144
the	O	145-148
cardioprotective	O	149-165
potential	O	166-175
of	O	176-178
salvianolic	O	179-190
acid	O	191-195
A	O	196-197
on	O	198-200
isoproterenol	O	201-214
-	O	214-215
induced	O	215-222
myocardial	B	223-233
infarction	I	234-244
in	O	245-247
rats	O	248-252
.	O	252-253

Hemodynamic	O	254-265
parameters	O	266-276
and	O	277-280
lead	O	281-285
II	O	286-288
electrocardiograph	O	289-307
were	O	308-312
monitored	O	313-322
and	O	323-326
recorded	O	327-335
continuously	O	336-348
.	O	348-349

Cardiac	O	350-357
marker	O	358-364
enzymes	O	365-372
and	O	373-376
antioxidative	O	377-390
parameters	O	391-401
in	O	402-404
serum	O	405-410
and	O	411-414
heart	O	415-420
tissues	O	421-428
were	O	429-433
measured	O	434-442
.	O	442-443

Assay	O	444-449
for	O	450-453
mitochondrial	O	454-467
respiratory	O	468-479
function	O	480-488
and	O	489-492
histopathological	O	493-510
examination	O	511-522
of	O	523-525
heart	O	526-531
tissues	O	532-539
were	O	540-544
performed	O	545-554
.	O	554-555

Isoproterenol	O	556-569
-	O	569-570
treated	O	570-577
rats	O	578-582
showed	O	583-589
significant	O	590-601
increases	O	602-611
in	O	612-614
the	O	615-618
levels	O	619-625
of	O	626-628
lactate	O	629-636
dehydrogenase	O	637-650
,	O	650-651
aspartate	O	652-661
transaminase	O	662-674
,	O	674-675
creatine	O	676-684
kinase	O	685-691
and	O	692-695
malondialdehyde	O	696-711
and	O	712-715
significant	O	716-727
decreases	O	728-737
in	O	738-740
the	O	741-744
activities	O	745-755
of	O	756-758
superoxide	O	759-769
dismutase	O	770-779
,	O	779-780
catalase	O	781-789
and	O	790-793
glutathione	O	794-805
peroxidase	O	806-816
in	O	817-819
serum	O	820-825
and	O	826-829
heart	O	830-835
.	O	835-836

These	O	837-842
rats	O	843-847
also	O	848-852
showed	O	853-859
declines	O	860-868
in	O	869-871
left	O	872-876
ventricular	O	877-888
systolic	O	889-897
pressure	O	898-906
,	O	906-907
maximum	O	908-915
and	O	916-919
minimum	O	920-927
rate	O	928-932
of	O	933-935
developed	O	936-945
left	O	946-950
ventricular	O	951-962
pressure	O	963-971
,	O	971-972
and	O	973-976
elevation	O	977-986
of	O	987-989
left	O	990-994
ventricular	O	995-1006
end	O	1007-1010
-	O	1010-1011
diastolic	O	1011-1020
pressure	O	1021-1029
and	O	1030-1033
ST	O	1034-1036
-	O	1036-1037
segment	O	1037-1044
.	O	1044-1045

In	O	1046-1048
addition	O	1049-1057
,	O	1057-1058
mitochondrial	O	1059-1072
respiratory	B	1073-1084
dysfunction	I	1085-1096
characterized	O	1097-1110
by	O	1111-1113
decreased	O	1114-1123
respiratory	O	1124-1135
control	O	1136-1143
ratio	O	1144-1149
and	O	1150-1153
ADP	O	1154-1157
/	O	1157-1158
O	O	1158-1159
was	O	1160-1163
observed	O	1164-1172
in	O	1173-1175
isoproterenol	O	1176-1189
-	O	1189-1190
treated	O	1190-1197
rats	O	1198-1202
.	O	1202-1203

Administration	O	1204-1218
of	O	1219-1221
salvianolic	O	1222-1233
acid	O	1234-1238
A	O	1239-1240
for	O	1241-1244
a	O	1245-1246
period	O	1247-1253
of	O	1254-1256
8	O	1257-1258
days	O	1259-1263
significantly	O	1264-1277
attenuated	O	1278-1288
isoproterenol	O	1289-1302
-	O	1302-1303
induced	O	1303-1310
cardiac	B	1311-1318
dysfunction	I	1319-1330
and	O	1331-1334
myocardial	B	1335-1345
injury	I	1346-1352
and	O	1353-1356
improved	O	1357-1365
mitochondrial	O	1366-1379
respiratory	O	1380-1391
function	O	1392-1400
.	O	1400-1401

The	O	1402-1405
protective	O	1406-1416
role	O	1417-1421
of	O	1422-1424
salvianolic	O	1425-1436
acid	O	1437-1441
A	O	1442-1443
against	O	1444-1451
isoproterenol	O	1452-1465
-	O	1465-1466
induced	O	1466-1473
myocardial	B	1474-1484
damage	I	1485-1491
was	O	1492-1495
further	O	1496-1503
confirmed	O	1504-1513
by	O	1514-1516
histopathological	O	1517-1534
examination	O	1535-1546
.	O	1546-1547

The	O	1548-1551
results	O	1552-1559
of	O	1560-1562
our	O	1563-1566
study	O	1567-1572
suggest	O	1573-1580
that	O	1581-1585
salvianolic	O	1586-1597
acid	O	1598-1602
A	O	1603-1604
possessing	O	1605-1615
antioxidant	O	1616-1627
activity	O	1628-1636
has	O	1637-1640
a	O	1641-1642
significant	O	1643-1654
protective	O	1655-1665
effect	O	1666-1672
against	O	1673-1680
isoproterenol	O	1681-1694
-	O	1694-1695
induced	O	1695-1702
myocardial	B	1703-1713
infarction	I	1714-1724
.	O	1724-1725

Acute	O	0-5
effects	O	6-13
of	O	14-16
N	O	17-18
-	O	18-19
(	O	19-20
2	O	20-21
-	O	18-19
propylpentanoyl	O	22-37
)	O	37-38
urea	O	38-42
on	O	43-45
hippocampal	O	46-57
amino	O	58-63
acid	O	64-68
neurotransmitters	O	69-86
in	O	87-89
pilocarpine	O	90-101
-	O	101-102
induced	O	102-109
seizure	B	110-117
in	O	118-120
rats	O	121-125
.	O	125-126

The	O	127-130
present	O	131-138
study	O	139-144
aimed	O	145-150
to	O	151-153
investigate	O	154-165
the	O	166-169
anticonvulsant	O	170-184
activity	O	185-193
as	O	194-196
well	O	197-201
as	O	202-204
the	O	205-208
effects	O	209-216
on	O	217-219
the	O	220-223
level	O	224-229
of	O	230-232
hippocampal	O	233-244
amino	O	245-250
acid	O	251-255
neurotransmitters	O	256-273
(	O	274-275
glutamate	O	275-284
,	O	284-285
aspartate	O	286-295
,	O	295-296
glycine	O	297-304
and	O	305-308
GABA	O	309-313
)	O	313-314
of	O	315-317
N	O	318-319
-	O	319-320
(	O	320-321
2	O	321-322
-	O	319-320
propylpentanoyl	O	323-338
)	O	338-339
urea	O	339-343
(	O	344-345
VPU	O	345-348
)	O	348-349
in	O	350-352
comparison	O	353-363
to	O	364-366
its	O	367-370
parent	O	371-377
compound	O	378-386
,	O	386-387
valproic	O	388-396
acid	O	397-401
(	O	402-403
VPA	O	403-406
)	O	406-407
.	O	407-408

VPU	O	409-412
was	O	413-416
more	O	417-421
potent	O	422-428
than	O	429-433
VPA	O	434-437
,	O	437-438
exhibiting	O	439-449
the	O	450-453
median	O	454-460
effective	O	461-470
dose	O	471-475
(	O	476-477
ED	O	477-479
(	O	476-477
50	O	480-482
)	O	482-483
)	O	482-483
of	O	485-487
49	O	488-490
mg	O	491-493
/	O	493-494
kg	O	494-496
in	O	497-499
protecting	O	500-510
rats	O	511-515
against	O	516-523
pilocarpine	O	524-535
-	O	535-536
induced	O	536-543
seizure	B	544-551
whereas	O	552-559
the	O	560-563
corresponding	O	564-577
value	O	578-583
for	O	584-587
VPA	O	588-591
was	O	592-595
322	O	596-599
mg	O	600-602
/	O	602-603
kg	O	603-605
.	O	605-606

In	O	607-609
vivo	O	610-614
microdialysis	O	615-628
demonstrated	O	629-641
that	O	642-646
an	O	647-649
intraperitoneal	O	650-665
administration	O	666-680
of	O	681-683
pilocarpine	O	684-695
induced	O	696-703
a	O	704-705
pronounced	O	706-716
increment	O	717-726
of	O	727-729
hippocampal	O	730-741
glutamate	O	742-751
and	O	752-755
aspartate	O	756-765
whereas	O	766-773
no	O	774-776
significant	O	777-788
change	O	789-795
was	O	796-799
observed	O	800-808
on	O	809-811
the	O	812-815
level	O	816-821
of	O	822-824
glycine	O	825-832
and	O	833-836
GABA	O	837-841
.	O	841-842

Pretreatment	O	843-855
with	O	856-860
either	O	861-867
VPU	O	868-871
(	O	872-873
50	O	873-875
and	O	876-879
100	O	880-883
mg	O	884-886
/	O	886-887
kg	O	887-889
)	O	889-890
or	O	891-893
VPA	O	894-897
(	O	898-899
300	O	899-902
and	O	903-906
600	O	907-910
mg	O	911-913
/	O	913-914
kg	O	914-916
)	O	916-917
completely	O	918-928
abolished	O	929-938
pilocarpine	O	939-950
-	O	950-951
evoked	O	951-957
increases	O	958-967
in	O	968-970
extracellular	O	971-984
glutamate	O	985-994
and	O	995-998
aspartate	O	999-1008
.	O	1008-1009

In	O	1010-1012
addition	O	1013-1021
,	O	1021-1022
a	O	1023-1024
statistically	O	1025-1038
significant	O	1039-1050
reduction	O	1051-1060
was	O	1061-1064
also	O	1065-1069
observed	O	1070-1078
on	O	1079-1081
the	O	1082-1085
level	O	1086-1091
of	O	1092-1094
GABA	O	1095-1099
and	O	1100-1103
glycine	O	1104-1111
but	O	1112-1115
less	O	1116-1120
than	O	1121-1125
a	O	1126-1127
drastic	O	1128-1135
reduction	O	1136-1145
of	O	1146-1148
glutamate	O	1149-1158
and	O	1159-1162
aspartate	O	1163-1172
level	O	1173-1178
.	O	1178-1179

Based	O	1180-1185
on	O	1186-1188
the	O	1189-1192
finding	O	1193-1200
that	O	1201-1205
VPU	O	1206-1209
and	O	1210-1213
VPA	O	1214-1217
could	O	1218-1223
protect	O	1224-1231
the	O	1232-1235
animals	O	1236-1243
against	O	1244-1251
pilocarpine	O	1252-1263
-	O	1263-1264
induced	O	1264-1271
seizure	B	1272-1279
it	O	1280-1282
is	O	1283-1285
suggested	O	1286-1295
that	O	1296-1300
the	O	1301-1304
reduction	O	1305-1314
of	O	1315-1317
inhibitory	O	1318-1328
amino	O	1329-1334
acid	O	1335-1339
neurotransmitters	O	1340-1357
was	O	1358-1361
comparatively	O	1362-1375
minor	O	1376-1381
and	O	1382-1385
offset	O	1386-1392
by	O	1393-1395
a	O	1396-1397
pronounced	O	1398-1408
reduction	O	1409-1418
of	O	1419-1421
glutamate	O	1422-1431
and	O	1432-1435
aspartate	O	1436-1445
.	O	1445-1446

Therefore	O	1447-1456
,	O	1456-1457
like	O	1458-1462
VPA	O	1463-1466
,	O	1466-1467
the	O	1468-1471
finding	O	1472-1479
that	O	1480-1484
VPU	O	1485-1488
could	O	1489-1494
drastically	O	1495-1506
reduce	O	1507-1513
pilocarpine	O	1514-1525
-	O	1525-1526
induced	O	1526-1533
increases	O	1534-1543
in	O	1544-1546
glutamate	O	1547-1556
and	O	1557-1560
aspartate	O	1561-1570
should	O	1571-1577
account	O	1578-1585
,	O	1585-1586
at	O	1587-1589
least	O	1590-1595
partly	O	1596-1602
,	O	1602-1603
for	O	1604-1607
its	O	1608-1611
anticonvulsant	O	1612-1626
activity	O	1627-1635
observed	O	1636-1644
in	O	1645-1647
pilocarpine	O	1648-1659
-	O	1659-1660
induced	O	1660-1667
seizure	B	1668-1675
in	O	1676-1678
experimental	O	1679-1691
animals	O	1692-1699
.	O	1699-1700

Some	O	1701-1705
other	O	1706-1711
mechanism	O	1712-1721
than	O	1722-1726
those	O	1727-1732
being	O	1733-1738
reported	O	1739-1747
herein	O	1748-1754
should	O	1755-1761
be	O	1762-1764
further	O	1765-1772
investigated	O	1773-1785
.	O	1785-1786

Acute	O	0-5
hepatitis	B	6-15
attack	O	16-22
after	O	23-28
exposure	O	29-37
to	O	38-40
telithromycin	O	41-54
.	O	54-55

INTRODUCTION	O	56-68
:	O	68-69
Antibiotic	O	70-80
-	O	80-81
associated	O	81-91
hepatotoxicity	B	92-106
is	O	107-109
rare	O	110-114
.	O	114-115

With	O	116-120
widespread	O	121-131
use	O	132-135
of	O	136-138
antimicrobial	O	139-152
agents	O	153-159
,	O	159-160
however	O	161-168
,	O	168-169
hepatic	B	170-177
injury	I	178-184
occurs	O	185-191
frequently	O	192-202
,	O	202-203
and	O	204-207
among	O	208-213
adverse	B	214-221
drug	I	222-226
reactions	I	227-236
,	O	236-237
idiosyncratic	O	238-251
reactions	O	252-261
are	O	262-265
the	O	266-269
most	O	270-274
serious	O	275-282
.	O	282-283

CASE	O	284-288
SUMMARY	O	289-296
:	O	296-297
A	O	298-299
25	O	300-302
-	O	302-303
year	O	303-307
-	O	302-303
old	O	308-311
male	O	312-316
patient	O	317-324
,	O	324-325
with	O	326-330
a	O	331-332
height	O	333-339
of	O	340-342
175	O	343-346
cm	O	347-349
and	O	350-353
weight	O	354-360
of	O	361-363
72	O	364-366
kg	O	367-369
presented	O	370-379
to	O	380-382
Marmara	O	383-390
University	O	391-401
Hospital	O	402-410
Emergency	O	411-420
Department	O	421-431
,	O	431-432
Istanbul	O	433-441
,	O	441-442
Turkey	O	443-449
,	O	449-450
with	O	451-455
5	O	456-457
days	O	458-462
'	O	462-463
history	O	464-471
of	O	472-474
jaundice	B	475-483
,	O	483-484
malaise	O	485-492
,	O	492-493
nausea	B	494-500
,	O	500-501
and	O	502-505
vomiting	B	506-514
.	O	514-515

He	O	516-518
had	O	519-522
been	O	523-527
prescribed	O	528-538
telithromycin	O	539-552
400	O	553-556
mg	O	557-559
/	O	559-560
d	O	560-561
PO	O	562-564
to	O	565-567
treat	O	568-573
an	O	574-576
upper	B	577-582
respiratory	I	583-594
tract	I	595-600
infection	I	601-610
7	O	611-612
days	O	613-617
prior	O	618-623
.	O	623-624

Admission	O	625-634
laboratory	O	635-645
tests	O	646-651
were	O	652-656
as	O	657-659
follows	O	660-667
:	O	667-668
alanine	O	669-676
aminotransferase	O	677-693
,	O	693-694
67	O	695-697
U	O	698-699
/	O	699-700
L	O	700-701
(	O	702-703
reference	O	703-712
range	O	713-718
,	O	718-719
10	O	720-722
-	O	722-723
37	O	723-725
U	O	726-727
/	O	727-728
L	O	728-729
)	O	729-730
;	O	730-731
aspartate	O	732-741
aminotransferase	O	742-758
,	O	758-759
98	O	760-762
U	O	763-764
/	O	764-765
L	O	765-766
(	O	767-768
10	O	768-770
-	O	770-771
40	O	771-773
U	O	774-775
/	O	775-776
L	O	776-777
)	O	777-778
;	O	778-779
alkaline	O	780-788
phosphatase	O	789-800
,	O	800-801
513	O	802-805
U	O	806-807
/	O	807-808
L	O	808-809
(	O	810-811
0	O	811-812
-	O	812-813
270	O	813-816
U	O	817-818
/	O	818-819
L	O	819-820
)	O	820-821
;	O	821-822
gamma	O	823-828
-	O	828-829
glutamyltransferase	O	829-848
,	O	848-849
32	O	850-852
U	O	853-854
/	O	854-855
L	O	855-856
(	O	857-858
7	O	858-859
-	O	859-860
49	O	860-862
U	O	863-864
/	O	864-865
L	O	865-866
)	O	866-867
;	O	867-868
amylase	O	869-876
,	O	876-877
46	O	878-880
U	O	881-882
/	O	882-883
L	O	883-884
(	O	885-886
0	O	886-887
-	O	887-888
220	O	888-891
U	O	892-893
/	O	893-894
L	O	894-895
)	O	895-896
;	O	896-897
total	O	898-903
bilirubin	O	904-913
,	O	913-914
20	O	915-917
.	O	917-918
1	O	918-919
mg	O	920-922
/	O	922-923
dL	O	923-925
(	O	926-927
0	O	927-928
.	O	928-929
2	O	929-930
-	O	930-931
1	O	931-932
.	O	928-929
0	O	927-928
mg	O	935-937
/	O	937-938
dL	O	938-940
)	O	940-941
;	O	941-942
direct	O	943-949
bilirubin	O	950-959
,	O	959-960
14	O	961-963
.	O	963-964
8	O	964-965
mg	O	966-968
/	O	968-969
dL	O	969-971
(	O	972-973
0	O	973-974
-	O	974-975
0	O	973-974
.	O	976-977
3	O	977-978
mg	O	979-981
/	O	981-982
dL	O	982-984
)	O	984-985
;	O	985-986
and	O	987-990
albumin	O	991-998
,	O	998-999
4	O	1000-1001
.	O	1001-1002
7	O	1002-1003
mg	O	1004-1006
/	O	1006-1007
dL	O	1007-1009
(	O	1010-1011
3	O	1011-1012
.	O	1012-1013
5	O	1013-1014
-	O	1014-1015
5	O	1013-1014
.	O	1012-1013
4	O	1017-1018
mg	O	1019-1021
/	O	1021-1022
dL	O	1022-1024
)	O	1024-1025
.	O	1025-1026

No	O	1027-1029
toxin	O	1030-1035
,	O	1035-1036
alcohol	O	1037-1044
,	O	1044-1045
or	O	1046-1048
other	O	1049-1054
drugs	O	1055-1060
were	O	1061-1065
reported	O	1066-1074
.	O	1074-1075

The	O	1076-1079
patient	O	1080-1087
had	O	1088-1091
suffered	O	1092-1100
a	O	1101-1102
previous	O	1103-1111
episode	O	1112-1119
of	O	1120-1122
"	O	1123-1124
acute	O	1124-1129
hepatitis	B	1130-1139
of	O	1140-1142
unknown	O	1143-1150
origin	O	1151-1157
,	O	1157-1158
"	O	1158-1159
that	O	1160-1164
occurred	O	1165-1173
after	O	1174-1179
telithromycin	O	1180-1193
usage	O	1194-1199
.	O	1199-1200

Both	O	1201-1205
incidents	O	1206-1215
occurred	O	1216-1224
within	O	1225-1231
a	O	1232-1233
year	O	1234-1238
.	O	1238-1239

DISCUSSION	O	1240-1250
:	O	1250-1251
Telithromycin	O	1252-1265
is	O	1266-1268
the	O	1269-1272
first	O	1273-1278
of	O	1279-1281
the	O	1282-1285
ketolide	O	1286-1294
antibacterials	O	1295-1309
to	O	1310-1312
receive	O	1313-1320
US	O	1321-1323
Food	O	1324-1328
and	O	1329-1332
Drug	O	1333-1337
Administration	O	1338-1352
approval	O	1353-1361
for	O	1362-1365
clinical	O	1366-1374
use	O	1375-1378
.	O	1378-1379

It	O	1380-1382
has	O	1383-1386
been	O	1387-1391
associated	O	1392-1402
with	O	1403-1407
infrequent	O	1408-1418
and	O	1419-1422
usually	O	1423-1430
reversible	O	1431-1441
severe	O	1442-1448
hepatic	B	1449-1456
dysfunction	I	1457-1468
.	O	1468-1469

Based	O	1470-1475
on	O	1476-1478
a	O	1479-1480
score	O	1481-1486
of	O	1487-1489
8	O	1490-1491
on	O	1492-1494
the	O	1495-1498
Naranjo	O	1499-1506
adverse	B	1507-1514
drug	I	1515-1519
reaction	I	1520-1528
probability	O	1529-1540
scale	O	1541-1546
,	O	1546-1547
telithromycin	O	1548-1561
was	O	1562-1565
the	O	1566-1569
probable	O	1570-1578
cause	O	1579-1584
of	O	1585-1587
acute	O	1588-1593
hepatitis	B	1594-1603
in	O	1604-1606
this	O	1607-1611
patient	O	1612-1619
,	O	1619-1620
and	O	1621-1624
pathological	O	1625-1637
findings	O	1638-1646
suggested	O	1647-1656
drug	O	1657-1661
-	O	1661-1662
induced	O	1662-1669
toxic	B	1670-1675
hepatitis	I	1676-1685
.	O	1685-1686

Recurrence	O	1687-1697
of	O	1698-1700
hepatitis	B	1701-1710
attack	O	1711-1717
might	O	1718-1723
have	O	1724-1728
been	O	1729-1733
avoided	O	1734-1741
if	O	1742-1744
the	O	1745-1748
initial	O	1749-1756
incident	O	1757-1765
had	O	1766-1769
been	O	1770-1774
communicated	O	1775-1787
to	O	1788-1790
the	O	1791-1794
attending	O	1795-1804
physician	O	1805-1814
who	O	1815-1818
prescribed	O	1819-1829
telithromycin	O	1830-1843
the	O	1844-1847
second	O	1848-1854
time	O	1855-1859
.	O	1859-1860

CONCLUSION	O	1861-1871
:	O	1871-1872
Here	O	1873-1877
we	O	1878-1880
report	O	1881-1887
a	O	1888-1889
case	O	1890-1894
of	O	1895-1897
acute	O	1898-1903
hepatitis	B	1904-1913
probably	O	1914-1922
associated	O	1923-1933
with	O	1934-1938
the	O	1939-1942
administration	O	1943-1957
of	O	1958-1960
telithromycin	O	1961-1974
.	O	1974-1975

Spironolactone	O	0-14
-	O	14-15
induced	O	15-22
renal	B	23-28
insufficiency	I	29-42
and	O	43-46
hyperkalemia	B	47-59
in	O	60-62
patients	O	63-71
with	O	72-76
heart	B	77-82
failure	I	83-90
.	O	90-91

BACKGROUND	O	92-102
:	O	102-103
A	O	104-105
previous	O	106-114
randomized	O	115-125
controlled	O	126-136
trial	O	137-142
evaluating	O	143-153
the	O	154-157
use	O	158-161
of	O	162-164
spironolactone	O	165-179
in	O	180-182
heart	B	183-188
failure	I	189-196
patients	O	197-205
reported	O	206-214
a	O	215-216
low	O	217-220
risk	O	221-225
of	O	226-228
hyperkalemia	B	229-241
(	O	242-243
2	O	243-244
%	O	244-245
)	O	245-246
and	O	247-250
renal	B	251-256
insufficiency	I	257-270
(	O	271-272
0	O	272-273
%	O	273-274
)	O	274-275
.	O	275-276

Because	O	277-284
treatments	O	285-295
for	O	296-299
heart	B	300-305
failure	I	306-313
have	O	314-318
changed	O	319-326
since	O	327-332
the	O	333-336
benefits	O	337-345
of	O	346-348
spironolactone	O	349-363
were	O	364-368
reported	O	369-377
,	O	377-378
the	O	379-382
prevalence	O	383-393
of	O	394-396
these	O	397-402
complications	O	403-416
may	O	417-420
differ	O	421-427
in	O	428-430
current	O	431-438
clinical	O	439-447
practice	O	448-456
.	O	456-457

We	O	458-460
therefore	O	461-470
sought	O	471-477
to	O	478-480
determine	O	481-490
the	O	491-494
prevalence	O	495-505
and	O	506-509
clinical	O	510-518
associations	O	519-531
of	O	532-534
hyperkalemia	B	535-547
and	O	548-551
renal	B	552-557
insufficiency	I	558-571
in	O	572-574
heart	B	575-580
failure	I	581-588
patients	O	589-597
treated	O	598-605
with	O	606-610
spironolactone	O	611-625
.	O	625-626

METHODS	O	627-634
:	O	634-635
We	O	636-638
performed	O	639-648
a	O	649-650
case	O	651-655
control	O	656-663
study	O	664-669
of	O	670-672
heart	B	673-678
failure	I	679-686
patients	O	687-695
treated	O	696-703
with	O	704-708
spironolactone	O	709-723
in	O	724-726
our	O	727-730
clinical	O	731-739
practice	O	740-748
.	O	748-749

Cases	O	750-755
were	O	756-760
patients	O	761-769
who	O	770-773
developed	O	774-783
hyperkalemia	B	784-796
(	O	797-798
K	O	798-799
(	O	797-798
+	O	800-801
)	O	801-802
>	O	803-804
5	O	804-805
.	O	805-806
0	O	806-807
mEq	O	808-811
/	O	811-812
L	O	812-813
)	O	813-814
or	O	815-817
renal	B	818-823
insufficiency	I	824-837
(	O	838-839
Cr	O	839-841
>	O	842-843
or	O	843-845
=	O	845-846
2	O	846-847
.	O	847-848
5	O	848-849
mg	O	850-852
/	O	852-853
dL	O	853-855
)	O	855-856
,	O	856-857
and	O	858-861
they	O	862-866
were	O	867-871
compared	O	872-880
to	O	881-883
2	O	884-885
randomly	O	886-894
selected	O	895-903
controls	O	904-912
per	O	913-916
case	O	917-921
.	O	921-922

Clinical	O	923-931
characteristics	O	932-947
,	O	947-948
medications	O	949-960
,	O	960-961
and	O	962-965
serum	O	966-971
chemistries	O	972-983
at	O	984-986
baseline	O	987-995
and	O	996-999
follow	O	1000-1006
-	O	1006-1007
up	O	1007-1009
time	O	1010-1014
periods	O	1015-1022
were	O	1023-1027
compared	O	1028-1036
.	O	1036-1037

RESULTS	O	1038-1045
:	O	1045-1046
Sixty	O	1047-1052
-	O	1052-1053
seven	O	1053-1058
of	O	1059-1061
926	O	1062-1065
patients	O	1066-1074
(	O	1075-1076
7	O	1076-1077
.	O	1077-1078
2	O	1078-1079
%	O	1079-1080
)	O	1080-1081
required	O	1082-1090
discontinuation	O	1091-1106
of	O	1107-1109
spironolactone	O	1110-1124
due	O	1125-1128
to	O	1129-1131
hyperkalemia	B	1132-1144
(	O	1145-1146
n	O	1146-1147
=	O	1148-1149
33	O	1150-1152
)	O	1152-1153
or	O	1154-1156
renal	B	1157-1162
failure	I	1163-1170
(	O	1171-1172
n	O	1172-1173
=	O	1174-1175
34	O	1176-1178
)	O	1178-1179
.	O	1179-1180

Patients	O	1181-1189
who	O	1190-1193
developed	O	1194-1203
hyperkalemia	B	1204-1216
were	O	1217-1221
older	O	1222-1227
and	O	1228-1231
more	O	1232-1236
likely	O	1237-1243
to	O	1244-1246
have	O	1247-1251
diabetes	B	1252-1260
,	O	1260-1261
had	O	1262-1265
higher	O	1266-1272
baseline	O	1273-1281
serum	O	1282-1287
potassium	O	1288-1297
levels	O	1298-1304
and	O	1305-1308
lower	O	1309-1314
baseline	O	1315-1323
potassium	O	1324-1333
supplement	O	1334-1344
doses	O	1345-1350
,	O	1350-1351
and	O	1352-1355
were	O	1356-1360
more	O	1361-1365
likely	O	1366-1372
to	O	1373-1375
be	O	1376-1378
treated	O	1379-1386
with	O	1387-1391
beta	O	1392-1396
-	O	1396-1397
blockers	O	1397-1405
than	O	1406-1410
controls	O	1411-1419
(	O	1420-1421
n	O	1421-1422
=	O	1423-1424
134	O	1425-1428
)	O	1428-1429
.	O	1429-1430

Patients	O	1431-1439
who	O	1440-1443
developed	O	1444-1453
renal	B	1454-1459
insufficiency	I	1460-1473
had	O	1474-1477
lower	O	1478-1483
baseline	O	1484-1492
body	O	1493-1497
weight	O	1498-1504
and	O	1505-1508
higher	O	1509-1515
baseline	O	1516-1524
serum	O	1525-1530
creatinine	O	1531-1541
,	O	1541-1542
required	O	1543-1551
higher	O	1552-1558
doses	O	1559-1564
of	O	1565-1567
loop	O	1568-1572
diuretics	O	1573-1582
,	O	1582-1583
and	O	1584-1587
were	O	1588-1592
more	O	1593-1597
likely	O	1598-1604
to	O	1605-1607
be	O	1608-1610
treated	O	1611-1618
with	O	1619-1623
thiazide	O	1624-1632
diuretics	O	1633-1642
than	O	1643-1647
controls	O	1648-1656
.	O	1656-1657

CONCLUSIONS	O	1658-1669
:	O	1669-1670
Spironolactone	O	1671-1685
-	O	1685-1686
induced	O	1686-1693
hyperkalemia	B	1694-1706
and	O	1707-1710
renal	B	1711-1716
insufficiency	I	1717-1730
are	O	1731-1734
more	O	1735-1739
common	O	1740-1746
in	O	1747-1749
our	O	1750-1753
clinical	O	1754-1762
experience	O	1763-1773
than	O	1774-1778
reported	O	1779-1787
previously	O	1788-1798
.	O	1798-1799

This	O	1800-1804
difference	O	1805-1815
is	O	1816-1818
explained	O	1819-1828
by	O	1829-1831
patient	O	1832-1839
comorbidities	O	1840-1853
and	O	1854-1857
more	O	1858-1862
frequent	O	1863-1871
use	O	1872-1875
of	O	1876-1878
beta	O	1879-1883
-	O	1883-1884
blockers	O	1884-1892
.	O	1892-1893

End	B	0-3
-	I	3-4
stage	I	4-9
renal	I	10-15
disease	I	16-23
(	O	24-25
ESRD	B	25-29
)	O	29-30
after	O	31-36
orthotopic	O	37-47
liver	O	48-53
transplantation	O	54-69
(	O	70-71
OLTX	O	71-75
)	O	75-76
using	O	77-82
calcineurin	O	83-94
-	O	94-95
based	O	95-100
immunotherapy	O	101-114
:	O	114-115
risk	O	116-120
of	O	121-123
development	O	124-135
and	O	136-139
treatment	O	140-149
.	O	149-150

BACKGROUND	O	151-161
:	O	161-162
The	O	163-166
calcineurin	O	167-178
inhibitors	O	179-189
cyclosporine	O	190-202
and	O	203-206
tacrolimus	O	207-217
are	O	218-221
both	O	222-226
known	O	227-232
to	O	233-235
be	O	236-238
nephrotoxic	B	239-250
.	O	250-251

Their	O	252-257
use	O	258-261
in	O	262-264
orthotopic	O	265-275
liver	O	276-281
transplantation	O	282-297
(	O	298-299
OLTX	O	299-303
)	O	303-304
has	O	305-308
dramatically	O	309-321
improved	O	322-330
success	O	331-338
rates	O	339-344
.	O	344-345

Recently	O	346-354
,	O	354-355
however	O	356-363
,	O	363-364
we	O	365-367
have	O	368-372
had	O	373-376
an	O	377-379
increase	O	380-388
of	O	389-391
patients	O	392-400
who	O	401-404
are	O	405-408
presenting	O	409-419
after	O	420-425
OLTX	O	426-430
with	O	431-435
end	B	436-439
-	I	439-440
stage	I	440-445
renal	I	446-451
disease	I	452-459
(	O	460-461
ESRD	B	461-465
)	O	465-466
.	O	466-467

This	O	468-472
retrospective	O	473-486
study	O	487-492
examines	O	493-501
the	O	502-505
incidence	O	506-515
and	O	516-519
treatment	O	520-529
of	O	530-532
ESRD	B	533-537
and	O	538-541
chronic	B	542-549
renal	I	550-555
failure	I	556-563
(	O	564-565
CRF	B	565-568
)	O	568-569
in	O	570-572
OLTX	O	573-577
patients	O	578-586
.	O	586-587

METHODS	O	588-595
:	O	595-596
Patients	O	597-605
receiving	O	606-615
an	O	616-618
OLTX	O	619-623
only	O	624-628
from	O	629-633
June	O	634-638
1985	O	639-643
through	O	644-651
December	O	652-660
of	O	661-663
1994	O	664-668
who	O	669-672
survived	O	673-681
6	O	682-683
months	O	684-690
postoperatively	O	691-706
were	O	707-711
studied	O	712-719
(	O	720-721
n	O	721-722
=	O	722-723
834	O	723-726
)	O	726-727
.	O	727-728

Our	O	729-732
prospectively	O	733-746
collected	O	747-756
database	O	757-765
was	O	766-769
the	O	770-773
source	O	774-780
of	O	781-783
information	O	784-795
.	O	795-796

Patients	O	797-805
were	O	806-810
divided	O	811-818
into	O	819-823
three	O	824-829
groups	O	830-836
:	O	836-837
Controls	O	838-846
,	O	846-847
no	O	848-850
CRF	B	851-854
or	O	855-857
ESRD	B	858-862
,	O	862-863
n	O	864-865
=	O	865-866
748	O	866-869
;	O	869-870
CRF	B	871-874
,	O	874-875
sustained	O	876-885
serum	O	886-891
creatinine	O	892-902
>	O	903-904
2	O	904-905
.	O	905-906
5	O	906-907
mg	O	908-910
/	O	910-911
dl	O	911-913
,	O	913-914
n	O	915-916
=	O	916-917
41	O	917-919
;	O	919-920
and	O	921-924
ESRD	B	925-929
,	O	929-930
n	O	931-932
=	O	932-933
45	O	933-935
.	O	935-936

Groups	O	937-943
were	O	944-948
compared	O	949-957
for	O	958-961
preoperative	O	962-974
laboratory	O	975-985
variables	O	986-995
,	O	995-996
diagnosis	O	997-1006
,	O	1006-1007
postoperative	O	1008-1021
variables	O	1022-1031
,	O	1031-1032
survival	O	1033-1041
,	O	1041-1042
type	O	1043-1047
of	O	1048-1050
ESRD	B	1051-1055
therapy	O	1056-1063
,	O	1063-1064
and	O	1065-1068
survival	O	1069-1077
from	O	1078-1082
onset	O	1083-1088
of	O	1089-1091
ESRD	B	1092-1096
.	O	1096-1097

RESULTS	O	1098-1105
:	O	1105-1106
At	O	1107-1109
13	O	1110-1112
years	O	1113-1118
after	O	1119-1124
OLTX	O	1125-1129
,	O	1129-1130
the	O	1131-1134
incidence	O	1135-1144
of	O	1145-1147
severe	O	1148-1154
renal	B	1155-1160
dysfunction	I	1161-1172
was	O	1173-1176
18	O	1177-1179
.	O	1179-1180
1	O	1177-1178
%	O	1181-1182
(	O	1183-1184
CRF	B	1184-1187
8	O	1188-1189
.	O	1189-1190
6	O	1190-1191
%	O	1191-1192
and	O	1193-1196
ESRD	B	1197-1201
9	O	1202-1203
.	O	1203-1204
5	O	1204-1205
%	O	1205-1206
)	O	1206-1207
.	O	1203-1204

Compared	O	1209-1217
with	O	1218-1222
control	O	1223-1230
patients	O	1231-1239
,	O	1239-1240
CRF	B	1241-1244
and	O	1245-1248
ESRD	B	1249-1253
patients	O	1254-1262
had	O	1263-1266
higher	O	1267-1273
preoperative	O	1274-1286
serum	O	1287-1292
creatinine	O	1293-1303
levels	O	1304-1310
,	O	1310-1311
a	O	1312-1313
greater	O	1314-1321
percentage	O	1322-1332
of	O	1333-1335
patients	O	1336-1344
with	O	1345-1349
hepatorenal	B	1350-1361
syndrome	I	1362-1370
,	O	1370-1371
higher	O	1372-1378
percentage	O	1379-1389
requirement	O	1390-1401
for	O	1402-1405
dialysis	O	1406-1414
in	O	1415-1417
the	O	1418-1421
first	O	1422-1427
3	O	1428-1429
months	O	1430-1436
postoperatively	O	1437-1452
,	O	1452-1453
and	O	1454-1457
a	O	1458-1459
higher	O	1460-1466
1	O	1467-1468
-	O	1468-1469
year	O	1469-1473
serum	O	1474-1479
creatinine	O	1480-1490
.	O	1490-1491

Multivariate	O	1492-1504
stepwise	O	1505-1513
logistic	O	1514-1522
regression	O	1523-1533
analysis	O	1534-1542
using	O	1543-1548
preoperative	O	1549-1561
and	O	1562-1565
postoperative	O	1566-1579
variables	O	1580-1589
identified	O	1590-1600
that	O	1601-1605
an	O	1606-1608
increase	O	1609-1617
of	O	1618-1620
serum	O	1621-1626
creatinine	O	1627-1637
compared	O	1638-1646
with	O	1647-1651
average	O	1652-1659
at	O	1660-1662
1	O	1663-1664
year	O	1665-1669
,	O	1669-1670
3	O	1671-1672
months	O	1673-1679
,	O	1679-1680
and	O	1681-1684
4	O	1685-1686
weeks	O	1687-1692
postoperatively	O	1693-1708
were	O	1709-1713
independent	O	1714-1725
risk	O	1726-1730
factors	O	1731-1738
for	O	1739-1742
the	O	1743-1746
development	O	1747-1758
of	O	1759-1761
CRF	B	1762-1765
or	O	1766-1768
ESRD	B	1769-1773
with	O	1774-1778
odds	O	1779-1783
ratios	O	1784-1790
of	O	1791-1793
2	O	1794-1795
.	O	1795-1796
6	O	1796-1797
,	O	1797-1798
2	O	1799-1800
.	O	1800-1801
2	O	1799-1800
,	O	1802-1803
and	O	1804-1807
1	O	1808-1809
.	O	1809-1810
6	O	1810-1811
,	O	1811-1812
respectively	O	1813-1825
.	O	1825-1826

Overall	O	1827-1834
survival	O	1835-1843
from	O	1844-1848
the	O	1849-1852
time	O	1853-1857
of	O	1858-1860
OLTX	O	1861-1865
was	O	1866-1869
not	O	1870-1873
significantly	O	1874-1887
different	O	1888-1897
among	O	1898-1903
groups	O	1904-1910
,	O	1910-1911
but	O	1912-1915
by	O	1916-1918
year	O	1919-1923
13	O	1924-1926
,	O	1926-1927
the	O	1928-1931
survival	O	1932-1940
of	O	1941-1943
the	O	1944-1947
patients	O	1948-1956
who	O	1957-1960
had	O	1961-1964
ESRD	B	1965-1969
was	O	1970-1973
only	O	1974-1978
28	O	1979-1981
.	O	1981-1982
2	O	1979-1980
%	O	1983-1984
compared	O	1985-1993
with	O	1994-1998
54	O	1999-2001
.	O	2001-2002
6	O	2002-2003
%	O	2003-2004
in	O	2005-2007
the	O	2008-2011
control	O	2012-2019
group	O	2020-2025
.	O	2025-2026

Patients	O	2027-2035
developing	O	2036-2046
ESRD	B	2047-2051
had	O	2052-2055
a	O	2056-2057
6	O	2058-2059
-	O	2059-2060
year	O	2060-2064
survival	O	2065-2073
after	O	2074-2079
onset	O	2080-2085
of	O	2086-2088
ESRD	B	2089-2093
of	O	2094-2096
27	O	2097-2099
%	O	2099-2100
for	O	2101-2104
the	O	2105-2108
patients	O	2109-2117
receiving	O	2118-2127
hemodialysis	O	2128-2140
versus	O	2141-2147
71	O	2148-2150
.	O	2150-2151
4	O	2151-2152
%	O	2152-2153
for	O	2154-2157
the	O	2158-2161
patients	O	2162-2170
developing	O	2171-2181
ESRD	B	2182-2186
who	O	2187-2190
subsequently	O	2191-2203
received	O	2204-2212
kidney	O	2213-2219
transplants	O	2220-2231
.	O	2231-2232

CONCLUSIONS	O	2233-2244
:	O	2244-2245
Patients	O	2246-2254
who	O	2255-2258
are	O	2259-2262
more	O	2263-2267
than	O	2268-2272
10	O	2273-2275
years	O	2276-2281
post	O	2282-2286
-	O	2286-2287
OLTX	O	2287-2291
have	O	2292-2296
CRF	B	2297-2300
and	O	2301-2304
ESRD	B	2305-2309
at	O	2310-2312
a	O	2313-2314
high	O	2315-2319
rate	O	2320-2324
.	O	2324-2325

The	O	2326-2329
development	O	2330-2341
of	O	2342-2344
ESRD	B	2345-2349
decreases	O	2350-2359
survival	O	2360-2368
,	O	2368-2369
particularly	O	2370-2382
in	O	2383-2385
those	O	2386-2391
patients	O	2392-2400
treated	O	2401-2408
with	O	2409-2413
dialysis	O	2414-2422
only	O	2423-2427
.	O	2427-2428

Patients	O	2429-2437
who	O	2438-2441
develop	O	2442-2449
ESRD	B	2450-2454
have	O	2455-2459
a	O	2460-2461
higher	O	2462-2468
preoperative	O	2469-2481
and	O	2482-2485
1	O	2486-2487
-	O	2487-2488
year	O	2488-2492
serum	O	2493-2498
creatinine	O	2499-2509
and	O	2510-2513
are	O	2514-2517
more	O	2518-2522
likely	O	2523-2529
to	O	2530-2532
have	O	2533-2537
hepatorenal	B	2538-2549
syndrome	I	2550-2558
.	O	2558-2559

However	O	2560-2567
,	O	2567-2568
an	O	2569-2571
increase	O	2572-2580
of	O	2581-2583
serum	O	2584-2589
creatinine	O	2590-2600
at	O	2601-2603
various	O	2604-2611
times	O	2612-2617
postoperatively	O	2618-2633
is	O	2634-2636
more	O	2637-2641
predictive	O	2642-2652
of	O	2653-2655
the	O	2656-2659
development	O	2660-2671
of	O	2672-2674
CRF	B	2675-2678
or	O	2679-2681
ESRD	B	2682-2686
.	O	2686-2687

New	O	2688-2691
strategies	O	2692-2702
for	O	2703-2706
long	O	2707-2711
-	O	2711-2712
term	O	2712-2716
immunosuppression	O	2717-2734
may	O	2735-2738
be	O	2739-2741
needed	O	2742-2748
to	O	2749-2751
decrease	O	2752-2760
this	O	2761-2765
complication	O	2766-2778
.	O	2778-2779

Effect	O	0-6
of	O	7-9
intravenous	O	10-21
nimodipine	O	22-32
on	O	33-35
blood	O	36-41
pressure	O	42-50
and	O	51-54
outcome	O	55-62
after	O	63-68
acute	B	69-74
stroke	I	75-81
.	O	81-82

BACKGROUND	O	83-93
AND	O	94-97
PURPOSE	O	98-105
:	O	105-106
The	O	107-110
Intravenous	O	111-122
Nimodipine	O	123-133
West	O	134-138
European	O	139-147
Stroke	B	148-154
Trial	O	155-160
(	O	161-162
INWEST	O	162-168
)	O	168-169
found	O	170-175
a	O	176-177
correlation	O	178-189
between	O	190-197
nimodipine	O	198-208
-	O	208-209
induced	O	209-216
reduction	B	217-226
in	I	227-229
blood	I	230-235
pressure	I	236-244
(	O	245-246
BP	O	246-248
)	O	248-249
and	O	250-253
an	O	254-256
unfavorable	O	257-268
outcome	O	269-276
in	O	277-279
acute	B	280-285
stroke	I	286-292
.	O	292-293

We	O	294-296
sought	O	297-303
to	O	304-306
confirm	O	307-314
this	O	315-319
correlation	O	320-331
with	O	332-336
and	O	337-340
without	O	341-348
adjustment	O	349-359
for	O	360-363
prognostic	O	364-374
variables	O	375-384
and	O	385-388
to	O	389-391
investigate	O	392-403
outcome	O	404-411
in	O	412-414
subgroups	O	415-424
with	O	425-429
increasing	O	430-440
levels	O	441-447
of	O	448-450
BP	B	451-453
reduction	I	454-463
.	O	463-464

METHODS	O	465-472
:	O	472-473
Patients	O	474-482
with	O	483-487
a	O	488-489
clinical	O	490-498
diagnosis	O	499-508
of	O	509-511
ischemic	B	512-520
stroke	I	521-527
(	O	528-529
within	O	529-535
24	O	536-538
hours	O	539-544
)	O	544-545
were	O	546-550
consecutively	O	551-564
allocated	O	565-574
to	O	575-577
receive	O	578-585
placebo	O	586-593
(	O	594-595
n	O	595-596
=	O	596-597
100	O	597-600
)	O	600-601
,	O	601-602
1	O	603-604
mg	O	605-607
/	O	607-608
h	O	608-609
(	O	610-611
low	O	611-614
-	O	614-615
dose	O	615-619
)	O	619-620
nimodipine	O	621-631
(	O	632-633
n	O	633-634
=	O	634-635
101	O	635-638
)	O	638-639
,	O	639-640
or	O	641-643
2	O	644-645
mg	O	646-648
/	O	648-649
h	O	649-650
(	O	651-652
high	O	652-656
-	O	656-657
dose	O	657-661
)	O	661-662
nimodipine	O	663-673
(	O	674-675
n	O	675-676
=	O	676-677
94	O	677-679
)	O	679-680
.	O	680-681

The	O	682-685
correlation	O	686-697
between	O	698-705
average	O	706-713
BP	O	714-716
change	O	717-723
during	O	724-730
the	O	731-734
first	O	735-740
2	O	741-742
days	O	743-747
and	O	748-751
the	O	752-755
outcome	O	756-763
at	O	764-766
day	O	767-770
21	O	771-773
was	O	774-777
analyzed	O	778-786
.	O	786-787

RESULTS	O	788-795
:	O	795-796
Two	O	797-800
hundred	O	801-808
sixty	O	809-814
-	O	814-815
five	O	815-819
patients	O	820-828
were	O	829-833
included	O	834-842
in	O	843-845
this	O	846-850
analysis	O	851-859
(	O	860-861
n	O	861-862
=	O	862-863
92	O	863-865
,	O	865-866
93	O	867-869
,	O	869-870
and	O	871-874
80	O	875-877
for	O	878-881
placebo	O	882-889
,	O	889-890
low	O	891-894
dose	O	895-899
,	O	899-900
and	O	901-904
high	O	905-909
dose	O	910-914
,	O	914-915
respectively	O	916-928
)	O	928-929
.	O	929-930

Nimodipine	O	931-941
treatment	O	942-951
resulted	O	952-960
in	O	961-963
a	O	964-965
statistically	O	966-979
significant	O	980-991
reduction	B	992-1001
in	I	1002-1004
systolic	I	1005-1013
BP	I	1014-1016
(	O	1017-1018
SBP	O	1018-1021
)	O	1021-1022
and	O	1023-1026
diastolic	O	1027-1036
BP	O	1037-1039
(	O	1040-1041
DBP	O	1041-1044
)	O	1044-1045
from	O	1046-1050
baseline	O	1051-1059
compared	O	1060-1068
with	O	1069-1073
placebo	O	1074-1081
during	O	1082-1088
the	O	1089-1092
first	O	1093-1098
few	O	1099-1102
days	O	1103-1107
.	O	1107-1108

In	O	1109-1111
multivariate	O	1112-1124
analysis	O	1125-1133
,	O	1133-1134
a	O	1135-1136
significant	O	1137-1148
correlation	O	1149-1160
between	O	1161-1168
DBP	B	1169-1172
reduction	I	1173-1182
and	O	1183-1186
worsening	O	1187-1196
of	O	1197-1199
the	O	1200-1203
neurological	O	1204-1216
score	O	1217-1222
was	O	1223-1226
found	O	1227-1232
for	O	1233-1236
the	O	1237-1240
high	O	1241-1245
-	O	1245-1246
dose	O	1246-1250
group	O	1251-1256
(	O	1257-1258
beta	O	1258-1262
=	O	1262-1263
0	O	1263-1264
.	O	1264-1265
49	O	1265-1267
,	O	1267-1268

P	O	1269-1270
=	O	1270-1271
0	O	1271-1272
.	O	1272-1273

048	O	1274-1277
)	O	1277-1278
.	O	1278-1279

Patients	O	1280-1288
with	O	1289-1293
a	O	1294-1295
DBP	B	1296-1299
reduction	I	1300-1309
of	O	1310-1312
>	O	1313-1314
or	O	1315-1317
=	O	1318-1319
20	O	1319-1321
%	O	1321-1322
in	O	1323-1325
the	O	1326-1329
high	O	1330-1334
-	O	1334-1335
dose	O	1335-1339
group	O	1340-1345
had	O	1346-1349
a	O	1350-1351
significantly	O	1352-1365
increased	O	1366-1375
adjusted	O	1376-1384
OR	O	1385-1387
for	O	1388-1391
the	O	1392-1395
compound	O	1396-1404
outcome	O	1405-1412
variable	O	1413-1421
death	B	1422-1427
or	O	1428-1430
dependency	O	1431-1441
(	O	1442-1443
Barthel	O	1443-1450
Index	O	1451-1456
<	O	1457-1458
60	O	1458-1460
)	O	1460-1461
(	O	1462-1463
n	O	1463-1464
/	O	1464-1465
N	O	1465-1466
=	O	1466-1467
25	O	1467-1469
/	O	1464-1465
26	O	1470-1472
,	O	1472-1473
OR	O	1474-1476
10	O	1477-1479
.	O	1479-1480
16	O	1481-1483
,	O	1483-1484
95	O	1485-1487
%	O	1487-1488
CI	O	1489-1491
1	O	1492-1493
.	O	1493-1494
02	O	1494-1496
to	O	1497-1499
101	O	1500-1503
.	O	1503-1504
74	O	1504-1506
)	O	1506-1507
and	O	1508-1511
death	B	1512-1517
alone	O	1518-1523
(	O	1524-1525
n	O	1525-1526
/	O	1526-1527
N	O	1527-1528
=	O	1528-1529
9	O	1529-1530
/	O	1526-1527
26	O	1531-1533
,	O	1533-1534
OR	O	1535-1537
4	O	1538-1539
.	O	1539-1540
336	O	1540-1543
,	O	1543-1544
95	O	1545-1547
%	O	1547-1548
CI	O	1549-1551
1	O	1552-1553
.	O	1553-1554
131	O	1554-1557
16	O	1558-1560
.	O	1560-1561
619	O	1561-1564
)	O	1564-1565
compared	O	1566-1574
with	O	1575-1579
all	O	1580-1583
placebo	O	1584-1591
patients	O	1592-1600
(	O	1601-1602
n	O	1602-1603
/	O	1603-1604
N	O	1604-1605
=	O	1605-1606
62	O	1606-1608
/	O	1603-1604
92	O	1609-1611
and	O	1612-1615
14	O	1616-1618
/	O	1618-1619
92	O	1619-1621
,	O	1621-1622
respectively	O	1623-1635
)	O	1635-1636
.	O	1636-1637

There	O	1638-1643
was	O	1644-1647
no	O	1648-1650
correlation	O	1651-1662
between	O	1663-1670
SBP	O	1671-1674
change	O	1675-1681
and	O	1682-1685
outcome	O	1686-1693
.	O	1693-1694

CONCLUSIONS	O	1695-1706
:	O	1706-1707
DBP	O	1708-1711
,	O	1711-1712
but	O	1713-1716
not	O	1717-1720
SBP	O	1721-1724
,	O	1724-1725
reduction	O	1726-1735
was	O	1736-1739
associated	O	1740-1750
with	O	1751-1755
neurological	O	1756-1768
worsening	O	1769-1778
after	O	1779-1784
the	O	1785-1788
intravenous	O	1789-1800
administration	O	1801-1815
of	O	1816-1818
high	O	1819-1823
-	O	1823-1824
dose	O	1824-1828
nimodipine	O	1829-1839
after	O	1840-1845
acute	B	1846-1851
stroke	I	1852-1858
.	O	1858-1859

For	O	1860-1863
low	O	1864-1867
-	O	1867-1868
dose	O	1868-1872
nimodipine	O	1873-1883
,	O	1883-1884
the	O	1885-1888
results	O	1889-1896
were	O	1897-1901
not	O	1902-1905
conclusive	O	1906-1916
.	O	1916-1917

These	O	1918-1923
results	O	1924-1931
do	O	1932-1934
not	O	1935-1938
confirm	O	1939-1946
or	O	1947-1949
exclude	O	1950-1957
a	O	1958-1959
neuroprotective	O	1960-1975
property	O	1976-1984
of	O	1985-1987
nimodipine	O	1988-1998
.	O	1998-1999

Transient	B	0-9
neurologic	I	10-20
symptoms	I	21-29
after	O	30-35
spinal	O	36-42
anesthesia	O	43-53
:	O	53-54
a	O	55-56
lower	O	57-62
incidence	O	63-72
with	O	73-77
prilocaine	O	78-88
and	O	89-92
bupivacaine	O	93-104
than	O	105-109
with	O	110-114
lidocaine	O	115-124
.	O	124-125

BACKGROUND	O	126-136
:	O	136-137
Recent	O	138-144
evidence	O	145-153
suggests	O	154-162
that	O	163-167
transient	B	168-177
neurologic	I	178-188
symptoms	I	189-197
(	O	198-199
TNSs	B	199-203
)	O	203-204
frequently	O	205-215
follow	O	216-222
lidocaine	O	223-232
spinal	O	233-239
anesthesia	O	240-250
but	O	251-254
are	O	255-258
infrequent	O	259-269
with	O	270-274
bupivacaine	O	275-286
.	O	286-287

However	O	288-295
,	O	295-296
identification	O	297-311
of	O	312-314
a	O	315-316
short	O	317-322
-	O	322-323
acting	O	323-329
local	O	330-335
anesthetic	O	336-346
to	O	347-349
substitute	O	350-360
for	O	361-364
lidocaine	O	365-374
for	O	375-378
brief	O	379-384
surgical	O	385-393
procedures	O	394-404
remains	O	405-412
an	O	413-415
important	O	416-425
goal	O	426-430
.	O	430-431

Prilocaine	O	432-442
is	O	443-445
an	O	446-448
amide	O	449-454
local	O	455-460
anesthetic	O	461-471
with	O	472-476
a	O	477-478
duration	O	479-487
of	O	488-490
action	O	491-497
similar	O	498-505
to	O	506-508
that	O	509-513
of	O	514-516
lidocaine	O	517-526
.	O	526-527

Accordingly	O	528-539
,	O	539-540
the	O	541-544
present	O	545-552
,	O	552-553
prospective	O	554-565
double	O	566-572
-	O	572-573
blind	O	573-578
study	O	579-584
compares	O	585-593
prilocaine	O	594-604
with	O	605-609
lidocaine	O	610-619
and	O	620-623
bupivacaine	O	624-635
with	O	636-640
respect	O	641-648
to	O	649-651
duration	O	652-660
of	O	661-663
action	O	664-670
and	O	671-674
relative	O	675-683
risk	O	684-688
of	O	689-691
TNSs	B	692-696
.	O	696-697

METHODS	O	698-705
:	O	705-706
Ninety	O	707-713
patients	O	714-722
classified	O	723-733
as	O	734-736
American	O	737-745
Society	O	746-753
of	O	754-756
Anesthesiologists	O	757-774
physical	O	775-783
status	O	784-790
I	O	791-792
or	O	793-795
II	O	796-798
who	O	799-802
were	O	803-807
scheduled	O	808-817
for	O	818-821
short	O	822-827
gynecologic	O	828-839
procedures	O	840-850
under	O	851-856
spinal	O	857-863
anesthesia	O	864-874
were	O	875-879
randomly	O	880-888
allocated	O	889-898
to	O	899-901
receive	O	902-909
2	O	910-911
.	O	911-912
5	O	912-913
ml	O	914-916
2	O	917-918
%	O	918-919
lidocaine	O	920-929
in	O	930-932
7	O	933-934
.	O	934-935
5	O	935-936
%	O	936-937
glucose	O	938-945
,	O	945-946
2	O	947-948
%	O	948-949
prilocaine	O	950-960
in	O	961-963
7	O	964-965
.	O	965-966
5	O	966-967
%	O	967-968
glucose	O	969-976
,	O	976-977
or	O	978-980
0	O	981-982
.	O	982-983
5	O	983-984
%	O	984-985
bupivacaine	O	986-997
in	O	998-1000
7	O	1001-1002
.	O	1002-1003
5	O	1003-1004
%	O	1004-1005
glucose	O	1006-1013
.	O	1013-1014

All	O	1015-1018
solutions	O	1019-1028
were	O	1029-1033
provided	O	1034-1042
in	O	1043-1045
blinded	O	1046-1053
vials	O	1054-1059
by	O	1060-1062
the	O	1063-1066
hospital	O	1067-1075
pharmacy	O	1076-1084
.	O	1084-1085

Details	O	1086-1093
of	O	1094-1096
spinal	O	1097-1103
puncture	O	1104-1112
,	O	1112-1113
extension	O	1114-1123
and	O	1124-1127
regression	O	1128-1138
of	O	1139-1141
spinal	O	1142-1148
block	O	1149-1154
,	O	1154-1155
and	O	1156-1159
the	O	1160-1163
times	O	1164-1169
to	O	1170-1172
reach	O	1173-1178
discharge	O	1179-1188
criteria	O	1189-1197
were	O	1198-1202
noted	O	1203-1208
.	O	1208-1209

In	O	1210-1212
the	O	1213-1216
evening	O	1217-1224
of	O	1225-1227
postoperative	O	1228-1241
day	O	1242-1245
1	O	1246-1247
,	O	1247-1248
patients	O	1249-1257
were	O	1258-1262
evaluated	O	1263-1272
for	O	1273-1276
TNSs	B	1277-1281
by	O	1282-1284
a	O	1285-1286
physician	O	1287-1296
unaware	O	1297-1304
of	O	1305-1307
the	O	1308-1311
drug	O	1312-1316
administered	O	1317-1329
and	O	1330-1333
the	O	1334-1337
details	O	1338-1345
of	O	1346-1348
the	O	1349-1352
anesthetic	O	1353-1363
procedure	O	1364-1373
.	O	1373-1374

RESULTS	O	1375-1382
:	O	1382-1383
Nine	O	1384-1388
of	O	1389-1391
30	O	1392-1394
patients	O	1395-1403
receiving	O	1404-1413
lidocaine	O	1414-1423
experienced	O	1424-1435
TNSs	B	1436-1440
,	O	1440-1441
1	O	1442-1443
of	O	1444-1446
30	O	1447-1449
patients	O	1450-1458
receiving	O	1459-1468
prilocaine	O	1469-1479
(	O	1480-1481
P	O	1481-1482
=	O	1483-1484
0	O	1485-1486
.	O	1486-1487
03	O	1487-1489
)	O	1489-1490
had	O	1491-1494
them	O	1495-1499
,	O	1499-1500
and	O	1501-1504
none	O	1505-1509
of	O	1510-1512
30	O	1513-1515
patients	O	1516-1524
receiving	O	1525-1534
bupivacaine	O	1535-1546
had	O	1547-1550
TNSs	B	1551-1555
.	O	1555-1556

Times	O	1557-1562
to	O	1563-1565
ambulate	O	1566-1574
and	O	1575-1578
to	O	1579-1581
void	O	1582-1586
were	O	1587-1591
similar	O	1592-1599
after	O	1600-1605
lidocaine	O	1606-1615
and	O	1616-1619
prilocaine	O	1620-1630
(	O	1631-1632
150	O	1632-1635
vs	O	1636-1638
.	O	1638-1639
165	O	1640-1643
min	O	1644-1647
and	O	1648-1651
238	O	1652-1655
vs	O	1656-1658
.	O	1658-1659
253	O	1660-1663
min	O	1664-1667
,	O	1667-1668
respectively	O	1669-1681
)	O	1681-1682
but	O	1683-1686
prolonged	O	1687-1696
after	O	1697-1702
bupivacaine	O	1703-1714
(	O	1715-1716
200	O	1716-1719
and	O	1720-1723
299	O	1724-1727
min	O	1728-1731
,	O	1731-1732
respectively	O	1733-1745
;	O	1745-1746
P	O	1747-1748
<	O	1749-1750
0	O	1751-1752
.	O	1752-1753
05	O	1753-1755
)	O	1755-1756
.	O	1752-1753

CONCLUSIONS	O	1758-1769
:	O	1769-1770
Prilocaine	O	1771-1781
may	O	1782-1785
be	O	1786-1788
preferable	O	1789-1799
to	O	1800-1802
lidocaine	O	1803-1812
for	O	1813-1816
short	O	1817-1822
surgical	O	1823-1831
procedures	O	1832-1842
because	O	1843-1850
it	O	1851-1853
has	O	1854-1857
a	O	1858-1859
similar	O	1860-1867
duration	O	1868-1876
of	O	1877-1879
action	O	1880-1886
but	O	1887-1890
a	O	1891-1892
lower	O	1893-1898
incidence	O	1899-1908
of	O	1909-1911
TNSs	B	1912-1916
.	O	1916-1917

The	O	0-3
role	O	4-8
of	O	9-11
nicotine	O	12-20
in	O	21-23
smoking	O	24-31
-	O	31-32
related	O	32-39
cardiovascular	B	40-54
disease	I	55-62
.	O	62-63

Nicotine	O	64-72
activates	O	73-82
the	O	83-86
sympathetic	O	87-98
nervous	O	99-106
system	O	107-113
and	O	114-117
in	O	118-120
this	O	121-125
way	O	126-129
could	O	130-135
contribute	O	136-146
to	O	147-149
cardiovascular	B	150-164
disease	I	165-172
.	O	172-173

Animal	O	174-180
studies	O	181-188
and	O	189-192
mechanistic	O	193-204
studies	O	205-212
indicate	O	213-221
that	O	222-226
nicotine	O	227-235
could	O	236-241
play	O	242-246
a	O	247-248
role	O	249-253
in	O	254-256
accelerating	O	257-269
atherosclerosis	B	270-285
,	O	285-286
but	O	287-290
evidence	O	291-299
among	O	300-305
humans	O	306-312
is	O	313-315
too	O	316-319
inadequate	O	320-330
to	O	331-333
be	O	334-336
definitive	O	337-347
about	O	348-353
such	O	354-358
an	O	359-361
effect	O	362-368
.	O	368-369

Almost	O	370-376
certainly	O	377-386
,	O	386-387
nicotine	O	388-396
via	O	397-400
its	O	401-404
hemodynamic	O	405-416
effects	O	417-424
contributes	O	425-436
to	O	437-439
acute	O	440-445
cardiovascular	O	446-460
events	O	461-467
,	O	467-468
although	O	469-477
current	O	478-485
evidence	O	486-494
suggests	O	495-503
that	O	504-508
the	O	509-512
effects	O	513-520
of	O	521-523
nicotine	O	524-532
are	O	533-536
much	O	537-541
less	O	542-546
important	O	547-556
than	O	557-561
are	O	562-565
the	O	566-569
prothrombotic	O	570-583
effects	O	584-591
of	O	592-594
cigarette	O	595-604
smoking	O	605-612
or	O	613-615
the	O	616-619
effects	O	620-627
of	O	628-630
carbon	O	631-637
monoxide	O	638-646
.	O	646-647

Nicotine	O	648-656
does	O	657-661
not	O	662-665
appear	O	666-672
to	O	673-675
enhance	O	676-683
thrombosis	B	684-694
among	O	695-700
humans	O	701-707
.	O	707-708

Clinical	O	709-717
studies	O	718-725
of	O	726-728
pipe	O	729-733
smokers	O	734-741
and	O	742-745
people	O	746-752
using	O	753-758
transdermal	O	759-770
nicotine	O	771-779
support	O	780-787
the	O	788-791
idea	O	792-796
that	O	797-801
toxins	O	802-808
other	O	809-814
than	O	815-819
nicotine	O	820-828
are	O	829-832
the	O	833-836
most	O	837-841
important	O	842-851
causes	O	852-858
of	O	859-861
acute	O	862-867
cardiovascular	O	868-882
events	O	883-889
.	O	889-890

Finally	O	891-898
,	O	898-899
the	O	900-903
dose	O	904-908
response	O	909-917
for	O	918-921
cardiovascular	O	922-936
events	O	937-943
of	O	944-946
nicotine	O	947-955
appears	O	956-963
to	O	964-966
be	O	967-969
flat	O	970-974
,	O	974-975
suggesting	O	976-986
that	O	987-991
if	O	992-994
nicotine	O	995-1003
is	O	1004-1006
involved	O	1007-1015
,	O	1015-1016
adverse	O	1017-1024
effects	O	1025-1032
might	O	1033-1038
be	O	1039-1041
seen	O	1042-1046
with	O	1047-1051
relatively	O	1052-1062
low	O	1063-1066
-	O	1066-1067
level	O	1067-1072
cigarette	O	1073-1082
exposures	O	1083-1092
.	O	1092-1093

Seizure	B	0-7
resulting	O	8-17
from	O	18-22
a	O	23-24
venlafaxine	O	25-36
overdose	B	37-45
.	O	45-46

OBJECTIVE	O	47-56
:	O	56-57
To	O	58-60
report	O	61-67
a	O	68-69
case	O	70-74
of	O	75-77
venlafaxine	O	78-89
overdose	B	90-98
.	O	98-99

CASE	O	100-104
SUMMARY	O	105-112
:	O	112-113
A	O	114-115
40	O	116-118
-	O	118-119
year	O	119-123
-	O	118-119
old	O	124-127
woman	O	128-133
with	O	134-138
major	B	139-144
depression	I	145-155
took	O	156-160
an	O	161-163
overdose	B	164-172
of	O	173-175
venlafaxine	O	176-187
in	O	188-190
an	O	191-193
apparent	O	194-202
suicide	O	203-210
attempt	O	211-218
.	O	218-219

After	O	220-225
the	O	226-229
ingestion	O	230-239
of	O	240-242
26	O	243-245
venlafaxine	O	246-257
50	O	258-260
-	O	260-261
mg	O	261-263
tablets	O	264-271
,	O	271-272
the	O	273-276
patient	O	277-284
experienced	O	285-296
a	O	297-298
witnessed	O	299-308
generalized	O	309-320
seizure	B	321-328
.	O	328-329

She	O	330-333
was	O	334-337
admitted	O	338-346
to	O	347-349
the	O	350-353
medical	O	354-361
intensive	O	362-371
care	O	372-376
unit	O	377-381
,	O	381-382
venlafaxine	O	383-394
was	O	395-398
discontinued	O	399-411
,	O	411-412
and	O	413-416
no	O	417-419
further	O	420-427
sequelae	O	428-436
were	O	437-441
seen	O	442-446
.	O	446-447

DISCUSSION	O	448-458
:	O	458-459
To	O	460-462
our	O	463-466
knowledge	O	467-476
,	O	476-477
this	O	478-482
is	O	483-485
the	O	486-489
first	O	490-495
reported	O	496-504
case	O	505-509
of	O	510-512
venlafaxine	O	513-524
overdose	B	525-533
that	O	534-538
resulted	O	539-547
in	O	548-550
a	O	551-552
generalized	O	553-564
seizure	B	565-572
.	O	572-573

Based	O	574-579
on	O	580-582
nonoverdose	O	583-594
pharmacokinetics	O	595-611
and	O	612-615
pharmacodynamics	O	616-632
of	O	633-635
venlafaxine	O	636-647
and	O	648-651
the	O	652-655
potential	O	656-665
risks	O	666-671
of	O	672-674
available	O	675-684
interventions	O	685-698
,	O	698-699
no	O	700-702
emergent	O	703-711
therapy	O	712-719
was	O	720-723
instituted	O	724-734
.	O	734-735

CONCLUSIONS	O	736-747
:	O	747-748
The	O	749-752
venlafaxine	O	753-764
overdose	B	765-773
in	O	774-776
our	O	777-780
patient	O	781-788
resulted	O	789-797
in	O	798-800
a	O	801-802
single	O	803-809
episode	O	810-817
of	O	818-820
generalized	O	821-832
seizure	B	833-840
but	O	841-844
elicited	O	845-853
no	O	854-856
further	O	857-864
sequelae	O	865-873
.	O	873-874

Effect	O	0-6
of	O	7-9
nifedipine	O	10-20
on	O	21-23
renal	O	24-29
function	O	30-38
in	O	39-41
liver	O	42-47
transplant	O	48-58
recipients	O	59-69
receiving	O	70-79
tacrolimus	O	80-90
.	O	90-91

The	O	92-95
effect	O	96-102
of	O	103-105
nifedipine	O	106-116
on	O	117-119
renal	O	120-125
function	O	126-134
in	O	135-137
liver	O	138-143
transplant	O	144-154
recipients	O	155-165
who	O	166-169
were	O	170-174
receiving	O	175-184
tacrolimus	O	185-195
was	O	196-199
evaluated	O	200-209
between	O	210-217
January	O	218-225
1992	O	226-230
and	O	231-234
January	O	235-242
1996	O	243-247
.	O	247-248

Two	O	249-252
groups	O	253-259
of	O	260-262
patients	O	263-271
receiving	O	272-281
tacrolimus	O	282-292
were	O	293-297
compared	O	298-306
over	O	307-311
a	O	312-313
period	O	314-320
of	O	321-323
1	O	324-325
year	O	326-330
,	O	330-331
one	O	332-335
group	O	336-341
comprising	O	342-352
hypertensive	B	353-365
patients	O	366-374
who	O	375-378
were	O	379-383
receiving	O	384-393
nifedipine	O	394-404
,	O	404-405
and	O	406-409
the	O	410-413
other	O	414-419
comprising	O	420-430
nonhypertensive	O	431-446
patients	O	447-455
not	O	456-459
receiving	O	460-469
nifedipine	O	470-480
.	O	480-481

The	O	482-485
time	O	486-490
from	O	491-495
transplant	O	496-506
to	O	507-509
baseline	O	510-518
was	O	519-522
similar	O	523-530
in	O	531-533
all	O	534-537
patients	O	538-546
.	O	546-547

Nifedipine	O	548-558
significantly	O	559-572
improved	O	573-581
kidney	O	582-588
function	O	589-597
as	O	598-600
indicated	O	601-610
by	O	611-613
a	O	614-615
significant	O	616-627
lowering	O	628-636
of	O	637-639
serum	O	640-645
creatinine	O	646-656
levels	O	657-663
at	O	664-666
6	O	667-668
and	O	669-672
12	O	673-675
months	O	676-682
.	O	682-683

The	O	684-687
observed	O	688-696
positive	O	697-705
impact	O	706-712
of	O	713-715
nifedipine	O	716-726
on	O	727-729
reducing	O	730-738
the	O	739-742
nephrotoxicity	B	743-757
associated	O	758-768
with	O	769-773
tacrolimus	O	774-784
in	O	785-787
liver	O	788-793
transplant	O	794-804
recipients	O	805-815
should	O	816-822
be	O	823-825
an	O	826-828
important	O	829-838
factor	O	839-845
in	O	846-848
selecting	O	849-858
an	O	859-861
agent	O	862-867
to	O	868-870
treat	O	871-876
hypertension	B	877-889
in	O	890-892
this	O	893-897
population	O	898-908
.	O	908-909

Sinus	B	0-5
arrest	I	6-12
associated	O	13-23
with	O	24-28
continuous	O	29-39
-	O	39-40
infusion	O	40-48
cimetidine	O	49-59
.	O	59-60

The	O	61-64
administration	O	65-79
of	O	80-82
intermittent	O	83-95
intravenous	O	96-107
infusions	O	108-117
of	O	118-120
cimetidine	O	121-131
is	O	132-134
infrequently	O	135-147
associated	O	148-158
with	O	159-163
the	O	164-167
development	O	168-179
of	O	180-182
bradyarrhythmias	B	183-199
.	O	199-200

A	O	201-202
40	O	203-205
-	O	205-206
year	O	206-210
-	O	205-206
old	O	211-214
man	O	215-218
with	O	219-223
leukemia	B	224-232
and	O	233-236
no	O	237-239
history	O	240-247
of	O	248-250
cardiac	B	251-258
disease	I	259-266
developed	O	267-276
recurrent	O	277-286
,	O	286-287
brief	O	288-293
episodes	O	294-302
of	O	303-305
apparent	O	306-314
sinus	B	315-320
arrest	I	321-327
while	O	328-333
receiving	O	334-343
continuous	O	344-354
-	O	354-355
infusion	O	355-363
cimetidine	O	364-374
50	O	375-377
mg	O	378-380
/	O	380-381
hour	O	381-385
.	O	385-386

The	O	387-390
arrhythmias	B	391-402
were	O	403-407
temporally	O	408-418
related	O	419-426
to	O	427-429
cimetidine	O	430-440
administration	O	441-455
,	O	455-456
disappeared	O	457-468
after	O	469-474
dechallenge	O	475-486
,	O	486-487
and	O	488-491
did	O	492-495
not	O	496-499
recur	O	500-505
during	O	506-512
ranitidine	O	513-523
treatment	O	524-533
.	O	533-534

This	O	535-539
is	O	540-542
the	O	543-546
first	O	547-552
reported	O	553-561
case	O	562-566
of	O	567-569
sinus	B	570-575
arrest	I	576-582
associated	O	583-593
with	O	594-598
continuous	O	599-609
-	O	609-610
infusion	O	610-618
cimetidine	O	619-629
.	O	629-630

Composition	O	0-11
of	O	12-14
gall	B	15-19
bladder	I	20-27
stones	I	28-34
associated	O	35-45
with	O	46-50
octreotide	O	51-61
:	O	61-62
response	O	63-71
to	O	72-74
oral	O	75-79
ursodeoxycholic	O	80-95
acid	O	96-100
.	O	100-101

Octreotide	O	102-112
,	O	112-113
an	O	114-116
effective	O	117-126
treatment	O	127-136
for	O	137-140
acromegaly	B	141-151
,	O	151-152
induces	O	153-160
gall	B	161-165
bladder	I	166-173
stones	I	174-180
in	O	181-183
13	O	184-186
-	O	186-187
60	O	187-189
%	O	189-190
of	O	191-193
patients	O	194-202
.	O	202-203

Because	O	204-211
knowledge	O	212-221
of	O	222-224
stone	O	225-230
composition	O	231-242
is	O	243-245
essential	O	246-255
for	O	256-259
studies	O	260-267
of	O	268-270
their	O	271-276
pathogenesis	O	277-289
,	O	289-290
treatment	O	291-300
,	O	300-301
and	O	302-305
prevention	O	306-316
,	O	316-317
this	O	318-322
was	O	323-326
investigated	O	327-339
by	O	340-342
direct	O	343-349
and	O	350-353
indirect	O	354-362
methods	O	363-370
in	O	371-373
14	O	374-376
octreotide	O	377-387
treated	O	388-395
acromegalic	B	396-407
patients	O	408-416
with	O	417-421
gall	B	422-426
stones	I	427-433
.	O	433-434

Chemical	O	435-443
analysis	O	444-452
of	O	453-455
gall	B	456-460
stones	I	461-467
retrieved	O	468-477
at	O	478-480
cholecystectomy	O	481-496
from	O	497-501
two	O	502-505
patients	O	506-514
,	O	514-515
showed	O	516-522
that	O	523-527
they	O	528-532
contained	O	533-542
71	O	543-545
%	O	545-546
and	O	547-550
87	O	551-553
%	O	553-554
cholesterol	O	555-566
by	O	567-569
weight	O	570-576
.	O	576-577

In	O	578-580
the	O	581-584
remaining	O	585-594
12	O	595-597
patients	O	598-606
,	O	606-607
localised	O	608-617
computed	O	618-626
tomography	O	627-637
of	O	638-640
the	O	641-644
gall	O	645-649
bladder	O	650-657
showed	O	658-664
that	O	665-669
eight	O	670-675
had	O	676-679
stones	O	680-686
with	O	687-691
maximum	O	692-699
attenuation	O	700-711
scores	O	712-718
of	O	719-721
<	O	722-723
100	O	724-727
Hounsfield	O	728-738
units	O	739-744
(	O	745-746
values	O	746-752
of	O	753-755
<	O	756-757
100	O	758-761
HU	O	762-764
predict	O	765-772
cholesterol	O	773-784
rich	O	785-789
,	O	789-790
dissolvable	O	791-802
stones	O	803-809
)	O	809-810
.	O	810-811

Gall	O	812-816
bladder	O	817-824
bile	O	825-829
was	O	830-833
obtained	O	834-842
by	O	843-845
ultrasound	O	846-856
guided	O	857-863
,	O	863-864
fine	O	865-869
needle	O	870-876
puncture	O	877-885
from	O	886-890
six	O	891-894
patients	O	895-903
.	O	903-904

All	O	905-908
six	O	909-912
patients	O	913-921
had	O	922-925
supersaturated	O	926-940
bile	O	941-945
(	O	946-947
mean	O	947-951
(	O	952-953
SEM	O	953-956
)	O	956-957
cholesterol	O	958-969
saturation	O	970-980
index	O	981-986
of	O	987-989
1	O	990-991
.	O	991-992
19	O	992-994
(	O	995-996
0	O	996-997
.	O	997-998
08	O	998-1000
)	O	1000-1001
(	O	1002-1003
range	O	1003-1008
1	O	1009-1010
.	O	1010-1011
01	O	1011-1013
-	O	1013-1014
1	O	1009-1010
.	O	1010-1011
53	O	1016-1018
)	O	1018-1019
)	O	1018-1019

and	O	1021-1024
all	O	1025-1028
had	O	1029-1032
abnormally	O	1033-1043
rapid	O	1044-1049
cholesterol	O	1050-1061
microcrystal	O	1062-1074
nucleation	O	1075-1085
times	O	1086-1091
(	O	1092-1093
<	O	1093-1094
4	O	1095-1096
days	O	1097-1101
(	O	1102-1103
range	O	1103-1108
1	O	1109-1110
-	O	1110-1111
4	O	1111-1112
)	O	1112-1113
)	O	1112-1113
,	O	1114-1115
whilst	O	1116-1122
in	O	1123-1125
four	O	1126-1130
,	O	1130-1131
the	O	1132-1135
bile	O	1136-1140
contained	O	1141-1150
cholesterol	O	1151-1162
microcrystals	O	1163-1176
immediately	O	1177-1188
after	O	1189-1194
sampling	O	1195-1203
.	O	1203-1204

Of	O	1205-1207
the	O	1208-1211
12	O	1212-1214
patients	O	1215-1223
considered	O	1224-1234
for	O	1235-1238
oral	O	1239-1243
ursodeoxycholic	O	1244-1259
acid	O	1260-1264
(	O	1265-1266
UDCA	O	1266-1270
)	O	1270-1271
treatment	O	1272-1281
,	O	1281-1282
two	O	1283-1286
had	O	1287-1290
a	O	1291-1292
blocked	O	1293-1300
cystic	O	1301-1307
duct	O	1308-1312
and	O	1313-1316
were	O	1317-1321
not	O	1322-1325
started	O	1326-1333
on	O	1334-1336
UDCA	O	1337-1341
while	O	1342-1347
one	O	1348-1351
was	O	1352-1355
lost	O	1356-1360
to	O	1361-1363
follow	O	1364-1370
up	O	1371-1373
.	O	1373-1374

After	O	1375-1380
one	O	1381-1384
year	O	1385-1389
of	O	1390-1392
treatment	O	1393-1402
,	O	1402-1403
five	O	1404-1408
of	O	1409-1411
the	O	1412-1415
remaining	O	1416-1425
nine	O	1426-1430
patients	O	1431-1439
showed	O	1440-1446
either	O	1447-1453
partial	O	1454-1461
(	O	1462-1463
n	O	1463-1464
=	O	1465-1466
3	O	1467-1468
)	O	1468-1469
or	O	1470-1472
complete	O	1473-1481
(	O	1482-1483
n	O	1483-1484
=	O	1485-1486
2	O	1487-1488
)	O	1488-1489
gall	B	1490-1494
stone	I	1495-1500
dissolution	O	1501-1512
,	O	1512-1513
suggesting	O	1514-1524
that	O	1525-1529
their	O	1530-1535
stones	O	1536-1542
were	O	1543-1547
cholesterol	O	1548-1559
rich	O	1560-1564
.	O	1564-1565

This	O	1566-1570
corresponds	O	1571-1582
,	O	1582-1583
by	O	1584-1586
actuarial	O	1587-1596
(	O	1597-1598
life	O	1598-1602
table	O	1603-1608
)	O	1608-1609
analysis	O	1610-1618
,	O	1618-1619
to	O	1620-1622
a	O	1623-1624
combined	O	1625-1633
gall	B	1634-1638
stone	I	1639-1644
dissolution	O	1645-1656
rate	O	1657-1661
of	O	1662-1664
58	O	1665-1667
.	O	1667-1668
3	O	1668-1669
(	O	1670-1671
15	O	1671-1673
.	O	1673-1674
9	O	1674-1675
%	O	1675-1676
)	O	1676-1677
.	O	1673-1674

In	O	1679-1681
conclusion	O	1682-1692
,	O	1692-1693
octreotide	O	1694-1704
induced	O	1705-1712
gall	B	1713-1717
stones	I	1718-1724
are	O	1725-1728
generally	O	1729-1738
small	O	1739-1744
,	O	1744-1745
multiple	O	1746-1754
,	O	1754-1755
and	O	1756-1759
cholesterol	O	1760-1771
rich	O	1772-1776
although	O	1777-1785
,	O	1785-1786
in	O	1787-1789
common	O	1790-1796
with	O	1797-1801
spontaneous	O	1802-1813
gall	B	1814-1818
stone	I	1819-1824
disease	I	1825-1832
,	O	1832-1833
at	O	1834-1836
presentation	O	1837-1849
some	O	1850-1854
patients	O	1855-1863
will	O	1864-1868
have	O	1869-1873
a	O	1874-1875
blocked	O	1876-1883
cystic	O	1884-1890
duct	O	1891-1895
and	O	1896-1899
some	O	1900-1904
gall	B	1905-1909
stones	I	1910-1916
containing	O	1917-1927
calcium	O	1928-1935
.	O	1935-1936

Cardiovascular	B	0-14
complications	I	15-28
associated	O	29-39
with	O	40-44
terbutaline	O	45-56
treatment	O	57-66
for	O	67-70
preterm	B	71-78
labor	I	79-84
.	O	84-85

Severe	O	86-92
cardiovascular	B	93-107
complications	I	108-121
occurred	O	122-130
in	O	131-133
eight	O	134-139
of	O	140-142
160	O	143-146
patients	O	147-155
treated	O	156-163
with	O	164-168
terbutaline	O	169-180
for	O	181-184
preterm	B	185-192
labor	I	193-198
.	O	198-199

Associated	O	200-210
corticosteroid	O	211-225
therapy	O	226-233
and	O	234-237
twin	O	238-242
gestations	O	243-253
appear	O	254-260
to	O	261-263
be	O	264-266
predisposing	O	267-279
factors	O	280-287
.	O	287-288

Potential	O	289-298
mechanisms	O	299-309
of	O	310-312
the	O	313-316
pathophysiology	O	317-332
are	O	333-336
briefly	O	337-344
discussed	O	345-354
.	O	354-355

Neurologic	O	0-10
effects	O	11-18
of	O	19-21
subarachnoid	O	22-34
administration	O	35-49
of	O	50-52
2	O	53-54
-	O	54-55
chloroprocaine	O	55-69
-	O	54-55
CE	O	70-72
,	O	72-73
bupivacaine	O	74-85
,	O	85-86
and	O	87-90
low	O	91-94
pH	O	95-97
normal	O	98-104
saline	O	105-111
in	O	112-114
dogs	O	115-119
.	O	119-120

The	O	121-124
purpose	O	125-132
of	O	133-135
this	O	136-140
study	O	141-146
was	O	147-150
to	O	151-153
evaluate	O	154-162
the	O	163-166
neurologic	O	167-177
consequences	O	178-190
of	O	191-193
deliberate	O	194-204
subarachnoid	O	205-217
injection	O	218-227
of	O	228-230
large	O	231-236
volumes	O	237-244
of	O	245-247
2	O	248-249
-	O	249-250
chloroprocaine	O	250-264
-	O	249-250
CE	O	265-267
in	O	268-270
experimental	O	271-283
animals	O	284-291
.	O	291-292

The	O	293-296
possible	O	297-305
role	O	306-310
of	O	311-313
low	O	314-317
pH	O	318-320
as	O	321-323
well	O	324-328
as	O	329-331
total	O	332-337
volume	O	338-344
as	O	345-347
potential	O	348-357
factors	O	358-365
in	O	366-368
causing	O	369-376
neurotoxicity	B	377-390
was	O	391-394
evaluated	O	395-404
.	O	404-405

The	O	406-409
65	O	410-412
dogs	O	413-417
in	O	418-420
the	O	421-424
study	O	425-430
received	O	431-439
injections	O	440-450
in	O	451-453
the	O	454-457
subarachnoid	O	458-470
space	O	471-476
as	O	477-479
follows	O	480-487
:	O	487-488
6	O	489-490
to	O	491-493
8	O	494-495
ml	O	496-498
of	O	499-501
bupivacaine	O	502-513
(	O	514-515
N	O	515-516
=	O	517-518
15	O	519-521
)	O	521-522
,	O	522-523
2	O	524-525
-	O	525-526
chloroprocaine	O	526-540
-	O	525-526
CE	O	541-543
(	O	544-545
N	O	545-546
=	O	547-548
20	O	549-551
)	O	551-552
,	O	552-553
low	O	554-557
pH	O	558-560
normal	O	561-567
saline	O	568-574
(	O	575-576
pH	O	576-578
3	O	579-580
.	O	580-581
0	O	581-582
)	O	582-583
(	O	584-585
N	O	585-586
=	O	587-588
20	O	589-591
)	O	591-592
,	O	592-593
or	O	594-596
normal	O	597-603
saline	O	604-610
(	O	611-612
N	O	612-613
=	O	614-615
10	O	616-618
)	O	618-619
.	O	619-620

Of	O	621-623
the	O	624-627
20	O	628-630
animals	O	631-638
that	O	639-643
received	O	644-652
subarachnoid	O	653-665
injection	O	666-675
of	O	676-678
2	O	679-680
-	O	680-681
chloroprocaine	O	681-695
-	O	680-681
CE	O	696-698
seven	O	699-704
(	O	705-706
35	O	706-708
%	O	708-709
)	O	709-710
developed	O	711-720
hind	O	721-725
-	O	725-726
limb	O	726-730
paralysis	B	731-740
.	O	740-741

None	O	742-746
of	O	747-749
the	O	750-753
animals	O	754-761
that	O	762-766
received	O	767-775
bupivacaine	O	776-787
,	O	787-788
normal	O	789-795
saline	O	796-802
,	O	802-803
or	O	804-806
normal	O	807-813
saline	O	814-820
titrated	O	821-829
to	O	830-832
a	O	833-834
pH	O	835-837
3	O	838-839
.	O	839-840
0	O	840-841
developed	O	842-851
hind	O	852-856
-	O	856-857
limb	O	857-861
paralysis	B	862-871
.	O	871-872

Of	O	873-875
the	O	876-879
15	O	880-882
spinal	O	883-889
cords	O	890-895
of	O	896-898
the	O	899-902
animals	O	903-910
that	O	911-915
received	O	916-924
2	O	925-926
-	O	926-927
chloroprocaine	O	927-941
-	O	926-927
CE	O	942-944
,	O	944-945
13	O	946-948
showed	O	949-955
subpial	B	956-963
necrosis	I	964-972
;	O	972-973
the	O	974-977
nerve	O	978-983
roots	O	984-989
and	O	990-993
subarachnoid	O	994-1006
vessels	O	1007-1014
were	O	1015-1019
normal	O	1020-1026
.	O	1026-1027

The	O	1028-1031
spinal	O	1032-1038
cords	O	1039-1044
of	O	1045-1047
the	O	1048-1051
animals	O	1052-1059
that	O	1060-1064
received	O	1065-1073
bupivacaine	O	1074-1085
,	O	1085-1086
low	O	1087-1090
pH	O	1091-1093
normal	O	1094-1100
saline	O	1101-1107
(	O	1108-1109
pH	O	1109-1111
3	O	1112-1113
.	O	1113-1114
0	O	1114-1115
)	O	1115-1116
,	O	1116-1117
or	O	1118-1120
normal	O	1121-1127
saline	O	1128-1134
did	O	1135-1138
not	O	1139-1142
show	O	1143-1147
abnormal	O	1148-1156
findings	O	1157-1165
.	O	1165-1166

Early	O	0-5
adjuvant	O	6-14
adriamycin	O	15-25
in	O	26-28
superficial	O	29-40
bladder	B	41-48
carcinoma	I	49-58
.	O	58-59

A	O	60-61
multicenter	O	62-73
study	O	74-79
was	O	80-83
performed	O	84-93
in	O	94-96
110	O	97-100
patients	O	101-109
with	O	110-114
superficial	O	115-126
transitional	O	127-139
cell	O	140-144
carcinoma	B	145-154
of	I	155-157
the	I	158-161
bladder	I	162-169
.	O	169-170

Adriamycin	O	171-181
(	O	182-183
50	O	183-185
mg	O	186-188
/	O	188-189
50	O	189-191
ml	O	192-194
)	O	194-195
was	O	196-199
administered	O	200-212
intravesically	O	213-227
within	O	228-234
24	O	235-237
h	O	238-239
after	O	240-245
transurethral	O	246-259
resection	O	260-269
of	O	270-272
TA	O	273-275
-	O	275-276
T1	O	276-278
(	O	279-280
O	O	280-281
-	O	281-282
A	O	282-283
)	O	283-284
bladder	B	285-292
tumors	I	293-299
.	O	299-300

Instillation	O	301-313
was	O	314-317
repeated	O	318-326
twice	O	327-332
during	O	333-339
the	O	340-343
first	O	344-349
week	O	350-354
,	O	354-355
then	O	356-360
weekly	O	361-367
during	O	368-374
the	O	375-378
first	O	379-384
month	O	385-390
and	O	391-394
afterwards	O	395-405
monthly	O	406-413
for	O	414-417
1	O	418-419
year	O	420-424
.	O	424-425

The	O	426-429
tolerance	O	430-439
was	O	440-443
evaluated	O	444-453
in	O	454-456
these	O	457-462
110	O	463-466
patients	O	467-475
,	O	475-476
and	O	477-480
29	O	481-483
patients	O	484-492
presented	O	493-502
with	O	503-507
local	O	508-513
side	O	514-518
-	O	518-519
effects	O	519-526
.	O	526-527

In	O	528-530
24	O	531-533
of	O	534-536
these	O	537-542
patients	O	543-551
chemical	O	552-560
cystitis	B	561-569
was	O	570-573
severe	O	574-580
enough	O	581-587
for	O	588-591
them	O	592-596
to	O	597-599
drop	O	600-604
out	O	605-608
of	O	609-611
the	O	612-615
study	O	616-621
.	O	621-622

No	O	623-625
systemic	O	626-634
side	O	635-639
-	O	639-640
effects	O	640-647
were	O	648-652
observed	O	653-661
.	O	661-662

Recurrence	O	663-673
was	O	674-677
studied	O	678-685
in	O	686-688
82	O	689-691
evaluable	O	692-701
patients	O	702-710
after	O	711-716
1	O	717-718
year	O	719-723
of	O	724-726
follow	O	727-733
-	O	733-734
up	O	734-736
and	O	737-740
in	O	741-743
72	O	744-746
patients	O	747-755
followed	O	756-764
for	O	765-768
2	O	769-770
-	O	770-771
3	O	771-772
years	O	773-778
(	O	779-780
mean	O	780-784
32	O	785-787
months	O	788-794
)	O	794-795
.	O	795-796

Of	O	797-799
the	O	800-803
82	O	804-806
patients	O	807-815
studied	O	816-823
after	O	824-829
1	O	830-831
year	O	832-836
,	O	836-837
23	O	838-840
had	O	841-844
primary	O	845-852
and	O	853-856
59	O	857-859
recurrent	O	860-869
disease	O	870-877
.	O	877-878

Of	O	879-881
the	O	882-885
82	O	886-888
evaluable	O	889-898
patients	O	899-907
,	O	907-908
50	O	909-911
did	O	912-915
not	O	916-919
show	O	920-924
any	O	925-928
recurrence	O	929-939
after	O	940-945
1	O	946-947
year	O	948-952
(	O	953-954
61	O	954-956
%	O	956-957
)	O	957-958
,	O	958-959
while	O	960-965
32	O	966-968
presented	O	969-978
with	O	979-983
one	O	984-987
or	O	988-990
more	O	991-995
recurrences	O	996-1007
(	O	1008-1009
39	O	1009-1011
%	O	1011-1012
)	O	1012-1013
.	O	1013-1014

Of	O	1015-1017
these	O	1018-1023
recurrences	O	1024-1035
,	O	1035-1036
27	O	1037-1039
were	O	1040-1044
T1	O	1045-1047
tumors	B	1048-1054
while	O	1055-1060
five	O	1061-1065
progressed	O	1066-1076
to	O	1077-1079
more	O	1080-1084
highly	O	1085-1091
invasive	O	1092-1100
lesions	O	1101-1108
.	O	1108-1109

In	O	1110-1112
patients	O	1113-1121
that	O	1122-1126
were	O	1127-1131
free	O	1132-1136
of	O	1137-1139
recurrence	O	1140-1150
during	O	1151-1157
the	O	1158-1161
first	O	1162-1167
year	O	1168-1172
,	O	1172-1173
80	O	1174-1176
%	O	1176-1177
remained	O	1178-1186
tumor	B	1187-1192
-	O	1192-1193
free	O	1193-1197
during	O	1198-1204
the	O	1205-1208
2	O	1209-1210
-	O	1210-1211
to	O	1212-1214
3	O	1215-1216
-	O	1216-1217
year	O	1217-1221
follow	O	1222-1228
-	O	1228-1229
up	O	1229-1231
period	O	1232-1238
.	O	1238-1239

Of	O	1240-1242
the	O	1243-1246
patients	O	1247-1255
developing	O	1256-1266
one	O	1267-1270
or	O	1271-1273
more	O	1274-1278
recurrences	O	1279-1290
during	O	1291-1297
the	O	1298-1301
first	O	1302-1307
year	O	1308-1312
,	O	1312-1313
only	O	1314-1318
50	O	1319-1321
%	O	1321-1322
presented	O	1323-1332
with	O	1333-1337
further	O	1338-1345
recurrence	O	1346-1356
once	O	1357-1361
the	O	1362-1365
instillations	O	1366-1379
were	O	1380-1384
stopped	O	1385-1392
.	O	1392-1393

The	O	1394-1397
beneficial	O	1398-1408
effect	O	1409-1415
of	O	1416-1418
Adriamycin	O	1419-1429
appears	O	1430-1437
obvious	O	1438-1445
and	O	1446-1449
might	O	1450-1455
be	O	1456-1458
related	O	1459-1466
to	O	1467-1469
the	O	1470-1473
drug	O	1474-1478
itself	O	1479-1485
,	O	1485-1486
the	O	1487-1490
early	O	1491-1496
and	O	1497-1500
repeated	O	1501-1509
instillations	O	1510-1523
after	O	1524-1529
TUR	O	1530-1533
,	O	1533-1534
or	O	1535-1537
both	O	1538-1542
.	O	1542-1543

Hyperkalemia	B	0-12
associated	O	13-23
with	O	24-28
sulindac	O	29-37
therapy	O	38-45
.	O	45-46

Hyperkalemia	B	47-59
has	O	60-63
recently	O	64-72
been	O	73-77
recognized	O	78-88
as	O	89-91
a	O	92-93
complication	O	94-106
of	O	107-109
nonsteroidal	O	110-122
antiinflammatory	O	123-139
agents	O	140-146
(	O	147-148
NSAID	O	148-153
)	O	153-154
such	O	155-159
as	O	160-162
indomethacin	O	163-175
.	O	175-176

Several	O	177-184
recent	O	185-191
studies	O	192-199
have	O	200-204
stressed	O	205-213
the	O	214-217
renal	O	218-223
sparing	O	224-231
features	O	232-240
of	O	241-243
sulindac	O	244-252
,	O	252-253
owing	O	254-259
to	O	260-262
its	O	263-266
lack	O	267-271
of	O	272-274
interference	O	275-287
with	O	288-292
renal	O	293-298
prostacyclin	O	299-311
synthesis	O	312-321
.	O	321-322

We	O	323-325
describe	O	326-334
4	O	335-336
patients	O	337-345
in	O	346-348
whom	O	349-353
hyperkalemia	B	354-366
ranging	O	367-374
from	O	375-379
6	O	380-381
.	O	381-382
1	O	382-383
to	O	384-386
6	O	387-388
.	O	388-389
9	O	389-390
mEq	O	391-394
/	O	394-395
l	O	395-396
developed	O	397-406
within	O	407-413
3	O	414-415
to	O	416-418
8	O	419-420
days	O	421-425
of	O	426-428
sulindac	O	429-437
administration	O	438-452
.	O	452-453

In	O	454-456
all	O	457-460
of	O	461-463
them	O	464-468
normal	O	469-475
serum	O	476-481
potassium	O	482-491
levels	O	492-498
reached	O	499-506
within	O	507-513
2	O	514-515
to	O	516-518
4	O	519-520
days	O	521-525
of	O	526-528
stopping	O	529-537
sulindac	O	538-546
.	O	546-547

As	O	548-550
no	O	551-553
other	O	554-559
medications	O	560-571
known	O	572-577
to	O	578-580
effect	O	581-587
serum	O	588-593
potassium	O	594-603
had	O	604-607
been	O	608-612
given	O	613-618
concomitantly	O	619-632
,	O	632-633
this	O	634-638
course	O	639-645
of	O	646-648
events	O	649-655
is	O	656-658
suggestive	O	659-669
of	O	670-672
a	O	673-674
cause	O	675-680
-	O	680-681
and	O	681-684
-	O	680-681
effect	O	685-691
relationship	O	692-704
between	O	705-712
sulindac	O	713-721
and	O	722-725
hyperkalemia	B	726-738
.	O	738-739

These	O	740-745
observations	O	746-758
indicate	O	759-767
that	O	768-772
initial	O	773-780
hopes	O	781-786
that	O	787-791
sulindac	O	792-800
may	O	801-804
not	O	805-808
be	O	809-811
associated	O	812-822
with	O	823-827
the	O	828-831
adverse	O	832-839
renal	O	840-845
effects	O	846-853
of	O	854-856
other	O	857-862
NSAID	O	863-868
are	O	869-872
probably	O	873-881
not	O	882-885
justified	O	886-895
.	O	895-896

Ventricular	B	0-11
tachyarrhythmias	I	12-28
during	O	29-35
cesarean	O	36-44
section	O	45-52
after	O	53-58
ritodrine	O	59-68
therapy	O	69-76
:	O	76-77
interaction	O	78-89
with	O	90-94
anesthetics	O	95-106
.	O	106-107

This	O	108-112
case	O	113-117
illustrates	O	118-129
that	O	130-134
patients	O	135-143
receiving	O	144-153
ritodrine	O	154-163
for	O	164-167
preterm	B	168-175
labor	I	176-181
may	O	182-185
risk	O	186-190
interactions	O	191-203
between	O	204-211
the	O	212-215
residual	O	216-224
betamimetic	O	225-236
effects	O	237-244
of	O	245-247
ritodrine	O	248-257
and	O	258-261
the	O	262-265
effects	O	266-273
of	O	274-276
anesthetics	O	277-288
during	O	289-295
cesarean	O	296-304
section	O	305-312
.	O	312-313

Such	O	314-318
interactions	O	319-331
may	O	332-335
result	O	336-342
in	O	343-345
serious	O	346-353
cardiovascular	B	354-368
complications	I	369-382
even	O	383-387
after	O	388-393
cessation	O	394-403
of	O	404-406
an	O	407-409
infusion	O	410-418
of	O	419-421
ritodrine	O	422-431
.	O	431-432

Preoperative	O	433-445
assessment	O	446-456
should	O	457-463
focus	O	464-469
on	O	470-472
cardiovascular	O	473-487
status	O	488-494
and	O	495-498
serum	O	499-504
potassium	O	505-514
level	O	515-520
.	O	520-521

Delaying	O	522-530
induction	O	531-540
of	O	541-543
anesthesia	O	544-554
should	O	555-561
be	O	562-564
considered	O	565-575
whenever	O	576-584
possible	O	585-593
.	O	593-594

Careful	O	595-602
fluid	O	603-608
administration	O	609-623
and	O	624-627
cautious	O	628-636
use	O	637-640
of	O	641-643
titrated	O	644-652
doses	O	653-658
of	O	659-661
ephedrine	O	662-671
are	O	672-675
advised	O	676-683
.	O	683-684

After	O	685-690
delivery	O	691-699
of	O	700-702
the	O	703-706
infant	O	707-713
,	O	713-714
there	O	715-720
should	O	721-727
be	O	728-730
no	O	731-733
contraindication	O	734-750
to	O	751-753
the	O	754-757
use	O	758-761
of	O	762-764
an	O	765-767
alpha	O	768-773
-	O	773-774
adrenergic	O	774-784
vasopressor	O	785-796
such	O	797-801
as	O	802-804
phenylephrine	O	805-818
to	O	819-821
treat	O	822-827
hypotensive	B	828-839
patients	O	840-848
with	O	849-853
tachycardia	B	854-865
.	O	865-866

Immunohistochemical	O	0-19
,	O	19-20
electron	O	21-29
microscopic	O	30-41
and	O	42-45
morphometric	O	46-58
studies	O	59-66
of	O	67-69
estrogen	O	70-78
-	O	78-79
induced	O	79-86
rat	O	87-90
prolactinomas	B	91-104
after	O	105-110
bromocriptine	O	111-124
treatment	O	125-134
.	O	134-135

To	O	136-138
clarify	O	139-146
the	O	147-150
effects	O	151-158
of	O	159-161
bromocriptine	O	162-175
on	O	176-178
prolactinoma	B	179-191
cells	O	192-197
in	O	198-200
vivo	O	201-205
,	O	205-206
immunohistochemical	O	207-226
,	O	226-227
ultrastructural	O	228-243
and	O	244-247
morphometrical	O	248-262
analyses	O	263-271
were	O	272-276
applied	O	277-284
to	O	285-287
estrogen	O	288-296
-	O	296-297
induced	O	297-304
rat	O	305-308
prolactinoma	B	309-321
cells	O	322-327
1	O	328-329
h	O	330-331
and	O	332-335
6	O	336-337
h	O	338-339
after	O	340-345
injection	O	346-355
of	O	356-358
bromocriptine	O	359-372
(	O	373-374
3	O	374-375
mg	O	376-378
/	O	378-379
kg	O	379-381
of	O	382-384
body	O	385-389
weight	O	390-396
)	O	396-397
.	O	397-398

One	O	399-402
h	O	403-404
after	O	405-410
treatment	O	411-420
,	O	420-421
serum	O	422-427
prolactin	O	428-437
levels	O	438-444
decreased	O	445-454
markedly	O	455-463
.	O	463-464

Electron	O	465-473
microscopy	O	474-484
disclosed	O	485-494
many	O	495-499
secretory	O	500-509
granules	O	510-518
,	O	518-519
slightly	O	520-528
distorted	O	529-538
rough	O	539-544
endoplasmic	O	545-556
reticulum	O	557-566
,	O	566-567
and	O	568-571
partially	O	572-581
dilated	O	582-589
Golgi	O	590-595
cisternae	O	596-605
in	O	606-608
the	O	609-612
prolactinoma	B	613-625
cells	O	626-631
.	O	631-632

Morphometric	O	633-645
analysis	O	646-654
revealed	O	655-663
that	O	664-668
the	O	669-672
volume	O	673-679
density	O	680-687
of	O	688-690
secretory	O	691-700
granules	O	701-709
increased	O	710-719
,	O	719-720
while	O	721-726
the	O	727-730
volume	O	731-737
density	O	738-745
of	O	746-748
cytoplasmic	O	749-760
microtubules	O	761-773
decreased	O	774-783
.	O	783-784

These	O	785-790
findings	O	791-799
suggest	O	800-807
that	O	808-812
lowered	O	813-820
serum	O	821-826
prolactin	O	827-836
levels	O	837-843
in	O	844-846
the	O	847-850
early	O	851-856
phase	O	857-862
of	O	863-865
bromocriptine	O	866-879
treatment	O	880-889
may	O	890-893
result	O	894-900
from	O	901-905
an	O	906-908
impaired	O	909-917
secretion	O	918-927
of	O	928-930
prolactin	O	931-940
due	O	941-944
to	O	945-947
decreasing	O	948-958
numbers	O	959-966
of	O	967-969
cytoplasmic	O	970-981
microtubules	O	982-994
.	O	994-995

At	O	996-998
6	O	999-1000
h	O	1001-1002
after	O	1003-1008
injection	O	1009-1018
,	O	1018-1019
serum	O	1020-1025
prolactin	O	1026-1035
levels	O	1036-1042
were	O	1043-1047
still	O	1048-1053
considerably	O	1054-1066
lower	O	1067-1072
than	O	1073-1077
in	O	1078-1080
controls	O	1081-1089
.	O	1089-1090

The	O	1091-1094
prolactinoma	B	1095-1107
cells	O	1108-1113
at	O	1114-1116
this	O	1117-1121
time	O	1122-1126
were	O	1127-1131
well	O	1132-1136
granulated	O	1137-1147
,	O	1147-1148
with	O	1149-1153
vesiculated	O	1154-1165
rough	O	1166-1171
endoplasmic	O	1172-1183
reticulum	O	1184-1193
and	O	1194-1197
markedly	O	1198-1206
dilated	O	1207-1214
Golgi	O	1215-1220
cisternae	O	1221-1230
.	O	1230-1231

Electron	O	1232-1240
microscopical	O	1241-1254
immunohistochemistry	O	1255-1275
revealed	O	1276-1284
positive	O	1285-1293
reaction	O	1294-1302
products	O	1303-1311
noted	O	1312-1317
on	O	1318-1320
the	O	1321-1324
secretory	O	1325-1334
granules	O	1335-1343
,	O	1343-1344
Golgi	O	1345-1350
cisternae	O	1351-1360
,	O	1360-1361
and	O	1362-1365
endoplasmic	O	1366-1377
reticulum	O	1378-1387
of	O	1388-1390
the	O	1391-1394
untreated	O	1395-1404
rat	O	1405-1408
prolactinoma	B	1409-1421
cells	O	1422-1427
.	O	1427-1428

However	O	1429-1436
,	O	1436-1437
only	O	1438-1442
secretory	O	1443-1452
granules	O	1453-1461
showed	O	1462-1468
the	O	1469-1472
positive	O	1473-1481
reaction	O	1482-1490
products	O	1491-1499
for	O	1500-1503
prolactin	O	1504-1513
6	O	1514-1515
h	O	1516-1517
after	O	1518-1523
bromocriptine	O	1524-1537
treatment	O	1538-1547
of	O	1548-1550
the	O	1551-1554
adenoma	B	1555-1562
cells	O	1563-1568
.	O	1568-1569

An	O	1570-1572
increase	O	1573-1581
in	O	1582-1584
the	O	1585-1588
volume	O	1589-1595
density	O	1596-1603
of	O	1604-1606
secretory	O	1607-1616
granules	O	1617-1625
and	O	1626-1629
a	O	1630-1631
decrease	O	1632-1640
in	O	1641-1643
the	O	1644-1647
volume	O	1648-1654
densities	O	1655-1664
of	O	1665-1667
rough	O	1668-1673
endoplasmic	O	1674-1685
reticulum	O	1686-1695
and	O	1696-1699
microtubules	O	1700-1712
was	O	1713-1716
determined	O	1717-1727
by	O	1728-1730
morphometric	O	1731-1743
analysis	O	1744-1752
,	O	1752-1753
suggesting	O	1754-1764
that	O	1765-1769
bromocriptine	O	1770-1783
inhibits	O	1784-1792
protein	O	1793-1800
synthesis	O	1801-1810
as	O	1811-1813
well	O	1814-1818
as	O	1819-1821
bringing	O	1822-1830
about	O	1831-1836
a	O	1837-1838
disturbance	O	1839-1850
of	O	1851-1853
the	O	1854-1857
prolactin	O	1858-1867
secretion	O	1868-1877
.	O	1877-1878

On	O	0-2
two	O	3-6
paradoxical	O	7-18
side	O	19-23
-	O	23-24
effects	O	24-31
of	O	32-34
prednisolone	O	35-47
in	O	48-50
rats	O	51-55
,	O	55-56
ribosomal	O	57-66
RNA	O	67-70
biosyntheses	O	71-83
,	O	83-84
and	O	85-88
a	O	89-90
mechanism	O	91-100
of	O	101-103
action	O	104-110
.	O	110-111

Liver	B	112-117
enlargement	I	118-129
and	O	130-133
muscle	B	134-140
wastage	I	141-148
occurred	O	149-157
in	O	158-160
Wistar	O	161-167
rats	O	168-172
following	O	173-182
the	O	183-186
subcutaneous	O	187-199
administration	O	200-214
of	O	215-217
prednisolone	O	218-230
.	O	230-231

In	O	232-234
the	O	235-238
liver	O	239-244
both	O	245-249
the	O	250-253
content	O	254-261
of	O	262-264
RNA	O	265-268
and	O	269-272
the	O	273-276
biosynthesis	O	277-289
of	O	290-292
ribosomal	O	293-302
RNA	O	303-306
increased	O	307-316
while	O	317-322
both	O	323-327
the	O	328-331
RNA	O	332-335
content	O	336-343
and	O	344-347
ribosomal	O	348-357
RNA	O	358-361
biosynthesis	O	362-374
were	O	375-379
reduced	O	380-387
in	O	388-390
the	O	391-394
gastrocnemius	O	395-408
muscle	O	409-415
.	O	415-416

It	O	417-419
is	O	420-422
suggested	O	423-432
that	O	433-437
the	O	438-441
drug	O	442-446
acted	O	447-452
in	O	453-455
a	O	456-457
selective	O	458-467
and	O	468-471
tissue	O	472-478
-	O	478-479
specific	O	479-487
manner	O	488-494
to	O	495-497
enhance	O	498-505
ribosomal	O	506-515
RNA	O	516-519
synthesis	O	520-529
in	O	530-532
the	O	533-536
liver	O	537-542
and	O	543-546
depress	O	547-554
such	O	555-559
synthesis	O	560-569
in	O	570-572
the	O	573-576
muscle	O	577-583
.	O	583-584

This	O	585-589
view	O	590-594
supports	O	595-603
the	O	604-607
contention	O	608-618
that	O	619-623
the	O	624-627
liver	O	628-633
and	O	634-637
muscle	O	638-644
are	O	645-648
independent	O	649-660
sites	O	661-666
of	O	667-669
prednisolone	O	670-682
action	O	683-689
.	O	689-690

Possible	O	0-8
intramuscular	O	9-22
midazolam	O	23-32
-	O	32-33
associated	O	33-43
cardiorespiratory	B	44-61
arrest	I	62-68
and	O	69-72
death	B	73-78
.	O	78-79

Midazolam	O	80-89
hydrochloride	O	90-103
is	O	104-106
commonly	O	107-115
used	O	116-120
for	O	121-124
dental	O	125-131
or	O	132-134
endoscopic	O	135-145
procedures	O	146-156
.	O	156-157

Although	O	158-166
generally	O	167-176
consisted	O	177-186
safe	O	187-191
when	O	192-196
given	O	197-202
intramuscularly	O	203-218
,	O	218-219
intravenous	O	220-231
administration	O	232-246
is	O	247-249
known	O	250-255
to	O	256-258
cause	O	259-264
respiratory	B	265-276
and	I	277-280
cardiovascular	I	281-295
depression	I	296-306
.	O	306-307

This	O	308-312
report	O	313-319
describes	O	320-329
the	O	330-333
first	O	334-339
published	O	340-349
case	O	350-354
of	O	355-357
cardiorespiratory	B	358-375
arrest	I	376-382
and	O	383-386
death	B	387-392
associated	O	393-403
with	O	404-408
intramuscular	O	409-422
administration	O	423-437
of	O	438-440
midazolam	O	441-450
.	O	450-451

Information	O	452-463
regarding	O	464-473
midazolam	O	474-483
use	O	484-487
is	O	488-490
reviewed	O	491-499
to	O	500-502
provide	O	503-510
recommendation	O	511-525
for	O	526-529
safe	O	530-534
administration	O	535-549
.	O	549-550

Serial	O	0-6
epilepsy	B	7-15
caused	O	16-22
by	O	23-25
levodopa	O	26-34
/	O	34-35
carbidopa	O	35-44
administration	O	45-59
in	O	60-62
two	O	63-66
patients	O	67-75
on	O	76-78
hemodialysis	O	79-91
.	O	91-92

Two	O	93-96
patients	O	97-105
with	O	106-110
similar	O	111-118
clinical	O	119-127
features	O	128-136
are	O	137-140
presented	O	141-150
:	O	150-151
both	O	152-156
patients	O	157-165
had	O	166-169
chronic	B	170-177
renal	I	178-183
failure	I	184-191
,	O	191-192
on	O	193-195
hemodialysis	O	196-208
for	O	209-212
many	O	213-217
years	O	218-223
but	O	224-227
recently	O	228-236
begun	O	237-242
on	O	243-245
a	O	246-247
high	O	248-252
-	O	252-253
flux	O	253-257
dialyzer	O	258-266
;	O	266-267
both	O	268-272
had	O	273-276
been	O	277-281
receiving	O	282-291
a	O	292-293
carbidopa	O	294-303
/	O	303-304
levodopa	O	304-312
preparation	O	313-324
;	O	324-325
and	O	326-329
both	O	330-334
had	O	335-338
the	O	339-342
onset	O	343-348
of	O	349-351
hallucinosis	B	352-364
and	O	365-368
recurrent	O	369-378
seizures	B	379-387
,	O	387-388
which	O	389-394
were	O	395-399
refractory	O	400-410
to	O	411-413
anticonvulsants	O	414-429
.	O	429-430

The	O	431-434
first	O	435-440
patient	O	441-448
died	O	449-453
without	O	454-461
a	O	462-463
diagnosis	O	464-473
;	O	473-474
the	O	475-478
second	O	479-485
patient	O	486-493
had	O	494-497
a	O	498-499
dramatic	O	500-508
recovery	O	509-517
following	O	518-527
the	O	528-531
administration	O	532-546
of	O	547-549
vitamin	O	550-557
B6	O	558-560
.	O	560-561

Neither	O	562-569
patient	O	570-577
was	O	578-581
considered	O	582-592
to	O	593-595
have	O	596-600
a	O	601-602
renal	O	603-608
state	O	609-614
sufficiently	O	615-627
severe	O	628-634
enough	O	635-641
to	O	642-644
explain	O	645-652
their	O	653-658
presentation	O	659-671
.	O	671-672

Effect	O	0-6
of	O	7-9
L	O	10-11
-	O	11-12
alpha	O	12-17
-	O	11-12
glyceryl	O	18-26
-	O	11-12
phosphorylcholine	O	27-44
on	O	45-47
amnesia	B	48-55
caused	O	56-62
by	O	63-65
scopolamine	O	66-77
.	O	77-78

The	O	79-82
present	O	83-90
study	O	91-96
was	O	97-100
carried	O	101-108
out	O	109-112
to	O	113-115
test	O	116-120
the	O	121-124
effects	O	125-132
of	O	133-135
L	O	136-137
-	O	137-138
alpha	O	138-143
-	O	137-138
glycerylphosphorylcholine	O	144-169
(	O	170-171
L	O	171-172
-	O	172-173
alpha	O	173-178
-	O	172-173
GFC	O	179-182
)	O	182-183
on	O	184-186
memory	B	187-193
impairment	I	194-204
induced	O	205-212
by	O	213-215
scopolamine	O	216-227
in	O	228-230
man	O	231-234
.	O	234-235

Thirty	O	236-242
-	O	242-243
two	O	243-246
healthy	O	247-254
young	O	255-260
volunteers	O	261-271
were	O	272-276
randomly	O	277-285
allocated	O	286-295
to	O	296-298
four	O	299-303
different	O	304-313
groups	O	314-320
.	O	320-321

They	O	322-326
were	O	327-331
given	O	332-337
a	O	338-339
ten	O	340-343
day	O	344-347
pretreatment	O	348-360
with	O	361-365
either	O	366-372
L	O	373-374
-	O	374-375
alpha	O	375-380
-	O	374-375
GFC	O	381-384
or	O	385-387
placebo	O	388-395
,	O	395-396
p	O	397-398
.	O	398-399
o	O	399-400
.	O	398-399
,	O	401-402
and	O	403-406
on	O	407-409
the	O	410-413
eleventh	O	414-422
day	O	423-426
either	O	427-433
scopolamine	O	434-445
or	O	446-448
placebo	O	449-456
,	O	456-457
i	O	458-459
.	O	459-460
m	O	460-461
.	O	459-460

Before	O	463-469
and	O	470-473
0	O	474-475
.	O	475-476
5	O	476-477
,	O	477-478
1	O	479-480
,	O	480-481
2	O	482-483
,	O	483-484
3	O	485-486
,	O	486-487
and	O	488-491
6	O	492-493
h	O	494-495
after	O	496-501
injection	O	502-511
the	O	512-515
subjects	O	516-524
were	O	525-529
given	O	530-535
attention	O	536-545
and	O	546-549
mnemonic	O	550-558
tests	O	559-564
.	O	564-565

The	O	566-569
findings	O	570-578
of	O	579-581
this	O	582-586
study	O	587-592
indicate	O	593-601
that	O	602-606
the	O	607-610
drug	O	611-615
is	O	616-618
able	O	619-623
to	O	624-626
antagonize	O	627-637
impairment	B	638-648
of	I	649-651
attention	I	652-661
and	I	662-665
memory	I	666-672
induced	O	673-680
by	O	681-683
scopolamine	O	684-695
.	O	695-696

Seizures	B	0-8
induced	O	9-16
by	O	17-19
the	O	20-23
cocaine	O	24-31
metabolite	O	32-42
benzoylecgonine	O	43-58
in	O	59-61
rats	O	62-66
.	O	66-67

The	O	68-71
half	O	72-76
-	O	76-77
life	O	77-81
(	O	82-83
t1	O	83-85
/	O	85-86
2	O	86-87
)	O	87-88
of	O	89-91
cocaine	O	92-99
is	O	100-102
relatively	O	103-113
short	O	114-119
,	O	119-120
but	O	121-124
some	O	125-129
of	O	130-132
the	O	133-136
consequences	O	137-149
of	O	150-152
its	O	153-156
use	O	157-160
,	O	160-161
such	O	162-166
as	O	167-169
seizures	B	170-178
and	O	179-182
strokes	B	183-190
,	O	190-191
can	O	192-195
occur	O	196-201
hours	O	202-207
after	O	208-213
exposure	O	214-222
.	O	222-223

This	O	224-228
led	O	229-232
us	O	233-235
to	O	236-238
hypothesize	O	239-250
that	O	251-255
a	O	256-257
metabolite	O	258-268
of	O	269-271
cocaine	O	272-279
may	O	280-283
be	O	284-286
responsible	O	287-298
for	O	299-302
some	O	303-307
of	O	308-310
those	O	311-316
delayed	O	317-324
sequelae	O	325-333
.	O	333-334

We	O	335-337
evaluated	O	338-347
the	O	348-351
potential	O	352-361
of	O	362-364
the	O	365-368
major	O	369-374
metabolite	O	375-385
of	O	386-388
cocaine	O	389-396
,	O	396-397
benzoylecgonine	O	398-413
(	O	414-415
BE	O	415-417
)	O	417-418
,	O	418-419
to	O	420-422
cause	O	423-428
seizures	B	429-437
.	O	437-438

Two	O	439-442
separate	O	443-451
equimolar	O	452-461
doses	O	462-467
(	O	468-469
0	O	469-470
.	O	470-471
2	O	471-472
and	O	473-476
0	O	477-478
.	O	478-479
4	O	479-480
mumol	O	481-486
)	O	486-487
of	O	488-490
either	O	491-497
cocaine	O	498-505
or	O	506-508
BE	O	509-511
were	O	512-516
injected	O	517-525
ventricularly	O	526-539
in	O	540-542
unanesthetized	O	543-557
juvenile	O	558-566
rats	O	567-571
.	O	571-572

Treated	O	573-580
rats	O	581-585
were	O	586-590
then	O	591-595
evaluated	O	596-605
for	O	606-609
incidence	O	610-619
,	O	619-620
latency	O	621-628
,	O	628-629
and	O	630-633
seizure	B	634-641
pattern	O	642-649
or	O	650-652
for	O	653-656
locomotor	O	657-666
activity	O	667-675
in	O	676-678
animals	O	679-686
without	O	687-694
seizures	B	695-703
.	O	703-704

BE	O	705-707
-	O	707-708
Induced	O	708-715
seizures	B	716-724
occurred	O	725-733
more	O	734-738
frequently	O	739-749
and	O	750-753
had	O	754-757
significantly	O	758-771
longer	O	772-778
latencies	O	779-788
than	O	789-793
those	O	794-799
induced	O	800-807
by	O	808-810
equimolar	O	811-820
amounts	O	821-828
of	O	829-831
cocaine	O	832-839
.	O	839-840

Whereas	O	841-848
cocaine	O	849-856
-	O	856-857
induced	O	857-864
seizures	B	865-873
were	O	874-878
best	O	879-883
characterized	O	884-897
as	O	898-900
brief	O	901-906
,	O	906-907
generalized	O	908-919
,	O	919-920
and	O	921-924
tonic	O	925-930
and	O	931-934
resulted	O	935-943
in	O	944-946
death	B	947-952
,	O	952-953
those	O	954-959
induced	O	960-967
by	O	968-970
BE	O	971-973
were	O	974-978
prolonged	O	979-988
,	O	988-989
often	O	990-995
multiple	O	996-1004
and	O	1005-1008
mixed	O	1009-1014
in	O	1015-1017
type	O	1018-1022
,	O	1022-1023
and	O	1024-1027
rarely	O	1028-1034
resulted	O	1035-1043
in	O	1044-1046
death	B	1047-1052
.	O	1052-1053

Electrical	O	1054-1064
recordings	O	1065-1075
from	O	1076-1080
the	O	1081-1084
hippocampus	O	1085-1096
showed	O	1097-1103
a	O	1104-1105
rhythmic	O	1106-1114
progression	O	1115-1126
in	O	1127-1129
EEG	O	1130-1133
frequency	O	1134-1143
and	O	1144-1147
voltage	O	1148-1155
with	O	1156-1160
clinical	O	1161-1169
seizure	B	1170-1177
expression	O	1178-1188
.	O	1188-1189

BE	O	1190-1192
-	O	1192-1193
Injected	O	1193-1201
rats	O	1202-1206
that	O	1207-1211
did	O	1212-1215
not	O	1216-1219
have	O	1220-1224
seizures	B	1225-1233
had	O	1234-1237
significantly	O	1238-1251
more	O	1252-1256
locomotor	O	1257-1266
activity	O	1267-1275
than	O	1276-1280
cocaine	O	1281-1288
-	O	1288-1289
injected	O	1289-1297
animals	O	1298-1305
without	O	1306-1313
seizures	B	1314-1322
.	O	1322-1323

The	O	1324-1327
finding	O	1328-1335
that	O	1336-1340
cocaine	O	1341-1348
-	O	1348-1349
and	O	1350-1353
BE	O	1354-1356
-	O	1356-1357
induced	O	1357-1364
seizures	B	1365-1373
differ	O	1374-1380
in	O	1381-1383
several	O	1384-1391
respects	O	1392-1400
suggests	O	1401-1409
more	O	1410-1414
than	O	1415-1419
one	O	1420-1423
mechanism	O	1424-1433
for	O	1434-1437
cocaine	O	1438-1445
-	O	1445-1446
induced	O	1446-1453
seizures	B	1454-1462
and	O	1463-1466
emphasizes	O	1467-1477
the	O	1478-1481
importance	O	1482-1492
of	O	1493-1495
a	O	1496-1497
cocaine	O	1498-1505
metabolite	O	1506-1516
,	O	1516-1517
BE	O	1518-1520
.	O	1520-1521

Protection	O	0-10
against	O	11-18
amphetamine	O	19-30
-	O	30-31
induced	O	31-38
neurotoxicity	B	39-52
toward	O	53-59
striatal	O	60-68
dopamine	O	69-77
neurons	O	78-85
in	O	86-88
rodents	O	89-96
by	O	97-99
LY274614	O	100-108
,	O	108-109
an	O	110-112
excitatory	O	113-123
amino	O	124-129
acid	O	130-134
antagonist	O	135-145
.	O	145-146

LY274614	O	147-155
,	O	155-156
3SR	O	157-160
,	O	160-161
4aRS	O	161-165
,	O	160-161
6SR	O	166-169
,	O	160-161
8aRS	O	170-174
-	O	174-175
6	O	166-167
-	O	174-175
[	O	177-178
phosphonomethyl	O	178-193
]	O	193-194
decahydr	O	194-202
oisoquinoline	O	203-216
-	O	216-217
3	O	217-218
-	O	216-217
carboxylic	O	220-230
acid	O	231-235
,	O	235-236
has	O	237-240
been	O	241-245
described	O	246-255
as	O	256-258
a	O	259-260
potent	O	261-267
antagonist	O	268-278
of	O	279-281
the	O	282-285
N	O	286-287
-	O	287-288
methyl	O	288-294
-	O	287-288
D	O	295-296
-	O	287-288
aspartate	O	297-306
(	O	307-308
NMDA	O	308-312
)	O	312-313
subtype	O	314-321
of	O	322-324
glutamate	O	325-334
receptor	O	335-343
.	O	343-344

Here	O	345-349
its	O	350-353
ability	O	354-361
to	O	362-364
antagonize	O	365-375
the	O	376-379
prolonged	O	380-389
depletion	O	390-399
of	O	400-402
dopamine	O	403-411
in	O	412-414
the	O	415-418
striatum	O	419-427
by	O	428-430
amphetamine	O	431-442
in	O	443-445
iprindole	O	446-455
-	O	455-456
treated	O	456-463
rats	O	464-468
is	O	469-471
reported	O	472-480
.	O	480-481

A	O	482-483
single	O	484-490
18	O	491-493
.	O	493-494
4	O	494-495
mg	O	496-498
/	O	498-499
kg	O	499-501
(	O	502-503
i	O	503-504
.	O	504-505
p	O	505-506
.	O	504-505
)	O	507-508
dose	O	509-513
of	O	514-516
(	O	517-518
+	O	518-519
/	O	519-520
-	O	520-521
)	O	521-522
-	O	520-521
amphetamine	O	523-534
hemisulfate	O	535-546
,	O	546-547
given	O	548-553
to	O	554-556
rats	O	557-561
pretreated	O	562-572
with	O	573-577
iprindole	O	578-587
,	O	587-588
resulted	O	589-597
in	O	598-600
persistent	O	601-611
depletion	O	612-621
of	O	622-624
dopamine	O	625-633
in	O	634-636
the	O	637-640
striatum	O	641-649
1	O	650-651
week	O	652-656
later	O	657-662
.	O	662-663

This	O	664-668
prolonged	O	669-678
depletion	O	679-688
of	O	689-691
dopamine	O	692-700
in	O	701-703
the	O	704-707
striatum	O	708-716
was	O	717-720
antagonized	O	721-732
by	O	733-735
dizocilpine	O	736-747
(	O	748-749
MK	O	749-751
-	O	751-752
801	O	752-755
,	O	755-756
a	O	757-758
non	O	759-762
-	O	762-763
competitive	O	763-774
antagonist	O	775-785
of	O	786-788
NMDA	O	789-793
receptors	O	794-803
)	O	803-804
or	O	805-807
by	O	808-810
LY274614	O	811-819
(	O	820-821
a	O	821-822
competitive	O	823-834
antagonist	O	835-845
of	O	846-848
NMDA	O	849-853
receptors	O	854-863
)	O	863-864
.	O	864-865

The	O	866-869
protective	O	870-880
effect	O	881-887
of	O	888-890
LY274614	O	891-899
was	O	900-903
dose	O	904-908
-	O	908-909
dependent	O	909-918
,	O	918-919
being	O	920-925
maximum	O	926-933
at	O	934-936
10	O	937-939
-	O	939-940
40	O	940-942
mgkg	O	943-947
(	O	948-949
i	O	949-950
.	O	950-951
p	O	951-952
.	O	950-951
)	O	953-954
.	O	950-951

A	O	956-957
10	O	958-960
mg	O	961-963
/	O	963-964
kg	O	964-966
dose	O	967-971
of	O	972-974
LY274614	O	975-983
was	O	984-987
effective	O	988-997
in	O	998-1000
antagonizing	O	1001-1013
the	O	1014-1017
depletion	O	1018-1027
of	O	1028-1030
dopamine	O	1031-1039
in	O	1040-1042
the	O	1043-1046
striatum	O	1047-1055
,	O	1055-1056
when	O	1057-1061
given	O	1062-1067
as	O	1068-1070
long	O	1071-1075
as	O	1076-1078
8	O	1079-1080
hr	O	1081-1083
prior	O	1084-1089
to	O	1090-1092
amphetamine	O	1093-1104
but	O	1105-1108
not	O	1109-1112
when	O	1113-1117
given	O	1118-1123
24	O	1124-1126
hr	O	1127-1129
prior	O	1130-1135
to	O	1136-1138
amphetamine	O	1139-1150
.	O	1150-1151

Depletion	O	1152-1161
of	O	1162-1164
dopamine	O	1165-1173
in	O	1174-1176
the	O	1177-1180
striatum	O	1181-1189
was	O	1190-1193
also	O	1194-1198
antagonized	O	1199-1210
when	O	1211-1215
LY274614	O	1216-1224
was	O	1225-1228
given	O	1229-1234
after	O	1235-1240
the	O	1241-1244
injection	O	1245-1254
of	O	1255-1257
amphetamine	O	1258-1269
;	O	1269-1270
LY274614	O	1271-1279
protected	O	1280-1289
when	O	1290-1294
given	O	1295-1300
up	O	1301-1303
to	O	1304-1306
4	O	1307-1308
hr	O	1309-1311
after	O	1312-1317
but	O	1318-1321
not	O	1322-1325
when	O	1326-1330
given	O	1331-1336
8	O	1337-1338
or	O	1339-1341
24	O	1342-1344
hr	O	1345-1347
after	O	1348-1353
amphetamine	O	1354-1365
.	O	1365-1366

The	O	1367-1370
prolonged	O	1371-1380
depletion	O	1381-1390
of	O	1391-1393
dopamine	O	1394-1402
in	O	1403-1405
the	O	1406-1409
striatum	O	1410-1418
in	O	1419-1421
mice	O	1422-1426
,	O	1426-1427
given	O	1428-1433
multiple	O	1434-1442
injections	O	1443-1453
of	O	1454-1456
methamphetamine	O	1457-1472
,	O	1472-1473
was	O	1474-1477
also	O	1478-1482
antagonized	O	1483-1494
dose	O	1495-1499
-	O	1499-1500
dependently	O	1500-1511
and	O	1512-1515
completely	O	1516-1526
by	O	1527-1529
LY274614	O	1530-1538
.	O	1538-1539

The	O	1540-1543
data	O	1544-1548
strengthen	O	1549-1559
the	O	1560-1563
evidence	O	1564-1572
that	O	1573-1577
the	O	1578-1581
neurotoxic	B	1582-1592
effect	O	1593-1599
of	O	1600-1602
amphetamine	O	1603-1614
and	O	1615-1618
related	O	1619-1626
compounds	O	1627-1636
toward	O	1637-1643
nigrostriatal	O	1644-1657
dopamine	O	1658-1666
neurons	O	1667-1674
involves	O	1675-1683
NMDA	O	1684-1688
receptors	O	1689-1698
and	O	1699-1702
that	O	1703-1707
LY274614	O	1708-1716
is	O	1717-1719
an	O	1720-1722
NMDA	O	1723-1727
receptor	O	1728-1736
antagonist	O	1737-1747
with	O	1748-1752
long	O	1753-1757
-	O	1757-1758
lasting	O	1758-1765
in	O	1766-1768
vivo	O	1769-1773
effects	O	1774-1781
in	O	1782-1784
rats	O	1785-1789
.	O	1789-1790

Neonatal	O	0-8
pyridoxine	O	9-19
responsive	O	20-30
convulsions	B	31-42
due	O	43-46
to	O	47-49
isoniazid	O	50-59
therapy	O	60-67
.	O	67-68

A	O	69-70
17	O	71-73
-	O	73-74
day	O	74-77
-	O	73-74
old	O	78-81
infant	O	82-88
on	O	89-91
isoniazid	O	92-101
therapy	O	102-109
13	O	110-112
mg	O	113-115
/	O	115-116
kg	O	116-118
daily	O	119-124
from	O	125-129
birth	O	130-135
because	O	136-143
of	O	144-146
maternal	O	147-155
tuberculosis	B	156-168
was	O	169-172
admitted	O	173-181
after	O	182-187
4	O	188-189
days	O	190-194
of	O	195-197
clonic	B	198-204
fits	I	205-209
.	O	209-210

No	O	211-213
underlying	O	214-224
infective	O	225-234
or	O	235-237
biochemical	O	238-249
cause	O	250-255
could	O	256-261
be	O	262-264
found	O	265-270
.	O	270-271

The	O	272-275
fits	B	276-280
ceased	O	281-287
within	O	288-294
4	O	295-296
hours	O	297-302
of	O	303-305
administering	O	306-319
intramuscular	O	320-333
pyridoxine	O	334-344
,	O	344-345
suggesting	O	346-356
an	O	357-359
aetiology	O	360-369
of	O	370-372
pyridoxine	O	373-383
deficiency	O	384-394
secondary	O	395-404
to	O	405-407
isoniazid	O	408-417
medication	O	418-428
.	O	428-429

Reversal	O	0-8
by	O	9-11
phenylephrine	O	12-25
of	O	26-28
the	O	29-32
beneficial	O	33-43
effects	O	44-51
of	O	52-54
intravenous	O	55-66
nitroglycerin	O	67-80
in	O	81-83
patients	O	84-92
with	O	93-97
acute	B	98-103
myocardial	I	104-114
infarction	I	115-125
.	O	125-126

Nitroglycerin	O	127-140
has	O	141-144
been	O	145-149
shown	O	150-155
to	O	156-158
reduce	O	159-165
ST	O	166-168
-	O	168-169
segment	O	169-176
elevation	O	177-186
during	O	187-193
acute	B	194-199
myocardial	I	200-210
infarction	I	211-221
,	O	221-222
an	O	223-225
effect	O	226-232
potentiated	O	233-244
in	O	245-247
the	O	248-251
dog	O	252-255
by	O	256-258
agents	O	259-265
that	O	266-270
reverse	O	271-278
nitroglycerin	O	279-292
-	O	292-293
induced	O	293-300
hypotension	B	301-312
.	O	312-313

Our	O	314-317
study	O	318-323
was	O	324-327
designed	O	328-336
to	O	337-339
determine	O	340-349
the	O	350-353
effects	O	354-361
of	O	362-364
combined	O	365-373
nitroglycerin	O	374-387
and	O	388-391
phenylephrine	O	392-405
therapy	O	406-413
.	O	413-414

Ten	O	415-418
patients	O	419-427
with	O	428-432
acute	O	433-438
transmural	O	439-449
myocardial	B	450-460
infarctions	I	461-472
received	O	473-481
intravenous	O	482-493
nitroglycerin	O	494-507
,	O	507-508
sufficient	O	509-519
to	O	520-522
reduce	O	523-529
mean	O	530-534
arterial	O	535-543
pressure	O	544-552
from	O	553-557
107	O	558-561
+	O	562-563
/	O	563-564
-	O	564-565
6	O	566-567
to	O	568-570
85	O	571-573
+	O	574-575
/	O	575-576
-	O	576-577
6	O	578-579
mm	O	580-582
Hg	O	583-585
(	O	586-587
P	O	587-588
less	O	589-593
than	O	594-598
0	O	599-600
.	O	600-601
001	O	601-604
)	O	604-605
,	O	605-606
for	O	607-610
60	O	611-613
minutes	O	614-621
.	O	621-622

Left	O	623-627
ventricular	O	628-639
filling	O	640-647
pressure	O	648-656
decreased	O	657-666
from	O	667-671
19	O	672-674
+	O	675-676
/	O	676-677
-	O	677-678
2	O	679-680
to	O	681-683
11	O	684-686
+	O	687-688
/	O	688-689
-	O	689-690
2	O	691-692
mm	O	693-695
Hg	O	696-698
(	O	699-700
P	O	700-701
less	O	702-706
than	O	707-711
0	O	712-713
.	O	713-714
001	O	714-717
)	O	717-718
.	O	713-714

SigmaST	O	720-727
,	O	727-728
the	O	729-732
sum	O	733-736
of	O	737-739
ST	O	740-742
-	O	742-743
segment	O	743-750
elevations	O	751-761
in	O	762-764
16	O	765-767
precordial	O	768-778
leads	O	779-784
,	O	784-785
decreased	O	786-795
(	O	796-797
P	O	797-798
less	O	799-803
than	O	804-808
0	O	809-810
.	O	810-811
02	O	811-813
)	O	813-814
with	O	815-819
intravenous	O	820-831
nitroglycerin	O	832-845
.	O	845-846

Subsequent	O	847-857
addition	O	858-866
of	O	867-869
phenylephrine	O	870-883
infusion	O	884-892
,	O	892-893
sufficient	O	894-904
to	O	905-907
re	O	908-910
-	O	910-911
elevate	O	911-918
mean	O	919-923
arterial	O	924-932
pressure	O	933-941
to	O	942-944
106	O	945-948
+	O	949-950
/	O	950-951
-	O	951-952
4	O	953-954
mm	O	955-957
Hg	O	958-960
(	O	961-962
P	O	962-963
less	O	964-968
than	O	969-973
0	O	974-975
.	O	975-976
001	O	976-979
)	O	979-980
for	O	981-984
30	O	985-987
minutes	O	988-995
,	O	995-996
increased	O	997-1006
left	O	1007-1011
ventricular	O	1012-1023
filling	O	1024-1031
pressure	O	1032-1040
to	O	1041-1043
17	O	1044-1046
+	O	1047-1048
/	O	1048-1049
-	O	1049-1050
2	O	1051-1052
mm	O	1053-1055
Hg	O	1056-1058
(	O	1059-1060
P	O	1060-1061
less	O	1062-1066
than	O	1067-1071
0	O	1072-1073
.	O	1073-1074
05	O	1074-1076
)	O	1076-1077
and	O	1078-1081
also	O	1082-1086
significantly	O	1087-1100
increased	O	1101-1110
sigmaST	O	1111-1118
(	O	1119-1120
P	O	1120-1121
less	O	1122-1126
than	O	1127-1131
0	O	1132-1133
.	O	1133-1134
05	O	1134-1136
)	O	1136-1137
.	O	1133-1134

Our	O	1139-1142
results	O	1143-1150
suggest	O	1151-1158
that	O	1159-1163
addition	O	1164-1172
of	O	1173-1175
phenylephrine	O	1176-1189
to	O	1190-1192
nitroglycerin	O	1193-1206
is	O	1207-1209
not	O	1210-1213
beneficial	O	1214-1224
in	O	1225-1227
the	O	1228-1231
treatment	O	1232-1241
of	O	1242-1244
patients	O	1245-1253
with	O	1254-1258
acute	B	1259-1264
myocardial	I	1265-1275
infarction	I	1276-1286
.	O	1286-1287

Elevation	O	0-9
of	O	10-12
ADAM10	O	13-19
,	O	19-20
ADAM17	O	21-27
,	O	27-28
MMP	O	29-32
-	O	32-33
2	O	33-34
and	O	35-38
MMP	O	39-42
-	O	42-43
9	O	43-44
expression	O	45-55
with	O	56-60
media	O	61-66
degeneration	O	67-79
features	O	80-88
CaCl2	O	89-94
-	O	94-95
induced	O	95-102
thoracic	B	103-111
aortic	I	112-118
aneurysm	I	119-127
in	O	128-130
a	O	131-132
rat	O	133-136
model	O	137-142
.	O	142-143

PURPOSE	O	144-151
:	O	151-152
This	O	153-157
study	O	158-163
was	O	164-167
designed	O	168-176
to	O	177-179
establish	O	180-189
a	O	190-191
rat	O	192-195
model	O	196-201
of	O	202-204
thoracic	B	205-213
aortic	I	214-220
aneurysm	I	221-229
(	O	230-231
TAA	B	231-234
)	O	234-235
by	O	236-238
calcium	O	239-246
chloride	O	247-255
(	O	256-257
CaCl	O	257-261
(	O	256-257
2	O	262-263
)	O	263-264
)	O	263-264
-	O	265-266
induced	O	266-273
arterial	B	274-282
injury	I	283-289
and	O	290-293
to	O	294-296
explore	O	297-304
the	O	305-308
potential	O	309-318
role	O	319-323
of	O	324-326
a	O	327-328
disintegrin	O	329-340
and	O	341-344
metalloproteinase	O	345-362
(	O	363-364
ADAM	O	364-368
)	O	368-369
,	O	369-370
matrix	O	371-377
metalloproteinases	O	378-396
(	O	397-398
MMPs	O	398-402
)	O	402-403
and	O	404-407
their	O	408-413
endogenous	O	414-424
inhibitors	O	425-435
(	O	436-437
TIMPs	O	437-442
)	O	442-443
in	O	444-446
TAA	B	447-450
formation	O	451-460
.	O	460-461

METHODS	O	462-469
:	O	469-470
Thoracic	O	471-479
aorta	O	480-485
of	O	486-488
male	O	489-493
Sprague	O	494-501
-	O	501-502
Dawley	O	502-508
rats	O	509-513
was	O	514-517
exposed	O	518-525
to	O	526-528
0	O	529-530
.	O	530-531
5M	O	531-533
CaCl	O	534-538
(	O	538-539
2	O	539-540
)	O	540-541
or	O	542-544
normal	O	545-551
saline	O	552-558
(	O	559-560
NaCl	O	560-564
)	O	564-565
.	O	565-566

After	O	567-572
12weeks	O	573-580
,	O	580-581
animals	O	582-589
were	O	590-594
euthanized	O	595-605
,	O	605-606
and	O	607-610
CaCl	O	611-615
(	O	615-616
2	O	616-617
)	O	617-618
-	O	618-619
treated	O	619-626
,	O	626-627
CaCl	O	628-632
(	O	632-633
2	O	633-634
)	O	634-635
-	O	635-636
untreated	O	636-645
(	O	646-647
n	O	647-648
=	O	648-649
12	O	649-651
)	O	651-652
and	O	653-656
NaCl	O	657-661
-	O	661-662
treated	O	662-669
aortic	O	670-676
segments	O	677-685
(	O	686-687
n	O	687-688
=	O	688-689
12	O	689-691
)	O	691-692
were	O	693-697
collected	O	698-707
for	O	708-711
histological	O	712-724
and	O	725-728
molecular	O	729-738
assessments	O	739-750
.	O	750-751

MMP	O	752-755
-	O	755-756
TIMP	O	756-760
and	O	761-764
ADAM	O	765-769
mRNAs	O	770-775
were	O	776-780
semi	O	781-785
-	O	785-786
quantitatively	O	786-800
analyzed	O	801-809
and	O	810-813
protein	O	814-821
expressions	O	822-833
were	O	834-838
determined	O	839-849
by	O	850-852
immunohistochemistry	O	853-873
.	O	873-874
RESULTS	O	875-882
:	O	882-883
Despite	O	884-891
similar	O	892-899
external	O	900-908
diameters	O	909-918
among	O	919-924
CaCl	O	925-929
(	O	929-930
2	O	930-931
)	O	931-932
-	O	932-933
treated	O	933-940
,	O	940-941
non	O	942-945
-	O	945-946
CaCl	O	946-950
(	O	950-951
2	O	951-952
)	O	952-953
-	O	945-946
treated	O	954-961
and	O	962-965
NaCl	O	966-970
-	O	970-971
treated	O	971-978
segments	O	979-987
,	O	987-988
aneurymal	O	989-998
alteration	O	999-1009
(	O	1010-1011
n	O	1011-1012
=	O	1012-1013
6	O	1013-1014
,	O	1014-1015
50	O	1016-1018
%	O	1018-1019
)	O	1019-1020
,	O	1020-1021
media	O	1022-1027
degeneration	O	1028-1040
with	O	1041-1045
regional	O	1046-1054
disruption	O	1055-1065
,	O	1065-1066
fragmentation	O	1067-1080
of	O	1081-1083
elastic	O	1084-1091
fiber	O	1092-1097
,	O	1097-1098
and	O	1099-1102
increased	O	1103-1112
collagen	O	1113-1121
deposition	O	1122-1132
(	O	1133-1134
n	O	1134-1135
=	O	1135-1136
12	O	1136-1138
,	O	1138-1139
100	O	1140-1143
%	O	1143-1144
)	O	1144-1145
were	O	1146-1150
demonstrated	O	1151-1163
in	O	1164-1166
CaCl	O	1167-1171
(	O	1171-1172
2	O	1172-1173
)	O	1173-1174
-	O	1174-1175
treated	O	1175-1182
segments	O	1183-1191
.	O	1191-1192

MMP	O	1193-1196
-	O	1196-1197
2	O	1197-1198
,	O	1198-1199
MMP	O	1200-1203
-	O	1203-1204
9	O	1204-1205
,	O	1205-1206
ADAM	O	1207-1211
-	O	1211-1212
10	O	1212-1214
and	O	1215-1218
ADAM	O	1219-1223
-	O	1223-1224
17	O	1224-1226
mRNA	O	1227-1231
levels	O	1232-1238
were	O	1239-1243
increased	O	1244-1253
in	O	1254-1256
CaCl	O	1257-1261
(	O	1261-1262
2	O	1262-1263
)	O	1263-1264
-	O	1264-1265
treated	O	1265-1272
segments	O	1273-1281
(	O	1282-1283
all	O	1283-1286
p	O	1287-1288
<	O	1288-1289
0	O	1289-1290
.	O	1290-1291
01	O	1291-1293
)	O	1293-1294
,	O	1294-1295
with	O	1296-1300
trends	O	1301-1307
of	O	1308-1310
elevation	O	1311-1320
in	O	1321-1323
CaCl	O	1324-1328
(	O	1328-1329
2	O	1329-1330
)	O	1330-1331
-	O	1331-1332
untreated	O	1332-1341
segments	O	1342-1350
,	O	1350-1351
as	O	1352-1354
compared	O	1355-1363
with	O	1364-1368
NaCl	O	1369-1373
-	O	1373-1374
treated	O	1374-1381
segments	O	1382-1390
.	O	1390-1391

Immunohistochemistry	O	1392-1412
displayed	O	1413-1422
significantly	O	1423-1436
increased	O	1437-1446
expressions	O	1447-1458
of	O	1459-1461
MMP	O	1462-1465
-	O	1465-1466
2	O	1466-1467
,	O	1467-1468
MMP	O	1469-1472
-	O	1472-1473
9	O	1473-1474
,	O	1474-1475
ADAM	O	1476-1480
-	O	1480-1481
10	O	1481-1483
and	O	1484-1487
ADAM	O	1488-1492
-	O	1492-1493
17	O	1493-1495
(	O	1496-1497
all	O	1497-1500
p	O	1501-1502
<	O	1502-1503
0	O	1503-1504
.	O	1504-1505
01	O	1505-1507
)	O	1507-1508
in	O	1509-1511
intima	O	1512-1518
and	O	1519-1522
media	O	1523-1528
for	O	1529-1532
CaCl	O	1533-1537
(	O	1537-1538
2	O	1538-1539
)	O	1539-1540
-	O	1540-1541
treated	O	1541-1548
segments	O	1549-1557
.	O	1557-1558

TIMP	O	1559-1563
mRNA	O	1564-1568
and	O	1569-1572
tissue	O	1573-1579
levels	O	1580-1586
did	O	1587-1590
not	O	1591-1594
differ	O	1595-1601
obviously	O	1602-1611
among	O	1612-1617
the	O	1618-1621
three	O	1622-1627
aortic	O	1628-1634
segments	O	1635-1643
.	O	1643-1644

CONCLUSION	O	1645-1655
:	O	1655-1656
This	O	1657-1661
study	O	1662-1667
establishes	O	1668-1679
a	O	1680-1681
TAA	B	1682-1685
model	O	1686-1691
by	O	1692-1694
periarterial	O	1695-1707
CaCl	O	1708-1712
(	O	1712-1713
2	O	1713-1714
)	O	1714-1715
exposure	O	1716-1724
in	O	1725-1727
rats	O	1728-1732
,	O	1732-1733
and	O	1734-1737
demonstrates	O	1738-1750
a	O	1751-1752
significant	O	1753-1764
elevation	O	1765-1774
of	O	1775-1777
expression	O	1778-1788
of	O	1789-1791
MMP	O	1792-1795
-	O	1795-1796
2	O	1796-1797
,	O	1797-1798
MMP	O	1799-1802
-	O	1802-1803
9	O	1803-1804
,	O	1804-1805
ADAM10	O	1806-1812
and	O	1813-1816
ADAM17	O	1817-1823
in	O	1824-1826
the	O	1827-1830
pathogenesis	O	1831-1843
of	O	1844-1846
vascular	O	1847-1855
remodeling	O	1856-1866
.	O	1866-1867

When	O	0-4
drugs	O	5-10
disappear	O	11-20
from	O	21-25
the	O	26-29
patient	O	30-37
:	O	37-38
elimination	O	39-50
of	O	51-53
intravenous	O	54-65
medication	O	66-76
by	O	77-79
hemodiafiltration	O	80-97
.	O	97-98

Twenty	O	99-105
-	O	105-106
three	O	106-111
hours	O	112-117
after	O	118-123
heart	O	124-129
transplantation	O	130-145
,	O	145-146
life	O	147-151
-	O	151-152
threatening	O	152-163
acute	O	164-169
right	B	170-175
heart	I	176-181
failure	I	182-189
was	O	190-193
diagnosed	O	194-203
in	O	204-206
a	O	207-208
patient	O	209-216
requiring	O	217-226
continuous	O	227-237
venovenous	O	238-248
hemodiafiltration	O	249-266
(	O	267-268
CVVHDF	O	268-274
)	O	274-275
.	O	275-276

Increasing	O	277-287
doses	O	288-293
of	O	294-296
catecholamines	O	297-311
,	O	311-312
sedatives	O	313-322
,	O	322-323
and	O	324-327
muscle	O	328-334
relaxants	O	335-344
administered	O	345-357
through	O	358-365
a	O	366-367
central	O	368-375
venous	O	376-382
catheter	O	383-391
were	O	392-396
ineffective	O	397-408
.	O	408-409

However	O	410-417
,	O	417-418
a	O	419-420
bolus	O	421-426
of	O	427-429
epinephrine	O	430-441
injected	O	442-450
through	O	451-458
an	O	459-461
alternative	O	462-473
catheter	O	474-482
provoked	O	483-491
a	O	492-493
hypertensive	B	494-506
crisis	O	507-513
.	O	513-514

Thus	O	515-519
,	O	519-520
interference	O	521-533
with	O	534-538
the	O	539-542
central	O	543-550
venous	O	551-557
infusion	O	558-566
by	O	567-569
the	O	570-573
dialysis	O	574-582
catheter	O	583-591
was	O	592-595
suspected	O	596-605
.	O	605-606

The	O	607-610
catheters	O	611-620
were	O	621-625
changed	O	626-633
,	O	633-634
and	O	635-638
hemodynamics	O	639-651
stabilized	O	652-662
at	O	663-665
lower	O	666-671
catecholamine	O	672-685
doses	O	686-691
.	O	691-692

When	O	693-697
the	O	698-701
effects	O	702-709
of	O	710-712
IV	O	713-715
drugs	O	716-721
are	O	722-725
inadequate	O	726-736
in	O	737-739
patients	O	740-748
receiving	O	749-758
CVVHDF	O	759-765
,	O	765-766
interference	O	767-779
with	O	780-784
adjacent	O	785-793
catheters	O	794-803
resulting	O	804-813
in	O	814-816
elimination	O	817-828
of	O	829-831
the	O	832-835
drug	O	836-840
by	O	841-843
CVVHDF	O	844-850
should	O	851-857
be	O	858-860
suspected	O	861-870
.	O	870-871

Long	O	0-4
-	O	4-5
term	O	5-9
glutamate	O	10-19
supplementation	O	20-35
failed	O	36-42
to	O	43-45
protect	O	46-53
against	O	54-61
peripheral	B	62-72
neurotoxicity	I	73-86
of	O	87-89
paclitaxel	O	90-100
.	O	100-101

Toxic	O	102-107
peripheral	B	108-118
neuropathy	I	119-129
is	O	130-132
still	O	133-138
a	O	139-140
significant	O	141-152
limiting	O	153-161
factor	O	162-168
for	O	169-172
chemotherapy	O	173-185
with	O	186-190
paclitaxel	O	191-201
(	O	202-203
PAC	O	203-206
)	O	206-207
,	O	207-208
although	O	209-217
glutamate	O	218-227
and	O	228-231
its	O	232-235
closely	O	236-243
related	O	244-251
amino	O	252-257
acid	O	258-262
glutamine	O	263-272
were	O	273-277
claimed	O	278-285
to	O	286-288
ameliorate	O	289-299
PAC	O	300-303
neurotoxicity	B	304-317
.	O	317-318

This	O	319-323
pilot	O	324-329
trial	O	330-335
aimed	O	336-341
to	O	342-344
evaluate	O	345-353
the	O	354-357
role	O	358-362
of	O	363-365
glutamate	O	366-375
supplementation	O	376-391
for	O	392-395
preventing	O	396-406
PAC	O	407-410
-	O	410-411
induced	O	411-418
peripheral	B	419-429
neuropathy	I	430-440
in	O	441-443
a	O	444-445
randomized	O	446-456
,	O	456-457
placebo	O	458-465
-	O	465-466
controlled	O	466-476
,	O	476-477
double	O	478-484
-	O	484-485
blinded	O	485-492
clinical	O	493-501
and	O	502-505
electro	O	506-513
-	O	513-514
diagnostic	O	514-524
study	O	525-530
.	O	530-531

Forty	O	532-537
-	O	537-538
three	O	538-543
ovarian	B	544-551
cancer	I	552-558
patients	O	559-567
were	O	568-572
available	O	573-582
for	O	583-586
analysis	O	587-595
following	O	596-605
six	O	606-609
cycles	O	610-616
of	O	617-619
the	O	620-623
same	O	624-628
PAC	O	629-632
-	O	632-633
containing	O	633-643
regimen	O	644-651
:	O	651-652
23	O	653-655
had	O	656-659
been	O	660-664
supplemented	O	665-677
by	O	678-680
glutamate	O	681-690
all	O	691-694
along	O	695-700
the	O	701-704
treatment	O	705-714
period	O	715-721
,	O	721-722
at	O	723-725
a	O	726-727
daily	O	728-733
dose	O	734-738
of	O	739-741
three	O	742-747
times	O	748-753
500	O	754-757
mg	O	758-760
(	O	761-762
group	O	762-767
G	O	768-769
)	O	769-770
,	O	770-771
and	O	772-775
20	O	776-778
had	O	779-782
received	O	783-791
a	O	792-793
placebo	O	794-801
(	O	802-803
group	O	803-808
P	O	809-810
)	O	810-811
.	O	811-812

Patients	O	813-821
were	O	822-826
evaluated	O	827-836
by	O	837-839
neurological	O	840-852
examinations	O	853-865
,	O	865-866
questionnaires	O	867-881
and	O	882-885
sensory	O	886-893
-	O	893-894
motor	O	894-899
nerve	O	900-905
conduction	O	906-916
studies	O	917-924
.	O	924-925

There	O	926-931
was	O	932-935
no	O	936-938
significant	O	939-950
difference	O	951-961
in	O	962-964
the	O	965-968
frequency	O	969-978
of	O	979-981
signs	O	982-987
or	O	988-990
symptoms	O	991-999
between	O	1000-1007
the	O	1008-1011
two	O	1012-1015
groups	O	1016-1022
although	O	1023-1031
neurotoxicity	B	1032-1045
symptoms	O	1046-1054
presented	O	1055-1064
mostly	O	1065-1071
with	O	1072-1076
lower	O	1077-1082
scores	O	1083-1089
of	O	1090-1092
severity	O	1093-1101
in	O	1102-1104
group	O	1105-1110
G	O	1111-1112
.	O	1112-1113

However	O	1114-1121
,	O	1121-1122
this	O	1123-1127
difference	O	1128-1138
reached	O	1139-1146
statistical	O	1147-1158
significance	O	1159-1171
only	O	1172-1176
with	O	1177-1181
regard	O	1182-1188
to	O	1189-1191
reported	O	1192-1200
pain	B	1201-1205
sensation	O	1206-1215
(	O	1216-1217
P	O	1217-1218
=	O	1219-1220
0	O	1221-1222
.	O	1222-1223
011	O	1223-1226
)	O	1226-1227
.	O	1222-1223

Also	O	1229-1233
the	O	1234-1237
frequency	O	1238-1247
of	O	1248-1250
abnormal	O	1251-1259
electro	O	1260-1267
-	O	1267-1268
diagnostic	O	1268-1278
findings	O	1279-1287
showed	O	1288-1294
similarity	O	1295-1305
between	O	1306-1313
the	O	1314-1317
two	O	1318-1321
groups	O	1322-1328
(	O	1329-1330
G	O	1330-1331
:	O	1331-1332
7	O	1333-1334
/	O	1334-1335
23	O	1335-1337
=	O	1338-1339
30	O	1340-1342
.	O	1342-1343
4	O	1343-1344
%	O	1344-1345
;	O	1345-1346

P	O	1347-1348
:	O	1348-1349
6	O	1350-1351
/	O	1351-1352
20	O	1352-1354
=	O	1355-1356
30	O	1357-1359
%	O	1359-1360
)	O	1360-1361
.	O	1361-1362

This	O	1363-1367
pilot	O	1368-1373
study	O	1374-1379
leads	O	1380-1385
to	O	1386-1388
the	O	1389-1392
conclusion	O	1393-1403
that	O	1404-1408
glutamate	O	1409-1418
supplementation	O	1419-1434
at	O	1435-1437
the	O	1438-1441
chosen	O	1442-1448
regimen	O	1449-1456
fails	O	1457-1462
to	O	1463-1465
protect	O	1466-1473
against	O	1474-1481
peripheral	B	1482-1492
neurotoxicity	I	1493-1506
of	O	1507-1509
PAC	O	1510-1513
.	O	1513-1514

Attentional	O	0-11
modulation	O	12-22
of	O	23-25
perceived	O	26-35
pain	B	36-40
intensity	O	41-50
in	O	51-53
capsaicin	O	54-63
-	O	63-64
induced	O	64-71
secondary	O	72-81
hyperalgesia	B	82-94
.	O	94-95

Perceived	O	96-105
pain	B	106-110
intensity	O	111-120
is	O	121-123
modulated	O	124-133
by	O	134-136
attention	O	137-146
.	O	146-147

However	O	148-155
,	O	155-156
it	O	157-159
is	O	160-162
not	O	163-166
known	O	167-172
that	O	173-177
how	O	178-181
pain	B	182-186
intensity	O	187-196
ratings	O	197-204
are	O	205-208
affected	O	209-217
by	O	218-220
attention	O	221-230
in	O	231-233
capsaicin	O	234-243
-	O	243-244
induced	O	244-251
secondary	O	252-261
hyperalgesia	B	262-274
.	O	274-275

Here	O	276-280
we	O	281-283
show	O	284-288
that	O	289-293
perceived	O	294-303
pain	B	304-308
intensity	O	309-318
in	O	319-321
secondary	O	322-331
hyperalgesia	B	332-344
is	O	345-347
decreased	O	348-357
when	O	358-362
attention	O	363-372
is	O	373-375
distracted	O	376-386
away	O	387-391
from	O	392-396
the	O	397-400
painful	O	401-408
pinprick	O	409-417
stimulus	O	418-426
with	O	427-431
a	O	432-433
visual	O	434-440
task	O	441-445
.	O	445-446

Furthermore	O	447-458
,	O	458-459
it	O	460-462
was	O	463-466
found	O	467-472
that	O	473-477
the	O	478-481
magnitude	O	482-491
of	O	492-494
attentional	O	495-506
modulation	O	507-517
in	O	518-520
secondary	O	521-530
hyperalgesia	B	531-543
is	O	544-546
very	O	547-551
similar	O	552-559
to	O	560-562
that	O	563-567
of	O	568-570
capsaicin	O	571-580
-	O	580-581
untreated	O	581-590
,	O	590-591
control	O	592-599
condition	O	600-609
.	O	609-610

Our	O	611-614
findings	O	615-623
,	O	623-624
showing	O	625-632
no	O	633-635
interaction	O	636-647
between	O	648-655
capsaicin	O	656-665
treatment	O	666-675
and	O	676-679
attentional	O	680-691
modulation	O	692-702
suggest	O	703-710
that	O	711-715
capsaicin	O	716-725
-	O	725-726
induced	O	726-733
secondary	O	734-743
hyperalgesia	B	744-756
and	O	757-760
attention	O	761-770
might	O	771-776
affect	O	777-783
mechanical	O	784-794
pain	B	795-799
through	O	800-807
independent	O	808-819
mechanisms	O	820-830
.	O	830-831

Testosterone	O	0-12
-	O	12-13
dependent	O	13-22
hypertension	B	23-35
and	O	36-39
upregulation	O	40-52
of	O	53-55
intrarenal	O	56-66
angiotensinogen	O	67-82
in	O	83-85
Dahl	O	86-90
salt	O	91-95
-	O	95-96
sensitive	O	96-105
rats	O	106-110
.	O	110-111

Blood	O	112-117
pressure	O	118-126
(	O	127-128
BP	O	128-130
)	O	130-131
is	O	132-134
more	O	135-139
salt	O	140-144
sensitive	O	145-154
in	O	155-157
men	O	158-161
than	O	162-166
in	O	167-169
premenopausal	O	170-183
women	O	184-189
.	O	189-190

In	O	191-193
Dahl	O	194-198
salt	O	199-203
-	O	203-204
sensitive	O	204-213
rats	O	214-218
(	O	219-220
DS	O	220-222
)	O	222-223
,	O	223-224
high	O	225-229
-	O	229-230
salt	O	230-234
(	O	235-236
HS	O	236-238
)	O	238-239
diet	O	240-244
increases	O	245-254
BP	O	255-257
more	O	258-262
in	O	263-265
males	O	266-271
than	O	272-276
females	O	277-284
.	O	284-285

In	O	286-288
contrast	O	289-297
to	O	298-300
the	O	301-304
systemic	O	305-313
renin	O	314-319
-	O	319-320
angiotensin	O	320-331
system	O	332-338
,	O	338-339
which	O	340-345
is	O	346-348
suppressed	O	349-359
in	O	360-362
response	O	363-371
to	O	372-374
HS	O	375-377
in	O	378-380
male	O	381-385
DS	O	386-388
,	O	388-389
intrarenal	O	390-400
angiotensinogen	O	401-416
expression	O	417-427
is	O	428-430
increased	O	431-440
,	O	440-441
and	O	442-445
intrarenal	O	446-456
levels	O	457-463
of	O	464-466
ANG	O	467-470
II	O	471-473
are	O	474-477
not	O	478-481
suppressed	O	482-492
.	O	492-493

In	O	494-496
this	O	497-501
study	O	502-507
,	O	507-508
the	O	509-512
hypothesis	O	513-523
was	O	524-527
tested	O	528-534
that	O	535-539
there	O	540-545
is	O	546-548
a	O	549-550
sexual	O	551-557
dimorphism	O	558-568
in	O	569-571
HS	O	572-574
-	O	574-575
induced	O	575-582
upregulation	O	583-595
of	O	596-598
intrarenal	O	599-609
angiotensinogen	O	610-625
mediated	O	626-634
by	O	635-637
testosterone	O	638-650
that	O	651-655
also	O	656-660
causes	O	661-667
increases	O	668-677
in	O	678-680
BP	O	681-683
and	O	684-687
renal	B	688-693
injury	I	694-700
.	O	700-701

On	O	702-704
a	O	705-706
low	O	707-710
-	O	710-711
salt	O	711-715
(	O	716-717
LS	O	717-719
)	O	719-720
diet	O	721-725
,	O	725-726
male	O	727-731
DS	O	732-734
had	O	735-738
higher	O	739-745
levels	O	746-752
of	O	753-755
intrarenal	O	756-766
angiotensinogen	O	767-782
mRNA	O	783-787
than	O	788-792
females	O	793-800
.	O	800-801

HS	O	802-804
diet	O	805-809
for	O	810-813
4	O	814-815
wk	O	816-818
increased	O	819-828
renal	O	829-834
cortical	O	835-843
angiotensinogen	O	844-859
mRNA	O	860-864
and	O	865-868
protein	O	869-876
only	O	877-881
in	O	882-884
male	O	885-889
DS	O	890-892
,	O	892-893
which	O	894-899
was	O	900-903
prevented	O	904-913
by	O	914-916
castration	O	917-927
.	O	927-928

Ovariectomy	O	929-940
of	O	941-943
female	O	944-950
DS	O	951-953
had	O	954-957
no	O	958-960
effect	O	961-967
on	O	968-970
intrarenal	O	971-981
angiotensinogen	O	982-997
expression	O	998-1008
on	O	1009-1011
either	O	1012-1018
diet	O	1019-1023
.	O	1023-1024

Radiotelemetric	O	1025-1040
BP	O	1041-1043
was	O	1044-1047
similar	O	1048-1055
between	O	1056-1063
males	O	1064-1069
and	O	1070-1073
castrated	O	1074-1083
rats	O	1084-1088
on	O	1089-1091
LS	O	1092-1094
diet	O	1095-1099
.	O	1099-1100

HS	O	1101-1103
diet	O	1104-1108
for	O	1109-1112
4	O	1113-1114
wk	O	1115-1117
caused	O	1118-1124
a	O	1125-1126
progressive	O	1127-1138
increase	O	1139-1147
in	O	1148-1150
BP	O	1151-1153
,	O	1153-1154
protein	O	1155-1162
and	O	1163-1166
albumin	O	1167-1174
excretion	O	1175-1184
,	O	1184-1185
and	O	1186-1189
glomerular	B	1190-1200
sclerosis	I	1201-1210
in	O	1211-1213
male	O	1214-1218
DS	O	1219-1221
rats	O	1222-1226
,	O	1226-1227
which	O	1228-1233
were	O	1234-1238
attenuated	O	1239-1249
by	O	1250-1252
castration	O	1253-1263
.	O	1263-1264

Testosterone	O	1265-1277
replacement	O	1278-1289
in	O	1290-1292
castrated	O	1293-1302
DS	O	1303-1305
rats	O	1306-1310
increased	O	1311-1320
BP	O	1321-1323
,	O	1323-1324
renal	B	1325-1330
injury	I	1331-1337
,	O	1337-1338
and	O	1339-1342
upregulation	O	1343-1355
of	O	1356-1358
renal	O	1359-1364
angiotensinogen	O	1365-1380
associated	O	1381-1391
with	O	1392-1396
HS	O	1397-1399
diet	O	1400-1404
.	O	1404-1405

Testosterone	O	1406-1418
contributes	O	1419-1430
to	O	1431-1433
the	O	1434-1437
development	O	1438-1449
of	O	1450-1452
hypertension	B	1453-1465
and	O	1466-1469
renal	B	1470-1475
injury	I	1476-1482
in	O	1483-1485
male	O	1486-1490
DS	O	1491-1493
rats	O	1494-1498
on	O	1499-1501
HS	O	1502-1504
diet	O	1505-1509
possibly	O	1510-1518
through	O	1519-1526
upregulation	O	1527-1539
of	O	1540-1542
the	O	1543-1546
intrarenal	O	1547-1557
renin	O	1558-1563
-	O	1563-1564
angiotensin	O	1564-1575
system	O	1576-1582
.	O	1582-1583

Prenatal	O	0-8
protein	O	9-16
deprivation	O	17-28
alters	O	29-35
dopamine	O	36-44
-	O	44-45
mediated	O	45-53
behaviors	O	54-63
and	O	64-67
dopaminergic	O	68-80
and	O	81-84
glutamatergic	O	85-98
receptor	O	99-107
binding	O	108-115
.	O	115-116

Epidemiological	O	117-132
evidence	O	133-141
indicates	O	142-151
that	O	152-156
prenatal	O	157-165
nutritional	O	166-177
deprivation	O	178-189
may	O	190-193
increase	O	194-202
the	O	203-206
risk	O	207-211
of	O	212-214
schizophrenia	B	215-228
.	O	228-229

The	O	230-233
goal	O	234-238
of	O	239-241
these	O	242-247
studies	O	248-255
was	O	256-259
to	O	260-262
use	O	263-266
an	O	267-269
animal	O	270-276
model	O	277-282
to	O	283-285
examine	O	286-293
the	O	294-297
effects	O	298-305
of	O	306-308
prenatal	O	309-317
protein	O	318-325
deprivation	O	326-337
on	O	338-340
behaviors	O	341-350
and	O	351-354
receptor	O	355-363
binding	O	364-371
with	O	372-376
relevance	O	377-386
to	O	387-389
schizophrenia	B	390-403
.	O	403-404

We	O	405-407
report	O	408-414
that	O	415-419
prenatally	O	420-430
protein	O	431-438
deprived	O	439-447
(	O	448-449
PD	O	449-451
)	O	451-452
female	O	453-459
rats	O	460-464
showed	O	465-471
an	O	472-474
increased	O	475-484
stereotypic	O	485-496
response	O	497-505
to	O	506-508
apomorphine	O	509-520
and	O	521-524
an	O	525-527
increased	O	528-537
locomotor	O	538-547
response	O	548-556
to	O	557-559
amphetamine	O	560-571
in	O	572-574
adulthood	O	575-584
.	O	584-585

These	O	586-591
differences	O	592-603
were	O	604-608
not	O	609-612
observed	O	613-621
during	O	622-628
puberty	O	629-636
.	O	636-637

No	O	638-640
changes	O	641-648
in	O	649-651
haloperidol	O	652-663
-	O	663-664
induced	O	664-671
catalepsy	B	672-681
or	O	682-684
MK	O	685-687
-	O	687-688
801	O	688-691
-	O	687-688
induced	O	692-699
locomotion	O	700-710
were	O	711-715
seen	O	716-720
following	O	721-730
PD	O	731-733
.	O	733-734

In	O	735-737
addition	O	738-746
,	O	746-747
PD	O	748-750
female	O	751-757
rats	O	758-762
showed	O	763-769
increased	O	770-779
(	O	780-781
3	O	781-782
)	O	782-783
H	O	783-784
-	O	784-785
MK	O	785-787
-	O	784-785
801	O	788-791
binding	O	792-799
in	O	800-802
the	O	803-806
striatum	O	807-815
and	O	816-819
hippocampus	O	820-831
,	O	831-832
but	O	833-836
not	O	837-840
in	O	841-843
the	O	844-847
cortex	O	848-854
.	O	854-855

PD	O	856-858
female	O	859-865
rats	O	866-870
also	O	871-875
showed	O	876-882
increased	O	883-892
(	O	893-894
3	O	894-895
)	O	895-896
H	O	896-897
-	O	897-898
haloperidol	O	898-909
binding	O	910-917
and	O	918-921
decreased	O	922-931
dopamine	O	932-940
transporter	O	941-952
binding	O	953-960
in	O	961-963
striatum	O	964-972
.	O	972-973

No	O	974-976
statistically	O	977-990
significant	O	991-1002
changes	O	1003-1010
in	O	1011-1013
behavior	O	1014-1022
or	O	1023-1025
receptor	O	1026-1034
binding	O	1035-1042
were	O	1043-1047
found	O	1048-1053
in	O	1054-1056
PD	O	1057-1059
males	O	1060-1065
with	O	1066-1070
the	O	1071-1074
exception	O	1075-1084
of	O	1085-1087
increased	O	1088-1097
(	O	1098-1099
3	O	1099-1100
)	O	1100-1101
H	O	1101-1102
-	O	1102-1103
MK	O	1103-1105
-	O	1102-1103
801	O	1106-1109
binding	O	1110-1117
in	O	1118-1120
cortex	O	1121-1127
.	O	1127-1128

This	O	1129-1133
animal	O	1134-1140
model	O	1141-1146
may	O	1147-1150
be	O	1151-1153
useful	O	1154-1160
to	O	1161-1163
explore	O	1164-1171
the	O	1172-1175
mechanisms	O	1176-1186
by	O	1187-1189
which	O	1190-1195
prenatal	O	1196-1204
nutritional	B	1205-1216
deficiency	I	1217-1227
enhances	O	1228-1236
risk	O	1237-1241
for	O	1242-1245
schizophrenia	B	1246-1259
in	O	1260-1262
humans	O	1263-1269
and	O	1270-1273
may	O	1274-1277
also	O	1278-1282
have	O	1283-1287
implications	O	1288-1300
for	O	1301-1304
developmental	O	1305-1318
processes	O	1319-1328
leading	O	1329-1336
to	O	1337-1339
differential	O	1340-1352
sensitivity	O	1353-1364
to	O	1365-1367
drugs	O	1368-1373
of	O	1374-1376
abuse	O	1377-1382
.	O	1382-1383

mToR	O	0-4
inhibitors	O	5-15
-	O	15-16
induced	O	16-23
proteinuria	B	24-35
:	O	35-36
mechanisms	O	37-47
,	O	47-48
significance	O	49-61
,	O	61-62
and	O	63-66
management	O	67-77
.	O	77-78

Massive	O	79-86
urinary	O	87-94
protein	O	95-102
excretion	O	103-112
has	O	113-116
been	O	117-121
observed	O	122-130
after	O	131-136
conversion	O	137-147
from	O	148-152
calcineurin	O	153-164
inhibitors	O	165-175
to	O	176-178
mammalian	O	179-188
target	O	189-195
of	O	196-198
rapamycin	O	199-208
(	O	209-210
mToR	O	210-214
)	O	214-215
inhibitors	O	216-226
,	O	226-227
especially	O	228-238
sirolimus	O	239-248
,	O	248-249
in	O	250-252
renal	O	253-258
transplant	O	259-269
recipients	O	270-280
with	O	281-285
chronic	B	286-293
allograft	I	294-303
nephropathy	I	304-315
.	O	315-316

Because	O	317-324
proteinuria	B	325-336
is	O	337-339
a	O	340-341
major	O	342-347
predictive	O	348-358
factor	O	359-365
of	O	366-368
poor	O	369-373
transplantation	O	374-389
outcome	O	390-397
,	O	397-398
many	O	399-403
studies	O	404-411
focused	O	412-419
on	O	420-422
this	O	423-427
adverse	O	428-435
event	O	436-441
during	O	442-448
the	O	449-452
past	O	453-457
years	O	458-463
.	O	463-464

Whether	O	465-472
proteinuria	B	473-484
was	O	485-488
due	O	489-492
to	O	493-495
sirolimus	O	496-505
or	O	506-508
only	O	509-513
a	O	514-515
consequence	O	516-527
of	O	528-530
calcineurin	O	531-542
inhibitors	O	543-553
withdrawal	O	554-564
remained	O	565-573
unsolved	O	574-582
until	O	583-588
high	O	589-593
range	O	594-599
proteinuria	B	600-611
has	O	612-615
been	O	616-620
observed	O	621-629
during	O	630-636
sirolimus	O	637-646
therapy	O	647-654
in	O	655-657
islet	O	658-663
transplantation	O	664-679
and	O	680-683
in	O	684-686
patients	O	687-695
who	O	696-699
received	O	700-708
sirolimus	O	709-718
de	O	719-721
novo	O	722-726
.	O	726-727

Podocyte	O	728-736
injury	O	737-743
and	O	744-747
focal	O	748-753
segmental	O	754-763
glomerulosclerosis	B	764-782
have	O	783-787
been	O	788-792
related	O	793-800
to	O	801-803
mToR	O	804-808
inhibition	O	809-819
in	O	820-822
some	O	823-827
patients	O	828-836
,	O	836-837
but	O	838-841
the	O	842-845
pathways	O	846-854
underlying	O	855-865
these	O	866-871
lesions	O	872-879
remain	O	880-886
hypothetic	O	887-897
.	O	897-898

We	O	899-901
discuss	O	902-909
herein	O	910-916
the	O	917-920
possible	O	921-929
mechanisms	O	930-940
and	O	941-944
the	O	945-948
significance	O	949-961
of	O	962-964
mToR	O	965-969
blockade	O	970-978
-	O	978-979
induced	O	979-986
proteinuria	B	987-998
.	O	998-999

Hypothalamic	O	0-12
prolactin	O	13-22
receptor	O	23-31
messenger	O	32-41
ribonucleic	O	42-53
acid	O	54-58
levels	O	59-65
,	O	65-66
prolactin	O	67-76
signaling	O	77-86
,	O	86-87
and	O	88-91
hyperprolactinemic	B	92-110
inhibition	O	111-121
of	O	122-124
pulsatile	O	125-134
luteinizing	O	135-146
hormone	O	147-154
secretion	O	155-164
are	O	165-168
dependent	O	169-178
on	O	179-181
estradiol	O	182-191
.	O	191-192

Hyperprolactinemia	B	193-211
can	O	212-215
reduce	O	216-222
fertility	O	223-232
and	O	233-236
libido	O	237-243
.	O	243-244

Although	O	245-253
central	O	254-261
prolactin	O	262-271
actions	O	272-279
are	O	280-283
thought	O	284-291
to	O	292-294
contribute	O	295-305
to	O	306-308
this	O	309-313
,	O	313-314
the	O	315-318
mechanisms	O	319-329
are	O	330-333
poorly	O	334-340
understood	O	341-351
.	O	351-352

We	O	353-355
first	O	356-361
tested	O	362-368
whether	O	369-376
chronic	O	377-384
hyperprolactinemia	B	385-403
inhibited	O	404-413
two	O	414-417
neuroendocrine	O	418-432
parameters	O	433-443
necessary	O	444-453
for	O	454-457
female	O	458-464
fertility	O	465-474
:	O	474-475
pulsatile	O	476-485
LH	O	486-488
secretion	O	489-498
and	O	499-502
the	O	503-506
estrogen	O	507-515
-	O	515-516
induced	O	516-523
LH	O	524-526
surge	O	527-532
.	O	532-533

Chronic	O	534-541
hyperprolactinemia	B	542-560
induced	O	561-568
by	O	569-571
the	O	572-575
dopamine	O	576-584
antagonist	O	585-595
sulpiride	O	596-605
caused	O	606-612
a	O	613-614
40	O	615-617
%	O	617-618
reduction	O	619-628
LH	O	629-631
pulse	O	632-637
frequency	O	638-647
in	O	648-650
ovariectomized	O	651-665
rats	O	666-670
,	O	670-671
but	O	672-675
only	O	676-680
in	O	681-683
the	O	684-687
presence	O	688-696
of	O	697-699
chronic	O	700-707
low	O	708-711
levels	O	712-718
of	O	719-721
estradiol	O	722-731
.	O	731-732

Sulpiride	O	733-742
did	O	743-746
not	O	747-750
affect	O	751-757
the	O	758-761
magnitude	O	762-771
of	O	772-774
a	O	775-776
steroid	O	777-784
-	O	784-785
induced	O	785-792
LH	O	793-795
surge	O	796-801
or	O	802-804
the	O	805-808
percentage	O	809-819
of	O	820-822
GnRH	O	823-827
neurons	O	828-835
activated	O	836-845
during	O	846-852
the	O	853-856
surge	O	857-862
.	O	862-863

Estradiol	O	864-873
is	O	874-876
known	O	877-882
to	O	883-885
influence	O	886-895
expression	O	896-906
of	O	907-909
the	O	910-913
long	O	914-918
form	O	919-923
of	O	924-926
prolactin	O	927-936
receptors	O	937-946
(	O	947-948
PRL	O	948-951
-	O	951-952
R	O	949-950
)	O	953-954
and	O	955-958
components	O	959-969
of	O	970-972
prolactin	O	973-982
'	O	982-983
s	O	983-984
signaling	O	985-994
pathway	O	995-1002
.	O	1002-1003

To	O	1004-1006
test	O	1007-1011
the	O	1012-1015
hypothesis	O	1016-1026
that	O	1027-1031
estrogen	O	1032-1040
increases	O	1041-1050
PRL	O	1051-1054
-	O	1054-1055
R	O	1052-1053
expression	O	1057-1067
and	O	1068-1071
sensitivity	O	1072-1083
to	O	1084-1086
prolactin	O	1087-1096
,	O	1096-1097
we	O	1098-1100
next	O	1101-1105
demonstrated	O	1106-1118
that	O	1119-1123
estradiol	O	1124-1133
greatly	O	1134-1141
augments	O	1142-1150
prolactin	O	1151-1160
-	O	1160-1161
induced	O	1161-1168
STAT5	O	1169-1174
activation	O	1175-1185
.	O	1185-1186

Lastly	O	1187-1193
,	O	1193-1194
we	O	1195-1197
measured	O	1198-1206
PRL	O	1207-1210
-	O	1210-1211
R	O	1208-1209
and	O	1213-1216
suppressor	O	1217-1227
of	O	1228-1230
cytokine	O	1231-1239
signaling	O	1240-1249
(	O	1250-1251
SOCS	O	1251-1255
-	O	1255-1256
1	O	1256-1257
and	O	1258-1261
-	O	1262-1263
3	O	1263-1264
and	O	1265-1268
CIS	O	1269-1272
,	O	1272-1273
which	O	1274-1279
reflect	O	1280-1287
the	O	1288-1291
level	O	1292-1297
of	O	1298-1300
prolactin	O	1301-1310
signaling	O	1311-1320
)	O	1320-1321
mRNAs	O	1322-1327
in	O	1328-1330
response	O	1331-1339
to	O	1340-1342
sulpiride	O	1343-1352
and	O	1353-1356
estradiol	O	1357-1366
.	O	1366-1367

Sulpiride	O	1368-1377
induced	O	1378-1385
only	O	1386-1390
SOCS	O	1391-1395
-	O	1395-1396
1	O	1396-1397
in	O	1398-1400
the	O	1401-1404
medial	O	1405-1411
preoptic	O	1412-1420
area	O	1421-1425
,	O	1425-1426
where	O	1427-1432
GnRH	O	1433-1437
neurons	O	1438-1445
are	O	1446-1449
regulated	O	1450-1459
,	O	1459-1460
but	O	1461-1464
in	O	1465-1467
the	O	1468-1471
arcuate	O	1472-1479
nucleus	O	1480-1487
and	O	1488-1491
choroid	O	1492-1499
plexus	O	1500-1506
,	O	1506-1507
PRL	O	1508-1511
-	O	1511-1512
R	O	1509-1510
,	O	1513-1514
SOCS	O	1515-1519
-	O	1519-1520
3	O	1520-1521
,	O	1521-1522
and	O	1523-1526
CIS	O	1527-1530
mRNA	O	1531-1535
levels	O	1536-1542
were	O	1543-1547
also	O	1548-1552
induced	O	1553-1560
.	O	1560-1561

Estradiol	O	1562-1571
enhanced	O	1572-1580
these	O	1581-1586
effects	O	1587-1594
on	O	1595-1597
SOCS	O	1598-1602
-	O	1602-1603
3	O	1603-1604
and	O	1605-1608
CIS	O	1609-1612
.	O	1612-1613

Interestingly	O	1614-1627
,	O	1627-1628
estradiol	O	1629-1638
also	O	1639-1643
induced	O	1644-1651
PRL	O	1652-1655
-	O	1655-1656
R	O	1653-1654
,	O	1657-1658
SOCS	O	1659-1663
-	O	1663-1664
3	O	1664-1665
,	O	1665-1666
and	O	1667-1670
CIS	O	1671-1674
mRNA	O	1675-1679
levels	O	1680-1686
independently	O	1687-1700
.	O	1700-1701

These	O	1702-1707
data	O	1708-1712
show	O	1713-1717
that	O	1718-1722
GnRH	O	1723-1727
pulse	O	1728-1733
frequency	O	1734-1743
is	O	1744-1746
inhibited	O	1747-1756
by	O	1757-1759
chronic	O	1760-1767
hyperprolactinemia	B	1768-1786
in	O	1787-1789
a	O	1790-1791
steroid	O	1792-1799
-	O	1799-1800
dependent	O	1800-1809
manner	O	1810-1816
.	O	1816-1817

They	O	1818-1822
also	O	1823-1827
provide	O	1828-1835
evidence	O	1836-1844
for	O	1845-1848
estradiol	O	1849-1858
-	O	1858-1859
dependent	O	1859-1868
and	O	1869-1872
brain	O	1873-1878
region	O	1879-1885
-	O	1885-1886
specific	O	1886-1894
regulation	O	1895-1905
of	O	1906-1908
PRL	O	1909-1912
-	O	1912-1913
R	O	1910-1911
expression	O	1915-1925
and	O	1926-1929
signaling	O	1930-1939
responses	O	1940-1949
by	O	1950-1952
prolactin	O	1953-1962
.	O	1962-1963

Estrogen	O	0-8
prevents	O	9-17
cholesteryl	O	18-29
ester	O	30-35
accumulation	O	36-48
in	O	49-51
macrophages	O	52-63
induced	O	64-71
by	O	72-74
the	O	75-78
HIV	O	79-82
protease	O	83-91
inhibitor	O	92-101
ritonavir	O	102-111
.	O	111-112

Individuals	O	113-124
with	O	125-129
HIV	O	130-133
can	O	134-137
now	O	138-141
live	O	142-146
long	O	147-151
lives	O	152-157
with	O	158-162
drug	O	163-167
therapy	O	168-175
that	O	176-180
often	O	181-186
includes	O	187-195
protease	O	196-204
inhibitors	O	205-215
such	O	216-220
as	O	221-223
ritonavir	O	224-233
.	O	233-234

Many	O	235-239
patients	O	240-248
,	O	248-249
however	O	250-257
,	O	257-258
develop	O	259-266
negative	O	267-275
long	O	276-280
-	O	280-281
term	O	281-285
side	O	286-290
effects	O	291-298
such	O	299-303
as	O	304-306
premature	B	307-316
atherosclerosis	I	317-332
.	O	332-333

We	O	334-336
have	O	337-341
previously	O	342-352
demonstrated	O	353-365
that	O	366-370
ritonavir	O	371-380
treatment	O	381-390
increases	O	391-400
atherosclerotic	B	401-416
lesion	I	417-423
formation	O	424-433
in	O	434-436
male	O	437-441
mice	O	442-446
to	O	447-449
a	O	450-451
greater	O	452-459
extent	O	460-466
than	O	467-471
in	O	472-474
female	O	475-481
mice	O	482-486
.	O	486-487

Furthermore	O	488-499
,	O	499-500
peripheral	O	501-511
blood	O	512-517
monocytes	O	518-527
isolated	O	528-536
from	O	537-541
ritonavir	O	542-551
-	O	551-552
treated	O	552-559
females	O	560-567
had	O	568-571
less	O	572-576
cholesteryl	O	577-588
ester	O	589-594
accumulation	O	595-607
.	O	607-608

In	O	609-611
the	O	612-615
present	O	616-623
study	O	624-629
,	O	629-630
we	O	631-633
have	O	634-638
investigated	O	639-651
the	O	652-655
molecular	O	656-665
mechanisms	O	666-676
by	O	677-679
which	O	680-685
female	O	686-692
hormones	O	693-701
influence	O	702-711
cholesterol	O	712-723
metabolism	O	724-734
in	O	735-737
macrophages	O	738-749
in	O	750-752
response	O	753-761
to	O	762-764
the	O	765-768
HIV	O	769-772
protease	O	773-781
inhibitor	O	782-791
ritonavir	O	792-801
.	O	801-802

We	O	803-805
have	O	806-810
utilized	O	811-819
the	O	820-823
human	O	824-829
monocyte	O	830-838
cell	O	839-843
line	O	844-848
,	O	848-849
THP	O	850-853
-	O	853-854
1	O	854-855
as	O	856-858
a	O	859-860
model	O	861-866
to	O	867-869
address	O	870-877
this	O	878-882
question	O	883-891
.	O	891-892

Briefly	O	893-900
,	O	900-901
cells	O	902-907
were	O	908-912
differentiated	O	913-927
for	O	928-931
72	O	932-934
h	O	935-936
with	O	937-941
100	O	942-945
nM	O	946-948
PMA	O	949-952
to	O	953-955
obtain	O	956-962
a	O	963-964
macrophage	O	965-975
-	O	975-976
like	O	976-980
phenotype	O	981-990
in	O	991-993
the	O	994-997
presence	O	998-1006
or	O	1007-1009
absence	O	1010-1017
of	O	1018-1020
1	O	1021-1022
nM	O	1023-1025
17beta	O	1026-1032
-	O	1032-1033
estradiol	O	1033-1042
(	O	1043-1044
E2	O	1044-1046
)	O	1046-1047
,	O	1047-1048
100	O	1049-1052
nM	O	1053-1055
progesterone	O	1056-1068
or	O	1069-1071
vehicle	O	1072-1079
(	O	1080-1081
0	O	1081-1082
.	O	1082-1083
01	O	1083-1085
%	O	1085-1086
ethanol	O	1087-1094
)	O	1094-1095
.	O	1095-1096

Cells	O	1097-1102
were	O	1103-1107
then	O	1108-1112
treated	O	1113-1120
with	O	1121-1125
30	O	1126-1128
ng	O	1129-1131
/	O	1131-1132
ml	O	1132-1134
ritonavir	O	1135-1144
or	O	1145-1147
vehicle	O	1148-1155
in	O	1156-1158
the	O	1159-1162
presence	O	1163-1171
of	O	1172-1174
aggregated	O	1175-1185
LDL	O	1186-1189
for	O	1190-1193
24	O	1194-1196
h	O	1197-1198
.	O	1198-1199

Cell	O	1200-1204
extracts	O	1205-1213
were	O	1214-1218
harvested	O	1219-1228
,	O	1228-1229
and	O	1230-1233
lipid	O	1234-1239
or	O	1240-1242
total	O	1243-1248
RNA	O	1249-1252
was	O	1253-1256
isolated	O	1257-1265
.	O	1265-1266

E2	O	1267-1269
decreased	O	1270-1279
the	O	1280-1283
accumulation	O	1284-1296
of	O	1297-1299
cholesteryl	O	1300-1311
esters	O	1312-1318
in	O	1319-1321
macrophages	O	1322-1333
following	O	1334-1343
ritonavir	O	1344-1353
treatment	O	1354-1363
.	O	1363-1364

Ritonavir	O	1365-1374
increased	O	1375-1384
the	O	1385-1388
expression	O	1389-1399
of	O	1400-1402
the	O	1403-1406
scavenger	O	1407-1416
receptor	O	1417-1425
,	O	1425-1426
CD36	O	1427-1431
mRNA	O	1432-1436
,	O	1436-1437
responsible	O	1438-1449
for	O	1450-1453
the	O	1454-1457
uptake	O	1458-1464
of	O	1465-1467
LDL	O	1468-1471
.	O	1471-1472

Additionally	O	1473-1485
,	O	1485-1486
ritonavir	O	1487-1496
treatment	O	1497-1506
selectively	O	1507-1518
increased	O	1519-1528
the	O	1529-1532
relative	O	1533-1541
levels	O	1542-1548
of	O	1549-1551
PPARgamma	O	1552-1561
mRNA	O	1562-1566
,	O	1566-1567
a	O	1568-1569
transcription	O	1570-1583
factor	O	1584-1590
responsible	O	1591-1602
for	O	1603-1606
the	O	1607-1610
regulation	O	1611-1621
of	O	1622-1624
CD36	O	1625-1629
mRNA	O	1630-1634
expression	O	1635-1645
.	O	1645-1646

Treatment	O	1647-1656
with	O	1657-1661
E2	O	1662-1664
,	O	1664-1665
however	O	1666-1673
,	O	1673-1674
failed	O	1675-1681
to	O	1682-1684
prevent	O	1685-1692
these	O	1693-1698
increases	O	1699-1708
at	O	1709-1711
the	O	1712-1715
mRNA	O	1716-1720
level	O	1721-1726
.	O	1726-1727

E2	O	1728-1730
did	O	1731-1734
,	O	1734-1735
however	O	1736-1743
,	O	1743-1744
significantly	O	1745-1758
suppress	O	1759-1767
CD36	O	1768-1772
protein	O	1773-1780
levels	O	1781-1787
as	O	1788-1790
measured	O	1791-1799
by	O	1800-1802
fluorescent	O	1803-1814
immunocytochemistry	O	1815-1834
.	O	1834-1835

This	O	1836-1840
data	O	1841-1845
suggests	O	1846-1854
that	O	1855-1859
E2	O	1860-1862
modifies	O	1863-1871
the	O	1872-1875
expression	O	1876-1886
of	O	1887-1889
CD36	O	1890-1894
at	O	1895-1897
the	O	1898-1901
level	O	1902-1907
of	O	1908-1910
protein	O	1911-1918
expression	O	1919-1929
in	O	1930-1932
monocyte	O	1933-1941
-	O	1941-1942
derived	O	1942-1949
macrophages	O	1950-1961
resulting	O	1962-1971
in	O	1972-1974
reduced	O	1975-1982
cholesteryl	O	1983-1994
ester	O	1995-2000
accumulation	O	2001-2013
following	O	2014-2023
ritonavir	O	2024-2033
treatment	O	2034-2043
.	O	2043-2044

Upregulation	O	0-12
of	O	13-15
brain	O	16-21
expression	O	22-32
of	O	33-35
P	O	36-37
-	O	37-38
glycoprotein	O	38-50
in	O	51-53
MRP2	O	54-58
-	O	58-59
deficient	O	59-68
TR	O	69-71
(	O	71-72
-	O	72-73
)	O	73-74
rats	O	75-79
resembles	O	80-89
seizure	B	90-97
-	O	97-98
induced	O	98-105
up	O	106-108
-	O	108-109
regulation	O	109-119
of	O	120-122
this	O	123-127
drug	O	128-132
efflux	O	133-139
transporter	O	140-151
in	O	152-154
normal	O	155-161
rats	O	162-166
.	O	166-167

PURPOSE	O	168-175
:	O	175-176
The	O	177-180
multidrug	O	181-190
resistance	O	191-201
protein	O	202-209
2	O	210-211
(	O	212-213
MRP2	O	213-217
)	O	217-218
is	O	219-221
a	O	222-223
drug	O	224-228
efflux	O	229-235
transporter	O	236-247
that	O	248-252
is	O	253-255
expressed	O	256-265
predominantly	O	266-279
at	O	280-282
the	O	283-286
apical	O	287-293
domain	O	294-300
of	O	301-303
hepatocytes	O	304-315
but	O	316-319
seems	O	320-325
also	O	326-330
to	O	331-333
be	O	334-336
expressed	O	337-346
at	O	347-349
the	O	350-353
apical	O	354-360
membrane	O	361-369
of	O	370-372
brain	O	373-378
capillary	O	379-388
endothelial	O	389-400
cells	O	401-406
that	O	407-411
form	O	412-416
the	O	417-420
blood	O	421-426
-	O	426-427
brain	O	427-432
barrier	O	433-440
(	O	441-442
BBB	O	442-445
)	O	445-446
.	O	446-447

MRP2	O	448-452
is	O	453-455
absent	O	456-462
in	O	463-465
the	O	466-469
transport	O	470-479
-	O	479-480
deficient	O	480-489
(	O	490-491
TR	O	491-493
(	O	490-491
-	O	494-495
)	O	495-496
)	O	495-496
Wistar	O	498-504
rat	O	505-508
mutant	O	509-515
,	O	515-516
so	O	517-519
that	O	520-524
this	O	525-529
rat	O	530-533
strain	O	534-540
was	O	541-544
very	O	545-549
helpful	O	550-557
in	O	558-560
defining	O	561-569
substrates	O	570-580
of	O	581-583
MRP2	O	584-588
by	O	589-591
comparing	O	592-601
tissue	O	602-608
concentrations	O	609-623
or	O	624-626
functional	O	627-637
activities	O	638-648
of	O	649-651
compounds	O	652-661
in	O	662-664
MRP2	O	665-669
-	O	669-670
deficient	O	670-679
rats	O	680-684
with	O	685-689
those	O	690-695
in	O	696-698
transport	O	699-708
-	O	708-709
competent	O	709-718
Wistar	O	719-725
rats	O	726-730
.	O	730-731

By	O	732-734
using	O	735-740
this	O	741-745
strategy	O	746-754
to	O	755-757
study	O	758-763
the	O	764-767
involvement	O	768-779
of	O	780-782
MRP2	O	783-787
in	O	788-790
brain	O	791-796
access	O	797-803
of	O	804-806
antiepileptic	O	807-820
drugs	O	821-826
(	O	827-828
AEDs	O	828-832
)	O	832-833
,	O	833-834
we	O	835-837
recently	O	838-846
reported	O	847-855
that	O	856-860
phenytoin	O	861-870
is	O	871-873
a	O	874-875
substrate	O	876-885
for	O	886-889
MRP2	O	890-894
in	O	895-897
the	O	898-901
BBB	O	902-905
.	O	905-906

However	O	907-914
,	O	914-915
one	O	916-919
drawback	O	920-928
of	O	929-931
such	O	932-936
studies	O	937-944
in	O	945-947
genetically	O	948-959
deficient	O	960-969
rats	O	970-974
is	O	975-977
the	O	978-981
fact	O	982-986
that	O	987-991
compensatory	O	992-1004
changes	O	1005-1012
with	O	1013-1017
upregulation	O	1018-1030
of	O	1031-1033
other	O	1034-1039
transporters	O	1040-1052
can	O	1053-1056
occur	O	1057-1062
.	O	1062-1063

This	O	1064-1068
prompted	O	1069-1077
us	O	1078-1080
to	O	1081-1083
study	O	1084-1089
the	O	1090-1093
brain	O	1094-1099
expression	O	1100-1110
of	O	1111-1113
P	O	1114-1115
-	O	1115-1116
glycoprotein	O	1116-1128
(	O	1129-1130
Pgp	O	1130-1133
)	O	1133-1134
,	O	1134-1135
a	O	1136-1137
major	O	1138-1143
drug	O	1144-1148
efflux	O	1149-1155
transporter	O	1156-1167
in	O	1168-1170
many	O	1171-1175
tissues	O	1176-1183
,	O	1183-1184
including	O	1185-1194
the	O	1195-1198
BBB	O	1199-1202
,	O	1202-1203
in	O	1204-1206
TR	O	1207-1209
(	O	1209-1210
-	O	1210-1211
)	O	1211-1212
rats	O	1213-1217
compared	O	1218-1226
with	O	1227-1231
nonmutant	O	1232-1241
(	O	1242-1243
wild	O	1243-1247
-	O	1247-1248
type	O	1248-1252
)	O	1252-1253
Wistar	O	1254-1260
rats	O	1261-1265
.	O	1265-1266

METHODS	O	1267-1274
:	O	1274-1275
The	O	1276-1279
expression	O	1280-1290
of	O	1291-1293
MRP2	O	1294-1298
and	O	1299-1302
Pgp	O	1303-1306
in	O	1307-1309
brain	O	1310-1315
and	O	1316-1319
liver	O	1320-1325
sections	O	1326-1334
of	O	1335-1337
TR	O	1338-1340
(	O	1340-1341
-	O	1341-1342
)	O	1342-1343
rats	O	1344-1348
and	O	1349-1352
normal	O	1353-1359
Wistar	O	1360-1366
rats	O	1367-1371
was	O	1372-1375
determined	O	1376-1386
with	O	1387-1391
immunohistochemistry	O	1392-1412
,	O	1412-1413
by	O	1414-1416
using	O	1417-1422
a	O	1423-1424
novel	O	1425-1430
,	O	1430-1431
highly	O	1432-1438
selective	O	1439-1448
monoclonal	O	1449-1459
MRP2	O	1460-1464
antibody	O	1465-1473
and	O	1474-1477
the	O	1478-1481
monoclonal	O	1482-1492
Pgp	O	1493-1496
antibody	O	1497-1505
C219	O	1506-1510
,	O	1510-1511
respectively	O	1512-1524
.	O	1524-1525

RESULTS	O	1526-1533
:	O	1533-1534
Immunofluorescence	O	1535-1553
staining	O	1554-1562
with	O	1563-1567
the	O	1568-1571
MRP2	O	1572-1576
antibody	O	1577-1585
was	O	1586-1589
found	O	1590-1595
to	O	1596-1598
label	O	1599-1604
a	O	1605-1606
high	O	1607-1611
number	O	1612-1618
of	O	1619-1621
microvessels	O	1622-1634
throughout	O	1635-1645
the	O	1646-1649
brain	O	1650-1655
in	O	1656-1658
normal	O	1659-1665
Wistar	O	1666-1672
rats	O	1673-1677
,	O	1677-1678
whereas	O	1679-1686
such	O	1687-1691
labeling	O	1692-1700
was	O	1701-1704
absent	O	1705-1711
in	O	1712-1714
TR	O	1715-1717
(	O	1717-1718
-	O	1718-1719
)	O	1719-1720
rats	O	1721-1725
.	O	1725-1726

TR	O	1727-1729
(	O	1729-1730
-	O	1730-1731
)	O	1731-1732
rats	O	1733-1737
exhibited	O	1738-1747
a	O	1748-1749
significant	O	1750-1761
up	O	1762-1764
-	O	1764-1765
regulation	O	1765-1775
of	O	1776-1778
Pgp	O	1779-1782
in	O	1783-1785
brain	O	1786-1791
capillary	O	1792-1801
endothelial	O	1802-1813
cells	O	1814-1819
compared	O	1820-1828
with	O	1829-1833
wild	O	1834-1838
-	O	1838-1839
type	O	1839-1843
controls	O	1844-1852
.	O	1852-1853

No	O	1854-1856
such	O	1857-1861
obvious	O	1862-1869
upregulation	O	1870-1882
of	O	1883-1885
Pgp	O	1886-1889
was	O	1890-1893
observed	O	1894-1902
in	O	1903-1905
liver	O	1906-1911
sections	O	1912-1920
.	O	1920-1921

A	O	1922-1923
comparable	O	1924-1934
overexpression	O	1935-1949
of	O	1950-1952
Pgp	O	1953-1956
in	O	1957-1959
the	O	1960-1963
BBB	O	1964-1967
was	O	1968-1971
obtained	O	1972-1980
after	O	1981-1986
pilocarpine	O	1987-1998
-	O	1998-1999
induced	O	1999-2006
seizures	B	2007-2015
in	O	2016-2018
wild	O	2019-2023
-	O	2023-2024
type	O	2024-2028
Wistar	O	2029-2035
rats	O	2036-2040
.	O	2040-2041

Experiments	O	2042-2053
with	O	2054-2058
systemic	O	2059-2067
administration	O	2068-2082
of	O	2083-2085
the	O	2086-2089
Pgp	O	2090-2093
substrate	O	2094-2103
phenobarbital	O	2104-2117
and	O	2118-2121
the	O	2122-2125
selective	O	2126-2135
Pgp	O	2136-2139
inhibitor	O	2140-2149
tariquidar	O	2150-2160
in	O	2161-2163
TR	O	2164-2166
(	O	2166-2167
-	O	2167-2168
)	O	2168-2169
rats	O	2170-2174
substantiated	O	2175-2188
that	O	2189-2193
Pgp	O	2194-2197
is	O	2198-2200
functional	O	2201-2211
and	O	2212-2215
compensates	O	2216-2227
for	O	2228-2231
the	O	2232-2235
lack	O	2236-2240
of	O	2241-2243
MRP2	O	2244-2248
in	O	2249-2251
the	O	2252-2255
BBB	O	2256-2259
.	O	2259-2260

CONCLUSIONS	O	2261-2272
:	O	2272-2273
The	O	2274-2277
data	O	2278-2282
on	O	2283-2285
TR	O	2286-2288
(	O	2288-2289
-	O	2289-2290
)	O	2290-2291
rats	O	2292-2296
indicate	O	2297-2305
that	O	2306-2310
Pgp	O	2311-2314
plays	O	2315-2320
an	O	2321-2323
important	O	2324-2333
role	O	2334-2338
in	O	2339-2341
the	O	2342-2345
compensation	O	2346-2358
of	O	2359-2361
MRP2	O	2362-2366
deficiency	O	2367-2377
in	O	2378-2380
the	O	2381-2384
BBB	O	2385-2388
.	O	2388-2389

Because	O	2390-2397
such	O	2398-2402
a	O	2403-2404
compensatory	O	2405-2417
mechanism	O	2418-2427
most	O	2428-2432
likely	O	2433-2439
occurs	O	2440-2446
to	O	2447-2449
reduce	O	2450-2456
injury	B	2457-2463
to	I	2464-2466
the	I	2467-2470
brain	I	2471-2476
from	O	2477-2481
cytotoxic	O	2482-2491
compounds	O	2492-2501
,	O	2501-2502
the	O	2503-2506
present	O	2507-2514
data	O	2515-2519
substantiate	O	2520-2532
the	O	2533-2536
concept	O	2537-2544
that	O	2545-2549
MRP2	O	2550-2554
performs	O	2555-2563
a	O	2564-2565
protective	O	2566-2576
role	O	2577-2581
in	O	2582-2584
the	O	2585-2588
BBB	O	2589-2592
.	O	2592-2593

Furthermore	O	2594-2605
,	O	2605-2606
our	O	2607-2610
data	O	2611-2615
suggest	O	2616-2623
that	O	2624-2628
TR	O	2629-2631
(	O	2631-2632
-	O	2632-2633
)	O	2633-2634
rats	O	2635-2639
are	O	2640-2643
an	O	2644-2646
interesting	O	2647-2658
tool	O	2659-2663
to	O	2664-2666
study	O	2667-2672
consequences	O	2673-2685
of	O	2686-2688
overexpression	O	2689-2703
of	O	2704-2706
Pgp	O	2707-2710
in	O	2711-2713
the	O	2714-2717
BBB	O	2718-2721
on	O	2722-2724
access	O	2725-2731
of	O	2732-2734
drugs	O	2735-2740
in	O	2741-2743
the	O	2744-2747
brain	O	2748-2753
,	O	2753-2754
without	O	2755-2762
the	O	2763-2766
need	O	2767-2771
of	O	2772-2774
inducing	O	2775-2783
seizures	B	2784-2792
or	O	2793-2795
other	O	2796-2801
Pgp	O	2802-2805
-	O	2805-2806
enhancing	O	2806-2815
events	O	2816-2822
for	O	2823-2826
this	O	2827-2831
purpose	O	2832-2839
.	O	2839-2840

Use	O	0-3
of	O	4-6
chromosome	O	7-17
substitution	O	18-30
strains	O	31-38
to	O	39-41
identify	O	42-50
seizure	B	51-58
susceptibility	O	59-73
loci	O	74-78
in	O	79-81
mice	O	82-86
.	O	86-87

Seizure	B	88-95
susceptibility	O	96-110
varies	O	111-117
among	O	118-123
inbred	O	124-130
mouse	O	131-136
strains	O	137-144
.	O	144-145

Chromosome	O	146-156
substitution	O	157-169
strains	O	170-177
(	O	178-179
CSS	O	179-182
)	O	182-183
,	O	183-184
in	O	185-187
which	O	188-193
a	O	194-195
single	O	196-202
chromosome	O	203-213
from	O	214-218
one	O	219-222
inbred	O	223-229
strain	O	230-236
(	O	237-238
donor	O	238-243
)	O	243-244
has	O	245-248
been	O	249-253
transferred	O	254-265
onto	O	266-270
a	O	271-272
second	O	273-279
strain	O	280-286
(	O	287-288
host	O	288-292
)	O	292-293
by	O	294-296
repeated	O	297-305
backcrossing	O	306-318
,	O	318-319
may	O	320-323
be	O	324-326
used	O	327-331
to	O	332-334
identify	O	335-343
quantitative	O	344-356
trait	O	357-362
loci	O	363-367
(	O	368-369
QTLs	O	369-373
)	O	373-374
that	O	375-379
contribute	O	380-390
to	O	391-393
seizure	B	394-401
susceptibility	O	402-416
.	O	416-417

QTLs	O	418-422
for	O	423-426
susceptibility	O	427-441
to	O	442-444
pilocarpine	O	445-456
-	O	456-457
induced	O	457-464
seizures	B	465-473
,	O	473-474
a	O	475-476
model	O	477-482
of	O	483-485
temporal	B	486-494
lobe	I	495-499
epilepsy	I	500-508
,	O	508-509
have	O	510-514
not	O	515-518
been	O	519-523
reported	O	524-532
,	O	532-533
and	O	534-537
CSS	O	538-541
have	O	542-546
not	O	547-550
previously	O	551-561
been	O	562-566
used	O	567-571
to	O	572-574
localize	O	575-583
seizure	B	584-591
susceptibility	O	592-606
genes	O	607-612
.	O	612-613

We	O	614-616
report	O	617-623
QTLs	O	624-628
identified	O	629-639
using	O	640-645
a	O	646-647
B6	O	648-650
(	O	651-652
host	O	652-656
)	O	656-657
x	O	658-659
A	O	660-661
/	O	661-662
J	O	662-663
(	O	664-665
donor	O	665-670
)	O	670-671
CSS	O	672-675
panel	O	676-681
to	O	682-684
localize	O	685-693
genes	O	694-699
involved	O	700-708
in	O	709-711
susceptibility	O	712-726
to	O	727-729
pilocarpine	O	730-741
-	O	741-742
induced	O	742-749
seizures	B	750-758
.	O	758-759

Three	O	760-765
hundred	O	766-773
fifty	O	774-779
-	O	779-780
five	O	780-784
adult	O	785-790
male	O	791-795
CSS	O	796-799
mice	O	800-804
,	O	804-805
58	O	806-808
B6	O	809-811
,	O	811-812
and	O	813-816
39	O	817-819
A	O	820-821
/	O	821-822
J	O	822-823
were	O	824-828
tested	O	829-835
for	O	836-839
susceptibility	O	840-854
to	O	855-857
pilocarpine	O	858-869
-	O	869-870
induced	O	870-877
seizures	B	878-886
.	O	886-887

Highest	O	888-895
stage	O	896-901
reached	O	902-909
and	O	910-913
latency	O	914-921
to	O	922-924
each	O	925-929
stage	O	930-935
were	O	936-940
recorded	O	941-949
for	O	950-953
all	O	954-957
mice	O	958-962
.	O	962-963

B6	O	964-966
mice	O	967-971
were	O	972-976
resistant	O	977-986
to	O	987-989
seizures	B	990-998
and	O	999-1002
slower	O	1003-1009
to	O	1010-1012
reach	O	1013-1018
stages	O	1019-1025
compared	O	1026-1034
to	O	1035-1037
A	O	1038-1039
/	O	1039-1040
J	O	1040-1041
mice	O	1042-1046
.	O	1046-1047

The	O	1048-1051
CSS	O	1052-1055
for	O	1056-1059
Chromosomes	O	1060-1071
10	O	1072-1074
and	O	1075-1078
18	O	1079-1081
progressed	O	1082-1092
to	O	1093-1095
the	O	1096-1099
most	O	1100-1104
severe	O	1105-1111
stages	O	1112-1118
,	O	1118-1119
diverging	O	1120-1129
dramatically	O	1130-1142
from	O	1143-1147
the	O	1148-1151
B6	O	1152-1154
phenotype	O	1155-1164
.	O	1164-1165

Latencies	O	1166-1175
to	O	1176-1178
stages	O	1179-1185
were	O	1186-1190
also	O	1191-1195
significantly	O	1196-1209
shorter	O	1210-1217
for	O	1218-1221
CSS10	O	1222-1227
and	O	1228-1231
CSS18	O	1232-1237
mice	O	1238-1242
.	O	1242-1243

CSS	O	1244-1247
mapping	O	1248-1255
suggests	O	1256-1264
seizure	B	1265-1272
susceptibility	O	1273-1287
loci	O	1288-1292
on	O	1293-1295
mouse	O	1296-1301
Chromosomes	O	1302-1313
10	O	1314-1316
and	O	1317-1320
18	O	1321-1323
.	O	1323-1324

This	O	1325-1329
approach	O	1330-1338
provides	O	1339-1347
a	O	1348-1349
framework	O	1350-1359
for	O	1360-1363
identifying	O	1364-1375
potentially	O	1376-1387
novel	O	1388-1393
homologous	O	1394-1404
candidate	O	1405-1414
genes	O	1415-1420
for	O	1421-1424
human	O	1425-1430
temporal	B	1431-1439
lobe	I	1440-1444
epilepsy	I	1445-1453
.	O	1453-1454

Investigation	O	0-13
of	O	14-16
mitochondrial	O	17-30
involvement	O	31-42
in	O	43-45
the	O	46-49
experimental	O	50-62
model	O	63-68
of	O	69-71
epilepsy	B	72-80
induced	O	81-88
by	O	89-91
pilocarpine	O	92-103
.	O	103-104

Mitochondrial	B	105-118
abnormalities	I	119-132
have	O	133-137
been	O	138-142
associated	O	143-153
with	O	154-158
several	O	159-166
aspects	O	167-174
of	O	175-177
epileptogenesis	O	178-193
,	O	193-194
such	O	195-199
as	O	200-202
energy	O	203-209
generation	O	210-220
,	O	220-221
control	O	222-229
of	O	230-232
cell	O	233-237
death	B	238-243
,	O	243-244
neurotransmitter	O	245-261
synthesis	O	262-271
,	O	271-272
and	O	273-276
free	O	277-281
radical	O	282-289
(	O	290-291
FR	O	291-293
)	O	293-294
production	O	295-305
.	O	305-306

Increased	O	307-316
production	O	317-327
of	O	328-330
FRs	O	331-334
may	O	335-338
cause	O	339-344
mtDNA	O	345-350
damage	O	351-357
leading	O	358-365
to	O	366-368
decreased	O	369-378
activities	O	379-389
of	O	390-392
oxidative	O	393-402
phosphorylation	O	403-418
complexes	O	419-428
containing	O	429-439
mtDNA	O	440-445
-	O	445-446
encoded	O	446-453
subunits	O	454-462
.	O	462-463

In	O	464-466
this	O	467-471
study	O	472-477
,	O	477-478
we	O	479-481
investigated	O	482-494
whether	O	495-502
increased	O	503-512
generation	O	513-523
of	O	524-526
FR	O	527-529
during	O	530-536
status	B	537-543
epilepticus	I	544-555
would	O	556-561
be	O	562-564
sufficient	O	565-575
to	O	576-578
provoke	O	579-586
abnormalities	O	587-600
in	O	601-603
mtDNA	O	604-609
and	O	610-613
in	O	614-616
the	O	617-620
expression	O	621-631
and	O	632-635
activity	O	636-644
of	O	645-647
cytochrome	O	648-658
c	O	659-660
oxidase	O	661-668
(	O	669-670
CCO	O	670-673
)	O	673-674
,	O	674-675
complex	O	676-683
IV	O	684-686
of	O	687-689
the	O	690-693
respiratory	O	694-705
chain	O	706-711
,	O	711-712
in	O	713-715
the	O	716-719
chronic	O	720-727
phase	O	728-733
of	O	734-736
the	O	737-740
pilocarpine	O	741-752
model	O	753-758
of	O	759-761
temporal	B	762-770
lobe	I	771-775
epilepsy	I	776-784
.	O	784-785

DNA	O	786-789
analysis	O	790-798
revealed	O	799-807
low	O	808-811
amounts	O	812-819
of	O	820-822
a	O	823-824
4	O	825-826
.	O	826-827
8	O	827-828
kb	O	829-831
mtDNA	O	832-837
deletion	O	838-846
but	O	847-850
with	O	851-855
no	O	856-858
differences	O	859-870
in	O	871-873
frequency	O	874-883
or	O	884-886
quantity	O	887-895
in	O	896-898
the	O	899-902
control	O	903-910
and	O	911-914
experimental	O	915-927
groups	O	928-934
.	O	934-935

We	O	936-938
did	O	939-942
not	O	943-946
find	O	947-951
abnormalities	O	952-965
in	O	966-968
the	O	969-972
expression	O	973-983
and	O	984-987
distribution	O	988-1000
of	O	1001-1003
an	O	1004-1006
mtDNA	O	1007-1012
-	O	1012-1013
encoded	O	1013-1020
subunit	O	1021-1028
of	O	1029-1031
CCO	O	1032-1035
(	O	1036-1037
CCO	O	1037-1040
-	O	1040-1041
I	O	1041-1042
)	O	1042-1043
or	O	1044-1046
a	O	1047-1048
relative	O	1049-1057
decrease	O	1058-1066
in	O	1067-1069
CCO	O	1070-1073
-	O	1073-1074
I	O	1074-1075
when	O	1076-1080
compared	O	1081-1089
with	O	1090-1094
nuclear	O	1095-1102
-	O	1102-1103
encoded	O	1103-1110
subunits	O	1111-1119
(	O	1120-1121
CCO	O	1121-1124
-	O	1124-1125
IV	O	1125-1127
and	O	1128-1131
SDH	O	1132-1135
-	O	1135-1136
fp	O	1136-1138
)	O	1138-1139
.	O	1139-1140

No	O	1141-1143
abnormality	O	1144-1155
in	O	1156-1158
CCO	O	1159-1162
activity	O	1163-1171
was	O	1172-1175
observed	O	1176-1184
through	O	1185-1192
histochemistry	O	1193-1207
.	O	1207-1208

Although	O	1209-1217
evidences	O	1218-1227
of	O	1228-1230
mitochondrial	B	1231-1244
abnormalities	I	1245-1258
were	O	1259-1263
found	O	1264-1269
in	O	1270-1272
previously	O	1273-1283
published	O	1284-1293
studies	O	1294-1301
,	O	1301-1302
our	O	1303-1306
results	O	1307-1314
do	O	1315-1317
not	O	1318-1321
suggest	O	1322-1329
that	O	1330-1334
the	O	1335-1338
FRs	O	1339-1342
,	O	1342-1343
generated	O	1344-1353
during	O	1354-1360
the	O	1361-1364
acute	O	1365-1370
phase	O	1371-1376
,	O	1376-1377
determined	O	1378-1388
important	O	1389-1398
abnormalities	O	1399-1412
in	O	1413-1415
mtDNA	O	1416-1421
,	O	1421-1422
in	O	1423-1425
expression	O	1426-1436
of	O	1437-1439
CCO	O	1440-1443
-	O	1443-1444
I	O	1444-1445
,	O	1445-1446
and	O	1447-1450
in	O	1451-1453
CCO	O	1454-1457
activity	O	1458-1466
.	O	1466-1467

Causes	O	0-6
of	O	7-9
acute	O	10-15
thrombotic	B	16-26
microangiopathy	I	27-42
in	O	43-45
patients	O	46-54
receiving	O	55-64
kidney	O	65-71
transplantation	O	72-87
.	O	87-88

OBJECTIVES	O	89-99
:	O	99-100
Thrombotic	B	101-111
microangiopathy	I	112-127
is	O	128-130
a	O	131-132
well	O	133-137
-	O	137-138
known	O	138-143
problem	O	144-151
in	O	152-154
patients	O	155-163
following	O	164-173
renal	O	174-179
transplantation	O	180-195
.	O	195-196

In	O	197-199
postrenal	O	200-209
transplantation	O	210-225
,	O	225-226
thrombotic	B	227-237
microangiopathy	I	238-253
is	O	254-256
often	O	257-262
a	O	263-264
reflection	O	265-275
of	O	276-278
hemolytic	B	279-288
uremic	I	289-295
syndrome	I	296-304
.	O	304-305

We	O	306-308
aimed	O	309-314
to	O	315-317
determine	O	318-327
the	O	328-331
causes	O	332-338
of	O	339-341
thrombotic	B	342-352
microangiopathy	I	353-368
in	O	369-371
a	O	372-373
population	O	374-384
of	O	385-387
renal	O	388-393
transplantation	O	394-409
recipients	O	410-420
and	O	421-424
discuss	O	425-432
the	O	433-436
literature	O	437-447
.	O	447-448

MATERIALS	O	449-458
AND	O	459-462
METHODS	O	463-470
:	O	470-471
We	O	472-474
investigated	O	475-487
the	O	488-491
causes	O	492-498
of	O	499-501
thrombotic	B	502-512
microangiopathy	I	513-528
during	O	529-535
a	O	536-537
1	O	538-539
-	O	539-540
year	O	540-544
period	O	545-551
,	O	551-552
from	O	553-557
June	O	558-562
2003	O	563-567
to	O	568-570
June	O	571-575
2004	O	576-580
,	O	580-581
at	O	582-584
the	O	585-588
King	O	589-593
Fahad	O	594-599
National	O	600-608
Guard	O	609-614
Hospital	O	615-623
in	O	624-626
Riyadh	O	627-633
,	O	633-634
Saudi	O	635-640
Arabia	O	641-647
,	O	647-648
by	O	649-651
reviewing	O	652-661
the	O	662-665
slides	O	666-672
of	O	673-675
all	O	676-679
transplant	O	680-690
biopsies	O	691-699
(	O	700-701
n	O	701-702
=	O	702-703
25	O	703-705
)	O	705-706
performed	O	707-716
during	O	717-723
this	O	724-728
interval	O	729-737
.	O	737-738

Pre	O	739-742
-	O	742-743
and	O	744-747
posttransplant	O	748-762
crossmatching	O	763-776
was	O	777-780
done	O	781-785
when	O	786-790
possible	O	791-799
.	O	799-800

RESULTS	O	801-808
:	O	808-809
Five	O	810-814
cases	O	815-820
of	O	821-823
thrombotic	B	824-834
microangiopathy	I	835-850
were	O	851-855
found	O	856-861
.	O	861-862

Three	O	863-868
of	O	869-871
these	O	872-877
cases	O	878-883
were	O	884-888
from	O	889-893
the	O	894-897
25	O	898-900
transplantations	O	901-917
performed	O	918-927
at	O	928-930
King	O	931-935
Fahad	O	936-941
National	O	942-950
Guard	O	951-956
Hospital	O	957-965
,	O	965-966
while	O	967-972
the	O	973-976
other	O	977-982
2	O	983-984
transplantations	O	985-1001
had	O	1002-1005
been	O	1006-1010
performed	O	1011-1020
abroad	O	1021-1027
and	O	1028-1031
were	O	1032-1036
referred	O	1037-1045
to	O	1046-1048
us	O	1049-1051
for	O	1052-1055
follow	O	1056-1062
-	O	1062-1063
up	O	1063-1065
.	O	1065-1066

Three	O	1067-1072
cases	O	1073-1078
were	O	1079-1083
related	O	1084-1091
to	O	1092-1094
cyclosporine	O	1095-1107
,	O	1107-1108
and	O	1109-1112
1	O	1113-1114
case	O	1115-1119
was	O	1120-1123
secondary	O	1124-1133
to	O	1134-1136
both	O	1137-1141
cyclosporine	O	1142-1154
and	O	1155-1158
tacrolimus	O	1159-1169
.	O	1169-1170

The	O	1171-1174
fifth	O	1175-1180
case	O	1181-1185
had	O	1186-1189
features	O	1190-1198
of	O	1199-1201
thrombotic	B	1202-1212
microangiopathy	I	1213-1228
related	O	1229-1236
to	O	1237-1239
an	O	1240-1242
antiphospholipid	B	1243-1259
syndrome	I	1260-1268
in	O	1269-1271
a	O	1272-1273
patient	O	1274-1281
with	O	1282-1286
systemic	B	1287-1295
lupus	I	1296-1301
erythematosus	I	1302-1315
.	O	1315-1316

CONCLUSIONS	O	1317-1328
:	O	1328-1329
In	O	1330-1332
the	O	1333-1336
literature	O	1337-1347
,	O	1347-1348
the	O	1349-1352
most	O	1353-1357
-	O	1357-1358
frequent	O	1358-1366
cause	O	1367-1372
of	O	1373-1375
hemolytic	B	1376-1385
uremic	I	1386-1392
syndrome	I	1393-1401
in	O	1402-1404
patients	O	1405-1413
following	O	1414-1423
renal	O	1424-1429
transplantation	O	1430-1445
is	O	1446-1448
recurrence	O	1449-1459
of	O	1460-1462
the	O	1463-1466
hemolytic	B	1467-1476
uremic	I	1477-1483
syndrome	I	1484-1492
.	O	1492-1493

Other	O	1494-1499
causes	O	1500-1506
include	O	1507-1514
drug	O	1515-1519
-	O	1519-1520
related	O	1520-1527
(	O	1528-1529
cyclosporine	O	1529-1541
,	O	1541-1542
tacrolimus	O	1543-1553
)	O	1553-1554
toxicity	B	1555-1563
,	O	1563-1564
procoagulant	O	1565-1577
status	O	1578-1584
,	O	1584-1585
and	O	1586-1589
antibody	O	1590-1598
-	O	1598-1599
mediated	O	1599-1607
rejection	O	1608-1617
.	O	1617-1618

We	O	1619-1621
found	O	1622-1627
that	O	1628-1632
the	O	1633-1636
most	O	1637-1641
-	O	1641-1642
frequent	O	1642-1650
cause	O	1651-1656
of	O	1657-1659
thrombotic	B	1660-1670
microangiopathy	I	1671-1686
was	O	1687-1690
drug	O	1691-1695
related	O	1696-1703
,	O	1703-1704
secondary	O	1705-1714
mainly	O	1715-1721
to	O	1722-1724
cyclosporine	O	1725-1737
.	O	1737-1738

In	O	1739-1741
the	O	1742-1745
current	O	1746-1753
study	O	1754-1759
,	O	1759-1760
the	O	1761-1764
frequency	O	1765-1774
of	O	1775-1777
thrombotic	B	1778-1788
microangiopathy	I	1789-1804
was	O	1805-1808
similar	O	1809-1816
to	O	1817-1819
the	O	1820-1823
percentage	O	1824-1834
reported	O	1835-1843
in	O	1844-1846
the	O	1847-1850
literature	O	1851-1861
(	O	1862-1863
20	O	1863-1865
%	O	1865-1866
)	O	1866-1867
.	O	1867-1868

Severe	O	0-6
reversible	O	7-17
left	B	18-22
ventricular	I	23-34
systolic	I	35-43
and	I	44-47
diastolic	I	48-57
dysfunction	I	58-69
due	O	70-73
to	O	74-76
accidental	O	77-87
iatrogenic	O	88-98
epinephrine	O	99-110
overdose	B	111-119
.	O	119-120

Catecholamine	O	121-134
-	O	134-135
induced	O	135-142
cardiomyopathy	B	143-157
due	O	158-161
to	O	162-164
chronic	O	165-172
excess	O	173-179
of	O	180-182
endogenous	O	183-193
catecholamines	O	194-208
has	O	209-212
been	O	213-217
recognized	O	218-228
for	O	229-232
decades	O	233-240
as	O	241-243
a	O	244-245
clinical	O	246-254
phenomenon	O	255-265
.	O	265-266

In	O	267-269
contrast	O	270-278
,	O	278-279
reports	O	280-287
of	O	288-290
myocardial	B	291-301
dysfunction	I	302-313
due	O	314-317
to	O	318-320
acute	O	321-326
iatrogenic	O	327-337
overdose	B	338-346
are	O	347-350
rare	O	351-355
.	O	355-356

A	O	357-358
35	O	359-361
-	O	361-362
year	O	362-366
-	O	361-362
old	O	367-370
woman	O	371-376
whose	O	377-382
cervix	O	383-389
uteri	O	390-395
was	O	396-399
inadvertently	O	400-413
injected	O	414-422
with	O	423-427
8	O	428-429
mg	O	430-432
of	O	433-435
epinephrine	O	436-447
developed	O	448-457
myocardial	B	458-468
stunning	I	469-477
that	O	478-482
was	O	483-486
characterized	O	487-500
by	O	501-503
severe	O	504-510
hemodynamic	O	511-522
compromise	O	523-533
,	O	533-534
profound	O	535-543
,	O	543-544
albeit	O	545-551
transient	O	552-561
,	O	561-562
left	B	563-567
ventricular	I	568-579
systolic	I	580-588
and	I	589-592
diastolic	I	593-602
dysfunction	I	603-614
,	O	614-615
and	O	616-619
only	O	620-624
modestly	O	625-633
elevated	O	634-642
biochemical	O	643-654
markers	O	655-662
of	O	663-665
myocardial	B	666-676
necrosis	I	677-685
.	O	685-686

Our	O	687-690
case	O	691-695
illustrates	O	696-707
the	O	708-711
serious	O	712-719
consequences	O	720-732
of	O	733-735
medical	O	736-743
errors	O	744-750
that	O	751-755
can	O	756-759
be	O	760-762
avoided	O	763-770
through	O	771-778
improved	O	779-787
medication	O	788-798
labeling	O	799-807
and	O	808-811
staff	O	812-817
supervision	O	818-829
.	O	829-830

Urinary	B	0-7
bladder	I	8-15
cancer	I	16-22
in	O	23-25
Wegener	B	26-33
'	I	33-34
s	I	34-35
granulomatosis	I	36-50
:	O	50-51
risks	O	52-57
and	O	58-61
relation	O	62-70
to	O	71-73
cyclophosphamide	O	74-90
.	O	90-91

OBJECTIVE	O	92-101
:	O	101-102
To	O	103-105
assess	O	106-112
and	O	113-116
characterise	O	117-129
the	O	130-133
risk	O	134-138
of	O	139-141
bladder	B	142-149
cancer	I	150-156
,	O	156-157
and	O	158-161
its	O	162-165
relation	O	166-174
to	O	175-177
cyclophosphamide	O	178-194
,	O	194-195
in	O	196-198
patients	O	199-207
with	O	208-212
Wegener	B	213-220
'	I	220-221
s	I	221-222
granulomatosis	I	223-237
.	O	237-238

METHODS	O	239-246
:	O	246-247
In	O	248-250
the	O	251-254
population	O	255-265
based	O	266-271
,	O	271-272
nationwide	O	273-283
Swedish	O	284-291
Inpatient	O	292-301
Register	O	302-310
a	O	311-312
cohort	O	313-319
of	O	320-322
1065	O	323-327
patients	O	328-336
with	O	337-341
Wegener	B	342-349
'	I	349-350
s	I	350-351
granulomatosis	I	352-366
,	O	366-367
1969	O	368-372
-	O	372-373
95	O	373-375
,	O	375-376
was	O	377-380
identified	O	381-391
.	O	391-392

Through	O	393-400
linkage	O	401-408
with	O	409-413
the	O	414-417
Swedish	O	418-425
Cancer	B	426-432
Register	O	433-441
,	O	441-442
all	O	443-446
subjects	O	447-455
in	O	456-458
this	O	459-463
cohort	O	464-470
diagnosed	O	471-480
with	O	481-485
bladder	B	486-493
cancer	I	494-500
were	O	501-505
identified	O	506-516
.	O	516-517

Nested	O	518-524
within	O	525-531
the	O	532-535
cohort	O	536-542
,	O	542-543
a	O	544-545
matched	O	546-553
case	O	554-558
-	O	558-559
control	O	559-566
study	O	567-572
was	O	573-576
performed	O	577-586
to	O	587-589
estimate	O	590-598
the	O	599-602
association	O	603-614
between	O	615-622
cyclophosphamide	O	623-639
and	O	640-643
bladder	B	644-651
cancer	I	652-658
using	O	659-664
odds	O	665-669
ratios	O	670-676
(	O	677-678
ORs	O	678-681
)	O	681-682
as	O	683-685
relative	O	686-694
risk	O	695-699
.	O	699-700

In	O	701-703
the	O	704-707
cohort	O	708-714
the	O	715-718
cumulative	O	719-729
risk	O	730-734
of	O	735-737
bladder	B	738-745
cancer	I	746-752
after	O	753-758
Wegener	B	759-766
'	I	766-767
s	I	767-768
granulomatosis	I	769-783
,	O	783-784
and	O	785-788
the	O	789-792
relative	O	793-801
prevalence	O	802-812
of	O	813-815
a	O	816-817
history	O	818-825
of	O	826-828
bladder	B	829-836
cancer	I	837-843
at	O	844-846
the	O	847-850
time	O	851-855
of	O	856-858
diagnosis	O	859-868
of	O	869-871
Wegener	B	872-879
'	I	879-880
s	I	880-881
granulomatosis	I	882-896
,	O	896-897
were	O	898-902
also	O	903-907
estimated	O	908-917
.	O	917-918

RESULTS	O	919-926
:	O	926-927
The	O	928-931
median	O	932-938
cumulative	O	939-949
doses	O	950-955
of	O	956-958
cyclophosphamide	O	959-975
among	O	976-981
cases	O	982-987
(	O	988-989
n	O	989-990
=	O	991-992
11	O	993-995
)	O	995-996
and	O	997-1000
controls	O	1001-1009
(	O	1010-1011
n	O	1011-1012
=	O	1013-1014
25	O	1015-1017
)	O	1017-1018
were	O	1019-1023
113	O	1024-1027
g	O	1028-1029
and	O	1030-1033
25	O	1034-1036
g	O	1037-1038
,	O	1038-1039
respectively	O	1040-1052
.	O	1052-1053

The	O	1054-1057
risk	O	1058-1062
of	O	1063-1065
bladder	B	1066-1073
cancer	I	1074-1080
doubled	O	1081-1088
for	O	1089-1092
every	O	1093-1098
10	O	1099-1101
g	O	1102-1103
increment	O	1104-1113
in	O	1114-1116
cyclophosphamide	O	1117-1133
(	O	1134-1135
OR	O	1135-1137
=	O	1138-1139
2	O	1140-1141
.	O	1141-1142
0	O	1142-1143
,	O	1143-1144
95	O	1145-1147
%	O	1147-1148
confidence	O	1149-1159
interval	O	1160-1168
(	O	1169-1170
CI	O	1170-1172
)	O	1172-1173
0	O	1174-1175
.	O	1175-1176
8	O	1176-1177
to	O	1178-1180
4	O	1181-1182
.	O	1182-1183
9	O	1183-1184
)	O	1184-1185
.	O	1182-1183

Treatment	O	1187-1196
duration	O	1197-1205
longer	O	1206-1212
than	O	1213-1217
1	O	1218-1219
year	O	1220-1224
was	O	1225-1228
associated	O	1229-1239
with	O	1240-1244
an	O	1245-1247
eightfold	O	1248-1257
increased	O	1258-1267
risk	O	1268-1272
(	O	1273-1274
OR	O	1274-1276
=	O	1277-1278
7	O	1279-1280
.	O	1280-1281
7	O	1279-1280
,	O	1282-1283
95	O	1284-1286
%	O	1286-1287
CI	O	1288-1290
0	O	1291-1292
.	O	1292-1293
9	O	1293-1294
to	O	1295-1297
69	O	1298-1300
)	O	1300-1301
.	O	1301-1302

The	O	1303-1306
absolute	O	1307-1315
risk	O	1316-1320
for	O	1321-1324
bladder	B	1325-1332
cancer	I	1333-1339
in	O	1340-1342
the	O	1343-1346
cohort	O	1347-1353
reached	O	1354-1361
10	O	1362-1364
%	O	1364-1365
16	O	1366-1368
years	O	1369-1374
after	O	1375-1380
diagnosis	O	1381-1390
of	O	1391-1393
Wegener	B	1394-1401
'	I	1401-1402
s	I	1402-1403
granulomatosis	I	1404-1418
,	O	1418-1419
and	O	1420-1423
a	O	1424-1425
history	O	1426-1433
of	O	1434-1436
bladder	B	1437-1444
cancer	I	1445-1451
was	O	1452-1455
(	O	1456-1457
non	O	1457-1460
-	O	1460-1461
significantly	O	1461-1474
)	O	1474-1475
twice	O	1476-1481
as	O	1482-1484
common	O	1485-1491
as	O	1492-1494
expected	O	1495-1503
at	O	1504-1506
the	O	1507-1510
time	O	1511-1515
of	O	1516-1518
diagnosis	O	1519-1528
of	O	1529-1531
Wegener	B	1532-1539
'	I	1539-1540
s	I	1540-1541
granulomatosis	I	1542-1556
.	O	1556-1557

CONCLUSION	O	1558-1568
:	O	1568-1569
The	O	1570-1573
results	O	1574-1581
indicate	O	1582-1590
a	O	1591-1592
dose	O	1593-1597
-	O	1597-1598
response	O	1598-1606
relationship	O	1607-1619
between	O	1620-1627
cyclophosphamide	O	1628-1644
and	O	1645-1648
the	O	1649-1652
risk	O	1653-1657
of	O	1658-1660
bladder	B	1661-1668
cancer	I	1669-1675
,	O	1675-1676
high	O	1677-1681
cumulative	O	1682-1692
risks	O	1693-1698
in	O	1699-1701
the	O	1702-1705
entire	O	1706-1712
cohort	O	1713-1719
,	O	1719-1720
and	O	1721-1724
also	O	1725-1729
the	O	1730-1733
possibility	O	1734-1745
of	O	1746-1748
risk	O	1749-1753
factors	O	1754-1761
operating	O	1762-1771
even	O	1772-1776
before	O	1777-1783
Wegener	B	1784-1791
'	I	1791-1792
s	I	1792-1793
granulomatosis	I	1794-1808
.	O	1808-1809

L	O	0-1
-	O	1-2
arginine	O	2-10
transport	O	11-20
in	O	21-23
humans	O	24-30
with	O	31-35
cortisol	O	36-44
-	O	44-45
induced	O	45-52
hypertension	B	53-65
.	O	65-66

A	O	67-68
deficient	O	69-78
L	O	79-80
-	O	80-81
arginine	O	81-89
-	O	80-81
nitric	O	90-96
oxide	O	97-102
system	O	103-109
is	O	110-112
implicated	O	113-123
in	O	124-126
cortisol	O	127-135
-	O	135-136
induced	O	136-143
hypertension	B	144-156
.	O	156-157

We	O	158-160
investigate	O	161-172
whether	O	173-180
abnormalities	O	181-194
in	O	195-197
L	O	198-199
-	O	199-200
arginine	O	200-208
uptake	O	209-215
contribute	O	216-226
to	O	227-229
this	O	230-234
deficiency	O	235-245
.	O	245-246

Eight	O	247-252
healthy	O	253-260
men	O	261-264
were	O	265-269
recruited	O	270-279
.	O	279-280

Hydrocortisone	O	281-295
acetate	O	296-303
(	O	304-305
50	O	305-307
mg	O	308-310
)	O	310-311
was	O	312-315
given	O	316-321
orally	O	322-328
every	O	329-334
6	O	335-336
hours	O	337-342
for	O	343-346
24	O	347-349
hours	O	350-355
after	O	356-361
a	O	362-363
5	O	364-365
-	O	365-366
day	O	366-369
fixed	O	370-375
-	O	375-376
salt	O	376-380
diet	O	381-385
(	O	386-387
150	O	387-390
mmol	O	391-395
/	O	395-396
d	O	396-397
)	O	397-398
.	O	398-399

Crossover	O	400-409
studies	O	410-417
were	O	418-422
performed	O	423-432
2	O	433-434
weeks	O	435-440
apart	O	441-446
.	O	446-447

Thirty	O	448-454
milliliters	O	455-466
of	O	467-469
blood	O	470-475
was	O	476-479
obtained	O	480-488
for	O	489-492
isolation	O	493-502
of	O	503-505
peripheral	O	506-516
blood	O	517-522
mononuclear	O	523-534
cells	O	535-540
after	O	541-546
each	O	547-551
treatment	O	552-561
period	O	562-568
.	O	568-569

L	O	570-571
-	O	571-572
arginine	O	572-580
uptake	O	581-587
was	O	588-591
assessed	O	592-600
in	O	601-603
mononuclear	O	604-615
cells	O	616-621
incubated	O	622-631
with	O	632-636
L	O	637-638
-	O	638-639
arginine	O	639-647
(	O	648-649
1	O	649-650
to	O	651-653
300	O	654-657
micromol	O	658-666
/	O	666-667
L	O	667-668
)	O	668-669
,	O	669-670
incorporating	O	671-684
100	O	685-688
nmol	O	689-693
/	O	693-694
L	O	694-695
[	O	696-697
3H	O	697-699
]	O	699-700
-	O	700-701
l	O	701-702
-	O	700-701
arginine	O	703-711
for	O	712-715
a	O	716-717
period	O	718-724
of	O	725-727
5	O	728-729
minutes	O	730-737
at	O	738-740
37	O	741-743
degrees	O	744-751
C	O	752-753
.	O	753-754
Forearm	O	755-762
[	O	763-764
3H	O	764-766
]	O	766-767
-	O	767-768
L	O	768-769
-	O	767-768
arginine	O	770-778
extraction	O	779-789
was	O	790-793
calculated	O	794-804
after	O	805-810
infusion	O	811-819
of	O	820-822
[	O	823-824
3H	O	824-826
]	O	826-827
-	O	827-828
L	O	828-829
-	O	827-828
arginine	O	830-838
into	O	839-843
the	O	844-847
brachial	O	848-856
artery	O	857-863
at	O	864-866
a	O	867-868
rate	O	869-873
of	O	874-876
100	O	877-880
nCi	O	881-884
/	O	884-885
min	O	885-888
for	O	889-892
80	O	893-895
minutes	O	896-903
.	O	903-904

Deep	O	905-909
forearm	O	910-917
venous	O	918-924
samples	O	925-932
were	O	933-937
collected	O	938-947
for	O	948-951
determination	O	952-965
of	O	966-968
L	O	969-970
-	O	970-971
arginine	O	971-979
extraction	O	980-990
.	O	990-991

Plasma	O	992-998
cortisol	O	999-1007
concentrations	O	1008-1022
were	O	1023-1027
significantly	O	1028-1041
raised	O	1042-1048
during	O	1049-1055
the	O	1056-1059
active	O	1060-1066
phase	O	1067-1072
(	O	1073-1074
323	O	1074-1077
+	O	1077-1078
/	O	1078-1079
-	O	1079-1080
43	O	1080-1082
to	O	1083-1085
1082	O	1086-1090
+	O	1090-1091
/	O	1091-1092
-	O	1092-1093
245	O	1093-1096
mmol	O	1097-1101
/	O	1101-1102
L	O	1102-1103
,	O	1103-1104
P	O	1105-1106
<	O	1106-1107
0	O	1107-1108
.	O	1108-1109
05	O	1109-1111
)	O	1111-1112
.	O	1108-1109

Systolic	O	1114-1122
blood	O	1123-1128
pressure	O	1129-1137
was	O	1138-1141
elevated	O	1142-1150
by	O	1151-1153
an	O	1154-1156
average	O	1157-1164
of	O	1165-1167
7	O	1168-1169
mm	O	1170-1172
Hg	O	1173-1175
.	O	1175-1176

Neither	O	1177-1184
L	O	1185-1186
-	O	1186-1187
arginine	O	1187-1195
transport	O	1196-1205
into	O	1206-1210
mononuclear	O	1211-1222
cells	O	1223-1228
(	O	1229-1230
placebo	O	1230-1237
vs	O	1238-1240
active	O	1241-1247
,	O	1247-1248
26	O	1249-1251
.	O	1251-1252
3	O	1252-1253
+	O	1253-1254
/	O	1254-1255
-	O	1255-1256
3	O	1252-1253
.	O	1251-1252
6	O	1250-1251

vs	O	1260-1262
29	O	1263-1265
.	O	1265-1266
0	O	1266-1267
+	O	1267-1268
/	O	1268-1269
-	O	1269-1270
2	O	1263-1264
.	O	1265-1266
1	O	1272-1273
pmol	O	1274-1278
/	O	1278-1279
10	O	1279-1281
000	O	1282-1285
cells	O	1286-1291
per	O	1292-1295
5	O	1296-1297
minutes	O	1298-1305
,	O	1305-1306
respectively	O	1307-1319
,	O	1319-1320
at	O	1321-1323
an	O	1324-1326
l	O	1327-1328
-	O	1328-1329
arginine	O	1329-1337
concentration	O	1338-1351
of	O	1352-1354
300	O	1355-1358
micromol	O	1359-1367
/	O	1367-1368
L	O	1368-1369
)	O	1369-1370
nor	O	1371-1374
L	O	1375-1376
-	O	1376-1377
arginine	O	1377-1385
extraction	O	1386-1396
in	O	1397-1399
the	O	1400-1403
forearm	O	1404-1411
(	O	1412-1413
at	O	1413-1415
80	O	1416-1418
minutes	O	1419-1426
,	O	1426-1427
placebo	O	1428-1435
vs	O	1436-1438
active	O	1439-1445
,	O	1445-1446
1	O	1447-1448
868	O	1449-1452
904	O	1453-1456
+	O	1456-1457
/	O	1457-1458
-	O	1458-1459
434	O	1459-1462
962	O	1463-1466
vs	O	1467-1469
2	O	1470-1471
013	O	1472-1475
910	O	1476-1479
+	O	1479-1480
/	O	1480-1481
-	O	1481-1482
770	O	1482-1485
619	O	1486-1489
disintegrations	O	1490-1505
per	O	1506-1509
minute	O	1510-1516
)	O	1516-1517
was	O	1518-1521
affected	O	1522-1530
by	O	1531-1533
cortisol	O	1534-1542
treatment	O	1543-1552
;	O	1552-1553
ie	O	1554-1556
,	O	1556-1557
that	O	1558-1562
L	O	1563-1564
-	O	1564-1565
arginine	O	1565-1573
uptake	O	1574-1580
is	O	1581-1583
not	O	1584-1587
affected	O	1588-1596
by	O	1597-1599
short	O	1600-1605
-	O	1605-1606
term	O	1606-1610
cortisol	O	1611-1619
treatment	O	1620-1629
.	O	1629-1630

We	O	1631-1633
conclude	O	1634-1642
that	O	1643-1647
cortisol	O	1648-1656
-	O	1656-1657
induced	O	1657-1664
increases	B	1665-1674
in	I	1675-1677
blood	I	1678-1683
pressure	I	1684-1692
are	O	1693-1696
not	O	1697-1700
associated	O	1701-1711
with	O	1712-1716
abnormalities	O	1717-1730
in	O	1731-1733
the	O	1734-1737
l	O	1738-1739
-	O	1739-1740
arginine	O	1740-1748
transport	O	1749-1758
system	O	1759-1765
.	O	1765-1766

MR	O	0-2
imaging	O	3-10
with	O	11-15
quantitative	O	16-28
diffusion	O	29-38
mapping	O	39-46
of	O	47-49
tacrolimus	O	50-60
-	O	60-61
induced	O	61-68
neurotoxicity	B	69-82
in	O	83-85
organ	O	86-91
transplant	O	92-102
patients	O	103-111
.	O	111-112

Our	O	113-116
objective	O	117-126
was	O	127-130
to	O	131-133
investigate	O	134-145
brain	O	146-151
MR	O	152-154
imaging	O	155-162
findings	O	163-171
and	O	172-175
the	O	176-179
utility	O	180-187
of	O	188-190
diffusion	O	191-200
-	O	200-201
weighted	O	201-209
(	O	210-211
DW	O	211-213
)	O	213-214
imaging	O	215-222
in	O	223-225
organ	O	226-231
transplant	O	232-242
patients	O	243-251
who	O	252-255
developed	O	256-265
neurologic	O	266-276
symptoms	O	277-285
during	O	286-292
tacrolimus	O	293-303
therapy	O	304-311
.	O	311-312

Brain	O	313-318
MR	O	319-321
studies	O	322-329
,	O	329-330
including	O	331-340
DW	O	341-343
imaging	O	344-351
,	O	351-352
were	O	353-357
prospectively	O	358-371
performed	O	372-381
in	O	382-384
14	O	385-387
organ	O	388-393
transplant	O	394-404
patients	O	405-413
receiving	O	414-423
tacrolimus	O	424-434
who	O	435-438
developed	O	439-448
neurologic	B	449-459
complications	I	460-473
.	O	473-474

In	O	475-477
each	O	478-482
patient	O	483-490
who	O	491-494
had	O	495-498
abnormalities	O	499-512
on	O	513-515
the	O	516-519
initial	O	520-527
MR	O	528-530
study	O	531-536
,	O	536-537
a	O	538-539
follow	O	540-546
-	O	546-547
up	O	547-549
MR	O	550-552
study	O	553-558
was	O	559-562
performed	O	563-572
1	O	573-574
month	O	575-580
later	O	581-586
.	O	586-587

Apparent	O	588-596
diffusion	O	597-606
coefficient	O	607-618
(	O	619-620
ADC	O	620-623
)	O	623-624
values	O	625-631
on	O	632-634
the	O	635-638
initial	O	639-646
MR	O	647-649
study	O	650-655
were	O	656-660
correlated	O	661-671
with	O	672-676
reversibility	O	677-690
of	O	691-693
the	O	694-697
lesions	O	698-705
.	O	705-706

Of	O	707-709
the	O	710-713
14	O	714-716
patients	O	717-725
,	O	725-726
5	O	727-728
(	O	729-730
35	O	730-732
.	O	732-733
7	O	733-734
%	O	734-735
)	O	735-736
had	O	737-740
white	B	741-746
matter	I	747-753
abnormalities	I	754-767
,	O	767-768
1	O	769-770
(	O	771-772
7	O	772-773
.	O	773-774
1	O	774-775
%	O	775-776
)	O	776-777
had	O	778-781
putaminal	B	782-791
hemorrhage	I	792-802
,	O	802-803
and	O	804-807
8	O	808-809
(	O	810-811
57	O	811-813
.	O	813-814
1	O	814-815
%	O	815-816
)	O	816-817
had	O	818-821
normal	O	822-828
findings	O	829-837
on	O	838-840
initial	O	841-848
MR	O	849-851
images	O	852-858
.	O	858-859

Among	O	860-865
the	O	866-869
5	O	870-871
patients	O	872-880
with	O	881-885
white	B	886-891
matter	I	892-898
abnormalities	I	899-912
,	O	912-913
4	O	914-915
patients	O	916-924
(	O	925-926
80	O	926-928
.	O	928-929
0	O	927-928
%	O	930-931
)	O	931-932
showed	O	933-939
higher	O	940-946
than	O	947-951
normal	O	952-958
ADC	O	959-962
values	O	963-969
on	O	970-972
initial	O	973-980
MR	O	981-983
images	O	984-990
,	O	990-991
and	O	992-995
all	O	996-999
showed	O	1000-1006
complete	O	1007-1015
resolution	O	1016-1026
on	O	1027-1029
follow	O	1030-1036
-	O	1036-1037
up	O	1037-1039
images	O	1040-1046
.	O	1046-1047

The	O	1048-1051
remaining	O	1052-1061
1	O	1062-1063
patient	O	1064-1071
(	O	1072-1073
20	O	1073-1075
.	O	1075-1076
0	O	1074-1075
%	O	1077-1078
)	O	1078-1079
showed	O	1080-1086
lower	O	1087-1092
than	O	1093-1097
normal	O	1098-1104
ADC	O	1105-1108
value	O	1109-1114
and	O	1115-1118
showed	O	1119-1125
incomplete	O	1126-1136
resolution	O	1137-1147
with	O	1148-1152
cortical	B	1153-1161
laminar	I	1162-1169
necrosis	I	1170-1178
.	O	1178-1179

Diffusion	O	1180-1189
-	O	1189-1190
weighted	O	1190-1198
imaging	O	1199-1206
may	O	1207-1210
be	O	1211-1213
useful	O	1214-1220
in	O	1221-1223
predicting	O	1224-1234
the	O	1235-1238
outcomes	O	1239-1247
of	O	1248-1250
the	O	1251-1254
lesions	O	1255-1262
of	O	1263-1265
tacrolimus	O	1266-1276
-	O	1276-1277
induced	O	1277-1284
neurotoxicity	B	1285-1298
.	O	1298-1299

Octreotide	O	0-10
-	O	10-11
induced	O	11-18
hypoxemia	B	19-28
and	O	29-32
pulmonary	B	33-42
hypertension	I	43-55
in	O	56-58
premature	O	59-68
neonates	O	69-77
.	O	77-78

The	O	79-82
authors	O	83-90
report	O	91-97
2	O	98-99
cases	O	100-105
of	O	106-108
premature	O	109-118
neonates	O	119-127
who	O	128-131
had	O	132-135
enterocutaneous	O	136-151
fistula	B	152-159
complicating	O	160-172
necrotizing	B	173-184
enterocolitis	I	185-198
.	O	198-199

Pulmonary	B	200-209
hypertension	I	210-222
developed	O	223-232
after	O	233-238
administration	O	239-253
of	O	254-256
a	O	257-258
somatostatin	O	259-271
analogue	O	272-280
,	O	280-281
octreotide	O	282-292
,	O	292-293
to	O	294-296
enhance	O	297-304
resolution	O	305-315
of	O	316-318
the	O	319-322
fistula	B	323-330
.	O	330-331

The	O	332-335
authors	O	336-343
discuss	O	344-351
the	O	352-355
mechanism	O	356-365
of	O	366-368
the	O	369-372
occurrence	O	373-383
of	O	384-386
this	O	387-391
complication	O	392-404
and	O	405-408
recommend	O	409-418
caution	O	419-426
of	O	427-429
its	O	430-433
use	O	434-437
in	O	438-440
high	O	441-445
-	O	445-446
risk	O	446-450
premature	O	451-460
neonates	O	461-469
.	O	469-470

Sequential	O	0-10
observations	O	11-23
of	O	24-26
exencephaly	B	27-38
and	O	39-42
subsequent	O	43-53
morphological	O	54-67
changes	O	68-75
by	O	76-78
mouse	O	79-84
exo	O	85-88
utero	O	89-94
development	O	95-106
system	O	107-113
:	O	113-114
analysis	O	115-123
of	O	124-126
the	O	127-130
mechanism	O	131-140
of	O	141-143
transformation	O	144-158
from	O	159-163
exencephaly	B	164-175
to	O	176-178
anencephaly	B	179-190
.	O	190-191

Anencephaly	B	192-203
has	O	204-207
been	O	208-212
suggested	O	213-222
to	O	223-225
develop	O	226-233
from	O	234-238
exencephaly	B	239-250
;	O	250-251
however	O	252-259
,	O	259-260
there	O	261-266
is	O	267-269
little	O	270-276
direct	O	277-283
experimental	O	284-296
evidence	O	297-305
to	O	306-308
support	O	309-316
this	O	317-321
,	O	321-322
and	O	323-326
the	O	327-330
mechanism	O	331-340
of	O	341-343
transformation	O	344-358
remains	O	359-366
unclear	O	367-374
.	O	374-375

We	O	376-378
examined	O	379-387
this	O	388-392
theory	O	393-399
using	O	400-405
the	O	406-409
exo	O	410-413
utero	O	414-419
development	O	420-431
system	O	432-438
that	O	439-443
allows	O	444-450
direct	O	451-457
and	O	458-461
sequential	O	462-472
observations	O	473-485
of	O	486-488
mid	O	489-492
-	O	492-493
to	O	494-496
late	O	497-501
-	O	501-502
gestation	O	502-511
mouse	O	512-517
embryos	O	518-525
.	O	525-526

We	O	527-529
observed	O	530-538
the	O	539-542
exencephaly	B	543-554
induced	O	555-562
by	O	563-565
5	O	566-567
-	O	567-568
azacytidine	O	568-579
at	O	580-582
embryonic	O	583-592
day	O	593-596
13	O	597-599
.	O	599-600
5	O	600-601
(	O	602-603
E13	O	603-606
.	O	606-607
5	O	607-608
)	O	608-609
,	O	609-610

let	O	611-614
the	O	615-618
embryos	O	619-626
develop	O	627-634
exo	O	635-638
utero	O	639-644
until	O	645-650
E18	O	651-654
.	O	654-655
5	O	655-656
,	O	656-657
and	O	658-661
re	O	662-664
-	O	664-665
observed	O	665-673
the	O	674-677
same	O	678-682
embryos	O	683-690
at	O	691-693
E18	O	694-697
.	O	697-698
5	O	698-699
.	O	697-698

We	O	701-703
confirmed	O	704-713
several	O	714-721
cases	O	722-727
of	O	728-730
transformation	O	731-745
from	O	746-750
exencephaly	B	751-762
to	O	763-765
anencephaly	B	766-777
.	O	777-778

However	O	779-786
,	O	786-787
in	O	788-790
many	O	791-795
cases	O	796-801
,	O	801-802
the	O	803-806
exencephalic	B	807-819
brain	O	820-825
tissue	O	826-832
was	O	833-836
preserved	O	837-846
with	O	847-851
more	O	852-856
or	O	857-859
less	O	860-864
reduction	O	865-874
during	O	875-881
this	O	882-886
period	O	887-893
.	O	893-894

To	O	895-897
analyze	O	898-905
the	O	906-909
transformation	O	910-924
patterns	O	925-933
,	O	933-934
we	O	935-937
classified	O	938-948
the	O	949-952
exencephaly	B	953-964
by	O	965-967
size	O	968-972
and	O	973-976
shape	O	977-982
of	O	983-985
the	O	986-989
exencephalic	B	990-1002
tissue	O	1003-1009
into	O	1010-1014
several	O	1015-1022
types	O	1023-1028
at	O	1029-1031
E13	O	1032-1035
.	O	1035-1036
5	O	1036-1037
and	O	1038-1041
E18	O	1042-1045
.	O	1045-1046
5	O	1046-1047
.	O	1045-1046

It	O	1049-1051
was	O	1052-1055
found	O	1056-1061
that	O	1062-1066
the	O	1067-1070
transformation	O	1071-1085
of	O	1086-1088
exencephalic	B	1089-1101
tissue	O	1102-1108
was	O	1109-1112
not	O	1113-1116
simply	O	1117-1123
size	O	1124-1128
-	O	1128-1129
dependent	O	1129-1138
,	O	1138-1139
and	O	1140-1143
all	O	1144-1147
cases	O	1148-1153
of	O	1154-1156
anencephaly	B	1157-1168
at	O	1169-1171
E18	O	1172-1175
.	O	1175-1176
5	O	1176-1177
resulted	O	1178-1186
from	O	1187-1191
embryos	O	1192-1199
with	O	1200-1204
a	O	1205-1206
large	O	1207-1212
amount	O	1213-1219
of	O	1220-1222
exencephalic	B	1223-1235
tissue	O	1236-1242
at	O	1243-1245
E13	O	1246-1249
.	O	1249-1250
5	O	1250-1251
.	O	1249-1250

Microscopic	O	1253-1264
observation	O	1265-1276
showed	O	1277-1283
the	O	1284-1287
configuration	O	1288-1301
of	O	1302-1304
exencephaly	B	1305-1316
at	O	1317-1319
E13	O	1320-1323
.	O	1323-1324
5	O	1324-1325
,	O	1325-1326
frequent	O	1327-1335
hemorrhaging	B	1336-1348
and	O	1349-1352
detachment	O	1353-1363
of	O	1364-1366
the	O	1367-1370
neural	O	1371-1377
plate	O	1378-1383
from	O	1384-1388
surface	O	1389-1396
ectoderm	O	1397-1405
in	O	1406-1408
the	O	1409-1412
exencephalic	B	1413-1425
head	O	1426-1430
at	O	1431-1433
E15	O	1434-1437
.	O	1437-1438
5	O	1436-1437
,	O	1439-1440
and	O	1441-1444
multiple	O	1445-1453
modes	O	1454-1459
of	O	1460-1462
reduction	O	1463-1472
in	O	1473-1475
the	O	1476-1479
exencephalic	B	1480-1492
tissue	O	1493-1499
at	O	1500-1502
E18	O	1503-1506
.	O	1506-1507
5	O	1507-1508
.	O	1506-1507

From	O	1510-1514
observations	O	1515-1527
of	O	1528-1530
the	O	1531-1534
vasculature	O	1535-1546
,	O	1546-1547
altered	O	1548-1555
distribution	O	1556-1568
patterns	O	1569-1577
of	O	1578-1580
vessels	O	1581-1588
were	O	1589-1593
identified	O	1594-1604
in	O	1605-1607
the	O	1608-1611
exencephalic	B	1612-1624
head	O	1625-1629
.	O	1629-1630

These	O	1631-1636
findings	O	1637-1645
suggest	O	1646-1653
that	O	1654-1658
overgrowth	O	1659-1669
of	O	1670-1672
the	O	1673-1676
exencephalic	B	1677-1689
neural	O	1690-1696
tissue	O	1697-1703
causes	O	1704-1710
the	O	1711-1714
altered	O	1715-1722
distribution	O	1723-1735
patterns	O	1736-1744
of	O	1745-1747
vessels	O	1748-1755
,	O	1755-1756
subsequent	O	1757-1767
peripheral	O	1768-1778
circulatory	B	1779-1790
failure	I	1791-1798
and	O	1799-1802
/	O	1802-1803
or	O	1803-1805
hemorrhaging	B	1806-1818
in	O	1819-1821
various	O	1822-1829
parts	O	1830-1835
of	O	1836-1838
the	O	1839-1842
exencephalic	B	1843-1855
head	O	1856-1860
,	O	1860-1861
leading	O	1862-1869
to	O	1870-1872
the	O	1873-1876
multiple	O	1877-1885
modes	O	1886-1891
of	O	1892-1894
tissue	O	1895-1901
reduction	O	1902-1911
during	O	1912-1918
transformation	O	1919-1933
from	O	1934-1938
exencephaly	B	1939-1950
to	O	1951-1953
anencephaly	B	1954-1965
.	O	1965-1966

Acute	O	0-5
cocaine	O	6-13
-	O	13-14
induced	O	14-21
seizures	B	22-30
:	O	30-31
differential	O	32-44
sensitivity	O	45-56
of	O	57-59
six	O	60-63
inbred	O	64-70
mouse	O	71-76
strains	O	77-84
.	O	84-85

Mature	O	86-92
male	O	93-97
and	O	98-101
female	O	102-108
mice	O	109-113
from	O	114-118
six	O	119-122
inbred	O	123-129
stains	O	130-136
were	O	137-141
tested	O	142-148
for	O	149-152
susceptibility	O	153-167
to	O	168-170
behavioral	O	171-181
seizures	B	182-190
induced	O	191-198
by	O	199-201
a	O	202-203
single	O	204-210
injection	O	211-220
of	O	221-223
cocaine	O	224-231
.	O	231-232

Cocaine	O	233-240
was	O	241-244
injected	O	245-253
ip	O	254-256
over	O	257-261
a	O	262-263
range	O	264-269
of	O	270-272
doses	O	273-278
(	O	279-280
50	O	280-282
-	O	282-283
100	O	283-286
mg	O	287-289
/	O	289-290
kg	O	290-292
)	O	292-293
and	O	294-297
behavior	O	298-306
was	O	307-310
monitored	O	311-320
for	O	321-324
20	O	325-327
minutes	O	328-335
.	O	335-336

Seizure	B	337-344
end	O	345-348
points	O	349-355
included	O	356-364
latency	O	365-372
to	O	373-375
forelimb	O	376-384
or	O	385-387
hindlimb	O	388-396
clonus	O	397-403
,	O	403-404
latency	O	405-412
to	O	413-415
clonic	O	416-422
running	O	423-430
seizure	B	431-438
and	O	439-442
latency	O	443-450
to	O	451-453
jumping	O	454-461
bouncing	O	462-470
seizure	B	471-478
.	O	478-479

A	O	480-481
range	O	482-487
of	O	488-490
strain	O	491-497
specific	O	498-506
sensitivities	O	507-520
was	O	521-524
documented	O	525-535
with	O	536-540
A	O	541-542
/	O	542-543
J	O	543-544
and	O	545-548
SJL	O	549-552
mice	O	553-557
being	O	558-563
most	O	564-568
sensitive	O	569-578
and	O	579-582
C57BL	O	583-588
/	O	588-589
6J	O	589-591
most	O	592-596
resistant	O	597-606
.	O	606-607

DBA	O	608-611
/	O	611-612
2J	O	612-614
,	O	614-615
BALB	O	616-620
/	O	620-621
cByJ	O	621-625
and	O	626-629
NZW	O	630-633
/	O	633-634
LacJ	O	634-638
strains	O	639-646
exhibited	O	647-656
intermediate	O	657-669
sensitivity	O	670-681
.	O	681-682

EEG	O	683-686
recordings	O	687-697
were	O	698-702
made	O	703-707
in	O	708-710
SJL	O	711-714
,	O	714-715
A	O	716-717
/	O	717-718
J	O	718-719
and	O	720-723
C57BL	O	724-729
/	O	729-730
6J	O	730-732
mice	O	733-737
revealing	O	738-747
a	O	748-749
close	O	750-755
correspondence	O	756-770
between	O	771-778
electrical	O	779-789
activity	O	790-798
and	O	799-802
behavior	O	803-811
.	O	811-812

Additionally	O	813-825
,	O	825-826
levels	O	827-833
of	O	834-836
cocaine	O	837-844
determined	O	845-855
in	O	856-858
hippocampus	O	859-870
and	O	871-874
cortex	O	875-881
were	O	882-886
not	O	887-890
different	O	891-900
between	O	901-908
sensitive	O	909-918
and	O	919-922
resistant	O	923-932
strains	O	933-940
.	O	940-941

Additional	O	942-952
studies	O	953-960
of	O	961-963
these	O	964-969
murine	O	970-976
strains	O	977-984
may	O	985-988
be	O	989-991
useful	O	992-998
for	O	999-1002
investigating	O	1003-1016
genetic	O	1017-1024
influences	O	1025-1035
on	O	1036-1038
cocaine	O	1039-1046
-	O	1046-1047
induced	O	1047-1054
seizures	B	1055-1063
.	O	1063-1064

Microangiopathic	B	0-16
hemolytic	I	17-26
anemia	I	27-33
complicating	O	34-46
FK506	O	47-52
(	O	53-54
tacrolimus	O	54-64
)	O	64-65
therapy	O	66-73
.	O	73-74

We	O	75-77
describe	O	78-86
3	O	87-88
episodes	O	89-97
of	O	98-100
microangiopathic	B	101-117
hemolytic	I	118-127
anemia	I	128-134
(	O	135-136
MAHA	B	136-140
)	O	140-141
in	O	142-144
2	O	145-146
solid	O	147-152
organ	O	153-158
recipients	O	159-169
under	O	170-175
FK506	O	176-181
(	O	182-183
tacrolimus	O	183-193
)	O	193-194
therapy	O	195-202
.	O	202-203

In	O	204-206
both	O	207-211
cases	O	212-217
,	O	217-218
discontinuation	O	219-234
of	O	235-237
FK506	O	238-243
and	O	244-247
treatment	O	248-257
with	O	258-262
plasma	O	263-269
exchange	O	270-278
,	O	278-279
fresh	O	280-285
frozen	O	286-292
plasma	O	293-299
replacement	O	300-311
,	O	311-312
corticosteroids	O	313-328
,	O	328-329
aspirin	O	330-337
,	O	337-338
and	O	339-342
dipyridamole	O	343-355
led	O	356-359
to	O	360-362
resolution	O	363-373
of	O	374-376
MAHA	B	377-381
.	O	381-382

In	O	383-385
one	O	386-389
patient	O	390-397
,	O	397-398
reintroduction	O	399-413
of	O	414-416
FK506	O	417-422
led	O	423-426
to	O	427-429
rapid	O	430-435
recurrence	O	436-446
of	O	447-449
MAHA	B	450-454
.	O	454-455

FK506	O	456-461
-	O	461-462
associated	O	462-472
MAHA	B	473-477
is	O	478-480
probably	O	481-489
rare	O	490-494
but	O	495-498
physicians	O	499-509
must	O	510-514
be	O	515-517
aware	O	518-523
of	O	524-526
this	O	527-531
severe	O	532-538
complication	O	539-551
.	O	551-552

In	O	553-555
our	O	556-559
experience	O	560-570
and	O	571-574
according	O	575-584
to	O	585-587
the	O	588-591
literature	O	592-602
,	O	602-603
FK506	O	604-609
does	O	610-614
not	O	615-618
seem	O	619-623
to	O	624-626
cross	O	627-632
-	O	632-633
react	O	633-638
with	O	639-643
cyclosporin	O	644-655
A	O	656-657
(	O	658-659
CyA	O	659-662
)	O	662-663
,	O	663-664
an	O	665-667
immuno	O	668-674
-	O	674-675
suppressive	O	675-686
drug	O	687-691
already	O	692-699
known	O	700-705
to	O	706-708
induce	O	709-715
MAHA	B	716-720
.	O	720-721

Variant	O	0-7
ventricular	B	8-19
tachycardia	I	20-31
in	O	32-34
desipramine	O	35-46
toxicity	B	47-55
.	O	55-56

We	O	57-59
report	O	60-66
a	O	67-68
case	O	69-73
of	O	74-76
variant	O	77-84
ventricular	B	85-96
tachycardia	I	97-108
induced	O	109-116
by	O	117-119
desipramine	O	120-131
toxicity	B	132-140
.	O	140-141

Unusual	O	142-149
features	O	150-158
of	O	159-161
the	O	162-165
arrhythmia	B	166-176
are	O	177-180
repetitive	O	181-191
group	O	192-197
beating	O	198-205
,	O	205-206
progressive	O	207-218
shortening	O	219-229
of	O	230-232
the	O	233-236
R	O	237-238
-	O	238-239
R	O	237-238
interval	O	241-249
,	O	249-250
progressive	O	251-262
widening	O	263-271
of	O	272-274
the	O	275-278
QRS	O	279-282
complex	O	283-290
with	O	291-295
eventual	O	296-304
failure	O	305-312
of	O	313-315
intraventricular	O	316-332
conduction	O	333-343
,	O	343-344
and	O	345-348
changes	O	349-356
in	O	357-359
direction	O	360-369
of	O	370-372
the	O	373-376
QRS	O	377-380
axis	O	381-385
.	O	385-386

Recognition	O	387-398
of	O	399-401
variant	O	402-409
ventricular	B	410-421
tachycardia	I	422-433
is	O	434-436
important	O	437-446
because	O	447-454
therapy	O	455-462
differs	O	463-470
from	O	471-475
that	O	476-480
of	O	481-483
classic	O	484-491
ventricular	B	492-503
tachycardia	I	504-515
.	O	515-516

Desipramine	O	0-11
-	O	11-12
induced	O	12-19
delirium	B	20-28
at	O	29-31
"	O	32-33
subtherapeutic	O	33-47
"	O	32-33
concentrations	O	49-63
:	O	63-64
a	O	65-66
case	O	67-71
report	O	72-78
.	O	78-79

An	O	80-82
elderly	O	83-90
patient	O	91-98
treated	O	99-106
with	O	107-111
low	O	112-115
dose	O	116-120
Desipramine	O	121-132
developed	O	133-142
a	O	143-144
delirium	B	145-153
while	O	154-159
her	O	160-163
plasma	O	164-170
level	O	171-176
was	O	177-180
in	O	181-183
the	O	184-187
"	O	188-189
subtherapeutic	O	189-203
"	O	188-189
range	O	205-210
.	O	210-211

Delirium	B	212-220
,	O	220-221
which	O	222-227
may	O	228-231
be	O	232-234
induced	O	235-242
by	O	243-245
tricyclic	O	246-255
drug	O	256-260
therapy	O	261-268
in	O	269-271
the	O	272-275
elderly	O	276-283
,	O	283-284
can	O	285-288
be	O	289-291
caused	O	292-298
by	O	299-301
tricyclics	O	302-312
with	O	313-317
low	O	318-321
anticholinergic	O	322-337
potency	O	338-345
.	O	345-346

Therapeutic	O	347-358
ranges	O	359-365
for	O	366-369
antidepressants	O	370-385
that	O	386-390
have	O	391-395
been	O	396-400
derived	O	401-408
from	O	409-413
general	O	414-421
adult	O	422-427
population	O	428-438
studies	O	439-446
may	O	447-450
not	O	451-454
be	O	455-457
appropriate	O	458-469
for	O	470-473
the	O	474-477
elderly	O	478-485
.	O	485-486

Further	O	487-494
studies	O	495-502
of	O	503-505
specifically	O	506-518
elderly	O	519-526
patients	O	527-535
are	O	536-539
now	O	540-543
required	O	544-552
to	O	553-555
establish	O	556-565
safer	O	566-571
and	O	572-575
more	O	576-580
appropriate	O	581-592
guidelines	O	593-603
for	O	604-607
drug	O	608-612
therapy	O	613-620
.	O	620-621

Mouse	O	0-5
strain	O	6-12
-	O	12-13
dependent	O	13-22
effect	O	23-29
of	O	30-32
amantadine	O	33-43
on	O	44-46
motility	O	47-55
and	O	56-59
brain	O	60-65
biogenic	O	66-74
amines	O	75-81
.	O	81-82

The	O	83-86
effect	O	87-93
of	O	94-96
amantadine	O	97-107
hydrochloride	O	108-121
,	O	121-122
injected	O	123-131
i	O	132-133
.	O	133-134
p	O	134-135
.	O	133-134
in	O	137-139
6	O	140-141
increments	O	142-152
of	O	153-155
100	O	156-159
mg	O	160-162
/	O	162-163
kg	O	163-165
each	O	166-170
over	O	171-175
30	O	176-178
hr	O	179-181
,	O	181-182
on	O	183-185
mouse	O	186-191
motility	O	192-200
and	O	201-204
whole	O	205-210
brain	O	211-216
content	O	217-224
of	O	225-227
selected	O	228-236
biogenic	O	237-245
amines	O	246-252
and	O	253-256
major	O	257-262
metabolites	O	263-274
was	O	275-278
studied	O	279-286
in	O	287-289
4	O	290-291
strains	O	292-299
of	O	300-302
mice	O	303-307
.	O	307-308

These	O	309-314
were	O	315-319
the	O	320-323
albino	O	324-330
Sprague	O	331-338
-	O	338-339
Dawley	O	339-345
ICR	O	346-349
and	O	350-353
BALB	O	354-358
/	O	358-359
C	O	359-360
,	O	360-361
the	O	362-365
black	O	366-371
C57BL	O	372-377
/	O	377-378
6	O	378-379
and	O	380-383
the	O	384-387
brown	O	388-393
CDF	O	394-397
-	O	397-398
I	O	398-399
mouse	O	400-405
strains	O	406-413
.	O	413-414

Amantadine	O	415-425
treatment	O	426-435
produced	O	436-444
a	O	445-446
biphasic	O	447-455
effect	O	456-462
on	O	463-465
mouse	O	466-471
motility	O	472-480
.	O	480-481

The	O	482-485
initial	O	486-493
dose	O	494-498
of	O	499-501
amantadine	O	502-512
depressed	B	513-522
locomotor	O	523-532
activity	O	533-541
in	O	542-544
all	O	545-548
mouse	O	549-554
strains	O	555-562
studied	O	563-570
with	O	571-575
the	O	576-579
BALB	O	580-584
/	O	584-585
C	O	585-586
mice	O	587-591
being	O	592-597
the	O	598-601
most	O	602-606
sensitive	O	607-616
.	O	616-617

Subsequent	O	618-628
amantadine	O	629-639
treatments	O	640-650
produced	O	651-659
enhancement	O	660-671
of	O	672-674
motility	O	675-683
from	O	684-688
corresponding	O	689-702
control	O	703-710
in	O	711-713
all	O	714-717
mouse	O	718-723
strains	O	724-731
with	O	732-736
the	O	737-740
BALB	O	741-745
/	O	745-746
C	O	746-747
mice	O	748-752
being	O	753-758
the	O	759-762
least	O	763-768
sensitive	O	769-778
.	O	778-779

The	O	780-783
locomotor	O	784-793
activity	O	794-802
was	O	803-806
decreased	O	807-816
from	O	817-821
corresponding	O	822-835
controls	O	836-844
in	O	845-847
all	O	848-851
strains	O	852-859
studied	O	860-867
,	O	867-868
except	O	869-875
for	O	876-879
the	O	880-883
ICR	O	884-887
mice	O	888-892
,	O	892-893
during	O	894-900
an	O	901-903
overnight	O	904-913
drug	O	914-918
-	O	918-919
free	O	919-923
period	O	924-930
following	O	931-940
the	O	941-944
fourth	O	945-951
amantadine	O	952-962
treatment	O	963-972
.	O	972-973

Readministration	O	974-990
of	O	991-993
amantadine	O	994-1004
,	O	1004-1005
after	O	1006-1011
a	O	1012-1013
drug	O	1014-1018
-	O	1018-1019
free	O	1019-1023
overnight	O	1024-1033
period	O	1034-1040
,	O	1040-1041
increased	O	1042-1051
motility	O	1052-1060
from	O	1061-1065
respective	O	1066-1076
saline	O	1077-1083
control	O	1084-1091
in	O	1092-1094
all	O	1095-1098
strains	O	1099-1106
with	O	1107-1111
exception	O	1112-1121
of	O	1122-1124
the	O	1125-1128
BALB	O	1129-1133
/	O	1133-1134
C	O	1134-1135
mice	O	1136-1140
where	O	1141-1146
suppression	B	1147-1158
of	I	1159-1161
motility	I	1162-1170
occurred	O	1171-1179
.	O	1179-1180

Treatment	O	1181-1190
with	O	1191-1195
amantadine	O	1196-1206
did	O	1207-1210
not	O	1211-1214
alter	O	1215-1220
whole	O	1221-1226
brain	O	1227-1232
dopamine	O	1233-1241
levels	O	1242-1248
but	O	1249-1252
decreased	O	1253-1262
the	O	1263-1266
amounts	O	1267-1274
of	O	1275-1277
3	O	1278-1279
,	O	1279-1280
4	O	1280-1281
-	O	1281-1282
dihydroxyphenylacetic	O	1282-1303
acid	O	1304-1308
in	O	1309-1311
the	O	1312-1315
BALB	O	1316-1320
/	O	1320-1321
C	O	1321-1322
mice	O	1323-1327
compared	O	1328-1336
to	O	1337-1339
saline	O	1340-1346
control	O	1347-1354
.	O	1354-1355

Conversely	O	1356-1366
,	O	1366-1367
brain	O	1368-1373
normetanephrine	O	1374-1389
concentration	O	1390-1403
was	O	1404-1407
increased	O	1408-1417
from	O	1418-1422
saline	O	1423-1429
control	O	1430-1437
by	O	1438-1440
amantadine	O	1441-1451
in	O	1452-1454
the	O	1455-1458
BALB	O	1459-1463
/	O	1463-1464
C	O	1464-1465
mice	O	1466-1470
.	O	1470-1471

The	O	1472-1475
results	O	1476-1483
suggest	O	1484-1491
a	O	1492-1493
strain	O	1494-1500
-	O	1500-1501
dependent	O	1501-1510
effect	O	1511-1517
of	O	1518-1520
amantadine	O	1521-1531
on	O	1532-1534
motility	O	1535-1543
and	O	1544-1547
indicate	O	1548-1556
a	O	1557-1558
differential	O	1559-1571
response	O	1572-1580
to	O	1581-1583
the	O	1584-1587
acute	O	1588-1593
and	O	1594-1597
multiple	O	1598-1606
dose	O	1607-1611
regimens	O	1612-1620
used	O	1621-1625
.	O	1625-1626

The	O	1627-1630
BALB	O	1631-1635
/	O	1635-1636
C	O	1636-1637
mouse	O	1638-1643
was	O	1644-1647
the	O	1648-1651
most	O	1652-1656
sensitive	O	1657-1666
strain	O	1667-1673
and	O	1674-1677
could	O	1678-1683
serve	O	1684-1689
as	O	1690-1692
the	O	1693-1696
strain	O	1697-1703
of	O	1704-1706
choice	O	1707-1713
for	O	1714-1717
evaluating	O	1718-1728
the	O	1729-1732
side	O	1733-1737
effects	O	1738-1745
of	O	1746-1748
amantadine	O	1749-1759
.	O	1759-1760

The	O	1761-1764
biochemical	O	1765-1776
results	O	1777-1784
of	O	1785-1787
brain	O	1788-1793
biogenic	O	1794-1802
amines	O	1803-1809
of	O	1810-1812
BALB	O	1813-1817
/	O	1817-1818
C	O	1818-1819
mouse	O	1820-1825
strain	O	1826-1832
suggest	O	1833-1840
a	O	1841-1842
probable	O	1843-1851
decrease	O	1852-1860
of	O	1861-1863
catecholamine	O	1864-1877
turnover	O	1878-1886
rate	O	1887-1891
and	O	1892-1895
/	O	1895-1896
or	O	1896-1898
metabolism	O	1899-1909
by	O	1910-1912
monoamine	O	1913-1922
oxidase	O	1923-1930
and	O	1931-1934
a	O	1935-1936
resulting	O	1937-1946
increase	O	1947-1955
in	O	1956-1958
O	O	1959-1960
-	O	1960-1961
methylation	O	1961-1972
of	O	1973-1975
norepinephrine	O	1976-1990
which	O	1991-1996
may	O	1997-2000
account	O	2001-2008
for	O	2009-2012
a	O	2013-2014
behavioral	B	2015-2025
depression	I	2026-2036
caused	O	2037-2043
by	O	2044-2046
amantadine	O	2047-2057
in	O	2058-2060
the	O	2061-2064
BALB	O	2065-2069
/	O	2069-2070
C	O	2070-2071
mice	O	2072-2076
.	O	2076-2077

No	O	0-2
enhancement	O	3-14
by	O	15-17
phenobarbital	O	18-31
of	O	32-34
the	O	35-38
hepatocarcinogenicity	O	39-60
of	O	61-63
a	O	64-65
choline	O	66-73
-	O	73-74
devoid	O	74-80
diet	O	81-85
in	O	86-88
the	O	89-92
rat	O	93-96
.	O	96-97

An	O	98-100
experiment	O	101-111
was	O	112-115
performed	O	116-125
to	O	126-128
test	O	129-133
whether	O	134-141
inclusion	O	142-151
of	O	152-154
phenobarbital	O	155-168
in	O	169-171
a	O	172-173
choline	O	174-181
-	O	181-182
devoid	O	182-188
diet	O	189-193
would	O	194-199
increase	O	200-208
the	O	209-212
hepatocarcinogenicity	O	213-234
of	O	235-237
the	O	238-241
diet	O	242-246
.	O	246-247

Groups	O	248-254
of	O	255-257
5	O	258-259
-	O	259-260
week	O	260-264
old	O	265-268
male	O	269-273
Fischer	O	274-281
-	O	281-282
344	O	282-285
rats	O	286-290
were	O	291-295
fed	O	296-299
for	O	300-303
7	O	304-305
-	O	305-306
25	O	306-308
months	O	309-315
semipurified	O	316-328
choline	O	329-336
-	O	336-337
devoid	O	337-343
or	O	344-346
choline	O	347-354
-	O	354-355
supplemented	O	355-367
diets	O	368-373
,	O	373-374
containing	O	375-385
or	O	386-388
not	O	389-392
0	O	393-394
.	O	394-395
06	O	395-397
%	O	397-398
phenobarbital	O	399-412
.	O	412-413

No	O	414-416
hepatic	O	417-424
preneoplastic	O	425-438
nodules	O	439-446
or	O	447-449
hepatocellular	B	450-464
carcinomas	I	465-475
developed	O	476-485
in	O	486-488
rats	O	489-493
fed	O	494-497
the	O	498-501
plain	O	502-507
choline	O	508-515
-	O	515-516
supplemented	O	516-528
diet	O	529-533
,	O	533-534
while	O	535-540
one	O	541-544
preneoplastic	O	545-558
nodule	O	559-565
and	O	566-569
one	O	570-573
hepatocellular	B	574-588
carcinoma	I	589-598
developed	O	599-608
in	O	609-611
two	O	612-615
rats	O	616-620
fed	O	621-624
the	O	625-628
same	O	629-633
diet	O	634-638
containing	O	639-649
phenobarbital	O	650-663
.	O	663-664

The	O	665-668
incidence	O	669-678
of	O	679-681
preneoplastic	O	682-695
nodules	O	696-703
and	O	704-707
of	O	708-710
hepatocellular	B	711-725
carcinomas	I	726-736
was	O	737-740
10	O	741-743
%	O	743-744
and	O	745-748
37	O	749-751
%	O	751-752
,	O	752-753
respectively	O	754-766
,	O	766-767
in	O	768-770
rats	O	771-775
fed	O	776-779
the	O	780-783
plain	O	784-789
choline	O	790-797
-	O	797-798
devoid	O	798-804
diet	O	805-809
,	O	809-810
and	O	811-814
17	O	815-817
%	O	817-818
and	O	819-822
30	O	823-825
%	O	825-826
,	O	826-827
in	O	828-830
rats	O	831-835
fed	O	836-839
the	O	840-843
phenobarbital	O	844-857
-	O	857-858
containing	O	858-868
choline	O	869-876
-	O	876-877
devoid	O	877-883
diet	O	884-888
.	O	888-889

The	O	890-893
results	O	894-901
evinced	O	902-909
no	O	910-912
enhancement	O	913-924
of	O	925-927
the	O	928-931
hepatocarcinogenicity	O	932-953
of	O	954-956
the	O	957-960
choline	O	961-968
-	O	968-969
devoid	O	969-975
diet	O	976-980
by	O	981-983
phenobarbital	O	984-997
.	O	997-998

Sporadic	O	999-1007
neoplastic	O	1008-1018
lesions	O	1019-1026
were	O	1027-1031
observed	O	1032-1040
in	O	1041-1043
organs	O	1044-1050
other	O	1051-1056
than	O	1057-1061
the	O	1062-1065
liver	O	1066-1071
of	O	1072-1074
some	O	1075-1079
of	O	1080-1082
the	O	1083-1086
animals	O	1087-1094
,	O	1094-1095
irrespective	O	1096-1108
of	O	1109-1111
the	O	1112-1115
diet	O	1116-1120
fed	O	1121-1124
.	O	1124-1125

Effect	O	0-6
of	O	7-9
direct	O	10-16
intracoronary	O	17-30
administration	O	31-45
of	O	46-48
methylergonovine	O	49-65
in	O	66-68
patients	O	69-77
with	O	78-82
and	O	83-86
without	O	87-94
variant	B	95-102
angina	I	103-109
.	O	109-110

The	O	111-114
effects	O	115-122
of	O	123-125
intracoronary	O	126-139
administration	O	140-154
of	O	155-157
methylergonovine	O	158-174
were	O	175-179
studied	O	180-187
in	O	188-190
21	O	191-193
patients	O	194-202
with	O	203-207
variant	B	208-215
angina	I	216-222
and	O	223-226
22	O	227-229
patients	O	230-238
with	O	239-243
atypical	O	244-252
chest	B	253-258
pain	I	259-263
and	O	264-267
in	O	268-270
others	O	271-277
without	O	278-285
angina	B	286-292
pectoris	I	293-301
(	O	302-303
control	O	303-310
group	O	311-316
)	O	316-317
.	O	317-318

Methylergonovine	O	319-335
was	O	336-339
administered	O	340-352
continuously	O	353-365
at	O	366-368
a	O	369-370
rate	O	371-375
of	O	376-378
10	O	379-381
micrograms	O	382-392
/	O	392-393
min	O	393-396
up	O	397-399
to	O	400-402
50	O	403-405
micrograms	O	406-416
.	O	416-417

In	O	418-420
all	O	421-424
patients	O	425-433
with	O	434-438
variant	B	439-446
angina	I	447-453
,	O	453-454
coronary	B	455-463
spasm	I	464-469
was	O	470-473
provoked	O	474-482
at	O	483-485
a	O	486-487
mean	O	488-492
dose	O	493-497
of	O	498-500
28	O	501-503
+	O	504-505
/	O	505-506
-	O	506-507
13	O	508-510
micrograms	O	511-521
(	O	522-523
mean	O	523-527
+	O	528-529
/	O	529-530
-	O	530-531
SD	O	532-534
)	O	534-535
.	O	535-536

In	O	537-539
the	O	540-543
control	O	544-551
group	O	552-557
neither	O	558-565
ischemic	O	566-574
ST	O	575-577
change	O	578-584
nor	O	585-588
localized	O	589-598
spasm	B	599-604
occurred	O	605-613
.	O	613-614

The	O	615-618
basal	O	619-624
tone	O	625-629
of	O	630-632
the	O	633-636
right	O	637-642
coronary	O	643-651
artery	O	652-658
was	O	659-662
significantly	O	663-676
lower	O	677-682
than	O	683-687
that	O	688-692
of	O	693-695
the	O	696-699
left	O	700-704
coronary	O	705-713
artery	O	714-720
.	O	720-721

The	O	722-725
percentage	O	726-736
of	O	737-739
vasoconstriction	O	740-756
of	O	757-759
the	O	760-763
right	O	764-769
coronary	O	770-778
artery	O	779-785
was	O	786-789
significantly	O	790-803
higher	O	804-810
than	O	811-815
that	O	816-820
of	O	821-823
the	O	824-827
left	O	828-832
coronary	O	833-841
artery	O	842-848
.	O	848-849

These	O	850-855
results	O	856-863
suggest	O	864-871
that	O	872-876
spasm	B	877-882
provocation	O	883-894
tests	O	895-900
,	O	900-901
which	O	902-907
use	O	908-911
an	O	912-914
intracoronary	O	915-928
injection	O	929-938
of	O	939-941
a	O	942-943
relatively	O	944-954
low	O	955-958
dose	O	959-963
of	O	964-966
methylergonovine	O	967-983
,	O	983-984
have	O	985-989
a	O	990-991
high	O	992-996
sensitivity	O	997-1008
in	O	1009-1011
variant	B	1012-1019
angina	I	1020-1026
and	O	1027-1030
the	O	1031-1034
vasoreactivity	O	1035-1049
of	O	1050-1052
the	O	1053-1056
right	O	1057-1062
coronary	O	1063-1071
artery	O	1072-1078
may	O	1079-1082
be	O	1083-1085
greater	O	1086-1093
than	O	1094-1098
that	O	1099-1103
of	O	1104-1106
the	O	1107-1110
other	O	1111-1116
coronary	O	1117-1125
arteries	O	1126-1134
.	O	1134-1135

Dobutamine	O	0-10
stress	O	11-17
echocardiography	O	18-34
:	O	34-35
a	O	36-37
sensitive	O	38-47
indicator	O	48-57
of	O	58-60
diminished	O	61-71
myocardial	O	72-82
function	O	83-91
in	O	92-94
asymptomatic	O	95-107
doxorubicin	O	108-119
-	O	119-120
treated	O	120-127
long	O	128-132
-	O	132-133
term	O	133-137
survivors	O	138-147
of	O	148-150
childhood	O	151-160
cancer	B	161-167
.	O	167-168

Doxorubicin	O	169-180
is	O	181-183
an	O	184-186
effective	O	187-196
anticancer	O	197-207
chemotherapeutic	O	208-224
agent	O	225-230
known	O	231-236
to	O	237-239
cause	O	240-245
acute	O	246-251
and	O	252-255
chronic	O	256-263
cardiomyopathy	B	264-278
.	O	278-279

To	O	280-282
develop	O	283-290
a	O	291-292
more	O	293-297
sensitive	O	298-307
echocardiographic	O	308-325
screening	O	326-335
test	O	336-340
for	O	341-344
cardiac	B	345-352
damage	I	353-359
due	O	360-363
to	O	364-366
doxorubicin	O	367-378
,	O	378-379
a	O	380-381
cohort	O	382-388
study	O	389-394
was	O	395-398
performed	O	399-408
using	O	409-414
dobutamine	O	415-425
infusion	O	426-434
to	O	435-437
differentiate	O	438-451
asymptomatic	O	452-464
long	O	465-469
-	O	469-470
term	O	470-474
survivors	O	475-484
of	O	485-487
childhood	O	488-497
cancer	B	498-504
treated	O	505-512
with	O	513-517
doxorubicin	O	518-529
from	O	530-534
healthy	O	535-542
control	O	543-550
subjects	O	551-559
.	O	559-560

Echocardiographic	O	561-578
data	O	579-583
from	O	584-588
the	O	589-592
experimental	O	593-605
group	O	606-611
of	O	612-614
21	O	615-617
patients	O	618-626
(	O	627-628
mean	O	628-632
age	O	633-636
16	O	637-639
+	O	640-641
/	O	641-642
-	O	642-643
5	O	644-645
years	O	646-651
)	O	651-652
treated	O	653-660
from	O	661-665
1	O	666-667
.	O	667-668
6	O	668-669
to	O	670-672
14	O	673-675
.	O	675-676
3	O	676-677
years	O	678-683
(	O	684-685
median	O	685-691
5	O	692-693
.	O	693-694
3	O	694-695
)	O	695-696
before	O	697-703
this	O	704-708
study	O	709-714
with	O	715-719
27	O	720-722
to	O	723-725
532	O	726-729
mg	O	730-732
/	O	732-733
m2	O	733-735
of	O	736-738
doxorubicin	O	739-750
(	O	751-752
mean	O	752-756
196	O	757-760
)	O	760-761
were	O	762-766
compared	O	767-775
with	O	776-780
echocardiographic	O	781-798
data	O	799-803
from	O	804-808
12	O	809-811
normal	O	812-818
age	O	819-822
-	O	822-823
matched	O	823-830
control	O	831-838
subjects	O	839-847
.	O	847-848

Graded	O	849-855
dobutamine	O	856-866
infusions	O	867-876
of	O	877-879
0	O	880-881
.	O	881-882
5	O	882-883
,	O	883-884
2	O	885-886
.	O	886-887
5	O	887-888
,	O	888-889
5	O	890-891
and	O	892-895
10	O	896-898
micrograms	O	899-909
/	O	909-910
kg	O	910-912
per	O	913-916
min	O	917-920
were	O	921-925
administered	O	926-938
.	O	938-939

Echocardiographic	O	940-957
Doppler	O	958-965
studies	O	966-973
were	O	974-978
performed	O	979-988
before	O	989-995
infusion	O	996-1004
and	O	1005-1008
after	O	1009-1014
15	O	1015-1017
min	O	1018-1021
of	O	1022-1024
infusion	O	1025-1033
at	O	1034-1036
each	O	1037-1041
rate	O	1042-1046
.	O	1046-1047

Dobutamine	O	1048-1058
infusion	O	1059-1067
at	O	1068-1070
10	O	1071-1073
micrograms	O	1074-1084
/	O	1084-1085
kg	O	1085-1087
per	O	1088-1091
min	O	1092-1095
was	O	1096-1099
discontinued	O	1100-1112
after	O	1113-1118
six	O	1119-1122
studies	O	1123-1130
secondary	O	1131-1140
to	O	1141-1143
a	O	1144-1145
50	O	1146-1148
%	O	1148-1149
incidence	O	1150-1159
rate	O	1160-1164
of	O	1165-1167
adverse	O	1168-1175
symptoms	O	1176-1184
.	O	1184-1185

The	O	1186-1189
most	O	1190-1194
important	O	1195-1204
findings	O	1205-1213
were	O	1214-1218
that	O	1219-1223
compared	O	1224-1232
with	O	1233-1237
values	O	1238-1244
in	O	1245-1247
control	O	1248-1255
subjects	O	1256-1264
,	O	1264-1265
end	O	1266-1269
-	O	1269-1270
systolic	O	1270-1278
left	O	1279-1283
ventricular	O	1284-1295
posterior	O	1296-1305
wall	O	1306-1310
dimension	O	1311-1320
and	O	1321-1324
percent	O	1325-1332
of	O	1333-1335
left	O	1336-1340
ventricular	O	1341-1352
posterior	O	1353-1362
wall	O	1363-1367
thickening	O	1368-1378
in	O	1379-1381
doxorubicin	O	1382-1393
-	O	1393-1394
treated	O	1394-1401
patients	O	1402-1410
were	O	1411-1415
decreased	O	1416-1425
at	O	1426-1428
baseline	O	1429-1437
study	O	1438-1443
and	O	1444-1447
these	O	1448-1453
findings	O	1454-1462
were	O	1463-1467
more	O	1468-1472
clearly	O	1473-1480
delineated	O	1481-1491
with	O	1492-1496
dobutamine	O	1497-1507
stimulation	O	1508-1519
.	O	1519-1520

End	O	1521-1524
-	O	1524-1525
systolic	O	1525-1533
left	O	1534-1538
ventricular	O	1539-1550
posterior	O	1551-1560
wall	O	1561-1565
dimension	O	1566-1575
at	O	1576-1578
baseline	O	1579-1587
for	O	1588-1591
the	O	1592-1595
doxorubicin	O	1596-1607
-	O	1607-1608
treated	O	1608-1615
group	O	1616-1621
was	O	1622-1625
11	O	1626-1628
+	O	1629-1630
/	O	1630-1631
-	O	1631-1632
1	O	1633-1634
.	O	1634-1635
9	O	1635-1636
mm	O	1637-1639
versus	O	1640-1646
13	O	1647-1649
.	O	1649-1650
1	O	1647-1648
+	O	1652-1653
/	O	1653-1654
-	O	1654-1655
1	O	1656-1657
.	O	1657-1658
5	O	1658-1659
mm	O	1660-1662
for	O	1663-1666
control	O	1667-1674
subjects	O	1675-1683
(	O	1684-1685
p	O	1685-1686
less	O	1687-1691
than	O	1692-1696
0	O	1697-1698
.	O	1698-1699
01	O	1699-1701
)	O	1701-1702
.	O	1698-1699

End	O	1704-1707
-	O	1707-1708
systolic	O	1708-1716
left	O	1717-1721
ventricular	O	1722-1733
posterior	O	1734-1743
wall	O	1744-1748
dimension	O	1749-1758
at	O	1759-1761
the	O	1762-1765
5	O	1766-1767
-	O	1767-1768
micrograms	O	1768-1778
/	O	1778-1779
kg	O	1779-1781
per	O	1782-1785
min	O	1786-1789
dobutamine	O	1790-1800
infusion	O	1801-1809
for	O	1810-1813
the	O	1814-1817
doxorubicin	O	1818-1829
-	O	1829-1830
treated	O	1830-1837
group	O	1838-1843
was	O	1844-1847
14	O	1848-1850
.	O	1850-1851
1	O	1848-1849
+	O	1853-1854
/	O	1854-1855
-	O	1855-1856
2	O	1857-1858
.	O	1858-1859
4	O	1859-1860
mm	O	1861-1863
versus	O	1864-1870
19	O	1871-1873
.	O	1873-1874
3	O	1874-1875
+	O	1876-1877
/	O	1877-1878
-	O	1878-1879
2	O	1880-1881
.	O	1881-1882
6	O	1882-1883
mm	O	1884-1886
for	O	1887-1890
control	O	1891-1898
subjects	O	1899-1907
(	O	1908-1909
p	O	1909-1910
less	O	1911-1915
than	O	1916-1920
0	O	1921-1922
.	O	1922-1923
01	O	1923-1925
)	O	1925-1926
.	O	1922-1923
(	O	1927-1928
ABSTRACT	O	1928-1936

TRUNCATED	O	1937-1946
AT	O	1947-1949
250	O	1950-1953
WORDS	O	1954-1959
)	O	1959-1960

Effects	O	0-7
of	O	8-10
aminophylline	O	11-24
on	O	25-27
the	O	28-31
threshold	O	32-41
for	O	42-45
initiating	O	46-56
ventricular	B	57-68
fibrillation	I	69-81
during	O	82-88
respiratory	B	89-100
failure	I	101-108
.	O	108-109

Cardiac	B	110-117
arrhythmias	I	118-129
have	O	130-134
frequently	O	135-145
been	O	146-150
reported	O	151-159
in	O	160-162
association	O	163-174
with	O	175-179
respiratory	B	180-191
failure	I	192-199
.	O	199-200

The	O	201-204
possible	O	205-213
additive	O	214-222
role	O	223-227
of	O	228-230
pharmacologic	O	231-244
agents	O	245-251
in	O	252-254
precipitating	O	255-268
cardiac	B	269-276
disturbances	I	277-289
in	O	290-292
patients	O	293-301
with	O	302-306
respiratory	B	307-318
failure	I	319-326
has	O	327-330
only	O	331-335
recently	O	336-344
been	O	345-349
emphasized	O	350-360
.	O	360-361

The	O	362-365
effects	O	366-373
of	O	374-376
aminophylline	O	377-390
on	O	391-393
the	O	394-397
ventricular	B	398-409
fibrillation	I	410-422
threshold	O	423-432
during	O	433-439
normal	O	440-446
acid	O	447-451
-	O	451-452
base	O	452-456
conditions	O	457-467
and	O	468-471
during	O	472-478
respiratory	B	479-490
failure	I	491-498
were	O	499-503
studied	O	504-511
in	O	512-514
anesthetized	O	515-527
open	O	528-532
chest	O	533-538
dogs	O	539-543
.	O	543-544

The	O	545-548
ventricular	B	549-560
fibrillation	I	561-573
threshold	O	574-583
was	O	584-587
measured	O	588-596
by	O	597-599
passing	O	600-607
a	O	608-609
gated	O	610-615
train	O	616-621
of	O	622-624
12	O	625-627
constant	O	628-636
current	O	637-644
pulses	O	645-651
through	O	652-659
the	O	660-663
ventricular	O	664-675
myocardium	O	676-686
during	O	687-693
the	O	694-697
vulnerable	O	698-708
period	O	709-715
of	O	716-718
the	O	719-722
cardiac	O	723-730
cycle	O	731-736
.	O	736-737

During	O	738-744
the	O	745-748
infusion	O	749-757
of	O	758-760
aminophylline	O	761-774
,	O	774-775
the	O	776-779
ventricular	B	780-791
fibrillation	I	792-804
threshold	O	805-814
was	O	815-818
reduced	O	819-826
by	O	827-829
30	O	830-832
to	O	833-835
40	O	836-838
percent	O	839-846
of	O	847-849
the	O	850-853
control	O	854-861
when	O	862-866
pH	O	867-869
and	O	870-873
partial	O	874-881
pressures	O	882-891
of	O	892-894
oxygen	O	895-901
(	O	902-903
PO2	O	903-906
)	O	906-907
and	O	908-911
carbon	O	912-918
dioxide	O	919-926
(	O	927-928
CO2	O	928-931
)	O	931-932
were	O	933-937
kept	O	938-942
within	O	943-949
normal	O	950-956
limits	O	957-963
.	O	963-964

When	O	965-969
respiratory	B	970-981
failure	I	982-989
was	O	990-993
produced	O	994-1002
by	O	1003-1005
hypoventilation	B	1006-1021
(	O	1022-1023
pH	O	1023-1025
7	O	1026-1027
.	O	1027-1028
05	O	1028-1030
to	O	1031-1033
7	O	1034-1035
.	O	1035-1036
25	O	1036-1038
;	O	1038-1039
PC02	O	1040-1044
70	O	1045-1047
to	O	1048-1050
100	O	1051-1054
mm	O	1055-1057
Hg	O	1058-1060
:	O	1060-1061
P02	O	1062-1065
20	O	1066-1068
to	O	1069-1071
40	O	1072-1074
mm	O	1075-1077
Hg	O	1078-1080
)	O	1080-1081
,	O	1081-1082
infusion	O	1083-1091
of	O	1092-1094
aminophylline	O	1095-1108
resulted	O	1109-1117
in	O	1118-1120
an	O	1121-1123
even	O	1124-1128
greater	O	1129-1136
decrease	O	1137-1145
in	O	1146-1148
ventricular	B	1149-1160
fibrillation	I	1161-1173
threshold	O	1174-1183
to	O	1184-1186
60	O	1187-1189
percent	O	1190-1197
of	O	1198-1200
the	O	1201-1204
control	O	1205-1212
level	O	1213-1218
.	O	1218-1219

These	O	1220-1225
experiments	O	1226-1237
suggest	O	1238-1245
that	O	1246-1250
although	O	1251-1259
many	O	1260-1264
factors	O	1265-1272
may	O	1273-1276
contribute	O	1277-1287
to	O	1288-1290
the	O	1291-1294
increased	O	1295-1304
incidence	O	1305-1314
of	O	1315-1317
ventricular	B	1318-1329
arrhythmias	I	1330-1341
in	O	1342-1344
respiratory	B	1345-1356
failure	I	1357-1364
,	O	1364-1365
pharmacologic	O	1366-1379
agents	O	1380-1386
,	O	1386-1387
particularly	O	1388-1400
aminophylline	O	1401-1414
,	O	1414-1415
may	O	1416-1419
play	O	1420-1424
a	O	1425-1426
significant	O	1427-1438
role	O	1439-1443
.	O	1443-1444

Case	O	0-4
report	O	5-11
:	O	11-12
acute	O	13-18
unintentional	O	19-32
carbachol	O	33-42
intoxication	O	43-55
.	O	55-56

INTRODUCTION	O	57-69
:	O	69-70
Intoxications	O	71-84
with	O	85-89
carbachol	O	90-99
,	O	99-100
a	O	101-102
muscarinic	O	103-113
cholinergic	O	114-125
receptor	O	126-134
agonist	O	135-142
are	O	143-146
rare	O	147-151
.	O	151-152

We	O	153-155
report	O	156-162
an	O	163-165
interesting	O	166-177
case	O	178-182
investigating	O	183-196
a	O	197-198
(	O	199-200
near	O	200-204
)	O	204-205
fatal	O	206-211
poisoning	B	212-221
.	O	221-222

METHODS	O	223-230
:	O	230-231
The	O	232-235
son	O	236-239
of	O	240-242
an	O	243-245
84	O	246-248
-	O	248-249
year	O	249-253
-	O	248-249
old	O	254-257
male	O	258-262
discovered	O	263-273
a	O	274-275
newspaper	O	276-285
report	O	286-292
stating	O	293-300
clinical	O	301-309
success	O	310-317
with	O	318-322
plant	O	323-328
extracts	O	329-337
in	O	338-340
Alzheimer	B	341-350
'	I	350-351
s	I	351-352
disease	I	353-360
.	O	360-361

The	O	362-365
mode	O	366-370
of	O	371-373
action	O	374-380
was	O	381-384
said	O	385-389
to	O	390-392
be	O	393-395
comparable	O	396-406
to	O	407-409
that	O	410-414
of	O	415-417
the	O	418-421
synthetic	O	422-431
compound	O	432-440
'	O	441-442
carbamylcholin	O	442-456
'	O	441-442
;	O	457-458
that	O	459-463
is	O	464-466
,	O	466-467
carbachol	O	468-477
.	O	477-478

He	O	479-481
bought	O	482-488
25	O	489-491
g	O	492-493
of	O	494-496
carbachol	O	497-506
as	O	507-509
pure	O	510-514
substance	O	515-524
in	O	525-527
a	O	528-529
pharmacy	O	530-538
,	O	538-539
and	O	540-543
the	O	544-547
father	O	548-554
was	O	555-558
administered	O	559-571
400	O	572-575
to	O	576-578
500	O	579-582
mg	O	583-585
.	O	585-586

Carbachol	O	587-596
concentrations	O	597-611
in	O	612-614
serum	O	615-620
and	O	621-624
urine	O	625-630
on	O	631-633
day	O	634-637
1	O	638-639
and	O	640-643
2	O	644-645
of	O	646-648
hospital	O	649-657
admission	O	658-667
were	O	668-672
analysed	O	673-681
by	O	682-684
HPLC	O	685-689
-	O	689-690
mass	O	690-694
spectrometry	O	695-707
.	O	707-708

RESULTS	O	709-716
:	O	716-717
Minutes	O	718-725
after	O	726-731
oral	O	732-736
administration	O	737-751
,	O	751-752
the	O	753-756
patient	O	757-764
developed	O	765-774
nausea	B	775-781
,	O	781-782
sweating	O	783-791
and	O	792-795
hypotension	B	796-807
,	O	807-808
and	O	809-812
finally	O	813-820
collapsed	O	821-830
.	O	830-831

Bradycardia	B	832-843
,	O	843-844
cholinergic	O	845-856
symptoms	O	857-865
and	O	866-869
asystole	B	870-878
occurred	O	879-887
.	O	887-888

Initial	O	889-896
cardiopulmonary	O	897-912
resuscitation	O	913-926
and	O	927-930
immediate	O	931-940
treatment	O	941-950
with	O	951-955
adrenaline	O	956-966
(	O	967-968
epinephrine	O	968-979
)	O	979-980
,	O	980-981
atropine	O	982-990
and	O	991-994
furosemide	O	995-1005
was	O	1006-1009
successful	O	1010-1020
.	O	1020-1021

On	O	1022-1024
hospital	O	1025-1033
admission	O	1034-1043
,	O	1043-1044
blood	O	1045-1050
pressure	O	1051-1059
of	O	1060-1062
the	O	1063-1066
intubated	O	1067-1076
,	O	1076-1077
bradyarrhythmic	O	1078-1093
patient	O	1094-1101
was	O	1102-1105
100	O	1106-1109
/	O	1109-1110
65	O	1110-1112
mmHg	O	1113-1117
.	O	1117-1118

Further	O	1119-1126
signs	O	1127-1132
were	O	1133-1137
hyperhidrosis	B	1138-1151
,	O	1151-1152
hypersalivation	B	1153-1168
,	O	1168-1169
bronchorrhoea	B	1170-1183
,	O	1183-1184
and	O	1185-1188
severe	O	1189-1195
miosis	B	1196-1202
;	O	1202-1203
the	O	1204-1207
electrocardiographic	O	1208-1228
finding	O	1229-1236
was	O	1237-1240
atrio	B	1241-1246
-	I	1246-1247
ventricular	I	1247-1258
dissociation	I	1259-1271
.	O	1271-1272

High	O	1273-1277
doses	O	1278-1283
of	O	1284-1286
atropine	O	1287-1295
(	O	1296-1297
up	O	1297-1299
to	O	1300-1302
50	O	1303-1305
mg	O	1306-1308
per	O	1309-1312
24	O	1313-1315
hours	O	1316-1321
)	O	1321-1322
,	O	1322-1323
adrenaline	O	1324-1334
and	O	1335-1338
dopamine	O	1339-1347
were	O	1348-1352
necessary	O	1353-1362
.	O	1362-1363

The	O	1364-1367
patient	O	1368-1375
was	O	1376-1379
extubated	O	1380-1389
1	O	1390-1391
week	O	1392-1396
later	O	1397-1402
.	O	1402-1403

However	O	1404-1411
,	O	1411-1412
increased	O	1413-1422
dyspnoea	B	1423-1431
and	O	1432-1435
bronchospasm	B	1436-1448
necessitated	O	1449-1461
reintubation	O	1462-1474
.	O	1474-1475

Respiratory	B	1476-1487
insufficiency	I	1488-1501
was	O	1502-1505
further	O	1506-1513
worsened	O	1514-1522
by	O	1523-1525
Proteus	B	1526-1533
mirabilis	I	1534-1543
infection	I	1544-1553
and	O	1554-1557
severe	O	1558-1564
bronchoconstriction	O	1565-1584
.	O	1584-1585

One	O	1586-1589
week	O	1590-1594
later	O	1595-1600
,	O	1600-1601
the	O	1602-1605
patient	O	1606-1613
was	O	1614-1617
again	O	1618-1623
extubated	O	1624-1633
and	O	1634-1637
3	O	1638-1639
days	O	1640-1644
later	O	1645-1650
was	O	1651-1654
transferred	O	1655-1666
to	O	1667-1669
a	O	1670-1671
peripheral	O	1672-1682
ward	O	1683-1687
.	O	1687-1688

On	O	1689-1691
the	O	1692-1695
next	O	1696-1700
day	O	1701-1704
he	O	1705-1707
died	O	1708-1712
,	O	1712-1713
probably	O	1714-1722
as	O	1723-1725
a	O	1726-1727
result	O	1728-1734
of	O	1735-1737
heart	B	1738-1743
failure	I	1744-1751
.	O	1751-1752

Serum	O	1753-1758
samples	O	1759-1766
from	O	1767-1771
the	O	1772-1775
first	O	1776-1781
and	O	1782-1785
second	O	1786-1792
days	O	1793-1797
contained	O	1798-1807
3	O	1808-1809
.	O	1809-1810
6	O	1810-1811
and	O	1812-1815
1	O	1816-1817
.	O	1817-1818
9	O	1818-1819
mg	O	1820-1822
/	O	1822-1823
l	O	1823-1824
carbachol	O	1825-1834
,	O	1834-1835
respectively	O	1836-1848
.	O	1848-1849

The	O	1850-1853
corresponding	O	1854-1867
urine	O	1868-1873
concentrations	O	1874-1888
amounted	O	1889-1897
to	O	1898-1900
374	O	1901-1904
and	O	1905-1908
554	O	1909-1912
mg	O	1913-1915
/	O	1915-1916
l	O	1916-1917
.	O	1917-1918

CONCLUSION	O	1919-1929
:	O	1929-1930
This	O	1931-1935
case	O	1936-1940
started	O	1941-1948
with	O	1949-1953
a	O	1954-1955
media	O	1956-1961
report	O	1962-1968
in	O	1969-1971
a	O	1972-1973
popular	O	1974-1981
newspaper	O	1982-1991
,	O	1991-1992
initiated	O	1993-2002
by	O	2003-2005
published	O	2006-2015
,	O	2015-2016
peer	O	2017-2021
-	O	2021-2022
reviewed	O	2022-2030
research	O	2031-2039
on	O	2040-2042
herbals	O	2043-2050
,	O	2050-2051
and	O	2052-2055
involved	O	2056-2064
human	O	2065-2070
failure	O	2071-2078
in	O	2079-2081
a	O	2082-2083
case	O	2084-2088
history	O	2089-2096
,	O	2096-2097
medical	O	2098-2105
examination	O	2106-2117
and	O	2118-2121
clinical	O	2122-2130
treatment	O	2131-2140
.	O	2140-2141

For	O	2142-2145
the	O	2146-2149
first	O	2150-2155
time	O	2156-2160
,	O	2160-2161
an	O	2162-2164
analytical	O	2165-2175
method	O	2176-2182
for	O	2183-2186
the	O	2187-2190
determination	O	2191-2204
of	O	2205-2207
carbachol	O	2208-2217
in	O	2218-2220
plasma	O	2221-2227
and	O	2228-2231
urine	O	2232-2237
has	O	2238-2241
been	O	2242-2246
developed	O	2247-2256
.	O	2256-2257

The	O	2258-2261
analysed	O	2262-2270
carbachol	O	2271-2280
concentration	O	2281-2294
exceeded	O	2295-2303
the	O	2304-2307
supposed	O	2308-2316
serum	O	2317-2322
level	O	2323-2328
resulting	O	2329-2338
from	O	2339-2343
a	O	2344-2345
therapeutic	O	2346-2357
dose	O	2358-2362
by	O	2363-2365
a	O	2366-2367
factor	O	2368-2374
of	O	2375-2377
130	O	2378-2381
to	O	2382-2384
260	O	2385-2388
.	O	2388-2389

Especially	O	2390-2400
in	O	2401-2403
old	O	2404-2407
patients	O	2408-2416
,	O	2416-2417
intensivists	O	2418-2430
should	O	2431-2437
consider	O	2438-2446
intoxications	O	2447-2460
(	O	2461-2462
with	O	2462-2466
cholinergics	O	2467-2479
)	O	2479-2480
as	O	2481-2483
a	O	2484-2485
cause	O	2486-2491
of	O	2492-2494
acute	B	2495-2500
cardiovascular	I	2501-2515
failure	I	2516-2523
.	O	2523-2524

Crossover	O	0-9
comparison	O	10-20
of	O	21-23
efficacy	O	24-32
and	O	33-36
preference	O	37-47
for	O	48-51
rizatriptan	O	52-63
10	O	64-66
mg	O	67-69
versus	O	70-76
ergotamine	O	77-87
/	O	87-88
caffeine	O	88-96
in	O	97-99
migraine	B	100-108
.	O	108-109

Rizatriptan	O	110-121
is	O	122-124
a	O	125-126
selective	O	127-136
5	O	137-138
-	O	138-139
HT	O	139-141
(	O	141-142
1B	O	142-144
/	O	144-145
1D	O	145-147
)	O	147-148
receptor	O	149-157
agonist	O	158-165
with	O	166-170
rapid	O	171-176
oral	O	177-181
absorption	O	182-192
and	O	193-196
early	O	197-202
onset	O	203-208
of	O	209-211
action	O	212-218
in	O	219-221
the	O	222-225
acute	O	226-231
treatment	O	232-241
of	O	242-244
migraine	B	245-253
.	O	253-254

This	O	255-259
randomized	O	260-270
double	O	271-277
-	O	277-278
blind	O	279-284
crossover	O	285-294
outpatient	O	295-305
study	O	306-311
assessed	O	312-320
the	O	321-324
preference	O	325-335
for	O	336-339
1	O	340-341
rizatriptan	O	342-353
10	O	354-356
mg	O	357-359
tablet	O	360-366
to	O	367-369
2	O	370-371
ergotamine	O	372-382
1	O	383-384
mg	O	385-387
/	O	387-388
caffeine	O	388-396
100	O	397-400
mg	O	401-403
tablets	O	404-411
in	O	412-414
439	O	415-418
patients	O	419-427
treating	O	428-436
a	O	437-438
single	O	439-445
migraine	B	446-454
attack	O	455-461
with	O	462-466
each	O	467-471
therapy	O	472-479
.	O	479-480

Of	O	481-483
patients	O	484-492
expressing	O	493-503
a	O	504-505
preference	O	506-516
(	O	517-518
89	O	518-520
.	O	520-521
1	O	521-522
%	O	522-523
)	O	523-524
,	O	524-525
more	O	526-530
than	O	531-535
twice	O	536-541
as	O	542-544
many	O	545-549
preferred	O	550-559
rizatriptan	O	560-571
to	O	572-574
ergotamine	O	575-585
/	O	585-586
caffeine	O	586-594
(	O	595-596
69	O	596-598
.	O	598-599
9	O	597-598
vs	O	601-603
.	O	603-604
30	O	605-607
.	O	607-608
1	O	608-609
%	O	609-610
,	O	610-611

p	O	612-613
<	O	614-615
or	O	616-618
=	O	619-620
0	O	621-622
.	O	622-623
001	O	623-626
)	O	626-627
.	O	622-623

Faster	O	629-635
relief	O	636-642
of	O	643-645
headache	B	646-654
was	O	655-658
the	O	659-662
most	O	663-667
important	O	668-677
reason	O	678-684
for	O	685-688
preference	O	689-699
,	O	699-700
cited	O	701-706
by	O	707-709
67	O	710-712
.	O	712-713
3	O	713-714
%	O	714-715
of	O	716-718
patients	O	719-727
preferring	O	728-738
rizatriptan	O	739-750
and	O	751-754
54	O	755-757
.	O	757-758
2	O	758-759
%	O	759-760
of	O	761-763
patients	O	764-772
who	O	773-776
preferred	O	777-786
ergotamine	O	787-797
/	O	797-798
caffeine	O	798-806
.	O	806-807

The	O	808-811
co	O	812-814
-	O	814-815
primary	O	815-822
endpoint	O	823-831
of	O	832-834
being	O	835-840
pain	B	841-845
free	O	846-850
at	O	851-853
2	O	854-855
h	O	856-857
was	O	858-861
also	O	862-866
in	O	867-869
favor	O	870-875
of	O	876-878
rizatriptan	O	879-890
.	O	890-891

Forty	O	892-897
-	O	897-898
nine	O	898-902
percent	O	903-910
of	O	911-913
patients	O	914-922
were	O	923-927
pain	B	928-932
free	O	933-937
2	O	938-939
h	O	940-941
after	O	942-947
rizatriptan	O	948-959
,	O	959-960
compared	O	961-969
with	O	970-974
24	O	975-977
.	O	977-978
3	O	978-979
%	O	979-980
treated	O	981-988
with	O	989-993
ergotamine	O	994-1004
/	O	1004-1005
caffeine	O	1005-1013
(	O	1014-1015
p	O	1015-1016
<	O	1017-1018
or	O	1019-1021
=	O	1022-1023
0	O	1024-1025
.	O	1025-1026
001	O	1026-1029
)	O	1029-1030
,	O	1030-1031
rizatriptan	O	1032-1043
being	O	1044-1049
superior	O	1050-1058
within	O	1059-1065
1	O	1066-1067
h	O	1068-1069
of	O	1070-1072
treatment	O	1073-1082
.	O	1082-1083

Headache	B	1084-1092
relief	O	1093-1099
at	O	1100-1102
2	O	1103-1104
h	O	1105-1106
was	O	1107-1110
75	O	1111-1113
.	O	1113-1114
9	O	1114-1115
%	O	1115-1116
for	O	1117-1120
rizatriptan	O	1121-1132
and	O	1133-1136
47	O	1137-1139
.	O	1139-1140
3	O	1140-1141
%	O	1141-1142
for	O	1143-1146
ergotamine	O	1147-1157
/	O	1157-1158
caffeine	O	1158-1166
(	O	1167-1168
p	O	1168-1169
<	O	1170-1171
or	O	1172-1174
=	O	1175-1176
0	O	1177-1178
.	O	1178-1179
001	O	1179-1182
)	O	1182-1183
,	O	1183-1184
with	O	1185-1189
rizatriptan	O	1190-1201
being	O	1202-1207
superior	O	1208-1216
to	O	1217-1219
ergotamine	O	1220-1230
/	O	1230-1231
caffeine	O	1231-1239
within	O	1240-1246
30	O	1247-1249
min	O	1250-1253
of	O	1254-1256
dosing	O	1257-1263
.	O	1263-1264

Almost	O	1265-1271
36	O	1272-1274
%	O	1274-1275
of	O	1276-1278
patients	O	1279-1287
taking	O	1288-1294
rizatriptan	O	1295-1306
were	O	1307-1311
pain	B	1312-1316
free	O	1317-1321
at	O	1322-1324
2	O	1325-1326
h	O	1327-1328
and	O	1329-1332
had	O	1333-1336
no	O	1337-1339
recurrence	O	1340-1350
or	O	1351-1353
need	O	1354-1358
for	O	1359-1362
additional	O	1363-1373
medication	O	1374-1384
within	O	1385-1391
24	O	1392-1394
h	O	1395-1396
,	O	1396-1397
compared	O	1398-1406
to	O	1407-1409
20	O	1410-1412
%	O	1412-1413
of	O	1414-1416
patients	O	1417-1425
on	O	1426-1428
ergotamine	O	1429-1439
/	O	1439-1440
caffeine	O	1440-1448
(	O	1449-1450
p	O	1450-1451
<	O	1452-1453
or	O	1454-1456
=	O	1457-1458
0	O	1459-1460
.	O	1460-1461
001	O	1461-1464
)	O	1464-1465
.	O	1460-1461

Rizatriptan	O	1467-1478
was	O	1479-1482
also	O	1483-1487
superior	O	1488-1496
to	O	1497-1499
ergotamine	O	1500-1510
/	O	1510-1511
caffeine	O	1511-1519
in	O	1520-1522
the	O	1523-1526
proportions	O	1527-1538
of	O	1539-1541
patients	O	1542-1550
with	O	1551-1555
no	O	1556-1558
nausea	B	1559-1565
,	O	1565-1566
vomiting	B	1567-1575
,	O	1575-1576
phonophobia	B	1577-1588
or	O	1589-1591
photophobia	B	1592-1603
and	O	1604-1607
for	O	1608-1611
patients	O	1612-1620
with	O	1621-1625
normal	O	1626-1632
function	O	1633-1641
2	O	1642-1643
h	O	1644-1645
after	O	1646-1651
drug	O	1652-1656
intake	O	1657-1663
(	O	1664-1665
p	O	1665-1666
<	O	1667-1668
or	O	1669-1671
=	O	1672-1673
0	O	1674-1675
.	O	1675-1676
001	O	1676-1679
)	O	1679-1680
.	O	1675-1676

More	O	1682-1686
patients	O	1687-1695
were	O	1696-1700
(	O	1701-1702
completely	O	1702-1712
,	O	1712-1713
very	O	1714-1718
or	O	1719-1721
somewhat	O	1722-1730
)	O	1730-1731
satisfied	O	1732-1741
2	O	1742-1743
h	O	1744-1745
after	O	1746-1751
treatment	O	1752-1761
with	O	1762-1766
rizatriptan	O	1767-1778
(	O	1779-1780
69	O	1780-1782
.	O	1782-1783
8	O	1783-1784
%	O	1784-1785
)	O	1785-1786
than	O	1787-1791
at	O	1792-1794
2	O	1795-1796
h	O	1797-1798
after	O	1799-1804
treatment	O	1805-1814
with	O	1815-1819
ergotamine	O	1820-1830
/	O	1830-1831
caffeine	O	1831-1839
(	O	1840-1841
38	O	1841-1843
.	O	1843-1844
6	O	1844-1845
%	O	1845-1846
,	O	1846-1847
p	O	1848-1849
<	O	1850-1851
or	O	1852-1854
=	O	1855-1856
0	O	1857-1858
.	O	1858-1859
001	O	1859-1862
)	O	1862-1863
.	O	1858-1859

Recurrence	O	1865-1875
rates	O	1876-1881
were	O	1882-1886
31	O	1887-1889
.	O	1889-1890
4	O	1890-1891
%	O	1891-1892
with	O	1893-1897
rizatriptan	O	1898-1909
and	O	1910-1913
15	O	1914-1916
.	O	1916-1917
3	O	1917-1918
%	O	1918-1919
with	O	1920-1924
ergotamine	O	1925-1935
/	O	1935-1936
caffeine	O	1936-1944
.	O	1944-1945

Both	O	1946-1950
active	O	1951-1957
treatments	O	1958-1968
were	O	1969-1973
well	O	1974-1978
tolerated	O	1979-1988
.	O	1988-1989

The	O	1990-1993
most	O	1994-1998
common	O	1999-2005
adverse	O	2006-2013
events	O	2014-2020
(	O	2021-2022
incidence	O	2022-2031
>	O	2032-2033
or	O	2034-2036
=	O	2037-2038
5	O	2039-2040
%	O	2040-2041
in	O	2042-2044
one	O	2045-2048
group	O	2049-2054
)	O	2054-2055
after	O	2056-2061
rizatriptan	O	2062-2073
and	O	2074-2077
ergotamine	O	2078-2088
/	O	2088-2089
caffeine	O	2089-2097
,	O	2097-2098
respectively	O	2099-2111
,	O	2111-2112
were	O	2113-2117
dizziness	B	2118-2127
(	O	2128-2129
6	O	2129-2130
.	O	2130-2131
7	O	2131-2132
and	O	2133-2136
5	O	2137-2138
.	O	2138-2139
3	O	2139-2140
%	O	2140-2141
)	O	2141-2142
,	O	2142-2143
nausea	B	2144-2150
(	O	2151-2152
4	O	2152-2153
.	O	2153-2154
2	O	2154-2155
and	O	2156-2159
8	O	2160-2161
.	O	2161-2162
5	O	2162-2163
%	O	2163-2164
)	O	2164-2165
and	O	2166-2169
somnolence	B	2170-2180
(	O	2181-2182
5	O	2182-2183
.	O	2183-2184
5	O	2182-2183
and	O	2186-2189
2	O	2190-2191
.	O	2191-2192
3	O	2192-2193
%	O	2193-2194
)	O	2194-2195
.	O	2191-2192

Thrombotic	B	0-10
microangiopathy	I	11-26
and	O	27-30
renal	B	31-36
failure	I	37-44
associated	O	45-55
with	O	56-60
antineoplastic	O	61-75
chemotherapy	O	76-88
.	O	88-89

Five	O	90-94
patients	O	95-103
with	O	104-108
carcinoma	B	109-118
developed	O	119-128
thrombotic	B	129-139
microangiopathy	I	140-155
(	O	156-157
characterized	O	157-170
by	O	171-173
renal	B	174-179
insufficiency	I	180-193
,	O	193-194
microangiopathic	B	195-211
hemolytic	I	212-221
anemia	I	222-228
,	O	228-229
and	O	230-233
usually	O	234-241
thrombocytopenia	B	242-258
)	O	258-259
after	O	260-265
treatment	O	266-275
with	O	276-280
cisplatin	O	281-290
,	O	290-291
bleomycin	O	292-301
,	O	301-302
and	O	303-306
a	O	307-308
vinca	O	309-314
alkaloid	O	315-323
.	O	323-324

One	O	325-328
patient	O	329-336
had	O	337-340
thrombotic	B	341-351
thrombocytopenic	I	352-368
purpura	I	369-376
,	O	376-377
three	O	378-383
the	O	384-387
hemolytic	B	388-397
-	I	397-398
uremic	I	398-404
syndrome	I	405-413
,	O	413-414
and	O	415-418
one	O	419-422
an	O	423-425
apparent	O	426-434
forme	O	435-440
fruste	O	441-447
of	O	448-450
one	O	451-454
of	O	455-457
these	O	458-463
disorders	O	464-473
.	O	473-474

Histologic	O	475-485
examination	O	486-497
of	O	498-500
the	O	501-504
renal	O	505-510
tissue	O	511-517
showed	O	518-524
evidence	O	525-533
of	O	534-536
intravascular	B	537-550
coagulation	I	551-562
,	O	562-563
primarily	O	564-573
affecting	O	574-583
the	O	584-587
small	O	588-593
arteries	O	594-602
,	O	602-603
arterioles	O	604-614
,	O	614-615
and	O	616-619
glomeruli	O	620-629
.	O	629-630

Because	O	631-638
each	O	639-643
patient	O	644-651
was	O	652-655
tumor	B	656-661
-	O	661-662
free	O	662-666
or	O	667-669
had	O	670-673
only	O	674-678
a	O	679-680
small	O	681-686
tumor	B	687-692
at	O	693-695
the	O	696-699
onset	O	700-705
of	O	706-708
this	O	709-713
syndrome	O	714-722
,	O	722-723
the	O	724-727
thrombotic	B	728-738
microangiopathy	I	739-754
may	O	755-758
have	O	759-763
been	O	764-768
induced	O	769-776
by	O	777-779
chemotherapy	O	780-792
.	O	792-793

Diagnosis	O	794-803
of	O	804-806
this	O	807-811
potentially	O	812-823
fatal	O	824-829
complication	O	830-842
may	O	843-846
be	O	847-849
delayed	O	850-857
or	O	858-860
missed	O	861-867
if	O	868-870
renal	O	871-876
tissue	O	877-883
or	O	884-886
the	O	887-890
peripheral	O	891-901
blood	O	902-907
smear	O	908-913
is	O	914-916
not	O	917-920
examined	O	921-929
,	O	929-930
because	O	931-938
renal	B	939-944
failure	I	945-952
may	O	953-956
be	O	957-959
ascribed	O	960-968
to	O	969-971
cisplatin	O	972-981
nephrotoxicity	B	982-996
and	O	997-1000
the	O	1001-1004
anemia	B	1005-1011
and	O	1012-1015
thrombocytopenia	B	1016-1032
to	O	1033-1035
drug	O	1036-1040
-	O	1040-1041
induced	O	1041-1048
bone	B	1049-1053
marrow	I	1054-1060
suppression	I	1061-1072
.	O	1072-1073

Salvage	O	0-7
therapy	O	8-15
with	O	16-20
nelarabine	O	21-31
,	O	31-32
etoposide	O	33-42
,	O	42-43
and	O	44-47
cyclophosphamide	O	48-64
in	O	65-67
relapsed	O	68-76
/	O	76-77
refractory	O	77-87
paediatric	O	88-98
T	B	99-100
-	I	100-101
cell	I	101-105
lymphoblastic	I	106-119
leukaemia	I	120-129
and	I	130-133
lymphoma	I	134-142
.	O	142-143

A	O	144-145
combination	O	146-157
of	O	158-160
5	O	161-162
d	O	163-164
of	O	165-167
nelarabine	O	168-178
(	O	179-180
AraG	O	180-184
)	O	184-185
with	O	186-190
5	O	191-192
d	O	193-194
of	O	195-197
etoposide	O	198-207
(	O	208-209
VP	O	209-211
)	O	211-212
and	O	213-216
cyclophosphamide	O	217-233
(	O	234-235
CPM	O	235-238
)	O	238-239
and	O	240-243
prophylactic	O	244-256
intrathecal	O	257-268
chemotherapy	O	269-281
was	O	282-285
used	O	286-290
as	O	291-293
salvage	O	294-301
therapy	O	302-309
in	O	310-312
seven	O	313-318
children	O	319-327
with	O	328-332
refractory	O	333-343
or	O	344-346
relapsed	O	347-355
T	B	356-357
-	I	357-358
cell	I	358-362
leukaemia	I	363-372
or	I	373-375
lymphoma	I	376-384
.	O	384-385

The	O	386-389
most	O	390-394
common	O	395-401
side	O	402-406
effects	O	407-414
attributable	O	415-427
to	O	428-430
the	O	431-434
AraG	O	435-439
included	O	440-448
Grade	O	449-454
2	O	455-456
and	O	457-460
3	O	461-462
sensory	O	463-470
and	O	471-474
motor	O	475-480
neuropathy	B	481-491
and	O	492-495
musculoskeletal	B	496-511
pain	I	512-516
.	O	516-517

Haematological	B	518-532
toxicity	I	533-541
was	O	542-545
greater	O	546-553
for	O	554-557
the	O	558-561
combination	O	562-573
than	O	574-578
AraG	O	579-583
alone	O	584-589
,	O	589-590
although	O	591-599
median	O	600-606
time	O	607-611
to	O	612-614
neutrophil	O	615-625
and	O	626-629
platelet	O	630-638
recovery	O	639-647
was	O	648-651
consistent	O	652-662
with	O	663-667
other	O	668-673
salvage	O	674-681
therapies	O	682-691
.	O	691-692

All	O	693-696
patients	O	697-705
had	O	706-709
some	O	710-714
response	O	715-723
to	O	724-726
the	O	727-730
combined	O	731-739
therapy	O	740-747
and	O	748-751
five	O	752-756
of	O	757-759
the	O	760-763
seven	O	764-769
went	O	770-774
into	O	775-779
complete	O	780-788
remission	O	789-798
after	O	799-804
one	O	805-808
or	O	809-811
two	O	812-815
courses	O	816-823
of	O	824-826
AraG	O	827-831
/	O	831-832
VP	O	832-834
/	O	831-832
CPM	O	835-838
.	O	838-839

Our	O	840-843
experience	O	844-854
supports	O	855-863
the	O	864-867
safety	O	868-874
of	O	875-877
giving	O	878-884
AraG	O	885-889
as	O	890-892
salvage	O	893-900
therapy	O	901-908
in	O	909-911
synchrony	O	912-921
with	O	922-926
etoposide	O	927-936
and	O	937-940
cyclophosphamide	O	941-957
,	O	957-958
although	O	959-967
neurological	B	968-980
toxicity	I	981-989
must	O	990-994
be	O	995-997
closely	O	998-1005
monitored	O	1006-1015
.	O	1015-1016

The	O	0-3
3	O	4-5
-	O	5-6
week	O	6-10
sulphasalazine	O	11-25
syndrome	O	26-34
strikes	O	35-42
again	O	43-48
.	O	48-49

A	O	50-51
34	O	52-54
-	O	54-55
year	O	55-59
-	O	54-55
old	O	60-63
lady	O	64-68
developed	O	69-78
a	O	79-80
constellation	O	81-94
of	O	95-97
dermatitis	B	98-108
,	O	108-109
fever	B	110-115
,	O	115-116
lymphadenopathy	B	117-132
and	O	133-136
hepatitis	B	137-146
,	O	146-147
beginning	O	148-157
on	O	158-160
the	O	161-164
17th	O	165-169
day	O	170-173
of	O	174-176
a	O	177-178
course	O	179-185
of	O	186-188
oral	O	189-193
sulphasalazine	O	194-208
for	O	209-212
sero	O	213-217
-	O	217-218
negative	O	218-226
rheumatoid	B	227-237
arthritis	I	238-247
.	O	247-248

Cervical	O	249-257
and	O	258-261
inguinal	O	262-270
lymph	O	271-276
node	O	277-281
biopsies	O	282-290
showed	O	291-297
the	O	298-301
features	O	302-310
of	O	311-313
severe	O	314-320
necrotising	O	321-332
lymphadenitis	B	333-346
,	O	346-347
associated	O	348-358
with	O	359-363
erythrophagocytosis	O	364-383
and	O	384-387
prominent	O	388-397
eosinophilic	O	398-410
infiltrates	O	411-422
,	O	422-423
without	O	424-431
viral	O	432-437
inclusion	O	438-447
bodies	O	448-454
,	O	454-455
suggestive	O	456-466
of	O	467-469
an	O	470-472
adverse	B	473-480
drug	I	481-485
reaction	I	486-494
.	O	494-495
A	O	495-496
week	O	497-501
later	O	502-507
,	O	507-508
fulminant	O	509-518
drug	B	519-523
-	I	523-524
induced	I	524-531
hepatitis	I	532-541
,	O	541-542
associated	O	543-553
with	O	554-558
the	O	559-562
presence	O	563-571
of	O	572-574
anti	O	575-579
-	O	579-580
nuclear	O	580-587
autoantibodies	O	588-602
(	O	603-604
but	O	604-607
not	O	608-611
with	O	612-616
other	O	617-622
markers	O	623-630
of	O	631-633
autoimmunity	B	634-646
)	O	646-647
,	O	647-648
and	O	649-652
accompanied	O	653-664
by	O	665-667
multi	B	668-673
-	I	673-674
organ	I	674-679
failure	I	680-687
and	O	688-691
sepsis	B	692-698
,	O	698-699
supervened	O	700-710
.	O	710-711

She	O	712-715
subsequently	O	716-728
died	O	729-733
some	O	734-738
5	O	739-740
weeks	O	741-746
after	O	747-752
the	O	753-756
commencement	O	757-769
of	O	770-772
her	O	773-776
drug	O	777-781
therapy	O	782-789
.	O	789-790
Post	O	790-794
-	O	794-795
mortem	O	795-801
examination	O	802-813
showed	O	814-820
evidence	O	821-829
of	O	830-832
massive	B	833-840
hepatocellular	I	841-855
necrosis	I	856-864
,	O	864-865
acute	O	866-871
hypersensitivity	O	872-888
myocarditis	B	889-900
,	O	900-901
focal	O	902-907
acute	O	908-913
tubulo	O	914-920
-	O	920-921
interstitial	O	921-933
nephritis	B	934-943
and	O	944-947
extensive	O	948-957
bone	B	958-962
marrow	I	963-969
necrosis	I	970-978
,	O	978-979
with	O	980-984
no	O	985-987
evidence	O	988-996
of	O	997-999
malignancy	B	1000-1010
.	O	1010-1011

It	O	1012-1014
is	O	1015-1017
thought	O	1018-1025
that	O	1026-1030
the	O	1031-1034
clinico	O	1035-1042
-	O	1042-1043
pathological	O	1043-1055
features	O	1056-1064
and	O	1065-1068
chronology	O	1069-1079
of	O	1080-1082
this	O	1083-1087
case	O	1088-1092
bore	O	1093-1097
the	O	1098-1101
hallmarks	O	1102-1111
of	O	1112-1114
the	O	1115-1118
so	O	1119-1121
-	O	1121-1122
called	O	1122-1128
"	O	1129-1130
3	O	1130-1131
-	O	1131-1132
week	O	1132-1136
sulphasalazine	O	1137-1151
syndrome	O	1152-1160
"	O	1160-1161
,	O	1161-1162
a	O	1163-1164
rare	O	1165-1169
,	O	1169-1170
but	O	1171-1174
often	O	1175-1180
fatal	O	1181-1186
,	O	1186-1187
immunoallergic	O	1188-1202
reaction	O	1203-1211
to	O	1212-1214
sulphasalazine	O	1215-1229
.	O	1229-1230

Bupropion	O	0-9
(	O	10-11
Zyban	O	11-16
)	O	16-17
toxicity	B	18-26
.	O	26-27

Bupropion	O	28-37
is	O	38-40
a	O	41-42
monocyclic	O	43-53
antidepressant	O	54-68
structurally	O	69-81
related	O	82-89
to	O	90-92
amphetamine	O	93-104
.	O	104-105

Zyban	O	106-111
,	O	111-112
a	O	113-114
sustained	O	115-124
-	O	124-125
release	O	125-132
formulation	O	133-144
of	O	145-147
bupropion	O	148-157
hydrochloride	O	158-171
,	O	171-172
was	O	173-176
recently	O	177-185
released	O	186-194
in	O	195-197
Ireland	O	198-205
,	O	205-206
as	O	207-209
a	O	210-211
smoking	O	212-219
cessation	O	220-229
aid	O	230-233
.	O	233-234

In	O	235-237
the	O	238-241
initial	O	242-249
6	O	250-251
months	O	252-258
since	O	259-264
it	O	265-267
'	O	267-268
s	O	268-269
introduction	O	270-282
,	O	282-283
12	O	284-286
overdose	B	287-295
cases	O	296-301
have	O	302-306
been	O	307-311
reported	O	312-320
to	O	321-323
The	O	324-327
National	O	328-336
Poisons	O	337-344
Information	O	345-356
Centre	O	357-363
.	O	363-364

8	O	365-366
patients	O	367-375
developed	O	376-385
symptoms	O	386-394
of	O	395-397
toxicity	B	398-406
.	O	406-407

Common	O	408-414
features	O	415-423
included	O	424-432
tachycardia	B	433-444
,	O	444-445
drowsiness	O	446-456
,	O	456-457
hallucinations	B	458-472
and	O	473-476
convulsions	B	477-488
.	O	488-489

Two	O	490-493
patients	O	494-502
developed	O	503-512
severe	O	513-519
cardiac	B	520-527
arrhythmias	I	528-539
,	O	539-540
including	O	541-550
one	O	551-554
patient	O	555-562
who	O	563-566
was	O	567-570
resuscitated	O	571-583
following	O	584-593
a	O	594-595
cardiac	B	596-603
arrest	I	604-610
.	O	610-611

All	O	612-615
patients	O	616-624
recovered	O	625-634
without	O	635-642
sequelae	O	643-651
.	O	651-652

We	O	653-655
report	O	656-662
a	O	663-664
case	O	665-669
of	O	670-672
a	O	673-674
31	O	675-677
year	O	678-682
old	O	683-686
female	O	687-693
who	O	694-697
required	O	698-706
admission	O	707-716
to	O	717-719
the	O	720-723
Intensive	O	724-733
Care	O	734-738
Unit	O	739-743
for	O	744-747
ventilation	O	748-759
and	O	760-763
full	O	764-768
supportive	O	769-779
therapy	O	780-787
,	O	787-788
following	O	789-798
ingestion	O	799-808
of	O	809-811
13	O	812-814
.	O	814-815
5g	O	815-817
bupropion	O	818-827
.	O	827-828

Recurrent	O	829-838
seizures	B	839-847
were	O	848-852
treated	O	853-860
with	O	861-865
diazepam	O	866-874
and	O	875-878
broad	O	879-884
complex	O	885-892
tachycardia	B	893-904
was	O	905-908
successfully	O	909-921
treated	O	922-929
with	O	930-934
adenosine	O	935-944
.	O	944-945

Zyban	O	946-951
caused	O	952-958
significant	O	959-970
neurological	B	971-983
and	I	984-987
cardiovascular	I	988-1002
toxicity	I	1003-1011
in	O	1012-1014
overdose	B	1015-1023
.	O	1023-1024

The	O	1025-1028
potential	O	1029-1038
toxic	O	1039-1044
effects	O	1045-1052
should	O	1053-1059
be	O	1060-1062
considered	O	1063-1073
when	O	1074-1078
prescribing	O	1079-1090
it	O	1091-1093
as	O	1094-1096
a	O	1097-1098
smoking	O	1099-1106
cessation	O	1107-1116
aid	O	1117-1120
.	O	1120-1121

Survey	O	0-6
of	O	7-9
complications	O	10-23
of	O	24-26
indocyanine	O	27-38
green	O	39-44
angiography	O	45-56
in	O	57-59
Japan	O	60-65
.	O	65-66

PURPOSE	O	67-74
:	O	74-75
We	O	76-78
evaluated	O	79-88
the	O	89-92
safety	O	93-99
of	O	100-102
indocyanine	O	103-114
green	O	115-120
for	O	121-124
use	O	125-128
in	O	129-131
fundus	O	132-138
angiography	O	139-150
.	O	150-151

METHODS	O	152-159
:	O	159-160
We	O	161-163
sent	O	164-168
a	O	169-170
questionnaire	O	171-184
concerning	O	185-195
complications	O	196-209
of	O	210-212
indocyanine	O	213-224
green	O	225-230
to	O	231-233
32	O	234-236
institutions	O	237-249
in	O	250-252
Japan	O	253-258
,	O	258-259
which	O	260-265
were	O	266-270
selected	O	271-279
on	O	280-282
the	O	283-286
basis	O	287-292
of	O	293-295
the	O	296-299
client	O	300-306
list	O	307-311
from	O	312-316
the	O	317-320
Topcon	O	321-327
Company	O	328-335
,	O	335-336
which	O	337-342
manufactures	O	343-355
the	O	356-359
indocyanine	O	360-371
green	O	372-377
fundus	O	378-384
camera	O	385-391
.	O	391-392

RESULTS	O	393-400
:	O	400-401
Ophthalmologists	O	402-418
at	O	419-421
15	O	422-424
institutions	O	425-437
responded	O	438-447
,	O	447-448
reporting	O	449-458
a	O	459-460
total	O	461-466
of	O	467-469
3	O	470-471
,	O	471-472
774	O	472-475
indocyanine	O	476-487
green	O	488-493
angiograms	O	494-504
performed	O	505-514
on	O	515-517
2	O	518-519
,	O	519-520
820	O	520-523
patients	O	524-532
between	O	533-540
June	O	541-545
1984	O	546-550
and	O	551-554
September	O	555-564
1992	O	565-569
.	O	569-570

Before	O	571-577
angiography	O	578-589
,	O	589-590
intradermal	O	591-602
or	O	603-605
intravenous	O	606-617
indocyanine	O	618-629
green	O	630-635
testing	O	636-643
,	O	643-644
or	O	645-647
both	O	648-652
was	O	653-656
performed	O	657-666
at	O	667-669
13	O	670-672
of	O	673-675
15	O	676-678
institutions	O	679-691
.	O	691-692

For	O	693-696
three	O	697-702
patients	O	703-711
,	O	711-712
the	O	713-716
decision	O	717-725
was	O	726-729
made	O	730-734
not	O	735-738
to	O	739-741
proceed	O	742-749
with	O	750-754
angiography	O	755-766
after	O	767-772
positive	O	773-781
preangiographic	O	782-797
testing	O	798-805
.	O	805-806

The	O	807-810
dosage	O	811-817
of	O	818-820
indocyanine	O	821-832
green	O	833-838
used	O	839-843
for	O	844-847
angiography	O	848-859
varied	O	860-866
from	O	867-871
25	O	872-874
to	O	875-877
75	O	878-880
mg	O	881-883
,	O	883-884
depending	O	885-894
upon	O	895-899
the	O	900-903
institution	O	904-915
.	O	915-916

There	O	917-922
were	O	923-927
13	O	928-930
cases	O	931-936
of	O	937-939
adverse	O	940-947
reactions	O	948-957
(	O	958-959
0	O	959-960
.	O	960-961
34	O	961-963
%	O	963-964
)	O	964-965
,	O	965-966
ten	O	967-970
of	O	971-973
which	O	974-979
were	O	980-984
mild	O	985-989
reactions	O	990-999
such	O	1000-1004
as	O	1005-1007
nausea	B	1008-1014
,	O	1014-1015
exanthema	B	1016-1025
,	O	1025-1026
urtication	B	1027-1037
,	O	1037-1038
itchiness	B	1039-1048
,	O	1048-1049
and	O	1050-1053
urgency	O	1054-1061
to	O	1062-1064
defecate	O	1065-1073
,	O	1073-1074
and	O	1075-1078
did	O	1079-1082
not	O	1083-1086
require	O	1087-1094
treatment	O	1095-1104
.	O	1104-1105

Also	O	1106-1110
recorded	O	1111-1119
were	O	1120-1124
one	O	1125-1128
case	O	1129-1133
of	O	1134-1136
pain	B	1137-1141
of	O	1142-1144
the	O	1145-1148
vein	O	1149-1153
,	O	1153-1154
which	O	1155-1160
required	O	1161-1169
treatment	O	1170-1179
,	O	1179-1180
and	O	1181-1184
two	O	1185-1188
cases	O	1189-1194
of	O	1195-1197
hypotension	B	1198-1209
.	O	1209-1210

The	O	1211-1214
two	O	1215-1218
hypotensive	B	1219-1230
patients	O	1231-1239
required	O	1240-1248
treatment	O	1249-1258
for	O	1259-1262
shock	B	1263-1268
.	O	1268-1269

CONCLUSIONS	O	1270-1281
:	O	1281-1282
A	O	1283-1284
comparison	O	1285-1295
of	O	1296-1298
frequency	O	1299-1308
of	O	1309-1311
adverse	O	1312-1319
reactions	O	1320-1329
to	O	1330-1332
indocyanine	O	1333-1344
green	O	1345-1350
with	O	1351-1355
the	O	1356-1359
previously	O	1360-1370
reported	O	1371-1379
frequency	O	1380-1389
of	O	1390-1392
such	O	1393-1397
reactions	O	1398-1407
to	O	1408-1410
fluorescein	O	1411-1422
sodium	O	1423-1429
indicated	O	1430-1439
that	O	1440-1444
indocyanine	O	1445-1456
green	O	1457-1462
is	O	1463-1465
a	O	1466-1467
safe	O	1468-1472
as	O	1473-1475
fluorescein	O	1476-1487
for	O	1488-1491
use	O	1492-1495
in	O	1496-1498
angiography	O	1499-1510
.	O	1510-1511

Bradykinin	O	0-10
receptors	O	11-20
antagonists	O	21-32
and	O	33-36
nitric	O	37-43
oxide	O	44-49
synthase	O	50-58
inhibitors	O	59-69
in	O	70-72
vincristine	O	73-84
and	O	85-88
streptozotocin	O	89-103
induced	O	104-111
hyperalgesia	B	112-124
in	O	125-127
chemotherapy	O	128-140
and	O	141-144
diabetic	B	145-153
neuropathy	I	154-164
rat	O	165-168
model	O	169-174
.	O	174-175

PURPOSE	O	176-183
:	O	183-184
The	O	185-188
influence	O	189-198
of	O	199-201
an	O	202-204
irreversible	O	205-217
inhibitor	O	218-227
of	O	228-230
constitutive	O	231-243
NO	O	244-246
synthase	O	247-255
(	O	256-257
L	O	257-258
-	O	258-259
NOArg	O	259-264
;	O	264-265
1	O	266-267
.	O	267-268
0	O	268-269
mg	O	270-272
/	O	272-273
kg	O	273-275
ip	O	276-278
)	O	278-279
,	O	279-280
a	O	281-282
relatively	O	283-293
selective	O	294-303
inhibitor	O	304-313
of	O	314-316
inducible	O	317-326
NO	O	327-329
synthase	O	330-338
(	O	339-340
L	O	340-341
-	O	341-342
NIL	O	342-345
;	O	345-346
1	O	347-348
.	O	348-349
0	O	349-350
mg	O	351-353
/	O	353-354
kg	O	354-356
ip	O	357-359
)	O	359-360
and	O	361-364
a	O	365-366
relatively	O	367-377
specific	O	378-386
inhibitor	O	387-396
of	O	397-399
neuronal	O	400-408
NO	O	409-411
synthase	O	412-420
(	O	421-422
7	O	422-423
-	O	423-424
NI	O	424-426
;	O	426-427
0	O	428-429
.	O	429-430
1	O	430-431
mg	O	432-434
/	O	434-435
kg	O	435-437
ip	O	438-440
)	O	440-441
,	O	441-442
on	O	443-445
antihyperalgesic	O	446-462
action	O	463-469
of	O	470-472
selective	O	473-482
antagonists	O	483-494
of	O	495-497
B2	O	498-500
and	O	501-504
B1	O	505-507
receptors	O	508-517
:	O	517-518
D	O	519-520
-	O	520-521
Arg	O	521-524
-	O	520-521
[	O	525-526
Hyp3	O	526-530
,	O	530-531
Thi5	O	531-535
,	O	530-531
D	O	519-520
-	O	520-521
Tic7	O	538-542
,	O	530-531
Oic8	O	543-547
]	O	547-548
bradykinin	O	549-559
(	O	560-561
HOE	O	561-564
140	O	565-568
;	O	568-569
70	O	570-572
nmol	O	573-577
/	O	577-578
kg	O	578-580
ip	O	581-583
)	O	583-584
or	O	585-587
des	O	588-591
Arg10	O	592-597
HOE	O	598-601
140	O	602-605
(	O	606-607
70	O	607-609
nmol	O	610-614
/	O	614-615
kg	O	615-617
ip	O	618-620
)	O	620-621
respectively	O	622-634
,	O	634-635
in	O	636-638
model	O	639-644
of	O	645-647
diabetic	B	648-656
(	I	657-658
streptozotocin	I	658-672
-	I	672-673
induced	I	673-680
)	I	680-681
and	I	682-685
toxic	I	686-691
(	I	692-693
vincristine	I	693-704
-	I	704-705
induced	I	705-712
)	I	712-713
neuropathy	I	714-724
was	O	725-728
investigated	O	729-741
.	O	741-742

METHODS	O	743-750
:	O	750-751
The	O	752-755
changes	O	756-763
in	O	764-766
pain	B	767-771
thresholds	O	772-782
were	O	783-787
determined	O	788-798
using	O	799-804
mechanical	O	805-815
stimuli	O	816-823
-	O	823-824
-	O	823-824
the	O	825-828
modification	O	829-841
of	O	842-844
the	O	845-848
classic	O	849-856
paw	O	857-860
withdrawal	O	861-871
test	O	872-876
described	O	877-886
by	O	887-889
Randall	O	890-897
-	O	897-898
Selitto	O	898-905
.	O	905-906

RESULTS	O	907-914
:	O	914-915
The	O	916-919
results	O	920-927
of	O	928-930
this	O	931-935
paper	O	936-941
confirm	O	942-949
that	O	950-954
inhibition	O	955-965
of	O	966-968
bradykinin	O	969-979
receptors	O	980-989
and	O	990-993
inducible	O	994-1003
NO	O	1004-1006
synthase	O	1007-1015
but	O	1016-1019
not	O	1020-1023
neuronal	O	1024-1032
NO	O	1033-1035
synthase	O	1036-1044
activity	O	1045-1053
reduces	O	1054-1061
diabetic	B	1062-1070
hyperalgesia	I	1071-1083
.	O	1083-1084

Pretreatment	O	1085-1097
with	O	1098-1102
L	O	1103-1104
-	O	1104-1105
NOArg	O	1105-1110
and	O	1111-1114
L	O	1115-1116
-	O	1116-1117
NIL	O	1117-1120
but	O	1121-1124
not	O	1125-1128
7	O	1129-1130
-	O	1130-1131
NI	O	1131-1133
,	O	1133-1134
significantly	O	1135-1148
increases	O	1149-1158
antihyperalgesic	O	1159-1175
activity	O	1176-1184
both	O	1185-1189
HOE	O	1190-1193
140	O	1194-1197
and	O	1198-1201
des	O	1202-1205
Arg10	O	1206-1211
HOE	O	1212-1215
140	O	1216-1219
.	O	1219-1220

It	O	1221-1223
was	O	1224-1227
also	O	1228-1232
shown	O	1233-1238
that	O	1239-1243
both	O	1244-1248
products	O	1249-1257
of	O	1258-1260
inducible	O	1261-1270
NO	O	1271-1273
synthase	O	1274-1282
and	O	1283-1286
neuronal	O	1287-1295
NO	O	1296-1298
synthase	O	1299-1307
activation	O	1308-1318
as	O	1319-1321
well	O	1322-1326
as	O	1327-1329
bradykinin	O	1330-1340
are	O	1341-1344
involved	O	1345-1353
in	O	1354-1356
hyperalgesia	B	1357-1369
produced	O	1370-1378
by	O	1379-1381
vincristine	O	1382-1393
.	O	1393-1394

Moreover	O	1395-1403
,	O	1403-1404
L	O	1405-1406
-	O	1406-1407
NOArg	O	1407-1412
and	O	1413-1416
7	O	1417-1418
-	O	1418-1419
NI	O	1419-1421
but	O	1422-1425
not	O	1426-1429
L	O	1430-1431
-	O	1431-1432
NIL	O	1432-1435
intensify	O	1436-1445
antihyperalgesic	O	1446-1462
activity	O	1463-1471
of	O	1472-1474
HOE	O	1475-1478
140	O	1479-1482
or	O	1483-1485
des	O	1486-1489
-	O	1489-1490
Arg10HOE	O	1490-1498
140	O	1499-1502
in	O	1503-1505
toxic	B	1506-1511
neuropathy	I	1512-1522
.	O	1522-1523

CONCLUSIONS	O	1524-1535
:	O	1535-1536
Results	O	1537-1544
of	O	1545-1547
these	O	1548-1553
studies	O	1554-1561
suggest	O	1562-1569
that	O	1570-1574
B1	O	1575-1577
and	O	1578-1581
B2	O	1582-1584
receptors	O	1585-1594
are	O	1595-1598
engaged	O	1599-1606
in	O	1607-1609
transmission	O	1610-1622
of	O	1623-1625
nociceptive	O	1626-1637
stimuli	O	1638-1645
in	O	1646-1648
both	O	1649-1653
diabetic	B	1654-1662
and	I	1663-1666
toxic	I	1667-1672
neuropathy	I	1673-1683
.	O	1683-1684

In	O	1685-1687
streptozotocin	O	1688-1702
-	O	1702-1703
induced	O	1703-1710
hyperalgesia	B	1711-1723
,	O	1723-1724
inducible	O	1725-1734
NO	O	1735-1737
synthase	O	1738-1746
participates	O	1747-1759
in	O	1760-1762
pronociceptive	O	1763-1777
activity	O	1778-1786
of	O	1787-1789
bradykinin	O	1790-1800
,	O	1800-1801
whereas	O	1802-1809
in	O	1810-1812
vincristine	O	1813-1824
-	O	1824-1825
induced	O	1825-1832
hyperalgesia	B	1833-1845
bradykinin	O	1846-1856
seemed	O	1857-1863
to	O	1864-1866
activate	O	1867-1875
neuronal	O	1876-1884
NO	O	1885-1887
synthase	O	1888-1896
pathway	O	1897-1904
.	O	1904-1905

Therefore	O	1906-1915
,	O	1915-1916
concomitant	O	1917-1928
administration	O	1929-1943
of	O	1944-1946
small	O	1947-1952
doses	O	1953-1958
of	O	1959-1961
bradykinin	O	1962-1972
receptor	O	1973-1981
antagonists	O	1982-1993
and	O	1994-1997
NO	O	1998-2000
synthase	O	2001-2009
inhibitors	O	2010-2020
can	O	2021-2024
be	O	2025-2027
effective	O	2028-2037
in	O	2038-2040
alleviation	O	2041-2052
of	O	2053-2055
neuropathic	B	2056-2067
pain	I	2068-2072
,	O	2072-2073
even	O	2074-2078
in	O	2079-2081
hospital	O	2082-2090
care	O	2091-2095
.	O	2095-2096

Cardiac	B	0-7
toxicity	I	8-16
observed	O	17-25
in	O	26-28
association	O	29-40
with	O	41-45
high	O	46-50
-	O	50-51
dose	O	51-55
cyclophosphamide	O	56-72
-	O	72-73
based	O	73-78
chemotherapy	O	79-91
for	O	92-95
metastatic	O	96-106
breast	B	107-113
cancer	I	114-120
.	O	120-121

INTRODUCTION	O	122-134
:	O	134-135
Cyclophosphamide	O	136-152
is	O	153-155
an	O	156-158
alkylating	O	159-169
agent	O	170-175
given	O	176-181
frequently	O	182-192
as	O	193-195
a	O	196-197
component	O	198-207
of	O	208-210
many	O	211-215
conditioning	O	216-228
regimens	O	229-237
.	O	237-238

In	O	239-241
high	O	242-246
doses	O	247-252
,	O	252-253
its	O	254-257
nonhematological	O	258-274
dose	O	275-279
-	O	279-280
limiting	O	280-288
toxicity	B	289-297
is	O	298-300
cardiomyopathy	B	301-315
.	O	315-316

STUDY	O	317-322
DESIGN	O	323-329
:	O	329-330
We	O	331-333
combined	O	334-342
paclitaxel	O	343-353
,	O	353-354
melphalan	O	355-364
and	O	365-368
high	O	369-373
-	O	373-374
dose	O	374-378
cyclophosphamide	O	379-395
,	O	395-396
thiotepa	O	397-405
,	O	405-406
and	O	407-410
carboplatin	O	411-422
in	O	423-425
a	O	426-427
triple	O	428-434
sequential	O	435-445
high	O	446-450
-	O	450-451
dose	O	451-455
regimen	O	456-463
for	O	464-467
patients	O	468-476
with	O	477-481
metastatic	O	482-492
breast	B	493-499
cancer	I	500-506
.	O	506-507

Analysis	O	508-516
was	O	517-520
performed	O	521-530
on	O	531-533
61	O	534-536
women	O	537-542
with	O	543-547
chemotherapy	O	548-560
-	O	560-561
responsive	O	561-571
metastatic	O	572-582
breast	B	583-589
cancer	I	590-596
receiving	O	597-606
96	O	607-609
-	O	609-610
h	O	610-611
infusional	O	612-622
cyclophosphamide	O	623-639
as	O	640-642
part	O	643-647
of	O	648-650
a	O	651-652
triple	O	653-659
sequential	O	660-670
high	O	671-675
-	O	675-676
dose	O	676-680
regimen	O	681-688
to	O	689-691
assess	O	692-698
association	O	699-710
between	O	711-718
presence	O	719-727
of	O	728-730
peritransplant	O	731-745
congestive	B	746-756
heart	I	757-762
failure	I	763-770
(	O	771-772
CHF	B	772-775
)	O	775-776
and	O	777-780
the	O	781-784
following	O	785-794
pretreatment	O	795-807
characteristics	O	808-823
:	O	823-824
presence	O	825-833
of	O	834-836
electrocardiogram	O	837-854
(	O	855-856
EKG	O	856-859
)	O	859-860
abnormalities	O	861-874
,	O	874-875
age	O	876-879
,	O	879-880
hypertension	B	881-893
,	O	893-894
prior	O	895-900
cardiac	O	901-908
history	O	909-916
,	O	916-917
smoking	O	918-925
,	O	925-926
diabetes	B	927-935
mellitus	I	936-944
,	O	944-945
prior	O	946-951
use	O	952-955
of	O	956-958
anthracyclines	O	959-973
,	O	973-974
and	O	975-978
left	O	979-983
-	O	983-984
sided	O	984-989
chest	O	990-995
irradiation	O	996-1007
.	O	1007-1008

RESULTS	O	1009-1016
:	O	1016-1017
Six	O	1018-1021
of	O	1022-1024
61	O	1025-1027
women	O	1028-1033
(	O	1034-1035
10	O	1035-1037
%	O	1037-1038
)	O	1038-1039
developed	O	1040-1049
clinically	O	1050-1060
reversible	O	1061-1071
grade	O	1072-1077
3	O	1078-1079
CHF	B	1080-1083
following	O	1084-1093
infusional	O	1094-1104
cyclophosphamide	O	1105-1121
with	O	1122-1126
a	O	1127-1128
median	O	1129-1135
percent	O	1136-1143
decline	O	1144-1151
in	O	1152-1154
ejection	O	1155-1163
fraction	O	1164-1172
of	O	1173-1175
31	O	1176-1178
%	O	1178-1179
.	O	1179-1180

Incidence	O	1181-1190
of	O	1191-1193
transient	O	1194-1203
cyclophosphamide	O	1204-1220
-	O	1220-1221
related	O	1221-1228
cardiac	B	1229-1236
toxicity	I	1237-1245
(	O	1246-1247
10	O	1247-1249
%	O	1249-1250
)	O	1250-1251
is	O	1252-1254
comparable	O	1255-1265
to	O	1266-1268
previous	O	1269-1277
recorded	O	1278-1286
literature	O	1287-1297
.	O	1297-1298

Older	O	1299-1304
age	O	1305-1308
was	O	1309-1312
significantly	O	1313-1326
correlated	O	1327-1337
with	O	1338-1342
the	O	1343-1346
CHF	B	1347-1350
development	O	1351-1362
;	O	1362-1363
with	O	1364-1368
median	O	1369-1375
ages	O	1376-1380
for	O	1381-1384
the	O	1385-1388
entire	O	1389-1395
group	O	1396-1401
and	O	1402-1405
for	O	1406-1409
patients	O	1410-1418
developing	O	1419-1429
CHF	B	1430-1433
of	O	1434-1436
45	O	1437-1439
and	O	1440-1443
59	O	1444-1446
,	O	1446-1447
respectively	O	1448-1460
.	O	1460-1461

No	O	1462-1464
association	O	1465-1476
was	O	1477-1480
found	O	1481-1486
with	O	1487-1491
other	O	1492-1497
pretreatment	O	1498-1510
characteristics	O	1511-1526
.	O	1526-1527

CONCLUSIONS	O	1528-1539
:	O	1539-1540
As	O	1541-1543
a	O	1544-1545
result	O	1546-1552
of	O	1553-1555
these	O	1556-1561
findings	O	1562-1570
,	O	1570-1571
oncologists	O	1572-1583
should	O	1584-1590
carefully	O	1591-1600
monitor	O	1601-1608
fluid	O	1609-1614
balance	O	1615-1622
in	O	1623-1625
older	O	1626-1631
patients	O	1632-1640
.	O	1640-1641

Routine	O	1642-1649
EKG	O	1650-1653
monitoring	O	1654-1664
during	O	1665-1671
infusional	O	1672-1682
cyclophosphamide	O	1683-1699
did	O	1700-1703
not	O	1704-1707
predict	O	1708-1715
CHF	B	1716-1719
development	O	1720-1731
.	O	1731-1732

Inappropriate	O	0-13
use	O	14-17
of	O	18-20
carbamazepine	O	21-34
and	O	35-38
vigabatrin	O	39-49
in	O	50-52
typical	O	53-60
absence	B	61-68
seizures	I	69-77
.	O	77-78

Carbamazepine	O	79-92
and	O	93-96
vigabatrin	O	97-107
are	O	108-111
contraindicated	O	112-127
in	O	128-130
typical	O	131-138
absence	B	139-146
seizures	I	147-155
.	O	155-156

Of	O	157-159
18	O	160-162
consecutive	O	163-174
referrals	O	175-184
of	O	185-187
children	O	188-196
with	O	197-201
resistant	O	202-211
typical	O	212-219
absences	O	220-228
only	O	229-233
,	O	233-234
eight	O	235-240
were	O	241-245
erroneously	O	246-257
treated	O	258-265
with	O	266-270
carbamazepine	O	271-284
either	O	285-291
as	O	292-294
monotherapy	O	295-306
or	O	307-309
as	O	310-312
an	O	313-315
add	O	316-319
-	O	319-320
on	O	320-322
.	O	322-323

Vigabatrin	O	324-334
was	O	335-338
also	O	339-343
used	O	344-348
in	O	349-351
the	O	352-355
treatment	O	356-365
of	O	366-368
two	O	369-372
children	O	373-381
.	O	381-382

Frequency	O	383-392
of	O	393-395
absences	O	396-404
increased	O	405-414
in	O	415-417
four	O	418-422
children	O	423-431
treated	O	432-439
with	O	440-444
carbamazepine	O	445-458
and	O	459-462
two	O	463-466
of	O	467-469
these	O	470-475
developed	O	476-485
myoclonic	B	486-495
jerks	I	496-501
,	O	501-502
which	O	503-508
resolved	O	509-517
on	O	518-520
withdrawal	O	521-531
of	O	532-534
carbamazepine	O	535-548
.	O	548-549

Absences	O	550-558
were	O	559-563
aggravated	O	564-574
in	O	575-577
both	O	578-582
cases	O	583-588
where	O	589-594
vigabatrin	O	595-605
was	O	606-609
added	O	610-615
on	O	616-618
to	O	619-621
concurrent	O	622-632
treatment	O	633-642
.	O	642-643

Optimal	O	644-651
control	O	652-659
of	O	660-662
the	O	663-666
absences	O	667-675
was	O	676-679
achieved	O	680-688
with	O	689-693
sodium	O	694-700
valproate	O	701-710
,	O	710-711
lamotrigine	O	712-723
,	O	723-724
or	O	725-727
ethosuximide	O	728-740
alone	O	741-746
or	O	747-749
in	O	750-752
combination	O	753-764
.	O	764-765

Hemolytic	B	0-9
anemia	I	10-16
associated	O	17-27
with	O	28-32
the	O	33-36
use	O	37-40
of	O	41-43
omeprazole	O	44-54
.	O	54-55

Omeprazole	O	56-66
is	O	67-69
the	O	70-73
first	O	74-79
drug	O	80-84
designed	O	85-93
to	O	94-96
block	O	97-102
the	O	103-106
final	O	107-112
step	O	113-117
in	O	118-120
the	O	121-124
acid	O	125-129
secretory	O	130-139
process	O	140-147
within	O	148-154
the	O	155-158
parietal	O	159-167
cell	O	168-172
.	O	172-173

It	O	174-176
has	O	177-180
been	O	181-185
shown	O	186-191
to	O	192-194
be	O	195-197
extremely	O	198-207
effective	O	208-217
in	O	218-220
the	O	221-224
treatment	O	225-234
of	O	235-237
peptic	B	238-244
ulcer	I	245-250
disease	I	251-258
,	O	258-259
reflux	B	260-266
esophagitis	I	267-278
,	O	278-279
and	O	280-283
the	O	284-287
Zollinger	B	288-297
-	I	297-298
Ellison	I	298-305
syndrome	I	306-314
.	O	314-315

Although	O	316-324
clinical	O	325-333
experience	O	334-344
with	O	345-349
omeprazole	O	350-360
is	O	361-363
still	O	364-369
limited	O	370-377
,	O	377-378
many	O	379-383
controlled	O	384-394
studies	O	395-402
have	O	403-407
established	O	408-419
the	O	420-423
short	O	424-429
-	O	429-430
term	O	430-434
safety	O	435-441
of	O	442-444
this	O	445-449
drug	O	450-454
.	O	454-455

We	O	456-458
report	O	459-465
the	O	466-469
first	O	470-475
case	O	476-480
of	O	481-483
a	O	484-485
serious	O	486-493
short	O	494-499
-	O	499-500
term	O	500-504
adverse	O	505-512
reaction	O	513-521
with	O	522-526
the	O	527-530
use	O	531-534
of	O	535-537
omeprazole	O	538-548
:	O	548-549
hemolytic	B	550-559
anemia	I	560-566
.	O	566-567

The	O	568-571
patient	O	572-579
developed	O	580-589
weakness	O	590-598
,	O	598-599
lethargy	B	600-608
,	O	608-609
and	O	610-613
shortness	B	614-623
of	I	624-626
breath	I	627-633
2	O	634-635
days	O	636-640
after	O	641-646
starting	O	647-655
therapy	O	656-663
with	O	664-668
omeprazole	O	669-679
.	O	679-680

Two	O	681-684
weeks	O	685-690
after	O	691-696
the	O	697-700
initiation	O	701-711
of	O	712-714
therapy	O	715-722
,	O	722-723
her	O	724-727
hematocrit	O	728-738
had	O	739-742
decreased	O	743-752
from	O	753-757
44	O	758-760
.	O	760-761
1	O	761-762
%	O	762-763
to	O	764-766
20	O	767-769
.	O	769-770
4	O	770-771
%	O	771-772
,	O	772-773
and	O	774-777
she	O	778-781
had	O	782-785
a	O	786-787
positive	O	788-796
direct	O	797-803
Coombs	O	804-810
antiglobulin	O	811-823
test	O	824-828
and	O	829-832
an	O	833-835
elevated	O	836-844
indirect	O	845-853
bilirubin	O	854-863
.	O	863-864

After	O	865-870
she	O	871-874
discontinued	O	875-887
the	O	888-891
omeprazole	O	892-902
,	O	902-903
her	O	904-907
hemoglobin	O	908-918
and	O	919-922
hematocrit	O	923-933
gradually	O	934-943
returned	O	944-952
to	O	953-955
normal	O	956-962
.	O	962-963

The	O	964-967
mechanism	O	968-977
by	O	978-980
which	O	981-986
omeprazole	O	987-997
caused	O	998-1004
the	O	1005-1008
patient	O	1009-1016
'	O	1016-1017
s	O	1017-1018
hemolytic	B	1019-1028
anemia	I	1029-1035
is	O	1036-1038
uncertain	O	1039-1048
,	O	1048-1049
but	O	1050-1053
physicians	O	1054-1064
should	O	1065-1071
be	O	1072-1074
alerted	O	1075-1082
to	O	1083-1085
this	O	1086-1090
possible	O	1091-1099
adverse	O	1100-1107
effect	O	1108-1114
.	O	1114-1115

The	O	0-3
use	O	4-7
and	O	8-11
toxicity	B	12-20
of	O	21-23
didanosine	O	24-34
(	O	35-36
ddI	O	36-39
)	O	39-40
in	O	41-43
HIV	B	44-47
antibody	I	48-56
-	I	56-57
positive	I	57-65
individuals	O	66-77
intolerant	O	78-88
to	O	89-91
zidovudine	O	92-102
(	O	103-104
AZT	O	104-107
)	O	107-108
One	O	109-112
hundred	O	113-120
and	O	121-124
fifty	O	125-130
-	O	130-131
one	O	131-134
patients	O	135-143
intolerant	O	144-154
to	O	155-157
zidovudine	O	158-168
(	O	169-170
AZT	O	170-173
)	O	173-174
received	O	175-183
didanosine	O	184-194
(	O	195-196
ddI	O	196-199
)	O	199-200
to	O	201-203
a	O	204-205
maximum	O	206-213
dose	O	214-218
of	O	219-221
12	O	222-224
.	O	224-225
5	O	225-226
mg	O	227-229
/	O	229-230
kg	O	230-232
/	O	229-230
day	O	233-236
.	O	236-237

Patient	O	238-245
response	O	246-254
was	O	255-258
assessed	O	259-267
using	O	268-273
changes	O	274-281
in	O	282-284
CD4	O	285-288
+	O	288-289
lymphocyte	O	290-300
subset	O	301-307
count	O	308-313
,	O	313-314
HIV	O	315-318
p24	O	319-322
antigen	O	323-330
,	O	330-331
weight	O	332-338
,	O	338-339
and	O	340-343
quality	O	344-351
of	O	352-354
life	O	355-359
.	O	359-360

Seventy	O	361-368
patients	O	369-377
developed	O	378-387
major	O	388-393
opportunistic	B	394-407
infections	I	408-418
whilst	O	419-425
on	O	426-428
therapy	O	429-436
;	O	436-437
this	O	438-442
was	O	443-446
the	O	447-450
first	O	451-456
AIDS	B	457-461
diagnosis	O	462-471
in	O	472-474
17	O	475-477
.	O	477-478

Only	O	479-483
minor	O	484-489
changes	O	490-497
in	O	498-500
CD4	O	501-504
+	O	504-505
lymphocyte	O	506-516
subset	O	517-523
count	O	524-529
were	O	530-534
observed	O	535-543
in	O	544-546
AIDS	B	547-551
patients	O	552-560
,	O	560-561
although	O	562-570
a	O	571-572
more	O	573-577
significant	O	578-589
rise	O	590-594
occurred	O	595-603
in	O	604-606
those	O	607-612
with	O	613-617
earlier	O	618-625
stages	O	626-632
of	O	633-635
disease	O	636-643
.	O	643-644

Of	O	645-647
those	O	648-653
positive	O	654-662
for	O	663-666
p24	O	667-670
antigen	O	671-678
at	O	679-681
the	O	682-685
commencement	O	686-698
of	O	699-701
the	O	702-705
study	O	706-711
67	O	712-714
%	O	714-715
showed	O	716-722
a	O	723-724
positive	O	725-733
response	O	734-742
,	O	742-743
and	O	744-747
this	O	748-752
was	O	753-756
most	O	757-761
likely	O	762-768
in	O	769-771
those	O	772-777
with	O	778-782
CD4	O	783-786
+	O	786-787
lymphocyte	O	788-798
subset	O	799-805
counts	O	806-812
above	O	813-818
100	O	819-822
mm3	O	823-826
.	O	826-827

A	O	828-829
positive	O	830-838
weight	O	839-845
response	O	846-854
was	O	855-858
seen	O	859-863
in	O	864-866
16	O	867-869
%	O	869-870
of	O	871-873
patients	O	874-882
.	O	882-883

Most	O	884-888
patients	O	889-897
showed	O	898-904
improvement	O	905-916
in	O	917-919
individual	O	920-930
parameters	O	931-941
and	O	942-945
global	O	946-952
score	O	953-958
of	O	959-961
quality	O	962-969
of	O	970-972
life	O	973-977
.	O	977-978

Adverse	O	979-986
reactions	O	987-996
possibly	O	997-1005
attributable	O	1006-1018
to	O	1019-1021
didanosine	O	1022-1032
were	O	1033-1037
common	O	1038-1044
.	O	1044-1045

The	O	1046-1049
most	O	1050-1054
common	O	1055-1061
side	O	1062-1066
-	O	1066-1067
effect	O	1067-1073
was	O	1074-1077
diarrhoea	B	1078-1087
,	O	1087-1088
which	O	1089-1094
resulted	O	1095-1103
in	O	1104-1106
cessation	O	1107-1116
of	O	1117-1119
therapy	O	1120-1127
in	O	1128-1130
19	O	1131-1133
individuals	O	1134-1145
.	O	1145-1146

Peripheral	B	1147-1157
neuropathy	I	1158-1168
occurred	O	1169-1177
in	O	1178-1180
12	O	1181-1183
patients	O	1184-1192
and	O	1193-1196
pancreatitis	B	1197-1209
in	O	1210-1212
six	O	1213-1216
.	O	1216-1217

Thirteen	O	1218-1226
patients	O	1227-1235
developed	O	1236-1245
a	O	1246-1247
raised	O	1248-1254
serum	O	1255-1260
amylase	O	1261-1268
without	O	1269-1276
abdominal	B	1277-1286
pain	I	1287-1291
.	O	1291-1292

Seven	O	1293-1298
patients	O	1299-1307
developed	O	1308-1317
glucose	B	1318-1325
tolerance	I	1326-1335
curves	I	1336-1342
characteristic	O	1343-1357
of	O	1358-1360
diabetes	B	1361-1369
but	O	1370-1373
these	O	1374-1379
were	O	1380-1384
mild	O	1385-1389
,	O	1389-1390
did	O	1391-1394
not	O	1395-1398
require	O	1399-1406
treatment	O	1407-1416
and	O	1417-1420
returned	O	1421-1429
to	O	1430-1432
normal	O	1433-1439
on	O	1440-1442
ceasing	O	1443-1450
didanosine	O	1451-1461
.	O	1461-1462

Can	O	0-3
angiogenesis	O	4-16
be	O	17-19
a	O	20-21
target	O	22-28
of	O	29-31
treatment	O	32-41
for	O	42-45
ribavirin	O	46-55
associated	O	56-66
hemolytic	B	67-76
anemia	I	77-83
?	O	83-84

BACKGROUND	O	85-95
/	O	95-96
AIMS	O	96-100
:	O	100-101
Recently	O	102-110
ribavirin	O	111-120
has	O	121-124
been	O	125-129
found	O	130-135
to	O	136-138
inhibit	O	139-146
angiogenesis	O	147-159
and	O	160-163
a	O	164-165
number	O	166-172
of	O	173-175
angiogenesis	O	176-188
inhibitors	O	189-199
such	O	200-204
as	O	205-207
sunitinib	O	208-217
and	O	218-221
sorafenib	O	222-231
have	O	232-236
been	O	237-241
found	O	242-247
to	O	248-250
cause	O	251-256
acute	O	257-262
hemolysis	B	263-272
.	O	272-273

We	O	274-276
aimed	O	277-282
to	O	283-285
investigate	O	286-297
whether	O	298-305
there	O	306-311
is	O	312-314
a	O	315-316
relation	O	317-325
between	O	326-333
hemoglobin	O	334-344
,	O	344-345
haptoglobin	O	346-357
and	O	358-361
angiogenesis	O	362-374
soluble	O	375-382
markers	O	383-390
which	O	391-396
are	O	397-400
modifiable	O	401-411
and	O	412-415
can	O	416-419
help	O	420-424
in	O	425-427
developing	O	428-438
strategies	O	439-449
against	O	450-457
anemia	B	458-464
.	O	464-465

METHODS	O	466-473
:	O	473-474
Fourteen	O	475-483
patients	O	484-492
chronically	B	493-504
infected	I	505-513
with	I	514-518
hepatitis	I	519-528
C	I	529-530
virus	I	531-536
were	O	537-541
treated	O	542-549
by	O	550-552
pegylated	O	553-562
interferon	O	563-573
alpha	O	574-579
2a	O	580-582
and	O	583-586
ribavirin	O	587-596
.	O	596-597

Serum	O	598-603
hemoglobin	O	604-614
,	O	614-615
haptoglobin	O	616-627
and	O	628-631
angiogenesis	O	632-644
markers	O	645-652
of	O	653-655
vascular	O	656-664
endothelial	O	665-676
growth	O	677-683
factor	O	684-690
and	O	691-694
angiopoetin	O	695-706
-	O	706-707
2	O	707-708
were	O	709-713
investigated	O	714-726
before	O	727-733
and	O	734-737
after	O	738-743
therapy	O	744-751
.	O	751-752

RESULTS	O	753-760
:	O	760-761
We	O	762-764
observed	O	765-773
a	O	774-775
significant	O	776-787
decrease	O	788-796
in	O	797-799
haptoglobin	O	800-811
levels	O	812-818
at	O	819-821
the	O	822-825
end	O	826-829
of	O	830-832
the	O	833-836
treatment	O	837-846
period	O	847-853
.	O	853-854

Hemoglobin	O	855-865
levels	O	866-872
also	O	873-877
decreased	O	878-887
but	O	888-891
insignificantly	O	892-907
by	O	908-910
treatment	O	911-920
.	O	920-921

In	O	922-924
contrast	O	925-933
with	O	934-938
the	O	939-942
literature	O	943-953
,	O	953-954
serum	O	955-960
levels	O	961-967
of	O	968-970
angiogenesis	O	971-983
factors	O	984-991
did	O	992-995
not	O	996-999
change	O	1000-1006
significantly	O	1007-1020
by	O	1021-1023
pegylated	O	1024-1033
interferon	O	1034-1044
and	O	1045-1048
ribavirin	O	1049-1058
therapy	O	1059-1066
.	O	1066-1067

We	O	1068-1070
found	O	1071-1076
no	O	1077-1079
correlation	O	1080-1091
of	O	1092-1094
angiogenesis	O	1095-1107
soluble	O	1108-1115
markers	O	1116-1123
with	O	1124-1128
either	O	1129-1135
hemoglobin	O	1136-1146
or	O	1147-1149
haptoglobin	O	1150-1161
.	O	1161-1162

CONCLUSION	O	1163-1173
:	O	1173-1174
This	O	1175-1179
is	O	1180-1182
the	O	1183-1186
first	O	1187-1192
study	O	1193-1198
in	O	1199-1201
the	O	1202-1205
literature	O	1206-1216
investigating	O	1217-1230
a	O	1231-1232
link	O	1233-1237
between	O	1238-1245
angiogenesis	O	1246-1258
soluble	O	1259-1266
markers	O	1267-1274
and	O	1275-1278
ribavirin	O	1279-1288
induced	O	1289-1296
anemia	B	1297-1303
in	O	1304-1306
patients	O	1307-1315
with	O	1316-1320
hepatitis	B	1321-1330
C	I	1331-1332
and	O	1333-1336
we	O	1337-1339
could	O	1340-1345
not	O	1346-1349
find	O	1350-1354
any	O	1355-1358
relation	O	1359-1367
.	O	1367-1368

Future	O	1369-1375
research	O	1376-1384
with	O	1385-1389
larger	O	1390-1396
number	O	1397-1403
of	O	1404-1406
patients	O	1407-1415
is	O	1416-1418
needed	O	1419-1425
to	O	1426-1428
find	O	1429-1433
out	O	1434-1437
modifiable	O	1438-1448
factors	O	1449-1456
that	O	1457-1461
will	O	1462-1466
improve	O	1467-1474
the	O	1475-1478
safety	O	1479-1485
of	O	1486-1488
ribavirin	O	1489-1498
therapy	O	1499-1506
.	O	1506-1507

Cocaine	O	0-7
causes	O	8-14
memory	B	15-21
and	I	22-25
learning	I	26-34
impairments	I	35-46
in	O	47-49
rats	O	50-54
:	O	54-55
involvement	O	56-67
of	O	68-70
nuclear	O	71-78
factor	O	79-85
kappa	O	86-91
B	O	92-93
and	O	94-97
oxidative	O	98-107
stress	O	108-114
,	O	114-115
and	O	116-119
prevention	O	120-130
by	O	131-133
topiramate	O	134-144
.	O	144-145

Different	O	146-155
mechanisms	O	156-166
have	O	167-171
been	O	172-176
suggested	O	177-186
for	O	187-190
cocaine	O	191-198
toxicity	B	199-207
including	O	208-217
an	O	218-220
increase	O	221-229
in	O	230-232
oxidative	O	233-242
stress	O	243-249
but	O	250-253
the	O	254-257
association	O	258-269
between	O	270-277
oxidative	O	278-287
status	O	288-294
in	O	295-297
the	O	298-301
brain	O	302-307
and	O	308-311
cocaine	O	312-319
induced	O	320-327
-	O	327-328
behaviour	O	328-337
is	O	338-340
poorly	O	341-347
understood	O	348-358
.	O	358-359

Nuclear	O	360-367
factor	O	368-374
kappa	O	375-380
B	O	381-382
(	O	383-384
NFkappaB	O	384-392
)	O	392-393
is	O	394-396
a	O	397-398
sensor	O	399-405
of	O	406-408
oxidative	O	409-418
stress	O	419-425
and	O	426-429
participates	O	430-442
in	O	443-445
memory	O	446-452
formation	O	453-462
that	O	463-467
could	O	468-473
be	O	474-476
involved	O	477-485
in	O	486-488
drug	O	489-493
toxicity	B	494-502
and	O	503-506
addiction	O	507-516
mechanisms	O	517-527
.	O	527-528

Therefore	O	529-538
NFkappaB	O	539-547
activity	O	548-556
,	O	556-557
oxidative	O	558-567
stress	O	568-574
,	O	574-575
neuronal	O	576-584
nitric	O	585-591
oxide	O	592-597
synthase	O	598-606
(	O	607-608
nNOS	O	608-612
)	O	612-613
activity	O	614-622
,	O	622-623
spatial	O	624-631
learning	O	632-640
and	O	641-644
memory	O	645-651
as	O	652-654
well	O	655-659
as	O	660-662
the	O	663-666
effect	O	667-673
of	O	674-676
topiramate	O	677-687
,	O	687-688
a	O	689-690
previously	O	691-701
proposed	O	702-710
therapy	O	711-718
for	O	719-722
cocaine	B	723-730
addiction	I	731-740
,	O	740-741
were	O	742-746
evaluated	O	747-756
in	O	757-759
an	O	760-762
experimental	O	763-775
model	O	776-781
of	O	782-784
cocaine	O	785-792
administration	O	793-807
in	O	808-810
rats	O	811-815
.	O	815-816

NFkappaB	O	817-825
activity	O	826-834
was	O	835-838
decreased	O	839-848
in	O	849-851
the	O	852-855
frontal	O	856-863
cortex	O	864-870
of	O	871-873
cocaine	O	874-881
treated	O	882-889
rats	O	890-894
,	O	894-895
as	O	896-898
well	O	899-903
as	O	904-906
GSH	O	907-910
concentration	O	911-924
and	O	925-928
glutathione	O	929-940
peroxidase	O	941-951
activity	O	952-960
in	O	961-963
the	O	964-967
hippocampus	O	968-979
,	O	979-980
whereas	O	981-988
nNOS	O	989-993
activity	O	994-1002
in	O	1003-1005
the	O	1006-1009
hippocampus	O	1010-1021
was	O	1022-1025
increased	O	1026-1035
.	O	1035-1036

Memory	O	1037-1043
retrieval	O	1044-1053
of	O	1054-1056
experiences	O	1057-1068
acquired	O	1069-1077
prior	O	1078-1083
to	O	1084-1086
cocaine	O	1087-1094
administration	O	1095-1109
was	O	1110-1113
impaired	O	1114-1122
and	O	1123-1126
negatively	O	1127-1137
correlated	O	1138-1148
with	O	1149-1153
NFkappaB	O	1154-1162
activity	O	1163-1171
in	O	1172-1174
the	O	1175-1178
frontal	O	1179-1186
cortex	O	1187-1193
.	O	1193-1194

In	O	1195-1197
contrast	O	1198-1206
,	O	1206-1207
learning	O	1208-1216
of	O	1217-1219
new	O	1220-1223
tasks	O	1224-1229
was	O	1230-1233
enhanced	O	1234-1242
and	O	1243-1246
correlated	O	1247-1257
with	O	1258-1262
the	O	1263-1266
increase	O	1267-1275
of	O	1276-1278
nNOS	O	1279-1283
activity	O	1284-1292
and	O	1293-1296
the	O	1297-1300
decrease	O	1301-1309
of	O	1310-1312
glutathione	O	1313-1324
peroxidase	O	1325-1335
.	O	1335-1336

These	O	1337-1342
results	O	1343-1350
provide	O	1351-1358
evidence	O	1359-1367
for	O	1368-1371
a	O	1372-1373
possible	O	1374-1382
mechanistic	O	1383-1394
role	O	1395-1399
of	O	1400-1402
oxidative	O	1403-1412
and	O	1413-1416
nitrosative	O	1417-1428
stress	O	1429-1435
and	O	1436-1439
NFkappaB	O	1440-1448
in	O	1449-1451
the	O	1452-1455
alterations	O	1456-1467
induced	O	1468-1475
by	O	1476-1478
cocaine	O	1479-1486
.	O	1486-1487

Topiramate	O	1488-1498
prevented	O	1499-1508
all	O	1509-1512
the	O	1513-1516
alterations	O	1517-1528
observed	O	1529-1537
,	O	1537-1538
showing	O	1539-1546
novel	O	1547-1552
neuroprotective	O	1553-1568
properties	O	1569-1579
.	O	1579-1580

Antinociceptive	O	0-15
and	O	16-19
antiamnesic	O	20-31
properties	O	32-42
of	O	43-45
the	O	46-49
presynaptic	O	50-61
cholinergic	O	62-73
amplifier	O	74-83
PG	O	84-86
-	O	86-87
9	O	87-88
.	O	88-89

The	O	90-93
antinociceptive	O	94-109
effect	O	110-116
of	O	117-119
3	O	120-121
alpha	O	122-127
-	O	127-128
tropyl	O	128-134
2	O	135-136
-	O	136-137
(	O	137-138
p	O	138-139
-	O	136-137
bromophenyl	O	140-151
)	O	151-152
propionate	O	152-162
[	O	163-164
(	O	164-165
+	O	165-166
/	O	166-167
-	O	167-168
)	O	168-169
-	O	167-168
PG	O	170-172
-	O	167-168
9	O	173-174
]	O	174-175
(	O	176-177
10	O	177-179
-	O	179-180
40	O	180-182
mg	O	183-185
kg	O	186-188
-	O	188-189
1	O	189-190
s	O	191-192
.	O	192-193
c	O	193-194
.	O	192-193
;	O	195-196
30	O	197-199
-	O	199-200
60	O	200-202
mg	O	203-205
kg	O	206-208
-	O	208-209
1	O	209-210
p	O	211-212
.	O	212-213
o	O	213-214
.	O	212-213
;	O	215-216
10	O	217-219
-	O	219-220
30	O	220-222
mg	O	223-225
kg	O	226-228
-	O	228-229
1	O	229-230
i	O	231-232
.	O	232-233
v	O	233-234
.	O	232-233
;	O	235-236
10	O	237-239
-	O	239-240
30	O	240-242
micrograms	O	243-253
/	O	253-254
mouse	O	254-259
i	O	260-261
.	O	261-262
c	O	262-263
.	O	261-262
v	O	264-265
.	O	261-262
)	O	266-267
was	O	268-271
examined	O	272-280
in	O	281-283
mice	O	284-288
,	O	288-289
rats	O	290-294
and	O	295-298
guinea	O	299-305
pigs	O	306-310
by	O	311-313
use	O	314-317
of	O	318-320
the	O	321-324
hot	O	325-328
-	O	328-329
plate	O	329-334
,	O	334-335
abdominal	O	336-345
-	O	345-346
constriction	O	346-358
,	O	358-359
tail	O	360-364
-	O	364-365
flick	O	365-370
and	O	371-374
paw	O	375-378
-	O	378-379
pressure	O	379-387
tests	O	388-393
.	O	393-394

(	O	395-396
+	O	396-397
/	O	397-398
-	O	398-399
)	O	399-400
-	O	398-399
PG	O	401-403
-	O	398-399
9	O	404-405
antinociception	O	406-421
peaked	O	422-428
15	O	429-431
min	O	432-435
after	O	436-441
injection	O	442-451
and	O	452-455
then	O	456-460
slowly	O	461-467
diminished	O	468-478
.	O	478-479

The	O	480-483
antinociception	O	484-499
produced	O	500-508
by	O	509-511
(	O	512-513
+	O	513-514
/	O	514-515
-	O	515-516
)	O	516-517
-	O	515-516
PG	O	518-520
-	O	515-516
9	O	521-522
was	O	523-526
prevented	O	527-536
by	O	537-539
the	O	540-543
unselective	O	544-555
muscarinic	O	556-566
antagonist	O	567-577
atropine	O	578-586
,	O	586-587
the	O	588-591
M1	O	592-594
-	O	594-595
selective	O	595-604
antagonists	O	605-616
pirenzepine	O	617-628
and	O	629-632
dicyclomine	O	633-644
and	O	645-648
the	O	649-652
acetylcholine	O	653-666
depletor	O	667-675
hemicholinium	O	676-689
-	O	689-690
3	O	690-691
,	O	691-692
but	O	693-696
not	O	697-700
by	O	701-703
the	O	704-707
opioid	O	708-714
antagonist	O	715-725
naloxone	O	726-734
,	O	734-735
the	O	736-739
gamma	O	740-745
-	O	745-746
aminobutyric	O	746-758
acidB	O	759-764
antagonist	O	765-775
3	O	776-777
-	O	777-778
aminopropyl	O	778-789
-	O	777-778
diethoxy	O	790-798
-	O	777-778
methyl	O	799-805
-	O	777-778
phosphinic	O	806-816
acid	O	817-821
,	O	821-822
the	O	823-826
H3	O	827-829
agonist	O	830-837
R	O	838-839
-	O	839-840
(	O	840-841
alpha	O	841-846
)	O	846-847
-	O	839-840
methylhistamine	O	848-863
,	O	863-864
the	O	865-868
D2	O	869-871
antagonist	O	872-882
quinpirole	O	883-893
,	O	893-894
the	O	895-898
5	O	899-900
-	O	900-901
hydroxytryptamine4	O	901-919
antagonist	O	920-930
2	O	931-932
-	O	932-933
methoxy	O	933-940
-	O	932-933
4	O	941-942
-	O	932-933
amino	O	943-948
-	O	932-933
5	O	949-950
-	O	932-933
chlorobenzoic	O	951-964
acid	O	965-969
2	O	970-971
-	O	971-972
(	O	972-973
diethylamino	O	973-985
)	O	985-986
ethyl	O	975-980
ester	O	992-997
hydrochloride	O	998-1011
,	O	1011-1012
the	O	1013-1016
5	O	1017-1018
-	O	1018-1019
hydroxytryptamin1A	O	1019-1037
antagonist	O	1038-1048
1	O	1049-1050
-	O	1050-1051
(	O	1051-1052
2	O	1052-1053
-	O	1050-1051
methoxyphenyl	O	1054-1067
)	O	1067-1068
-	O	1050-1051
4	O	1069-1070
-	O	1050-1051
[	O	1071-1072
4	O	1069-1070
-	O	1050-1051
(	O	1051-1052
2	O	1052-1053
-	O	1050-1051
phthalimido	O	1077-1088
)	O	1067-1068
butyl	O	1089-1094
]	O	1094-1095
piperazine	O	1095-1105
hydrobromide	O	1106-1118
and	O	1119-1122
the	O	1123-1126
polyamines	O	1127-1137
depletor	O	1138-1146
reserpine	O	1147-1156
.	O	1156-1157

Based	O	1158-1163
on	O	1164-1166
these	O	1167-1172
data	O	1173-1177
,	O	1177-1178
it	O	1179-1181
can	O	1182-1185
be	O	1186-1188
postulated	O	1189-1199
that	O	1200-1204
(	O	1205-1206
+	O	1206-1207
/	O	1207-1208
-	O	1208-1209
)	O	1209-1210
-	O	1208-1209
PG	O	1211-1213
-	O	1208-1209
9	O	1214-1215
exerted	O	1216-1223
an	O	1224-1226
antinociceptive	O	1227-1242
effect	O	1243-1249
mediated	O	1250-1258
by	O	1259-1261
a	O	1262-1263
central	O	1264-1271
potentiation	O	1272-1284
of	O	1285-1287
cholinergic	O	1288-1299
transmission	O	1300-1312
.	O	1312-1313

(	O	1314-1315
+	O	1315-1316
/	O	1316-1317
-	O	1317-1318
)	O	1318-1319
-	O	1317-1318
PG	O	1320-1322
-	O	1317-1318
9	O	1323-1324
(	O	1325-1326
10	O	1326-1328
-	O	1328-1329
40	O	1329-1331
mg	O	1332-1334
kg	O	1335-1337
-	O	1337-1338
1	O	1338-1339
i	O	1340-1341
.	O	1341-1342
p	O	1342-1343
.	O	1341-1342
)	O	1344-1345
was	O	1346-1349
able	O	1350-1354
to	O	1355-1357
prevent	O	1358-1365
amnesia	B	1366-1373
induced	O	1374-1381
by	O	1382-1384
scopolamine	O	1385-1396
(	O	1397-1398
1	O	1398-1399
mg	O	1400-1402
kg	O	1403-1405
-	O	1405-1406
1	O	1406-1407
i	O	1408-1409
.	O	1409-1410
p	O	1410-1411
.	O	1409-1410
)	O	1412-1413
and	O	1414-1417
dicyclomine	O	1418-1429
(	O	1430-1431
2	O	1431-1432
mg	O	1433-1435
kg	O	1436-1438
-	O	1438-1439
1	O	1439-1440
i	O	1441-1442
.	O	1442-1443
p	O	1443-1444
.	O	1442-1443
)	O	1445-1446
in	O	1447-1449
the	O	1450-1453
mouse	O	1454-1459
passive	O	1460-1467
-	O	1467-1468
avoidance	O	1468-1477
test	O	1478-1482
.	O	1482-1483

Affinity	O	1484-1492
profiles	O	1493-1501
of	O	1502-1504
(	O	1505-1506
+	O	1506-1507
/	O	1507-1508
-	O	1508-1509
)	O	1509-1510
-	O	1508-1509
PG	O	1511-1513
-	O	1508-1509
9	O	1514-1515
for	O	1516-1519
muscarinic	O	1520-1530
receptor	O	1531-1539
subtypes	O	1540-1548
,	O	1548-1549
determined	O	1550-1560
by	O	1561-1563
functional	O	1564-1574
studies	O	1575-1582
(	O	1583-1584
rabbit	O	1584-1590
vas	O	1591-1594
deferens	O	1595-1603
for	O	1604-1607
M1	O	1608-1610
,	O	1610-1611
guinea	O	1612-1618
pig	O	1619-1622
atrium	O	1623-1629
for	O	1630-1633
M2	O	1634-1636
,	O	1636-1637
guinea	O	1638-1644
pig	O	1645-1648
ileum	O	1649-1654
for	O	1655-1658
M3	O	1659-1661
and	O	1662-1665
immature	O	1666-1674
guinea	O	1675-1681
pig	O	1682-1685
uterus	O	1686-1692
for	O	1693-1696
putative	O	1697-1705
M4	O	1706-1708
)	O	1708-1709
,	O	1709-1710
have	O	1711-1715
shown	O	1716-1721
an	O	1722-1724
M4	O	1725-1727
/	O	1727-1728
M1	O	1728-1730
selectivity	O	1731-1742
ratio	O	1743-1748
of	O	1749-1751
10	O	1752-1754
.	O	1754-1755
2	O	1755-1756
that	O	1757-1761
might	O	1762-1767
be	O	1768-1770
responsible	O	1771-1782
for	O	1783-1786
the	O	1787-1790
antinociception	O	1791-1806
and	O	1807-1810
the	O	1811-1814
anti	O	1815-1819
-	O	1819-1820
amnesic	B	1820-1827
effect	O	1828-1834
induced	O	1835-1842
by	O	1843-1845
(	O	1846-1847
+	O	1847-1848
/	O	1848-1849
-	O	1849-1850
)	O	1850-1851
-	O	1849-1850
PG	O	1852-1854
-	O	1849-1850
9	O	1855-1856
through	O	1857-1864
an	O	1865-1867
increase	O	1868-1876
in	O	1877-1879
acetylcholine	O	1880-1893
extracellular	O	1894-1907
levels	O	1908-1914
.	O	1914-1915

In	O	1916-1918
the	O	1919-1922
antinociceptive	O	1923-1938
and	O	1939-1942
antiamnesic	O	1943-1954
dose	O	1955-1959
range	O	1960-1965
,	O	1965-1966
(	O	1967-1968
+	O	1968-1969
/	O	1969-1970
-	O	1970-1971
)	O	1971-1972
-	O	1970-1971
PG	O	1973-1975
-	O	1970-1971
9	O	1976-1977
did	O	1978-1981
not	O	1982-1985
impair	O	1986-1992
mouse	O	1993-1998
performance	O	1999-2010
evaluated	O	2011-2020
by	O	2021-2023
the	O	2024-2027
rota	O	2028-2032
-	O	2032-2033
rod	O	2033-2036
test	O	2037-2041
and	O	2042-2045
Animex	O	2046-2052
apparatus	O	2053-2062
.	O	2062-2063

Hyperbaric	O	0-10
oxygen	O	11-17
therapy	O	18-25
for	O	26-29
control	O	30-37
of	O	38-40
intractable	O	41-52
cyclophosphamide	O	53-69
-	O	69-70
induced	O	70-77
hemorrhagic	B	78-89
cystitis	I	90-98
.	O	98-99

We	O	100-102
report	O	103-109
a	O	110-111
case	O	112-116
of	O	117-119
intractable	O	120-131
hemorrhagic	B	132-143
cystitis	I	144-152
due	O	153-156
to	O	157-159
cyclophosphamide	O	160-176
therapy	O	177-184
for	O	185-188
Wegener	B	189-196
'	I	196-197
s	I	197-198
granulomatosis	I	199-213
.	O	213-214

Conservative	O	215-227
treatment	O	228-237
,	O	237-238
including	O	239-248
bladder	O	249-256
irrigation	O	257-267
with	O	268-272
physiological	O	273-286
saline	O	287-293
and	O	294-297
instillation	O	298-310
of	O	311-313
prostaglandin	O	314-327
F2	O	328-330
alpha	O	331-336
,	O	336-337
failed	O	338-344
to	O	345-347
totally	O	348-355
control	O	356-363
hemorrhage	B	364-374
.	O	374-375

We	O	376-378
then	O	379-383
used	O	384-388
hyperbaric	O	389-399
oxygen	O	400-406
at	O	407-409
an	O	410-412
absolute	O	413-421
pressure	O	422-430
of	O	431-433
2	O	434-435
atm	O	436-439
,	O	439-440
5	O	441-442
days	O	443-447
a	O	448-449
week	O	450-454
for	O	455-458
8	O	459-460
consecutive	O	461-472
weeks	O	473-478
.	O	478-479

The	O	480-483
bleeding	B	484-492
ceased	O	493-499
completely	O	500-510
by	O	511-513
the	O	514-517
end	O	518-521
of	O	522-524
treatment	O	525-534
and	O	535-538
the	O	539-542
patient	O	543-550
remained	O	551-559
free	O	560-564
of	O	565-567
hematuria	B	568-577
thereafter	O	578-588
.	O	588-589

No	O	590-592
side	O	593-597
effect	O	598-604
was	O	605-608
noted	O	609-614
during	O	615-621
the	O	622-625
course	O	626-632
of	O	633-635
therapy	O	636-643
.	O	643-644

In	O	645-647
future	O	648-654
,	O	654-655
this	O	656-660
form	O	661-665
of	O	666-668
therapy	O	669-676
can	O	677-680
offer	O	681-686
a	O	687-688
safe	O	689-693
alternative	O	694-705
in	O	706-708
the	O	709-712
treatment	O	713-722
of	O	723-725
cyclophosphamide	O	726-742
-	O	742-743
induced	O	743-750
hemorrhagic	B	751-762
cystitis	I	763-771
.	O	771-772

Further	O	0-7
studies	O	8-15
on	O	16-18
effects	O	19-26
of	O	27-29
irrigation	O	30-40
solutions	O	41-50
on	O	51-53
rat	O	54-57
bladders	O	58-66
.	O	66-67

Further	O	68-75
studies	O	76-83
on	O	84-86
the	O	87-90
effects	O	91-98
of	O	99-101
certain	O	102-109
irrigating	O	110-120
fluids	O	121-127
on	O	128-130
the	O	131-134
rat	O	135-138
bladder	O	139-146
for	O	147-150
18	O	151-153
hours	O	154-159
are	O	160-163
reported	O	164-172
.	O	172-173

The	O	174-177
results	O	178-185
have	O	186-190
shown	O	191-196
that	O	197-201
the	O	202-205
degradation	O	206-217
product	O	218-225
p	O	226-227
-	O	227-228
choloroaniline	O	228-242
is	O	243-245
not	O	246-249
a	O	250-251
significant	O	252-263
factor	O	264-270
in	O	271-273
chlorhexidine	O	274-287
-	O	287-288
digluconate	O	288-299
associated	O	300-310
erosive	O	311-318
cystitis	B	319-327
.	O	327-328

A	O	329-330
high	O	331-335
percentage	O	336-346
of	O	347-349
kanamycin	O	350-359
-	O	359-360
colistin	O	360-368
and	O	369-372
povidone	O	373-381
-	O	381-382
iodine	O	382-388
irrigations	O	389-400
were	O	401-405
associated	O	406-416
with	O	417-421
erosive	O	422-429
cystitis	B	430-438
and	O	439-442
suggested	O	443-452
a	O	453-454
possible	O	455-463
complication	O	464-476
with	O	477-481
human	O	482-487
usage	O	488-493
.	O	493-494

Picloxydine	O	495-506
irrigations	O	507-518
appeared	O	519-527
to	O	528-530
have	O	531-535
a	O	536-537
lower	O	538-543
incidence	O	544-553
of	O	554-556
erosive	O	557-564
cystitis	B	565-573
but	O	574-577
further	O	578-585
studies	O	586-593
would	O	594-599
have	O	600-604
to	O	605-607
be	O	608-610
performed	O	611-620
before	O	621-627
it	O	628-630
could	O	631-636
be	O	637-639
recommended	O	640-651
for	O	652-655
use	O	656-659
in	O	660-662
urological	O	663-673
procedures	O	674-684
.	O	684-685

Clinical	O	0-8
experiences	O	9-20
in	O	21-23
an	O	24-26
open	O	27-31
and	O	32-35
a	O	36-37
double	O	38-44
-	O	44-45
blind	O	45-50
trial	O	51-56
.	O	56-57

A	O	58-59
total	O	60-65
of	O	66-68
sixty	O	69-74
patients	O	75-83
were	O	84-88
trated	O	89-95
with	O	96-100
bromperidol	O	101-112
first	O	113-118
in	O	119-121
open	O	122-126
conditions	O	127-137
(	O	138-139
20	O	139-141
patients	O	142-150
)	O	150-151
,	O	151-152
then	O	153-157
on	O	158-160
a	O	161-162
double	O	163-169
blind	O	170-175
basis	O	176-181
(	O	182-183
40	O	183-185
patients	O	186-194
)	O	194-195
with	O	196-200
haloperidol	O	201-212
as	O	213-215
the	O	216-219
reference	O	220-229
substance	O	230-239
.	O	239-240

The	O	241-244
open	O	245-249
study	O	250-255
lasted	O	256-262
for	O	263-266
four	O	267-271
weeks	O	272-277
;	O	277-278
the	O	279-282
drug	O	283-287
was	O	288-291
administrated	O	292-305
in	O	306-308
the	O	309-312
form	O	313-317
of	O	318-320
1	O	321-322
mg	O	323-325
tablets	O	326-333
.	O	333-334

The	O	335-338
daily	O	339-344
dose	O	345-349
(	O	350-351
initial	O	351-358
dose	O	359-363
:	O	363-364
1	O	365-366
mg	O	367-369
;	O	369-370
mean	O	371-375
dose	O	376-380
at	O	381-383
the	O	384-387
end	O	388-391
of	O	392-394
the	O	395-398
trial	O	399-404
:	O	404-405
4	O	406-407
.	O	407-408
47	O	408-410
mg	O	411-413
)	O	413-414
was	O	415-418
always	O	419-425
administered	O	426-438
in	O	439-441
one	O	442-445
single	O	446-452
dose	O	453-457
.	O	457-458

Nineteen	O	459-467
patients	O	468-476
finished	O	477-485
the	O	486-489
trial	O	490-495
,	O	495-496
and	O	497-500
in	O	501-503
18	O	504-506
cases	O	507-512
the	O	513-516
therapeutic	O	517-528
result	O	529-535
was	O	536-539
considered	O	540-550
very	O	551-555
good	O	556-560
to	O	561-563
good	O	564-568
.	O	568-569

These	O	570-575
results	O	576-583
were	O	584-588
confirmed	O	589-598
by	O	599-601
statistical	O	602-613
analysis	O	614-622
.	O	622-623

Nine	O	624-628
patients	O	629-637
exhibited	O	638-647
mild	O	648-652
to	O	653-655
moderate	O	656-664
extrapyramidal	B	665-679
concomitant	I	680-691
symptoms	I	692-700
;	O	700-701
no	O	702-704
other	O	705-710
side	O	711-715
effects	O	716-723
were	O	724-728
observed	O	729-737
.	O	737-738

The	O	739-742
results	O	743-750
of	O	751-753
detailed	O	754-762
laboratory	O	763-773
tests	O	774-779
and	O	780-783
evaluations	O	784-795
of	O	796-798
various	O	799-806
quantitative	O	807-819
and	O	820-823
qualitative	O	824-835
tolerability	O	836-848
parameters	O	849-859
were	O	860-864
not	O	865-868
indicative	O	869-879
of	O	880-882
toxic	O	883-888
effects	O	889-896
.	O	896-897

In	O	898-900
the	O	901-904
double	O	905-911
blind	O	912-917
study	O	918-923
with	O	924-928
haloperidol	O	929-940
,	O	940-941
both	O	942-946
substances	O	947-957
were	O	958-962
found	O	963-968
to	O	969-971
be	O	972-974
highly	O	975-981
effective	O	982-991
in	O	992-994
the	O	995-998
treatment	O	999-1008
of	O	1009-1011
psychotic	B	1012-1021
syndromes	I	1022-1031
belonging	I	1032-1041
predominantly	I	1042-1055
to	I	1056-1058
the	I	1059-1062
schizophrenia	I	1063-1076
group	I	1077-1082
.	O	1082-1083

Certain	O	1084-1091
clues	O	1092-1097
,	O	1097-1098
including	O	1099-1108
the	O	1109-1112
onset	O	1113-1118
of	O	1119-1121
action	O	1122-1128
,	O	1128-1129
seem	O	1130-1134
to	O	1135-1137
be	O	1138-1140
indicative	O	1141-1151
of	O	1152-1154
the	O	1155-1158
superiority	O	1159-1170
of	O	1171-1173
bromperidol	O	1174-1185
.	O	1185-1186

No	O	1187-1189
differences	O	1190-1201
were	O	1202-1206
observed	O	1207-1215
with	O	1216-1220
respect	O	1221-1228
to	O	1229-1231
side	O	1232-1236
effects	O	1237-1244
and	O	1245-1248
general	O	1249-1256
tolerability	O	1257-1269
.	O	1269-1270

Curcumin	O	0-8
ameliorates	O	9-20
cognitive	B	21-30
dysfunction	I	31-42
and	O	43-46
oxidative	O	47-56
damage	O	57-63
in	O	64-66
phenobarbitone	O	67-81
and	O	82-85
carbamazepine	O	86-99
administered	O	100-112
rats	O	113-117
.	O	117-118

The	O	119-122
antiepileptic	O	123-136
drugs	O	137-142
,	O	142-143
phenobarbitone	O	144-158
and	O	159-162
carbamazepine	O	163-176
are	O	177-180
well	O	181-185
known	O	186-191
to	O	192-194
cause	O	195-200
cognitive	B	201-210
impairment	I	211-221
on	O	222-224
chronic	O	225-232
use	O	233-236
.	O	236-237

The	O	238-241
increase	O	242-250
in	O	251-253
free	O	254-258
radical	O	259-266
generation	O	267-277
has	O	278-281
been	O	282-286
implicated	O	287-297
as	O	298-300
one	O	301-304
of	O	305-307
the	O	308-311
important	O	312-321
mechanisms	O	322-332
of	O	333-335
cognitive	B	336-345
impairment	I	346-356
by	O	357-359
antiepileptic	O	360-373
drugs	O	374-379
.	O	379-380

Curcumin	O	381-389
has	O	390-393
shown	O	394-399
antioxidant	O	400-411
,	O	411-412
anti	O	413-417
-	O	417-418
inflammatory	O	418-430
and	O	431-434
neuro	O	435-440
-	O	440-441
protective	O	441-451
properties	O	452-462
.	O	462-463

Therefore	O	464-473
,	O	473-474
the	O	475-478
present	O	479-486
study	O	487-492
was	O	493-496
carried	O	497-504
out	O	505-508
to	O	509-511
investigate	O	512-523
the	O	524-527
effect	O	528-534
of	O	535-537
chronic	O	538-545
curcumin	O	546-554
administration	O	555-569
on	O	570-572
phenobarbitone	O	573-587
-	O	587-588
and	O	589-592
carbamazepine	O	593-606
-	O	606-607
induced	O	607-614
cognitive	B	615-624
impairment	I	625-635
and	O	636-639
oxidative	O	640-649
stress	O	650-656
in	O	657-659
rats	O	660-664
.	O	664-665

Pharmacokinetic	O	666-681
interactions	O	682-694
of	O	695-697
curcumin	O	698-706
with	O	707-711
phenobarbitone	O	712-726
and	O	727-730
carbamazepine	O	731-744
were	O	745-749
also	O	750-754
studied	O	755-762
.	O	762-763

Vehicle	O	764-771
/	O	771-772
drugs	O	772-777
were	O	778-782
administered	O	783-795
daily	O	796-801
for	O	802-805
21days	O	806-812
to	O	813-815
male	O	816-820
Wistar	O	821-827
rats	O	828-832
.	O	832-833

Passive	O	834-841
avoidance	O	842-851
paradigm	O	852-860
and	O	861-864
elevated	O	865-873
plus	O	874-878
maze	O	879-883
test	O	884-888
were	O	889-893
used	O	894-898
to	O	899-901
assess	O	902-908
cognitive	O	909-918
function	O	919-927
.	O	927-928

At	O	929-931
the	O	932-935
end	O	936-939
of	O	940-942
study	O	943-948
period	O	949-955
,	O	955-956
serum	O	957-962
phenobarbitone	O	963-977
and	O	978-981
carbamazepine	O	982-995
,	O	995-996
whole	O	997-1002
brain	O	1003-1008
malondialdehyde	O	1009-1024
and	O	1025-1028
reduced	O	1029-1036
glutathione	O	1037-1048
levels	O	1049-1055
were	O	1056-1060
estimated	O	1061-1070
.	O	1070-1071

The	O	1072-1075
administration	O	1076-1090
of	O	1091-1093
phenobarbitone	O	1094-1108
and	O	1109-1112
carbamazepine	O	1113-1126
for	O	1127-1130
21days	O	1131-1137
caused	O	1138-1144
a	O	1145-1146
significant	O	1147-1158
impairment	B	1159-1169
of	I	1170-1172
learning	I	1173-1181
and	I	1182-1185
memory	I	1186-1192
as	O	1193-1195
well	O	1196-1200
as	O	1201-1203
an	O	1204-1206
increased	O	1207-1216
oxidative	O	1217-1226
stress	O	1227-1233
.	O	1233-1234

Concomitant	O	1235-1246
curcumin	O	1247-1255
administration	O	1256-1270
prevented	O	1271-1280
the	O	1281-1284
cognitive	B	1285-1294
impairment	I	1295-1305
and	O	1306-1309
decreased	O	1310-1319
the	O	1320-1323
increased	O	1324-1333
oxidative	O	1334-1343
stress	O	1344-1350
induced	O	1351-1358
by	O	1359-1361
these	O	1362-1367
antiepileptic	O	1368-1381
drugs	O	1382-1387
.	O	1387-1388

Curcumin	O	1389-1397
co	O	1398-1400
-	O	1400-1401
administration	O	1401-1415
did	O	1416-1419
not	O	1420-1423
cause	O	1424-1429
any	O	1430-1433
significant	O	1434-1445
alteration	O	1446-1456
in	O	1457-1459
the	O	1460-1463
serum	O	1464-1469
concentrations	O	1470-1484
of	O	1485-1487
both	O	1488-1492
phenobarbitone	O	1493-1507
as	O	1508-1510
well	O	1511-1515
as	O	1516-1518
carbamazepine	O	1519-1532
.	O	1532-1533

These	O	1534-1539
results	O	1540-1547
show	O	1548-1552
that	O	1553-1557
curcumin	O	1558-1566
has	O	1567-1570
beneficial	O	1571-1581
effect	O	1582-1588
in	O	1589-1591
mitigating	O	1592-1602
the	O	1603-1606
deterioration	B	1607-1620
of	I	1621-1623
cognitive	I	1624-1633
functions	I	1634-1643
and	O	1644-1647
oxidative	O	1648-1657
damage	O	1658-1664
in	O	1665-1667
rats	O	1668-1672
treated	O	1673-1680
with	O	1681-1685
phenobarbitone	O	1686-1700
and	O	1701-1704
carbamazepine	O	1705-1718
without	O	1719-1726
significantly	O	1727-1740
altering	O	1741-1749
their	O	1750-1755
serum	O	1756-1761
concentrations	O	1762-1776
.	O	1776-1777

The	O	1778-1781
findings	O	1782-1790
suggest	O	1791-1798
that	O	1799-1803
curcumin	O	1804-1812
can	O	1813-1816
be	O	1817-1819
considered	O	1820-1830
as	O	1831-1833
a	O	1834-1835
potential	O	1836-1845
safe	O	1846-1850
and	O	1851-1854
effective	O	1855-1864
adjuvant	O	1865-1873
to	O	1874-1876
phenobarbitone	O	1877-1891
and	O	1892-1895
carbamazepine	O	1896-1909
therapy	O	1910-1917
in	O	1918-1920
preventing	O	1921-1931
cognitive	B	1932-1941
impairment	I	1942-1952
associated	O	1953-1963
with	O	1964-1968
these	O	1969-1974
drugs	O	1975-1980
.	O	1980-1981

Pyrrolidine	O	0-11
dithiocarbamate	O	12-27
protects	O	28-36
the	O	37-40
piriform	O	41-49
cortex	O	50-56
in	O	57-59
the	O	60-63
pilocarpine	O	64-75
status	B	76-82
epilepticus	I	83-94
model	O	95-100
.	O	100-101

Pyrrolidine	O	102-113
dithiocarbamate	O	114-129
(	O	130-131
PDTC	O	131-135
)	O	135-136
has	O	137-140
a	O	141-142
dual	O	143-147
mechanism	O	148-157
of	O	158-160
action	O	161-167
as	O	168-170
an	O	171-173
antioxidant	O	174-185
and	O	186-189
an	O	190-192
inhibitor	O	193-202
of	O	203-205
the	O	206-209
transcription	O	210-223
factor	O	224-230
kappa	O	231-236
-	O	236-237
beta	O	237-241
.	O	241-242
Both	O	243-247
,	O	247-248
production	O	249-259
of	O	260-262
reactive	O	263-271
oxygen	O	272-278
species	O	279-286
as	O	287-289
well	O	290-294
as	O	295-297
activation	O	298-308
of	O	309-311
NF	O	312-314
-	O	314-315
kappaB	O	315-321
have	O	322-326
been	O	327-331
implicated	O	332-342
in	O	343-345
severe	O	346-352
neuronal	B	353-361
damage	I	362-368
in	O	369-371
different	O	372-381
sub	O	382-385
-	O	385-386
regions	O	386-393
of	O	394-396
the	O	397-400
hippocampus	O	401-412
as	O	413-415
well	O	416-420
as	O	421-423
in	O	424-426
the	O	427-430
surrounding	O	431-442
cortices	O	443-451
.	O	451-452

The	O	453-456
effect	O	457-463
of	O	464-466
PDTC	O	467-471
on	O	472-474
status	B	475-481
epilepticus	I	482-493
-	O	493-494
associated	O	494-504
cell	O	505-509
loss	O	510-514
in	O	515-517
the	O	518-521
hippocampus	O	522-533
and	O	534-537
piriform	O	538-546
cortex	O	547-553
was	O	554-557
evaluated	O	558-567
in	O	568-570
the	O	571-574
rat	O	575-578
fractionated	O	579-591
pilocarpine	O	592-603
model	O	604-609
.	O	609-610

Treatment	O	611-620
with	O	621-625
150	O	626-629
mg	O	630-632
/	O	632-633
kg	O	633-635
PDTC	O	636-640
before	O	641-647
and	O	648-651
following	O	652-661
status	B	662-668
epilepticus	I	669-680
significantly	O	681-694
increased	O	695-704
the	O	705-708
mortality	O	709-718
rate	O	719-723
to	O	724-726
100	O	727-730
%	O	730-731
.	O	731-732

Administration	O	733-747
of	O	748-750
50	O	751-753
mg	O	754-756
/	O	756-757
kg	O	757-759
PDTC	O	760-764
(	O	765-766
low	O	766-769
-	O	769-770
dose	O	770-774
)	O	774-775
did	O	776-779
not	O	780-783
exert	O	784-789
major	O	790-795
effects	O	796-803
on	O	804-806
the	O	807-810
development	O	811-822
of	O	823-825
a	O	826-827
status	B	828-834
epilepticus	I	835-846
or	O	847-849
the	O	850-853
mortality	O	854-863
rate	O	864-868
.	O	868-869

In	O	870-872
vehicle	O	873-880
-	O	880-881
treated	O	881-888
rats	O	889-893
,	O	893-894
status	B	895-901
epilepticus	I	902-913
caused	O	914-920
pronounced	O	921-931
neuronal	B	932-940
damage	I	941-947
in	O	948-950
the	O	951-954
piriform	O	955-963
cortex	O	964-970
comprising	O	971-981
both	O	982-986
pyramidal	O	987-996
cells	O	997-1002
and	O	1003-1006
interneurons	O	1007-1019
.	O	1019-1020

Low	O	1021-1024
-	O	1024-1025
dose	O	1025-1029
PDTC	O	1030-1034
treatment	O	1035-1044
almost	O	1045-1051
completely	O	1052-1062
protected	O	1063-1072
from	O	1073-1077
lesions	O	1078-1085
in	O	1086-1088
the	O	1089-1092
piriform	O	1093-1101
cortex	O	1102-1108
.	O	1108-1109

A	O	1110-1111
significant	O	1112-1123
decrease	O	1124-1132
in	O	1133-1135
neuronal	O	1136-1144
density	O	1145-1152
of	O	1153-1155
the	O	1156-1159
hippocampal	O	1160-1171
hilar	O	1172-1177
formation	O	1178-1187
was	O	1188-1191
identified	O	1192-1202
in	O	1203-1205
vehicle	O	1206-1213
-	O	1213-1214
and	O	1215-1218
PDTC	O	1219-1223
-	O	1223-1224
treated	O	1224-1231
rats	O	1232-1236
following	O	1237-1246
status	B	1247-1253
epilepticus	I	1254-1265
.	O	1265-1266

In	O	1267-1269
conclusion	O	1270-1280
,	O	1280-1281
the	O	1282-1285
NF	O	1286-1288
-	O	1288-1289
kappaB	O	1289-1295
inhibitor	O	1296-1305
and	O	1306-1309
antioxidant	O	1310-1321
PDTC	O	1322-1326
protected	O	1327-1336
the	O	1337-1340
piriform	O	1341-1349
cortex	O	1350-1356
,	O	1356-1357
whereas	O	1358-1365
it	O	1366-1368
did	O	1369-1372
not	O	1373-1376
affect	O	1377-1383
hilar	O	1384-1389
neuronal	B	1390-1398
loss	I	1399-1403
.	O	1403-1404

These	O	1405-1410
data	O	1411-1415
might	O	1416-1421
indicate	O	1422-1430
that	O	1431-1435
the	O	1436-1439
generation	O	1440-1450
of	O	1451-1453
reactive	O	1454-1462
oxygen	O	1463-1469
species	O	1470-1477
and	O	1478-1481
activation	O	1482-1492
of	O	1493-1495
NF	O	1496-1498
-	O	1498-1499
kappaB	O	1499-1505
plays	O	1506-1511
a	O	1512-1513
more	O	1514-1518
central	O	1519-1526
role	O	1527-1531
in	O	1532-1534
seizure	B	1535-1542
-	O	1542-1543
associated	O	1543-1553
neuronal	B	1554-1562
damage	I	1563-1569
in	O	1570-1572
the	O	1573-1576
temporal	O	1577-1585
cortex	O	1586-1592
as	O	1593-1595
compared	O	1596-1604
to	O	1605-1607
the	O	1608-1611
hippocampal	O	1612-1623
hilus	O	1624-1629
.	O	1629-1630

However	O	1631-1638
,	O	1638-1639
future	O	1640-1646
investigations	O	1647-1661
are	O	1662-1665
necessary	O	1666-1675
to	O	1676-1678
exactly	O	1679-1686
analyze	O	1687-1694
the	O	1695-1698
biochemical	O	1699-1710
mechanisms	O	1711-1721
by	O	1722-1724
which	O	1725-1730
PDTC	O	1731-1735
exerted	O	1736-1743
its	O	1744-1747
beneficial	O	1748-1758
effects	O	1759-1766
in	O	1767-1769
the	O	1770-1773
piriform	O	1774-1782
cortex	O	1783-1789
.	O	1789-1790

Safety	O	0-6
profile	O	7-14
of	O	15-17
a	O	18-19
nicotine	O	20-28
lozenge	O	29-36
compared	O	37-45
with	O	46-50
that	O	51-55
of	O	56-58
nicotine	O	59-67
gum	O	68-71
in	O	72-74
adult	O	75-80
smokers	O	81-88
with	O	89-93
underlying	O	94-104
medical	O	105-112
conditions	O	113-123
:	O	123-124
a	O	125-126
12	O	127-129
-	O	129-130
week	O	130-134
,	O	134-135
randomized	O	136-146
,	O	146-147
open	O	148-152
-	O	152-153
label	O	153-158
study	O	159-164
.	O	164-165

BACKGROUND	O	166-176
:	O	176-177
Nicotine	O	178-186
polacrilex	O	187-197
lozenges	O	198-206
deliver	O	207-214
25	O	215-217
%	O	217-218
to	O	219-221
27	O	222-224
%	O	224-225
more	O	226-230
nicotine	O	231-239
compared	O	240-248
with	O	249-253
equivalent	O	254-264
doses	O	265-270
of	O	271-273
nicotine	O	274-282
polacrilex	O	283-293
gum	O	294-297
.	O	297-298

The	O	299-302
increased	O	303-312
nicotine	O	313-321
exposure	O	322-330
from	O	331-335
the	O	336-339
lozenge	O	340-347
has	O	348-351
raised	O	352-358
questions	O	359-368
about	O	369-374
the	O	375-378
relative	O	379-387
safety	O	388-394
of	O	395-397
the	O	398-401
lozenge	O	402-409
and	O	410-413
gum	O	414-417
.	O	417-418

OBJECTIVE	O	419-428
:	O	428-429
The	O	430-433
objective	O	434-443
of	O	444-446
this	O	447-451
study	O	452-457
was	O	458-461
to	O	462-464
compare	O	465-472
the	O	473-476
safety	O	477-483
profiles	O	484-492
of	O	493-495
the	O	496-499
4	O	500-501
-	O	501-502
mg	O	502-504
nicotine	O	505-513
lozenge	O	514-521
and	O	522-525
4	O	526-527
-	O	527-528
mg	O	528-530
nicotine	O	531-539
gum	O	540-543
in	O	544-546
smokers	O	547-554
with	O	555-559
selected	O	560-568
label	O	569-574
-	O	574-575
restricted	O	575-585
diseases	O	586-594
.	O	594-595

METHODS	O	596-603
:	O	603-604
This	O	605-609
was	O	610-613
a	O	614-615
multicenter	O	616-627
,	O	627-628
randomized	O	629-639
,	O	639-640
open	O	641-645
-	O	645-646
label	O	646-651
study	O	652-657
in	O	658-660
adult	O	661-666
smokers	O	667-674
with	O	675-679
heart	B	680-685
disease	I	686-693
,	O	693-694
hypertension	B	695-707
not	O	708-711
controlled	O	712-722
by	O	723-725
medication	O	726-736
,	O	736-737
and	O	738-741
/	O	741-742
or	O	742-744
diabetes	B	745-753
mellitus	I	754-762
.	O	762-763

Patients	O	764-772
were	O	773-777
randomized	O	778-788
in	O	789-791
a	O	792-793
1	O	794-795
:	O	795-796
1	O	794-795
ratio	O	798-803
to	O	804-806
receive	O	807-814
the	O	815-818
4	O	819-820
-	O	820-821
mg	O	821-823
nicotine	O	824-832
lozenge	O	833-840
or	O	841-843
4	O	844-845
-	O	845-846
mg	O	846-848
nicotine	O	849-857
gum	O	858-861
.	O	861-862

Safety	O	863-869
assessments	O	870-881
were	O	882-886
made	O	887-891
at	O	892-894
baseline	O	895-903
and	O	904-907
at	O	908-910
2	O	911-912
,	O	912-913
4	O	914-915
,	O	915-916
6	O	917-918
,	O	918-919
and	O	920-923
12	O	924-926
weeks	O	927-932
after	O	933-938
the	O	939-942
start	O	943-948
of	O	949-951
product	O	952-959
use	O	960-963
.	O	963-964

RESULTS	O	965-972
:	O	972-973
Nine	O	974-978
hundred	O	979-986
one	O	987-990
patients	O	991-999
were	O	1000-1004
randomized	O	1005-1015
to	O	1016-1018
treatment	O	1019-1028
,	O	1028-1029
447	O	1030-1033
who	O	1034-1037
received	O	1038-1046
the	O	1047-1050
lozenge	O	1051-1058
and	O	1059-1062
454	O	1063-1066
who	O	1067-1070
received	O	1071-1079
the	O	1080-1083
gum	O	1084-1087
(	O	1088-1089
safety	O	1089-1095
population	O	1096-1106
)	O	1106-1107
.	O	1107-1108

The	O	1109-1112
majority	O	1113-1121
were	O	1122-1126
women	O	1127-1132
(	O	1133-1134
52	O	1134-1136
.	O	1136-1137
7	O	1137-1138
%	O	1138-1139
)	O	1139-1140
.	O	1136-1137

Patients	O	1142-1150
'	O	1150-1151
mean	O	1152-1156
age	O	1157-1160
was	O	1161-1164
53	O	1165-1167
.	O	1167-1168
9	O	1168-1169
years	O	1170-1175
,	O	1175-1176
their	O	1177-1182
mean	O	1183-1187
weight	O	1188-1194
was	O	1195-1198
193	O	1199-1202
.	O	1202-1203
9	O	1200-1201
pounds	O	1205-1211
,	O	1211-1212
and	O	1213-1216
they	O	1217-1221
smoked	O	1222-1228
a	O	1229-1230
mean	O	1231-1235
of	O	1236-1238
25	O	1239-1241
.	O	1241-1242
2	O	1239-1240
cigarettes	O	1244-1254
per	O	1255-1258
day	O	1259-1262
at	O	1263-1265
baseline	O	1266-1274
.	O	1274-1275

Five	O	1276-1280
hundred	O	1281-1288
fifty	O	1289-1294
-	O	1294-1295
three	O	1295-1300
patients	O	1301-1309
,	O	1309-1310
264	O	1311-1314
taking	O	1315-1321
the	O	1322-1325
lozenge	O	1326-1333
and	O	1334-1337
289	O	1338-1341
taking	O	1342-1348
the	O	1349-1352
gum	O	1353-1356
,	O	1356-1357
used	O	1358-1362
the	O	1363-1366
study	O	1367-1372
product	O	1373-1380
for	O	1381-1384
>	O	1385-1386
or	O	1387-1389
=	O	1390-1391
4	O	1391-1392
days	O	1393-1397
per	O	1398-1401
week	O	1402-1406
during	O	1407-1413
the	O	1414-1417
first	O	1418-1423
2	O	1424-1425
weeks	O	1426-1431
(	O	1432-1433
evaluable	O	1433-1442
population	O	1443-1453
)	O	1453-1454
.	O	1454-1455

The	O	1456-1459
nicotine	O	1460-1468
lozenge	O	1469-1476
and	O	1477-1480
nicotine	O	1481-1489
gum	O	1490-1493
were	O	1494-1498
equally	O	1499-1506
well	O	1507-1511
tolerated	O	1512-1521
,	O	1521-1522
despite	O	1523-1530
increased	O	1531-1540
nicotine	O	1541-1549
exposure	O	1550-1558
from	O	1559-1563
the	O	1564-1567
lozenge	O	1568-1575
.	O	1575-1576

The	O	1577-1580
incidence	O	1581-1590
of	O	1591-1593
adverse	O	1594-1601
events	O	1602-1608
in	O	1609-1611
the	O	1612-1615
2	O	1616-1617
groups	O	1618-1624
was	O	1625-1628
similar	O	1629-1636
during	O	1637-1643
the	O	1644-1647
first	O	1648-1653
2	O	1654-1655
weeks	O	1656-1661
of	O	1662-1664
product	O	1665-1672
use	O	1673-1676
(	O	1677-1678
evaluation	O	1678-1688
population	O	1689-1699
:	O	1699-1700
55	O	1701-1703
.	O	1703-1704
3	O	1704-1705
%	O	1705-1706
lozenge	O	1707-1714
,	O	1714-1715
54	O	1716-1718
.	O	1718-1719
7	O	1719-1720
%	O	1720-1721
gum	O	1722-1725
)	O	1725-1726
,	O	1726-1727
as	O	1728-1730
well	O	1731-1735
as	O	1736-1738
during	O	1739-1745
the	O	1746-1749
entire	O	1750-1756
study	O	1757-1762
(	O	1763-1764
safety	O	1764-1770
population	O	1771-1781
:	O	1781-1782
63	O	1783-1785
.	O	1785-1786
8	O	1786-1787
%	O	1787-1788
and	O	1789-1792
58	O	1793-1795
.	O	1795-1796
6	O	1796-1797
%	O	1797-1798
,	O	1798-1799
respectively	O	1800-1812
)	O	1812-1813
.	O	1813-1814

Stratification	O	1815-1829
of	O	1830-1832
patients	O	1833-1841
by	O	1842-1844
sex	O	1845-1848
,	O	1848-1849
age	O	1850-1853
,	O	1853-1854
extent	O	1855-1861
of	O	1862-1864
concurrent	O	1865-1875
smoking	O	1876-1883
,	O	1883-1884
extent	O	1885-1891
of	O	1892-1894
product	O	1895-1902
use	O	1903-1906
,	O	1906-1907
and	O	1908-1911
severity	O	1912-1920
of	O	1921-1923
adverse	O	1924-1931
events	O	1932-1938
revealed	O	1939-1947
no	O	1948-1950
clinically	O	1951-1961
significant	O	1962-1973
differences	O	1974-1985
between	O	1986-1993
the	O	1994-1997
lozenge	O	1998-2005
and	O	2006-2009
gum	O	2010-2013
.	O	2013-2014

The	O	2015-2018
most	O	2019-2023
common	O	2024-2030
adverse	O	2031-2038
events	O	2039-2045
were	O	2046-2050
nausea	B	2051-2057
(	O	2058-2059
17	O	2059-2061
.	O	2061-2062
2	O	2062-2063
%	O	2063-2064
and	O	2065-2068
16	O	2069-2071
.	O	2071-2072
1	O	2069-2070
%	O	2073-2074
;	O	2074-2075
95	O	2076-2078
%	O	2078-2079
CI	O	2080-2082
,	O	2082-2083
-	O	2084-2085
3	O	2085-2086
.	O	2086-2087
7	O	2087-2088
to	O	2089-2091
6	O	2092-2093
.	O	2093-2094
0	O	2094-2095
)	O	2095-2096
,	O	2096-2097
hiccups	B	2098-2105
(	O	2106-2107
10	O	2107-2109
.	O	2109-2110
7	O	2110-2111
%	O	2111-2112
and	O	2113-2116
6	O	2117-2118
.	O	2118-2119
6	O	2117-2118
%	O	2120-2121
;	O	2121-2122
95	O	2123-2125
%	O	2125-2126
CI	O	2127-2129
,	O	2129-2130
0	O	2131-2132
.	O	2132-2133
5	O	2133-2134
to	O	2135-2137
7	O	2138-2139
.	O	2139-2140
8	O	2140-2141
)	O	2141-2142
,	O	2142-2143
and	O	2144-2147
headache	B	2148-2156
(	O	2157-2158
8	O	2158-2159
.	O	2159-2160
7	O	2160-2161
%	O	2161-2162
and	O	2163-2166
9	O	2167-2168
.	O	2168-2169
9	O	2167-2168
%	O	2170-2171
;	O	2171-2172
95	O	2173-2175
%	O	2175-2176
Cl	O	2177-2179
,	O	2179-2180
-	O	2181-2182
5	O	2182-2183
.	O	2183-2184
0	O	2184-2185
to	O	2186-2188
2	O	2189-2190
.	O	2190-2191
6	O	2191-2192
)	O	2192-2193
.	O	2190-2191

Serious	O	2195-2202
adverse	O	2203-2210
events	O	2211-2217
were	O	2218-2222
reported	O	2223-2231
in	O	2232-2234
11	O	2235-2237
and	O	2238-2241
13	O	2242-2244
patients	O	2245-2253
in	O	2254-2256
the	O	2257-2260
respective	O	2261-2271
groups	O	2272-2278
.	O	2278-2279

Fewer	O	2280-2285
than	O	2286-2290
6	O	2291-2292
%	O	2292-2293
of	O	2294-2296
patients	O	2297-2305
in	O	2306-2308
either	O	2309-2315
group	O	2316-2321
were	O	2322-2326
considered	O	2327-2337
by	O	2338-2340
the	O	2341-2344
investigator	O	2345-2357
to	O	2358-2360
have	O	2361-2365
a	O	2366-2367
worsening	O	2368-2377
of	O	2378-2380
their	O	2381-2386
overall	O	2387-2394
disease	O	2395-2402
condition	O	2403-2412
during	O	2413-2419
the	O	2420-2423
study	O	2424-2429
.	O	2429-2430

The	O	2431-2434
majority	O	2435-2443
of	O	2444-2446
patients	O	2447-2455
(	O	2456-2457
>	O	2457-2458
60	O	2458-2460
%	O	2460-2461
)	O	2461-2462
experienced	O	2463-2474
no	O	2475-2477
change	O	2478-2484
in	O	2485-2487
their	O	2488-2493
disease	O	2494-2501
status	O	2502-2508
from	O	2509-2513
baseline	O	2514-2522
.	O	2522-2523

CONCLUSION	O	2524-2534
:	O	2534-2535
The	O	2536-2539
4	O	2540-2541
-	O	2541-2542
mg	O	2542-2544
nicotine	O	2545-2553
lozenge	O	2554-2561
and	O	2562-2565
4	O	2566-2567
-	O	2567-2568
mg	O	2568-2570
nicotine	O	2571-2579
gum	O	2580-2583
had	O	2584-2587
comparable	O	2588-2598
safety	O	2599-2605
profiles	O	2606-2614
in	O	2615-2617
these	O	2618-2623
patients	O	2624-2632
with	O	2633-2637
label	O	2638-2643
-	O	2643-2644
restricted	O	2644-2654
medical	O	2655-2662
conditions	O	2663-2673
.	O	2673-2674

Development	O	0-11
of	O	12-14
levodopa	O	15-23
-	O	23-24
induced	O	24-31
dyskinesias	B	32-43
in	O	44-46
parkinsonian	B	47-59
monkeys	O	60-67
may	O	68-71
depend	O	72-78
upon	O	79-83
rate	O	84-88
of	O	89-91
symptom	O	92-99
onset	O	100-105
and	O	106-109
/	O	109-110
or	O	110-112
duration	O	113-121
of	O	122-124
symptoms	O	125-133
.	O	133-134

Levodopa	O	135-143
-	O	143-144
induced	O	144-151
dyskinesias	B	152-163
(	O	164-165
LIDs	B	165-169
)	O	169-170
present	O	171-178
a	O	179-180
major	O	181-186
problem	O	187-194
for	O	195-198
the	O	199-202
long	O	203-207
-	O	207-208
term	O	208-212
management	O	213-223
of	O	224-226
Parkinson	B	227-236
'	I	236-237
s	I	233-234
disease	I	239-246
(	O	247-248
PD	B	248-250
)	O	250-251
patients	O	252-260
.	O	260-261

Due	O	262-265
to	O	266-268
the	O	269-272
interdependence	O	273-288
of	O	289-291
risk	O	292-296
factors	O	297-304
in	O	305-307
clinical	O	308-316
populations	O	317-328
,	O	328-329
it	O	330-332
is	O	333-335
difficult	O	336-345
to	O	346-348
independently	O	349-362
examine	O	363-370
factors	O	371-378
that	O	379-383
may	O	384-387
influence	O	388-397
the	O	398-401
development	O	402-413
of	O	414-416
LIDs	B	417-421
.	O	421-422

Using	O	423-428
macaque	O	429-436
monkeys	O	437-444
with	O	445-449
different	O	450-459
types	O	460-465
of	O	466-468
MPTP	O	469-473
-	O	473-474
induced	O	474-481
parkinsonism	B	482-494
,	O	494-495
the	O	496-499
current	O	500-507
study	O	508-513
evaluated	O	514-523
the	O	524-527
degree	O	528-534
to	O	535-537
which	O	538-543
rate	O	544-548
of	O	549-551
symptom	O	552-559
progression	O	560-571
,	O	571-572
symptom	O	573-580
severity	O	581-589
,	O	589-590
and	O	591-594
response	O	595-603
to	O	604-606
and	O	607-610
duration	O	611-619
of	O	620-622
levodopa	O	623-631
therapy	O	632-639
may	O	640-643
be	O	644-646
involved	O	647-655
in	O	656-658
the	O	659-662
development	O	663-674
of	O	675-677
LIDs	B	678-682
.	O	682-683

Monkeys	O	684-691
with	O	692-696
acute	O	697-702
(	O	703-704
short	O	704-709
-	O	709-710
term	O	710-714
)	O	714-715
MPTP	O	716-720
exposure	O	721-729
,	O	729-730
rapid	O	731-736
symptom	O	737-744
onset	O	745-750
and	O	751-754
short	O	755-760
symptom	O	761-768
duration	O	769-777
prior	O	778-783
to	O	784-786
initiation	O	787-797
of	O	798-800
levodopa	O	801-809
therapy	O	810-817
developed	O	818-827
dyskinesia	B	828-838
between	O	839-846
11	O	847-849
and	O	850-853
24	O	854-856
days	O	857-861
of	O	862-864
daily	O	865-870
levodopa	O	871-879
administration	O	880-894
.	O	894-895

In	O	896-898
contrast	O	899-907
,	O	907-908
monkeys	O	909-916
with	O	917-921
long	O	922-926
-	O	926-927
term	O	927-931
MPTP	O	932-936
exposure	O	937-945
,	O	945-946
slow	O	947-951
symptom	O	952-959
progression	O	960-971
and	O	972-975
/	O	975-976
or	O	976-978
long	O	979-983
symptom	O	984-991
duration	O	992-1000
prior	O	1001-1006
to	O	1007-1009
initiation	O	1010-1020
of	O	1021-1023
levodopa	O	1024-1032
therapy	O	1033-1040
were	O	1041-1045
more	O	1046-1050
resistant	O	1051-1060
to	O	1061-1063
developing	O	1064-1074
LIDs	B	1075-1079
(	O	1080-1081
e	O	1081-1082
.	O	1082-1083
g	O	1083-1084
.	O	1082-1083
,	O	1085-1086
dyskinesia	B	1087-1097
developed	O	1098-1107
no	O	1108-1110
sooner	O	1111-1117
than	O	1118-1122
146	O	1123-1126
days	O	1127-1131
of	O	1132-1134
chronic	O	1135-1142
levodopa	O	1143-1151
administration	O	1152-1166
)	O	1166-1167
.	O	1167-1168

All	O	1169-1172
animals	O	1173-1180
were	O	1181-1185
similarly	O	1186-1195
symptomatic	O	1196-1207
at	O	1208-1210
the	O	1211-1214
start	O	1215-1220
of	O	1221-1223
levodopa	O	1224-1232
treatment	O	1233-1242
and	O	1243-1246
had	O	1247-1250
similar	O	1251-1258
therapeutic	O	1259-1270
responses	O	1271-1280
to	O	1281-1283
the	O	1284-1287
drug	O	1288-1292
.	O	1292-1293

These	O	1294-1299
data	O	1300-1304
suggest	O	1305-1312
distinct	O	1313-1321
differences	O	1322-1333
in	O	1334-1336
the	O	1337-1340
propensity	O	1341-1351
to	O	1352-1354
develop	O	1355-1362
LIDs	B	1363-1367
in	O	1368-1370
monkeys	O	1371-1378
with	O	1379-1383
different	O	1384-1393
rates	O	1394-1399
of	O	1400-1402
symptom	O	1403-1410
progression	O	1411-1422
or	O	1423-1425
symptom	O	1426-1433
durations	O	1434-1443
prior	O	1444-1449
to	O	1450-1452
levodopa	O	1453-1461
and	O	1462-1465
demonstrate	O	1466-1477
the	O	1478-1481
value	O	1482-1487
of	O	1488-1490
these	O	1491-1496
models	O	1497-1503
for	O	1504-1507
further	O	1508-1515
studying	O	1516-1524
the	O	1525-1528
pathophysiology	O	1529-1544
of	O	1545-1547
LIDs	B	1548-1552
.	O	1552-1553

Propylthiouracil	O	0-16
-	O	16-17
induced	O	17-24
perinuclear	O	25-36
-	O	36-37
staining	O	37-45
antineutrophil	O	46-60
cytoplasmic	O	61-72
autoantibody	O	73-85
-	O	85-86
positive	O	86-94
vasculitis	B	95-105
in	O	106-108
conjunction	O	109-120
with	O	121-125
pericarditis	B	126-138
.	O	138-139

OBJECTIVE	O	140-149
:	O	149-150
To	O	151-153
describe	O	154-162
a	O	163-164
case	O	165-169
of	O	170-172
propylthiouracil	O	173-189
-	O	189-190
induced	O	190-197
vasculitis	B	198-208
manifesting	O	209-220
with	O	221-225
pericarditis	B	226-238
.	O	238-239

METHODS	O	240-247
:	O	247-248
We	O	249-251
present	O	252-259
the	O	260-263
first	O	264-269
case	O	270-274
report	O	275-281
of	O	282-284
a	O	285-286
woman	O	287-292
with	O	293-297
hyperthyroidism	B	298-313
treated	O	314-321
with	O	322-326
propylthiouracil	O	327-343
in	O	344-346
whom	O	347-351
a	O	352-353
syndrome	O	354-362
of	O	363-365
pericarditis	B	366-378
,	O	378-379
fever	B	380-385
,	O	385-386
and	O	387-390
glomerulonephritis	B	391-409
developed	O	410-419
.	O	419-420

Serologic	O	421-430
testing	O	431-438
and	O	439-442
immunologic	O	443-454
studies	O	455-462
were	O	463-467
done	O	468-472
,	O	472-473
and	O	474-477
a	O	478-479
pericardial	O	480-491
biopsy	O	492-498
was	O	499-502
performed	O	503-512
.	O	512-513

RESULTS	O	514-521
:	O	521-522
A	O	523-524
25	O	525-527
-	O	527-528
year	O	528-532
-	O	527-528
old	O	533-536
woman	O	537-542
with	O	543-547
Graves	B	548-554
'	I	554-555
disease	I	556-563
had	O	564-567
a	O	568-569
febrile	B	570-577
illness	I	578-585
and	O	586-589
evidence	O	590-598
of	O	599-601
pericarditis	B	602-614
,	O	614-615
which	O	616-621
was	O	622-625
confirmed	O	626-635
by	O	636-638
biopsy	O	639-645
.	O	645-646

Serologic	O	647-656
evaluation	O	657-667
revealed	O	668-676
the	O	677-680
presence	O	681-689
of	O	690-692
perinuclear	O	693-704
-	O	704-705
staining	O	705-713
antineutrophil	O	714-728
cytoplasmic	O	729-740
autoantibodies	O	741-755
(	O	756-757
pANCA	O	757-762
)	O	762-763
against	O	764-771
myeloperoxidase	O	772-787
(	O	788-789
MPO	O	789-792
)	O	792-793
.	O	793-794

Propylthiouracil	O	795-811
therapy	O	812-819
was	O	820-823
withdrawn	O	824-833
,	O	833-834
and	O	835-838
she	O	839-842
was	O	843-846
treated	O	847-854
with	O	855-859
a	O	860-861
1	O	862-863
-	O	863-864
month	O	864-869
course	O	870-876
of	O	877-879
prednisone	O	880-890
,	O	890-891
which	O	892-897
alleviated	O	898-908
her	O	909-912
symptoms	O	913-921
.	O	921-922

A	O	923-924
literature	O	925-935
review	O	936-942
revealed	O	943-951
no	O	952-954
prior	O	955-960
reports	O	961-968
of	O	969-971
pericarditis	B	972-984
in	O	985-987
anti	O	988-992
-	O	992-993
MPO	O	993-996
pANCA	O	997-1002
-	O	1002-1003
positive	O	1003-1011
vasculitis	B	1012-1022
associated	O	1023-1033
with	O	1034-1038
propylthio	O	1039-1049
-	O	1049-1050
uracil	O	1051-1057
therapy	O	1058-1065
.	O	1065-1066

CONCLUSION	O	1067-1077
:	O	1077-1078
Pericarditis	B	1079-1091
may	O	1092-1095
be	O	1096-1098
the	O	1099-1102
initial	O	1103-1110
manifestation	O	1111-1124
of	O	1125-1127
drug	O	1128-1132
-	O	1132-1133
induced	O	1133-1140
vasculitis	B	1141-1151
attributable	O	1152-1164
to	O	1165-1167
propylthio	O	1168-1178
-	O	1178-1179
uracil	O	1180-1186
therapy	O	1187-1194
.	O	1194-1195

Two	O	0-3
mouse	O	4-9
lines	O	10-15
selected	O	16-24
for	O	25-28
differential	O	29-41
sensitivities	O	42-55
to	O	56-58
beta	O	59-63
-	O	63-64
carboline	O	64-73
-	O	63-64
induced	O	74-81
seizures	B	82-90
are	O	91-94
also	O	95-99
differentially	O	100-114
sensitive	O	115-124
to	O	125-127
various	O	128-135
pharmacological	O	136-151
effects	O	152-159
of	O	160-162
other	O	163-168
GABA	O	169-173
(	O	173-174
A	O	170-171
)	O	175-176
receptor	O	177-185
ligands	O	186-193
.	O	193-194

Two	O	195-198
mouse	O	199-204
lines	O	205-210
were	O	211-215
selectively	O	216-227
bred	O	228-232
according	O	233-242
to	O	243-245
their	O	246-251
sensitivity	O	252-263
(	O	264-265
BS	O	265-267
line	O	268-272
)	O	272-273
or	O	274-276
resistance	O	277-287
(	O	288-289
BR	O	289-291
line	O	292-296
)	O	296-297
to	O	298-300
seizures	B	301-309
induced	O	310-317
by	O	318-320
a	O	321-322
single	O	323-329
i	O	330-331
.	O	331-332
p	O	332-333
.	O	331-332
injection	O	335-344
of	O	345-347
methyl	O	348-354
beta	O	355-359
-	O	359-360
carboline	O	360-369
-	O	359-360
3	O	370-371
-	O	359-360
carboxylate	O	372-383
(	O	384-385
beta	O	385-389
-	O	389-390
CCM	O	390-393
)	O	393-394
,	O	394-395
an	O	396-398
inverse	O	399-406
agonist	O	407-414
of	O	415-417
the	O	418-421
GABA	O	422-426
(	O	426-427
A	O	423-424
)	O	428-429
receptor	O	430-438
benzodiazepine	O	439-453
site	O	454-458
.	O	458-459

Our	O	460-463
aim	O	464-467
was	O	468-471
to	O	472-474
characterize	O	475-487
both	O	488-492
lines	O	493-498
'	O	498-499
sensitivities	O	500-513
to	O	514-516
various	O	517-524
physiological	O	525-538
effects	O	539-546
of	O	547-549
other	O	550-555
ligands	O	556-563
of	O	564-566
the	O	567-570
GABA	O	571-575
(	O	575-576
A	O	572-573
)	O	577-578
receptor	O	579-587
.	O	587-588

We	O	589-591
measured	O	592-600
diazepam	O	601-609
-	O	609-610
induced	O	610-617
anxiolysis	O	618-628
with	O	629-633
the	O	634-637
elevated	O	638-646
plus	O	647-651
-	O	651-652
maze	O	652-656
test	O	657-661
,	O	661-662
diazepam	O	663-671
-	O	671-672
induced	O	672-679
sedation	O	680-688
by	O	689-691
recording	O	692-701
the	O	702-705
vigilance	O	706-715
states	O	716-722
,	O	722-723
and	O	724-727
picrotoxin	O	728-738
-	O	738-739
and	O	740-743
pentylenetetrazol	O	744-761
-	O	761-762
induced	O	762-769
seizures	B	770-778
after	O	779-784
i	O	785-786
.	O	786-787
p	O	787-788
.	O	786-787
injections	O	790-800
.	O	800-801

Results	O	802-809
presented	O	810-819
here	O	820-824
show	O	825-829
that	O	830-834
the	O	835-838
differential	O	839-851
sensitivities	O	852-865
of	O	866-868
BS	O	869-871
and	O	872-875
BR	O	876-878
lines	O	879-884
to	O	885-887
beta	O	888-892
-	O	892-893
CCM	O	893-896
can	O	897-900
be	O	901-903
extended	O	904-912
to	O	913-915
diazepam	O	916-924
,	O	924-925
picrotoxin	O	926-936
,	O	936-937
and	O	938-941
pentylenetetrazol	O	942-959
,	O	959-960
suggesting	O	961-971
a	O	972-973
genetic	O	974-981
selection	O	982-991
of	O	992-994
a	O	995-996
general	O	997-1004
sensitivity	O	1005-1016
and	O	1017-1020
resistance	O	1021-1031
to	O	1032-1034
several	O	1035-1042
ligands	O	1043-1050
of	O	1051-1053
the	O	1054-1057
GABA	O	1058-1062
(	O	1062-1063
A	O	1059-1060
)	O	1064-1065
receptor	O	1066-1074
.	O	1074-1075

Analgesic	O	0-9
effect	O	10-16
of	O	17-19
intravenous	O	20-31
ketamine	O	32-40
in	O	41-43
cancer	B	44-50
patients	O	51-59
on	O	60-62
morphine	O	63-71
therapy	O	72-79
:	O	79-80
a	O	81-82
randomized	O	83-93
,	O	93-94
controlled	O	95-105
,	O	105-106
double	O	107-113
-	O	113-114
blind	O	114-119
,	O	119-120
crossover	O	121-130
,	O	130-131
double	O	132-138
-	O	138-139
dose	O	139-143
study	O	144-149
.	O	149-150

Pain	B	151-155
not	O	156-159
responsive	O	160-170
to	O	171-173
morphine	O	174-182
is	O	183-185
often	O	186-191
problematic	O	192-203
.	O	203-204

Animal	O	205-211
and	O	212-215
clinical	O	216-224
studies	O	225-232
have	O	233-237
suggested	O	238-247
that	O	248-252
N	O	253-254
-	O	254-255
methyl	O	255-261
-	O	254-255
D	O	262-263
-	O	254-255
aspartate	O	264-273
(	O	274-275
NMDA	O	275-279
)	O	279-280
antagonists	O	281-292
,	O	292-293
such	O	294-298
as	O	299-301
ketamine	O	302-310
,	O	310-311
may	O	312-315
be	O	316-318
effective	O	319-328
in	O	329-331
improving	O	332-341
opioid	O	342-348
analgesia	O	349-358
in	O	359-361
difficult	O	362-371
pain	B	372-376
syndromes	O	377-386
,	O	386-387
such	O	388-392
as	O	393-395
neuropathic	B	396-407
pain	I	408-412
.	O	412-413

A	O	414-415
slow	O	416-420
bolus	O	421-426
of	O	427-429
subhypnotic	O	430-441
doses	O	442-447
of	O	448-450
ketamine	O	451-459
(	O	460-461
0	O	461-462
.	O	462-463
25	O	463-465
mg	O	466-468
/	O	468-469
kg	O	469-471
or	O	472-474
0	O	475-476
.	O	476-477
50	O	477-479
mg	O	480-482
/	O	482-483
kg	O	483-485
)	O	485-486
was	O	487-490
given	O	491-496
to	O	497-499
10	O	500-502
cancer	B	503-509
patients	O	510-518
whose	O	519-524
pain	B	525-529
was	O	530-533
unrelieved	O	534-544
by	O	545-547
morphine	O	548-556
in	O	557-559
a	O	560-561
randomized	O	562-572
,	O	572-573
double	O	574-580
-	O	580-581
blind	O	581-586
,	O	586-587
crossover	O	588-597
,	O	597-598
double	O	599-605
-	O	605-606
dose	O	606-610
study	O	611-616
.	O	616-617

Pain	B	618-622
intensity	O	623-632
on	O	633-635
a	O	636-637
0	O	638-639
to	O	640-642
10	O	643-645
numerical	O	646-655
scale	O	656-661
;	O	661-662
nausea	B	663-669
and	O	670-673
vomiting	B	674-682
,	O	682-683
drowsiness	O	684-694
,	O	694-695
confusion	B	696-705
,	O	705-706
and	O	707-710
dry	B	711-714
mouth	I	715-720
,	O	720-721
using	O	722-727
a	O	728-729
scale	O	730-735
from	O	736-740
0	O	741-742
to	O	743-745
3	O	746-747
(	O	748-749
not	O	749-752
at	O	753-755
all	O	756-759
,	O	759-760
slight	O	761-767
,	O	767-768
a	O	769-770
lot	O	771-774
,	O	774-775
awful	O	776-781
)	O	781-782
;	O	782-783
Mini	O	784-788
-	O	788-789
Mental	O	789-795
State	O	796-801
Examination	O	802-813
(	O	814-815
MMSE	O	815-819
)	O	819-820
(	O	821-822
0	O	822-823
-	O	823-824
30	O	824-826
)	O	826-827
;	O	827-828
and	O	829-832
arterial	O	833-841
pressure	O	842-850
were	O	851-855
recorded	O	856-864
before	O	865-871
administration	O	872-886
of	O	887-889
drugs	O	890-895
(	O	896-897
T0	O	897-899
)	O	899-900
and	O	901-904
after	O	905-910
30	O	911-913
minutes	O	914-921
(	O	922-923
T30	O	923-926
)	O	926-927
,	O	927-928
60	O	929-931
minutes	O	932-939
(	O	940-941
T60	O	941-944
)	O	944-945
,	O	945-946
120	O	947-950
minutes	O	951-958
(	O	959-960
T120	O	960-964
)	O	964-965
,	O	965-966
and	O	967-970
180	O	971-974
minutes	O	975-982
(	O	983-984
T180	O	984-988
)	O	988-989
.	O	989-990

Ketamine	O	991-999
,	O	999-1000
but	O	1001-1004
not	O	1005-1008
saline	O	1009-1015
solution	O	1016-1024
,	O	1024-1025
significantly	O	1026-1039
reduced	O	1040-1047
the	O	1048-1051
pain	B	1052-1056
intensity	O	1057-1066
in	O	1067-1069
almost	O	1070-1076
all	O	1077-1080
the	O	1081-1084
patients	O	1085-1093
at	O	1094-1096
both	O	1097-1101
doses	O	1102-1107
.	O	1107-1108

This	O	1109-1113
effect	O	1114-1120
was	O	1121-1124
more	O	1125-1129
relevant	O	1130-1138
in	O	1139-1141
patients	O	1142-1150
treated	O	1151-1158
with	O	1159-1163
higher	O	1164-1170
doses	O	1171-1176
.	O	1176-1177

Hallucinations	B	1178-1192
occurred	O	1193-1201
in	O	1202-1204
4	O	1205-1206
patients	O	1207-1215
,	O	1215-1216
and	O	1217-1220
an	O	1221-1223
unpleasant	O	1224-1234
sensation	O	1235-1244
(	O	1245-1246
"	O	1246-1247
empty	O	1247-1252
head	O	1253-1257
"	O	1257-1258
)	O	1258-1259
was	O	1260-1263
also	O	1264-1268
reported	O	1269-1277
by	O	1278-1280
2	O	1281-1282
patients	O	1283-1291
.	O	1291-1292

These	O	1293-1298
episodes	O	1299-1307
reversed	O	1308-1316
after	O	1317-1322
the	O	1323-1326
administration	O	1327-1341
of	O	1342-1344
diazepam	O	1345-1353
1	O	1354-1355
mg	O	1356-1358
intravenously	O	1359-1372
.	O	1372-1373

Significant	O	1374-1385
increases	O	1386-1395
in	O	1396-1398
drowsiness	O	1399-1409
were	O	1410-1414
reported	O	1415-1423
in	O	1424-1426
patients	O	1427-1435
treated	O	1436-1443
with	O	1444-1448
ketamine	O	1449-1457
in	O	1458-1460
both	O	1461-1465
groups	O	1466-1472
and	O	1473-1476
were	O	1477-1481
more	O	1482-1486
marked	O	1487-1493
with	O	1494-1498
ketamine	O	1499-1507
0	O	1508-1509
.	O	1509-1510
50	O	1510-1512
mg	O	1513-1515
/	O	1515-1516
kg	O	1516-1518
.	O	1518-1519

A	O	1520-1521
significant	O	1522-1533
difference	O	1534-1544
in	O	1545-1547
MMSE	O	1548-1552
was	O	1553-1556
observed	O	1557-1565
at	O	1566-1568
T30	O	1569-1572
in	O	1573-1575
patients	O	1576-1584
who	O	1585-1588
received	O	1589-1597
0	O	1598-1599
.	O	1599-1600
50	O	1600-1602
mg	O	1603-1605
/	O	1605-1606
kg	O	1606-1608
of	O	1609-1611
ketamine	O	1612-1620
.	O	1620-1621

Ketamine	O	1622-1630
can	O	1631-1634
improve	O	1635-1642
morphine	O	1643-1651
analgesia	O	1652-1661
in	O	1662-1664
difficult	O	1665-1674
pain	B	1675-1679
syndromes	O	1680-1689
,	O	1689-1690
such	O	1691-1695
as	O	1696-1698
neuropathic	B	1699-1710
pain	I	1711-1715
.	O	1715-1716

However	O	1717-1724
,	O	1724-1725
the	O	1726-1729
occurrence	O	1730-1740
of	O	1741-1743
central	O	1744-1751
adverse	O	1752-1759
effects	O	1760-1767
should	O	1768-1774
be	O	1775-1777
taken	O	1778-1783
into	O	1784-1788
account	O	1789-1796
,	O	1796-1797
especially	O	1798-1808
when	O	1809-1813
using	O	1814-1819
higher	O	1820-1826
doses	O	1827-1832
.	O	1832-1833

This	O	1834-1838
observation	O	1839-1850
should	O	1851-1857
be	O	1858-1860
tested	O	1861-1867
in	O	1868-1870
studies	O	1871-1878
of	O	1879-1881
prolonged	O	1882-1891
ketamine	O	1892-1900
administration	O	1901-1915
.	O	1915-1916

Endocrine	O	0-9
screening	O	10-19
in	O	20-22
1	O	23-24
,	O	24-25
022	O	25-28
men	O	29-32
with	O	33-37
erectile	B	38-46
dysfunction	I	47-58
:	O	58-59
clinical	O	60-68
significance	O	69-81
and	O	82-85
cost	O	86-90
-	O	90-91
effective	O	91-100
strategy	O	101-109
.	O	109-110

PURPOSE	O	111-118
:	O	118-119
We	O	120-122
reviewed	O	123-131
the	O	132-135
results	O	136-143
of	O	144-146
serum	O	147-152
testosterone	O	153-165
and	O	166-169
prolactin	O	170-179
determination	O	180-193
in	O	194-196
1	O	197-198
,	O	198-199
022	O	199-202
patients	O	203-211
referred	O	212-220
because	O	221-228
of	O	229-231
erectile	B	232-240
dysfunction	I	241-252
and	O	253-256
compared	O	257-265
the	O	266-269
data	O	270-274
with	O	275-279
history	O	280-287
,	O	287-288
results	O	289-296
of	O	297-299
physical	O	300-308
examination	O	309-320
,	O	320-321
other	O	322-327
etiological	O	328-339
investigations	O	340-354
and	O	355-358
effects	O	359-366
of	O	367-369
endocrine	O	370-379
therapy	O	380-387
to	O	388-390
refine	O	391-397
the	O	398-401
rules	O	402-407
of	O	408-410
cost	O	411-415
-	O	415-416
effective	O	416-425
endocrine	O	426-435
screening	O	436-445
and	O	446-449
to	O	450-452
pinpoint	O	453-461
actual	O	462-468
responsibility	O	469-483
for	O	484-487
hormonal	O	488-496
abnormalities	O	497-510
.	O	510-511

MATERIALS	O	512-521
AND	O	522-525
METHODS	O	526-533
:	O	533-534
Testosterone	O	535-547
and	O	548-551
prolactin	O	552-561
were	O	562-566
determined	O	567-577
by	O	578-580
radioimmunoassay	O	581-597
.	O	597-598

Every	O	599-604
patient	O	605-612
was	O	613-616
screened	O	617-625
for	O	626-629
testosterone	O	630-642
and	O	643-646
451	O	647-650
were	O	651-655
screened	O	656-664
for	O	665-668
prolactin	O	669-678
on	O	679-681
the	O	682-685
basis	O	686-691
of	O	692-694
low	B	695-698
sexual	I	699-705
desire	I	706-712
,	O	712-713
gynecomastia	B	714-726
or	O	727-729
testosterone	O	730-742
less	O	743-747
than	O	748-752
4	O	753-754
ng	O	755-757
.	O	757-758
/	O	758-759
ml	O	759-761
.	O	757-758

Determination	O	763-776
was	O	777-780
repeated	O	781-789
in	O	790-792
case	O	793-797
of	O	798-800
abnormal	O	801-809
first	O	810-815
results	O	816-823
.	O	823-824

Prolactin	O	825-834
results	O	835-842
were	O	843-847
compared	O	848-856
with	O	857-861
those	O	862-867
of	O	868-870
a	O	871-872
previous	O	873-881
personal	O	882-890
cohort	O	891-897
of	O	898-900
1	O	901-902
,	O	902-903
340	O	903-906
patients	O	907-915
with	O	916-920
erectile	B	921-929
dysfunction	I	930-941
and	O	942-945
systematic	O	946-956
prolactin	O	957-966
determination	O	967-980
.	O	980-981

Main	O	982-986
clinical	O	987-995
criteria	O	996-1004
tested	O	1005-1011
regarding	O	1012-1021
efficiency	O	1022-1032
in	O	1033-1035
hormone	O	1036-1043
determination	O	1044-1057
were	O	1058-1062
low	B	1063-1066
sexual	I	1067-1073
desire	I	1074-1080
,	O	1080-1081
small	O	1082-1087
testes	O	1088-1094
and	O	1095-1098
gynecomastia	B	1099-1111
.	O	1111-1112

Endocrine	O	1113-1122
therapy	O	1123-1130
consisted	O	1131-1140
of	O	1141-1143
testosterone	O	1144-1156
heptylate	O	1157-1166
or	O	1167-1169
human	O	1170-1175
chorionic	O	1176-1185
gonadotropin	O	1186-1198
for	O	1199-1202
hypogonadism	B	1203-1215
and	O	1216-1219
bromocriptine	O	1220-1233
for	O	1234-1237
hyperprolactinemia	B	1238-1256
.	O	1256-1257

RESULTS	O	1258-1265
:	O	1265-1266
Testosterone	O	1267-1279
was	O	1280-1283
less	O	1284-1288
than	O	1289-1293
3	O	1294-1295
ng	O	1296-1298
.	O	1298-1299
/	O	1299-1300
ml	O	1300-1302
.	O	1298-1299
in	O	1304-1306
107	O	1307-1310
patients	O	1311-1319
but	O	1320-1323
normal	O	1324-1330
in	O	1331-1333
40	O	1334-1336
%	O	1336-1337
at	O	1338-1340
repeat	O	1341-1347
determination	O	1348-1361
.	O	1361-1362

The	O	1363-1366
prevalence	O	1367-1377
of	O	1378-1380
repeatedly	O	1381-1391
low	O	1392-1395
testosterone	O	1396-1408
increased	O	1409-1418
with	O	1419-1423
age	O	1424-1427
(	O	1428-1429
4	O	1429-1430
%	O	1430-1431
before	O	1432-1438
age	O	1439-1442
50	O	1443-1445
years	O	1446-1451
and	O	1452-1455
9	O	1456-1457
%	O	1457-1458
50	O	1459-1461
years	O	1462-1467
or	O	1468-1470
older	O	1471-1476
)	O	1476-1477
.	O	1477-1478

Two	O	1479-1482
pituitary	B	1483-1492
tumors	I	1493-1499
were	O	1500-1504
discovered	O	1505-1515
after	O	1516-1521
testosterone	O	1522-1534
determination	O	1535-1548
.	O	1548-1549

Most	O	1550-1554
of	O	1555-1557
the	O	1558-1561
other	O	1562-1567
low	O	1568-1571
testosterone	O	1572-1584
levels	O	1585-1591
seemed	O	1592-1598
to	O	1599-1601
result	O	1602-1608
from	O	1609-1613
nonorganic	O	1614-1624
hypothalamic	B	1625-1637
dysfunction	I	1638-1649
because	O	1650-1657
of	O	1658-1660
normal	O	1661-1667
serum	O	1668-1673
luteinizing	O	1674-1685
hormone	O	1686-1693
and	O	1694-1697
prolactin	O	1698-1707
and	O	1708-1711
to	O	1712-1714
have	O	1715-1719
only	O	1720-1724
a	O	1725-1726
small	O	1727-1732
role	O	1733-1737
in	O	1738-1740
erectile	B	1741-1749
dysfunction	I	1750-1761
(	O	1762-1763
definite	O	1763-1771
improvement	O	1772-1783
in	O	1784-1786
only	O	1787-1791
16	O	1792-1794
of	O	1795-1797
44	O	1798-1800
[	O	1801-1802
36	O	1802-1804
%	O	1804-1805
]	O	1805-1806
after	O	1807-1812
androgen	O	1813-1821
therapy	O	1822-1829
,	O	1829-1830
normal	O	1831-1837
morning	O	1838-1845
or	O	1846-1848
nocturnal	O	1849-1858
erections	O	1859-1868
in	O	1869-1871
30	O	1872-1874
%	O	1874-1875
and	O	1876-1879
definite	O	1880-1888
vasculogenic	O	1889-1901
contributions	O	1902-1915
in	O	1916-1918
42	O	1919-1921
%	O	1921-1922
)	O	1922-1923
.	O	1923-1924

Determining	O	1925-1936
testosterone	O	1937-1949
only	O	1950-1954
in	O	1955-1957
cases	O	1958-1963
of	O	1964-1966
low	B	1967-1970
sexual	I	1971-1977
desire	I	1978-1984
or	O	1985-1987
abnormal	O	1988-1996
physical	O	1997-2005
examination	O	2006-2017
would	O	2018-2023
have	O	2024-2028
missed	O	2029-2035
40	O	2036-2038
%	O	2038-2039
of	O	2040-2042
the	O	2043-2046
cases	O	2047-2052
with	O	2053-2057
low	O	2058-2061
testosterone	O	2062-2074
,	O	2074-2075
including	O	2076-2085
37	O	2086-2088
%	O	2088-2089
of	O	2090-2092
those	O	2093-2098
subsequently	O	2099-2111
improved	O	2112-2120
by	O	2121-2123
androgen	O	2124-2132
therapy	O	2133-2140
.	O	2140-2141

Prolactin	O	2142-2151
exceeded	O	2152-2160
20	O	2161-2163
ng	O	2164-2166
.	O	2166-2167
/	O	2167-2168
ml	O	2168-2170
.	O	2166-2167
in	O	2172-2174
5	O	2175-2176
men	O	2177-2180
and	O	2181-2184
was	O	2185-2188
normal	O	2189-2195
in	O	2196-2198
2	O	2199-2200
at	O	2201-2203
repeat	O	2204-2210
determination	O	2211-2224
.	O	2224-2225

Only	O	2226-2230
1	O	2231-2232
prolactinoma	B	2233-2245
was	O	2246-2249
discovered	O	2250-2260
.	O	2260-2261

These	O	2262-2267
data	O	2268-2272
are	O	2273-2276
lower	O	2277-2282
than	O	2283-2287
those	O	2288-2293
we	O	2294-2296
found	O	2297-2302
during	O	2303-2309
the	O	2310-2313
last	O	2314-2318
2	O	2319-2320
decades	O	2321-2328
(	O	2329-2330
overall	O	2330-2337
prolactin	O	2338-2347
greater	O	2348-2355
than	O	2356-2360
20	O	2361-2363
ng	O	2364-2366
.	O	2366-2367
/	O	2367-2368
ml	O	2368-2370
.	O	2366-2367
in	O	2372-2374
1	O	2375-2376
.	O	2376-2377
86	O	2377-2379
%	O	2379-2380
of	O	2381-2383
1	O	2384-2385
,	O	2385-2386
821	O	2386-2389
patients	O	2390-2398
,	O	2398-2399
prolactinomas	B	2400-2413
in	O	2414-2416
7	O	2417-2418
,	O	2418-2419
0	O	2420-2421
.	O	2421-2422
38	O	2422-2424
%	O	2424-2425
)	O	2425-2426
.	O	2421-2422

Bromocriptine	O	2428-2441
was	O	2442-2445
definitely	O	2446-2456
effective	O	2457-2466
in	O	2467-2469
cases	O	2470-2475
with	O	2476-2480
prolactin	O	2481-2490
greater	O	2491-2498
than	O	2499-2503
35	O	2504-2506
ng	O	2507-2509
.	O	2509-2510
/	O	2510-2511
ml	O	2511-2513
.	O	2509-2510

(	O	2515-2516
8	O	2516-2517
of	O	2518-2520
12	O	2521-2523
compared	O	2524-2532
to	O	2533-2535
only	O	2536-2540
9	O	2541-2542
of	O	2543-2545
22	O	2546-2548
cases	O	2549-2554
with	O	2555-2559
prolactin	O	2560-2569
between	O	2570-2577
20	O	2578-2580
and	O	2581-2584
35	O	2585-2587
ng	O	2588-2590
.	O	2590-2591
/	O	2591-2592
ml	O	2592-2594
.	O	2590-2591
)	O	2595-2596
.	O	2590-2591

Testosterone	O	2598-2610
was	O	2611-2614
low	O	2615-2618
in	O	2619-2621
less	O	2622-2626
than	O	2627-2631
50	O	2632-2634
%	O	2634-2635
of	O	2636-2638
cases	O	2639-2644
with	O	2645-2649
prolactin	O	2650-2659
greater	O	2660-2667
than	O	2668-2672
35	O	2673-2675
ng	O	2676-2678
.	O	2678-2679
/	O	2679-2680
ml	O	2680-2682
.	O	2678-2679

CONCLUSIONS	O	2684-2695
:	O	2695-2696
Low	O	2697-2700
prevalences	O	2701-2712
and	O	2713-2716
effects	O	2717-2724
of	O	2725-2727
low	O	2728-2731
testosterone	O	2732-2744
and	O	2745-2748
high	O	2749-2753
prolactin	O	2754-2763
in	O	2764-2766
erectile	B	2767-2775
dysfunction	I	2776-2787
cannot	O	2788-2794
justify	O	2795-2802
their	O	2803-2808
routine	O	2809-2816
determination	O	2817-2830
.	O	2830-2831

However	O	2832-2839
,	O	2839-2840
cost	O	2841-2845
-	O	2845-2846
effective	O	2846-2855
screening	O	2856-2865
strategies	O	2866-2876
recommended	O	2877-2888
so	O	2889-2891
far	O	2892-2895
missed	O	2896-2902
40	O	2903-2905
to	O	2906-2908
50	O	2909-2911
%	O	2911-2912
of	O	2913-2915
cases	O	2916-2921
improved	O	2922-2930
with	O	2931-2935
endocrine	O	2936-2945
therapy	O	2946-2953
and	O	2954-2957
the	O	2958-2961
pituitary	B	2962-2971
tumors	I	2972-2978
.	O	2978-2979

We	O	2980-2982
now	O	2983-2986
advocate	O	2987-2995
that	O	2996-3000
before	O	3001-3007
age	O	3008-3011
50	O	3012-3014
years	O	3015-3020
testosterone	O	3021-3033
be	O	3034-3036
determined	O	3037-3047
only	O	3048-3052
in	O	3053-3055
cases	O	3056-3061
of	O	3062-3064
low	B	3065-3068
sexual	I	3069-3075
desire	I	3076-3082
and	O	3083-3086
abnormal	O	3087-3095
physical	O	3096-3104
examination	O	3105-3116
but	O	3117-3120
that	O	3121-3125
it	O	3126-3128
be	O	3129-3131
measured	O	3132-3140
in	O	3141-3143
all	O	3144-3147
men	O	3148-3151
older	O	3152-3157
than	O	3158-3162
50	O	3163-3165
years	O	3166-3171
.	O	3171-3172

Prolactin	O	3173-3182
should	O	3183-3189
be	O	3190-3192
determined	O	3193-3203
only	O	3204-3208
in	O	3209-3211
cases	O	3212-3217
of	O	3218-3220
low	B	3221-3224
sexual	I	3225-3231
desire	I	3232-3238
,	O	3238-3239
gynecomastia	B	3240-3252
and	O	3253-3256
/	O	3256-3257
or	O	3257-3259
testosterone	O	3260-3272
less	O	3273-3277
than	O	3278-3282
4	O	3283-3284
ng	O	3285-3287
.	O	3287-3288
/	O	3288-3289
ml	O	3289-3291
.	O	3287-3288

Thiopentone	O	0-11
pretreatment	O	12-24
for	O	25-28
propofol	O	29-37
injection	O	38-47
pain	B	48-52
in	O	53-55
ambulatory	O	56-66
patients	O	67-75
.	O	75-76

This	O	77-81
study	O	82-87
investigated	O	88-100
propofol	O	101-109
injection	O	110-119
pain	B	120-124
in	O	125-127
patients	O	128-136
undergoing	O	137-147
ambulatory	O	148-158
anaesthesia	O	159-170
.	O	170-171

In	O	172-174
a	O	175-176
randomized	O	177-187
,	O	187-188
double	O	189-195
-	O	195-196
blind	O	196-201
trial	O	202-207
,	O	207-208
90	O	209-211
women	O	212-217
were	O	218-222
allocated	O	223-232
to	O	233-235
receive	O	236-243
one	O	244-247
of	O	248-250
three	O	251-256
treatments	O	257-267
prior	O	268-273
to	O	274-276
induction	O	277-286
of	O	287-289
anaesthesia	O	290-301
with	O	302-306
propofol	O	307-315
.	O	315-316

Patients	O	317-325
in	O	326-328
Group	O	329-334
C	O	335-336
received	O	337-345
2	O	346-347
ml	O	348-350
normal	O	351-357
saline	O	358-364
,	O	364-365
Group	O	366-371
L	O	372-373
,	O	373-374
2	O	375-376
ml	O	377-379
,	O	379-380
lidocaine	O	381-390
2	O	391-392
%	O	392-393
(	O	394-395
40	O	395-397
mg	O	398-400
)	O	400-401
and	O	402-405
Group	O	406-411
T	O	412-413
,	O	413-414
2	O	415-416
ml	O	417-419
thiopentone	O	420-431
2	O	432-433
.	O	433-434
5	O	434-435
%	O	435-436
(	O	437-438
50	O	438-440
mg	O	441-443
)	O	443-444
.	O	444-445

Venous	O	446-452
discomfort	O	453-463
was	O	464-467
assessed	O	468-476
with	O	477-481
a	O	482-483
visual	O	484-490
analogue	O	491-499
scale	O	500-505
(	O	506-507
VAS	O	507-510
)	O	510-511
5	O	512-513
-	O	513-514
15	O	514-516
sec	O	517-520
after	O	521-526
commencing	O	527-537
propofol	O	538-546
administration	O	547-561
using	O	562-567
an	O	568-570
infusion	O	571-579
pump	O	580-584
(	O	585-586
rate	O	586-590
1000	O	591-595
micrograms	O	596-606
.	O	606-607
kg	O	607-609
-	O	609-610
1	O	610-611
.	O	606-607
min	O	612-615
-	O	609-610
1	O	610-611
)	O	617-618
.	O	606-607

Loss	B	620-624
of	I	625-627
consciousness	I	628-641
occurred	O	642-650
in	O	651-653
60	O	654-656
-	O	656-657
90	O	657-659
sec	O	660-663
.	O	663-664

Visual	O	665-671
analogue	O	672-680
scores	O	681-687
(	O	688-689
mean	O	689-693
+	O	694-695
/	O	695-696
-	O	696-697
SD	O	698-700
)	O	700-701
during	O	702-708
induction	O	709-718
were	O	719-723
lower	O	724-729
in	O	730-732
Groups	O	733-739
L	O	740-741
(	O	742-743
3	O	743-744
.	O	744-745
3	O	743-744
+	O	747-748
/	O	748-749
-	O	749-750
2	O	751-752
.	O	752-753
5	O	753-754
)	O	754-755
and	O	756-759
T	O	760-761
(	O	762-763
4	O	763-764
.	O	764-765
1	O	765-766
+	O	767-768
/	O	768-769
-	O	769-770
2	O	771-772
.	O	772-773
7	O	773-774
)	O	774-775
than	O	776-780
in	O	781-783
Group	O	784-789
C	O	790-791
(	O	792-793
5	O	793-794
.	O	794-795
6	O	795-796
+	O	797-798
/	O	798-799
-	O	799-800
2	O	801-802
.	O	802-803
3	O	803-804
)	O	804-805
;	O	805-806
P	O	807-808
=	O	809-810
0	O	811-812
.	O	812-813
0031	O	813-817
.	O	812-813

The	O	819-822
incidence	O	823-832
of	O	833-835
venous	O	836-842
discomfort	O	843-853
was	O	854-857
lower	O	858-863
in	O	864-866
Group	O	867-872
L	O	873-874
(	O	875-876
76	O	876-878
.	O	878-879
6	O	877-878
%	O	880-881
;	O	881-882
P	O	883-884
<	O	885-886
0	O	887-888
.	O	888-889
05	O	889-891
)	O	891-892
than	O	893-897
in	O	898-900
Group	O	901-906
C	O	907-908
(	O	909-910
100	O	910-913
%	O	913-914
)	O	914-915
but	O	916-919
not	O	920-923
different	O	924-933
from	O	934-938
Group	O	939-944
T	O	945-946
(	O	947-948
90	O	948-950
%	O	950-951
)	O	951-952
.	O	952-953

The	O	954-957
VAS	O	958-961
scores	O	962-968
for	O	969-972
recall	O	973-979
of	O	980-982
pain	B	983-987
in	O	988-990
the	O	991-994
recovery	O	995-1003
room	O	1004-1008
were	O	1009-1013
correlated	O	1014-1024
with	O	1025-1029
the	O	1030-1033
VAS	O	1034-1037
scores	O	1038-1044
during	O	1045-1051
induction	O	1052-1061
(	O	1062-1063
r	O	1063-1064
=	O	1065-1066
0	O	1067-1068
.	O	1068-1069
7045	O	1069-1073
;	O	1073-1074
P	O	1075-1076
<	O	1077-1078
0	O	1079-1080
.	O	1080-1081
0001	O	1081-1085
)	O	1085-1086
.	O	1080-1081

Recovery	O	1088-1096
room	O	1097-1101
discharge	O	1102-1111
times	O	1112-1117
were	O	1118-1122
similar	O	1123-1130
:	O	1130-1131
C	O	1132-1133
(	O	1134-1135
75	O	1135-1137
.	O	1137-1138
9	O	1138-1139
+	O	1140-1141
/	O	1141-1142
-	O	1142-1143
19	O	1144-1146
.	O	1146-1147
4	O	1147-1148
min	O	1149-1152
)	O	1152-1153
;	O	1153-1154
L	O	1155-1156
73	O	1157-1159
.	O	1159-1160
6	O	1160-1161
+	O	1162-1163
/	O	1163-1164
-	O	1164-1165
21	O	1166-1168
.	O	1168-1169
6	O	1169-1170
min	O	1171-1174
)	O	1174-1175
;	O	1175-1176
T	O	1177-1178
(	O	1179-1180
77	O	1180-1182
.	O	1182-1183
1	O	1183-1184
+	O	1185-1186
/	O	1186-1187
-	O	1187-1188
18	O	1189-1191
.	O	1191-1192
9	O	1192-1193
min	O	1194-1197
)	O	1197-1198
.	O	1198-1199

Assessing	O	1200-1209
their	O	1210-1215
overall	O	1216-1223
satisfaction	O	1224-1236
,	O	1236-1237
89	O	1238-1240
.	O	1240-1241
7	O	1241-1242
%	O	1242-1243
would	O	1244-1249
choose	O	1250-1256
propofol	O	1257-1265
anaesthesia	O	1266-1277
again	O	1278-1283
.	O	1283-1284

We	O	1285-1287
conclude	O	1288-1296
that	O	1297-1301
lidocaine	O	1302-1311
reduces	O	1312-1319
the	O	1320-1323
incidence	O	1324-1333
and	O	1334-1337
severity	O	1338-1346
of	O	1347-1349
propofol	O	1350-1358
injection	O	1359-1368
pain	B	1369-1373
in	O	1374-1376
ambulatory	O	1377-1387
patients	O	1388-1396
whereas	O	1397-1404
thiopentone	O	1405-1416
only	O	1417-1421
reduces	O	1422-1429
its	O	1430-1433
severity	O	1434-1442
.	O	1442-1443

Comparison	O	0-10
of	O	11-13
i	O	14-15
.	O	15-16
v	O	16-17
.	O	15-16

glycopyrrolate	O	19-33
and	O	34-37
atropine	O	38-46
in	O	47-49
the	O	50-53
prevention	O	54-64
of	O	65-67
bradycardia	B	68-79
and	O	80-83
arrhythmias	B	84-95
following	O	96-105
repeated	O	106-114
doses	O	115-120
of	O	121-123
suxamethonium	O	124-137
in	O	138-140
children	O	141-149
.	O	149-150

The	O	151-154
effectiveness	O	155-168
of	O	169-171
administration	O	172-186
of	O	187-189
glycopyrrolate	O	190-204
5	O	205-206
and	O	207-210
10	O	211-213
micrograms	O	214-224
kg	O	225-227
-	O	227-228
1	O	228-229
and	O	230-233
atropine	O	234-242
10	O	243-245
and	O	246-249
20	O	250-252
micrograms	O	253-263
kg	O	264-266
-	O	266-267
1	O	267-268
i	O	269-270
.	O	270-271
v	O	271-272
.	O	270-271

immediately	O	274-285
before	O	286-292
the	O	293-296
induction	O	297-306
of	O	307-309
anaesthesia	O	310-321
,	O	321-322
to	O	323-325
prevent	O	326-333
arrhythmia	B	334-344
and	O	345-348
bradycardia	B	349-360
following	O	361-370
repeated	O	371-379
doses	O	380-385
of	O	386-388
suxamethonium	O	389-402
in	O	403-405
children	O	406-414
,	O	414-415
was	O	416-419
studied	O	420-427
.	O	427-428

A	O	429-430
control	O	431-438
group	O	439-444
was	O	445-448
included	O	449-457
for	O	458-461
comparison	O	462-472
with	O	473-477
the	O	478-481
lower	O	482-487
dose	O	488-492
range	O	493-498
of	O	499-501
glycopyrrolate	O	502-516
and	O	517-520
atropine	O	521-529
.	O	529-530

A	O	531-532
frequency	O	533-542
of	O	543-545
bradycardia	B	546-557
of	O	558-560
50	O	561-563
%	O	563-564
was	O	565-568
noted	O	569-574
in	O	575-577
the	O	578-581
control	O	582-589
group	O	590-595
,	O	595-596
but	O	597-600
this	O	601-605
was	O	606-609
not	O	610-613
significantly	O	614-627
different	O	628-637
from	O	638-642
the	O	643-646
frequency	O	647-656
with	O	657-661
the	O	662-665
active	O	666-672
drugs	O	673-678
.	O	678-679

Bradycardia	B	680-691
(	O	692-693
defined	O	693-700
as	O	701-703
a	O	704-705
decrease	O	706-714
in	O	715-717
heart	O	718-723
rate	O	724-728
to	O	729-731
less	O	732-736
than	O	737-741
50	O	742-744
beat	O	745-749
min	O	750-753
-	O	753-754
1	O	754-755
)	O	755-756
was	O	757-760
prevented	O	761-770
when	O	771-775
the	O	776-779
larger	O	780-786
dose	O	787-791
of	O	792-794
either	O	795-801
active	O	802-808
drug	O	809-813
was	O	814-817
used	O	818-822
.	O	822-823

It	O	824-826
is	O	827-829
recommended	O	830-841
that	O	842-846
either	O	847-853
glycopyrrolate	O	854-868
10	O	869-871
micrograms	O	872-882
kg	O	883-885
-	O	885-886
1	O	886-887
or	O	888-890
atropine	O	891-899
20	O	900-902
micrograms	O	903-913
kg	O	914-916
-	O	916-917
1	O	917-918
i	O	919-920
.	O	920-921
v	O	921-922
.	O	920-921

should	O	924-930
immediately	O	931-942
precede	O	943-950
induction	O	951-960
of	O	961-963
anaesthesia	O	964-975
,	O	975-976
in	O	977-979
children	O	980-988
,	O	988-989
if	O	990-992
the	O	993-996
repeated	O	997-1005
administration	O	1006-1020
of	O	1021-1023
suxamethonium	O	1024-1037
is	O	1038-1040
anticipated	O	1041-1052
.	O	1052-1053

Reduction	O	0-9
in	O	10-12
caffeine	O	13-21
toxicity	B	22-30
by	O	31-33
acetaminophen	O	34-47
.	O	47-48

A	O	49-50
patient	O	51-58
who	O	59-62
allegedly	O	63-72
consumed	O	73-81
100	O	82-85
tablets	O	86-93
of	O	94-96
an	O	97-99
over	O	100-104
-	O	104-105
the	O	105-108
-	O	104-105
counter	O	109-116
analgesic	O	117-126
containing	O	127-137
sodium	O	138-144
acetylsalicylate	O	145-161
,	O	161-162
caffeine	O	163-171
,	O	171-172
and	O	173-176
acetaminophen	O	177-190
displayed	O	191-200
no	O	201-203
significant	O	204-215
CNS	O	216-219
stimulation	O	220-231
despite	O	232-239
the	O	240-243
presence	O	244-252
of	O	253-255
175	O	256-259
micrograms	O	260-270
of	O	271-273
caffeine	O	274-282
per	O	283-286
mL	O	287-289
of	O	290-292
serum	O	293-298
.	O	298-299

Because	O	300-307
salicylates	O	308-319
have	O	320-324
been	O	325-329
reported	O	330-338
to	O	339-341
augment	O	342-349
the	O	350-353
stimulatory	O	354-365
effects	O	366-373
of	O	374-376
caffeine	O	377-385
on	O	386-388
the	O	389-392
CNS	O	393-396
,	O	396-397
attention	O	398-407
was	O	408-411
focused	O	412-419
on	O	420-422
the	O	423-426
possibility	O	427-438
that	O	439-443
the	O	444-447
presence	O	448-456
of	O	457-459
acetaminophen	O	460-473
(	O	474-475
52	O	475-477
micrograms	O	478-488
/	O	488-489
mL	O	489-491
)	O	491-492
reduced	O	493-500
the	O	501-504
CNS	O	505-508
toxicity	B	509-517
of	O	518-520
caffeine	O	521-529
.	O	529-530

Studies	O	531-538
in	O	539-541
DBA	O	542-545
/	O	545-546
2J	O	546-548
mice	O	549-553
showed	O	554-560
that	O	561-565
:	O	565-566
1	O	567-568
)	O	568-569
pretreatment	O	570-582
with	O	583-587
acetaminophen	O	588-601
(	O	602-603
100	O	603-606
mg	O	607-609
/	O	609-610
kg	O	610-612
)	O	612-613
increased	O	614-623
the	O	624-627
interval	O	628-636
between	O	637-644
the	O	645-648
administration	O	649-663
of	O	664-666
caffeine	O	667-675
(	O	676-677
300	O	677-680
to	O	681-683
450	O	684-687
mg	O	688-690
/	O	690-691
kg	O	691-693
IP	O	694-696
)	O	696-697
and	O	698-701
the	O	702-705
onset	O	706-711
of	O	712-714
fatal	O	715-720
convulsions	B	721-732
by	O	733-735
a	O	736-737
factor	O	738-744
of	O	745-747
about	O	748-753
two	O	754-757
;	O	757-758
and	O	759-762
2	O	763-764
)	O	764-765
pretreatment	O	766-778
with	O	779-783
acetaminophen	O	784-797
(	O	798-799
75	O	799-801
mg	O	802-804
/	O	804-805
kg	O	805-807
)	O	807-808
reduced	O	809-816
the	O	817-820
incidence	O	821-830
of	O	831-833
audiogenic	O	834-844
seizures	B	845-853
produced	O	854-862
in	O	863-865
the	O	866-869
presence	O	870-878
of	O	879-881
caffeine	O	882-890
(	O	891-892
12	O	892-894
.	O	894-895
5	O	895-896
to	O	897-899
75	O	900-902
mg	O	903-905
/	O	905-906
kg	O	906-908
IP	O	909-911
)	O	911-912
.	O	912-913

The	O	914-917
frequency	O	918-927
of	O	928-930
sound	O	931-936
-	O	936-937
induced	O	937-944
seizures	B	945-953
after	O	954-959
12	O	960-962
.	O	962-963
5	O	963-964
or	O	965-967
25	O	968-970
mg	O	971-973
/	O	973-974
kg	O	974-976
caffeine	O	977-985
was	O	986-989
reduced	O	990-997
from	O	998-1002
50	O	1003-1005
to	O	1006-1008
5	O	1009-1010
%	O	1010-1011
by	O	1012-1014
acetaminophen	O	1015-1028
.	O	1028-1029

In	O	1030-1032
the	O	1033-1036
absence	O	1037-1044
of	O	1045-1047
caffeine	O	1048-1056
,	O	1056-1057
acetaminophen	O	1058-1071
(	O	1072-1073
up	O	1073-1075
to	O	1076-1078
300	O	1079-1082
mg	O	1083-1085
/	O	1085-1086
kg	O	1086-1088
)	O	1088-1089
did	O	1090-1093
not	O	1094-1097
modify	O	1098-1104
the	O	1105-1108
seizures	B	1109-1117
induced	O	1118-1125
by	O	1126-1128
maximal	O	1129-1136
electroshock	O	1137-1149
and	O	1150-1153
did	O	1154-1157
not	O	1158-1161
alter	O	1162-1167
the	O	1168-1171
convulsant	O	1172-1182
dose	O	1183-1187
of	O	1188-1190
pentylenetetrezol	O	1191-1208
in	O	1209-1211
mice	O	1212-1216
(	O	1217-1218
tests	O	1218-1223
performed	O	1224-1233
by	O	1234-1236
the	O	1237-1240
Anticonvulsant	O	1241-1255
Screening	O	1256-1265
Project	O	1266-1273
of	O	1274-1276
NINCDS	O	1277-1283
)	O	1283-1284
.	O	1284-1285

Acetaminophen	O	1286-1299
(	O	1300-1301
up	O	1301-1303
to	O	1304-1306
150	O	1307-1310
micrograms	O	1311-1321
/	O	1321-1322
mL	O	1322-1324
)	O	1324-1325
did	O	1326-1329
not	O	1330-1333
retard	O	1334-1340
the	O	1341-1344
incorporation	O	1345-1358
of	O	1359-1361
radioactive	O	1362-1373
adenosine	O	1374-1383
into	O	1384-1388
ATP	O	1389-1392
in	O	1393-1395
slices	O	1396-1402
of	O	1403-1405
rat	O	1406-1409
cerebral	O	1410-1418
cortex	O	1419-1425
.	O	1425-1426

Thus	O	1427-1431
the	O	1432-1435
mechanism	O	1436-1445
by	O	1446-1448
which	O	1449-1454
acetaminophen	O	1455-1468
antagonizes	O	1469-1480
the	O	1481-1484
actions	O	1485-1492
of	O	1493-1495
caffeine	O	1496-1504
in	O	1505-1507
the	O	1508-1511
CNS	O	1512-1515
remains	O	1516-1523
unknown	O	1524-1531
.	O	1531-1532

Flestolol	O	0-9
:	O	9-10
an	O	11-13
ultra	O	14-19
-	O	19-20
short	O	20-25
-	O	19-20
acting	O	26-32
beta	O	33-37
-	O	37-38
adrenergic	O	38-48
blocking	O	49-57
agent	O	58-63
.	O	63-64

Flestolol	O	65-74
(	O	75-76
ACC	O	76-79
-	O	79-80
9089	O	80-84
)	O	84-85
is	O	86-88
a	O	89-90
nonselective	O	91-103
,	O	103-104
competitive	O	105-116
,	O	116-117
ultra	O	118-123
-	O	123-124
short	O	124-129
-	O	123-124
acting	O	130-136
beta	O	137-141
-	O	141-142
adrenergic	O	142-152
blocking	O	153-161
agent	O	162-167
,	O	167-168
without	O	169-176
any	O	177-180
intrinsic	O	181-190
sympathomimetic	O	191-206
activity	O	207-215
.	O	215-216

Flestolol	O	217-226
is	O	227-229
metabolized	O	230-241
by	O	242-244
plasma	O	245-251
esterases	O	252-261
and	O	262-265
has	O	266-269
an	O	270-272
elimination	O	273-284
half	O	285-289
-	O	289-290
life	O	290-294
of	O	295-297
approximately	O	298-311
6	O	312-313
.	O	313-314
5	O	314-315
minutes	O	316-323
.	O	323-324

This	O	325-329
agent	O	330-335
was	O	336-339
well	O	340-344
tolerated	O	345-354
in	O	355-357
healthy	O	358-365
volunteers	O	366-376
at	O	377-379
doses	O	380-385
up	O	386-388
to	O	389-391
100	O	392-395
micrograms	O	396-406
/	O	406-407
kg	O	407-409
/	O	406-407
min	O	410-413
.	O	413-414

In	O	415-417
long	O	418-422
-	O	422-423
term	O	423-427
infusion	O	428-436
studies	O	437-444
,	O	444-445
flestolol	O	446-455
was	O	456-459
well	O	460-464
tolerated	O	465-474
at	O	475-477
the	O	478-481
effective	O	482-491
beta	O	492-496
-	O	496-497
blocking	O	497-505
dose	O	506-510
(	O	511-512
5	O	512-513
micrograms	O	514-524
/	O	524-525
kg	O	525-527
/	O	524-525
min	O	528-531
)	O	531-532
for	O	533-536
up	O	537-539
to	O	540-542
seven	O	543-548
days	O	549-553
.	O	553-554

Flestolol	O	555-564
blood	O	565-570
concentrations	O	571-585
increased	O	586-595
linearly	O	596-604
with	O	605-609
increasing	O	610-620
dose	O	621-625
and	O	626-629
good	O	630-634
correlation	O	635-646
exists	O	647-653
between	O	654-661
blood	O	662-667
concentrations	O	668-682
of	O	683-685
flestolol	O	686-695
and	O	696-699
beta	O	700-704
-	O	704-705
adrenergic	O	705-715
blockade	O	716-724
.	O	724-725

Flestolol	O	726-735
produced	O	736-744
a	O	745-746
dose	O	747-751
-	O	751-752
dependent	O	752-761
attenuation	O	762-773
of	O	774-776
isoproterenol	O	777-790
-	O	790-791
induced	O	791-798
tachycardia	B	799-810
.	O	810-811

Electrophysiologic	O	812-830
and	O	831-834
hemodynamic	O	835-846
effects	O	847-854
of	O	855-857
flestolol	O	858-867
are	O	868-871
similar	O	872-879
to	O	880-882
those	O	883-888
of	O	889-891
other	O	892-897
beta	O	898-902
blockers	O	903-911
.	O	911-912

In	O	913-915
contrast	O	916-924
with	O	925-929
other	O	930-935
beta	O	936-940
blockers	O	941-949
,	O	949-950
flestolol	O	951-960
-	O	960-961
induced	O	961-968
effects	O	969-976
reverse	O	977-984
rapidly	O	985-992
(	O	993-994
within	O	994-1000
30	O	1001-1003
minutes	O	1004-1011
)	O	1011-1012
following	O	1013-1022
discontinuation	O	1023-1038
because	O	1039-1046
of	O	1047-1049
its	O	1050-1053
short	O	1054-1059
half	O	1060-1064
-	O	1064-1065
life	O	1065-1069
.	O	1069-1070

Flestolol	O	1071-1080
effectively	O	1081-1092
reduced	O	1093-1100
heart	O	1101-1106
rate	O	1107-1111
in	O	1112-1114
patients	O	1115-1123
with	O	1124-1128
supraventricular	B	1129-1145
tachyarrhythmia	I	1146-1161
.	O	1161-1162

In	O	1163-1165
patients	O	1166-1174
with	O	1175-1179
unstable	B	1180-1188
angina	I	1189-1195
,	O	1195-1196
flestolol	O	1197-1206
infusion	O	1207-1215
was	O	1216-1219
found	O	1220-1225
to	O	1226-1228
be	O	1229-1231
safe	O	1232-1236
and	O	1237-1240
effective	O	1241-1250
in	O	1251-1253
controlling	O	1254-1265
chest	B	1266-1271
pain	I	1272-1276
.	O	1276-1277

It	O	1278-1280
is	O	1281-1283
concluded	O	1284-1293
that	O	1294-1298
flestolol	O	1299-1308
is	O	1309-1311
a	O	1312-1313
potent	O	1314-1320
,	O	1320-1321
well	O	1322-1326
-	O	1326-1327
tolerated	O	1327-1336
,	O	1336-1337
ultra	O	1338-1343
-	O	1343-1344
short	O	1344-1349
-	O	1343-1344
acting	O	1350-1356
beta	O	1357-1361
-	O	1361-1362
adrenergic	O	1362-1372
blocking	O	1373-1381
agent	O	1382-1387
.	O	1387-1388

Use	O	1389-1392
of	O	1393-1395
flestolol	O	1396-1405
in	O	1406-1408
the	O	1409-1412
critical	O	1413-1421
care	O	1422-1426
setting	O	1427-1434
is	O	1435-1437
currently	O	1438-1447
undergoing	O	1448-1458
investigation	O	1459-1472
.	O	1472-1473

Adverse	O	0-7
effect	O	8-14
of	O	15-17
the	O	18-21
calcium	O	22-29
channel	O	30-37
blocker	O	38-45
nitrendipine	O	46-58
on	O	59-61
nephrosclerosis	B	62-77
in	O	78-80
rats	O	81-85
with	O	86-90
renovascular	B	91-103
hypertension	I	104-116
.	O	116-117

The	O	118-121
effect	O	122-128
of	O	129-131
a	O	132-133
6	O	134-135
-	O	135-136
week	O	136-140
treatment	O	141-150
with	O	151-155
the	O	156-159
calcium	O	160-167
channel	O	168-175
blocker	O	176-183
nitrendipine	O	184-196
or	O	197-199
the	O	200-203
angiotensin	O	204-215
converting	O	216-226
enzyme	O	227-233
inhibitor	O	234-243
enalapril	O	244-253
on	O	254-256
blood	O	257-262
pressure	O	263-271
,	O	271-272
albuminuria	B	273-284
,	O	284-285
renal	O	286-291
hemodynamics	O	292-304
,	O	304-305
and	O	306-309
morphology	O	310-320
of	O	321-323
the	O	324-327
nonclipped	O	328-338
kidney	O	339-345
was	O	346-349
studied	O	350-357
in	O	358-360
rats	O	361-365
with	O	366-370
two	O	371-374
-	O	374-375
kidney	O	375-381
,	O	381-382
one	O	383-386
clip	O	387-391
renovascular	B	392-404
hypertension	I	405-417
.	O	417-418

Six	O	419-422
weeks	O	423-428
after	O	429-434
clipping	O	435-443
of	O	444-446
one	O	447-450
renal	O	451-456
artery	O	457-463
,	O	463-464
hypertensive	B	465-477
rats	O	478-482
(	O	483-484
178	O	484-487
+	O	488-489
/	O	489-490
-	O	490-491
4	O	492-493
mm	O	494-496
Hg	O	497-499
)	O	499-500
were	O	501-505
randomly	O	506-514
assigned	O	515-523
to	O	524-526
three	O	527-532
groups	O	533-539
:	O	539-540
untreated	O	541-550
hypertensive	B	551-563
controls	O	564-572
(	O	573-574
n	O	574-575
=	O	576-577
8	O	578-579
)	O	579-580
,	O	580-581
enalapril	O	582-591
-	O	591-592
treated	O	592-599
(	O	600-601
n	O	601-602
=	O	603-604
8	O	605-606
)	O	606-607
,	O	607-608
or	O	609-611
nitrendipine	O	612-624
-	O	624-625
treated	O	625-632
(	O	633-634
n	O	634-635
=	O	636-637
10	O	638-640
)	O	640-641
.	O	641-642

Sham	O	643-647
-	O	647-648
operated	O	648-656
rats	O	657-661
served	O	662-668
as	O	669-671
normotensive	O	672-684
controls	O	685-693
(	O	694-695
128	O	695-698
+	O	699-700
/	O	700-701
-	O	701-702
3	O	703-704
mm	O	705-707
Hg	O	708-710
,	O	710-711
n	O	712-713
=	O	714-715
8	O	716-717
)	O	717-718
.	O	718-719

After	O	720-725
6	O	726-727
weeks	O	728-733
of	O	734-736
treatment	O	737-746
,	O	746-747
renal	O	748-753
hemodynamics	O	754-766
(	O	767-768
glomerular	O	768-778
filtration	O	779-789
rate	O	790-794
and	O	795-798
renal	O	799-804
plasma	O	805-811
flow	O	812-816
)	O	816-817
were	O	818-822
measured	O	823-831
in	O	832-834
the	O	835-838
anesthetized	O	839-851
rats	O	852-856
.	O	856-857

Renal	O	858-863
tissue	O	864-870
was	O	871-874
obtained	O	875-883
for	O	884-887
determination	O	888-901
of	O	902-904
glomerular	O	905-915
size	O	916-920
and	O	921-924
sclerosis	O	925-934
.	O	934-935

Enalapril	O	936-945
but	O	946-949
not	O	950-953
nitrendipine	O	954-966
reduced	O	967-974
blood	O	975-980
pressure	O	981-989
significantly	O	990-1003
.	O	1003-1004

After	O	1005-1010
6	O	1011-1012
weeks	O	1013-1018
of	O	1019-1021
therapy	O	1022-1029
,	O	1029-1030
glomerular	O	1031-1041
filtration	O	1042-1052
rate	O	1053-1057
was	O	1058-1061
not	O	1062-1065
different	O	1066-1075
among	O	1076-1081
the	O	1082-1085
studied	O	1086-1093
groups	O	1094-1100
.	O	1100-1101

Renal	O	1102-1107
plasma	O	1108-1114
flow	O	1115-1119
increased	O	1120-1129
,	O	1129-1130
but	O	1131-1134
albumin	O	1135-1142
excretion	O	1143-1152
and	O	1153-1156
glomerulosclerosis	B	1157-1175
did	O	1176-1179
not	O	1180-1183
change	O	1184-1190
after	O	1191-1196
enalapril	O	1197-1206
treatment	O	1207-1216
.	O	1216-1217

In	O	1218-1220
contrast	O	1221-1229
,	O	1229-1230
in	O	1231-1233
the	O	1234-1237
nitrendipine	O	1238-1250
-	O	1250-1251
treated	O	1251-1258
group	O	1259-1264
albuminuria	B	1265-1276
increased	O	1277-1286
from	O	1287-1291
12	O	1292-1294
.	O	1294-1295
8	O	1295-1296
+	O	1297-1298
/	O	1298-1299
-	O	1299-1300
2	O	1301-1302
progressively	O	1303-1316
to	O	1317-1319
163	O	1320-1323
+	O	1324-1325
/	O	1325-1326
-	O	1326-1327
55	O	1328-1330
compared	O	1331-1339
with	O	1340-1344
19	O	1345-1347
.	O	1347-1348
2	O	1348-1349
+	O	1350-1351
/	O	1351-1352
-	O	1352-1353
9	O	1354-1355
mg	O	1356-1358
/	O	1358-1359
24	O	1359-1361
hr	O	1362-1364
in	O	1365-1367
the	O	1368-1371
hypertensive	B	1372-1384
controls	O	1385-1393
.	O	1393-1394

Furthermore	O	1395-1406
,	O	1406-1407
glomerulosclerosis	B	1408-1426
index	O	1427-1432
was	O	1433-1436
significantly	O	1437-1450
increased	O	1451-1460
in	O	1461-1463
the	O	1464-1467
nitrendipine	O	1468-1480
-	O	1480-1481
treated	O	1481-1488
group	O	1489-1494
compared	O	1495-1503
with	O	1504-1508
the	O	1509-1512
hypertensive	B	1513-1525
controls	O	1526-1534
(	O	1535-1536
0	O	1536-1537
.	O	1537-1538
38	O	1538-1540
+	O	1541-1542
/	O	1542-1543
-	O	1543-1544
0	O	1545-1546
.	O	1546-1547
1	O	1547-1548
versus	O	1549-1555
0	O	1556-1557
.	O	1557-1558
13	O	1558-1560
+	O	1561-1562
/	O	1562-1563
-	O	1563-1564
0	O	1565-1566
.	O	1566-1567
04	O	1567-1569
)	O	1569-1570
.	O	1566-1567

In	O	1572-1574
addition	O	1575-1583
,	O	1583-1584
glomerular	O	1585-1595
size	O	1596-1600
was	O	1601-1604
higher	O	1605-1611
in	O	1612-1614
the	O	1615-1618
nitrendipine	O	1619-1631
-	O	1631-1632
treated	O	1632-1639
group	O	1640-1645
(	O	1646-1647
14	O	1647-1649
.	O	1649-1650
9	O	1650-1651
+	O	1652-1653
/	O	1653-1654
-	O	1654-1655
0	O	1656-1657
.	O	1657-1658
17	O	1658-1660
10	O	1661-1663
(	O	1663-1664
-	O	1664-1665
3	O	1665-1666
)	O	1666-1667
mm2	O	1668-1671
)	O	1671-1672
but	O	1673-1676
lower	O	1677-1682
in	O	1683-1685
the	O	1686-1689
enalapril	O	1690-1699
-	O	1699-1700
treated	O	1700-1707
group	O	1708-1713
(	O	1714-1715
11	O	1715-1717
.	O	1717-1718
5	O	1718-1719
+	O	1720-1721
/	O	1721-1722
-	O	1722-1723
0	O	1724-1725
.	O	1725-1726
15	O	1726-1728
10	O	1729-1731
(	O	1731-1732
-	O	1732-1733
3	O	1733-1734
)	O	1734-1735
mm2	O	1736-1739
)	O	1739-1740
compared	O	1741-1749
with	O	1750-1754
the	O	1755-1758
hypertensive	B	1759-1771
controls	O	1772-1780
(	O	1781-1782
12	O	1782-1784
.	O	1784-1785
1	O	1782-1783
+	O	1787-1788
/	O	1788-1789
-	O	1789-1790
0	O	1791-1792
.	O	1792-1793
17	O	1793-1795
10	O	1796-1798
(	O	1798-1799
-	O	1799-1800
3	O	1800-1801
)	O	1801-1802
mm2	O	1803-1806
)	O	1806-1807
.	O	1807-1808
(	O	1808-1809
ABSTRACT	O	1809-1817

TRUNCATED	O	1818-1827
AT	O	1828-1830
250	O	1831-1834
WORDS	O	1835-1840
)	O	1840-1841

Treatment	O	0-9
of	O	10-12
tinnitus	B	13-21
by	O	22-24
intratympanic	O	25-38
instillation	O	39-51
of	O	52-54
lignocaine	O	55-65
(	O	66-67
lidocaine	O	67-76
)	O	76-77
2	O	78-79
per	O	80-83
cent	O	84-88
through	O	89-96
ventilation	O	97-108
tubes	O	109-114
.	O	114-115

Idiopathic	B	116-126
subjective	I	127-137
tinnitus	I	138-146
(	O	147-148
IST	B	148-151
)	O	151-152
is	O	153-155
one	O	156-159
of	O	160-162
the	O	163-166
most	O	167-171
obscure	O	172-179
otological	O	180-190
pathologies	O	191-202
.	O	202-203

This	O	204-208
paper	O	209-214
presents	O	215-223
the	O	224-227
results	O	228-235
of	O	236-238
treating	O	239-247
IST	B	248-251
by	O	252-254
intratympanic	O	255-268
instillation	O	269-281
of	O	282-284
lignocaine	O	285-295
(	O	296-297
lidocaine	O	297-306
)	O	306-307
2	O	308-309
per	O	310-313
cent	O	314-318
through	O	319-326
a	O	327-328
grommet	O	329-336
,	O	336-337
for	O	338-341
five	O	342-346
weekly	O	347-353
courses	O	354-361
.	O	361-362

Fifty	O	363-368
-	O	368-369
two	O	369-372
patients	O	373-381
suffering	O	382-391
from	O	392-396
intractable	O	397-408
tinnitus	B	409-417
entered	O	418-425
this	O	426-430
therapeutic	O	431-442
trial	O	443-448
,	O	448-449
but	O	450-453
only	O	454-458
nine	O	459-463
finished	O	464-472
all	O	473-476
five	O	477-481
courses	O	482-489
.	O	489-490

In	O	491-493
one	O	494-497
patient	O	498-505
,	O	505-506
the	O	507-510
tinnitus	B	511-519
was	O	520-523
almost	O	524-530
completely	O	531-541
abolished	O	542-551
,	O	551-552
but	O	553-556
in	O	557-559
all	O	560-563
the	O	564-567
nine	O	568-572
patients	O	573-581
the	O	582-585
decompensated	O	586-599
tinnitus	B	600-608
changed	O	609-616
to	O	617-619
a	O	620-621
compensated	O	622-633
one	O	634-637
.	O	637-638

We	O	639-641
suggest	O	642-649
this	O	650-654
mode	O	655-659
of	O	660-662
treatment	O	663-672
for	O	673-676
patients	O	677-685
that	O	686-690
were	O	691-695
previously	O	696-706
treated	O	707-714
by	O	715-717
drugs	O	718-723
,	O	723-724
acupuncture	O	725-736
and	O	737-740
biofeedback	O	741-752
,	O	752-753
with	O	754-758
disappointing	O	759-772
results	O	773-780
.	O	780-781

Patients	O	782-790
should	O	791-797
be	O	798-800
warned	O	801-807
about	O	808-813
the	O	814-817
side	O	818-822
effects	O	823-830
of	O	831-833
vertigo	B	834-841
and	O	842-845
vomiting	B	846-854
,	O	854-855
which	O	856-861
subsides	O	862-870
gradually	O	871-880
with	O	881-885
every	O	886-891
new	O	892-895
instillation	O	896-908
,	O	908-909
and	O	910-913
that	O	914-918
the	O	919-922
tinnitus	B	923-931
may	O	932-935
not	O	936-939
disappear	O	940-949
but	O	950-953
will	O	954-958
be	O	959-961
alleviated	O	962-972
,	O	972-973
enabling	O	974-982
them	O	983-987
to	O	988-990
cope	O	991-995
more	O	996-1000
easily	O	1001-1007
with	O	1008-1012
the	O	1013-1016
disease	O	1017-1024
and	O	1025-1028
lead	O	1029-1033
a	O	1034-1035
more	O	1036-1040
normal	O	1041-1047
life	O	1048-1052
.	O	1052-1053

Perhexiline	O	0-11
maleate	O	12-19
and	O	20-23
peripheral	B	24-34
neuropathy	I	35-45
.	O	45-46

Peripheral	B	47-57
neuropathy	I	58-68
has	O	69-72
been	O	73-77
noted	O	78-83
as	O	84-86
a	O	87-88
complication	O	89-101
of	O	102-104
therapy	O	105-112
with	O	113-117
perhexiline	O	118-129
maleate	O	130-137
,	O	137-138
a	O	139-140
drug	O	141-145
widely	O	146-152
used	O	153-157
in	O	158-160
France	O	161-167
(	O	168-169
and	O	169-172
in	O	173-175
clinical	O	176-184
trials	O	185-191
in	O	192-194
the	O	195-198
United	O	199-205
States	O	206-212
)	O	212-213
for	O	214-217
the	O	218-221
prophylactic	O	222-234
treatment	O	235-244
of	O	245-247
angina	B	248-254
pectoris	I	255-263
.	O	263-264

In	O	265-267
24	O	268-270
patients	O	271-279
with	O	280-284
this	O	285-289
complication	O	290-302
,	O	302-303
the	O	304-307
marked	O	308-314
slowing	O	315-322
of	O	323-325
motor	O	326-331
nerve	O	332-337
conduction	O	338-348
velocity	O	349-357
and	O	358-361
the	O	362-365
electromyographic	O	366-383
changes	O	384-391
imply	O	392-397
mainly	O	398-404
a	O	405-406
demyelinating	B	407-420
disorder	I	421-429
.	O	429-430

Improvement	O	431-442
was	O	443-446
noted	O	447-452
with	O	453-457
cessation	O	458-467
of	O	468-470
therapy	O	471-478
.	O	478-479

In	O	480-482
a	O	483-484
few	O	485-488
cases	O	489-494
the	O	495-498
presence	O	499-507
of	O	508-510
active	O	511-517
denervation	O	518-529
signified	O	530-539
a	O	540-541
poor	O	542-546
prognosis	O	547-556
,	O	556-557
with	O	558-562
only	O	563-567
slight	O	568-574
improvement	O	575-586
.	O	586-587

The	O	588-591
underlying	O	592-602
mechanism	O	603-612
causing	O	613-620
the	O	621-624
neuropathy	B	625-635
is	O	636-638
not	O	639-642
yet	O	643-646
fully	O	647-652
known	O	653-658
,	O	658-659
although	O	660-668
some	O	669-673
evidence	O	674-682
indicates	O	683-692
that	O	693-697
it	O	698-700
may	O	701-704
be	O	705-707
a	O	708-709
lipid	O	710-715
storage	O	716-723
process	O	724-731
.	O	731-732

Effect	O	0-6
of	O	7-9
humoral	O	10-17
modulators	O	18-28
of	O	29-31
morphine	O	32-40
-	O	40-41
induced	O	41-48
increase	B	49-57
in	I	58-60
locomotor	I	61-70
activity	I	71-79
of	O	80-82
mice	O	83-87
.	O	87-88

The	O	89-92
effect	O	93-99
of	O	100-102
humoral	O	103-110
modulators	O	111-121
on	O	122-124
the	O	125-128
morphine	O	129-137
-	O	137-138
induced	O	138-145
increase	B	146-154
in	I	155-157
locomotor	I	158-167
activity	I	168-176
of	O	177-179
mice	O	180-184
was	O	185-188
studied	O	189-196
.	O	196-197

The	O	198-201
subcutaneous	O	202-214
administration	O	215-229
of	O	230-232
10	O	233-235
mg	O	236-238
/	O	238-239
kg	O	239-241
of	O	242-244
morphine	O	245-253
-	O	253-254
HC1	O	254-257
produced	O	258-266
a	O	267-268
marked	O	269-275
increase	B	276-284
in	I	285-287
locomotor	I	288-297
activity	I	298-306
in	O	307-309
mice	O	310-314
.	O	314-315

The	O	316-319
morphine	O	320-328
-	O	328-329
induced	O	329-336
hyperactivity	B	337-350
was	O	351-354
potentiated	O	355-366
by	O	367-369
scopolamine	O	370-381
and	O	382-385
attenuated	O	386-396
by	O	397-399
physostigmine	O	400-413
.	O	413-414

In	O	415-417
contrast	O	418-426
,	O	426-427
both	O	428-432
methscopolamine	O	433-448
and	O	449-452
neostigmine	O	453-464
,	O	464-465
which	O	466-471
do	O	472-474
not	O	475-478
penetrate	O	479-488
the	O	489-492
blood	O	493-498
-	O	498-499
brain	O	499-504
barrier	O	505-512
,	O	512-513
had	O	514-517
no	O	518-520
effect	O	521-527
on	O	528-530
the	O	531-534
hyperactivity	B	535-548
produced	O	549-557
by	O	558-560
morphine	O	561-569
.	O	569-570

Pretreatment	O	571-583
of	O	584-586
mice	O	587-591
with	O	592-596
alpha	O	597-602
-	O	602-603
methyltyrosine	O	603-617
(	O	618-619
20	O	619-621
mg	O	622-624
/	O	624-625
kg	O	625-627
i	O	628-629
.	O	629-630
p	O	630-631
.	O	629-630
,	O	632-633
one	O	634-637
hour	O	638-642
)	O	642-643
,	O	643-644
an	O	645-647
inhibitor	O	648-657
of	O	658-660
tyrosine	O	661-669
hydroxylase	O	670-681
,	O	681-682
significantly	O	683-696
decreased	O	697-706
the	O	707-710
activity	O	711-719
-	O	719-720
increasing	O	720-730
effects	O	731-738
of	O	739-741
morphine	O	742-750
.	O	750-751

On	O	752-754
the	O	755-758
other	O	759-764
hand	O	765-769
,	O	769-770
pretreatment	O	771-783
with	O	784-788
p	O	789-790
-	O	790-791
chlorophenylalamine	O	791-810
(	O	811-812
3	O	812-813
X	O	814-815
320	O	816-819
mg	O	820-822
/	O	822-823
kg	O	823-825
i	O	826-827
.	O	827-828
p	O	828-829
.	O	827-828
,	O	830-831
24	O	832-834
hr	O	835-837
)	O	837-838
,	O	838-839
a	O	840-841
serotonin	O	842-851
depletor	O	852-860
,	O	860-861
caused	O	862-868
no	O	869-871
significant	O	872-883
change	O	884-890
in	O	891-893
the	O	894-897
hyperactivity	B	898-911
.	O	911-912

The	O	913-916
study	O	917-922
suggests	O	923-931
that	O	932-936
the	O	937-940
activity	O	941-949
-	O	949-950
increasing	O	950-960
effects	O	961-968
of	O	969-971
morphine	O	972-980
are	O	981-984
mediated	O	985-993
by	O	994-996
the	O	997-1000
release	O	1001-1008
of	O	1009-1011
catecholamines	O	1012-1026
from	O	1027-1031
adrenergic	O	1032-1042
neurons	O	1043-1050
in	O	1051-1053
the	O	1054-1057
brain	O	1058-1063
.	O	1063-1064

And	O	1065-1068
the	O	1069-1072
results	O	1073-1080
are	O	1081-1084
consistent	O	1085-1095
with	O	1096-1100
the	O	1101-1104
hypothesis	O	1105-1115
that	O	1116-1120
morphine	O	1121-1129
acts	O	1130-1134
by	O	1135-1137
retarding	O	1138-1147
the	O	1148-1151
release	O	1152-1159
of	O	1160-1162
acetylcholine	O	1163-1176
at	O	1177-1179
some	O	1180-1184
central	O	1185-1192
cholinergic	O	1193-1204
synapses	O	1205-1213
.	O	1213-1214

It	O	1215-1217
is	O	1218-1220
also	O	1221-1225
suggested	O	1226-1235
from	O	1236-1240
collected	O	1241-1250
evidence	O	1251-1259
that	O	1260-1264
the	O	1265-1268
activity	O	1269-1277
-	O	1277-1278
increasing	O	1278-1288
effects	O	1289-1296
of	O	1297-1299
morphine	O	1300-1308
in	O	1309-1311
mice	O	1312-1316
are	O	1317-1320
mediated	O	1321-1329
by	O	1330-1332
mechanisms	O	1333-1343
different	O	1344-1353
from	O	1354-1358
those	O	1359-1364
which	O	1365-1370
mediate	O	1371-1378
the	O	1379-1382
activity	O	1383-1391
-	O	1391-1392
increasing	O	1392-1402
effects	O	1403-1410
of	O	1411-1413
morphine	O	1414-1422
in	O	1423-1425
rats	O	1426-1430
.	O	1430-1431

Mechanisms	O	0-10
of	O	11-13
FK	O	14-16
506	O	17-20
-	O	20-21
induced	O	21-28
hypertension	B	29-41
in	O	42-44
the	O	45-48
rat	O	49-52
.	O	52-53

-	O	54-55
Tacrolimus	O	55-65
(	O	66-67
FK	O	67-69
506	O	70-73
)	O	73-74
is	O	75-77
a	O	78-79
powerful	O	80-88
,	O	88-89
widely	O	90-96
used	O	97-101
immunosuppressant	O	102-119
.	O	119-120

The	O	121-124
clinical	O	125-133
utility	O	134-141
of	O	142-144
FK	O	145-147
506	O	148-151
is	O	152-154
complicated	O	155-166
by	O	167-169
substantial	O	170-181
hypertension	B	182-194
and	O	195-198
nephrotoxicity	B	199-213
.	O	213-214

To	O	215-217
clarify	O	218-225
the	O	226-229
mechanisms	O	230-240
of	O	241-243
FK	O	244-246
506	O	247-250
-	O	250-251
induced	O	251-258
hypertension	B	259-271
,	O	271-272
we	O	273-275
studied	O	276-283
the	O	284-287
chronic	O	288-295
effects	O	296-303
of	O	304-306
FK	O	307-309
506	O	310-313
on	O	314-316
the	O	317-320
synthesis	O	321-330
of	O	331-333
endothelin	O	334-344
-	O	344-345
1	O	345-346
(	O	347-348
ET	O	348-350
-	O	350-351
1	O	351-352
)	O	352-353
,	O	353-354
the	O	355-358
expression	O	359-369
of	O	370-372
mRNA	O	373-377
of	O	378-380
ET	O	381-383
-	O	383-384
1	O	384-385
and	O	386-389
endothelin	O	390-400
-	O	400-401
converting	O	401-411
enzyme	O	412-418
-	O	418-419
1	O	419-420
(	O	421-422
ECE	O	422-425
-	O	425-426
1	O	426-427
)	O	427-428
,	O	428-429
the	O	430-433
endothelial	O	434-445
nitric	O	446-452
oxide	O	453-458
synthase	O	459-467
(	O	468-469
eNOS	O	469-473
)	O	473-474
activity	O	475-483
,	O	483-484
and	O	485-488
the	O	489-492
expression	O	493-503
of	O	504-506
mRNA	O	507-511
of	O	512-514
eNOS	O	515-519
and	O	520-523
C	O	524-525
-	O	525-526
type	O	526-530
natriuretic	O	531-542
peptide	O	543-550
(	O	551-552
CNP	O	552-555
)	O	555-556
in	O	557-559
rat	O	560-563
blood	O	564-569
vessels	O	570-577
.	O	577-578

In	O	579-581
addition	O	582-590
,	O	590-591
the	O	592-595
effect	O	596-602
of	O	603-605
the	O	606-609
specific	O	610-618
endothelin	O	619-629
type	O	630-634
A	O	635-636
receptor	O	637-645
antagonist	O	646-656
FR	O	657-659
139317	O	660-666
on	O	667-669
FK	O	670-672
506	O	673-676
-	O	676-677
induced	O	677-684
hypertension	B	685-697
in	O	698-700
rats	O	701-705
was	O	706-709
studied	O	710-717
.	O	717-718

FK	O	719-721
506	O	722-725
,	O	725-726
5	O	727-728
mg	O	729-731
.	O	731-732

kg	O	733-735
-	O	735-736
1	O	736-737
.	O	737-738

d	O	739-740
-	O	740-741
1	O	741-742
given	O	743-748
for	O	749-752
4	O	753-754
weeks	O	755-760
,	O	760-761
elevated	O	762-770
blood	O	771-776
pressure	O	777-785
from	O	786-790
102	O	791-794
+	O	794-795
/	O	795-796
-	O	796-797
13	O	797-799
to	O	800-802
152	O	803-806
+	O	806-807
/	O	807-808
-	O	808-809
15	O	803-805
mm	O	812-814
Hg	O	815-817
and	O	818-821
increased	O	822-831
the	O	832-835
synthesis	O	836-845
of	O	846-848
ET	O	849-851
-	O	851-852
1	O	852-853
and	O	854-857
the	O	858-861
levels	O	862-868
of	O	869-871
ET	O	872-874
-	O	874-875
1	O	875-876
mRNA	O	877-881
in	O	882-884
the	O	885-888
mesenteric	O	889-899
artery	O	900-906
(	O	907-908
240	O	908-911
%	O	911-912
and	O	913-916
230	O	917-920
%	O	920-921
,	O	921-922
respectively	O	923-935
)	O	935-936
.	O	936-937

Little	O	938-944
change	O	945-951
was	O	952-955
observed	O	956-964
in	O	965-967
the	O	968-971
expression	O	972-982
of	O	983-985
ECE	O	986-989
-	O	989-990
1	O	990-991
mRNA	O	992-996
and	O	997-1000
CNP	O	1001-1004
mRNA	O	1005-1009
.	O	1009-1010

FK	O	1011-1013
506	O	1014-1017
decreased	O	1018-1027
eNOS	O	1028-1032
activity	O	1033-1041
and	O	1042-1045
the	O	1046-1049
levels	O	1050-1056
of	O	1057-1059
eNOS	O	1060-1064
mRNA	O	1065-1069
in	O	1070-1072
the	O	1073-1076
aorta	O	1077-1082
(	O	1083-1084
48	O	1084-1086
%	O	1086-1087
and	O	1088-1091
55	O	1092-1094
%	O	1094-1095
,	O	1095-1096
respectively	O	1097-1109
)	O	1109-1110
.	O	1110-1111

The	O	1112-1115
administration	O	1116-1130
of	O	1131-1133
FR	O	1134-1136
139317	O	1137-1143
(	O	1144-1145
10	O	1145-1147
mg	O	1148-1150
.	O	1150-1151

kg	O	1152-1154
-	O	1154-1155
1	O	1155-1156
.	O	1156-1157

d	O	1158-1159
-	O	1159-1160
1	O	1160-1161
)	O	1161-1162
prevented	O	1163-1172
FK	O	1173-1175
506	O	1176-1179
-	O	1179-1180
induced	O	1180-1187
hypertension	B	1188-1200
in	O	1201-1203
rats	O	1204-1208
.	O	1208-1209

These	O	1210-1215
results	O	1216-1223
indicate	O	1224-1232
that	O	1233-1237
FK	O	1238-1240
506	O	1241-1244
may	O	1245-1248
increase	O	1249-1257
blood	O	1258-1263
pressure	O	1264-1272
not	O	1273-1276
only	O	1277-1281
by	O	1282-1284
increasing	O	1285-1295
ET	O	1296-1298
-	O	1298-1299
1	O	1299-1300
production	O	1301-1311
but	O	1312-1315
also	O	1316-1320
by	O	1321-1323
decreasing	O	1324-1334
NO	O	1335-1337
synthesis	O	1338-1347
in	O	1348-1350
the	O	1351-1354
vasculature	O	1355-1366
.	O	1366-1367

Suxamethonium	O	0-13
induced	O	14-21
prolonged	O	22-31
apnea	B	32-37
in	O	38-40
a	O	41-42
patient	O	43-50
receiving	O	51-60
electroconvulsive	O	61-78
therapy	O	79-86
.	O	86-87

Suxamethonium	O	88-101
causes	O	102-108
prolonged	O	109-118
apnea	B	119-124
in	O	125-127
patients	O	128-136
in	O	137-139
whom	O	140-144
pseudocholinesterase	O	145-165
enzyme	O	166-172
gets	O	173-177
deactivated	O	178-189
by	O	190-192
organophosphorus	O	193-209
(	O	210-211
OP	O	211-213
)	O	213-214
poisons	O	215-222
.	O	222-223

Here	O	224-228
,	O	228-229
we	O	230-232
present	O	233-240
a	O	241-242
similar	O	243-250
incident	O	251-259
in	O	260-262
a	O	263-264
severely	O	265-273
depressed	B	274-283
patient	O	284-291
who	O	292-295
received	O	296-304
electroconvulsive	O	305-322
therapy	O	323-330
(	O	331-332
ECT	O	332-335
)	O	335-336
.	O	336-337

Prolonged	O	338-347
apnea	B	348-353
in	O	354-356
our	O	357-360
case	O	361-365
ensued	O	366-372
because	O	373-380
the	O	381-384
information	O	385-396
about	O	397-402
suicidal	O	403-411
attempt	O	412-419
by	O	420-422
OP	O	423-425
compound	O	426-434
was	O	435-438
concealed	O	439-448
from	O	449-453
the	O	454-457
treating	O	458-466
team	O	467-471
.	O	471-472

The	O	0-3
effects	O	4-11
of	O	12-14
the	O	15-18
adjunctive	O	19-29
bupropion	O	30-39
on	O	40-42
male	O	43-47
sexual	B	48-54
dysfunction	I	55-66
induced	O	67-74
by	O	75-77
a	O	78-79
selective	O	80-89
serotonin	O	90-99
reuptake	O	100-108
inhibitor	O	109-118
:	O	118-119
a	O	120-121
double	O	122-128
-	O	128-129
blind	O	129-134
placebo	O	135-142
-	O	142-143
controlled	O	143-153
and	O	154-157
randomized	O	158-168
study	O	169-174
.	O	174-175

OBJECTIVE	O	176-185
:	O	185-186
To	O	187-189
determine	O	190-199
the	O	200-203
safety	O	204-210
and	O	211-214
efficacy	O	215-223
of	O	224-226
adjunctive	O	227-237
bupropion	O	238-247
sustained	O	248-257
-	O	257-258
release	O	258-265
(	O	266-267
SR	O	267-269
)	O	269-270
on	O	271-273
male	O	274-278
sexual	B	279-285
dysfunction	I	286-297
(	O	298-299
SD	B	299-301
)	O	301-302
induced	O	303-310
by	O	311-313
a	O	314-315
selective	O	316-325
serotonin	O	326-335
reuptake	O	336-344
inhibitor	O	345-354
(	O	355-356
SSRI	O	356-360
)	O	360-361
,	O	361-362
as	O	363-365
SD	B	366-368
is	O	369-371
a	O	372-373
common	O	374-380
side	O	381-385
-	O	385-386
effect	O	386-392
of	O	393-395
SSRIs	O	396-401
and	O	402-405
the	O	406-409
most	O	410-414
effective	O	415-424
treatments	O	425-435
have	O	436-440
yet	O	441-444
to	O	445-447
be	O	448-450
determined	O	451-461
.	O	461-462

PATIENTS	O	463-471
AND	O	472-475
METHODS	O	476-483
:	O	483-484
The	O	485-488
randomized	O	489-499
sample	O	500-506
consisted	O	507-516
of	O	517-519
234	O	520-523
euthymic	O	524-532
men	O	533-536
who	O	537-540
were	O	541-545
receiving	O	546-555
some	O	556-560
type	O	561-565
of	O	566-568
SSRI	O	569-573
.	O	573-574

The	O	575-578
men	O	579-582
were	O	583-587
randomly	O	588-596
assigned	O	597-605
to	O	606-608
bupropion	O	609-618
SR	O	619-621
(	O	622-623
150	O	623-626
mg	O	627-629
twice	O	630-635
daily	O	636-641
,	O	641-642
117	O	643-646
)	O	646-647
or	O	648-650
placebo	O	651-658
(	O	659-660
twice	O	660-665
daily	O	666-671
,	O	671-672
117	O	673-676
)	O	676-677
for	O	678-681
12	O	682-684
weeks	O	685-690
.	O	690-691

Efficacy	O	692-700
was	O	701-704
evaluated	O	705-714
using	O	715-720
the	O	721-724
Clinical	O	725-733
Global	O	734-740
Impression	O	741-751
-	O	751-752
Sexual	O	752-758
Function	O	759-767
(	O	768-769
CGI	O	769-772
-	O	772-773
SF	O	773-775
;	O	775-776
the	O	777-780
primary	O	781-788
outcome	O	789-796
measure	O	797-804
)	O	804-805
,	O	805-806
the	O	807-810
International	O	811-824
Index	O	825-830
of	O	831-833
Erectile	O	834-842
Function	O	843-851
(	O	852-853
IIEF	O	853-857
)	O	857-858
,	O	858-859
Arizona	O	860-867
Sexual	O	868-874
Experience	O	875-885
Scale	O	886-891
(	O	892-893
ASEX	O	893-897
)	O	897-898
,	O	898-899
and	O	900-903
Erectile	B	904-912
Dysfunction	I	913-924
Inventory	O	925-934
of	O	935-937
Treatment	O	938-947
Satisfaction	O	948-960
(	O	961-962
EDITS	O	962-967
)	O	967-968
(	O	969-970
secondary	O	970-979
outcome	O	980-987
measures	O	988-996
)	O	996-997
.	O	997-998

Participants	O	999-1011
were	O	1012-1016
followed	O	1017-1025
biweekly	O	1026-1034
during	O	1035-1041
study	O	1042-1047
period	O	1048-1054
.	O	1054-1055

RESULTS	O	1056-1063
:	O	1063-1064
After	O	1065-1070
12	O	1071-1073
weeks	O	1074-1079
of	O	1080-1082
treatment	O	1083-1092
,	O	1092-1093
the	O	1094-1097
mean	O	1098-1102
(	O	1103-1104
sd	O	1104-1106
)	O	1106-1107
scores	O	1108-1114
for	O	1115-1118
CGI	O	1119-1122
-	O	1122-1123
SF	O	1123-1125
were	O	1126-1130
significantly	O	1131-1144
lower	O	1145-1150
,	O	1150-1151
i	O	1152-1153
.	O	1153-1154
e	O	1154-1155
.	O	1153-1154
better	O	1157-1163
,	O	1163-1164
in	O	1165-1167
patients	O	1168-1176
on	O	1177-1179
bupropion	O	1180-1189
SR	O	1190-1192
,	O	1192-1193
at	O	1194-1196
2	O	1197-1198
.	O	1198-1199
4	O	1199-1200
(	O	1201-1202
1	O	1202-1203
.	O	1203-1204
2	O	1204-1205
)	O	1205-1206
,	O	1206-1207
than	O	1208-1212
in	O	1213-1215
the	O	1216-1219
placebo	O	1220-1227
group	O	1228-1233
,	O	1233-1234
at	O	1235-1237
3	O	1238-1239
.	O	1239-1240
9	O	1240-1241
(	O	1242-1243
1	O	1243-1244
.	O	1244-1245
1	O	1243-1244
)	O	1246-1247
(	O	1248-1249
P	O	1249-1250
=	O	1250-1251
0	O	1252-1253
.	O	1253-1254
01	O	1254-1256
)	O	1256-1257
.	O	1253-1254

Men	O	1259-1262
who	O	1263-1266
received	O	1267-1275
bupropion	O	1276-1285
had	O	1286-1289
a	O	1290-1291
significant	O	1292-1303
increase	O	1304-1312
in	O	1313-1315
the	O	1316-1319
total	O	1320-1325
IIEF	O	1326-1330
score	O	1331-1336
(	O	1337-1338
54	O	1338-1340
.	O	1340-1341
4	O	1339-1340
%	O	1342-1343
vs	O	1344-1346
1	O	1347-1348
.	O	1348-1349
2	O	1349-1350
%	O	1350-1351
;	O	1351-1352
P	O	1353-1354
=	O	1354-1355
0	O	1356-1357
.	O	1357-1358
003	O	1358-1361
)	O	1361-1362
,	O	1362-1363
and	O	1364-1367
in	O	1368-1370
the	O	1371-1374
five	O	1375-1379
different	O	1380-1389
domains	O	1390-1397
of	O	1398-1400
the	O	1401-1404
IIEF	O	1405-1409
.	O	1409-1410

Total	O	1411-1416
ASEX	O	1417-1421
scores	O	1422-1428
were	O	1429-1433
significantly	O	1434-1447
lower	O	1448-1453
,	O	1453-1454
i	O	1455-1456
.	O	1456-1457
e	O	1457-1458
.	O	1456-1457
better	O	1460-1466
,	O	1466-1467
among	O	1468-1473
men	O	1474-1477
who	O	1478-1481
received	O	1482-1490
bupropion	O	1491-1500
than	O	1501-1505
placebo	O	1506-1513
,	O	1513-1514
at	O	1515-1517
15	O	1518-1520
.	O	1520-1521
5	O	1519-1520
(	O	1523-1524
4	O	1524-1525
.	O	1525-1526
3	O	1526-1527
)	O	1527-1528
vs	O	1529-1531
21	O	1532-1534
.	O	1534-1535
5	O	1535-1536
(	O	1537-1538
4	O	1538-1539
.	O	1539-1540
7	O	1540-1541
)	O	1541-1542
(	O	1543-1544
P	O	1544-1545
=	O	1545-1546
0	O	1547-1548
.	O	1548-1549
002	O	1549-1552
)	O	1552-1553
.	O	1548-1549

The	O	1555-1558
EDITS	O	1559-1564
scores	O	1565-1571
were	O	1572-1576
67	O	1577-1579
.	O	1579-1580
4	O	1580-1581
(	O	1582-1583
10	O	1583-1585
.	O	1585-1586
2	O	1586-1587
)	O	1587-1588
for	O	1589-1592
the	O	1593-1596
bupropion	O	1597-1606
and	O	1607-1610
36	O	1611-1613
.	O	1613-1614
3	O	1611-1612
(	O	1616-1617
11	O	1617-1619
.	O	1619-1620
7	O	1620-1621
)	O	1621-1622
for	O	1623-1626
the	O	1627-1630
placebo	O	1631-1638
group	O	1639-1644
(	O	1645-1646
P	O	1646-1647
=	O	1647-1648
0	O	1649-1650
.	O	1650-1651
001	O	1651-1654
)	O	1654-1655
.	O	1650-1651

The	O	1657-1660
ASEX	O	1661-1665
score	O	1666-1671
and	O	1672-1675
CGI	O	1676-1679
-	O	1679-1680
SF	O	1680-1682
score	O	1683-1688
were	O	1689-1693
correlated	O	1694-1704
(	O	1705-1706
P	O	1706-1707
=	O	1707-1708
0	O	1709-1710
.	O	1710-1711
003	O	1711-1714
)	O	1714-1715
.	O	1710-1711

In	O	1717-1719
linear	O	1720-1726
regression	O	1727-1737
analyses	O	1738-1746
the	O	1747-1750
CGI	O	1751-1754
-	O	1754-1755
SF	O	1755-1757
score	O	1758-1763
was	O	1764-1767
not	O	1768-1771
affected	O	1772-1780
significantly	O	1781-1794
by	O	1795-1797
the	O	1798-1801
duration	O	1802-1810
of	O	1811-1813
SD	B	1814-1816
,	O	1816-1817
type	O	1818-1822
of	O	1823-1825
SSRI	O	1826-1830
used	O	1831-1835
and	O	1836-1839
age	O	1840-1843
.	O	1843-1844

CONCLUSIONS	O	1845-1856
:	O	1856-1857
Bupropion	O	1858-1867
is	O	1868-1870
an	O	1871-1873
effective	O	1874-1883
treatment	O	1884-1893
for	O	1894-1897
male	O	1898-1902
SD	B	1903-1905
induced	O	1906-1913
by	O	1914-1916
SSRIs	O	1917-1922
.	O	1922-1923

These	O	1924-1929
results	O	1930-1937
provide	O	1938-1945
empirical	O	1946-1955
support	O	1956-1963
for	O	1964-1967
conducting	O	1968-1978
a	O	1979-1980
further	O	1981-1988
study	O	1989-1994
of	O	1995-1997
bupropion	O	1998-2007
.	O	2007-2008

Lamivudine	O	0-10
for	O	11-14
the	O	15-18
prevention	O	19-29
of	O	30-32
hepatitis	B	33-42
B	I	43-44
virus	O	45-50
reactivation	O	51-63
in	O	64-66
hepatitis	O	67-76
-	O	76-77
B	O	77-78
surface	O	79-86
antigen	O	87-94
(	O	95-96
HBSAG	O	96-101
)	O	101-102
seropositive	O	103-115
cancer	B	116-122
patients	O	123-131
undergoing	O	132-142
cytotoxic	O	143-152
chemotherapy	O	153-165
.	O	165-166

Hepatitis	B	167-176
B	I	177-178
virus	O	179-184
(	O	185-186
HBV	O	186-189
)	O	189-190
is	O	191-193
one	O	194-197
of	O	198-200
the	O	201-204
major	O	205-210
causes	O	211-217
of	O	218-220
chronic	O	221-228
liver	B	229-234
disease	I	235-242
worldwide	O	243-252
.	O	252-253

Cancer	B	254-260
patients	O	261-269
who	O	270-273
are	O	274-277
chronic	O	278-285
carriers	O	286-294
of	O	295-297
HBV	O	298-301
have	O	302-306
a	O	307-308
higher	O	309-315
hepatic	B	316-323
complication	I	324-336
rate	O	337-341
while	O	342-347
receiving	O	348-357
cytotoxic	O	358-367
chemotherapy	O	368-380
(	O	381-382
CT	O	382-384
)	O	384-385
and	O	386-389
this	O	390-394
has	O	395-398
mainly	O	399-405
been	O	406-410
attributed	O	411-421
to	O	422-424
HBV	O	425-428
reactivation	O	429-441
.	O	441-442

In	O	443-445
this	O	446-450
study	O	451-456
,	O	456-457
cancer	B	458-464
patients	O	465-473
who	O	474-477
have	O	478-482
solid	O	483-488
and	O	489-492
hematological	B	493-506
malignancies	I	507-519
with	O	520-524
chronic	O	525-532
HBV	B	533-536
infection	I	537-546
received	O	547-555
the	O	556-559
antiviral	O	560-569
agent	O	570-575
lamivudine	O	576-586
prior	O	587-592
and	O	593-596
during	O	597-603
CT	O	604-606
compared	O	607-615
with	O	616-620
historical	O	621-631
control	O	632-639
group	O	640-645
who	O	646-649
did	O	650-653
not	O	654-657
receive	O	658-665
lamivudine	O	666-676
.	O	676-677

The	O	678-681
objectives	O	682-692
were	O	693-697
to	O	698-700
assess	O	701-707
the	O	708-711
efficacy	O	712-720
of	O	721-723
lamivudine	O	724-734
in	O	735-737
reducing	O	738-746
the	O	747-750
incidence	O	751-760
of	O	761-763
HBV	O	764-767
reactivation	O	768-780
,	O	780-781
and	O	782-785
diminishing	O	786-797
morbidity	O	798-807
and	O	808-811
mortality	O	812-821
during	O	822-828
CT	O	829-831
.	O	831-832

Two	O	833-836
groups	O	837-843
were	O	844-848
compared	O	849-857
in	O	858-860
this	O	861-865
study	O	866-871
.	O	871-872

The	O	873-876
prophylactic	O	877-889
lamivudin	O	890-899
group	O	900-905
consisted	O	906-915
of	O	916-918
37	O	919-921
patients	O	922-930
who	O	931-934
received	O	935-943
prophylactic	O	944-956
lamivudine	O	957-967
treatment	O	968-977
.	O	977-978

The	O	979-982
historical	O	983-993
controls	O	994-1002
consisted	O	1003-1012
of	O	1013-1015
50	O	1016-1018
consecutive	O	1019-1030
patients	O	1031-1039
who	O	1040-1043
underwent	O	1044-1053
CT	O	1054-1056
without	O	1057-1064
prophylactic	O	1065-1077
lamivudine	O	1078-1088
.	O	1088-1089

They	O	1090-1094
were	O	1095-1099
followed	O	1100-1108
up	O	1109-1111
during	O	1112-1118
and	O	1119-1122
for	O	1123-1126
8	O	1127-1128
weeks	O	1129-1134
after	O	1135-1140
CT	O	1141-1143
.	O	1143-1144

The	O	1145-1148
outcomes	O	1149-1157
were	O	1158-1162
compared	O	1163-1171
for	O	1172-1175
both	O	1176-1180
groups	O	1181-1187
.	O	1187-1188

Of	O	1189-1191
our	O	1192-1195
control	O	1196-1203
group	O	1204-1209
(	O	1210-1211
n	O	1211-1212
=	O	1212-1213
50	O	1214-1216
)	O	1216-1217
,	O	1217-1218
21	O	1219-1221
patients	O	1222-1230
(	O	1231-1232
42	O	1232-1234
%	O	1234-1235
)	O	1235-1236
were	O	1237-1241
established	O	1242-1253
hepatitis	B	1254-1263
.	O	1263-1264

Twelve	O	1265-1271
(	O	1272-1273
24	O	1273-1275
%	O	1275-1276
)	O	1276-1277
of	O	1278-1280
them	O	1281-1285
were	O	1286-1290
evaluated	O	1291-1300
as	O	1301-1303
severe	O	1304-1310
hepatitis	B	1311-1320
.	O	1320-1321

In	O	1322-1324
the	O	1325-1328
prophylactic	O	1329-1341
lamivudine	O	1342-1352
group	O	1353-1358
severe	O	1359-1365
hepatitis	B	1366-1375
were	O	1376-1380
observed	O	1381-1389
only	O	1390-1394
in	O	1395-1397
1	O	1398-1399
patient	O	1400-1407
(	O	1408-1409
2	O	1409-1410
.	O	1410-1411
7	O	1411-1412
%	O	1412-1413
)	O	1413-1414
of	O	1415-1417
37	O	1418-1420
patients	O	1421-1429
(	O	1430-1431
p	O	1431-1432
<	O	1433-1434
0	O	1435-1436
.	O	1436-1437
006	O	1437-1440
)	O	1440-1441
.	O	1436-1437

Comparison	O	1443-1453
of	O	1454-1456
the	O	1457-1460
mean	O	1461-1465
ALT	O	1466-1469
values	O	1470-1476
revealed	O	1477-1485
significantly	O	1486-1499
higher	O	1500-1506
mean	O	1507-1511
alanine	O	1512-1519
aminotransferase	O	1520-1536
(	O	1537-1538
ALT	O	1538-1541
)	O	1541-1542
values	O	1543-1549
in	O	1550-1552
the	O	1553-1556
control	O	1557-1564
group	O	1565-1570
than	O	1571-1575
the	O	1576-1579
prophylactic	O	1580-1592
lamivudine	O	1593-1603
group	O	1604-1609
;	O	1609-1610
154	O	1611-1614
:	O	1614-1615
64	O	1615-1617
(	O	1618-1619
p	O	1619-1620
<	O	1621-1622
0	O	1623-1624
.	O	1624-1625
32	O	1625-1627
)	O	1627-1628
.	O	1624-1625

Our	O	1630-1633
study	O	1634-1639
suggests	O	1640-1648
that	O	1649-1653
prophylactic	O	1654-1666
lamivudine	O	1667-1677
significantly	O	1678-1691
decreases	O	1692-1701
the	O	1702-1705
incidence	O	1706-1715
of	O	1716-1718
HBV	O	1719-1722
reactivation	O	1723-1735
and	O	1736-1739
overall	O	1740-1747
morbidity	O	1748-1757
in	O	1758-1760
cancer	B	1761-1767
patients	O	1768-1776
during	O	1777-1783
and	O	1784-1787
after	O	1788-1793
immunosuppressive	O	1794-1811
therapy	O	1812-1819
.	O	1819-1820

Further	O	1821-1828
studies	O	1829-1836
are	O	1837-1840
needed	O	1841-1847
to	O	1848-1850
determine	O	1851-1860
the	O	1861-1864
most	O	1865-1869
appropriate	O	1870-1881
nucleoside	O	1882-1892
or	O	1893-1895
nucleotide	O	1896-1906
analogue	O	1907-1915
for	O	1916-1919
antiviral	O	1920-1929
prophylaxis	O	1930-1941
during	O	1942-1948
CT	O	1949-1951
and	O	1952-1955
the	O	1956-1959
optimal	O	1960-1967
duration	O	1968-1976
of	O	1977-1979
administration	O	1980-1994
after	O	1995-2000
completion	O	2001-2011
of	O	2012-2014
CT	O	2015-2017
.	O	2017-2018

Ginsenoside	O	0-11
Rg1	O	12-15
restores	O	16-24
the	O	25-28
impairment	B	29-39
of	I	40-42
learning	I	43-51
induced	O	52-59
by	O	60-62
chronic	O	63-70
morphine	O	71-79
administration	O	80-94
in	O	95-97
rats	O	98-102
.	O	102-103

Rg1	O	104-107
,	O	107-108
as	O	109-111
a	O	112-113
ginsenoside	O	114-125
extracted	O	126-135
from	O	136-140
Panax	O	141-146
ginseng	O	147-154
,	O	154-155
could	O	156-161
ameliorate	O	162-172
spatial	O	173-180
learning	B	181-189
impairment	I	190-200
.	O	200-201

Previous	O	202-210
studies	O	211-218
have	O	219-223
demonstrated	O	224-236
that	O	237-241
Rg1	O	242-245
might	O	246-251
be	O	252-254
a	O	255-256
useful	O	257-263
agent	O	264-269
for	O	270-273
the	O	274-277
prevention	O	278-288
and	O	289-292
treatment	O	293-302
of	O	303-305
the	O	306-309
adverse	O	310-317
effects	O	318-325
of	O	326-328
morphine	O	329-337
.	O	337-338

The	O	339-342
aim	O	343-346
of	O	347-349
this	O	350-354
study	O	355-360
was	O	361-364
to	O	365-367
investigate	O	368-379
the	O	380-383
effect	O	384-390
of	O	391-393
Rg1	O	394-397
on	O	398-400
learning	B	401-409
impairment	I	410-420
by	O	421-423
chronic	O	424-431
morphine	O	432-440
administration	O	441-455
and	O	456-459
the	O	460-463
mechanism	O	464-473
responsible	O	474-485
for	O	486-489
this	O	490-494
effect	O	495-501
.	O	501-502

Male	O	503-507
rats	O	508-512
were	O	513-517
subcutaneously	O	518-532
injected	O	533-541
with	O	542-546
morphine	O	547-555
(	O	556-557
10	O	557-559
mg	O	560-562
/	O	562-563
kg	O	563-565
)	O	565-566
twice	O	567-572
a	O	573-574
day	O	575-578
at	O	579-581
12	O	582-584
hour	O	585-589
intervals	O	590-599
for	O	600-603
10	O	604-606
days	O	607-611
,	O	611-612
and	O	613-616
Rg1	O	617-620
(	O	621-622
30	O	622-624
mg	O	625-627
/	O	627-628
kg	O	628-630
)	O	630-631
was	O	632-635
intraperitoneally	O	636-653
injected	O	654-662
2	O	663-664
hours	O	665-670
after	O	671-676
the	O	677-680
second	O	681-687
injection	O	688-697
of	O	698-700
morphine	O	701-709
once	O	710-714
a	O	715-716
day	O	717-720
for	O	721-724
10	O	725-727
days	O	728-732
.	O	732-733

Spatial	O	734-741
learning	O	742-750
capacity	O	751-759
was	O	760-763
assessed	O	764-772
in	O	773-775
the	O	776-779
Morris	O	780-786
water	O	787-792
maze	O	793-797
.	O	797-798

The	O	799-802
results	O	803-810
showed	O	811-817
that	O	818-822
rats	O	823-827
treated	O	828-835
with	O	836-840
Morphine	O	841-849
/	O	849-850
Rg1	O	850-853
decreased	O	854-863
escape	O	864-870
latency	O	871-878
and	O	879-882
increased	O	883-892
the	O	893-896
time	O	897-901
spent	O	902-907
in	O	908-910
platform	O	911-919
quadrant	O	920-928
and	O	929-932
entering	O	933-941
frequency	O	942-951
.	O	951-952

By	O	953-955
implantation	O	956-968
of	O	969-971
electrodes	O	972-982
and	O	983-986
electrophysiological	O	987-1007
recording	O	1008-1017
in	O	1018-1020
vivo	O	1021-1025
,	O	1025-1026
the	O	1027-1030
results	O	1031-1038
showed	O	1039-1045
that	O	1046-1050
Rg1	O	1051-1054
restored	O	1055-1063
the	O	1064-1067
long	O	1068-1072
-	O	1072-1073
term	O	1073-1077
potentiation	O	1078-1090
(	O	1091-1092
LTP	O	1092-1095
)	O	1095-1096
impaired	O	1097-1105
by	O	1106-1108
morphine	O	1109-1117
in	O	1118-1120
both	O	1121-1125
freely	O	1126-1132
moving	O	1133-1139
and	O	1140-1143
anaesthetised	O	1144-1157
rats	O	1158-1162
.	O	1162-1163

The	O	1164-1167
electrophysiological	O	1168-1188
recording	O	1189-1198
in	O	1199-1201
vitro	O	1202-1207
showed	O	1208-1214
that	O	1215-1219
Rg1	O	1220-1223
restored	O	1224-1232
the	O	1233-1236
LTP	O	1237-1240
in	O	1241-1243
slices	O	1244-1250
from	O	1251-1255
the	O	1256-1259
rats	O	1260-1264
treated	O	1265-1272
with	O	1273-1277
morphine	O	1278-1286
,	O	1286-1287
but	O	1288-1291
not	O	1292-1295
changed	O	1296-1303
LTP	O	1304-1307
in	O	1308-1310
the	O	1311-1314
slices	O	1315-1321
from	O	1322-1326
normal	O	1327-1333
saline	O	1334-1340
-	O	1340-1341
or	O	1342-1344
morphine	O	1345-1353
/	O	1353-1354
Rg1	O	1354-1357
-	O	1357-1358
treated	O	1358-1365
rats	O	1366-1370
;	O	1370-1371
this	O	1372-1376
restoration	O	1377-1388
could	O	1389-1394
be	O	1395-1397
inhibited	O	1398-1407
by	O	1408-1410
N	O	1411-1412
-	O	1412-1413
methyl	O	1413-1419
-	O	1412-1413
D	O	1420-1421
-	O	1412-1413
aspartate	O	1422-1431
(	O	1432-1433
NMDA	O	1433-1437
)	O	1437-1438
receptor	O	1439-1447
antagonist	O	1448-1458
MK801	O	1459-1464
.	O	1464-1465

We	O	1466-1468
conclude	O	1469-1477
that	O	1478-1482
Rg1	O	1483-1486
may	O	1487-1490
significantly	O	1491-1504
improve	O	1505-1512
the	O	1513-1516
spatial	O	1517-1524
learning	O	1525-1533
capacity	O	1534-1542
impaired	O	1543-1551
by	O	1552-1554
chonic	O	1555-1561
morphine	O	1562-1570
administration	O	1571-1585
and	O	1586-1589
restore	O	1590-1597
the	O	1598-1601
morphine	O	1602-1610
-	O	1610-1611
inhibited	O	1611-1620
LTP	O	1621-1624
.	O	1624-1625

This	O	1626-1630
effect	O	1631-1637
is	O	1638-1640
NMDA	O	1641-1645
receptor	O	1646-1654
dependent	O	1655-1664
.	O	1664-1665

A	O	0-1
study	O	2-7
on	O	8-10
the	O	11-14
effect	O	15-21
of	O	22-24
the	O	25-28
duration	O	29-37
of	O	38-40
subcutaneous	O	41-53
heparin	O	54-61
injection	O	62-71
on	O	72-74
bruising	B	75-83
and	O	84-87
pain	B	88-92
.	O	92-93

AIM	O	94-97
:	O	97-98
This	O	99-103
study	O	104-109
was	O	110-113
carried	O	114-121
out	O	122-125
to	O	126-128
determine	O	129-138
the	O	139-142
effect	O	143-149
of	O	150-152
injection	O	153-162
duration	O	163-171
on	O	172-174
bruising	B	175-183
and	O	184-187
pain	B	188-192
following	O	193-202
the	O	203-206
administration	O	207-221
of	O	222-224
the	O	225-228
subcutaneous	O	229-241
injection	O	242-251
of	O	252-254
heparin	O	255-262
.	O	262-263

BACKGROUND	O	264-274
:	O	274-275
Although	O	276-284
different	O	285-294
methods	O	295-302
to	O	303-305
prevent	O	306-313
bruising	B	314-322
and	O	323-326
pain	B	327-331
following	O	332-341
the	O	342-345
subcutaneous	O	346-358
injection	O	359-368
of	O	369-371
heparin	O	372-379
have	O	380-384
been	O	385-389
widely	O	390-396
studied	O	397-404
and	O	405-408
described	O	409-418
,	O	418-419
the	O	420-423
effect	O	424-430
of	O	431-433
injection	O	434-443
duration	O	444-452
on	O	453-455
the	O	456-459
occurrence	O	460-470
of	O	471-473
bruising	B	474-482
and	O	483-486
pain	B	487-491
is	O	492-494
little	O	495-501
documented	O	502-512
.	O	512-513

DESIGN	O	514-520
:	O	520-521
This	O	522-526
study	O	527-532
was	O	533-536
designed	O	537-545
as	O	546-548
within	O	549-555
-	O	555-556
subject	O	556-563
,	O	563-564
quasi	O	565-570
-	O	570-571
experimental	O	571-583
research	O	584-592
.	O	592-593

METHOD	O	594-600
:	O	600-601
The	O	602-605
sample	O	606-612
for	O	613-616
the	O	617-620
study	O	621-626
consisted	O	627-636
of	O	637-639
50	O	640-642
patients	O	643-651
to	O	652-654
whom	O	655-659
subcutaneous	O	660-672
heparin	O	673-680
was	O	681-684
administered	O	685-697
.	O	697-698

Heparin	O	699-706
was	O	707-710
injected	O	711-719
over	O	720-724
10	O	725-727
seconds	O	728-735
on	O	736-738
the	O	739-742
right	O	743-748
abdominal	O	749-758
site	O	759-763
and	O	764-767
30	O	768-770
seconds	O	771-778
on	O	779-781
the	O	782-785
left	O	786-790
abdominal	O	791-800
site	O	801-805
.	O	805-806

Injections	O	807-817
areas	O	818-823
were	O	824-828
assessed	O	829-837
for	O	838-841
the	O	842-845
presence	O	846-854
of	O	855-857
bruising	B	858-866
at	O	867-869
48	O	870-872
and	O	873-876
72	O	877-879
hours	O	880-885
after	O	886-891
each	O	892-896
injection	O	897-906
.	O	906-907

Dimensions	O	908-918
of	O	919-921
the	O	922-925
bruising	B	926-934
on	O	935-937
the	O	938-941
heparin	O	942-949
applied	O	950-957
areas	O	958-963
were	O	964-968
measured	O	969-977
using	O	978-983
transparent	O	984-995
millimetric	O	996-1007
measuring	O	1008-1017
paper	O	1018-1023
.	O	1023-1024

The	O	1025-1028
visual	O	1029-1035
analog	O	1036-1042
scale	O	1043-1048
(	O	1049-1050
VAS	O	1050-1053
)	O	1053-1054
was	O	1055-1058
used	O	1059-1063
to	O	1064-1066
measure	O	1067-1074
pain	B	1075-1079
intensity	O	1080-1089
and	O	1090-1093
a	O	1094-1095
stop	O	1096-1100
-	O	1100-1101
watch	O	1101-1106
was	O	1107-1110
used	O	1111-1115
to	O	1116-1118
time	O	1119-1123
the	O	1124-1127
pain	B	1128-1132
period	O	1133-1139
.	O	1139-1140

Data	O	1141-1145
were	O	1146-1150
analysed	O	1151-1159
using	O	1160-1165
chi	O	1166-1169
-	O	1169-1170
square	O	1170-1176
test	O	1177-1181
,	O	1181-1182
Mann	O	1183-1187
-	O	1187-1188
Whitney	O	1188-1195
U	O	1196-1197
,	O	1197-1198
Wilcoxon	O	1199-1207
signed	O	1208-1214
ranks	O	1215-1220
tests	O	1221-1226
and	O	1227-1230
correlation	O	1231-1242
.	O	1242-1243

RESULTS	O	1244-1251
:	O	1251-1252
The	O	1253-1256
percentage	O	1257-1267
of	O	1268-1270
bruising	B	1271-1279
occurrence	O	1280-1290
was	O	1291-1294
64	O	1295-1297
%	O	1297-1298
with	O	1299-1303
the	O	1304-1307
injection	O	1308-1317
of	O	1318-1320
10	O	1321-1323
seconds	O	1324-1331
duration	O	1332-1340
and	O	1341-1344
42	O	1345-1347
%	O	1347-1348
in	O	1349-1351
the	O	1352-1355
30	O	1356-1358
-	O	1358-1359
second	O	1359-1365
injection	O	1366-1375
.	O	1375-1376

It	O	1377-1379
was	O	1380-1383
determined	O	1384-1394
that	O	1395-1399
the	O	1400-1403
size	O	1404-1408
of	O	1409-1411
the	O	1412-1415
bruising	B	1416-1424
was	O	1425-1428
smaller	O	1429-1436
in	O	1437-1439
the	O	1440-1443
30	O	1444-1446
-	O	1446-1447
second	O	1447-1453
injection	O	1454-1463
.	O	1463-1464

Pain	B	1465-1469
intensity	O	1470-1479
and	O	1480-1483
pain	B	1484-1488
period	O	1489-1495
were	O	1496-1500
statistically	O	1501-1514
significantly	O	1515-1528
lower	O	1529-1534
for	O	1535-1538
the	O	1539-1542
30	O	1543-1545
-	O	1545-1546
second	O	1546-1552
injection	O	1553-1562
than	O	1563-1567
for	O	1568-1571
the	O	1572-1575
10	O	1576-1578
-	O	1578-1579
second	O	1579-1585
injection	O	1586-1595
.	O	1595-1596

CONCLUSIONS	O	1597-1608
:	O	1608-1609
It	O	1610-1612
was	O	1613-1616
determined	O	1617-1627
that	O	1628-1632
injection	O	1633-1642
duration	O	1643-1651
had	O	1652-1655
an	O	1656-1658
effect	O	1659-1665
on	O	1666-1668
bruising	B	1669-1677
and	O	1678-1681
pain	B	1682-1686
following	O	1687-1696
the	O	1697-1700
subcutaneous	O	1701-1713
administration	O	1714-1728
of	O	1729-1731
heparin	O	1732-1739
.	O	1739-1740

This	O	1741-1745
study	O	1746-1751
should	O	1752-1758
be	O	1759-1761
repeated	O	1762-1770
on	O	1771-1773
a	O	1774-1775
larger	O	1776-1782
sample	O	1783-1789
.	O	1789-1790

RELEVANCE	O	1791-1800
TO	O	1801-1803
CLINICAL	O	1804-1812
PRACTICE	O	1813-1821
:	O	1821-1822
When	O	1823-1827
administering	O	1828-1841
subcutaneous	O	1842-1854
heparin	O	1855-1862
injections	O	1863-1873
,	O	1873-1874
it	O	1875-1877
is	O	1878-1880
important	O	1881-1890
to	O	1891-1893
extend	O	1894-1900
the	O	1901-1904
duration	O	1905-1913
of	O	1914-1916
the	O	1917-1920
injection	O	1921-1930
.	O	1930-1931

Acute	O	0-5
reserpine	O	6-15
and	O	16-19
subchronic	O	20-30
haloperidol	O	31-42
treatments	O	43-53
change	O	54-60
synaptosomal	O	61-73
brain	O	74-79
glutamate	O	80-89
uptake	O	90-96
and	O	97-100
elicit	O	101-107
orofacial	B	108-117
dyskinesia	I	118-128
in	O	129-131
rats	O	132-136
.	O	136-137

Reserpine	O	138-147
-	O	147-148
and	O	149-152
haloperidol	O	153-164
-	O	164-165
induced	O	165-172
orofacial	B	173-182
dyskinesia	I	183-193
are	O	194-197
putative	O	198-206
animal	O	207-213
models	O	214-220
of	O	221-223
tardive	B	224-231
dyskinesia	I	232-242
(	O	243-244
TD	B	244-246
)	O	246-247
whose	O	248-253
pathophysiology	O	254-269
has	O	270-273
been	O	274-278
related	O	279-286
to	O	287-289
free	O	290-294
radical	O	295-302
generation	O	303-313
and	O	314-317
oxidative	O	318-327
stress	O	328-334
.	O	334-335

In	O	336-338
the	O	339-342
present	O	343-350
study	O	351-356
,	O	356-357
the	O	358-361
authors	O	362-369
induced	O	370-377
orofacial	B	378-387
dyskinesia	I	388-398
by	O	399-401
acute	O	402-407
reserpine	O	408-417
and	O	418-421
subchronic	O	422-432
haloperidol	O	433-444
administration	O	445-459
to	O	460-462
rats	O	463-467
.	O	467-468

Reserpine	O	469-478
injection	O	479-488
(	O	489-490
one	O	490-493
dose	O	494-498
of	O	499-501
1	O	502-503
mg	O	504-506
/	O	506-507
kg	O	507-509
s	O	510-511
.	O	511-512
c	O	512-513
.	O	511-512
)	O	514-515
every	O	516-521
other	O	522-527
day	O	528-531
for	O	532-535
3	O	536-537
days	O	538-542
caused	O	543-549
a	O	550-551
significant	O	552-563
increase	O	564-572
in	O	573-575
vacuous	O	576-583
chewing	O	584-591
,	O	591-592
tongue	O	593-599
protrusion	O	600-610
and	O	611-614
duration	O	615-623
of	O	624-626
facial	O	627-633
twitching	O	634-643
,	O	643-644
compared	O	645-653
to	O	654-656
the	O	657-660
control	O	661-668
.	O	668-669

Haloperidol	O	670-681
administration	O	682-696
(	O	697-698
one	O	698-701
dose	O	702-706
of	O	707-709
12	O	710-712
mg	O	713-715
/	O	715-716
kg	O	716-718
once	O	719-723
a	O	724-725
week	O	726-730
s	O	731-732
.	O	732-733
c	O	733-734
.	O	732-733
)	O	735-736
for	O	737-740
4	O	741-742
weeks	O	743-748
caused	O	749-755
an	O	756-758
increase	O	759-767
in	O	768-770
vacuous	O	771-778
chewing	O	779-786
,	O	786-787
tongue	O	788-794
protrusion	O	795-805
and	O	806-809
duration	O	810-818
of	O	819-821
facial	O	822-828
twitching	O	829-838
observed	O	839-847
in	O	848-850
four	O	851-855
weekly	O	856-862
evaluations	O	863-874
.	O	874-875

After	O	876-881
the	O	882-885
treatments	O	886-896
and	O	897-900
behavioral	O	901-911
observation	O	912-923
,	O	923-924
glutamate	O	925-934
uptake	O	935-941
by	O	942-944
segments	O	945-953
of	O	954-956
the	O	957-960
brain	O	961-966
was	O	967-970
analyzed	O	971-979
.	O	979-980

A	O	981-982
decreased	O	983-992
glutamate	O	993-1002
uptake	O	1003-1009
was	O	1010-1013
observed	O	1014-1022
in	O	1023-1025
the	O	1026-1029
subcortical	O	1030-1041
parts	O	1042-1047
of	O	1048-1050
animals	O	1051-1058
treated	O	1059-1066
with	O	1067-1071
reserpine	O	1072-1081
and	O	1082-1085
haloperidol	O	1086-1097
,	O	1097-1098
compared	O	1099-1107
to	O	1108-1110
the	O	1111-1114
control	O	1115-1122
.	O	1122-1123

Importantly	O	1124-1135
,	O	1135-1136
a	O	1137-1138
decrease	O	1139-1147
in	O	1148-1150
glutamate	O	1151-1160
uptake	O	1161-1167
correlates	O	1168-1178
negatively	O	1179-1189
with	O	1190-1194
an	O	1195-1197
increase	O	1198-1206
in	O	1207-1209
the	O	1210-1213
incidence	O	1214-1223
of	O	1224-1226
orofacial	B	1227-1236
diskinesia	I	1237-1247
.	O	1247-1248

These	O	1249-1254
results	O	1255-1262
indicate	O	1263-1271
that	O	1272-1276
early	O	1277-1282
changes	O	1283-1290
in	O	1291-1293
glutamate	O	1294-1303
transport	O	1304-1313
may	O	1314-1317
be	O	1318-1320
related	O	1321-1328
to	O	1329-1331
the	O	1332-1335
development	O	1336-1347
of	O	1348-1350
vacuous	O	1351-1358
chewing	O	1359-1366
movements	O	1367-1376
in	O	1377-1379
rats	O	1380-1384
.	O	1384-1385

Acute	B	0-5
psychosis	I	6-15
due	O	16-19
to	O	20-22
treatment	O	23-32
with	O	33-37
phenytoin	O	38-47
in	O	48-50
a	O	51-52
nonepileptic	O	53-65
patient	O	66-73
.	O	73-74

The	O	75-78
development	O	79-90
of	O	91-93
psychosis	B	94-103
related	O	104-111
to	O	112-114
antiepileptic	O	115-128
drug	O	129-133
treatment	O	134-143
is	O	144-146
usually	O	147-154
attributed	O	155-165
to	O	166-168
the	O	169-172
interaction	O	173-184
between	O	185-192
the	O	193-196
epileptic	B	197-206
brain	O	207-212
substratum	O	213-223
and	O	224-227
the	O	228-231
antiepileptic	O	232-245
drugs	O	246-251
.	O	251-252

The	O	253-256
case	O	257-261
of	O	262-264
a	O	265-266
nonepileptic	O	267-279
patient	O	280-287
who	O	288-291
developed	O	292-301
psychosis	B	302-311
following	O	312-321
phenytoin	O	322-331
treatment	O	332-341
for	O	342-345
trigeminal	B	346-356
neuralgia	I	357-366
is	O	367-369
described	O	370-379
.	O	379-380

This	O	381-385
case	O	386-390
suggests	O	391-399
that	O	400-404
the	O	405-408
psychotic	B	409-418
symptoms	I	419-427
that	O	428-432
occur	O	433-438
following	O	439-448
phenytoin	O	449-458
treatment	O	459-468
in	O	469-471
some	O	472-476
epileptic	B	477-486
patients	O	487-495
may	O	496-499
be	O	500-502
the	O	503-506
direct	O	507-513
result	O	514-520
of	O	521-523
medication	O	524-534
,	O	534-535
unrelated	O	536-545
to	O	546-548
seizures	B	549-557
.	O	557-558

The	O	0-3
effect	O	4-10
of	O	11-13
treatment	O	14-23
with	O	24-28
gum	O	29-32
Arabic	O	33-39
on	O	40-42
gentamicin	O	43-53
nephrotoxicity	B	54-68
in	O	69-71
rats	O	72-76
:	O	76-77
a	O	78-79
preliminary	O	80-91
study	O	92-97
.	O	97-98

In	O	99-101
the	O	102-105
present	O	106-113
work	O	114-118
we	O	119-121
assessed	O	122-130
the	O	131-134
effect	O	135-141
of	O	142-144
treatment	O	145-154
of	O	155-157
rats	O	158-162
with	O	163-167
gum	O	168-171
Arabic	O	172-178
on	O	179-181
acute	B	182-187
renal	I	188-193
failure	I	194-201
induced	O	202-209
by	O	210-212
gentamicin	O	213-223
(	O	224-225
GM	O	225-227
)	O	227-228
nephrotoxicity	B	229-243
.	O	243-244

Rats	O	245-249
were	O	250-254
treated	O	255-262
with	O	263-267
the	O	268-271
vehicle	O	272-279
(	O	280-281
2	O	281-282
mL	O	283-285
/	O	285-286
kg	O	286-288
of	O	289-291
distilled	O	292-301
water	O	302-307
and	O	308-311
5	O	312-313
%	O	313-314
w	O	315-316
/	O	316-317
v	O	317-318
cellulose	O	319-328
,	O	328-329
10	O	330-332
days	O	333-337
)	O	337-338
,	O	338-339
gum	O	340-343
Arabic	O	344-350
(	O	351-352
2	O	352-353
mL	O	354-356
/	O	356-357
kg	O	357-359
of	O	360-362
a	O	363-364
10	O	365-367
%	O	367-368
w	O	369-370
/	O	370-371
v	O	371-372
aqueous	O	373-380
suspension	O	381-391
of	O	392-394
gum	O	395-398
Arabic	O	399-405
powder	O	406-412
,	O	412-413
orally	O	414-420
for	O	421-424
10	O	425-427
days	O	428-432
)	O	432-433
,	O	433-434
or	O	435-437
gum	O	438-441
Arabic	O	442-448
concomitantly	O	449-462
with	O	463-467
GM	O	468-470
(	O	471-472
80mg	O	472-476
/	O	476-477
kg	O	477-479
/	O	476-477
day	O	480-483
intramuscularly	O	484-499
,	O	499-500
during	O	501-507
the	O	508-511
last	O	512-516
six	O	517-520
days	O	521-525
of	O	526-528
the	O	529-532
treatment	O	533-542
period	O	543-549
)	O	549-550
.	O	550-551

Nephrotoxicity	B	552-566
was	O	567-570
assessed	O	571-579
by	O	580-582
measuring	O	583-592
the	O	593-596
concentrations	O	597-611
of	O	612-614
creatinine	O	615-625
and	O	626-629
urea	O	630-634
in	O	635-637
the	O	638-641
plasma	O	642-648
and	O	649-652
reduced	O	653-660
glutathione	O	661-672
(	O	673-674
GSH	O	674-677
)	O	677-678
in	O	679-681
the	O	682-685
kidney	O	686-692
cortex	O	693-699
,	O	699-700
and	O	701-704
by	O	705-707
light	O	708-713
microscopic	O	714-725
examination	O	726-737
of	O	738-740
kidney	O	741-747
sections	O	748-756
.	O	756-757

The	O	758-761
results	O	762-769
indicated	O	770-779
that	O	780-784
concomitant	O	785-796
treatment	O	797-806
with	O	807-811
gum	O	812-815
Arabic	O	816-822
and	O	823-826
GM	O	827-829
significantly	O	830-843
increased	O	844-853
creatinine	O	854-864
and	O	865-868
urea	O	869-873
by	O	874-876
about	O	877-882
183	O	883-886
and	O	887-890
239	O	891-894
%	O	894-895
,	O	895-896
respectively	O	897-909
(	O	910-911
compared	O	911-919
to	O	920-922
432	O	923-926
and	O	927-930
346	O	931-934
%	O	934-935
,	O	935-936
respectively	O	937-949
,	O	949-950
in	O	951-953
rats	O	954-958
treated	O	959-966
with	O	967-971
cellulose	O	972-981
and	O	982-985
GM	O	986-988
)	O	988-989
,	O	989-990
and	O	991-994
decreased	O	995-1004
that	O	1005-1009
of	O	1010-1012
cortical	O	1013-1021
GSH	O	1022-1025
by	O	1026-1028
21	O	1029-1031
%	O	1031-1032
(	O	1033-1034
compared	O	1034-1042
to	O	1043-1045
27	O	1046-1048
%	O	1048-1049
in	O	1050-1052
the	O	1053-1056
cellulose	O	1057-1066
plus	O	1067-1071
GM	O	1072-1074
group	O	1075-1080
)	O	1080-1081
The	O	1082-1085
GM	O	1086-1088
-	O	1088-1089
induced	O	1089-1096
proximal	O	1097-1105
tubular	B	1106-1113
necrosis	I	1114-1122
appeared	O	1123-1131
to	O	1132-1134
be	O	1135-1137
slightly	O	1138-1146
less	O	1147-1151
severe	O	1152-1158
in	O	1159-1161
rats	O	1162-1166
given	O	1167-1172
GM	O	1173-1175
together	O	1176-1184
with	O	1185-1189
gum	O	1190-1193
Arabic	O	1194-1200
than	O	1201-1205
in	O	1206-1208
those	O	1209-1214
given	O	1215-1220
GM	O	1221-1223
and	O	1224-1227
cellulose	O	1228-1237
.	O	1237-1238

It	O	1239-1241
could	O	1242-1247
be	O	1248-1250
inferred	O	1251-1259
that	O	1260-1264
gum	O	1265-1268
Arabic	O	1269-1275
treatment	O	1276-1285
has	O	1286-1289
induced	O	1290-1297
a	O	1298-1299
modest	O	1300-1306
amelioration	O	1307-1319
of	O	1320-1322
some	O	1323-1327
of	O	1328-1330
the	O	1331-1334
histological	O	1335-1347
and	O	1348-1351
biochemical	O	1352-1363
indices	O	1364-1371
of	O	1372-1374
GM	O	1375-1377
nephrotoxicity	B	1378-1392
.	O	1392-1393

Further	O	1394-1401
work	O	1402-1406
is	O	1407-1409
warranted	O	1410-1419
on	O	1420-1422
the	O	1423-1426
effect	O	1427-1433
of	O	1434-1436
the	O	1437-1440
treatments	O	1441-1451
on	O	1452-1454
renal	O	1455-1460
functional	O	1461-1471
aspects	O	1472-1479
in	O	1480-1482
models	O	1483-1489
of	O	1490-1492
chronic	B	1493-1500
renal	I	1501-1506
failure	I	1507-1514
,	O	1514-1515
and	O	1516-1519
on	O	1520-1522
the	O	1523-1526
mechanism	O	1527-1536
(	O	1536-1537
s	O	1534-1535
)	O	1538-1539
involved	O	1540-1548
.	O	1548-1549

Visual	B	0-6
hallucinations	I	7-21
associated	O	22-32
with	O	33-37
zonisamide	O	38-48
.	O	48-49

Zonisamide	O	50-60
is	O	61-63
a	O	64-65
broad	O	66-71
-	O	71-72
spectrum	O	72-80
antiepileptic	O	81-94
drug	O	95-99
used	O	100-104
to	O	105-107
treat	O	108-113
various	O	114-121
types	O	122-127
of	O	128-130
seizures	B	131-139
.	O	139-140

Although	O	141-149
visual	B	150-156
hallucinations	I	157-171
have	O	172-176
not	O	177-180
been	O	181-185
reported	O	186-194
as	O	195-197
an	O	198-200
adverse	O	201-208
effect	O	209-215
of	O	216-218
this	O	219-223
agent	O	224-229
,	O	229-230
we	O	231-233
describe	O	234-242
three	O	243-248
patients	O	249-257
who	O	258-261
experienced	O	262-273
complex	O	274-281
visual	B	282-288
hallucinations	I	289-303
and	O	304-307
altered	O	308-315
mental	O	316-322
status	O	323-329
after	O	330-335
zonisamide	O	336-346
treatment	O	347-356
was	O	357-360
begun	O	361-366
or	O	367-369
its	O	370-373
dosage	O	374-380
increased	O	381-390
.	O	390-391

All	O	392-395
three	O	396-401
had	O	402-405
been	O	406-410
diagnosed	O	411-420
earlier	O	421-428
with	O	429-433
epilepsy	B	434-442
,	O	442-443
and	O	444-447
their	O	448-453
electroencephalogram	O	454-474
(	O	475-476
EEG	O	476-479
)	O	479-480
findings	O	481-489
were	O	490-494
abnormal	O	495-503
.	O	503-504

During	O	505-511
monitoring	O	512-522
,	O	522-523
visual	B	524-530
hallucinations	I	531-545
did	O	546-549
not	O	550-553
correlate	O	554-563
with	O	564-568
EEG	O	569-572
readings	O	573-581
,	O	581-582
nor	O	583-586
did	O	587-590
video	O	591-596
recording	O	597-606
capture	O	607-614
any	O	615-618
of	O	619-621
the	O	622-625
described	O	626-635
events	O	636-642
.	O	642-643

None	O	644-648
of	O	649-651
the	O	652-655
patients	O	656-664
had	O	665-668
experienced	O	669-680
visual	B	681-687
hallucinations	I	688-702
before	O	703-709
this	O	710-714
event	O	715-720
.	O	720-721

The	O	722-725
only	O	726-730
recent	O	731-737
change	O	738-744
in	O	745-747
their	O	748-753
treatment	O	754-763
was	O	764-767
the	O	768-771
introduction	O	772-784
or	O	785-787
increased	O	788-797
dosage	O	798-804
of	O	805-807
zonisamide	O	808-818
.	O	818-819

With	O	820-824
either	O	825-831
discontinuation	O	832-847
or	O	848-850
decreased	O	851-860
dosage	O	861-867
of	O	868-870
the	O	871-874
drug	O	875-879
the	O	880-883
symptoms	O	884-892
disappeared	O	893-904
and	O	905-908
did	O	909-912
not	O	913-916
recur	O	917-922
.	O	922-923

Further	O	924-931
observations	O	932-944
and	O	945-948
reports	O	949-956
will	O	957-961
help	O	962-966
clarify	O	967-974
this	O	975-979
adverse	O	980-987
effect	O	988-994
.	O	994-995

Until	O	996-1001
then	O	1002-1006
,	O	1006-1007
clinicians	O	1008-1018
need	O	1019-1023
to	O	1024-1026
be	O	1027-1029
aware	O	1030-1035
of	O	1036-1038
this	O	1039-1043
possible	O	1044-1052
complication	O	1053-1065
associated	O	1066-1076
with	O	1077-1081
zonisamide	O	1082-1092
.	O	1092-1093

GLEPP1	O	0-6
receptor	O	7-15
tyrosine	O	16-24
phosphatase	O	25-36
(	O	37-38
Ptpro	O	38-43
)	O	43-44
in	O	45-47
rat	O	48-51
PAN	O	52-55
nephrosis	B	56-65
.	O	65-66

A	O	67-68
marker	O	69-75
of	O	76-78
acute	O	79-84
podocyte	O	85-93
injury	O	94-100
.	O	100-101

Glomerular	O	102-112
epithelial	O	113-123
protein	O	124-131
1	O	132-133
(	O	134-135
GLEPP1	O	135-141
)	O	141-142
is	O	143-145
a	O	146-147
podocyte	O	148-156
receptor	O	157-165
membrane	O	166-174
protein	O	175-182
tyrosine	O	183-191
phosphatase	O	192-203
located	O	204-211
on	O	212-214
the	O	215-218
apical	O	219-225
cell	O	226-230
membrane	O	231-239
of	O	240-242
visceral	O	243-251
glomerular	O	252-262
epithelial	O	263-273
cell	O	274-278
and	O	279-282
foot	O	283-287
processes	O	288-297
.	O	297-298

This	O	299-303
receptor	O	304-312
plays	O	313-318
a	O	319-320
role	O	321-325
in	O	326-328
regulating	O	329-339
the	O	340-343
structure	O	344-353
and	O	354-357
function	O	358-366
of	O	367-369
podocyte	O	370-378
foot	O	379-383
process	O	384-391
.	O	391-392

To	O	393-395
better	O	396-402
understand	O	403-413
the	O	414-417
utility	O	418-425
of	O	426-428
GLEPP1	O	429-435
as	O	436-438
a	O	439-440
marker	O	441-447
of	O	448-450
glomerular	B	451-461
injury	I	462-468
,	O	468-469
the	O	470-473
amount	O	474-480
and	O	481-484
distribution	O	485-497
of	O	498-500
GLEPP1	O	501-507
protein	O	508-515
and	O	516-519
mRNA	O	520-524
were	O	525-529
examined	O	530-538
by	O	539-541
immunohistochemistry	O	542-562
,	O	562-563
Western	O	564-571
blot	O	572-576
and	O	577-580
RNase	O	581-586
protection	O	587-597
assay	O	598-603
in	O	604-606
a	O	607-608
model	O	609-614
of	O	615-617
podocyte	O	618-626
injury	O	627-633
in	O	634-636
the	O	637-640
rat	O	641-644
.	O	644-645

Puromycin	O	646-655
aminonucleoside	O	656-671
nephrosis	B	672-681
was	O	682-685
induced	O	686-693
by	O	694-696
single	O	697-703
intraperitoneal	O	704-719
injection	O	720-729
of	O	730-732
puromycin	O	733-742
aminonucleoside	O	743-758
(	O	759-760
PAN	O	760-763
,	O	763-764
20	O	765-767
mg	O	768-770
/	O	770-771
100g	O	771-775
BW	O	776-778
)	O	778-779
.	O	779-780

Tissues	O	781-788
were	O	789-793
analyzed	O	794-802
at	O	803-805
0	O	806-807
,	O	807-808
5	O	809-810
,	O	810-811
7	O	812-813
,	O	813-814
11	O	815-817
,	O	817-818
21	O	819-821
,	O	821-822
45	O	823-825
,	O	825-826
80	O	827-829
and	O	830-833
126	O	834-837
days	O	838-842
after	O	843-848
PAN	O	849-852
injection	O	853-862
so	O	863-865
as	O	866-868
to	O	869-871
include	O	872-879
both	O	880-884
the	O	885-888
acute	O	889-894
phase	O	895-900
of	O	901-903
proteinuria	B	904-915
associated	O	916-926
with	O	927-931
foot	O	932-936
process	O	937-944
effacement	O	945-955
(	O	956-957
days	O	957-961
5	O	962-963
-	O	963-964
11	O	964-966
)	O	966-967
and	O	968-971
the	O	972-975
chronic	O	976-983
phase	O	984-989
of	O	990-992
proteinuria	B	993-1004
associated	O	1005-1015
with	O	1016-1020
glomerulosclerosis	B	1021-1039
(	O	1040-1041
days	O	1041-1045
45	O	1046-1048
-	O	1048-1049
126	O	1049-1052
)	O	1052-1053
.	O	1053-1054

At	O	1055-1057
day	O	1058-1061
5	O	1062-1063
,	O	1063-1064
GLEPP1	O	1065-1071
protein	O	1072-1079
and	O	1080-1083
mRNA	O	1084-1088
were	O	1089-1093
reduced	O	1094-1101
from	O	1102-1106
the	O	1107-1110
normal	O	1111-1117
range	O	1118-1123
(	O	1124-1125
265	O	1125-1128
.	O	1128-1129
2	O	1125-1126
+	O	1131-1132
/	O	1132-1133
-	O	1133-1134
79	O	1135-1137
.	O	1137-1138
6	O	1138-1139
x	O	1140-1141
10	O	1142-1144
(	O	1144-1145
6	O	1145-1146
)	O	1146-1147
moles	O	1148-1153
/	O	1153-1154
glomerulus	O	1154-1164
and	O	1165-1168
100	O	1169-1172
%	O	1172-1173
)	O	1173-1174
to	O	1175-1177
15	O	1178-1180
%	O	1180-1181
of	O	1182-1184
normal	O	1185-1191
(	O	1192-1193
41	O	1193-1195
.	O	1195-1196
8	O	1196-1197
+	O	1198-1199
/	O	1199-1200
-	O	1200-1201
4	O	1202-1203
.	O	1203-1204
8	O	1204-1205
x	O	1206-1207
10	O	1208-1210
(	O	1210-1211
6	O	1211-1212
)	O	1212-1213
moles	O	1214-1219
/	O	1219-1220
glomerulus	O	1220-1230
,	O	1230-1231
p	O	1232-1233
<	O	1234-1235
0	O	1236-1237
.	O	1237-1238
005	O	1238-1241
)	O	1241-1242
.	O	1237-1238

This	O	1244-1248
occurred	O	1249-1257
in	O	1258-1260
association	O	1261-1272
with	O	1273-1277
an	O	1278-1280
increase	O	1281-1289
in	O	1290-1292
urinary	O	1293-1300
protein	O	1301-1308
content	O	1309-1316
from	O	1317-1321
1	O	1322-1323
.	O	1323-1324
8	O	1324-1325
+	O	1326-1327
/	O	1327-1328
-	O	1328-1329
1	O	1330-1331
to	O	1332-1334
99	O	1335-1337
.	O	1337-1338
0	O	1338-1339
+	O	1340-1341
/	O	1341-1342
-	O	1342-1343
61	O	1344-1346
mg	O	1347-1349
/	O	1349-1350
day	O	1350-1353
(	O	1354-1355
p	O	1355-1356
<	O	1357-1358
0	O	1359-1360
.	O	1360-1361
001	O	1361-1364
)	O	1364-1365
.	O	1360-1361

In	O	1367-1369
contrast	O	1370-1378
,	O	1378-1379
podocalyxin	O	1380-1391
did	O	1392-1395
not	O	1396-1399
change	O	1400-1406
significantly	O	1407-1420
at	O	1421-1423
this	O	1424-1428
time	O	1429-1433
.	O	1433-1434

By	O	1435-1437
day	O	1438-1441
11	O	1442-1444
,	O	1444-1445
GLEPP1	O	1446-1452
protein	O	1453-1460
and	O	1461-1464
mRNA	O	1465-1469
had	O	1470-1473
begun	O	1474-1479
to	O	1480-1482
return	O	1483-1489
towards	O	1490-1497
baseline	O	1498-1506
.	O	1506-1507

By	O	1508-1510
day	O	1511-1514
45	O	1515-1517
-	O	1517-1518
126	O	1518-1521
,	O	1521-1522
at	O	1523-1525
a	O	1526-1527
time	O	1528-1532
when	O	1533-1537
glomerular	O	1538-1548
scarring	O	1549-1557
was	O	1558-1561
present	O	1562-1569
,	O	1569-1570
GLEPP1	O	1571-1577
was	O	1578-1581
absent	O	1582-1588
from	O	1589-1593
glomerulosclerotic	O	1594-1612
areas	O	1613-1618
although	O	1619-1627
the	O	1628-1631
total	O	1632-1637
glomerular	O	1638-1648
content	O	1649-1656
of	O	1657-1659
GLEPP1	O	1660-1666
was	O	1667-1670
not	O	1671-1674
different	O	1675-1684
from	O	1685-1689
normal	O	1690-1696
.	O	1696-1697

We	O	1698-1700
conclude	O	1701-1709
that	O	1710-1714
GLEPP1	O	1715-1721
expression	O	1722-1732
,	O	1732-1733
unlike	O	1734-1740
podocalyxin	O	1741-1752
,	O	1752-1753
reflects	O	1754-1762
podocyte	O	1763-1771
injury	O	1772-1778
induced	O	1779-1786
by	O	1787-1789
PAN	O	1790-1793
.	O	1793-1794

GLEPP1	O	1795-1801
expression	O	1802-1812
may	O	1813-1816
be	O	1817-1819
a	O	1820-1821
useful	O	1822-1828
marker	O	1829-1835
of	O	1836-1838
podocyte	O	1839-1847
injury	O	1848-1854
.	O	1854-1855

Ticlopidine	O	0-11
-	O	11-12
induced	O	12-19
aplastic	B	20-28
anemia	I	29-35
:	O	35-36
report	O	37-43
of	O	44-46
three	O	47-52
Chinese	O	53-60
patients	O	61-69
and	O	70-73
review	O	74-80
of	O	81-83
the	O	84-87
literature	O	88-98
.	O	98-99

In	O	100-102
this	O	103-107
study	O	108-113
,	O	113-114
three	O	115-120
Chinese	O	121-128
patients	O	129-137
with	O	138-142
ticlopidine	O	143-154
-	O	154-155
induced	O	155-162
aplastic	B	163-171
anemia	I	172-178
were	O	179-183
reported	O	184-192
and	O	193-196
another	O	197-204
13	O	205-207
patients	O	208-216
in	O	217-219
the	O	220-223
English	O	224-231
literature	O	232-242
were	O	243-247
reviewed	O	248-256
.	O	256-257

We	O	258-260
attempted	O	261-270
to	O	271-273
find	O	274-278
underlying	O	279-289
similarities	O	290-302
,	O	302-303
evaluate	O	304-312
the	O	313-316
risk	O	317-321
factors	O	322-329
,	O	329-330
and	O	331-334
identify	O	335-343
appropriate	O	344-355
treatment	O	356-365
for	O	366-369
this	O	370-374
complication	O	375-387
.	O	387-388

All	O	389-392
but	O	393-396
one	O	397-400
of	O	401-403
the	O	404-407
patients	O	408-416
were	O	417-421
over	O	422-426
60	O	427-429
years	O	430-435
old	O	436-439
,	O	439-440
and	O	441-444
the	O	445-448
6	O	449-450
who	O	451-454
died	O	455-459
were	O	460-464
all	O	465-468
older	O	469-474
than	O	475-479
65	O	480-482
.	O	482-483

Therefore	O	484-493
,	O	493-494
old	O	495-498
age	O	499-502
may	O	503-506
be	O	507-509
a	O	510-511
risk	O	512-516
factor	O	517-523
for	O	524-527
developing	O	528-538
this	O	539-543
complication	O	544-556
.	O	556-557

Agranulocytosis	B	558-573
occurred	O	574-582
3	O	583-584
-	O	584-585
20	O	585-587
weeks	O	588-593
after	O	594-599
initiation	O	600-610
of	O	611-613
ticlopidine	O	614-625
,	O	625-626
so	O	627-629
frequent	O	630-638
examination	O	639-650
of	O	651-653
white	O	654-659
cell	O	660-664
count	O	665-670
during	O	671-677
treatment	O	678-687
is	O	688-690
recommended	O	691-702
.	O	702-703

There	O	704-709
seemed	O	710-716
to	O	717-719
be	O	720-722
no	O	723-725
direct	O	726-732
correlation	O	733-744
between	O	745-752
the	O	753-756
dose	O	757-761
or	O	762-764
duration	O	765-773
used	O	774-778
and	O	779-782
the	O	783-786
severity	O	787-795
of	O	796-798
bone	B	799-803
marrow	I	804-810
suppression	I	811-822
.	O	822-823

Treatment	O	824-833
for	O	834-837
ticlopidine	O	838-849
-	O	849-850
induced	O	850-857
aplastic	B	858-866
anemia	I	867-873
with	O	874-878
colony	O	879-885
-	O	885-886
stimulating	O	886-897
factors	O	898-905
seemed	O	906-912
to	O	913-915
have	O	916-920
little	O	921-927
effect	O	928-934
.	O	934-935

The	O	936-939
fact	O	940-944
that	O	945-949
5	O	950-951
of	O	952-954
the	O	955-958
6	O	959-960
patients	O	961-969
who	O	970-973
received	O	974-982
concurrent	O	983-993
calcium	O	994-1001
channel	O	1002-1009
blockers	O	1010-1018
died	O	1019-1023
,	O	1023-1024
should	O	1025-1031
alert	O	1032-1037
clinicians	O	1038-1048
to	O	1049-1051
be	O	1052-1054
more	O	1055-1059
cautious	O	1060-1068
when	O	1069-1073
using	O	1074-1079
these	O	1080-1085
two	O	1086-1089
drugs	O	1090-1095
simultaneously	O	1096-1110
.	O	1110-1111

Facilitation	O	0-12
of	O	13-15
memory	O	16-22
retrieval	O	23-32
by	O	33-35
pre	O	36-39
-	O	39-40
test	O	40-44
morphine	O	45-53
and	O	54-57
its	O	58-61
state	O	62-67
dependency	O	68-78
in	O	79-81
the	O	82-85
step	O	86-90
-	O	90-91
through	O	91-98
type	O	99-103
passive	O	104-111
avoidance	O	112-121
learning	O	122-130
test	O	131-135
in	O	136-138
mice	O	139-143
.	O	143-144

Amnesia	B	145-152
produced	O	153-161
by	O	162-164
scopolamine	O	165-176
and	O	177-180
cycloheximide	O	181-194
were	O	195-199
reversed	O	200-208
by	O	209-211
morphine	O	212-220
given	O	221-226
30	O	227-229
min	O	230-233
before	O	234-240
the	O	241-244
test	O	245-249
trial	O	250-255
(	O	256-257
pre	O	257-260
-	O	260-261
test	O	261-265
)	O	265-266
,	O	266-267
and	O	268-271
pre	O	272-275
-	O	275-276
test	O	276-280
morphine	O	281-289
also	O	290-294
facilitated	O	295-306
the	O	307-310
memory	O	311-317
retrieval	O	318-327
in	O	328-330
the	O	331-334
animals	O	335-342
administered	O	343-355
naloxone	O	356-364
during	O	365-371
the	O	372-375
training	O	376-384
trial	O	385-390
.	O	390-391

Similarly	O	392-401
,	O	401-402
pre	O	403-406
-	O	406-407
test	O	407-411
scopolamine	O	412-423
partially	O	424-433
reversed	O	434-442
the	O	443-446
scopolamine	O	447-458
-	O	458-459
induced	O	459-466
amnesia	B	467-474
,	O	474-475
but	O	476-479
not	O	480-483
significantly	O	484-497
;	O	497-498
and	O	499-502
pre	O	503-506
-	O	506-507
test	O	507-511
cycloheximide	O	512-525
failed	O	526-532
to	O	533-535
reverse	O	536-543
the	O	544-547
cycloheximide	O	548-561
-	O	561-562
induced	O	562-569
amnesia	B	570-577
.	O	577-578

These	O	579-584
results	O	585-592
suggest	O	593-600
that	O	601-605
the	O	606-609
facilitation	O	610-622
of	O	623-625
memory	O	626-632
retrieval	O	633-642
by	O	643-645
pre	O	646-649
-	O	649-650
test	O	650-654
morphine	O	655-663
might	O	664-669
be	O	670-672
the	O	673-676
direct	O	677-683
action	O	684-690
of	O	691-693
morphine	O	694-702
rather	O	703-709
than	O	710-714
a	O	715-716
state	O	717-722
dependent	O	723-732
effect	O	733-739
.	O	739-740

Test	O	0-4
conditions	O	5-15
influence	O	16-25
the	O	26-29
response	O	30-38
to	O	39-41
a	O	42-43
drug	O	44-48
challenge	O	49-58
in	O	59-61
rodents	O	62-69
.	O	69-70

These	O	71-76
studies	O	77-84
were	O	85-89
conducted	O	90-99
to	O	100-102
examine	O	103-110
the	O	111-114
differential	O	115-127
response	O	128-136
to	O	137-139
a	O	140-141
drug	O	142-146
challenge	O	147-156
under	O	157-162
varied	O	163-169
experimental	O	170-182
test	O	183-187
conditions	O	188-198
routinely	O	199-208
employed	O	209-217
to	O	218-220
study	O	221-226
drug	O	227-231
-	O	231-232
induced	O	232-239
behavioral	O	240-250
and	O	251-254
neurophysiological	O	255-273
responses	O	274-283
in	O	284-286
rodents	O	287-294
.	O	294-295

Apomorphine	O	296-307
,	O	307-308
a	O	309-310
nonselective	O	311-323
dopamine	O	324-332
agonist	O	333-340
,	O	340-341
was	O	342-345
selected	O	346-354
due	O	355-358
to	O	359-361
its	O	362-365
biphasic	O	366-374
behavioral	O	375-385
effects	O	386-393
,	O	393-394
its	O	395-398
ability	O	399-406
to	O	407-409
induce	O	410-416
hypothermia	B	417-428
,	O	428-429
and	O	430-433
to	O	434-436
produce	O	437-444
distinct	O	445-453
changes	O	454-461
to	O	462-464
dopamine	O	465-473
turnover	O	474-482
in	O	483-485
the	O	486-489
rodent	O	490-496
brain	O	497-502
.	O	502-503

From	O	504-508
such	O	509-513
experiments	O	514-525
there	O	526-531
is	O	532-534
evidence	O	535-543
that	O	544-548
characterization	O	549-565
and	O	566-569
detection	O	570-579
of	O	580-582
apomorphine	O	583-594
-	O	594-595
induced	O	595-602
activity	O	603-611
in	O	612-614
rodents	O	615-622
critically	O	623-633
depends	O	634-641
upon	O	642-646
the	O	647-650
test	O	651-655
conditions	O	656-666
employed	O	667-675
.	O	675-676

In	O	677-679
rats	O	680-684
,	O	684-685
detection	O	686-695
of	O	696-698
apomorphine	O	699-710
-	O	710-711
induced	O	711-718
hyperactivity	B	719-732
was	O	733-736
facilitated	O	737-748
by	O	749-751
a	O	752-753
period	O	754-760
of	O	761-763
acclimatization	O	764-779
to	O	780-782
the	O	783-786
test	O	787-791
conditions	O	792-802
.	O	802-803

Moreover	O	804-812
,	O	812-813
test	O	814-818
conditions	O	819-829
can	O	830-833
impact	O	834-840
upon	O	841-845
other	O	846-851
physiological	O	852-865
responses	O	866-875
to	O	876-878
apomorphine	O	879-890
such	O	891-895
as	O	896-898
drug	O	899-903
-	O	903-904
induced	O	904-911
hypothermia	B	912-923
.	O	923-924

In	O	925-927
mice	O	928-932
,	O	932-933
apomorphine	O	934-945
produced	O	946-954
qualitatively	O	955-968
different	O	969-978
responses	O	979-988
under	O	989-994
novel	O	995-1000
conditions	O	1001-1011
when	O	1012-1016
compared	O	1017-1025
to	O	1026-1028
those	O	1029-1034
behaviors	O	1035-1044
elicited	O	1045-1053
in	O	1054-1056
the	O	1057-1060
home	O	1061-1065
test	O	1066-1070
cage	O	1071-1075
.	O	1075-1076

Drug	O	1077-1081
-	O	1081-1082
induced	O	1082-1089
gross	O	1090-1095
activity	O	1096-1104
counts	O	1105-1111
were	O	1112-1116
increased	O	1117-1126
in	O	1127-1129
the	O	1130-1133
novel	O	1134-1139
exploratory	O	1140-1151
box	O	1152-1155
only	O	1156-1160
,	O	1160-1161
while	O	1162-1167
measures	O	1168-1176
of	O	1177-1179
stereotypic	O	1180-1191
behavior	O	1192-1200
were	O	1201-1205
similar	O	1206-1213
in	O	1214-1216
both	O	1217-1221
.	O	1221-1222

By	O	1223-1225
contrast	O	1226-1234
,	O	1234-1235
apomorphine	O	1236-1247
-	O	1247-1248
induced	O	1248-1255
locomotion	O	1256-1266
was	O	1267-1270
more	O	1271-1275
prominent	O	1276-1285
in	O	1286-1288
the	O	1289-1292
novel	O	1293-1298
exploratory	O	1299-1310
box	O	1311-1314
.	O	1314-1315

Dopamine	O	1316-1324
turnover	O	1325-1333
ratios	O	1334-1340
(	O	1341-1342
DOPAC	O	1342-1347
:	O	1347-1348
DA	O	1348-1350
and	O	1351-1354
HVA	O	1355-1358
:	O	1358-1359
DA	O	1359-1361
)	O	1361-1362
were	O	1363-1367
found	O	1368-1373
to	O	1374-1376
be	O	1377-1379
lower	O	1380-1385
in	O	1386-1388
those	O	1389-1394
animals	O	1395-1402
exposed	O	1403-1410
to	O	1411-1413
the	O	1414-1417
exploratory	O	1418-1429
box	O	1430-1433
when	O	1434-1438
compared	O	1439-1447
to	O	1448-1450
their	O	1451-1456
home	O	1457-1461
cage	O	1462-1466
counterparts	O	1467-1479
.	O	1479-1480

However	O	1481-1488
,	O	1488-1489
apomorphine	O	1490-1501
-	O	1501-1502
induced	O	1502-1509
reductions	O	1510-1520
in	O	1521-1523
striatal	O	1524-1532
dopamine	O	1533-1541
turnover	O	1542-1550
were	O	1551-1555
detected	O	1556-1564
in	O	1565-1567
both	O	1568-1572
novel	O	1573-1578
and	O	1579-1582
home	O	1583-1587
cage	O	1588-1592
environments	O	1593-1605
.	O	1605-1606

The	O	1607-1610
implications	O	1611-1623
of	O	1624-1626
these	O	1627-1632
findings	O	1633-1641
are	O	1642-1645
discussed	O	1646-1655
with	O	1656-1660
particular	O	1661-1671
emphasis	O	1672-1680
upon	O	1681-1685
conducting	O	1686-1696
psychopharmacological	O	1697-1718
challenge	O	1719-1728
tests	O	1729-1734
in	O	1735-1737
rodents	O	1738-1745
.	O	1745-1746

